{"id": "batch_req_OcmM6vdut4Sl3IoTJtg5TWSS", "custom_id": "1_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "453c83a7631e1d2bb1b802e724fafd59", "body": {"id": "chatcmpl-9St5Lv30KbvvKdk9lxlHuL9Hh7eMG", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is a medication used primarily in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Here are some key points you should know about abemaciclib:\n\n1. **Mechanism of Action**: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor, specifically inhibiting CDK4 and CDK6. These kinases are involved in promoting the cell cycle progression from G1 to S phase. By inhibiting these kinases, abemaciclib effectively halts the proliferation of cancer cells.\n\n2. **Indications**:\n   - It is approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.\n   - It is also approved for use in combination with fulvestrant for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_rtpG9UMftoiWkwXofwKPXCf7", "custom_id": "2_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2647d110169a6da72788081849ccb62b", "body": {"id": "chatcmpl-9St5MpDVbwvyEJ1g8k3OdX6Eu6mRL", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer. Here are some key points you should know about Abiraterone as a physician:\n\n1. **Mechanism of Action**: Abiraterone works by inhibiting CYP17A1, an enzyme critical in the production of androgens (testosterone and other androgens) not only in the testicular tissue but also in other parts such as the adrenal glands and the tumor tissue itself. This inhibition significantly reduces the levels of androgens that can stimulate prostate cancer cells to grow.\n\n2. **Indications**: It is approved for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It is typically used in patients who have not responded adequately to androgen deprivation therapy.\n\n3. **Administration**: Abiraterone is administered orally, and the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Gb0TkiihU65upQZISOORcAlZ", "custom_id": "3_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fbbfc6dadbab5b79f6af4c26b38ab313", "body": {"id": "chatcmpl-9St5NdyYIzQ6dbEriGrSgyKUyFlCR", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, sold under the brand name Calquence, is a medication used in the treatment of certain types of cancers, particularly hematologic malignancies. Here are some key points you should know about acalabrutinib:\n\n1. **Indications**: Acalabrutinib is primarily indicated for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is also approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**: Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor. It works by selectively binding to BTK and inhibiting its activity, which is crucial for the growth and proliferation of B-cells. This inhibition disrupts signaling pathways necessary for B-cell survival and proliferation.\n\n3. **Administration**: Acalabrutinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_56Wgx3T9hxB3W9ex8mlTdqJg", "custom_id": "4_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "03aeafbddcf813b7a962af69e90b0bf2", "body": {"id": "chatcmpl-9St5PPn9gRwMFJ9bfei8VE71Cpig1", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as Aclacinomycin A, is an anthracycline antibiotic that is used primarily as a chemotherapeutic agent. It is similar in structure and mechanism to other anthracyclines such as doxorubicin and daunorubicin. Here are some key points you should know about Aclarubicin:\n\n1. **Mechanism of Action**: Aclarubicin intercalates into DNA, disrupting the replication and transcription processes. It also inhibits topoisomerase II, an enzyme critical for DNA replication. These actions lead to the induction of apoptosis in rapidly dividing cells.\n\n2. **Indications**: Aclarubicin is primarily used in the treatment of acute myeloid leukemia (AML) and has been studied in various other types of cancer, including other leukemias and solid tumors. Its use may vary by country and specific medical guidelines.\n\n3. **Administration**: Aclarubicin is administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9WXE3Voghjr5DFZYs7NgwEbo", "custom_id": "5_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46174e8bab8f7ddacf0d25c6afac6712", "body": {"id": "chatcmpl-9St5UOhrktjpR3Y9nmWoppiZXLjGe", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by its brand name Kadcyla, is a targeted therapy used in the treatment of HER2-positive breast cancer. It is particularly used in patients who have previously received trastuzumab and a taxane, separately or in combination. Here are some key points you should know about Trastuzumab emtansine:\n\n1. **Mechanism of Action**: Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1 (emtansine). Trastuzumab binds to the HER2 receptor on cancer cells, and upon internalization, the DM1 is released, leading to cell death.\n\n2. **Indications**: It is approved for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3NqUKZHd0yYd9savwNl1KL06", "custom_id": "6_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ae46eff812edc4bd98aaebc7f8fed21", "body": {"id": "chatcmpl-9St5UoBqEu35KAMuIZQOA9VKgdbWl", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a targeted therapy drug used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about afatinib:\n\n1. **Mechanism of Action**: Afatinib is a tyrosine kinase inhibitor that irreversibly binds to and inhibits the epidermal growth factor receptor (EGFR) family of tyrosine kinases. It is particularly effective against cancers that express mutations in the EGFR gene.\n\n2. **Indications**: Afatinib is approved for the first-line treatment of patients with NSCLC whose tumors have specific types of EGFR mutations (most commonly deletions in exon 19 or the L858R mutation in exon 21). It is also used in some other clinical scenarios and settings, depending on the regulatory approval in the country.\n\n3. **Efficacy**: Clinical trials have shown that afatinib can significantly improve progression-free survival compared to standard chemotherapy in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T0ILoyXfrwiSrG46HlNVERu7", "custom_id": "7_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a925531fcaf60df6e82f8d08f52db890", "body": {"id": "chatcmpl-9St5joT6Tn1TEdRyOVDUdb64Re0nw", "object": "chat.completion", "created": 1716671983, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known as interleukin-2 (IL-2), is a cytokine used primarily in the treatment of metastatic renal cell carcinoma and metastatic melanoma. It is a form of immunotherapy that works by stimulating the immune system to attack cancer cells. Here are some key points you should know about Aldesleukin:\n\n1. **Mechanism of Action**: Aldesleukin functions by binding to the IL-2 receptor on the surface of immune cells, such as T-cells and natural killer (NK) cells, promoting their proliferation and activation. This enhances the body's immune response against cancer cells.\n\n2. **Indications**:\n   - **Metastatic Renal Cell Carcinoma**: It is approved for the treatment of this condition when the disease is advanced.\n   - **Metastatic Melanoma**: It is also used in the treatment of this skin cancer in advanced stages.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_8K0jUiAToHfEMC2zMNWQpljs", "custom_id": "8_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a8f96abb74df89a850df1b2144b89885", "body": {"id": "chatcmpl-9St60Hz9miidqWdBmq1LwnpzYd0Jj", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib (brand name Alecensa) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC), particularly for cases that are positive for anaplastic lymphoma kinase (ALK) genetic alterations. Here are some key points about alectinib that you, as a physician, might find useful:\n\n1. **Indications**: Alectinib is approved for the treatment of ALK-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Alectinib is an oral ALK inhibitor. It works by blocking the activity of the ALK protein, which can promote tumor growth in some cancers. By inhibiting this protein, alectinib can help to stop or slow the growth of the cancer.\n\n3. **Efficacy**: Clinical trials have shown that alectin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j8nkxli7EFhbSQRlObdoQLbk", "custom_id": "9_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "12f056f9464ec41a44aac19e692eaf3b", "body": {"id": "chatcmpl-9St6HNvAyQsU0Cn2XKnn1pHpoBP0u", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily in the treatment of multiple sclerosis (MS) and previously for chronic lymphocytic leukemia (CLL). Here are some key points you should know about alemtuzumab:\n\n### Mechanism of Action\nAlemtuzumab targets CD52, a protein present on the surface of mature lymphocytes, but not on stem cells. By binding to CD52, alemtuzumab mediates the lysis of lymphocytes through antibody-dependent cellular cytotoxicity and complement-mediated lysis. This leads to a profound depletion of circulating T and B lymphocytes.\n\n### Indications\n- **Multiple Sclerosis (MS)**: Alemtuzumab is approved for the treatment of relapsing forms of multiple sclerosis (MS). It has been shown to reduce the frequency of relapses and to slow the progression of disability in MS. It is generally considered for use in patients who have not responded adequately to two or more"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HuwKfjBjbObtsboRXiYiQtQL", "custom_id": "10_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ff21c90ecd3d5341c09941de617e0832", "body": {"id": "chatcmpl-9St6Kl8TxRYHduC9MSUsCpULU8OT1", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and is primarily used in the treatment of acute promyelocytic leukemia (APL) and various skin disorders. Here are some key points you should know about ATRA, especially focusing on its use in APL:\n\n### Mechanism of Action\n- **APL Treatment**: ATRA works by binding to the retinoic acid receptor (RAR) on promyelocytes, which alters gene expression and promotes the differentiation and maturation of these cells into normal white blood cells. This mechanism is crucial in treating APL, where there is an accumulation of immature promyelocytes due to a genetic mutation (typically involving the retinoic acid receptor alpha, RARA).\n- **Skin Conditions**: For dermatological uses, ATRA promotes the turnover of epithelial cells, thereby reducing the formation of comedones and affecting the pathology of acne.\n\n### Clinical Use\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_blfAXrssizMgLwv1ePkFCmXB", "custom_id": "11_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "366dae152f6acc861145bb9faf164b36", "body": {"id": "chatcmpl-9St6MZxjjgwMuvjkqJBAy0gF4voUY", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine (also known by its brand name Hexalen) is a chemotherapy drug used primarily to treat ovarian cancer, particularly in cases where other treatments have failed or the cancer has recurred. Here are some key points you should know about altretamine:\n\n1. **Mechanism of Action**: Altretamine is considered a cytotoxic agent, though its exact mechanism of action is not fully understood. It is thought to act as an alkylating agent, causing damage to DNA in cancer cells, which inhibits their ability to reproduce and leads to cell death.\n\n2. **Indications**: Altretamine is approved for use in the treatment of persistent or recurrent ovarian cancer. It is often used after other first-line therapies have not been successful.\n\n3. **Administration**: Altretamine is administered orally in capsule form. The dosage and treatment regimen depend on various factors including the patient's size, the condition being treated, and the patient's overall health.\n\n4. **Side Effects**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B1hbmKeWGWAvZLKRh1aWLHjB", "custom_id": "12_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df7c1a0f723689cf33ff1e7807b71197", "body": {"id": "chatcmpl-9St6QM7nu9M6quXYaO9cCPld0mZXE", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a medication that was originally developed as an anticonvulsant but is now primarily used for its ability to inhibit adrenal steroid synthesis. Here are some key points about aminoglutethimide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Aminoglutethimide inhibits the enzymatic conversion of cholesterol to pregnenolone, thereby reducing the synthesis of all steroidal hormones, including glucocorticoids, mineralocorticoids, estrogens, and androgens. This is primarily achieved by blocking the activity of the enzyme P450scc (cytochrome P450 side chain cleavage enzyme) in the adrenal cortex.\n\n2. **Clinical Uses**:\n   - **Cushing's Syndrome**: It is used in the management of Cushing's syndrome (hypercortisolism) to control cortisol production before surgery, or in cases where surgery is not feasible.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_d0WcgcgmYSIUjIl7m3JvWc8U", "custom_id": "13_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a9d67ce247981ef335ed1da3236653c7", "body": {"id": "chatcmpl-9St6TrrE6UA6ry1GFQKHCtEfgM9Vc", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amrubicin is a synthetic anthracycline derivative that is used primarily in the treatment of lung cancer. Here are some key points you should know about Amrubicin:\n\n1. **Mechanism of Action**: Amrubicin acts as a topoisomerase II inhibitor, which leads to the inhibition of DNA replication and transcription. This results in cytotoxicity and apoptosis (programmed cell death) in cancer cells.\n\n2. **Indications**: It is mainly used for the treatment of small cell lung cancer (SCLC) and has shown efficacy in both first-line and refractory settings. It may also be used in other types of cancers as part of research or in specific circumstances.\n\n3. **Administration**: Amrubicin is administered intravenously. The dosage and schedule depend on various factors including the patient's condition, body surface area, and whether it is being used as monotherapy or in combination with other chemotherapeutic agents.\n\n4. **E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Wi5YCcEEIvZpbxOU7yxBIE8D", "custom_id": "14_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "97c9b75a1244bade8dd87399ca1a0ab2", "body": {"id": "chatcmpl-9St6YoGaV1vKD3NiqONhjFkV5XQ0m", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amsacrine, also known by its brand name Amsidine, is an antineoplastic (anti-cancer) agent used primarily in the treatment of leukemia. It belongs to the class of drugs known as acridine derivatives and functions as a topoisomerase II inhibitor, which disrupts DNA synthesis and thus inhibits the growth of cancer cells. Here are some key points you should know about amsacrine:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibition:** Amsacrine interferes with the enzyme topoisomerase II, which is essential for DNA replication and transcription. By stabilizing the DNA-topoisomerase II complex, it induces DNA breaks, leading to cell death.\n\n### Indications\n- **Acute Leukemias:** It is most commonly used in the treatment of acute myeloid leukemia (AML) and sometimes in other types of leukemia. It is often used when other treatments have failed or in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_WFzTgDfewoh8A52e0IkwjK2P", "custom_id": "15_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c6b08e2263d3f4cf8af19e2221fcea0", "body": {"id": "chatcmpl-9St6Z0CEKoKUTgALASJfyps9hZCUi", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole is a medication primarily used in the treatment of breast cancer. Here are some key points you should know about anastrozole, especially if you are a physician prescribing this medication:\n\n1. **Mechanism of Action**: Anastrozole is a non-steroidal aromatase inhibitor. It works by decreasing the amount of estrogen the body makes. This can slow or stop the growth of many types of breast cancer cells that need estrogen to grow.\n\n2. **Indications**: It is commonly prescribed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is often used as adjuvant therapy for early-stage breast cancer and also for the treatment of advanced or metastatic breast cancer.\n\n3. **Dosage and Administration**: The typical dosage of anastrozole is 1 mg taken orally once daily, with or without food.\n\n4. **Side Effects**: Common side effects include hot flashes, joint pain/stiffness, and muscle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Mvf7P7k6CKXnsVQ6OLCEJNCU", "custom_id": "16_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eeb113d16c8addb22322721ef367a341", "body": {"id": "chatcmpl-9St6hKaX3rD9jvVEnFC8avfp1WDR3", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apalutamide is a medication used primarily in the treatment of prostate cancer. Here are some key points you should know about apalutamide:\n\n1. **Indications**: Apalutamide is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). It is used in patients who are at high risk of developing metastatic disease.\n\n2. **Mechanism of Action**: Apalutamide is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its action, which prevents the androgen receptor signaling that promotes prostate cancer cell growth.\n\n3. **Administration**: Apalutamide is administered orally, typically at a dose of 240 mg once daily, taken as four 60 mg tablets. It is recommended to be taken with food.\n\n4. **Side Effects**: Common side effects include fatigue, hypertension, rash, diarrhea, nausea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZQiXeHbYNysFHom6B07XFQP3", "custom_id": "17_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "504f46b477e441cc1b4df905e3091fb0", "body": {"id": "chatcmpl-9St6hKhQrABz6t3e8SjmkQADgMmMC", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib, also known as Aitan, is a tyrosine kinase inhibitor specifically targeting the vascular endothelial growth factor receptor 2 (VEGFR-2). It is primarily used in the treatment of advanced gastric cancer and has been studied for use in other types of cancers as well. Here are some key points you should know about Apatinib:\n\n1. **Mechanism of Action**: Apatinib inhibits VEGFR-2, which plays a key role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting this receptor, Apatinib helps to reduce the supply of blood to tumors, thereby inhibiting their growth and spread.\n\n2. **Indications**: It is approved in China for the treatment of advanced gastric cancer patients who have failed at least two lines of prior chemotherapy. Research and clinical trials are ongoing to explore its effectiveness and safety in other cancers, including hepatocellular carcinoma, non-small"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eERARyJzLlS1G3D65fhMnyCL", "custom_id": "18_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7ed3e0bbe4d33f56c939d83487436aee", "body": {"id": "chatcmpl-9St6mfzyXXE3f34htFRQNMB2k6aIi", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenic trioxide is an important chemotherapeutic agent primarily used in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the presence of the t(15;17) translocation. Here are some key points you should know about arsenic trioxide:\n\n1. **Mechanism of Action**: Arsenic trioxide induces apoptosis and partial differentiation of leukemic cells. It is believed to exert its effects by causing degradation of the promyelocytic leukemia (PML) protein and the PML-retinoic acid receptor alpha (RAR\u03b1) fusion protein, which is produced by the t(15;17) translocation in APL.\n\n2. **Indications**: It is approved by the FDA for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy. Additionally, it is used in newly diagnosed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j3e0tF1dYt1uJdBgAlLvdxkP", "custom_id": "19_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "51747a2c587b8e2dda50c5a99c1b9cd0", "body": {"id": "chatcmpl-9St6parB83XGs4kxAhIrxpbuIjAP4", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an important chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points about asparaginase that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Asparaginase works by hydrolyzing the amino acid asparagine into aspartic acid and ammonia. This deprives the leukemia cells of asparagine, which is essential for their growth and survival, as they are unable to synthesize it themselves.\n\n2. **Indications**:\n   - Primarily used in the treatment of acute lymphoblastic leukemia (ALL).\n   - It may also be used in some non-Hodgkin lymphomas.\n\n3. **Forms and Administration**:\n   - Asparaginase is available in several forms including E. coli-derived asparaginase, pegylated asparaginase (PEG-asparagin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_BClFNY37CTXcTpMoGenqrW3E", "custom_id": "20_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "adb37d8147cd8010e941dc602e1780e3", "body": {"id": "chatcmpl-9St6wUWs6hHzbjWX8GI8AMRwPlIcO", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi is an important medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about this drug:\n\n1. **Mechanism of Action**: Asparaginase Erwinia chrysanthemi works by depleting the amino acid asparagine. Leukemia cells, particularly those in ALL, require asparagine for protein synthesis and survival. By breaking down asparagine, this drug starves the leukemia cells of a necessary nutrient, leading to cell death.\n\n2. **Indications**: It is specifically used in patients who have developed hypersensitivity to E. coli-derived asparaginase, which is commonly used in ALL treatment. Asparaginase Erwinia chrysanthemi serves as an alternative in these cases.\n\n3. **Administration**: The drug is typically administered intramuscularly. The dosing and schedule may vary based on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7dCELDEF06rHGzNnZnV45h15", "custom_id": "21_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "721418dd8c7e16066e66f5cb166d8bd7", "body": {"id": "chatcmpl-9St6xzjogTEYM9CfdL7ullSxFFGWy", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab (brand name Tecentriq) is an immune checkpoint inhibitor used in the treatment of certain types of cancer. It is a monoclonal antibody that targets the programmed death-ligand 1 (PD-L1), a protein expressed on cancer cells and tumor-infiltrating immune cells. By inhibiting PD-L1, atezolizumab helps to enhance the body's immune response against cancer cells.\n\nHere are some key points you should know about atezolizumab:\n\n1. **Indications**: Atezolizumab is approved for use in several types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, and triple-negative breast cancer that is locally advanced or metastatic and expresses PD-L1.\n\n2. **Mechanism of Action**: Atezolizumab works by binding to PD-L1 and blocking its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gdYFFfJZJuwNjFrcqYa37wvQ", "custom_id": "22_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "817dd35603a0e0c13be9ecdea96dce8e", "body": {"id": "chatcmpl-9St79tIvQ9wm2avOtKapl9Xox11ES", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab is a monoclonal antibody used in immunotherapy for treating certain types of cancer. It is a programmed death-ligand 1 (PD-L1) blocking antibody, which means it works by enhancing the body's immune response against cancer cells. Here are some key points you should know about Avelumab:\n\n1. **Mechanism of Action**: Avelumab binds to PD-L1 and blocks its interaction with PD-1 receptors on T cells and B7-1 receptors on immune cells. This blockade helps in reactivating the immune system to detect and fight cancer cells.\n\n2. **Indications**: Avelumab is approved for the treatment of metastatic Merkel cell carcinoma (a rare type of skin cancer) and locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum-containing chemotherapy. It is also used for other cancers in a clinical trial setting.\n\n3. **Administration**: Avelumab is administered intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_5usnvIoZl1ZwL6Fn104rDKrz", "custom_id": "23_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e671205655a1f52443d2cd37d046fd31", "body": {"id": "chatcmpl-9St7Gk6Q5uiUwwoaPHKVB5pspILbM", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel, marketed under the brand name Yescarta, is a type of cancer immunotherapy known as a chimeric antigen receptor (CAR) T-cell therapy. It is specifically designed for the treatment of certain types of B-cell lymphomas. Here are some key points you should know about this therapy:\n\n1. **Indications**: Axicabtagene ciloleucel is approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**: The therapy involves genetically modifying the patient's T cells to include a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of B-cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fbqWUF5LEuAxdsKYIPIzy7Pw", "custom_id": "24_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f918d39c39885f1baaf63c006e318ec7", "body": {"id": "chatcmpl-9St7GGmOyUJzqoQJpgtacAf5gSeZc", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axitinib is a tyrosine kinase inhibitor specifically designed to selectively inhibit vascular endothelial growth factor receptors (VEGFRs), which are implicated in the pathway of angiogenesis (the formation of new blood vessels). This inhibition can reduce the blood supply to tumors, thereby inhibiting tumor growth. Here are some key points you should know about axitinib:\n\n1. **Indications**: Axitinib is primarily used for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. It may also be studied or used off-label for other types of cancers.\n\n2. **Mechanism of Action**: Axitinib selectively inhibits the activity of VEGFR-1, VEGFR-2, and VEGFR-3 kinases. By blocking these receptors, axitinib can inhibit angiogenesis, which is critical for the growth and metastasis of solid tumors.\n\n3. **Administration**: Axitinib is administered orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8HV7u0ZFOnjWXfyGQ3NLOSPC", "custom_id": "25_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "83e9e8acc5346b105b1ab86edb10a19e", "body": {"id": "chatcmpl-9St7L9Br7CNvw0RIyooZPFz6gXXXj", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, marketed under the brand name Vidaza, is a chemotherapy medication primarily used to treat myelodysplastic syndromes (MDS) and certain types of leukemia. Here are some key points you should know about azacitidine:\n\n1. **Mechanism of Action**: Azacitidine is a nucleoside analog of cytidine that integrates into RNA and DNA. Its primary mechanism is the inhibition of DNA methyltransferases, leading to hypomethylation of DNA. This action can reactivate certain genes that are critical for cell cycle regulation and differentiation, potentially leading to the death of abnormal cells.\n\n2. **Indications**:\n   - Treatment of myelodysplastic syndromes (MDS), including certain subtypes such as refractory anemia or refractory anemia with excess blasts.\n   - Treatment of acute myeloid leukemia (AML), particularly in older patients who are not candidates for standard induction chemotherapy.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_6WfUQ4tMuIcgSumiph6bZiLJ", "custom_id": "26_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e32569bec836ab411c2b33667ae76e85", "body": {"id": "chatcmpl-9St7XCWMvcRQxxd6GrytPSYIDEZNB", "object": "chat.completion", "created": 1716672095, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is a vaccine primarily used against tuberculosis (TB). Here are some key points that you, as a physician, should know about BCG:\n\n1. **Development and Composition**: BCG is a live attenuated vaccine derived from Mycobacterium bovis, which is related to M. tuberculosis, the bacterium that causes tuberculosis. The vaccine strain was developed by Albert Calmette and Camille Gu\u00e9rin at the Pasteur Institute in France by attenuating M. bovis through serial subculturing over a period of 13 years.\n\n2. **Indications for Use**:\n   - **Tuberculosis Prevention**: BCG is most commonly used in countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease. However, its effectiveness in preventing pulmonary TB in adults is variable and generally considered limited.\n   - **Bladder Cancer**: BCG is also an important adjunct"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Znwgro1idXnNBe6kpxgKrdTl", "custom_id": "27_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cbcb32192594e270c430803d7f8728ad", "body": {"id": "chatcmpl-9St7Y8iTZyr5QEqoHPAIVgXRSgOif", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is an investigational monoclonal antibody that targets phosphatidylserine (PS), a molecule that is typically located on the inner leaflet of the cell membrane but becomes exposed on the outer leaflet in certain pathological conditions, including cancer and viral infections. The exposure of PS on the cell surface is thought to help these cells evade immune detection. By targeting PS, bavituximab aims to modulate the immune system to recognize and destroy these cells.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Bavituximab binds to phosphatidylserine (PS) on the external surface of cells in the tumor microenvironment or on virally infected cells.\n   - This binding may help in the activation of the immune system, particularly promoting the activity of macrophages and other cells to attack the tumor or infected cells.\n\n2. **Clinical Applications**:\n   - **Oncology**: Bavitux"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ennPfPNopb4HNkkzqcOp8XmT", "custom_id": "28_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1365ccb9323a72a9f78817352c1e90a0", "body": {"id": "chatcmpl-9St7YyeIypKSKoe8tLtEtzvYmWL79", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat (trade name Beleodaq) is a drug used in the treatment of peripheral T-cell lymphoma (PTCL), a type of non-Hodgkin lymphoma. It is classified as a histone deacetylase (HDAC) inhibitor. Here are some key points you should know about Belinostat:\n\n1. **Mechanism of Action**: Belinostat works by inhibiting the enzyme histone deacetylase. This action leads to an increase in the acetylation of histone proteins, resulting in alterations in gene expression that can induce cell cycle arrest, apoptosis, and differentiation of cancer cells.\n\n2. **Indications**: It is approved by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This approval is based on the results of clinical trials that showed efficacy in this setting.\n\n3. **Administration**: Belinostat is administered intravenously. The typical dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_y1oljhNJmYYiCclSKZdDpmiv", "custom_id": "29_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "23bc21928ec10b6c9553199aa117ca9e", "body": {"id": "chatcmpl-9St7gJEQjNaxoLVDhSnGgnXYtSFKK", "object": "chat.completion", "created": 1716672104, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan (also known as CKD-602) is a camptothecin derivative that acts as a topoisomerase I inhibitor. It is primarily used in the treatment of cancer, particularly for ovarian cancer and small cell lung cancer. Belotecan inhibits the DNA enzyme topoisomerase I, which is necessary for DNA replication and transcription. By inhibiting this enzyme, Belotecan causes DNA damage that leads to apoptosis (cell death) in rapidly dividing cancer cells.\n\n### Key Points for Physicians:\n\n1. **Indications**: Belotecan is mainly used in the treatment of ovarian cancer and small cell lung cancer. It may be used in other cancers as part of clinical trials or based on physician discretion.\n\n2. **Mechanism of Action**: As a topoisomerase I inhibitor, Belotecan interferes with the ability of topoisomerase I to religate single-strand breaks in DNA that it has created, leading to accumulation of DNA breaks"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FLB0cH1PQPHXOt32YdOGEnSQ", "custom_id": "30_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1b7e516802f501a43a542e6cad6a5c5d", "body": {"id": "chatcmpl-9St7ocg2Y8hmpOnmfLF8KOIuu5b5A", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy drug used primarily in the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. It is a bifunctional mechlorethamine derivative, which means it has both alkylating and purine analog properties. Here are some key points you should know about Bendamustine:\n\n1. **Mechanism of Action**: Bendamustine causes cross-linking of DNA, leading to disruption of DNA synthesis and function, which results in cell death. Its dual mechanism allows it to act in both non-dividing and dividing cells, making it effective against various types of cancer cells.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is approved for the treatment of CLL, especially for patients who have not responded to initial treatment.\n   - **Non-Hodgkin's Lymphoma**: Bendamustine is used for ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_g38IB7XB22Wc2br72EXe6uAs", "custom_id": "31_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5839036fc8cc388b457b031739c8053", "body": {"id": "chatcmpl-9St7tZhIUWF1gZmUS1NmiaglWifC7", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat various types of cancers and a specific eye disease. Here are some key points you should know about bevacizumab:\n\n1. **Mechanism of Action**: Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis, the growth of new blood vessels. By inhibiting VEGF-A, bevacizumab reduces the vascularization of tumors, which can inhibit their growth and metastasis.\n\n2. **Indications**: Bevacizumab is used in the treatment of several types of cancers, including colorectal cancer, non-small cell lung cancer, glioblastoma (a type of brain cancer), kidney cancer, and ovarian cancer. It is also used to treat neovascular (wet) age-related macular deg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B1c6By6GCvjlLTZaF3HWiYDs", "custom_id": "32_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "94512e026e047bf0f30df6b56664b75c", "body": {"id": "chatcmpl-9St7wOVukJ8MBoHvXuYcUTJehIRI8", "object": "chat.completion", "created": 1716672120, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is a medication used primarily in the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about bexarotene as a physician:\n\n1. **Mechanism of Action**: Bexarotene belongs to a class of drugs known as retinoids, which are synthetic derivatives of vitamin A. It specifically binds and activates retinoid X receptors (RXRs), which play a role in regulating cell growth, differentiation, and apoptosis. This action is believed to be responsible for its effectiveness in treating CTCL.\n\n2. **Indications**: Bexarotene is approved for the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least one prior systemic therapy. It is used in cases where the disease is persistent or has recurred following other treatments.\n\n3. **Formulations**: It is available in both topical and oral formulations. The topical form is generally used for localized lesions,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GOTBCaaoMRl9OQgTL8Ab8Hvn", "custom_id": "33_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c8b6368a80901b6430c081a88cfe219", "body": {"id": "chatcmpl-9St7y8KSgH1NqE3sCm7CVT5brltqv", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a medication primarily used in the treatment of prostate cancer. Here are some key points about the drug that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Bicalutamide is a non-steroidal anti-androgen. It works by binding to androgen receptors and inhibiting the action of androgens (such as testosterone), which can stimulate the growth of prostate cancer cells.\n\n2. **Indications**:\n   - Bicalutamide is most commonly used in the treatment of prostate cancer.\n   - It is typically used in combination with a luteinizing hormone-releasing hormone (LHRH) analog (e.g., leuprolide or goserelin) in the treatment of advanced prostate cancer.\n   - It may also be used as monotherapy in the treatment of early-stage prostate cancer, although this is less common.\n\n3. **Dosage and Administration**:\n   - The typical dosage for b"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eYgetzbGS2rwPHqPwbAQkoaq", "custom_id": "34_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f8af061fa9255a084c266711809334a", "body": {"id": "chatcmpl-9St8Gi3K7smM6QpVk1nZIKZccAQRX", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Binimetinib is a medication used in the treatment of cancer, specifically approved for use in patients with advanced melanoma that harbors a BRAF V600E or V600K mutation, often in combination with another medication called encorafenib. Here are some key points you should know about binimetinib:\n\n1. **Mechanism of Action**: Binimetinib is a kinase inhibitor that specifically targets and inhibits MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is often activated in cancers due to mutations in BRAF, leading to increased cell growth and survival. By inhibiting MEK, binimetinib can help to stop or slow the growth of cancer cells.\n\n2. **Indications**: It is primarily indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib. The presence of the mutation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1DkOKuJ7ewxgldPOrEiNumkf", "custom_id": "35_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48cd473f36085c5c37ec2555e44a1208", "body": {"id": "chatcmpl-9St8LfqjsB05yTgyBRNy7VC5GxSCG", "object": "chat.completion", "created": 1716672145, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antibiotic that exhibits antineoplastic activity, commonly used in the treatment of various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and cervical cancer. It is also used in the treatment of pleural effusions due to its sclerosing properties. Here are some key points about Bleomycin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nBleomycin works primarily by causing breaks in DNA strands, leading to inhibition of DNA synthesis and ultimately cell death. It binds to DNA and induces oxidative damage via free radical formation, which leads to strand breaks.\n\n### Administration\nBleomycin can be administered intravenously, intramuscularly, subcutaneously, or directly into the pleural cavity (for malignant pleural effusions). The route of administration often depends on the specific condition being treated.\n\n### Dosage\nThe dosage of Bleom"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_tqoV9Gzwixocxv7XObcRTgWU", "custom_id": "36_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59f85737bacb5c2fbd96581229737651", "body": {"id": "chatcmpl-9St8NPxLnP5Icpehfi8sqTNV8a5MU", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab (trade name Blincyto) is a bispecific CD19-directed CD3 T-cell engager (BiTE) used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points about Blinatumomab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Blinatumomab works by connecting CD3-positive cytotoxic T cells to CD19-positive B cells, leading to T-cell activation and subsequent lysis of the B cells. This mechanism is particularly effective against B-cell malignancies.\n\n2. **Indications**: It is approved by the FDA for the treatment of:\n   - Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n   - Philadelphia chromosome-positive ALL in patients who are resistant or intolerant to tyrosine kinase inhibitor (TKI) therapy.\n\n3. **Administration**: Blinatumomab is administered via continuous intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_g8qt5APFzLPhrxvqE3OyUzgE", "custom_id": "37_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "95c97ad0e1cfd1085b0167792e1992e2", "body": {"id": "chatcmpl-9St8ShesWUSUL3vcOukcoUQYU7wPS", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Here are some key points about Bortezomib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Bortezomib works by reversibly inhibiting the 26S proteasome, a complex that degrades ubiquitinated proteins. By inhibiting this proteasome, bortezomib disrupts various cellular processes, including the regulation of cell cycle, cell survival, and apoptosis. This leads to an accumulation of defective proteins in cells, causing cell stress and death, particularly in cancer cells.\n\n2. **Indications**:\n   - **Multiple Myeloma**: Bortezomib is approved for the treatment of multiple myeloma. It can be used in newly diagnosed patients as well as those who have received prior treatment.\n   - **Mantle Cell Lymphoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hibVW5A3odyicx2N8F9wHQdz", "custom_id": "38_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "756f761f3265c5a9aa9e1390535c848d", "body": {"id": "chatcmpl-9St8WFCauIyzCt0K8gF0YCS3a8NTz", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib is a tyrosine kinase inhibitor (TKI) primarily used in the treatment of chronic myelogenous leukemia (CML). Here are some key points about bosutinib that you, as a physician, might find useful:\n\n1. **Indications**: Bosutinib is approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.\n\n2. **Mechanism of Action**: Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also active against Src-family kinases. This inhibition interferes with the growth and proliferation of Bcr-Abl positive cells.\n\n3. **Dosage and Administration**: The typical starting dose of bosutinib is 500 mg orally once daily with food. Dose adjustments may be necessary based on patient response and tolerability, as well as hepatic and renal function.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AqYxr0H1swIfuEsdHGEBjXgH", "custom_id": "39_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f50c4e7ed7fcc110b5f1020cc876067", "body": {"id": "chatcmpl-9St8XygMxKymXO9ABFyZL3KyNyhYL", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brentuximab vedotin (Adcetris) is a targeted therapy used primarily in the treatment of certain types of lymphomas, specifically Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Here are some key points about Brentuximab vedotin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Brentuximab vedotin is an antibody-drug conjugate (ADC) that combines an anti-CD30 monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE). The antibody component binds to CD30, a cell surface protein expressed on Hodgkin Reed-Sternberg cells (in HL) and anaplastic large cell lymphoma cells. Upon binding, the conjugate is internalized, and MMAE is released to inhibit microtubule polymerization, leading to cell cycle arrest and apoptosis.\n\n2. **Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_emY8fOEIh4rYrr11qOA2xbQD", "custom_id": "40_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5fb02d5a1c024a7804b233e6af75f1b8", "body": {"id": "chatcmpl-9St8fJ3YLyYmb3az2Ph0PZGJ04Mev", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is a targeted therapy used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about brigatinib:\n\n1. **Indications**: Brigatinib is primarily indicated for the treatment of patients with metastatic NSCLC whose tumors have anaplastic lymphoma kinase (ALK) gene alterations. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Brigatinib is a tyrosine kinase inhibitor that targets ALK, ROS1, and other kinases. By inhibiting these kinases, brigatinib can block the growth and spread of cancer cells.\n\n3. **Administration**: Brigatinib is administered orally, typically once daily. The starting dose is usually 90 mg once daily for the first week, which may be increased to 180 mg once daily depending on the patient\u2019s"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YrxrQmQcHS8uweCiOD0CplmL", "custom_id": "41_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30945203adf68c63587c78d051f7fc4d", "body": {"id": "chatcmpl-9St8mjAipEJeZjRN9I6YSI5i8PAww", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is a chemotherapy medication primarily used in the treatment of chronic myelogenous leukemia (CML) and to prepare patients for bone marrow transplant by suppressing bone marrow activity. Here are some key points you should know about Busulfan:\n\n1. **Mechanism of Action**: Busulfan is an alkylating agent. It works by binding to DNA, causing cross-linking of DNA strands, abnormal base pairing, or DNA strand breaks, thereby inhibiting DNA replication and RNA transcription. This results in the suppression of cancer cell growth.\n\n2. **Indications**:\n   - Primarily used in the treatment of chronic myelogenous leukemia (CML).\n   - Used as a conditioning agent before hematopoietic progenitor cell transplantation.\n\n3. **Administration**:\n   - Busulfan can be administered orally or intravenously.\n   - The dosing regimen can vary depending on the indication and whether it is used in combination with other chemotherapy agents.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YnYE9SUW824X5NYYemEOsM4q", "custom_id": "42_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9576dc121f1062e5639655747ea2f19", "body": {"id": "chatcmpl-9St8mUsagnqx5Z93DkjKBoCGz6W6i", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapy drug used primarily in the treatment of prostate cancer. Here are some key points you should know about cabazitaxel:\n\n1. **Indications**: Cabazitaxel is approved for the treatment of hormone-refractory metastatic prostate cancer. It is typically used in patients who have progressed during or after treatment with docetaxel.\n\n2. **Mechanism of Action**: Cabazitaxel is a microtubule inhibitor. It works by inhibiting the disassembly of microtubules, thereby disrupting mitotic and interphase cellular functions. This leads to cell cycle arrest and apoptosis (cell death).\n\n3. **Administration**: Cabazitaxel is administered intravenously. The dosage and schedule can vary based on the treatment regimen, patient's health status, and previous treatments.\n\n4. **Side Effects**: Common side effects of cabazitaxel include neutropenia (which can be severe), anemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0GUA5PtR4Wo9A8QBxfWB4PIw", "custom_id": "43_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b7b47a546193202d1fbaed53ca27ed0", "body": {"id": "chatcmpl-9St8n2e6gavBPyBsCHDdXUzOflfDw", "object": "chat.completion", "created": 1716672173, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is a tyrosine kinase inhibitor used primarily in the treatment of various types of cancer. Here are some key points you should know about cabozantinib:\n\n1. **Mechanism of Action**: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. These include MET, VEGFR, and RET. By inhibiting these pathways, cabozantinib can reduce tumor growth, angiogenesis, and metastatic potential.\n\n2. **Indications**:\n   - **Renal Cell Carcinoma (RCC)**: It is approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.\n   - **Hepatocellular Carcinoma (HCC)**: Approved for patients with previously treated advanced hepatocellular carcinoma.\n   - **Medullary Thyroid Cancer (MTC)**: Approved for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MoEmGDNN21URC7iUUfmE6UXd", "custom_id": "44_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f81d55e5df2318578f4a167de4d3708c", "body": {"id": "chatcmpl-9St8pA5oqQul167tluOYSCXf77Vuz", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol-mknl, sold under the brand name Asparlas, is a chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL). It is a modified form of L-asparaginase, an enzyme that depletes the amino acid asparagine. Here are some key points you should know about Calaspargase pegol-mknl:\n\n1. **Mechanism of Action**: Calaspargase pegol-mknl works by breaking down asparagine, an amino acid that is necessary for the growth and survival of leukemia cells. Normal cells can synthesize asparagine, but leukemia cells cannot, making them dependent on external sources of the amino acid. By depleting asparagine, calaspargase pegol-mknl starves the leukemia cells and inhibits their ability to proliferate.\n\n2. **Indications**: It is approved for use in pediatric and young adult patients up to "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bK80WiYIwKk2tmSBi7aIPk2G", "custom_id": "45_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e97d34a4bd003167acc232f4a76c1196", "body": {"id": "chatcmpl-9St8qBU6Yf5E9eFdZL4Qo1dfonlsS", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapeutic agent commonly used in the treatment of various cancers, including breast, colorectal, and gastric cancers. Here are some key points you should know about capecitabine:\n\n1. **Mechanism of Action**: Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body. It undergoes a three-step enzymatic conversion, with the final step occurring preferentially in tumor tissue, thereby providing a targeted cytotoxic effect. The active drug, 5-FU, inhibits thymidylate synthase, an enzyme involved in DNA synthesis, leading to cell death.\n\n2. **Indications**:\n   - **Colorectal Cancer**: It is approved for adjuvant treatment in patients with Dukes' C colon cancer and for first-line treatment of metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c1UthFORc6oyFVtCw2GUAt9U", "custom_id": "46_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "389b5dc58fb1b60c26de39a09e95892c", "body": {"id": "chatcmpl-9St8q3V9xdEi2ImWZnZiYA2bkA3Wu", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used primarily to treat various forms of cancer, including ovarian, lung, head and neck, endometrial, esophageal, bladder, breast, and cervical cancer, among others. It is a platinum-based drug that works by interfering with the DNA replication process in cancer cells, which prevents them from dividing and growing. Here are some key points you should know about Carboplatin:\n\n### Mechanism of Action\nCarboplatin forms platinum-DNA adducts. When it binds to DNA, it causes cross-linking of DNA strands, ultimately inhibiting DNA synthesis and transcription, leading to cell death. This is similar to other platinum compounds like cisplatin, although carboplatin tends to be somewhat less potent but better tolerated.\n\n### Administration\nCarboplatin is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the purpose of the treatment (e.g., curative, palliative), the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T8DzdtaMcadJUyDSYawzrpCs", "custom_id": "47_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cdb121bb7eca5fe2fc71a2346920917f", "body": {"id": "chatcmpl-9St8wWTi8Pbj0XeDMje1g1J2lV7h0", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma. As a physician, here are several key aspects you should be aware of regarding Carfilzomib:\n\n1. **Mechanism of Action**: Carfilzomib works by irreversibly inhibiting the 20S proteasome, which is a protein complex that degrades ubiquitinated proteins. Inhibition of the proteasome leads to the accumulation of these proteins, which can induce cell cycle arrest and apoptosis in cancer cells.\n\n2. **Indications**: It is approved for use in patients with multiple myeloma who have received at least one prior therapy. It is often used in combination with other medications such as dexamethasone or lenalidomide and dexamethasone.\n\n3. **Administration**: Carfilzomib is administered intravenously. The dosing schedule can vary depending on the combination regimen, but it typically involves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xH3lI9kuaeQveei83PJMwibY", "custom_id": "48_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4935a11cc584fc0ded3e83a5ad0d8fd1", "body": {"id": "chatcmpl-9St8wAhLqxk80viS1xHWPg4bdHr5M", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine is a chemotherapy drug used primarily to treat various types of brain tumors, including gliomas, glioblastoma multiforme, medulloblastoma, astrocytoma, and brain metastases. It is also used in the treatment of multiple myeloma and lymphomas. Here are some key points about Carmustine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCarmustine belongs to the class of alkylating agents. It works by cross-linking DNA and RNA, thereby inhibiting DNA synthesis and RNA transcription. This results in the disruption of cellular replication and ultimately leads to cell death.\n\n### Administration\nCarmustine can be administered intravenously or as an implant (Gliadel wafer). The wafer is placed in the surgical cavity after tumor removal and slowly releases the drug locally at the site of the tumor.\n\n### Dosage\nThe dosage of Carmustine varies depending on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s2pNA3TNOkoEh38LcVl4vxHv", "custom_id": "49_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "80c8ca22d14c9c4cfc89f833bc876257", "body": {"id": "chatcmpl-9St8wRKB3tzXeOPnjcl6bZxxobaCB", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafers (polifeprosan 20 with carmustine implant) are used in the treatment of high-grade malignant gliomas, such as glioblastoma multiforme. These wafers are implanted directly into the brain after surgical resection of the tumor, providing localized chemotherapy. Here are some key points you should know about this treatment:\n\n1. **Composition and Mechanism**: Each wafer contains 7.7 mg of carmustine (BCNU) and is made from a biodegradable polymer (polifeprosan 20). Once implanted, the wafers slowly release carmustine directly into the site of the tumor, maximizing local drug concentration while minimizing systemic exposure.\n\n2. **Indications**: Carmustine wafers are indicated for use in newly diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. They are also used in recurrent glioma cases where surgical resection is feasible.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EivgUIVejvWAT0UNttEYdv14", "custom_id": "50_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "58a59797d343a1273eceee78053ae0d5", "body": {"id": "chatcmpl-9St8xN8lilbKjzNEkyVsZ0zfgYyof", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is an oral small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It is primarily used in the treatment of various cancers, including ovarian cancer, renal cell carcinoma, and glioblastoma. Here are some key points you should know about Cediranib:\n\n1. **Mechanism of Action**: Cediranib works by inhibiting the activity of VEGFR tyrosine kinases, which are involved in the regulation of angiogenesis (formation of new blood vessels). By blocking these receptors, cediranib reduces the blood supply to tumors, which can inhibit their growth and reduce their ability to metastasize.\n\n2. **Clinical Uses**: Cediranib has been studied in various clinical trials for different types of cancer. It has shown promise in ovarian cancer, particularly in combination with other therapies such as olaparib, a PARP inhibitor. The combination has been evaluated for its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qvXSJ3zLqAKOpK01BvUsGuuA", "custom_id": "51_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02df340bf52365805ae3d7f59561bce0", "body": {"id": "chatcmpl-9St8ymM80VDMAX04XSUzZflqQpv08", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab, marketed under the brand name Libtayo, is a monoclonal antibody used in the treatment of certain types of cancers. It is specifically designed to inhibit the immune checkpoint receptor programmed cell death protein 1 (PD-1), which is a mechanism that tumors use to evade the immune system. By blocking PD-1, cemiplimab helps to restore the body's immune response against cancer cells.\n\nHere are some key points about cemiplimab that you, as a physician, might find useful:\n\n1. **Indications**: As of the last update, cemiplimab is approved for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. It is also approved for the treatment of basal cell carcinoma (BCC) that has metastasized or cannot be cured by surgery or radiation, and for non-small cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9C1lUNOkrucG50GrU8nWstXa", "custom_id": "52_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df9e8b6ba3f5173eb1c16d8ca036bfd6", "body": {"id": "chatcmpl-9St91TfQPOqfLSibWjmlg9uedjsNP", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about ceritinib:\n\n1. **Indications**: Ceritinib is specifically indicated for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Ceritinib is a small-molecule kinase inhibitor that targets ALK and inhibits its autophosphorylation, leading to decreased tumor cell viability. ALK gene rearrangements are oncogenic drivers in a subset of NSCLC, making ALK inhibition a targeted therapeutic strategy.\n\n3. **Administration**: Ceritinib is administered orally. The recommended dosage is 450 mg once daily with food.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VcYdJCkp6drm7nqoyFfpioEy", "custom_id": "53_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5d14f85674d966fb65f9bf49e65e53b4", "body": {"id": "chatcmpl-9St926w9NWFGl9oMAN8j26MCnJYjr", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab is a monoclonal antibody used primarily in the treatment of certain types of cancer. Here are some key points you should know about cetuximab:\n\n1. **Mechanism of Action**: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor. It binds to the EGFR on both normal and tumor cells, preventing the binding of natural ligands like EGF and TGF-alpha. This inhibition blocks the phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased production of pro-inflammatory cytokines and vascular growth factors.\n\n2. **Indications**:\n   - **Colorectal Cancer**: It is approved for use in metastatic colorectal cancer, particularly in patients whose tumors express EGFR and who do not have KRAS mutations (since KRAS mutations are associated with resistance to EGFR inhibitors).\n   - **Head and Neck Cancer**: Cetuximab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zqW1RTyqxweB29hJqHdos3Np", "custom_id": "54_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "425b0363c9290313f4f91c2a5059cb43", "body": {"id": "chatcmpl-9St91NX8307TvTnp8CLr7m2oMDLe7", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide, also known as CS055 or HBI-8000, is a benzamide class of histone deacetylase (HDAC) inhibitor. It is primarily used in the treatment of cancer, particularly lymphoma. Here are some key points you should know about Chidamide:\n\n1. **Mechanism of Action**: Chidamide selectively inhibits the activity of HDAC1, HDAC2, HDAC3, and HDAC10. By inhibiting these enzymes, Chidamide increases the acetylation of histone proteins, leading to alterations in gene expression. This can result in growth arrest, differentiation, and apoptosis of cancer cells.\n\n2. **Indications**: Chidamide has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research is ongoing to evaluate its effectiveness and safety for other types of cancer, including breast cancer and lung cancer.\n\n3. **Administration**: Chidamide is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XcVw72Om8dTyHqJk9oLloaX5", "custom_id": "55_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "478b82692b20c78841e07aab90d10083", "body": {"id": "chatcmpl-9St94XLJFF3U3EKP6zLSdQfr9EpIU", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is a chemotherapy drug used primarily to treat chronic lymphocytic leukemia (CLL) and some types of non-Hodgkin's lymphoma. It belongs to the class of drugs known as alkylating agents, which work by binding to DNA and preventing the cancer cells from growing and dividing.\n\nHere are some key points about chlorambucil that you, as a physician, might find useful:\n\n1. **Indications**: Chlorambucil is mainly indicated for the treatment of CLL and Hodgkin\u2019s and non-Hodgkin's lymphomas. It may also be used in the management of other malignancies such as Waldenstrom macroglobulinemia and ovarian cancer.\n\n2. **Mechanism of Action**: As an alkylating agent, chlorambucil interferes with DNA replication and RNA transcription, ultimately leading to cell death. It forms covalent bonds with the guanine base in DNA, causing cross-linking and strand breaks"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_hdBst4UyoVuewYqoQaBnwwsF", "custom_id": "56_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "978beddaf0f855baa88d19b4a26aaddd", "body": {"id": "chatcmpl-9St94Invx2YVPp3BaEEkOx4lo4MIv", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a chemotherapy medication widely used to treat a variety of cancers. As a physician, here are key aspects you should know about Cisplatin:\n\n### Mechanism of Action\nCisplatin works primarily by causing DNA damage. It forms platinum-DNA adducts, which lead to cross-linking of DNA, inhibiting DNA synthesis and transcription, ultimately triggering apoptosis (cell death) in rapidly dividing cancer cells.\n\n### Indications\nCisplatin is used to treat various types of cancers including:\n- Testicular cancer\n- Ovarian cancer\n- Cervical cancer\n- Bladder cancer\n- Lung cancer, particularly small cell lung cancer and non-small cell lung cancer\n- Head and neck cancers\n\n### Administration\nCisplatin is administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's body surface area, renal function, and whether Cisplatin is being given alone or in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BJumyFiXYByV4VVWjwtAOX2r", "custom_id": "57_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7533a8393af65ca1b4f6dda07f9cedab", "body": {"id": "chatcmpl-9St970SVrJ9KxBmrI6julMmm0aaQW", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine is a medication primarily used in the treatment of hairy cell leukemia and multiple sclerosis. Here are some key points you should know about Cladribine:\n\n1. **Mechanism of Action**: Cladribine is a purine nucleoside analog that disrupts DNA synthesis and repair, leading to cell death. It is selectively toxic to lymphocytes and monocytes, which are particularly sensitive to its effects. This makes it effective in diseases characterized by abnormal lymphocyte proliferation.\n\n2. **Indications**:\n   - **Hairy Cell Leukemia**: Cladribine is highly effective in treating hairy cell leukemia, leading to long-term remission in many patients.\n   - **Multiple Sclerosis (MS)**: It is approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease. It reduces the frequency of clinical exacerbations and may delay the progression of disability.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SK6bUBA9LEtFuHTSrB0ziuS9", "custom_id": "58_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c01f8f0093d6a22991eedad9d2e24dd8", "body": {"id": "chatcmpl-9St97KSezYSqb6zgMdlg9OaY8yaUG", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clarithromycin is an antibiotic that belongs to the class of macrolide antibiotics. It is commonly used to treat various bacterial infections including respiratory tract infections, skin infections, and Helicobacter pylori infection, which is associated with peptic ulcer disease. Here are some key points you should know about clarithromycin:\n\n1. **Mechanism of Action**: Clarithromycin works by inhibiting protein synthesis in bacteria by binding to the 50S ribosomal subunit. This action prevents the growth of bacteria and helps in controlling the infection.\n\n2. **Spectrum of Activity**: It is effective against a wide range of gram-positive and gram-negative bacteria. It is particularly useful against atypical pathogens and is often used in the treatment of respiratory infections caused by Mycoplasma pneumoniae, Legionella spp., and Chlamydophila pneumoniae.\n\n3. **Indications**:\n   - Community-acquired pneumonia\n   - Acute bacterial exacerbation of chronic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZoMRfIKv7hZY6mca9PcCQNtN", "custom_id": "59_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e8e934cd4fd5f86f73d1b4b945a15515", "body": {"id": "chatcmpl-9St98NkMe9CtvmZQR7Woz13vcVC2u", "object": "chat.completion", "created": 1716672194, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about clofarabine:\n\n1. **Mechanism of Action**: Clofarabine is a purine nucleoside analog. It inhibits ribonucleotide reductase and DNA polymerase, leading to inhibition of DNA synthesis and repair. This results in apoptosis of leukemic cells.\n\n2. **Indications**: It is approved for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. It is also used in adults under similar conditions but is less commonly used in this group.\n\n3. **Administration**: Clofarabine is administered intravenously. The dosage and schedule may vary based on factors like age, body surface area, renal function, and the specific treatment protocol being followed.\n\n4. **Side Effects**: Common side effects include myelos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_8mcRJh79syNKw56PjgnRZN3K", "custom_id": "60_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "23a96085a5dc688aa34eae3da6405466", "body": {"id": "chatcmpl-9St9HXejEYA1MRJnyWjs6MsHs7kXB", "object": "chat.completion", "created": 1716672203, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib is a medication used primarily in the treatment of cancer, specifically for melanoma that has a certain type of abnormal \"BRAF\" gene. Here are some key points you should know about cobimetinib:\n\n1. **Mechanism of Action**: Cobimetinib is a MEK inhibitor. MEK (mitogen-activated protein kinase kinase) is part of the MAPK/ERK pathway, which is involved in cell division and can be hyperactive in some types of cancer cells. By inhibiting MEK, cobimetinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**: It is approved for use in combination with vemurafenib, another cancer medication, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. This mutation should be confirmed by an FDA-approved test before starting treatment.\n\n3. **Administration**: Cobimetin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iVsjGJR7DAjNLfuL4eOTfDvN", "custom_id": "61_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e9c691bcac11deb603e93a3467e8cb2", "body": {"id": "chatcmpl-9St9I2Pqgy81MmKpFCdOVgqLcxT4Q", "object": "chat.completion", "created": 1716672204, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Copanlisib:\n\n1. **Mechanism of Action**: Copanlisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor, specifically targeting the PI3K-alpha and PI3K-delta isoforms found in malignant cells. By inhibiting these pathways, copanlisib helps to stop cancer cell growth and survival.\n\n2. **Indications**: It is approved by the FDA for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Research is ongoing to explore its use in other types of cancers.\n\n3. **Administration**: Copanlisib is administered intravenously. The dosing regimen typically involves administration on days 1, 8, and 15 of a 28-day cycle, but this can vary based on the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CqlawnIsskBLA1KaQEziNI7b", "custom_id": "62_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a1c309b0ff4b92a77bfce5cddabf2a0", "body": {"id": "chatcmpl-9St9JRrMHsHVGMSBsrOTdaGwVNWIx", "object": "chat.completion", "created": 1716672205, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib is an important medication in the field of oncology, particularly for treating certain types of cancer that are driven by specific genetic alterations. Here are key points you should know about Crizotinib:\n\n1. **Mechanism of Action**: Crizotinib is an oral small-molecule kinase inhibitor. It primarily targets anaplastic lymphoma kinase (ALK), but it also inhibits other kinases including MET (hepatocyte growth factor receptor) and ROS1 (c-ros oncogene 1). By inhibiting these kinases, Crizotinib interferes with the growth and proliferation of cancer cells.\n\n2. **Indications**: Crizotinib is FDA-approved for the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive, which is determined by an FDA-approved test. It is also approved for the treatment of ROS1-positive NSCLC. The presence of these genetic alterations can be identified"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_AO4NpH5AN6T0wYoRWHnjlIUo", "custom_id": "63_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74080bb7b0a3b1e165b18852863299e3", "body": {"id": "chatcmpl-9St9JiATxmtvnELoKvUKsaz541NNs", "object": "chat.completion", "created": 1716672205, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is a chemotherapy medication used primarily to treat various types of cancer. It is also used to suppress the immune system in certain autoimmune disorders. Here are some key points about cyclophosphamide that you, as a physician, might find useful:\n\n### Mechanism of Action\nCyclophosphamide belongs to the class of drugs known as alkylating agents. It works by interfering with the normal function of DNA in the cells, preventing their replication and thus inhibiting tumor growth. It is a prodrug, meaning it requires metabolic activation by liver enzymes to form its active metabolites, phosphoramide mustard and acrolein.\n\n### Indications\nCyclophosphamide is used to treat a variety of cancers including:\n- Lymphomas\n- Leukemias\n- Multiple myeloma\n- Breast cancer\n- Ovarian cancer\n- Some types of lung cancer\n\nIt is also used in lower doses to treat autoimmune conditions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1IC01R6bEZ0Wx6xkiUDY4zok", "custom_id": "64_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4625af9ff6d51e5be3e07c4627fe6cb", "body": {"id": "chatcmpl-9St9L0nybng23EqvjHRWg4hUg4aK0", "object": "chat.completion", "created": 1716672207, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyproterone acetate (CPA) is a medication that has both antiandrogenic and progestogenic properties. It is primarily used in the treatment of androgen-related conditions and has several key aspects that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   - **Antiandrogenic Effects**: CPA works by blocking androgen receptors, which reduces the effect of androgens (such as testosterone) in the body. This can help in conditions where androgen levels are undesirably high or their effects need to be minimized.\n   - **Progestogenic Effects**: CPA also acts as a progestogen, which means it can influence the menstrual cycle and has contraceptive effects when used in combination with estrogen.\n\n2. **Indications**:\n   - **Hyperandrogenism**: It is often prescribed for conditions like polycystic ovary syndrome (PCOS), severe acne, and hirsutism in women"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xt2KFGQPainETVaSGKIKS7LV", "custom_id": "65_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ff3fd1642fc4a0d68ab1197f2d727fda", "body": {"id": "chatcmpl-9St9LcRGIwqxdAhs4IizNefXoZPJD", "object": "chat.completion", "created": 1716672207, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as cytosine arabinoside (Ara-C), is a chemotherapeutic agent primarily used in the treatment of hematologic malignancies. Here are some key points about cytarabine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. It is incorporated into DNA during the S-phase of the cell cycle, leading to chain termination. It also inhibits DNA polymerase, which is crucial for DNA repair and replication.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Cytarabine is a cornerstone in the treatment of AML. It is used in various regimens, both in induction and consolidation therapy.\n- **Acute Lymphoblastic Leukemia (ALL)**: It is used in the treatment of ALL, often in combination with other"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7pRd57LmYWPesG3mS4x3NLsW", "custom_id": "66_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a52dea7a7a72f6717e1087851f143f7", "body": {"id": "chatcmpl-9St9NIIzPEzMw4ow3oFYEktA0iVP0", "object": "chat.completion", "created": 1716672209, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine and daunorubicin liposomal (brand name Vyxeos) is a combination chemotherapy medication used primarily in the treatment of certain types of acute myeloid leukemia (AML), specifically therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Here are some key points you should know about this medication:\n\n1. **Mechanism of Action**: This combination encapsulates cytarabine, a nucleoside metabolic inhibitor, and daunorubicin, an anthracycline antibiotic, in a liposomal formulation. The liposomal delivery allows for enhanced uptake and retention in the bone marrow, which may improve the therapeutic effects and reduce systemic toxicity. The ratio of cytarabine to daunorubicin in the liposomes is fixed at 5:1.\n\n2. **Indications**: Vyxeos is specifically approved for the treatment of adults with newly diagnosed therapy-related A"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 51, "completion_tokens": 200, "total_tokens": 251}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_SFFRHVMrd9lhetbARDWofTnf", "custom_id": "67_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "127232c77bca15b00c9516daa3e89745", "body": {"id": "chatcmpl-9St9OF7dMs1XfhzJJhG07MwZbQG0N", "object": "chat.completion", "created": 1716672210, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about dabrafenib as a physician:\n\n1. **Mechanism of Action**: Dabrafenib is a BRAF inhibitor. It specifically targets and inhibits the activity of the BRAF V600E kinase, which is a mutation that promotes cancer cell growth in various cancers. By inhibiting this kinase, dabrafenib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**: Dabrafenib is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation. It is also used in combination with trametinib, another kinase inhibitor, for the treatment of certain types of non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer that harbor the same mutation.\n\n3. **Administration**: Dabrafenib is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_DVOgZqCp79CaEDvU4XDYoPih", "custom_id": "68_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "131ca84a886be45d67cb2570aaa040fc", "body": {"id": "chatcmpl-9St9PEZs1gKKZYfOMMofHVNXYUdN3", "object": "chat.completion", "created": 1716672211, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine is a chemotherapy medication used primarily to treat various types of cancer, including malignant melanoma, Hodgkin's lymphoma, and sarcomas. Here are some key points you should know about dacarbazine:\n\n1. **Mechanism of Action**:\n   - Dacarbazine works as an alkylating agent. It undergoes hepatic metabolism to form an active compound that methylates guanine bases in DNA, which leads to DNA strand breaks and apoptosis of cancer cells.\n\n2. **Administration**:\n   - It is administered intravenously. Proper handling and administration are crucial due to its cytotoxic nature.\n\n3. **Dosage**:\n   - The dosage of dacarbazine can vary based on the type of cancer, the size of the patient, the specific treatment protocol, and the patient\u2019s overall health and liver function. It is often given in cycles, combined with rest periods.\n\n4. **Side Effects**:\n   - Common side effects include nausea"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ThXt1rKVUCc8dddm4KLf2x6x", "custom_id": "69_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ec3c699929db97c7dc498d16a59cc12", "body": {"id": "chatcmpl-9St9P1A1L8qGeO8fjJe9ajIFbApIO", "object": "chat.completion", "created": 1716672211, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacomitinib is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about dacomitinib:\n\n1. **Mechanism of Action**: Dacomitinib is a second-generation, irreversible tyrosine kinase inhibitor (TKI) that specifically targets the epidermal growth factor receptor (EGFR). It binds irreversibly to the ATP binding site of the EGFR, leading to inhibition of the EGFR signaling pathways which are involved in the growth and development of cancer cells.\n\n2. **Indications**: Dacomitinib is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations as detected by an FDA-approved test. These mutations lead to increased growth factor signaling and are found in a subset of NSCLC patients.\n\n3. **Efficacy**: Clinical trials,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_zD6qFQWbm9m9ZEWC2dZtDDrp", "custom_id": "70_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a3027daf28897435796d9aef671fd03b", "body": {"id": "chatcmpl-9St9PUuPy9m0G4bdIVaZsNpGM5Clk", "object": "chat.completion", "created": 1716672211, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapy medication used primarily to treat a variety of cancers. Here are some key points you should know about dactinomycin:\n\n1. **Mechanism of Action**: Dactinomycin binds to DNA and inhibits RNA synthesis, which is crucial for cell growth and replication. It intercalates between guanine-cytosine base pairs, blocking the transcription of DNA into RNA by RNA polymerase.\n\n2. **Indications**: It is used in the treatment of various types of cancer, including Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, and trophoblastic neoplasms. It is also used in the treatment of testicular cancer and certain types of ovarian cancer.\n\n3. **Administration**: Dactinomycin is administered intravenously. The dosage and schedule depend on the type of cancer being treated, the purpose of treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZKbRQoqsvi6ndlblp7jmJbzy", "custom_id": "71_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36d183334a187bc632178fa00cb5410f", "body": {"id": "chatcmpl-9St9PRsEMO0RqSA66p7ffpohJKNes", "object": "chat.completion", "created": 1716672211, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid with both androgenic and antigonadotropic properties, used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Here are some key points you should know about Danazol:\n\n1. **Mechanism of Action**: Danazol works by inhibiting the pituitary output of gonadotropins, which leads to a decrease in ovarian production of estrogen and progesterone. It also has direct effects on the endometrium (uterine lining) and immune modulation.\n\n2. **Indications**:\n   - **Endometriosis**: Danazol is used to relieve pain and reduce lesions, although it is less commonly prescribed today due to the availability of other treatments with fewer side effects.\n   - **Fibrocystic Breast Disease**: It helps reduce pain and nodularity.\n   - **Hereditary Angioedema**: Danazol increases the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_I7PYt5Vbv0Vc2muxJeBLUORJ", "custom_id": "72_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "800939a55a894bd288e8264df186ba3f", "body": {"id": "chatcmpl-9St9QeT7R93thGXoqvy8oemXD6xBH", "object": "chat.completion", "created": 1716672212, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab is a monoclonal antibody used primarily in the treatment of multiple myeloma, a type of cancer that affects plasma cells. Here are some key points you should know about daratumumab:\n\n1. **Mechanism of Action**: Daratumumab targets and binds to CD38, a surface protein that is highly expressed on multiple myeloma cells. By binding to CD38, daratumumab induces tumor cell death through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.\n\n2. **Indications**: Daratumumab is approved for use in patients with multiple myeloma who have received at least one prior therapy. It is used both as a monotherapy and in combination with other treatments such as lenalidomide, bortezomib, and dexamethasone.\n\n3. **Administration**: Daratumumab is administered via intravenous infusion. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_vshFwAU5CX4gtuUlgG2xwgMQ", "custom_id": "73_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3dc32c97367f27eabcc4db0009dc4268", "body": {"id": "chatcmpl-9St9QhTH9uXqZNpky0TKSU0DvRLHu", "object": "chat.completion", "created": 1716672212, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darolutamide is a medication used primarily in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). Here are some key points you should know about darolutamide:\n\n1. **Mechanism of Action**: Darolutamide is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its action, which is crucial in the growth and survival of prostate cancer cells. Unlike other androgen receptor antagonists, darolutamide has a structure that reduces its ability to cross the blood-brain barrier, potentially leading to fewer central nervous system side effects.\n\n2. **Efficacy**: Clinical trials, such as the ARAMIS trial, have demonstrated that darolutamide significantly extends metastasis-free survival in men with nmCRPC compared to placebo. This benefit is achieved with a maintenance of quality of life and a delay in the time to pain progression.\n\n3. **Administration**: Darolutamide is administered orally. The typical dosage is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iI63fm6b83JJa9fKqCnp3Uw2", "custom_id": "74_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "295525908aeccf468d4739025988e23a", "body": {"id": "chatcmpl-9St9QPiTGWCWNrjFxh36OcKqfcbeH", "object": "chat.completion", "created": 1716672212, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dasatinib, marketed under the brand name Sprycel, is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer, most notably chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). Here are some key points about dasatinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   - Dasatinib works by inhibiting a range of tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, EPHA2, and PDGFR\u03b2. Its ability to inhibit BCR-ABL tyrosine kinase is particularly relevant in the treatment of CML and Ph+ ALL, as this enzyme is a product of the Philadelphia chromosome mutation, a common abnormality in these leukemias.\n\n2. **Indications**:\n   - Dasatinib is approved for the treatment of all"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_HpQkkPkGy9zajlZolSOge8ZO", "custom_id": "75_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "101b3d7a60bdb71286848f60a0e33853", "body": {"id": "chatcmpl-9St9Q3ahvxIMSW9uMtjjSAGRwhwlW", "object": "chat.completion", "created": 1716672212, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is an anthracycline antibiotic that is widely used as a chemotherapeutic agent. Here are some key points you should know about daunorubicin:\n\n1. **Mechanism of Action**: Daunorubicin works primarily by intercalating DNA, disrupting the replication process and inhibiting topoisomerase II, which leads to DNA damage and cell death. It also generates free radicals, contributing to its cytotoxic effects.\n\n2. **Indications**: It is commonly used in the treatment of various cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and other hematologic cancers. It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Daunorubicin is typically administered intravenously. The dosage and schedule depend on the specific condition being treated, the patient's health status, and response to therapy.\n\n4. **Side Effects**: Like other anthr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_6upFC3fB74JuaX2zdPyjv3Ce", "custom_id": "76_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "57878cfe8c5a3f7bcf8c383770d64683", "body": {"id": "chatcmpl-9St9Rb2pih7W264z3qf4w6gKSZRQm", "object": "chat.completion", "created": 1716672213, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a form of chemotherapy drug used primarily in the treatment of specific types of cancer. It is a liposome-encapsulated form of daunorubicin, which allows for better targeting and penetration of the drug into the tumor cells, potentially reducing some of the systemic side effects associated with conventional formulations. Here are some key points you should know about Daunorubicin liposomal:\n\n### Indications\n- **Kaposi's Sarcoma**: Daunorubicin liposomal is commonly used in the treatment of AIDS-related Kaposi's sarcoma. It is indicated for patients who have low CD4 counts and extensive mucocutaneous or visceral disease.\n- **Acute Lymphoblastic Leukemia (ALL)**: It is also used in specific cases of ALL, particularly in pediatric patients.\n\n### Mechanism of Action\nDaunorubicin liposomal works by intercalating DNA, which disrupts the replication of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VgRaZOEYWboO4M8EOwQL1lkM", "custom_id": "77_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b525c3045b0fc5e30e81dca4779074ea", "body": {"id": "chatcmpl-9St9Rhkpt9IxxVNSJ0Xcos2GuAB2u", "object": "chat.completion", "created": 1716672213, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine, also known by its brand name Dacogen, is a medication primarily used in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic disorders characterized by ineffective production of blood cells. Decitabine is a hypomethylating agent, meaning it works by inhibiting DNA methylation, which can help to reactivate genes that stop abnormal cell growth. Here are some key points you should know about Decitabine:\n\n### Mechanism of Action\n- Decitabine is a nucleoside analog of cytidine that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This action can reactivate silenced genes that control cell differentiation and proliferation.\n\n### Indications\n- **Primary Indication:** Treatment of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xdWb2NgNmbBSbmagWpaTSib0", "custom_id": "78_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a094ffb5060d5b4eec090793785e639b", "body": {"id": "chatcmpl-9St9RHquSJtjdusRIDUbIiX6IFWLK", "object": "chat.completion", "created": 1716672213, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a medication used primarily in the treatment of advanced prostate cancer. It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) antagonists, which work by rapidly reducing the production of testosterone, a hormone that can promote the growth of prostate cancer cells. Here are some key points about Degarelix that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Degarelix acts by directly inhibiting the GnRH receptors in the pituitary gland, leading to a rapid decrease in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently a reduction in testosterone levels.\n\n2. **Indications**: It is approved for the treatment of advanced prostate cancer. It is particularly useful in situations where rapid reduction in testosterone levels is desired or when other hormonal therapies that initially increase testosterone levels (due to a tumor flare) are not suitable.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zEn8bGkZ9j26TS1Qs36waB92", "custom_id": "79_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b66952468098511a9e8d54d383d9171e", "body": {"id": "chatcmpl-9St9Ro5IeJfF3KTJbUsrrsIeQ4F7L", "object": "chat.completion", "created": 1716672213, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denileukin diftitox is a targeted therapy used primarily in the treatment of certain types of lymphoma, particularly cutaneous T-cell lymphoma (CTCL). It is a fusion protein that combines interleukin-2 (IL-2) with diphtheria toxin. The drug targets cells that express the IL-2 receptor, which are typically overexpressed in certain lymphocyte subsets, including those involved in CTCL.\n\nHere are some key points about Denileukin diftitox:\n\n1. **Mechanism of Action**: Denileukin diftitox binds to the IL-2 receptor on the surface of cells, which is followed by internalization of the drug-receptor complex. The diphtheria toxin portion of the molecule then inhibits protein synthesis in the cell, leading to cell death.\n\n2. **Indications**: It is approved by the FDA for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kinlbVwImjfCvP2LtBdpL8SL", "custom_id": "80_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "70010ddf80e16594c7835a1de832cc5c", "body": {"id": "chatcmpl-9St9SUgQJSWRdHAsh6VI06Lq4wRRG", "object": "chat.completion", "created": 1716672214, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is a medication used primarily in the treatment of osteoporosis and the prevention of bone fractures. It is also used in the management of bone loss associated with hormone ablation therapy in cancer patients. Here are some key points about Denosumab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Denosumab is a monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a protein essential for the formation, function, and survival of osteoclasts, which are cells responsible for bone resorption. By inhibiting RANKL, Denosumab decreases bone resorption and increases bone mass and strength.\n\n2. **Indications**:\n   - **Osteoporosis**: It is approved for use in postmenopausal women and men at high risk of fractures.\n   - **Bone Loss Related to Cancer**: It is used to prevent bone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qxS08C9vfYx6OxFm6L4ExEa9", "custom_id": "81_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "61b6fea96812460dc0f9e80d207a8b19", "body": {"id": "chatcmpl-9St9SMltGJlZdqaMN9E1YcEblW2CO", "object": "chat.completion", "created": 1716672214, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. Here are some key points you should know about dexamethasone:\n\n1. **Mechanism of Action**: Dexamethasone works by decreasing inflammation through suppression of the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It also suppresses normal immune response.\n\n2. **Indications**: It is used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. Common indications include:\n   - Cerebral edema\n   - Severe allergies and asthma\n   - Rheumatic disorders such as rheumatoid arthritis\n   - Certain autoimmune diseases like systemic lupus erythematosus\n   - Management of acute exacerbations of multiple sclerosis\n   - Prevention and treatment of nausea and vomiting associated with chemotherapy\n   - COVID-19 (for hospitalized patients requiring oxygen, including those on mechanical ventilation)\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eCF3smBFYlZeRBYaEpYBdt3o", "custom_id": "82_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36fa729446b7c52b5426297d537c7de5", "body": {"id": "chatcmpl-9St9Sd7yAuNUmAruy4UK4nzfsBmb7", "object": "chat.completion", "created": 1716672214, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a cytoprotective agent used primarily to reduce the incidence and severity of cardiotoxicity associated with certain chemotherapeutic agents, particularly anthracyclines like doxorubicin. Here are some key points you should know about dexrazoxane:\n\n1. **Mechanism of Action**: Dexrazoxane is believed to exert its cardioprotective effects by chelating iron, thereby reducing the formation of iron-mediated free radicals that contribute to cardiotoxicity. It may also inhibit topoisomerase II, although this is not its primary mechanism of action for cardioprotection.\n\n2. **Indications**:\n   - **Cardioprotection**: It is approved for use in adult patients who have received a cumulative doxorubicin dose of 300 mg/m\u00b2 and are continuing treatment with doxorubicin. It is also used in pediatric patients in certain situations, although its use in children can be controversial due to potential"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fv6ofxNkf54pE4uJx61xZp9H", "custom_id": "83_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6621a79a96e318fcb965658ca2c91623", "body": {"id": "chatcmpl-9St9T88T1C0JFjXvUnLwfQPWeIxxQ", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic estrogen that was first synthesized in 1938. It was prescribed to pregnant women between the 1940s and 1970s to prevent miscarriages, premature labor, and related complications of pregnancy. However, it was later found to be ineffective for these purposes and was subsequently linked to a variety of serious adverse health effects.\n\nHere are some key points that physicians should be aware of regarding DES:\n\n1. **Cancer Risks**: Exposure to DES has been linked to an increased risk of clear cell adenocarcinoma (CCA) of the vagina and cervix in daughters exposed in utero (commonly referred to as \"DES daughters\"). There is also some evidence suggesting increased risks of other types of cancer, such as breast cancer in DES mothers and possibly in DES daughters as they age.\n\n2. **Reproductive Issues**: Women exposed to DES in utero may have an increased risk of reproductive problems, including infertility, ect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LnVIqh33GqAH5LSMjR22ZvpO", "custom_id": "84_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a16bfc5df4322d10e53e43ae0e408eda", "body": {"id": "chatcmpl-9St9T34CMKpdzvApUFr9Q2MfVeE2k", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a monoclonal antibody used primarily in the treatment of high-risk neuroblastoma, a type of cancer that most commonly affects children. Here are some key points you should know about dinutuximab:\n\n1. **Mechanism of Action**: Dinutuximab targets the GD2 glycolipid, which is highly expressed on the surface of neuroblastoma cells. By binding to GD2, dinutuximab activates both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells.\n\n2. **Indications**: It is approved for use in pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multi-agent, multimodality therapy. Dinutuximab is often used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_C7x8JjrE4yuOKR95k8D1De8g", "custom_id": "85_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "85c8d08f55b6115ee1708be117a71d9f", "body": {"id": "chatcmpl-9St9TD8GFiyWj2z1B55wt00W1vk9F", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is a chemotherapy medication used primarily in the treatment of various cancers. It is a member of the taxane family, which also includes paclitaxel. Here are some key points about docetaxel that you, as a physician, might find useful:\n\n### Mechanism of Action\nDocetaxel works by inhibiting microtubule depolymerization in the cell, which is essential for cell division. By stabilizing the microtubule polymer and preventing its disassembly, docetaxel leads to cell cycle arrest at the G2/M phase, ultimately resulting in apoptosis (cell death).\n\n### Indications\nDocetaxel is approved for the treatment of:\n- Breast cancer\n- Non-small cell lung cancer (NSCLC)\n- Prostate cancer\n- Gastric cancer\n- Head and neck cancer\n\nIt is often used in combination with other chemotherapeutic agents depending on the specific cancer type and stage.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sOkLl441gJjSBr0GcMVAFhMw", "custom_id": "86_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5f46bfa4e40a33d433ff2c5cf9b52df", "body": {"id": "chatcmpl-9St9T2OmRxs284kChKoGbeldMhA8w", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine is a chemotherapeutic agent, primarily used in the treatment of various cancers. It is a fluoropyrimidine derivative, which is a prodrug of 5-fluorouracil (5-FU). Here are some key points you should know about doxifluridine:\n\n1. **Mechanism of Action**: Doxifluridine is converted in the body to 5-fluorouracil, which then inhibits thymidylate synthase, an enzyme involved in DNA synthesis. This results in the disruption of DNA replication and cell division, leading to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**: It is used in the treatment of various cancers, including colorectal cancer, breast cancer, and stomach cancer. Its use may vary based on regional approval and clinical guidelines.\n\n3. **Administration**: Doxifluridine is typically administered orally, which can be more convenient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RowdsLSDDTnwoHfKwnmwvIkM", "custom_id": "87_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "11cf2caa7f3da17653d37514dade27c0", "body": {"id": "chatcmpl-9St9TwSaiaMKbTelgNOCaycv5QyrT", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is a chemotherapy medication used primarily to treat various types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is an anthracycline antibiotic, functioning as an antineoplastic agent. Here are some key points you should know about doxorubicin:\n\n### Mechanism of Action\nDoxorubicin works by intercalating DNA, disrupting the function of topoisomerase II, and generating free radicals. These actions inhibit the growth of cancer cells and lead to cell death.\n\n### Administration\nDoxorubicin is typically administered intravenously, often as part of a combination chemotherapy regimen. The dosage and schedule depend on the type of cancer being treated, the purpose of the treatment (e.g., curative, adjuvant, neoadjuvant), the patient's size, and their overall health.\n\n### Side Effects\nDoxorubicin has a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nTxCYVBrv6FWJ9xbuWJbLtqM", "custom_id": "88_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "abcd21839158e890f49c9f63ef65b878", "body": {"id": "chatcmpl-9St9TUU8bml6mtI2Vcy9PcfvVW8YU", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab (brand name Imfinzi) is a monoclonal antibody that is part of a class of cancer therapies known as immune checkpoint inhibitors. It specifically targets the programmed death-ligand 1 (PD-L1), which is a protein expressed on cancer cells and tumor-infiltrating immune cells. PD-L1 on tumor cells binds to PD-1 receptors on T cells, inhibiting T cell function and allowing cancer cells to evade the immune system. By blocking this interaction, durvalumab helps to reactivate the immune response against cancer cells.\n\nHere are some key points about durvalumab:\n\n1. **Indications**: Durvalumab is approved for use in several types of cancer. It is commonly used for the treatment of locally advanced or metastatic urothelial carcinoma and for locally advanced, unresectable non-small cell lung cancer (NSCLC) following chemoradiation therapy. The specific indications can vary by country, so it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_kkmAPcBPvC6hRJvi6xlXE4Ik", "custom_id": "89_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fcac77541984f82b931509ff67c6c270", "body": {"id": "chatcmpl-9St9TSd6GfEDKd0EbMl85tTgUbUhV", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication primarily used in the treatment of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland that can cause urinary difficulties. Here are some key points about Dutasteride that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) by blocking both type I and type II 5-alpha reductase enzymes. DHT is a hormone involved in the development and enlargement of the prostate gland. By reducing DHT levels, Dutasteride helps to shrink the prostate and relieve symptoms of BPH.\n\n2. **Indications**: The primary indication for Dutasteride is the treatment of symptomatic BPH. It may also be used off-label for the treatment of male pattern baldness (androgenetic alopecia) in men, although this is more commonly treated with finasteride, a similar type of medication"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9ZAzmSJvpOM4ZG0paIevSshh", "custom_id": "90_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9190915b6815c359d9d22b95cdffb5a6", "body": {"id": "chatcmpl-9St9TeiDRxvhS6IDLAC3k2C8GPkDe", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisib is a medication used primarily in the treatment of certain hematologic malignancies. Here are some key points you should know about duvelisib:\n\n1. **Mechanism of Action**: Duvelisib is a small molecule inhibitor of phosphoinositide 3-kinase (PI3K), specifically targeting the delta and gamma isoforms. These isoforms are predominantly expressed in hematopoietic cells. By inhibiting these pathways, duvelisib disrupts the survival and proliferation of malignant B-cells and affects the tumor microenvironment.\n\n2. **Indications**: Duvelisib is approved by the FDA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. It is also indicated for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. These approvals are based on the results of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0q8ZZ5lRH6g5foo2sTFI7Tw6", "custom_id": "91_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af155f52b3a59f43e35a980ed0c0829b", "body": {"id": "chatcmpl-9St9THaIU6ArKth8yRk8dT0FFBvP6", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab (also known by its trade name, Panorex) is a monoclonal antibody that was used in the treatment of colorectal cancer. It targets the Ep-CAM (epithelial cell adhesion molecule), which is highly expressed on the surface of many cancer cells, including those in colorectal cancer. Edrecolomab is a murine antibody, meaning it is derived from mouse cells.\n\n### Clinical Use and Efficacy\nEdrecolomab was primarily investigated for its potential to treat colorectal cancer, particularly in the adjuvant setting to prevent recurrence after surgical resection of the tumor. However, its clinical use has been limited due to mixed results in clinical trials:\n\n1. **Early Trials**: Initial studies showed some promise in reducing the risk of cancer recurrence when used as an adjuvant therapy in patients with stage III colorectal cancer.\n   \n2. **Subsequent Trials**: Later, larger-scale clinical trials did not demonstrate a significant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tIIcPwRjBV1Dc5DIT5Y8AzpC", "custom_id": "92_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b9fd1f11939a9baa01507444ea045282", "body": {"id": "chatcmpl-9St9TAxV8fg932ZRmjXnBg4gj3CJV", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab (brand name Empliciti) is a monoclonal antibody used in the treatment of multiple myeloma. Here are some key points you should know about elotuzumab:\n\n1. **Mechanism of Action**: Elotuzumab specifically targets the SLAMF7 protein (Signaling Lymphocytic Activation Molecule Family member 7), which is highly expressed on myeloma cells and natural killer cells. It works by directly activating natural killer cells and by targeting myeloma cells for destruction by the immune system.\n\n2. **Indications**: Elotuzumab is approved for use in combination with other medications such as lenalidomide and dexamethasone, or with bortezomib and dexamethasone, for the treatment of multiple myeloma in patients who have received one to three prior therapies.\n\n3. **Administration**: Elotuzumab is administered via intravenous infusion."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yP8U9ds4Gm109Dg7HvY9bYcm", "custom_id": "93_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba2fa78955c389d5251c318b3facea52", "body": {"id": "chatcmpl-9St9TqSbILKSBESjJREqFmAFOMEFu", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib (brand name Idhifa) is an important medication that you, as a physician, should be familiar with if you are treating patients with certain types of cancer. Here are some key points about Enasidenib:\n\n1. **Mechanism of Action**: Enasidenib is an inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme. Mutations in the IDH2 gene are found in various types of cancer, leading to abnormal cell proliferation. Enasidenib targets and inhibits the mutant IDH2 enzyme, which helps in reducing the abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), thereby promoting the differentiation of malignant cells.\n\n2. **Indications**: Enasidenib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LKbT6MK9E7Uwj5LIs3r7o3gv", "custom_id": "94_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d825118111e1e7e299f4b566cb67a7a", "body": {"id": "chatcmpl-9St9Tr4KpH0EQxo219FDUCcWRdga4", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Encorafenib (brand name Braftovi) is a medication used in oncology, primarily for the treatment of melanoma and other cancers that harbor specific genetic mutations. Here are some key points you should know about Encorafenib:\n\n1. **Mechanism of Action**: Encorafenib is a kinase inhibitor that specifically targets and inhibits the activity of BRAF V600E kinase. This mutation leads to the activation of the MAPK signaling pathway, which promotes cancer cell growth. By inhibiting this kinase, Encorafenib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**:\n   - **Melanoma**: Encorafenib, in combination with binimetinib (a MEK inhibitor), is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n   - **Colorectal Cancer**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FnFxU4c1Vkn5ODb759eHDwUg", "custom_id": "95_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "78832859d103cdb9041c9998f627dc4b", "body": {"id": "chatcmpl-9St9Tw5CoswmyPXIGGCvWHHd1Bowl", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib is a targeted therapy drug used in oncology, particularly for treating cancers that have specific genetic abnormalities. Here are some key points you should know about entrectinib:\n\n1. **Mechanism of Action**: Entrectinib is a tyrosine kinase inhibitor that targets NTRK1, NTRK2, NTRK3 (neurotrophic tyrosine receptor kinase genes), ROS1, and ALK (anaplastic lymphoma kinase) gene fusions. By inhibiting these kinases, entrectinib can block the growth and spread of cancer cells.\n\n2. **Indications**:\n   - **NTRK Fusion-Positive Tumors**: Entrectinib is approved for the treatment of adult and pediatric patients (12 years and older) with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Fb4DXbrGMs6jCma4xhpNs9Ea", "custom_id": "96_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0f576feabf5f6a9e576d40895a206144", "body": {"id": "chatcmpl-9St9TsYgKekKMYCGSHSn4UVk7J17H", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is a medication primarily used in the treatment of prostate cancer. Here are some key points you should know about enzalutamide:\n\n1. **Mechanism of Action**: Enzalutamide is an androgen receptor inhibitor. It works by binding to the androgen receptors and inhibiting the action of androgens (such as testosterone), which can promote the growth of prostate cancer cells.\n\n2. **Indications**: It is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and also for non-metastatic castration-resistant prostate cancer. It has shown to improve survival and delay the progression of the disease in these settings.\n\n3. **Administration**: Enzalutamide is administered orally, typically at a dose of 160 mg once daily, and can be taken with or without food.\n\n4. **Side Effects**: Common side effects include fatigue, back pain, hot flushes, hypertension, diarrhea"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_S6qb3T13GOdoxhQdLgXJJ3Ku", "custom_id": "97_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "486faf542928b59d1dbe7d345b7b2ebc", "body": {"id": "chatcmpl-9St9T055IHPZaMCCBJUqlIjIzey9F", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin is an anthracycline antibiotic that is widely used as a chemotherapeutic agent. Here are some key points you should know about Epirubicin:\n\n1. **Mechanism of Action**: Epirubicin works primarily by intercalating DNA strands. It inhibits the progression of the enzyme topoisomerase II, which is necessary for DNA replication. This causes DNA damage and induces apoptosis in dividing cells.\n\n2. **Indications**: Epirubicin is commonly used in the treatment of various cancers, including breast cancer, ovarian cancer, gastric cancer, and others. It is often used in combination with other chemotherapeutic agents.\n\n3. **Administration**: Epirubicin is administered intravenously. The dosage and schedule depend on the type of cancer, the purpose of the treatment (adjuvant, neoadjuvant, palliative), the patient's body surface area, and overall health status.\n\n4. **Pharmacokinetics**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_queAVtIf705hwT4Ms4MRuhgr", "custom_id": "98_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af0c97a7249c0e012b158a98aabc205b", "body": {"id": "chatcmpl-9St9TxL9DsKA4GcTquX9QACLbhpUD", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib is a targeted therapy drug used primarily in the treatment of urothelial carcinoma. Here are some key points you should know about erdafitinib:\n\n1. **Mechanism of Action**: Erdafitinib is a small molecule kinase inhibitor specifically targeting the fibroblast growth factor receptor (FGFR) family, which includes FGFR1, FGFR2, FGFR3, and FGFR4. The inhibition of FGFR kinases leads to the blocking of FGFR signaling pathways that drive cell viability in FGFR-altered cancers.\n\n2. **Indications**: It is approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and who have progressed during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n3. **Efficacy**: Clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_0GXuUWkJh6nVUZoJnqdab2GR", "custom_id": "99_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef0f202334c1212d5c479b61729cad0d", "body": {"id": "chatcmpl-9St9TFooMm8swmcGeUg0qwkF63XqU", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin mesylate, marketed under the brand name Halaven, is a chemotherapeutic agent used primarily in the treatment of cancer. Here are some key points you should know about eribulin:\n\n1. **Mechanism of Action**: Eribulin is a microtubule dynamics inhibitor. It works by inhibiting the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its anticancer effects by triggering apoptosis of cancer cells following prolonged and irreversible mitotic blockade.\n\n2. **Indications**: Eribulin is approved for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane, unless patients were not suitable for these treatments. It is also approved for the treatment of liposarcoma in patients who have received a prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QsR3k0HqzGbutEUXSiE8OtVq", "custom_id": "100_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4347852e0fa09184b1a124a63ddfbe12", "body": {"id": "chatcmpl-9St9Tr17EOUIV8UY2MUO5vQnCjuUG", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points you should know about erlotinib:\n\n1. **Mechanism of Action**: Erlotinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds reversibly to the ATP binding site of the receptor, thus inhibiting the intracellular phosphorylation of tyrosine kinase associated with the receptor. This inhibition blocks the signal transduction events that lead to DNA synthesis and cell proliferation.\n\n2. **Indications**:\n   - **Non-small cell lung cancer (NSCLC)**: Erlotinib is approved for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. It is particularly effective in patients whose tumors express EGFR mutations.\n   - **Pancreatic cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LXTOI847xkbr9aBOJqAzTDeA", "custom_id": "101_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "648f9a29684323bd8b60a08c9427e1f9", "body": {"id": "chatcmpl-9St9THBREkfnzn9hmM54yBei3YPcc", "object": "chat.completion", "created": 1716672215, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Estramustine is a chemotherapy drug primarily used in the treatment of prostate cancer. It combines the properties of an estrogen and a nitrogen mustard derivative, which allows it to act as both a hormone therapy and a chemotherapeutic agent. Here are some key points you should know about estramustine:\n\n1. **Mechanism of Action**: Estramustine is unique in that it targets microtubule-dependent processes by binding to microtubule-associated proteins, disrupting the microtubule network, and thereby inhibiting mitosis in rapidly dividing cells. Additionally, due to its estrogen component, it can bind to estrogen receptors, exerting antitumor effects on hormone-sensitive tissues.\n\n2. **Indications**: It is primarily used for the treatment of metastatic or progressive prostate cancer, particularly in patients who have not responded to other forms of treatment.\n\n3. **Administration**: Estramustine is typically administered orally in capsule form. The dosage and treatment regimen depend on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KLwBpVxQDhYmFXGVVahZX6XW", "custom_id": "102_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "88d0c45a0450aa45d3a72acc839df22f", "body": {"id": "chatcmpl-9St9US7LiIg1PnSCg68ujhs3I6Snj", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is a chemotherapeutic agent used primarily in the treatment of various types of cancer. It is classified as a topoisomerase II inhibitor, which means it works by preventing DNA replication in cancer cells, leading to cell death. Here are some key points about etoposide that you, as a physician, might find useful:\n\n### Mechanism of Action\n- **Topoisomerase II inhibition:** Etoposide forms a ternary complex with DNA and the topoisomerase II enzyme, leading to breaks in the DNA strands. This interrupts the DNA repair mechanisms and leads to cell death, particularly affecting rapidly dividing cells such as cancer cells.\n\n### Indications\n- **Testicular cancer:** Often used in combination with other drugs for the treatment of testicular cancer.\n- **Small cell lung cancer (SCLC):** It is commonly used in the treatment of SCLC, both as first-line treatment and in recurrent cases.\n- **Lymph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_UL7SfyxuuXNReK6i4MYDZfoJ", "custom_id": "103_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4674ca94204aca17e22872a0c141453", "body": {"id": "chatcmpl-9St9Uk8366909YdLXcRJNWaLgZNX5", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is a medication used in various clinical settings, primarily for its immunosuppressive and antiproliferative properties. Here are some key points about Everolimus that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Everolimus works by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase. This inhibition leads to a decrease in the activity of effector T cells and the proliferation of B cells, which can help in reducing the immune response and the proliferation of cancer cells.\n\n2. **Indications**:\n   - **Transplant Rejection Prevention**: Everolimus is used to prevent organ rejection in kidney and liver transplant patients. It is often used in combination with other immunosuppressants such as cyclosporine and corticosteroids.\n   - **Oncology**: It is approved for the treatment of various types of cancers, including advanced renal cell carcinoma, progressive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BuqYNsJGnHykaEtW4k41Uxah", "custom_id": "104_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "04c866ecc1dbdc6e34357d432a8106e5", "body": {"id": "chatcmpl-9St9U7bbN6cmmhHbkGawYNAwAZZTp", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane, marketed under the brand name Aromasin among others, is a medication used in the treatment of breast cancer. It is specifically indicated for postmenopausal women with estrogen-receptor positive breast cancer. Here are some key points about Exemestane that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Exemestane is a steroidal aromatase inhibitor. It works by irreversibly binding to the aromatase enzyme, which is responsible for converting androgens to estrogens. By inhibiting this enzyme, Exemestane reduces estrogen levels in the body, which can help slow the growth of certain types of breast tumors that need estrogen to grow.\n\n2. **Indications**: It is primarily used for the treatment of estrogen-receptor positive breast cancer in postmenopausal women. It is often administered following initial treatment (e.g., surgery, chemotherapy, radiation) and after 2-3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aoQiwwJd6UrVqPRbs97Zu2Gz", "custom_id": "105_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "08770aa5ef0d8b6451f3d9966dc25481", "body": {"id": "chatcmpl-9St9UDZFF5io3P5HCKCWDLCh5ESZ3", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine, also known by its brand name FUDR, is a chemotherapeutic agent primarily used in the treatment of cancer. It is a fluorinated pyrimidine analog, which classifies it as an antimetabolite. Here are some key points you should know about Floxuridine:\n\n1. **Mechanism of Action**: Floxuridine works by interfering with the synthesis of DNA, thus inhibiting the growth of rapidly dividing cancer cells. It is metabolized into fluorouracil in the body and then further into active metabolites that incorporate into RNA and DNA to exert cytotoxic effects.\n\n2. **Indications**: Floxuridine is most commonly used in the treatment of metastatic colorectal cancer, particularly when the cancer has spread to the liver. It is often administered via hepatic arterial infusion, which allows high concentrations of the drug to be delivered directly to the liver while minimizing systemic exposure and toxicity.\n\n3. **Administration**: It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qBHOraSWk17TNfIJuvzpYrjl", "custom_id": "106_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "954b06bf55191582dbf212b2fa4fdcb0", "body": {"id": "chatcmpl-9St9Ulwu68PiuOqeqA5pPbgS2mY3k", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fludarabine is a chemotherapy medication primarily used to treat hematological malignancies, particularly chronic lymphocytic leukemia (CLL). Here are some key points about fludarabine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Fludarabine is a purine analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase, leading to cell death. It is more active in non-dividing cells than in dividing cells, making it particularly effective against slow-growing cancers like CLL.\n\n2. **Indications**: The primary indication for fludarabine is the treatment of B-cell chronic lymphocytic leukemia (CLL), especially in patients who have not responded to initial treatment. It may also be used in treating other hematological cancers such as non-Hodgkin lymphoma.\n\n3. **Administration**: Fludarabine is administered intravenously, typically over"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tf6lnblUitiPT0a63fwApfRb", "custom_id": "107_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4bb598f28c384f2620c1b79ffe34b58", "body": {"id": "chatcmpl-9St9UEz8KK5C6ywbWzoIm8OzpM8ss", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil (5-FU) is a chemotherapy medication used to treat various types of cancer, including cancers of the colon, esophageal, stomach, pancreatic, breast, and skin (particularly basal cell carcinoma and actinic keratosis). Here are some key points about Fluorouracil that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Fluorouracil belongs to the class of drugs known as antimetabolites. It works by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis, leading to the disruption of DNA replication and cell death, particularly in rapidly dividing cancer cells.\n\n2. **Administration**: Fluorouracil can be administered intravenously, topically, or as an injection into a vein or artery, depending on the type and location of the cancer being treated. The dosage and schedule depend on the patient's condition, body size, and response to therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_oVv0JP2OMSl98atb4CB9eGda", "custom_id": "108_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e3f0aba28e45f041432ae27e4f87623", "body": {"id": "chatcmpl-9St9UdU0WI2qxX8bF0LcXGQCjeni2", "object": "chat.completion", "created": 1716672216, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone is an anabolic androgenic steroid (AAS) used primarily in the treatment of low testosterone levels in men. It is also used for treating breast cancer in women and, occasionally, for increasing hemoglobin and red cell mass in patients with anemia due to bone marrow failure. Here are some key points you should know about fluoxymesterone:\n\n1. **Indications**: Fluoxymesterone is indicated for replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. It is also used in certain adolescent boys to cause puberty in those with delayed puberty. It may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal.\n\n2. **Mechanism of Action**: Fluoxymesterone is a synthetic derivative of testosterone, modifying the structure to increase its anabolic properties and reduce its androgenic effects. However,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lUPtKjS9oeUt04tmXXH0DDUE", "custom_id": "109_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e001fcfd37443d5931e1f5f8d6c43af3", "body": {"id": "chatcmpl-9St9Vmcx6E4pxOVMo5i7pjFmpyHsW", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points about Flutamide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Flutamide acts as a selective antagonist of the androgen receptor (AR), thereby inhibiting androgen (such as testosterone and dihydrotestosterone) action. This inhibition interferes with the growth stimulus that androgens provide to prostate cancer cells.\n\n2. **Indications**:\n   - **Prostate Cancer**: Flutamide is most commonly used in the management of advanced prostate cancer, particularly in combination with a gonadotropin-releasing hormone (GnRH) agonist or surgical castration to achieve maximal androgen blockade.\n   - It may also be used off-label for other conditions influenced by androgens, such as hirsutism in women.\n\n3. **Administration**: Flutamide is administered orally and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4YEAWU6if2BNwFaqpxeIUlLN", "custom_id": "110_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4aa2e687a32a2725d6eb1b517578179a", "body": {"id": "chatcmpl-9St9VodRsZPVLD8088QbNDPAuM5k3", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a medication and a form of folate (vitamin B9) that is used to promote cell growth and replication. Here are some key points you should know about folinic acid:\n\n1. **Uses**: Folinic acid is primarily used to:\n   - Reduce the toxic effects of methotrexate, a chemotherapy agent, by rescuing normal cells from the effects of methotrexate-induced folate antagonism.\n   - Enhance the efficacy of fluorouracil, another chemotherapy drug, in the treatment of colorectal cancer.\n   - Treat certain types of anemia (megaloblastic anemia) caused by folate deficiency, though it is not typically used for common folate deficiency.\n\n2. **Mechanism of Action**: Unlike folic acid, folinic acid does not require reduction by dihydrofolate reductase to be converted to tetrahydrofolate, the active form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XkHMCsGTSPyG3PuyZvPOENgB", "custom_id": "111_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ecf6e6cb06b4a51640c353c9a410a49a", "body": {"id": "chatcmpl-9St9VaIIFo55MlE6Tua3bO1j1Dbh5", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane, chemically known as 4-hydroxyandrostenedione, is a type I steroidal aromatase inhibitor. It was primarily used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. This reduction in estrogen levels is beneficial in treating hormone-sensitive breast cancers.\n\nHere are some key points about Formestane:\n\n1. **Mechanism of Action**: Formestane inhibits the aromatase enzyme, leading to a significant reduction in estrogen biosynthesis. This is particularly useful in cancers that grow in response to estrogen.\n\n2. **Administration**: Originally, formestane was available for oral administration, but it was not very effective this way due to poor bioavailability. It was later developed as an intramuscular depot injection, which proved to be more effective.\n\n3. **Side Effects**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zOfljsb50nOPO9T9SqGbI2m9", "custom_id": "112_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa61ce1dd9691014a46c569763e76da1", "body": {"id": "chatcmpl-9St9VXmK6wArTK0tJMU6gj4I5pW4a", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine is an investigational drug primarily studied for its potential use in treating certain types of cancer, particularly hematological malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about Forodesine:\n\n1. **Mechanism of Action**: Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor. By inhibiting PNP, forodesine causes an increase in deoxyguanosine triphosphate (dGTP) and a decrease in guanine-based nucleotides, leading to apoptosis of lymphocytes. This is particularly effective in malignant T-cells which are more sensitive to the toxic effects of dGTP accumulation.\n\n2. **Clinical Trials**: Forodesine has been evaluated in several clinical trials, particularly in patients with relapsed or refractory T-cell leukemia and lymphoma. The results have shown some promise, but as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zHhjh6DApvwTuXQgTI5wf1LU", "custom_id": "113_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b66804116d632d1bd75c65537baaa6f", "body": {"id": "chatcmpl-9St9VTnhdOyu1AE2eTO9yaDSKgbbd", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is a medication used primarily in the treatment of chronic immune thrombocytopenia (ITP), a condition where the immune system attacks and destroys platelets, leading to bleeding and easy bruising. Here are some key points about Fostamatinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor. SYK is a key enzyme in the signaling pathways of B cells and macrophages, which are involved in the immune destruction of platelets in ITP. By inhibiting SYK, Fostamatinib reduces the destruction of platelets.\n\n2. **Indications**: It is approved for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment. It is not typically a first-line treatment but is considered when other treatments have failed or are contraindicated.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Wd1KRFYGYSfNyfxnve3l8KX7", "custom_id": "114_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7221d07a13657f53fb595ab6bd186998", "body": {"id": "chatcmpl-9St9VdPWmTogUX6K8Vb4dakfCbQrG", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is a nitrosourea compound used primarily in the treatment of metastatic melanoma, particularly when the disease has spread to the brain. It is also used in the treatment of certain other cancers, such as malignant glioma and Hodgkin\u2019s lymphoma. Here are some key points about fotemustine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Fotemustine acts as an alkylating agent. It interferes with the growth of cancer cells by cross-linking DNA strands and inhibiting DNA synthesis, which ultimately leads to cell death.\n\n2. **Administration**: Fotemustine is administered intravenously. The dosing regimen can vary depending on the specific condition being treated and the protocol being followed.\n\n3. **Pharmacokinetics**: Fotemustine has a unique ability among nitrosoureas to cross the blood-brain barrier, which makes it particularly useful in treating brain metastases from"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_45t2b54Eo6g0hJuzyyfJ5rws", "custom_id": "115_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4fe7b15775b8a73345aa59582132ead1", "body": {"id": "chatcmpl-9St9VpJ2qzS19ABt5h7oVYaRdaiaJ", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestrant is a medication used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Here are some key points about Fulvestrant that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Fulvestrant is a selective estrogen receptor degrader (SERD). It binds to the estrogen receptor (ER) with a high affinity, leading to the degradation of the estrogen receptor and thus inhibiting the proliferative action of estrogen on breast cancer cells. This mechanism is distinct from that of aromatase inhibitors and selective estrogen receptor modulators (SERMs).\n\n2. **Indications**:\n   - It is primarily used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women.\n   - It is also used for disease progression following antiestrogen therapy, and in some cases, it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KaYA2cq3Mf6aCpUcv1EffzBo", "custom_id": "116_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d1e8642e730bd56a75985d993d8db572", "body": {"id": "chatcmpl-9St9Vx64TGwjstDGtnMXFh9JIkCi0", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is a targeted therapy drug used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points about Gefitinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It works by blocking the tyrosine kinase enzyme in the EGFR pathway, which is involved in the growth and spread of cancer cells. By inhibiting this pathway, Gefitinib helps to stop or slow the growth of cancer.\n\n2. **Indications**: Gefitinib is approved for the treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Testing for EGFR mutation status is essential before initiating treatment with Gefitinib.\n\n3. **Administration**: Gefitinib is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s3HrHGOcl6MemLpBWpIBbpeN", "custom_id": "117_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a8984f943679bab88e22b3ec54e22762", "body": {"id": "chatcmpl-9St9Vdia6QtqoWQMTlVzFRFQiowl1", "object": "chat.completion", "created": 1716672217, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine is a chemotherapy drug used primarily in the treatment of various cancers, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer. It is a nucleoside analog, which means it interferes with DNA synthesis, ultimately inhibiting cell replication. Here are some key points about gemcitabine that you, as a physician, might find useful:\n\n### Mechanism of Action\nGemcitabine is a cytidine analog. After entering the cells, it gets phosphorylated to gemcitabine diphosphate and triphosphate forms. These active forms incorporate into DNA during the S phase of the cell cycle, causing chain termination and preventing DNA synthesis, which leads to cell death.\n\n### Indications\n- **Pancreatic Cancer:** It is used as a first-line treatment for locally advanced or metastatic pancreatic cancer and in adjuvant settings.\n- **Non-Small Cell Lung Cancer (NSCLC):** Used as a single"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Btc3RTgZCf62ttbgtqewjaRC", "custom_id": "118_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "15b00cf0ece59296f188a42914da6bce", "body": {"id": "chatcmpl-9St9WIXpEoB5EjPtfHQ2MAJ2UOboA", "object": "chat.completion", "created": 1716672218, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is an important drug used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about this medication:\n\n1. **Mechanism of Action**: Gemtuzumab ozogamicin is a monoclonal antibody-drug conjugate. The monoclonal antibody (gemtuzumab) targets CD33, an antigen expressed on the surface of leukemic cells in most types of AML. The drug is conjugated to ozogamicin, a cytotoxic antitumor antibiotic (a derivative of calicheamicin). Once the conjugate binds to the CD33 antigen, it is internalized and the cytotoxic agent is released inside the cell, leading to cell death.\n\n2. **Indications**: It is approved for the treatment of newly diagnosed CD33-positive AML in adults, as well as for relapsed or refractory CD33-positive AML in adults and pediatric patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3qBvODSjp2ecbzFmjr01DKOv", "custom_id": "119_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d6752ade0d5ba5a0f62225c6408fa4a4", "body": {"id": "chatcmpl-9St9WwJmuaMdjgZzxKaAxnoE7860N", "object": "chat.completion", "created": 1716672218, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib, marketed under the brand name Xospata, is an oral medication used for the treatment of acute myeloid leukemia (AML) with specific genetic mutations. Here are some key points you should know about gilteritinib:\n\n1. **Indications**: Gilteritinib is specifically indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test. FLT3 (FMS-like tyrosine kinase 3) mutations are one of the most common genetic abnormalities in AML and are associated with a poor prognosis.\n\n2. **Mechanism of Action**: Gilteritinib is a tyrosine kinase inhibitor that targets FLT3 mutations. It inhibits the FLT3 receptor signaling and proliferation in leukemic cells that express FLT3-ITD (internal tandem duplication) or FLT3-TKD (tyrosine kinase domain) mutations.\n\n3. **Efficacy**: Clinical trials,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wxiVR1CxtYO5STDbU98Gth4J", "custom_id": "120_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48f086f7ae244fe3208573a6ce9b0b09", "body": {"id": "chatcmpl-9St9WjoIIKNgqDCS5AMG5o4FUF7SX", "object": "chat.completion", "created": 1716672218, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Glasdegib, marketed under the brand name Daurismo, is a medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Glasdegib:\n\n1. **Mechanism of Action**: Glasdegib works by inhibiting the smoothened (SMO) receptor, which is a component of the hedgehog signaling pathway. This pathway is involved in the regulation of cell differentiation, tissue polarity, and stem cell maintenance. Aberrant activation of the hedgehog pathway has been implicated in the pathogenesis of various cancers, including AML.\n\n2. **Indications**: Glasdegib is approved for use in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n3. **Efficacy**: Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_d0CSb8OOS8eIMiVuMh9O3eb5", "custom_id": "121_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a1b1a42d5a5b81111831ce9caf2e75d", "body": {"id": "chatcmpl-9St9W8JTuS3lbuuIRKAplxXRHmcW0", "object": "chat.completion", "created": 1716672218, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Goserelin is a medication used primarily in the treatment of hormone-sensitive cancers such as prostate cancer in men and breast cancer in women, as well as for certain benign gynecological disorders. It is a type of drug known as a gonadotropin-releasing hormone (GnRH) agonist, which acts by initially increasing and then subsequently decreasing the production of certain hormones (estrogen and testosterone) in the body. Here are some key points you should know about Goserelin:\n\n### Mechanism of Action\n- Goserelin works by overstimulating the body's production of certain hormones, which leads to a temporary increase in hormone levels (flare phenomenon). After this initial phase, the production of these hormones is significantly reduced (chemical castration).\n- The drug is administered as a slow-release formulation via a subcutaneous implant.\n\n### Indications\n- **Prostate Cancer:** Used for the management of advanced prostate cancer. It helps in reducing the production of testosterone,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SldvSUyZ0ACKkTkGNorZUtYh", "custom_id": "122_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb8538b53786b5fada2b6a0423d7b201", "body": {"id": "chatcmpl-9St9ZObjNAp1ppTp4nNue13zoCoxP", "object": "chat.completion", "created": 1716672221, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Histrelin is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. It is a synthetic analog of naturally occurring GnRH, a hormone that regulates the release of sex hormones, such as testosterone and estrogen, from the gonads. Here are some key points about Histrelin that you, as a physician, might find useful:\n\n### Indications\n1. **Central Precocious Puberty (CPP)**: Histrelin is used for the treatment of children with central precocious puberty, which is the premature development of sexual characteristics before the age of 8 in girls and 9 in boys.\n2. **Prostate Cancer**: In adults, Histrelin is used for the palliative treatment of advanced prostate cancer. It helps to decrease the production of testosterone, which can slow the growth of prostate cancer cells.\n\n### Mechanism of Action\nHistrelin works by initially stimulating the pituitary gland"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GzS1rnfxBi42qhTHaHURFCuq", "custom_id": "123_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "369aa54aab40d5087829310dd1b9a5a0", "body": {"id": "chatcmpl-9St9XSoase3yaVOs0RJMCLIWiHHsq", "object": "chat.completion", "created": 1716672219, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydrocortisone is a corticosteroid medication used in a wide range of conditions for its anti-inflammatory and immunosuppressive properties. Here are some key points you should know about hydrocortisone:\n\n1. **Mechanism of Action**: Hydrocortisone works by mimicking the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability. It also suppresses the immune response.\n\n2. **Indications**: Hydrocortisone is used to treat a variety of conditions, including:\n   - Adrenal insufficiency (e.g., Addison's disease)\n   - Inflammatory conditions (e.g., arthritis, lupus, and psoriasis)\n   - Allergic reactions\n   - Asthma and COPD exacerbations\n   - Skin conditions (e.g., eczema, dermatitis)\n   - Some types of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iWiBFwnDhvWeXYZd3cYm4SPb", "custom_id": "124_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f8d6abc6684cad835291c905c656246a", "body": {"id": "chatcmpl-9St9XJA2duLHj2sTR4axr5oSHb9WS", "object": "chat.completion", "created": 1716672219, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxyurea is a medication used primarily to treat several conditions related to blood cells. Here are some key points you should know about hydroxyurea, especially if you are a physician prescribing this medication:\n\n1. **Indications**:\n   - **Sickle Cell Disease**: Hydroxyurea is used to reduce the frequency of painful crises and to decrease the need for blood transfusions in adults and children with sickle cell anemia.\n   - **Chronic Myeloid Leukemia (CML)**: It is used in the management of chronic myeloid leukemia.\n   - **Polycythemia Vera**: Hydroxyurea is used to reduce the red blood cell mass.\n   - **Essential Thrombocythemia**: It is used to reduce platelet count and control the risk of thrombosis.\n   - **Myelofibrosis**: It can be used to manage symptoms and improve blood counts.\n\n2. **Mechanism of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fCYOBGbDxcA7rQmJJycPl7Gh", "custom_id": "125_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a4e8fa0aa6f056cfa0727037e43c8435", "body": {"id": "chatcmpl-9St9X5L9xhICQDEl8tO5dDdXUUNKS", "object": "chat.completion", "created": 1716672219, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan, marketed under the brand name Zevalin, is a radioimmunotherapy drug used primarily in the treatment of non-Hodgkin's lymphoma (NHL). It is a monoclonal antibody that targets the CD20 antigen on the surface of normal and malignant B cells. Here are some key points you should know about ibritumomab tiuxetan:\n\n1. **Mechanism of Action**: Ibritumomab tiuxetan is a conjugate of the monoclonal antibody ibritumomab and the chelator tiuxetan, which binds to the radioactive isotope yttrium-90 or indium-111. The antibody targets CD20-positive cells, and the bound radioisotope delivers beta radiation directly to the targeted cells and nearby lymphoma cells, leading to cell death.\n\n2. **Indications**: It is approved for the treatment of relapsed or refractory, low"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wiPOsBm6DLRfOoXtFyYCf4Ya", "custom_id": "126_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "15b6de8548341df1709815b025dcce50", "body": {"id": "chatcmpl-9St9YbomKJ8FnFsw15TLqlCOMv92l", "object": "chat.completion", "created": 1716672220, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about ibrutinib as a physician:\n\n1. **Mechanism of Action**: Ibrutinib is a tyrosine kinase inhibitor that selectively inhibits Bruton's tyrosine kinase (BTK). BTK is a crucial enzyme in the B-cell receptor signaling pathway, which plays an important role in the survival and proliferation of B lymphocytes. By inhibiting BTK, ibrutinib effectively blocks the growth and survival of B cells.\n\n2. **Indications**: Ibrutinib is approved for the treatment of several types of B-cell malignancies, including:\n   - Chronic lymphocytic leukemia (CLL)\n   - Small lymphocytic lymphoma (SLL)\n   - Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy\n   - Walden"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rt10CY3HPc3hUK22XSzRck76", "custom_id": "127_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba1e8d3f5d9ada655a9297314207a3cc", "body": {"id": "chatcmpl-9St9ZhPC517AmsbsFEKkPDHZnZrx4", "object": "chat.completion", "created": 1716672221, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is a small molecule tyrosine kinase inhibitor (TKI) specifically designed to target the epidermal growth factor receptor (EGFR), which is a critical component in the signaling pathways that regulate cell growth and survival. Here are some key points about Icotinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Icotinib selectively inhibits the tyrosine kinase activity of EGFR, which leads to the blockade of EGFR signaling pathways involved in the proliferation and survival of cancer cells.\n\n2. **Indications**: Icotinib is primarily used for the treatment of non-small cell lung cancer (NSCLC), particularly in patients who have specific mutations in the EGFR gene. These mutations increase the activity of the receptor, leading to enhanced growth and survival of the tumor.\n\n3. **Efficacy**: Clinical trials have shown that Icotinib is effective in improving progression-free survival in patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BfXOOhKlvTsvwj50UegCZolF", "custom_id": "128_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d5fcc5bfa2f24a5bbe06542200bdfb88", "body": {"id": "chatcmpl-9St9ZvXEbprBuminF1wKmamo26ved", "object": "chat.completion", "created": 1716672221, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an anthracycline antineoplastic agent commonly used in the treatment of various cancers, most notably acute myeloid leukemia (AML). Here are some key points about Idarubicin that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Idarubicin acts primarily by intercalating DNA strands. It inhibits the enzyme topoisomerase II, which is essential for DNA replication and transcription. This leads to DNA damage and ultimately cell death. Idarubicin also generates free radicals, contributing to its cytotoxic effects.\n\n2. **Indications**:\n   - Primarily used for the treatment of acute myeloid leukemia (AML).\n   - It may also be used in other types of leukemia and lymphomas, depending on the specific case and in combination with other chemotherapeutic agents.\n\n3. **Administration**:\n   - Idarubicin is administered intravenously. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FVA26SgT9I2FvoiTNKD6zttN", "custom_id": "129_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2859e3affb972658b2a9319880df493e", "body": {"id": "chatcmpl-9St9aQxL7YnOwAODs6H9VowxByEfp", "object": "chat.completion", "created": 1716672222, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib, marketed under the brand name Zydelig, is a medication used in the treatment of certain hematological cancers. It is specifically indicated for use in patients with chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL), particularly in cases where the disease has relapsed. Here are some key points about Idelalisib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Idelalisib is a selective inhibitor of the enzyme phosphoinositide 3-kinase delta (PI3K\u03b4). PI3K\u03b4 plays a critical role in the activation, proliferation, and survival of B cells. By inhibiting this enzyme, Idelalisib disrupts signaling pathways essential for B-cell malignancy growth and survival.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GBrYbqDjWZDtn7twwVRWB03Q", "custom_id": "130_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad489dbb6e8554008a21668c26b939c5", "body": {"id": "chatcmpl-9St9bNKoxAGTf5CE9aWYXheyEnLwR", "object": "chat.completion", "created": 1716672223, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ifosfamide is a chemotherapy medication used primarily to treat various types of cancer, including testicular cancer, sarcomas (such as soft tissue sarcoma), and some lymphomas. It is an alkylating agent, which works by interfering with the growth of cancer cells, ultimately leading to cell death. Here are some key points about ifosfamide that you, as a physician, should be aware of:\n\n### Mechanism of Action\nIfosfamide is similar in structure and function to cyclophosphamide. It requires metabolic activation by liver enzymes to form its active metabolites. These metabolites alkylate DNA and RNA, which disrupts the growth of cancer cells by causing cross-linking of DNA strands, abnormal base pairing, or strand breaks.\n\n### Indications\n- **Testicular cancer**: Often used in combination with other chemotherapy agents.\n- **Sarcomas**: Including osteosarcoma, Ewing sarcoma, and soft tissue sarcom"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5WHWBmXPM3VqeQWWDDHfVHtC", "custom_id": "131_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5ddb32e09c7fcf072d1ecef780237997", "body": {"id": "chatcmpl-9St9dnuG6MQNrndPx0TY09JyPXNuB", "object": "chat.completion", "created": 1716672225, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib (also known by its brand name Gleevec among others) is a crucial medication used primarily in the treatment of certain types of cancer. It is most notably used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib represents a class of drugs known as tyrosine kinase inhibitors, which function by specifically targeting and inhibiting certain protein kinases involved in the growth of cancer cells.\n\n### Key Points for Physicians:\n\n#### Mechanism of Action:\n- Imatinib works by inhibiting the activity of specific tyrosine kinases, including BCR-ABL, c-KIT, and PDGF receptors. In CML, the BCR-ABL tyrosine kinase is produced by the Philadelphia chromosome abnormality, which is essential for the proliferation of leukemic cells.\n\n#### Indications:\n- **Chronic Myeloid Leukemia (CML):** Particularly effective in the chronic phase of CML and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ox9Wyfba3SVmZswulVzpQX8o", "custom_id": "132_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a63eca5df99971650858bea21800f9d0", "body": {"id": "chatcmpl-9St9d1qpkf1VcYMrKcJA1IaGw1Ge9", "object": "chat.completion", "created": 1716672225, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib is a targeted therapy used in the treatment of cancer, specifically designed to inhibit certain tyrosine kinases. Here are some key points you should know about Infigratinib:\n\n1. **Mechanism of Action**: Infigratinib is a kinase inhibitor that primarily targets fibroblast growth factor receptors (FGFRs). FGFRs are involved in various cellular processes including cell growth, survival, migration, and angiogenesis. By inhibiting these receptors, infigratinib can block the growth and spread of FGFR-driven cancer cells.\n\n2. **Indications**: As of the latest updates, infigratinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that harbors a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_QGKI16vG0FXdiSmlFzTWU5Qt", "custom_id": "133_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fcd2711f329d3604d84cabce3a93daf0", "body": {"id": "chatcmpl-9St9eIJSyQ4FXBzu80TvqvPIbHWe8", "object": "chat.completion", "created": 1716672226, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is an important drug used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about this medication:\n\n1. **Mechanism of Action**: Inotuzumab ozogamicin is a monoclonal antibody-drug conjugate. The monoclonal antibody targets CD22, a protein expressed on the surface of B-cell precursors. It is conjugated to ozogamicin, a cytotoxic agent. Once bound to CD22, the conjugate is internalized and the cytotoxic agent (a calicheamicin derivative) is released inside the cell, leading to DNA damage and apoptotic cell death.\n\n2. **Indications**: It is approved by the FDA for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is often considered when other treatments have failed or when the disease has recurred.\n\n3. **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EowrIEUQjQBrVJSD5AaElOZn", "custom_id": "134_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc2f3908b6e7018539ddec4f986daa45", "body": {"id": "chatcmpl-9St9fABOqn2YLogR3NXTvkc08iP9K", "object": "chat.completion", "created": 1716672227, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a recombinant form of interferon used primarily in the treatment of certain viral infections and cancers. It is a type of cytokine that the body naturally produces in response to viral infections, and it has antiviral, antiproliferative, and immunomodulatory effects. Here are some key points about Interferon alfa-2a that you, as a physician, might find useful:\n\n1. **Indications**: Interferon alfa-2a is approved for the treatment of chronic hepatitis B and C, certain types of cancer such as hairy cell leukemia, follicular lymphoma, and AIDS-related Kaposi's sarcoma. It may also be used in some clinical settings for malignant melanoma and other conditions.\n\n2. **Mechanism of Action**: Interferon alfa-2a works by binding to specific receptors on the surface of human cells, initiating a complex cascade of intracellular events that lead"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_u3hPKLSa5WQsF3iYB8klWVXn", "custom_id": "135_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b6032a2bd410f9b3826f89b71fb214d0", "body": {"id": "chatcmpl-9St9fAN63PjzDytxldkaa1T7e1khR", "object": "chat.completion", "created": 1716672227, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of interferon used in the treatment of various medical conditions, primarily those involving viral infections and certain types of cancers. It is a recombinant form of interferon, which is a naturally occurring protein that the body produces in response to viral infections. Here are some key points you should know about Interferon alfa-2b:\n\n### Mechanism of Action\nInterferon alfa-2b works by enhancing the immune system's response to diseases. It exerts its effects by binding to specific receptors on the surface of human cells, initiating a complex cascade of intracellular events that lead to the expression of numerous interferon-stimulated genes. These genes activate several immunomodulatory and antiviral mechanisms.\n\n### Indications\nInterferon alfa-2b is approved for the treatment of several conditions, including:\n- **Hepatitis B and C**: It is used to treat chronic hepatitis B and C"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fNAO5AboLQyp2Tae9SEXreI4", "custom_id": "136_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c3cb7a74cd4ee56a0e45c6398f6ead4a", "body": {"id": "chatcmpl-9St9gDKmouOVDSmK105pcX1sYdHkN", "object": "chat.completion", "created": 1716672228, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b (IFN-gamma-1b) is a synthetic version of a naturally occurring protein that plays a critical role in the immune response. As a physician, here are some key aspects you should know about Interferon gamma-1b:\n\n### 1. **Mechanism of Action**\n   - Interferon gamma-1b is part of the interferon family, which are cytokines with antiviral, immunomodulatory, and antiproliferative effects.\n   - It enhances macrophage activity, promotes antigen presentation, and stimulates the production of antibodies, thereby boosting the immune response.\n\n### 2. **Indications**\n   - **Chronic Granulomatous Disease (CGD)**: It is primarily used as a treatment to reduce the frequency and severity of infections in patients with CGD, a rare genetic disorder that affects the immune system.\n   - **Severe Malignant Osteopetrosis ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jzV3psFAL8nhuJK6b2Wd73T1", "custom_id": "137_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f21607d1537e78d42a3161e266a3ae12", "body": {"id": "chatcmpl-9St1ndDGWW4gitoBc7JLy37X69Rah", "object": "chat.completion", "created": 1716671739, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab is an immunotherapy drug used primarily in the treatment of certain cancers. Here are some key points you should know about Ipilimumab:\n\n1. **Mechanism of Action**: Ipilimumab is a monoclonal antibody that targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, Ipilimumab enhances the body's immune response against cancer cells.\n\n2. **Indications**: It is approved by the FDA for the treatment of metastatic melanoma, and it is also used in the treatment of other types of cancers such as renal cell carcinoma and colorectal cancer in combination with other therapies.\n\n3. **Administration**: Ipilimumab is administered intravenously. The dosage and schedule may vary depending on the indication and combination therapies.\n\n4. **Side Effects**: The enhancement of the immune response can lead to immune-related adverse"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SF479dY1JYs8mIdn3aVBL5oJ", "custom_id": "138_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b5097a0b933917d23f1c65acda8914f", "body": {"id": "chatcmpl-9St1nM5uD8SzJ4bR8GqLOk7Dhmr0q", "object": "chat.completion", "created": 1716671739, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapy drug used primarily to treat cancers of the colon and rectum, particularly in cases where the disease has metastasized or other treatments have not been effective. It is often used in combination with other chemotherapy agents. Here are some key points about Irinotecan that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Irinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that relieves torsional strain in DNA by inducing single-strand breaks. Irinotecan prevents the religation of these DNA breaks, leading to DNA damage and cell death.\n\n2. **Indications**: Irinotecan is approved for the treatment of metastatic colorectal cancer. It is used as a part of first-line therapy in combination with 5-fluorouracil and leucovorin, and can also be used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hZ3tg4Qvq1uWE0LMQEXFmQFN", "custom_id": "139_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3edfe5d9b830c5804314acbd7f878d24", "body": {"id": "chatcmpl-9St1ok19fzP3jTlF9OBBt3HtJXP2o", "object": "chat.completion", "created": 1716671740, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome injection is a form of chemotherapy used primarily in the treatment of pancreatic cancer, specifically metastatic adenocarcinoma of the pancreas. It is a liposomal encapsulation of the drug irinotecan, which allows for a prolonged circulation time and potentially improved delivery to the tumor site.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - Irinotecan liposome is approved for use in combination with fluorouracil and leucovorin for patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy.\n\n2. **Mechanism of Action**:\n   - Irinotecan is a prodrug that is converted to its active metabolite, SN-38. SN-38 inhibits topoisomerase I, an enzyme involved in DNA replication and transcription. This inhibition leads to DNA damage and cell death. The liposomal formulation is designed to enhance the delivery of irinotecan to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WzM8jDgbYNwTzKolq6B6Wjtf", "custom_id": "140_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f8f6428947f015fc098302217d4c7de", "body": {"id": "chatcmpl-9St1puQkhTalmWIcfeGEgQ8mYNDPC", "object": "chat.completion", "created": 1716671741, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab is a monoclonal antibody used primarily in the treatment of multiple myeloma. Here are some key points you should know about isatuximab:\n\n1. **Mechanism of Action**: Isatuximab works by targeting a specific protein called CD38, which is highly expressed on the surface of multiple myeloma cells. It functions through various mechanisms, including inducing direct apoptosis, triggering immune-mediated cytotoxicity, and enhancing the immune response against tumor cells.\n\n2. **Indications**: Isatuximab is approved for use in combination with other medications such as pomalidomide and dexamethasone, or carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The specific combinations depend on the patient's previous treatments and overall health status.\n\n3. **Administration**: Isatuximab is administered intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DQ726VJj3UvSJYGbTzBQ3sZf", "custom_id": "141_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "953eda11aa93f02be4a3dcc597318505", "body": {"id": "chatcmpl-9St1qmuxqOUuRNh3nOHtTbKgFOT0I", "object": "chat.completion", "created": 1716671742, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isotretinoin, commonly known by its former brand name Accutane, is a potent medication primarily used to treat severe acne, particularly nodular or cystic acne that hasn't responded to other treatments. It is a derivative of vitamin A and belongs to a class of medications called retinoids. Here are some key points you should know about isotretinoin:\n\n### Indications\n- **Severe acne (nodular or cystic acne)**: Isotretinoin is typically reserved for severe cases due to its strength and potential side effects.\n- **Refractory acne**: For cases of acne that do not respond to other treatment modalities like topical treatments and oral antibiotics.\n\n### Mechanism of Action\n- Isotretinoin works by reducing the size and output of the sebaceous glands. It also helps normalize skin cell shedding, which prevents clogging of pores, reduces inflammation, and inhibits the growth of acne-causing bacteria.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BDpMVUhnSY4VC1uFR5BadHpM", "custom_id": "142_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "026810e9585be6ba9e58d53d012bf323", "body": {"id": "chatcmpl-9St1q43q6vvnrFM9S4CweKNqlaShO", "object": "chat.completion", "created": 1716671742, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib (marketed under the brand name Tibsovo) is a medication used in the treatment of certain types of cancer. It is specifically approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) that exhibits a specific genetic mutation in the isocitrate dehydrogenase-1 (IDH1) gene. Ivosidenib is also used for treating cholangiocarcinoma (bile duct cancer) with an IDH1 mutation in patients who have previously been treated with other therapies.\n\nHere are some key points about Ivosidenib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Ivosidenib works by inhibiting the mutant IDH1 enzyme, which is involved in the abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG). High levels of 2-HG are thought to contribute to the growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_prhoGlf78ObgATGcHN0W62z1", "custom_id": "143_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a2694f56d1c8427cd7d65f402fe7783", "body": {"id": "chatcmpl-9St1wjIXQyOSafSE1THBbzeJ8l1E0", "object": "chat.completion", "created": 1716671748, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixabepilone is a chemotherapeutic agent used primarily in the treatment of breast cancer. Here are some key points you should know about ixabepilone:\n\n1. **Mechanism of Action**: Ixabepilone is a microtubule inhibitor that belongs to the epothilone class of antineoplastic agents. It works by stabilizing microtubules and inhibiting their depolymerization, which disrupts mitotic spindle formation, leading to cell cycle arrest and apoptosis in cancer cells.\n\n2. **Indications**: Ixabepilone is approved by the FDA for the treatment of metastatic or locally advanced breast cancer. It is specifically indicated for use in patients who are resistant to anthracycline and taxane therapy, or whose cancer has progressed following therapy with these drugs.\n\n3. **Administration**: Ixabepilone is administered intravenously. The dosing regimen typically involves a dose of 40 mg/m\u00b2 administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i2pUWZJbzn4z9Keaa9XVXQFq", "custom_id": "144_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "76ad177084f2655c342863cf28d9b787", "body": {"id": "chatcmpl-9St1uqfhNqAwlSY9gDFoRmsPfCziu", "object": "chat.completion", "created": 1716671746, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib is an oral proteasome inhibitor used primarily in the treatment of multiple myeloma. Here are some key points you should know about ixazomib:\n\n1. **Mechanism of Action**: Ixazomib works by reversibly inhibiting the 20S proteasome, a complex that degrades ubiquitinated proteins. Inhibition of the proteasome leads to an accumulation of proteins within cells, which can induce cell cycle arrest and apoptosis, particularly in rapidly dividing cells like cancer cells.\n\n2. **Indications**: It is approved for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. This combination has been shown to improve progression-free survival compared to lenalidomide and dexamethasone alone.\n\n3. **Administration**: Ixazomib is administered orally, which can be more convenient for patients compared to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tqCHtvvHYn713ufUFtqdFP4k", "custom_id": "145_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29a53de2e0555af586325c9e946b552a", "body": {"id": "chatcmpl-9St1wYEZPvZYDbUZt346vCht9ovkk", "object": "chat.completion", "created": 1716671748, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketoconazole is an antifungal medication primarily used to treat fungal infections. Here are some key points you should know about ketoconazole as a physician:\n\n1. **Mechanism of Action**: Ketoconazole works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. Without ergosterol, the cell membrane becomes permeable and leaks essential intracellular components, leading to fungal cell death.\n\n2. **Spectrum of Activity**: It is effective against a broad range of fungi including dermatophytes, yeasts, and dimorphic fungi. It is commonly used to treat infections such as athlete's foot, ringworm, candidiasis, and more severe systemic infections like histoplasmosis or blastomycosis, especially in immunocompromised patients.\n\n3. **Formulations**: Ketoconazole is available in various forms including tablets, creams, shampoos, and foams. The choice of formulation depends on the location and severity"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qvxn6rxT1UA1hHMTDhjDVfgL", "custom_id": "146_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f8cc36077ef9d7f322fcfbc190321b6a", "body": {"id": "chatcmpl-9St1xAoBinAD9zHZEBDK0xJtadQQU", "object": "chat.completion", "created": 1716671749, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide is a medication used primarily in the management of acromegaly, a condition characterized by excessive growth hormone production, typically due to a pituitary adenoma. It is also used for the treatment of neuroendocrine tumors, particularly those of the gastrointestinal tract and the pancreas.\n\nHere are some key points about Lanreotide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Lanreotide is a somatostatin analog. It works by mimicking the action of natural somatostatin, thereby inhibiting the secretion of several hormones, including growth hormone (GH) and insulin-like growth factor 1 (IGF-1). This results in decreased symptoms and complications associated with hormone overproduction.\n\n2. **Forms and Administration**: Lanreotide is available as a deep subcutaneous (under the skin) injection. It is typically administered via a prefilled syringe. The most common formulation is Lanreotide Aut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kinTCGWPwMjIk0DqiWKgsuhE", "custom_id": "147_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c4e777af86e0eda7e47c538b768f247", "body": {"id": "chatcmpl-9St1ytYsi6sgpfpPsb91Ap4XcylIo", "object": "chat.completion", "created": 1716671750, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lansoprazole is a proton pump inhibitor (PPI) that is commonly used to treat conditions related to excessive stomach acid production. Here are some key points you should know about lansoprazole:\n\n1. **Mechanism of Action**: Lansoprazole works by irreversibly blocking the hydrogen-potassium ATPase enzyme system (the proton pump) of the gastric parietal cells. This action significantly reduces the production of stomach acid.\n\n2. **Indications**:\n   - Gastroesophageal reflux disease (GERD)\n   - Erosive esophagitis\n   - Zollinger-Ellison syndrome\n   - Peptic ulcers, including those induced by Helicobacter pylori when used in combination with antibiotics\n   - Maintenance of healing of erosive esophagitis\n\n3. **Dosage and Administration**: Lansoprazole is typically administered orally and is available in capsule form or as an orally disintegrating"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a1Q5Z2goQP7ixVBWM0B6ejZ9", "custom_id": "148_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5794eba2a49db0d42792ba23b448754b", "body": {"id": "chatcmpl-9St1zaNxbDsJSfTYRGXkEBbq3V9KQ", "object": "chat.completion", "created": 1716671751, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatinib is a targeted therapy drug used primarily in the treatment of certain types of breast cancer. Here are key points you should know about lapatinib:\n\n1. **Mechanism of Action**: Lapatinib is a tyrosine kinase inhibitor that specifically targets the HER2/neu (ErbB2) and the epidermal growth factor receptor (EGFR, ErbB1) pathways. By inhibiting these receptors, lapatinib helps to block the growth and division of cancer cells that overexpress these proteins.\n\n2. **Indications**: It is commonly used for the treatment of HER2-positive breast cancer, particularly in patients who have advanced or metastatic breast cancer. Lapatinib is often used in combination with other drugs, such as capecitabine or letrozole, depending on the hormone receptor status of the tumor and prior treatments.\n\n3. **Administration**: Lapatinib is administered orally, which can be more convenient for patients compared to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dO1T6jaUisH5JQx0dNYbHN03", "custom_id": "149_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "935bd43c31a17307b35747e14a8626b8", "body": {"id": "chatcmpl-9St21CZvTdbBgZDGlzZOLxPIkOStE", "object": "chat.completion", "created": 1716671753, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib, sold under the brand name Vitrakvi, is a medication used in the treatment of cancer. It is specifically designed to target and inhibit tropomyosin receptor kinases (TRKs), which are proteins involved in the growth and spread of cancer cells. Here are some key points you should know about larotrectinib:\n\n1. **Mechanism of Action**: Larotrectinib is a selective inhibitor of the TRK family of receptors, which includes TRKA, TRKB, and TRKC. These receptors can become abnormally activated in some cancers due to gene fusions, leading to uncontrolled cell growth. By inhibiting these receptors, larotrectinib can help to stop the growth and spread of cancer cells.\n\n2. **Indications**: Larotrectinib is approved for the treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ot4XeW4UKY7gHLkErJI3sGdG", "custom_id": "150_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d349913429079f98c137982df59bb401", "body": {"id": "chatcmpl-9St21msYpNppTcsi8jtzr6RTVYF9M", "object": "chat.completion", "created": 1716671753, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide is an immunomodulatory drug that is primarily used in the treatment of multiple myeloma and certain myelodysplastic syndromes. Here are some key points you should know about lenalidomide:\n\n1. **Mechanism of Action**: Lenalidomide is a derivative of thalidomide and acts by modulating the immune system. It has anti-inflammatory, anti-angiogenic, and anti-neoplastic properties. It enhances T cell and natural killer (NK) cell-mediated immunity and inhibits pro-inflammatory cytokines. Lenalidomide also affects the tumor microenvironment, reducing angiogenesis and promoting apoptosis of malignant cells.\n\n2. **Indications**:\n   - **Multiple Myeloma**: It is approved for use in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n   - **Myelodysplastic Synd"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0WUE2M1fxlJpCEaELvM4sHSI", "custom_id": "151_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "431903d2eb8c6bc047e84db1decb7339", "body": {"id": "chatcmpl-9St23fbS3SZojGfr4Hb742UEVARHg", "object": "chat.completion", "created": 1716671755, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the production of white blood cells (neutrophils) in patients undergoing chemotherapy, among other indications. It is a recombinant form of human G-CSF and is produced using biotechnology. Here are some key points you should know about lenograstim:\n\n1. **Indications**: Lenograstim is primarily used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy. It is also used for mobilizing peripheral blood progenitor cells for transplantation and may be used in the treatment of severe chronic neutropenia.\n\n2. **Mechanism of Action**: Lenograstim acts by binding to the G-CSF receptor, which stimulates the proliferation, differentiation, and activation of neutrophils within the bone marrow. This leads to an increased production and release of functional neutrophils into the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wyBt1KmEoUR3g6E1ZSo5QzmT", "custom_id": "152_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4578c587ea91732812a58c4fbd7bf865", "body": {"id": "chatcmpl-9St24nz4AvwD3rPTXxRW41myO9WYl", "object": "chat.completion", "created": 1716671756, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about lenvatinib:\n\n1. **Mechanism of Action**: Lenvatinib is a tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases (RTKs) involved in angiogenesis, tumor growth, and cancer progression. These include vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), platelet-derived growth factor receptor alpha (PDGFR\u03b1), RET, and KIT.\n\n2. **Indications**:\n   - **Thyroid Cancer**: Lenvatinib is approved for the treatment of progressive, differentiated thyroid cancer (DTC) that does not respond to radioactive iodine treatment.\n   - **Renal Cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8PTOqENxuddJR2cwACyyfhom", "custom_id": "153_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d4084dd8e5bafd61b041a7b4e6ef434f", "body": {"id": "chatcmpl-9St24nxU78vRAlD0W3c61EiVERzJl", "object": "chat.completion", "created": 1716671756, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole is a medication commonly used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points about letrozole that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Letrozole is a type of aromatase inhibitor. It works by decreasing the amount of estrogen produced by the body. This reduction in estrogen levels can slow or stop the growth of some breast cancer cells that need estrogen to grow.\n\n2. **Indications**:\n   - **Primary Treatment**: Often used as an initial treatment for hormone receptor-positive breast cancer in postmenopausal women.\n   - **Adjuvant Treatment**: It can be used as adjuvant therapy to prevent cancer recurrence after surgery.\n   - **Extended Adjuvant Treatment**: Letrozole is also used for extended adjuvant treatment (following standard adjuvant tamoxifen therapy) to further reduce the risk of breast cancer recurrence.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1mkUmOFINr4mqt45QrDDiO8j", "custom_id": "154_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6efecd6c17382ed334fd0d7887fa3410", "body": {"id": "chatcmpl-9St253J91vDI9GGcqRnpZ2cd7Ksv9", "object": "chat.completion", "created": 1716671757, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide, also known by its brand name Lupron among others, is a medication used in the management of several medical conditions related to hormone regulation. It is a type of gonadotropin-releasing hormone (GnRH) agonist, which acts by initially increasing and then subsequently decreasing the secretion of gonadotropins (LH and FSH) from the pituitary gland, leading to a decrease in testosterone in males and estrogen in females. Here are some key points about Leuprolide that you, as a physician, might find useful:\n\n### Indications\n1. **Prostate Cancer**: Used in the management of advanced prostate cancer. It helps by reducing the level of testosterone, which is often required for the growth of prostate cancer cells.\n2. **Endometriosis**: Helps in managing pain and reducing the size of endometriotic lesions by suppressing estrogen production.\n3. **Uterine Fibroids**: Used to reduce the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_zRm85kywpPZy0HImB2NF7rab", "custom_id": "155_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5236db93bfb9a8c7942b9bb9eeca02b1", "body": {"id": "chatcmpl-9St26zZLPHnOYHL4UItnshIaxhSJ9", "object": "chat.completion", "created": 1716671758, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is a medication that was originally used as an anthelmintic to treat parasitic worm infections in both humans and animals. However, its use in humans has decreased due to significant side effects, though it is still widely used in veterinary medicine. Here are some key points you should know about levamisole:\n\n1. **Medical Uses**: In humans, levamisole was primarily used to treat helminthiasis, such as nematode infections. It has also been investigated for its immunomodulatory effects and has been used as an adjuvant treatment in colorectal cancer.\n\n2. **Mechanism of Action**: Levamisole works as an anthelmintic by paralyzing worms, which are then expelled from the host's body. It acts as a nicotinic acetylcholine receptor agonist, affecting the muscle function of the worm. Its immunomodulatory effects are believed to involve modulation of various cytokine and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lmHYWIDYOkZNHoSni6foRH37", "custom_id": "156_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "951faf50812d69d12685f4d88f10ff39", "body": {"id": "chatcmpl-9St28yRJoAxqeSuy5VGz1kZl0r78l", "object": "chat.completion", "created": 1716671760, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin is a chemically reduced derivative of folic acid and is used primarily as an antidote to reduce the toxic effects of high doses of methotrexate in cancer therapies. It is also used in combination with fluorouracil to treat metastatic colorectal cancer. Here are some key points you should know about Levoleucovorin:\n\n1. **Mechanism of Action**: Levoleucovorin is used to \"rescue\" normal cells by replenishing folate stores, necessary for normal cellular functions, after high-dose methotrexate therapy. It is converted to the active form of folic acid (tetrahydrofolate) more quickly than folic acid itself. In the treatment of colorectal cancer, it enhances the cytotoxic effect of fluorouracil.\n\n2. **Usage**: \n   - **High-Dose Methotrexate Rescue**: Levoleucovorin is administered after methotrexate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_K39xrl9MycelqXh5GZ6D63Zo", "custom_id": "157_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec869693e6cde2b14289d97e27dfae7b", "body": {"id": "chatcmpl-9St2SmMliysmZUitPtK3XtfZSxabu", "object": "chat.completion", "created": 1716671780, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine is a chemotherapy drug used primarily to treat various types of cancer, including brain tumors, Hodgkin's lymphoma, and other malignancies. It belongs to the class of drugs known as nitrosoureas, which are alkylating agents. Here are some key points about lomustine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nLomustine causes cross-linking of DNA and RNA, leading to the inhibition of DNA synthesis and function. It is cell-cycle nonspecific, meaning it can kill cells at various phases of the cell cycle.\n\n### Indications\n- **Primary and metastatic brain tumors:** Lomustine is often used in the treatment of gliomas, brainstem glioma, and other types of brain cancer.\n- **Hodgkin\u2019s lymphoma:** It is used as a second-line treatment for Hodgkin's lymphoma.\n- Lomustine can also be used in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1D5O8VmkPF2Hgb7R0klGoijb", "custom_id": "158_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a273585a74e6592361d540a83174b4a1", "body": {"id": "chatcmpl-9St2D800yg9G9P2qVMxJKqMTYb2uq", "object": "chat.completion", "created": 1716671765, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about lorlatinib:\n\n1. **Indications**: Lorlatinib is specifically indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC who have progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.\n\n2. **Mechanism of Action**: Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI). It is designed to inhibit the activity of the ALK protein, which can contribute to the growth and development of cancer cells in NSCLC. Lorlatinib is also effective against ROS1 kinases and can penetrate the blood-brain barrier, which is beneficial for treating brain metast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GmJ0g4Z4l6OOnhUcDUQbb5DV", "custom_id": "159_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea78388db455da539254bdea59d245dc", "body": {"id": "chatcmpl-9St2Ekr3KeU1jxn0i6QDxb4KSip4w", "object": "chat.completion", "created": 1716671766, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate, marketed under the brand name Lutathera, is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs). Here are some key points you should know about this treatment:\n\n1. **Indications**: Lutetium Lu 177 dotatate is approved for use in adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in patients who require systemic therapy.\n\n2. **Mechanism of Action**: This drug is a radiolabeled somatostatin analog. The active substance, lutetium Lu 177, is a beta-emitting radioactive isotope that is linked to a somatostatin analog, dotatate. The dotatate targets somatostatin receptors, which are commonly overexpressed in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4t0tRe0Puxz2TuyHtPrSGo39", "custom_id": "160_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3305202e64987628434dfa837836ccdf", "body": {"id": "chatcmpl-9St2FaVURXJpulsNasHC06qQq6JED", "object": "chat.completion", "created": 1716671767, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab is a monoclonal antibody used in the treatment of certain types of cancer. Here are some key points you should know about tafasitamab:\n\n1. **Indications**: Tafasitamab is approved for use in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).\n\n2. **Mechanism of Action**: Tafasitamab is a CD19-directed cytolytic antibody. CD19 is a protein expressed on the surface of B-cell precursors and mature B cells, but not on stem cells. The binding of tafasitamab to CD19 triggers a host immune response that leads to the destruction of malignant cells.\n\n3. **Administration**: Tafas"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VQzUeYO0Gpj0c028IvaydwED", "custom_id": "161_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b717d44ecdf7b920315a6198e2fff1fc", "body": {"id": "chatcmpl-9St2GBFFMoKB8T3lxs2yGYJJvRC7I", "object": "chat.completion", "created": 1716671768, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard or by its trade name Mustargen, is a chemotherapy agent used primarily in the treatment of cancer. It belongs to the class of alkylating agents, which work by binding to DNA and preventing the cancer cells from dividing and growing. Here are some key points you should know about mechlorethamine:\n\n1. **Mechanism of Action**: Mechlorethamine forms electrophilic alkyl groups that can cross-link DNA strands at the N7 position of guanine bases, leading to cell cycle arrest and apoptosis. This cross-linking can prevent the replication of DNA and the transcription of RNA, ultimately leading to cell death.\n\n2. **Indications**: It is used to treat various types of cancers including Hodgkin\u2019s lymphoma, non-Hodgkin lymphomas, and cutaneous T-cell lymphoma. It may also be used in certain leukemias and mycosis fungoides.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Q91VvdpBbpuxxGsUPg7u7LCj", "custom_id": "162_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fdff26b8bffafa3ffe270a2d8e1941d8", "body": {"id": "chatcmpl-9St2I07EfkwqBDyS629NEIOVvzyF9", "object": "chat.completion", "created": 1716671770, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone acetate (MPA) is a synthetic progestin, a form of the hormone progesterone. It is used in various clinical settings, primarily for its effects on the uterus, making it useful in a range of gynecological and endocrine disorders. Here are some key points about medroxyprogesterone that you, as a physician, might find useful:\n\n### Indications\n1. **Contraception**: Medroxyprogesterone is used as a contraceptive, either as an injectable form (Depo-Provera) which is typically given every 3 months, or in oral form.\n2. **Hormone Replacement Therapy (HRT)**: It is used in combination with estrogen in postmenopausal women to prevent endometrial hyperplasia.\n3. **Menstrual Disorders**: It helps in managing conditions like secondary amenorrhea, irregular menstrual periods, and heavy bleeding.\n4. **Endomet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K72DazAsvVn5R5WExeXRvvoN", "custom_id": "163_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f1a120e1b49e63157e0acfd9d53918ed", "body": {"id": "chatcmpl-9St2KFP6vmPIWuoWgsWTVEnaVChwf", "object": "chat.completion", "created": 1716671772, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol acetate, commonly known simply as megestrol, is a synthetic progestin often used for its antineoplastic and appetite-stimulating properties. Here are some key points you should know about megestrol, especially in a clinical setting:\n\n1. **Indications**:\n   - **Appetite Stimulation**: Megestrol is frequently prescribed to promote weight gain in patients suffering from anorexia, cachexia, or unexplained significant weight loss, particularly in cancer patients and those with AIDS.\n   - **Cancer Treatment**: It is used in the treatment of advanced breast cancer and endometrial cancer. Its efficacy in other cancers is being studied.\n\n2. **Mechanism of Action**:\n   - Megestrol acts primarily as a potent progestogen. Its antineoplastic effects are believed to be primarily related to the direct action on the progesterone receptors in the tumor cells, leading to decreased proliferation.\n   - It also"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_NneIuSkjpWuQ7slOJMzr59jd", "custom_id": "164_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aac3fec3da3a473f2f69c4ee975b0f95", "body": {"id": "chatcmpl-9St2KDk1q0LtlpUJ0EbJibkwip89h", "object": "chat.completion", "created": 1716671772, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is a chemotherapy drug used primarily to treat multiple myeloma and ovarian cancer, though it may also be used for other malignancies. Here are some key points you should know about Melphalan:\n\n1. **Mechanism of Action**: Melphalan is an alkylating agent. It works by cross-linking guanine bases in DNA double-helix strands, directly attacking the DNA, which prevents the cancer cells from dividing and leads to cell death.\n\n2. **Administration**: Melphalan can be administered orally or intravenously. The route of administration depends on the specific treatment protocol and the condition being treated.\n\n3. **Dosage**: The dosage of Melphalan varies depending on the condition being treated, the route of administration, the size of the patient, and their overall health. Dosage adjustments may be necessary for renal impairment.\n\n4. **Side Effects**: Common side effects include bone marrow suppression, nausea, vomiting, diarrhea, oral ulcers, and alo"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IuBYORVohlzJ9l4nHI2t2k7L", "custom_id": "165_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "42ab0a4969f827692ea83e327f42b0ac", "body": {"id": "chatcmpl-9St2LlycDQL1CisFN7heomBfEbsYH", "object": "chat.completion", "created": 1716671773, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, also known by its brand name Purinethol among others, is a medication used in the treatment of cancer and autoimmune diseases. Here are some key points you should know about mercaptopurine, especially if you are a physician prescribing this medication:\n\n### Mechanism of Action\nMercaptopurine is a purine analog that interferes with nucleic acid synthesis. It inhibits the synthesis of DNA, RNA, and proteins, and promotes apoptosis in certain cells, particularly rapidly dividing cells like cancer cells. It is also an immunosuppressant.\n\n### Indications\n- **Leukemia**: Mercaptopurine is primarily used in the treatment of acute lymphoblastic leukemia (ALL). It is often part of a combination chemotherapy regimen.\n- **Autoimmune diseases**: It is also used off-label for managing certain autoimmune conditions, such as inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, particularly when other treatments have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BM2iFCmu3zPhHFd18AQGw5Kt", "custom_id": "166_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b725f302cce1d0f9c06cdfaf6fc6544b", "body": {"id": "chatcmpl-9St2MV1kKee0Xkl5gLvWe5C2S6dLs", "object": "chat.completion", "created": 1716671774, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mesna (2-mercaptoethane sulfonate sodium) is a medication primarily used as a prophylactic agent to reduce the risk of hemorrhagic cystitis caused by certain chemotherapy drugs, particularly cyclophosphamide and ifosfamide. Here are some key points you should know about Mesna:\n\n1. **Mechanism of Action**: Mesna works by binding to acrolein, a toxic metabolite of cyclophosphamide and ifosfamide that is responsible for causing bladder damage and hemorrhagic cystitis. By binding to acrolein, Mesna neutralizes its harmful effects, thereby protecting the bladder mucosa.\n\n2. **Administration**: Mesna can be administered orally or intravenously. The route of administration may depend on the specific chemotherapy regimen and the patient's overall condition. When given intravenously, Mesna is typically administered immediately before and after the chemotherapy, and then again several hours later.\n\n3. **Dosage**: The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nVodqWlcmsFds0iTnk7JmLaV", "custom_id": "167_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1dc07c050b494612e6483665982fb032", "body": {"id": "chatcmpl-9St2MPieP0GCrlh5e1e2igpW97Dsg", "object": "chat.completion", "created": 1716671774, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methotrexate is a medication that is widely used in the treatment of various medical conditions, primarily in oncology and rheumatology. Here are some key points that you, as a physician, should be aware of regarding methotrexate:\n\n### Mechanism of Action\n- **Antimetabolite:** Methotrexate is a folate analog that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell replication. This action is particularly effective in rapidly dividing cells, such as cancer cells and inflammatory cells in autoimmune diseases.\n\n### Indications\n- **Oncology:** Used in the treatment of leukemias, lymphomas, breast cancer, lung cancer, and osteosarcoma, among others.\n- **Rheumatology:** Commonly prescribed for rheumatoid arthritis, psoriatic arthritis, and severe psoriasis. It helps in controlling inflammation and disease progression.\n- **Dermatology:** Used for severe psoriasis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T6L2A4B4zRRPZcJslpflAfTH", "custom_id": "168_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a3e36942cce77ffede38dd7ceeae7428", "body": {"id": "chatcmpl-9St2Nkl6nx5M7nUvrKWTEHJQ76zyW", "object": "chat.completion", "created": 1716671775, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen (also known as 8-methoxypsoralen, 8-MOP, xanthotoxin) is a drug used primarily in the treatment of psoriasis, eczema, vitiligo, and some types of cutaneous lymphoma. It belongs to a group of naturally occurring compounds known as psoralens, or furocoumarins. Here are some key points you should know about Methoxsalen:\n\n### Mechanism of Action\nMethoxsalen works by intercalating into DNA and, upon activation by long-wave ultraviolet light (UVA), it forms cross-links with the DNA. This action inhibits DNA synthesis and cell division, reducing the pathological proliferation of skin cells, which is particularly useful in conditions like psoriasis.\n\n### Uses\n1. **Psoriasis:** Methoxsalen is used in combination with UVA light in a treatment known as PUVA (psoralen and UVA light) for severe"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mt7T8e03B0rF2Feudaz23Dnn", "custom_id": "169_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1abfe23f8b4e39a761842cf2cc45d5e8", "body": {"id": "chatcmpl-9St2ObrLPOzTIC6YrvY9f6RUIjvNY", "object": "chat.completion", "created": 1716671776, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. It is commonly used to treat a variety of conditions, including inflammatory and autoimmune disorders, allergic reactions, and certain types of cancer. Here are some key points you should know about methylprednisolone:\n\n1. **Mechanism of Action**: Methylprednisolone works by inhibiting the accumulation of inflammatory cells at inflammation sites and suppressing the immune response. It does this by decreasing the production of inflammatory mediators and reversing the increased capillary permeability.\n\n2. **Forms and Dosage**: Methylprednisolone is available in several forms, including oral tablets, injectable solutions, and as a topical application. The dosage depends on the condition being treated, the severity of the condition, and the patient\u2019s response to therapy. It is crucial to individualize and titrate the dosage based on the specific clinical situation.\n\n3. **Indications**: It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_0148CND6CUKSMpT45Pq3qtmS", "custom_id": "170_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5239f6f4fe98a890ea8855cbee1b2850", "body": {"id": "chatcmpl-9St2OlLEbpz3GJHOCWAnfm5wUTJ41", "object": "chat.completion", "created": 1716671776, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is a kinase inhibitor used in the treatment of certain types of blood cancers. Here are some key points you should know about midostaurin:\n\n1. **Indications**: Midostaurin is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. It is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Midostaurin is also approved for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.\n\n2. **Mechanism of Action**: Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3, KIT, PDGFR\u03b1/\u03b2, and VEGFR2. This inhibition blocks several signaling pathways that are important for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SFlenmGcs7rH1XDYkjgzfiuz", "custom_id": "171_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da1d2b8f18e5126086273697c18e05fd", "body": {"id": "chatcmpl-9St2OSwxZBYtQIf2L8dp639waGJcY", "object": "chat.completion", "created": 1716671776, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin C is a chemotherapy drug used primarily to treat various types of cancer, including gastric and pancreatic cancer. It is an antineoplastic antibiotic that exerts its effect by cross-linking DNA, thereby inhibiting DNA synthesis and function. Here are some key points you should know about Mitomycin:\n\n1. **Mechanism of Action**: Mitomycin C acts as an alkylating agent. After metabolic activation, it covalently crosslinks DNA strands, which inhibits DNA synthesis and function, leading to cell death. This action is cell cycle phase-nonspecific.\n\n2. **Indications**: Mitomycin is commonly used for the treatment of adenocarcinoma of the stomach or pancreas in combination with other chemotherapeutic agents. It is also used in the treatment of other cancers, such as bladder cancer, where it may be administered intravesically.\n\n3. **Administration**: Mitomycin can be administered intravenously or intravesically,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AQWGfClIkrJNiZFYmxmbEKuJ", "custom_id": "172_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "347438adea7588be584636ed86a2e32e", "body": {"id": "chatcmpl-9St2Pf1ysVmYc1XnXsdtQST4VpXRR", "object": "chat.completion", "created": 1716671777, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane, also known by its brand name Lysodren, is a medication primarily used in the treatment of adrenocortical carcinoma, a rare tumor of the adrenal glands. Here are some key points you should know about mitotane:\n\n1. **Mechanism of Action**: Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. It has adrenolytic activity and can cause atrophy of the zona fasciculata and zona reticularis of the adrenal cortex, leading to reduced steroid production.\n\n2. **Indications**: Mitotane is used for the treatment of inoperable adrenocortical carcinoma and can be used as an adjuvant therapy post-operatively. It may also be used in cases where the tumor has metastasized.\n\n3. **Administration**: Mitotane is administered orally. The dosage and duration of treatment depend on the patient's response and tolerance to the medication. It is important to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gQZUgHYjtBxKGqNvuMgpPueB", "custom_id": "173_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cd4ebfab536fdbbe35f4994b2f5b5b60", "body": {"id": "chatcmpl-9St2PYhrYF6X9NKWEOhQvSkvwWqjH", "object": "chat.completion", "created": 1716671777, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is a type II topoisomerase inhibitor that is used primarily in the treatment of certain types of cancers and multiple sclerosis. Here are some key points you should know about Mitoxantrone:\n\n### Mechanism of Action\nMitoxantrone works by intercalating into DNA and inhibiting topoisomerase II, an enzyme critical for DNA replication and repair. This action leads to the disruption of DNA synthesis and repair, ultimately causing cell death.\n\n### Indications\n1. **Cancer Treatment**: Mitoxantrone is used in the treatment of certain types of cancers, including:\n   - Acute myeloid leukemia (AML)\n   - Non-Hodgkin's lymphoma\n   - Advanced prostate cancer\n\n2. **Multiple Sclerosis (MS)**: It is approved for reducing neurological disability and/or the frequency of clinical relapses in patients with secondary progressive, progressive relapsing, or worsening relapsing-remitting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gd1pIwePjebiADSN9BiV4685", "custom_id": "174_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cb17743c90007cf87b66e3f3f02b0acc", "body": {"id": "chatcmpl-9St2QNYt54wjL18I1ZOsMd0oApGrG", "object": "chat.completion", "created": 1716671778, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumab, marketed under the brand name Poteligeo, is a monoclonal antibody used for the treatment of certain types of cutaneous T-cell lymphoma (CTCL), specifically for adult patients with relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS) after at least one prior systemic therapy. Here are some key points you should know about mogamulizumab:\n\n1. **Mechanism of Action**: Mogamulizumab targets CC chemokine receptor 4 (CCR4), which is frequently expressed on the surface of tumor cells in CTCL. By binding to CCR4, mogamulizumab mediates antibody-dependent cellular cytotoxicity (ADCC) against the tumor cells.\n\n2. **Approval and Indications**: Mogamulizumab was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of adult"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yrEWXTUn36e2mUr3ZfY4wIkh", "custom_id": "175_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02050bcf72b91e8fccb0c6f641dadd1c", "body": {"id": "chatcmpl-9St2RJU350aC7cZQRMzSYSCJjDuqP", "object": "chat.completion", "created": 1716671779, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox, also known by its brand name Lumoxiti, is a targeted therapy used in the treatment of certain types of cancer. It is specifically indicated for the treatment of adult patients with hairy cell leukemia (HCL) who have relapsed or refractory disease. Here are some key points about moxetumomab pasudotox that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Moxetumomab pasudotox is a recombinant immunotoxin composed of a monoclonal antibody that targets CD22, a protein expressed on the surface of B cells, fused to a bacterial toxin, Pseudomonas exotoxin A. The drug binds to CD22 on malignant B cells, is internalized, and then the toxin portion induces cell death by inhibiting protein synthesis.\n\n2. **Indications**: As mentioned, it is approved for the treatment of adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_4PzSqZQOtHgcwPwhwbIgHvtE", "custom_id": "176_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4d36161439d3ec4278d238d41994d29", "body": {"id": "chatcmpl-9St2REIJydEOhgC92cSzkvrEqQRau", "object": "chat.completion", "created": 1716671779, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) used primarily for the prevention and treatment of thromboembolic disorders. Here are some key points you should know about nadroparin:\n\n1. **Mechanism of Action**: Nadroparin works by enhancing the inhibition of Factor Xa and Factor IIa (thrombin) through its action on antithrombin III. This results in reduced formation of fibrin, thereby preventing clot formation.\n\n2. **Indications**:\n   - Prevention of venous thromboembolic events (VTE) in patients undergoing surgery, especially orthopedic or general surgery.\n   - Treatment of deep vein thrombosis (DVT) with or without pulmonary embolism.\n   - Prevention of clotting in extracorporeal circulation during hemodialysis.\n\n3. **Dosage and Administration**: The dosage of nadroparin varies based on the indication, patient's body weight, and renal function. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_grudSB8jS4CktJjvIUyoSonc", "custom_id": "177_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f82a49f45cfef954e76de2eb1e31e350", "body": {"id": "chatcmpl-9St2RUJCj78Vw6TSqvBLMXZRTfV72", "object": "chat.completion", "created": 1716671779, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab (trade name Portrazza) is a recombinant human IgG1 monoclonal antibody used as a treatment for cancer. It specifically targets the epidermal growth factor receptor (EGFR), a receptor found on the surface of many tumor cells as well as normal cells. Here are some key points you should know about necitumumab:\n\n1. **Indications**: Necitumumab is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.\n\n2. **Mechanism of Action**: Necitumumab binds to the EGFR with high affinity and blocks the binding of the natural ligands, such as EGF and transforming growth factor-alpha. This inhibition prevents the activation of the receptor and the subsequent activation of downstream signaling pathways that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XpyoQGxeyDZqJNqDrNAqKHYt", "custom_id": "178_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b745fcc3dc2b490a48de96389193259b", "body": {"id": "chatcmpl-9St2RPUAoABH1rt8D2JpwPDPQhvdW", "object": "chat.completion", "created": 1716671779, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is a platinum-based antineoplastic medication used primarily in cancer chemotherapy. It is similar to cisplatin, another platinum-containing drug, but is generally associated with fewer side effects, particularly nephrotoxicity (kidney damage) and neurotoxicity (nerve damage). Here are some key points about nedaplatin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Nedaplatin works by causing cross-linking of DNA, which inhibits DNA synthesis and function, leading to cell death. This mechanism is similar to other platinum-based drugs.\n\n2. **Indications**: It is commonly used in the treatment of various cancers, including cervical cancer, non-small cell lung cancer, and esophageal cancer. Its effectiveness in these cancers has been demonstrated in several studies, often showing comparable efficacy to cisplatin but with a different side effect profile.\n\n3. **Administration**: Nedaplatin is administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TO0Thgdu806jxdLJJ76W65ju", "custom_id": "179_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bf63be387b4f9bc66d144e8dbc92e0e7", "body": {"id": "chatcmpl-9St2SCrGbzHEVtkqQZUTH5bRCBTNp", "object": "chat.completion", "created": 1716671780, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nelarabine is a chemotherapy medication used primarily to treat certain types of leukemia and lymphoma, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are some key points about nelarabine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Nelarabine is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), a nucleoside analog. It gets converted into ara-GTP, which is incorporated into DNA, leading to inhibition of DNA synthesis and cell death. It is specifically cytotoxic to T-cells.\n\n2. **Indications**:\n   - Nelarabine is approved for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy reg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_Twju7CMjffhA1necdCDRflj8", "custom_id": "180_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f31543a98e3aad4622462b7b97ce8f39", "body": {"id": "chatcmpl-9St2SsXGexqr5MrWcY4dzDvOyna6z", "object": "chat.completion", "created": 1716671780, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib (brand name Nerlynx) is an oral tyrosine kinase inhibitor specifically designed for the treatment of breast cancer. Here are some key points you should know about neratinib:\n\n1. **Indications**: Neratinib is primarily used for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. It is also used in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.\n\n2. **Mechanism of Action**: Neratinib works by irreversibly binding to the HER2 receptor tyrosine kinase and other HER family receptors (EGFR, HER4), inhibiting their activity and blocking signal transduction pathways that promote cell growth and survival.\n\n3. **Dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B9vO2OVx1TSUqBFW5Uyi3KKH", "custom_id": "181_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e26d86a088bfda476bd06e5ff3fbbcd", "body": {"id": "chatcmpl-9St2T8C6WMRwMcHnjuB2triSfIZYr", "object": "chat.completion", "created": 1716671781, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilotinib, marketed under the name Tasigna, is a tyrosine kinase inhibitor specifically used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Nilotinib:\n\n1. **Indications**: Nilotinib is primarily indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive CML in adults who are resistant to or intolerant of prior therapy that included imatinib. It is also approved for newly diagnosed adult patients with Philadelphia chromosome-positive CML in the chronic phase.\n\n2. **Mechanism of Action**: Nilotinib works by selectively inhibiting the BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome in CML cells. This inhibition blocks the proliferation and promotes the apoptosis (programmed cell death) of leukemic cells.\n\n3. **Administration**: Nilotinib is administered orally, and its absorption is affected by food intake. It should be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K65q8JT1hTgBkJuOeaOvuoGh", "custom_id": "182_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e3be8394616cf4fe33231296584697b5", "body": {"id": "chatcmpl-9St2UqoxnDpaC7YEjq2zkcnruOMl6", "object": "chat.completion", "created": 1716671782, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen (NSAA) primarily used in the treatment of prostate cancer. Here are some key points you should know about nilutamide:\n\n1. **Indications**: Nilutamide is used for the treatment of advanced prostate cancer, particularly in the setting of metastatic disease. It is often used in combination with surgical or chemical castration.\n\n2. **Mechanism of Action**: Nilutamide acts by binding to androgen receptors and inhibiting their interaction with androgens (such as testosterone and dihydrotestosterone). This prevents the stimulation of androgen-dependent prostate cancer cells.\n\n3. **Administration**: Nilutamide is administered orally. The dosage and treatment regimen may vary based on the stage of cancer and the specific characteristics of the patient.\n\n4. **Side Effects**: Common side effects include hot flashes, nausea, and constipation. Nilutamide can also cause more serious side effects such as interstitial pneumonitis, hepatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gsddHTAcalL2PPHL3b5i4hYh", "custom_id": "183_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f20267d63dee5a417ad96ea0a1836eaf", "body": {"id": "chatcmpl-9St2UdyqFC3TQNYmKkOr47hYkhjzr", "object": "chat.completion", "created": 1716671782, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine (also known as ACNU) is a nitrosourea compound used as a chemotherapeutic agent. It is primarily used in the treatment of various types of brain tumors, including gliomas, astrocytomas, and malignant gliomas. Nimustine can also be used in the treatment of Hodgkin's disease and other lymphomas. Here are some key points you should know about Nimustine:\n\n1. **Mechanism of Action**: Nimustine is an alkylating agent that works by cross-linking DNA and RNA, thereby inhibiting DNA synthesis and function. This leads to cell cycle arrest and apoptosis in rapidly dividing tumor cells.\n\n2. **Administration**: Nimustine is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's body surface area, and overall health.\n\n3. **Side Effects**: Like other chemotherapy drugs, Nimustine can cause a range of side effects. Common side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AbdpwnVGw4szqnphif3u8W54", "custom_id": "184_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb7ef955929a4697d2f510966287cf28", "body": {"id": "chatcmpl-9St2VUs6DTZd9ihtxfuWAqSMGdMYe", "object": "chat.completion", "created": 1716671783, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib is a medication primarily used in the management of certain chronic lung diseases. Here are some key points about Nintedanib that you, as a physician, might find useful:\n\n1. **Indications**:\n   - **Idiopathic Pulmonary Fibrosis (IPF)**: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis, where it helps to slow the progression of the disease.\n   - **Chronic Fibrosing Interstitial Lung Diseases (ILDs)**: It is also indicated for use in other chronic fibrosing ILDs with a progressive phenotype.\n   - **Scleroderma-Associated ILD**: Nintedanib can be used to slow the rate of decline in pulmonary function in patients with this condition.\n   - **Non-Small Cell Lung Cancer (NSCLC)**: In some regions, nintedanib is used in combination with docetaxel for NSCL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ufN1KCbW0XUMtx6Pld0q6dTo", "custom_id": "185_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d374396ac6477aaa33f9797718d664a", "body": {"id": "chatcmpl-9St2Wm3a425Ds5m1hXCgMMuq1avS3", "object": "chat.completion", "created": 1716671784, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib is a medication used primarily in the treatment of ovarian cancer. Here are some key points you should know about Niraparib:\n\n1. **Mechanism of Action**: Niraparib is a selective inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, which play a role in DNA repair. By inhibiting PARP, niraparib causes DNA damage to accumulate in cancer cells, ultimately leading to cell death. This is particularly effective in cells that are already compromised in their ability to repair DNA, such as those with BRCA mutations.\n\n2. **Indications**: Niraparib is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Additionally, it is approved for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in patients who have been"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2n0EEPaC2MVVFDRTuBuuaV6L", "custom_id": "186_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a500ef00ca3bf8b2d19bf385133e686d", "body": {"id": "chatcmpl-9St2WeeUZcfRe8H9SVzERuxsajeBt", "object": "chat.completion", "created": 1716671784, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab, marketed under the brand name Opdivo, is a medication used in cancer immunotherapy. It is a type of drug known as a programmed death-1 (PD-1) inhibitor, which works by blocking the PD-1 protein on the surface of certain immune cells, allowing the immune system to attack cancer cells more effectively. Here are some key points about Nivolumab that you, as a physician, might find useful:\n\n### Mechanism of Action\n- **PD-1 Inhibition:** Nivolumab binds to the PD-1 receptor on T cells and prevents its interaction with PD-L1 and PD-L2 on tumor cells and other cells in the tumor environment. This blockade enhances T-cell responses, including anti-tumor responses.\n\n### Indications\nNivolumab has been approved for the treatment of various types of cancers, including but not limited to:\n- **Melanoma:** For the treatment of unresectable or metastatic melan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8ou1Olt8KvmneSrFag6zKIUu", "custom_id": "187_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "511da2405b6afaadaf12f5cbf86e9077", "body": {"id": "chatcmpl-9St2Xav02MpdeBf9tuVAUPfePxbKS", "object": "chat.completion", "created": 1716671785, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Non-pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin that is encapsulated within liposomes without the addition of polyethylene glycol (PEG). This encapsulation helps to alter the distribution of the drug, potentially reducing some of the cardiotoxicity and other side effects associated with conventional doxorubicin, while maintaining its antitumor efficacy.\n\nHere are some key points you should know about non-pegylated liposomal doxorubicin:\n\n1. **Mechanism of Action**: Like traditional doxorubicin, non-pegylated liposomal doxorubicin interferes with the growth of cancer cells by intercalating DNA, disrupting topoisomerase-II-mediated DNA repair, and generating free radicals that damage cellular components.\n\n2. **Indications**: It is commonly used for the treatment of various cancers, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. The specific indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cZtZ4tOymgme26YTkJ56iZhE", "custom_id": "188_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6026d14478cacae0d9514f7f0ca4a131", "body": {"id": "chatcmpl-9St2XmoNxSJTl6Ux5VtQePFFHyfeE", "object": "chat.completion", "created": 1716671785, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone is a synthetic, orally active anabolic-androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone). It was first synthesized in the 1950s and has been used in the medical field for various purposes, though its use has become less common over time due to the development of newer drugs and concerns about side effects.\n\n### Medical Uses\nHistorically, norethandrolone has been used for a variety of indications, including:\n- To stimulate muscle growth and appetite in conditions causing muscle wasting or significant weight loss.\n- As part of treatment for certain types of anemia.\n- To support recovery from severe burns.\n- To treat osteoporosis and other conditions leading to bone loss.\n\n### Mechanism of Action\nNorethandrolone acts similarly to other anabolic steroids by increasing protein synthesis within cells, which results in the buildup of cellular tissue (anabolism), especially in muscles. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_FQMJYIRH7qzCNrzVJ0Lnv2GY", "custom_id": "189_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c462e03e814faea86b2b8b08608534ec", "body": {"id": "chatcmpl-9St2YjJcB7qDuGPQQfe2mNoDW2pY6", "object": "chat.completion", "created": 1716671786, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Obinutuzumab (also known by its brand name Gazyva) is a monoclonal antibody used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about obinutuzumab:\n\n1. **Indications**: Obinutuzumab is approved for use in treating:\n   - Chronic lymphocytic leukemia (CLL), often in combination with chlorambucil for patients who have not previously been treated.\n   - Follicular lymphoma (FL), where it is used in patients who have relapsed or are refractory to a rituximab-containing regimen. It is also used in combination with chemotherapy followed by obinutuzumab monotherapy in patients achieving a response.\n\n2. **Mechanism of Action**: Obinutuzumab is a type II anti-CD20 monoclonal antibody. It binds to the CD20 antigen on B-cells, leading to cell death."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LC1k7bVzB4k9I1jv8JSD08c9", "custom_id": "190_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8f47af1126e3ae20fcac77cf0592cdc5", "body": {"id": "chatcmpl-9St2YqJrj9U9qQLRlUnYVzZIdaXn0", "object": "chat.completion", "created": 1716671786, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It is primarily used in the management of acromegaly and gastroenteropancreatic neuroendocrine tumors, such as carcinoid syndrome and vasoactive intestinal peptide secreting tumors (VIPomas).\n\nHere are some key points about Octreotide that you, as a physician, might find useful:\n\n### Indications\n1. **Acromegaly**: Octreotide is used to reduce growth hormone (GH) production and IGF-1 levels in patients with acromegaly, particularly when surgery and radiotherapy are not viable options.\n2. **Carcinoid Tumors**: It helps in controlling the symptoms of carcinoid syndrome such as flushing and diarrhea.\n3. **VIPomas**: Octreotide can reduce symptoms such as watery diarrhea, hyp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wRN7y6UEcV6tpzaIbTj3wdGK", "custom_id": "191_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "725bc9264447ca0fdb85ba34e91231b2", "body": {"id": "chatcmpl-9St2ZxjMtGKY4fdSXHNGXPIhjL05L", "object": "chat.completion", "created": 1716671787, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide long-acting release (LAR) is a synthetic octapeptide analog of naturally occurring somatostatin, used primarily to treat acromegaly and symptoms caused by neuroendocrine tumors, most commonly carcinoid tumors and vasoactive intestinal peptide (VIP) secreting adenomas. Here are some key points about Octreotide LAR that you, as a physician, might find useful:\n\n### Mechanism of Action\nOctreotide works by mimicking natural somatostatin pharmacologically, albeit with a longer duration of action. It inhibits the secretion of several hormones, such as growth hormone (GH), insulin, glucagon, thyroid-stimulating hormone (TSH), and certain gastrointestinal hormones.\n\n### Indications\n- **Acromegaly**: Octreotide LAR is used for long-term treatment in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom these therapies are not appropriate.\n- **Carcin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gWJrd2v8oYojBbJNnSGyksEO", "custom_id": "192_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "225fba6d01864fabdf1dafb19f3e5114", "body": {"id": "chatcmpl-9St2ZNVfGg3CYtGLc4KOSjeOylZK5", "object": "chat.completion", "created": 1716671787, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a monoclonal antibody used primarily in the treatment of certain medical conditions, including chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). Here are some key points you should know about ofatumumab:\n\n1. **Mechanism of Action**: Ofatumumab targets the CD20 molecule found on the surface of B cells. It binds to the small and large extracellular loops of CD20, which leads to B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Ofatumumab is approved for the treatment of CLL, particularly in patients who are refractory to fludarabine and alemtuzumab.\n   - **Multiple Sclerosis (MS)**: Ofatumumab (sold under the brand name Kesimpta) is approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E9ksX383qx5fBBBAmVotGSY3", "custom_id": "193_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b24d3fe82524f6a9b7c551101296d7d", "body": {"id": "chatcmpl-9St2ZaNAQ4enCPvbGcdhEcS2LUwnI", "object": "chat.completion", "created": 1716671787, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib (brand name Lynparza) is a medication used primarily in oncology, particularly for treating certain types of cancers that are associated with genetic mutations. Here are some key points about Olaparib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes play a role in DNA repair, particularly in repairing single-strand breaks. By inhibiting PARP, Olaparib causes DNA damage to accumulate in cells, which can lead to cell death. This is particularly effective in cancer cells that have defective homologous recombination repair mechanisms, such as those with BRCA1 or BRCA2 mutations.\n\n2. **Indications**: Olaparib is approved for the treatment of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients who have BRCA mutations and who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Su97CDWQmqGfa6ZLx8RQIQmS", "custom_id": "194_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e453461c0f2eb9364ebfea292ea2858a", "body": {"id": "chatcmpl-9St2Z3BPNpFr790E2H1Sl39dDCSiE", "object": "chat.completion", "created": 1716671787, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaratumab (trade name Lartruvo) is a monoclonal antibody that was used in the treatment of cancer, specifically for soft tissue sarcoma. It targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), a protein that plays a role in tumor growth and development. Here are some key points you should know about Olaratumab:\n\n1. **Mechanism of Action**: Olaratumab works by binding to PDGFR-\u03b1, inhibiting its activation and signaling which can contribute to the growth and spread of cancer cells.\n\n2. **Indications**: Initially, Olaratumab was approved for use in combination with doxorubicin for the treatment of adults with certain types of soft tissue sarcoma that are unresectable or metastatic and who have not been previously treated with doxorubicin.\n\n3. **Approval and Withdrawal**: Olaratumab received accelerated approval by the FDA in 2016 based on phase II"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_o7rWTTiXDt66XJdSlnrzqIPi", "custom_id": "195_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a36fcc4b386ea6f5c8034e0c0273bb2", "body": {"id": "chatcmpl-9St2alBO5YlbzVEU37eMesyIrhV2C", "object": "chat.completion", "created": 1716671788, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, marketed under the brand name Synribo, is a medication used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about omacetaxine:\n\n1. **Mechanism of Action**: Omacetaxine works differently from other CML treatments. It is a cephalotaxine ester that acts as a protein translation inhibitor. It primarily works by inhibiting the synthesis of certain proteins which are necessary for cancer cell survival and proliferation. This mechanism is distinct from tyrosine kinase inhibitors (TKIs) that target the BCR-ABL fusion protein directly.\n\n2. **Indications**: Omacetaxine is approved for the treatment of adult patients with chronic or accelerated phase CML who are resistant or intolerant to two or more tyrosine kinase inhibitors. It provides an option for patients who have limited responses to other therapies.\n\n3. **Administration**: The drug"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sMOCiEj0R8KYXhzUP88kG2Uf", "custom_id": "196_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "09f3ab39005b65ea3fde7af3d952a24e", "body": {"id": "chatcmpl-9St2b7n5rcAx8cBrWNoQsbSBwA8q0", "object": "chat.completion", "created": 1716671789, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omeprazole is a commonly prescribed medication that falls under the category of proton pump inhibitors (PPIs). It is primarily used to treat conditions related to excessive stomach acid production. Here are some key points you should know about omeprazole:\n\n1. **Mechanism of Action**: Omeprazole works by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. This action blocks the final step of acid production, thereby reducing gastric acidity.\n\n2. **Indications**:\n   - **Gastroesophageal Reflux Disease (GERD)**: It is used for the treatment of erosive esophagitis and for maintenance of healing in erosive esophagitis.\n   - **Peptic Ulcer Disease**: It can be used for the treatment of duodenal and gastric ulcers.\n   - **Zollinger-Ellison Syndrome**: Omeprazole is effective in treating this condition,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GxTdDUvvBzHCbCG7LIAOAs0s", "custom_id": "197_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55f2da8706e382694d8655d4779a12b6", "body": {"id": "chatcmpl-9St2bFCcEd7C4aFeL2HSsagVbGZM4", "object": "chat.completion", "created": 1716671789, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib (marketed under the brand name Tagrisso) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points about Osimertinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This specificity helps in managing resistance to first and second-generation EGFR TKIs.\n\n2. **Indications**:\n   - It is primarily used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific types of EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations).\n   - It is also used as a first-line"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EEtHLPKCqTckwubBK73pAKvp", "custom_id": "198_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6bbe8487ffc7fbf70ccef54f3ef79715", "body": {"id": "chatcmpl-9St2c3AEZD6qLSeC9G9OHMpXx4BQ6", "object": "chat.completion", "created": 1716671790, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. It is often used in combination with other drugs such as fluorouracil and leucovorin in a regimen known as FOLFOX. Here are some key points about oxaliplatin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Oxaliplatin works by forming platinum-DNA adducts in cancer cells, which inhibit DNA synthesis and transcription, leading to cell death. This is similar to other platinum compounds like cisplatin and carboplatin.\n\n2. **Indications**:\n   - Primarily used for the treatment of stage III and stage IV colorectal cancer.\n   - It can be used as adjuvant therapy in stage III colon cancer patients following complete resection of the primary tumor.\n   - It is also used in the treatment of metastatic colorectal cancer.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sv3Er6POTMeftC4nZRKyUkpR", "custom_id": "199_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc4ce7f176e6a506d32c1d13aa19a8b0", "body": {"id": "chatcmpl-9St2cSJfpT6hlzzwbFn3cYkTL1gvT", "object": "chat.completion", "created": 1716671790, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel nanoparticle albumin-bound (nab-paclitaxel) is a novel formulation of the chemotherapeutic agent paclitaxel, which is traditionally used in the treatment of various cancers. This formulation is designed to improve the solubility and delivery of paclitaxel, enhancing its efficacy and reducing some of its common side effects. Here are some key points you should know about nab-paclitaxel:\n\n1. **Mechanism of Action**: Nab-paclitaxel works by stabilizing microtubules and inhibiting their disassembly, which disrupts mitosis and inhibits cell division. This is similar to the mechanism of action of conventional paclitaxel but delivered in a novel formulation.\n\n2. **Formulation**: Unlike traditional paclitaxel, which requires solvents like Cremophor EL that can cause hypersensitivity reactions, nab-paclitaxel uses albumin nanoparticles as a delivery vehicle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5fR8QnMCSyOeqS8TiJQsFV8M", "custom_id": "200_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46aab0ec29b73cfdcea28de3a7218d09", "body": {"id": "chatcmpl-9St2cc9ItgIYT7mqgpGC5yx7x6rvv", "object": "chat.completion", "created": 1716671790, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is a chemotherapy medication used primarily to treat various forms of cancer, including ovarian, breast, lung, pancreatic, and other cancers. It is also used in the treatment of Kaposi's sarcoma. Here are some key points about Paclitaxel that you, as a physician, should be aware of:\n\n### Mechanism of Action\nPaclitaxel works by inhibiting cell division by stabilizing microtubules and preventing their depolymerization, which in turn inhibits the normal breakdown of microtubules during cell division. This action blocks the progression of mitosis, leading to cell cycle arrest at the G2/M phase, and eventually leads to cell death.\n\n### Indications\n- **Breast cancer:** Used as a first-line treatment and for metastatic cases.\n- **Ovarian cancer:** Used in cases where there is resistance to platinum-based chemotherapy.\n- **Lung cancer:** Effective in non-small cell lung"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fpIfeEx1JX1ptnXQRAzrdKC9", "custom_id": "201_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7b0aa7f3095f3c83b369e5d7f04b1674", "body": {"id": "chatcmpl-9St2cwg4UddbfMynGoWuBXkxlj6pi", "object": "chat.completion", "created": 1716671790, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is a medication that has been developed for the treatment of certain conditions, primarily myelofibrosis, a type of bone marrow cancer that disrupts the body's normal production of blood cells. Here are some key points you should know about pacritinib:\n\n1. **Mechanism of Action**: Pacritinib is a kinase inhibitor that targets Janus Associated Kinases (JAKs), with activity against JAK2 and FLT3. JAK signaling is involved in the regulation of blood cell production and immune function. By inhibiting these pathways, pacritinib can help manage the proliferation of malignant cells in myelofibrosis.\n\n2. **Indications**: Pacritinib is primarily used for the treatment of adults with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tQ8Zk1YdzmUWH4BOQPujs5Am", "custom_id": "202_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fdc66d137c59a8dda426de388d582cab", "body": {"id": "chatcmpl-9St2dugB0O0P9vEXszEAwuBLytNPB", "object": "chat.completion", "created": 1716671791, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib, marketed under the brand name Ibrance among others, is a medication used in the treatment of HR-positive, HER2-negative breast cancer. It is specifically indicated for use in combination with an aromatase inhibitor or fulvestrant in women with metastatic or advanced-stage disease. Here are some key points about palbociclib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, palbociclib causes a cell cycle arrest at the G1 phase, leading to inhibition of DNA synthesis and cell proliferation.\n\n2. **Indications**:\n   - In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with estrogen receptor (ER)-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vG7kFaDAK6KCs82hcnxhQGny", "custom_id": "203_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90c8419c638105fdc7303b6176b30725", "body": {"id": "chatcmpl-9St2e9U0BYCG2xiQS706v5k6iRTFd", "object": "chat.completion", "created": 1716671792, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab (brand name Vectibix) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points you should know about panitumumab:\n\n1. **Mechanism of Action**: Panitumumab is an epidermal growth factor receptor (EGFR) antagonist. It binds specifically to the EGFR on both normal and tumor cells and competitively inhibits the binding of ligands for EGFR. This inhibition blocks the phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased pro-inflammatory cytokine and vascular growth factor production.\n\n2. **Indications**: It is approved for use in patients with metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The effectiveness of panitumumab depends on the absence of RAS mutations in the tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_R3HBBvQgneQEzvKyhSYT2fBl", "custom_id": "204_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "990053819a451333654fd885c6d028c4", "body": {"id": "chatcmpl-9St2eYFiKeF3DAaQ36pbbQp4M2vrD", "object": "chat.completion", "created": 1716671792, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat is a potent oral histone deacetylase (HDAC) inhibitor used primarily in the treatment of multiple myeloma. Here are some key points you should know about Panobinostat:\n\n1. **Mechanism of Action**: Panobinostat works by inhibiting the activity of histone deacetylase enzymes. This inhibition leads to an increase in acetylation of histone proteins, resulting in altered gene expression. The effect of increased acetylation can lead to cell cycle arrest, apoptosis, and inhibition of tumor growth and angiogenesis.\n\n2. **Indications**: Panobinostat is approved for use in combination with bortezomib (a proteasome inhibitor) and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. This combination is typically used in patients who have shown"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aMsgmd8uJ0elUF5SxvYIHcv4", "custom_id": "205_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0fae012c910895c4e8186b56314271c6", "body": {"id": "chatcmpl-9St2enk8vVuIrgCpyzcm7BWjts5fB", "object": "chat.completion", "created": 1716671792, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib is a medication used primarily in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. Here are some key points you should know about pazopanib as a physician:\n\n1. **Mechanism of Action**: Pazopanib is a tyrosine kinase inhibitor. It works by inhibiting multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-\u03b1 and \u03b2, and c-KIT. These receptors are involved in both tumor growth and angiogenesis (the formation of new blood vessels that supply the tumor with nutrients and oxygen).\n\n2. **Indications**:\n   - **Renal Cell Carcinoma (RCC)**: It is approved for the treatment of advanced RCC.\n   - **Soft Tissue Sarcoma (STS)**: It is also approved for the treatment of advanced soft tissue sarcomas in patients who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nSv9DcjzT0l2fpPOcGKg9QHK", "custom_id": "206_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1628cfa8552a3f579be6864ce4b276f5", "body": {"id": "chatcmpl-9St2e0SFj2Ps8x6RvVXBgQmUhOomd", "object": "chat.completion", "created": 1716671792, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is a modified enzyme that catalyzes the conversion of the amino acid asparagine into aspartic acid and ammonia, effectively depleting asparagine. Since certain malignant cells, such as those in ALL, are unable to synthesize asparagine, they rely on the circulating supply of this amino acid. By depleting asparagine, pegaspargase starves the cancer cells, inhibiting their ability to proliferate.\n\nHere are some key points you should know about Pegaspargase:\n\n1. **Mechanism of Action**: Pegaspargase is a pegylated form of L-asparaginase. Pegylation extends the enzyme's circulating half-life, allowing for less frequent dosing compared to non-pegylated forms.\n\n2. **Indications**: It is primarily used for the treatment of patients with acute lymph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WMHdxhUlrYSHhEE1smUgd5iu", "custom_id": "207_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4181afdb8775f9d257fdce73abe69d65", "body": {"id": "chatcmpl-9St2frISQiSRZfD02huqFFZHWPftQ", "object": "chat.completion", "created": 1716671793, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2a is a medication used primarily in the treatment of hepatitis C and, in some cases, hepatitis B. It is a pegylated form of interferon alfa-2a, which means it has been chemically modified to improve its stability and duration of action in the body. Here are some key points you should know about Peginterferon alfa-2a:\n\n### Mechanism of Action\nPeginterferon alfa-2a works by stimulating the body's immune system to fight off viral infections. It binds to interferon receptors on cell surfaces, activating intracellular signaling pathways that lead to the expression of genes that inhibit viral replication, enhance the degradation of viral RNA, and increase the antigen presentation to immune cells.\n\n### Indications\n- **Chronic Hepatitis C:** It is used either alone or more commonly in combination with other antiviral drugs such as ribavirin and direct-acting antivir"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EhXi8IgT9ZA2WO7zryNmeixO", "custom_id": "208_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52cd6c042ee1509f5108997327254b73", "body": {"id": "chatcmpl-9St2gDWUGUtJkbY5MT6T4RXA0YjXZ", "object": "chat.completion", "created": 1716671794, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a medication used primarily for the treatment of hepatitis C and, in some cases, for melanoma. It is a pegylated form of interferon alfa-2b, meaning it has been chemically modified with polyethylene glycol to improve its pharmacokinetic properties, allowing for less frequent dosing and more stable blood levels compared to its non-pegylated counterpart. Here are some key points you should know about Peginterferon alfa-2b:\n\n### Mechanism of Action\nPeginterferon alfa-2b works by stimulating the immune system to fight off viral infections and inhibit tumor growth. It binds to interferon receptors on cell surfaces, activating intracellular signaling pathways that lead to the expression of interferon-stimulated genes. These genes help in antiviral, antiproliferative, and immunomodulatory activities.\n\n### Indications\n- **Chronic Hepatitis C"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6dxeSURX9qWVt4au8QcVBuR3", "custom_id": "209_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "795bb24bc76b361209bb3c20eb9e0f27", "body": {"id": "chatcmpl-9St2heZfVNof1Ahi4hMyrnbS8lkzP", "object": "chat.completion", "created": 1716671795, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin, which is encapsulated in liposomes coated with polyethylene glycol (PEG). This formulation alters the pharmacokinetics of the drug, allowing for better distribution to the tumor sites and reduced toxicity compared to conventional doxorubicin. Here are some key points you should know about pegylated liposomal doxorubicin:\n\n1. **Indications**: It is primarily used for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. It may also be used in the treatment of other cancers as part of research or in cases where traditional chemotherapy has failed.\n\n2. **Mechanism of Action**: Doxorubicin works by intercalating DNA strands, inhibiting topoisomerase II, and producing free radicals, which collectively prevent cancer cells from replicating and ultimately lead to cell death. The liposomal delivery system allows for prolonged"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Y1e9TA6dgmNn1Q7XLthxwwKY", "custom_id": "210_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5298b19183e24d1483182e721a85fdf", "body": {"id": "chatcmpl-9St2heM8USZ7HCdtX67daDP9yoRaV", "object": "chat.completion", "created": 1716671795, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab (brand name Keytruda) is an immune checkpoint inhibitor used in cancer immunotherapy. It is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on lymphocytes, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1, pembrolizumab allows the immune system to better recognize and attack cancer cells.\n\nHere are some key points about pembrolizumab that you, as a physician, might find useful:\n\n### Indications\nPembrolizumab is approved for use in various types of cancers, including but not limited to:\n- Melanoma\n- Non-small cell lung cancer (NSCLC)\n- Small cell lung cancer (SCLC)\n- Head and neck squamous cell carcinoma (HNSCC)\n- Classical Hodgkin lymphoma\n- Urothelial carcinoma\n- Microsatellite instability-high (MSI-H)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WThqb4PE8sMbUdcsCQzBWoN1", "custom_id": "211_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea6267788b0c10f20dbc650dca6cffb1", "body": {"id": "chatcmpl-9St2hOZtIQSFMSncCMbEKmpz1eLZY", "object": "chat.completion", "created": 1716671795, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed (brand name Alimta) is a chemotherapy drug primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer. As a physician, here are several key aspects of pemetrexed you should be aware of:\n\n### Mechanism of Action\nPemetrexed is a multitargeted antifolate, which means it inhibits several of the enzymes involved in the purine and pyrimidine synthesis pathways. This inhibition leads to the disruption of DNA and RNA synthesis, which is more harmful to rapidly dividing cells, such as cancer cells.\n\n### Indications\n- **Malignant Pleural Mesothelioma:** Pemetrexed is used in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.\n- **Non-Small Cell Lung Cancer (NSCLC):** It is used as a first-line"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X1bXTWCNLoQjeOkL1gGEse58", "custom_id": "212_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2956c420609d2d40ddab149d46eae2e0", "body": {"id": "chatcmpl-9St2hLLygVRhj9dMlRvN3z6VsgirW", "object": "chat.completion", "created": 1716671795, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin, also known by its brand name Nipent, is a chemotherapy medication primarily used in the treatment of hairy cell leukemia. It is a nucleoside analog that inhibits adenosine deaminase, an enzyme that is necessary for the growth and survival of lymphocytes, particularly B cells. Here are some key points you should know about Pentostatin:\n\n1. **Indications**: Pentostatin is most commonly used for the treatment of hairy cell leukemia. It may also be considered for other conditions as part of clinical trials or off-label use, including certain types of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma.\n\n2. **Mechanism of Action**: Pentostatin is a potent inhibitor of adenosine deaminase, leading to the accumulation of deoxyadenosine triphosphate (dATP). This accumulation causes a disruption in DNA synthesis and repair, leading to cell death, particularly in lymphoid cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wri1BpFnC5ykRRrb4bQaEoDQ", "custom_id": "213_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47bd5d9b10ea2d3e485772bfeecf0884", "body": {"id": "chatcmpl-9St2itIr7qsrhkVrZ0ciittBdpxuj", "object": "chat.completion", "created": 1716671796, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pertuzumab (brand name Perjeta) is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. It works by targeting the HER2 receptor, a protein overexpressed in some types of breast cancer, which promotes the growth of cancer cells. Here are some key points about pertuzumab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pertuzumab binds to the extracellular dimerization domain (subdomain II) of the HER2 receptor and inhibits the dimerization of HER2 with other HER family members, including HER1, HER3, and HER4. This mechanism is complementary to trastuzumab, another HER2-targeted therapy, which binds to a different domain (subdomain IV) of HER2.\n\n2. **Clinical Use**: Pertuzumab is used for the treatment of HER2-positive breast cancer, particularly in the neoadjuvant ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_V8gG5EOKp3mfxZMo0sb92e4R", "custom_id": "214_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "103c73fccf26271a011ff5e0dde348e1", "body": {"id": "chatcmpl-9St2jmxzzyCNfUM0A0p9Cxeegu7fs", "object": "chat.completion", "created": 1716671797, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin, also known as THP-adriamycin, is a chemotherapeutic agent that belongs to the anthracycline class of drugs, similar to doxorubicin. It is used primarily in the treatment of various cancers, including breast cancer, bladder cancer, and lymphomas. Here are some key points you should know about pirarubicin:\n\n1. **Mechanism of Action**: Pirarubicin acts by intercalating into DNA, thereby disrupting the replication and transcription processes. It also inhibits topoisomerase II, an enzyme critical for DNA replication. These actions lead to the induction of apoptosis in rapidly dividing cancer cells.\n\n2. **Pharmacokinetics**: Compared to doxorubicin, pirarubicin has a slightly different pharmacokinetic profile, which may result in different tissue distribution and potentially reduced cardiotoxicity, although heart damage is still a significant risk.\n\n3. **Indications**: Pirarubicin is used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tSCt3OKMa6nUTgbAgKPnvGWU", "custom_id": "215_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7b9540082c179d65365c615b65f2257b", "body": {"id": "chatcmpl-9St2jgb3mPI8kxWPkJLmT5z5DRIx1", "object": "chat.completion", "created": 1716671797, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a novel aza-anthracenedione antineoplastic agent that is structurally related to anthracyclines but designed to reduce the potential for cardiotoxicity. It is primarily used in the treatment of non-Hodgkin's lymphoma. Here are some key points you should know about pixantrone:\n\n1. **Mechanism of Action**: Pixantrone intercalates into DNA and inhibits topoisomerase II, leading to breaks in double-stranded DNA and ultimately cell death. Its structure allows it to form stable DNA adducts and generate free radicals, which contribute to its cytotoxic effects.\n\n2. **Indications**: It is approved for use in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) who have previously received other therapies. The specific indications and approval status can vary by country, so it's important to check local guidelines.\n\n3. **Administration**: Pix"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_F7eM2SXGH0E63RhLQRcYBJQ3", "custom_id": "216_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "262ef8509617c48db5d78dabf545c2fc", "body": {"id": "chatcmpl-9St2jElCs9Bn1fxcvCdxbttNstnoo", "object": "chat.completion", "created": 1716671797, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin, also known as mithramycin, is a cytotoxic antibiotic that was historically used in the treatment of various types of cancer, including testicular carcinoma, and Paget's disease of bone. It is derived from the bacterium Streptomyces plicatus. Here are some key points you should know about plicamycin:\n\n1. **Mechanism of Action**: Plicamycin binds to DNA and inhibits RNA synthesis, which in turn disrupts protein synthesis. This action primarily affects rapidly proliferating cells, such as cancer cells.\n\n2. **Clinical Uses**: Historically, plicamycin has been used to treat testicular cancer, hypercalcemia of malignancy, and Paget\u2019s disease. However, its use has declined due to the availability of newer agents with better efficacy and safety profiles.\n\n3. **Side Effects**: Plicamycin can cause severe side effects, which have limited its use. These include thrombocytopen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xnZ2UI3rzU0HyHw2JB8UAiPj", "custom_id": "217_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea770a857203ff875f63eb6c1b39af2f", "body": {"id": "chatcmpl-9St2lSGLz7tbfXveuWyzHsrdkRiDA", "object": "chat.completion", "created": 1716671799, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is a medication primarily used in the treatment of multiple myeloma, a type of cancer that affects plasma cells. It belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs), which also includes thalidomide and lenalidomide. Here are some key points about pomalidomide that you, as a physician, might find useful:\n\n1. **Indications**: Pomalidomide is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\n2. **Mechanism of Action**: Pomalidomide's mechanism is similar to other IMiDs. It modulates the immune system and also has anti-angiogenic properties. It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells, mod"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_imWtq30ox8h8MCt2tEnjkMUB", "custom_id": "218_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "05913284d5c0b9e6629c4fa9a7348209", "body": {"id": "chatcmpl-9St2lQPjjRh9pVglkcuW57ObFAbJs", "object": "chat.completion", "created": 1716671799, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinib is a potent tyrosine kinase inhibitor (TKI) primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some key points you should know about Ponatinib:\n\n1. **Mechanism of Action**:\n   Ponatinib works by inhibiting the activity of BCR-ABL tyrosine kinase, an abnormal protein that signals cancer cells to multiply. It is particularly effective against the T315I mutation in the BCR-ABL gene, which is resistant to other available TKIs.\n\n2. **Indications**:\n   - **Chronic Myeloid Leukemia (CML)**: Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase CML who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n   - **Philadelphia Chromosome-Positive Acute Lymphoblastic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TAHX2biHfuuNswKu9hVcRqyg", "custom_id": "219_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "596354da85c58b762d8bd708221cd850", "body": {"id": "chatcmpl-9St2mIGbQZeaXd14Do8XVRJuU1mjm", "object": "chat.completion", "created": 1716671800, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralatrexate (brand name Folotyn) is a chemotherapeutic agent used primarily in the treatment of peripheral T-cell lymphoma (PTCL), a type of non-Hodgkin lymphoma. Here are some key points about pralatrexate that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Pralatrexate is a folate analogue metabolic inhibitor that selectively enters cells via the reduced folate carrier and folate receptors. Its mechanism involves inhibiting dihydrofolate reductase (DHFR), which leads to the inhibition of DNA synthesis and cellular replication.\n\n2. **Indications**:\n   Pralatrexate is approved by the FDA for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This approval is based on the overall response rate observed in clinical trials.\n\n3. **Administration**:\n   Pralatrexate is administered via intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JUNWRugtxaKShovkSCuHIc38", "custom_id": "220_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "047a5aab283efa720863409b9a84502c", "body": {"id": "chatcmpl-9St2nm62Cr4c9JB57PPs47pp6WUvM", "object": "chat.completion", "created": 1716671801, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a member of the statin class of drugs, primarily used to manage elevated cholesterol levels and prevent cardiovascular disease. Here are some key points you should know about pravastatin:\n\n1. **Mechanism of Action**: Pravastatin works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This leads to a decrease in the level of low-density lipoprotein (LDL) cholesterol and triglycerides, and a modest increase in high-density lipoprotein (HDL) cholesterol.\n\n2. **Indications**:\n   - Hypercholesterolemia (primary and mixed)\n   - Primary prevention of cardiovascular events in patients with multiple risk factors for coronary heart disease (CHD) such as age, smoking, hypertension, low HDL-C, or a family history of early heart disease.\n   - Secondary prevention of cardiovascular events in patients with clinically evident CHD.\n\n3. **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CWFZSM5VAcCOPoZAR9lGGw3h", "custom_id": "221_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3187c4e745cbc3f98be1021420dffd3c", "body": {"id": "chatcmpl-9St2nvNTarLruhjtmJUBaBMGt10lo", "object": "chat.completion", "created": 1716671801, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisolone is a corticosteroid medication commonly used to reduce inflammation and suppress the immune system. It is used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and inflammatory conditions such as arthritis. Here are some key points you should know about prednisolone:\n\n### Pharmacology\n- **Mechanism of Action**: Prednisolone mimics the effects of cortisol, a steroid hormone produced by the adrenal glands. It acts primarily by modulating gene expression, leading to decreased production of inflammatory mediators and suppression of immune response.\n- **Bioavailability**: Prednisolone has high bioavailability when taken orally.\n\n### Indications\n- **Autoimmune Disorders**: Such as lupus and multiple sclerosis.\n- **Respiratory Diseases**: Including asthma and COPD.\n- **Allergic Reactions**: Severe allergies and anaphylactic reactions.\n- **Dermatological Conditions**: Such as eczema and psoriasis.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HQb0X16sGFIo4FTZqPrFCeOD", "custom_id": "222_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b12a0d091373b3e4bc9feae8b39ca318", "body": {"id": "chatcmpl-9St2oPc1xf7INVIj2E3SBaYG6oH4Z", "object": "chat.completion", "created": 1716671802, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisone is a corticosteroid drug that is commonly used to reduce inflammation and suppress the immune system. It is used to treat a variety of conditions, including autoimmune diseases, inflammatory conditions (such as arthritis), and some types of cancer. Here are some key points you should know about prednisone:\n\n1. **Mechanism of Action**: Prednisone mimics the effects of cortisol, a steroid hormone produced by the adrenal glands. It reduces inflammation by inhibiting multiple inflammatory pathways and suppressing the migration of neutrophils and reversal of increased capillary permeability. It also suppresses the immune system by reducing the activity and volume of the lymphatic system.\n\n2. **Indications**: Prednisone is prescribed for a wide range of conditions, including rheumatoid arthritis, lupus, asthma, allergies, and chronic obstructive pulmonary disease (COPD). It is also used in the treatment of inflammatory bowel diseases like Crohn's disease and ulcerative colitis,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iioNVr6QY6pkQHq9g9Pr8waT", "custom_id": "223_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c421e674053a741bf04a4e4ea2522351", "body": {"id": "chatcmpl-9St2omWPExqwzI0R75NejFekFsf06", "object": "chat.completion", "created": 1716671802, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is a chemotherapy medication primarily used in the treatment of Hodgkin's lymphoma and brain cancers. It is often administered as part of combination chemotherapy regimens, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) for Hodgkin's lymphoma. Here are some key points about procarbazine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nProcarbazine works by inhibiting DNA, RNA, and protein synthesis, which leads to the death of rapidly dividing cancer cells. Its exact mechanism is not fully understood, but it is thought to act as an alkylating agent and also to generate hydrogen peroxide, which damages cellular components.\n\n### Indications\n- **Primary**: Hodgkin's lymphoma (as part of combination therapy).\n- **Other Uses**: It has also been used in the treatment of brain tumors (e.g., gliomas), and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kBKSHic2SPvreiUHYSQOUIQ7", "custom_id": "224_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "028d07c6c9a3b29147fbb8f5ce14464c", "body": {"id": "chatcmpl-9St2pqN6oNKnBF4d2FLoTdGPvYO1m", "object": "chat.completion", "created": 1716671803, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinine is a medication primarily used for the treatment and prevention of malaria. It is derived from the bark of the cinchona tree and has been used for centuries. Here are some key points you should know about quinine as a physician:\n\n1. **Indications**: Quinine is most commonly used for the treatment of malaria. It is particularly effective against Plasmodium falciparum malaria when used in combination with other antimalarials. It can also be used for nocturnal leg cramps, although this use is less common and can be controversial due to potential side effects.\n\n2. **Mechanism of Action**: Quinine acts primarily as a blood schizonticide, meaning it kills the erythrocytic stages of the malaria parasite, which are responsible for the clinical symptoms of malaria. It interferes with the parasite's ability to metabolize and utilize erythrocyte hemoglobin.\n\n3. **Administration**: Quinine is available in oral and intravenous forms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZaRBhTaUZ2tAxVXRwg3HQxKy", "custom_id": "225_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fad678212bb1f15cb9da311c6ec8e5b3", "body": {"id": "chatcmpl-9St2qUMlzocFjXKeByGUW2lPhWnaG", "object": "chat.completion", "created": 1716671804, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib is a tyrosine kinase inhibitor that specifically targets FLT3 (FMS-like tyrosine kinase 3). FLT3 is a commonly mutated gene in acute myeloid leukemia (AML), and these mutations are associated with a poor prognosis in AML patients. Quizartinib inhibits the FLT3 signaling pathway, which is involved in the proliferation and survival of leukemic cells.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Quizartinib is primarily investigated for use in patients with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation. The presence of FLT3-ITD (internal tandem duplication) mutations can particularly influence the response to this drug.\n\n2. **Mechanism of Action:**\n   - Quizartinib selectively inhibits the FLT3 enzyme, which can be constitutively active in some forms of leukemia due to genetic mutations like FLT3-ITD or FLT3-TKD ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_eNQwnRe2YFdDB8nKuYGzKNuh", "custom_id": "226_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "95bd3ef5cc8fddf8cf4e53bf2acc07cc", "body": {"id": "chatcmpl-9St2rqSkjXE6UJN6jRUpoBHTr9sjP", "object": "chat.completion", "created": 1716671805, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinib (INNO-406) is a tyrosine kinase inhibitor (TKI) specifically designed to target BCR-ABL, a fusion protein that is the hallmark of chronic myeloid leukemia (CML). It is primarily used in the treatment of CML, particularly in cases where patients have developed resistance or intolerance to first-line treatments such as imatinib, or other second-generation TKIs like dasatinib or nilotinib.\n\n### Key Points about Radotinib:\n\n1. **Mechanism of Action**:\n   - Radotinib inhibits the BCR-ABL tyrosine kinase, an abnormal protein produced by the Philadelphia chromosome in CML cells. By inhibiting this protein, radotinib helps to control the proliferation of leukemic cells.\n\n2. **Indications**:\n   - It is mainly used for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive CML in adult patients who are resistant or intolerant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_W8svLrUc1Z8bqxqmybBnjDIM", "custom_id": "227_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cef7bf22ace4c3163f69f3f09e4bd407", "body": {"id": "chatcmpl-9St2rnOQo9gXiIxNIgQec2w0WapO6", "object": "chat.completion", "created": 1716671805, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed is a chemotherapy drug primarily used in the treatment of colorectal cancer. It belongs to the class of drugs known as antifolates, which inhibit the synthesis of thymidylate, an essential precursor for DNA synthesis. Here are some key points you should know about raltitrexed:\n\n1. **Mechanism of Action**: Raltitrexed inhibits thymidylate synthase (TS), an enzyme that catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). This inhibition leads to a depletion of thymidine triphosphate (dTTP), which is necessary for DNA replication and repair, thereby causing cell death in rapidly dividing cells.\n\n2. **Indications**: It is primarily used for the treatment of advanced colorectal cancer, particularly in patients who cannot tolerate or have contraindications to fluoropyrimidine-based therapy.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BUb4eX2xsN0GRz12m6Si7y3v", "custom_id": "228_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32b17efe5a5f2dc8931245bf5d54d366", "body": {"id": "chatcmpl-9St2sZMmUUMsf9vnHdqNBF05HTX7w", "object": "chat.completion", "created": 1716671806, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab (brand name Cyramza) is a monoclonal antibody used primarily in the treatment of certain types of cancer. It functions as an angiogenesis inhibitor by targeting the vascular endothelial growth factor receptor 2 (VEGFR2), which plays a key role in the formation of blood vessels (angiogenesis) that supply tumors with nutrients and oxygen, which are essential for their growth and survival.\n\nHere are some key points about Ramucirumab that you, as a physician, might find useful:\n\n### Indications\nRamucirumab is approved for use in various cancers, often in combination with other chemotherapy agents. Its indications include:\n- **Gastric cancer and gastro-esophageal junction adenocarcinoma**: It is approved for advanced cases as a single agent or in combination with paclitaxel.\n- **Non-small cell lung cancer (NSCLC)**: Used in combination with docetaxel for metastatic NS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MgLEJlSnlqBJ3eD3LHsM4Opy", "custom_id": "229_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0e2edebe584783c771707a4558b9dfe1", "body": {"id": "chatcmpl-9St2teHpHLC5eqYG708Kx86WMabD0", "object": "chat.completion", "created": 1716671807, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine, also known by its chemical name ranimustine and under the brand name Cymerin, is a nitrosourea compound used in chemotherapy. It is primarily used in Japan for the treatment of various cancers, including malignant lymphoma and multiple myeloma. Here are some key points you should know about ranimustine:\n\n1. **Mechanism of Action**: Ranimustine acts by alkylating DNA and RNA, which leads to cross-linking and ultimately the disruption of DNA function, inhibiting the replication of cancer cells. This is similar to the mechanism of action of other nitrosoureas.\n\n2. **Usage**: It is used to treat certain types of cancers, particularly hematological malignancies. The specific indications and usage might vary, and it's important to refer to the local guidelines and product information for detailed indications.\n\n3. **Administration**: Ranimustine is typically administered intravenously. The dosage and schedule depend on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TkR6fQS5duwV3WmUBrPXgms7", "custom_id": "230_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ced0043b42a0b67ca442b83f716f0a21", "body": {"id": "chatcmpl-9St2uv0so1RY05lgRtY6Hlxa7pmik", "object": "chat.completion", "created": 1716671808, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib (brand name Stivarga) is a medication used in the treatment of certain types of cancers. It is a multi-kinase inhibitor, which means it works by blocking several enzymes that promote cancer growth. Here are some key points you should know about Regorafenib:\n\n1. **Indications**:\n   - Regorafenib is approved for use in the treatment of metastatic colorectal cancer (CRC) in patients who have previously been treated with other therapies.\n   - It is also used for the treatment of locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) that has progressed on or is intolerant to imatinib and sunitinib.\n   - Additionally, it is indicated for the treatment of hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib.\n\n2. **Mechanism of Action**:\n   - Regorafenib is a small molecule inhibitor of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Xf6RgWDvyCqVSPwlnmX3yyyQ", "custom_id": "231_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb82bb41c6a7e5eaf5ba89d8148579d1", "body": {"id": "chatcmpl-9St2wZqbjS5UhSsrNyDw6AC6JvVYh", "object": "chat.completion", "created": 1716671810, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib, sold under the brand name Kisqali among others, is a medication used primarily in the treatment of HR-positive, HER2-negative breast cancer. Here are some key points you should know about Ribociclib:\n\n1. **Indications**: Ribociclib is approved for use in combination with an aromatase inhibitor (such as letrozole) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is also used in combination with fulvestrant in women with disease progression following endocrine therapy.\n\n2. **Mechanism of Action**: Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the cell cycle progression and cellular proliferation. By inhibiting these kinases, riboc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dUUPUYOQIoX90XmVzFSDApmp", "custom_id": "232_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0a52f613cb70dd2a8b7b362c6a1c0481", "body": {"id": "chatcmpl-9St2x5RxoG46pWF2fZbpnrO3NzHJZ", "object": "chat.completion", "created": 1716671811, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab is a monoclonal antibody that targets the CD20 antigen on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis, which can be through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Here are some key points you should know about rituximab:\n\n### Indications\nRituximab is used in the treatment of various conditions, including:\n- **Non-Hodgkin's lymphoma (NHL)**: It is effective in treating both indolent and aggressive forms of NHL.\n- **Chronic lymphocytic leukemia (CLL)**: It is used in combination with chemotherapy for CLL.\n- **Rheumatoid arthritis (RA)**: Rituximab is used in RA patients who have had an inadequate response to TNF inhibitors.\n- **Granulomatosis with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4r6lXCOJU98ZQNRCiPs2U1os", "custom_id": "233_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fca78bb969cdf521b9b784dda4b22ca4", "body": {"id": "chatcmpl-9St2xpuKrtV1AQaVg5VK04tXDNf2Y", "object": "chat.completion", "created": 1716671811, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication used primarily in the treatment of certain types of cancer and autoimmune diseases. This combination includes rituximab, a monoclonal antibody that targets the CD20 antigen on B lymphocytes, and hyaluronidase, an enzyme that increases tissue permeability, allowing the rituximab to be administered subcutaneously rather than intravenously. This can significantly reduce administration time and improve patient comfort.\n\n### Indications\nRituximab and hyaluronidase human is approved for use in:\n- Non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy.\n- Chronic lymphocytic leukemia (CLL) in combination with chemotherapy.\n- It may also be used off-label for other conditions that are typically treated with rituximab.\n\n### Administration\n- The medication is administered subcutaneously, which allows for a faster and potentially more convenient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GXgNoo5FGuS0EOVzE4vfetsJ", "custom_id": "234_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4227b70e42f2b81a85af66fc6bd044ce", "body": {"id": "chatcmpl-9St2yovfuxMIO3i0JXXpVfwp3A1H2", "object": "chat.completion", "created": 1716671812, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin, also known by its brand name Istodax, is a chemotherapy medication used primarily in the treatment of certain types of cancer, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is classified as a histone deacetylase (HDAC) inhibitor. Here are some key points you should know about Romidepsin:\n\n1. **Mechanism of Action**: Romidepsin works by inhibiting the activity of histone deacetylases (HDAC). This inhibition leads to an increase in acetylation of histone proteins, resulting in alterations in gene expression that can induce cell cycle arrest, apoptosis, and differentiation of cancer cells.\n\n2. **Indications**:\n   - **Cutaneous T-cell lymphoma (CTCL)**: Romidepsin is approved for the treatment of CTCL in patients who have received at least one prior systemic therapy.\n   - **Peripheral T-cell lymph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_b7zSuw3yzUjnqlB6hQhDglFE", "custom_id": "235_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "93101f3151109b152a160d9a36025ffb", "body": {"id": "chatcmpl-9St2y90qIMKqWF1qtJplyLfZFgYyF", "object": "chat.completion", "created": 1716671812, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b is a medication used primarily in the treatment of polycythemia vera, a type of blood cancer characterized by the overproduction of red blood cells. It is a long-acting, mono-pegylated form of interferon, designed to be administered less frequently than other types of interferon. Here are some key points you should know about Ropeginterferon alfa-2b:\n\n1. **Mechanism of Action**: Ropeginterferon alfa-2b works by mimicking the body's natural immune responses. Interferons are proteins that are part of the immune response and have antiviral, antiproliferative, and immunomodulatory effects. This drug specifically targets the JAK-STAT signaling pathway, which is often dysregulated in polycythemia vera.\n\n2. **Indications**: It is approved for the treatment of adults with polycythemia vera without symptomatic spl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Y7AQqM0pgeluYsc2DqOdeJyd", "custom_id": "236_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5fcfc34b6163ded822f831ad65d2c99b", "body": {"id": "chatcmpl-9St2zxmHRVgT3WYdg5mifviR1eaxu", "object": "chat.completion", "created": 1716671813, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rucaparib is a medication primarily used in the treatment of ovarian cancer. Here are some key points you should know about rucaparib:\n\n1. **Indications**: Rucaparib is approved for the treatment of advanced ovarian cancer in patients who have received two or more chemotherapies and whose tumors have a deleterious BRCA mutation (germline and/or somatic). It is also used for the maintenance treatment of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status.\n\n2. **Mechanism of Action**: Rucaparib is a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes play a role in DNA repair, and inhibitors like rucaparib can prevent the repair of DNA damage in cancer cells, particularly those with existing defects in DNA repair pathways such as those caused by BRCA mutations. This leads to an accumulation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QMDt23yDmPVICgAA70V7nExy", "custom_id": "237_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "63e957bf029b5972e908ce71382de4df", "body": {"id": "chatcmpl-9St2z5JoCnHqP6KkNaK7HIW0PBvm7", "object": "chat.completion", "created": 1716671813, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication used primarily in the treatment of certain blood disorders. Here are some key points you should know about ruxolitinib:\n\n1. **Mechanism of Action**: Ruxolitinib is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which is crucial in the regulation of blood cell production. By inhibiting this pathway, ruxolitinib can help control overactive signaling that contributes to the pathology of certain diseases.\n\n2. **Indications**:\n   - **Myelofibrosis**: Ruxolitinib is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n   - **Polycythemia Vera**: It is used in patients with polycythemia vera who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HBaThQNjelgnch7ZPhn65Tqb", "custom_id": "238_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fbdeaedca5761d449782a900468ccf34", "body": {"id": "chatcmpl-9St30eD476W6csr2DnLqjwj4cVVh9", "object": "chat.completion", "created": 1716671814, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sacituzumab govitecan, also known by its brand name Trodelvy, is an antibody-drug conjugate (ADC) used in oncology, particularly for the treatment of certain types of cancer. It consists of an anti-Trop-2 antibody linked to the cytotoxic agent SN-38, which is the active metabolite of irinotecan. Trop-2 is a cell surface glycoprotein that is overexpressed in many epithelial cancers, making it a suitable target for targeted cancer therapy.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - As of the last update, Sacituzumab govitecan has been approved by the FDA for the treatment of triple-negative breast cancer (TNBC) in patients who have received at least two prior therapies for metastatic disease.\n   - It has also been approved for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2BptrfyBK40K389yGwTLXrE5", "custom_id": "239_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "599692026c084d5918489822d476ea12", "body": {"id": "chatcmpl-9St30fA5b4TM4l4RLIYJ2EXPLW6kQ", "object": "chat.completion", "created": 1716671814, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used primarily to promote bone marrow recovery after myelosuppressive chemotherapy, bone marrow transplantation, or in conditions like severe chronic neutropenia. It is a critical cytokine that stimulates the production and function of white blood cells, particularly neutrophils, monocytes, and macrophages. Here are some key points you should know about Sargramostim:\n\n### Indications\n1. **Neutrophil Recovery After Chemotherapy**: Sargramostim is used to accelerate neutrophil recovery and reduce the incidence of infection in patients who have undergone autologous or allogeneic bone marrow transplantation or have been treated with myelosuppressive chemotherapy.\n2. **Bone Marrow Transplantation**: It is used to promote engraftment of autologous or allogeneic bone marrow transplants.\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aoNRIw5foA2fjy73wLVSnsFG", "custom_id": "240_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9806796a1b336da6bb6367f62f30006c", "body": {"id": "chatcmpl-9St30PzxZJHRQlhxoGvBBBbS4O2EG", "object": "chat.completion", "created": 1716671814, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexor (brand name Xpovio) is an oral selective inhibitor of nuclear export (SINE) compound that specifically inhibits the nuclear export protein exportin 1 (XPO1 or CRM1). Here are some key points about Selinexor that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Selinexor works by inhibiting the nuclear export protein XPO1. This inhibition leads to the accumulation of tumor suppressor proteins in the cell nucleus, enhancing their anti-cancer activity and potentially leading to cancer cell death.\n\n2. **Indications**: Selinexor has been approved by the U.S. Food and Drug Administration (FDA) for specific oncological indications. As of the last update:\n   - In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Bv8xXXY5ZWmQEOt9u9hMsoHe", "custom_id": "241_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c893ee68a070a38220e89fff84b7a9a", "body": {"id": "chatcmpl-9St32FG5ncx8eYuJEMVs4zjRKHHZI", "object": "chat.completion", "created": 1716671816, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selumetinib is a medication used in the treatment of certain types of cancers. It is a kinase inhibitor, specifically targeting the mitogen-activated protein kinases 1 and 2 (MEK1 and MEK2). MEK1 and MEK2 are part of the RAS/RAF/MEK/ERK signaling pathway, which regulates cell division and survival. By inhibiting MEK, selumetinib can help to stop the growth and spread of cancer cells.\n\nHere are some key points about selumetinib:\n\n1. **Indications**: Selumetinib is approved for specific indications, such as the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. The effectiveness of selumetinib in these cases has been shown in clinical trials.\n\n2. **Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_SnntwZ8czDJTj5eRSKh6YlC3", "custom_id": "242_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c147753dac461b6065a2dc846461bc53", "body": {"id": "chatcmpl-9St33ITW7bRU3IdvLRF2SA1f0reXa", "object": "chat.completion", "created": 1716671817, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known by its chemical name methyl-CCNU or under the brand name Me-CCNU, is a type of chemotherapy drug that belongs to the nitrosourea class. It is primarily used in the treatment of various types of cancer, including brain tumors, Hodgkin\u2019s disease, and gastrointestinal cancers. Here are some key points you should know about Semustine:\n\n1. **Mechanism of Action**: Semustine works by cross-linking DNA and RNA, thereby inhibiting DNA synthesis. This action leads to cell death, particularly in rapidly dividing cancer cells. Like other nitrosoureas, Semustine is alkylating in nature and can cross the blood-brain barrier, which makes it useful in treating brain tumors.\n\n2. **Administration**: Semustine is typically administered orally in capsule form.\n\n3. **Dosage**: The dosage of Semustine can vary based on the type of cancer being treated, the patient's body surface area, overall"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_gNlerfIQYbqStF7k49GEzBR8", "custom_id": "243_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2f446bbcf59abca62fac673fcc50403", "body": {"id": "chatcmpl-9St33zlxZC7tNkCrdfvSC9m1xUkw3", "object": "chat.completion", "created": 1716671817, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T (brand name Provenge) is an immunotherapy treatment specifically designed for advanced prostate cancer, particularly for metastatic castration-resistant prostate cancer (mCRPC). Here are some key points you should know about Sipuleucel-T:\n\n1. **Mechanism of Action**: Sipuleucel-T is a form of cancer vaccine that uses the patient's own immune cells to stimulate an immune response against prostate cancer. It is not a traditional vaccine that prevents disease, but rather a therapeutic one that treats existing disease. The treatment involves collecting a patient's peripheral blood mononuclear cells (including antigen-presenting cells) via leukapheresis, which are then exposed to a fusion protein (PA2024) in vitro. PA2024 is a recombinant protein that links prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, to an immune-stimulating factor (GM-CSF). The activated cells are then re"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zIzdijHAbpFoGYytKpISxbX9", "custom_id": "244_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "744659b25a1d74d42ee417cfa291f2b2", "body": {"id": "chatcmpl-9St33igDImZggKMtJDhactQcQNiui", "object": "chat.completion", "created": 1716671817, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib, also known by its brand name Odomzo, is a medication used in the treatment of locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in cases where neither surgery nor radiation is appropriate. Here are some key points about Sonidegib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Sonidegib is an inhibitor of the Hedgehog signaling pathway, which is active in most basal cell carcinomas. It specifically inhibits the protein Smoothened (SMO), which plays a pivotal role in the Hedgehog pathway.\n\n2. **Indications**: It is approved for use in patients with locally advanced basal cell carcinoma that has recurred after surgery or radiation, or for patients who are not candidates for these therapies.\n\n3. **Administration**: Sonidegib is taken orally, and the dosage is typically 200 mg once daily, taken on an empty stomach"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fihXE1KHp1wxS22G6OGeG1sh", "custom_id": "245_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d1fdf317bf3a5b2414efdc444225172c", "body": {"id": "chatcmpl-9St34sOGtJnX9UgoxuCdvGkCU70dq", "object": "chat.completion", "created": 1716671818, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib, marketed under the brand name Nexavar, is a kinase inhibitor drug used primarily for the treatment of certain types of cancers. Here are some key points you should know about Sorafenib:\n\n1. **Indications**: Sorafenib is approved for the treatment of advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinoma (HCC), and radioactive iodine-resistant advanced thyroid carcinoma.\n\n2. **Mechanism of Action**: Sorafenib works by inhibiting multiple intracellular (CRAF, BRAF, and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-\u03b2). These kinases are involved in both tumor cell proliferation and tumor angiogenesis. By inhibiting these pathways, Sorafenib helps to decrease tumor growth and spread.\n\n3. **Administration**: Sorafenib is administered orally, and the dosage may vary based on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_akjMuu2dREDRbpwse1KpiGXK", "custom_id": "246_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a6148e3829c306bc3a689235d1e33aac", "body": {"id": "chatcmpl-9St353pc98PeFhIaLX1VxGLCNwJYQ", "object": "chat.completion", "created": 1716671819, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also spelled streptozotocin) is a chemotherapy drug used primarily to treat pancreatic islet cell tumors, such as those found in patients with metastatic islet cell carcinoma or gastrinoma. It is particularly useful in treating tumors that secrete hormones. Here are some key points about streptozocin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   - Streptozocin is a naturally occurring alkylating agent derived from Streptomyces achromogenes. It specifically targets pancreatic beta cells. The drug causes alkylation of DNA, which leads to DNA strand breaks and ultimately cell death. It is also toxic to the insulin-secreting pancreatic beta cells, which explains its effectiveness in treating insulinomas.\n\n2. **Indications**:\n   - Streptozocin is approved for use in the treatment of metastatic islet cell carcinoma of the pancreas"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_efkJA2hNwq4EMt0eprdqH1NC", "custom_id": "247_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "352e08047de4d8a3651d233dde58f7e6", "body": {"id": "chatcmpl-9St35QOGoakzsyof7YWcThxWTp7M3", "object": "chat.completion", "created": 1716671819, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib, marketed under the brand name Sutent among others, is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of certain types of cancers. Here are some key points about Sunitinib that you, as a physician, might find useful:\n\n### Indications\nSunitinib is primarily used for the treatment of:\n- Advanced renal cell carcinoma (RCC)\n- Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate\n- Advanced pancreatic neuroendocrine tumors (pNETs)\n\n### Mechanism of Action\nSunitinib inhibits multiple receptor tyrosine kinases (RTKs). These include platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_juvPycL4XDbOTfHt19lQRilz", "custom_id": "248_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3837aa2d6cf7f6fd3161c75da1922f87", "body": {"id": "chatcmpl-9St35XZX1Jzld2qoYT2Sj8T6gN1P3", "object": "chat.completion", "created": 1716671819, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp, also known by its trade name Elzonris, is a targeted therapy used in the treatment of certain types of cancer. It is particularly indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy. Here are some key points about Tagraxofusp that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tagraxofusp is a fusion protein that combines interleukin-3 (IL-3) with a truncated diphtheria toxin. The IL-3 component binds to the IL-3 receptor (CD123) which is overexpressed on the surface of BPDCN cells and some other hematologic malignancy cells. Once bound, the toxin component is internalized, inhibiting protein synthesis and leading to cell death.\n\n2. **Indications**: As of the latest updates, Tagraxofusp is approved by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oDqgYOwoAItviv3zh950IjDL", "custom_id": "249_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b35f1ac231a6fb64e0819b467b1edea2", "body": {"id": "chatcmpl-9St36ON2nqo3BAMHihXeuJw6GGJ16", "object": "chat.completion", "created": 1716671820, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib (brand name Talzenna) is a medication used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about talazoparib:\n\n1. **Mechanism of Action**: Talazoparib is a PARP (poly ADP-ribose polymerase) inhibitor. It works by inhibiting the PARP enzyme, which plays a role in DNA repair. By inhibiting PARP, talazoparib causes DNA damage to accumulate in cancer cells, leading to cell death. This is particularly effective in cells that are already compromised in their ability to repair DNA, such as those with BRCA mutations.\n\n2. **Indications**: Talazoparib is approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients should be selected for therapy based on an FDA-approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_tx8GCMSUbInavQFOwTsRtzrO", "custom_id": "250_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c98622d593615e81b88cc7f3330cdf90", "body": {"id": "chatcmpl-9St36IOURjFS4dI0t9gNp8sLBaD8X", "object": "chat.completion", "created": 1716671820, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec, commonly known by its brand name Imlygic, is an oncolytic virus therapy used for the treatment of melanoma lesions in the skin and lymph nodes that cannot be surgically removed. It was the first oncolytic virus therapy approved by the U.S. Food and Drug Administration (FDA) in October 2015. Here are some key points you should know about talimogene laherparepvec:\n\n1. **Mechanism of Action**: Talimogene laherparepvec is derived from the herpes simplex virus type 1 (HSV-1). It has been genetically modified to selectively replicate within tumors and to produce the immune-stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). This modification both causes direct lysis (destruction) of tumor cells and stimulates a systemic immune response against cancer cells.\n\n2. **Indications**: It is specifically indicated for the local"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_z3DrlohCbznLznG527B91xZ9", "custom_id": "251_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c3c6e89b96aada1ef2a00e2a5f673fd2", "body": {"id": "chatcmpl-9St37uGyqQQtZsDErOmc0tUOx6hEk", "object": "chat.completion", "created": 1716671821, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene, also known by its chemical name Am80, is a synthetic retinoid that has been developed for the treatment of various diseases, primarily acute promyelocytic leukemia (APL). Here are some key points you should know about tamibarotene:\n\n1. **Mechanism of Action**: Tamibarotene is believed to work by binding to retinoic acid receptors (RARs), particularly RAR\u03b1 and RAR\u03b2. This binding alters gene expression, promoting the differentiation and apoptosis of leukemic cells. It is structurally similar to all-trans retinoic acid (ATRA) but has been designed to be more potent and less toxic.\n\n2. **Indications**: It is primarily used for the treatment of acute promyelocytic leukemia, especially in cases where ATRA (all-trans retinoic acid) is either not effective or causes severe side effects. It may also have potential uses in other conditions, but these"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aAyB0RFAY8JipqnyGgGYrSJh", "custom_id": "252_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d83c2915c8693c09c5eca8ea92557e07", "body": {"id": "chatcmpl-9St373p3O3VM1HLjiXrC0uJCrortR", "object": "chat.completion", "created": 1716671821, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a medication that is primarily used in the treatment and prevention of breast cancer. As a physician, here are some key points you should know about Tamoxifen:\n\n1. **Mechanism of Action**: Tamoxifen is a selective estrogen receptor modulator (SERM). It works by binding to estrogen receptors on breast cells, thereby blocking estrogen from binding to these receptors. This inhibition is crucial in breast cancer types that are estrogen receptor-positive (ER-positive), as these cancers require estrogen to grow.\n\n2. **Indications**:\n   - **Treatment of breast cancer**: Tamoxifen is used in the treatment of ER-positive breast cancer in both premenopausal and postmenopausal women and men.\n   - **Prevention of breast cancer**: It is also used to reduce the risk of developing breast cancer in individuals at high risk.\n\n3. **Administration**: Tamoxifen is typically administered orally, and the dosage may vary based on the indication and patient characteristics.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NTj24oc4mCPTlESGveHdfAGn", "custom_id": "253_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b11b6a2982731597cec2fc8bafec133", "body": {"id": "chatcmpl-9St371C2whNsAc3cpAIBNu4mgQgnC", "object": "chat.completion", "created": 1716671821, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur/gimeracil/oteracil, also known by the brand name Teysuno or S-1, is a chemotherapy medication used primarily in the treatment of gastric cancer, including gastroesophageal junction cancer. It is a combination drug that includes three active substances: tegafur, gimeracil, and oteracil, each playing a specific role in enhancing the efficacy and reducing the toxicity of the treatment.\n\n### Components and Mechanism of Action:\n1. **Tegafur**: This is a prodrug of 5-fluorouracil (5-FU), which itself is a widely used chemotherapeutic agent. Tegafur is converted into 5-FU in the body. 5-FU is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in DNA synthesis and function, which is particularly effective in rapidly dividing cancer cells.\n\n2. **Gimeracil"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OD7T6NWIwUlVBE8V3zV0d7wU", "custom_id": "254_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3bdb065f39222b65f1384e5cb1858f38", "body": {"id": "chatcmpl-9St38gvw0wlRqIi60ug8YyFr4r88a", "object": "chat.completion", "created": 1716671822, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil are components of a combination chemotherapy drug used primarily in the treatment of various cancers, including colorectal cancer, gastric cancer, and pancreatic cancer. This combination is often referred to by the brand name UFT or as tegafur-uracil. Here are some key points you should know about this combination:\n\n1. **Mechanism of Action**:\n   - **Tegafur**: Tegafur is a prodrug of 5-fluorouracil (5-FU), which means it is converted into 5-FU in the body. 5-FU is a pyrimidine analog that inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This inhibition results in the disruption of DNA synthesis and function, leading to cell death, particularly in rapidly dividing cancer cells.\n   - **Uracil**: Uracil is included in the combination because it inhibits the degradation of 5-F"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_BezbFZBJRrh1Ybx9sMYTbpxz", "custom_id": "255_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "803b9d930a2c9d721f39096f2df04faf", "body": {"id": "chatcmpl-9St38mVxMaBvJ7h34lFoBntqJ47R5", "object": "chat.completion", "created": 1716671822, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is an oral chemotherapy drug commonly used to treat certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here are some key points about temozolomide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Temozolomide is an alkylating agent that works by adding an alkyl group to DNA, which damages the DNA and triggers cell death. It is particularly effective against rapidly dividing cells, such as cancer cells.\n\n2. **Indications**: Temozolomide is primarily used for the treatment of high-grade malignant gliomas. It is often used in conjunction with radiation therapy for newly diagnosed glioblastoma multiforme following surgical resection, and as a second-line treatment for gliomas that have recurred or progressed after standard therapy.\n\n3. **Administration**: Temozolomide is available in capsule form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fO0nevJcIntelCot9NBq1g1U", "custom_id": "256_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "daf32ecca474b784150552c0372535e5", "body": {"id": "chatcmpl-9St38tY0UuYU0IrfhwBGn0DfpoVSL", "object": "chat.completion", "created": 1716671822, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temsirolimus, sold under the brand name Torisel, is an intravenous drug primarily used in the treatment of advanced renal cell carcinoma (kidney cancer). It is a specific inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase. By inhibiting mTOR, temsirolimus interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells.\n\nHere are some key points you should know about temsirolimus:\n\n### Mechanism of Action\n- Temsirolimus inhibits the mTOR pathway, which is a central regulator of tumor cell division and angiogenesis (growth of new blood vessels essential for tumor growth). This inhibition leads to a decrease in the synthesis of proteins that are critical for the survival of cancer cells.\n\n### Indications\n- The primary indication for temsirolimus is the treatment of advanced renal cell carcinoma. It may also be considered in other types of cancers as part of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2FVidGI40ZcYNS790qECjHo9", "custom_id": "257_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d29c77081d90d3d763ff9f69c222e4a4", "body": {"id": "chatcmpl-9St39gYNc70r7JW1CtvtcqDF7aBYX", "object": "chat.completion", "created": 1716671823, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teniposide is a chemotherapeutic agent primarily used in the treatment of cancer. Here are some key points you should know about teniposide:\n\n1. **Mechanism of Action**: Teniposide is a type II topoisomerase inhibitor. It works by causing DNA damage by stabilizing the DNA-topoisomerase II complex, preventing the ligation of the DNA strands and thereby inhibiting DNA synthesis and triggering cell death.\n\n2. **Indications**: It is most commonly used to treat certain types of cancer, including childhood acute lymphoblastic leukemia (ALL), Hodgkin's and non-Hodgkin's lymphoma, and certain brain tumors. It is often used in combination with other chemotherapeutic agents.\n\n3. **Administration**: Teniposide is administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's size, and their overall health, among other factors.\n\n4. **Side Effects**: Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IRWMWy5dUOhSuAFqarWEW3xk", "custom_id": "258_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec8c1598c314e06130181ad9abddb723", "body": {"id": "chatcmpl-9St39PwlnhL22KuTy1bJeaGseOySi", "object": "chat.completion", "created": 1716671823, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a medication with a complex history and significant implications for medical practice, particularly in terms of its teratogenic effects and its use in certain diseases. Here are key points you should know:\n\n1. **Historical Context**: Thalidomide was first marketed in 1957 in Germany as a sedative or hypnotic, and it was later found to be effective for morning sickness in pregnant women. However, it was not subjected to the rigorous testing standards that are required today, leading to unforeseen consequences.\n\n2. **Teratogenic Effects**: Thalidomide became infamous in the early 1960s after it was linked to severe birth defects, primarily phocomelia (a condition involving malformation of the limbs). The drug was found to cause a range of severe deformities in the limbs, eyes, ears, and hearts of fetuses when taken by women during pregnancy. This led to its withdrawal from the market in many countries by 196"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZGoY9VUknZlIijLwVAMZ1g31", "custom_id": "259_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "783e12366309273f95d251fc3eefc9c3", "body": {"id": "chatcmpl-9St3906hRFEAwBwcy4Re8IRnLp1zg", "object": "chat.completion", "created": 1716671823, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine (6-TG), is a chemotherapy medication used primarily in the treatment of acute myeloid leukemia (AML). It is also sometimes used for treating other types of leukemia and chronic myeloid leukemia (CML). Here are some key points about thioguanine that you, as a physician, might find useful:\n\n### Mechanism of Action\nThioguanine is a purine analog. It works by incorporating into DNA and RNA, substituting for the normal nucleotides, which leads to errors in replication and transcription, ultimately causing cell death. It interferes with nucleic acid synthesis by inhibiting the enzyme involved in purine synthesis, which is crucial for rapidly dividing cells such as cancer cells.\n\n### Indications\n- **Primary**: Treatment of acute myeloid leukemia (AML).\n- **Other Uses**: May be used in treating other leukemias as part of a combination chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hAZKFDvCKgkRFkKNfKx6JvlR", "custom_id": "260_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "463e51c2c90a17cd7a9c723fdae56fea", "body": {"id": "chatcmpl-9St3AgXuadQtm7sNJzKRXqU6iUhkj", "object": "chat.completion", "created": 1716671824, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thiotepa (thiophosphamide) is a chemotherapy drug used primarily to treat various types of cancer, including breast cancer, ovarian cancer, and bladder cancer. It belongs to a class of drugs known as alkylating agents, which work by binding to DNA and preventing cancer cells from dividing and growing. Here are some key points you should know about Thiotepa:\n\n1. **Mechanism of Action**: Thiotepa is an alkylating agent that causes cross-linking of DNA, leading to cell death. It is cell cycle non-specific.\n\n2. **Indications**: Thiotepa is used in the treatment of adenocarcinoma of the breast, ovarian cancer, bladder cancer, and is also used for intracavitary effusions caused by malignant diseases. It may be used in high doses to prepare patients for hematopoietic stem cell transplantation.\n\n3. **Administration**: Thiotepa can be administered intravenously, intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z86q2KoJuHDZdiorZ9bKrPEh", "custom_id": "261_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "908698fc5ca7dd58289beec3852e0015", "body": {"id": "chatcmpl-9St3Afdquwuti5H0KTUTzAccQJfDP", "object": "chat.completion", "created": 1716671824, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel, marketed under the brand name Kymriah, is a type of immunotherapy known as CAR T-cell therapy (chimeric antigen receptor T-cell therapy). It represents a significant advancement in the treatment of certain types of blood cancers. Here are some key points you should know about Tisagenlecleucel:\n\n1. **Indications**: Tisagenlecleucel is approved for use in:\n   - Pediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.\n   - Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**: Tisagenlecleucel is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bR2jjWOOdKilhh1on9pAIW9Q", "custom_id": "262_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a07894b7ca2da5ae8d09f630da53c44", "body": {"id": "chatcmpl-9St3AtcjrZMDCbxFXot1w0WzOsh93", "object": "chat.completion", "created": 1716671824, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is a medication primarily used in the treatment of advanced renal cell carcinoma (RCC), which is a type of kidney cancer. Here are some key points you should know about tivozanib:\n\n1. **Mechanism of Action**: Tivozanib is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. These receptors are implicated in the pathway that leads to angiogenesis (formation of new blood vessels), which is crucial for tumor growth and metastasis. By inhibiting these receptors, tivozanib helps to reduce angiogenesis and thus tumor growth.\n\n2. **Indications**: It is approved for the treatment of adult patients with advanced renal cell carcinoma (RCC) who are at a later stage and have received prior therapy. The specifics can vary by country, so it's important to check local guidelines.\n\n3. **Administration**: Tivozan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ySOKKnThcWPHp1N7p1xfhux0", "custom_id": "263_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a0deed49512b610e131b1b0d7401e79", "body": {"id": "chatcmpl-9St3BtazGVBpOwN7Wy0rM8g90IS1X", "object": "chat.completion", "created": 1716671825, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Topotecan is a chemotherapy medication used primarily to treat certain types of cancer, including ovarian cancer, small cell lung cancer, and cervical cancer. It belongs to a class of drugs known as topoisomerase 1 inhibitors. Here are some key points you should know about Topotecan:\n\n### Mechanism of Action\nTopotecan inhibits the enzyme topoisomerase I, which is crucial for DNA replication. By inhibiting this enzyme, Topotecan causes DNA damage, which ultimately leads to apoptosis (cell death) of cancer cells.\n\n### Indications\n- **Ovarian Cancer:** Used for the treatment of metastatic ovarian cancer in patients who have failed initial or subsequent chemotherapy.\n- **Small Cell Lung Cancer:** Indicated for patients with recurrent or relapsed small cell lung cancer.\n- **Cervical Cancer:** Approved for use in combination with cisplatin for late-stage cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_zxmCDuC7HThTYwjimdItfCub", "custom_id": "264_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a165eb95dbd5b8912e952cd37733c876", "body": {"id": "chatcmpl-9St3BxqLIXtiiocq6cZljQJ5hwCX8", "object": "chat.completion", "created": 1716671825, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene (brand name Fareston) is a medication that belongs to the class of drugs known as selective estrogen receptor modulators (SERMs). It is primarily used in the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors. Here are some key points about toremifene that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Toremifene works by binding to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects. It is thought to exert its antitumor effects by blocking the growth-promoting effects of estrogen on the cancerous tissue.\n\n2. **Indications**: The primary indication for toremifene is the treatment of metastatic breast cancer in postmenopausal women. It may be considered when an antiestrogen therapy is appropriate.\n\n3. **Dosage and Administration**: The typical dose of toremif"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j6I6cpftrp1C1b1OPMU5bIy0", "custom_id": "265_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "78b0382b8d1a9e0c09d829078bf907cd", "body": {"id": "chatcmpl-9St3BYwpAIgSyRtXgobUpxt279wAY", "object": "chat.completion", "created": 1716671825, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 tositumomab (also known as Bexxar) was a radioimmunotherapy regimen that combined a monoclonal antibody, tositumomab, targeting the CD20 antigen on B cells, with a radioactive isotope, iodine-131. This treatment was specifically used for patients with CD20-positive, follicular, non-Hodgkin's lymphoma. It was particularly employed in cases where the disease was refractory to rituximab and had relapsed following chemotherapy.\n\n### Mechanism of Action:\n1. **Tositumomab**: This is a murine monoclonal antibody that binds to the CD20 antigen on normal and malignant B cells. The binding facilitates an immune response that leads to the destruction of B cells.\n2. **Iodine-131**: This is a radioactive isotope that emits both beta and gamma radiation. When conjugated to tositumomab, it delivers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TlIlHhzydU7uYqbLrjRO6rxV", "custom_id": "266_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e296750d6b0f60c5c6fa9097a77dacf", "body": {"id": "chatcmpl-9St3CgPgL0lkhQYiIoqSyZ4renINz", "object": "chat.completion", "created": 1716671826, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin (brand name Yondelis) is a chemotherapy drug used primarily for the treatment of certain types of cancer, including advanced soft tissue sarcoma and relapsed ovarian cancer. Here are some key points you should know about Trabectedin:\n\n1. **Mechanism of Action**: Trabectedin binds to the minor groove of DNA, bending the helix to interfere with DNA binding proteins and DNA repair mechanisms. This action causes cell cycle arrest and apoptosis (cell death).\n\n2. **Indications**:\n   - **Soft Tissue Sarcoma**: Trabectedin is approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy including an anthracycline.\n   - **Ovarian Cancer**: It is also approved for the treatment of relapsed ovarian cancer in combination with pegylated liposomal doxorubicin (PLD) in patients who have received prior platinum-based chemotherapy.\n\n3. **Administration**: Trabected"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GEHeRiPytQqIf08WaZk81Oe3", "custom_id": "267_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d76863082878580488664b67385274f", "body": {"id": "chatcmpl-9St3CMGilG57rHcvxiCVcupxbNzpg", "object": "chat.completion", "created": 1716671826, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trametinib is a medication used in the treatment of cancer, specifically indicated for certain types of melanoma, non-small cell lung cancer (NSCLC), and thyroid cancer. Here are some key points about Trametinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Trametinib is a MEK inhibitor. It works by inhibiting mitogen-activated protein kinase enzymes MEK1 and MEK2. This inhibition prevents the activation of MEK-dependent effector proteins and downstream signaling pathways, which can result in a decrease in tumor cell proliferation and an increase in apoptosis (programmed cell death).\n\n2. **Indications**:\n   - **Melanoma**: Trametinib is approved for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. It is often used in combination with dab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QWVzFAwqGotWrOaV9bAv0taZ", "custom_id": "268_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b426576f3586ebeb8e83c82f5153acfc", "body": {"id": "chatcmpl-9St3D8mbgNy1aWIaDGhyPpzLo2i6P", "object": "chat.completion", "created": 1716671827, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tranexamic acid is a medication that is primarily used to treat or prevent excessive bleeding. Here are some key points that you, as a physician, should know about tranexamic acid:\n\n1. **Mechanism of Action**:\n   Tranexamic acid works by inhibiting plasminogen activation and plasmin activity, which are crucial components in the fibrinolysis process. By doing so, it helps prevent the breakdown of fibrin clots, thereby reducing bleeding.\n\n2. **Indications**:\n   - **Heavy Menstrual Bleeding**: It is commonly prescribed to treat heavy menstrual bleeding.\n   - **Surgical Bleeding**: It is used to reduce blood loss during and after surgery, including in cardiac, orthopedic, and dental surgeries, among others.\n   - **Trauma**: It has been shown to reduce mortality in patients with traumatic bleeding if administered within the first three hours post-injury.\n   - **Hereditary Angioedema"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s7J4XtAKqps0Vyh6a0tx6poa", "custom_id": "269_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8c599aace197bd013e1c8ef382db7620", "body": {"id": "chatcmpl-9St3DdA7bmLXPf4vYQqQtNaYXGvkT", "object": "chat.completion", "created": 1716671827, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. It targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast cancer tumors. Here are some key points you should know about Trastuzumab:\n\n1. **Mechanism of Action**: Trastuzumab binds specifically to the HER2 receptor on the surface of cancer cells, inhibiting the proliferation of cells that overexpress this receptor. It can also mediate antibody-dependent cellular cytotoxicity (ADCC) by recruiting immune cells to kill the cancer cells.\n\n2. **Indications**:\n   - **Breast Cancer**: It is approved for the treatment of HER2-positive breast cancer, which can be early-stage, locally advanced, or metastatic. It is often used in combination with chemotherapy or other targeted therapies.\n   - **Gastric Cancer**: Trastuzumab is also approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aJdoe2MZj7Jh8rAsa61Uvv9Z", "custom_id": "270_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02cd5a5a188e2d9b31a5c2af83f73aff", "body": {"id": "chatcmpl-9St3DvP6A7jMfVmQT6Ee4vdNCqgre", "object": "chat.completion", "created": 1716671827, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is a monoclonal antibody that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a protein receptor that downregulates the immune system. CTLA-4 is a negative regulator of T-cell activation, and by blocking its activity, tremelimumab aims to enhance the body's immune response against cancer cells.\n\nHere are some key points about tremelimumab:\n\n1. **Mechanism of Action**: Tremelimumab works by inhibiting CTLA-4, similar to the more widely known ipilimumab. This inhibition can potentially enhance the body's immune response against tumor cells by promoting the activation and proliferation of T-cells.\n\n2. **Clinical Uses**: Tremelimumab has been investigated in various clinical trials for several types of cancer, including melanoma, mesothelioma, and non-small cell lung cancer (NSCLC). It has shown promise in some trials, particularly in combination with other"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jSALAqeimRoDecwspmVTty2S", "custom_id": "271_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b0e2092ef39a99f94576516a692213a1", "body": {"id": "chatcmpl-9St3FG1tlwwVSFgPHqiqjHP6B51fH", "object": "chat.completion", "created": 1716671829, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a medication primarily used in the treatment of ovarian cancer and as a conditioning treatment before hematopoietic stem cell transplantation (HSCT). Here are some key points you should know about Treosulfan:\n\n1. **Mechanism of Action**: Treosulfan is a prodrug that undergoes conversion in the liver to its active alkylating metabolites, which cross-link DNA, leading to cell death. This mechanism is crucial for its effectiveness in both cancer treatment and conditioning before transplantation.\n\n2. **Indications**:\n   - **Ovarian Cancer**: Treosulfan is used for the treatment of advanced ovarian cancer, particularly in patients who cannot tolerate other more aggressive chemotherapy regimens.\n   - **Conditioning Regimen**: Treosulfan is used as part of the conditioning regimen before hematopoietic stem cell transplantation, especially in older patients or those with comorbidities that make them less suitable for high-intensity conditioning regimens.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qtL2H3JxuGBpFpMagYhmfK3n", "custom_id": "272_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4837844a073244e3f28071ec612611b", "body": {"id": "chatcmpl-9St3FvpuG1IKJOkYI4ZeHSD5OrmFp", "object": "chat.completion", "created": 1716671829, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil, marketed under the brand name Lonsurf, is a combination oral chemotherapy medication used primarily for the treatment of certain types of colorectal cancer and gastric cancer. Here are some key points you should know about this medication:\n\n1. **Indications**:\n   - **Colorectal Cancer**: Trifluridine and tipiracil is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.\n   - **Gastric Cancer**: It is also approved for the treatment of patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotec"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3RsSgbwulfORkvSXO1Ak3Spn", "custom_id": "273_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba44c3a4ea0eb36e87b5f87a80843bb5", "body": {"id": "chatcmpl-9St3Fr6Xh7QXbemdCaytGv7SANjnc", "object": "chat.completion", "created": 1716671829, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist used to treat hormone-responsive cancers such as prostate cancer in men and endometriosis and uterine fibroids in women. It is also used for the treatment of precocious (early-onset) puberty in children. Here are some key points about Triptorelin:\n\n1. **Mechanism of Action**: Triptorelin works by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a temporary increase in testosterone (in men) and estrogen (in women) levels. However, with continuous administration, it desensitizes the pituitary gland, leading to a decrease in LH and FSH secretion and ultimately reducing the levels of sex hormones.\n\n2. **Administration**: Triptorelin is administered as an injection. The frequency of administration depends on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lyhcNbrOWk8psu3fhiIG8y4B", "custom_id": "274_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef002519deea7ddf75b9060c34884f5f", "body": {"id": "chatcmpl-9St3FBs0TkXoJ6un49cahrIZ09cHV", "object": "chat.completion", "created": 1716671829, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate (also known as valproic acid or divalproex sodium) is a medication primarily used to treat epilepsy and bipolar disorder, and to prevent migraine headaches. It is available under various brand names, such as Depakote, Depakene, and others. Here are some key points you should know about valproate:\n\n### Mechanism of Action\nValproate is thought to affect the function of the neurotransmitter GABA in the brain. It enhances GABAergic inhibition and reduces excitatory neurotransmission, which helps in stabilizing neuronal firing and preventing seizure activity.\n\n### Indications\n1. **Epilepsy**: It is used to treat various forms of epilepsy, including generalized seizures (such as absence, myoclonic, and tonic-clonic seizures) and focal seizures.\n2. **Bipolar Disorder**: It is effective in managing and preventing manic episodes associated with bipolar disorder.\n3. **Migraine Prevention**: It can be used proph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_naLfaPNSlzn3DTtRJZbLjxiF", "custom_id": "275_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7037a2b98458b0260bfe7e3e56257f89", "body": {"id": "chatcmpl-9St3Gk6e91lG7wG1pRTsxiep8S2bs", "object": "chat.completion", "created": 1716671830, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin (brand name Valstar) is a chemotherapy medication primarily used in the treatment of Bacillus Calmette-Gu\u00e9rin (BCG)-resistant carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here are some key points about valrubicin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Valrubicin is an anthracycline antibiotic that interferes with the growth of cancer cells, which are eventually destroyed. It is believed to work by intercalating DNA and inhibiting topoisomerase II, leading to inhibition of DNA synthesis and induction of apoptosis.\n\n2. **Administration**: Valrubicin is administered intravesically, which involves instillation directly into the bladder through a catheter. This localized delivery helps to maximize the drug concentration at the site of the tumor while minimizing systemic exposure and toxicity.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rsL1dAhbjU5sDMRnOLBmgTRr", "custom_id": "276_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca1e1c3e7e48b47051f2172b3cdfc442", "body": {"id": "chatcmpl-9St3GKqU4ldFtYJAHsjXPOUNcB1Zm", "object": "chat.completion", "created": 1716671830, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a medication used in the treatment of certain types of cancer, most notably medullary thyroid cancer. Here are some key points you should know about vandetanib:\n\n1. **Mechanism of Action**: Vandetanib is a tyrosine kinase inhibitor that targets several tyrosine kinases, including RET, VEGFR, and EGFR. These kinases are involved in the pathways that regulate cell growth and angiogenesis. By inhibiting these kinases, vandetanib can reduce tumor growth and spread.\n\n2. **Indications**: Vandetanib is primarily used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It is important to confirm the diagnosis with genetic testing for RET mutations, which are common in medullary thyroid cancer.\n\n3. **Administration**: Vandetanib is administered orally. The dosage and duration of treatment depend on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cRmW5BzAYISX6YmGa6myjqqt", "custom_id": "277_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c19934898b9b96b6d717ddb83a5d72c0", "body": {"id": "chatcmpl-9St3GJziD78L7Py43FeKYkoHbTuQz", "object": "chat.completion", "created": 1716671830, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib (brand name Zelboraf) is a medication used primarily for the treatment of late-stage melanoma, a type of skin cancer. It is specifically indicated for use in patients with a mutation in the BRAF V600 gene. Here are some key points about vemurafenib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Vemurafenib is a BRAF inhibitor. It specifically targets and inhibits the activity of the BRAF V600E kinase, which is a mutated form of the BRAF protein. This mutation leads to uncontrolled cell growth and is present in about 50% of melanoma cases. By inhibiting this mutated kinase, vemurafenib can help control the growth of the cancer cells.\n\n2. **Indications**:\n   Vemurafenib is approved for the treatment of unresectable or metastatic melanoma with the BRAF V600 mutation."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xl8P2AVT0pvZq6ZKnaNFNDO0", "custom_id": "278_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52db14dd69aee37770b43fea20a5e84a", "body": {"id": "chatcmpl-9St3HU2ho4oukspMdigKKdX8ZjYcs", "object": "chat.completion", "created": 1716671831, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is a targeted therapy medication used primarily in the treatment of certain types of chronic lymphocytic leukemia (CLL) and some other hematological malignancies. Here are some key points you should know about venetoclax:\n\n1. **Mechanism of Action**: Venetoclax is a BCL-2 inhibitor. BCL-2 is a protein that helps cancer cells survive by inhibiting cell death (apoptosis). Venetoclax binds to the BCL-2 protein, displacing pro-apoptotic proteins (such as BIM), thereby triggering apoptosis in cancer cells.\n\n2. **Indications**:\n   - It is approved for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).\n   - Venetoclax is also used in combination with other drugs for the treatment of acute myeloid leukemia (AML) in adults who are age 75 years or older,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RBso5dLUdRXE9sojyxovPRSp", "custom_id": "279_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da64982addd70f06b54aeb4f6ded6051", "body": {"id": "chatcmpl-9St3HT4qSH1gtYUoqRSD7LmhRbTTD", "object": "chat.completion", "created": 1716671831, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication used primarily to treat various types of cancer. It belongs to a class of drugs known as vinca alkaloids, which are derived from the periwinkle plant (Catharanthus roseus). Here are some key points you should know about vinblastine:\n\n### Mechanism of Action\nVinblastine works by inhibiting microtubule formation during cell division. It binds to tubulin, disrupting the assembly of microtubules and thus inhibiting mitosis (cell division). This leads to cell cycle arrest at the metaphase stage and eventually causes cell death.\n\n### Indications\nVinblastine is used to treat a variety of cancers, including:\n- Hodgkin's lymphoma\n- Non-Hodgkin's lymphoma\n- Testicular cancer\n- Breast cancer\n- Kaposi's sarcoma\n- Choriocarcinoma\n- Langerhans cell histiocytosis\n\n### Administration\nVinblast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7Tu90b2ti0bgeiucSx2UGrus", "custom_id": "280_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41c87eca8b5692922bff1c349e6ebf1f", "body": {"id": "chatcmpl-9St3H2YeHdBQ6eUJAlrGyPvayz8ha", "object": "chat.completion", "created": 1716671831, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is a chemotherapy medication used primarily to treat various types of cancer. It is a member of the vinca alkaloid class of drugs and works by inhibiting microtubule formation in the mitotic spindle, leading to cell cycle arrest at the metaphase. Here are some key points you should know about Vincristine:\n\n### Mechanism of Action\n- **Microtubule Inhibition:** Vincristine binds to tubulin, disrupting microtubule formation necessary for mitotic spindle assembly, thereby inhibiting mitosis and triggering apoptosis in rapidly dividing cells.\n\n### Indications\n- **Cancers:** Commonly used in the treatment of acute lymphoblastic leukemia (ALL), Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas, and other solid tumors like Wilms tumor, rhabdomyosarcoma, and neuroblastoma.\n- **Other Uses:** Sometimes used off-label for other conditions, such as thrombotic thromb"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OIukm8j58N1lkED8o91FQ8dG", "custom_id": "281_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "50996b440dfdcde7d5f1f1513c3e31a9", "body": {"id": "chatcmpl-9St3I4XA3DwwSzgoULjKL2UxkOlWI", "object": "chat.completion", "created": 1716671832, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal is a form of the chemotherapy drug vincristine that is encapsulated within liposomes, a type of tiny spherical vesicle. This encapsulation can alter the distribution of the drug, potentially enhancing its efficacy and reducing some of its toxicity. Here are some key points you should know about vincristine liposomal:\n\n1. **Mechanism of Action**: Vincristine, a vinca alkaloid, works by inhibiting microtubule formation in the mitotic spindle, causing cell cycle arrest at the metaphase. The liposomal formulation is designed to allow the drug to circulate longer in the bloodstream, increasing its uptake into the tumor cells while reducing exposure to normal tissues.\n\n2. **Indications**: Vincristine liposomal is primarily used for the treatment of specific types of cancer. The indications can vary based on regulatory approval, so it's important to check the latest guidelines or approvals for the specific conditions it is indicated for. For example"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kgxNRSrDfdq0IudEH6SY4BbE", "custom_id": "282_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c82d67f52e34271a9e66fa4e4e1c3a71", "body": {"id": "chatcmpl-9St3IeL8kgUMG7nJ7TFRdgB2aCr51", "object": "chat.completion", "created": 1716671832, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is a chemotherapeutic agent that belongs to the class of vinca alkaloids, which are derived from the periwinkle plant (Catharanthus roseus). It is primarily used in the treatment of various types of cancer, including acute lymphocytic leukemia, non-small cell lung cancer, and breast cancer, among others. Here are some key points you should know about vindesine:\n\n1. **Mechanism of Action**: Vindesine works by inhibiting microtubule dynamics, which is essential for mitotic and interphase cellular functions. It binds to tubulin and prevents the assembly of microtubules, disrupting the mitotic spindle formation and thus inhibiting cell division.\n\n2. **Administration**: Vindesine is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's size, and their overall health, among other factors.\n\n3. **Side Effects**: Like other chemotherapy drugs,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_u0JYC7tMnb7edTw9oWSnaAzz", "custom_id": "283_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a397818f0ee7cd07205789ed3842b65e", "body": {"id": "chatcmpl-9St3INKz396XHQKzO5fyXr9zuPaZ0", "object": "chat.completion", "created": 1716671832, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a semi-synthetic vinca alkaloid microtubule inhibitor used primarily in the treatment of urothelial carcinoma. It is derived from vinorelbine, and like other drugs in the vinca alkaloid class, it works by inhibiting microtubule dynamics, which disrupts mitotic spindle formation, leading to cell cycle arrest at the G2/M phase and eventually apoptosis (cell death).\n\nHere are some key points about Vinflunine that you, as a physician, might find useful:\n\n1. **Indications**: Vinflunine is approved in Europe for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Its use might vary by country, so it's important to check local guidelines.\n\n2. **Mechanism of Action**: Vinflunine stabilizes tubulin in microtubules, preventing their disassembly which is crucial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7LSgKD6lU9IHYwSqyztCMUrg", "custom_id": "284_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0baa42756f2f5a941796287f1f1f8d88", "body": {"id": "chatcmpl-9St3I9VPnxRGCsymgsXeE3aemRNOw", "object": "chat.completion", "created": 1716671832, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine (also known by its brand name Navelbine) is a chemotherapy medication used primarily in the treatment of various cancers, including non-small cell lung cancer and breast cancer. It belongs to the class of drugs known as vinca alkaloids, which are derived from the periwinkle plant. Here are some key points you should know about vinorelbine:\n\n### Mechanism of Action\nVinorelbine works by interfering with the microtubule structures within the cell. It inhibits the ability of microtubules to polymerize and depolymerize, which is essential for cell division. This disruption leads to the inhibition of mitosis in the metaphase, causing cell death.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Vinorelbine is used as a first-line treatment for advanced NSCLC, often in combination with other chemotherapeutic agents.\n- **Breast Cancer:** It is used for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pv8QrlDlKgiBmJh69raER6Bj", "custom_id": "285_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3c1a178926eb60d355178b4d6764d570", "body": {"id": "chatcmpl-9St3Jwqwz1dLtaoVYqtQNCvaouSUy", "object": "chat.completion", "created": 1716671833, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib is a medication used primarily in the treatment of advanced basal cell carcinoma (BCC), particularly when surgery or radiation are not appropriate treatment options. Here are some key points about Vismodegib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Vismodegib works by inhibiting the Hedgehog signaling pathway, which is active in most basal cell carcinomas. It specifically targets and inhibits the Smoothened (SMO) receptor, which plays a role in the proliferation and survival of cancer cells.\n\n2. **Indications**: It is approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation.\n\n3. **Administration**: Vismodegib is taken orally, and the typical dosage is 150 mg once daily. It can be taken with or without food.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KfJzGTRORWVDK6qRsUERejJY", "custom_id": "286_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb36aa5d36b7545f2efefc94f648c3e1", "body": {"id": "chatcmpl-9St3JpLCgfLyXfvpGo8FmdmDtCxBv", "object": "chat.completion", "created": 1716671833, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its brand name Zolinza, is a medication used in the treatment of cancer, specifically for cutaneous T-cell lymphoma (CTCL) when the disease persists, worsens, or comes back following two systemic therapies. Here are some key points about Vorinostat that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Vorinostat is classified as a histone deacetylase (HDAC) inhibitor. It works by inhibiting the enzymatic activity of histone deacetylases, which play a key role in the regulation of gene expression. This inhibition leads to an accumulation of acetylated histones and other proteins, resulting in cell cycle arrest, differentiation, and/or apoptosis of some cancer cells.\n\n2. **Indications**: Vorinostat is approved by the FDA for the treatment of cutaneous manifestations in patients with CTCL who have not responded adequately to other therapies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_DGlaRIAYcx0SHx5QARTjRdvk", "custom_id": "287_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "186036388b2a75c8dc2361adba9c2b6c", "body": {"id": "chatcmpl-9St3JtnfWP9a0t4vKoz3IdSxyhK7m", "object": "chat.completion", "created": 1716671833, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zidovudine, also known by its brand name Retrovir, is an antiretroviral medication used primarily for the treatment and prevention of HIV/AIDS. It is a nucleoside reverse transcriptase inhibitor (NRTI), which works by inhibiting the enzyme reverse transcriptase, an essential viral enzyme that HIV uses to replicate its genetic material and multiply.\n\nHere are some key points you should know about Zidovudine:\n\n1. **Indications**:\n   - Treatment of HIV infection in combination with other antiretroviral agents.\n   - Prevention of maternal-fetal HIV transmission during childbirth.\n   - Post-exposure prophylaxis in cases of potential HIV exposure.\n\n2. **Dosage and Administration**:\n   - The dosage of Zidovudine varies based on the indication, age, and renal function of the patient. It is available in capsule, tablet, and syrup forms, as well as an intravenous formulation.\n   - For adults"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_uj0fypOkLLehfTCxGpm3JFzo", "custom_id": "288_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "20087f9d8e14b5300997e338394fdbe4", "body": {"id": "chatcmpl-9St3J50wCs11GnKhsVS4LWSeIzHW6", "object": "chat.completion", "created": 1716671833, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, also known by its brand name Zaltrap, is a biopharmaceutical drug used primarily in the treatment of metastatic colorectal cancer, particularly in cases where the disease has progressed following treatment with an oxaliplatin-containing regimen. Here are some key points about ziv-aflibercept that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Ziv-aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It works by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting the binding of these factors to their receptors on the surface of endothelial cells. This inhibition blocks the blood supply that tumors need to grow and metastasize.\n\n2. **Indications**: It is approved for use in combination with FOLFIRI (irinotecan, fluorour"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6b62aGHf4DgNQDvFdLxPwMQN", "custom_id": "289_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e21af631ed66e85a0fc077dadcc92ef4", "body": {"id": "chatcmpl-9St3KCJdjWvUZT0UXa8wCd0JH7U6Z", "object": "chat.completion", "created": 1716671834, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib is a targeted therapy drug used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Capmatinib:\n\n1. **Mechanism of Action**: Capmatinib is a small molecule kinase inhibitor that specifically targets the c-MET receptor tyrosine kinase. Abnormal activation of the MET pathway has been implicated in the growth, progression, and spread of various types of cancer, including NSCLC. By inhibiting this pathway, Capmatinib can help to stop or slow the growth of cancer cells.\n\n2. **Indications**: As of the latest updates, Capmatinib is approved for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation leading to MET exon 14 skipping. This mutation is relatively rare, so testing for MET exon 14 skipping is necessary to identify eligible patients.\n\n3. **Administration**: Capmatinib is administered orally, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OrPnDgvhs3MDGgaNmGVMaEfe", "custom_id": "290_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71eeaebe1741db6424952a20c8746cce", "body": {"id": "chatcmpl-9St3KfjMbWqp58fAlG3nue049FqsS", "object": "chat.completion", "created": 1716671834, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (brand name: Padcev) is a targeted therapy used in the treatment of cancer, specifically for urothelial carcinoma, which is the most common type of bladder cancer. Here are some key points you should know about enfortumab vedotin:\n\n1. **Mechanism of Action**: Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of an anti-Nectin-4 monoclonal antibody linked to a microtubule-disrupting agent, monomethyl auristatin E (MMAE). The drug binds to Nectin-4, a protein expressed on the surface of urothelial cancer cells, and is internalized into the cancer cell where it releases MMAE, leading to cell cycle arrest and apoptotic cell death.\n\n2. **Indications**: As of the last update, enfortumab vedotin is approved by the FDA for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E0byNmbs5O4Mfk5bxF8NQw4C", "custom_id": "291_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f785fca3fedc10361d5b87093650cb94", "body": {"id": "chatcmpl-9St3KFMwKoQoBWqc0OBzjJ5n36X63", "object": "chat.completion", "created": 1716671834, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan (also known by its brand name Enhertu) is a novel antibody-drug conjugate (ADC) used primarily in the treatment of certain types of breast cancer and other HER2-expressing cancers. Here are some key points you should know about this medication:\n\n1. **Mechanism of Action**: Trastuzumab deruxtecan consists of three components: a HER2-targeting antibody (trastuzumab), a stable linker, and a cytotoxic agent (deruxtecan, a topoisomerase I inhibitor). The trastuzumab component binds to the HER2 receptor on cancer cells, allowing the conjugate to be internalized into the cell where the cytotoxic drug is released, leading to cell death.\n\n2. **Indications**:\n   - **Breast Cancer**: It is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_WIP4x0s9aiXZGrTwmhbzVKS3", "custom_id": "292_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "72fa839ebc42f8cca8be4b6c1a40a85e", "body": {"id": "chatcmpl-9St3KjTfyYlAmSooBAYR1H8adNRj2", "object": "chat.completion", "created": 1716671834, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a medication primarily used in the management of advanced prostate cancer. It is a synthetic decapeptide and acts as a gonadotropin-releasing hormone (GnRH) antagonist. Here are some key points about Abarelix that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Abarelix works by directly blocking the GnRH receptors in the pituitary gland, leading to a rapid reduction in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently a decrease in testosterone levels. This mechanism is beneficial in prostate cancer treatment, as the growth of many prostate cancers is testosterone-dependent.\n\n2. **Indications**: Abarelix is used for the treatment of hormone-responsive advanced prostate cancer. It is particularly useful in patients who require rapid suppression of testosterone levels to alleviate symptoms or to prevent imminent complications from the cancer.\n\n3. **Administration**: Abarelix is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_F8FamqT62Z1qLZlHLgxi8DTc", "custom_id": "293_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d92a4c81bec7129023dc2126bad116fc", "body": {"id": "chatcmpl-9St3LhzKmz48LVGu5HJCiOHyEsQpy", "object": "chat.completion", "created": 1716671835, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin, also known by its brand name Blenrep, is a monoclonal antibody-drug conjugate used for the treatment of multiple myeloma. It was approved by the U.S. Food and Drug Administration (FDA) in August 2020. Here are some key points you should know about this medication:\n\n1. **Indication**: Belantamab mafodotin is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n2. **Mechanism of Action**: The drug consists of a monoclonal antibody that targets B-cell maturation antigen (BCMA), a protein commonly expressed on the surface of myeloma cells. The antibody is conjugated to a cytotoxic agent, monomethyl auristatin F (M"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3kv4NUyBfH52kxLYv0q68ewT", "custom_id": "294_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "20426122d0a93dc6a876e617e0451809", "body": {"id": "chatcmpl-9St3LMsbSdAcuTk5jUW8rSi1doHno", "object": "chat.completion", "created": 1716671835, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is a medication used in the treatment of cancer, specifically for patients with HER2-positive breast cancer. Here are some key points you should know about tucatinib:\n\n1. **Mechanism of Action**: Tucatinib is a tyrosine kinase inhibitor that selectively inhibits the kinase activity of HER2 (human epidermal growth factor receptor 2), which is overexpressed in some forms of breast cancer. By inhibiting HER2 signaling, tucatinib can help control the growth of cancer cells.\n\n2. **Indications**: Tucatinib is approved for use in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n3. **Administration**: Tucatinib is administered orally, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cVCLIWx9KYNBCDj8W3Xq1D7m", "custom_id": "295_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ac34c46dde8e72f2b3e0081f59a3c51d", "body": {"id": "chatcmpl-9St3Lq6oqegvOtFMZVUo5Lx3VqHfQ", "object": "chat.completion", "created": 1716671835, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab and hyaluronidase-fihj (brand name: Darzalex Faspro) is a combination medication used in the treatment of multiple myeloma, a type of blood cancer. This combination allows for subcutaneous injection, which can be more convenient and less painful compared to the intravenous administration of daratumumab alone. Here are some key points you should know about this medication:\n\n1. **Mechanism of Action**:\n   - **Daratumumab** is a monoclonal antibody that targets CD38, a surface protein widely expressed on multiple myeloma cells. By binding to CD38, daratumumab induces immune-mediated killing of the cancer cells.\n   - **Hyaluronidase** is an enzyme that temporarily degrades hyaluronan, a component of the extracellular matrix, which facilitates the dispersion and absorption of administered drugs, such as daratumumab.\n\n2. **Indications**:\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1YBLCVlsJF7ZngxmFWHiYK8j", "custom_id": "296_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2da8132696b76d7612a56d5df09e253c", "body": {"id": "chatcmpl-9St3LisjL5qj1fzojjqs7w6e6w9Mj", "object": "chat.completion", "created": 1716671835, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin, also known as 9-cis-retinoic acid, is a medication used primarily to treat chronic hand eczema. It is also used for other dermatological conditions that do not respond to other treatments. Here are some key points about alitretinoin that you, as a physician, might find useful:\n\n1. **Indications**: Alitretinoin is approved for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. It may also be considered for other severe eczema cases when standard treatments have failed.\n\n2. **Mechanism of Action**: Alitretinoin is a retinoid that binds to both retinoic acid receptors (RAR) and retinoid X receptors (RXR). This binding activates these nuclear receptors, leading to modulation of gene expression, which in turn reduces inflammation and normalizes keratinocyte growth and differentiation.\n\n3. **Administration**: Alitretinoin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BHfUWaXKWKjUdxgy44G3U364", "custom_id": "297_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "693a152b4484ec3025aaf5f7250a2d8a", "body": {"id": "chatcmpl-9St3LDcM6F2CzAagkCk7tp78DkIHF", "object": "chat.completion", "created": 1716671835, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, also known by its brand name Tecartus, is an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It is specifically designed for the treatment of certain types of B-cell malignancies. Here are some key points you should know about this therapy:\n\n1. **Indications**: As of the last update, brexucabtagene autoleucel has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n\n2. **Mechanism of Action**: This therapy involves reprogramming the patient\u2019s own T cells to include a gene for a special receptor that binds to a specific protein on the patient's cancer cells. In the case of brexuc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HbBpKRHigJxWcXiNlIpfso79", "custom_id": "298_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5f518b2e57b55b1d35b86226ba314e98", "body": {"id": "chatcmpl-9St3M177x82bQsvX5xf2l1ba0D2en", "object": "chat.completion", "created": 1716671836, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alpelisib is a medication used primarily in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Here are some key points you should know about alpelisib:\n\n1. **Mechanism of Action**: Alpelisib is a phosphoinositide 3-kinase (PI3K) inhibitor, specifically targeting the PI3K\u03b1 isoform. PI3K is a part of the PI3K/AKT/mTOR pathway, which is involved in cell growth, proliferation, and survival. Mutations in PIK3CA, the gene encoding the p110\u03b1 subunit of PI3K, can lead to activation of this pathway, promoting cancer cell growth and survival.\n\n2. **Indications**: Alpelisib is approved for use in combination with fulvestrant for the treatment of postmenopausal women, and men"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6M5ZxnAcVK3CDwYw7udgz2nG", "custom_id": "299_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2454ffa081dc38bd01a72f9595c546af", "body": {"id": "chatcmpl-9St3MvFQoz5W5pHAoEXDyBFQE3jZg", "object": "chat.completion", "created": 1716671836, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide (also known by its developmental code name AS1413) is a drug that belongs to the class of anticancer agents known as topoisomerase inhibitors. It works by interfering with the DNA replication process in cancer cells, which prevents their proliferation and leads to cell death. Here are some key points you should know about Amonafide:\n\n1. **Mechanism of Action**: Amonafide is a DNA intercalator and inhibits topoisomerase II, an enzyme critical for DNA replication. By intercalating into DNA, Amonafide disrupts the DNA double helix and inhibits the ligation step of the topoisomerase II cycle, causing DNA damage and leading to apoptosis (cell death) in rapidly dividing cells.\n\n2. **Clinical Uses**: Amonafide has been investigated in clinical trials for the treatment of various types of cancer, including breast cancer, leukemia, and non-small cell lung cancer. However, it is important"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_uu1MRLcb8FHOndxfk1z2nJhp", "custom_id": "300_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8473c63da474007b8ff14054c764a822", "body": {"id": "chatcmpl-9St3NqInAdo1YSXJUwfMvtRXXm86K", "object": "chat.completion", "created": 1716671837, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin is a commonly used antibiotic that falls under the penicillin class of antibiotics. It is used to treat a wide range of bacterial infections. Here are some key points you should know about amoxicillin:\n\n1. **Spectrum of Activity**:\n   - Amoxicillin is effective against a variety of bacteria including many strains of Gram-positive and Gram-negative bacteria. It is particularly effective against bacteria such as Streptococcus spp., Enterococcus spp., and Escherichia coli, among others.\n\n2. **Mechanism of Action**:\n   - Amoxicillin works by inhibiting the synthesis of bacterial cell walls. It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, which ultimately leads to the lysis and death of the bacteria.\n\n3. **Indications**:\n   - Common indications for amoxicillin include otitis media, sinusitis, respiratory tract infections, urinary tract infections, Helicobacter pylori"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7piHtjsGjrBEHOvbbY0sQiTP", "custom_id": "301_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "12a289628d599aaeadbef17de14445a4", "body": {"id": "chatcmpl-9St3Nl9bAuT8cLCxIT7hNfkHljKKB", "object": "chat.completion", "created": 1716671837, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Aumolertinib (also known by its developmental code name Almonertinib or HS-10296) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Aumolertinib:\n\n1. **Mechanism of Action**: Aumolertinib selectively inhibits the activity of EGFR tyrosine kinase, which includes mutations that are resistant to first and second-generation EGFR inhibitors. It is particularly effective against the T790M mutation, a common resistance mechanism in NSCLC patients who have failed previous EGFR TKI therapy.\n\n2. **Indications**: It is approved in certain regions, such as China, for the treatment of NSCLC patients who have specific EGFR mutations and have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VtoBiNLO2UWfrjTrdZaz6NAn", "custom_id": "302_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "661688afbff216fb040c5187e8d24a12", "body": {"id": "chatcmpl-9St3OeFtFOe2ECPOVTiHPU5riplFh", "object": "chat.completion", "created": 1716671838, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy used in oncology, specifically for the treatment of certain types of cancer. Here are some key points you should know about pemigatinib:\n\n1. **Mechanism of Action**: Pemigatinib is a kinase inhibitor that specifically targets fibroblast growth factor receptors (FGFR) 1, 2, and 3. These receptors are involved in important processes such as cell growth, survival, migration, and angiogenesis. In some cancers, these receptors are dysregulated, leading to tumor growth. By inhibiting these receptors, pemigatinib can help to control cancer progression.\n\n2. **Indications**: As of the last update, pemigatinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZOyIC2cJnwlwaEYEC2X4aJbO", "custom_id": "303_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2c032c13122e33c7fa19b9fefa92af23", "body": {"id": "chatcmpl-9St3P0kwq7UrY1NuW3wFDFxGG31XL", "object": "chat.completion", "created": 1716671839, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib, marketed under the brand name Qinlock, is a kinase inhibitor used in the treatment of cancer. It was specifically developed for the treatment of gastrointestinal stromal tumors (GIST) and received approval from the U.S. Food and Drug Administration (FDA) in May 2020. Here are some key points about Ripretinib that you, as a physician, might find useful:\n\n1. **Indications**: Ripretinib is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.\n\n2. **Mechanism of Action**: Ripretinib is a switch-control kinase inhibitor that targets a broad spectrum of mutations in KIT and PDGFRA. It works by inhibiting the kinase activity of these proteins, which are often mutated in GIST and drive the growth of these tumors.\n\n3. **Dosage and Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MIVvyr7iBt2jXzrunyrkcujQ", "custom_id": "304_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6806b346e7a824fec5630a9f577ec5f3", "body": {"id": "chatcmpl-9St3PhJLVyfeX8NgBKJipkqONiXv8", "object": "chat.completion", "created": 1716671839, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib, sold under the brand name Retevmo, is a medication used in the treatment of certain types of thyroid cancers and non-small cell lung cancer (NSCLC) that have specific genetic mutations in the RET (rearranged during transfection) proto-oncogene. Here are some key points you should know about selpercatinib:\n\n1. **Indications**: Selpercatinib is approved for the treatment of:\n   - Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\n   - Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n2. **Mechanism of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KT9lKik0eUdFbDrwZFGAHUBU", "custom_id": "305_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b998ceb633151f246b4d4f07e66c11f3", "body": {"id": "chatcmpl-9St3QrBiA3bLVamwcpDY4YBYzFGHb", "object": "chat.completion", "created": 1716671840, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination medication used in the treatment of myelodysplastic syndromes (MDS), which are a group of disorders caused by poorly formed or dysfunctional blood cells. This combination is specifically designed to improve the bioavailability of decitabine, allowing for oral administration, which provides a more convenient option compared to the intravenous form of decitabine alone.\n\n### Key Points about Decitabine and Cedazuridine:\n\n1. **Mechanism of Action**:\n   - **Decitabine**: A nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA and cellular differentiation or apoptosis. It is active against both dividing and non-dividing cells.\n   - **Cedazuridine**: A cytidine deaminase inhibitor that prevents the degradation of decitabine in the intestine and liver, enhancing its oral bioavailability.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_sD9fVEHoBBi8zKDntMSwuKOU", "custom_id": "306_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1b48bb74a78f8974b128ba6c383a47d8", "body": {"id": "chatcmpl-9St3Rnn5edHQNlvfYchvyFPhg9b93", "object": "chat.completion", "created": 1716671841, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as nausea, heartburn, indigestion, upset stomach, and diarrhea. It is also used in the prevention of travelers' diarrhea and has an antibacterial effect against Helicobacter pylori in the stomach. Here are some key points you should know about bismuth subsalicylate:\n\n1. **Mechanism of Action**: Bismuth subsalicylate has antacid and antibacterial properties. It works by coating the lining of the gastrointestinal tract and protecting it from stomach acid. It also has mild antimicrobial activity and may stimulate absorption of fluids and electrolytes by the intestinal wall.\n\n2. **Indications**: It is primarily used for:\n   - Relief of nausea, heartburn, indigestion, and upset stomach.\n   - Treatment and prevention of diarrhea, including travelers' diarrhea.\n   - Part of quadruple therapy for Helic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QD8f9gABprkhG5PO9KxGLDCn", "custom_id": "307_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0656649d57bd0f2f4fd75034ff43f6c1", "body": {"id": "chatcmpl-9St3SFudkGFBXkALlb5oVE7uxxo7u", "object": "chat.completion", "created": 1716671842, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camrelizumab, also known by its research code SHR-1210, is an anti-PD-1 monoclonal antibody used in the treatment of various types of cancer. It functions by targeting the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1 interactions, camrelizumab enhances the body's immune response against cancer cells.\n\nHere are some key points you should know about camrelizumab:\n\n1. **Indications**: Camrelizumab has been approved in China for several indications, including Hodgkin's lymphoma, hepatocellular carcinoma, and non-small cell lung cancer. Its use is being explored in various other cancers in clinical trials around the world.\n\n2. **Mechanism of Action**: Camrelizumab binds to the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2 on tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9YWtoXkxa4wJg77dPuwCBpcM", "custom_id": "308_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6f7e0a25e1018f26cc53c00ef8b309c2", "body": {"id": "chatcmpl-9St3T1UilKNbeccc3uQgQrZQP2HrG", "object": "chat.completion", "created": 1716671843, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Relugolix is an oral medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists. It is used to treat various conditions related to hormone-sensitive tissues and glands. Here are some key points about Relugolix that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Relugolix works by competitively blocking GnRH receptors in the pituitary gland. This inhibition decreases the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces the production of sex hormones such as testosterone and estrogen.\n\n2. **Indications**:\n   - **Prostate Cancer**: Relugolix is approved for the treatment of advanced prostate cancer. It is used to reduce the levels of testosterone, which is known to promote the growth of prostate cancer cells.\n   - **Uterine Fibroids and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OuA0jTtIyvweoiFT3jgZrQV7", "custom_id": "309_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "623d6109e6976033041a57db4e0a75d0", "body": {"id": "chatcmpl-9St3UvN8OtIBCaI9NYT1uAKjfeSav", "object": "chat.completion", "created": 1716671844, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant (also known by its developmental code name RAD1901) is a selective estrogen receptor degrader (SERD) that has been investigated for its potential use in treating estrogen receptor-positive (ER+) breast cancer. As of my last update, here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Elacestrant functions by binding to the estrogen receptor and promoting its degradation, thereby inhibiting the receptor's activity. This mechanism is particularly useful in targeting ER+ breast cancer cells, which rely on estrogen signals for growth and survival.\n\n2. **Clinical Trials**: Elacestrant has been evaluated in various clinical trials. For instance, the EMERALD Phase 3 trial has been a significant study assessing its efficacy and safety. This trial specifically looked at elacestrant as a treatment for patients with ER+, HER2- advanced or metastatic breast cancer who have received prior therapy with an aromatase inhibitor and a CDK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sjLjoToCLtLLBJ7FQsvkA5cQ", "custom_id": "310_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "01637d5e14166b02e2352e76777d24b3", "body": {"id": "chatcmpl-9St3VmoiGe6cFXXHQGhhntKdklwWr", "object": "chat.completion", "created": 1716671845, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is a chemotherapeutic agent that belongs to the class of drugs known as dihydrofolate reductase inhibitors. It is structurally similar to methotrexate but has some unique characteristics and uses. Here are some key points you should know about trimetrexate:\n\n1. **Mechanism of Action**: Trimetrexate works by inhibiting dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate, which is necessary for the synthesis of nucleic acids. By inhibiting DHFR, trimetrexate disrupts DNA and RNA synthesis, leading to cell death. This mechanism is particularly effective in rapidly dividing cells, such as cancer cells and some bacteria.\n\n2. **Indications**: Trimetrexate was primarily used in the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in patients with AIDS when first-line treatments were not suitable. It has"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_cgznPHskY2KZVyN9ZnjR1pBD", "custom_id": "311_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9acec404cc459c277f2eca3878794091", "body": {"id": "chatcmpl-9St3WozRXn4p8YBDWpwIUzd2qp2ZM", "object": "chat.completion", "created": 1716671846, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is a targeted therapy drug used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about tepotinib:\n\n1. **Mechanism of Action**: Tepotinib is a tyrosine kinase inhibitor that specifically targets the MET gene. It inhibits the hepatocyte growth factor receptor (HGFR), which can be abnormally activated in some cancers due to mutations or amplifications. This inhibition can block MET-mediated signaling pathways involved in tumor growth and survival.\n\n2. **Indications**: Tepotinib is specifically indicated for the treatment of adult patients with metastatic NSCLC harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. This mutation can be identified through molecular testing, which is essential for the selection of patients who would benefit from this therapy.\n\n3. **Administration**: Tepotinib is administered orally, which can be more convenient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6yVjS4b5gCgVJZ5INR8iSUst", "custom_id": "312_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f106037c9f80297a67e35424fce80780", "body": {"id": "chatcmpl-9St3WdEqRJo5fl29Rc0rgu6LIEpdk", "object": "chat.completion", "created": 1716671846, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib (also known by its developmental code TAS-120) is a targeted therapy drug primarily used in the treatment of cancer. It is a small molecule inhibitor specifically designed to target and inhibit the activity of fibroblast growth factor receptors (FGFRs). These receptors are involved in the regulation of important biological processes such as cell growth, survival, migration, and angiogenesis. Abnormal FGFR signaling has been implicated in the development and progression of various cancers.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Futibatinib is an irreversible inhibitor of FGFR 1, 2, 3, and 4. By binding covalently to these receptors, it effectively inhibits their kinase activity, which can block the FGFR signaling pathway that is often upregulated in certain types of cancer cells.\n\n2. **Indications**:\n   - As of my last update, futibatinib is being investigated for its efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BFUxkq2AO6mx6MjAEQVAt2eN", "custom_id": "313_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e593506a1881457d0249759333e5c87", "body": {"id": "chatcmpl-9St3XRBR9CnQPTl1gLZ1BdpsezznK", "object": "chat.completion", "created": 1716671847, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, also known as Optune, is a medical device used for the treatment of glioblastoma (GBM), a type of brain cancer. It is a non-invasive, antimitotic treatment that uses Tumor Treating Fields (TTFields) technology to inhibit tumor growth. Here are some key points you should know about the Optune system:\n\n1. **Mechanism of Action**: The device generates low-intensity, alternating electric fields (TTFields) that are tuned specifically to target cells undergoing mitosis. These fields disrupt the normal mitotic spindle formation during cell division, thereby selectively inhibiting the proliferation of rapidly dividing tumor cells.\n\n2. **Indications**: Optune is approved for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide after maximal debulking surgery and radiation therapy. It is also approved for the treatment of recurrent GBM as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GMhlpetaN53TL09EGdsyLYOk", "custom_id": "314_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fa026f877823fc23d44b7ffb866e13fe", "body": {"id": "chatcmpl-9St3Xz9Ksqi5R1u6gooDqAQYEYYqU", "object": "chat.completion", "created": 1716671847, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel, also known as liso-cel and marketed under the brand name Breyanzi, is a chimeric antigen receptor (CAR) T-cell therapy used in the treatment of certain types of B-cell lymphomas. This therapy represents a significant advancement in the field of oncology, particularly for patients with relapsed or refractory large B-cell lymphoma. Here are some key points you should know about lisocabtagene maraleucel:\n\n1. **Indications**: As of my last update, lisocabtagene maraleucel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1gs6bUchdvUNQeV6p76vCGVL", "custom_id": "315_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c5b4eaa0097801fc16c2af9d5af44e06", "body": {"id": "chatcmpl-9St3YbPKF02asBGIR0BqeRsntc7ps", "object": "chat.completion", "created": 1716671848, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel, often abbreviated as ide-cel and marketed under the name Abecma, is a CAR T-cell therapy approved for the treatment of multiple myeloma. It is specifically indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\nHere are some key points about idecabtagene vicleucel:\n\n1. **Mechanism of Action**: Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It involves reprogramming the patient\u2019s own T cells to include a chimeric antigen receptor (CAR) that targets BCMA, a protein commonly expressed on the surface of myeloma cells.\n\n2. **Manufacturing and Administration**: The process involves collecting the patient's T cells through leukaph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7BwkQqCjLFDNyI932RapnoQI", "custom_id": "316_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65fd67c700e331edbb5f962034be3c93", "body": {"id": "chatcmpl-9St3ZRsMO4CeGzcKtTfbuQfzqlXat", "object": "chat.completion", "created": 1716671849, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib (brand name Ayvakit) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about avapritinib:\n\n1. **Indications**: Avapritinib is primarily indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) that harbor a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It is also being investigated for other conditions and may have broader applications in other cancers with similar mutations.\n\n2. **Mechanism of Action**: Avapritinib is a tyrosine kinase inhibitor that specifically targets KIT and PDGFRA mutant kinases. It is particularly effective against the PDGFRA D842V mutation, which is resistant to many other tyrosine kinase inhibitors.\n\n3. **Administration**: Avapritinib is administered orally. The dosage and treatment regimen may vary based on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iO8vZepE0300MtOmXOIjcPrA", "custom_id": "317_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e26f4ca50a44398713cbb2b131cc087", "body": {"id": "chatcmpl-9St3c7pa0YblQjHfQQiBOPm9VWHhN", "object": "chat.completion", "created": 1716671852, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib, marketed under the brand name Turalio, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. TGCT, also known as pigmented villonodular synovitis (PVNS), is a rare disorder that affects the synovium, bursae, and tendon sheaths, causing joint pain, swelling, and reduced mobility.\n\nHere are some key points about pexidartinib that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Pexidartinib is a tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R), which is a driver of TGCT. By inhibiting CSF1R, pexidartinib helps reduce the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_frelQW3gNVmIsy2R7Tonfvy4", "custom_id": "318_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef4503d5b3bb41800069c6474f60f07c", "body": {"id": "chatcmpl-9St3aWYj5229pVafI2b7LRlv345qR", "object": "chat.completion", "created": 1716671850, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib, marketed under the brand name Gavreto, is a targeted therapy used in oncology, particularly for the treatment of certain types of cancer that exhibit specific genetic alterations. Here are key points you should know about pralsetinib:\n\n1. **Mechanism of Action**: Pralsetinib is a tyrosine kinase inhibitor that specifically targets rearranged during transfection (RET) proto-oncogene. RET gene fusions and mutations are important drivers in various cancers, including thyroid cancer and non-small cell lung cancer (NSCLC).\n\n2. **Indications**:\n   - **NSCLC**: Pralsetinib is approved for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\n   - **Thyroid Cancer**: It is also approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_y5UAMXKKpssb29TX0HhEccjh", "custom_id": "319_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d2e3beecdf450d3079ee1619b33a748a", "body": {"id": "chatcmpl-9St3a1JA0xLmWPkMAJ227Yd3KbWGb", "object": "chat.completion", "created": 1716671850, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin is a medication used in oncology, primarily for the treatment of certain types of cancer. Here are some key points you should know about lurbinectedin:\n\n1. **Mechanism of Action**: Lurbinectedin works by binding to the minor groove of DNA, interfering with transcription processes and inducing apoptosis (cell death). It is considered a selective inhibitor of oncogenic transcription.\n\n2. **Indications**: As of the latest updates, lurbinectedin has been approved for use in patients with metastatic small cell lung cancer (SCLC) who have progressed after prior platinum-containing therapy. Research is ongoing to evaluate its efficacy and safety in other types of cancer.\n\n3. **Administration**: Lurbinectedin is administered intravenously. The dosing regimen typically involves administration once every three weeks, but this can vary based on the patient's condition, response to treatment, and as per clinical guidelines.\n\n4. **Side Effects**: Common side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2tgBX1tx1sKgJeL4MZuHAojQ", "custom_id": "320_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cb750c15178385702e364eaa98fc6b29", "body": {"id": "chatcmpl-9St3bGIO28MlOWUjfxjhv97Nlz9o4", "object": "chat.completion", "created": 1716671851, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antibiotic and antiprotozoal medication that is commonly used to treat a variety of infections, including those caused by bacteria and protozoa. Here are some key points you should know about metronidazole:\n\n1. **Indications**: Metronidazole is effective against anaerobic bacteria and certain protozoa. It is commonly prescribed for bacterial vaginosis, trichomoniasis, giardiasis, and amebiasis. It is also used in the treatment of infections such as intra-abdominal infections, skin and skin structure infections, bone and joint infections, and lower respiratory tract infections, particularly those caused by Bacteroides species including the B. fragilis group.\n\n2. **Mechanism of Action**: Metronidazole works by entering the microbial cell and interacting with DNA, causing a loss of helical DNA structure and strand breakage, which results in inhibition of bacterial nucleic acid synthesis and cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_lJuu83KYTpNfnwHA7mI2pYiz", "custom_id": "321_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74cbc1d4200f182cea40debffe069d7a", "body": {"id": "chatcmpl-9St3bmSpHoYdJ4UromApnpg38lTuc", "object": "chat.completion", "created": 1716671851, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab, marketed under the brand name Danyelza, is a monoclonal antibody used in the treatment of neuroblastoma, a type of cancer that most commonly affects children. Here are some key points you should know about naxitamab:\n\n1. **Indications**: Naxitamab is approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n2. **Mechanism of Action**: Naxitamab targets the GD2 antigen, which is highly expressed on neuroblastoma cells. By binding to this antigen, naxitamab can promote antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FdO2LgbRVM39Pg38bcrOu47i", "custom_id": "322_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ac62f4c02efe82c8573906c887ba6e8c", "body": {"id": "chatcmpl-9St3coczNYvOQ3OwuMZMvDuXndbyS", "object": "chat.completion", "created": 1716671852, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tetracycline is an antibiotic that belongs to a class of medications known as tetracyclines. It is used to treat a variety of bacterial infections including those affecting the skin, respiratory tract, urinary tract, and more. Here are some key points you should know about tetracycline:\n\n1. **Spectrum of Activity**: Tetracycline is effective against a broad range of gram-positive and gram-negative bacteria. It is also used to treat other infections including chlamydia, Lyme disease, and acne.\n\n2. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria, thereby preventing them from growing and multiplying. It binds to the 30S ribosomal subunit, blocking the attachment of tRNA to the mRNA-ribosome complex.\n\n3. **Administration**: Tetracycline is typically administered orally, but it can also be given intravenously in more severe cases. The absorption of oral tetracycline can be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_HgpxyKOyM4NAx8O3Lfy40Mna", "custom_id": "323_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cd50a6fe8ffe3806b4f962f949c1f1c0", "body": {"id": "chatcmpl-9St3dSUN99yXOPwTGY8d0307xZKfU", "object": "chat.completion", "created": 1716671853, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, commonly known as bismuth subcitrate, is a medication used primarily in the treatment of peptic ulcers and as part of a quadruple therapy for Helicobacter pylori eradication. Here are some key points you should know about this compound:\n\n1. **Mechanism of Action**: Bismuth subcitrate works by coating ulcers and erosions, creating a protective layer against stomach acid and pepsin. This can help to heal ulcers and reduce symptoms. Additionally, it possesses antimicrobial activity against H. pylori, contributing to its effectiveness in eradication regimens.\n\n2. **Usage**: It is often used in combination with other medications such as proton pump inhibitors (PPIs), and antibiotics like metronidazole and tetracycline, as part of the treatment for H. pylori infections. This combination therapy helps to increase the eradication rates of the bacteria.\n\n3. **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_pLkSlP9PvgicHMWVkrz81XsS", "custom_id": "324_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24dfef74bab4786d3bfcfe9ac75dbdf3", "body": {"id": "chatcmpl-9St3eyIJC5RkVWp0td2dmWNLlHIOg", "object": "chat.completion", "created": 1716671854, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan (brand name Welireg) is a medication approved by the U.S. Food and Drug Administration (FDA) in August 2021. It is indicated for the treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.\n\n### Mechanism of Action:\nBelzutifan is a hypoxia-inducible factor (HIF) inhibitor. It specifically inhibits HIF-2\u03b1, which is a transcription factor that plays a crucial role in the body\u2019s response to low oxygen levels. In certain cancers, including those associated with VHL disease, HIF-2\u03b1 is overactivated, leading to tumor growth and vascularization. By inhibiting HIF-2\u03b1, belzutifan can help reduce tumor size and number.\n\n### Key Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3MeUU5CyeaBoiJKk7UTH8Djx", "custom_id": "325_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5b228197d9bfefb6389c09496d2bf55", "body": {"id": "chatcmpl-9St3f8NibpH0gLSITc9hx2NMDfffO", "object": "chat.completion", "created": 1716671855, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab is a novel therapeutic agent used in the treatment of cancer, specifically non-small cell lung cancer (NSCLC). Here are some key points you should know about Amivantamab:\n\n1. **Mechanism of Action**: Amivantamab is a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET) receptor tyrosine kinase. This dual targeting is designed to inhibit the signaling pathways that promote cancer cell growth and survival.\n\n2. **Indications**: As of the latest updates, Amivantamab is approved for the treatment of adult patients with NSCLC whose tumors have specific genetic alterations, namely EGFR exon 20 insertion mutations. These mutations are associated with a poor response to conventional EGFR tyrosine kinase inhibitors.\n\n3. **Administration**: Amivantamab is administered via intravenous infusion. The dosing regimen typically involves an initial loading dose followed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_svjFSmqxDL4fnniDPBXfQC8X", "custom_id": "326_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6245531d496711b6cf4c0c596b4d5aa7", "body": {"id": "chatcmpl-9St3f6FeHX3V7UGHmUfKu990ersRu", "object": "chat.completion", "created": 1716671855, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, available in both injectable and oral forms, is primarily used for the treatment of myelodysplastic syndromes (MDS), a group of hematopoietic disorders characterized by dysfunctional blood cell production. The oral form of azacitidine, known as Onureg (generic name: azacitidine), was approved by the FDA in September 2020. Here are some key points you should know about oral azacitidine:\n\n### Indications\n- **Onureg (azacitidine tablets)** is indicated for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.\n\n### Mechanism of Action\n- Azacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA. It is believed to work"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4k7nK2GD1fukHeiATnyHLGKm", "custom_id": "327_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "349b2e3b39b389291fb3c6bb9112583c", "body": {"id": "chatcmpl-9St3g4Ae4XCiKomGEchal27ODPBkg", "object": "chat.completion", "created": 1716671856, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colchicine is a medication commonly used in the treatment of gout and familial Mediterranean fever (FMF). It has anti-inflammatory properties and works by reducing the build-up of uric acid crystals that can cause pain and inflammation in the joints. Here are some key points about colchicine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Colchicine disrupts the assembly of microtubules by binding to tubulin, which inhibits the migration of neutrophils to sites of inflammation and blocks the production and release of inflammatory mediators.\n\n2. **Indications**:\n   - **Gout**: Used both for acute attacks and for prophylaxis to prevent recurrent attacks.\n   - **Familial Mediterranean Fever (FMF)**: Used to prevent attacks of FMF.\n   - It may also be used off-label for other conditions such as pericarditis and Beh\u00e7et's disease.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_oO3tqaDroCihQ0LpQECRfAmS", "custom_id": "328_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7e893d41668e879ec4926dfa1cdbf76", "body": {"id": "chatcmpl-9St3fAV4GPUEZ02FBsUS1MWXv2po3", "object": "chat.completion", "created": 1716671855, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab, marketed under the brand name Jemperli, is a monoclonal antibody used in the treatment of certain types of cancer. It is specifically designed to target the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking PD-1 interactions, dostarlimab helps to restore the body's immune response against cancer cells.\n\nHere are some key points about dostarlimab that you, as a physician, might find useful:\n\n1. **Indications**: As of the last update, dostarlimab is approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. It is also being investigated for other types of cancers in clinical trials.\n\n2. **Mechanism of Action**: Dostarlimab is a PD-1 blocking antibody."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_C4Q7m4IxOh4ISH49G1TU5bVl", "custom_id": "329_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "487bd927a34c44fea6408e3b9353e69e", "body": {"id": "chatcmpl-9St3gJr4Z00Um7HPCSL60eWpX8y4a", "object": "chat.completion", "created": 1716671856, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Serplulimab is an anti-PD-1 monoclonal antibody used in the treatment of various cancers. It functions by targeting the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1 interactions, serplulimab enhances the body's immune response against cancer cells.\n\nHere are some key points you should know about Serplulimab:\n\n1. **Mechanism of Action**: Serplulimab binds to the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2 ligands. This blockade prevents the inhibitory effects of PD-1 signaling, thereby activating T cells and promoting their ability to kill cancer cells.\n\n2. **Indications**: As of the last update, serplulimab has been primarily studied in clinical trials for various types of cancer, including non-small cell lung cancer (NSCLC) and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HWIen2FFkAbFbxeHfNVxWUZ5", "custom_id": "330_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "25ede8464c9d180baa74974f3f32c9a6", "body": {"id": "chatcmpl-9St3gvgikVMbkJtchwVFVvkrsVTmu", "object": "chat.completion", "created": 1716671856, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sugemalimab is an anti-PD-L1 monoclonal antibody used in oncology for the treatment of certain types of cancer. PD-L1 (programmed death-ligand 1) is a protein that can be expressed on the surface of tumor cells and immune cells; it plays a significant role in suppressing the immune system by binding to the PD-1 receptors on T-cells. By inhibiting this interaction, sugemalimab helps to enhance the body's immune response against cancer cells.\n\nHere are some key points you might consider as a physician:\n\n1. **Indications**: As of my last update, sugemalimab has been investigated for use in non-small cell lung cancer (NSCLC) and potentially other types of cancers. The specific indications and approval status may vary by country, so it's important to check the local regulatory status.\n\n2. **Mechanism of Action**: Sugemalimab blocks the interaction between PD-L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_m88MFEHJK29l75YhFiVAikA1", "custom_id": "331_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b19353ae8402042250bec79a5370c019", "body": {"id": "chatcmpl-9St3hXhtG1CfBxIrlwEnZvEvseG5S", "object": "chat.completion", "created": 1716671857, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus protein-bound particles for injectable suspension (brand name Afinitor DISPERZ) is a formulation of sirolimus that is used primarily in the treatment of specific medical conditions. Sirolimus, also known as rapamycin, is a macrolide compound that has immunosuppressive and antiproliferative properties. Here are some key points you should know about this medication:\n\n1. **Indications**: Sirolimus protein-bound particles are approved for specific indications such as the treatment of certain types of tumors and cancers, for example, advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. It is also used in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients who require therapeutic intervention but are not candidates for curative surgical resection.\n\n2. **Mech"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JtB3kzodfJ2pURWCXpa3Xzr5", "custom_id": "332_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b9ccef3f8f2a63deecd8816d391875a", "body": {"id": "chatcmpl-9St3h9YRxu0yzQ1xi9xdW4fiGCVse", "object": "chat.completion", "created": 1716671857, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication with several important aspects that physicians should be aware of, including its uses, mechanism of action, administration, and potential side effects. Here\u2019s a detailed overview:\n\n### Uses\nSuramin is primarily used for the treatment of:\n- **Human African trypanosomiasis (HAT)**, also known as sleeping sickness, caused by *Trypanosoma brucei gambiense* and *Trypanosoma brucei rhodesiense*. It is more effective in the early hemolymphatic stage of the disease.\n- **Onchocerciasis (river blindness)**, caused by *Onchocerca volvulus*. However, its use in onchocerciasis is limited due to availability of better tolerated drugs like ivermectin.\n\n### Mechanism of Action\nSuramin works by inhibiting enzymes that are essential for the energy metabolism of the parasite. It inhibits parasite-specific enzymes and cellular receptors,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_UrZp7964iuOSn3RJWulHLbyO", "custom_id": "333_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d6cee5eaee9011d6b315f2a8a96a9d60", "body": {"id": "chatcmpl-9St3iQI58Kxbt9qyl5iEiTZbiUxCu", "object": "chat.completion", "created": 1716671858, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Adagrasib (also known by its developmental code MRTX849) is an investigational small molecule that targets a specific mutation in the KRAS gene known as KRAS G12C. KRAS is a gene that acts as an on/off switch in cell signaling, and when it mutates, it can result in the continuous growth and division of cells, often leading to cancer. The G12C mutation, specifically, occurs in approximately 13% of non-small cell lung cancers (NSCLC), as well as in other solid tumors.\n\n### Mechanism of Action:\nAdagrasib works by selectively and irreversibly binding to the KRAS G12C mutant protein, locking it in an inactive state. This inhibits the downstream signaling pathways that promote tumor growth and survival, thereby exerting anti-tumor effects.\n\n### Clinical Trials:\nAdagrasib has been evaluated in various clinical trials, primarily focusing on patients with advanced solid tumors harb"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wvKg0fE1C2wXunJ0fbR0KYro", "custom_id": "334_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae85d53069fdee15ba31dec0b6eabf87", "body": {"id": "chatcmpl-9St3i9K2RLfKj0zTcvteeVfiNGuyR", "object": "chat.completion", "created": 1716671858, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp (tebentafusp-tebn) is a novel bispecific protein therapeutic used in the treatment of uveal melanoma, a rare and aggressive form of melanoma that occurs in the eye. It was approved by the U.S. Food and Drug Administration (FDA) in January 2022 for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Here are some key points about Tebentafusp:\n\n1. **Mechanism of Action**: Tebentafusp is a bispecific fusion protein that consists of a soluble T cell receptor fused to an anti-CD3 single-chain variable fragment. It specifically targets the gp100 peptide presented by HLA-A*02:01 on melanoma cells. By binding to both the T cell (via CD3) and the melanoma cell (via gp100), Tebentafusp redirects T cells to kill the melanoma cells.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SbJu7vg3lzCyfi8oHmNN4MBN", "custom_id": "335_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9f46260b1624db69d87f0fe06a4aab7e", "body": {"id": "chatcmpl-9St3iyzMio2Aqx2DpybTfhzEW2Mrw", "object": "chat.completion", "created": 1716671858, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a medication used primarily for the treatment of certain types of myelofibrosis, a form of myeloproliferative disorder. Here are some key points you should know about fedratinib:\n\n1. **Indications**: Fedratinib is approved by the FDA for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n2. **Mechanism of Action**: Fedratinib is a kinase inhibitor that primarily targets Janus Associated Kinases (JAKs), with a high selectivity for JAK2. The JAK/STAT pathway is a common signaling pathway used by various cytokines and growth factors, and its dysregulation is implicated in the pathogenesis of myelofibrosis. By inhibiting JAK2, fedratinib can reduce the aberrant signaling that contributes to disease symptoms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LicBrTiQaQgkCrDp00Rp2Pmd", "custom_id": "336_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4662ba2aec0794231d0dac26fdeb2c5", "body": {"id": "chatcmpl-9St3ilFcirYNKP8vBZQcand5ALGgh", "object": "chat.completion", "created": 1716671858, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab and hyaluronidase-oysk is a combination medication used in the treatment of certain types of breast cancer and gastric cancer. Here are some key points you should know about this medication:\n\n1. **Indications**: Trastuzumab and hyaluronidase-oysk is specifically indicated for the treatment of HER2-overexpressing breast cancer. It is used for the treatment of adult patients with early breast cancer that is HER2-positive and has spread to the lymph nodes, or is HER2-positive and has not spread to the lymph nodes but has other risk factors for recurrence. It is also used in metastatic settings. Additionally, it is indicated for HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n2. **Mechanism of Action**: Trastuzumab is a monoclonal antibody that targets the HER2 receptor, a protein overexpressed in some types of cancer cells."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P3sBmnbhOXOMIMzFatHFRNyg", "custom_id": "337_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "037ee26f0b8542f80da5fba2c3e85577", "body": {"id": "chatcmpl-9St3jAcdBJPdJPfG5hqfyeeX6c1e6", "object": "chat.completion", "created": 1716671859, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib (sold under the brand name Brukinsa) is a medication used in the treatment of certain types of B-cell malignancies, specifically mantle cell lymphoma (MCL) and Waldenstr\u00f6m's macroglobulinemia. It is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking BTK, a key enzyme in the B-cell receptor signaling complex that plays a crucial role in the growth and proliferation of malignant B cells.\n\nHere are some key points you should know about Zanubrutinib:\n\n1. **Indications**:\n   - Zanubrutinib is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.\n   - It is also approved for the treatment of Waldenstr\u00f6m's macroglobulinemia.\n\n2. **Mechanism of Action**:\n   - Zanubrutinib selectively inhibits"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r5UCwDsY1r7qfJ3925lAfO34", "custom_id": "338_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "54266763b559ef018faff36ac8bf17e3", "body": {"id": "chatcmpl-9St3jlNjrWp75LAjiGCGACgCcSvdY", "object": "chat.completion", "created": 1716671859, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furmonertinib (also known by its developmental code name AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. As a physician, here are some key points you should know about Furmonertinib:\n\n1. **Mechanism of Action**: Furmonertinib targets and inhibits the activity of EGFR mutations, which are common drivers of cancer cell growth and survival in some types of NSCLC. It is particularly effective against tumors with T790M mutations, which are a common mechanism of resistance to earlier-generation EGFR inhibitors.\n\n2. **Indications**: It is approved for use in patients with NSCLC who have specific EGFR mutations and who have developed resistance to first-line EGFR TKIs due to the T790M mutation. The approval and indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_VIAHjkNyw4KbhPRXCFX9x21X", "custom_id": "339_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e995cc1d75dc4b0bee5abffdf48360c", "body": {"id": "chatcmpl-9St3kdECOS7Em0YZlpKfpI38mbuR6", "object": "chat.completion", "created": 1716671860, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel, also known as cilta-cel, is a chimeric antigen receptor (CAR) T-cell therapy that has been developed for the treatment of multiple myeloma. This therapy represents a significant advancement in the field of hematologic malignancies, particularly for patients who have relapsed or refractory multiple myeloma. Here are some key points you should know about ciltacabtagene autoleucel:\n\n1. **Mechanism of Action**: Ciltacabtagene autoleucel involves reprogramming the patient's T cells to include a CAR that specifically targets BCMA (B-cell maturation antigen), a protein that is predominantly expressed on the surface of myeloma cells. This allows the modified T cells to recognize and kill BCMA-expressing cells.\n\n2. **Indications**: As of the last update, ciltacabtagene autoleucel has been approved by the FDA for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h76zD6ATvyBRPG6oJdlcjmr6", "custom_id": "340_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe8170b9c12f2ca74c885976f4b48e48", "body": {"id": "chatcmpl-9St3kVCt1iiESmrBKlR7Djofs6Qgv", "object": "chat.completion", "created": 1716671860, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a medication used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about asciminib:\n\n1. **Mechanism of Action**: Asciminib is a first-in-class allosteric inhibitor of the BCR-ABL1 tyrosine kinase. Unlike other tyrosine kinase inhibitors (TKIs) that target the ATP-binding site of BCR-ABL1, asciminib binds to the myristoyl site of the ABL1 kinase, leading to a different mode of inhibition. This unique mechanism allows it to be effective even in cases where there is resistance to other TKIs.\n\n2. **Indications**: As of the latest updates, asciminib has been approved by the FDA for the treatment of adult patients with chronic-phase CML who have received two or more prior therapies, including at least one tyrosine kinase inhibitor. It is also indicated for patients with CML harboring the T"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AW1rmwVnxw1KsFALfotA0gjO", "custom_id": "341_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f10e8f16986bad5185d7c4f8069b29a9", "body": {"id": "chatcmpl-9St3kWB9Oxb204BcGC4Ii4Y742aHo", "object": "chat.completion", "created": 1716671860, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine, also known by its brand name Zynlonta, is a CD19-directed antibody-drug conjugate (ADC) used in the treatment of certain types of B-cell lymphomas. This medication is particularly indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and also other lymphomas that are classified as large B-cell lymphomas.\n\n### Mechanism of Action:\nLoncastuximab tesirine works by targeting the CD19 antigen on B-cells, which is a common marker on these cells in various types of B-cell lymphomas. The drug consists of a monoclonal antibody linked to a cytotoxic agent, pyrrolobenzodiazepine (PBD) dimer. Once loncastuximab tesirine binds"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2vzdx0jY6SYQDxlkdiS12x5O", "custom_id": "342_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7a3d8c22a4703da5d6030f10492dbf4", "body": {"id": "chatcmpl-9St3kbDs6M50jOgVOE8k3Gyx9Z498", "object": "chat.completion", "created": 1716671860, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat is an oral, small molecule inhibitor of the EZH2 (enhancer of zeste homolog 2) enzyme, which is a part of the polycomb repressive complex 2 (PRC2) that plays a role in gene silencing. It has been studied and used primarily in the treatment of certain types of cancer, particularly those that involve defects in the SWI/SNF complex which can lead to aberrant EZH2 activity.\n\nHere are some key points about Tazemetostat that you, as a physician, might find useful:\n\n1. **FDA Approval and Indications:**\n   - Tazemetostat was approved by the U.S. Food and Drug Administration (FDA) in June 2020 for the treatment of:\n     - Adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ou7Ygp7momMFG3PWxx2FPDE5", "custom_id": "343_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca0dbdd7fed48483386a72709fde8f13", "body": {"id": "chatcmpl-9St3l1gLp8CCQooSCGdKVUPM4XSgj", "object": "chat.completion", "created": 1716671861, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab and relatlimab are immunotherapeutic agents used in the treatment of various cancers. Here\u2019s a detailed overview of each:\n\n### Nivolumab\nNivolumab, marketed under the brand name Opdivo, is a monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, a part of the immune checkpoint pathway. By blocking PD-1, nivolumab enhances the immune system's ability to detect and destroy cancer cells. It is used for the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, and others.\n\n#### Key Points for Physicians:\n- **Indications**: Check specific indications as they vary by cancer type and staging, often used in advanced or metastatic cases.\n- **Administration**: Typically administered intravenously.\n- **Side Effects**: Can include immune-related adverse effects such as pneumonitis, col"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uyVCnIh6h4sCuDIPdGY29hZE", "custom_id": "344_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7cc0d49ac7807a290ea2dc091c8e7a0c", "body": {"id": "chatcmpl-9St3lCTQKdZzORmQ0177uCsJPjHNj", "object": "chat.completion", "created": 1716671861, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Interferon alfa-2c is not a commonly referenced drug in clinical practice or medical literature. It's possible you meant Interferon alfa-2b or another type of interferon, which are more commonly used.\n\nInterferons are a group of signaling proteins made and released by host cells in response to the presence of several pathogens, including viruses, bacteria, parasites, and also tumor cells. In medical practice, synthetic versions are used to treat various conditions, including viral infections and cancers.\n\n### Interferon Alfa-2b\nInterferon alfa-2b is one of the more commonly used interferons. It is used for the treatment of various conditions, including:\n- Hepatitis B and C\n- Malignant melanoma\n- Follicular lymphoma\n- Kaposi's sarcoma associated with AIDS\n- Condylomata acuminata\n\n### Mechanism of Action\nInterferon alfa"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_drufn96a7MmWJL5ZAZdUcTak", "custom_id": "345_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c583f7df6957aba4598624561e63cbc", "body": {"id": "chatcmpl-9St3ltKvwbV8cqu8ShJwIONMSOgDV", "object": "chat.completion", "created": 1716671861, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1, also known as Wellferon, is one of the several types of interferon alphas used in the treatment of various diseases. Interferons are a group of signaling proteins made and released by host cells in response to the presence of several pathogens, such as viruses, bacteria, parasites, and also tumor cells. Interferon alfa-n1 is primarily produced from leukocytes and is used for its antiviral, antiproliferative, and immunomodulatory effects.\n\n### Clinical Uses\nInterferon alfa-n1 has been used in the treatment of:\n- **Chronic hepatitis B and C**: It helps reduce viral load and liver inflammation.\n- **Certain cancers**: Including hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma. It works by slowing the growth of cancer cells and affecting their function.\n\n### Mechanism of Action\nInterferon alfa-n1 works by binding to specific receptors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_09GlmOyLJScAWcguYijFxzcQ", "custom_id": "346_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b351fe2deab3e768266dc31384c3d960", "body": {"id": "chatcmpl-9St3mHs4A97ZuA2vQfBaWC804ItWS", "object": "chat.completion", "created": 1716671862, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is a monoclonal antibody that is used in the treatment of certain types of cancer. Here are some key points you should know about margetuximab:\n\n1. **Indication**: Margetuximab is approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margetuximab is a monoclonal antibody that targets the HER2/neu receptor, a protein overexpressed in some breast cancer cells. It is designed to block the growth of cancer cells by binding to the HER2 receptor. Additionally, margetuximab has been engineered with an altered Fc region, which may enhance the engagement of the immune system's natural killer (NK) cells and improve the antibody-dependent cellular cytotoxicity (ADCC) against"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uAPYLPEeU7RiB6NMeGrrG07j", "custom_id": "347_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b6c1813dcefbd304b44d7f95c00e4e22", "body": {"id": "chatcmpl-9St3mL522C84SE1Fcs0iFy34YF6ry", "object": "chat.completion", "created": 1716671862, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib (brand name Lumakras) is a targeted anticancer medication specifically designed to inhibit the KRAS G12C mutation. This mutation is found in a subset of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and other solid tumors. Here are some key points about Sotorasib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Sotorasib selectively and irreversibly binds to the KRAS G12C mutant protein, locking it in an inactive GDP-bound state. This inhibits downstream signaling pathways that promote tumor growth and survival.\n\n2. **Indications**: As of the latest updates, Sotorasib has been approved by the FDA for the treatment of adults with locally advanced or metastatic NSCLC with the KRAS G12C mutation who have received at least one prior systemic therapy. Research is ongoing to potentially expand its indications.\n\n3. **Efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OR8Nacx1xkF6XPZQL5TMoHpt", "custom_id": "348_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3df8e970786b582f900f70be99387a4a", "body": {"id": "chatcmpl-9St3nAw5xteV1OklG9waVj6gudM65", "object": "chat.completion", "created": 1716671863, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib, also known by its brand name Ukoniq, is a medication used in the treatment of certain types of cancers, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is classified as a PI3K inhibitor, targeting the phosphoinositide 3-kinase delta (PI3K\u03b4) enzyme, which is involved in the activation, proliferation, and survival of B cells. By inhibiting this enzyme, umbralisib can help to control the growth of cancer cells.\n\nHere are some key points you should know about umbralisib:\n\n1. **Indications**: Umbralisib is approved for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8jchBIe1ucmPQHjLoRwHv5Tt", "custom_id": "349_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a10b7de4e902447ea0d860c73a883fb3", "body": {"id": "chatcmpl-9St3o8O973F3wOACqMVqmAfX6ZLq3", "object": "chat.completion", "created": 1716671864, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sintilimab is an immune checkpoint inhibitor used in the treatment of various types of cancer. It is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1, sintilimab helps to restore the body's immune response against cancer cells.\n\nHere are some key points you should know about sintilimab:\n\n1. **Mechanism of Action**: Sintilimab binds to the PD-1 receptors on T-cells and blocks its interaction with PD-L1 and PD-L2 ligands on tumor cells and other cells in the tumor microenvironment. This blockade enhances T-cell function and proliferation, thereby increasing the immune system's ability to fight cancer.\n\n2. **Indications**: Sintilimab has been approved in several countries for the treatment of various cancers. For example, it has been used in non-small cell lung"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Dg1V6euqkk1DazySQQGQPe6x", "custom_id": "350_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6e5133b952279bfbd0f1f1d9c485f666", "body": {"id": "chatcmpl-9St3ogrX1zroDkLNBmqes9WYQlhau", "object": "chat.completion", "created": 1716671864, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirtobrutinib (also known by its developmental code name LOXO-305) is a novel, highly selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). It is designed to inhibit both wild-type and mutated forms of BTK. The molecule has shown promise in treating various B-cell malignancies, including conditions where patients have developed resistance to other BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Pirtobrutinib binds reversibly to BTK, providing inhibition that is both potent and selective. This reversible binding is thought to contribute to its efficacy in cases where BTK mutations confer resistance to irreversible inhibitors.\n\n2. **Indications**:\n   - As of the last update, pirtobrutinib is primarily being investigated in clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_88vWfrEHe8JMAogAVElhcPkD", "custom_id": "351_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "19448cd293afb58965ce7344ee62093d", "body": {"id": "chatcmpl-9St3o2GhSOZ2r76o8bXPi9q2nFOrf", "object": "chat.completion", "created": 1716671864, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimab is an immune checkpoint inhibitor specifically targeting the programmed cell death protein 1 (PD-1) receptor, a key molecule in the immune response against cancer. It is part of a broader class of drugs known as monoclonal antibodies designed to enhance the body's immune response against cancer cells. Here are some key points you should know about Toripalimab:\n\n1. **Mechanism of Action**: Toripalimab works by binding to the PD-1 receptors on T cells, blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the \"off\" signal that cancer cells use to evade immune detection, thereby enhancing the body's ability to attack and destroy cancer cells.\n\n2. **Indications**: As of the last update, Toripalimab has been investigated and used for various types of cancer, including melanoma, nasopharyngeal carcinoma, and urothelial carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DxRGTMOauhBbEZs24ZLFa0Pf", "custom_id": "352_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55d83593a4489a8f5890577b91e71258", "body": {"id": "chatcmpl-9St3pKeLtykzorvjnpsm1FrV97kAm", "object": "chat.completion", "created": 1716671865, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab (brand name Tecvayli) is a bispecific antibody used in the treatment of multiple myeloma. It was approved by the U.S. Food and Drug Administration (FDA) in October 2022. Here are some key points about Teclistamab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Teclistamab is designed to target both CD3 on T cells and BCMA (B-cell maturation antigen) on myeloma cells. This dual targeting helps to direct T cells to recognize and eliminate BCMA-expressing myeloma cells.\n\n2. **Indications**: It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n3. **Administration**: Teclistamab is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i6DUfxlTGwy9uBvw3NkrNcdL", "custom_id": "353_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ca21efdf08da8d07bafc2952850b343", "body": {"id": "chatcmpl-9St3pLPC5LfBGo2DFJPz7qUgzVYNS", "object": "chat.completion", "created": 1716671865, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib (previously known as TAK-788) is a targeted therapy drug used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about mobocertinib:\n\n1. **Mechanism of Action**: Mobocertinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are associated with a subset of non-small cell lung cancers and are generally resistant to other EGFR-targeted therapies.\n\n2. **Approval**: As of my last update, mobocertinib received accelerated approval from the U.S. Food and Drug Administration (FDA) in September 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy.\n\n3. **Efficacy**: Clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SV8lQyj8h2gerjHQqYkBq3MS", "custom_id": "354_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "160667c8d9ed96259c75474ffa21d83b", "body": {"id": "chatcmpl-9St3pkZg2sKud54ePlvgnLNQlmbMX", "object": "chat.completion", "created": 1716671865, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin, also known by its brand name Tivdak, is a novel antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Here are some key points you should know about Tisotumab vedotin:\n\n1. **Indication**: As of the last update, Tisotumab vedotin is approved for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.\n\n2. **Mechanism of Action**: Tisotumab vedotin combines a human tissue factor-specific monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE), using a linker. Tissue factor is a protein that is often overexpressed in various types of cancers, including cervical cancer. The antibody component of Tisotumab vedotin binds to tissue factor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AClcjdDhZZzHDJp9MWXxoyOE", "custom_id": "355_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc02bd70e8d992319fd2ed89bc030434", "body": {"id": "chatcmpl-9St3q6Uiy8psWsYvih3CUTVZqMTJA", "object": "chat.completion", "created": 1716671866, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide LAR (long-acting release) is a synthetic somatostatin analog used primarily in the management of acromegaly and gastroenteropancreatic neuroendocrine tumors. Here are some key points you should know about Lanreotide LAR:\n\n1. **Indications**:\n   - **Acromegaly**: Lanreotide is used for the treatment of patients with acromegaly when surgery or radiotherapy have not been fully successful, or when surgery is not an option. It helps to reduce the levels of growth hormone and IGF-1 (Insulin-like Growth Factor 1).\n   - **Neuroendocrine Tumors**: It is indicated for the treatment of unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve symptoms and potentially slow tumor progression.\n\n2. **Mechanism of Action**:\n   - Lanreotide works by mimicking the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4UJH2rZQlnwvXZj4RuUIaLLx", "custom_id": "356_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ab7a31882da6097c456de79c2c95274", "body": {"id": "chatcmpl-9St3qr4DDveGJy7V8f2teULBtgiCf", "object": "chat.completion", "created": 1716671866, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Pimitespib (also known by its developmental code TAS-116) is a small molecule inhibitor specifically targeting heat shock protein 90 (HSP90), a chaperone protein that plays a key role in the folding, stability, and function of various \"client\" proteins, many of which are involved in cancer progression. By inhibiting HSP90, Pimitespib aims to disrupt these processes, leading to the degradation of oncogenic proteins and ultimately inhibiting tumor growth.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Pimitespib binds to the ATP-binding domain of HSP90, inhibiting its activity. This leads to the degradation of client proteins that are crucial for tumor cell growth and survival.\n\n2. **Clinical Trials and Indications**:\n   - As of the last update, Pimitespib has been under investigation in clinical trials, primarily focusing on solid tumors and hematological malignancies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_V7b0AVXaNIkRzc3BEHPer6Sh", "custom_id": "357_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a29f300ab9664c0dcc9a2422d03e729", "body": {"id": "chatcmpl-9St3rzGkduPHTH4QhytxgHZwuB58I", "object": "chat.completion", "created": 1716671867, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapy medication that combines the properties of two other drugs: prednisolone and chlorambucil. It is primarily used in the treatment of certain types of cancers, including lymphomas and leukemias. Here are some key points you should know about prednimustine:\n\n1. **Mechanism of Action**: Prednimustine is designed to deliver both a corticosteroid (prednisolone) and an alkylating agent (chlorambucil). The prednisolone component helps in reducing inflammation and immune response, while chlorambucil is involved in cross-linking DNA, which disrupts cancer cell growth and induces apoptosis.\n\n2. **Indications**: It is typically used in the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Its use might be considered when other first-line treatments are not suitable or have failed.\n\n3. **Administration**: Prednimustine is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B3TMJIsCvJuYZWvhuGljaXzS", "custom_id": "358_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74a3b54514095525631a98dc3658b343", "body": {"id": "chatcmpl-9St3rj8gTw7cag1R2olElMs84e4CA", "object": "chat.completion", "created": 1716671867, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is a drug primarily used in the treatment of certain blood disorders, notably polycythemia vera and essential thrombocythemia. These are myeloproliferative disorders characterized by the overproduction of blood cells in the bone marrow. Here are some key points you should know about Pipobroman:\n\n1. **Mechanism of Action**: Pipobroman works as an alkylating agent, meaning it interferes with DNA replication in cells, thereby reducing the overproduction of blood cells. Its exact mechanism, however, is not fully understood but is believed to involve the induction of DNA damage which leads to apoptosis (cell death) particularly in rapidly dividing cells.\n\n2. **Indications**: It is primarily indicated for the treatment of polycythemia vera and essential thrombocythemia. It may also be used in some cases of chronic myeloid leukemia (CML).\n\n3. **Administration**: Pipobroman is administered orally. The dosage and treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rPQqpHO6H5WAFogQxG6uuoQ7", "custom_id": "359_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f7ad7e249be63da22a4c5cc4ed582584", "body": {"id": "chatcmpl-9St3sk9syAFCGcBgUK04uDHhNVR5p", "object": "chat.completion", "created": 1716671868, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin, marketed under the brand name Polivy, is a monoclonal antibody-drug conjugate (ADC) used in oncology, particularly for the treatment of certain types of non-Hodgkin lymphoma. Here are some key points you should know about Polatuzumab vedotin:\n\n1. **Mechanism of Action**: Polatuzumab vedotin targets the protein CD79b, which is expressed on the surface of B cells. It is conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to CD79b, the ADC is internalized, and MMAE is released inside the cell, leading to cell cycle arrest and apoptosis of the B-cell.\n\n2. **Indications**: It is approved for use in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_azFhcX1jpis5KVuugKJHNFRl", "custom_id": "360_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5c55625bdd8113cbad4c477b19e13954", "body": {"id": "chatcmpl-9St3sEUTH7lgFy09gtTf1TQJqcbWu", "object": "chat.completion", "created": 1716671868, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) designed for the treatment of cancer, specifically targeting cancers that express folate receptor alpha (FR\u03b1). This receptor is frequently overexpressed in certain types of cancers, including ovarian cancer, which makes it a promising target for targeted therapy.\n\n### Key Points about Mirvetuximab Soravtansine:\n\n1. **Mechanism of Action**:\n   - Mirvetuximab soravtansine consists of three parts: an antibody that binds to FR\u03b1, a linker, and a cytotoxic drug. Once the antibody binds to FR\u03b1 on the surface of cancer cells, the conjugate is internalized and the cytotoxic drug is released inside the cancer cell, leading to cell death.\n\n2. **Indications**:\n   - As of the last update, it has been primarily investigated for its use in ovarian cancer, particularly in patients who have tumors that highly express FR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_lh0BRBdMl5nmXLbwdUJeLunr", "custom_id": "361_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "378b6bff33bdea20cd69f3bfb4aea308", "body": {"id": "chatcmpl-9St3s34UsHruuGkbdCDGiOoiHK7jv", "object": "chat.completion", "created": 1716671868, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab is a bispecific antibody designed for the treatment of certain types of B-cell non-Hodgkin lymphoma. As a physician, here are some key points you should know about mosunetuzumab:\n\n1. **Mechanism of Action**: Mosunetuzumab is designed to target CD20 on B cells and CD3 on T cells. It brings these two cell types into close proximity, which helps activate T cells to kill the B cells. This dual targeting is intended to enhance the immune system's ability to detect and destroy malignant B cells.\n\n2. **Indications**: As of the latest updates, mosunetuzumab has been primarily investigated for its use in treating relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). It is particularly considered for patients who have failed other treatments, such as chemotherapy and other targeted therapies.\n\n3. **Clinical Trials**: Mos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_mebC84ox699uoEv8zaKJgrnS", "custom_id": "362_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b1bab288ef12b0fdd1ce7014af717687", "body": {"id": "chatcmpl-9St3sZoUp6d2QXjBDewPvDLaaAzPp", "object": "chat.completion", "created": 1716671868, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec (also known as rAd-IFN/Syn3) is a novel gene therapy used for the treatment of high-grade, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC). It was developed to provide an alternative treatment option for patients who are not candidates for more invasive procedures like cystectomy.\n\n### Mechanism of Action:\nNadofaragene firadenovec works by delivering a recombinant adenovirus vector containing the human interferon alpha-2b gene directly into the bladder through intravesical administration. Once administered, the virus infects the bladder cells, which then begin to produce interferon alpha-2b. This protein has antitumor effects, including direct antiproliferative effects on cancer cells and stimulation of the immune system to fight the cancer.\n\n### Administration:\nThe treatment involves the intravesical instillation of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kd0ynUDouiOcnWPd3ae1nWX7", "custom_id": "363_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8c8c939f4130be8488f003338832a7c3", "body": {"id": "chatcmpl-9St3sDBYiZzcdOEJgZFf2JqK9vXEj", "object": "chat.completion", "created": 1716671868, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olutasidenib is an investigational drug that targets isocitrate dehydrogenase-1 (IDH1) mutations. IDH1 mutations are found in various types of cancer, including acute myeloid leukemia (AML), cholangiocarcinoma, and gliomas. These mutations lead to abnormal cell proliferation and reduced differentiation, contributing to cancer progression.\n\n### Key Points about Olutasidenib:\n1. **Mechanism of Action**:\n   - Olutasidenib inhibits the mutant IDH1 enzyme, which normally catalyzes the conversion of isocitrate to \u03b1-ketoglutarate. The mutated form results in the production of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis. By inhibiting this pathway, olutasidenib aims to reduce levels of 2-HG and restore normal cellular differentiation and proliferation.\n\n2. **Clinical Trials**:\n   - Ol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7W4Wn6Y7MvC86clV9ItrCB3E", "custom_id": "364_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1857f459b69d983f48dccced28ad9cd4", "body": {"id": "chatcmpl-9St3tyQKYveE0IAyHX1NeVWuhc6zO", "object": "chat.completion", "created": 1716671869, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is an oral tyrosine kinase inhibitor that targets both HER1 (EGFR) and HER2 receptors. It has been primarily studied and used in the treatment of HER2-positive breast cancer. Here are some key points you should know about Pyrotinib:\n\n1. **Mechanism of Action**: Pyrotinib works by inhibiting the tyrosine kinase activities of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By blocking these receptors, pyrotinib inhibits downstream signaling pathways that promote cell proliferation and survival in cancer cells overexpressing these receptors.\n\n2. **Clinical Use**: It is mainly used for the treatment of HER2-positive breast cancer. Studies have shown that pyrotinib can be effective in patients who have received prior therapies, including trastuzumab and chemotherapy.\n\n3. **Effectiveness**: Clinical trials, such as the PHOEBE trial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VkmyFZinfLOYnAwWGvKWqm9P", "custom_id": "365_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "39cae0e6bd09dbcb439671be7f94e4c4", "body": {"id": "chatcmpl-9St3tHAkjjzAJd5Ss6ZTuaoLp3ST3", "object": "chat.completion", "created": 1716671869, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. It is a synthetic analog of naturally occurring GnRH and is used primarily in the treatment of hormone-sensitive cancers such as prostate cancer, in assisted reproduction, and in the management of endometriosis and uterine fibroids. Here are some key points about Buserelin that you, as a physician, might find useful:\n\n### Mechanism of Action\n- **Initial Stimulation**: Buserelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which increases the production of sex hormones (testosterone and estrogen).\n- **Downregulation**: With continuous administration, Buserelin eventually causes downregulation of GnRH receptors in the pituitary gland, leading to a significant reduction in LH and FSH secretion, and consequently"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eET2Tiuq2W7btYOLTnRQWlnJ", "custom_id": "366_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b9c0f698bc139b41674b2b4ce9758a16", "body": {"id": "chatcmpl-9St3uFJlSVhTCH7EuRgx2XjJfT6ET", "object": "chat.completion", "created": 1716671870, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel (also known by its research name LN-144) is an advanced cell therapy used in the treatment of certain types of cancer, specifically metastatic melanoma. It is a form of adoptive cell transfer (ACT) therapy that involves the use of tumor-infiltrating lymphocytes (TILs). Here are some key points you should know about Lifileucel:\n\n1. **Mechanism of Action**: Lifileucel therapy involves extracting TILs from a patient's tumor tissue. These lymphocytes are naturally occurring immune cells that have infiltrated the tumor. The cells are then expanded in large numbers in a laboratory and subsequently infused back into the patient. The goal is to enhance the body\u2019s immune response against cancer cells by providing a large population of TILs that are primed to fight the tumor.\n\n2. **Treatment Process**: The process starts with the surgical removal of a tumor sample from which lymphocytes are isolated. After the expansion of these cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8mMRJ9e9LV55heddmfYu1u4I", "custom_id": "367_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2c65bcacc066c6a163eb4e2dea5da05f", "body": {"id": "chatcmpl-9St3uoXAkH7XoRCbJ3SmhQ24ekifC", "object": "chat.completion", "created": 1716671870, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel, often referred to as tab-cel, is an investigational off-the-shelf, allogeneic T-cell immunotherapy that is being developed for the treatment of Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD), as well as other EBV-associated diseases. Here are some key points you should know about tabelecleucel:\n\n1. **Mechanism of Action**: Tabelecleucel is designed to target and eliminate EBV-infected cells. It is composed of T cells from healthy donors that have been exposed to EBV antigens, causing them to become activated and primed to target EBV-infected cells.\n\n2. **Clinical Trials**: Tabelecleucel has been evaluated in several clinical trials, particularly focusing on patients who have undergone organ or hematopoietic stem cell transplants and subsequently developed EBV+ PTLD, a condition that can be life-threatening"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tbg7vobgLdDG1NIQXRW1gFw8", "custom_id": "368_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "79042ce7552e0a81bc37864623fa592b", "body": {"id": "chatcmpl-9St3utbH9K5yM4WSuyZEmRMY4b2Zb", "object": "chat.completion", "created": 1716671870, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (abemaciclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Verzenio:\n\n1. **Indications**: Verzenio is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients with disease progression following endocrine therapy.\n\n2. **Mechanism of Action**: Verzenio is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by interfering with the proliferation of cancer cells by selectively inhibiting CDK4 and CDK6, key proteins involved in the cell cycle, particularly in the transition from G1 to S phase.\n\n3. **Administration**: Verzenio is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tx2saSyysmubaxTnxfEtQARZ", "custom_id": "369_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5101b528905e3d5ec2ea410561a23c1a", "body": {"id": "chatcmpl-9St3vH9I2jPD1U7dEGL5BDrUbOkTd", "object": "chat.completion", "created": 1716671871, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Abatitor\" in the context of medicine or healthcare. It's possible that the term could be a misspelling, a non-English term, a new development not yet included in my training data, or something specific to a particular study or regional healthcare practice.\n\nIf you meant something specific or need information on a similarly named medication, condition, or concept, please provide more details or check the spelling so I can assist you more accurately. Alternatively, consulting the most current medical literature or databases might provide the most reliable and up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 127, "total_tokens": 168}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DPhL9EUsAZH9TuXn6aW2veX1", "custom_id": "370_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dda5ab2d1609255ee6b87d4dd8567b3d", "body": {"id": "chatcmpl-9St3vujBMhI1eTJ6WgYmeuoqzfZlX", "object": "chat.completion", "created": 1716671871, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a medication used in the treatment of certain types of blood cancers. Here are some key points you should know about Calquence:\n\n1. **Indications**: Calquence is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**: Calquence is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking BTK, a key molecule in the B cell receptor signaling complex, which plays a crucial role in the survival and proliferation of malignant B cells.\n\n3. **Administration**: Calquence is administered orally, typically as a capsule taken twice daily. It can be taken with or without food.\n\n4. **Side Effects**: Common side effects include headache, diarrhea, muscle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UtVGMChWRXqrHeu9gZwSUOOn", "custom_id": "371_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4257e3bd3dc38f9c5ec6395c545bade3", "body": {"id": "chatcmpl-9St3vPvFhPRkzqqPj9pyRQ7aPkAp5", "object": "chat.completion", "created": 1716671871, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacinomycin A, also known as Aclarubicin, is an anthracycline antibiotic that is used primarily in the treatment of cancer. It functions similarly to other drugs in its class, such as doxorubicin, by intercalating DNA and inhibiting macromolecular biosynthesis. This interference with DNA replication and transcription ultimately leads to cell death, making it effective against rapidly dividing cancer cells.\n\n### Key Points for Physicians:\n\n1. **Indications**: Aclacinomycin A is primarily used in the treatment of acute myeloid leukemia (AML). It may also be used in other types of leukemia and cancers as part of a combination chemotherapy regimen.\n\n2. **Mechanism of Action**: It works by intercalating into DNA, disrupting the topoisomerase II enzyme, and generating free radicals that damage cellular components.\n\n3. **Administration**: Aclacinomycin A is administered intravenously. The dosage and schedule depend on the specific condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EWYaDGrXz0btBWpMsMxoE63S", "custom_id": "372_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fafed9112b6b8d789beb16a861564d4d", "body": {"id": "chatcmpl-9St3wAHJh15F69LNJVtaAU9XQdSRF", "object": "chat.completion", "created": 1716671872, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kadcyla (ado-trastuzumab emtansine) is a targeted therapy used in the treatment of HER2-positive breast cancer. It is particularly used for patients who have previously received trastuzumab and a taxane, either separately or in combination. Here are some key points about Kadcyla that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Kadcyla is a conjugate of the monoclonal antibody trastuzumab and the cytotoxic agent DM1 (emtansine). Trastuzumab binds to the HER2 receptor on cancer cells, and after internalization, DM1 is released, which inhibits microtubule polymerization, leading to cell death.\n\n2. **Indications**:\n   - Treatment of HER2-positive, metastatic breast cancer in patients who have previously received trastuzumab and a taxane.\n   - Approved for use in certain early"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_O9gAI9y6VWJuWwPuh2qYXo96", "custom_id": "373_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "37395f738f5c3ccebaf8c6ef3730fbae", "body": {"id": "chatcmpl-9St3xks8V60OhmJHwaak6lpPmpx9o", "object": "chat.completion", "created": 1716671873, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Afanix\" does not appear to be a recognized medication or treatment in standard medical resources. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in widely available medical literature.\n\nIf \"Afanix\" refers to a specific drug or treatment you've encountered in practice or literature, it might be helpful to check the following:\n\n1. **Spelling and Nomenclature**: Verify the spelling or see if it\u2019s known by another name or abbreviation.\n2. **Local Drug Registers**: Some drugs are marketed under different names in different countries or might be a newly released drug.\n3. **Pharmaceutical Sources**: Contacting the manufacturer or checking their website could provide up-to-date product information.\n4. **Latest Medical Literature**: Searching medical journals or databases might yield information on newly developed drugs or treatments.\n5. **Drug Regulatory Websites**: Websites like the FDA (U.S. Food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0MIBm7X9RD6YKtPTCQmGfdYH", "custom_id": "374_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d4a508acb6959db19a9ecb691530d04b", "body": {"id": "chatcmpl-9St3xp3L3OsNS3fqZoDWysyJf2NOt", "object": "chat.completion", "created": 1716671873, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Macrolin\" does not appear to be a widely recognized medication or substance in standard medical resources. It's possible that it could be a brand name, a less common name for a drug, or a substance not widely used or approved. It's also possible that there might be a spelling error or a regional name that is not widely recognized.\n\nIf you are referring to a specific medication intended for treatment or any medical use, it would be helpful to have the correct spelling or additional context such as its active ingredients, its intended use, or the region where it is being prescribed or discussed. This information would allow for a more accurate and detailed response.\n\nIf you are dealing with a specific case or need information about a particular substance, I recommend consulting a reliable pharmaceutical database, contacting the manufacturer, or reviewing the latest clinical guidelines relevant to the substance in question. Always ensure that your sources are up-to-date and credible to provide the best care for your patients."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 198, "total_tokens": 239}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_PFkApVTvwESzotdVCYvxeWhV", "custom_id": "375_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "679a7a2c5f060137834efd068638676c", "body": {"id": "chatcmpl-9St3x7moMzlTOkuza0aUie65NzdnP", "object": "chat.completion", "created": 1716671873, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alecensa (alectinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC), specifically for cancers that are anaplastic lymphoma kinase (ALK)-positive. Here are some key points you should know about Alecensa:\n\n1. **Indications**: Alecensa is approved for the treatment of ALK-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Alecensa is an ALK inhibitor. It works by targeting and inhibiting the activity of the ALK protein, which can be abnormally active in some types of cancer cells. By inhibiting this protein, Alecensa can help in controlling the growth of cancer.\n\n3. **Administration**: Alecensa is administered orally, typically twice a day. It's important for patients to follow the dosage prescribed by their healthcare provider.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aSuyew5PjrRP0bQgaHPKhxTG", "custom_id": "376_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa14868398f223c69db14b9323677fc5", "body": {"id": "chatcmpl-9St3yxXYOn1JsTxPjlUWmz4PN2dlh", "object": "chat.completion", "created": 1716671874, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Campath (alemtuzumab) is a monoclonal antibody used primarily in the treatment of certain medical conditions, including chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). Here are some key points you should know about Campath:\n\n1. **Mechanism of Action**: Alemtuzumab targets the CD52 antigen present on the surface of mature lymphocytes and other cells of the immune system. Binding to CD52 leads to the depletion of B and T lymphocytes through antibody-dependent cellular cytotoxicity and complement-mediated lysis.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is approved for the treatment of B-cell CLL, particularly in patients who have been treated previously or are refractory to fludarabine.\n   - **Multiple Sclerosis (MS)**: Alemtuzumab is also used under the brand name Lemtrada for the treatment of relaps"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kivsLEHFvY4tqGUjWdpkO3ye", "custom_id": "377_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "88d8e16db394c6707240a158178b9ea1", "body": {"id": "chatcmpl-9St3yORQh42bF5kC9bONreyUnNjG4", "object": "chat.completion", "created": 1716671874, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a medication primarily used in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the presence of the t(15;17) translocation. Here are some key points you should know about ATRA as a physician:\n\n1. **Mechanism of Action**:\n   - ATRA works by binding to the retinoic acid receptor (RAR) which is involved in the transcription of genes necessary for cell differentiation and growth. In APL, the fusion protein produced by the t(15;17) translocation typically disrupts normal cell differentiation. ATRA helps to overcome this by inducing terminal differentiation and apoptosis of the abnormal promyelocytic cells.\n\n2. **Clinical Use**:\n   - ATRA is primarily used in the treatment of APL, where it has dramatically improved outcomes when used in combination with chemotherapy or arsenic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_154KWuEZyuw9WiRCwFI40s1j", "custom_id": "378_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "272abf3965864d95fe0e58d6e81b8ff8", "body": {"id": "chatcmpl-9St3zrMuJ01jIAe4mh1BTN6bxszsO", "object": "chat.completion", "created": 1716671875, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen, with the generic name altretamine, is a chemotherapy drug used primarily to treat ovarian cancer, particularly in cases where other treatments have failed. Here are some key points you should know about Hexalen:\n\n1. **Mechanism of Action**: Altretamine is considered an alkylating agent, though its exact mechanism of action is not fully understood. It is believed to damage the DNA of cancer cells, which prevents them from multiplying and causes them to die.\n\n2. **Indications**: Hexalen is approved for use in treating persistent or recurrent ovarian cancer. It is often considered when other chemotherapy options have not been successful.\n\n3. **Administration**: Altretamine is administered orally. The dosage and treatment regimen depend on factors such as the patient's size, the condition being treated, and the patient's overall health.\n\n4. **Side Effects**: Common side effects of Hexalen include nausea, vomiting, loss of appetite, and mild to moderate myelosuppression. Neuro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z4Yg5mNpAmvG9CBUDHRmBOqK", "custom_id": "379_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "309119ee3521906eb448a5e103e800cf", "body": {"id": "chatcmpl-9St3z5wl0TizbzsrwfPKis5bOJUeF", "object": "chat.completion", "created": 1716671875, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aminoblastin\" is not a widely recognized or standard medication or supplement in medical literature. It's possible that it could be a brand name, a non-standard term, or a product not approved or recognized by major medical regulatory bodies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency).\n\nIf you encounter a product or a term like \"Aminoblastin\" in your practice, here are a few steps you might consider:\n\n1. **Verify the Name**: Double-check the spelling or see if it\u2019s known by another name or abbreviation. Sometimes, drugs are known by different names in different countries or could be a brand name.\n\n2. **Ingredient Check**: Look into the active ingredients of the product. This can provide insights into its potential uses, effects, and safety profile.\n\n3. **Regulatory Status**: Check if the product is approved by relevant health authorities like the FDA, EMA,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VSe2QRsL0qfyRXMbMFK3ucrg", "custom_id": "380_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e37b9e61175b0459cff2825a45303069", "body": {"id": "chatcmpl-9St40BKC04LMO28ea2KPMSOYw4xdi", "object": "chat.completion", "created": 1716671876, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calsed is a brand name for tamsulosin, a medication primarily used to treat the symptoms of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland commonly seen in older men. Tamsulosin belongs to a class of drugs known as alpha blockers. Here are some key points about tamsulosin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tamsulosin works by selectively blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate and the bladder neck. This relaxation improves urine flow and reduces the symptoms of BPH.\n\n2. **Indications**: The primary indication for tamsulosin is the treatment of the signs and symptoms of BPH. It is not typically used for hypertension, unlike some other alpha blockers.\n\n3. **Dosage and Administration**: Tamsulosin is usually administered once daily, often after the same meal each day to maintain consistent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pjoC5p8YmWu7NYP0byiA2FOE", "custom_id": "381_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4bc57153ae4a4af1502d482e8b5ad0fb", "body": {"id": "chatcmpl-9St40Ij3KkMXub5qjIon4Sxel5rBN", "object": "chat.completion", "created": 1716671876, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Amekrin\" does not appear to be a widely recognized medication or substance in standard medical resources or databases. It's possible that it could be a new drug, a drug used in specific regions outside of mainstream Western medicine, or it might be known by a different name or spelling.\n\nIf \"Amekrin\" is a new or experimental drug, or if it is a drug used in specific medical practices not widely recognized in mainstream medicine, here are a few general steps you might consider as a physician:\n\n1. **Verify the Name and Details**: Double-check the spelling and details of the drug. Sometimes, similar or alternative names can lead to confusion.\n\n2. **Consult Updated Resources**: Use the most current and comprehensive medical databases available to you, such as PubMed, Medline, or specialized drug information databases like the FDA's drug database, or the European Medicines Agency (EMA) database.\n\n3. **Contact a Specialist**: If"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_IBl8V0f4V1QfcoYilYWr9v2V", "custom_id": "382_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2f2e09287be2c94bc1f6ec5f394eaf03", "body": {"id": "chatcmpl-9St40D7Yv22JjF3ilEwuVtASwqyTU", "object": "chat.completion", "created": 1716671876, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altraz is a brand name for the medication anastrozole, which is primarily used in the treatment of breast cancer. Anastrozole is a non-steroidal aromatase inhibitor, which works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some breast cancers that need estrogen to grow.\n\nHere are some key points about Altraz (anastrozole) that you, as a physician, might find useful:\n\n1. **Indications**: Anastrozole is commonly prescribed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is often used as adjuvant therapy for early-stage breast cancer and as first-line treatment for advanced or metastatic breast cancer.\n\n2. **Mechanism of Action**: Anastrozole inhibits the enzyme aromatase, which is involved in estrogen synthesis. By blocking this enzyme, anastrozole reduces the levels of estrogen in the body, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TnCgdUdmnmlc51YooVYRIBQj", "custom_id": "383_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "435161c1454be487e5fb40d0bb8a45f8", "body": {"id": "chatcmpl-9St41oxZCYDY8zy90P88CNMbXCP9W", "object": "chat.completion", "created": 1716671877, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (apalutamide) is a medication used in the treatment of prostate cancer. Here are some key points you should know about Erleada as a physician:\n\n1. **Indications**: Erleada is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is used in patients who are at high risk of developing metastatic disease.\n\n2. **Mechanism of Action**: Apalutamide, the active ingredient in Erleada, is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its action, which prevents the androgen receptor signaling that promotes prostate cancer cell growth.\n\n3. **Dosage and Administration**: The typical dosage of Erleada is 240 mg (four 60 mg tablets) taken orally once daily, with or without food. It is important to continue treatment until disease progression or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MPCBq5Omd9XjAg17Ttrwh5Mb", "custom_id": "384_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "81d42d7bd48f6e5aa28fb69706213e55", "body": {"id": "chatcmpl-9St41wyWjNkIRlK9inZXy8WDyodcs", "object": "chat.completion", "created": 1716671877, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Aitan\" does not correspond to any known medical condition, medication, or treatment that I am aware of. Could you please provide more context or clarify what you are referring to? If it's a specific drug, condition, or a term that is new or less common, any additional information would be helpful to provide an accurate response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 82, "total_tokens": 122}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_u9v2R2bLPC0U1cKqRzLiFYsZ", "custom_id": "385_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "817a0c1821f74bcbdc68866e0c946649", "body": {"id": "chatcmpl-9St42y9YZr1dbkAaUX0sdTkhL43YS", "object": "chat.completion", "created": 1716671878, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or substance known as \"Arsenol\" commonly recognized in medical literature or practice. It's possible that there might be a typo or a misunderstanding regarding the name. However, if you are referring to a compound related to arsenic, it's important to note that arsenic is a toxic chemical element, and its compounds are used in various contexts, including some therapeutic applications, historically in the treatment of syphilis and trypanosomiasis, and more recently in the form of arsenic trioxide for acute promyelocytic leukemia (APL).\n\nArsenic trioxide is specifically approved for use in treating APL, and it works by causing the leukemic cells to differentiate and die. It is a potent drug and must be used under strict medical supervision due to its toxicity profile, which can include serious side effects such as QT interval prolongation, which can lead to potentially fatal arrhythmias, and other side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Lna3ayiZWDzXMgFery4E5GQU", "custom_id": "386_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8730495617f02ac6baa60ee39ccbcf69", "body": {"id": "chatcmpl-9St42dYxAi3vT35f6FVfMO43vpdKP", "object": "chat.completion", "created": 1716671878, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an important medication used primarily in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients. It works by depleting the amino acid asparagine, which is essential for the growth and survival of leukemia cells. Here are some key points you should know about asparaginase:\n\n1. **Mechanism of Action**: Asparaginase hydrolyzes asparagine into aspartic acid and ammonia, thereby depriving leukemia cells of the asparagine they require for protein synthesis and survival. Normal cells, however, are less affected because they can synthesize asparagine.\n\n2. **Types of Asparaginase**:\n   - **E. coli-derived asparaginase** (e.g., L-asparaginase, Elspar) is the most commonly used form.\n   - **Erwinia chrysanthemi-derived asparaginase** is used primarily in patients who develop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_y7EKFBXRbr04nkKvIeK4FGhd", "custom_id": "387_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6dc2002ec057f22a24f373226a384a8f", "body": {"id": "chatcmpl-9St42D2To7AZ9u8utOqW6iT8QDZra", "object": "chat.completion", "created": 1716671878, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase, also known as Erwinia L-asparaginase, is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is particularly used in patients who have developed hypersensitivity to E. coli-derived asparaginase, which is a more commonly used form of the enzyme in ALL treatment. Here are some key points you should know about Erwinase:\n\n1. **Mechanism of Action**: Erwinase works by breaking down asparagine, an amino acid that is essential for the growth and survival of leukemia cells. Normal cells can synthesize asparagine, but leukemia cells cannot; they rely on the asparagine available in the bloodstream. By depleting asparagine, Erwinase starves the leukemia cells.\n\n2. **Indications**: It is specifically indicated for patients with hypersensitivity to E. coli-derived asparaginase. It is often used as part of a multi-drug chemotherapy regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ydxVHmO985VEDInMaOI7420E", "custom_id": "388_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "79d69c0de81b13697590fb0352ccc77b", "body": {"id": "chatcmpl-9St43a7dveD7r5LahHAJgaxP0BShG", "object": "chat.completion", "created": 1716671879, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is a monoclonal antibody used in cancer immunotherapy. It is specifically designed to bind to a protein called programmed death-ligand 1 (PD-L1), which is expressed on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1, Tecentriq helps to reactivate the immune system to recognize and attack cancer cells.\n\nHere are some key points you should know about Tecentriq:\n\n1. **Indications**: Tecentriq is approved for use in various types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, and triple-negative breast cancer that is locally advanced or metastatic. The specific indications can depend on factors such as the presence of specific biomarkers, previous treatments, and the stage of the disease.\n\n2. **Mechanism of Action**: Tecentriq works by inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z3i9MBzhnMWhFg8V0HNEA0zb", "custom_id": "389_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "53148900ffbad1a41ad37aaca528f33d", "body": {"id": "chatcmpl-9St43ivRRn6ip54LWQz4YMWSLTc8N", "object": "chat.completion", "created": 1716671879, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio (avelumab) is a monoclonal antibody used as an immunotherapy for treating certain types of cancer. It is specifically a programmed death ligand-1 (PD-L1) blocking antibody. By inhibiting PD-L1, Bavencio helps the immune system detect and destroy cancer cells. Here are some key points you should know about Bavencio:\n\n1. **Indications**: Bavencio is approved for the treatment of:\n   - Metastatic Merkel cell carcinoma (MCC) in adults and pediatric patients 12 years and older. This was the first FDA-approved treatment for metastatic MCC.\n   - Locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.\n   - In combination with axitinib, it is approved for the first-line treatment of patients with advanced renal cell carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BFddtXpfWVKXvA1jdlv2fcQO", "custom_id": "390_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab63ea3a82091f2075a72f38c4ab7fb7", "body": {"id": "chatcmpl-9St43674e9zEj59n7fNlE0GwSqBHK", "object": "chat.completion", "created": 1716671879, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a type of immunotherapy used in the treatment of certain cancers, specifically adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. It is not indicated for the treatment of patients with primary central nervous system lymphoma.\n\nYescarta is a CAR T-cell therapy, which involves modifying the patient\u2019s own T cells to include a chimeric antigen receptor (CAR) that targets cancer cells. Here are some key points you should know about Yescarta:\n\n1. **Mechanism of Action**: Yescarta works by genetically modifying the patient's T cells to express a CAR that specifically targets the CD19 antigen, a protein expressed on the surface of B-cell lymphomas"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RqT3ARg8Ywf1D3TQvsDh58QW", "custom_id": "391_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2758419305262c28f0f3968436e4fe03", "body": {"id": "chatcmpl-9St45EfdwIHH2vYmV9WrDUatiCs8M", "object": "chat.completion", "created": 1716671881, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Axishil.\" It's possible that the term could be a misspelling, a brand name not widely recognized, or a new product not yet documented in mainstream medical literature.\n\nIf you meant something specific related to medicine or pharmaceuticals and think \"Axishil\" might be a typo or a brand name under a different spelling, please provide more context or check the spelling so I can offer more accurate information. If it's a new drug or treatment, I recommend consulting the latest clinical trials, FDA releases, or pharmaceutical registries for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 130, "total_tokens": 171}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x96zZE5Hm6y9z9xVC048GzB9", "custom_id": "392_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "963fdf622d66b9440d1484c8f82b6cec", "body": {"id": "chatcmpl-9St45s44XaVW7E8mSJp2f4lk9dqck", "object": "chat.completion", "created": 1716671881, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, marketed under the name Vidaza, is a chemotherapy drug primarily used in the treatment of myelodysplastic syndromes (MDS), which are a group of hematologic conditions characterized by ineffective production of blood cells. Here are some key points about azacitidine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Azacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA. It works by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The hypomethylation may restore normal function to genes that are critical for cell differentiation and proliferation.\n\n2. **Indications**:\n   - Primarily used for the treatment of myelodysplastic syndromes (MDS), particularly in patients who are not candidates for stem cell transplant.\n   - It is also used for the treatment of acute"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a8DP3GLhFa8ojTqD2ErKFD6x", "custom_id": "393_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef273a5b717fe08ff39b8a0b67222b1d", "body": {"id": "chatcmpl-9St45iTLYaTusdfPeDikvX4fb2hgL", "object": "chat.completion", "created": 1716671881, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "TheraCys\u00ae is a Bacillus Calmette-Gu\u00e9rin (BCG) product used primarily as a bladder instillation for the treatment of certain forms of bladder cancer. It is a live, attenuated strain of Mycobacterium bovis and is used to induce an immune response that helps to prevent the recurrence of bladder tumors following surgical removal.\n\nHere are some key points you should know about TheraCys:\n\n1. **Indications**: TheraCys is indicated for the intravesical treatment of carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.\n\n2. **Mechanism of Action**: The exact mechanism by which TheraCys exerts its therapeutic effects is not fully understood. It is believed to work by stimulating the immune system to attack bladder cancer cells. The BCG causes an immune response in the bladder"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_oHTGnOHN5IfepKnR925XdSAp", "custom_id": "394_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e651becfcc428fb9ce1eb7985b1614f", "body": {"id": "chatcmpl-9St45gwlxdCroVTaedAVZbXd4CwSh", "object": "chat.completion", "created": 1716671881, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no drug named \"Tarvacin\" that is recognized in standard medical or pharmaceutical references. It's possible that the name could be a brand name, a drug still in development, or not widely recognized under this name. It could also be a misspelling or a misunderstanding of the drug's actual name.\n\nIf \"Tarvacin\" is a new or experimental drug, it would be important to look up the most current and reliable sources of medical information such as clinical trial registries, pharmaceutical company releases, or the latest medical literature. Additionally, databases like those from the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) could provide updates on approvals, indications, and safety profiles.\n\nIf you have more specific information or a different spelling, I can help look up more detailed information. Always ensure to consult updated, peer-reviewed sources or official drug information databases for the most accurate and relevant information"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pnXJan2sykBuLUZXgSqwFfxC", "custom_id": "395_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "40a79e544b22595751735adfd77e7f85", "body": {"id": "chatcmpl-9St46VNQeXeod3k7yUarguvmmJA0e", "object": "chat.completion", "created": 1716671882, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (belinostat) is a medication used in the treatment of cancer, specifically indicated for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. Here are some key points about Beleodaq that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Beleodaq is a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC, Beleodaq causes an accumulation of acetylated histones and other proteins, leading to cell cycle arrest and apoptotic cell death in cancer cells.\n\n2. **Indications**: It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a rare type of non-Hodgkin lymphoma that affects T-cells, and treatment options are limited after first-line therapy fails.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Wj5GWsYtt5iLmzJv1gkp5ihh", "custom_id": "396_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "232465af8094d2dc977d3bafa3cf1d7a", "body": {"id": "chatcmpl-9St46ZtU6BsNMjZ8uzeLqKssxQ8Q2", "object": "chat.completion", "created": 1716671882, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Camptobell\" in the context of healthcare or medicine. It's possible that the term could be a misspelling, a brand name, a new development, or something specific to a particular region or study that hasn't become widely known yet.\n\nIf you meant something specific or need information on a similarly named medication, condition, or concept, please provide more details or check the spelling so I can assist you more accurately. Alternatively, consulting the latest medical literature or databases might provide the most current and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 121, "total_tokens": 163}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jT4lru0jR1KfxiG1F57SXtCI", "custom_id": "397_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f6a2c4d747db85c5c4ecc2fe4d1addf", "body": {"id": "chatcmpl-9St46zxq7dUDyY1tUMePMUJRnFMt8", "object": "chat.completion", "created": 1716671882, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo (bendamustine hydrochloride) is a chemotherapy drug used primarily for the treatment of certain types of blood cancers. It is a formulation of bendamustine that is approved for use in patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\n\nHere are some key points you should know about Belrapzo:\n\n1. **Mechanism of Action**: Bendamustine, the active ingredient in Belrapzo, is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. It acts as an alkylating agent, causing cross-linking of DNA strands and inducing DNA damage, which leads to cell death. It also has properties of a purine analog, which contributes to its cytotoxic effects.\n\n2. **Indic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_17gfSWqkIT46uE2D1Zrg1zLW", "custom_id": "398_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9fc329e10e3f98da458b14cf9c255bef", "body": {"id": "chatcmpl-9St47LhYuyR4MIHvtonew6fqBKmbT", "object": "chat.completion", "created": 1716671883, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan, known in the U.S. as bevacizumab and marketed under the brand name Avastin, is a monoclonal antibody used in the treatment of various cancers. It works by inhibiting angiogenesis, the process by which new blood vessels form, thereby cutting off the blood supply that tumors need to grow.\n\nHere are some key points you should know about Altuzan (bevacizumab):\n\n1. **Indications**: Bevacizumab is approved for the treatment of several types of cancer, including colorectal cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, cervical cancer, and renal cell carcinoma. It is often used in combination with other chemotherapeutic agents.\n\n2. **Mechanism of Action**: Bevacizumab targets and inhibits the vascular endothelial growth factor (VEGF), a key substance that promotes blood vessel formation in tumors. By blocking VEGF, bevacizumab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_CiFE9N5HLu2vVSqs5Fa7ekvs", "custom_id": "399_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a976b63dcf0c6af2a717c6a9dd2f280c", "body": {"id": "chatcmpl-9St48aY0flZqx3wZmmG13WhMb0Do5", "object": "chat.completion", "created": 1716671884, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or substance known as \"Bexgratin\" recognized in standard medical resources or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a very new development not yet widely documented.\n\nIf you are referring to a specific medication, treatment, or substance, please check the spelling or provide additional context so I can assist you more accurately. If it's a new or experimental treatment, I recommend consulting the latest clinical research or pharmaceutical databases for the most current information. Additionally, discussing with colleagues or checking in specialized medical forums might provide more insights."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 128, "total_tokens": 170}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eM7Tt93NoDWKsBAOO3advtTY", "custom_id": "400_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "839c74352aeae2602d4c1a4859b6376e", "body": {"id": "chatcmpl-9St48S2QC43Z3Ukz3V0U5O1DaXNyE", "object": "chat.completion", "created": 1716671884, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide (Bicalutamide) is a medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Calutide:\n\n1. **Mechanism of Action**: Calutide is a non-steroidal anti-androgen. It works by binding to the androgen receptor and inhibiting the action of androgens (such as testosterone), which can promote the growth of prostate cancer cells.\n\n2. **Indications**: It is commonly used in the management of locally advanced or metastatic prostate cancer. It is often used in combination with a luteinizing hormone-releasing hormone (LHRH) agonist or surgical castration to achieve maximum androgen blockade.\n\n3. **Dosage and Administration**: The typical dosage is 50 mg once daily, taken orally. It can be taken with or without food.\n\n4. **Side Effects**: Common side effects include hot flashes, pain (including back pain), constipation, nausea, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dMPv7SFE48J9NoTnmj6RLR4Q", "custom_id": "401_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c6ce2eae6f277ca6ae869f73d7b4513f", "body": {"id": "chatcmpl-9St49k0JIyZgioEhDQpxEWD20fKLO", "object": "chat.completion", "created": 1716671885, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication used in the treatment of cancer, specifically for patients with melanoma that has a certain type of abnormal \"BRAF\" gene. Mektovi is used in combination with another medication called encorafenib (Braftovi). Here are some key points you should know about Mektovi:\n\n1. **Indications**: Mektovi, in combination with encorafenib, is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Mektovi is a kinase inhibitor that specifically targets MEK1 and MEK2, which are part of the MAPK signaling pathway. This pathway is involved in the growth and development of cancer cells. By inhibiting MEK, Mektovi helps to stop or slow the growth of cancer cells.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DTS8KT5H64JOen4NPlTazmCQ", "custom_id": "402_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "01518a7a69c2b41efe00520b21ce7701", "body": {"id": "chatcmpl-9St49JRyMaM16qtIQMSDppC2eIhi9", "object": "chat.completion", "created": 1716671885, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenoxane, known generically as bleomycin, is a medication used primarily in the treatment of various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and ovarian cancer, among others. It is also used in the treatment of pleural effusions caused by tumors. Here are some key points you should know about Blenoxane:\n\n1. **Mechanism of Action**: Bleomycin acts by binding to DNA, leading to strand breaks and inhibition of DNA synthesis and function. This action ultimately results in cell cycle arrest and apoptosis (cell death).\n\n2. **Administration**: Bleomycin can be administered intravenously, intramuscularly, or subcutaneously. For pleural effusion, it can be administered directly into the pleural space (intrapleural).\n\n3. **Dosage and Scheduling**: The dosage of bleomycin depends on the type of cancer, the size of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_3frSJM8gqUutJROtyhjd7t8U", "custom_id": "403_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "741ef60fbdeafbcd8d9bb21abf211d02", "body": {"id": "chatcmpl-9St49I0L8DBB5Dp5dXC10Tt85nhOS", "object": "chat.completion", "created": 1716671885, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager used primarily in the treatment of certain types of leukemia. Here are some key points you should know about Blincyto:\n\n1. **Indications**: Blincyto is approved by the FDA for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in relapse. It is used in both pediatric and adult patients. The specific indications may vary, so it's important to check the latest guidelines or regulatory approvals.\n\n2. **Mechanism of Action**: Blincyto works by connecting CD3-positive cytotoxic T cells to CD19-positive B cells, leading to T-cell activation and subsequent lysis of the B cells. This bispecific T-cell engager (BiTE) technology is innovative in that it harnesses the body's own immune system to fight cancer.\n\n3. **Administration**: Blincyto is administered via continuous intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6sbDq08OIWw7OPYkywSBaH7R", "custom_id": "404_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce088d38167073e506e2171e8ea2b074", "body": {"id": "chatcmpl-9St49oI1qm7K6zZXsBeZg003jBrIf", "object": "chat.completion", "created": 1716671885, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Biocure\" is not a specific medication or treatment that is widely recognized in the medical community. It could be a term used by certain brands or in alternative medicine, but it does not correspond to a standard pharmaceutical or a medically recognized therapy.\n\nIf you are referring to a specific product or concept named \"Biocure\" that has emerged recently, I would recommend checking the latest medical literature, clinical trial registries, or drug approval agencies for up-to-date and reliable information. It's important to verify the source of the information, understand the clinical evidence supporting its use, and review any regulatory approvals or guidelines regarding its application.\n\nFor any new treatment or medication, consider the following:\n\n1. **Clinical Evidence**: Look for peer-reviewed studies or clinical trial results that demonstrate efficacy and safety.\n2. **Regulatory Approval**: Check if the product has been approved by relevant health authorities like the FDA, EMA, or other national bodies.\n3. **Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RnvpkeFu7sMovA2JFVFwOT8C", "custom_id": "405_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae28632d3c76d4908e7db13ae62deba5", "body": {"id": "chatcmpl-9St4ArSCoVKOXOjseuzDvU5vjv7W4", "object": "chat.completion", "created": 1716671886, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosulif (bosutinib) is a medication used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Bosulif:\n\n1. **Indications**: Bosulif is approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.\n\n2. **Mechanism of Action**: Bosutinib is a tyrosine kinase inhibitor (TKI). It specifically targets the Bcr-Abl kinase that results from the Philadelphia chromosome abnormality in CML, as well as Src-family kinases.\n\n3. **Dosage and Administration**: The starting dose of Bosulif is typically 500 mg orally once daily with food. Dose adjustments may be necessary based on patient response and tolerability. Monitoring of blood counts and managing any side effects is crucial.\n\n4. **Side Effects**: Common side effects include diarrhea, nausea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JpIonWpehBmqRUMlHkrkfMm2", "custom_id": "406_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "33159db95e957dee1bbae08b358f08d5", "body": {"id": "chatcmpl-9St4BwgKRIaZYqluxbxuf0ajalh5Y", "object": "chat.completion", "created": 1716671887, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (brentuximab vedotin) is a targeted therapy used in the treatment of certain types of lymphomas, specifically Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Here are some key points about Adcetris that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Adcetris is an antibody-drug conjugate (ADC) that combines an anti-CD30 monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE). The antibody component binds to CD30, a cell surface protein expressed on Hodgkin Reed-Sternberg cells and other lymphoma cells. After binding, the conjugate is internalized, and the cytotoxic agent is released inside the cell, leading to cell death.\n\n2. **Indications**:\n   - **Hodgkin Lymphoma (HL)**: Adcet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_njwfRe4EmZkb5b7TSK95EU0r", "custom_id": "407_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e370cd622597bce44dc08dbb886f5c1", "body": {"id": "chatcmpl-9St4CFEHMKnq1AXwNtYHCKfJt6UKU", "object": "chat.completion", "created": 1716671888, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig, known generically as brigatinib, is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Alunbrig:\n\n1. **Indication**: Alunbrig is specifically indicated for the treatment of patients with NSCLC that is anaplastic lymphoma kinase-positive (ALK+) as detected by an FDA-approved test. It is used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Brigatinib is a tyrosine kinase inhibitor that targets ALK, ROS1, and other kinases. By inhibiting these kinases, it interferes with the growth and spread of cancer cells.\n\n3. **Administration**: Alunbrig is administered orally, typically starting with a seven-day lead-in period at a lower dose to reduce the risk of pulmonary side effects, followed by an increased dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FXQihPtbVYMTKMS7yp4OZ8cs", "custom_id": "408_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a782d19d7459e7c3fb65a033c1549c5", "body": {"id": "chatcmpl-9St4C3YHvL3aiHmVevnS9Was3pmW5", "object": "chat.completion", "created": 1716671888, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex (busulfan) is a chemotherapy medication used primarily as a conditioning agent before hematopoetic stem cell transplantation, particularly in the treatment of chronic myelogenous leukemia (CML) and other hematological disorders. Here are some key points you should know about Busilvex:\n\n1. **Mechanism of Action**: Busulfan is an alkylating agent. It works by cross-linking DNA, which prevents the cancer cells from dividing and leads to cell death. This property makes it effective in preparing the bone marrow for transplantation by reducing the number of existing bone marrow cells and making space for new stem cells.\n\n2. **Administration**: Busilvex can be administered orally or intravenously. The intravenous form is often preferred in the clinical setting to ensure precise dosing and to reduce variability in absorption seen with oral administration.\n\n3. **Dosage and Treatment Regimen**: The dosage and treatment regimen of Busilvex can vary depending on the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dDTq9efgPhOXJl4syRtBfd4e", "custom_id": "409_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee306eaa26e8c5e68c6c1b1e3e0d0b9f", "body": {"id": "chatcmpl-9St4CuD3T3xuomCFicoysycK07Ejb", "object": "chat.completion", "created": 1716671888, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication known as \"Cabapan\" recognized in standard pharmaceutical references. It's possible that there might be a typo or a misunderstanding regarding the name of the medication. It's also possible that \"Cabapan\" could be a brand name or a drug available in specific regions under different regulations, or it might be a new drug that was not widely recognized as of my last update.\n\nIf you're referring to a specific medication, I recommend double-checking the spelling or providing additional context such as its intended use, active ingredients, or any other details you might have. This will help in providing accurate and relevant information. If \"Cabapan\" is a brand name or a less common medication, consulting the most recent and local pharmaceutical databases or drug regulatory authority websites might provide the most up-to-date and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 172, "total_tokens": 212}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LWZKSH3jDGxnHRALbl4MBcXG", "custom_id": "410_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d007456b10ee48f2f82dcc7f62fa6848", "body": {"id": "chatcmpl-9St4CeuEa8Fu50An0GzUAbW90S3Mg", "object": "chat.completion", "created": 1716671888, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx, the brand name for cabozantinib, is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Cabometyx:\n\n1. **Indications**: Cabometyx is approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) in patients who have previously received sorafenib, and previously treated advanced medullary thyroid cancer.\n\n2. **Mechanism of Action**: Cabozantinib is a tyrosine kinase inhibitor (TKI). It works by inhibiting multiple receptor tyrosine kinases (RTKs) involved in the pathogenesis of cancer, including MET, VEGFRs, and RET. These are involved in both normal cellular function and in pathologies such as tumor growth, pathologic angiogenesis, metastatic progression, and drug resistance.\n\n3. **Administration**: Cabometyx is administered orally. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kqVeak3b43Zya8oDQZ4vQPPc", "custom_id": "411_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a09ac7d5213fdbb908d96b91916977ff", "body": {"id": "chatcmpl-9St4DZ4VQR8aqM5YvshmFSC1ZolW6", "object": "chat.completion", "created": 1716671889, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparlas, also known by its generic name calaspargase pegol-mknl, is a chemotherapy medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is a modified version of L-asparaginase, an enzyme that depletes the amino acid asparagine. Cancer cells, particularly those in ALL, require asparagine to grow and survive, and the depletion of asparagine by Asparlas starves these cells.\n\nHere are some key points about Asparlas that you, as a physician, might find useful:\n\n1. **Indications**: Asparlas is approved for use in pediatric and young adult patients aged 1 month to 21 years who have been diagnosed with ALL or lymphoblastic lymphoma. It is typically used as part of a multi-agent chemotherapeutic regimen.\n\n2. **Mechanism of Action**: Asparlas works by converting asparagine into aspartic acid and ammonia, thereby de"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oEZhdX85knE9FHhdNNEbx4ch", "custom_id": "412_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "18f5465c404925af49edbee0caa975bd", "body": {"id": "chatcmpl-9St4Dq9FbIC2udtLDVhliM0GwOTyY", "object": "chat.completion", "created": 1716671889, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a widely recognized medication or treatment specifically known as \"Cabita\" in standard medical resources. It's possible that the name could be a brand name, a less common term, or perhaps a misspelling. If you could provide more context or details about the substance or its intended use, I could try to offer more relevant information. Alternatively, it might be helpful to check the latest medical databases, pharmaceutical references, or consult with a pharmacist for the most current and accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 105, "total_tokens": 145}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_VoawVjAf866vT6H8ECqI9vIE", "custom_id": "413_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59dd067498173ac9c324890a96fb80af", "body": {"id": "chatcmpl-9St4DekL9UNNKiap2BcWAt14FKkeR", "object": "chat.completion", "created": 1716671889, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biocarb is not a standard or commonly recognized medication or supplement in medical literature, as of my last update. It's possible that \"Biocarb\" could be a brand name, a non-standard term, or a colloquial name for a product or substance. If it is being referred to in a specific context, such as a dietary supplement, a local medication, or a product in a specific market, it would be important to look at the specific ingredients or formulation under discussion.\n\nIf you are dealing with a product named Biocarb that is intended for patient use, here are a few general steps you might consider:\n\n1. **Ingredient Analysis**: Check the specific active and inactive ingredients in the product. This can help in understanding any potential therapeutic benefits, side effects, or risks associated with its use.\n\n2. **Clinical Evidence**: Look for any clinical trials, research studies, or scientific evaluations that provide evidence on the efficacy and safety of the product.\n\n3. **Regulatory Status"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1bzUibkAoMAx6TvKxu34wXPo", "custom_id": "414_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a83cedd5248a60777845a2998a8160a", "body": {"id": "chatcmpl-9St4DWbKmUzsnNujtYl8vB8mhuotC", "object": "chat.completion", "created": 1716671889, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilnat is a brand name for the drug carfilzomib, which is a proteasome inhibitor used primarily in the treatment of multiple myeloma. Carfilzomib works by inhibiting the proteasome, a complex that breaks down proteins in cells, which leads to an accumulation of proteins within cancer cells and ultimately causes cell death. Here are some key points you should know about Carfilnat (carfilzomib):\n\n1. **Indications**: Carfilzomib is approved for the treatment of patients with relapsed or refractory multiple myeloma. It is often used in patients who have received one or more prior therapies.\n\n2. **Administration**: Carfilzomib is administered intravenously. The dosing schedule can vary, but it is commonly given in cycles, with administration on two consecutive days each week for three weeks, followed by a rest week.\n\n3. **Combination Therapy**: Carfilzomib is frequently"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KFf1MCnY20vSqQk9ng7R5My7", "custom_id": "415_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6ed4c7510b56fc76a78faa456f282fd5", "body": {"id": "chatcmpl-9St4EelDJTpxRJtCKYFoisYCrSjc1", "object": "chat.completion", "created": 1716671890, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Becenun (generic name: carmustine) is a chemotherapy medication used primarily to treat various types of cancer, including brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphoma. It belongs to a class of drugs known as alkylating agents, which work by damaging the DNA of cancer cells, thereby inhibiting their growth and proliferation.\n\nHere are some key points you should know about Becenun:\n\n1. **Indications**: Becenun is used in the treatment of certain brain tumors (glioma, glioblastoma multiforme, medulloblastoma, astrocytoma), multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphoma. It may be used alone or in combination with other chemotherapy drugs.\n\n2. **Administration**: Carmustine can be administered intravenously or as an implant (Gliadel wafer) that is placed in the surgical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ahNdEJxwKQxoBik0AQNJqeRd", "custom_id": "416_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc9b9c8e82ed36813a69013979fdaed6", "body": {"id": "chatcmpl-9St4EJf1gA6RNifVUSHOzaXNhUnhL", "object": "chat.completion", "created": 1716671890, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Biodel Inc. was a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's approach involved reformulating existing drugs to improve their efficacy and delivery. One of their notable products was a rapid-acting form of insulin designed to begin working faster than traditional formulations, potentially benefiting diabetic patients who need quick blood sugar control around meal times.\n\nHowever, it's important to note that Biodel Inc. has undergone significant changes, including financial difficulties and strategic shifts. For the most current and detailed information, including any ongoing pharmaceutical developments, clinical trials, or newly launched products, I recommend checking the latest updates from reliable medical and pharmaceutical sources, or directly reviewing information from the company if it is still operational. Additionally, consulting recent peer-reviewed journals and attending relevant medical conferences can provide up-to-date insights into treatments and innovations in diabetes care that may involve Biodel or similar companies."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 186, "total_tokens": 226}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_SecScQHJklTWWPcQnxS3DlpP", "custom_id": "417_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a56b96030e86c9114302e90c76c8738b", "body": {"id": "chatcmpl-9St4FAVsAKyMH4379kiKPjBWUVnXH", "object": "chat.completion", "created": 1716671891, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Recentin is not a widely recognized drug under that specific name in major pharmacological databases or medical literature. It's possible that \"Recentin\" could be a brand name, a name used in specific markets, or even an alternative name for a more commonly known drug. It's also possible that it could be a new drug still under development or recently approved.\n\nIf Recentin is a name used in specific regions or under certain circumstances, it would be essential to know its generic name or the active ingredient to provide accurate information. Typically, for any drug, a physician should be aware of the following:\n\n1. **Indications**: What conditions or diseases is the drug approved to treat?\n2. **Mechanism of Action**: How does the drug work in the body?\n3. **Dosage and Administration**: What are the recommended doses and routes of administration?\n4. **Contraindications**: In what situations or with which patients should the drug not be used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qJ3yAUN3HrjoR0qBHFHCcHtD", "custom_id": "418_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "80d64d092ea34fe398f131ffab49b3fd", "body": {"id": "chatcmpl-9St4Gcx9RuRTq0sy9c2LYXJh4vyXi", "object": "chat.completion", "created": 1716671892, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Libtayo (cemiplimab) is a prescription medication used in the treatment of certain types of cancers. It is a type of immunotherapy drug known as a checkpoint inhibitor, specifically targeting the PD-1 (programmed death receptor-1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1, Libtayo helps to restore the body's immune system to recognize and fight cancer cells.\n\nHere are some key points about Libtayo:\n\n1. **Indications**: As of the last update, Libtayo has been approved for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. It is also approved for the treatment of basal cell carcinoma (BCC) that has metastasized or cannot be cured by surgery or radiation, and for advanced non-small cell lung cancer (NSCLC) with certain characteristics.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Qi6sWyvssGgOtulXUW7bKNe1", "custom_id": "419_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a219478601eb9da81e06c9e35117503", "body": {"id": "chatcmpl-9St4G9NvTBOyH9RNprUkoMEIGlfxZ", "object": "chat.completion", "created": 1716671892, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or confusion in your question regarding \"Lucicer.\" There is no recognized medical term or medication by that name. If you meant \"luciferase,\" it is an enzyme used in biotechnology for its luminescent properties, commonly used in research and diagnostic applications. If you are referring to something else, could you please clarify or provide additional context? This will help me provide the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 90, "total_tokens": 130}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_UWlxVrAuByYXMYPSgfbl0VT9", "custom_id": "420_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dee8bcbb4c9fc5a2e9fb97212b8ea29a", "body": {"id": "chatcmpl-9St4GweuqcipRWnkguXwTgUklUG76", "object": "chat.completion", "created": 1716671892, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab, marketed under the brand name Erbitux among others, is a chimeric monoclonal antibody used to treat certain types of cancer. It works by interfering with the epidermal growth factor receptor (EGFR) on the surface of cancer cells, which is often involved in the growth and spread of cancer cells. Here are some key points you should know about cetuximab:\n\n1. **Indications**: Cetuximab is primarily used for the treatment of metastatic colorectal cancer and head and neck cancers. In colorectal cancer, it is specifically used for tumors that express EGFR and do not have mutations in the KRAS gene, as KRAS mutations are associated with resistance to EGFR inhibitors.\n\n2. **Mechanism of Action**: Cetuximab binds to the extracellular domain of the EGFR, preventing the natural ligands (such as EGF) from binding and activating the receptor. This inhibition results in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vzaweOj8hr1HRaeF4WiYlk3W", "custom_id": "421_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca08b38b8330d4fd87bd7586391f80ed", "body": {"id": "chatcmpl-9St4GF6hBmwJnecu2ntgPxE13w12R", "object": "chat.completion", "created": 1716671892, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a medication specifically named \"Epidaza\" recognized in standard pharmaceutical references. It's possible that there might be a typo or a brand name that is not widely recognized or used in different regions. It's also possible that it could be a new drug that has come into use after my last update.\n\nIf you meant \"Epidaza\" and it's a new or less common medication, I would recommend checking the most current medical literature or pharmaceutical databases for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals might provide insights into the drug, including its uses, side effects, interactions, and other relevant clinical information.\n\nIf you meant a different medication or have any more details, please provide them, and I can offer more specific information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 165, "total_tokens": 205}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yn8UVcwE7p2v3qO1d3vjUvvi", "custom_id": "422_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36a428c7292ac14014166415b482945d", "body": {"id": "chatcmpl-9St4G4GrkET9ZCD3HQEelfUxWVD6a", "object": "chat.completion", "created": 1716671892, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is a chemotherapy drug used primarily to treat various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstr\u00f6m's macroglobulinemia. It belongs to a class of medications known as alkylating agents, which work by binding to DNA and preventing cancer cells from dividing and growing.\n\nHere are some key points you should know about chlorambucil:\n\n1. **Indications**: Chlorambucil is mainly used for the treatment of chronic lymphocytic leukemia (CLL) but is also indicated for other types of hematological malignancies as mentioned above.\n\n2. **Mechanism of Action**: As an alkylating agent, chlorambucil interferes with the replication of DNA by forming cross-links between DNA strands, thereby inhibiting tumor growth.\n\n3. **Administration**: Chlorambucil is typically administered orally. The dosage and treatment schedule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JnZhi5qC1wUm3VuiL2k8l9rs", "custom_id": "423_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a0b9826b8e5aab29484649ac59e4f586", "body": {"id": "chatcmpl-9St4Hady9dyfwzDQraEeAg8nKOGh8", "object": "chat.completion", "created": 1716671893, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiplatin is not a widely recognized drug name in standard medical references, and it may be a less common or brand name not universally recognized. It's possible that you might be referring to a drug with a similar name or a new drug that has not yet been widely documented. However, if you meant \"cisplatin,\" which is a commonly used platinum-based chemotherapy drug, I can provide information on that.\n\nCisplatin is used to treat various types of cancers, including testicular, ovarian, cervical, bladder, and lung cancer. Here are some key points about cisplatin:\n\n1. **Mechanism of Action**: Cisplatin works by forming platinum-DNA adducts in cancer cells, which inhibit DNA synthesis and transcription, leading to cell death.\n\n2. **Administration**: It is typically administered intravenously and dosage depends on the type of cancer, the stage of the disease, the patient's kidney function, and overall health status.\n\n3. **Side Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VXeBcswipdmN9HDdBLVDlLbh", "custom_id": "424_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ef679cc8b42bd0bd21cdda66bcd3304", "body": {"id": "chatcmpl-9St4IVrfANo1tvZaJe2UtD3Ag3hV5", "object": "chat.completion", "created": 1716671894, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin, known generically as cladribine, is a medication primarily used in the treatment of hairy cell leukemia and other hematologic malignancies. Here are some key points you should know about Leustatin:\n\n1. **Mechanism of Action**: Cladribine is a purine nucleoside analog that interferes with the synthesis and repair of DNA, primarily targeting lymphocytes and lymphocyte precursors. This action makes it effective in treating certain types of leukemias and lymphomas.\n\n2. **Indications**:\n   - Primarily used for the treatment of hairy cell leukemia.\n   - It may also be used in other conditions such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple sclerosis (though formulations and indications can vary, and for MS, it's typically administered as Mavenclad).\n\n3. **Administration**: Leustatin is typically administered intravenously. The dosage and treatment schedule can vary depending on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_M24S2aOwCHMobodFzbnLIBYZ", "custom_id": "425_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "746fdfdfefe35edd7e855524a960824b", "body": {"id": "chatcmpl-9St4ID0Hoi5HZ4wJf5k3EnclO39ow", "object": "chat.completion", "created": 1716671894, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biaxin (clarithromycin) is an antibiotic that belongs to a class of drugs known as macrolides. It is used to treat various bacterial infections including respiratory tract infections, skin infections, and Helicobacter pylori infection associated with duodenal ulcers. Here are some key points you should know about Biaxin:\n\n1. **Mechanism of Action**: Clarithromycin works by inhibiting protein synthesis in bacteria, thereby stopping bacterial growth. It binds to the 50S subunit of the bacterial ribosome.\n\n2. **Spectrum of Activity**: It has a broad spectrum of activity, effective against a variety of gram-positive and gram-negative bacteria. It is particularly useful against atypical pathogens and is often used in respiratory infections.\n\n3. **Indications**:\n   - Treatment of infections like bronchitis, pneumonia, sinusitis, and pharyngitis.\n   - Skin and soft tissue infections.\n   - Eradication of Helic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_HpEEtocvtigFhrwuZYj0yTPy", "custom_id": "426_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59d7bce4bf987593cd975f0666a14e3b", "body": {"id": "chatcmpl-9St4IviHQlPadUWHkWBDaOlr7oWNV", "object": "chat.completion", "created": 1716671894, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clolar (clofarabine) is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Clolar:\n\n1. **Indications**: Clolar is approved by the FDA for the treatment of pediatric patients aged 1 to 21 years with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens. Its use in adults is off-label but can be considered based on clinical judgment and individual patient needs.\n\n2. **Mechanism of Action**: Clofarabine is a nucleoside analog that inhibits DNA synthesis and repair, leading to apoptosis of leukemic cells. It is thought to incorporate into DNA strands and inhibit ribonucleotide reductase and DNA polymerase, which are essential for DNA repair and synthesis.\n\n3. **Administration**: Clolar is administered intravenously. The dosing regimen typically involves daily infusions for five consecutive days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CY5v6IMfz9MeEr4POqpSSWDM", "custom_id": "427_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9596434301c2901cfb7be3f4792408e5", "body": {"id": "chatcmpl-9St4IpG8MoxRYtAHh7KhNFaEIhqpb", "object": "chat.completion", "created": 1716671894, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (cobimetinib) is a medication used in the treatment of cancer, specifically for melanoma that cannot be removed by surgery or has metastasized. It is often used in combination with another medication called vemurafenib, which targets the BRAF V600 mutation. Here are some key points you should know about Cotellic:\n\n1. **Mechanism of Action**: Cobimetinib is a MEK inhibitor. MEK is a protein kinase that helps regulate cell division. By inhibiting MEK, cobimetinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**: Cotellic, in combination with vemurafenib, is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is important to confirm the presence of a BRAF V600 mutation in patients before starting treatment.\n\n3. **Administration**: Cotellic is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_50i8zeGJo3fNqTWMIBGuuVdv", "custom_id": "428_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba742720bfaded314d09649cdbeca274", "body": {"id": "chatcmpl-9St4JFPDNQjirLzq6RywPCrPysW5J", "object": "chat.completion", "created": 1716671895, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aliqopa (copanlisib) is a medication used in the treatment of certain types of cancer, specifically for adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Here are some key points you should know about Aliqopa:\n\n1. **Mechanism of Action**: Aliqopa is a kinase inhibitor that primarily targets phosphoinositide 3-kinase (PI3K) with predominant activity against PI3K-alpha and PI3K-delta isoforms found in malignant cells. By inhibiting these pathways, Aliqopa can induce apoptosis and inhibit proliferation of cancer cells.\n\n2. **Approval and Indications**: The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa in 2017 based on the overall response rate and duration of response observed in clinical trials. It is specifically indicated for the treatment of adult patients with relapsed follicular lymphoma.\n\n3. **Administration**: Aliqopa"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MOYETUP8OB0w3jfko2Rg5Wij", "custom_id": "429_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3eb7a16e5933375c40a90c75d5323eea", "body": {"id": "chatcmpl-9St4JiDzFJXZGcdxrQQNvn9jKjcDo", "object": "chat.completion", "created": 1716671895, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizalk is the brand name for crizotinib, which is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Crizalk:\n\n1. **Mechanism of Action**: Crizotinib is an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the activity of the ALK protein, which can be abnormally active in some types of cancer cells and promote their growth and proliferation. By inhibiting ALK, crizotinib can help to slow down or stop the growth of these cancer cells.\n\n2. **Indications**: Crizotinib is specifically indicated for the treatment of patients with locally advanced or metastatic NSCLC that is ALK-positive as determined by an FDA-approved test. It is important to confirm the presence of ALK rearrangement before initiating treatment with Crizalk.\n\n3. **Administration**: Crizot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r4cIYO8veevC0ibrZ81sscQn", "custom_id": "430_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62441fb068a26735e8e3125e0e670e1c", "body": {"id": "chatcmpl-9St4MLIZzAlfNBR9FefFazXe70XHl", "object": "chat.completion", "created": 1716671898, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized drug or compound specifically named \"Alkyloxan\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, a lesser-known chemical, or a brand name not widely used. It could also be a new development that has emerged after my last update.\n\nIf you meant \"Alloxan,\" this is a compound known for its use in research settings, particularly in inducing diabetes in laboratory animals for the study of diabetes treatment. Alloxan selectively destroys insulin-producing cells in the pancreas, which results in an insulin-dependent diabetes state.\n\nIf \"Alkyloxan\" is a specific drug or compound you are referring to, I would recommend checking the most current medical literature or pharmaceutical databases for the most accurate and up-to-date information. Additionally, consulting with colleagues or pharmacists might provide more insight if this is a new or less common substance in medical practice."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 190, "total_tokens": 232}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4yrCxYLmZQ6xcgj2wqMMkk5K", "custom_id": "431_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9b7c582a8fdde56e62ee3949fb63471", "body": {"id": "chatcmpl-9St4KePn1HfVzU3iTFpDMUBZdCMUS", "object": "chat.completion", "created": 1716671896, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Androcur, known generically as cyproterone acetate, is a medication primarily used in the treatment of androgen-dependent conditions like prostate cancer, hirsutism, and severe acne. It also serves as a component in some forms of hormonal therapy for transgender women. Here are key points you should know about Androcur:\n\n1. **Mechanism of Action**: Cyproterone acetate is a progestin with anti-androgen properties. It works by blocking androgen receptors and lowering testosterone levels, which helps in reducing the effects of excess androgen.\n\n2. **Indications**:\n   - **Prostate Cancer**: It is used in the management of advanced prostate cancer.\n   - **Hyperandrogenism**: It helps in conditions like hirsutism (excessive hair growth) and severe acne by reducing the effects of androgens.\n   - **Transgender Hormone Therapy**: Used as part of feminizing hormone therapy for transgender women to reduce"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_OWgiCKfKgw8zZUgk1BikbX9I", "custom_id": "432_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b70ab83ff6c4db6a469978ee5a6944b", "body": {"id": "chatcmpl-9St4KD3NFJ8lnkTwtw3UTP3zWGWy4", "object": "chat.completion", "created": 1716671896, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Alcysten\" in standard medical resources or pharmacological databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in mainstream sources.\n\nIf \"Alcysten\" is a specific drug or treatment you've encountered, I recommend checking the following:\n\n1. **Spelling and Nomenclature**: Verify the spelling or see if it goes by another name or is known by its generic name.\n\n2. **Pharmacological Databases**: Consult up-to-date and comprehensive pharmacological databases or resources like the FDA or EMA websites for the most current information.\n\n3. **Medical Literature**: Search through medical journals or publications for any mentions or studies related to \"Alcysten\".\n\n4. **Colleagues and Specialists**: Discuss with pharmacy specialists or colleagues who might be more familiar with emerging treatments or lesser-known drugs.\n\n5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_jfvX946l05z3nTz92CBNRyQc", "custom_id": "433_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66cfbe814d015f64e0cc13d90a52f8d6", "body": {"id": "chatcmpl-9St4KFvsovi8HWxA1DKGQNPBk54MU", "object": "chat.completion", "created": 1716671896, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos (liposomal daunorubicin and cytarabine) is a chemotherapy drug used for the treatment of certain types of acute myeloid leukemia (AML), specifically for newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Here are some key points you should know about Vyxeos:\n\n1. **Mechanism of Action**: Vyxeos is a liposomal formulation that encapsulates both daunorubicin and cytarabine in a fixed molar ratio of 1:5. This encapsulation allows for a more targeted delivery of the drugs to leukemic cells and a reduced impact on normal cells. The combination of these two drugs works by intercalating into DNA (daunorubicin) and inhibiting DNA synthesis (cytarabine), leading to cell death.\n\n2. **Indications**: Vyxeos is specifically indicated for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LpD4XL8mTUpXYe8kT1SXb8kV", "custom_id": "434_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73bf6e1ef054307daf7851061a08facd", "body": {"id": "chatcmpl-9St4L7qWtzQ3OMUatARbxPKhlNdkk", "object": "chat.completion", "created": 1716671897, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Rafinlar\" does not appear to be a recognized medication or treatment in standard medical resources. It's possible that there might be a spelling error or it could be a brand name not widely recognized or new on the market. If you meant \"Mekinist\" (trametinib) or \"Tafinlar\" (dabrafenib), which are commonly used in the treatment of certain types of cancer, I can provide information on those.\n\n**Tafinlar (dabrafenib)** is a BRAF inhibitor used primarily for the treatment of certain types of melanoma that express the BRAF V600E mutation. It is often used in combination with trametinib, a MEK inhibitor, to treat melanoma as well as non-small cell lung cancer and anaplastic thyroid cancer harboring the same mutation.\n\n**Key points about Tafinlar include:**\n1. **Indications**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vuh7gnXB5lE65SfrpHhLxkO4", "custom_id": "435_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a834fc4c6d7b1a3e71344271df93266c", "body": {"id": "chatcmpl-9St4MfsFzrkm9VYFwyZyVPeVB5oDe", "object": "chat.completion", "created": 1716671898, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Bazipar\" does not correspond to any known medication or medical term commonly recognized in the healthcare field. It's possible that there might be a spelling error or it could be a brand name or a term not widely used or new on the market.\n\nIf you meant something else or have more context, please provide additional details so I can assist you more accurately. If \"Bazipar\" is a new drug or a term from a specific medical context not included in my training data, I recommend consulting the latest medical literature or a pharmaceutical database for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 123, "total_tokens": 164}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_pdagkpaLy6qHcfHqlLqmcTDT", "custom_id": "436_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd716d839b9a11845e35e43c6f0d50cd", "body": {"id": "chatcmpl-9St4MRbQSw6CvNhf1V3V2aflIKZGL", "object": "chat.completion", "created": 1716671898, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vizimpro (dacomitinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Vizimpro:\n\n1. **Indication**: Vizimpro is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Vizimpro is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It is designed to inhibit the kinase activity of EGFR as well as the EGFR mutations that are commonly found in NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.\n\n3. **Administration**: Vizimpro is administered orally, and the typical dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FCuyXboyib1E0UGmWMQlLaFJ", "custom_id": "437_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9e1aa2708f2ebaa5823e761891c1187d", "body": {"id": "chatcmpl-9St4MxDyGVopQWGnBKTtQZYWMph7W", "object": "chat.completion", "created": 1716671898, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen, known generically as dactinomycin, is a chemotherapy medication used primarily to treat various types of cancer. It is classified as an antineoplastic antibiotic and functions by binding to DNA and inhibiting RNA synthesis, which effectively interferes with the growth and spread of cancer cells.\n\nHere are some key points you should know about Cosmegen:\n\n1. **Indications**: Cosmegen is used to treat a variety of cancers including Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, trophoblastic neoplasia, and testicular cancer. It may be used alone or in combination with other chemotherapy agents.\n\n2. **Administration**: Cosmegen is administered intravenously. The dosage and schedule depend on the specific cancer type, the purpose of the therapy (e.g., adjuvant, neoadjuvant), the patient's size, and their overall health status.\n\n3. **Mechanism of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XLr3ydaGEV93UxvhR1BQHB1Y", "custom_id": "438_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0aeed6ab5aa1efb1e52e0b26b11fb26f", "body": {"id": "chatcmpl-9St4Npl2ZvNWH3uS0jE6nSAgHuaLZ", "object": "chat.completion", "created": 1716671899, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danatrol, also known by its generic name danazol, is a synthetic steroid used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. It is classified as an attenuated androgen or a weak androgen, meaning it has some of the biological activities of male hormones. Here are some key points you should know about Danatrol:\n\n1. **Mechanism of Action**: Danazol acts by suppressing the pituitary-ovarian axis by inhibiting the output of pituitary gonadotropins, which decreases estrogen and progesterone levels. This suppression leads to a decrease in the growth and symptoms of diseases like endometriosis. Additionally, it has immunomodulatory effects and increases levels of C1 esterase inhibitor, which is beneficial in managing hereditary angioedema.\n\n2. **Indications**:\n   - **Endometriosis**: Used to manage pain"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j7GXsTpLtEgySjhBw0zdTIpj", "custom_id": "439_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "14ad71d67e4e78de839c026610f21ce9", "body": {"id": "chatcmpl-9St4NXSiZiTL1RE29pukL1UfRL58M", "object": "chat.completion", "created": 1716671899, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex (generic name: daratumumab) is a monoclonal antibody used primarily in the treatment of multiple myeloma. It targets the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Here are some key points you should know about Darzalex:\n\n1. **Indications**: Darzalex is approved for use in patients with multiple myeloma who have received at least one prior therapy. It can be used alone or in combination with other treatments such as lenalidomide and dexamethasone, or bortezomib and dexamethasone.\n\n2. **Mechanism of Action**: Daratumumab works by binding to the CD38 molecule on myeloma cells, leading to their destruction through various immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_WUCkKYgx1Jp0iZEIwaIEyeBz", "custom_id": "440_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b35260dc57f6d274c0b4c2b1c47716d", "body": {"id": "chatcmpl-9St4O2tKZjxrAQxM6eky1p46rjJDM", "object": "chat.completion", "created": 1716671900, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is a medication used in the treatment of prostate cancer. Here are some key points you should know about Nubeqa:\n\n1. **Indication**: Nubeqa is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). This is a stage of prostate cancer where the cancer does not respond to hormonal or surgical treatment to lower testosterone but has not yet spread to other parts of the body.\n\n2. **Mechanism of Action**: Darolutamide is an androgen receptor inhibitor. It works by binding to the androgen receptors in prostate cancer cells, thereby inhibiting the receptor's interaction with androgens (male hormones). This helps slow down the growth of prostate cancer cells.\n\n3. **Administration**: Nubeqa is administered orally. The typical dosage is 600 mg taken twice daily, with food.\n\n4. **Side Effects**: Common side effects of Nubeqa include fatigue, pain in extremities,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_u47974D95s45S9VjmmKXwpdt", "custom_id": "441_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98a07e8dd0bea0673e960d757076299a", "body": {"id": "chatcmpl-9St4OH1BIdfqfnUDRn1SUYWceLRpA", "object": "chat.completion", "created": 1716671900, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel, known generically as dasatinib, is a medication used primarily in the treatment of certain types of cancer, most notably chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). Here are some key points about Sprycel that you, as a physician, might find useful:\n\n### Mechanism of Action\nSprycel is a tyrosine kinase inhibitor (TKI). It specifically inhibits a number of tyrosine kinases including BCR-ABL, SRC family kinases, c-KIT, EPHA2, and PDGFR\u03b2. Its primary target, BCR-ABL tyrosine kinase, is produced by the Philadelphia chromosome abnormality in CML and ALL, which is crucial for the proliferation and survival of leukemic cells.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Sprycel is approved for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1S8mnFP3NosM5VDUHJtj4cpm", "custom_id": "442_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4f6e6af6d8cdeb3db41a5579d650c5a", "body": {"id": "chatcmpl-9St4OK0BHbaudAM8i0nhAyESKyqWi", "object": "chat.completion", "created": 1716671900, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidine (daunorubicin) is a chemotherapy medication used primarily to treat certain types of leukemia, including acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). It belongs to the anthracycline class of chemotherapeutic agents and works by interfering with the growth and proliferation of cancer cells.\n\nHere are some key points you should know about Cerubidine:\n\n### Mechanism of Action\nDaunorubicin acts by intercalating into DNA, which inhibits the synthesis of DNA and, to a lesser extent, RNA. It also generates free radicals, which cause cytotoxicity by damaging cellular membranes, DNA, and proteins.\n\n### Indications\n- **Acute Lymphocytic Leukemia (ALL)**\n- **Acute Myeloid Leukemia (AML)**\nIt may also be used in other settings as part of a combination chemotherapy regimen.\n\n### Administration\nCerubidine is typically administered intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LZQ5qWgrXCdl1wDtTXbAtMTJ", "custom_id": "443_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29288475b8a089630ff2476fece741da", "body": {"id": "chatcmpl-9St4PBt934NV0dWKVTqSxyEqVmXaG", "object": "chat.completion", "created": 1716671901, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome is a liposomal formulation of the chemotherapeutic agent daunorubicin. It is specifically designed to target tumor cells more effectively while reducing the exposure of normal tissues to the drug, potentially lowering some side effects compared to conventional daunorubicin formulations. Here are some key points you should know about DaunoXome:\n\n1. **Indications**: DaunoXome is primarily used in the treatment of HIV-associated Kaposi's sarcoma. It has been found effective in treating this condition, particularly in patients with advanced disease or those who have not responded to prior chemotherapy.\n\n2. **Mechanism of Action**: DaunoXome works by intercalating DNA strands, which inhibits the replication of DNA and promotes apoptosis (cell death). The liposomal delivery system allows for enhanced accumulation of the drug in tumor tissues due to the enhanced permeability and retention (EPR) effect of tumors.\n\n3. **Administration**: DaunoXome is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DQbep7UVemzzT30b773GyxWF", "custom_id": "444_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "efb68c3ca47dd0ccf1e3f1afd54f118d", "body": {"id": "chatcmpl-9St4PG0T6i5lILPBJIuWzjl3Rq5cF", "object": "chat.completion", "created": 1716671901, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen (decitabine) is a medication used primarily in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic disorders characterized by dysfunctional blood cell production and a risk of progression to acute myeloid leukemia (AML). Here are some key points about Dacogen that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Dacogen is a hypomethylating agent. It works by inhibiting DNA methyltransferase, leading to hypomethylation of DNA. This action can reactivate genes that are silenced in cancer, which can inhibit the growth of cancer cells.\n\n2. **Indications**:\n   - Primarily used for the treatment of myelodysplastic syndromes (MDS).\n   - It is also being investigated for use in other conditions, including acute myeloid leukemia (AML) and in certain solid tumors,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fJmcKVNtJqGozskPBiBgqb6K", "custom_id": "445_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "57051b677b2bf83445809f817a63d2de", "body": {"id": "chatcmpl-9St4QvqcwscRLFaJVhYmuZHUoUOSG", "object": "chat.completion", "created": 1716671902, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon (degarelix) is a medication used primarily in the treatment of advanced prostate cancer. Here are some key points you should know about Firmagon:\n\n1. **Mechanism of Action**: Firmagon is a gonadotropin-releasing hormone (GnRH) antagonist. It works by rapidly reducing the production of testosterone, which is crucial because testosterone can promote the growth of prostate cancer cells. Unlike GnRH agonists, which initially cause a surge in testosterone levels before decreasing them, degarelix reduces testosterone levels quickly without the initial surge.\n\n2. **Indications**: Firmagon is approved for the treatment of advanced prostate cancer. It is particularly useful in situations where avoiding the testosterone surge is important, such as in patients with symptomatic prostate cancer, where rapid symptom control is needed.\n\n3. **Administration**: Firmagon is administered as a subcutaneous injection in the abdominal area. The initial dose is typically a higher loading dose, followed by monthly maintenance doses.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2mUcpKDxWKuDiPRJG4imjBAp", "custom_id": "446_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2f0f156301e9827a2c56675cef67b7e1", "body": {"id": "chatcmpl-9St4PKVkue1DkFuot5iLfG7fwtgJN", "object": "chat.completion", "created": 1716671901, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ontak (denileukin diftitox) is a targeted therapy used primarily in the treatment of certain types of lymphoma, particularly cutaneous T-cell lymphoma (CTCL). It is a fusion protein that combines portions of diphtheria toxin with interleukin-2 (IL-2). The drug binds to the IL-2 receptor on the surface of the cancer cells, which are then killed by the toxin.\n\nHere are some key points you should know about Ontak:\n\n1. **Mechanism of Action**: Ontak targets cells that express the IL-2 receptor, which are typically overexpressed in certain lymphocyte subsets found in CTCL and other lymphomas. After binding to the IL-2 receptor, the diphtheria toxin portion of the molecule enters the cells and inhibits protein synthesis, leading to cell death.\n\n2. **Indications**: Ontak is approved by the FDA for the treatment of persistent or recurrent CTCL in patients whose malignant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_7lJtTVrXDA36OARyZSw2P8DV", "custom_id": "447_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d66be6fa503100e58b772f11bdd860b0", "body": {"id": "chatcmpl-9St4Qz0gpTEbuCyhOFVm6y5Q5bci8", "object": "chat.completion", "created": 1716671902, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prolia (denosumab) is a medication commonly used in the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as in patients with bone loss due to hormone therapy for cancer. Here are some key points about Prolia that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Prolia is a monoclonal antibody that targets and binds to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). RANKL is a protein essential for the formation, function, and survival of osteoclasts, which are cells involved in bone resorption. By inhibiting RANKL, Prolia decreases bone resorption and increases bone mass and strength.\n\n2. **Indications**:\n   - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures.\n   - Treatment to increase bone mass in men at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MzfgNkYnv9N5OyYGyuCsfZ1K", "custom_id": "448_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f61506b1772c8d34cb8bf2679bd89653", "body": {"id": "chatcmpl-9St4QHVnUjPuYP4P0aeudVEOaZOdZ", "object": "chat.completion", "created": 1716671902, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aacidexam\" does not appear to be a recognized medication or substance in standard medical resources or databases. It's possible that there might be a spelling error or it could be a brand name not widely recognized or new on the market. If you meant \"Dexamethasone\" which is sometimes abbreviated in different ways, I can provide information on that.\n\nDexamethasone is a type of corticosteroid medication used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. It is used to treat conditions such as rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis. In COVID-19, it is used in hospitalized people who need supplemental oxygen.\n\nIf you meant a different drug or need information on another topic, please provide more details or check the spelling so I can assist you better."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 198, "total_tokens": 239}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G2GagIn5JxUIyR9gEHpielpe", "custom_id": "449_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "189b6656755f6fa9e309d356422fddaa", "body": {"id": "chatcmpl-9St4QNy3No9LQZv3XeeMkhSNq0nwV", "object": "chat.completion", "created": 1716671902, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane, also known by its generic name dexrazoxane, is primarily used to prevent or reduce the cardiotoxic effects of certain chemotherapy drugs, particularly anthracyclines like doxorubicin. It is important for physicians to be aware of several key aspects of Cardioxane:\n\n1. **Indications**: Dexrazoxane is indicated for use in adult patients who have received a cumulative doxorubicin dose of 300 mg/m\u00b2 and are expected to benefit from continued doxorubicin treatment. It is also used in pediatric patients who have received a cumulative doxorubicin dose of 300 mg/m\u00b2 and may receive additional doxorubicin to treat cancer. Additionally, it is used for treating extravasation resulting from intravenous anthracycline chemotherapy.\n\n2. **Mechanism of Action**: Dexrazoxane works by chelating iron, thereby reducing the formation of free radicals and reactive oxygen species that are believed to contribute to cardiomy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_4BqJzxp9AnFY6Ap75E1B7UG0", "custom_id": "450_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e44948b7779d87c48eab5a39d98f4be7", "body": {"id": "chatcmpl-9St4R12jhpybEP1FEqwudH1SvNTHy", "object": "chat.completion", "created": 1716671903, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Desplex\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf \"Desplex\" is a specific drug or treatment you've encountered, I recommend checking the following:\n\n1. **Spelling**: Verify the spelling of the drug. It's possible that a slight misspelling is leading to difficulty in finding the correct information.\n\n2. **Local Brand Names**: Sometimes drugs are marketed under different names in different countries. Consider checking if this is a brand name specific to a particular region.\n\n3. **New Developments**: If \"Desplex\" is a new drug or a new term, consult the latest medical literature or pharmaceutical updates. Websites like PubMed, FDA, or EMA can be useful for the most recent information.\n\n4. **Pharmacological Resources**: Use trusted"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3qqzlwcHsKSK9KuuH4JJey2F", "custom_id": "451_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e0508123d16aa3f3b230394ad98d908", "body": {"id": "chatcmpl-9St4RWHIwXu8dMYntUawTFgMivte9", "object": "chat.completion", "created": 1716671903, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is an important medication that physicians, especially those involved in pediatric oncology, should be familiar with. Here are some key points about Unituxin:\n\n1. **Indication**: Unituxin is approved for the treatment of pediatric patients with high-risk neuroblastoma. It is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin after the patient has achieved at least a partial response to prior first-line multiagent, multimodality therapy.\n\n2. **Mechanism of Action**: Dinutuximab is a chimeric monoclonal antibody that binds to the GD2 antigen. GD2 is a disialoganglioside expressed on the surface of neuroblastoma cells and other tumors but with limited expression on normal cells. Binding of dinutuximab to GD2-positive cells leads to antibody-dependent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YwrpBYppfeqImwNIK8VLC0Xl", "custom_id": "452_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b08745dd97b2a33bab417b177b8ec60", "body": {"id": "chatcmpl-9St4RSPKlMfwVqj69v34kizsnozxE", "object": "chat.completion", "created": 1716671903, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medication or substance named \"Asodocel\" in standard medical resources or databases. It's possible that the name might be misspelled, or it could be a brand name or a new drug not yet widely recognized or documented in standard references.\n\nIf \"Asodocel\" is a specific drug or treatment you're inquiring about, I recommend checking the most current medical literature, pharmaceutical databases, or contacting pharmaceutical companies for the most accurate and up-to-date information. Additionally, verifying the spelling or checking for alternative names might help in finding the correct information.\n\nIf you have more details or a different spelling, I'd be happy to help look into it further!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 144, "total_tokens": 186}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JU1MDxmsBRPc9mZxAilxvpaJ", "custom_id": "453_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a3cc17ff7bc8f486871e6a84e2d1135", "body": {"id": "chatcmpl-9St4Rkm71SeIS7yVWRAI0BycBplCe", "object": "chat.completion", "created": 1716671903, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox (chemical name: 3,4-dihydroxybenzohydroxamic acid) is a synthetic chemical compound that has been studied primarily for its potential use in medical treatments, particularly in cancer therapy. It is known to act as a ribonucleotide reductase inhibitor. Ribonucleotide reductase is an enzyme that is crucial for DNA synthesis and repair, and by inhibiting this enzyme, Didox can potentially interfere with the proliferation of cancer cells.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Didox inhibits ribonucleotide reductase, which is essential for DNA synthesis. This inhibition can lead to a decrease in DNA replication and repair, primarily affecting rapidly dividing cells such as cancer cells.\n\n2. **Research and Trials**:\n   - Most of the studies involving Didox have been preclinical or early clinical trials. It's important to review the latest research to understand its efficacy and safety profile in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Wv5AaVuhrWg7J0ZidAGUwQ2X", "custom_id": "454_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aedfb4d080e7570c22eca14fdf60198c", "body": {"id": "chatcmpl-9St4S7ZM6CL5u0aWoTTi4KaWp20Ok", "object": "chat.completion", "created": 1716671904, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriablastina is a brand name for the drug doxorubicin, which is a chemotherapy medication used primarily to treat various types of cancer. Doxorubicin belongs to a class of drugs known as anthracyclines. It works by interfering with the growth and spread of cancer cells in the body.\n\nHere are some key points you should know about doxorubicin (Adriablastina):\n\n1. **Indications**: Doxorubicin is used to treat several types of cancer, including breast cancer, bladder cancer, ovarian cancer, thyroid cancer, stomach cancer, lung cancer, and certain types of leukemia and lymphomas.\n\n2. **Mechanism of Action**: Doxorubicin works by intercalating DNA, disrupting the function of topoisomerase II, and generating free radicals. These actions inhibit the replication of rapidly growing cancer cells and ultimately lead to cell death.\n\n3. **Administration**: Doxorubicin is typically administered intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xQkZqi36ej4OTJGKJ4pxK8oG", "custom_id": "455_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55cd411d6ac832119a7234724995fa2d", "body": {"id": "chatcmpl-9St4SCdTlD0zMGeHkwdTYIWKFduBU", "object": "chat.completion", "created": 1716671904, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imfinzi (durvalumab) is a medication used in the treatment of certain types of cancer. It is a type of immunotherapy that works by targeting the PD-L1 pathway, a mechanism that tumors use to evade the immune system. By blocking PD-L1, Imfinzi helps the immune system to detect and attack cancer cells. Here are some key points you should know about Imfinzi:\n\n1. **Indications**: Imfinzi is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. It is also approved for the treatment of unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.\n\n2. **Mechanism of Action**: Imfinzi is a monoclonal antibody that binds to PD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JNEMWXUxQXRO1Dz0U6mUB1WR", "custom_id": "456_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4e9334048ea260c9caf802c1dae46a97", "body": {"id": "chatcmpl-9St4SGjupLoHTN1CQbg0SWMMfGtAx", "object": "chat.completion", "created": 1716671904, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avodart, known generically as dutasteride, is a medication primarily used to treat symptoms of benign prostatic hyperplasia (BPH), or enlargement of the prostate gland. Here are some key points you should know about Avodart as a physician:\n\n1. **Mechanism of Action**: Dutasteride inhibits the enzyme 5-alpha-reductase, which is responsible for converting testosterone to dihydrotestosterone (DHT). DHT is a hormone that contributes to prostate growth. By lowering DHT levels, dutasteride helps reduce the size of an enlarged prostate, thereby improving urinary symptoms.\n\n2. **Indications**: Avodart is approved for the treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It helps improve urinary flow and may also reduce the need for prostate surgery later on.\n\n3. **Dosage and Administration**: The typical dose of Avodart is 0.5 mg taken orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AU3QXuRUeOXzmcbkGLAjBhRQ", "custom_id": "457_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a816bd7257b78a08ae49e4054b4078f2", "body": {"id": "chatcmpl-9St4Skmj9V7w8cSfBXqT0XJbNFlH1", "object": "chat.completion", "created": 1716671904, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain hematologic cancers. Here are some key points you should know about Copiktra:\n\n1. **Indications**: Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior therapies. It is also approved for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. This approval is based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\n\n2. **Mechanism of Action**: Duvelisib is a phosphoinositide 3-kinase (PI3K) inhibitor, specifically targeting the delta and gamma isoforms of PI3K. These iso"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WM2Pa0mYD0StAgZvUCAc3u3o", "custom_id": "458_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b579c2cbc14c578366f910546e853bd", "body": {"id": "chatcmpl-9St4STinppQ3E14GBgJvOayYFj11b", "object": "chat.completion", "created": 1716671904, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to understand the basics and clinical applications of a Panorex, which is a type of dental X-ray. Officially known as a panoramic radiograph, it captures a single image of the entire dental structure\u2014upper and lower jaws, all teeth, and surrounding tissues and bones. Here are some key points about Panorex that you might find useful:\n\n1. **Overview and Purpose**: A Panorex provides a panoramic view of the mouth, helping to see a comprehensive view of a patient\u2019s oral conditions. This includes the positioning of all teeth, the mandible, maxillary sinuses, and other bony structures and abnormalities. It is particularly useful for assessing impacted teeth, diagnosing bony pathology, evaluating jaw joint disorders (TMJ), and planning orthodontic treatments.\n\n2. **Technology**: Unlike traditional dental X-rays which focus on specific sections of the mouth, the Panorex equipment rotates around the patient\u2019s head. The patient's head"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aDDorlz7DDQYvtfrQy1LCcxd", "custom_id": "459_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c83467ef063aa13226ca216129813bca", "body": {"id": "chatcmpl-9St4Tf2fz3hDx9zsJxicOhntA1qaN", "object": "chat.completion", "created": 1716671905, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that forms in plasma cells. It is specifically indicated for use in combination with other medications, such as lenalidomide and dexamethasone, or with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received one to three prior therapies.\n\nHere are some key points about Empliciti:\n\n1. **Mechanism of Action**: Empliciti specifically targets the SLAMF7 protein, which is highly expressed on myeloma cells and also present on natural killer cells. The drug works by directly activating the body\u2019s immune system to attack and kill the myeloma cells, and by enhancing the immune response through other immune cells.\n\n2. **Administration**: Empliciti is administered via intravenous infusion. The dosing schedule typically involves weekly administrations for the first"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ULgiym3dCztQMCcSUHryJmMb", "custom_id": "460_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "68155726b6df28fa4fb5834f2f6ca7eb", "body": {"id": "chatcmpl-9St4TTPmscTsYcjcjJa8AROqOk7nG", "object": "chat.completion", "created": 1716671905, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idhifa (enasidenib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Idhifa:\n\n1. **Indication**: Idhifa is specifically indicated for the treatment of adult patients with relapsed or refractory AML who have an isocitrate dehydrogenase-2 (IDH2) mutation. The presence of IDH2 mutations should be confirmed using an FDA-approved test before starting treatment with Idhifa.\n\n2. **Mechanism of Action**: Enasidenib, the active ingredient in Idhifa, is an inhibitor of the IDH2 enzyme. In AML, mutations in the IDH2 gene lead to abnormal enzyme activity that promotes the growth of cancer cells. By inhibiting this mutated enzyme, Idhifa can help induce cellular differentiation and potentially lead to remission in some patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HmJUyFTpGwPq5KZoDndqQ9vX", "custom_id": "461_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b8f08f92e1ca6e9ee9493ce56bdf16db", "body": {"id": "chatcmpl-9St4UpyqDLmWnnknZSj2m0BeiwZTU", "object": "chat.completion", "created": 1716671906, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi (encorafenib) is a medication used in the treatment of cancer, specifically for patients with certain types of melanoma. Here are some key points you should know about Braftovi as a physician:\n\n1. **Indications**: Braftovi is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. It is often used in combination with another medication called binimetinib (Mektovi).\n\n2. **Mechanism of Action**: Braftovi is a BRAF inhibitor. It works by selectively targeting and inhibiting the activity of the BRAF V600E and V600K mutations. These mutations lead to the activation of the MAPK/ERK pathway, which promotes cell growth and division. By inhibiting this pathway, Braftovi helps to slow down or stop the growth of cancer cells.\n\n3. **Administration**: B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oRAmtBv6s8u7SMt7t6TnawPH", "custom_id": "462_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90780680d969ed3276be383be08b5cf1", "body": {"id": "chatcmpl-9St4UbyESxr6UXuRM2sPEh9w1VDm9", "object": "chat.completion", "created": 1716671906, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rozlytrek (entrectinib) is a targeted therapy approved by the FDA for the treatment of certain types of solid tumors. Here are some key points you should know about Rozlytrek:\n\n1. **Indications**: Rozlytrek is indicated for the treatment of adult and pediatric patients (12 years of age and older) with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation. It is also indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.\n\n2. **Mechanism of Action**: Rozlytrek is a kinase inhibitor. It works by targeting and inhibiting the kinase activities of TRKA/CDK6, ROS1, and ALK, which are involved in the growth and spread of cancer cells.\n\n3. **Efficacy**: Clinical trials have shown that Rozlytrek is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hi1O71yXr0tJFLjnLu2EhoiY", "custom_id": "463_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e582110fb286a592a2182733c85b2ca3", "body": {"id": "chatcmpl-9St4Unio1nKwGAuRn8FS6SxFgBZcp", "object": "chat.completion", "created": 1716671906, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azel refers to azelastine, which is a medication primarily used as an antihistamine for the management of allergic symptoms. Here are some key points about azelastine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Azelastine is a potent, second-generation, selective histamine antagonist (H1-receptor antagonist). It inhibits the release of histamine and other mediators involved in the allergic response.\n\n2. **Forms and Usage**: Azelastine is available in two main forms:\n   - **Nasal spray**: Used for the treatment of allergic rhinitis. It can reduce symptoms such as sneezing, runny nose, itching, and congestion.\n   - **Eye drops**: Used for the treatment of allergic conjunctivitis, helping to alleviate eye symptoms like itching, redness, and watering.\n\n3. **Dosage and Administration**:\n   - **Nasal spray**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X746xlZcOKQMykjvJDMu1sfN", "custom_id": "464_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8d01cf5048dbb38d0310f823fd724d35", "body": {"id": "chatcmpl-9St4UZ0toPYwwoogqAKdEHGk6qKj9", "object": "chat.completion", "created": 1716671906, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no drug named \"Alrubicin\" recognized in standard pharmacological sources or medical literature. It's possible that there might be a typo or a misunderstanding regarding the name of the drug. It's also possible that it could be a new or experimental drug not widely recognized yet.\n\nIf you meant \"Doxorubicin,\" which is a commonly used chemotherapeutic agent, I can provide information on that. Doxorubicin is an anthracycline antibiotic that is widely used in the treatment of various cancers, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It works by intercalating DNA, disrupting topoisomerase-II-mediated DNA repair, and generating free radicals that damage cellular components.\n\nFor any drug, it's crucial to verify its name and details using reliable medical resources or databases like the FDA or EMA websites, or trusted medical literature. If \"Alr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1OqzsBemscuS6S2xGD5o8N56", "custom_id": "465_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "11233f3274df83b09ef7d4395f5109ff", "body": {"id": "chatcmpl-9St4Um9YOZzgAofSpvRacvWvgbNld", "object": "chat.completion", "created": 1716671906, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has susceptible fibroblast growth factor receptor (FGFR) genetic alterations. This approval, which came in April 2019, marked Balversa as the first targeted therapy approved for urothelial cancer with these specific genetic alterations.\n\nHere are some key points about Balversa:\n\n1. **Indication**: Balversa is specifically indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has a susceptible FGFR3 or FGFR2 genetic alteration, and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n2. **Mechanism of Action**: Erdafitinib is a kinase inhibitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JqsRtENTIOvn6ntUYQNDbLHm", "custom_id": "466_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee9b63980b13c4475c3ae42d41491657", "body": {"id": "chatcmpl-9St4VVfM4H7f0nNay1Yuq6tjC0zQs", "object": "chat.completion", "created": 1716671907, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medication or substance known as \"Brutravon\" recognized in standard medical or pharmaceutical references. It's possible that the name could be a misspelling, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf \"Brutravon\" is a drug you've encountered in a specific context, such as a new research trial, a drug in development, or a product available in a specific region outside of mainstream pharmaceutical markets, I recommend consulting the latest clinical data or pharmaceutical databases. Additionally, contacting the manufacturer or reviewing regulatory agency materials from entities like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) could provide reliable information.\n\nIf you need information on a drug with a similar name or a drug for a specific condition, I can certainly help with that if you provide more details."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 185, "total_tokens": 227}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wB8f1Tw7sBrHBwH5B11AqGG8", "custom_id": "467_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "80bb52546488ae890941cc3b0bc4c724", "body": {"id": "chatcmpl-9St4VfnI13Q17GTbRSmEpI4DhJ0yg", "object": "chat.completion", "created": 1716671907, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug erlotinib, which is used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points you should know about Erlocip:\n\n1. **Mechanism of Action**: Erlotinib belongs to a class of anticancer agents known as tyrosine kinase inhibitors. It specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and development of cancer cells. By inhibiting EGFR, erlotinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**:\n   - **Non-small cell lung cancer (NSCLC)**: Erlotinib is approved for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. It is particularly effective in patients whose tumors express EGFR mutations.\n   - **Pancre"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_XwyYPag40aqQUEENaGLxUdiL", "custom_id": "468_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b369d4488a11e780ef1ad57c3138a625", "body": {"id": "chatcmpl-9St4WJzzmTburgxLeKKj3J1cX2f9d", "object": "chat.completion", "created": 1716671908, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt (estramustine phosphate sodium) is a chemotherapy drug used primarily in the treatment of prostate cancer. Here are some key points you should know about Emcyt:\n\n1. **Mechanism of Action**: Emcyt combines the properties of an estrogen (estradiol) and a nitrogen mustard-derived alkylating agent. Its mechanism involves binding to microtubule-associated proteins, disrupting microtubule function, which is critical for cell division, and also has some hormonal effects due to its estrogen component.\n\n2. **Indications**: It is specifically indicated for the palliative treatment of metastatic and/or progressive prostate cancer. It is often used when the cancer does not respond to other hormonal therapies.\n\n3. **Administration**: Emcyt is administered orally in capsule form. The dosage and treatment schedule can vary based on factors like the patient's overall health, the stage of cancer, and how well the cancer is responding to the treatment.\n\n4. **Side Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_V01ZM1fB7NHQcOeSI4hUyf2Y", "custom_id": "469_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a0924d62fc74a65b421ea1839ea91ad8", "body": {"id": "chatcmpl-9St4WdMegeJ8yu4bZYcqduMtf96um", "object": "chat.completion", "created": 1716671908, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Aside\" isn't clearly related to a medical context. If you meant \"Aspirin\" or another drug, medical condition, or treatment, please clarify so I can provide you with accurate and relevant information. If \"Aside\" refers to something specific in your field or a new development, additional context would be helpful to give you the best possible answer."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 86, "total_tokens": 125}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3a2CLw67MlEcLxQCPJVyESOt", "custom_id": "470_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dac1a4d31815588738aab39e90d865a3", "body": {"id": "chatcmpl-9St4WxR9uPsuwj0bwdnuwB819l5jX", "object": "chat.completion", "created": 1716671908, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Advacan\" in standard medical resources or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf you meant a different medication, or if \"Advacan\" is a new or less common drug, I recommend checking the most current medical databases, pharmaceutical references, or regulatory agency databases like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals might provide more insights.\n\nIf you have more specific information or another question about a different drug, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 162, "total_tokens": 203}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YNcjy80tB28k3LfWH7FCNgyM", "custom_id": "471_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb59ad6fadfb954b136ad2e269d32269", "body": {"id": "chatcmpl-9St4XFRkw6iAPQGChLvgH1Q4aolgZ", "object": "chat.completion", "created": 1716671909, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aromadex\" does not appear to be a widely recognized medication or supplement in standard medical or pharmaceutical references. It's possible that it could be a brand name or a trade name not commonly used or known, or it might be a misspelling or mispronunciation of a different drug.\n\nIf you meant \"Arimidex,\" which is a brand name for the drug anastrozole, here is some relevant information:\n\n**Anastrozole (Arimidex)** is a medication used primarily in the treatment of breast cancer. It is classified as an aromatase inhibitor, which works by decreasing the amount of estrogen the body makes. This can slow or stop the growth of many types of breast cancer cells that need estrogen to grow.\n\n### Indications\n- **Breast Cancer in Postmenopausal Women**: Anastrozole is commonly prescribed for hormone receptor-positive breast cancer in postmenopausal women. It is used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rmcY09dbCyIlFTDHInlrzlW9", "custom_id": "472_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8c4155fd4b6901922d117ef468abb94e", "body": {"id": "chatcmpl-9St4XxAUXTW32kJojdHQGl7WjEs3C", "object": "chat.completion", "created": 1716671909, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "FUDR, or floxuridine, is a chemotherapy medication primarily used in the treatment of colorectal cancer. It is a fluorinated pyrimidine analog, which functions as an antimetabolite. Here are some key points you should know about FUDR:\n\n1. **Mechanism of Action**: Floxuridine works by interfering with the synthesis of DNA and RNA, making it difficult for cancer cells to multiply. It is incorporated into the DNA where it inhibits thymidylate synthase and DNA synthesis.\n\n2. **Administration**: FUDR is commonly administered via hepatic arterial infusion (HAI), which delivers the drug directly to the liver. This is particularly useful for treating liver metastases from colorectal cancer. It can also be administered intravenously.\n\n3. **Indications**: The primary indication for FUDR is the treatment of gastrointestinal cancers, especially metastatic colorectal cancer localized in the liver. It may be used alone or in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qeLZM3YTbalJcRJYZqm2PSNt", "custom_id": "473_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "42ec9e93c22e1228493ebae5de4ad684", "body": {"id": "chatcmpl-9St4XMxd1TToNgegro4K22Kgg9ipq", "object": "chat.completion", "created": 1716671909, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Beneflur\" does not appear to be a recognized medication or substance commonly known in the medical community. It's possible that the name might be misspelled, or it could be a brand name that is not widely recognized, or perhaps a new or experimental treatment.\n\nIf you are referring to a specific medication or treatment, I recommend double-checking the spelling or providing more context. Alternatively, you can consult reliable medical databases, such as those maintained by the FDA or WHO, or peer-reviewed medical literature for the most accurate and up-to-date information. If Beneflur is a brand name, it might also help to know its generic name or the active ingredients it contains.\n\nIf you have any other questions or need information on a different topic, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 162, "total_tokens": 203}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZvPkpITU8ycfF3I2kAJ7wbcO", "custom_id": "474_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8725f865749923be8ee9a208879dbcd6", "body": {"id": "chatcmpl-9St4Xw3R4UIZCW3NjEuilg7H7bS9o", "object": "chat.completion", "created": 1716671909, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Accusite is a drug delivery system used primarily in the treatment of ophthalmic conditions. It is designed to provide targeted and controlled release of medication directly to the eye, which can be beneficial in treating diseases such as age-related macular degeneration (AMD) and diabetic retinopathy.\n\nHere are some key points you should know about Accusite:\n\n1. **Mechanism of Action**: Accusite utilizes a localized, controlled-release technology to deliver medication directly to the affected area in the eye. This can help in achieving higher local drug concentrations at the site of pathology while minimizing systemic exposure and potential side effects.\n\n2. **Applications**: It is commonly used for delivering drugs that inhibit vascular endothelial growth factor (VEGF), which are used in the treatment of neovascular (wet) AMD and other similar conditions. The system can be adapted for various drugs depending on the specific needs of the patient.\n\n3. **Benefits**: The main benefits of using Accusite include improved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G4XJ67hkMfko4pyqzyiqnSQ0", "custom_id": "475_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "18cb0d1c0a13c1bb8d6adedea14313e9", "body": {"id": "chatcmpl-9St4YyHpbVshOkfEtiF4jzqu8fTKB", "object": "chat.completion", "created": 1716671910, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin, known generically as fluoxymesterone, is a synthetic androgenic anabolic steroid (AAS). It is primarily used in the treatment of low testosterone levels in men, and in the treatment of breast cancer in women. Here are some key points you should know about Halotestin:\n\n1. **Indications**: Halotestin is indicated for replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. It is also used for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone-dependent tumor as evidenced by previous beneficial response to castration.\n\n2. **Mechanism of Action**: Fluoxymesterone is a potent androgen that produces effects by binding to androgen receptors, leading to increased protein synthesis and muscle strength. It has a higher anabolic and androgenic rating compared to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K1vmDsQaN3HiJHSbRVrzUtWQ", "custom_id": "476_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dba9a8da69f05d078e485ed639b98a65", "body": {"id": "chatcmpl-9St4YyfbKImr80qyCQ2dF9Kj9r2NR", "object": "chat.completion", "created": 1716671910, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid is a medication primarily used in the management of prostate cancer. Its active ingredient is flutamide, which is a nonsteroidal antiandrogen. Here are some key points about Cytomid (flutamide) that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Flutamide acts as a competitive antagonist at the androgen receptor. It inhibits the action of androgens (male hormones) by preventing their binding to the androgen receptors in target tissues such as the prostate gland. This helps in reducing the growth of androgen-dependent prostate cancer cells.\n\n2. **Indications**: Cytomid is primarily indicated for the treatment of advanced prostate cancer. It is often used in combination with a gonadotropin-releasing hormone (GnRH) agonist or surgical castration to achieve a more complete androgen blockade.\n\n3. **Dosage and Administration**: The typical dosage of flutamide is 250"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rhO1q1GeN1skB6uhh86b76DY", "custom_id": "477_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "19bf3ae8fbe98ea0265ef24f35c415a5", "body": {"id": "chatcmpl-9St4YXSn8yXN9wsdBGqmUuA6qYPsR", "object": "chat.completion", "created": 1716671910, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or substance called \"Antrex\" that is widely recognized in standard medical references or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet well-documented in public sources.\n\nIf you meant a different medication, or if \"Antrex\" is a new or less common drug, I recommend checking the most current medical databases, pharmaceutical references, or regulatory agency databases for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals might provide more insights.\n\nIf you provide more context or details, I might be able to offer more specific assistance or direct you to the right resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 149, "total_tokens": 189}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SjZhXFqCzkgGdL657KmckCEA", "custom_id": "478_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "82e44132db48d2ef00877a028ab7e19e", "body": {"id": "chatcmpl-9St4YcEQQfCewzfIQua3SYsZld01Z", "object": "chat.completion", "created": 1716671910, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lentaron, known generically as formestane, is a type II steroidal aromatase inhibitor used in the treatment of estrogen receptor-positive breast cancer in post-menopausal women. It works by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. By lowering estrogen levels, formestane can help reduce the growth of hormone-sensitive breast cancer cells.\n\nHere are some key points about Lentaron (formestane):\n\n1. **Indications**: Lentaron is primarily used for the treatment of estrogen receptor-positive breast cancer in post-menopausal women. It may be used when the cancer has progressed following tamoxifen therapy.\n\n2. **Administration**: Formestane was originally available as an injectable form, administered intramuscularly. This is different from many other aromatase inhibitors, which are typically administered orally.\n\n3. **Side Effects**: Common side effects of formestane include hot flashes, fatigue, increased sweating"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tnb2g5gbVPt6qCGtEVVnXPJB", "custom_id": "479_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bfb850d63e5bc8582eaca4ad59d68204", "body": {"id": "chatcmpl-9St4ZiV9Yb3vXMga8Eexl65nm0ob7", "object": "chat.completion", "created": 1716671911, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine, also known by its chemical name forodesine, is a purine nucleoside phosphorylase (PNP) inhibitor. It is an investigational drug that has been studied for its potential use in treating various hematological malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and chronic lymphocytic leukemia (CLL).\n\n### Mechanism of Action:\nForodesine inhibits the enzyme purine nucleoside phosphorylase, which plays a crucial role in the purine salvage pathway. By inhibiting this enzyme, forodesine causes an accumulation of deoxyguanosine triphosphate (dGTP) in lymphocytes, leading to apoptosis, particularly in T-cells and B-cells which are highly dependent on the purine salvage pathway for proliferation.\n\n### Clinical Trials and Usage:\n- **T-cell Acute Lymphoblastic Leukemia (T-ALL):** Forodesine has been evaluated in clinical trials for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_omu16Zpk4FSxw6dAOda3Hlco", "custom_id": "480_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a1777c789f2775c561282d3132aaa110", "body": {"id": "chatcmpl-9St4ZwnQMuenNy54mEIoJFTJWAGjN", "object": "chat.completion", "created": 1716671911, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tavalisse (fostamatinib disodium hexahydrate) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. Here are some key points about Tavalisse that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tavalisse is a spleen tyrosine kinase (SYK) inhibitor. SYK is a key enzyme in the signaling pathways of immune cells, including B cells and macrophages. By inhibiting SYK, Tavalisse helps to reduce the destruction of platelets, which is a central problem in ITP.\n\n2. **Indications**: It is specifically indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments, such as corticoster"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FrFoW2zk3yAhPTTJcEFdfF8t", "custom_id": "481_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "630390d3bbfecdf9a8d95cd3f1f60bd9", "body": {"id": "chatcmpl-9St4Z2RE0piWbnCipwNWOWmyWGbkH", "object": "chat.completion", "created": 1716671911, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Muphoran (fotemustine) is a type of chemotherapy drug classified as a nitrosourea alkylating agent. It is primarily used in the treatment of metastatic melanoma, particularly when the disease has spread to the brain (cerebral metastases). Fotemustine has also been investigated for use in other types of cancers, such as certain brain tumors (gliomas) and other advanced malignancies.\n\nHere are some key points about fotemustine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Fotemustine works by cross-linking DNA strands and inhibiting DNA synthesis, which leads to cell death. Its ability to cross the blood-brain barrier makes it particularly useful in treating brain metastases from melanoma.\n\n2. **Administration**: Fotemustine is typically administered intravenously. The dosing regimen can vary, but it often involves an initial loading phase followed by maintenance doses, depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w1RwFNiu71JG0xZOLydttPRn", "custom_id": "482_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "867db7faa5759a72fb5864a50ffca4cd", "body": {"id": "chatcmpl-9St4ZNQ0cm3jFjRo4d4660zWMA7Qt", "object": "chat.completion", "created": 1716671911, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faslodex (fulvestrant) is a medication used primarily in the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women. Here are some key points you should know about Faslodex:\n\n1. **Mechanism of Action**: Faslodex is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors and causes their degradation, thereby inhibiting the estrogen signaling pathway which is crucial for the growth of certain types of breast cancer cells.\n\n2. **Indications**:\n   - It is approved for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.\n   - It is often used in women who have disease progression following anti-estrogen therapy (e.g., tamoxifen).\n   - It can also be used as first-line therapy in some cases of advanced breast cancer.\n\n3. **Administration**: Faslodex is administered as an intramus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zCcBwBMbu8LU1CLqiNEz1KV9", "custom_id": "483_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b88423b6537838b58b3764cfab4c9935", "body": {"id": "chatcmpl-9St4aKOYBZsmYHLX4kkAR5YuAxAr9", "object": "chat.completion", "created": 1716671912, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Cangib\" in the medical community. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug that has not been documented in mainstream medical sources yet.\n\nIf you are referring to a specific medication, treatment, or substance, please provide more details or check the spelling so I can offer more accurate and helpful information. Additionally, for the most current and detailed information, especially for new or less common drugs, consulting specialized databases, pharmaceutical references, or regulatory agencies' websites might be necessary."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 125, "total_tokens": 166}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NJ2eWz4a4H6SBNvrXbY3tpUP", "custom_id": "484_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab15e26d3a3234ae29ec845967185c5a", "body": {"id": "chatcmpl-9St4aNSCBaRSTIroEHLBocmCJ0EwH", "object": "chat.completion", "created": 1716671912, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine, marketed under the brand name Gemzar among others, is a chemotherapy medication used to treat several types of cancer. These include breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and bladder cancer. It is given by injection into a vein.\n\nHere are some key points about gemcitabine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nGemcitabine is a nucleoside analog, specifically a deoxycytidine analog, which interferes with DNA synthesis. It gets incorporated into DNA during the S phase of the cell cycle, leading to inhibition of DNA synthesis and eventually cell death.\n\n### Indications\n- **Pancreatic Cancer:** Used as first-line treatment for locally advanced or metastatic pancreatic cancer.\n- **Non-Small Cell Lung Cancer (NSCLC):** Used alone or in combination with other agents like cisplatin.\n- **Breast Cancer:** For the treatment of metastatic breast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Kdzl3cMMqEULxk5xP9C8nZLw", "custom_id": "485_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea12affd9abc12949b16fc4767e3cbe7", "body": {"id": "chatcmpl-9St4aY4PiKah5tVAnjIct6VpnVeMe", "object": "chat.completion", "created": 1716671912, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (gemtuzumab ozogamicin) is a targeted therapy used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about Mylotarg:\n\n1. **Indications**: Mylotarg is approved for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older. It is also approved for the treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.\n\n2. **Mechanism of Action**: Mylotarg is a conjugate of a monoclonal antibody and a cytotoxic agent. The antibody specifically targets the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and other myeloid cells. Once bound, the conjugate is internalized, and the cytotoxic agent (calicheamicin) is released inside"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ksPsLipMn44AET6iSjEtQztc", "custom_id": "486_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47ed56da1fcdeaf1759c5a0f588286e3", "body": {"id": "chatcmpl-9St4bb0r2uyp89FCp0e0ySQzlETyd", "object": "chat.completion", "created": 1716671913, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata, known generically as gilteritinib, is a medication used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about Xospata:\n\n1. **Indication**: Xospata is specifically indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test. This mutation is associated with a poor prognosis in AML patients, and testing prior to initiation of treatment is crucial to confirm the presence of FLT3 mutations.\n\n2. **Mechanism of Action**: Gilteritininib is a tyrosine kinase inhibitor that targets FLT3 (FMS-like tyrosine kinase 3). FLT3 mutations lead to the activation of downstream signaling pathways that promote the survival and proliferation of leukemic cells. By inhibiting FLT3, gilteritinib helps to reduce the proliferation of these mutated cells.\n\n3. **Administration**: Xospata is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tk4mKHF8BoaqeUIPBDup7hkx", "custom_id": "487_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55299a27f07d40a250a207598f4a44df", "body": {"id": "chatcmpl-9St4bcPNNtPmZukURtR37WvUC3oEC", "object": "chat.completion", "created": 1716671913, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daurismo (glasdegib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Daurismo:\n\n1. **Indications**: Daurismo is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years of age or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. It is used in combination with low-dose cytarabine (LDAC).\n\n2. **Mechanism of Action**: Glasdegib works by inhibiting the Smoothened (SMO) receptor, which is a component of the Hedgehog signaling pathway. This pathway is involved in the regulation of cell differentiation, tissue polarity, and stem cell maintenance. Aberrant activation of the Hedgehog pathway has been implicated in the pathogenesis of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tp8KmNgCikzOKzohULx7fRSP", "custom_id": "488_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59901cd7f17348d13795d1362089bf7f", "body": {"id": "chatcmpl-9St4c13xVKGrxtq8kJOW5fLOMIAmz", "object": "chat.completion", "created": 1716671914, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't any specific information available about \"Novgos\" in the context of medicine or healthcare. It's possible that you might be referring to a term, drug, or concept that is either misspelled, very new, or not widely recognized under this name. Could you please provide more details or clarify what you are referring to? This will help me provide you with the most accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 88, "total_tokens": 128}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a7sYvyNyMucQOCwPSc3BpbQh", "custom_id": "489_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "119889a44fb5ebb23e2bb0901d63f5ff", "body": {"id": "chatcmpl-9St4cG4yW8hBreo6bbXo4mDFXnZ7a", "object": "chat.completion", "created": 1716671914, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin LA (histrelin acetate) is an implant that is used primarily in the treatment of central precocious puberty (CPP), which is the early onset of puberty. The implant contains a synthetic analogue of gonadotropin-releasing hormone (GnRH) and works by continuously releasing the medication over a 12-month period, which helps to suppress the pituitary gland's secretion of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone). This suppression helps to halt the premature sexual development associated with CPP.\n\nHere are some key points you should know about Supprelin LA:\n\n1. **Indications**: Supprelin LA is specifically approved for the treatment of children with central precocious puberty, which is typically defined as the development of secondary sexual characteristics before age 8 in girls and age 9 in boys.\n\n2. **Mechanism of Action**: Supprelin LA acts by des"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mMlDm226dDNNqmsI0DwFoFpS", "custom_id": "490_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "82c8ef1351a35e377fe1c7db6db16461", "body": {"id": "chatcmpl-9St4cxuYvHTrJ0JUrsOY3gR7QXZNs", "object": "chat.completion", "created": 1716671914, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cortef, known generically as hydrocortisone, is a glucocorticoid medication used to treat a variety of conditions that involve inflammation, and it is also used as a replacement therapy in adrenal insufficiency. Here are some key points you should know about Cortef:\n\n### Indications\n1. **Adrenal Insufficiency**: It is primarily used in conditions like Addison's disease where the adrenal glands do not produce enough steroid hormones.\n2. **Inflammatory and Immune Conditions**: It helps manage symptoms of conditions such as arthritis, lupus, psoriasis, ulcerative colitis, allergic reactions, and others.\n3. **Other Uses**: It can be used in the treatment of high blood calcium due to cancer, thyroiditis, and to prevent nausea and vomiting associated with chemotherapy.\n\n### Mechanism of Action\nHydrocortisone mimics the action of cortisol, a naturally occurring hormone produced by the adrenal glands. It works by reducing inflammation and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uW685C1cZUKuqFgDSs9NKuJB", "custom_id": "491_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9bb48e8f716d860f8ae8a296d87d53ef", "body": {"id": "chatcmpl-9St4dxzElwGA6VDNCEPBZ1HlzNDd1", "object": "chat.completion", "created": 1716671915, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Biosupressin\" in standard medical or pharmaceutical references. It's possible that the name could be a brand name, a non-standard term, or a misspelling of a different drug. It's also possible that it could be a new or experimental treatment not yet widely documented.\n\nTo provide accurate information, I would recommend checking the following:\n\n1. **Verify the Spelling**: Ensure that the name \"Biosupressin\" is spelled correctly. It might be a typographical error or a misunderstanding of the drug's actual name.\n\n2. **Consult Reliable Sources**: Check trusted medical databases like PubMed, the FDA database, or the European Medicines Agency (EMA) for any information. These databases will have information on approved drugs, their uses, side effects, and clinical trial data.\n\n3. **Ask for Context**: If this inquiry came from a patient or another healthcare provider, ask for more"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_jtXRrmn28Uk9KLIuyda6fHG9", "custom_id": "492_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec2ae5f240e61d5d2e15a5ee4c7c43a3", "body": {"id": "chatcmpl-9St4eVTiloJkltbDtM37a9473gPh6", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radioimmunotherapy medication used primarily in the treatment of non-Hodgkin's lymphoma (NHL). It combines a monoclonal antibody (ibritumomab, which targets the CD20 antigen on the surface of normal and malignant B-cells) with a radioactive isotope (either yttrium-90 or indium-111), allowing the antibody to deliver targeted radiation directly to the tumor cells.\n\nHere are some key points you should know about Zevalin:\n\n1. **Indications**: Zevalin is approved for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma. It is also used for patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.\n\n2. **Mechanism of Action**: Zevalin targets the CD20 antigen on B-cells. After binding to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DOUnw36bViRyBabCmJ2I6bHF", "custom_id": "493_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "008dd96b414dfa41040069a090faa5cc", "body": {"id": "chatcmpl-9St4dAvqmPVTt0Ep7EuU3pqUmOWT0", "object": "chat.completion", "created": 1716671915, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica among others, is a medication used to treat certain cancers, primarily B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenstr\u00f6m's macroglobulinemia, and marginal zone lymphoma. It is also indicated for chronic graft versus host disease after failure of one or more lines of systemic therapy.\n\nHere are some key points about ibrutinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Ibrutinib is a small molecule drug that inhibits Bruton's tyrosine kinase (BTK). BTK is a crucial component in the B-cell receptor signaling complex, which plays a significant role in the survival, proliferation, and migration of B lymphocytes. By inhibiting BTK, ibrutinib impedes the growth and survival of B cells.\n\n2. **Indications**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ZrWo73yO7iG7yWybYRW9nRe9", "custom_id": "494_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71bf4ec1fd197f6de87c0cc05e3eaa6f", "body": {"id": "chatcmpl-9St4dvRwseERE8PjBxN1ixqaduKOc", "object": "chat.completion", "created": 1716671915, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Conmana is the brand name for the drug icotinib, which is an oral tyrosine kinase inhibitor specifically targeting the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Conmana (icotinib):\n\n1. **Indications**: Conmana is approved for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have specific mutations in the EGFR gene. These mutations lead to enhanced signaling through the EGFR pathway, promoting cancer cell proliferation and survival.\n\n2. **Mechanism of Action**: Icotinib works by selectively inhibiting the tyrosine kinase activity of the EGFR, which is a receptor found on the surface of many tumor cells as well as normal cells. By blocking this activity, icotinib can reduce tumor cell growth and division.\n\n3. **Efficacy**: Clinical trials have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rbDjoupHD606qG8dLGuSDMpA", "custom_id": "495_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c36ec7130defc6ad13c5a722596e0df7", "body": {"id": "chatcmpl-9St4eBTCTZueyaoDvm2VlAOARSp0W", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, which is the brand name for idarubicin, is an anthracycline antibiotic that is commonly used in chemotherapy. It is particularly effective in treating various types of leukemia, including acute myeloid leukemia (AML). Here are some key points you should know about Idamycin:\n\n1. **Mechanism of Action**: Idarubicin works by intercalating DNA strands, inhibiting the enzyme topoisomerase II, and producing free radicals that damage cellular membranes, DNA, and proteins. This action prevents the replication of rapidly dividing cancer cells and leads to cell death.\n\n2. **Indications**: Idarubicin is primarily used for the treatment of acute myeloid leukemia (AML). It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Idarubicin is administered intravenously. The dosage and schedule depend on the patient's condition, body size, and treatment regimen. It is crucial to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bUuxT4U2ZAcEAjDRzQtGMHdE", "custom_id": "496_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7410b49dd778225a7a566b5f8fed0779", "body": {"id": "chatcmpl-9St4eZdjJCGHcKoMj45Wbtrj4xECB", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zydelig (idelalisib) is a medication used in the treatment of certain hematologic cancers. Here are some key points you should know about Zydelig:\n\n1. **Indications**: Zydelig is approved for the treatment of several types of blood cancers, including:\n   - Chronic lymphocytic leukemia (CLL) in patients who have received at least one prior therapy.\n   - Follicular B-cell non-Hodgkin lymphoma (FL) in patients who have relapsed after at least two prior systemic therapies.\n   - Small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.\n\n2. **Mechanism of Action**: Zydelig is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4), a protein that plays a significant role in the signaling pathways involved in cell growth, survival, proliferation, and differentiation in B-cells. By inhibiting PI3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IYYP8Dv7ptOcujZTqDv2VlJ7", "custom_id": "497_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c76a31b2da9dbd83e535a354b9780186", "body": {"id": "chatcmpl-9St4eZjnyJ723xqdBnxpF7qm5rTrB", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Alquimid\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a substance not approved or recognized by major medical regulatory bodies such as the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency).\n\nIf \"Alquimid\" is a new or experimental drug, or if it is a drug marketed in a specific region outside of the major Western pharmaceutical markets, it would be important to consult the latest medical literature or drug regulatory updates for information. Alternatively, it could be a trade name or a name used in traditional or alternative medicine in certain cultures.\n\nFor accurate and professional advice, consider the following steps:\n1. Verify the spelling of the drug.\n2. Check the most recent and reputable medical and pharmacological databases.\n3. Consult with pharmacists or other medical professionals in your network.\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r9hLeS5uNlZGE1jGtNUjjq9C", "custom_id": "498_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "64888c3f0a47660a3b5db37bb35fb75b", "body": {"id": "chatcmpl-9St4ebZTEv3UZuteIGMRMAGZInDK9", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Enliven\" does not refer to a specific medication, treatment, or technology that is universally recognized in the medical community. It's possible that \"Enliven\" could be a brand name for a product, a service, or a concept in a specific region or within a particular health system that I'm not aware of. It could also be related to wellness programs, health supplements, or similar areas.\n\nIf \"Enliven\" is related to a specific new drug, device, or medical technology, it would be important to look at the following aspects:\n\n1. **Clinical Trials**: Review any clinical trial data available regarding its efficacy, safety, and recommended uses.\n\n2. **FDA Approval**: Check if the product has been approved by the Food and Drug Administration (FDA) or any other relevant regulatory body, depending on your location.\n\n3. **Indications**: Understand what medical conditions or symptoms the product is indicated for.\n\n4. **Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RzaCL5aytFCxHkdIqu1iRpam", "custom_id": "499_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "53f3b7f051746acc787ff27c854591b3", "body": {"id": "chatcmpl-9St4edtSHNR1iWctfcWl3dptAc13J", "object": "chat.completion", "created": 1716671916, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiq (infigratinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that harbors a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Here are some key points you should know about Truseltiq:\n\n1. **Mechanism of Action**: Truseltiq is an FGFR inhibitor. It works by targeting and inhibiting the activity of FGFR2 gene fusions and other FGFR alterations, which are known to drive cancer development in some cases of cholangiocarcinoma.\n\n2. **Indications**: It is specifically indicated for patients who have previously received treatment and whose tumors have an FGFR2 fusion or rearrangement, as identified by an FDA-approved test. It is not suitable for patients without these genetic alterations"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_n5WBoNp3YKDHXPI5vNilf8ut", "custom_id": "500_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d06a256705f4a3cf5b18efedf14ca7a6", "body": {"id": "chatcmpl-9St4fUbujxTWQUxqxcxJhKg414207", "object": "chat.completion", "created": 1716671917, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (inotuzumab ozogamicin) is a targeted therapy used in the treatment of certain types of B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Besponsa:\n\n1. **Indications**: Besponsa is approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is particularly used in cases where other treatments have failed or the disease has returned after treatment.\n\n2. **Mechanism of Action**: Inotuzumab ozogamicin, the active component of Besponsa, is a monoclonal antibody-drug conjugate. The monoclonal antibody specifically targets CD22, a protein expressed on the surface of B-cell precursors. Once bound, the conjugate is internalized and releases its cytotoxic agent, calicheamicin, which induces double-strand DNA breaks, leading to cell death.\n\n3. **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_sOLew6keutPJLoFuny7cJ2jf", "custom_id": "501_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a60139f5409ccb93d99b2c4e81294ffa", "body": {"id": "chatcmpl-9St4fi9Le6TQpkLLrGhApCfmpen4Q", "object": "chat.completion", "created": 1716671917, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Laroferon\" in standard medical references or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf \"Laroferon\" is a new or experimental drug, it would be important to consult the latest clinical trials, pharmaceutical updates, or drug approval announcements from regulatory bodies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) for accurate and up-to-date information.\n\nIf you have more specific information or a different spelling, I can try to help further. Additionally, checking with a pharmacist or consulting medical literature databases such as PubMed could provide more insights."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 161, "total_tokens": 203}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nmaxH4zUZqPS3owGkA4r6OCo", "custom_id": "502_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "005fde7d455cae0324803258c2b496f4", "body": {"id": "chatcmpl-9St4f4PF8xf9SpQRCWdXi8ppcudry", "object": "chat.completion", "created": 1716671917, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Advaferon\" is not recognized as a standard medication or treatment in the medical community. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet established in the medical literature.\n\nIf you are referring to a specific new treatment or drug, I recommend checking the most current medical databases, pharmaceutical registries, or drug approval agencies such as the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) for the latest information. Additionally, consulting peer-reviewed journals or attending medical conferences might provide updated insights into new treatments and drugs including their efficacy, safety profiles, and therapeutic indications.\n\nIf you provide more specific information or a different name, I could attempt to offer more detailed assistance."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 163, "total_tokens": 205}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5qXCYk8E6FYdiaRwW2Zu309z", "custom_id": "503_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a20a5acdbde658cacf6260822f9f664a", "body": {"id": "chatcmpl-9St4fW3tezqBKBoPZ4qqXiIxIiMgR", "object": "chat.completion", "created": 1716671917, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (interferon gamma-1b) is a medication used primarily to reduce the frequency and severity of serious infections associated with chronic granulomatous disease (CGD), a rare genetic disorder that affects the immune system. It is also indicated for delaying disease progression in severe, malignant osteopetrosis.\n\nHere are some key points about Actimmune:\n\n1. **Mechanism of Action**: Actimmune is a synthetic version of interferon gamma, a naturally occurring protein that modulates the activity of the immune system. It enhances the functioning of phagocytes and macrophages, which are crucial in fighting infections.\n\n2. **Administration**: Actimmune is administered by subcutaneous injection. It is typically dosed three times per week, and the dosing may vary based on the patient's weight and the specific condition being treated.\n\n3. **Side Effects**: Common side effects include flu-like symptoms such as fever, headache, chills, myalgia, or fatigue. These"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_sYoDAgCCWKrQOKpgqjnX16vc", "custom_id": "504_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b40026e05f748dd6a00fcb383a884f37", "body": {"id": "chatcmpl-9St4gjXUNU4E84BSq35wF2s1ykDjS", "object": "chat.completion", "created": 1716671918, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (ipilimumab) is a monoclonal antibody used in the treatment of melanoma and other types of cancer. It is specifically designed to inhibit cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, Yervoy enhances the body's immune response against tumor cells. Here are some key points you should know about Yervoy:\n\n1. **Indications**: Yervoy is approved for the treatment of metastatic melanoma and as adjuvant therapy for melanoma with a high risk of recurrence following surgery. It has also been studied and used in other cancers, including renal cell carcinoma and non-small cell lung cancer.\n\n2. **Mechanism of Action**: Yervoy works by blocking CTLA-4, a protein that normally helps keep immune responses in check. By blocking CTLA-4, Yervoy boosts the immune system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W8VNnJxqBUDgYEqJKkfSXYYY", "custom_id": "505_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e4c288b501852731f60da40ffb95e3d7", "body": {"id": "chatcmpl-9St4ggtK0zKfhiLta9vC4i9r6iHze", "object": "chat.completion", "created": 1716671918, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of any medication you prescribe, including Axinotecan. However, it seems there might be a typo or confusion in the drug name you've mentioned, as \"Axinotecan\" does not correspond to any known medication. You might be referring to \"Irinotecan,\" which is a commonly used chemotherapeutic agent. Here\u2019s an overview of Irinotecan:\n\n**Irinotecan (CPT-11)**\n\n1. **Mechanism of Action**:\n   - Irinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that facilitates the unwinding of DNA for replication. By inhibiting this enzyme, Irinotecan prevents DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Irinotecan is primarily used in the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_Z3yS6Vp5oUBvhl1tsyuc0T2V", "custom_id": "506_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24a2fc0bbdd1889aeb85d2763e6d7145", "body": {"id": "chatcmpl-9St4gJFSYXJQGcASIAZtTrPoUe33p", "object": "chat.completion", "created": 1716671918, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onivyde, also known by its generic name irinotecan liposome injection, is a chemotherapy drug used primarily in the treatment of pancreatic cancer. Here are some key points you should know about Onivyde:\n\n1. **Indications**: Onivyde is approved for use in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.\n\n2. **Mechanism of Action**: Onivyde is a liposomal formulation of irinotecan. The encapsulation in liposomes allows for a prolonged circulation time and increased tumor uptake, which enhances the delivery of irinotecan to the tumor site. Irinotecan itself is a prodrug that is converted in the body to its active metabolite, SN-38, which inhibits the enzyme topoisomerase I. This inhibition leads to DNA damage and cell death, particularly in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Cul3XwXfXxQPLIzs4Ckgqf32", "custom_id": "507_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e8043a0362d2cf19ea8baf8ef963793", "body": {"id": "chatcmpl-9St4h2SqEV3JrFThHb5u2RQwsDIqD", "object": "chat.completion", "created": 1716671919, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa (isatuximab) is a monoclonal antibody medication used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Sarclisa:\n\n1. **Indications**: Sarclisa is approved for use in combination with other medications for the treatment of multiple myeloma. Specifically, it is used in adult patients who have received at least one prior therapy. The combinations include:\n   - Sarclisa with pomalidomide and dexamethasone (for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor).\n   - Sarclisa with carfilzomib and dexamethasone (for patients who have received one to three prior lines of therapy).\n\n2. **Mechanism of Action**: Isatuximab works by targeting a specific protein called CD38, which is highly expressed on the surface of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9Hqk6AuDMIqH1JskD954XHB5", "custom_id": "508_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c21275e1879146a033b8871f3900e8c5", "body": {"id": "chatcmpl-9St4hxyTkaPKksFtMCjY2XRuaMaIg", "object": "chat.completion", "created": 1716671919, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Absorica is a brand name for isotretinoin, a potent form of vitamin A used primarily to treat severe nodular acne that has not responded to other treatments such as antibiotics. Here are some key points you should know about Absorica:\n\n1. **Indications**: Absorica is specifically indicated for the treatment of severe recalcitrant nodular acne. It is typically considered when other treatments, including systemic antibiotics, have failed.\n\n2. **Mechanism of Action**: Isotretinoin works by reducing the production of sebum (an oily substance that can lead to acne when overproduced), shrinking the size of the oil glands, inhibiting the growth of acne-causing bacteria, and reducing inflammation.\n\n3. **Administration**: Absorica is unique among isotretinoin products because it uses a proprietary formulation that improves the absorption of isotretinoin without the need for a high-fat meal. It should be taken as directed by the prescribing physician,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QqyL0V26FmGf9fg3VJj6R9br", "custom_id": "509_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f574cb454e1b857413cda439d736a8d", "body": {"id": "chatcmpl-9St4ha5CKRnxV9JPAfK1IA0mpJmRQ", "object": "chat.completion", "created": 1716671919, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tibsovo (generic name: ivosidenib) is an oral medication used in the treatment of certain types of cancer. It is specifically approved for the treatment of adult patients with acute myeloid leukemia (AML) that exhibits a specific genetic mutation in the isocitrate dehydrogenase-1 (IDH1) gene. This mutation must be detected by an FDA-approved test to confirm eligibility for treatment with Tibsovo.\n\nHere are some key points about Tibsovo:\n\n1. **Mechanism of Action**: Tibsovo works by inhibiting the enzyme IDH1, which in its mutated form promotes the growth of cancer cells by altering their metabolic and epigenetic regulation. By inhibiting this enzyme, Tibsovo can help to reduce the proliferation of cancer cells and induce differentiation.\n\n2. **Indications**:\n   - Tibsovo is approved for the treatment of AML in adult patients with an IDH1 mutation as detected by an FDA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_az4ZFXHJYSG4laYch6gYJIWC", "custom_id": "510_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "caceed8f28a599595d00f1da3b056d0f", "body": {"id": "chatcmpl-9St4hULiH9FWZFkDFFwxraNBgGeaq", "object": "chat.completion", "created": 1716671919, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (ixabepilone) is a chemotherapy medication used primarily in the treatment of breast cancer. Here are some key points you should know about Ixempra:\n\n1. **Mechanism of Action**: Ixempra is a microtubule inhibitor that belongs to a class of drugs known as epothilones. It works by stabilizing microtubules, thereby inhibiting their depolymerization which leads to G2/M phase cell cycle arrest and apoptosis (cell death).\n\n2. **Indications**: Ixempra is approved for the treatment of metastatic or locally advanced breast cancer. It is used in patients who have previously received an anthracycline and a taxane, either in the adjuvant or metastatic setting, and have developed resistance or relapsed.\n\n3. **Administration**: Ixempra is administered intravenously. The dosing regimen typically involves administration every three weeks, but the exact dosage and schedule can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G7k9dbbqm4jbYFDpsXrlnm4J", "custom_id": "511_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "03f8a3ad576dd021347711e640014a96", "body": {"id": "chatcmpl-9St4h6EbXA8mL8XDmccWGjIXSvo1Y", "object": "chat.completion", "created": 1716671919, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ninlaro (ixazomib) is an oral medication used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Ninlaro:\n\n1. **Mechanism of Action**: Ninlaro is a proteasome inhibitor. It works by blocking the activity of proteasomes, which are enzyme complexes that play a crucial role in cell function by breaking down proteins that are damaged or no longer needed. Inhibiting proteasomes causes an accumulation of proteins within cells, which can lead to cell death, particularly in myeloma cells which are more sensitive to protein buildup.\n\n2. **Indications**: Ninlaro is approved for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. This combination has been shown to be effective in improving progression-free survival in this patient population.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6IodqlVOrnQT1PDM7B5w2ndR", "custom_id": "512_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9397fdb0a44f35a479f23a58fd960d94", "body": {"id": "chatcmpl-9St4ibIrSI8KUlV0OXxT5fAnEfkjM", "object": "chat.completion", "created": 1716671920, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizoral is a brand name for the antifungal medication ketoconazole. It is primarily used to treat fungal infections where other antifungal treatments have failed or are not tolerated by the patient. Here are some key points you should know about Nizoral as a physician:\n\n1. **Indications**: Nizoral is used to treat various fungal infections, including candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, tinea corporis, tinea cruris, tinea pedis, and seborrheic dermatitis. It is also used to treat systemic fungal infections such as paracoccidioidomycosis, blastomycosis, and histoplasmosis when other treatments are not effective or suitable.\n\n2. **Mechanism of Action**: Ketoconazole works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. Without ergosterol, the cell membrane becomes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aAaHPNVDxJp2B0Zz9t73tsYm", "custom_id": "513_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "181b02230366545fccd9aa46c5e66ac5", "body": {"id": "chatcmpl-9St4itpgpqFmcZftNX1EpjNPv8Ir4", "object": "chat.completion", "created": 1716671920, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Ipstyl\" does not appear to be a widely recognized medication or treatment in the medical community. It's possible that the name might be misspelled, a brand name not available in certain regions, or a very new product not yet widely documented.\n\nIf \"Ipstyl\" refers to a specific drug or treatment you are inquiring about, I recommend checking the most current medical databases, pharmaceutical references, or regulatory agency databases for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other healthcare professionals might provide more insights.\n\nIf you provide more context or details, I might be able to offer more specific guidance or check if there is an alternative spelling or similar-sounding medication that you might be referring to."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 153, "total_tokens": 193}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IsZqC7jYJzZV7QiBZ9uRqBdJ", "custom_id": "514_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "87c3b187d0e93a10964548d700b95ea3", "body": {"id": "chatcmpl-9St4ilDcLIpgv1k0SkSsd28s7nKb6", "object": "chat.completion", "created": 1716671920, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prevacid is the brand name for lansoprazole, a proton pump inhibitor (PPI) used primarily to treat gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome. Here are some key points you should know about Prevacid:\n\n1. **Mechanism of Action**: Lansoprazole works by inhibiting the H+/K+ ATPase pump in the gastric parietal cells, reducing the production of stomach acid.\n\n2. **Indications**:\n   - Treatment of active duodenal ulcers\n   - Treatment of active gastric ulcers\n   - Management of GERD\n   - Treatment of erosive esophagitis\n   - Maintenance of healed erosive esophagitis\n   - Treatment of symptomatic GERD\n   - Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rvSCyBgh5T9BYvHs1pffezEB", "custom_id": "515_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8bb8724285fcd531da728f5ce8cef5b8", "body": {"id": "chatcmpl-9St4i184asWXOYOuRiVqlnl7uDevn", "object": "chat.completion", "created": 1716671920, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Abnib\" does not correspond to any known medication, medical condition, or term commonly recognized in the healthcare field. It's possible that there might be a spelling error or that the term is very new, obscure, or specific to a certain region or specialty that hasn't become widely recognized yet.\n\nIf you could provide more context or clarify the term, I would be better able to assist you. If \"Abnib\" refers to a drug, a disease, a medical device, or any other healthcare-related topic, additional information would be helpful to provide an accurate and helpful response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 133, "total_tokens": 174}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AHv00GXbOaeQnRScvzYEHaxO", "custom_id": "516_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22b02156d9d8d088dd9fd8c0fdd0d59f", "body": {"id": "chatcmpl-9St4jOMQrVHvQeA8iLUa4TJDIDRkq", "object": "chat.completion", "created": 1716671921, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vitrakvi (larotrectinib) is a medication used in the treatment of cancer. It is specifically designed to target and inhibit certain proteins (tropomyosin receptor kinases or TRKs) that drive the growth and spread of cancer cells. Here are some key points you should know about Vitrakvi:\n\n1. **Indication and Usage**: Vitrakvi is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. These tumors must be either metastatic or where surgical resection is likely to result in severe morbidity, and there should be no satisfactory alternative treatments or the cancer has progressed following treatment.\n\n2. **Mechanism of Action**: Larotrectinib is a selective inhibitor of the TRK family of receptors (TRKA, TRKB, and TRKC), which can become oncogenic as a result of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_AA0ubln8Y371vLq8RRCF1HnV", "custom_id": "517_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "620386330f237bb9ecc3ad2e2dbca2b8", "body": {"id": "chatcmpl-9St4jolmg3uti5cse8VsubOwUORF7", "object": "chat.completion", "created": 1716671921, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Adlinod.\" It's possible that the name might be misspelled, a new drug not yet widely documented, or a brand name not commonly known. To provide accurate information, I would need the correct name or more context about the drug. If it's a new or experimental drug, I recommend checking the latest medical literature, clinical trial registries, or drug databases for the most current information. Always ensure to use reliable sources or consult with pharmaceutical databases or colleagues in pharmacology for the most accurate and up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 123, "total_tokens": 164}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W6X3MxbhRfe99IXy5dXahwYF", "custom_id": "518_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "67494e60eede9b75fd1b925e3d6f4505", "body": {"id": "chatcmpl-9St4jwLp06kdovb8qHtq8EZFfb1jH", "object": "chat.completion", "created": 1716671921, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for lenograstim, which is a recombinant human granulocyte colony-stimulating factor (G-CSF). It is primarily used to stimulate the production of white blood cells (neutrophils) and is often prescribed to prevent or treat neutropenia, particularly in patients undergoing chemotherapy or bone marrow transplantation. Here are some key points you should know about Granocyte:\n\n1. **Indications**: Granocyte is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes) and to reduce the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation. It is also used for the mobilization of peripheral blood progenitor cells (PBPCs). In some countries, it may be used for treating severe chronic neutrop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Qb03LJy38K3Db9zH233L59gQ", "custom_id": "519_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "604f478723ef0c14ed184f5ba183791f", "body": {"id": "chatcmpl-9St4jvYPgQPBJ2EJEEdZxAJIwXNpS", "object": "chat.completion", "created": 1716671921, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisplyx (lenvatinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Kisplyx:\n\n1. **Indications**: Kisplyx is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), particularly in combination with everolimus after one prior anti-angiogenic therapy. It is also used for the treatment of hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib.\n\n2. **Mechanism of Action**: Lenvatinib, the active ingredient in Kisplyx, is a multi-targeted tyrosine kinase inhibitor. It inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3. These receptors play a key role in angiogenesis, the process by which tumors develop their own blood supply. By inhibiting these receptors, lenvatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3KfesVUNxoi3byND9yLX8S2U", "custom_id": "520_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f61592d7f148567af01fbca10bb0cf98", "body": {"id": "chatcmpl-9St4kSpfTo9MyOyzWjvbGpUsvTgCF", "object": "chat.completion", "created": 1716671922, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, which is the brand name for letrozole, is an oral medication primarily used as a treatment for breast cancer. Here are some key points you should know about Femara:\n\n1. **Classification**: Femara belongs to a class of drugs known as aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body, which can help slow or reverse the growth of certain types of breast cancer cells that require estrogen to grow.\n\n2. **Indications**: It is commonly prescribed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It may be used as first-line therapy or following other treatments such as surgery or radiation. Additionally, letrozole is sometimes used in women with advanced breast cancer that has progressed after treatment with tamoxifen.\n\n3. **Dosage and Administration**: The typical dose of Femara is 2.5 mg taken once daily, with or without food. It's important to take it at the same"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_09fTfN6kzLXMCIIA2H9KJoDo", "custom_id": "521_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7265cc691809f129eabfd0859693bdca", "body": {"id": "chatcmpl-9St4kO55l6q0tXx8RaG8OYhgOBBjo", "object": "chat.completion", "created": 1716671922, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camcevi (leuprolide mesylate) is a medication used in the treatment of advanced prostate cancer in adult patients. It is a gonadotropin-releasing hormone (GnRH) receptor agonist, which works by reducing the amount of testosterone produced by the testes. Lowering testosterone levels is a common approach in managing prostate cancer, as it can help slow the growth and progression of the disease.\n\nHere are some key points about Camcevi:\n\n1. **Formulation and Administration**: Camcevi is administered as a subcutaneous injection. It is available in a formulation that allows for dosing every 6 months, which can be convenient for patients and may improve adherence to treatment.\n\n2. **Mechanism of Action**: As a GnRH agonist, Camcevi initially increases the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary rise in testosterone levels (known as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SOZ9iYN8HdwawqeO2CJQZI8W", "custom_id": "522_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b0ae9438ac227e639e414dbf9af43c0a", "body": {"id": "chatcmpl-9St4kbOt6t6P91A39PSxWuQ3I346l", "object": "chat.completion", "created": 1716671922, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ergamisol, known generically as levamisole, is a medication that was originally used as an anthelmintic to treat worm infestations in humans and animals. However, its use in humans has largely been discontinued in many countries due to its side effects, although it is still used in veterinary medicine.\n\nHere are some key points you should know about levamisole:\n\n1. **Medical Uses**: Historically, levamisole was used to treat conditions such as colon cancer, melanoma, and head and neck cancer due to its immune-modulating properties. It was also used to treat rheumatoid arthritis and nephrotic syndrome.\n\n2. **Mechanism of Action**: Levamisole works as an immunomodulator and can stimulate the immune system. It also has antihelminthic properties, which make it effective against parasitic worms.\n\n3. **Side Effects**: Levamisole can cause a range of side effects, some of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PexsF9mPzqSKvfiI5bgVoerl", "custom_id": "523_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8a52009219e5b47ec5dc55079a220d0", "body": {"id": "chatcmpl-9St4l3SUNO5KhaukGPyQW8XVYaZJx", "object": "chat.completion", "created": 1716671923, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fusilev (levoleucovorin) is a chemically reduced derivative of folic acid used primarily in the treatment of cancer. It is the pharmacologically active isomer of leucovorin (5-formyl tetrahydrofolate). Here are some key points you should know about Fusilev:\n\n1. **Indications**:\n   - Fusilev is approved for use in combination with 5-fluorouracil to treat patients with metastatic colorectal cancer.\n   - It is also used to counteract the toxic effects of methotrexate in patients with osteosarcoma who have received high-dose methotrexate therapy.\n\n2. **Mechanism of Action**:\n   - Fusilev enhances the cytotoxic effects of 5-fluorouracil by stabilizing the binding of 5-fluorouracil to thymidylate synthase, thereby inhibiting DNA synthesis in rapidly dividing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UXbrOgVUFCDM2K07FVRaixF0", "custom_id": "524_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d2f32034b5dedb9efafb43ea4e57c5ef", "body": {"id": "chatcmpl-9St4lsdX7UkSQeZml6PoTumbx82Bk", "object": "chat.completion", "created": 1716671923, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu, which is the brand name for lomustine, is a chemotherapy drug used primarily to treat various types of cancer, including brain tumors, Hodgkin's lymphoma, and other malignancies. It belongs to a class of drugs known as alkylating agents, which work by damaging the DNA of cancer cells, thereby inhibiting their ability to reproduce and grow.\n\nHere are some key points you should know about CeeNu (lomustine):\n\n1. **Indications**: Lomustine is commonly used for the treatment of brain tumors (both primary and metastatic), Hodgkin\u2019s lymphoma, and other types of cancer. It may be used alone or in combination with other chemotherapy drugs.\n\n2. **Administration**: Lomustine is taken orally in capsule form. The dosing schedule can vary depending on the specific condition being treated, the patient's response to therapy, and their overall health. It is typically given in cycles with a rest period in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vKQv9C6sebBZenqRD68tqUZp", "custom_id": "525_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f26d514a916bf6ceaf301208e65ab138", "body": {"id": "chatcmpl-9St4mIWALybFI6tbS9yy10L621EpL", "object": "chat.completion", "created": 1716671924, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (lorlatinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. Here are some key points you should know about Lorbrena:\n\n1. **Indications**: Lorbrena is specifically indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib and at least one other ALK inhibitor for metastatic disease, or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.\n\n2. **Mechanism of Action**: Lorbrena is a third-generation ALK tyrosine kinase inhibitor (TKI). It works by targeting and inhibiting the activity of the ALK protein, which can contribute to the growth and development of cancer cells in ALK-positive NSCLC.\n\n3. **Administration**: Lorbrena is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hco3eIrPUQi28XVPitoNUtmQ", "custom_id": "526_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a166e03c485d0fa902b3e45f53574864", "body": {"id": "chatcmpl-9St4mSWkKVhSHiO1JXd6aUfPjVjCn", "object": "chat.completion", "created": 1716671924, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera (lutetium Lu 177 dotatate) is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs), specifically those that are somatostatin receptor-positive. Here are some key points you should know about Lutathera:\n\n1. **Indications**: Lutathera is approved for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in the United States and Europe.\n\n2. **Mechanism of Action**: Lutathera works as a radiolabeled somatostatin analog. The active substance, lutetium Lu 177 dotatate, targets somatostatin receptors (primarily subtype 2), which are commonly overexpressed in certain types of NETs. After binding to these receptors, the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qB68LLhNRJq7SO4ao4EJDLoH", "custom_id": "527_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a75b95f9c9217a8ac739b347018bbe3b", "body": {"id": "chatcmpl-9St4n1nli7ougaQ8ZU2yROI16bQ74", "object": "chat.completion", "created": 1716671925, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (tafasitamab-cxix) is a monoclonal antibody used in the treatment of certain types of cancer, specifically for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Minjuvi:\n\n1. **Indication and Usage**: Minjuvi, in combination with lenalidomide, is approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).\n\n2. **Mechanism of Action**: Tafasitamab is a CD19-directed cytolytic antibody. CD19 is a protein expressed on the surface of B-cells, a type of white blood cell that can become cancerous in DLBCL. Tafasitamab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_5FcgptDA4izMjzOIm7FpezHa", "custom_id": "528_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3797ab08ddd42493d2f2550194b04f70", "body": {"id": "chatcmpl-9St4nR3AMf1gBz383WluOMAtXTYOh", "object": "chat.completion", "created": 1716671925, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ledaga (chlormethine, also known as mechlorethamine) is a topical gel used for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare type of non-Hodgkin lymphoma that primarily affects the skin. Here are some key points you should know about Ledaga:\n\n1. **Indication**: Ledaga is specifically indicated for the topical treatment of MF-CTCL in adult patients. This medication is used for patients with Stage IA and IB disease who have received prior skin-directed therapy.\n\n2. **Mechanism of Action**: Chlormethine, the active ingredient in Ledaga, is a nitrogen mustard compound that has alkylating activity. It works by cross-linking DNA strands in cancer cells, which inhibits their replication and leads to cell death.\n\n3. **Application**: Ledaga gel is applied once daily to the affected areas of the skin. It is important to follow specific guidelines"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_daV9tnpW6TFO2geRkPbr0xRT", "custom_id": "529_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "daeefde13ddde7ba3f3326be45ba4c75", "body": {"id": "chatcmpl-9St4nweRi3LpUoNdgmIradPaXorIP", "object": "chat.completion", "created": 1716671925, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera, also known as depot medroxyprogesterone acetate (DMPA), is a hormonal contraceptive injection that contains the progestin medroxyprogesterone acetate. It is administered every three months, typically in the muscle or under the skin, and is highly effective in preventing pregnancy. Here are some key points you should know about Depo-Provera as a physician:\n\n1. **Mechanism of Action**:\n   - Depo-Provera works primarily by preventing ovulation. It also thickens cervical mucus to prevent sperm from reaching the egg and thins the lining of the uterus, which may prevent implantation of a fertilized egg.\n\n2. **Efficacy**:\n   - Depo-Provera is a highly effective contraceptive method when used correctly. The failure rate is approximately 0.2% in the first year of use with perfect use, but typical use failure rate is around 6% due to delays"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r5TudZLzvFjAj2B4bKnJVxQM", "custom_id": "530_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6bfeed2dbcaa37b91c0046cc3ad76611", "body": {"id": "chatcmpl-9St4n3UTVfvDWdEhDAwW47iDwB0ll", "object": "chat.completion", "created": 1716671925, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Maygace is a brand name for the drug megestrol acetate, which is a synthetic derivative of the hormone progesterone. It is primarily used as an appetite stimulant and for weight gain in patients experiencing severe weight loss associated with conditions such as AIDS or cancer. Megestrol acetate works by mimicking the effects of natural progesterone, which can help to increase appetite and body weight.\n\nHere are some key points you should know about Maygace:\n\n1. **Indications**: Maygace is often prescribed for the management of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of AIDS or cancer. It is also used in the treatment of advanced breast cancer and endometrial cancer.\n\n2. **Mechanism of Action**: Megestrol acetate primarily acts as a progesterone agonist. Its appetite-stimulating effects are believed to be mediated through its action on the hypothalamus to increase"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h4QDUBhArJWhgiWzI5vRgaJB", "custom_id": "531_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c2f7de2c7d3857fde0b8a86e465f84c5", "body": {"id": "chatcmpl-9St4oNTYUWitzqvCH5eMvUUwVnQfB", "object": "chat.completion", "created": 1716671926, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, which is the brand name for melphalan, is a chemotherapy drug used primarily to treat multiple myeloma, ovarian cancer, and amyloidosis. It belongs to the class of drugs known as alkylating agents, which work by binding to DNA and preventing the cancer cells from multiplying, leading to cell death.\n\nHere are some key points you should know about Alkeran:\n\n1. **Indications**: Alkeran is used in the treatment of multiple myeloma, ovarian cancer, and for palliative treatment of other malignancies. It is also used in conditioning regimens prior to hematopoietic progenitor (stem) cell transplantation.\n\n2. **Administration**: Melphalan is available in both oral and intravenous formulations. The route of administration depends on the specific condition being treated and the overall treatment plan.\n\n3. **Dosage**: The dosage of Alkeran varies depending on the condition being treated, the formulation used, patient body size,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VnrMsgooL3FFjDif1A07Dipz", "custom_id": "532_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab3db638416bee3518688900a5144f98", "body": {"id": "chatcmpl-9St4opwE50DNPSbNFAKbVx2PUh8u9", "object": "chat.completion", "created": 1716671926, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol, the brand name for mercaptopurine, is a medication primarily used in the treatment of cancer, specifically acute lymphoblastic leukemia (ALL). It is also used for certain autoimmune diseases, such as inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, when other treatments have not been effective. Here are some key points you should know about Purinethol:\n\n1. **Mechanism of Action**: Mercaptopurine is a purine analog that interferes with nucleic acid synthesis, leading to inhibition of DNA, RNA, and protein synthesis. This action makes it effective in both neoplastic and immune cells.\n\n2. **Indications**: While its primary indication is for the treatment of ALL, it is also used off-label for managing certain autoimmune disorders.\n\n3. **Administration**: Mercaptopurine is typically administered orally. The dosage and duration of treatment depend on the patient's condition, response to treatment, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lk6Y5QBEh8Kc4rRMvE8tNw3k", "custom_id": "533_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc2d42d23bb7d9d8cda1d3c15cc8c886", "body": {"id": "chatcmpl-9St4oYGmEHq4pxBfSNArxKg6AlETj", "object": "chat.completion", "created": 1716671926, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medication or substance known as \"Anti Uron\" in standard medical practice or pharmacology. It's possible that there might be a typo or a misunderstanding regarding the name. It could also be a brand name or a term not widely recognized.\n\nIf you are referring to a specific treatment, drug, or concept that might be new or less known, I recommend checking the most recent medical literature, databases like PubMed, or drug information databases for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals might provide more insight.\n\nIf you can provide more context or details, I might be able to offer more specific assistance or direct you to relevant resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 146, "total_tokens": 187}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ed1pOGhO25fPhym40S81Unki", "custom_id": "534_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "93fed9774d65892d01260e036c752175", "body": {"id": "chatcmpl-9St4ojs9lHfSohqJtqGJ6AXm38PfG", "object": "chat.completion", "created": 1716671926, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication commonly used in the treatment of various medical conditions, including certain types of cancer, rheumatoid arthritis, and psoriasis. Here are some key points you should know about methotrexate when prescribing or managing treatment:\n\n1. **Mechanism of Action**: Methotrexate is a folate analog that inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell replication. This action is particularly effective in rapidly dividing cells, such as cancer cells.\n\n2. **Indications**:\n   - **Oncology**: Used for treating certain types of cancers such as breast cancer, leukemia, and lymphoma.\n   - **Rheumatology**: Effective in managing rheumatoid arthritis, where it can reduce inflammation and slow disease progression.\n   - **Dermatology**: Used for severe psoriasis to control the speed of skin cell growth.\n\n3. **Administration**: Meth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ezkv0CSpLql5OCRE7qUqVsmh", "custom_id": "535_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "758544a0cc53f693f2f3c00421fbd2b9", "body": {"id": "chatcmpl-9St4pXItrzlBJ2iwxWubdfbrzj1fR", "object": "chat.completion", "created": 1716671927, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ammoidin, also known as xanthotoxin or methoxsalen, is a drug used primarily in the treatment of skin disorders such as psoriasis, vitiligo, and eczema. It belongs to a group of natural products known as furocoumarins. Ammoidin is used in combination with ultraviolet (UV) light in a treatment process called PUVA (psoralen and UVA therapy).\n\nHere are some key points you should know about Ammoidin:\n\n1. **Mechanism of Action**: Ammoidin intercalates into DNA and, upon exposure to UVA light, forms cross-links with the DNA. This inhibits DNA synthesis and cell division, reducing the proliferation of skin cells, which is particularly useful in conditions like psoriasis.\n\n2. **Indications**: It is primarily used for severe psoriasis that does not respond to other treatments. It is also used for vitiligo to increase skin re-pigmentation and for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WWnZoPRzqCRpH2HZcV6RdZVP", "custom_id": "536_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "11cd6a3583547c191c058fc529ec2d03", "body": {"id": "chatcmpl-9St4ptKdjqSTd5AdKKTxZLXZC0Jy9", "object": "chat.completion", "created": 1716671927, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adlone is a brand name for a medication that contains methylprednisolone, which is a corticosteroid used to reduce inflammation and suppress the immune system. It is commonly prescribed for a variety of conditions, including autoimmune disorders, allergic reactions, and other inflammatory conditions.\n\nHere are some key points you should know about Adlone (methylprednisolone):\n\n1. **Indications**: Adlone is used to treat conditions such as asthma, allergic reactions, rheumatoid arthritis, lupus, adrenal insufficiency, and certain types of arthritis. It is also used in the management of acute exacerbations of multiple sclerosis and other inflammatory conditions.\n\n2. **Mechanism of Action**: Methylprednisolone works by mimicking the effects of cortisol, a naturally occurring steroid hormone. It decreases inflammation and modifies the body's immune response.\n\n3. **Administration**: It can be administered orally, intravenously, or via intramuscular injection, depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_I3rogw0IUTXgu3Sr0TYR32Bi", "custom_id": "537_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6b13c40769d6f12e0ca668723025e67e", "body": {"id": "chatcmpl-9St4qZjqPSP5MMMmrZrplLSCCVsHG", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is a medication used in the treatment of certain types of blood cancers. It is specifically approved for use in adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Rydapt is used in combination with chemotherapy. It is also approved for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.\n\nHere are some key points about Rydapt:\n\n1. **Mechanism of Action**: Rydapt is a kinase inhibitor that works by blocking multiple enzymes that promote cell growth, including FLT3, which is commonly mutated in AML.\n\n2. **Administration**: Rydapt is taken orally, typically twice a day.\n\n3. **Side Effects**: Common side effects include nausea, vomiting, diarrhea, mucositis, headache, musculoskeletal pain,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_kCP54EUmMlvRgbi8DxKh4e7m", "custom_id": "538_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "12ae32138189ba9950fbb1007a88c999", "body": {"id": "chatcmpl-9St4qRJQovR3GfMmFugFz0QuPJPrC", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Lyomit\" in standard medical resources or databases. It's possible that the name could be a misspelling, a brand name not widely recognized, or a new drug not yet documented in common sources.\n\nIf \"Lyomit\" is a specific drug or treatment you've encountered, I recommend checking the following:\n\n1. **Spelling and Nomenclature**: Verify the spelling. It might be a brand name or an alternative name not widely used. Consider similar-sounding drugs or treatments.\n\n2. **Pharmacological Resources**: Consult up-to-date and reliable pharmacological databases or resources like the FDA website, WHO's list of essential medicines, or reputable medical journals.\n\n3. **Colleagues and Specialists**: Discuss with pharmacy colleagues or specialists in the field who might have more current information or context about new or less common treatments.\n\n4. **Continuing Education**: Stay updated through continuing medical education (CME"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_8hD3SnuaKfrcBNdRr8FE5NQT", "custom_id": "539_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7045147e4499f981add3a72051557e4f", "body": {"id": "chatcmpl-9St4qPWxtAVuDnxdRiwv2QCmnwnyR", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (mitotane) is a medication primarily used in the treatment of inoperable adrenal cortical carcinoma, a type of cancer that affects the adrenal glands. Here are some key points you should know about Lysodren:\n\n1. **Mechanism of Action**: Lysodren works by exerting a cytotoxic effect on the adrenal cortex. It selectively accumulates in the adrenal cortex and destroys the adrenal cells, which leads to decreased production of adrenal hormones.\n\n2. **Indications**: The primary indication for Lysodren is the treatment of inoperable adrenal cortical carcinoma. It may also be used off-label for the management of Cushing's syndrome when surgery is not an option.\n\n3. **Administration**: Lysodren is administered orally. The dosage and duration of treatment depend on the patient's response and tolerance to the medication. It is typically started at a lower dose, which is gradually increased based on patient tolerance and serum hormone levels.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zRwjho2EkcZdBBj6edBtdbXx", "custom_id": "540_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a4e366509b5663d1836029e8c50f4b8", "body": {"id": "chatcmpl-9St4q77gWoTOaHZxIz96tkQhUnvn6", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nitrol, commonly known as nitroglycerin, is a medication primarily used in the management of angina pectoris (chest pain) associated with coronary artery disease. Here are some key points you should know about Nitrol:\n\n1. **Mechanism of Action**: Nitroglycerin works by relaxing the smooth muscles of blood vessels, leading to vasodilation, particularly of the veins and, to a lesser extent, the arteries. This reduces myocardial oxygen demand by decreasing preload (via venous dilation) and afterload (through arterial dilation).\n\n2. **Indications**:\n   - **Acute Management of Angina Attacks**: It is used for quick relief of angina symptoms.\n   - **Prophylaxis of Angina**: It can be used before activities that may provoke angina.\n   - **Heart Failure Associated with Acute Myocardial Infarction**: It helps by reducing cardiac workload and improving blood flow.\n\n3. **Forms and Administration**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c0WVsDuxECukneeOAFInqIX5", "custom_id": "541_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "735e53eecc9f44ef87d5521e56a453c0", "body": {"id": "chatcmpl-9St4qqF63wgsDtp8QRJKiJ7JYVmdZ", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody used in the treatment of certain types of cancer, specifically adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS), which are types of cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about Poteligeo:\n\n1. **Mechanism of Action**: Mogamulizumab targets CC chemokine receptor 4 (CCR4) expressed on the surface of some cancer cells. By binding to CCR4, mogamulizumab mediates antibody-dependent cellular cytotoxicity (ADCC) against CCR4-expressing tumor cells, which helps in reducing the tumor burden.\n\n2. **Approval and Indications**: Poteligeo was approved by the U.S. Food and Drug Administration (FDA) in August 2018 for the treatment of adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_Xy4oOS8dJVIw6PH1i3tB5o4j", "custom_id": "542_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3be01e6ea44c5c25ad63b2eac8c228a5", "body": {"id": "chatcmpl-9St4qxK9ytGcqh81J9ZoEyObXH2SE", "object": "chat.completion", "created": 1716671928, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer, specifically hairy cell leukemia (HCL). Here are some key points you should know about Lumoxiti:\n\n1. **Indication**: Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.\n\n2. **Mechanism of Action**: Lumoxiti is a CD22-directed cytotoxin. It is composed of a recombinant immunotoxin: a fusion protein of a monoclonal antibody that targets CD22 (a cell surface antigen expressed on B lymphocytes) and a bacterial toxin (Pseudomonas exotoxin A). The drug binds to CD22 on B cells, is internalized,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_crRsaeGMoMkxkX1b2ibKrYgY", "custom_id": "543_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ee77483a7cc581afbdd0edd6eaa8874", "body": {"id": "chatcmpl-9St4rHJGYsX6rfEVCpc1atp4VhyiH", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine (nadroparin calcium) is a low molecular weight heparin (LMWH) used primarily for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in the management of unstable angina and non-Q wave myocardial infarction, as well as for the prevention of clotting during hemodialysis. Here are some key points you should know about Fraxiparine:\n\n1. **Mechanism of Action**: Fraxiparine works by enhancing the inhibition of Factor Xa and thrombin by antithrombin III. This prevents the conversion of fibrinogen to fibrin, which is a crucial step in the clotting cascade.\n\n2. **Indications**:\n   - Prevention of venous thromboembolic events in patients undergoing surgery who are at risk.\n   - Treatment of deep vein thrombosis with or without pulmonary embolism.\n   - Prevention of clot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tGGVZ1j4Seo0u8FlHYgTaVZY", "custom_id": "544_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e513423bce306e0aa9fbdf173c1263cf", "body": {"id": "chatcmpl-9St4r8L4tULHRCOZeV9LdlebknWDN", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a monoclonal antibody used in the treatment of cancer. It specifically targets the epidermal growth factor receptor (EGFR), which is often overexpressed in certain types of cancer cells. Here are some key points you should know about Portrazza:\n\n1. **Indication**: Portrazza is approved by the FDA for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for patients with non-squamous NSCLC.\n\n2. **Mechanism of Action**: Necitumumab binds to the EGFR on cancer cells, which is a receptor involved in the proliferation and survival of cancer cells. By binding to EGFR, necitumumab inhibits the receptor\u2019s activity, which can help in controlling tumor growth.\n\n3. **Administration**: Portrazza is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PKNO5UZYsfYoTCdf9z92gxzx", "custom_id": "545_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24b51f826b681673cc9cd1b720f050e2", "body": {"id": "chatcmpl-9St4rhWLIzMGyvxi3T8wYM32EOj83", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Aqupla\" in the context of healthcare or medicine. It's possible that the term might be a misspelling, a new development, or something not yet widely documented in mainstream medical literature.\n\nIf you are referring to a specific drug, treatment, or concept that might be new or emerging, I recommend checking the latest medical literature, clinical trial registries, or pharmaceutical updates for the most accurate and up-to-date information. Additionally, consulting databases like PubMed, the FDA website, or specific professional medical associations relevant to your field might provide more insights.\n\nIf you can provide more context or details, I might be able to assist you better."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 145, "total_tokens": 185}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YoCOhbP1UTyokLB4axFomRJo", "custom_id": "546_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "020067ecc80339e7e06d7632c7d7c417", "body": {"id": "chatcmpl-9St4r983fu7HEwWR5YHMvPfmmYLyP", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon (nelarabine) is a chemotherapy medication used primarily to treat certain types of leukemia and lymphoma, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that have not responded to or have relapsed after other treatments. Here are some key points about Arranon that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Nelarabine, the active ingredient in Arranon, is a prodrug of the deoxyguanosine analog 9-\u03b2-D-arabinofuranosylguanine (ara-G). Once administered, it is converted into ara-G, which then gets phosphorylated to ara-GTP. Ara-GTP accumulates in T-cells and disrupts DNA synthesis, leading to cell death. This selective toxicity in T-cells is due to their higher levels of activating enzymes compared to other cells.\n\n2. **Indic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nFL3YxbH3hGzwYbbfLGfgErJ", "custom_id": "547_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55c20129c942bcb88d0505ab27bed1b2", "body": {"id": "chatcmpl-9St4rM9NmUmFwNL1ZwOVNyD9g3X4D", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (neratinib) is a medication used primarily in the treatment of HER2-positive breast cancer. Here are some key points you should know about Nerlynx:\n\n1. **Indications**: Nerlynx is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. It is also used for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.\n\n2. **Mechanism of Action**: Neratinib is a tyrosine kinase inhibitor that irreversibly binds to HER1, HER2, and HER4, leading to inhibition of the proliferation of tumor cells that overexpress these receptors.\n\n3. **Dosage and Administration**: The typical dosage is 240 mg (six 40 mg tablets) taken orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kKP6o4hTfcjhNcZU8V1BfsVb", "custom_id": "548_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c6f9d6f3a96f2d73e177e17c02ce4532", "body": {"id": "chatcmpl-9St4rYNWlqdihIvzIc3DiTVdbiSn6", "object": "chat.completion", "created": 1716671929, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna (nilotinib) is a medication used primarily in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Tasigna as a physician:\n\n1. **Mechanism of Action**: Tasigna is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome in CML cells. By inhibiting this enzyme, Tasigna helps to stop the proliferation of cancer cells.\n\n2. **Indications**: It is approved for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive CML in the chronic phase, as well as for patients who have been previously treated with another BCR-ABL inhibitor, such as imatinib (Gleevec), and either did not respond to it or cannot tolerate it.\n\n3. **Dosage and Administration**: Tasigna is administered orally. The capsules should be taken on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3AyvTZYh21L0v6vujIPx9U0U", "custom_id": "549_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "31a40ee46e412e8b87871a495a309904", "body": {"id": "chatcmpl-9St4saTWlCY59gwmBpLuUcGCruc96", "object": "chat.completion", "created": 1716671930, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron, also known by its generic name nilutamide, is a medication primarily used in the treatment of prostate cancer. It belongs to a class of drugs known as nonsteroidal antiandrogens. Here are some key points you should know about Anandron:\n\n1. **Mechanism of Action**: Nilutamide works by blocking the action of androgens (male hormones) such as testosterone, which can promote the growth of prostate cancer cells. It does this by binding to androgen receptors in the prostate cancer cells, preventing natural androgens from binding.\n\n2. **Indications**: Anandron is typically used in combination with surgical castration for the treatment of metastatic prostate cancer (cancer that has spread to other parts of the body). It can help reduce the risk of disease progression and manage symptoms.\n\n3. **Administration**: It is usually administered orally, and the dosage may vary based on the specific needs and condition of the patient.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s03Cnl3ljXWNO45QCb2HhrNU", "custom_id": "550_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "276a4729f728f57b3da94e3733f77c0e", "body": {"id": "chatcmpl-9St4sB1yKu4BD3KHIRcYGLFTWdIyX", "object": "chat.completion", "created": 1716671930, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Nidran\" does not appear to be a recognized medication, treatment, or medical condition in standard medical resources or literature. It's possible that it could be a term that is not widely recognized, a brand name not commonly used, or potentially a misspelling.\n\nIf you are referring to a specific drug, treatment, or condition, could you please provide more details or clarify? This will help me provide the most accurate and relevant information. If \"Nidran\" is a term from non-English speaking countries, alternative medicine, or a newly emerging treatment, I recommend checking the latest medical literature or databases for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 136, "total_tokens": 177}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s8psQ25SxAWHwxWf9fOlbp3G", "custom_id": "551_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c083a36a7855436c7c4a4a24c5b64665", "body": {"id": "chatcmpl-9St4saWuwbOT50SzveXHJC6Zg6EoK", "object": "chat.completion", "created": 1716671930, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv, known generically as nintedanib, is a medication used primarily for the treatment of idiopathic pulmonary fibrosis (IPF) and other specific types of interstitial lung diseases. It is also approved for use in treating non-small cell lung cancer (NSCLC) in combination with other chemotherapy agents. Here are some key points you should know about Cyendiv:\n\n1. **Mechanism of Action**: Nintedanib is a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis, including platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). By inhibiting these pathways, nintedanib can help reduce fibrosis and slow disease progression.\n\n2. **Indications**:\n   - **Idiopathic Pulmonary Fibrosis (IPF)**: It is approved for the treatment of IPF, a chronic,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_slw1Iyaj0ZXFZDQuXrGtV3nv", "custom_id": "552_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e249c33677b01a5cbb1328d6fb81952", "body": {"id": "chatcmpl-9St4sWWi48IztZSmJo5lpx9u9WZLo", "object": "chat.completion", "created": 1716671930, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Niranib\" does not appear to be a recognized medication or substance in widely available medical literature or databases. It's possible that the name might be misspelled or it could be a brand name not widely recognized or new on the market. \n\nIf you meant \"Niraparib,\" this is a medication used primarily in the treatment of ovarian cancer. Niraparib is a PARP (poly ADP-ribose polymerase) inhibitor, which is used in cancer therapy to prevent cancer cells from repairing their DNA, thereby causing them to die. It's particularly used in treating ovarian cancer in patients who have finished platinum-based chemotherapy.\n\nIf \"Niranib\" is indeed what you meant, and it's a new or less common drug, I would recommend checking the latest medical databases, pharmaceutical records, or contacting a pharmaceutical company for the most accurate and up-to-date information. Always ensure to use reliable sources to get information about new drugs or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DJ3hJWWkVFXtMAhOavNAe5AA", "custom_id": "553_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd72419586d7a112ebaadd42aaa0f8ec", "body": {"id": "chatcmpl-9St4tJL0dd8SMkTQI62u6m1jHzAef", "object": "chat.completion", "created": 1716671931, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is a medication used in the treatment of various types of cancer. It is a type of immunotherapy that works by inhibiting the programmed death receptor-1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking PD-1, Opdivo helps the immune system to detect and attack cancer cells.\n\nHere are some key points about Opdivo that you, as a physician, might find useful:\n\n1. **Indications**: Opdivo is approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, classical Hodgkin lymphoma (cHL), and colorectal cancer with specific genetic features (MSI-H or dMMR). The specific indications can depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Yv7yfY7FoEQaTYBHg5dO6W6d", "custom_id": "554_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a115c9b280202d798defbd5d121747f", "body": {"id": "chatcmpl-9St4t2Ar8UH4QzOUcif0MaRd9qFBl", "object": "chat.completion", "created": 1716671931, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Myocet is a liposomal formulation of doxorubicin, which is a type of chemotherapy drug used primarily in the treatment of cancer. Doxorubicin is an anthracycline antibiotic that works by interfering with the growth and proliferation of cancer cells. The liposomal formulation is designed to allow the drug to stay in the bloodstream longer and to reduce some of the side effects associated with conventional doxorubicin.\n\nHere are some key points you should know about Myocet:\n\n1. **Indications**: Myocet is commonly used for the treatment of metastatic breast cancer, often in combination with other chemotherapeutic agents such as cyclophosphamide. It may also be used in other cancers as part of research or in specific clinical scenarios.\n\n2. **Mechanism of Action**: Myocet works by intercalating DNA strands, inhibiting topoisomerase II, and producing free radicals, which collectively lead to cell death. The liposomal encapsulation helps"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_btu0nkEy9wCXHBxWj2IGnmpl", "custom_id": "555_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a0af20323c1ec5dd55f0558cd681f0a8", "body": {"id": "chatcmpl-9St4tNAeH1nFETjqtndaB2EUaFWTN", "object": "chat.completion", "created": 1716671931, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilevar, known chemically as norethandrolone, is an anabolic steroid that was historically used for various medical purposes but is no longer commonly prescribed. Here are some key points you should know about Nilevar:\n\n1. **Chemical Properties**: Norethandrolone is a synthetic, orally active anabolic-androgenic steroid derived from ethylestrenol. It is structurally similar to norethisterone, a synthetic progestin.\n\n2. **Medical Uses**: Historically, Nilevar was used to treat chronic debilitating diseases, to promote weight gain and muscle growth in cachectic patients, and sometimes in the treatment of certain types of anemia. It was also used to counteract catabolic states, such as those occurring during chronic corticosteroid therapy or after major surgery.\n\n3. **Side Effects**: Like other anabolic steroids, Nilevar can have significant side effects, including but not limited to virilization in women"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LHhuyYiQausnehDbeMWe1tkX", "custom_id": "556_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8f2732d59db882d854ce5eadf0aa9d95", "body": {"id": "chatcmpl-9St4ue180bHAzpKTxJFgvtqONsgs9", "object": "chat.completion", "created": 1716671932, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva (obinutuzumab) is a monoclonal antibody used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about Gazyva:\n\n1. **Indications**: Gazyva is approved for use in treating:\n   - Chronic lymphocytic leukemia (CLL) in combination with chlorambucil for patients who have not previously been treated.\n   - Follicular lymphoma (FL) in patients who have relapsed after, or are refractory to, a rituximab-containing regimen. It is also used in combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission.\n\n2. **Mechanism of Action**: Obinutuzumab is a type II anti-CD20 monoclonal antibody. It binds to the CD20 antigen on B-cells, leading to cell death. It is thought to act through antibody-dependent cellular cytotoxicity ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LUAVWms3ExBTIVBC0jXGmp0l", "custom_id": "557_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "64d47269ab741b2e1ac923dd29aa4134", "body": {"id": "chatcmpl-9St4uZDk16F6G0E6wxpa5HOE42KJj", "object": "chat.completion", "created": 1716671932, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina is the trade name for a formulation of octreotide, which is a synthetic octapeptide analog of somatostatin, a naturally occurring inhibitory hormone. Octreotide is used primarily for the treatment of acromegaly, a condition characterized by excessive growth hormone production, and for the management of symptoms associated with neuroendocrine tumors, such as carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).\n\nHere are some key points about octreotide (Longastatina) that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Octreotide works by mimicking natural somatostatin, thereby inhibiting the secretion of several hormones, including growth hormone, insulin, glucagon, and gastrin. It has a longer duration of action compared to natural somatostatin.\n\n2. **Indications**:\n   - **Acromegaly**: It is used to reduce growth hormone and IGF"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4uOXz0BmJ6ICZ4pGea7a6mxP", "custom_id": "558_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df1161e58a47bd2deebf59bc74d49bf4", "body": {"id": "chatcmpl-9St4ujpcAdPazrjLrz8sgxahPPUnu", "object": "chat.completion", "created": 1716671932, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR (long-acting release), known generically as octreotide, is a synthetic octapeptide analog of somatostatin, a naturally occurring inhibitory hormone which suppresses the secretion of certain hormones. Octreotide has a longer half-life than somatostatin and has been used in the management of various medical conditions. Here are some key points you should know about Longastatina LAR:\n\n1. **Indications**: Longastatina LAR is primarily used for the treatment of acromegaly, a condition characterized by excessive growth hormone production. It is also used to control symptoms caused by certain types of tumors such as carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas). Additionally, it is used in the management of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and VIPomas.\n\n2. **Mechanism of Action**: Octreotide works by mimicking natural somatostatin, thereby inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lG8GttbN9chERBUZod6gwPc9", "custom_id": "559_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22cc1e5be848693dad97dc43a3b51174", "body": {"id": "chatcmpl-9St4uliPEofOSF204dbzGnLTn5shq", "object": "chat.completion", "created": 1716671932, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arzerra (ofatumumab) is a medication used primarily in the treatment of chronic lymphocytic leukemia (CLL). It is a monoclonal antibody that targets the CD20 antigen on B cells, which plays a role in the development and progression of CLL. Here are some key points you should know about Arzerra:\n\n1. **Indications**: Arzerra is approved for use in patients with CLL who have not responded to other treatments, such as fludarabine and alemtuzumab. It may also be used in combination with other chemotherapy agents.\n\n2. **Mechanism of Action**: Ofatumumab binds specifically to the CD20 molecule found on the surface of both normal and malignant B cells. This binding induces cell lysis through both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n3. **Administration**: Arzerra is administered via intravenous infusion. The dosing schedule can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_jV9ZmVWGk6xlwOm6JsCVY6nH", "custom_id": "560_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "725dfdc53b56b57d1c2a4228c10a714e", "body": {"id": "chatcmpl-9St4uzYD7xI3vykdw7KWDSzXzyTAD", "object": "chat.completion", "created": 1716671932, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza (olaparib) is a medication used primarily in the treatment of certain types of cancers, particularly ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It belongs to a class of drugs known as PARP inhibitors. PARP (poly ADP-ribose polymerase) inhibitors work by interfering with the DNA repair pathways in cancer cells, which can lead to cell death, particularly in cells that are already genetically predisposed to be deficient in certain other DNA repair mechanisms.\n\nHere are some key points about Lynparza that you, as a physician, might find useful:\n\n1. **Indications**: Lynparza is approved for:\n   - Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.\n   - BRCA-mutated HER2-negative metastatic breast cancer, treated with chemotherapy.\n   - Germline BRCA-mut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mslk9NpXhGlktmg4pcJtdumB", "custom_id": "561_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e973fe78e56b0804c451da3182a23fd0", "body": {"id": "chatcmpl-9St4vApOIUSFLTCx6VSgfyPDD4Vt8", "object": "chat.completion", "created": 1716671933, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a monoclonal antibody medication that was used in the treatment of soft tissue sarcoma. It targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), which is involved in tumor growth and development. Here are some key points you should know about Lartruvo:\n\n1. **Approval and Indications**: Lartruvo was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2016 for use in combination with doxorubicin for the treatment of adults with certain types of soft tissue sarcoma (STS) that cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment.\n\n2. **Mechanism of Action**: Lartruvo binds to PDGFR-\u03b1 and blocks its activity, which can help in slowing down the growth of certain types of cancer cells.\n\n3. **Clinical Trials and Efficacy**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hjNrdMqR5h3vp6vrTW0WwS6E", "custom_id": "562_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e3c2f110a041a5d440e45c6ad3e6f4c", "body": {"id": "chatcmpl-9St4vKPBEjBj01UzOSpLJHm5xvkfW", "object": "chat.completion", "created": 1716671933, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Omapro\" is not a widely recognized medication or treatment in the medical community. It's possible that you might be referring to a drug with a similar name or a new drug that has been introduced after my last update. If you are looking for information on a specific medication, it's important to verify the exact name.\n\nHowever, if you meant \"Omacor,\" which is known in the U.S. as Lovaza, it is an omega-3-acid ethyl esters medication used to lower triglyceride levels in adults with severe hypertriglyceridemia. It's derived from fish oils and works by decreasing the amount of triglycerides produced by the body.\n\nFor any medication, including Omacor/Lovaza, it's important to consider:\n\n1. **Indications**: Understand the specific conditions the medication is approved to treat.\n2. **Dosage and Administration**: Know the recommended dosages and any special administration guidelines"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DFTk0u8J2u5FTt1zdqP0qkn1", "custom_id": "563_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3d3155eddc83e1e5ec4392237dace9f", "body": {"id": "chatcmpl-9St4wfGnI08fdip4egw0IfQOaJlPm", "object": "chat.completion", "created": 1716671934, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prilosec, whose generic name is omeprazole, is a medication that belongs to a class of drugs known as proton pump inhibitors (PPIs). It is commonly used to treat conditions related to excessive stomach acid production such as gastroesophageal reflux disease (GERD), ulcers, and Zollinger-Ellison syndrome. Here are some key points you should know about Prilosec:\n\n1. **Mechanism of Action**: Prilosec works by blocking the proton pump in the stomach lining, a mechanism that is the final step in the production of gastric acid. This inhibition reduces the level of stomach acid.\n\n2. **Indications**:\n   - Treatment of GERD and erosive esophagitis\n   - Management of duodenal ulcers and prevention of recurrence\n   - Treatment of gastric ulcers, including those induced by NSAIDs\n   - Management of Zollinger-Ellison syndrome and other conditions involving hypersecretion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2V00q9ZVRHf3b0jZ44On05r1", "custom_id": "564_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90b31d6dcc62284eca6d7b7da4a02d0d", "body": {"id": "chatcmpl-9St4w4OGXatX90YBUrsaRildj04n8", "object": "chat.completion", "created": 1716671934, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib, marketed under the brand name Tagrisso, is a medication used in the treatment of non-small cell lung cancer (NSCLC). It is specifically designed for cases where the cancer cells exhibit certain mutations in the epidermal growth factor receptor (EGFR) gene. Here are some key points about osimertinib that you, as a physician, might find useful:\n\n1. **Indications**: Osimertinib is approved for the treatment of patients with metastatic non-small cell lung cancer whose tumors have specific types of EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations) as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Osimertinib is a tyrosine kinase inhibitor that targets the EGFR mutations. It is particularly effective against the T790M mutation, which is a common resistance mechanism against other first- and second-generation EGFR inhibitors.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Vs7pIstTsxpberv8pIvkE6Jo", "custom_id": "565_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9810b0d0236ad7f708f084ce7a0c66cd", "body": {"id": "chatcmpl-9St4wwbRA45SrLvwOBU7Hwb89Dxtd", "object": "chat.completion", "created": 1716671934, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Coxatin\" is not recognized as a standard medication or treatment in medical literature. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet well-documented in mainstream medical sources.\n\nIf you are referring to a specific medication, it would be helpful to verify the spelling or provide additional context. If it's a new or experimental drug, I recommend consulting the latest clinical trials, FDA releases, or pharmaceutical manufacturer information for the most accurate and up-to-date information.\n\nFor any medication, it's crucial to understand its mechanism of action, indications, contraindications, side effects, and interactions with other drugs. Always refer to reliable medical sources or databases for comprehensive and current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 157, "total_tokens": 197}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MMkiYwK5hAzHabpQohMRdsab", "custom_id": "566_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2f27560507ec56b0c638f1f772d5e7b6", "body": {"id": "chatcmpl-9St4wOVmJs5FZ3OZaanRbHxJTC7Tz", "object": "chat.completion", "created": 1716671934, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane (paclitaxel protein-bound particles) is a chemotherapeutic agent used in the treatment of various cancers. Here are some key points you should know about Abraxane:\n\n1. **Indications**: Abraxane is approved for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer. It is often used in patients who have not responded to first-line treatments or when other treatments are not suitable.\n\n2. **Mechanism of Action**: Abraxane is a nanoparticle formulation of paclitaxel, a taxane drug that inhibits cell division by stabilizing microtubules. The nanoparticle formulation, which uses albumin as a carrier, allows for a solvent-free suspension, potentially reducing some of the solvent-related side effects seen with conventional paclitaxel and improving drug delivery to the tumor cells.\n\n3. **Administration**: Abraxane is administered intravenously. The dosage and schedule depend on the type of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UreOhbL440zAeiGLDfs16JWQ", "custom_id": "567_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd67f5c7c2e36bc8a78d6cb0dcc7161e", "body": {"id": "chatcmpl-9St4xWk6TyhZEnHHkFcXjgpfcKAc1", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication known as \"Abitaxel.\" It's possible that you might be referring to \"Abraxane\" or \"paclitaxel,\" which are related to the taxane group of drugs used in chemotherapy. Here\u2019s a brief overview of paclitaxel and Abraxane:\n\n### Paclitaxel\nPaclitaxel is a chemotherapy drug used to treat various types of cancer, including ovarian, breast, lung, pancreatic, and AIDS-related Kaposi sarcoma. It works by inhibiting cell division, thus stopping the growth of cancer cells. Here are some key points about paclitaxel:\n\n- **Mechanism of Action**: Paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes them by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eIAoxI5WWiNvWdYHpjxK7MLo", "custom_id": "568_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6b1f1b639b6fb3b8f2abe1621eb545eb", "body": {"id": "chatcmpl-9St4xtoCzTKYaShWYpzOVO6LNdl4x", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Vonjo\" is not a widely recognized term in the medical community. It could be a brand name, a term from another language, or possibly a new or less common drug or treatment. If you are referring to a specific medication, treatment, or concept that has emerged recently, I recommend checking the latest medical literature or pharmaceutical databases for the most current information. Additionally, consulting with colleagues or pharmacists might provide more insight. If you can provide more context or details, I might be able to offer more specific guidance."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 112, "total_tokens": 152}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vXeh0HXh18mDM7KOC6WuH5l4", "custom_id": "569_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "abb9f2803a38f1f3cd49363ac4e2d256", "body": {"id": "chatcmpl-9St4xmbZXyCSG23Td2M0aHvMH7SEN", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrance (palbociclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Ibrance:\n\n1. **Indications**: Ibrance is primarily indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients who have received prior endocrine therapy.\n\n2. **Mechanism of Action**: Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, Ibrance can help to stop the cancer cells from proliferating and potentially slow the progression of the disease.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ggIXzMHgMqLuMhp1sGvP5sB0", "custom_id": "570_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e6cc013804963d7a0b2d5163cb26e8ac", "body": {"id": "chatcmpl-9St4xscEJ9UpXVddOUSnLv9epZSMe", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vectibix (panitumumab) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points you should know about Vectibix:\n\n1. **Mechanism of Action**: Vectibix specifically targets and binds to the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells. By binding to EGFR, Vectibix blocks the pathways that promote cell division and survival, thereby inhibiting tumor growth.\n\n2. **Indications**: Vectibix is approved for the treatment of metastatic colorectal cancer with wild-type KRAS gene, as tumors with mutated KRAS are not responsive to anti-EGFR therapy. It is used in patients who have not responded to chemotherapy regimens containing fluoropyrimidine, oxaliplatin, and irinotecan.\n\n3. **Administration**: Vectibix is administered via intravenous infusion. The dosing regimen typically involves an infusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pDFSVICo6oNVBExrcOTpULqn", "custom_id": "571_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8cb153e47d9d438255524e0f4fb34bee", "body": {"id": "chatcmpl-9St4xlbmkuKFWgQEpnmNp6TBpeTHu", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Faridak\" is not recognized as a standard medication or treatment in medical literature. It's possible that it could be a brand name, a drug not widely used, or perhaps a misspelling. To provide accurate and helpful information, I would need the correct name of the drug or more context about its use. If you are referring to a specific medication, please provide additional details or check the spelling so I can offer more precise information. If it's a new or experimental treatment, consulting the latest clinical trials or pharmaceutical updates might be necessary."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 116, "total_tokens": 156}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kBMKbfLjdU7cfs7JOU1n5NlO", "custom_id": "572_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e1aaf9903c31fd0691035aec761c6e91", "body": {"id": "chatcmpl-9St4x173zwwFDB79DXFa04fdUE62M", "object": "chat.completion", "created": 1716671935, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medication or substance named \"Pazopater\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, or it could be a brand name or a drug not widely recognized or newly introduced.\n\nIf you meant a different medication or if \"Pazopater\" is a new or less common drug, I recommend checking the most current medical literature or drug databases. Additionally, consulting with pharmacists or other medical professionals might provide more up-to-date information. If you have more details or a different spelling, I can try to help further."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 125, "total_tokens": 166}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VB43ZeHo4X7N1dxcGM5uGEam", "custom_id": "573_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "572428581559dcf09dfce098adc93b1c", "body": {"id": "chatcmpl-9St4ym9Q209lyOTNwrWkr2dau6DsB", "object": "chat.completion", "created": 1716671936, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is a modified form of the enzyme L-asparaginase, which is conjugated to polyethylene glycol (PEG), enhancing its stability and prolonging its circulating half-life in the body. Here are some key points you should know about Oncaspar:\n\n1. **Mechanism of Action**: Oncaspar works by depleting the amino acid asparagine. Leukemia cells, particularly those in ALL, are unable to synthesize asparagine due to a lack of asparagine synthetase and are thus dependent on circulating asparagine. By depleting asparagine, Oncaspar starves the leukemia cells, inhibiting their ability to synthesize proteins necessary for survival and proliferation.\n\n2. **Indications**: Oncaspar is approved for use in patients with acute lymphoblastic leukemia as part of a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gr1MGqIY38Mp7WPGWk4bPsr4", "custom_id": "574_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a00e57e6af0e2bb4528d9642f3adc75", "body": {"id": "chatcmpl-9St4yDZHgKjGKqf7CrxWZCSKpxnnP", "object": "chat.completion", "created": 1716671936, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegasys (peginterferon alfa-2a) is a medication used primarily for the treatment of chronic hepatitis B and C infections. It is a form of interferon, a protein that modulates the immune response. As a pegylated interferon, Pegasys has a polyethylene glycol (PEG) molecule attached, which helps to prolong its duration of action in the body. Here are some key points you should know about Pegasys:\n\n1. **Indications**:\n   - **Chronic Hepatitis C**: Pegasys is used alone or in combination with other medications, such as ribavirin or direct-acting antiviral agents, to treat chronic hepatitis C.\n   - **Chronic Hepatitis B**: It is also used for the treatment of chronic hepatitis B, although its use may depend on specific patient factors and viral characteristics.\n\n2. **Mechanism of Action**:\n   - Pegasys works by enhancing the immune system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_jSKejm2NzPzdD4l2t2KJZDGZ", "custom_id": "575_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b181d70a64c456278198869340f7ce05", "body": {"id": "chatcmpl-9St4yRPaTLIVgRHIXDGFpur1BJh1Q", "object": "chat.completion", "created": 1716671936, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron (peginterferon alfa-2b) is a medication used primarily for the treatment of chronic hepatitis C infections. It is a form of interferon, a protein that modulates the immune response. PEG-Intron is a pegylated form of interferon, which means it has been chemically modified with polyethylene glycol to improve its stability and half-life in the body, allowing for less frequent dosing compared to unmodified interferon.\n\nHere are some key points you should know about PEG-Intron:\n\n### Indications\n- **Chronic Hepatitis C**: PEG-Intron is used, often in combination with other antiviral drugs such as ribavirin, to treat chronic hepatitis C virus (HCV) infection. It may be used in patients with compensated liver disease who have not previously received interferon therapy.\n\n### Mechanism of Action\n- PEG-Intron works by enhancing the body's immune response to help fight off"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DSTLxJh3DIRX8Bd3WJIOYz2A", "custom_id": "576_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9673e5da9728e0fbd8efa031f1010a16", "body": {"id": "chatcmpl-9St4zCXt29VcG8WZzPbr1hfUiO3e6", "object": "chat.completion", "created": 1716671937, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx, also known as Doxil in the United States, is a formulation of doxorubicin encapsulated in liposomes. It is used primarily in the treatment of various cancers, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. The liposomal encapsulation allows for a longer circulation time in the bloodstream and can help target the delivery of the drug to the tumor site, potentially reducing some of the systemic side effects associated with conventional doxorubicin.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - **Ovarian Cancer**: Caelyx is indicated for patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.\n   - **AIDS-related Kaposi's Sarcoma**: It is indicated for patients with advanced AIDS-related Kaposi's sarcoma who have not responded to prior combination antiretroviral therapy.\n   - **Multiple Myeloma**: Caelyx"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_alScgvOCG1asPlN1CW0l0tic", "custom_id": "577_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6124e5551873c429a2ac9562d4632457", "body": {"id": "chatcmpl-9St4zcrafJlH4UV6p9ZjseXHNMdeJ", "object": "chat.completion", "created": 1716671937, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda (pembrolizumab) is a medication used in the treatment of various types of cancer. It is a type of immunotherapy that works by targeting and blocking the programmed death receptor-1 (PD-1) pathway, a pathway that tumors use to shield themselves from the immune system. By blocking PD-1, Keytruda helps the immune system to detect and fight cancer cells.\n\nHere are some key points about Keytruda:\n\n1. **Indications**: Keytruda is approved for use in several types of cancers, including melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, and renal cell carcinoma. It is also used for tumors that are microsatellite instability-high (MS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2R3JnLRKgli2LFT3CaxaV2Yx", "custom_id": "578_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "07428129718b9f855b60d4567279e768", "body": {"id": "chatcmpl-9St4zXfFzhqi8u4hrvnMjpaSmp0Q0", "object": "chat.completion", "created": 1716671937, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta (pemetrexed) is a chemotherapy drug used primarily to treat malignant pleural mesothelioma and non-small cell lung cancer. Here are some key points you should know about Alimta:\n\n1. **Indications**:\n   - **Malignant Pleural Mesothelioma**: Alimta is used in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.\n   - **Non-Small Cell Lung Cancer (NSCLC)**: It is used as a first-line treatment in combination with cisplatin for advanced or metastatic NSCLC. Additionally, it is used as a single agent for maintenance treatment or as a second-line treatment after prior chemotherapy has failed.\n\n2. **Mechanism of Action**:\n   - Alimta inhibits several folate-dependent enzymes, which are necessary for purine and pyrim"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c4QaSdhjAJ36yQi0t12iOSp3", "custom_id": "579_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bbffa2293b086f4937b92624c9fa9c40", "body": {"id": "chatcmpl-9St4ziU7bYK0lkzF6D1YodIjiqYbt", "object": "chat.completion", "created": 1716671937, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nipent (pentostatin) is a chemotherapy medication used primarily in the treatment of hairy cell leukemia. It is classified as a purine analog, which means it interferes with DNA synthesis, thereby stopping the growth of cancer cells. Here are some key points you should know about Nipent:\n\n1. **Indications**: Nipent is approved for the treatment of hairy cell leukemia. It may also be used off-label for other conditions as determined by a physician.\n\n2. **Mechanism of Action**: Pentostatin is a potent inhibitor of adenosine deaminase, an enzyme that is necessary for the breakdown of adenosine from DNA. This inhibition leads to an accumulation of deoxyadenosine triphosphate (dATP), which in turn causes cell death in lymphocytes, particularly affecting B cells.\n\n3. **Administration**: Nipent is administered intravenously. The dosage and schedule depend on the patient's condition, response to treatment, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TzD8CxjUfxZUImmmeMmWGe8B", "custom_id": "580_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e9823c42115cf5a47d681f6c256878a", "body": {"id": "chatcmpl-9St50Uo0D1gwVU0fqz3uWMqRvBY8f", "object": "chat.completion", "created": 1716671938, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omnitarg, also known by its generic name pertuzumab, is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. It is designed to target the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some forms of breast cancer. Pertuzumab works by binding to the HER2 receptor and inhibiting its ability to receive growth signals, thereby helping to stop the growth and spread of cancer cells.\n\nHere are some key points about pertuzumab (Omnitarg) that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pertuzumab binds to the dimerization domain (domain II) of the HER2 receptor, which is different from the binding site of trastuzumab (another HER2-targeted therapy). This binding prevents the pairing (dimerization) of HER2 with other HER receptors (HER1, HER3,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vy377v3jW7VVoAyxuLt4yGUm", "custom_id": "581_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b500d207ab5f6f642ed1aca3f9458961", "body": {"id": "chatcmpl-9St50dBKreIUoZOyvamGHeeMo0OAT", "object": "chat.completion", "created": 1716671938, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no drug specifically named \"Pinorubicin\" recognized in standard pharmaceutical references. It's possible there might be a typo or confusion with a similarly named drug. However, you might be referring to \"Pirarubicin,\" which is a chemotherapy agent, or \"Doxorubicin,\" which is a well-known anthracycline antibiotic used in cancer treatment.\n\nIf you meant **Pirarubicin**:\nPirarubicin is an anthracycline antibiotic closely related to doxorubicin and is used in the treatment of various cancers, including breast cancer, bladder cancer, and lymphomas. It works by intercalating DNA strands, thereby inhibiting the synthesis of DNA and RNA and leading to cell death.\n\nIf you meant **Doxorubicin**:\nDoxorubicin is used to treat various types of cancer, including breast cancer, leukemia, and lymphomas. It works by intercalating DNA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_y1DKRNA2UAEclF3Bh2DpRTPy", "custom_id": "582_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "892de624835350eaf083e2760835acac", "body": {"id": "chatcmpl-9St50OzNL1YRwAHUO1DXDW4Qzm9ST", "object": "chat.completion", "created": 1716671938, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a cancer medication used primarily in the treatment of non-Hodgkin lymphoma. Here are some key points you should know about Pixuvri:\n\n1. **Indication**: Pixuvri is specifically indicated for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. This medication is generally considered when other treatment options have failed or have not been suitable.\n\n2. **Mechanism of Action**: Pixantrone is a cytotoxic aza-anthracenedione that works by intercalating into DNA and inhibiting topoisomerase II, leading to the induction of DNA strand breaks and apoptosis in dividing cells. Its structure is designed to reduce the potential for cardiac damage compared to other anthracyclines.\n\n3. **Administration**: Pixuvri is administered intravenously. The dosing regimen typically involves administration on days 1, 8, and 15 of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K2XPoSooxOAfjRjKppA2hT6B", "custom_id": "583_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f31e6f829ab5b065d7a13b6aefa35389", "body": {"id": "chatcmpl-9St50JZs1ALt5HTOl78upqeOw5r1e", "object": "chat.completion", "created": 1716671938, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin, also known as plicamycin, is a chemotherapy drug that was used primarily for the treatment of testicular cancer and certain types of tumors such as malignant mesothelioma and sarcomas. It is an antibiotic cytotoxic agent derived from the bacterium Streptomyces plicatus.\n\n### Key Points for Physicians:\n1. **Mechanism of Action**:\n   - Mithracin acts by binding to DNA and inhibiting RNA synthesis, which leads to cell death. It interferes with the growth of cancer cells, which are then eventually destroyed by the body.\n\n2. **Indications**:\n   - Historically, Mithracin was used to treat testicular cancer and other tumors. It has also been used in the treatment of hypercalcemia (high calcium levels in the blood) and hypercalciuria (high calcium levels in urine) primarily associated with cancer.\n\n3. **Administration**:\n   - Mithracin was"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Kc2U2LXVkIP6rILHmHuGGD6Y", "custom_id": "584_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "662483320d269721d86c6297924a3688", "body": {"id": "chatcmpl-9St52N7nw3jgrGCosEG0Ccpi3RqgT", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Actimid, also known as pomalidomide, is a derivative of thalidomide and belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs). It is primarily used in the treatment of multiple myeloma, particularly in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\nHere are some key points about pomalidomide (Actimid) that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pomalidomide works by modulating the immune system and also has anti-angiogenic properties. It enhances T-cell and natural killer (NK) cell-mediated immunity and inhibits the production of pro-inflammatory cytokines. Additionally, it disrupts the microenvironment of tumor cells, which can inhibit tumor growth.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PPEP6QSZEdJZJraGTuKDdBGV", "custom_id": "585_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5a5c7b49a106f6783d65079ba555d78a", "body": {"id": "chatcmpl-9St51Xvzd5QQcSfzry5rLkI8ovz5S", "object": "chat.completion", "created": 1716671939, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a prescription medication used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients who are resistant to or unable to tolerate other tyrosine kinase inhibitors (TKIs). Here are some key points you should know about Iclusig:\n\n1. **Mechanism of Action**: Ponatinib is a third-generation tyrosine kinase inhibitor that specifically targets BCR-ABL, an abnormal tyrosine kinase that promotes cancer growth in these leukemias. It is effective against a wide range of BCR-ABL mutations, including the T315I mutation, which is resistant to other available TKIs.\n\n2. **Indications**:\n   - Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) in adult patients resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n   - T"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j0CB8oyfEBri3oux6ImouUsp", "custom_id": "586_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "324e0147cde53254679cba031fced3a6", "body": {"id": "chatcmpl-9St52BHshP9xdxP6ykz4RonlF3rPC", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn, known generically as pralatrexate, is a chemotherapeutic agent used primarily in the treatment of peripheral T-cell lymphoma (PTCL). Here are some key points you should know about Folotyn:\n\n1. **Indications**: Folotyn is approved by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.\n\n2. **Mechanism of Action**: Pralatrexate is a folate analogue metabolic inhibitor. It competitively inhibits dihydrofolate reductase, an enzyme that participates in the tetrahydrofolate synthesis. The drug also incorporates into DNA and RNA, which inhibits thymidylate synthase, leading to cell death.\n\n3. **Administration**: Folotyn is administered via intravenous infusion. The dosing regimen typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7bpwBtYRySS5CpD4j1mfO0pF", "custom_id": "587_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "476722db9ddc316bb7a1f5b0471a45e4", "body": {"id": "chatcmpl-9St52Ob91cEsNuSrtbfO7umNIcygY", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, whose generic name is pravastatin, is a member of the drug class known as statins or HMG-CoA reductase inhibitors. It is primarily used to lower lipid levels and to reduce the risk of cardiovascular disease. Here are some key points you should know about Pravachol:\n\n### Mechanism of Action\nPravachol works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. This inhibition leads to a decrease in liver cholesterol levels, which in turn stimulates the uptake of LDL cholesterol from the blood, thereby lowering the blood levels of LDL cholesterol (\"bad\" cholesterol).\n\n### Indications\n- **Hypercholesterolemia**: Treatment of adults with elevated cholesterol levels.\n- **Primary Prevention**: Reduces the risk of myocardial infarction, stroke, and coronary revascularization procedures in individuals without clinical evidence of coronary heart disease but with multiple risk"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eZ6LLrkzzbPtDRWrQqN5iKLp", "custom_id": "588_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5982577ee861a93441c08b41a525421", "body": {"id": "chatcmpl-9St52IZp3GXBXTZjTx5hhJDBPM94e", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adnisolone appears to be a typographical error or a less common name for a medication. It's possible you meant \"prednisolone,\" which is a widely used corticosteroid medication. Here\u2019s an overview of prednisolone, assuming that's the drug in question:\n\n**Prednisolone Overview:**\n\n1. **Classification**: Prednisolone is a corticosteroid that mimics the effects of hormones produced by the adrenal gland. It is used to suppress the immune system and reduce inflammation.\n\n2. **Indications**: It is prescribed for a wide range of conditions, including autoimmune disorders, inflammatory conditions (such as arthritis), allergies, asthma, and certain types of cancer. It is also used in the management of adrenal insufficiency.\n\n3. **Forms**: Prednisolone is available in several forms, including tablets, oral solutions, and injectable formulations.\n\n4. **Mechanism of Action**: Prednisolone works by decreasing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JIVjFxofqCnJvQFfMQevQFGB", "custom_id": "589_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d893a85d55611fa9b1bcea3edcc972f", "body": {"id": "chatcmpl-9St52gElDCW3H5cMBUsdfnAQMLwQM", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or misunderstanding in your question regarding \"Artinizona.\" If you meant \"arthritis\" or another medical term, I can certainly provide information on that. However, if \"Artinizona\" refers to something specific, could you please clarify or provide more details? I'm here to help with accurate and relevant information once the topic is clear."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 76, "total_tokens": 117}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_S8wz5szQP4cGYSD4Pw8aPppG", "custom_id": "590_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ccad6109663d4c33a1d5e57dbf2c9d5c", "body": {"id": "chatcmpl-9St52lTycXTmz2WtRvp3fwORxr4fV", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Indicarb is not a widely recognized medication or substance in standard medical resources, including pharmacological databases. It's possible that \"Indicarb\" could be a brand name, a regional name, or an alternative name for a drug, or it might be misspelled or misheard. To provide accurate and helpful information, I would need the correct name or additional context about the drug. If you have more details or can clarify the name, I can offer more specific information. Alternatively, you might want to consult a reliable drug database or pharmacology resource for accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 116, "total_tokens": 157}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_b1e2P7WsCotk9kC8sV3FNiA0", "custom_id": "591_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3377e5c6587dc30f950fef84731a1d6c", "body": {"id": "chatcmpl-9St53vwzESXkxlqEjzMcEuE6VIc2X", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin is the brand name for quinine sulfate, which is primarily used to treat malaria. Here are some key points you should know about Qualaquin:\n\n1. **Indications**: Qualaquin is approved for the treatment of uncomplicated Plasmodium falciparum malaria. It is important to note that it is not recommended for use in treating severe or complicated malaria.\n\n2. **Mechanism of Action**: Quinine acts primarily as a blood schizonticide, meaning it targets the asexual intraerythrocytic stages of Plasmodium species. It interferes with the parasite's ability to metabolize and utilize erythrocyte hemoglobin.\n\n3. **Dosage and Administration**: The typical adult dose for malaria is 648 mg every 8 hours for 7 days. It is crucial to adjust the dose in patients with renal impairment, as quinine is primarily eliminated by the kidneys.\n\n4. **Side Effects**: Common side effects include cin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YM4pTX0KjSUuXu2cxss9G0Dh", "custom_id": "592_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "efb609cafbaa8efca60e23be5e20cf81", "body": {"id": "chatcmpl-9St52NLXR7i1d1QFext6HImmzWEoO", "object": "chat.completion", "created": 1716671940, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vanflyta (quizartinib) is a medication used in the treatment of certain types of acute myeloid leukemia (AML), specifically for patients with FLT3-ITD positive AML. FLT3 (FMS-like tyrosine kinase 3) is a common type of mutation found in AML that leads to the aggressive growth of leukemia cells. Quizartinib works as a tyrosine kinase inhibitor, specifically targeting the FLT3 mutation, thereby inhibiting the proliferation of leukemia cells.\n\nHere are some key points you should know about Vanflyta:\n\n1. **Indications**: Vanflyta is specifically indicated for the treatment of adult patients with relapsed or refractory AML who are FLT3-ITD positive. It is important to confirm the presence of FLT3-ITD mutation in AML patients through molecular diagnostic testing before initiating treatment with Vanflyta.\n\n2. **Mechanism of Action**: Quizartinib, the active ingredient in Vanflyta,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_XaWYr7nEWQz38Dc49pBFE3oz", "custom_id": "593_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "67e706b95773658991263fd5bf10919f", "body": {"id": "chatcmpl-9St53fG3ezEMC0xaeHBn9hbwbHSFN", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Supect\" does not appear to be a recognized medication or medical term. It's possible that there might be a typo or misunderstanding regarding the name. If you are referring to a specific drug, treatment, or concept, could you please provide more details or clarify the name? This will help me provide you with the most accurate and relevant information. If you're looking for information on a specific subject related to medicine or healthcare, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 97, "total_tokens": 137}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3HtSH1p1z4cCTx0gWS1Ulw2y", "custom_id": "594_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6e43bf46b5752238ebebfe1f31dd654a", "body": {"id": "chatcmpl-9St53m3U5Jdeu3uVXNATuvtvPNVrA", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex, known generically as raltitrexed, is a chemotherapy medication used primarily in the treatment of colorectal cancer. Here are some key points you should know about Tomudex:\n\n1. **Mechanism of Action**: Raltitrexed is a folate analogue that inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. By inhibiting this enzyme, raltitrexed causes DNA damage and cell death in rapidly dividing cancer cells.\n\n2. **Indications**: It is primarily used for the treatment of advanced colorectal cancer, particularly in patients who cannot tolerate or have not responded to fluorouracil-based chemotherapy.\n\n3. **Administration**: Raltitrexed is administered intravenously. The typical dosing regimen involves administration once every three weeks.\n\n4. **Side Effects**: Common side effects include myelosuppression (leading to neutropenia, thrombocytopenia, and anemia), nausea"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Rw06DKEnjS0isVfvudmjbJuh", "custom_id": "595_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d4b3afeb00ce847f0f24ac685f950a7a", "body": {"id": "chatcmpl-9St53fdClKfEi5Y1v6i3nwKBpHDYq", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyramza (ramucirumab) is a monoclonal antibody used as a targeted therapy for certain types of cancer. It works by inhibiting angiogenesis, the process by which new blood vessels form, thereby reducing the blood supply to tumors and limiting their growth. Here are some key points you should know about Cyramza:\n\n1. **Indications**: Cyramza is approved for use in various cancers, including:\n   - Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with chemotherapy.\n   - Metastatic non-small cell lung cancer (NSCLC), in combination with docetaxel, after prior chemotherapy.\n   - Metastatic colorectal cancer, used with FOLFIRI (folinic acid, fluorouracil, and irinotecan) following progression on a prior therapy.\n   - Hepatocellular carcinoma who have an alpha-fetoprotein (AFP) of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_NEVjq5ViZEjpx2SRs7CdrDZ5", "custom_id": "596_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65f1977105af38c4a235011d8d5ef1b8", "body": {"id": "chatcmpl-9St536qx57TMgdiZ7oUVIDdbR1IVt", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Cymer\" is not widely recognized as a medical term or condition. It is possible that you might be referring to something specific that is not captured in the available data or that there might be a spelling error or misunderstanding about the term. Cymer is known as a company that specializes in creating deep ultraviolet light sources used in the manufacturing of microelectronics, including semiconductor devices.\n\nIf you are referring to a medical topic, drug, or condition that sounds similar, please provide more details or check the spelling so I can offer the most accurate and relevant information. If \"Cymer\" relates to a specific piece of medical equipment or technology developed by the Cymer company for medical applications, additional specific details would be helpful to provide a precise response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 155, "total_tokens": 195}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_dUmSTlszII87w3UAxfE7LH58", "custom_id": "597_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62eb9498fa41f9112f74574c784b82aa", "body": {"id": "chatcmpl-9St53k9GssZHzheg8NH0Ww88XtDmq", "object": "chat.completion", "created": 1716671941, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Nublexa is not a recognized or commonly known medication. It's possible that you might be referring to a drug with a similar name or a brand name that is not widely recognized. One possibility is that you meant \"Nexavar\" (sorafenib), which is a medication used in the treatment of certain types of cancers, such as kidney cancer, liver cancer, and thyroid carcinoma.\n\nIf you are referring to a specific drug under a brand name that is not widely recognized or is new on the market, I would recommend checking the latest medical literature or pharmaceutical references for the most accurate and up-to-date information. Additionally, consulting databases like the FDA or EMA can provide official information on drug approvals, indications, and usage guidelines.\n\nIf you provide more specific information or context, I can try to offer more targeted assistance!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 174, "total_tokens": 216}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wa4MiZugT1PwDw7mRPnq6rhZ", "custom_id": "598_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c93af42e4f16b8b3fff53fa689bbfa00", "body": {"id": "chatcmpl-9St54Ysqtk5Xwf9XO4bXYrIekgtfT", "object": "chat.completion", "created": 1716671942, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (generic name: ribociclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Kisqali:\n\n1. **Indications**: Kisqali is approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor (as initial endocrine-based therapy) or with fulvestrant in women who have received prior hormone therapy.\n\n2. **Mechanism of Action**: Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, Kisqali helps to stop the proliferation of cancer cells.\n\n3. **Administration**: Kisqali is administered orally, typically in a 28-day"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uqsL1Xf7w8glmhG9pklkXUgX", "custom_id": "599_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "61289c5c04b3b4bbbd2807f60d95a7b8", "body": {"id": "chatcmpl-9St548pedatGuc4b4NRLFDrxJWjWy", "object": "chat.completion", "created": 1716671942, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medical or pharmaceutical reference to \"Ikgdar\" in standard resources or literature. It's possible that there might be a typo or a misunderstanding regarding the name. If you can provide more context or details, I might be able to assist you better. Alternatively, if \"Ikgdar\" is a new drug, treatment, or concept that has emerged after my last update, I recommend checking the latest medical literature or databases like PubMed, or consulting with pharmaceutical companies for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 108, "total_tokens": 149}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_31rIIhv73Tl15KQL6euknpgH", "custom_id": "600_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4889953e9a78bdb3e83ac8fa53e3ef31", "body": {"id": "chatcmpl-9St54EDuswXFCQafH4s9jlGvki3nz", "object": "chat.completion", "created": 1716671942, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela (rituximab and hyaluronidase human) is a combination medication used in the treatment of certain cancers and autoimmune diseases. It combines rituximab, a monoclonal antibody that targets the CD20 antigen on B lymphocytes, with hyaluronidase, an enzyme that increases tissue permeability and facilitates the dispersion and absorption of rituximab. Here are some key points you should know about Rituxan Hycela:\n\n1. **Indications**: Rituxan Hycela is approved for use in adults to treat:\n   - Follicular Lymphoma (FL) as a single agent, previously untreated, or relapsed/refractory.\n   - Diffuse Large B-Cell Lymphoma (DLBCL) as a single agent in patients who are relapsed or refractory.\n   - Chronic Lymphocytic Leukemia (CLL) in combination with chemotherapy.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X1txX09EuckNdojLKV7QCMF9", "custom_id": "601_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3588d2a05cb0239f84dbf0facdccbcfc", "body": {"id": "chatcmpl-9St54RFXBzObQrT49Tmo1TeVb4avt", "object": "chat.completion", "created": 1716671942, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istodax (romidepsin) is a medication used in the treatment of certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) when other treatments have failed. It is classified as a histone deacetylase (HDAC) inhibitor. Here are some key points about Istodax that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Romidepsin works by inhibiting the activity of histone deacetylase enzymes. This inhibition leads to an increase in acetylation of histone proteins, resulting in altered gene expression. This can induce cell cycle arrest, apoptosis, and differentiation of cancer cells.\n\n2. **Indications**:\n   - **Cutaneous T-cell lymphoma (CTCL)**: Istodax is approved for the treatment of CTCL in patients who have received at least one prior systemic therapy.\n   - **Peripheral T"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kPkAPgSwaeTcytf5hhlCEwC7", "custom_id": "602_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "21f0df247c11f9973ca3bf09dd7825a9", "body": {"id": "chatcmpl-9St55aicsgRe8rjxRtNydpVEBP7vn", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besremi (ropeginterferon alfa-2b-njft) is a medication approved by the FDA for the treatment of adults with polycythemia vera (PV), a type of blood cancer characterized by the excessive production of red blood cells. This approval was granted in November 2021. Besremi is notable for being the first interferon therapy specifically indicated for PV that offers a once-every-two-week dosing schedule after an initial titration period.\n\n### Mechanism of Action:\nBesremi is a long-acting, mono-pegylated form of interferon. Interferons are proteins that modulate the response of the immune system. Ropeginterferon alfa-2b-njft works by binding to interferon receptors and activating intracellular signaling pathways that lead to various biological effects, including the inhibition of cell proliferation and modulation of immune responses. This action helps to control the overproduction of blood cells, particularly red blood cells,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rxAaaZOymDgwUpXZk0a85UCU", "custom_id": "603_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "908ae2ef2e06d79b15d5f946b8731d4f", "body": {"id": "chatcmpl-9St55sG2cu8Ni4MTNrY3nJCCuB9UW", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rubraca (rucaparib) is an oral medication used primarily in the treatment of certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It belongs to a class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors, which work by interfering with the DNA repair pathways in cancer cells, specifically targeting and killing cells that are deficient in the BRCA1 or BRCA2 genes.\n\nHere are some key points about Rubraca that you, as a physician, might find useful:\n\n1. **Indications**: Rubraca is approved by the FDA for the treatment of adult patients with:\n   - Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n   - BRCA-mutated ovarian cancer treated with two or more chemotherapies and who have selected for therapy based on an FDA-approved companion diagnostic for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_A7vvIZVoFzOruyeqJlZBGesZ", "custom_id": "604_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6cc30b10832c21636959f803b9d991ca", "body": {"id": "chatcmpl-9St55g8Wrnng60zVxvEu9SnXHSY07", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitinib) is a medication used primarily in the treatment of certain bone marrow disorders. Here are some key points you should know about Jakafi:\n\n1. **Indications**: Jakafi is approved by the FDA for the treatment of adults with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It is also approved for the treatment of polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea. Additionally, Jakafi is used for treating steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.\n\n2. **Mechanism of Action**: Jakafi is a Janus kinase (JAK) inhibitor. It inhibits JAK1 and JAK2, which are enzymes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wGOUhlKgWIE9eQ4pS4xWTq5t", "custom_id": "605_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b1e5922b38d86c79754c209e5c31893", "body": {"id": "chatcmpl-9St55iPrFq2VDEx2RJTPaCz2GEb7N", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) specifically designed for the treatment of various types of cancer. It was first approved by the U.S. Food and Drug Administration (FDA) in April 2020. Here are some key points about Trodelvy that you, as a physician, might find useful:\n\n1. **Indications**: Trodelvy is primarily used for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Additionally, it has been approved for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n2. **Mechanism of Action**: Trodelvy is composed of a monoclonal antibody that targets Trop-2, a cell-surface glycoprotein expressed in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bmKy8qheD7DGFOs2QVrMfEJm", "custom_id": "606_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "129ec09d43bc6286c761793ff2d878d2", "body": {"id": "chatcmpl-9St556IBvKrYaghTcuEAS1FsgYmif", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leukine (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used primarily to promote bone marrow recovery after chemotherapy, bone marrow transplantation, or other conditions that cause bone marrow suppression. It is also used in the treatment of neutropenia and to enhance the hematopoietic reconstitution following autologous or allogeneic bone marrow transplantation.\n\nHere are some key points about Leukine:\n\n1. **Mechanism of Action**: Leukine acts by stimulating the proliferation and differentiation of various hematopoietic progenitor cells, including neutrophils, monocytes, macrophages, and eosinophils. It binds to the GM-CSF receptor, triggering a cascade of cellular processes that lead to enhanced production and function of white blood cells.\n\n2. **Indications**:\n   - To shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_JCjqDzrF2TtlWlRbh3eV3glS", "custom_id": "607_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "319c211e6db7b5f6e32bd0341fc50ee8", "body": {"id": "chatcmpl-9St55h0XsImrEIuMnLwkVI29TZYgL", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Nexpovio (selinexor) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. It is primarily used in the treatment of multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Nexpovio:\n\n1. **Mechanism of Action**: Selinexor works by inhibiting the nuclear export protein XPO1. This leads to the accumulation of tumor suppressor proteins in the nucleus, which can promote the death of cancer cells and reduce their proliferation.\n\n2. **Indications**:\n   - **Multiple Myeloma**: Nexpovio, in combination with dexamethasone, is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G8ZDC0YJIgSI4vtkEPDgZeAU", "custom_id": "608_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7794083b71ae7a976d0b877706d99c3", "body": {"id": "chatcmpl-9St55CuHjUkhUGLWyvcOZx28BOVSc", "object": "chat.completion", "created": 1716671943, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication approved for specific medical conditions, particularly in the field of oncology. Here are some key points you should know about Koselugo:\n\n1. **Indication**: Koselugo is approved by the FDA for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. These are tumors that develop along the nerves and can cause significant morbidity.\n\n2. **Mechanism of Action**: Selumetinib, the active ingredient in Koselugo, is a kinase inhibitor. It specifically inhibits MEK1 and MEK2, which are part of the RAS/RAF/MEK/ERK pathway. This pathway is often activated in cells with NF1 mutations, leading to uncontrolled cell growth and tumor formation.\n\n3. **Dosage and Administration**: Kosel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CnDeqb6wCQTJJBhlQRrXotyw", "custom_id": "609_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e65fa01db434f99e8a99c19ba7d9338", "body": {"id": "chatcmpl-9St56pKaZxOa8ncLTqDdW344ENnpH", "object": "chat.completion", "created": 1716671944, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no drug or substance named \"Semustina\" recognized in standard medical resources or pharmacological databases. It's possible that the name might be misspelled or it could be a brand name not widely recognized, or perhaps a new drug still under development or not widely known.\n\nIf you meant \"Semustine,\" it is important to note that semustine is a type of chemotherapy drug, a derivative of lomustine, belonging to the class of nitrosoureas used in cancer treatment. Nitrosoureas are alkylating agents that work by cross-linking DNA and RNA, thereby inhibiting DNA synthesis which is crucial for cancer cell growth and replication.\n\nHere are some key points about semustine:\n\n1. **Mechanism of Action**: Semustine forms interstrand cross-links in DNA, which prevents DNA replication and RNA transcription. This is effective in killing rapidly dividing cells, particularly cancer cells.\n\n2. **Uses**: It has"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_otyKWuRitzGPQBcjyh1bLex1", "custom_id": "610_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a5f2eb60ff51fa1dc4b62df14d0574cc", "body": {"id": "chatcmpl-9St56CA1CCt3rG0mlMGcxDvYBBi8F", "object": "chat.completion", "created": 1716671944, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is an immunotherapy treatment specifically designed for advanced prostate cancer, particularly targeting asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. Here are some key points you should know about Provenge:\n\n1. **Mechanism of Action**: Provenge is a type of cancer vaccine that uses the patient's own immune cells to fight the cancer. It is designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers. The treatment involves collecting a patient's peripheral blood mononuclear cells (including antigen-presenting cells) through leukapheresis, which are then exposed to a recombinant protein that combines PAP with granulocyte-macrophage colony-stimulating factor (GM-CSF). This process activates the cells, which are then reinfused into the patient to stimulate the immune system to attack cancer cells expressing PAP"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aAqh1FTGdgUSeGCvfOMDKHgP", "custom_id": "611_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "00aa821ad64b1a382acb0a54c1806484", "body": {"id": "chatcmpl-9St56aWRf255xjCupC9MEhspfuJPE", "object": "chat.completion", "created": 1716671944, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Odomzo (sonidegib) is a medication used in the treatment of advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in cases where surgery or radiation therapy are not options. Here are some key points you should know about Odomzo:\n\n1. **Mechanism of Action**: Odomzo is an inhibitor of the Hedgehog signaling pathway, which is active in most basal cell carcinomas. It specifically targets and inhibits Smoothened, a protein involved in the Hedgehog pathway.\n\n2. **Indications**: It is approved for the treatment of adults with locally advanced basal cell carcinoma that has recurred following surgery or radiation, or those who are not candidates for surgery or radiation.\n\n3. **Administration**: Odomzo is taken orally, once daily, with a recommended dose of 200 mg. It should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CDOEOL6eG1i3WYrznw8G9APO", "custom_id": "612_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48f1cf93accd8bb14b87f9d1c917e2fa", "body": {"id": "chatcmpl-9St56VwLFGRvSoiWzlwtn5x5ePTAf", "object": "chat.completion", "created": 1716671944, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar, known generically as sorafenib, is a medication used primarily in the treatment of certain types of cancers. Here are some key points you should know about Nexavar:\n\n1. **Indications**: Nexavar is approved for the treatment of advanced renal cell carcinoma (kidney cancer), unresectable hepatocellular carcinoma (liver cancer), and differentiated thyroid carcinoma. It is important to confirm the specific indications as they can vary by country and over time.\n\n2. **Mechanism of Action**: Sorafenib is a tyrosine kinase inhibitor. It works by blocking multiple enzymes involved in cancer cell proliferation and angiogenesis (the growth of new blood vessels that tumors need to grow). This helps to slow the growth and spread of cancer cells.\n\n3. **Administration**: Nexavar is administered orally, typically in tablet form. The dosage and treatment regimen can vary based on the type of cancer, the patient's condition, and other factors such as body weight and response to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w5RvWAgIB3qb5suOMHEorFZG", "custom_id": "613_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "345271698fa36f28c2fbf9403af613d2", "body": {"id": "chatcmpl-9St575Va9UWPNToWfEvmYbDd4fwtO", "object": "chat.completion", "created": 1716671945, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanosar, known generically as streptozocin, is a chemotherapy medication primarily used to treat pancreatic cancer, specifically islet cell carcinoma of the pancreas. Here are some key points you should know about Zanosar:\n\n1. **Mechanism of Action**: Streptozocin is a nitrosourea compound that has both alkylating and glucosylating properties. It causes damage to the DNA of cancer cells, which leads to cell death. It is particularly effective against cells that secrete insulin, such as pancreatic islet cells.\n\n2. **Indications**: Zanosar is approved for the treatment of metastatic islet cell carcinoma of the pancreas. It may also be used in clinical trials for other types of cancers.\n\n3. **Administration**: Zanosar is administered intravenously. The dosage and schedule can vary depending on the specific case, the protocol being followed, and the patient's response and tolerance to the treatment.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_47B0M6CXjGU67PK0IhQMc2w1", "custom_id": "614_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d9bc1c2f5acab4d128d897144d2aeb4", "body": {"id": "chatcmpl-9St57nRaTkPLLp25fPav6kgbVgwIl", "object": "chat.completion", "created": 1716671945, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Kitent\" does not correspond to any known medication, medical condition, or concept that is widely recognized in the medical community. It's possible that there might be a spelling error or a mix-up with the term you intended to inquire about.\n\nIf you could provide more context or clarify the term, I would be more than happy to help you with the correct information. If you're referring to a specific drug, treatment, or medical concept, please provide the correct name or additional details."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 112, "total_tokens": 152}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1ASDc1ZXo48bRD9EzOY9QYED", "custom_id": "615_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "370411b4b4a837579eb167407353418d", "body": {"id": "chatcmpl-9St57iW2OgAnqwVphWe6v1EdutR9I", "object": "chat.completion", "created": 1716671945, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (tagraxofusp-erzs) is a targeted therapy approved for the treatment of certain types of cancer. Here are some key points you should know about Elzonris:\n\n1. **Indication**: Elzonris is approved by the U.S. Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years and older. BPDCN is a rare and aggressive form of blood cancer.\n\n2. **Mechanism of Action**: Elzonris is a CD123-directed cytotoxin. It is composed of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. The drug binds to CD123-expressing cells, which are then internalized, leading to the inhibition of protein synthesis and cell death.\n\n3. **Administration**: Elzonris is administered as an intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c8KSuofLY7mBJenvTlJ3EOjG", "custom_id": "616_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4cd47a6e886d1ff7284a064ca81fbd7", "body": {"id": "chatcmpl-9St57snB3yMXiFzYkHnJo3nhmVMNo", "object": "chat.completion", "created": 1716671945, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (talazoparib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Talzenna:\n\n1. **Indication**: Talzenna is approved by the FDA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for Talzenna.\n\n2. **Mechanism of Action**: Talzenna belongs to a class of drugs known as PARP (poly ADP ribose polymerase) inhibitors. It works by inhibiting the PARP enzyme, which helps repair DNA damage in cells. By inhibiting PARP, Talzenna causes DNA damage to accumulate in cancer cells, leading to cell death, particularly in cells that are already compromised genetically, such as those with BRCA mutations.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Sju2FQMlfqPIfzdfvnJFKaGD", "custom_id": "617_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b5ba47b5d4e62aa787d75b3d192b95b", "body": {"id": "chatcmpl-9St57eNfGrY9UuxIPhYn2i9pAyGpe", "object": "chat.completion", "created": 1716671945, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic (talimogene laherparepvec), commonly referred to as T-VEC, is an oncolytic virus therapy used for the treatment of melanoma lesions in the skin and lymph nodes that cannot be completely removed by surgery. Approved by the FDA in 2015, Imlygic is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce the immune-stimulating protein granulocyte-macrophage colony-stimulating factor (GM-CSF).\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - Imlygic is specifically indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.\n\n2. **Mechanism of Action**:\n   - Imlygic selectively replicates within tumor cells and causes their lysis, thereby releasing tumor-derived antigens. It also expresses GM-CSF, which may promote"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_AAF1pQ8ieD8HapGO51fjfQJu", "custom_id": "618_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a99e2bb480e1a89f516595990e19569", "body": {"id": "chatcmpl-9St58nAqRMNkTKUemEPSIrKf31KGL", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question. The term \"Amnoid\" does not correspond to any known medication, medical condition, or technology in widely accepted medical practice as of my last update. It's possible that there might be a spelling error or confusion with a similar-sounding term.\n\nIf you meant \"amniotic,\" this refers to anything related to the amnion, which is the innermost membrane that encloses the embryo in utero. Amniotic fluid, for example, is the fluid surrounding the fetus during pregnancy that protects and supports the baby's development.\n\nIf you are referring to something specific like a drug, a condition, or a technology, could you please provide more details or check the spelling? I'm here to help with the correct information once we clarify the topic."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 166, "total_tokens": 207}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_YUlQwh2ZTRS8VKIg9f0onPgq", "custom_id": "619_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "980db5d31488abfe3b8a82486b17218e", "body": {"id": "chatcmpl-9St58MjoFByJsqJPSKBwGCv8zUUgW", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istubal, also known as vismodegib, is a medication used primarily in the treatment of advanced basal cell carcinoma (BCC). Here are some key points you should know about Istubal:\n\n1. **Mechanism of Action**: Istubal works by inhibiting the Hedgehog signaling pathway, which is active in most basal cell carcinomas. By blocking this pathway, Istubal can help reduce the growth of cancer cells.\n\n2. **Indications**: It is approved for use in adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation.\n\n3. **Administration**: Istubal is taken orally, typically once a day.\n\n4. **Side Effects**: Common side effects include muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, diarrhea, and decreased appetite. It can also cause more serious side effects, including severe birth defects if taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_awxEhvTcdvWcI9Xo5ktqG8TL", "custom_id": "620_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e8595dd401912fc11d3f906317ff48f7", "body": {"id": "chatcmpl-9St58nxcLMDPh6agTfp9NZ6gAnQt7", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno, also known by its generic name tegafur/gimeracil/oteracil, is a combination oral chemotherapy medication used primarily to treat gastric cancer, including gastroesophageal junction cancer. It is often used in patients for whom curative resection is not possible, and it has been approved in various regions, including Europe and Japan, but it is not approved in the United States.\n\nHere are some key points about Teysuno:\n\n1. **Composition**: Teysuno consists of three active substances:\n   - **Tegafur**: A prodrug of fluorouracil (5-FU), which is a pyrimidine analog that inhibits DNA synthesis.\n   - **Gimeracil (5-chloro-2,4-dihydroxypyridine)**: Inhibits dihydropyrimidine dehydrogenase (DPD), an enzyme that degrades 5-FU, thereby increasing the level of 5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0shQcFhIhrmnMLg9rwxphD7J", "custom_id": "621_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46f2658ec868a48ed663562784f3782d", "body": {"id": "chatcmpl-9St58NbqJd8e1ZqxNRnUhJzahEUyH", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known as Tegafur, is a chemotherapeutic agent used primarily in the treatment of various cancers. It is a prodrug of 5-fluorouracil (5-FU), a widely used anticancer drug. Here are some key points you should know about Ftorafur:\n\n1. **Mechanism of Action**: Ftorafur is metabolized in the body to 5-fluorouracil, which then inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This inhibition leads to the disruption of DNA replication and transcription, which are critical processes for cancer cell survival and proliferation.\n\n2. **Indications**: It is commonly used in the treatment of cancers such as stomach, breast, colorectal, and pancreatic cancers. It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Ftorafur can be administered orally or intravenously,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XKZ29pL8kpBagTg6EMPyPwi3", "custom_id": "622_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1175f8f542c71a9e8a79b6306d53cceb", "body": {"id": "chatcmpl-9St587RyJaIhRV2AcFeN9auESh5y1", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem is a brand name for temozolomide, an oral chemotherapy drug used primarily to treat certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here are some key points you should know about Gliotem:\n\n1. **Mechanism of Action**: Temozolomide works by alkylating/methylating DNA, which damages the DNA and triggers cell death, particularly in rapidly dividing tumor cells. Its ability to cross the blood-brain barrier makes it effective in treating brain tumors.\n\n2. **Indications**: Gliotem is typically indicated for the treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. It is also used for refractory anaplastic astrocytoma, i.e., tumors that have not responded to standard treatments.\n\n3. **Administration**: Temozolomide is taken orally and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_qIsltfnPSEtWxB4pTmpOsz6t", "custom_id": "623_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "497244402bdd86a6b2940d3f900feb5a", "body": {"id": "chatcmpl-9St58uTRcbYEU3DjBiWuCXETdzkzq", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Torisel (temsirolimus) is an important medication used primarily in the treatment of advanced renal cell carcinoma (kidney cancer). Here are some key points you should know about Torisel:\n\n1. **Mechanism of Action**: Torisel is an inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase. By inhibiting mTOR, it interferes with the synthesis of proteins that control cell division, growth, and survival. This inhibition can lead to the arrest of cell cycle progression and ultimately the apoptosis of cancer cells.\n\n2. **Indications**: The primary indication for Torisel is the treatment of advanced renal cell carcinoma. It may also be investigated for use in other types of cancers as part of clinical trials.\n\n3. **Administration**: Torisel is administered intravenously. The dosing regimen typically involves a once-weekly infusion, but the specific regimen should be adjusted based on the patient's condition and response to therapy.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AJ8RNz8Lpv8f45nfCdGe2fRY", "custom_id": "624_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d5ed943aa9b3438f0d461364bfdc9942", "body": {"id": "chatcmpl-9St58QuPi3csz4BLcG0PTwtwNTwUu", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vumon (teniposide) is a chemotherapeutic agent used primarily in the treatment of cancer. It belongs to a class of drugs known as podophyllotoxin derivatives, which also includes etoposide. These drugs are often referred to as topoisomerase II inhibitors. Here are some key points about Vumon that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Vumon works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By interfering with this enzyme, teniposide causes DNA damage and leads to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**: Vumon is primarily used to treat certain types of leukemia, including acute lymphoblastic leukemia (ALL). It is often used in combination with other chemotherapeutic agents.\n\n3. **Administration**: Teniposide is administered intravenously. The dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YHUy7eKZynQEqUQu9QPXyo7c", "custom_id": "625_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d0fa0db6617edff66f9c8253c1fce35", "body": {"id": "chatcmpl-9St58AyYuvIuaAcfjr91rfcRKdPu6", "object": "chat.completion", "created": 1716671946, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan, known internationally as thalidomide, is a medication that was first developed and marketed in the 1950s by the German pharmaceutical company Chemie Gr\u00fcnenthal. It was originally promoted as a sedative or hypnotic, and later as a treatment for morning sickness in pregnant women. However, it became infamous for causing severe birth defects when taken during pregnancy.\n\n**Key Points for Physicians:**\n\n1. **History and Impact**: Thalidomide was introduced in the late 1950s and was found to cause a range of severe congenital deformities, such as limb abnormalities (phocomelia), heart defects, and malformations of the ears, eyes, and internal organs. The drug was withdrawn from the market in the early 1960s after these effects became apparent. The tragedy led to stricter drug regulations and better control systems globally.\n\n2. **Mechanism of Action**: Thalidomide acts in part by modulating the immune"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_MVTMYVkzoo9diERKs7EZ75DM", "custom_id": "626_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "78099ceb8884bbf8fbb39b7dd0b238bc", "body": {"id": "chatcmpl-9St59buUJtlizdq7UF5hYQ9Ap6EaO", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanvis, known generically as thioguanine, is a medication primarily used in the treatment of acute myeloid leukemia (AML). It belongs to a class of drugs known as purine analogs, which are a type of antimetabolite chemotherapy. Here are some key points you should know about thioguanine:\n\n1. **Mechanism of Action**:\n   Thioguanine works by incorporating into DNA and RNA, disrupting these vital cellular components and leading to cell death, particularly in rapidly dividing cells such as cancer cells.\n\n2. **Indications**:\n   - Primarily used for treating acute myeloid leukemia.\n   - It may also be used in other types of leukemia as part of a chemotherapy regimen.\n\n3. **Administration**:\n   - Thioguanine is administered orally.\n   - The dosage and duration of treatment depend on the specific condition being treated, the patient's response to therapy, and their overall health.\n\n4. **Side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_uT5Ox5oZaWmCDcJ36Pf0oB97", "custom_id": "627_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59d1805aaf6be147830706ae6c96c9a0", "body": {"id": "chatcmpl-9St59o0jReDEgAY7OhIWdDRyDEkkR", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina, known generically as thiotepa, is a chemotherapy medication used in the treatment of various types of cancer, including breast cancer, ovarian cancer, bladder cancer, and certain types of lymphoma. It is an alkylating agent, which works by cross-linking DNA and RNA, thereby inhibiting cancer cell growth and multiplication.\n\nHere are some key points you should know about Tepadina:\n\n1. **Indications**: Thiotepa is used for treating various cancers and is also employed in conditioning regimens prior to hematopoietic stem cell transplantation.\n\n2. **Administration**: Thiotepa can be administered intravenously, intracavitary, or intravesically, depending on the type and location of the cancer.\n\n3. **Dosage**: The dosage of thiotepa varies based on the type of cancer, the treatment regimen, patient body size, and overall health. It is crucial to adhere to established protocols and adjust dosages"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hl633RKrIxXB8VDtHS5rnG9x", "custom_id": "628_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "355c92b784d5f629ffcd711968bfb79d", "body": {"id": "chatcmpl-9St59jQWxQU1piAv8q6wtzvIFJtz8", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kymriah (tisagenlecleucel) is a form of therapy known as CAR T-cell therapy, which is used in the treatment of certain types of blood cancers. It represents a significant advancement in personalized medicine and involves reprogramming the patient's own immune cells to recognize and attack cancer cells. Here are some key points you should know about Kymriah:\n\n1. **Indications**: Kymriah is approved by the FDA for use in:\n   - Pediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.\n   - Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**: Kymri"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZPrQ7ZFHbJxksh8TUMI3ZvJE", "custom_id": "629_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "753921752530add6cc259734e2b75d37", "body": {"id": "chatcmpl-9St59726VMG4aAOv0yQvHytjCAPbb", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotivda (tivozanib) is a medication approved for the treatment of adult patients with advanced renal cell carcinoma (RCC), which is the most common type of kidney cancer. Here are some key points you should know about Fotivda:\n\n1. **Mechanism of Action**: Tivozanib is a tyrosine kinase inhibitor (TKI) that primarily targets vascular endothelial growth factor receptors (VEGFRs). These receptors play a crucial role in angiogenesis, the process by which tumors develop new blood vessels to support their growth. By inhibiting VEGFRs, tivozanib helps to reduce the tumor's blood supply and limit its growth.\n\n2. **Indications**: Fotivda is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.\n\n3. **Dosage and Administration**: The typical dosage of Fotivda is 1.34 mg taken orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_E2c395v3s4gAHLRc33xiSYHA", "custom_id": "630_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f595d330bc25179faab35490c52a0e6a", "body": {"id": "chatcmpl-9St59RNE0XiFYz0odxAByuHjFKNhK", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Evotopin\" does not appear to be a recognized medication or treatment in standard medical resources. It's possible that it could be a new drug, a drug under development, or perhaps a brand name that is not widely known. It could also be a misspelling or a non-conventional treatment not recognized by mainstream medicine.\n\nIf Evotopin is related to a specific treatment or drug that you're inquiring about, I recommend checking the most current medical literature or drug databases for the most accurate and up-to-date information. Additionally, consulting with pharmaceutical representatives, attending medical conferences, or participating in professional forums might provide insights into new treatments or drugs like Evotopin.\n\nIf you have more specific details or a different spelling, I can try to provide more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 165, "total_tokens": 207}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WTReH6vQhU6VkgMUSofMI9IG", "custom_id": "631_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "40bf0ae51f6a0b78acd022ce633f8499", "body": {"id": "chatcmpl-9St5983AfO4YHq6PeTeZSQQbzw3LF", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acapodene, known generically as toremifene, is a medication that belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). It is structurally similar to tamoxifen, another well-known SERM. Toremifene works by binding to estrogen receptors, thereby blocking the effects of estrogen in certain tissues. This action can be beneficial in conditions where estrogen promotes disease progression.\n\nHere are some key points about toremifene (Acapodene) that you, as a physician, might find useful:\n\n1. **Indications**: Toremifene is primarily approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors. It is used to slow down the growth of cancer cells that are stimulated by estrogen.\n\n2. **Mechanism of Action**: As a SERM, toremifene interacts with estrogen receptors in various tissues. It acts as an estrogen antagonist in breast tissue but"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W0NcjoqWF8IUW4xn5K1TCLTL", "custom_id": "632_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "059be283a9cc40ae13921d103641f4ff", "body": {"id": "chatcmpl-9St59nOZaEQjobKVOQ7UECET4nZQb", "object": "chat.completion", "created": 1716671947, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar (tositumomab and iodine I 131 tositumomab) was a radioimmunotherapy medication that was used for the treatment of certain types of non-Hodgkin's lymphoma. It combined a monoclonal antibody (tositumomab) with a radioactive iodine isotope (Iodine-131), targeting the CD20 antigen on the surface of normal and malignant B-cells. After binding to these cells, the radioactive iodine delivered a cytotoxic dose of radiation intended to destroy the lymphoma cells.\n\nHere are some key points you should know about Bexxar:\n\n1. **Mechanism of Action**: Bexxar worked by targeting the CD20 antigen on B-cells, which is commonly expressed in non-Hodgkin's lymphoma. The monoclonal antibody component (tositumomab) specifically bound to the CD20 antigen, and the radioactive component (Iodine-131"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aePaMObf6yMB8EHhcVW5z14x", "custom_id": "633_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0f25d5ff2aa4002851f8396b5dd74ea1", "body": {"id": "chatcmpl-9St5AvkpTEiOEDmw917xXFxDfAeNV", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis (trabectedin) is a chemotherapy drug used primarily for the treatment of certain types of cancer, including advanced soft tissue sarcoma and relapsed ovarian cancer. Here are some key points you should know about Yondelis:\n\n1. **Mechanism of Action**: Trabectedin binds to the minor groove of DNA, disrupting the cell cycle and leading to cell death. It is thought to have a dual mechanism: it interferes with cell division and also affects the tumor microenvironment, potentially impairing the cancer cells' ability to repair DNA.\n\n2. **Indications**:\n   - **Soft Tissue Sarcoma**: Yondelis is approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy including an anthracycline.\n   - **Ovarian Cancer**: It is also approved for the treatment of patients with relapsed ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_d5LdulSOX5agBrklsvXTjt7O", "custom_id": "634_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1da30e95d89728d391dde8e7744a424f", "body": {"id": "chatcmpl-9St5AdufyvFdY14wVVvRBQdKZ36iQ", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist (trametinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Mekinist:\n\n1. **Indications**: Mekinist is approved for the treatment of melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, that is metastatic or cannot be removed by surgery. It is often used in combination with dabrafenib, another medication targeting the BRAF mutation. Additionally, it is used for non-small cell lung cancer (NSCLC) with the same mutations and for advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation in combination with dabrafenib.\n\n2. **Mechanism of Action**: Trametinib is a MEK inhibitor. MEK is part of the MAPK/ERK pathway, which helps regulate cell growth. By inhibiting MEK, tramet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_k0yFuDdSmnlvV73tdYZoiHp3", "custom_id": "635_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b47f99f65a92c5b2eefa23027fc30e5", "body": {"id": "chatcmpl-9St5ApP7SvVgbiNbX9UqS94diDR5y", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Amixam\" does not appear to be a recognized medication or substance in standard medical resources. It's possible that the name might be misspelled or it could be a brand name not widely recognized, or perhaps a new drug not yet well-documented in the most commonly used medical references.\n\nIf \"Amixam\" is intended to be a medication or substance related to a specific treatment, I recommend double-checking the spelling or the context in which you found the name. If it's a new or experimental drug, consulting the latest clinical trials, FDA announcements, or pharmaceutical registries might provide more information. Additionally, reaching out to colleagues or pharmaceutical representatives could also yield insights.\n\nIf you have more specific information or a different spelling, I can help look up more detailed information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 164, "total_tokens": 205}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qbGtvSFqop5ScgB4oYoAG3Pm", "custom_id": "636_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "462a4672396ebc033eec3ebd364c13bf", "body": {"id": "chatcmpl-9St5AkBel1UnU7ZRy9Fe52gsnu5F5", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biceltis, known generically as trastuzumab, is a monoclonal antibody used primarily for the treatment of HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2) is a protein that can promote the growth of cancer cells. In some cancers, HER2 is overexpressed, and trastuzumab has been shown to be effective in targeting these cells.\n\nHere are some key points about Biceltis (trastuzumab) that you, as a physician, might find useful:\n\n1. **Indications**: Trastuzumab is approved for the treatment of HER2-positive breast cancer and may be used in both the adjuvant (post-surgery) setting and for metastatic disease. It is also approved for the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n2. **Mechanism of Action**: Trastuzumab works by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_tsRNZdQX3dA8dltbmamnPbIm", "custom_id": "637_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d6db024a2ad3960a469168b8efd5d2d", "body": {"id": "chatcmpl-9St5AEEDCdIYuY0engac0eXkEd8eC", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imjudo (tremelimumab) is a monoclonal antibody that is used in the treatment of certain types of cancers. It is designed to inhibit the activity of CTLA-4, a protein that plays a critical role in regulating the immune system. By blocking CTLA-4, Imjudo helps to enhance the body's immune response against cancer cells.\n\nHere are some key points you should know about Imjudo:\n\n1. **Indications**: Imjudo, often used in combination with other medications such as durvalumab, is approved for the treatment of specific types of cancers. For example, it has been used in the treatment of unresectable hepatocellular carcinoma (HCC). The specific indications can vary, so it's important to refer to the latest clinical guidelines and FDA approvals.\n\n2. **Mechanism of Action**: Imjudo works by inhibiting CTLA-4, a checkpoint protein on T cells that, when activated, damp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BXGnFH0IgliDmqN7tN1SeBcy", "custom_id": "638_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "206b180ae75cf5de2de7619a50e41e40", "body": {"id": "chatcmpl-9St5AuBqhFmaTIuqQ0mvX25miql1J", "object": "chat.completion", "created": 1716671948, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Ovastat\" does not appear to be a recognized medication or treatment in standard medical resources. It's possible that it could be a brand name, a supplement, or a product not widely recognized or available in many regions. It's also possible that the name might be misspelled or misremembered.\n\nIf \"Ovastat\" refers to a specific drug, treatment, or supplement that you are inquiring about, I recommend checking the following:\n\n1. **Official Drug Databases**: Check databases like the FDA in the U.S., EMA in Europe, or other national drug regulatory agencies depending on your location for the most accurate and reliable information.\n\n2. **Pharmacology Resources**: Resources like the British National Formulary (BNF), Merck Manuals, or UpToDate can provide information if this is a recognized medication.\n\n3. **Consult with Pharmacists**: Pharmacists can be a great resource for information on medications, including lesser-known"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EqYUw9rk2GwhQTAb4UFDcJNI", "custom_id": "639_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "45dcd4d146acac45872b752665c39bdc", "body": {"id": "chatcmpl-9St5BDsQuCRNP30wXsPP28V5yL8fI", "object": "chat.completion", "created": 1716671949, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine and tipiracil) is a combination oral chemotherapy medication used primarily for the treatment of certain types of colorectal cancer and gastric cancer. Here are some key points you should know about Lonsurf:\n\n1. **Indications**:\n   - Lonsurf is approved for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with chemotherapy and biological therapy.\n   - It is also approved for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy.\n\n2. **Mechanism of Action**:\n   - Trifluridine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits cell proliferation.\n   - Tipiracil increases the bioavailability of trifluridine by inhibiting its degradation by thymidine phosphorylase.\n\n3. **Dosage and Administration**:\n   - Lonsurf is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_KThfRD31xWtOptDRHCtiHuzE", "custom_id": "640_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3c2b8c4aede936b43d10dd4bfc04f97", "body": {"id": "chatcmpl-9St5BqWlsfwcQC2W6ZsnwQIYzeT6p", "object": "chat.completion", "created": 1716671949, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl (triptorelin) is a synthetic analogue of gonadotropin-releasing hormone (GnRH), commonly used in the management of hormone-responsive cancers such as prostate cancer, and in conditions like endometriosis, uterine fibroids, and in assisted reproduction. Here are some key points you should know about Decapeptyl:\n\n1. **Mechanism of Action**: Decapeptyl acts by initially stimulating the release of pituitary gonadotropins (luteinizing hormone and follicle-stimulating hormone), which in turn increases the levels of sex hormones (testosterone and estrogen). However, with continuous administration, Decapeptyl desensitizes the pituitary gland, leading to a significant reduction in hormone levels due to downregulation of GnRH receptors.\n\n2. **Indications**:\n   - **Prostate Cancer**: It is used for the treatment of advanced hormone-dependent prostate cancer.\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fIG9ZaeJPIGgWKiKtKkvIVfE", "custom_id": "641_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "82a571d0b3ffffe987f5562180e2082f", "body": {"id": "chatcmpl-9St5Bl90URJmrhJTWY4PVeA4Ewegr", "object": "chat.completion", "created": 1716671949, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depacon (valproate sodium) is an injectable form of the medication valproic acid, primarily used for treating seizure disorders, bipolar disorder, and for the prevention of migraine headaches. Here are some key points you should know about Depacon:\n\n1. **Indications**: Depacon is approved for the treatment of:\n   - Seizure disorders, including complex partial seizures and simple and complex absence seizures.\n   - Mania associated with bipolar disorder.\n   - Prevention of migraine headaches.\n\n2. **Mechanism of Action**: The exact mechanism of action is not fully understood, but it is believed to work by increasing the availability of gamma-aminobutyric acid (GABA) in the brain, which helps to calm the nerve activity.\n\n3. **Administration**: Depacon is administered intravenously and is often used when oral administration is not possible. The dosage and frequency of administration depend on the condition being treated, the severity of the condition, and the patient\u2019s response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_3GXZvZEWBfpsNu5jxC9aA5xZ", "custom_id": "642_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "988d67d5e0511b323f35d0c7f9fa7f5f", "body": {"id": "chatcmpl-9St5B8m8aW5CEPm18QB7OiaR5rYlv", "object": "chat.completion", "created": 1716671949, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is a chemotherapy drug used primarily in the treatment of bladder cancer, specifically for Bacillus Calmette-Gu\u00e9rin (BCG)-resistant carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here are some key points you should know about Valstar:\n\n1. **Mechanism of Action**: Valrubicin is an anthracycline antibiotic that interferes with the growth of cancer cells, which are eventually destroyed. It is believed to work by intercalating DNA and inhibiting topoisomerase II, leading to disrupted synthesis of DNA and RNA.\n\n2. **Administration**: Valstar is administered intravesically, which means it is directly instilled into the bladder through a catheter. This localized delivery helps to minimize systemic exposure and associated toxicities.\n\n3. **Dosage and Treatment Regimen**: The typical dose of Valstar is 800"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_SQlbaJegpsnBAwvN5g4Nts0n", "custom_id": "643_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef9a9e14ea1c34433a0676156d5f7ee4", "body": {"id": "chatcmpl-9St5Bz0ag27NISrQVbnabvJRdbxKC", "object": "chat.completion", "created": 1716671949, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication used in the treatment of certain types of thyroid cancer. Here are some key points you should know about Caprelsa:\n\n1. **Indications**: Caprelsa is specifically indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It targets cancer cells with specific genetic mutations and inhibits their growth.\n\n2. **Mechanism of Action**: Vandetanib is a tyrosine kinase inhibitor. It works by inhibiting multiple targets including RET, VEGFR, and EGFR signaling pathways, which play roles in the pathogenesis of thyroid cancers by promoting angiogenesis, metastasis, and cell proliferation.\n\n3. **Dosage and Administration**: The typical dose of Caprelsa is 300 mg taken orally once daily. It should be taken with or without food. Dose adjustments may be necessary based on individual patient response and the presence of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eJ55OdYBIkpe6KGfSy9Nk6q3", "custom_id": "644_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a5fb0e5771760e3235d0b3162e57b52e", "body": {"id": "chatcmpl-9St5CW3rzkwTzCQvu0kZt3ojBSa5u", "object": "chat.completion", "created": 1716671950, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf (vemurafenib) is a medication used in the treatment of certain types of cancer, most notably late-stage melanoma that is metastatic or cannot be removed by surgery. Here are some key points you should know about Zelboraf:\n\n1. **Indications**: Zelboraf is specifically indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation. It is important to confirm the presence of BRAF V600E mutation in the tumor prior to initiation of treatment because it targets this specific mutation.\n\n2. **Mechanism of Action**: Vemurafenib is a BRAF inhibitor that works by selectively inhibiting the BRAF V600E mutation. This mutation leads to the activation of the MAP kinase/ERK signaling pathway, which promotes cell proliferation. By inhibiting this mutation, vemurafenib helps to slow down or stop the growth of cancer cells.\n\n3. **Administration**: Z"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lTYnyZzuDT8BGLLoGv7VPCH0", "custom_id": "645_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b8583b7b64effb124a8a52b1fc064626", "body": {"id": "chatcmpl-9St5CsikEoYhSI694UcI3StFjcYLV", "object": "chat.completion", "created": 1716671950, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a targeted therapy used primarily in the treatment of certain types of chronic lymphocytic leukemia (CLL) and some other hematological malignancies. Here are some key points you should know about Venclexta:\n\n1. **Mechanism of Action**: Venetoclax is a selective small molecule inhibitor of the B-cell lymphoma-2 (BCL-2) protein. By inhibiting BCL-2, venetoclax helps to induce apoptosis (programmed cell death) in cancer cells.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Venetoclax is approved for use in patients with CLL, including those with 17p deletion, who have received at least one prior therapy. It is also used in combination with obinutuzumab for untreated CLL patients.\n   - **Acute Myeloid Leukemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iWw7NN8olrNSDlM1m1HaPWkm", "custom_id": "646_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "06dd18d436326fd7fea38b79e78fdcfc", "body": {"id": "chatcmpl-9St5DIcqWqekcEovUgf4nT2dBFxuN", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is not a widely recognized medication or substance in standard medical resources or pharmacological databases. It's possible that the name might be misspelled, outdated, or it could be a brand name not commonly used. To provide accurate and helpful information, it would be beneficial to have the correct name or additional details about the medication. If it's a specific treatment or substance you've encountered in practice or literature, please provide more context or check for alternative spellings, and I can help look up relevant information such as its uses, side effects, interactions, and more. If you're dealing with a specific patient case or a clinical scenario, knowing more about the symptoms or the condition being treated could also be useful."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 43, "completion_tokens": 147, "total_tokens": 190}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5Yz9ySimlcUR6c9B3tMXDlXS", "custom_id": "647_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a85827d2211057fc152271a45441e0d1", "body": {"id": "chatcmpl-9St5DIPZiajZUmNnkzy6LLjcRESM0", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medication or substance known as \"Alcrist\" recognized in standard medical resources or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf \"Alcrist\" refers to a specific drug or treatment, I recommend checking the most current medical databases, pharmaceutical references, or contacting a pharmaceutical company for the most accurate and up-to-date information. Additionally, consulting with colleagues or pharmacists might provide further insights.\n\nIf you have more details or a different spelling, I can try to provide more specific information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 132, "total_tokens": 173}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kkqAFLUdJSC7O4xYTUwoifAu", "custom_id": "648_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bcebb1d54cf257e16b9c096d0cc49524", "body": {"id": "chatcmpl-9St5DXHnLP9AdxDRmEYr10uslVsbY", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is a chemotherapeutic agent used in the treatment of certain types of cancer. Here are some key points you should know about Marqibo:\n\n1. **Indication**: Marqibo is specifically indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) who have relapsed two or more times or whose disease has progressed after two or more antileukemia therapies. It is not indicated for the treatment of patients with newly diagnosed disease.\n\n2. **Mechanism of Action**: Marqibo is a liposomal formulation of vincristine, a vinca alkaloid. The liposomal encapsulation is designed to provide a prolonged circulation time and increased drug accumulation at the tumor site. Vincristine works by inhibiting microtubule formation in mitotic spindles, thus arresting cell division at the metaphase stage.\n\n3. **Administration**: Marqibo is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Vikayx9wQurVaMREdwnNRhDJ", "custom_id": "649_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71a659985b3c7588557c6d86254b1b26", "body": {"id": "chatcmpl-9St5DfPyZPyb8sC0WvlWpjWB0AcOr", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Eldesine\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug that has not been documented in widely available sources as of my last training data in January 2023.\n\nIf \"Eldesine\" is a new or experimental drug, I recommend checking the most current medical literature, pharmaceutical databases, or drug regulatory authority websites for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals who might have access to real-time drug databases could be beneficial.\n\nIf you provide more context or details, I might be able to offer more specific guidance or check if there's a similar-sounding drug that you might be referring to."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 171, "total_tokens": 212}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Qz5nIg0sIDJel2DUUpTNFBsO", "custom_id": "650_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e799b7ba9b34d46f8fd2276051a4b446", "body": {"id": "chatcmpl-9St5DiAHZH3jOKfxhOZDHHf2Dq0Yr", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor is a brand name for vinflunine, which is a chemotherapy medication used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen. Vinflunine is a microtubule inhibitor and belongs to the vinca alkaloid class of antineoplastic agents.\n\nHere are some key points you should know about Javlor (vinflunine):\n\n1. **Mechanism of Action**: Vinflunine works by inhibiting microtubule dynamics, which results in the suppression of microtubule assembly and the induction of apoptosis (cell death) in cancer cells.\n\n2. **Indications**: The primary indication for Javlor is the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of prior platinum-containing chemotherapy.\n\n3. **Administration**: Javlor is administered intravenously. The dosing regimen typically involves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w0crxmeicxf60xgrVLCo8GZo", "custom_id": "651_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1bc311e875ee32b66df14c4f4e9fd1b4", "body": {"id": "chatcmpl-9St5DU61LXTcNAuTRbv0rtInd7P3O", "object": "chat.completion", "created": 1716671951, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance named \"Binorel\" in standard medical resources or pharmaceutical references. It's possible that the name could be a misspelling, a brand name not widely recognized, or a new drug not yet documented in widely available sources.\n\nIf you meant a different drug or if \"Binorel\" is a new or less common medication, I recommend checking the most current medical literature or pharmaceutical databases for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other medical professionals might provide more insights.\n\nIf you provide more context or details, I might be able to offer more specific assistance or direct you to relevant resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 141, "total_tokens": 182}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_09esrS7mMBmx0kiWYqd4FRZ4", "custom_id": "652_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a75b061694e9a2180f4d5daf4f4bb94", "body": {"id": "chatcmpl-9St5Eb4pa9rsJPcmwW1cfbzV3sC8k", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is a medication used in the treatment of advanced basal cell carcinoma (BCC), a type of skin cancer. Here are some key points you should know about Erivedge:\n\n1. **Mechanism of Action**: Erivedge works by inhibiting the Hedgehog signaling pathway, which is active in most basal cell cancers. By blocking this pathway, vismodegib can help reduce the growth of cancer cells.\n\n2. **Indications**: It is approved for use in adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred after surgery or who are not candidates for surgery or radiation.\n\n3. **Administration**: Erivedge is taken orally, typically as a once-daily capsule. It should be taken with or without food.\n\n4. **Side Effects**: Common side effects include muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, and diarrhea. More serious side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sLk79ZXogwK8kjE1kSmfsGGj", "custom_id": "653_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90a646aa4673de83414f84651e511e9b", "body": {"id": "chatcmpl-9St5EyJ7ohiP6OD2WNRQkBUpszOQ3", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza (vorinostat) is a medication used in the treatment of cancer, specifically for cutaneous T-cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. Here are some key points about Zolinza that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Vorinostat, the active ingredient in Zolinza, is a histone deacetylase (HDAC) inhibitor. It works by causing the accumulation of acetylated histones and other proteins, leading to cell cycle arrest and/or apoptosis of some cancer cells.\n\n2. **Indications**: Zolinza is approved by the FDA for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent, or recurrent disease on or following two systemic therapies.\n\n3. **Administration**: Zolinza is administered orally, and the recommended dosage is 400 mg once daily with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_my8f3Z1bFPPUqkKRiLfPVqpX", "custom_id": "654_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "acef70e6afb7a5b51f13f7af7b32087a", "body": {"id": "chatcmpl-9St5EyfBtAD7TKi966pHDzBKmm13v", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it might be useful to know about Aztec in terms of its historical and cultural context, particularly if you are interested in the history of medicine or if you are treating patients from indigenous backgrounds who may have cultural ties or a particular interest in Aztec traditions. Here are some relevant aspects:\n\n1. **Historical Background**: The Aztec civilization was a Mesoamerican culture that flourished in central Mexico in the post-classic period from 1300 to 1521, until the Spanish conquest. Understanding their history can provide insights into the development of medical practices in pre-Columbian America.\n\n2. **Medical Practices**: The Aztecs had advanced medical practices for their time. They used a variety of herbs, plants, and minerals to treat various ailments. Knowledge of these practices can be particularly useful in understanding the origins of some herbal medicines and treatments still used today.\n\n3. **Herbal Medicine**: Many modern drugs have been derived from plants used in traditional medicine, including"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5KDLDjyqSDVqN9hFi52OZlYR", "custom_id": "655_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ebc22fda8629f995b9e06485b63f297", "body": {"id": "chatcmpl-9St5E4uzfcojUxsa70dfkW4YSI4hG", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap (aflibercept) is a medication used in the treatment of various forms of cancer, most notably metastatic colorectal cancer. It is a type of angiogenesis inhibitor, which works by inhibiting the growth of new blood vessels that tumors need to grow and spread. Here are some key points you should know about Zaltrap:\n\n1. **Mechanism of Action**: Zaltrap is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factors (VEGFs). By binding to these factors, Zaltrap prevents them from activating their natural receptors on the surface of endothelial cells, thereby inhibiting the angiogenesis process.\n\n2. **Indications**: Zaltrap is approved for use in combination with a FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy regimen for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxalipl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1wPX0BpiDxiGEvrLRB5MsJJp", "custom_id": "656_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b123c065c5af4e0ed8f7c901d1e5256", "body": {"id": "chatcmpl-9St5ETScV0CVJtHK5qjvB0CTcbcE8", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has metastasized and whose tumors have mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping. This approval, which came in May 2020, marked Tabrecta as the first therapy specifically approved to target NSCLC driven by these mutations.\n\n### Key Points for Physicians:\n\n1. **Indication and Usage**:\n   - Tabrecta is specifically indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This mutation can be detected by an FDA-approved test, which is required for the use of Tabrecta.\n\n2. **Mechanism of Action**:\n   - Capmatinib is a kinase inhibitor that targets MET, including the genetically altered forms that lead to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CBXRTteAr9YiD1JA2pneOxVK", "custom_id": "657_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e2b0b4eb8bc7852bf06ee9cf2be9159", "body": {"id": "chatcmpl-9St5ENHDczQPGddAW8oZc0S0k7v4z", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (enfortumab vedotin-ejfv) is a prescription medication used in the treatment of cancer, specifically for adult patients with locally advanced or metastatic urothelial cancer (which is the most common type of bladder cancer) who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.\n\nHere are some key points about Padcev:\n\n1. **Mechanism of Action**: Padcev is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein located on the surface of cells and highly expressed in urothelial cancers. The drug combines an anti-Nectin-4 antibody with a molecule of the chemotherapy drug monomethyl auristatin E (MMAE). The antibody component binds to Nectin-4 expressing cells, facilitating the entry of MMAE into the cancer cells, where"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DSvehqr8w8p3Qqko2k1fnuZY", "custom_id": "658_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c708805d7cdfad98eeb6b5df8b9518d0", "body": {"id": "chatcmpl-9St5EmLZiBLCF6GFEelwwq5wc6LIL", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enhertu (generic name: fam-trastuzumab deruxtecan-nxki) is a targeted therapy used primarily in the treatment of certain types of breast cancer and, more recently, other cancers such as gastric cancer. It is a conjugate drug that combines trastuzumab, a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein, with a cytotoxic agent (deruxtecan), a topoisomerase I inhibitor. This combination allows for the targeted delivery of the chemotherapy agent to the cancer cells that overexpress HER2.\n\nHere are some key points you should know about Enhertu:\n\n1. **Indications**: Enhertu is approved for the treatment of:\n   - HER2-positive breast cancer in patients who have received two or more prior anti-HER2-based regimens.\n   - HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_jBscamwfsrHUrcBsbH4Hf9k1", "custom_id": "659_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd5e90108b62a993c41ad73470695641", "body": {"id": "chatcmpl-9St5ElYHbBdMPYI4TCDTNWKo0ZkHK", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis (abarelix) is a medication that was used primarily in the treatment of advanced symptomatic prostate cancer in men when other treatments were not suitable. It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) antagonists. These drugs work by quickly reducing the production of testosterone, a hormone that can promote the growth of prostate cancer cells.\n\nHere are some key points about Plenaxis:\n\n1. **Mechanism of Action**: Abarelix works by directly blocking the GnRH receptors in the pituitary gland, which leads to an immediate reduction in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby decreasing testosterone levels.\n\n2. **Usage**: It was specifically used for patients with advanced prostate cancer who exhibited symptoms and for whom other hormonal therapies were considered inappropriate. It was an option for patients who needed rapid testosterone suppression.\n\n3. **Administration**: Plenaxis was"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ak3VKVNswOf2A5aH41tfjKZO", "custom_id": "660_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "780997e81462a325fd9396ad33c088f4", "body": {"id": "chatcmpl-9St5E8sm3LdidfFfPgsOLqr5LPQ0O", "object": "chat.completion", "created": 1716671952, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin-blmf) is a medication approved for the treatment of multiple myeloma. Here are some key points you should know about Blenrep:\n\n1. **Indication**: Blenrep is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n2. **Mechanism of Action**: Blenrep is a first-in-class antibody-drug conjugate. The drug consists of a humanized anti-BCMA (B-cell maturation antigen) monoclonal antibody linked to a cytotoxic agent, monomethyl auristatin F (MMAF). It works by specifically targeting and binding to BCMA-expressing cells, predominantly malignant plasma cells in multiple myeloma, and delivering the cytotoxic agent directly to these cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3catI8azZ3u5t9yfJHjSOh9o", "custom_id": "661_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a17d548db6e291f30b2136797d85abcc", "body": {"id": "chatcmpl-9St5FtJSajl3PMXkxwujyCsHr69fw", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tukysa (chemical name: tucatinib) is a medication used in the treatment of cancer, specifically for patients with HER2-positive breast cancer. Here are some key points you should know about Tukysa:\n\n1. **Indications**: Tukysa is approved for use in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n2. **Mechanism of Action**: Tucatinib is a tyrosine kinase inhibitor that specifically binds to the HER2 (human epidermal growth factor receptor 2) tyrosine kinase domain, inhibiting the receptor\u2019s kinase activity. This inhibition leads to a blockage of downstream signaling pathways and induces cell death in HER2-expressing tumor cells.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DS6VGdLpakQn6o31J4FYqa43", "custom_id": "662_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e25c0977232eb0db7a47fa01566db4db", "body": {"id": "chatcmpl-9St5FknuN3YG6GwuyZlDSUQrIWjOp", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination medication used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Darzalex Faspro:\n\n1. **Composition and Mechanism of Action**: Darzalex Faspro combines daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an enzyme that helps increase the absorption of injected drugs. Daratumumab works by binding to CD38, which is highly expressed on the surface of multiple myeloma cells, leading to their destruction through various immune-mediated mechanisms and direct apoptosis.\n\n2. **Administration**: Unlike the original formulation of daratumumab, which is administered intravenously, Darzalex Faspro is given as a subcutaneous injection. This can significantly reduce administration time and improve patient comfort compared to intravenous infusions.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6WzZruZz8BBM8F383Er3rxQi", "custom_id": "663_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d8fa8474bb210f5d42b20e0f4747fc7d", "body": {"id": "chatcmpl-9St5FLBglVDZr4VJgoHE3ZGWpCNct", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin (alitretinoin) is a medication used primarily in the treatment of skin lesions in patients with AIDS-related Kaposi's sarcoma. Here are some key points you should know about Panretin:\n\n1. **Mechanism of Action**: Alitretinoin, the active ingredient in Panretin, is a retinoid, which is a synthetic derivative of vitamin A. It works by inhibiting the growth of Kaposi's sarcoma cells and inducing apoptosis (cell death).\n\n2. **Formulation**: Panretin is available as a gel for topical application. It is typically applied directly to the skin lesions.\n\n3. **Indications**: It is specifically indicated for the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma when other systemic treatments are not required.\n\n4. **Application**: The gel is usually applied two to four times daily, based on the response and tolerance of the patient. The area should be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7pCZEELHDRY9Qi55o65QwjRB", "custom_id": "664_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6bbd10e26190d5514ec1b399ea9636ff", "body": {"id": "chatcmpl-9St5FaWIkLCmBwcaNEgprNckz6Aoq", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is a type of immunotherapy used in the treatment of certain cancers, specifically indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) and for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is one of the CAR T-cell therapies that have been developed to harness the patient's immune system to fight cancer.\n\nHere are some key points about Tecartus:\n\n1. **Mechanism of Action**: Tecartus involves reprogramming the patient\u2019s T-cells to include a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of some cancer cells. This reprogramming is done ex vivo (outside the body), and the modified T-cells are then infused back into the patient where they can identify and kill cancer cells.\n\n2. **Approval and Indications**: Tecartus was first approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_idy4zB59pyPjdAaTRxC50Ql1", "custom_id": "665_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d41f13b0ec596dbdb23abd56863f098", "body": {"id": "chatcmpl-9St5FgF1hEJdB6qAng9L4deH8cqMG", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray (alpelisib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. Here are some key points you should know about Piqray:\n\n1. **Indication**: Piqray is specifically indicated for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant after disease progression following an endocrine-based regimen.\n\n2. **Mechanism of Action**: Piqray is a kinase inhibitor that specifically targets the PI3K pathway, a signaling pathway known to play a role in the growth and proliferation of cancer cells. Alpelisib specifically inhibits the alpha isoform of the PI3K enzyme, which is the most commonly mutated in PIK3CA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gDa7R2McgFwT8MnOOTcazKJ4", "custom_id": "666_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6d91f7cbadda65dbad9bc185a94b75c5", "body": {"id": "chatcmpl-9St5FWewitW9IbFSm3jEy8GcaSFPl", "object": "chat.completion", "created": 1716671953, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinamed is a brand name for the drug praziquantel, which is an anthelmintic medication used primarily to treat infections caused by schistosomes and other parasites such as liver flukes. Here are some key points you should know about Quinamed (praziquantel):\n\n1. **Indications**: Quinamed is indicated for the treatment of schistosomiasis (caused by Schistosoma haematobium, Schistosoma mansoni, and Schistosoma japonicum), clonorchiasis, and opisthorchiasis, which are infections caused by liver flukes.\n\n2. **Mechanism of Action**: Praziquantel increases the permeability of the membranes of schistosome cells to calcium ions, causing severe contractions and paralysis of the parasites' muscles, which leads to their detachment from blood vessel walls and eventual death.\n\n3. **Dosage and Administration**: The dosage of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9Pv5okA1qOd5Smkh04Vv5PN7", "custom_id": "667_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9cce5c023b118160ab29a745aeb3f3b7", "body": {"id": "chatcmpl-9St5GlfXcnDzmX7yXH7bLYsbq4igV", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin, often referred to by the brand name Amoxil and colloquially as \"Amoxi,\" is a widely used antibiotic that belongs to the penicillin class of antibiotics. It is effective against a broad range of bacterial infections and is commonly prescribed to treat conditions such as pneumonia, bronchitis, tonsillitis, and infections of the ear, nose, throat, urinary tract, and skin. Here are some key points you should know about amoxicillin:\n\n1. **Mechanism of Action**: Amoxicillin works by inhibiting the synthesis of bacterial cell walls, ultimately leading to cell lysis and death. It is bactericidal against a variety of gram-positive and some gram-negative bacteria.\n\n2. **Spectrum of Activity**: While effective against a broad spectrum of bacteria, resistance can be an issue, particularly with gram-negative bacteria. It is often used in combination with other medications, such as clavulanic acid (as in Augmentin), to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PfmrKE0MIKEw3srk1BGcWYTS", "custom_id": "668_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a334fd62ba14c83b30f366a43129faf4", "body": {"id": "chatcmpl-9St5GFnpy6f4WIsuGH1nIet5PBgF4", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Amelie\" (also known as \"Le Fabuleux Destin d'Am\u00e9lie Poulain\") is a French romantic comedy film directed by Jean-Pierre Jeunet and released in 2001. The film is not directly related to medical topics, as it focuses on the life of Am\u00e9lie Poulain, a young woman who decides to change the lives of those around her for the better while grappling with her own isolation.\n\nHowever, from a physician's perspective, there are a few indirect aspects related to health and psychology that might be of interest:\n\n1. **Mental Health and Well-being**: Amelie's actions in the film, which involve helping others through small, thoughtful acts, highlight the potential psychological benefits of altruism and kindness, both for the giver and the receiver. The film can be a good reminder of the impact of social connections and positive interactions on mental health.\n\n2. **Social Isolation**: The character of Amelie deals"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MCcBJuFCP51yyx8Vt37J9Bo3", "custom_id": "669_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "362be2447a4b4154ea7ba8ba8811504c", "body": {"id": "chatcmpl-9St5GsYz6F1fMMVjcJPb7AkmHCUPK", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemazyre (pemigatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Here are some key points you should know about Pemazyre:\n\n1. **Indications**: Pemazyre is specifically indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. It is important to confirm the presence of FGFR2 fusion or rearrangement before initiating treatment.\n\n2. **Mechanism of Action**: Pemigatinib is a kinase inhibitor that primarily targets fibroblast growth factor receptors (FGFR) 1, 2, and 3, which are involved in the growth and survival of certain cancer cells. By inhibiting these receptors,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KSDSjV5a3Thnyz3ugdGiSRxS", "custom_id": "670_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e57233e91819db61e94dad23c0ee0b1", "body": {"id": "chatcmpl-9St5GXzajH6Tz3kmxh6yxfiYnScil", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (generic name: ripretinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Here are some key points you should know about Qinlock:\n\n1. **Mechanism of Action**: Ripretinib is a kinase inhibitor that works by targeting a range of mutations in KIT and PDGFRA (platelet-derived growth factor receptor alpha). It acts as a switch-control inhibitor that blocks the kinase activity of these proteins, which are often mutated in GIST and drive the growth of cancer cells.\n\n2. **Indications**: Qinlock is specifically indicated for the treatment of fourth-line GIST. This means it is used in patients who have not responded to or cannot tolerate previous treatments including imatinib, sunitinib, and regorafenib.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BTjUMRhEDBIgyWJlaBQW8LK4", "custom_id": "671_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "25502c62bf1d00eaa609a8f2a34a22ac", "body": {"id": "chatcmpl-9St5GL7TlclrXS6BHKVZsgJxcAIYQ", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of thyroid cancers and non-small cell lung cancer (NSCLC) that harbor specific genetic alterations. Here are some key points you should know about Retevmo:\n\n1. **Indications**:\n   - Retevmo is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\n   - It is also approved for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - Additionally, it is indicated for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n2. **Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2GZU5FK3374YXYlHzpomS6NK", "custom_id": "672_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ab5e335030912805295c7d3c9943fbc", "body": {"id": "chatcmpl-9St5G4kLEkbAmGFVAz0rwJsL5QWnz", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi (decitabine and cedazuridine) is a medication approved by the FDA for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British (FAB) subtypes: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia (CMML). It is also indicated for intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.\n\nHere are some key points about Inqovi:\n\n1. **Combination Therapy**: Inqovi combines two drugs, decitabine, a hypomethylating agent, and cedazuridine, a cytidine deaminase inhibitor. Cedazuridine is included to increase the bioavailability of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Fv7PZgDkOoBABXF8rgdJr5py", "custom_id": "673_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f9ff1774638f13320ad0f30fff545a8", "body": {"id": "chatcmpl-9St5GHKhfEzEZnSVRNrHxCBmvtqG9", "object": "chat.completion", "created": 1716671954, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pepto-Bismol (bismuth subsalicylate) is an over-the-counter medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as nausea, heartburn, indigestion, upset stomach, and diarrhea. Here are some key points you should know about Pepto-Bismol as a physician:\n\n1. **Mechanism of Action**:\n   - Bismuth subsalicylate has antacid properties that can neutralize stomach acid.\n   - It also has antimicrobial effects against bacteria like H. pylori and may bind to toxins produced by E. coli.\n   - The salicylate component has anti-inflammatory properties.\n\n2. **Indications**:\n   - Pepto-Bismol is used for the relief of indigestion, nausea, heartburn, upset stomach, and diarrhea.\n   - It can also be used in the management of Helicobacter pylori infection as part of a combination therapy.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_08Xf0a1PXyCbNiBcSmzPwpHV", "custom_id": "674_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6b5e5c89d834607230364dfb1bfcb673", "body": {"id": "chatcmpl-9St5HmMiYbQYIU5HEZAzCj5bEs1L4", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, AiRuiKa does not refer to any specific medical condition, treatment, or technology that is widely recognized in the medical community. It's possible that the term could be a misspelling, a non-English term, or perhaps a brand or product not well-known or new on the market.\n\nIf AiRuiKa is related to a specific medical device, drug, or treatment method that has emerged recently, I would recommend checking the latest medical literature, FDA releases, or clinical trial registries for the most accurate and up-to-date information. Additionally, attending medical conferences or participating in professional forums might provide insights into new developments under this name.\n\nIf you have more context or details about AiRuiKa, I could help better by providing more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 159, "total_tokens": 201}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_lxpEk9TvSKSc8vsZgK4Jon7H", "custom_id": "675_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5a55b56a21151f920125a45e33ac6786", "body": {"id": "chatcmpl-9St5Ho1f9piI198LDksVtbZ47cUlt", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is a medication approved by the FDA for the treatment of advanced prostate cancer. Here are some key points you should know about Orgovyx:\n\n1. **Mechanism of Action**: Orgovyx is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by directly inhibiting the GnRH receptors in the pituitary gland, which leads to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, ultimately reducing the production of testosterone by the testes.\n\n2. **Indications**: Orgovyx is specifically indicated for the treatment of adult patients with advanced prostate cancer. It is a part of a class of medications known as hormone therapies, which are used to reduce the amount of testosterone made by the body, as testosterone can promote the growth of prostate cancer cells.\n\n3. **Administration**: Orgovyx is administered orally, which can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4fPxtVI15pLTpnCUXaeNnqtz", "custom_id": "676_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b751f34a84ac1ed6df9cfd365e78a284", "body": {"id": "chatcmpl-9St5H9vmdFud6iuRIqC7xoqeG3iLl", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Orserdu (elacestrant) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. Here are some key points you should know about Orserdu:\n\n1. **Indication**: Orserdu is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer with ESR1 mutations, which are detectable by an FDA-approved test, and who have received prior endocrine therapy.\n\n2. **Mechanism of Action**: Orserdu is an oral selective estrogen receptor degrader (SERD). It works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting the receptor's activity. This action helps to block the growth-promoting effects of estrogen on the cancer cells.\n\n3. **Administration**: Orser"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Xe6azdjn6HwO06mb0KPwfNrM", "custom_id": "677_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "54ec8b642e5a75dd192d991ae686995c", "body": {"id": "chatcmpl-9St5HJyCcdsuCYjdsjGA3BQHsbfsS", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin (trimetrexate glucuronate) is a medication that was used primarily as an antimicrobial agent. It is a dihydrofolate reductase inhibitor, which means it inhibits the enzyme responsible for the conversion of dihydrofolate to tetrahydrofolate. This is crucial in the synthesis of nucleic acids and proteins, making trimetrexate an effective inhibitor of cell growth and division.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Neutrexin was primarily used for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in patients with AIDS when conventional therapy was ineffective or not tolerated.\n   - It has also been investigated for use in treating certain cancers due to its mechanism of inhibiting cell growth.\n\n2. **Administration:**\n   - Neutrexin was administered intravenously. The dosing regimen typically required careful consideration of the patient\u2019s condition and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_e4Xpd1yS2uoQxatDru5eYwYM", "custom_id": "678_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "85a0a02418740e067f0f8ebcc17d8e26", "body": {"id": "chatcmpl-9St5HEmTlUOaVop3QHnlGJy7FzXkY", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tepmetko (tepotinib) is a medication approved for the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Tepmetko:\n\n1. **Indication and Usage**: Tepmetko is specifically indicated for the treatment of adult patients with metastatic NSCLC harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. This mutation can be identified through FDA-approved tests, which are used to detect specific genetic mutations in the tumor tissue or plasma.\n\n2. **Mechanism of Action**: Tepotinib is a MET inhibitor. It works by selectively targeting the MET tyrosine kinase, which is involved in the growth, migration, and angiogenesis of cancer cells. By inhibiting this pathway, tepotinib can help to control tumor growth and spread.\n\n3. **Administration**: Tepmetko is administered orally. The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yrnE6HhrUuzKEq5fUIMYxe8j", "custom_id": "679_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca4f1a0f3c7a4ad6f45bccfd6cd989e5", "body": {"id": "chatcmpl-9St5Hgm2Bm5NAkswVwHnBR56tfIXw", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Lytgobi (futibatinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intraheptic cholangiocarcinoma (bile duct cancer) who have a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Here are some key points you should know about Lytgobi:\n\n1. **Mechanism of Action**: Lytgobi is a kinase inhibitor that specifically targets FGFR1-4, which can be abnormally activated in several types of cancers. By inhibiting these receptors, Lytgobi can block the downstream signaling pathways that promote cancer cell proliferation and survival.\n\n2. **Indications**: It is specifically indicated for patients with FGFR2 fusion or rearrangement, which should be confirmed through an FDA-approved test prior to starting treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P9tJNwKIYC8fZ7B8RP6yRuoT", "custom_id": "680_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "28230e7c31d7937fb5da2610cd43b779", "body": {"id": "chatcmpl-9St5Hr5E6ssWfZeQEqdgdGCzr1qPs", "object": "chat.completion", "created": 1716671955, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used in the treatment of glioblastoma, which is one of the most aggressive types of brain cancer. It is a non-invasive, portable device that creates low-intensity electric fields, termed Tumor Treating Fields (TTFields), to disrupt cell division, inhibiting tumor growth and potentially killing cancer cells.\n\nHere are key points you should know about Optune:\n\n1. **Indications**: Optune is FDA-approved for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM) in combination with temozolomide after surgical and radiation therapy, and for the treatment of recurrent GBM as a monotherapy after surgical and radiation options have been exhausted.\n\n2. **Mechanism of Action**: The device generates alternating electric fields through adhesive transducer arrays placed on the scalp. These fields are believed to exert physical forces on electrically charged components of the cell during division, thereby disrupting the normal mitotic process and leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MmZPHUskuTRlHtmNYWnnXz2A", "custom_id": "681_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "09e279e97bd1ac954ba8d28ae14e5f5d", "body": {"id": "chatcmpl-9St5IKu3eiFhHH1AE3GCKP7oC3QKM", "object": "chat.completion", "created": 1716671956, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel, also known as liso-cel) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy used in the treatment of certain types of B-cell lymphomas. This therapy is specifically indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\nHere are some key points you should know about Breyanzi:\n\n1. **Mechanism of Action**: Breyanzi consists of autologous T cells that are genetically modified to include a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of B-cells. This allows the T cells to recognize and eliminate CD19-expressing cells.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_WpuoKXTMoefSfWjzhOKT9u4t", "custom_id": "682_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2428669f67b78872815b48deeef76a23", "body": {"id": "chatcmpl-9St5IyyoluPgEtRFefd2CyrkyWsVn", "object": "chat.completion", "created": 1716671956, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abecma (idecabtagene vicleucel) is a prescription medication used in the treatment of multiple myeloma, specifically indicated for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. It is a form of CAR T-cell therapy, which is a type of cancer treatment that uses a patient's own genetically modified T cells to attack cancer cells.\n\nHere are some key points about Abecma:\n\n1. **Mechanism of Action**: Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It involves reprogramming the patient\u2019s T cells to include a chimeric antigen receptor (CAR) that targets BCMA, a protein expressed on the surface of myeloma cells.\n\n2. **Administration**: The process involves collecting the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IHcfbWXovFBBVCzBynEJBYC8", "custom_id": "683_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "870f5c6f8ddd52fe0fbe7a80c9eb40ec", "body": {"id": "chatcmpl-9St5IHGKuVmmfZGafpzNylF7z0xWa", "object": "chat.completion", "created": 1716671956, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (avapritinib) is a prescription medication used to treat certain types of cancer. Here are some key points you should know about Ayvakit:\n\n1. **Indications**: Ayvakit is approved by the FDA for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) who harbor a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It is also approved for the treatment of advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.\n\n2. **Mechanism of Action**: Avapritinib is a kinase inhibitor that specifically targets KIT and PDGFRA mutant kinases. It is highly selective for these mutations, which are commonly involved in the pathogenesis of GIST and systemic mastocytosis.\n\n3. **Dosage and Administration**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_0dW4WYQQ0pxFt25BW5CLx1tE", "custom_id": "684_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "224d5b0ba0f9c876593e45176ca9d144", "body": {"id": "chatcmpl-9St5IModNwPipH4GW4EeE3HdsIW0v", "object": "chat.completion", "created": 1716671956, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Turalio (pexidartinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. TGCT, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath, is a rare tumor that affects the synovium, bursae, and tendon sheaths.\n\nHere are some key points about Turalio that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Turalio is a tyrosine kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R), which is a driver of the proliferation of abnormal cells in TGCT. By inhibiting CSF1R, Turalio helps reduce the growth of these cells.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z5usmman00HwjeRK4bLyEl1s", "custom_id": "685_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe2e214e7aba62568660ba9e6d8d9212", "body": {"id": "chatcmpl-9St5IWhBuqgs59SFkii5t2vAMu3uU", "object": "chat.completion", "created": 1716671956, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gavreto (pralsetinib) is a targeted therapy approved for the treatment of certain types of cancer. Here are some key points you should know about Gavreto:\n\n1. **Indications**: Gavreto is approved by the FDA for the treatment of:\n   - Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).\n   - Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n2. **Mechanism of Action**: Gavreto is a kinase inhibitor that specifically targets RET alterations, which are genetic abnormalities that can lead to uncontrolled cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pA4uZFY7VIfvSkffsv525n7N", "custom_id": "686_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "662e43e3a39aa07cfe1757bcbd65d5f2", "body": {"id": "chatcmpl-9St5JWjfL1SOx7tUZIj0goPcQNfzW", "object": "chat.completion", "created": 1716671957, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zepzelca (lurbinectedin) is a medication used in the treatment of cancer, specifically indicated for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. Here are some key points you should know about Zepzelca:\n\n1. **Mechanism of Action**: Lurbinectedin is a selective inhibitor of oncogenic transcription. It specifically binds to CG-rich sequences in the minor groove of DNA, blocking the transcription of oncogenes and other genes involved in the cell cycle. This leads to the halting of the cell cycle and induces apoptosis (cell death).\n\n2. **Approval and Indications**: Zepzelca was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in June 2020 based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Kp9DIuW0KLUn2A1L64COI4YF", "custom_id": "687_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e92585bc00229c36bff16d0627c4805d", "body": {"id": "chatcmpl-9St5JIianm7xyD9v4VxTynGtFcA1v", "object": "chat.completion", "created": 1716671957, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flagyl, the brand name for metronidazole, is an antibiotic that is commonly used to treat various infections, particularly those caused by bacteria and certain parasites. Here are some key points you should know about Flagyl as a physician:\n\n1. **Indications**: Flagyl is effective against anaerobic bacteria and protozoa. It is commonly prescribed for bacterial vaginosis, trichomoniasis, and infections of the stomach, skin, joints, and respiratory tract. It is also used in the treatment of pseudomembranous colitis caused by Clostridium difficile and in the eradication of Helicobacter pylori as part of combination therapy.\n\n2. **Mechanism of Action**: Metronidazole works by entering microbial cells and interacting with their DNA, causing a loss of helical DNA structure and strand breakage, which results in inhibition of nucleic acid synthesis and ultimately leads to the death of the bacterial cells.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6b6f9nCZqcYlVv3UNdvk2Ofp", "custom_id": "688_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62dff14c99caf0ff7aa5056349a910be", "body": {"id": "chatcmpl-9St5JtDO8TQDwZedkrQjFg6RqLqSw", "object": "chat.completion", "created": 1716671957, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danyelza (naxitamab) is a monoclonal antibody used in the treatment of certain types of cancer, specifically high-risk neuroblastoma in bone or bone marrow. Here are some key points you should know about Danyelza:\n\n1. **Indications**: Danyelza is approved by the FDA for use in pediatric patients aged one year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n2. **Mechanism of Action**: Danyelza targets the GD2 antigen, which is highly expressed on neuroblastoma cells. By binding to this antigen, Danyelza can activate immune cells to kill the cancer cells.\n\n3. **Administration**: Danyelza is administered via intravenous infusion. It is typically given in combination with granulocyte-macrophage colony-stimulating factor ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PnvmOz0RcfysB4rkw56TlYrm", "custom_id": "689_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3961708246b224e60fae42c27d87b3cf", "body": {"id": "chatcmpl-9St5JYzOkvmpEMKv4OaQiX3zP5TmS", "object": "chat.completion", "created": 1716671957, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panmycin is a brand name for tetracycline, an antibiotic used to treat a variety of bacterial infections. As a physician, here are some key points you should know about Panmycin:\n\n1. **Spectrum of Activity**: Tetracycline is effective against a broad range of gram-positive and gram-negative bacteria. It is commonly used for infections such as acne, chlamydia, Lyme disease, and respiratory tract infections.\n\n2. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria, thereby preventing their growth and multiplication. It binds to the 30S ribosomal subunit, blocking the attachment of tRNA to the mRNA-ribosome complex.\n\n3. **Administration**: Tetracycline is typically administered orally. It should be taken on an empty stomach, at least 1 hour before or 2 hours after meals, with a full glass of water. This is because food and some dairy products can interfere with its absorption"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8F3DeRP0phhaZPs6VftlMBdK", "custom_id": "690_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c49da07bdf8541c5bdd6ff7cbd6f7f4e", "body": {"id": "chatcmpl-9St5KTmJiQaR8WzlxvySZlo2PTgxr", "object": "chat.completion", "created": 1716671958, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab (tripotassium dicitrato bismuthate) is a medication used primarily for the treatment of peptic ulcers and gastritis. It works by coating the ulcer site and protecting it from stomach acid and enzymes, thus allowing healing to occur. Additionally, it has antibacterial effects against Helicobacter pylori, a bacterium often implicated in the pathogenesis of gastric ulcers and chronic gastritis.\n\nHere are some key points you should know about De-Noltab:\n\n1. **Mechanism of Action**: De-Noltab releases bismuth ions in the stomach, which have cytoprotective and antimicrobial properties. It forms a protective layer over the ulcer base and ulcer margins, and its antibacterial action helps reduce Helicobacter pylori colonization.\n\n2. **Indications**: It is primarily used for the treatment of peptic ulcers and gastritis. It can be used as part of combination therapy for Helicobacter"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lWCyvxGh8U959JuzbkssMHND", "custom_id": "691_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5f304ac901f92cb7afbf5cb645cacdb5", "body": {"id": "chatcmpl-9St5KuO86lJ2gi7zloUvlNMU1O1GW", "object": "chat.completion", "created": 1716671958, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication approved by the U.S. Food and Drug Administration (FDA) for treating certain types of tumors associated with von Hippel-Lindau (VHL) disease in adults who do not require immediate surgery. VHL disease is a rare genetic disorder that can cause tumors and cysts to grow in various parts of the body. These tumors can be either benign or cancerous.\n\nHere are some key points about Welireg:\n\n1. **Mechanism of Action**: Welireg works by inhibiting hypoxia-inducible factor 2 alpha (HIF-2\u03b1), which is a protein that plays a role in the body\u2019s response to low oxygen levels. Inhibiting HIF-2\u03b1 can help reduce the growth and spread of tumors.\n\n2. **Indications**: Welireg is specifically indicated for the treatment of patients with VHL disease who have renal cell carcinoma (RCC), central nervous system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RWE8qvWw77Xdvbi7TAB8jG0C", "custom_id": "692_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6074030715838374a7346eef2965ec90", "body": {"id": "chatcmpl-9St5N4ksKbUkZ3KvYS3G1OHnz4sxs", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rybrevant (amivantamab-vmjw) is a prescription medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Rybrevant:\n\n1. **Indication and Usage**: Rybrevant is approved by the FDA for the treatment of adult patients with NSCLC whose tumors have specific genetic mutations, namely epidermal growth factor receptor (EGFR) exon 20 insertion mutations. It is indicated for use after the disease has progressed on or after platinum-based chemotherapy.\n\n2. **Mechanism of Action**: Rybrevant is a bispecific antibody that targets both the EGFR and MET receptor tyrosine kinases. By binding to these receptors, Rybrevant inhibits tumor cell proliferation and induces tumor cell death.\n\n3. **Administration**: Rybrevant is administered via intravenous infusion. The initial dose is typically given as a split infusion to manage potential infusion-related reactions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yseyaOYMQZSCT7XqQTpWkRtQ", "custom_id": "693_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ec10964224563db0f3084809442da16", "body": {"id": "chatcmpl-9St5K7i1ntdZ1Hb9EgztNnmf9oC6d", "object": "chat.completion", "created": 1716671958, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg is the brand name for azacitidine, which is a form of oral hypomethylating agent. It is primarily used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about Onureg:\n\n1. **Indications**: Onureg is approved by the FDA for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. This indication is based on the results from clinical trials that showed an improvement in overall survival.\n\n2. **Mechanism of Action**: Azacitidine, the active ingredient in Onureg, is a nucleoside metabolic inhibitor that works by incorporating into RNA and DNA, which results in the inhibition of DNA methylation and RNA and protein synthesis. This leads to cell death in rapidly dividing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JVQYOZLTg13z3aqEYLLDTYpY", "custom_id": "694_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9110c0699c88b0974802d6fb5e8ead4e", "body": {"id": "chatcmpl-9St5L5DN3kD4PgHWDTToWQlHWCYVj", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys is the brand name for colchicine, a medication primarily used to treat and prevent gout attacks and familial Mediterranean fever (FMF). Here are some key points you should know about Colcrys:\n\n1. **Mechanism of Action**: Colchicine works by reducing inflammation through the inhibition of microtubule polymerization, which in turn affects the function of neutrophils. This action helps to alleviate inflammation and pain associated with gout flares.\n\n2. **Indications**:\n   - **Gout**: Colcrys is used to prevent and treat gout flares. It is effective at reducing pain and inflammation during acute attacks and can be used for prophylaxis in patients with recurrent episodes.\n   - **Familial Mediterranean Fever (FMF)**: It is used for the treatment of FMF, a hereditary inflammatory disorder.\n\n3. **Dosage and Administration**:\n   - The dosage of Colcrys may vary depending on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dx0c37LXlNuWzc13k9iy5JW6", "custom_id": "695_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc2db53e20a8cb7ebcbfd01f6424b386", "body": {"id": "chatcmpl-9St5LdiHIyP2IPowvC7zmcqvd5DT7", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jemperli (dostarlimab) is a medication used in the treatment of certain types of cancer. It is a programmed death receptor-1 (PD-1)\u2013blocking antibody, which is a type of immune checkpoint inhibitor. Dostarlimab works by enhancing the body's immune system to help it fight cancer.\n\nHere are some key points about Jemperli that you, as a physician, might find useful:\n\n1. **Indications**: As of the last update, Jemperli is approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. It is also approved for dMMR solid tumors that have progressed after treatment and who have no satisfactory alternative treatment options.\n\n2. **Mechanism of Action**: Dostarlimab binds to the PD-1 receptor on T cells and blocks its interaction with PD-L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MVRcXYdFl5bVQYlWB1SEMZ5g", "custom_id": "696_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb97ae49f1965e33a0981fc2407e4404", "body": {"id": "chatcmpl-9St5Lm0Td3mLX3zrjOU8bCcBf0F3r", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Hansizhuang\" does not refer to a specific medical condition, treatment, or concept that is commonly recognized within the medical community. It's possible that it could be a term from a different field or a misspelling. If you have more context or details about where you encountered this term or what it relates to, I could try to provide more relevant information. Alternatively, if it's a new or emerging topic, I recommend consulting the latest medical literature or a trusted medical database for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 111, "total_tokens": 153}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_U2ZdCa6AUy0br86egRpL8EA5", "custom_id": "697_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "10f68d269bec49c603b20e8ed309bb93", "body": {"id": "chatcmpl-9St5LgGYagGSYKwp6ubS8Hxw5xiHa", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Cejemly\" in standard medical or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in mainstream sources.\n\nIf \"Cejemly\" is a drug you've encountered in practice or literature, I recommend checking the following:\n\n1. **Spelling and Nomenclature**: Verify the spelling. It could be a brand name, generic name, or a drug marketed under a different name in different countries.\n\n2. **Pharmaceutical Databases**: Consult comprehensive pharmaceutical databases or resources like the U.S. National Library of Medicine, FDA database, or WHO's list of essential medicines for any updates or information.\n\n3. **Medical Literature**: Search through recent medical journals or publications. Sometimes new drugs or lesser-known treatments are discussed there before becoming widely recognized.\n\n4. **Drug Regulatory Agencies**: Check with drug regulatory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zpzV8QWW1gaSjL0p5xMLxE09", "custom_id": "698_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b87d26754ce566e1f7acc370fea4433", "body": {"id": "chatcmpl-9St5LEqT0rVr9xsbexVKZyfXvkRdR", "object": "chat.completion", "created": 1716671959, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Fyarro\" does not refer to any known medication, treatment, or medical technology recognized in standard medical practice. It's possible that you might be referring to something very new, or it could be a misspelling or a non-standard term. If you have more context or details about where you heard the term or what it pertains to, I could try to provide more relevant information. Alternatively, it might be helpful to consult the latest medical literature or databases for any updates or to confirm the correct terminology."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 110, "total_tokens": 151}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1pJqAeOpOE2FDCqtCLxKZ4Fo", "custom_id": "699_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "56cd499d787cef6faaa35739dbe25bd0", "body": {"id": "chatcmpl-9St5MuIkaXZFIi4DkFxLI4vIIuTdv", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Antrypol\" in standard medical or pharmaceutical references. It's possible that the name could be a misspelling, a brand name not widely recognized, or a new drug not yet documented in mainstream sources.\n\nIf \"Antrypol\" is a drug you've encountered in a specific context (such as a research trial, a drug in development, or a product in a specific market outside mainstream channels), I would recommend checking the following sources for more reliable information:\n\n1. **Official Drug Regulatory Agencies**: Websites like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), or other national bodies can provide information if the drug is under consideration or approved in their respective regions.\n\n2. **Scientific Journals**: Searching through databases like PubMed can help identify any research papers associated with the drug.\n\n3. **Drug Databases**: Resources like Micromedex, UpToDate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fqNzxzf0iwfOIMjooZrHNN4Q", "custom_id": "700_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "860195c78935240781159f34f0e12d2d", "body": {"id": "chatcmpl-9St5Mn7vM3d6dH5dsn7CA5c8i20SU", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medical or pharmaceutical reference to \"Krazati.\" It's possible that you might be referring to a term, drug, or concept that is either misspelled, very new, or not widely recognized in the medical community. If you could provide more context or details, I might be able to assist you better. Alternatively, if \"Krazati\" is a brand name, experimental treatment, or a term from a specific medical research area that has emerged recently, I recommend checking the latest medical literature or clinical trial registries for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 121, "total_tokens": 162}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qIoU26UVYt0cBK33oXHHh27A", "custom_id": "701_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b995439689f8017b18ab1c40794e5d8", "body": {"id": "chatcmpl-9St5MWGPlExKbA1RL0fCFi42uS3H1", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (tebentafusp-tebn) is a novel therapeutic agent approved by the U.S. Food and Drug Administration (FDA) in January 2022 for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Uveal melanoma is a rare and aggressive form of melanoma that occurs in the eye, and it has historically been challenging to treat effectively.\n\n### Mechanism of Action:\nKimmtrak is a bispecific fusion protein composed of a soluble T cell receptor fused to an anti-CD3 immune-effector function. It specifically targets the gp100 peptide presented by HLA-A*02:01 on melanoma cells. By binding to both the T cell (via CD3) and the melanoma cell (via gp100), Kimmtrak redirects T cells to kill the tumor cells, thereby harnessing the body\u2019s immune system to fight the cancer.\n\n### Key Points for Physicians:\n1."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9dwGdbDTm9I4DAqd8dw8BhDj", "custom_id": "702_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6e7a375066c71eb5ba11a3346b8468d6", "body": {"id": "chatcmpl-9St5M92xkPsYw8yBW8VUnZ74ee9As", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (fedratinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Here are some key points you should know about Inrebic:\n\n1. **Indications**: Inrebic is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n2. **Mechanism of Action**: Fedratinib is a kinase inhibitor that primarily targets Janus Associated Kinases (JAKs) with activity against JAK2 and FLT3. These kinases play roles in signaling pathways that are important for the maintenance and growth of myelofibrosis cells.\n\n3. **Dosage and Administration**: The recommended starting dose of Inrebic is 400 mg taken orally once daily with or without food. D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tl1gGhEmWiZvNQKjgcUvf19v", "custom_id": "703_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c262c5bb2c13f5ecd563d312df73bb2", "body": {"id": "chatcmpl-9St5M4jG50FCXCYm2t0Dw7GAIQk8y", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination medication used in the treatment of certain types of breast cancer. It is specifically indicated for patients with HER2-positive breast cancer, which is a subtype of breast cancer characterized by overexpression of the HER2 protein. Here are some key points you should know about Herceptin Hylecta:\n\n1. **Composition and Mechanism of Action**: Herceptin Hylecta combines trastuzumab, a monoclonal antibody that targets the HER2 receptor, with hyaluronidase, an enzyme that increases tissue permeability, facilitating the subcutaneous delivery of trastuzumab.\n\n2. **Indications**: It is approved for the treatment of HER2-overexpressing breast cancer. It can be used in several contexts:\n   - As part of a treatment regimen for early breast cancer, including use with chemotherapy or as part of a treatment plan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7hl51potrACW0YqqM7WIYQLO", "custom_id": "704_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5363898c0a5cbc46b208b979c4cd0d9b", "body": {"id": "chatcmpl-9St5M7yoFaOeKdZtrVUxelOhxLtqL", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brukinsa (zanubrutinib) is a medication used in the treatment of certain types of blood cancers. Here are some key points you should know about Brukinsa:\n\n1. **Indications**: Brukinsa is approved for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is also used in the treatment of Waldenstr\u00f6m's macroglobulinemia and for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**: Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking BTK, which is a key molecule in the B cell receptor signaling complex that plays a crucial role in the proliferation, survival, and migration of malignant B cells. By inhibiting BTK, zanubrutinib helps to halt the growth of cancerous cells.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_loDJHonChBs16dT0momaOWjl", "custom_id": "705_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41560485fa98b89d72a1ff829a3408e5", "body": {"id": "chatcmpl-9St5M2aB9Ag17gYXh1W4YVaCjfRQh", "object": "chat.completion", "created": 1716671960, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Ivesa\" in the context of healthcare, medicine, or pharmacology. It's possible that \"Ivesa\" could be a brand name, a term specific to certain regions, or a new development not covered in my training data.\n\nIf \"Ivesa\" refers to a drug, treatment, or medical concept that has emerged after my last update, I recommend consulting the latest medical literature, drug databases like the FDA or EMA websites, or pharmaceutical company releases for the most accurate and up-to-date information. Additionally, discussing with colleagues or attending relevant medical conferences might provide insights into new developments in the field."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 142, "total_tokens": 183}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wOQaHYevmh2h5hm8h4cctBGQ", "custom_id": "706_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "088e26aa4b75fe8e3638bd1f4c724b17", "body": {"id": "chatcmpl-9St5Nm4s5gyckHfMCI5Nwr2RxRkKY", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel, also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of multiple myeloma. Here are some key points you should know about Carvykti:\n\n1. **Indication and Usage**: Carvykti is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n2. **Mechanism of Action**: Carvykti is a CAR T-cell therapy, which involves modifying a patient's own T cells to include a chimeric antigen receptor that specifically targets B-cell maturation antigen (BCMA), a protein typically found on the surface of myel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_OlD0kdeRaipILZzVASCKqXdB", "custom_id": "707_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "393a47e350943a9d195e18cefb6eca57", "body": {"id": "chatcmpl-9St5NieUuKStRMklBZordK1l5tnH1", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Scemblix (asciminib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of chronic myeloid leukemia (CML). Here are some key points you should know about Scemblix:\n\n1. **Indications**: Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have received two or more prior therapies including tyrosine kinase inhibitors (TKIs). It was approved based on its efficacy in patients who have resistance or intolerance to previous therapies.\n\n2. **Mechanism of Action**: Asciminib, the active ingredient in Scemblix, is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. It works by a different mechanism compared to traditional TKIs. Asciminib binds to the myristoyl site of the ABL kinase, stabilizing the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_UIdoahonuHwhVX4rn8I119sH", "custom_id": "708_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7fc82615eedd6a0d88910b87b11c886b", "body": {"id": "chatcmpl-9St5NeC180hh9aFHKW6Jh9Y0mGJdt", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Zynlonta (loncastuximab tesirine) is a CD19-directed antibody-drug conjugate (ADC) used in the treatment of certain types of B-cell lymphomas. It is specifically indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and also other lymphomas that are classified as large B-cell lymphomas.\n\nHere are some key points about Zynlonta:\n\n1. **Mechanism of Action**: Zynlonta consists of a humanized monoclonal antibody against CD19, a protein expressed on the surface of B-cell lymphocytes and related malignancies. The antibody is conjugated to a cytotoxic agent, which is released upon binding to CD19-expressing cells, leading to targeted cell death.\n\n2. **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h8OaPJsctiLgztUI7ntTutpU", "custom_id": "709_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "330ed5b44e69409de53a877875886d13", "body": {"id": "chatcmpl-9St5N5rJ4SnGBGLuYVBYRzQrn8lCO", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tazverik (tazemetostat) is a medication approved by the U.S. Food and Drug Administration (FDA) for specific types of cancer. Here are some key points you should know about Tazverik:\n\n1. **Mechanism of Action**: Tazverik is an inhibitor of the enzyme EZH2 (enhancer of zeste homolog 2). EZH2 is a methyltransferase that can influence gene expression by modifying histone proteins. The inhibition of EZH2 can lead to reduced proliferation of cancer cells in diseases where EZH2 is dysregulated.\n\n2. **Indications**:\n   - **Epithelioid Sarcoma**: Tazverik is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This approval marks it as the first treatment specifically indicated for this rare type of sar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HNigCELifHKo3VCSwFBVUnRD", "custom_id": "710_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d0f2d8b6acd55724825da0c3cd7d1ef", "body": {"id": "chatcmpl-9St5NDFBPaYQkPQeTww1CdmUzSnno", "object": "chat.completion", "created": 1716671961, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag (nivolumab and relatlimab-rmbw) is a combination immunotherapy medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Here are some key points you should know about Opdualag:\n\n1. **Indications**: Opdualag is approved for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma. It is important to verify the specific indications and guidelines as they can evolve with ongoing research and regulatory review.\n\n2. **Mechanism of Action**: Opdualag combines two immune checkpoint inhibitors. Nivolumab is a PD-1 (Programmed Death-1) inhibitor, and relatlimab is an LAG-3 (Lymphocyte Activation Gene-3) blocking antibody. This combination aims to enhance the body's immune response against cancer cells by blocking these inhibitory receptors on T cells.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tGXC3ZBxQ7goTeKD6pZ4JPhA", "custom_id": "711_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc8342ece6dcd46b0bf47695255b46e6", "body": {"id": "chatcmpl-9St5OqeGt2snehdOq0XpAeYzPCO7U", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Berofor\" does not appear to be a recognized medication or treatment in standard medical resources. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet well-documented in mainstream medical literature.\n\nIf \"Berofor\" is a specific drug or treatment you've encountered, I recommend checking the following:\n\n1. **Spelling and Nomenclature**: Verify the spelling. It could be a brand name or a generic name that is not widely used or recognized.\n\n2. **Local Drug Databases**: Some drugs are marketed under different names in different countries or might be a newer drug that has not yet been widely documented. Checking local or national drug databases might provide more information.\n\n3. **Consult Pharmacists or Drug Representatives**: They might have the latest information on new or less common drugs, including usage, indications, and contraindications.\n\n4. **Latest Medical Literature**: Searching through the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MSCD8Q8JRpP2zv99lLOOLCMv", "custom_id": "712_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e99fba5a4812600eeb1c5c140102226", "body": {"id": "chatcmpl-9St5OaOIbId0idIXnXwes5DQh4Hem", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon, also known as interferon gamma-1b, is a medication used primarily in the treatment of chronic granulomatous disease (CGD) and severe malignant osteopetrosis. Here are some key points you should know about Wellferon:\n\n1. **Mechanism of Action**: Wellferon is a synthetic version of interferon gamma, a naturally occurring protein that modulates the activity of the immune system. It enhances the functioning of macrophages and neutrophils, which are crucial in fighting infections.\n\n2. **Indications**:\n   - **Chronic Granulomatous Disease (CGD)**: It is used to decrease the frequency and severity of infections in patients with CGD, a rare disorder that affects the immune system's ability to kill certain bacteria and fungi.\n   - **Severe Malignant Osteopetrosis**: It is used to treat certain forms of severe malignant osteopetrosis, a genetic disorder that affects bone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_68Dn18XzhVXyvP7RfPXrtFWw", "custom_id": "713_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9562e9eb08c88e79e20c44dc30bc8c1d", "body": {"id": "chatcmpl-9St5OrgC0Jpvx4ReAyVx0lXbXb30R", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a monoclonal antibody used in the treatment of cancer, specifically for patients with metastatic HER2-positive breast cancer. Here are some key points you should know about Margenza:\n\n1. **Indication and Usage**: Margenza, in combination with chemotherapy, is approved for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margenza is a monoclonal antibody that targets the HER2/neu receptor, a protein overexpressed in some breast cancer cells. It is engineered to have an increased ability to recruit immune cells and to improve the immune-mediated killing of tumor cells compared to older HER2-targeted therapies.\n\n3. **Administration**: Margenza is administered via intravenous infusion. The initial dose is typically given over 120 minutes, and if"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OtKssdSIUgyhgQkdbODgwFa9", "custom_id": "714_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dec87bc40260cbfea12e93ad4971e631", "body": {"id": "chatcmpl-9St5OJrUwDFVcsQJ4DmBO7FlnX0GS", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumakras (sotorasib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) who have specific genetic mutations. Here are some key points you should know about Lumakras:\n\n1. **Indication and Usage**:\n   - Lumakras is specifically indicated for the treatment of adults with locally advanced or metastatic NSCLC who have a Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. This mutation should be confirmed by an FDA-approved test prior to starting treatment.\n\n2. **Mechanism of Action**:\n   - Sotorasib, the active ingredient in Lumakras, is a KRAS G12C inhibitor. It works by selectively targeting and irreversibly binding to the KRAS G12C mutant protein, which is a common mutation in NSCLC. By inhibiting this protein, Lum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_gNYVk9OLY6xL9lW3s2JZIKH3", "custom_id": "715_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9659337ed93f32014f0979b8adbd4e5c", "body": {"id": "chatcmpl-9St5OGj4dVdYlzhsSqMfejKLkUgY2", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is a medication used in the treatment of certain types of cancers, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is important for physicians to be aware of several key aspects of this medication:\n\n1. **Indications**: Ukoniq is approved by the FDA for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies.\n\n2. **Mechanism of Action**: Ukoniq is a small molecule inhibitor of PI3K-delta and CK1-epsilon. PI3K-delta signaling is known to promote the survival, proliferation, and differentiation of B-cells, which are critical in the pathogenesis of many B-cell malignancies.\n\n3. **Administration**: Ukoniq is administered orally, which can be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qY5Vcwpa6bBr2tlwLedmBDc4", "custom_id": "716_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "94be20c49831b0642667f1d4602bd9b8", "body": {"id": "chatcmpl-9St5OJhWP2KNI9G819QPy2t6VDgXz", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (sintilimab injection) is an immunotherapy drug used in the treatment of certain types of cancer. It is a PD-1 (programmed death receptor-1) inhibitor, which works by enhancing the body's immune response against cancer cells. Sintilimab binds to the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, thereby activating T cells and enhancing the immune response to help kill cancer cells.\n\nHere are some key points you should know about Tyvyt:\n\n1. **Indications**: Tyvyt has been approved in some regions for the treatment of specific types of cancers, such as non-small cell lung cancer (NSCLC). The indications can vary by country, so it's important to check local regulatory approvals.\n\n2. **Administration**: Tyvyt is typically administered via intravenous infusion. The dosage and treatment regimen depend on the specific indication and patient factors such as body weight and overall"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c1tudmImLoFIYB2m7Fd19jn9", "custom_id": "717_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8a6daac2d429e00e249e714c26679527", "body": {"id": "chatcmpl-9St5OvG6wpE6zlHnbgxMcrz8TxZOd", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jaypirca (pirtobrutinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer, specifically adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a BTK inhibitor. This approval was granted in January 2023.\n\nJaypirca belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. It is designed to inhibit both wild-type and C481-mutated BTK. The mutation at C481 in BTK is a common mechanism of resistance to other BTK inhibitors, making Jaypirca a potentially effective option for patients who have developed resistance to previous BTK inhibitor therapies.\n\nHere are some key points about Jaypirca:\n\n1. **Mechanism of Action**: Jaypirca selectively inhibits the activity of BTK, an enzyme that plays a crucial role"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Bn0gAzTtTtPrXB8cEu88zKwr", "custom_id": "718_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4785f0ffcd0c94197776977799283e7f", "body": {"id": "chatcmpl-9St5OHjjFtfri1r6kOQAVRHbA3tnh", "object": "chat.completion", "created": 1716671962, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Tuoyi\" does not correspond to any widely recognized medical term, medication, or treatment in standard medical practice. It's possible that \"Tuoyi\" could be a brand name, a term from alternative medicine, or perhaps a misspelling or miscommunication.\n\nIf you are referring to a specific drug, treatment, or concept that might be known by a different name or is new on the market, I recommend checking the latest medical literature, drug databases, or clinical trial registries for the most accurate and up-to-date information. Additionally, consulting with pharmacists or other specialists in the field might provide more clarity. If you have more context or a different spelling, I can help look up more precise information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 151, "total_tokens": 192}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MZrZBgONnWZ7cPdvR708aiAi", "custom_id": "719_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1366f01a409306cecc0327a0c8542fe0", "body": {"id": "chatcmpl-9St5PsKrpofkg4iA45Im93Cwi7b66", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tecvayli (teclistamab) is an innovative medication approved for the treatment of multiple myeloma. Here are some key points you should know about Tecvayli:\n\n1. **Mechanism of Action**: Tecvayli is a bispecific antibody that targets both BCMA (B-cell maturation antigen) and CD3. BCMA is expressed on the surface of myeloma cells, and CD3 is present on T-cells. By binding to both, Tecvayli brings the T-cells into close proximity to the myeloma cells, which promotes T-cell activation and subsequent killing of the myeloma cells.\n\n2. **Indications**: Tecvayli is typically indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclon"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h6clNDSSm4xIG8JHLgEjDH7r", "custom_id": "720_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "894a50e4d13624a1345dee64053740d2", "body": {"id": "chatcmpl-9St5PqunUFDUYteWLr90zN9zf22hN", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exkivity (mobocertinib) is an oral medication approved by the FDA for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations are detected by an FDA-approved test and represent a subset of NSCLC that is particularly challenging to treat due to its resistance to conventional EGFR tyrosine kinase inhibitors.\n\nHere are some key points about Exkivity:\n\n1. **Mechanism of Action**: Mobocertinib is a kinase inhibitor that specifically targets EGFR exon 20 insertion mutations. By inhibiting these mutant forms of EGFR, mobocertinib can block the growth and proliferation of tumor cells.\n\n2. **Approval and Indications**: Exkivity was approved by the FDA in September 2021 based on the results of a clinical trial that demonstrated its efficacy in patients with NSCLC harboring EG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vK03QVvxVlSYvJUJCprYSsYb", "custom_id": "721_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d4fc9d343d17139d3e61b2dd105958f", "body": {"id": "chatcmpl-9St5Pcu2SC0R2uezZrZckAAqae1BI", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tivdak (tisotumab vedotin-tftv) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or metastatic cervical cancer who have previously undergone chemotherapy. Here are some key points you should know about Tivdak:\n\n1. **Mechanism of Action**: Tivdak is an antibody-drug conjugate (ADC) that consists of a human monoclonal antibody targeting tissue factor, which is linked to a cytotoxic agent, monomethyl auristatin E (MMAE). Tissue factor is a protein frequently found on the surface of cancer cells and is involved in tumor growth, angiogenesis, and metastasis. The drug binds to tissue factor-expressing cells, is internalized, and releases MMAE, leading to cell cycle arrest and apoptotic cell death.\n\n2. **Indications**: Tivdak is specifically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5wRjV4pjSw0b5Gh5psE0ktuK", "custom_id": "722_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c259ff81ec79d8862787a49b128a7347", "body": {"id": "chatcmpl-9St5P5heJVUigTxkN7618EwgJK2FQ", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a synthetic long-acting analog of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones. It is primarily used in the management of acromegaly, a condition characterized by excessive growth hormone (GH) production, and in the treatment of neuroendocrine tumors, specifically gastroenteropancreatic neuroendocrine tumors (GEP-NETs).\n\nHere are some key points about Somatuline Depot:\n\n1. **Indications**:\n   - **Acromegaly**: For the treatment of patients with acromegaly when surgery or radiotherapy have not been fully effective, or when surgery is not an option. It helps to reduce the levels of growth hormone and insulin-like growth factor 1 (IGF-1).\n   - **Neuroendocrine Tumors**: Approved for the treatment of unresectable, well or moderately differentiated, locally advanced or metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Qh1w7h2sP7eIJ2whU0PCTzK6", "custom_id": "723_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99da43869effbdabe49f929d5672ee7e", "body": {"id": "chatcmpl-9St5PaNvMI22zYhwfCUzmqeEhBGab", "object": "chat.completion", "created": 1716671963, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Jeselhy.\" It's possible that it could be a term from a different context, a new development, a brand name, or a misspelling. If you have more specific information or context about Jeselhy, I could try to help further. Alternatively, if it's a new drug or treatment, I recommend checking the latest medical literature or pharmaceutical databases for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 97, "total_tokens": 138}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dPX2AAWmBVHL9TLjX5riAwAK", "custom_id": "724_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ae8fcc2bb369ad314785cc45c1dbf42", "body": {"id": "chatcmpl-9St5Qm9cyzejZusWGOSVyLNBDdbfE", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Mostarina\" in the context of healthcare, medicine, or pharmacology. It's possible that \"Mostarina\" could be a term specific to a certain region, a brand name not widely recognized, or possibly a misspelling.\n\nIf you could provide more context or details about where you encountered the term or what it's related to, I might be able to offer more specific assistance or direct you to relevant resources. Alternatively, checking with pharmacological databases, medical literature, or consulting with colleagues might also help clarify the term's relevance and meaning in a medical context."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 133, "total_tokens": 174}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_VOFWrg39QPzXvfpfCdPTP3GP", "custom_id": "725_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e7a6332cdf545bd4f0d8a6cc0d4f42b", "body": {"id": "chatcmpl-9St5Qyiil4Z6psx0sSfim6VeJYyYX", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medication or substance known as \"Vercite\" in mainstream medical practice. It's possible that the name could be a misspelling, a brand name not widely recognized, or a new drug not yet covered in my training data.\n\nIf you meant something else or have a different spelling, please provide more details. Alternatively, if this is a new or experimental treatment, I recommend consulting the latest clinical databases, drug registries, or pharmaceutical updates for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 105, "total_tokens": 146}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zdGKEjNFRMFOGHtk58gkzxP9", "custom_id": "726_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fec57e7cefa901150042889d6ab04d7e", "body": {"id": "chatcmpl-9St5QwBDk5mjvn4zVvNUd4IsxaVxJ", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer, specifically B-cell lymphomas. It was approved by the U.S. Food and Drug Administration (FDA) in June 2019. Here are some key points about Polivy that you, as a physician, might find useful:\n\n1. **Indication and Usage**: Polivy is approved for use in combination with bendamustine and a rituximab product (a regimen known as \"BR\") for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two prior therapies.\n\n2. **Mechanism of Action**: Polivy is a monoclonal antibody (anti-CD79b) linked to a cytotoxic agent, monomethyl auristatin E ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CoZeH5OFhw5xJrZjk3Oxq4wz", "custom_id": "727_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "86229632cffe58a03fe4998ab0cccda6", "body": {"id": "chatcmpl-9St5Q5bBL4Hr7C4oZqmer5gbHP6u8", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or treatment known as \"Elahere.\" It's possible that it could be a new drug, a misspelling, or a term not widely recognized in the medical community. To provide accurate information, I would need the correct name or additional context regarding the substance or topic you are referring to. If it's a new drug or treatment, I recommend checking the latest medical literature, clinical trial registries, or pharmaceutical databases for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 103, "total_tokens": 144}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Cne40kl1r8YU7ay88asyeZ5x", "custom_id": "728_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f53f016dc52118ff916d6b9c759f8aef", "body": {"id": "chatcmpl-9St5Q034JVY7bkrNRWFiTh2l8fajJ", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lunsumio (mosunetuzumab) is a therapeutic agent used in the treatment of certain types of B-cell lymphomas. It is particularly indicated for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Here are some key points about Lunsumio:\n\n1. **Mechanism of Action**: Lunsumio is a bispecific CD20-directed and CD3-directed cytolytic antibody. It works by engaging both CD20-expressing B-cells and CD3-expressing T-cells, thereby facilitating the direct killing of target B-cells by redirecting T-cell cytotoxicity.\n\n2. **Approval and Clinical Trials**: The approval of Lunsumio by regulatory bodies like the FDA was based on the results from clinical trials that demonstrated its efficacy and safety in patients with R/R follicular lymphoma. The pivotal trials showed significant response rates in patients who had limited treatment options"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_j1GX05BG5Hwl39aumEeaimJf", "custom_id": "729_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a5f3e59a9aac60cbaa57c4daf9340bd3", "body": {"id": "chatcmpl-9St5QpWxElTkD0CVz18mLLJWdu7qw", "object": "chat.completion", "created": 1716671964, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used for the treatment of high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). It was approved by the FDA in December 2022. Here are some key points about Adstiladrin:\n\n1. **Mechanism of Action**: Adstiladrin is an adenovirus vector-based gene therapy. It delivers a copy of the interferon alfa-2b gene directly into the bladder cells via intravesical administration. Once inside the cells, the gene is expressed and produces interferon alfa-2b, a protein known for its anti-tumor effects, which include immune response modulation and inhibition of tumor cell proliferation.\n\n2. **Indications**: It is specifically indicated for the treatment of adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mbA5Fo4HsFSOLAIJ70yleIi5", "custom_id": "730_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d790cd0407d7ab55168b72b40683dd55", "body": {"id": "chatcmpl-9St5RuMjv4Iq8pqzEOt0aqRKYPH1h", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia (olutasidenib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of acute myeloid leukemia (AML). Specifically, it is indicated for adult patients with relapsed or refractory AML who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Rezlidhia was approved based on its ability to inhibit the mutant IDH1 enzyme, which is involved in the pathogenesis of AML by producing the oncometabolite 2-hydroxyglutarate (2-HG), thereby promoting leukemogenesis.\n\n### Key Points for Physicians:\n1. **Indication and Usage**:\n   - Rezlidhia is used for treating adult patients with relapsed or refractory AML who have an IDH1 mutation.\n   - It is important to confirm the presence of IDH1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cerKguhw4jEc1daUE1vkyrL1", "custom_id": "731_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9afac3976b1ed797bbddbcf63bd63350", "body": {"id": "chatcmpl-9St5ReBwKrkZtGNuzCMbQIEcaUDaV", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific patient named Irene, but without additional context or details, I can't provide personalized medical advice or information about an individual named Irene. If you're asking for general advice on how to approach a patient named Irene, it's important to maintain confidentiality, gather a comprehensive medical history, and provide a thorough assessment tailored to her needs and concerns. Always ensure to communicate clearly and empathetically, addressing any specific health issues or concerns she may have. If you have more specific details or need information on a particular condition or treatment, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 118, "total_tokens": 157}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_F0wsNhHPtjBuOFrVLUPkozbK", "custom_id": "732_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f62983520591337e2493fdf80eb72ef7", "body": {"id": "chatcmpl-9St5RkvfKE7qnWCHnKpQnh0nPYyYb", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance known as \"Bigonist\" in the medical community. It's possible that the name might be misspelled or it could be a brand name that is not well-known or new on the market. If you could provide more context or details about where you heard the name or its intended use, I might be able to offer more specific information or help clarify any confusion.\n\nIf you're looking for information on a specific drug or treatment, it's important to refer to reliable medical sources or databases, consult with colleagues, or check the latest medical literature for the most accurate and up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 134, "total_tokens": 175}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DQWa6FrrthQUTIF3R0FVUxQs", "custom_id": "733_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "16a6d9eef8278ee683ff086bdb311021", "body": {"id": "chatcmpl-9St5RVB3I9b6HlTUfClXRVL4ytw1Y", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Contego\" does not specifically refer to a known medical term, treatment, or technology directly related to healthcare or medicine. It's possible that \"Contego\" could be a brand name, a term used in a different context, or perhaps something new that has emerged after my last update. If \"Contego\" is related to a specific product, technology, or concept in medicine that has been introduced recently, I would recommend checking the latest medical literature, product databases, or regulatory authority updates for the most accurate and relevant information. Additionally, consulting with colleagues or attending relevant medical conferences might provide more insights into new developments including anything named \"Contego.\""}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 137, "total_tokens": 177}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Rh1Fj1ca4xPRptgX7iyxBX7C", "custom_id": "734_sentiment_question_physician_0.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce4339062a6c135664f60f0ffc6b179e", "body": {"id": "chatcmpl-9St5RF12p35pIp7VxwIvlknOnLLsj", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ebvallo (also known as MMRV) is a vaccine that combines vaccines for measles, mumps, rubella, and varicella (chickenpox) into one shot. This combination vaccine is designed to help simplify the vaccination process and increase compliance with vaccination schedules. Here are some key points you should know about Ebvallo:\n\n1. **Indications**: Ebvallo is typically indicated for children to protect against measles, mumps, rubella, and varicella. The vaccine is generally administered to children in two doses, with the first dose given at 12 to 15 months of age and the second dose at 4 to 6 years of age.\n\n2. **Efficacy**: The vaccine is highly effective in preventing these diseases, which can be serious or even fatal. It is important to maintain high vaccination rates to ensure community immunity and prevent outbreaks.\n\n3. **Contraindications**: The vaccine should not be given to individuals who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bAPn9yTJESLGSyfAVT54DQSg", "custom_id": "1_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2de8b26ab9786fa705418db706255780", "body": {"id": "chatcmpl-9St5Rb6sImWYPUyFvGnUDMCzInOzl", "object": "chat.completion", "created": 1716671965, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is a medication used primarily in the treatment of certain types of breast cancer. Below are key points that a physician should be aware of when considering or using Abemaciclib in a clinical setting:\n\n1. **Indications**: Abemaciclib is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or in men, or with fulvestrant in patients with disease progression following endocrine therapy.\n\n2. **Mechanism of Action**: Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the proliferation of cancer cells. By inhibiting these kinases, abemaciclib can help to prevent the progression of the cell cycle from"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_JwZlt3uMzYJY6afeQOnLhOCs", "custom_id": "2_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e1040a71940d96a7770765a480270af", "body": {"id": "chatcmpl-9St5SSeHbA69uO6irif5ksYZu6mz2", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication primarily used in the treatment of prostate cancer. Here are key points that physicians should be aware of regarding abiraterone:\n\n1. **Mechanism of Action**:\n   - Abiraterone works by inhibiting CYP17A1, an enzyme which is crucial in the production of androgens (testosterone and other androgens) not only in the testes but also in other parts such as the adrenal glands and the tumor itself. This results in lowered levels of androgens that can stimulate prostate cancer cells to grow.\n\n2. **Indications**:\n   - Abiraterone is typically indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is often used in patients who have not responded adequately to other hormone therapies.\n   - It has also been used in metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with prednisone or prednis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_obNdVZFhoiXhaeMMMpBam0BR", "custom_id": "3_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ca0d9d0e1723468ba46ed8b5683a5cd", "body": {"id": "chatcmpl-9St5Sbzs2fOVuSPT3MFEPKuej2DvC", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, sold under the brand name Calquence among others, is a medication used primarily for the treatment of certain types of blood cancers. Here are several key points that you, as a physician, should know about acalabrutinib:\n\n1. **Indications**: Acalabrutinib is approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**: Acalabrutinib is a second-generation, selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). By inhibiting BTK, acalabrutinib blocks the transmission of cell survival signals within the B-cell lineage, which is critical for the growth and proliferation of B-cells.\n\n3. **Administration**: It is administered orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bQrEOyO2pEsh5OunyoAIvpQW", "custom_id": "4_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4a28e8f29fe95c9f26e519ff42433cb", "body": {"id": "chatcmpl-9St5SNvG2lySpiSdOU5sRTIls0F7e", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin (also known as Aclacinomycin A) is a cytotoxic anthracycline antibiotic that is used in chemotherapy. It is structurally similar to other anthracyclines such as doxorubicin and daunorubicin. Here are key points a physician should know about aclarubicin:\n\n1. **Mechanism of Action**: Aclarubicin intercalates into DNA, disrupting the synthesis of DNA and RNA by inhibiting the action of DNA and RNA polymerases. The drug also generates free radicals that cause breaks in DNA strands, leading to cell death.\n\n2. **Clinical Use**: Aclarubicin is primarily used in the treatment of acute myeloid leukemia (AML) and has been studied in various other types of cancer, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas. It might be used alone or in combination with other chemotherapeutic agents.\n\n3. **Dosage and Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_RP75i981HJVVClD23YmDW5lv", "custom_id": "5_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "964345b86de0dbcecbff9a56534ca076", "body": {"id": "chatcmpl-9St5SzlwO5mg3W3kdm0zTcAWfTEC5", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by its brand name Kadcyla, is an antibody-drug conjugate (ADC) specifically designed for the treatment of HER2-positive breast cancer. This medication combines trastuzumab, a monoclonal antibody targeting the HER2 receptor, with emtansine (DM1), a cytotoxic agent. Here are some key points you should know about Trastuzumab emtansine:\n\n1. **Mechanism of Action**: Trastuzumab emtansine targets and binds to HER2-overexpressing cells. After binding, the complex is internalized, and the emtansine component is released inside the cell. Emtansine binds to tubulin, disrupting microtubule networks in the cell, which ultimately leads to cell death.\n\n2. **Indications**: It is primarily used for the treatment of HER2-positive metastatic breast cancer in patients who have previously received tr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1mdHhsOIIfdzBDFHDxoQnXUz", "custom_id": "6_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dfcc24ed47acf3ee6f59518c2a575a1f", "body": {"id": "chatcmpl-9St5ShrBMbq4T3nvi8YVUAjYuqqNG", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib, marketed under the brand name Gilotrif among others, is a medication used in the treatment of non-small cell lung cancer (NSCLC). Specifically, it is indicated for NSCLC patients whose tumors express certain types of epidermal growth factor receptor (EGFR) mutations. Here are key points about afatinib that you, as a physician, should be aware of:\n\n### Mechanism of Action\nAfatinib is a tyrosine kinase inhibitor that irreversibly binds to the ErbB family of receptors (EGFR, HER2, and HER4). By inhibiting these receptors, afatinib interferes with the growth and spread of cancer cells which express these mutations.\n\n### Indications\n- **NSCLC with Specific EGFR Mutations**: It is approved for first-line treatment of patients with NSCLC whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test.\n- **Squamous NSCLC**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_4n6Qm5NiAOtm2MYFDjVCgWL8", "custom_id": "7_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb0a7ec333ca983c785d65cc15ce3368", "body": {"id": "chatcmpl-9St5Sb1U9XCQbNhmGIy9VYuoUpdD7", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known as interleukin-2 (IL-2), is a cytokine used primarily in the treatment of advanced renal cell carcinoma and metastatic melanoma. Here are key points you should know about aldesleukin:\n\n1. **Mechanism of Action**:\n   - Aldesleukin acts by increasing the proliferation and activation of immune cells, particularly T lymphocytes and natural killer (NK) cells. This enhances the immune system\u2019s ability to target and destroy cancer cells.\n\n2. **Indications**:\n   - It is FDA-approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Research is ongoing for its use in other types of cancers and diseases.\n\n3. **Administration**:\n   - Aldesleukin is administered intravenously, and the dosing regimen can vary based on the treatment protocol and patient response.\n\n4. **Side Effects**:\n   - Common side effects include flu-like"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ciP4kPd8PFmej2LrsbwhZxYx", "custom_id": "8_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6caf6ecb8190c43cdb401d5d7d400cc0", "body": {"id": "chatcmpl-9St5SxPsDIRvwvNZan8BNQYvYLU6l", "object": "chat.completion", "created": 1716671966, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib (brand name Alecensa) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC), particularly for cancers that are anaplastic lymphoma kinase-positive (ALK-positive). Here are several key points about alectinib that you, as a physician, might find useful:\n\n1. **Indications**: Alectinib is specifically indicated for the treatment of ALK-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Alectinib is an oral, highly selective inhibitor of the anaplastic lymphoma kinase (ALK). By inhibiting this kinase, alectinib interferes with the growth and survival of cancer cells that express the ALK fusion gene.\n\n3. **Administration**: Alectinib is administered orally, typically twice a day with food. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T1PNe4r9GukMzflnHGCXDCAS", "custom_id": "9_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6d6f6483422e56e152a500dfd7fd0316", "body": {"id": "chatcmpl-9St5TM2Sq3WCuvfCQsndoDVJPjHFM", "object": "chat.completion", "created": 1716671967, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily for the treatment of certain medical conditions. Here are key points you should know about alemtuzumab:\n\n1. **Indications**: Alemtuzumab is approved for the treatment of multiple sclerosis (MS), specifically for relapsing forms of MS, including relapsing-remitting disease and active secondary progressive disease, in adults. It is also used in the treatment of chronic lymphocytic leukemia (CLL).\n\n2. **Mechanism of Action**: Alemtuzumab targets CD52, a protein present on the surface of mature lymphocytes, but not on stem cells. This binding to CD52 leads to the depletion of circulating T and B lymphocytes through antibody-dependent cellular cytotoxicity and complement fixation.\n\n3. **Administration**: Alemtuzumab is administered via intravenous infusion. It usually involves a specific dosing regimen where the first course consists of daily infusions for five consecutive days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gKnoL4cxaFcxBHFdhCHY2Vn7", "custom_id": "10_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7e91e29885b025031630f4583825817", "body": {"id": "chatcmpl-9St5TPnvPxu4feBm7ApTCl3Bu1h8j", "object": "chat.completion", "created": 1716671967, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A that has been widely used in the treatment of various medical conditions, most notably acute promyelocytic leukemia (APL). Here are some key points about ATRA that you, as a physician, might find useful:\n\n### 1. Mechanism of Action\n- **Acute Promyelocytic Leukemia (APL):** ATRA works primarily by binding to the retinoic acid receptors (RARs) which are part of the nuclear receptor superfamily. In APL, ATRA specifically targets the abnormal promyelocytes that express the PML-RAR\u03b1 fusion protein, leading to the differentiation and maturation of these cells into normal myeloid cells.\n- **Dermatology:** In dermatological uses, ATRA promotes differentiation of epithelial cells and can reduce the formation of microcomedones, which are precursors to acne lesions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ICOvK2AmuUDzImGtIkZUpjeq", "custom_id": "11_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c763ca48a1bb606d1751e7282c5b611c", "body": {"id": "chatcmpl-9St5TGdaxrJ2b2PYQvooPvjQHoqsp", "object": "chat.completion", "created": 1716671967, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine (marketed under the brand name Hexalen) is an antineoplastic (cancer-fighting) agent used primarily in the treatment of ovarian cancer. Here are some important aspects of altretamine that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - Altretamine is approved for use in the treatment of persistent or recurrent ovarian cancer after first-line therapy with cisplatin and/or alkylating agent-based combinations, or in patients who are intolerant to these regimens.\n\n2. **Mechanism of Action**:\n   - The exact mechanism by which altretamine exerts its antineoplastic effects is not fully understood. It is believed to act as an alkylating agent, causing damage to DNA in cancer cells, which inhibits their ability to replicate and ultimately leads to cell death.\n\n3. **Dosage and Administration**:\n   - Altretamine is administered orally. The typical dosage is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_vT72vrBjuuzubGff2TcSu9CL", "custom_id": "12_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "50b5322580dde74948f11b1673e37e05", "body": {"id": "chatcmpl-9St5TPJOT52OqrLPP10LMQIZwLjzw", "object": "chat.completion", "created": 1716671967, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a drug that was originally developed as an anticonvulsant but is now primarily used for its ability to inhibit adrenal steroid synthesis. Here are some key points about aminoglutethimide that you should know as a physician:\n\n1. **Mechanism of Action**: Aminoglutethimide inhibits the enzyme aromatase, which is involved in the biosynthesis of estrogens, and it also blocks the conversion of cholesterol to pregnenolone. This results in reduced production of all steroid hormones, including glucocorticoids, mineralocorticoids, estrogens, and androgens.\n\n2. **Clinical Uses**:\n   - **Hormone-sensitive cancers**: It is most commonly used in the treatment of hormone-sensitive cancers such as breast cancer and prostate cancer. By reducing estrogen production, it can help in managing hormone-responsive tumors.\n   - **Cushing's syndrome**: It can be used to manage C"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_d9ADhqOlweQHT5RSrGMSOpzy", "custom_id": "13_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d21f6cfa2c02f99afb5a8ad6cf61e270", "body": {"id": "chatcmpl-9St5UQgpjgQREV5SR3fMYR5liULqi", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amrubicin is a synthetic anthracycline derivative used primarily in the treatment of lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It functions as a topoisomerase II inhibitor, which leads to the disruption of DNA replication and transcription, ultimately resulting in cell death.\n\nHere are some key points you should know about Amrubicin:\n\n1. **Mechanism of Action**: Amrubicin inhibits topoisomerase II, preventing the ligation of the DNA strand breaks it induces, which leads to cell death. It is known for its potent cytotoxicity, particularly against lung cancer cells.\n\n2. **Indications**: It is primarily used in the treatment of small cell lung cancer, often in patients who have relapsed or who are refractory to first-line chemotherapy. It has also shown some efficacy in non-small cell lung cancer.\n\n3. **Administration**: Amrubicin is administered intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_utEbE5r5jTnFoGcmfAaWaKwm", "custom_id": "14_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1de1f42638922abbd2ccc9bfb544bce3", "body": {"id": "chatcmpl-9St5UMQSqKRdLeWmXmkAnkTM5ZxPN", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amsacrine, also known as m-AMSA, is an antineoplastic agent used primarily in the treatment of leukemia. It belongs to the class of drugs known as acridine derivatives. Here are some key points to consider when dealing with Amsacrine in a clinical setting:\n\n### Mechanism of Action\nAmsacrine works primarily by intercalating into DNA, disrupting the function of topoisomerase II, and inducing breaks in double-stranded DNA. This prevents DNA replication and transcription, leading to cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Indications\n- **Primary Use:** Amsacrine is most commonly used in the treatment of acute leukemias. \n- It has shown effectiveness in both adult and pediatric patients, particularly for acute myeloid leukemia (AML).\n\n### Administration\n- Amsacrine is administered intravenously. The dosing regimen can vary depending on factors like the patient's condition,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hgy8Qa0tg9ImwaapE5oMcLJL", "custom_id": "15_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc22dd95ddfe2f4a753554fb262bc920", "body": {"id": "chatcmpl-9St5UvkyqmNScAarvHe0y976hnDXB", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole is a medication primarily used in the treatment of breast cancer. It is classified as an aromatase inhibitor, which means it works by decreasing the amount of estrogen the body makes. This can slow or stop the growth of some breast cancers that need estrogen to grow. Here are key points about Anastrozole that you should know as a physician:\n\n1. **Indications**:\n   - Anastrozole is most commonly used to treat hormone receptor-positive early breast cancer in postmenopausal women.\n   - It is also used as a first-line treatment for locally advanced or metastatic breast cancer that is hormone receptor-positive or unknown in postmenopausal women.\n   - Additionally, it is used as adjuvant treatment for early breast cancer in hormone receptor-positive postmenopausal women following initial therapy (e.g., surgery, radiation, chemotherapy).\n\n2. **Mechanism of Action**:\n   - Anastrozole inhibits the enzyme aromatase"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G8oAA9IO0RO9x6kdtbA3r2rX", "custom_id": "16_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a124a4b3844060f0537f3a1232a333e4", "body": {"id": "chatcmpl-9St5U67QZ4ELWput63mh3zWJxZdqP", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apalutamide is a medication primarily used in the treatment of prostate cancer. Here are several key aspects that you, as a physician, might find useful:\n\n1. **Indications**: Apalutamide is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is designed to be used in conjunction with castration, either via bilateral orchiectomy or with a gonadotropin-releasing hormone (GnRH) analog.\n\n2. **Mechanism of Action**: Apalutamide functions as an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting androgen receptor signaling, which in turn decreases tumor growth in prostate cancer. This mechanism is pivotal, given that androgens (like testosterone) can promote the growth of prostate cancer cells.\n\n3. **Administration**: The usual dosage is 240 mg, taken orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cNqADiVELQtVZnpB4CeyHJwJ", "custom_id": "17_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47664b14b8101559384c84dc229c3229", "body": {"id": "chatcmpl-9St5UWqxSsYi8Nv6uSocRHkcZkRtb", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib, also known as Aitan, is a tyrosine kinase inhibitor specifically targeting the vascular endothelial growth factor receptor 2 (VEGFR-2). This receptor is a primary pathway for the mediation of tumor angiogenesis, which is critical for cancer growth and metastasis. Here are some key points you should know about Apatinib as a physician:\n\n1. **Indications**: Apatinib is primarily used for the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma. It is often considered when patients have not responded adequately to other treatments.\n\n2. **Mechanism of Action**: Apatinib inhibits VEGFR-2, which reduces angiogenesis, thereby inhibiting tumor growth. By blocking this pathway, apatinib can slow the progression of cancer and extend survival in some patients.\n\n3. **Dosage and Administration**: The typical starting dose of Apatinib is 500 mg taken orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x9vO8p5w6vmRpP7UrL6ZpFz8", "custom_id": "18_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dad6b6ec26d981c63aae1922e7fd5ffa", "body": {"id": "chatcmpl-9St5UXQRX5e2NGSNQKRXmbix20c5z", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenic trioxide is an inorganic compound used primarily in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the accumulation of cells called promyelocytes. Here are key points you should know about arsenic trioxide, particularly in a clinical setting:\n\n### Mechanism of Action\nArsenic trioxide induces apoptosis (programmed cell death) and has a cytotoxic effect on leukemia cells. It primarily works by causing the degradation of the promyelocytic leukemia (PML)/retinoic acid receptor alpha (RAR\u03b1) fusion protein, which plays a crucial role in the pathogenesis of APL. This leads to terminal differentiation and/or apoptosis of the malignant cells.\n\n### Indications\n- **Primary treatment**: Arsenic trioxide is approved for use in combination with all-trans retinoic acid (ATRA) for newly diagnosed low-risk APL.\n- **Relapsed or refractory APL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_xHGpl37u7WixiChumJWrzcEK", "custom_id": "19_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "816f261c6e81bf3eb1d91879a2b84655", "body": {"id": "chatcmpl-9St5Uyd0DmlGdyOeFi3HrvMpy9war", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an important chemotherapeutic agent primarily used in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about asparaginase:\n\n### Mechanism of Action\nAsparaginase works by hydrolyzing the amino acid asparagine into aspartic acid and ammonia. This deprives the leukemic cells of asparagine, which is essential for their growth and survival, as they are unable to synthesize it endogenously.\n\n### Types of Asparaginase\nThere are several forms of asparaginase available, including:\n- **E. coli asparaginase** (native form)\n- **Pegylated E. coli asparaginase** (PEG-asparaginase, which has a longer half-life and reduced immunogenicity)\n- **Erwinia chrysanthemi asparaginase** (used primarily in patients who develop hypers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bmH2Anuzzdy6hWg9LOveCCbi", "custom_id": "20_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "81fe33c0027dc0ed1ce217e4f29a5974", "body": {"id": "chatcmpl-9St5UQigVZlznOfeyGB5CxpzgS2LU", "object": "chat.completion", "created": 1716671968, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi is an important drug used primarily in the treatment of acute lymphoblastic leukemia (ALL), especially in patients who have developed hypersensitivity to E. coli-derived asparaginase preparations, such as pegaspargase or native E. coli asparaginase. Here are key aspects you should be aware of:\n\n1. **Mechanism of Action**: Asparaginase Erwinia chrysanthemi works by depleting the amino acid asparagine. Leukemia cells, particularly those in ALL, are unable to synthesize asparagine due to a lack of asparagine synthetase and are thus dependent on circulating asparagine. By depleting asparagine, the drug starves the leukemia cells of a necessary nutrient, leading to cell death.\n\n2. **Indications**: It is specifically indicated for patients with hypersensitivity to E. coli-derived asparaginase."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NDibOWJvKIc4t5lvvkPBLT5F", "custom_id": "21_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b5528b114d2be70b82f35ac98400849c", "body": {"id": "chatcmpl-9St5VfcgmdV9azIxBnaAQ6AIo7TgS", "object": "chat.completion", "created": 1716671969, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab (brand name Tecentriq) is a monoclonal antibody used in cancer immunotherapy. It specifically targets the programmed cell death-ligand 1 (PD-L1), a protein expressed by many cancer cells and immune cells in the tumor microenvironment. By inhibiting PD-L1, atezolizumab helps to reactivate immune responses against cancer cells, enhancing the body\u2019s ability to fight the tumor.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Atezolizumab is approved for use in various types of cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, and triple-negative breast cancer that is PD-L1 positive. The specific indications can depend on the tumor type, stage, prior treatments, and PD-L1 expression status.\n\n2. **Mechanism of Action:**\n   - Atez"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XcjOAGe1IPkIZTCvBdZyaU6h", "custom_id": "22_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe91da792372858af7285e0a54191929", "body": {"id": "chatcmpl-9St5VoXuL9neQnYs2j7mXpgJzceY0", "object": "chat.completion", "created": 1716671969, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab is a monoclonal antibody used in the field of oncology as an immune checkpoint inhibitor, specifically targeting the PD-L1 protein. Here are some key points you should know about Avelumab:\n\n1. **Mechanism of Action**: Avelumab binds to the programmed death-ligand 1 (PD-L1) on tumor cells and tumor-infiltrating immune cells, blocking its interaction with PD-1 receptors. This blockade enhances the body\u2019s immune response against cancer cells by activating T-cells.\n\n2. **Indications**:\n   - **Metastatic Merkel Cell Carcinoma (MCC)**: Avelumab is approved for the treatment of adult and pediatric patients 12 years and older with metastatic MCC.\n   - **Urothelial Carcinoma**: It is also approved for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hQfT4ZAxp7U5nb7APmSRFQwp", "custom_id": "23_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3c1aad41f4301c9053408e99fc75962b", "body": {"id": "chatcmpl-9St5VAZhvAOIIQjYTXsAeBtxQ4eAM", "object": "chat.completion", "created": 1716671969, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel, also known by its brand name Yescarta, is a type of immunotherapy used primarily to treat certain kinds of B-cell lymphomas, including relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. It is not indicated for the treatment of patients with primary central nervous system lymphoma.\n\nHere are key points about axicabtagene ciloleucel that you, as a physician, might find important:\n\n1. **Mechanism of Action**: Axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell therapy. It involves modifying the patient's T cells to include a CAR that targets CD19, a protein expressed on the surface of most B-cell lymph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_DppJOy7CpJnLlcsHCe7sXEiz", "custom_id": "24_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b1c8d7431ec7e2cb45161d6edbdeffc", "body": {"id": "chatcmpl-9St5VCgs2ygntsd3snIHqZ6KrBxSE", "object": "chat.completion", "created": 1716671969, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axitinib is a medication primarily used in the treatment of advanced renal cell carcinoma (RCC) and can also be considered for other types of cancers as part of research or clinical trials. As a physician, here are several key aspects of axitinib that you should be familiar with:\n\n1. **Mechanism of Action**: Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By blocking these receptors, axitinib inhibits angiogenesis (the formation of new blood vessels), which is a critical process in the growth and spread of tumors.\n\n2. **Indications**: The primary indication for axitinib is the treatment of advanced renal cell carcinoma, especially after failure of one prior systemic therapy. Its use in other cancers may be as part of clinical trials.\n\n3. **Dosage and Administration**: Axitinib is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kS8GxaxpMyftSa2kbfGKPGdt", "custom_id": "25_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b95f6bcc5f3737d7b70d5917f066925a", "body": {"id": "chatcmpl-9St5VNpi1s6iwQWkXclWDSYsW9Xk1", "object": "chat.completion", "created": 1716671969, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, marketed under the brand name Vidaza, is a chemotherapy medication primarily used to treat myelodysplastic syndromes (MDS) and certain types of leukemia. Here are some important aspects of azacitidine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nAzacitidine is a nucleoside metabolic inhibitor that works by inhibiting RNA and DNA methylation, which leads to the reactivation of genes that promote cell differentiation and reduce proliferation. It is classified as a hypomethylating agent.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS):** Azacitidine is indicated for the treatment of all subtypes of MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) classifications.\n- **Acute Myeloid Leukemia (AML):** It is used for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kxbKwJb5HWb7ZAEbR2eDexC3", "custom_id": "26_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6245083d7a158292a01c054f2c86ef7f", "body": {"id": "chatcmpl-9St5W2EPzRnmA2L4SDEnqs1Gaa7y5", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is a vaccine primarily used against tuberculosis (TB). Here are several important aspects of BCG that you, as a physician, may need to know:\n\n1. **Background and Development**:\n   - BCG was developed in the early 20th century by Albert Calmette and Camille Gu\u00e9rin, French bacteriologists, by attenuating Mycobacterium bovis, a cousin of Mycobacterium tuberculosis (the bacterium that causes TB).\n   - It is one of the oldest vaccines still in use and the only vaccine currently available for the prevention of TB in humans.\n\n2. **Efficacy and Usage**:\n   - The efficacy of the BCG vaccine varies. It is most effective in preventing severe forms of TB, such as TB meningitis in children. Its effectiveness in preventing pulmonary TB in adults is more variable and seems to depend on geographical location.\n   - The vaccine is administered via"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Asod3vFM4liH0JCCou3GefDC", "custom_id": "27_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc6f9c0bfed174920b9c538d6d6d76ee", "body": {"id": "chatcmpl-9St5WG14dJH6cPOCexW1Rv9nOBeXC", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is an investigational monoclonal antibody that was initially developed for the treatment of various types of cancer, including non-small cell lung cancer, pancreatic cancer, and breast cancer. It targets phosphatidylserine (PS), a molecule that is normally located on the inner leaflet of the cell membrane but becomes exposed on the outer leaflet in certain pathological conditions, including cancer and viral infections.\n\nPhosphatidylserine exposure on the outer leaflet of cell membranes can act as an immunosuppressive signal, helping to protect abnormal cells from immune detection and attack. By targeting phosphatidylserine, Bavituximab aims to block this immunosuppressive signal and promote an immune response against the tumor or infected cells.\n\nIn addition to its applications in cancer, Bavituximab has also been researched for its potential use in treating viral infections, such as hepatitis C and HIV, based on its ability to target phosphatidyl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_iWjatCkTLg1CYAyNp0mSDgPj", "custom_id": "28_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ebb564cc38c1c68bdd065a48776b5f1", "body": {"id": "chatcmpl-9St5W9Teu6du68NhUHSNpONb5zoNa", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat (trade name Beleodaq, among others) is a drug used in the treatment of peripheral T-cell lymphoma (PTCL), a type of cancer. It belongs to a class of drugs known as histone deacetylase inhibitors (HDAC inhibitors). Belinostat works by interfering with the function of histone deacetylases, which are enzymes that play a role in the regulation of gene expression. By inhibiting these enzymes, belinostat can induce cell cycle arrest and apoptosis (programmed cell death) of cancer cells.\n\nHere are some key points about belinostat that you, as a physician, might find important:\n\n### Indications\n- **Approved Use**: Belinostat is approved by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibition**: Belinostat inhibits the activity"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kDWeH5GMhEM2KwDXlup2GbpC", "custom_id": "29_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b2201c8180c46a34cb47e7e79b7228c6", "body": {"id": "chatcmpl-9St5WlcB9LTY51xFbzteQYvfN4RPJ", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan (also known as CKD-602) is a camptothecin derivative that functions as a topoisomerase I inhibitor. It is primarily used as a chemotherapeutic agent. Topoisomerase I inhibitors work by interfering with the ability of topoisomerase enzymes to relieve torsional strain in DNA by inducing reversible single-strand breaks. This action helps prevent DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\nHere are several key points about Belotecan:\n\n1. **Indications**: Belotecan has been mainly studied and used in the treatment of various types of cancer, including ovarian cancer, small cell lung cancer, and other solid tumors. It may be used where other treatments have failed or as part of a combination therapy regimen.\n\n2. **Mechanism of Action**: As a topoisomerase I inhibitor, Belotecan stabilizes the temporary single-strand breaks made by the topoisomerase I enzyme"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_73M8mWaaFA1IwcBqk3WEHcfr", "custom_id": "30_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "be08d4950f08b834f704f8a690768740", "body": {"id": "chatcmpl-9St5WjyalUmvll0ChJpFOfSvnAQ5Z", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy drug used primarily in the treatment of chronic lymphocytic leukemia (CLL) and some types of non-Hodgkin lymphoma. It functions as an alkylating agent, causing cross-linking of DNA strands and ultimately leading to cell death. Here are some important aspects about Bendamustine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nBendamustine combines the properties of an alkylating agent and a purine analog. Its dual mode of action contributes to its effectiveness in destroying rapidly dividing cancer cells by inducing intra-strand and inter-strand DNA crosslinks.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Bendamustine is approved for the treatment of CLL, especially in patients who have not responded well to initial treatment.\n- **Non-Hodgkin Lymphoma (NHL)**: It is also used to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_FGhK5uuuhUhTlmkMwRvxCSvg", "custom_id": "31_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73541f108d6538fd584ba5cfa18bbd97", "body": {"id": "chatcmpl-9St5W5PT9XqGlCfrXrr6r1oD7jFnZ", "object": "chat.completion", "created": 1716671970, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizumab, sold under the brand name Avastin among others, is a medication used in the treatment of various forms of cancer and certain specific eye diseases. Here are some key points about bevacizumab that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis, the formation of new blood vessels. By inhibiting VEGF-A, bevacizumab reduces the vascularization of tumors, which can limit their growth and reduce their ability to metastasize.\n\n2. **Indications**:\n   - **Cancer**: Bevacizumab is approved for the treatment of various types of cancers including metastatic colorectal cancer, non-small cell lung cancer (NSCLC), gliob"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0diVp0ar4hmAs81kDD2Gc6YS", "custom_id": "32_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cfc10b21b2069e0c8ba05dea277b6fa9", "body": {"id": "chatcmpl-9St5XEkVfWyANUZKaQlvEyLiRLAqf", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is a medication primarily used in the treatment of cutaneous T-cell lymphoma (CTCL). Here are key points that a physician should know about bexarotene:\n\n1. **Mechanism of Action**:\n   Bexarotene works as a rexinoid\u2014selective for retinoid X receptors (RXRs)\u2014and modulates the expression of target genes involved in cellular differentiation and proliferation. This mechanism is thought to contribute to its effectiveness in treating CTCL.\n\n2. **Indications**:\n   - It is approved for the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least one prior systemic therapy.\n   - It is available as both a topical gel and an oral capsule.\n\n3. **Dosage and Administration**:\n   - **Topical Gel**: Typically applied once or twice daily to the affected areas.\n   - **Oral Capsule**: The dose depends on the patient's size and is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nSjZvUGa5l1LH2zKKv2uxdLA", "custom_id": "33_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "295089d1bd8c0b0a2f4a808d70052d12", "body": {"id": "chatcmpl-9St5X6Vhw0hZAMpmN2MCbL4zhewDg", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a medication primarily used in the treatment of prostate cancer. Here are some key points about the drug that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Bicalutamide is a non-steroidal anti-androgen. It works by binding to androgen receptors and inhibiting the action of androgens (such as testosterone), which can stimulate the growth of prostate cancer cells.\n\n2. **Indications**: Bicalutamide is most commonly used in the treatment of prostate cancer. It is typically indicated for the treatment of advanced prostate cancer in combination with a luteinizing hormone-releasing hormone (LHRH) analog or surgical castration.\n\n3. **Dosage and Administration**: The usual dosage of bicalutamide for the treatment of prostate cancer is 50 mg taken once daily. However, the dosage can vary based on the specific circumstances and the stage of the disease. Bicalutamide is taken orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oLy7NMaMDuzZr06YkHZKOy02", "custom_id": "34_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d5600ecf1ddf4c59d46a5b9e711c99e3", "body": {"id": "chatcmpl-9St5XfTT7iDpd4aRh1IVqjDdWgGX3", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Binimetinib is a medication used in the treatment of cancer, specifically for certain types of melanoma. It is a kinase inhibitor that works by targeting and inhibiting specific enzymes involved in the growth and spread of cancer cells. Here are several key points about binimetinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Binimetinib specifically inhibits MEK1 and MEK2, components of the mitogen-activated protein kinase (MAPK) pathway. This pathway is often upregulated in some cancers, including melanoma with BRAF mutations. By inhibiting MEK enzymes, binimetinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**: It is approved for use in combination with another medication called encorafenib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uawIFFpApjrcsSCQlvpl4T0L", "custom_id": "35_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "feb04ee6173dd6c76ef3a5be74ac8740", "body": {"id": "chatcmpl-9St5Xl5fapUdjVcRmGA5dLj08wdkx", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antibiotic chemotherapeutic agent primarily used in the treatment of various types of cancer, including Hodgkin's lymphoma, non-Hodgolin's lymphoma, testicular cancer, and certain types of ovarian and cervical cancer. Here are some key aspects you should be familiar with:\n\n### Mechanism of Action\nBleomycin works by binding to DNA and inducing strand breaks, which in turn leads to cell cycle arrest and apoptosis (cell death). It is particularly effective during the G2 and M phases of the cell cycle.\n\n### Administration\nBleomycin can be administered intravenously, intramuscularly, or subcutaneously. The dosage and schedule depend on the patient\u2019s condition, type of cancer, body weight, and overall treatment plan. It is often given as part of a combination chemotherapy regimen.\n\n### Side Effects\nBleomycin has some unique toxicities among chemotherapeutic agents:\n- **Pulmonary Toxicity:** This is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4xcxNe9TW3lSB6vnjUUKvfOu", "custom_id": "36_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d0520b811d2789fcec62195458baec3a", "body": {"id": "chatcmpl-9St5XrxW4trmAXYjNABCREvfaOUBP", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab (brand name Blincyto) is a bispecific CD19-directed CD3 T-cell engager that is used in the treatment of certain types of acute lymphoblastic leukemia (ALL). Here are key points that physicians should be aware of regarding Blinatumomab:\n\n1. **Indications**: Blinatumomab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in relapse. It is used in both pediatric and adult patients. The specific indications may vary, so it's important to refer to the latest guidelines or regulatory approvals.\n\n2. **Mechanism of Action**: Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct. It binds simultaneously to CD19 expressed on B cells and CD3 expressed on T cells. This dual binding brings the T cells into close proximity with the target B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EwMzNIJGhattlYw2TaJW38Uy", "custom_id": "37_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "260c12b0e424aeae291a41ae0e36f7db", "body": {"id": "chatcmpl-9St5XhE5QVWrQaWblAbadmoU6azCe", "object": "chat.completion", "created": 1716671971, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Below are key points about its mechanism of action, uses, administration, side effects, and considerations:\n\n### Mechanism of Action\nBortezomib inhibits the 26S proteasome, a complex that degrades ubiquitinated proteins. By inhibiting this proteasome, bortezomib disrupts various cellular processes, including the regulation of cell cycle, cell proliferation, and apoptosis. This inhibition leads to an accumulation of misfolded proteins, which can induce cell stress and death, particularly in cancer cells that have a high rate of protein turnover.\n\n### Clinical Uses\n- **Multiple Myeloma:** Bortezomib is approved for the treatment of multiple myeloma. It can be used in newly diagnosed patients as well as those who have relapsed after previous treatment.\n- **Mantle Cell Lymphoma:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7aNhGrVdNDjsglCeSSUsrtnW", "custom_id": "38_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6e72ffb0a0e23f4bd11d9ddf15afcd0d", "body": {"id": "chatcmpl-9St5YwNycRhdR3jOTWm3EnWNndDn2", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib is a kinase inhibitor used primarily in the treatment of chronic myelogenous leukemia (CML). Here are some key points that you, as a physician, should know about Bosutinib:\n\n1. **Indications**: Bosutinib is approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.\n\n2. **Mechanism of Action**: Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it also inhibits Src-family kinases.\n\n3. **Administration**: Bosutinib is administered orally. The starting dose and adjustments may depend on the phase of CML being treated and the patient\u2019s prior treatments.\n\n4. **Dosage Adjustments**: Dose adjustments may be necessary based on response and tolerability. It is also important to adjust doses in patients with hepatic impairment.\n\n5. **Adverse Effects**: Common side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_KDWy3XvkBHCd94erw2nFuGQu", "custom_id": "39_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ef8dcf47d10d4e39b49232ad0fd8a08", "body": {"id": "chatcmpl-9St5YSXtdC36I67Z7gHsV5CbCqK5j", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Brentuximab vedotin, particularly if you are involved in the treatment of hematological malignancies. Here\u2019s a comprehensive overview:\n\n### 1. **Mechanism of Action**\n   Brentuximab vedotin is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody specifically targeting the CD30 antigen, a marker expressed on the surface of some cancer cells (notably in Hodgkin lymphoma and systemic anaplastic large cell lymphoma), linked to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to CD30, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis in the malignant cell.\n\n### 2. **Indications**\n   - **Hodgkin Lymphoma (HL)**: Brentuximab vedotin is approved for the treatment of adult patients with HL at high"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ie6zijuUMIoD8wzXrZddLmSV", "custom_id": "40_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4e5acca093a5f4c66a58e448a2ef2cbd", "body": {"id": "chatcmpl-9St5YJv1j3z5XWi5CK2ozhb7ZpGar", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is an oral medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are key points that a physician should know about Brigatinib:\n\n1. **Indications**: Brigatinib is approved for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase-positive (ALK+) as detected by an FDA-approved test. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Brigatinib is a tyrosine kinase inhibitor that targets ALK, which is a key driver in some NSCLC tumors. It also has activity against ROS1 and EGFR mutations, though its primary use is in ALK-positive NSCLC.\n\n3. **Dosage and Administration**: The typical starting dose of brigatininib is 90 mg once daily for the first 7 days,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Nfl6u1z6ODXuHQNHiUbbGExH", "custom_id": "41_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "68115ae4570916a52cbe91163cc18a87", "body": {"id": "chatcmpl-9St5YM2nMsImTUSLkcoviV3QhbMzw", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is a chemotherapy medication that belongs to the class of drugs known as alkylating agents. It is primarily used in the treatment of chronic myelogenous leukemia (CML) and is also used in conditioning regimens prior to hematopoietic stem cell transplantation. Here are some key points about Busulfan that you, as a physician, should be aware of:\n\n### Mechanism of Action\n- Busulfan works by causing cross-linking of DNA, which inhibits DNA replication and transcription. This leads to cell cycle arrest and apoptosis, particularly in rapidly dividing cells like cancer cells.\n\n### Indications\n- **Chronic Myelogenous Leukemia (CML)**: Busulfan is used in the management of CML, particularly in patients who are not candidates for more modern targeted therapies such as tyrosine kinase inhibitors.\n- **Conditioning Regimen Before Bone Marrow Transplant**: Busulfan is commonly used in the preparative regimen before hemat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NSn4TnASGnU6HYNUQhBvToPk", "custom_id": "42_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "591df87a7a1ada68f68640be2c398600", "body": {"id": "chatcmpl-9St5Y2sgtkQCS4llRcahm3sHRymgt", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapy drug used primarily in the treatment of prostate cancer. Here are some key points you should know about Cabazitaxel:\n\n1. **Indications**: Cabazitaxel is approved for the treatment of hormone-refractory metastatic prostate cancer, particularly in patients who have previously received a docetaxel-containing treatment regimen.\n\n2. **Mechanism of Action**: Cabazitaxel is a taxane drug that works by inhibiting the depolymerization of microtubules, which are essential components of the cell division machinery. This inhibition leads to cell cycle arrest and ultimately cell death, particularly in rapidly dividing tumor cells.\n\n3. **Administration**: Cabazitaxel is administered intravenously. The drug is typically given once every three weeks, often in combination with prednisone or prednisolone, which are administered orally.\n\n4. **Dosage**: The standard dosage of Cabazitaxel may vary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h00Ma7wj8p2tB7qJ5hutiXA5", "custom_id": "43_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4bc084b98b8a6d06f78032ea44201356", "body": {"id": "chatcmpl-9St5Y9TTDkoS8ki3RM6TEfhdfA6i7", "object": "chat.completion", "created": 1716671972, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is a medication used primarily for the treatment of certain types of cancer. It is a tyrosine kinase inhibitor that targets multiple pathways involved in tumor growth and angiogenesis, including MET, VEGFR, and AXL. Here are some key points about cabozantinib that you, as a physician, might find useful:\n\n1. **Indications:**\n   - **Renal cell carcinoma (RCC):** Cabozantinib is approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.\n   - **Hepatocellular carcinoma (HCC):** It is also approved for patients with hepatocellular carcinoma who have been previously treated with sorafenib.\n   - **Medullary thyroid cancer (MTC):** Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer.\n\n2. **Mechanism of Action:**\n   - Cab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nudvZ6brgMFSIk1XMS6YWgq7", "custom_id": "44_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "68280cb1ce73a98bc70f9c4832f0510e", "body": {"id": "chatcmpl-9St5ZQ9EcJY4AcuhT1W7OMo2hfHa2", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol-mknl, marketed under the name Asparlas, is an antineoplastic agent used in the treatment of acute lymphoblastic leukemia (ALL). Here are some essential points you should know about calaspargase:\n\n1. **Mechanism of Action**: Calaspargase pegol-mknl is a modified enzyme that works by depleting the amino acid asparagine. Leukemic cells, unlike normal cells, are unable to synthesize asparagine due to a lack of asparagine synthetase, making them dependent on an external source. By depleting asparagine, calaspargase starves the leukemic cells of a necessary nutrient, inhibiting their ability to proliferate.\n\n2. **Indications**: It is approved for use in pediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WBvgMwKbBS1i2UoJgGL1hVMm", "custom_id": "45_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8758ad58e9350f9086340150480b955d", "body": {"id": "chatcmpl-9St5ZabOKzX1UirQ8l7XixTutW0CU", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapy drug used primarily in the treatment of certain types of cancer, including breast, colorectal, and gastric cancers. As a prodrug, it is metabolized in the body to fluorouracil (5-FU), which is the active anti-neoplastic component. Here are some key points about capecitabine that physicians should consider:\n\n### Mechanism of Action\n- **Conversion to 5-FU:** Capecitabine itself is not active; it is converted into 5-FU in the tissues, particularly in tumor cells, through a three-step enzymatic process that culminates with the enzyme thymidine phosphorylase.\n- **Targeting Tumor Cells:** The conversion is more efficient in tumor cells due to higher concentrations of thymidine phosphorylase, which theoretically provides some degree of tumor selectivity.\n\n### Indications\n- **Colorectal Cancer:** Used both as adjuvant therapy and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TohzxPc976Gyph7C8IRGvjA4", "custom_id": "46_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0a41ac6c1c02f4e40302e50d0c14d518", "body": {"id": "chatcmpl-9St5ZcWa4OUJYrvmcoyQdaJFHVDO8", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used primarily to treat various forms of cancer, including ovarian, lung, head and neck, endometrial, and esophageal cancer, among others. It belongs to a class of drugs known as platinum-containing compounds, which also includes cisplatin and oxaliplatin. Here are some key aspects of carboplatin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCarboplatin works by interfering with the DNA repair mechanism in cancer cells, which leads to cell death. It forms platinum-DNA adducts, causing cross-links and denaturation of the DNA, which ultimately inhibits DNA synthesis and transcription. This action is similar to other alkylating agents, though it is specific to the platinum compound family.\n\n### Indications\n- **Ovarian cancer:** Carboplatin is commonly used to treat ovarian cancer and is often administered in combination with other chemotherapy agents.\n- **Lung"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8Oh4XHPH4INIedbEraiXeYDM", "custom_id": "47_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da457751069336f10ed4dce86b971e63", "body": {"id": "chatcmpl-9St5ZB0ZpduNITruN42fSGwvINVHM", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is an antineoplastic agent used primarily in the treatment of multiple myeloma. As a physician, here are some key aspects you should know about Carfilzomib:\n\n1. **Mechanism of Action**: Carfilzomib is a proteasome inhibitor. It specifically and irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the core particle within the 26S proteasome, thereby inhibiting its proteolytic function. This inhibition leads to an accumulation of ubiquitinated proteins, which in turn induces cell cycle arrest and apoptosis in cancer cells.\n\n2. **Indications**:\n   - Carfilzomib is approved for use in patients with multiple myeloma who have received at least one prior therapy. It is often used in combination with other agents such as dexamethasone or lenalidomide and dexamethasone.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x4rUfeDnI8Fzp2u3Qnqo4dGO", "custom_id": "48_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4511245973d85e479e2cd6270533d8b", "body": {"id": "chatcmpl-9St5ZfN5fokb2992K2hv5BWJfAgwU", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine is a chemotherapeutic agent used primarily in the treatment of various types of cancer, including brain tumors, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It belongs to the class of drugs known as nitrosoureas, which are alkylating agents that interfere with DNA replication and RNA transcription, ultimately leading to cell death.\n\nHere are several key aspects of Carmustine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCarmustine causes cross-linking of DNA and RNA strands, leading to inhibition of DNA synthesis and function. It is cell-cycle nonspecific, meaning it can affect cancer cells at various stages of their growth cycles.\n\n### Indications\n- **Brain tumors:** Including glioblastoma, astrocytoma, and brain metastases.\n- **Multiple myeloma:** Often used when other treatments have failed.\n- **Lymphomas:** Including"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JAFA1G0VK6WH4N5ONbMHCPUt", "custom_id": "49_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8508a25b618df552d0b9a19092dc55cc", "body": {"id": "chatcmpl-9St5ZAuOwwsfnwhLQbPyiOIgvxB4M", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafers (polifeprosan 20 with carmustine implant) are a treatment option used specifically in neurosurgery for patients with high-grade malignant glioma, such as glioblastoma multiforme. Here are key aspects you should know about this treatment:\n\n1. **Composition and Form**: The product consists of a biodegradable wafer that contains the chemotherapeutic agent carmustine (BCNU). Each wafer is about 1.45 cm in diameter and 1 mm thick, designed to be implanted directly into the brain.\n\n2. **Mechanism of Action**: Carmustine is an alkylating agent that interferes with DNA and RNA replication, leading to tumor cell death. By implanting the wafers directly into the surgical cavity after tumor resection, high local concentrations of carmustine can be achieved at the tumor site, which may enhance the tumoricidal effect while minimizing systemic exposure and toxicity.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zgeLBpmdL1TR3GQsf9q3oErR", "custom_id": "50_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af96fcd840a546c088f1a5d0ae97c716", "body": {"id": "chatcmpl-9St5Z4O4gxcNWmIFlOcXG6dN92G4B", "object": "chat.completion", "created": 1716671973, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is an oral medication used primarily in the treatment of cancer. As a physician, here are some key aspects of Cediranib that you should be aware of:\n\n1. **Mechanism of Action**: Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. These receptors are crucial for the processes of angiogenesis (formation of new blood vessels), which is essential for tumor growth and metastasis. By inhibiting these receptors, Cediranib can reduce the blood supply to tumors and thus inhibit their growth.\n\n2. **Indications**: Cediranib has been studied in various types of cancers including renal cell carcinoma, glioblastoma, and ovarian cancer. It is important to follow the specific indications and guidelines for use in your region or country, as approval can vary.\n\n3. **Administration**: Cediranib is administered orally, which can be more convenient for patients compared to intravenous therapies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gVWn4hFoPnqfbHGLwV0NnNXq", "custom_id": "51_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "33b76fc61d55e45aed8c96486433fca4", "body": {"id": "chatcmpl-9St5aK3sC3rTKMngQGUKdNUy6rGns", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab, marketed under the brand name Libtayo, is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that targets the PD-1 (programmed cell death protein 1) receptor on T cells. By inhibiting PD-1, cemiplimab enhances the body's immune response against cancer cells. Here are some key points about cemiplimab that you, as a physician, might find useful:\n\n1. **Indications**: Cemiplimab is approved for use in certain types of cancers, including:\n   - Cutaneous squamous cell carcinoma (CSCC) that is metastatic or locally advanced and not curable with surgery or radiation.\n   - Basal cell carcinoma (BCC) that is locally advanced or metastatic and has progressed following hedgehog pathway inhibitor therapy, or when those therapies are not appropriate.\n   - Non-small cell lung cancer (NSCLC) with certain characteristics,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_klWiVzq1CU8rbzby4TwkQMCt", "custom_id": "52_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "21f24d4e34cf212c318cd23a41163ac4", "body": {"id": "chatcmpl-9St5au0XnvGr5nb1KmGTV1hpvk2gX", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib (brand name Zykadia) is a medication used primarily for the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about ceritinib:\n\n1. **Indications**: Ceritinib is specifically approved for the treatment of patients with metastatic NSCLC that are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. It is often used in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n2. **Mechanism of Action**: Ceritinib is a small molecule ALK inhibitor. ALK is a receptor tyrosine kinase that can be genetically altered in some cancers. By inhibiting ALK, ceritinib can block the downstream signaling pathways that promote cancer cell growth and survival.\n\n3. **Administration**: Ceritinib is administered orally, and the typical starting dose is 450 mg once daily with food. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_aOARTEgpbk4VG59DW1hTth4y", "custom_id": "53_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "31e057b465a05bf16c4551df38e9bc91", "body": {"id": "chatcmpl-9St5a15cTsyMmJw1du85HyuSjYDQC", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician prescribing cetuximab or considering its use, it's important to be aware of the following key aspects:\n\n### Mechanism of Action\nCetuximab (brand name Erbitux) is a chimeric (mouse/human) monoclonal antibody that targets the epidermal growth factor receptor (EGFR). EGFR is overexpressed in many solid tumors, including colorectal and head and neck cancers. By binding to EGFR, cetuximab blocks the receptor's phosphorylation and activation, leading to inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production.\n\n### Indications\nCetuximab is approved for use in:\n- Metastatic colorectal cancer, particularly in patients with EGFR-expressing, RAS wild-type tumors. It is used in combination with chemotherapy or as a single agent in patients who are intolerant to certain chemotherapy drugs.\n- Head"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rD14Nmc2sYvVHouMuiFenvAa", "custom_id": "54_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe15fcbcd9aae9604ff57795fef33e45", "body": {"id": "chatcmpl-9St5aZTPONMDU20d8EGsDHb56NfNe", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide, also known as CS055 or Tucidinostat, is an orally active, benzamide class selective inhibitor of histone deacetylases (HDACs). It is primarily used in the treatment of cancer, with a particular focus on hematological malignancies.\n\nHere are some key aspects you should know about Chidamide:\n\n1. **Mechanism of Action**: Chidamide selectively inhibits HDAC1, HDAC2, HDAC3, and HDAC10. By inhibiting these enzymes, Chidamide leads to an increase in acetylation of histone proteins, thereby affecting gene expression. This alteration in gene expression can induce cell cycle arrest, apoptosis, and differentiation of cancer cells.\n\n2. **Indications**: It has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research is ongoing to determine its efficacy and safety for other types of cancer, including solid tumors.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_H8X66LPB1idCV8oftLYUrsxv", "custom_id": "55_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89fb90faedf364a66d351c1211231b66", "body": {"id": "chatcmpl-9St5aLk4MvcIdGqIlqVOXEH3nxJfs", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used primarily in the treatment of various hematologic malignancies. Here are some key points you should know about chlorambucil:\n\n1. **Indications**: Chlorambucil is most commonly used to treat chronic lymphocytic leukemia (CLL). It is also indicated for other types of non-Hodgkin's lymphoma, Hodgkin's lymphoma, and Waldenstr\u00f6m's macroglobulinemia. It can be used in treating some autoimmune disorders as well, such as nephrotic syndrome.\n\n2. **Mechanism of Action**: Chlorambucil works by binding to DNA, forming cross-links which prevent DNA replication and transcription. This leads to cell cycle arrest and eventual cell death, particularly in rapidly dividing cells such as cancer cells.\n\n3. **Administration**: It is typically administered orally, and dosing can vary based on the condition being treated, patient body weight or surface area, and overall patient response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bjtyNyM63IdY8wfxyW90ffIu", "custom_id": "56_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e65a7ca95e5c801159826de08ce1c0eb", "body": {"id": "chatcmpl-9St5adyZ5uItDB4HKig3p4O8dASBf", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a chemotherapy medication widely used to treat various types of cancers, including testicular, ovarian, cervical, bladder, lung, and stomach cancers, among others. Here are some key aspects about Cisplatin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCisplatin works by forming platinum-DNA adducts. Once cisplatin enters the cell, it forms covalent bonds with DNA, causing DNA cross-linking and preventing the DNA from unwinding and replicating. This leads to apoptosis or programmed cell death.\n\n### Administration\nCisplatin is typically administered intravenously, and the dosage and schedule depend on the type of cancer being treated, the patient's body surface area or weight, the patient's renal function, and whether cisplatin is being used alone or in combination with other drugs.\n\n### Efficacy\nCisplatin is effective as a single agent but is often used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NZFpwbganHgSwcPmtuacjtU0", "custom_id": "57_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e401362b047ad72b0c425feab71f4b16", "body": {"id": "chatcmpl-9St5alUpbYx7uvz0YhupkyfJBUgRV", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine is a medication used primarily in the treatment of hairy cell leukemia and multiple sclerosis. Here are some key points about Cladribine that you, as a physician, might find useful:\n\n### Mechanism of Action\n1. **Antimetabolite**: Cladribine is a purine analog that disrupts cellular metabolism and DNA synthesis.\n2. **Selective cytotoxicity**: It is selectively toxic to lymphocytes and monocytes, which is beneficial in conditions with pathological lymphocyte activity.\n\n### Indications\n1. **Hairy Cell Leukemia**: It is most commonly used for the treatment of hairy cell leukemia, showing high efficacy in inducing remission.\n2. **Multiple Sclerosis (MS)**: Approved for the treatment of multiple sclerosis, particularly relapsing forms including relapsing-remitting disease and active secondary progressive disease. It reduces the frequency of clinical exacerbations and delays the progression of physical disability.\n\n### Administration\n- **Routes**: Available"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_l15HODCUhgNH9tGbrVEqm37k", "custom_id": "58_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "53887a2562971404398fbf1d4d300eda", "body": {"id": "chatcmpl-9St5aTqGr9E73P72Xfl1zJEHI0nV4", "object": "chat.completion", "created": 1716671974, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clarithromycin is an antibiotic used to treat various bacterial infections, including respiratory tract infections, skin infections, and Helicobacter pylori infections associated with peptic ulcer disease. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Clarithromycin is a macrolide antibiotic. It works by inhibiting protein synthesis by binding to the 50S ribosomal subunit of the bacteria, which ultimately prevents bacterial growth.\n\n2. **Spectrum of Activity**: It is effective against a broad range of gram-positive and gram-negative bacteria. It has improved activity against certain gram-negative bacteria compared to erythromycin and is also effective against atypical pathogens such as Mycoplasma, Chlamydia, and Legionella.\n\n3. **Indications**: Clarithromycin is commonly prescribed for:\n   - Community-acquired pneumonia\n   - Acute bacterial exacerbation of chronic bronchitis\n   - Acute maxillary sinus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hqCeqrkyWpCc7tD4ptcwMePw", "custom_id": "59_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d694b043b64b045729c8bc2fde0cbff5", "body": {"id": "chatcmpl-9St5b31htP8fDErNDxNvh9DhvlFG1", "object": "chat.completion", "created": 1716671975, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent used primarily in the treatment of acute leukemias. Here are some key points you should know about clofarabine:\n\n1. **Indications**: Clofarabine is approved for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens. It is also used in adults, particularly for acute myeloid leukemia (AML), under similar conditions of relapse or refractoriness.\n\n2. **Mechanism of Action**: Clofarabine is a nucleoside analog that inhibits DNA synthesis and repair, leading to apoptosis (cell death). It is structurally and functionally similar to cladribine and fludarabine, but with potentially more potent activity.\n\n3. **Administration**: It is typically administered intravenously. Dosing and duration of therapy can vary based on factors like patient age, weight, renal function, and specific treatment protocols"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_QhWSvWj2yYrCLg9g9rTgtYsk", "custom_id": "60_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d116298986df7c740f963a241d6b5d2", "body": {"id": "chatcmpl-9St5bJXVy5y6NfeHp8BrWF3NGDXD6", "object": "chat.completion", "created": 1716671975, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib is a medication used primarily in the treatment of cancer, specifically for melanoma that has a certain type of abnormal \u201cBRAF\u201d gene. Here\u2019s a brief overview of important aspects you should know about cobimetinib:\n\n### Mechanism of Action:\nCobimetinib is a kinase inhibitor that works by inhibiting the mitogen-activated protein kinase (MEK) enzymes MEK1 and MEK2. MEK proteins are part of a signaling pathway that includes BRAF, MEK, and ERK, which helps cells grow and divide. By inhibiting MEK, cobimetinib helps to stop or slow the growth of cancer cells.\n\n### Indications:\n- **Melanoma with BRAF V600 Mutation**: Cobimetinib is approved for use in combination with vemurafenib, another kinase inhibitor, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P7KvCBfcM4C1zxpp0D527Nhf", "custom_id": "61_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a29a8606a49471708b4ed38c8a8393eb", "body": {"id": "chatcmpl-9St5b5vpJqaI4slEvVMrluVXdNftc", "object": "chat.completion", "created": 1716671975, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib is a medication used primarily in the treatment of certain types of cancers, particularly hematological malignancies. It is important for physicians to be aware of its mechanism of action, indications, dosing regimen, potential side effects, and monitoring requirements. Here\u2019s a detailed breakdown:\n\n### Mechanism of Action\nCopanlisib is a phosphatidylinositol-3-kinase (PI3K) inhibitor, specifically targeting the PI3K-alpha and PI3K-delta isoforms found in malignant cells. By inhibiting these pathways, copanlisib induces apoptosis and inhibits proliferation of cancer cells.\n\n### Indications\nAs of the latest updates, copanlisib has been approved by the FDA for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Research is ongoing to evaluate its effectiveness in other types of malignancies.\n\n### Administration\nCopanlisib is administered intravenously. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_seiLmpJXx7zGOOyJhKhtnQgj", "custom_id": "62_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9568b702b5f0d0cda85820f6274984b", "body": {"id": "chatcmpl-9St5bY8PWQwgtptf1xesswnrCHIMR", "object": "chat.completion", "created": 1716671975, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib is an important drug used primarily in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). Here are key points that you, as a physician, should consider:\n\n1. **Mechanism of Action**: Crizotinib is a tyrosine kinase inhibitor that targets multiple tyrosine kinases, including ALK (anaplastic lymphoma kinase), ROS1, and MET (hepatocyte growth factor receptor). It is particularly effective in cancers where these kinases are deregulated due to genetic alterations.\n\n2. **Indications**:\n   - **ALK-positive NSCLC**: Crizotinib is approved for the treatment of patients with locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test.\n   - **ROS1-positive NSCLC**: It is also indicated for the treatment of patients with locally advanced or metastatic NSCLC that is ROS1-positive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6Wwbb7xiLVmrqt3cxHUjQmPB", "custom_id": "63_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bdee51ef2c286c17b8f9375f5735bbb0", "body": {"id": "chatcmpl-9St5bFUuuYG9Natih9CLAxtO6XoS3", "object": "chat.completion", "created": 1716671975, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is a cytotoxic antineoplastic drug that also has immunosuppressive properties. It belongs to the class of alkylating agents and is used to treat various types of cancer and some autoimmune disorders. Here are some key points that a physician should know about cyclophosphamide:\n\n### Mechanism of Action:\nCyclophosphamide is a prodrug that requires hepatic metabolism to form its active metabolites, phosphoramide mustard and acrolein. These metabolites cross-link DNA strands, inhibit DNA synthesis and function, leading to cell death. This action is not phase-specific in the cell cycle.\n\n### Indications:\n- **Oncologic Uses**: Used in the treatment of lymphomas, leukemias, multiple myeloma, breast cancer, ovarian cancer, and as a part of various chemotherapy regimens.\n- **Autoimmune Disorders**: Used in severe cases of rheumatoid arthritis, systemic lupus erythematosus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_csirLIRU2qaghEphC64Ak2Vz", "custom_id": "64_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89db6adc5e1930aebada5f683abcc4f7", "body": {"id": "chatcmpl-9St5cFAckCVInFSIH55f8A4cq4UMd", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyproterone acetate is a medication with several important clinical uses and properties that you, as a physician, should be aware of. Here are the key points:\n\n### Mechanism of Action\n- **Antiandrogenic:** Cyproterone acetate (CPA) is a potent antiandrogen. It works primarily by blocking androgen receptors, thereby inhibiting the action of androgens (such as testosterone) in the body. This can help reduce the effects of excess androgen, such as certain types of acne, increased hair growth, and scalp hair loss.\n- **Progestogenic:** CPA also has progestogenic properties. It acts by suppressing gonadotropin secretion, which decreases the production of sex hormones from the gonads (both testes and ovaries).\n\n### Indications\n- **Prostate Cancer:** It is used in the treatment of advanced prostate cancer by controlling hormonal stimulation.\n- **Hyperandrogenism:** In women, CPA is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AwKhKXDA9m4y82rV5N3Jh4Ch", "custom_id": "65_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a90abd9b035247e3af156bbf1b5c439f", "body": {"id": "chatcmpl-9St5c43u4D2UKqpSTjugZjv9dJ0X7", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as cytosine arabinoside (Ara-C), is a chemotherapy medication primarily used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma. Here are some important aspects about Cytarabine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nCytarabine is a pyrimidine nucleoside analog that inhibits the synthesis of DNA. It is incorporated into DNA during the S-phase of the cell cycle, leading to chain termination. It has higher activity in rapidly dividing cells, which makes it effective against leukemic cells.\n\n### Indications\n- **Acute myeloid leukemia (AML)**\n- **Acute lymphocytic leukemia (ALL)**\n- **Non-Hodgkin's lymphoma**\n- It is also used in some cases for the treatment of chronic myelogenous leukemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G3Y6VcDlR6LorDUUqR0xRJ61", "custom_id": "66_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9bec19f2de3b61a4e935a0fb5f819233", "body": {"id": "chatcmpl-9St5cGzOjefFOfxPVTULvEhaYxy9d", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a thorough understanding of any medication you prescribe, including Cytarabine and Daunorubicin Liposomal. Here\u2019s a detailed overview:\n\n### Brand Name\nCytarabine and Daunorubicin Liposomal is commonly known under the brand name Vyxeos. This is a liposomal formulation which encapsulates cytarabine and daunorubicin in a fixed molar ratio.\n\n### Mechanism of Action\n- **Cytarabine** is a cytosine nucleoside analog that inhibits DNA polymerase, leading to DNA replication disruption and ultimately cell death. It is primarily active in the S phase of the cell cycle.\n- **Daunorubicin** works by intercalating into DNA and inhibiting topoisomerase II, which also interferes with DNA replication and repair. It generates free radicals that cause cell damage.\n\nThe liposomal encapsulation allows for a more controlled release"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 51, "completion_tokens": 200, "total_tokens": 251}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4K1V85axHAD7yfbmfVxpMNW9", "custom_id": "67_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "21e59fe32040e5dae25810921cb60555", "body": {"id": "chatcmpl-9St5c3il4u5ByRM9AWxRf6Io9VsrT", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a medication used primarily in the treatment of certain types of melanoma (skin cancer) that cannot be removed by surgery or that has metastasized (spread to other parts of the body). It is specifically used for melanomas that exhibit a mutation in the BRAF gene, known as BRAF V600E or V600K mutations. Here are some key points about Dabrafenib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Dabrafenib is a BRAF inhibitor. BRAF is a part of a signaling pathway that includes MEK, ERK, and others, which helps regulate cell growth. Mutations in the BRAF gene, such as V600E and V600K, lead to uncontrolled cell growth. Dabrafenib targets these specific mutations, thereby inhibiting the growth of cancer cells.\n\n2. **Indications**: Dabrafenib is approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_ryTBwMeXtlZS7uRw3rHMjdwl", "custom_id": "68_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e19d3dc38d6cc43939949b53ffe98d92", "body": {"id": "chatcmpl-9St5czlHYkvOCfOSEqEcs5rSv4koZ", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine (DTIC) is a chemotherapeutic agent used primarily in the treatment of various cancers, including malignant melanoma, Hodgkin's lymphoma, sarcoma, and is sometimes used in other tumors as part of combination chemotherapy. Here are some key points you should know about Dacarbazine:\n\n1. **Mechanism of Action**: Dacarbazine works as an alkylating agent, although it is technically a triazene derivative. It requires metabolic activation in the liver to form its active metabolites, which methylate DNA and RNA, ultimately inhibiting DNA synthesis and function.\n\n2. **Administration**: Dacarbazine is administered intravenously. Care must be taken in handling and preparing Dacarbazine, as it is cytotoxic and can cause severe local tissue damage if extravasation occurs during administration.\n\n3. **Dosage and Scheduling**: The dosage and schedule can vary depending on the type of cancer being treated, the specific protocol being used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2qIO48Uh9qEpXNTGCMm4RHr1", "custom_id": "69_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "985b7e888c8a1731911be418f25c529f", "body": {"id": "chatcmpl-9St5c8xM3HRunYaFEWSVbyakUsEkp", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about dacomitinib, especially if you are treating patients with cancer. Dacomitinib is an oral, small molecule, irreversible tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptor (HER) family of kinases. Here are key points to consider:\n\n### Mechanism of Action:\nDacomitinib inhibits the activity of HER1 (EGFR), HER2, and HER4 tyrosine kinases. By doing so, it blocks the signaling pathways which may result in growth inhibition and apoptosis of tumor cells that overexpress these receptors.\n\n### Indications:\nDacomitinib is primarily used for the treatment of metastatic non-small cell lung cancer (NSCLC). It is specifically indicated for the first-line treatment of patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations as detected by an FDA-approved test.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s2TarXMRTvLed9rogAZ8yJoT", "custom_id": "70_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a70bd9144e6799c9e89d9600fdacc12b", "body": {"id": "chatcmpl-9St5cxoXhXxpdTy5ZK01jb4fwV5fJ", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapy medication used primarily to treat a variety of cancers. Here are key points that you, as a physician, should know about dactinomycin:\n\n1. **Mechanism of Action**:\n   Dactinomycin binds to DNA and inhibits RNA synthesis, which effectively blocks the growth of cancer cells. It intercalates between guanine-cytosine base pairs, inhibiting DNA-dependent RNA polymerase.\n\n2. **Indications**:\n   It is commonly used in the treatment of:\n   - Wilms' tumor\n   - Rhabdomyosarcoma\n   - Ewing's sarcoma\n   - Trophoblastic neoplasms\n   - Certain types of testicular cancer\n   - It may also be used in treating other cancers as part of combination chemotherapy.\n\n3. **Administration**:\n   Dactinomycin is administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jUXv10Yljo6w7yAiRNe4dsnt", "custom_id": "71_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1af6dad13d58ac187394b17f1557cb8c", "body": {"id": "chatcmpl-9St5cpMg6RVMWH01Fub31PnAIi8OL", "object": "chat.completion", "created": 1716671976, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid with both androgenic and antigonadotropic properties. It was initially approved by the FDA in 1971 and is primarily used for the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol works mainly by suppressing the pituitary-ovarian axis through inhibiting the output of pituitary gonadotropins, which leads to a decrease in ovarian production of estrogens.\n\nHere are several key points about Danazol that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - **Endometriosis**: To alleviate pain and reduce the extent of lesions.\n   - **Fibrocystic Breast Disease**: Intended for use in patients unresponsive to simple measures.\n   - **Hereditary Angioedema**: Used to prevent attacks.\n\n2. **Mechanism of Action**:\n   - Danazol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YdvaMjwtQyppKmyovYvWOkqc", "custom_id": "72_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "863d345cc2fcf8e8fe0c8af8ca81d9b4", "body": {"id": "chatcmpl-9St5dxyxdVI4tNFtD89fD5zZImshf", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab is a monoclonal antibody used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are key points you should know about Daratumumab:\n\n1. **Mechanism of Action**:\n   - Daratumumab targets and binds to CD38, a glycoprotein highly expressed on the surface of multiple myeloma cells. By binding to CD38, daratumumab induces tumor cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.\n\n2. **Indications**:\n   - Daratumumab is approved for use in patients with multiple myeloma who have received at least one prior therapy. It can be used alone or in combination with other therapies such as lenalidomide and dexamethasone, or bortezomib and dexamethasone.\n\n3. **Administration**:\n   - Daratum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_uIkj9vShJisRmdJ4s5pmDHuU", "custom_id": "73_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55813396770f6ca541bf0ed4017a327c", "body": {"id": "chatcmpl-9St5dxe8EyVdNlNz9ohqcV6jqMSFQ", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darolutamide is an oral nonsteroidal antiandrogen medication that is primarily used to treat prostate cancer. Here are some key points that you, as a physician, might find useful:\n\n1. **Indications**: Darolutamide is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). This condition occurs when prostate cancer does not respond to treatment that lowers testosterone levels, but has not yet spread to other parts of the body.\n\n2. **Mechanism of Action**: Darolutamide acts by binding to the androgen receptor and inhibiting its action, which is crucial in the growth and development of prostate cancer cells. It differs from other antiandrogens in that it has a stronger affinity for the androgen receptor and is less likely to cross the blood-brain barrier, potentially reducing the risk of central nervous system side effects.\n\n3. **Administration**: It is administered orally, typically at a dose of 600 mg twice daily with food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qbMdSuHOLEUyDcnYn301HvSg", "custom_id": "74_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f8839039cfa61858e98243debb2f2399", "body": {"id": "chatcmpl-9St5dllYueQDH6IKzDSCLPoAQxHeM", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dasatinachemotherapy drug developed to treat certain cases of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). Here are some critical aspects of Dasatinib you should be aware of:\n\n1. **Mechanism of Action**: Dasatinib is a tyrosine kinase inhibitor (TKI). It works by inhibiting a range of tyrosine kinases, including BCR-ABL1, c-KIT, and SRC family kinases, which are involved in the signaling pathways that regulate cell growth and division. By blocking these enzymes, Dasatinib helps to stop the growth of cancer cells.\n\n2. **Indications**: Dasatinib is primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) where it can be used in different lines of therapy depending on the patient's resistance or intolerance to prior treatment including"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1GrsQWLkjeyPgrJUizXXAihU", "custom_id": "75_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "464cf8908d20d886532000b06f665eab", "body": {"id": "chatcmpl-9St5dNMUvibN3zxkA5YG8CmEMviS9", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is an anthracycline antibiotic that is primarily used in chemotherapy. It is commonly used to treat various types of cancer, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and other types of leukemia. Here are some key aspects about daunorubicin that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Daunorubicin works by intercalating into DNA, which inhibits the synthesis of DNA and RNA. It also generates free radicals that cause cell membrane and DNA damage, leading to apoptosis of the cancer cells.\n\n2. **Administration**: Daunorubicin is administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's health status, body surface area, and response to therapy.\n\n3. **Dosage and Scheduling**: Careful calculation of the dosage based on body surface area is crucial. Treatment schedules can vary depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VkUTLhjirsgzlLKwEOgBDwzV", "custom_id": "76_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60b9aa7dafee271f131ab0921c0f3e48", "body": {"id": "chatcmpl-9St5dmEu0GMhyyarjHOmMEzTcJpwZ", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a form of the chemotherapy drug daunorubicin that has been encapsulated in liposomes. This formulation allows the drug to stay in the bloodstream longer and to be delivered more specifically to cancer cells, potentially reducing some of the side effects associated with conventional daunorubicin. Here are some key points you should be aware of as a physician:\n\n1. **Indications**: Daunorubicin liposomal is primarily used for the treatment of specific types of cancer, most notably Kaposi's sarcoma in patients with AIDS. It is also used for treating acute myeloid leukemia (AML) and may be considered for other types of cancer as part of clinical trials.\n\n2. **Mechanism of Action**: Like traditional daunorubicin, the liposomal form interferes with the growth of cancer cells by intercalating into DNA, which inhibits the replication of DNA and the transcription of RNA. The liposomal encapsulation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_osAGsJWNO77j95ADLWz2LCp2", "custom_id": "77_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aaa275260a7406540704d7a680397514", "body": {"id": "chatcmpl-9St5d7mXQFgC1S6WKt0iZKe87Aps4", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine, also known by the trade name Dacogen, is a chemotherapeutic agent primarily used in the treatment of myelodysplastic syndromes (MDS), a group of hematopoietic disorders characterized by dysfunctional blood cell production. It is also used for the treatment of acute myeloid leukemia (AML), particularly in older patients who may not be good candidates for more intensive chemotherapy regimens.\n\nHere are some key points about Decitabine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Decitabine is a nucleoside analog of cytidine. It incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This action can reactivate genes that are silenced by hypermethylation, a common mechanism in certain types of cancers, including MDS and AML.\n\n2. **Indications**:\n   - Approved for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7kygYxwziM2bGIHPSbPaLg9R", "custom_id": "78_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b1f6c998de743d395be07a7a00e22119", "body": {"id": "chatcmpl-9St5dwpUZy8HuwT36A3d26ISKfFp6", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a medication commonly used in the treatment of prostate cancer. It is a type of hormone therapy that works by reducing the amount of testosterone produced by the body, which can help slow the growth of prostate cancer cells. Here are some key points you should know about Degarelix:\n\n1. **Mechanism of Action**: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which initially cause a surge in testosterone levels before suppressing them, Degarelix directly lowers testosterone levels without the initial surge. This can be particularly beneficial in patients where a flare-up of symptoms (from the testosterone surge) needs to be avoided.\n\n2. **Indications**: It is approved for the treatment of advanced prostate cancer. It might be particularly useful in situations where immediate reduction of testosterone is desired or when the testosterone surge from GnRH agonists is contraindicated.\n\n3. **Administration**: Degarelix is administered as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_BUyyuOqdFYcw9jUpDwxt7qxZ", "custom_id": "79_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "777e31b001a9ce7a51fd85ec8de004c4", "body": {"id": "chatcmpl-9St5dDjgy6FOPFHREd9rfPpcHzJWO", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denileukin diftitox is an anticancer medication designed to treat certain types of lymphoma, particularly cutaneous T-cell lymphoma (CTCL) in patients who have not responded to other treatments. It is a fusion protein that combines interleukin-2 (IL-2) with diphtheria toxin. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Denileukin diftitox targets cells that express the IL-2 receptor, which are typically more abundant in lymphoma cells. Once bound to the IL-2 receptor, the diphtheria toxin component enters the cells and inhibits protein synthesis, leading to cell death.\n\n2. **Indications**: It is specifically approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) and has been used in patients who have not responded to other standard treatments.\n\n3. **Administration**: Denileukin diftitox is administered intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QPzj43wEHPcJ0LGXJC6EowXn", "custom_id": "80_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71e9ffa652c44612728b07f51f2ea2f4", "body": {"id": "chatcmpl-9St5djFqggW8bek3Dj3shhm52k0ry", "object": "chat.completion", "created": 1716671977, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is an important medication in the management of certain bone-related disorders. Here are key points to consider:\n\n1. **Mechanism of Action**: Denosumab is a monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption. It targets and binds to the RANK ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.\n\n2. **Indications**:\n   - **Osteoporosis**: It is approved for the treatment of osteoporosis in postmenopausal women at high risk of fracture, to increase bone mass in men with osteoporosis at high risk of fracture, and in patients receiving androgen deprivation therapy for nonmetastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.\n   - **Bone metastases from solid tumors**: Denosumab is also indicated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0fFCBt4pdYg7eyZJsL1qclVo", "custom_id": "81_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ad08063cd96a3688b50c8b01e40844c", "body": {"id": "chatcmpl-9St5ePJglZLtdrZiYj2QbzPQWsmBy", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. Here are some key points that you, as a physician, should consider when dealing with dexamethasone:\n\n1. **Mechanism of Action**: Dexamethasone works by decreasing inflammation through suppression of the migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It also suppresses normal immune response.\n\n2. **Indications**:\n   - **Anti-inflammatory and immunosuppressive therapy**: Used in conditions such as rheumatic problems, skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease, and others.\n   - **Cerebral edema**: Particularly cerebral edema associated with primary or metastatic brain tumors, craniotomy, or head injury.\n   - **COVID-19**: Used in the management of certain cases of COVID-19, particularly in patients requiring oxygen or ventilatory support, based on its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_1DC05KZ7Suk3yUSIGkyPNFwY", "custom_id": "82_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6cb7ce8e9a3a11381cb43bbb98cb6434", "body": {"id": "chatcmpl-9St5eZY7pvImOgqXsUPVKzB4kkOZq", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a cytoprotective agent used primarily to reduce the incidence and severity of cardiotoxicity associated with certain chemotherapy agents, notably anthracyclines like doxorubicin. Here are some key points you should know about dexrazoxane:\n\n1. **Mechanism of Action**: Dexrazoxane is a bisdioxopiperazine compound that works principally by chelating iron, thereby reducing the formation of free radicals and preventing iron-mediated oxidative damage. This is particularly relevant in the context of anthracycline-induced cardiotoxicity, where iron plays a central role in the generation of free radicals that damage cardiac cells.\n\n2. **Indications**:\n   - **Cardioprotection**: It is approved for use in adult patients who have received a cumulative doxorubicin dose of 300 mg/m\u00b2 and are continuing therapy with doxorubicin. It helps to prevent cardiomyopathy associated with doxorubicin.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_m8SLRwI5fxWOnRMVirlTrfb4", "custom_id": "83_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c115af724f2d401c9e71efcb18392dd9", "body": {"id": "chatcmpl-9St5eAd2lRZVpZeunipt2ZANZVZ1s", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic form of estrogen that was first synthesized in 1938. It was primarily prescribed to pregnant women from the 1940s to the 1970s with the belief that it would reduce the risk of pregnancy complications and losses. However, in the early 1970s, studies revealed that DES did not prevent complications in pregnancies and, moreover, was associated with rare vaginal tumors in girls and women who had been exposed to the drug in utero, leading to its discontinuation for pregnant women.\n\nHere are some key points about DES that a physician should be aware of:\n\n1. **Health Effects in DES Daughters**: Women exposed to DES in utero, commonly referred to as \"DES Daughters,\" have an increased risk of clear cell adenocarcinoma of the vagina and cervix, although this cancer is still rare. They are also at higher risk for several other reproductive tract issues, including structural abnormalities of the uterus,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RwEQX2zsdl1P43NjMIhADgAg", "custom_id": "84_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46b7112c5ba2d8db63eb55d686bea65a", "body": {"id": "chatcmpl-9St5e0kgUo6iXW6Kks1MFfMiQ2z0c", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a monoclonal antibody used primarily in the treatment of high-risk neuroblastoma, a type of cancer that most commonly occurs in children. It targets a glycolipid called GD2, which is found on the surface of neuroblastoma cells and on some normal cells of the nervous system.\n\nHere are several key points you should know about Dinutuximab:\n\n1. **Indications**: Dinutuximab is approved for use in pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multi-agent, multimodality therapy. It is often used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.\n\n2. **Mechanism of Action**: Dinutuximab binds to the GD2 antigen on neuroblastoma cells, which leads to immune-mediated cell death."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yWD5SYsIDdpjhAv2SHiECovD", "custom_id": "85_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b992f64903d05fba354797a04a15114c", "body": {"id": "chatcmpl-9St5e6XIZBjrnJcCRLp4sZdLneQpI", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is an important chemotherapeutic agent commonly used in the treatment of various cancers, including breast, non-small cell lung, prostate, gastric, and head and neck cancers. Here are some key points you should know about docetaxel:\n\n1. **Mechanism of Action**: Docetaxel is a taxane, a class of drugs that stabilize microtubules and prevent their depolymerization, leading to cell cycle arrest at the G2/M phase and ultimately inducing apoptosis in cancer cells.\n\n2. **Administration**: It is administered intravenously, and the dosage and schedule depend on the type of cancer, the patient's body surface area, overall health, and other chemotherapy drugs being used.\n\n3. **Pre-medication**: To reduce the severity of hypersensitivity reactions, it is common to pre-medicate patients with corticosteroids prior to docetaxel administration.\n\n4. **Common Side Effects**:\n   - Neutropenia: This"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h2L2GQRlThTC5y2B2BWUaAR8", "custom_id": "86_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d8025a41c39e4704ce28bbf8007b5507", "body": {"id": "chatcmpl-9St5eZtGUHkhjxjHLx1JhCwDJdVCS", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine is a chemotherapeutic agent used primarily in the treatment of cancers. It is a fluoropyrimidine derivative and functions as an antimetabolite. Here are some key aspects you should know about Doxifluridine:\n\n### Mechanism of Action:\nDoxifluridine is a prodrug of 5-fluorouracil (5-FU), and it is converted into 5-FU in the body. The active metabolite, 5-FU, inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This inhibition results in the disruption of DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications:\nDoxifluridine has been used in the treatment of various cancers, including:\n- Stomach cancer\n- Colorectal cancer\n- Breast cancer\n- Esophageal cancer\n\nIt may be used alone or in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VVygKMoMKhxjXQA3J3RppNuE", "custom_id": "87_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "13da4a01ff274b295993e8b07ebe2855", "body": {"id": "chatcmpl-9St5ed7WzGugIrBh17HdzkNEhzswO", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is an anthracycline antibiotic that is widely used in chemotherapy. It is known for its effectiveness in treating a variety of cancers, including breast cancer, bladder cancer, lymphoma, and leukemia, among others. Here are some important points about doxorubicin that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Doxorubicin works primarily through intercalation into DNA, disrupting the replication process and inhibiting topoisomerase II, an enzyme crucial for DNA replication and repair. This leads to the generation of free radicals and oxidative damage to cellular components, ultimately causing cell death.\n\n2. **Administration**:\n   Doxorubicin is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the purpose of the treatment (e.g., adjuvant, neoadjuvant, palliative), patient body surface area, and overall health status.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5qmW2fI63OiE1tSmExMBE0u0", "custom_id": "88_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fec8e8d1ba8fcfe6bbbebe1a3dc7adb9", "body": {"id": "chatcmpl-9St5eMKWs1wKflJYHBvMWDZciDWrg", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab (brand name Imfinzi) is a monoclonal antibody that falls under the category of immune checkpoint inhibitors, specifically targeting the PD-L1 protein. This drug is used in oncology, primarily for the treatment of certain types of cancers. Here are some key aspects of Durvalumab that you, as a physician, might find important:\n\n### Mechanism of Action\nDurvalumab binds to the PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells, blocking its interaction with PD-1 and CD80 (B7.1). By inhibiting this interaction, Durvalumab helps reactivate the immune response against tumor cells. This mechanism is crucial in the body's ability to counteract the immune evasion strategies of cancer cells.\n\n### Indications\nDurvalumab is approved for use in several clinical scenarios:\n1. **Non-Small Cell Lung Cancer (NSCLC)**: It is approved for the treatment of locally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iwASdmT67rZh3a5HKRT0daEt", "custom_id": "89_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f8c79a41dc8c3d25c226ad6f4110367", "body": {"id": "chatcmpl-9St5eanH9z0R3FNwyjH48VawfNTzM", "object": "chat.completion", "created": 1716671978, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication primarily used to treat symptoms of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland that can cause difficulties with urination. Here are some key points you should know about Dutasteride:\n\n1. **Mechanism of Action**: Dutasteride inhibits the enzyme 5-alpha reductase, which is involved in the conversion of testosterone to dihydrotestosterone (DHT). DHT is a hormone that contributes to prostate growth. By lowering DHT levels, dutasteride reduces the size of an enlarged prostate, improving symptoms such as urinary retention and reducing the need for prostate surgery.\n\n2. **Indications**: The primary indication for dutasteride is the treatment of the symptoms of benign prostatic hyperplasia (BPH). It is also sometimes used off-label for the treatment of male pattern baldness (androgenetic alopecia).\n\n3. **Administration**: Dutasteride is typically administered orally in capsule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_53eaj70U9KJaV8s3KhBE0XR1", "custom_id": "90_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd1c60d8569f9d5952a8dca7adc10690", "body": {"id": "chatcmpl-9St5fnkXe7HUum84K9lH16MSFvH5H", "object": "chat.completion", "created": 1716671979, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisib is a small molecule inhibitor of phosphoinositide 3-kinase (PI3K), specifically targeting the delta and gamma isoforms of this enzyme, which are often involved in the signaling pathways of hematologic malignancies. Here are some key points you might find useful:\n\n1. **Indications**: Duvelisib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) after at least two prior systemic therapies.\n\n2. **Mechanism of Action**: Duvelisib inhibits PI3K-delta and PI3K-gamma, leading to the inhibition of the PI3K/AKT/mTOR signaling pathway. This action can reduce the proliferation of malignant cells and can also affect the tumor microenvironment, potentially reducing the survival signals and impacting the immune response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6A1sw2BbU7UMpY1VBqraVPsr", "custom_id": "91_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "406abd31a222f9d15694add45672d8c0", "body": {"id": "chatcmpl-9St5fTVJY1IvEOBbJH9X6UWIqTWb4", "object": "chat.completion", "created": 1716671979, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab (also known as Panorex) is a monoclonal antibody that was used for the treatment of colorectal cancer. It specifically targets the Ep-CAM (epithelial cell adhesion molecule), which is expressed at high levels on the surface of most epithelial cancers, including colorectal cancers. By binding to Ep-CAM, edrecolomab was intended to initiate an immune response against the tumor cells, leading to their destruction.\n\nEdrecolomab was studied in clinical trials for its potential to treat colorectal cancer, particularly in adjuvant settings. However, despite initial interest, it has not achieved widespread clinical use. The key clinical trial, a Phase III study, did not demonstrate a significant improvement in survival outcomes when edrecolomab was added to standard chemotherapy. As a result, edrecolomab is not currently an approved treatment option, and it is not widely available for clinical use.\n\nFor a physician treating patients with colore"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OuQJ3tXnhcVqQEHMnM9KrGFF", "custom_id": "92_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0df4f8ec29bc42aa10e23334418a4d13", "body": {"id": "chatcmpl-9St5fwxYLShlLSBTN7qIzSGMlG33B", "object": "chat.completion", "created": 1716671979, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab is a targeted monoclonal antibody used in the treatment of multiple myeloma. Here are some key points that you, as a physician, should know about Elotuzumab:\n\n1. **Mechanism of Action**:\n   Elotuzumab specifically targets the signaling lymphocytic activation molecule family member 7 (SLAMF7), which is highly expressed on myeloma cells and natural killer cells but not on normal tissues. The drug works by directly activating natural killer cells and by targeting SLAMF7 on myeloma cells for destruction by the immune system.\n\n2. **Indications**:\n   Elotuzumab is approved for use in combination with other medications. Typically, it is used in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one to three prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kVbsqek63fiRaXW55FSR3Akq", "custom_id": "93_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "97ca1319d1e7149ea568c6713b712e02", "body": {"id": "chatcmpl-9St5fORafThQF2lFkz81mKBWEKa00", "object": "chat.completion", "created": 1716671979, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib (brand name Idhifa) is a medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are some key aspects you should know about Enasidenib:\n\n1. **Indication**: Enasidenib is specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML who have an isocitrate dehydrogenase-2 (IDH2) mutation. The presence of the IDH2 mutation should be confirmed using an FDA-approved test before starting treatment with Enasidenib.\n\n2. **Mechanism of Action**: Enasidenib is an inhibitor of the IDH2 enzyme. Mutations in IDH2 result in abnormal enzyme activity that produces 2-hydroxyglutarate (2-HG), which can contribute to the growth and survival of malignant cells. By inhibiting IDH2, Enasidenib decreases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nnwrZC8mR6aipBSIL8pjVM2h", "custom_id": "94_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da010018fb3b65aa62032b3503f28d95", "body": {"id": "chatcmpl-9St5fayjLyvk32OBSyN4MjTKHRfVp", "object": "chat.completion", "created": 1716671979, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Encorafenib (brand name Braftovi) is a medication used in the treatment of certain types of cancer, most notably metastatic melanoma with a specific genetic mutation. Below are some of the key aspects of encorafenib that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Encorafenib is a kinase inhibitor that specifically targets and inhibits the activity of BRAF V600E kinase. This mutation leads to the activation of the MAPK/ERK pathway, which promotes cell proliferation in cancerous cells. By inhibiting this kinase, encorafenib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**: Encorafenib is approved for use in adults with unresectable or metastatic melanoma with a BRAF V600E mutation. It is often used in combination with binimetinib, a MEK inhibitor, which can enhance its anti-tumor activity.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tp4UQcJTgl0PwQU1HKHFMHQv", "custom_id": "95_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2800ac536ad4b0bf2cd505b1887fe44", "body": {"id": "chatcmpl-9St5g1nQbv10d78ulcQgAx5baypmk", "object": "chat.completion", "created": 1716671980, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib is a targeted anticancer medication used for treating cancers that have specific genetic abnormalities. Here are key points you should know about entrectinib:\n\n1. **Mechanism of Action**: Entrectinib is a tyrosine kinase inhibitor. It specifically targets and inhibits the tyrosine kinases TRKA/B/C (encoded by NTRK1/2/3 genes), ROS1, and ALK. By doing so, it can inhibit the growth of cancer cells that express these mutations.\n\n2. **Indications**:\n   - **NTRK Gene Fusion-Positive Solid Tumors**: Entrectinib is approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, who have metastatic disease or where surgical resection is likely to result in severe morbidity, and who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_SJHHa4MHrQVCaFzERaLovYAA", "custom_id": "96_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a06fe12c04a6a85817035e7e37e71ca", "body": {"id": "chatcmpl-9St5gpp5EoA4CBXqhmaE7aQpguV0h", "object": "chat.completion", "created": 1716671980, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is a medication primarily used in the treatment of prostate cancer. Here are several key points about enzalutamide that may be useful for you as a physician:\n\n1. **Mechanism of Action**: Enzalutamide is an androgen receptor inhibitor. It works by binding to the androgen receptors and inhibiting the receptor signaling that promotes the growth of prostate cancer cells. Unlike other anti-androgens, enzalutamide does not show any agonist activity when the androgen receptor is overexpressed.\n\n2. **Indications**:\n   - **Metastatic castration-resistant prostate cancer (CRPC)**: It is approved for patients who have previously received docetaxel.\n   - **Non-metastatic and metastatic castration-sensitive prostate cancer**: Its use has expanded to earlier stages in the disease process in combination with androgen deprivation therapy (ADT).\n\n3. **Administration**: Enzalutamide is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_slz27DmKp9mKS1uSG1ugfA23", "custom_id": "97_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc977bd32b90841f6d974df085412d25", "body": {"id": "chatcmpl-9St5hrRJUblLBZ4aFZkJ1ZbSzh8a0", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin hydrochloride is an anthracycline antibiotic that is widely used in chemotherapy. It is similar in structure and function to doxorubicin and is often used in the treatment of various cancers, including breast cancer, ovarian cancer, stomach cancer, and others. Here are several important aspects of epirubicin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nEpirubicin acts primarily through intercalation into DNA, disrupting the replication and transcription processes. This leads to the inhibition of DNA and RNA synthesis, which results in cytotoxicity towards proliferating cancer cells. It also generates free radicals, which cause additional damage to cellular structures.\n\n### Indications\nEpirubicin is approved for use in:\n- Breast cancer (especially in the adjuvant setting)\n- Gastric cancer\n- Ovarian cancer\n- Other solid tumors\n\nIt is often used in combination with other chemotherapeutic agents, depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PhlpoXCMsZGI6i2rbjdL2Trv", "custom_id": "98_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ac1ebdb784011393082ce57c6a1145a", "body": {"id": "chatcmpl-9St5g7TnvrMbnyiliRoOnl09vR8Hq", "object": "chat.completion", "created": 1716671980, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib, sold under the brand name Balversa, is a small molecule kinase inhibitor specifically indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy. Here are key points you should know about Erdafitinib:\n\n### Mechanism of Action\nErdafitinib targets and inhibits the fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, FGFR3, and FGFR4. The inhibition of these receptors helps to block the FGFR signaling pathway which is implicated in the proliferation and survival of certain types of cancer cells.\n\n### Indications\nErdafitinib is specifically approved for use in patients with FGFR3 or FGFR2 genetic alterations in urothelial carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sc4QWJOeN0rmxcKVHgBJ2En3", "custom_id": "99_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43a873b98e4caedabee1e020820dfdfc", "body": {"id": "chatcmpl-9St5gX6FWwspSGtCZufmvaTdcrV7f", "object": "chat.completion", "created": 1716671980, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin mesylate, marketed under the brand name Halaven, is a chemotherapy drug used primarily in the treatment of cancer. It is a synthetic analog of halichondrin B, a product isolated from the marine sponge Halichondria okadai. Here are some key aspects of eribulin that you, as a physician, might find important:\n\n1. **Indications**: Eribulin is approved for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens, including an anthracycline and a taxane. It is also approved in some regions for the treatment of advanced liposarcoma in patients who have received prior chemotherapy.\n\n2. **Mechanism of Action**: Eribulin works by inhibiting the growth phase of microtubule dynamics which prevents the mitotic spindle from functioning properly, thus leading to cell cycle arrest at the G2/M phase and ultimately cell death.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tb1I5xF7A7ZSV8wvkJTTDD5I", "custom_id": "100_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60bbc917dcf0b83dc16d94d6ae7b84c0", "body": {"id": "chatcmpl-9St5h6VBEeIcuxu9XbasOji9wMSpJ", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points about erlotinib that you, as a physician, might find useful:\n\n### Mechanism of Action\nErlotinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). EGFR is a component of the human epidermal growth factor receptor (HER) family, and it is overly expressed or dysregulated in many cancers. Erlotinib binds to the ATP-binding site of EGFR, thus inhibiting its activity which can lead to the inhibition of tumor growth.\n\n### Indications\n- **Non-small cell lung cancer (NSCLC):** Erlotinib is approved for the first-line treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_raETrUTvGnv8xVxPiCRUcWHb", "custom_id": "101_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2cc2596fd8e972c2d90682877b16c3fc", "body": {"id": "chatcmpl-9St5hvG3lxDwgDTX8vZwznZrrthn7", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Estramustine is a chemotherapy medication used primarily in the treatment of prostate cancer. It combines the properties of an estrogen and a nitrogen mustard derivative, giving it unique mechanisms of action. Here are some key points you should know about estramustine:\n\n1. **Mechanism of Action**: Estramustine is not just a simple chemotherapeutic agent; it also has hormonal properties due to its estrogen component. The drug acts by disrupting microtubule function, which is crucial for mitosis, and also by altering the hormonal environment, which can be particularly effective against hormone-sensitive tumors like prostate cancer.\n\n2. **Indications**: It is primarily indicated for the treatment of metastatic or progressive prostate cancer, particularly in patients who are not candidates for surgery or radiation therapy. It may be used alone or in combination with other therapies.\n\n3. **Administration**: Estramustine is typically administered orally in capsule form. The dosage and treatment schedule can vary based on factors like the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_emsIow2WffgaOD31IYO5CsNJ", "custom_id": "102_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d9b5eede9e7ab4da649107dae9be770", "body": {"id": "chatcmpl-9St5hXM0PkvDfo3w92QRMJtah6I6y", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is a chemotherapeutic agent commonly used in the treatment of various cancers. Here are key points about etoposide that you, as a physician, might find useful:\n\n**Mechanism of Action:**\nEtoposide is a topoisomerase II inhibitor. It works by preventing the religation of the DNA strands that are broken by the topoisomerase II enzyme, leading to DNA damage and apoptosis in dividing cells.\n\n**Indications:**\nEtoposide is used to treat a variety of cancers including:\n- Small cell lung cancer (SCLC)\n- Testicular cancer\n- Non-Hodgkin lymphoma\n- Acute myeloid leukemia\n- Ewing sarcoma\n- Kaposi's sarcoma\n\n**Formulations:**\nEtoposide is available in both oral and intravenous formulations, allowing flexibility in administration depending on the patient's condition and treatment setting.\n\n**Dosage and Administration:**\nThe dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BIdmWzjtDSqfkPjph5SRUER4", "custom_id": "103_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "97e38d83b4d8059a78f65353e4bc39e9", "body": {"id": "chatcmpl-9St5hn96dUF6d9Papeg3SdcNKA5Iw", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is a medication commonly used in various clinical contexts. Here are some key aspects you, as a physician, should know about Everolimus:\n\n1. **Mechanism of Action**: Everolimus is a derivative of sirolimus and falls within the class of mTOR (mammalian target of rapamycin) inhibitors. It works by inhibiting the mTOR pathway, which plays a crucial role in cell proliferation, growth, and survival. By inhibiting this pathway, Everolimus helps to stop cancer cells from growing and dividing.\n\n2. **Indications**:\n   - **Oncology**: Everolimus is used for the treatment of several types of cancer, including advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin, advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of letrozole or anastrozole, and subependymal giant cell astrocytoma (SEGA) associated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TcYum7G98ySckgdyRFNpfXPv", "custom_id": "104_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5138e3e4811e078fe8eed6e7d0dbb349", "body": {"id": "chatcmpl-9St5hkAmXFh9BAW9gBlwqR7bLzfEj", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane is a medication primarily used in the treatment of breast cancer. Here are key points you, as a physician, should be aware of regarding Exemestane:\n\n1. **Classification**: Exemestane belongs to a class of drugs known as aromatase inhibitors. It works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By reducing estrogen levels, exemestane helps to slow the growth of estrogen receptor-positive breast cancer cells.\n\n2. **Indications**: It is commonly prescribed for postmenopausal women with estrogen receptor-positive breast cancer. Exemestane is often used as adjuvant treatment following the initial therapy (like surgery and possibly chemotherapy and/or radiation) to decrease the risk of cancer recurrence. Additionally, it might be used for the treatment of advanced breast cancer where the disease has progressed following tamoxifen therapy.\n\n3. **Dosage and Administration**: The typical dose of exemestane is 25 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ljP1pbAvzSe75YqdTiwXViUz", "custom_id": "105_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ad0de327713cea5e278907bd074508b", "body": {"id": "chatcmpl-9St5hzJYGyB0juxHlBYFkloUvinvm", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine, also known by its brand name FUDR, is a chemotherapeutic agent used primarily in the treatment of cancer. It is particularly indicated for the treatment of metastatic colorectal cancer, specifically when the cancer cells have spread to the liver. Here are some key points about Floxuridine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Floxuridine is a fluorinated pyrimidine analog, which functions as an antimetabolite. It interferes with the synthesis of DNA by becoming incorporated into DNA itself, which prevents normal DNA function and replication. It is a thymidylate synthase inhibitor, leading to a decrease in thymidine, which is necessary for DNA replication.\n\n2. **Administration**: Floxuridine is primarily administered via the hepatic artery (intra-arterial). This method targets the liver directly, reducing some of the systemic toxicity associated with other routes of administration and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Zij7yGS2JzrBkVwYWoSq71q5", "custom_id": "106_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ec40460ca0c89234c68ec21c1349b17", "body": {"id": "chatcmpl-9St5hXokSnDmexs2henmIC49nXxN3", "object": "chat.completion", "created": 1716671981, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fludarabine is a chemotherapy medication used primarily to treat hematological malignancies, particularly chronic lymphocytic leukemia (CLL). Here are some key points about fludarabine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Fludarabine is a purine analog that interferes with DNA synthesis. It is metabolized into the active form, fludarabine triphosphate, which inhibits DNA polymerase and ribonucleotide reductase, leading to apoptosis of lymphocytes.\n\n2. **Indications**: The primary indication for fludarabine is in the treatment of B-cell chronic lymphocytic leukemia (CLL), especially in patients who are refractory to initial treatment. It may also be used in some non-Hodgkin lymphomas and in conditioning regimens for hematopoietic stem cell transplantation.\n\n3. **Administration**: Fludarabine is typically administered intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oTNHkglTcdginIU1WZ06Quih", "custom_id": "107_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7556305c048259ae00bfcbc38e7310d1", "body": {"id": "chatcmpl-9St5io2ooEJah1wCt9YQK7DfcbjpB", "object": "chat.completion", "created": 1716671982, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil, also known as 5-fluorouracil (5-FU), is a chemotherapy medication used to treat various types of cancer, including colorectal, breast, stomach, pancreatic, and skin cancers (particularly in the topical form for the latter). It is typically administered either intravenously or topically, depending on the cancer type and location. Here are some key points you should know about Fluorouracil as a physician:\n\n### Mechanism of Action\nFluorouracil belongs to the category of antimetabolites, specifically as a pyrimidine analog. It works primarily by inhibiting thymidylate synthase, an enzyme critical for DNA synthesis. By doing so, it prevents cancer cells from replicating DNA, thereby disrupting their growth and proliferation.\n\n### Indications\n- **Colorectal cancer**: Often used in combination with other drugs like leucovorin, oxaliplatin, and ir"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1GvSEEppmAYmBZZ7WrM9EuAY", "custom_id": "108_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e2c540246e74ecf2fa78dc75a70e15e", "body": {"id": "chatcmpl-9St5imyoN69YXpZbJdV2MDiL4Wj6R", "object": "chat.completion", "created": 1716671982, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone, marketed under the brand name Halotestin among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. It is taken by mouth.\n\nHere are several key points you, as a physician, should consider regarding Fluoxymesterone:\n\n### Mechanism of Action\nFluoxymesterone is a synthetic derivative of testosterone, modifying the structure to enhance its anabolic properties and reduce its metabolism by the liver. This medication acts as a testosterone replacement therapy by binding to and activating the androgen receptor (AR), which in turn influences the transcription of specific genes that are responsible for the development and maintenance of male sexual characteristics.\n\n### Indications\n- **Hypogonadism in Men:** Used to treat men with testosterone deficiency.\n- **Delayed Puberty in Boys:** Occasionally prescribed to stimulate puberty"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1PAwClHYZ0pT8oVkAFgfugIF", "custom_id": "109_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "64db5d9b1571a780633760d5f4df747a", "body": {"id": "chatcmpl-9St5kTKVucKdiMrIE5WpOKWZq7Pss", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a nonsteroidal antiandrogen primarily used in the treatment of prostate cancer. Here are key points about Flutamide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Flutamide works by inhibiting the action of androgens (male hormones) at the androgen receptor level. It competes with testosterone and dihydrotestosterone for binding to the androgen receptors in the prostate gland, blocking the growth-stimulating effects of androgens on cancer cells.\n\n2. **Indications**:\n   - Primarily used for the treatment of stage B2-C and D2 metastatic prostate carcinoma.\n   - It is often used in combination with a gonadotropin-releasing hormone (GnRH) agonist or before surgery or radiation therapy to decrease the risk of disease flare-up when used alone.\n   - Occasionally, it may be used off-label for other conditions like hirsutism in women"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dgWKESaxTpJB3mDhToiph5zX", "custom_id": "110_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1769fb947ae1be0f38fb75e8a6dd398e", "body": {"id": "chatcmpl-9St5iqyz9RrBAiX5XutRx9FE3sgvU", "object": "chat.completion", "created": 1716671982, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a medication and a form of the B vitamin folic acid. It is used to decrease the toxic effects of some medications and to increase the efficacy of some chemotherapy agents. Here are some key points you should know about Folinic acid:\n\n1. **Mechanism of Action**:\n   - Folinic acid is not the same as folic acid, although it is a derivative. It is metabolically active and does not require reduction by the enzyme dihydrofolate reductase (DHFR) to be biologically available. This allows it to bypass the inhibition effects that drugs like methotrexate have on DHFR.\n   - It works by providing a source of tetrahydrofolate, the active form of folic acid required for the synthesis of thymidine and purine nucleotides, which are essential for DNA synthesis.\n\n2. **Clinical Uses**:\n   - **Chemotherapy Ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_woxlqabra1BDbVPHswJccroo", "custom_id": "111_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "227be8365616778ad14bf3aac89623e4", "body": {"id": "chatcmpl-9St5iVSjgdNEBx1apdqv02KJtW4Mq", "object": "chat.completion", "created": 1716671982, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane, chemically known as 4-hydroxyandrostenedione, is an irreversible steroidal aromatase inhibitor, historically used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It was one of the first selective aromatase inhibitors developed. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Formestane inhibits the enzyme aromatase, which is responsible for converting androgens (like testosterone) into estrogens. This inhibition reduces the levels of estrogen in the body, which is beneficial in treating hormone-sensitive breast cancers that grow in response to estrogen.\n\n2. **Administration**: Originally, formestane was administered via intramuscular injection. Unlike other aromatase inhibitors (e.g., anastrozole, letrozole) that are taken orally, formestane's use is somewhat limited by its mode of administration.\n\n3. **Use in Cancer Treatment**: It was"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jMG2wCX3XINmihXUuvdndbjx", "custom_id": "112_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fdb5a8aae87881a842b6a107986dade6", "body": {"id": "chatcmpl-9St5ioBglUudi7aVC0vt9Hnt8WqHm", "object": "chat.completion", "created": 1716671982, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine is a drug that you as a physician should be aware of, particularly if your practice involves the treatment of hematological malignancies. Here are some key points about Forodesine:\n\n1. **Mechanism of Action**: Forodesine is a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP). This inhibition leads to an increase in deoxyguanosine triphosphate (dGTP) and a decrease in guanine nucleotide levels, which in turn causes apoptosis of lymphocytes. This is particularly effective in malignant B-cells.\n\n2. **Indications**: Forodesine has been primarily investigated for its efficacy in treating hematological malignancies such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and cutaneous T-cell lymphoma (CTCL). It is still under clinical investigation and not yet approved by the FDA. However, it has been granted orphan drug status for the treatment of T-cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uWV3p4tlfKUMmAZ54DIzsbpY", "custom_id": "113_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0155383dcdd90a6b46a93968923931e", "body": {"id": "chatcmpl-9St5jiRFtIQlHmEXPhlbMfOYaim3k", "object": "chat.completion", "created": 1716671983, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is a medication primarily used for the treatment of chronic immune thrombocytopenia (ITP), an autoimmune disorder characterized by a low platelet count, which can lead to easy bruising, bleeding gums, and internal bleeding. Here are some key points you should know about Fostamatinib:\n\n1. **Mechanism of Action**:\n   - Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor. It works by inhibiting the SYK enzyme, which is involved in the signaling pathways that lead to the destruction of platelets in patients with ITP.\n\n2. **Indications**:\n   - It is approved for the treatment of chronic ITP in adult patients who have had an insufficient response to a previous treatment.\n\n3. **Administration**:\n   - Fostamatinib is administered orally, typically starting with a dose of 100 mg twice daily, which can be increased based on response and toler"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_xqvf08I3H16bcwcSGTBnTsiV", "custom_id": "114_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f7fc5f313a22fd7c8d0fb43be8debe41", "body": {"id": "chatcmpl-9St5jfkc1XbB0JLs5MLRSbvLfmRTS", "object": "chat.completion", "created": 1716671983, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is a chemotherapeutic agent belonging to the class of nitrosoureas, which are alkylating agents used in the treatment of cancer. Here are some key points about fotemustine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Fotemustine works by alkylating DNA and RNA, which leads to cross-linking and ultimately the disruption of cellular function and DNA synthesis. Its mechanism allows it to be highly lipophilic, facilitating better penetration through the blood-brain barrier compared to other nitrosoureas.\n\n2. **Indications**:\n   Fotemustine is primarily used for the treatment of metastatic melanoma, especially when the disease involves the central nervous system (CNS). It may also be used in the treatment of other cancers like malignant glioma and Hodgkin's lymphoma under certain circumstances.\n\n3. **Administration**:\n   Fotemustine is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ix68DwYH9sghw0Ky9RgOXOuU", "custom_id": "115_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48689838d3876b3b2e219cc9e19bde83", "body": {"id": "chatcmpl-9St5jeG5AfCgW3Sn9db9u6f5dbzlJ", "object": "chat.completion", "created": 1716671983, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestrant is a medication used primarily for treating hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women. Here are some key points you should know about Fulvestrant:\n\n1. **Mechanism of Action**: Fulvestrant is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors competitively with estrogen, leading to receptor degradation and downregulation. This action inhibits the growth of estrogen-sensitive breast cancer cells.\n\n2. **Indications**:\n   - It is specifically indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.\n   - It can also be used as first-line treatment for HR-positive advanced breast cancer in postmenopausal women.\n\n3. **Administration**: Fulvestrant is administered via intramuscular injections. The typical dose is 500"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0xWkUTxcbwpXmimmSWThZiJn", "custom_id": "116_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2160bfa8901c0181165615b3774581b0", "body": {"id": "chatcmpl-9St5kPVeAAQTvPeVKK7j9lRPLhjdj", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is an important drug used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points about Gefitinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Gefitinib is a selective inhibitor of the epidermal growth factor receptor's (EGFR) tyrosine kinase domain. It binds to the adenosine triphosphate (ATP)-binding site of the enzyme, leading to inhibition of the intracellular phosphorylation of tyrosine kinase associated with the receptor. This inhibition subsequently blocks the downstream signaling and cellular proliferation involved in the development and progression of tumors.\n\n2. **Indications**:\n   Gefitinib is primarily indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (tyrosine kinase).\n\n3. **Efficacy**:\n   Gefitinib has shown"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AgIkY8DrFb168SNpM4pjueje", "custom_id": "117_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd67813533adc722a09fb21e8a63e01e", "body": {"id": "chatcmpl-9St5kloriI6b6jXmoLqRhRfTg0U7Q", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine is a nucleoside analog used primarily as a chemotherapeutic agent. It is commonly used to treat various types of cancer, including pancreatic cancer, breast cancer, ovarian cancer, and non-small cell lung cancer. Here are some key points about gemcitabine that you, as a physician, might find useful:\n\n### Mechanism of Action\nGemcitabine is a cytidine analog that gets incorporated into DNA during the S phase of the cell cycle, leading to inhibition of DNA synthesis. After being phosphorylated into its active diphosphate and triphosphate forms, gemcitabine causes chain termination during DNA replication, ultimately inhibiting tumor growth.\n\n### Indications\n- **Pancreatic Cancer:** It is used as first-line therapy for advanced pancreatic cancer.\n- **Breast Cancer:** Used in metastatic breast cancer, often in combination with other agents like paclitaxel.\n- **Ovarian Cancer:** Employed in recurrent cases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rrowTyAS9BRB7PKLEJaAcy4D", "custom_id": "118_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4173fe8d251c31467f7bec0ed775066", "body": {"id": "chatcmpl-9St5kcIvrzP5XatRZoJNLN4Bj4q9U", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is a targeted anticancer medication used primarily in the treatment of acute myeloid leukemia (AML). Here are key points you should know about the drug:\n\n1. **Mechanism of Action:**\n   Gemtuzumab ozogamicin is a conjugate of a monoclonal antibody and a cytotoxic agent. The antibody component specifically binds to the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and other myeloid cells. Once bound, the complex is internalized and the cytotoxic agent, a derivative of calicheamicin, is released inside the cell where it induces DNA breakage leading to cell death.\n\n2. **Indications:**\n   - It is approved for the treatment of newly diagnosed CD33-positive AML in adult patients.\n   - It's also indicated for the treatment of relapsed or refractory CD33-positive AML in adults and pediatric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MmdnoqfAxBcUtTAv6wJ0xJel", "custom_id": "119_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "076f223d115000936fa0229ae4e44eaf", "body": {"id": "chatcmpl-9St5kFtWN5UadN1UUNKZnAH0h6rrv", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib, marketed under the brand name Xospata, is a medication used in the treatment of acute myeloid leukemia (AML). Here are some key points that a physician should know about gilteritininb:\n\n1. **Indications**: Gilteritinib is specifically approved for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Gilteritininb is a tyrosine kinase inhibitor that targets the FLT3 (FMS-like tyrosine kinase 3) mutations. FLT3 is one of the most frequently mutated genes in AML. Gilteritinib inhibits multiple tyrosine kinases, primarily the FLT3 mutation, which helps in controlling the proliferation of leukemia cells.\n\n3. **Administration**: Gilteritinib is administered orally, which can be more convenient compared to treatments that require infusion or hospitalization.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cRjlQxAcKyUbVwobShpIZReS", "custom_id": "120_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad2a38f412275b65242e737e0576b800", "body": {"id": "chatcmpl-9St5k4gSMobICwyBzWymdy9fVpH9G", "object": "chat.completion", "created": 1716671984, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Glasdegib, marketed under the brand name Daurismo, is a medication used for the treatment of acute myeloid leukemia (AML). Here are some key aspects that you, as a physician, should know:\n\n1. **Indication**: Glasdegib is approved for use in adult patients with newly-diagnosed acute myeloid leukemia (AML) who are 75 years of age or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n2. **Mechanism of Action**: Glasdegib works as a hedgehog pathway inhibitor. It specifically inhibits the smoothened (SMO) protein, which is a key component in the hedgehog signaling pathway. This pathway is involved in the regulation of cell differentiation, tissue polarity, and stem cell maintenance. Aberrant activation of the hedgehog pathway has been implicated in the pathogenesis of various cancers, including AML.\n\n3. **Administration**: Glasdegib is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a1cwYawOAjAypaZ8BHx1bmK1", "custom_id": "121_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "92a3bf6e3a056d300f96067d0ce505c7", "body": {"id": "chatcmpl-9St5lBDOu64PuBIG0DiiIUFuS6UJ9", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Goserelin is a medication used primarily in the treatment of hormone-sensitive cancers such as prostate cancer in men and breast cancer in women. It is also utilized for conditions like endometriosis and uterine fibroids. Here are some key points you should know about Goserelin:\n\n1. **Mechanism of Action**: Goserelin is a type of luteinizing hormone-releasing hormone (LHRH) agonist. It works by initially increasing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn increases sex hormone levels (testosterone and estrogen). However, with continuous administration, it eventually desensitizes the pituitary gland, leading to a significant reduction in FSH and LH levels, and a consequent decrease in sex hormone production.\n\n2. **Formulation and Administration**: Goserelin is commonly administered as a subcutaneous implant under the abdominal skin. It is typically given in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_fn5yTZm4UpgqqKjVSCYJhwOg", "custom_id": "122_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "13ad0445fd96af95a067c3d7311d010e", "body": {"id": "chatcmpl-9St5lMhlAkxCKDzNQYQRQiiw5y79q", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Histrelin is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. It is a synthetic analogue of the naturally occurring GnRH and is used primarily in the management of hormone-responsive cancers such as prostate cancer and in the treatment of precocious puberty. Here are the key points you should know about histrelin:\n\n### Mechanism of Action:\nHistrelin works by initially stimulating the release of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the pituitary gland, which leads to an increase in sex steroid hormones (testosterone and estrogen). However, with continuous administration, histrelin desensitizes the pituitary gland, leading to a decrease in LH and FSH secretion, which ultimately reduces the levels of testosterone and estrogen.\n\n### Forms and Administration:\nHistrelin is available in two primary forms:\n1."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yQFKddPv0EomncfE94zH33it", "custom_id": "123_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2f9bf543660d78f9f22e02e7a44320e2", "body": {"id": "chatcmpl-9St5lamXrL2vxYpd9iDfyq0qyM8ec", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydrocortisone is a corticosteroid medication used to treat a variety of conditions due to its potent anti-inflammatory and immunosuppressive properties. Here are some key points you should know about hydrocortisone when prescribing or discussing it with patients:\n\n### Pharmacology\n- **Mechanism of Action**: Hydrocortisone works by mimicking the actions of steroids normally produced by the adrenal glands. It decreases inflammation by suppressing the migration of leukocytes and fibroblasts, and reversing capillary permeability. It also suppresses the immune system by reducing the activity and volume of the lymphatic system.\n\n### Indications\n- Hydrocortisone is used to treat numerous conditions including adrenal insufficiency, inflammatory conditions (such as arthritis and allergies), skin conditions (like eczema and psoriasis), and asthma. It is also utilized in the management of septic shock and other critical care interventions.\n\n### Forms and Dosage\n- **Forms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iaW8VIhvpbIXuvhHZ1OYtb5Y", "custom_id": "124_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "88c367fe5d89b64e092dbc195e4c95be", "body": {"id": "chatcmpl-9St5lZF0WI7L3hQfhc1fqsKmP6jgU", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxyurea is a medication commonly used in the treatment of certain cancers and chronic diseases. Here are key points that every physician should know about hydroxyurea:\n\n### 1. **Indications**\n   - **Cancers**: Primarily used in the management of chronic myeloid leukemia (CML) and some types of head and neck cancers.\n   - **Sickle Cell Disease**: It reduces the frequency of painful crises and the need for blood transfusions.\n   - **Other Conditions**: It's also used for polycythemia vera, essential thrombocythemia, and other myeloproliferative disorders.\n\n### 2. **Mechanism of Action**\n   - Hydroxyurea is an antineoplastic agent that works by inhibiting ribonucleotide reductase, leading to a decrease in DNA synthesis. This is particularly effective in diseases characterized by rapid cell turnover.\n\n### 3. **Administration**\n   - It is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5u2FZQGNqE8ahDooqHC3lFi4", "custom_id": "125_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99b85438fc2b026b4e9ea1c76291d6bd", "body": {"id": "chatcmpl-9St5lZXpzT8zF9e14eAlk3xvgfK8M", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan, marketed under the brand name Zevalin, is a radioimmunotherapy drug used primarily for the treatment of non-Hodgkin's lymphoma (NHL). It combines a monoclonal antibody (ibritumomab) that targets the CD20 antigen on B-cells, with a radioisotope (yttrium-90 or indium-111), providing a targeted approach to delivering radiation directly to the cancer cells.\n\nHere are some key points about ibritumomab tiuxetan that you, as a physician, might find useful:\n\n### Mechanism of Action\n- **Targeting**: Ibritumomab is an anti-CD20 monoclonal antibody, similar to rituximab. CD20 is a surface antigen expressed on pre-B and mature B lymphocytes.\n- **Radiation**: The radioisotope yttrium-90 or indium-111 is linked to the antibody,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_29Hx6NWHPXwDKp4u4stJuUcA", "custom_id": "126_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f79b6cfc1a24cce7d7b864accb1f4876", "body": {"id": "chatcmpl-9St5lCYenIGIRbPBdCNlWudAUmYm6", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a medication used primarily in the treatment of certain types of cancers, especially B-cell malignancies. It is important for physicians to understand its mechanism of action, indications, dosing regimen, potential side effects, and interactions with other drugs. Here\u2019s an overview:\n\n### Mechanism of Action\nIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a crucial enzyme in the B-cell receptor signaling pathway, which is essential for B-cell development, differentiation, and signaling. By inhibiting BTK, ibrutinib impairs B-cell activation and survival, thereby exerting its antitumor effects.\n\n### Indications\nIbrutinib is approved for use in various conditions including:\n- Chronic lymphocytic leukemia (CLL)\n- Mantle cell lymphoma (MCL) for patients who have received at least one prior therapy\n- Waldenstr\u00f6m's macroglobulinemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_iufmBONj57nsHehkBZtgdmmU", "custom_id": "127_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "adfd1108609edc4fd454e5e8090520ac", "body": {"id": "chatcmpl-9St5lv1Gi9H2mBhnUSDJMNrLBzcPA", "object": "chat.completion", "created": 1716671985, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is a small molecule medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Icotinib:\n\n1. **Mechanism of Action**: Icotinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). Mutations in the EGFR gene are common in non-small cell lung cancer, particularly in patients who never smoked. Icotinib binds to the ATP-binding site of the EGFR tyrosine kinase, which leads to inhibition of the EGFR signaling pathways that promote cell proliferation and survival.\n\n2. **Indications**: It is approved for the treatment of advanced NSCLC, particularly in patients with EGFR mutations. It has shown efficacy in patients who are either treatment-na\u00efve or have previously received chemotherapy.\n\n3. **Efficacy**: Clinical trials, such as the ICOGEN study, have demonstrated that icotin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KF9P2FEZLrY8vdoQZYMAzvj0", "custom_id": "128_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "caca95454cca11cab6d993aef845b764", "body": {"id": "chatcmpl-9St5mlnoJ6XR19rFAa2elTHeXLOjc", "object": "chat.completion", "created": 1716671986, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an anthracycline antibiotic that is commonly used as a chemotherapy agent. Here are key points that a physician should know about Idarubicin:\n\n1. **Mechanism of Action**:\n   - Idarubicin acts primarily by intercalating DNA strands. This intercalation disrupts the function of topoisomerase II, leading to DNA breaks and ultimately inhibiting DNA synthesis and function. It also generates free radicals that cause additional damage to cellular components.\n\n2. **Indications**:\n   - Idarubicin is primarily used for the treatment of acute myeloid leukemia (AML). It is often given in combination with other chemotherapeutic agents.\n\n3. **Administration**:\n   - Idarubicin can be administered both intravenously and orally. Dosage and schedule depend on the specific regimen and patient characteristics, including age, weight, and overall health.\n\n4. **Dosing Considerations**:\n   - Doses are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rlmslQFOKMXC6SRXyZn1SvTQ", "custom_id": "129_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89f9a36d133525f617d283ae371269d7", "body": {"id": "chatcmpl-9St5mPMqQJDeNR0rWvXjPdjwGFVgu", "object": "chat.completion", "created": 1716671986, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib, marketed under the name Zydelig, is an important drug used in the treatment of certain hematologic cancers. Here are some key points you should know about idelalisib as a physician:\n\n1. **Mechanism of Action**: Idelalisib is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4), a key enzyme in the signaling pathway that is active in many B-cell malignancies. By inhibiting PI3K\u03b4, idelalisib disrupts signaling pathways that promote survival, growth, and proliferation of malignant B-cells.\n\n2. **Indications**:\n   - Idelalisib is approved for the treatment of several conditions, primarily in patients who have received at least one prior therapy:\n     - Chronic lymphocytic leukemia (CLL), in combination with rituximab.\n     - Follicular lymphoma that is relapsed or refractory after two prior systemic therapies.\n     -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WCRaxB2zkTxfPytrx1TaMC6q", "custom_id": "130_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d55cf7a8c3590bfbf4d081ce3d3108e8", "body": {"id": "chatcmpl-9St5mDqhIgnxciTReX8RDzDzjqhpr", "object": "chat.completion", "created": 1716671986, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ifosfamide is a chemotherapy medication used primarily for treating various types of cancer. As a physician, here are several key aspects you should know about ifosfamide:\n\n###1. **Mechanism of Action**\n   Ifosfamide is an alkylating agent that works by interfering with the growth of cancer cells, which eventually leads to cell death. It is structurally similar to cyclophosphamide and acts on the DNA by forming cross-links, preventing DNA replication and transcription.\n\n###2. **Indications**\n   - **Testicular cancer**: It is often used in combination with other chemotherapeutic agents in the treatment of testicular cancer.\n   - **Sarcomas**: Effective in treating soft tissue sarcoma and osteosarcoma.\n   - **Lymphoma**: Can be used in the treatment of lymphomas.\n   - **Other cancers**: Might be used in treating cancers of the lung, breast, and ovary, and in certain pediatric cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bYM7c8KXY1ZMgialbjhF5sLL", "custom_id": "131_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b55e24bf8c68298dbcc468f3caaad958", "body": {"id": "chatcmpl-9St5mMoe5LcPhkKWfNt6N8erh9vSn", "object": "chat.completion", "created": 1716671986, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib (also known by its brand name, Gleevec, among others) is a crucial drug primarily used in the treatment of certain types of cancer. It is most notably used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Here are some key aspects of Imatinib that you, as a physician, should be aware of:\n\n### Mechanism of Action\nImatinib works by inhibiting specific tyrosine kinases, which are enzymes responsible for activating many proteins by signal transduction cascades. Imatinib specifically targets BCR-ABL tyrosine kinase, the abnormal enzyme produced by the Philadelphia chromosome in CML. It also inhibits other tyrosine kinases like c-KIT (involved in GIST) and PDGFR (platelet-derived growth factor receptor).\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Imatinib is used in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dfqsPWYxcUYkkUy5AQ57q9Fr", "custom_id": "132_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0da0870b6dce03ea71e1b8a3036a767", "body": {"id": "chatcmpl-9St5mMMddo0CP9BgsMpUajq6v0vzI", "object": "chat.completion", "created": 1716671986, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib is a targeted therapy used in the treatment of cancer, particularly for cases where the cancer cells have specific genetic mutations. Here are key points you should know about Infigratinib as a physician:\n\n1. **Mechanism of Action**: Infigratinib is a kinase inhibitor, specifically targeting the fibroblast growth factor receptor (FGFR) types 1, 2, and 3. These receptors are involved in the regulation of important biological processes including cell growth, survival, migration, and angiogenesis. By inhibiting these receptors, Infigratinib can help to control cancer cell proliferation and survival.\n\n2. **Indications**: As of the latest updates, Infigratinib is approved by the FDA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DNiluLfgRYulQ2y4wkH0XHSD", "custom_id": "133_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a15996ec911fe4c4b1d191b92d3a3c3", "body": {"id": "chatcmpl-9St5nxpDdocfjXb0fHCaLlSM9fLyq", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is an important drug in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL). Here are several key points that you, as a physician, might need to understand about this medication:\n\n1. **Mechanism of Action**:\n   Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 monoclonal antibody, which is linked to a cytotoxic agent, calicheamicin. The monoclonal antibody specifically binds to the CD22 antigen, a protein expressed on the surface of B-cell precursors. Once bound, the conjugate is internalized into the cell where the cytotoxic agent (calicheamicin) is released to induce DNA damage and apoptotic cell death.\n\n2. **Indications**:\n   It is primarily approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The approval and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HgmSmQk3EN4ulwrbrhvzmzac", "custom_id": "134_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea1e890e8378521ae428d48dc74d8c38", "body": {"id": "chatcmpl-9St5nArQ9J6BIa6wEzP42YEgAT15Q", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a recombinant form of interferon used to treat various viral infections and malignancies. Here\u2019s a detailed summary of its key aspects:\n\n1. **Mechanism of Action**: Interferon alfa-2a is a cytokine that modulates the immune response. It works by binding to specific cell surface receptors, activating intracellular signaling pathways that induce the expression of certain genes that inhibit viral replication, enhance immune cell activity, and increase the expression of major histocompatibility complex (MHC) molecules.\n\n2. **Indications**:\n   - **Chronic Hepatitis B and C**: It is used to reduce viral load and liver damage.\n   - **Hairy Cell Leukemia**: Effective in inducing remission.\n   - **Condylomata Acuminata**: Used in severe cases not responsive to other treatments.\n   - **Kaposi's Sarcoma**: Particularly in patients with AIDS.\n   - **Renal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8kRQdkcb1uaPMz3h5hDPK1ig", "custom_id": "135_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f79c6224241cfaec99b044dfcd3414aa", "body": {"id": "chatcmpl-9St5nfKDT9y0YWUV2hM2r4d5pej5j", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of interferon used in the treatment of various medical conditions, including certain types of cancers and viral infections. It is a recombinant protein that mimics the interferons produced naturally by the body, which play a role in the immune response against pathogens and tumor cells. Here are some key points you should know about Interferon alfa-2b:\n\n1. **Indications**: Interferon alfa-2b is approved for the treatment of multiple conditions including:\n   - Chronic hepatitis B and C\n   - Malignant melanoma\n   - Follicular lymphoma\n   - Kaposi's sarcoma associated with AIDS\n   - Condylomata acuminata (genital warts caused by HPV)\n\n2. **Mechanism of Action**: Interferon alfa-2b works by enhancing the immune system's natural ability to fight infections and tumors. It binds to specific cell surface receptors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_1ooz7x5lTvBknnP2H8zDZODK", "custom_id": "136_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7ed9a99b07e7b225a642b64c0db50e77", "body": {"id": "chatcmpl-9St5nOWTCLp9t5DkzQn9qo2JYMfBv", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b (brand name Actimmune) is a synthetic version of a naturally occurring protein in the body, used primarily to treat chronic granulomatous disease (CGD) and severe malignant osteopetrosis. Here are key points you should know about Interferon gamma-1b:\n\n1. **Indications:**\n   - **Chronic Granulomatous Disease (CGD):** Interferon gamma-1b is used to decrease the frequency and severity of infections in patients with CGD, a rare genetic disorder that affects the immune system's ability to kill bacteria and fungi.\n   - **Severe Malignant Osteopetrosis:** It is also used to delay the time to disease progression in patients with severe malignant osteopetrosis, a genetic disorder that affects bone resorption and formation.\n\n2. **Mechanism of Action:**\n   - Interferon gamma-1b works by enhancing the activity of the immune system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vPyjgUN6qm7wVZD95vM91zod", "custom_id": "137_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb096d556e3f968f6085128cd461596b", "body": {"id": "chatcmpl-9St5nYgxej8gjJZgl5Utau3iTFkKa", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab is an immunotherapy drug that is used primarily in the treatment of certain types of cancer. It is a monoclonal antibody that works by activating the immune system to help it attack cancer cells. Here are some key points you should know about Ipilimumab:\n\n1. **Mechanism of Action**: Ipilimumab targets the CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), a protein receptor that normally downregulates the immune system. By inhibiting CTLA-4, Ipilimumab enhances the immune response against cancer cells.\n\n2. **Indications**:\n   - **Melanoma**: Ipilimumab is approved for the treatment of advanced (metastatic) melanoma and adjuvant treatment of melanoma with involvement of lymph nodes following complete resection.\n   - **Other Cancers**: It is also being studied in other types of cancer, including lung cancer, renal cell carcinoma, and more.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cvQ2PuECNNSPGGTiinCbNSWA", "custom_id": "138_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f408c83470ba4220c00799b207daad07", "body": {"id": "chatcmpl-9St5nbujFkYnxUuz2DsCJxMUiYsDT", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapy drug used primarily in the treatment of cancer, particularly colorectal cancer. It can also be used for other cancers such as lung cancer, pancreatic cancer, and gastric cancer, depending on the specific case and treatment protocol. Here are some important aspects of Irinotecan that you, as a physician, should be aware of:\n\n### Mechanism of Action\nIrinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that relieves torsional strain in DNA by inducing single-strand breaks. Irinotecan prevents the religation of these single-strand breaks, leading to double-strand DNA damage and ultimately cell death.\n\n### Indications\n- **Metastatic colorectal cancer**: Irinotecan is commonly used either as a single agent or in combination with other drugs like fluorouracil and leucovorin.\n- It can also be used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3S6p8vLdJtV9B9ieiyROhnTS", "custom_id": "139_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ab74eab14d0dc082b909d163909a2ef", "body": {"id": "chatcmpl-9St5nGviw17XaZb8LEIAGRgWUu0kL", "object": "chat.completion", "created": 1716671987, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome injection is a form of chemotherapy used primarily for the treatment of pancreatic cancer, specifically metastatic adenocarcinoma of the pancreas. It is a liposomal encapsulation of irinotecan, a topoisomerase inhibitor, which allows for a prolonged circulation time and better distribution to the tumor site.\n\n### Key Information:\n\n1. **Indications**: Irinotecan liposome is approved for use in combination with fluorouracil and leucovorin for patients with metastatic pancreatic cancer following disease progression on gemcitabine-based therapy.\n\n2. **Mechanism of Action**: Irinotecan inhibits the enzyme topoisomerase I, which is necessary for DNA replication. By inhibiting this enzyme, DNA replication is disrupted, leading to cell death. The liposomal formulation allows for the drug to remain in the bloodstream longer and reach the tumor more effectively.\n\n3. **Administration**: It is administered intravenously. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_LzbaEux72LfvOhKTH0zFQgkn", "custom_id": "140_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e4cb36a4e745e7c1461345280d49b3e0", "body": {"id": "chatcmpl-9St5oGwYShQoMaSENLHHQ0DdLZybL", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab (sold under the brand name Sarclisa) is an anti-cancer medication used primarily in the treatment of multiple myeloma. Here are some key aspects you should be aware of:\n\n1. **Mechanism of Action**: Isatuximab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to CD38, isatuximab induces direct on-tumor effects such as apoptosis (programmed cell death) and immunomodulatory actions which include activation of natural killer cells, leading to antibody-dependent cellular cytotoxicity (ADCC).\n\n2. **Indications**: As of my last update, isatuximab is approved for use in combination with other medications such as pomalidomide and dexamethasone, or carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5vRjwsGUMsmXEmZKZITJf7jy", "custom_id": "141_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d5dc7044d67298f00e1880361b2a749", "body": {"id": "chatcmpl-9St5oggxHrX9ffR4aWiYtfuwfMz0C", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isotretinoin, also known by its brand name Accutane among others, is a medication primarily used to treat severe acne, typically after other treatments fail to produce results. It is a retinoid, meaning it is derived from vitamin A, and it works by decreasing sebaceous gland activity and changing the characteristics of the skin oil to reduce acne-causing bacteria and inflammation. Here are some key aspects that physicians should consider when prescribing isotretinoin:\n\n### Indications\n- **Severe acne (nodular or conglobate acne)** that is unresponsive to other treatments.\n- **Acne that is at risk of causing permanent scarring.**\n\n### Mechanism of Action\n- Isotretinoin normalizes the shedding of follicular epithelial cells, reducing the formation of comedones.\n- It reduces sebum production and the size of the sebaceous glands.\n- It has anti-inflammatory properties.\n\n### Administration\n- Isotretinoin is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_44NbYzrm2k3dYpMVqyNm9Nxf", "custom_id": "142_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "313ad36fc144396ae7d02a708262139f", "body": {"id": "chatcmpl-9St5ox1rK76l6gWHDd03tbC1HNjmB", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib, sold under the brand name Tibsovo, is a medication used in the treatment of certain types of cancer. It is specifically approved for use in adults with relapsed or refractory acute myeloid leukemia (AML) that exhibits a specific genetic mutation in the isocitrate dehydrogenase-1 (IDH1) gene. Additionally, it is indicated for patients with newly diagnosed AML who are aged 75 years or older, or who have comorbidities that preclude the use of intensive chemotherapy.\n\n### Mechanism of Action:\nIvosidenib works by inhibiting the mutant IDH1 enzyme. In cancers with IDH1 mutations, the enzyme catalyzes the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to cancer progression by impairing cellular differentiation and promoting leukemogenesis. By inhibiting this enzyme, ivosidenib helps to decrease the levels of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wEZr0nxSr0oAW3MxKfIePTpF", "custom_id": "143_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "19144df143ea960fcd375fa532ba8370", "body": {"id": "chatcmpl-9St5oShuUcBLp9wYAVycDJXwVOayv", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixabepilone is a chemotherapeutic agent primarily used in the treatment of breast cancer. Here are the key points you should know about ixabepilone:\n\n1. **Mechanism of Action**: Ixabepilone is a microtubule inhibitor that works by stabilizing microtubules and inhibiting their depolymerization to free tubulin, leading to G2-M cell cycle arrest and apoptosis. It is classified as an epothilone B analog.\n\n2. **Indications**: It is FDA-approved for the treatment of metastatic or locally advanced breast cancer. Ixabepilone is used in patients who have failed other therapies including an anthracycline, a taxane, and capecitabine.\n\n3. **Administration**: Ixabepilone is administered intravenously. It is typically dosed at 40 mg/m\u00b2 given over a 3-hour period every 3 weeks. Pre-medication with an ant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vz8iZK823vPEV7elToHtlepw", "custom_id": "144_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f813a5d7729b95beea160754ee2d71dd", "body": {"id": "chatcmpl-9St5ouiZWcvUImqIorlMuiWWrGRiM", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib is an oral proteasome inhibitor used primarily in the treatment of multiple myeloma. It is often used in combination with other medications such as lenalidomide and dexamethasone. Here are key points that you as a physician should know about Ixazomib:\n\n1. **Mechanism of Action**: Ixazomib works by inhibiting the 20S proteasome, a complex that degrades ubiquitinated proteins. This inhibition disrupts various cellular processes, including the regulation of the cell cycle, cell survival, and apoptosis, which are crucial for cancer cell proliferation and survival.\n\n2. **Indications**: The FDA approved Ixazomib for the treatment of multiple myeloma, particularly in combination with lenalidomide and dexamethasone, for patients who have received at least one prior therapy.\n\n3. **Administration**: Ixazomib is administered orally, which can be more convenient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_fvXROHfm5DpFSCVDFWEu0uuW", "custom_id": "145_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c0c361a327f4d869c396da952c6eb5dd", "body": {"id": "chatcmpl-9St5oJw50UwiH5vmW2Y9OZpCiW4cU", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketoconazole is a synthetic antifungal medication primarily used to treat fungal infections. It can be administered orally or applied topically, depending on the specific infection being treated. Here are some important aspects of ketoconazole that you, as a physician, should be aware of:\n\n### 1. **Mechanism of Action**\n   Ketoconazole works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. Without ergosterol, the cell membrane becomes defective and unable to function properly, leading to cell death.\n\n### 2. **Indications**\n   - **Topical Form**: Used for treating tinea infections such as athlete\u2019s foot, jock itch, ringworm, and dandruff or seborrheic dermatitis.\n   - **Oral Form**: Primarily used for more severe fungal infections such as candidiasis, chronic mucocutaneous candidiasis, and systemic infections like coccidioidomycosis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eWRpLeoytoylZFSuve5zELkW", "custom_id": "146_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc1618d7c3414f0a20350593e4ffe6b7", "body": {"id": "chatcmpl-9St5o63dv92wUlR11S9u9nUF4VYRp", "object": "chat.completion", "created": 1716671988, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide is a medication used primarily to treat acromegaly, a condition characterized by excessive growth hormone production, typically due to a pituitary tumor. It is also used for the treatment of neuroendocrine tumors, particularly those originating in the gastrointestinal tract and the pancreas.\n\nHere are key points about Lanreotide that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Lanreotide is a somatostatin analog, which means it mimics the action of natural somatostatin, a hormone that inhibits the secretion of several other hormones. It works by binding to somatostatin receptors, primarily in the pituitary gland, thereby reducing the secretion of growth hormone and insulin-like growth factor 1 (IGF-1).\n\n2. **Formulations and Administration**: Lanreotide is available in a long-acting depot formulation, typically administered via deep subcutaneous injection. The common dosing schedule is once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a0T8c61mKNA5wAHpkdpm45CR", "custom_id": "147_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "849cbf85038bbc0d17a441e3f2c73810", "body": {"id": "chatcmpl-9St5pZtw6Io1ldjoiE4IJKJ1K3Ffq", "object": "chat.completion", "created": 1716671989, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lansoprazole is a medication that belongs to a class of drugs known as proton pump inhibitors (PPIs), which are used to reduce the amount of acid produced by the stomach. It's commonly used to treat conditions that involve excessive stomach acid such as gastroesophageal reflux disease (GERD), ulcers, and Zollinger-Ellison syndrome. Here are some key points that you, as a physician, should know about lansoprazole:\n\n1. **Mechanism of Action**: Lansoprazole works by irreversibly blocking the hydrogen-potassium adenosine triphosphate (H+/K+ ATPase) enzyme system found on the gastric parietal cell surface (also known as the proton pump). This action significantly decreases gastric acid secretion.\n\n2. **Indications**:\n   - Treatment of active duodenal ulcers and active gastric ulcers.\n   - Long-term treatment and prevention of NSAID-associated gastric ulcers.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ERtvRVT4OkXmGQYtaFXIMQDg", "custom_id": "148_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "541ba3daff554911006aa3479a73a481", "body": {"id": "chatcmpl-9St5pIu9qFyYxIF97TYtL7KTfvupZ", "object": "chat.completion", "created": 1716671989, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatininb is a targeted cancer therapy used primarily in the treatment of breast cancer. Here are the key aspects you should be aware of:\n\n**1. Mechanism of Action:**\n   - Lapatinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu). By inhibiting these receptors, lapatinib helps to block the growth and spread of cancer cells.\n\n**2. Indications:**\n   - It is most commonly used in the treatment of advanced or metastatic breast cancer, particularly in patients whose tumors overexpress HER2 (ERBB2). \n   - It is often used in combination with other medications, such as capecitabine or letrozole, depending on the hormone receptor status and previous treatments the patient has undergone.\n\n**3. Administration:**\n   - Lapatinib is administered orally, which can be more convenient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TXaUStvjA1KEyHvD4PE5mLU7", "custom_id": "149_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5c1005fe9ef52469c15427ec27b2680", "body": {"id": "chatcmpl-9St5piUyy6UW4zaIoWD65J4PH1P51", "object": "chat.completion", "created": 1716671989, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib, sold under the brand name Vitrakvi, is a medication specifically designed to treat cancers with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Here are some essential aspects you should know about Larotrectinib:\n\n1. **Mechanism of Action**: Larotrectinib is a selective and potent inhibitor of the tropomyosin receptor kinases (TRK) family, which includes TRKA, TRKB, and TRKC. These proteins are encoded by the NTRK genes. Larotrectinib binds to these receptors and blocks the downstream signaling pathways, which can help in stopping the growth and spread of cancer cells.\n\n2. **Indications**: Larotrectinib is approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MOulcaZMDDIJT8vzf7Y0jJ1U", "custom_id": "150_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec3b405d0817529568525e9729850cd8", "body": {"id": "chatcmpl-9St5p6wWyQFEK3IPtGF8sBt51uU1R", "object": "chat.completion", "created": 1716671989, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide is an immunomodulatory drug that is structurally related to thalidomide and is used primarily in the treatment of multiple myeloma and certain myelodysplastic syndromes. Here are key points you should know about Lenalidomide:\n\n1. **Mechanism of Action:**\n   Lenalidomide acts by modulating the immune system and possesses anti-inflammatory, antiangiogenic, and antineoplastic properties. It enhances T cell and natural killer (NK) cell-mediated immunity and inhibits pro-inflammatory cytokines. It also disrupts the microenvironment of tumors, interfering with the growth and survival of malignant cells.\n\n2. **Indications:**\n   - **Multiple Myeloma:** Lenalidomide is approved for the treatment of multiple myeloma, particularly in combination with dexamethasone or as maintenance therapy following autologous hematopoietic stem cell transplantation.\n   - **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QTdAwXzAZzOKU4amXIGwvZ3t", "custom_id": "151_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0c9201f9df1496eb9c2baa3ac7cb78b9", "body": {"id": "chatcmpl-9St5p3oWKZm97CjkPGnAqdV4InJId", "object": "chat.completion", "created": 1716671989, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the production of granulocytes in various clinical settings. It is a glycoprotein that primarily acts on the hematopoietic system to increase the production and function of neutrophils. Here are some key points about lenograstim that you, as a physician, may find important:\n\n1. **Indications**:\n   - **Neutropenia**: Lenograstim is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy that is associated with a significant incidence of febrile neutropenia.\n   - **Bone Marrow Transplantation**: It is used to accelerate neutrophil recovery and reduce the incidence of infections in patients undergoing bone marrow transplantation.\n   - **Mobilization of Peripheral Blood Progenitor Cells**: In patients and healthy donors, lenograstim is used to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jyXm9zfxgiDVmKDi2e6yzdIH", "custom_id": "152_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ff383cf9d3e3795fddcfc6ac5979a79f", "body": {"id": "chatcmpl-9St5qY9doZc6EGyOgUzGvqRbl7yqG", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib is a medication used primarily in the treatment of certain types of thyroid cancer and other cancers. Here are some key points about lenvatinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Lenvatinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFR\u03b1), RET, and KIT signaling networks. These RTKs are involved in both angiogenesis and tumor growth. By inhibiting these pathways, lenvatinib can reduce blood supply to the tumor and limit tumor growth.\n\n2. **Indications**:\n   - **Differentiated Thyroid Cancer (DTC)**: Lenvatinib is approved for the treatment of locally recurrent or metastatic, progressive,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3mHiC5dygnFj21NS7wbKq7ES", "custom_id": "153_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0be0f98fdccc7784925c515653a4e5b0", "body": {"id": "chatcmpl-9St5qiXIMvxZ140kUUWszk3X2TNLN", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole, marketed under the brand name Femara, is an oral non-steroidal aromatase inhibitor used primarily in the treatment of hormonally-responsive breast cancer after surgery. It is also employed in various other conditions and here are several important aspects of letrozole that you, as a physician, might need to know:\n\n1. **Indications:**\n   - **Breast Cancer:** Letrozole is commonly prescribed for postmenopausal women with hormone receptor-positive breast cancer. It is used as adjuvant therapy (treatment given after the primary treatment to increase the chances of a cure), as extended adjuvant therapy (after 5 years of tamoxifen), and for the treatment of advanced breast cancer.\n   - **Fertility Treatments:** Although not FDA-approved for this use, letrozole is sometimes used off-label in women with ovulatory problems like polycystic ovary syndrome (PCOS) to induce ovulation.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_q6a25kYrtRdF6MXUXwRkQ7u6", "custom_id": "154_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "37c2fd0c23c947b84ca815b80c6def21", "body": {"id": "chatcmpl-9St5qFRtoXmeomoqyYIqMe2pOJAAO", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide, also known by its brand name Lupron among others, is a medication used in the management of various hormone-sensitive conditions. Here are some key aspects of leuprolide that you, as a physician, might find useful:\n\n### Indications\n1. **Prostate Cancer**: Leuprolide is used in the management of advanced prostate cancer. It works as a gonadotropin-releasing hormone (GnRH) agonist, which initially increases and then continuously suppresses the production of testosterone, which is often required for the growth of prostate cancer cells.\n2. **Endometriosis**: It is used to alleviate symptoms of endometriosis by suppressing estrogen production, which can help reduce pain and the progression of the condition.\n3. **Uterine Fibroids**: It reduces symptoms and size of uterine fibroids by suppressing estrogen production.\n4. **Central Precocious Puberty (CPP)**: In children with CPP, le"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DUaoUFlVVqwkQT4uigGevAuW", "custom_id": "155_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae3c096818562ee4ed31feb3d4fe09ac", "body": {"id": "chatcmpl-9St5qhxv9L9sHjCN9mIpfbSr8nNWd", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is a medication that was originally used as an anthelmintic to treat parasitic worm infections in both humans and animals. However, its use in humans has been largely discontinued in many countries due to its side effects, although it is still used in veterinary medicine. Here are some important things you, as a physician, should know about levamisole:\n\n1. **Medical Uses**: Historically, levamisole was used to treat conditions such as colon cancer, melanoma, and as an immunomodulatory drug for rheumatoid arthritis and nephrotic syndrome. It was effective in enhancing immune responses by stimulating antibody production, T-cell activity, and macrophage functionality.\n\n2. **Side Effects**: The use of levamisole in humans has been restricted due to serious side effects. One of the most severe is agranulocytosis, a potentially life-threatening condition that results in a dangerously low number of white blood cells, which increases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rTRrDzLjVw8WeHoYOGuqjGBs", "custom_id": "156_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71dd3a12804e2644c40c92f12af8a369", "body": {"id": "chatcmpl-9St5qJUTgyieK2oqhRULxsjWGBaPd", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin (also known as leucovorin calcium, levoleucovorin calcium, or L-leucovorin) is a chemically reduced derivative of folic acid, used primarily as an antidote to folic acid antagonists such as methotrexate, which is used in the treatment of cancer. It is also used in combination with fluorouracil to enhance its effectiveness in cancer therapy. Here are some key points about Levoleucovorin that you might find useful as a physician:\n\n1. **Mechanism of Action**: Levoleucovorin is used to \"rescue\" normal cells by replenishing folate stores following high-dose methotrexate therapy in cancer treatments, thereby helping to protect healthy cells from the toxic effects of methotrexate. Additionally, it enhances the cytotoxic effect of fluorouracil by stabilizing the fluorouracil-thymidylate synthase complex"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FxjJbdVRywOQLGTwhLW94hcQ", "custom_id": "157_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0de42735bdd45d1593bf831f95b1f9e", "body": {"id": "chatcmpl-9St5qlCdwXsTiJaXZ42tGhSFvf6br", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine is a chemotherapy drug used primarily to treat various types of cancer, including brain tumors, Hodgkin's disease, and other malignancies. It belongs to the class of drugs known as nitrosoureas, which work by damaging the DNA of cancer cells, thereby inhibiting their ability to replicate and ultimately causing cell death. Here are several key points about lomustine that you, as a physician, might find useful:\n\n1. **Indications**: Lomustine is used in the treatment of brain tumors (both primary and metastatic), Hodgkin\u2019s lymphoma, and other types of cancer. It is often used when other treatments have failed or in combination with other drugs.\n\n2. **Mechanism of Action**: Lomustine causes cross-links in DNA and RNA, leading to disruptions in DNA synthesis and function. It is cell cycle non-specific.\n\n3. **Administration**: Lomustine is administered orally, typically in capsule form. The dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dQDSBNshwOMh4ZX8OB65noOJ", "custom_id": "158_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3616a589cabecae7320fa74abe6aba97", "body": {"id": "chatcmpl-9St5q0HTIDVPdTh54Bfkw4tzKHxPP", "object": "chat.completion", "created": 1716671990, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly targeting cases that have specific genetic alterations. Here are some key points that you, as a physician, should know about Lorlatinib:\n\n1. **Indications and Usage**:\n   - Lorlatinib is approved for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.\n   - It is often used in patients who have progressed on or are intolerant to prior ALK inhibitors.\n\n2. **Mechanism of Action**:\n   - Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI). It is designed to inhibit the activity of the ALK protein, which can promote the growth of cancer cells in NSCLC patients with ALK mutations.\n   - Unlike earlier ALK inhibitors, Lorlatinib can penetrate the blood-brain barrier"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T583mKItKLNCIfsGa2crBdK6", "custom_id": "159_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b23a109a239aa19f7cadce3128cb0b74", "body": {"id": "chatcmpl-9St5rPAofjou1cuBA8jccUZrHuEs9", "object": "chat.completion", "created": 1716671991, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate, marketed under the name Lutathera, is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs). Here are some essential aspects you should be aware of:\n\n1. **Indications**: Lutetium Lu 177 dotatate is approved for use in adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. It is particularly used in cases where the tumors are inoperable or metastatic.\n\n2. **Mechanism of Action**: This drug works as a radiolabeled somatostatin analog. The active substance, Lu 177, is a radioactive isotope that emits beta radiation. It binds to somatostatin receptors (predominantly subtype 2) expressed on the surface of certain tumor cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_v0aoKUcAzmN6SoFam5Zq1ptK", "custom_id": "160_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a19c3d38c969d8067c702331265d5ab9", "body": {"id": "chatcmpl-9St5rc1baWQN6HFEZEw7IldQzYDZB", "object": "chat.completion", "created": 1716671991, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab is an anti-CD19 monoclonal antibody used in the treatment of certain types of B-cell lymphomas, primarily diffuse large B-cell lymphoma (DLBCL), which is a type of non-Hodgkin lymphoma. Here are some key points you should know about tafasitamab:\n\n1. **Mechanism of Action**:\n   Tafasitamab targets the CD19 antigen on B cells, a protein expressed on the surface of almost all B cells. This binding promotes direct cell death and mediates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).\n\n2. **Indications**:\n   Tafasitamab, in combination with lenalidomide, followed by tafasitamab monotherapy, is approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL),"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dvzKDSqFkQYRCHfnGU7hCqau", "custom_id": "161_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "17c45a3194dd3e06cfbe6cfc260bf7da", "body": {"id": "chatcmpl-9St5rAxCGqfDxwoScSTWiQOlW3vQx", "object": "chat.completion", "created": 1716671991, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard or by its chemical name mustine, is a chemotherapy agent used primarily in the treatment of various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, and mycosis fungoides. It is one of the oldest chemotherapy drugs and belongs to the class of alkylating agents, which work by binding with DNA and interfering with the cell's ability to replicate and repair itself.\n\nHere are some key points about mechlorethamine:\n\n1. **Mechanism of Action**:\n   - Mechlorethamine functions by forming electrophilic alkyl groups that can cross-link with nucleophilic sites on DNA bases, leading to the formation of interstrand DNA cross-links. This prevents DNA replication and transcription, ultimately leading to cell death.\n\n2. **Administration**:\n   - Mechlorethamine is typically administered intravenously, but it can also be used topically for cutaneous T-cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SXZYSyVuv3lvPPt9hUpW0qCF", "custom_id": "162_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c3d0be7f4c35ffb0c4a51dbe48b5719a", "body": {"id": "chatcmpl-9St5s0bQxZH1ss4ml3rmGCYbTgsFf", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone acetate (MPA) is a synthetic progestin, a form of the hormone progesterone. It is used in various clinical settings, including gynecology, oncology, and endocrinology. Here are several key points about medroxyprogesterone that are important for a physician to know:\n\n### 1. **Indications**\n   - **Contraception:** Medroxyprogesterone is commonly used as a contraceptive, either as an oral formulation or as a depot injection (Depo-Provera) which is administered every three months.\n   - **Hormone Replacement Therapy (HRT):** It is used in combination with estrogen in postmenopausal women to prevent endometrial hyperplasia.\n   - **Menstrual Disorders:** It can be prescribed for managing abnormal uterine bleeding, amenorrhea, and other menstrual disorders.\n   - **Endometriosis:** Helps in managing pain and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Ur9Fp2QbmpQws5OxllRT4phA", "custom_id": "163_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "035ecaf6291792c88d3803ede3938489", "body": {"id": "chatcmpl-9St5sALVDj1v1gIVHlbLtexZhfjxN", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol acetate is a synthetic derivative of the hormone progesterone, commonly used as an appetite stimulant and in the management of cachexia (wasting syndrome) associated with cancer, AIDS, and other conditions. It is also used in the treatment of advanced breast and endometrial cancers. Here are some key points you should know about megestrol:\n\n### Mechanism of Action\n- **Appetite Stimulation:** Megestrol acts as a progestational agent and has been shown to increase the levels of neuropeptide Y, a potent appetite stimulant produced in the hypothalamus.\n- **Antineoplastic Effects:** It exerts its effects on cancer by binding to progesterone receptors, which leads to a decrease in gonadotropin secretion and inhibition of tumor growth in hormone-sensitive tissues.\n\n### Indications\n- **Appetite Stimulation:** Used to treat anorexia, cachexia, or unexplained significant weight loss"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xEUrFSF9Dwk8ci8iLceaoQiJ", "custom_id": "164_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98bf73f4568f6ae6bcb69932d0073394", "body": {"id": "chatcmpl-9St5sqnQieKSYiOGvUnfzxPDGWNdl", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is a chemotherapy drug used primarily to treat multiple myeloma, a type of cancer that affects plasma cells, and ovarian cancer. It belongs to the class of alkylating agents, which work by binding to DNA and preventing the cancer cells from multiplying, leading to cell death. Here are some key points you should know about Melphalan:\n\n### Mechanism of Action\nMelphalan forms cross-links with DNA, which inhibits DNA replication and transcription. This leads to cell cycle arrest and ultimately apoptosis (cell death).\n\n### Indications\n- **Multiple Myeloma:** Melphalan is used often in combination with other medications.\n- **Ovarian Cancer:** It has been used in the treatment of advanced ovarian cancer.\n- **Other Uses:** It can also be used for conditions like neuroblastoma and as a conditioning regimen before bone marrow transplantation.\n\n### Administration\nMelphalan can be administered orally or intravenously. The route of administration depends on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CeI40dOokqYbZvVg4r7RYBlG", "custom_id": "165_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "be76d888550225c05c67c24aa8d5a87f", "body": {"id": "chatcmpl-9St5sNye3Z11gXvX3qTSvKSLWd6lP", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, also known as 6-mercaptopurine or 6-MP, is a medication primarily used in the treatment of certain types of cancer and autoimmune diseases. It is a purine analogue that interferes with DNA and RNA synthesis, which helps to stop the growth of cancer cells. Here are key points you should know about Mercaptopurine when prescribing or managing treatment:\n\n### Indications\n1. **Leukemia**: Mercaptopurine is most commonly used in the treatment of acute lymphoblastic leukemia (ALL).\n2. **Autoimmune Diseases**: It is sometimes used off-label for managing certain autoimmune conditions, such as inflammatory bowel disease (IBD), including Crohn\u2019s disease and ulcerative colitis.\n\n### Mechanism of Action\n- Mercaptopurine is a thiopurine drug that gets incorporated into DNA and RNA. It inhibits purine nucleotide synthesis and metabolism, disrupting both cell replication and survival, particularly in rapidly dividing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MAixNy1T0TP3b6IgxMnHeAyu", "custom_id": "166_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2bd04f103896d0f3ea2717f13c014ad", "body": {"id": "chatcmpl-9St5sAVXy9OWeoQKhR3AV2n9UwEnK", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mesna (mercaptoethane sulfonate sodium) is a medication primarily used to prevent or reduce the risk of hemorrhagic cystitis in patients receiving cyclophosphamide or ifosfamide, two chemotherapy drugs known to cause bladder damage as a side effect. Here are key points that you as a physician should know about Mesna:\n\n### Mechanism of Action\nMesna works by binding to acrolein, a toxic metabolite of cyclophosphamide and ifosfamide. Acrolein is responsible for causing hemorrhagic cystitis. By binding to and neutralizing acrolein, Mesna helps protect the bladder mucosa from injury.\n\n### Indications\n- **Prophylaxis against hemorrhagic cystitis** induced by cyclophosphamide and ifosfamide.\n- It is not effective in preventing hemorrhagic cystitis resulting from other chemotherapeutic agents.\n\n### Administration\n- Mesna can be administered orally or intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yRWAQz5CLa52rzl7eKKe0T4t", "custom_id": "167_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c1bfab9947b4f7c7c0f9df2af7a4ae18", "body": {"id": "chatcmpl-9St5shfEBPh2mjy0OrAL3ztCVXxNB", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methotrexate is a widely used medication that falls under the category of antimetabolites, specifically acting as a folate analog. It has multiple applications in medicine, primarily used for its immunosuppressive and anti-inflammatory properties. Here\u2019s an overview of what you, as a physician, should know about methotrexate:\n\n### Mechanism of Action:\n- Methotrexate inhibits dihydrofolate reductase, an enzyme involved in the synthesis of DNA, RNA, thymidylates, and proteins. This inhibition leads to decreased proliferation of rapidly dividing cells, particularly affecting cancer cells and immune cells.\n\n### Clinical Uses:\n1. **Rheumatology:** Methotrexate is a cornerstone in the treatment of rheumatoid arthritis, used for its disease-modifying antirheumatic drug (DMARD) properties. It is also used in other autoimmune conditions such as psoriasis and psoriatic arthritis.\n2. **Oncology:** It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yXODxZw5nDqLOk0fyayT1ioL", "custom_id": "168_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "422032b931d6f702a5d7cde61e37be76", "body": {"id": "chatcmpl-9St5s3qn0MxcxU4dU8spr8Bs49kp4", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen (also known as 8-methoxypsoralen or 8-MOP) is a drug that belongs to a group of medicines called psoralens, which are photosensitizing agents used primarily in the treatment of skin disorders. Here are the key points you should know about Methoxsalen:\n\n### Mechanism of Action\nMethoxsalen works by intercalating into DNA and, upon activation by long-wave ultraviolet (UVA) light, it forms cross-links with the DNA. This process inhibits DNA synthesis and cellular replication, altering the epidermal growth and inflammation process in psoriatic skin.\n\n### Indications\nMethoxsalen is primarily used in combination with UVA radiation for the treatment of:\n- **Psoriasis:** Particularly for severe, disabling psoriasis that is not responsive to other treatments.\n- **Vitiligo:** To increase skin re-pigmentation in patients with significant loss of skin pig"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9nmLBhjRQUmDDpirFSgTu6W8", "custom_id": "169_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55773d26e8dc7ca8e6fdc02306ccad3e", "body": {"id": "chatcmpl-9St5sLr3QNiWZV0bjCiHPYQa6HuGb", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a corticosteroid medication used to suppress the immune system and decrease inflammation. It is similar to prednisone but has a greater potency on a milligram basis. Here are several important aspects to consider when prescribing methylprednisolone:\n\n### Indications\nMethylprednisolone is used to treat a variety of conditions, including:\n- Autoimmune diseases (e.g., lupus, multiple sclerosis)\n- Inflammatory conditions (e.g., rheumatoid arthritis, inflammatory bowel disease)\n- Allergic reactions\n- Asthma and other respiratory conditions\n- Acute exacerbations of multiple sclerosis\n- Management of acute spinal cord injury\n\n### Forms and Dosage\nMethylprednisolone is available in several forms, including oral tablets, a solution for injection, and a powder for injection. The dosage depends on the condition being treated, the severity of the disease, the age and health status of the patient, and other factors."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_q3GV3fFB8mNonik3hTtH1mlO", "custom_id": "170_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "344e95f9c2cb288644db4dcc857f40a2", "body": {"id": "chatcmpl-9St5spAtIpLRmRrZGtTc7l0XwvKOO", "object": "chat.completion", "created": 1716671992, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is a multi-targeted kinase inhibitor used primarily in the treatment of certain types of blood cancers. Here are several key points about midostaurin that you, as a physician, might find important:\n\n1. **Indications**:\n   - **Acute Myeloid Leukemia (AML)**: Midostaurin is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.\n   - **Systemic Mastocytosis**: It is also used for treating adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).\n\n2. **Mechanism of Action**:\n   - Midostaurin inhibits multiple receptor tyrosine kinases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_68ru6jGQIasaqK7D9tUwfAOO", "custom_id": "171_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "04707c11dc085d5df249e79405ff67e2", "body": {"id": "chatcmpl-9St5tKbdtjh4g1sNxcowiYencmNup", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin C is a chemotherapeutic agent used primarily in the treatment of various cancers, including gastric and pancreatic cancer. Here are some key points to consider when using Mitomycin C in your practice:\n\n1. **Mechanism of Action**: Mitomycin C acts as an alkylating agent. It cross-links DNA, inhibiting DNA synthesis and function, which leads to cell death. Its cytotoxic effects are more pronounced in hypoxic cells, which makes it particularly effective against solid tumors.\n\n2. **Indications**:\n   - **Adenocarcinoma of the stomach or pancreas** when used in combination with other chemotherapeutic agents.\n   - **Bladder cancer**: It can be used for intravesical therapy, particularly for superficial bladder tumors following transurethral resection.\n\n3. **Administration**: \n   - For systemic use, Mitomycin is typically administered intravenously.\n   - For bladder cancer, it is administered via intraves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LwhtcqAnnG7wNmLFHptWqwSp", "custom_id": "172_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d47178beb7fc56a91563c6ad762d17c", "body": {"id": "chatcmpl-9St5thVfAEoXQ7N8THhamxx2hyI53", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane is a medication primarily used in the treatment of adrenocortical carcinoma, a rare type of cancer that affects the adrenal glands. It can be used for both functioning and non-functioning tumors. Here are some key points about Mitotane that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Mitotane modifies the metabolism of steroids in the adrenal cortex, and it has a cytotoxic effect on the adrenal cortex cells. It specifically targets cells in the adrenal gland, leading to decreased production of adrenal hormones.\n\n2. **Indications**: The primary indication for Mitotane is the treatment of inoperable, advanced, or metastatic adrenocortical carcinoma. It may also be used in cases where surgery is not a complete option or as an adjunct therapy post-surgery to help reduce the risk of recurrence.\n\n3. **Dosage and Administration**: The starting dose of Mitotane should be low and increased slowly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_R0YJ5WngknNz0hJMAMYDEojC", "custom_id": "173_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7524f28c6320ce0cac471aaec938727a", "body": {"id": "chatcmpl-9St5tX8SCl7v9aopSsUEQzQ32l9hv", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is a type of chemotherapy drug that is classified as an anthracenedione (antineoplastic or cytotoxic) agent. Here are some key points you should know about Mitoxantrone:\n\n1. **Mechanism of Action**: Mitoxantrone interferes with DNA replication and RNA synthesis by intercalating into DNA and inducing crosslinks and strand breaks. This action inhibits the proliferation of rapidly dividing cancer cells.\n\n2. **Indications**:\n   - **Cancer**: Primarily used to treat certain types of cancers, including acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and prostate cancer.\n   - **Multiple Sclerosis (MS)**: It is also approved for reducing neurological disability and/or the frequency of clinical relapses in patients with certain types of multiple sclerosis (MS), specifically secondary progressive, progressive relapsing, or worsening relapsing-remitting MS.\n\n3. **Administration**: Mit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qCgbf45XkHSYpUTbxHQSp86O", "custom_id": "174_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d045776cebe04addb064feb4539a9273", "body": {"id": "chatcmpl-9St5tB3ymz6pM6w83uuZqLJLM8a0J", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumab is a monoclonal antibody used in the treatment of certain types of cancer, specifically adult T-cell leukemia/lymphoma (ATL) and mycosis fungoides (MF), which is the most common form of cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about mogamulizumab:\n\n1. **Mechanism of Action**: Mogamulizumab targets a protein called C-C chemokine receptor type 4 (CCR4), which is frequently expressed on the surface of the tumor cells in these diseases. By binding to CCR4, mogamulizumab induces antibody-dependent cellular cytotoxicity (ADCC), leading to the destruction of the tumor cells.\n\n2. **Indications**:\n   - **Mycosis Fungoides (MF)**: It is approved for the treatment of mycosis fungoides (MF) in patients who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_t1lSvBp9vH8d4l6R9ItreQWI", "custom_id": "175_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f16acef85dac13a715c2c479f0fbf10f", "body": {"id": "chatcmpl-9St5tI4fD66SwFt5zOCFnsjOYULk5", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox, also known by the brand name Lumoxiti, is a targeted therapy approved by the FDA for the treatment of certain types of leukemia. Specifically, it is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.\n\nHere are key points that you, as a physician, should know about moxetumomab pasudotox:\n\n1. **Mechanism of Action**:\n   Moxetumomab pasudotox is a recombinant immunotoxin composed of a monoclonal antibody that targets CD22, a protein expressed on the surface of B cells and hairy cell leukemia cells, fused to a bacterial toxin, Pseudomonas exotoxin A. The drug binds to CD22 on the surface of B cells, is internalized, and then the toxin portion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_8c13xr1M3H08ANyvVn9lWVJE", "custom_id": "176_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ff27ec7a3b7c31d5abbed45264777ce0", "body": {"id": "chatcmpl-9St5ta5KVyS9uLcIUcJTephArv3aw", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) used primarily for anticoagulation to prevent and treat thromboembolic disorders. Here are key points about nadroparin that you, as a physician, should know:\n\n1. **Mechanism of Action**:\n   Nadroparin works by enhancing the inhibition of Factor Xa and thrombin by antithrombin III. It primarily inhibits the activity of Factor Xa, while having a lesser effect on thrombin (Factor IIa). This results in decreased formation of thrombin and ultimately prevents fibrin clot formation.\n\n2. **Indications**:\n   - Prophylaxis of venous thromboembolism (VTE) in surgical patients, particularly those undergoing orthopedic or general surgery.\n   - Prophylaxis of clotting in extracorporeal circuits during hemodialysis.\n   - Treatment of deep vein thrombosis (DVT) with or without pulmonary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pOJ6RXnz9s8YzmqgPaaTzh23", "custom_id": "177_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d308157d9954bda6c628b02deff03ab", "body": {"id": "chatcmpl-9St5tBMCojWehRMdivhgDB8wjz618", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab (trade name Portrazza) is a recombinant human IgG1 monoclonal antibody approved for use in medical oncology. It is specifically designed to target and block the activity of the epidermal growth factor receptor (EGFR), a protein that is often overexpressed in certain types of cancer cells. Here are some key points about Necitumumab:\n\n1. **Indications**: Necitumumab is approved by the FDA for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.\n\n2. **Mechanism of Action**: As an EGFR antagonist, Necitumumab binds to the EGFR on cancer cells, which prevents the receptor from being activated by its natural ligands. This inhibition can interfere with processes that promote cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nBKs0Zq6RYvWoFZML1pFat2C", "custom_id": "178_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4fb2f97b7e3133c803e5ad8bac73402b", "body": {"id": "chatcmpl-9St5ty4J6lDJQEwpduwhFbaA7voe5", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is a platinum-based antineoplastic chemotherapy agent, structurally related to cisplatin and carboplatin. It was developed to reduce some of the toxic side effects associated with cisplatin use. Here are some key aspects you should know about nedaplatin:\n\n1. **Mechanism of Action**: Nedaplatin, like other platinum compounds, exerts its anti-cancer effect by forming platinum-DNA adducts. This disrupts DNA synthesis and transcription, ultimately leading to cell death. It is believed to have a similar mechanism of action to cisplatin but differs in its chemical structure, which impacts its toxicity profile and side effects.\n\n2. **Indications**: Nedaplatin is primarily used in the treatment of various cancers including cervical cancer, non-small cell lung cancer, and esophageal cancer. It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Nedaplatin is administered intravenously. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PnoUvKH5U276P1KOER9kxrhJ", "custom_id": "179_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f66c25374bd0a722fd96860e669d4172", "body": {"id": "chatcmpl-9St5tJWRnLdZp2utTXUVoQ5ogqVnr", "object": "chat.completion", "created": 1716671993, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nelarabine is a chemotherapeutic agent used primarily in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are several key points about nelarabine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Nelarabine is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), a nucleoside analog. It gets converted into ara-GTP, which is then incorporated into DNA, leading to inhibition of DNA synthesis and cell death. Its activity is specific to T-cells due to higher levels of activating enzymes in these cells.\n\n2. **Indications**: Nelarabine is approved for the treatment of patients with T-ALL and T-LBL who have not responded to or have relapsed after at least two prior regimens. Effectiveness is based on overall response rates,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P6JNUibyzNVp7go9HwGEFv06", "custom_id": "180_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "84f8ea974e1ab34620d63ce9668bf540", "body": {"id": "chatcmpl-9St5uOOtCtopiXPjBYjnx7Se9oafF", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib is an oral tyrosine kinase inhibitor that is primarily used in the treatment of breast cancer. It specifically targets the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) kinases. Here are some key points you should know about neratinib:\n\n1. **Indications**: Neratinib is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. It is also used for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.\n\n2. **Mechanism of Action**: Neratinib works by irreversibly binding to the ATP-binding pocket of HER2 and EGFR, leading to inhibition of the kinase activity. This inhibition results in reduced phosphorylation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_QRGOAst5JfgKHfRUj8zK0Nq9", "custom_id": "181_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9b0a4414966050464393cf58a5f1e8c", "body": {"id": "chatcmpl-9St5uqfeQ3NSsF9radAu4ynRyNsbE", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilotinib, marketed under the name Tasigna, is a targeted therapy used primarily in the treatment of chronic myeloid leukemia (CML). Here are key points you should know about Nilotinib:\n\n1. **Mechanism of Action**:\n   Nilotinib is a tyrosine kinase inhibitor (TKI). It specifically targets the BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome that is found in most cases of CML. By inhibiting this kinase, Nilotinib impedes the growth and proliferation of leukemic cells.\n\n2. **Indications**:\n   It is approved for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase, as well as for patients with Ph+ CML in chronic phase and accelerated phase who are resistant to or intolerant of prior therapy that included imatinib.\n\n3. **Administration**:\n   Nilotinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_Fc6VsVmDdLvCR0KasN8mBnXy", "custom_id": "182_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c485453d8ba01b85af6bcd95633ad3e9", "body": {"id": "chatcmpl-9St5uOkZQ6mELoM9V1WKblf5Vhsoa", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen (NSAA) medication primarily used in the treatment of prostate cancer. Here are several key points about nilutamide that you, as a physician, might find useful:\n\n1. **Indications**: Nilutamide is mainly indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2). This combination helps to counter the flare-up of symptoms that can occur due to an initial surge in testosterone levels following castration.\n\n2. **Mechanism of Action**: Nilutamide works by blocking the action of androgens (male hormones) by binding to androgen receptors in prostate cancer cells, thereby inhibiting their growth and proliferation. It is specifically a pure antiandrogen, meaning it competes with androgens such as testosterone and its more potent metabolite dihydrotestosterone (DHT) at the receptor sites in target tissues.\n\n3. **Administration**: Nilutamide is taken orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZShTpUif6nyOM72AdMsyhT1y", "custom_id": "183_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ccc823a331ce3c3a99906f928490975", "body": {"id": "chatcmpl-9St5u5omiUcXtMT0o0DPOSWfBPnFU", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine (also known as ACNU, or nimustine hydrochloride) is a chemotherapeutic agent classified as a nitrosourea compound. It's used primarily in the treatment of various types of brain tumors, including gliomas, as well as in the treatment of Hodgkin\u2019s lymphoma and other malignancies. Here are several important aspects of Nimustine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   - Nimustine is an alkylating agent that works by cross-linking DNA and RNA, thereby disrupting the replication and transcription of DNA. This leads to the inhibition of tumor growth and cell death.\n\n2. **Indications**:\n   - It is mainly used for the treatment of malignant brain tumors. It may also be part of combined therapy for other cancers, depending on protocols and other chemotherapy agents involved.\n\n3. **Administration**:\n   - Nimustine is typically administered intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8ds1l1ifrZ9khGQTBnInF7FU", "custom_id": "184_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73efc96f05166dcd85af552779b902e0", "body": {"id": "chatcmpl-9St5u5t3P2Yvn6kJY0BFX3tG8lEmg", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib is a medication primarily used for the management of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases. It has also been approved for use in certain types of lung cancer. Here are key points about Nintedanib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Nintedanib is a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis, including platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). By inhibiting these pathways, nintedanib can help to reduce fibrosis and the rate of decline in lung function.\n\n2. **Indications**:\n   - **Idiopathic Pulmonary Fibrosis (IPF)**: It is used to treat IPF, which is a condition characterized by progressive scarring"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RmHBsAGNIZOMpzSWokOEJRZi", "custom_id": "185_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4303d78e5334a684da4b07f88c911b65", "body": {"id": "chatcmpl-9St5umRhn22W8Lky64oVS60L3xEy7", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib is an oral medication used primarily in the treatment of certain types of ovarian, fallopian tube, or primary peritoneal cancer. It belongs to a class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors, which work by interfering with the DNA repair pathways in cancer cells, leading to cell death, particularly in cells that are already deficient in repairing DNA damage.\n\n### Key Points for Physicians:\n\n#### Indications:\n- **Maintenance treatment** of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n- **Treatment** of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies and whose cancer has specific gene mutations (HRD-positive status including those with BRCA mutations).\n\n#### Mechanism of Action:\nNiraparib inhibits"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Q5FJCjAI6r20bZZci54G1O5n", "custom_id": "186_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fcae439b2073115e519b1d781e529e11", "body": {"id": "chatcmpl-9St5uGX3NurLnkyf6auiIQqYwuHOn", "object": "chat.completion", "created": 1716671994, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab, marketed under the brand name Opdivo, is a medication used in cancer immunotherapy. It is a type of drug known as a checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor on the surface of T cells. Nivolumab is designed to block PD-1, which can be exploited by cancer cells to avoid being attacked by the immune system. Here are some key points about Nivolumab that you, as a physician, might find useful:\n\n### Indications\nNivolumab is approved for the treatment of various types of cancers, including but not limited to:\n- Metastatic melanoma\n- Non-small cell lung cancer (NSCLC)\n- Advanced renal cell carcinoma\n- Head and neck squamous cell carcinoma\n- Hodgkin lymphoma\n- Urothelial carcinoma\n- Colorectal cancer (for MSI-H or dMMR cancers)\n\n### Mechanism of Action\nN"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_BhLfZd6BMDzQq2LuvhYSG4x6", "custom_id": "187_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c782a3e5785f7fa198c82293d03afab9", "body": {"id": "chatcmpl-9St5vjeCmPZR8RKduTzWLPPt7R93d", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Non-pegylated liposomal doxorubicin (NPLD) is a formulation of the chemotherapy drug doxorubicin, encapsulated within liposomes without the addition of polyethylene glycol (PEG). This liposomal encapsulation alters the pharmacokinetics of the drug, potentially reducing some of the common toxicities associated with conventional doxorubicin while maintaining its antitumor efficacy. Here are several key points about NPLD that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: NPLD retains the same mechanism of action as conventional doxorubicin, which involves intercalating DNA strands, inhibiting topoisomerase II enzyme, and generating free radicals that break DNA strands. This disrupts the replication and transcription processes, leading to cell death.\n\n2. **Benefits of Liposomal Formulation**: The liposomal encapsulation of doxorubicin improves the drug's pharmacokinetic profile by reducing the volume of distribution and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_hB7QLQdqMuAQTEUoUMbs3Fy5", "custom_id": "188_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1d06fb1ae93d1bb91ccbec83279349ea", "body": {"id": "chatcmpl-9St5vZvCmdq0QCaolIlchbcSnsKCu", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone is a synthetic, orally active anabolic-androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone). It has both anabolic and androgenic properties. Norethandrolone is used primarily in the treatment of chronic wasting conditions, including AIDS-associated wasting, severe burn injury, major surgery, and similar catabolic states. It has also been used in the treatment of anemias and some types of breast cancer. Here are some key points you should know:\n\n1. **Mechanism of Action**: Norethandrolone acts by promoting protein synthesis, nitrogen retention, and red blood cell production, leading to increased muscle mass and strength, as well as improved recovery times from physical stress and injury.\n\n2. **Medical Uses**: Beyond its uses in treating muscle wasting and anemia, it has been used in the past to stimulate growth in children with growth failure and to counteract corticoster"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bbIZrzHpR0p8ZlmXu9BGuV0y", "custom_id": "189_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3ed11a77e8aa835b1fe48384f823d5d0", "body": {"id": "chatcmpl-9St5vYSxMVAWLCrPaeWJlyj7zmc0n", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Obinutuzumab (also known by its brand name Gazyva) is a monoclonal antibody used primarily in the treatment of hematological malignancies. Here are some key aspects you should be aware of:\n\n### Mechanism of Action\nObinutuzumab is a type II anti-CD20 monoclonal antibody. It binds to the CD20 antigen on B-cells, leading to cell death. Unlike type I antibodies, such as rituximab, obinutuzumab induces direct cell death and has a stronger induction of antibody-dependent cellular cytotoxicity (ADCC).\n\n### Indications\nObinutuzumab is approved for use in several clinical settings:\n- **Chronic Lymphocytic Leukemia (CLL)**: It is used in combination with chlorambucil for untreated CLL, particularly in patients who have comorbidities making them unsuitable for more intensive therapies.\n- **Follicular L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lVQmk8ABpoHAIHCkbYLXTTIq", "custom_id": "190_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2fc07aba1b49975ceb27d76ce066f5c4", "body": {"id": "chatcmpl-9St5vTvEBVUIphMgS6QQFEljHAciK", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic octapeptide analog of somatostatin, a naturally occurring inhibitory hormone that suppresses the secretion of several other hormones. Here are key points that physicians should consider when using octreotide in clinical practice:\n\n### Indications\n- **Acromegaly**: Octreotide is used to reduce growth hormone (GH) and IGF-1 levels in patients with acromegaly, particularly when surgery is not feasible.\n- **Carcinoid Tumors**: It helps control symptoms such as flushing and diarrhea associated with carcinoid syndrome.\n- **Vasoactive Intestinal Peptide Tumors (VIPomas)**: Octreotide can help reduce watery diarrhea associated with VIPomas.\n- **Gastroenteropancreatic Neuroendocrine Tumors**: It is used to control symptoms and sometimes inhibit tumor growth.\n- **TSH-secreting Pituitary Adenomas**: Used to reduce thyroid-stimulating hormone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PtsXzc9vvRY3W8TupZymjfr6", "custom_id": "191_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce84ada08e844a7de385eb8f1b2c5801", "body": {"id": "chatcmpl-9St5v2OsAeeBiWypAatMYbtfk1FhA", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide long-acting release (LAR) is a synthetic octapeptide analog of naturally occurring somatostatin, with similar pharmacological effects but a much longer duration of action. It is primarily used in the management of certain medical conditions related to excessive secretion of hormones and related symptoms. Here are some important points that you, as a physician, should know about Octreotide LAR:\n\n1. **Indications**:\n   - **Acromegaly**: Used for long-term treatment in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.\n   - **Carcinoid Tumors**: Effective in reducing or alleviating symptoms of flushing and diarrhea associated with carcinoid syndrome.\n   - **VIPomas**: Helps in controlling symptoms such as watery diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas).\n\n2. **Mechanism of Action**:\n   - Octreotide mimics natural somat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z8ddDXpfJNotrflwKHmjOJ08", "custom_id": "192_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66066e6954bf005bf5e2c2bdc0b9c337", "body": {"id": "chatcmpl-9St5vXtyurggCJ97heIpOKCa9XjVw", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a medication used primarily in the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL). It is a monoclonal antibody that targets the CD20 antigen on B cells, which are a type of white blood cell that can become cancerous in CLL. Here are some key points you might consider as a physician:\n\n1. **Mechanism of Action**: Ofatumumab binds specifically to the CD20 molecule found on the surface of both normal and malignant B cells. This binding induces cell lysis primarily through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Ofatumumab is approved for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\n   - **Multiple Sclerosis (MS)**: Ofatum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qTJYRuaS9VxpZWNys5WUXzVF", "custom_id": "193_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0e9f3b9029319f7ebaa29040d5006e1f", "body": {"id": "chatcmpl-9St5vkqpQNk0K2LgDItHY0FRJkq15", "object": "chat.completion", "created": 1716671995, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib (marketed under the brand name Lynparza) is an important medication in the treatment of certain types of cancer, particularly those associated with genetic mutations. Here are key points to consider about Olaparib:\n\n1. **Mechanism of Action**:\n   Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor. PARP is an enzyme that helps repair DNA damage in cells. By inhibiting PARP, Olaparib causes DNA damage to accumulate in cancer cells, ultimately leading to their death. This is particularly effective in cells that are already compromised in their ability to repair DNA due to mutations in genes such as BRCA1 or BRCA2.\n\n2. **Indications**:\n   Olaparib is approved for the treatment of:\n   - Advanced ovarian cancer in patients who have received previous treatment and have a deleterious or suspected deleterious BRCA mutation (germline and/or somatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DVfY62GFpUgJnh0ljiAwSUkL", "custom_id": "194_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0e060e2095ed6190a96918e35c29d0fd", "body": {"id": "chatcmpl-9St5wVbFyI9t8JQMbYe82RoZNOEev", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaratumab, previously marketed under the brand name Lartruvo, is a monoclonal antibody that was initially developed for the treatment of certain types of soft tissue sarcoma. Here are some key points you should know about Olaratumab:\n\n1. **Mechanism of Action:**\n   Olaratumab targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1). By inhibiting this receptor, Olaratumab is believed to interfere with the tumor microenvironment and reduce tumor growth.\n\n2. **Indications:**\n   Olaratumab was initially approved by the FDA in 2016 for use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma (STS) who could not be cured with radiation or surgery and who had a type of STS for which an anthracycline-containing regimen was appropriate. This approval was based on the phase II trial data showing a significant improvement in overall survival.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yc3Oood1nsL34JhnirLcw8xI", "custom_id": "195_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "444f0863fd07e37cb12a0cb94339e01a", "body": {"id": "chatcmpl-9St5wFHgTlBcsDGNcoz84FzQlOlU9", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, marketed under the brand name Synribo, is a chemotherapeutic agent used for the treatment of chronic myeloid leukemia (CML). Here are some key points that you, as a physician, should know about omacetaxine:\n\n1. **Mechanism of Action**: Omacetaxine works primarily by inhibiting the synthesis of proteins. It acts as a protein translation inhibitor, specifically binding to the A-site cleft in the ribosome, thereby blocking the initial elongation step of protein synthesis. This mechanism is distinct from that of tyrosine kinase inhibitors (TKIs) like imatinib, which target the BCR-ABL tyrosine kinase enzyme produced by the Philadelphia chromosome in CML cells.\n\n2. **Indications**: Omacetaxine is approved for the treatment of adult patients with chronic or accelerated phase CML who are resistant or intolerant to two or more tyrosine kinase inhibitors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_G5brNCHZhRkHAVD4Q26D8J5b", "custom_id": "196_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ffe7d41ec7120e1af9fbb325e9855fec", "body": {"id": "chatcmpl-9St5wctVcHgjxuStq2rpuap9O5HyL", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omeprazole is a commonly used medication that belongs to a class of drugs known as proton pump inhibitors (PPIs). It is primarily used to treat certain stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). Here are key points about omeprazole that you, as a physician, might find useful:\n\n### Mechanism of Action\nOmeprazole works by blocking the proton pump in the gastric parietal cells, thereby reducing the production of stomach acid. This action helps decrease irritation and inflammation of the stomach lining and esophagus, allowing for healing of ulcers and improvement in symptoms of GERD.\n\n### Indications\n- **Gastroesophageal Reflux Disease (GERD):** Treatment and maintenance of healing.\n- **Peptic Ulcer Disease (PUD):** Treatment of gastric and duodenal ulcers, including those induced by non-steroidal anti-inflammatory drugs ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UC6rx53KEOKp1G3ug780MDzb", "custom_id": "197_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2c1d25b56c62edeac9ac488a7f975e7c", "body": {"id": "chatcmpl-9St5wlcRwM8HSn77p6Zso40WkbpRN", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib, marketed under the brand name Tagrisso, is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are several key points about Osimertinib that you, as a physician, should be aware of:\n\n1. **Indications**: Osimertinib is specifically approved for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. It is also approved for the first-line treatment of patients with metastatic NSCLC whose tumors have exon 19 deletions or exon 21 L858R mutations, as detected by an approved test.\n\n2. **Mechanism of Action**: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Unlike first and second-generation EGFR inhibitors, Osim"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SStMF5MfS8rqnxEMA9B09W0V", "custom_id": "198_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f6bc4860e27e3dcb268c0b0235a1e137", "body": {"id": "chatcmpl-9St5wLzI0vNgW9bjDRbZ4ubQ7O3GJ", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapy drug used primarily in the treatment of colorectal cancer. It is often administered in combination with other chemotherapeutic agents such as fluorouracil and leucovorin in a regimen known as FOLFOX. Here are some key points that you, as a physician, should be aware of when considering or administering oxaliplatin:\n\n### Mechanism of Action\nOxaliplatin works by forming platinum-DNA adducts in cancer cells, which inhibit DNA synthesis and transcription, leading to cell death. It is similar to other platinum compounds like cisplatin and carboplatin but has a unique activity profile and toxicity spectrum.\n\n### Indications\n- **Colorectal cancer:** Oxaliplatin is approved for the treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. It is used as adjuvant therapy in combination with fluorouracil and leucovorin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ipj6wPdViS01iFV6bNMN3KXw", "custom_id": "199_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "404bad828e3b8a716a3f41d3e6c1025e", "body": {"id": "chatcmpl-9St5wjsDkNbSzvIYrnftNBUa1XS0q", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to understand the key aspects of nanoparticle albumin-bound paclitaxel (nab-paclitaxel or Abraxane) to effectively incorporate it into your clinical practice. Here\u2019s a detailed overview:\n\n**1. Mechanism of Action:**\nNab-paclitaxel is a chemotherapeutic agent that interferes with the normal function of microtubules during cell division. It stabilizes the microtubule polymer and inhibits the cell cycle at the G2/M phase, leading to apoptosis, or programmed cell death. The albumin-bound formulation enhances the solubility and delivery of paclitaxel to tumor cells.\n\n**2. Indications:**\nNab-paclitaxel is approved for use in various cancers:\n   - **Metastatic Breast Cancer:** It is indicated for the treatment of breast cancer patients who have failed combination chemotherapy or relapsed within six months of adjuvant chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OdwglVe3Onzj4yqFwBOxxXo8", "custom_id": "200_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eb53fca2bebb574aefb178404ae99789", "body": {"id": "chatcmpl-9St5wgCHvrWOw8chyBmrwen2xe1jz", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is an important chemotherapeutic agent used primarily in the treatment of various cancers. Here are key aspects you should know about Paclitaxel as a physician:\n\n### Mechanism of Action\nPaclitaxel belongs to the taxane family of drugs. It works by stabilizing microtubules and inhibiting their depolymerization during cell division, effectively freezing the mitotic spindle and preventing the progression of mitosis. This leads to cell cycle arrest at the G2/M phase and ultimately induces apoptosis of cancer cells.\n\n### Indications\nPaclitaxel is commonly used for the treatment of:\n- Breast cancer\n- Ovarian cancer\n- Non-small cell lung cancer\n- AIDS-related Kaposi's sarcoma\n- Pancreatic cancer (as part of combination therapy)\n\n### Administration\nPaclitaxel is typically administered intravenously. The dosing regimen can vary based on the type of cancer, stage,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mwRFgevhiIJsxEcPhthzAzzX", "custom_id": "201_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65b5026fc1b4e05459e369efe0dfe03b", "body": {"id": "chatcmpl-9St5w0ZPMrSxRa79RIUH8oQ9AHlye", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is a medication used primarily in the treatment of certain types of myelofibrosis, a chronic bone marrow disorder that disrupts the body's normal production of blood cells. Here are some key points you should know about pacritinib:\n\n1. **Mechanism of Action**: Pacritinib is a kinase inhibitor that targets Janus Associated Kinases (JAKs) with particular activity against JAK2 and FLT3. These kinases play roles in the signaling pathways that regulate blood cell proliferation and immune function. By inhibiting these pathways, pacritinib can help manage symptoms and pathological processes associated with myelofibrosis.\n\n2. **Indications**: Pacritinib is specifically indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, including those with thrombocytopenia, which is often a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_l3q4MYFtRdcCFhzGXp9GjIRc", "custom_id": "202_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62422cb6964cbda003941e94bb4f553c", "body": {"id": "chatcmpl-9St5wfB0EMwuELrBv4cpTRGkxZJID", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib, marketed under the brand name Ibrance among others, is a targeted therapy medication used in the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer. Here are some important aspects about palbociclib that you, as a physician, might find useful:\n\n### Mechanism of Action\nPalbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. By inhibiting these kinases, palbociclib induces G1 phase cell cycle arrest, which in turn reduces cellular proliferation. This mechanism is particularly effective in hormone receptor-positive breast cancer, where these kinases promote the growth of cancer cells in response to hormone signals.\n\n### Indications\n- **Breast Cancer:** Palbociclib is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W5jDvZOsqiHSgNRdONvkmX3M", "custom_id": "203_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ffc962815951dc645087d6d8e783148a", "body": {"id": "chatcmpl-9St5w0CuXHFfPu1L3nkCwzPRniCGD", "object": "chat.completion", "created": 1716671996, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab (brand name Vectibix) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points about Panitumumab that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Panitumumab is an epidermal growth factor receptor (EGFR) antagonist. It binds specifically to the EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. This inhibition blocks the phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased pro-inflammatory cytokine and vascular growth factor production.\n\n2. **Indications**: Panitumumab is approved for use in patients with metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Importantly, it is indicated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FpRuBM2kLFhnuULDoMK93Tuh", "custom_id": "204_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa785f624cde91785aeb0e850c5861cf", "body": {"id": "chatcmpl-9St5xbJxxdXTWZ0vijPmV6WbzhNr4", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat is a medication used primarily in the treatment of multiple myeloma, a type of cancer that arises from plasma cells in the bone marrow. It is classified as a histone deacetylase (HDAC) inhibitor. Here are some key points you should know about Panobinostat:\n\n1. **Mechanism of Action**:\n   Panobinostat works by inhibiting the activity of histone deacetylases (HDACs). HDACs are enzymes involved in the removal of acetyl groups from histones, which leads to a more compact and less transcriptionally active form of chromatin. By inhibiting these enzymes, Panobinostat increases the acetylation of histone proteins, leading to an open chromatin structure, which can result in increased gene expression. Additionally, it affects various non-histone proteins related to cancer cell survival and proliferation, ultimately promoting cancer cell death.\n\n2. **Indications**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_I2atX4y9zyrLFiQ5fDuOK4Vw", "custom_id": "205_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9754bf6d69c0d14905730dfd5ad14f03", "body": {"id": "chatcmpl-9St5xHLQ0EslsQV5C3yWndMzajzPs", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib, marketed under the name Votrient, is a medication primarily used to treat kidney cancer (renal cell carcinoma) and soft tissue sarcoma. As a physician, here are several key aspects you should be aware of:\n\n1. **Mechanism of Action**: Pazopanib is a multi-targeted tyrosine kinase inhibitor. It inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), which play a key role in angiogenesis (formation of new blood vessels). It also inhibits other receptors like platelet-derived growth factor receptors (PDGFR-\u03b1 and PDGFR-\u03b2) and c-KIT. By blocking these pathways, pazopanib reduces angiogenesis, tumor growth, and metastatic progression.\n\n2. **Indications**:\n   - **Renal Cell Carcinoma (RCC)**: It is approved for the treatment of advanced RCC.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VDpvNVUNYLkxyO4D2tKKliHC", "custom_id": "206_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e98a789f8a1e07155ddcc5ab1d432269", "body": {"id": "chatcmpl-9St5x2NHx2e6fO4NqRsAaXP5wAn7u", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is a modified form of L-asparaginase, an enzyme that converts the amino acid asparagine into aspartic acid and ammonia. This conversion is critical in the context of leukemia because many leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase and thus rely on external sources of the amino acid to survive. By depleting asparagine, pegaspargase starves the leukemic cells of a necessary nutrient, leading to their death.\n\nHere are some key points about Pegaspargase you should be aware of:\n\n1. **Indications**: Pegaspargase is approved for use in patients with acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is often used in patients who are hypersensitive to native forms of L-aspar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_R9sbwQef5Yv3eYxyaAm7tiey", "custom_id": "207_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b9df84e7f00235250c1fa6a3bdda3df", "body": {"id": "chatcmpl-9St5xbq4oFpyU5aV3PSbSHcSGOwfR", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2a is a medication used primarily for the treatment of hepatitis C and, in some cases, hepatitis B. It is a pegylated form of interferon alfa-2a, which means it is interferon alfa-2a attached to a molecule of polyethylene glycol (PEG). This modification increases the half-life of the drug, allowing for less frequent dosing and more stable blood levels compared to non-pegylated interferon.\n\n### Key Points for Physicians:\n\n**1. Mechanism of Action:**\n   - Peginterferon alfa-2a works by stimulating the immune system to fight off viral infections. It binds to interferon receptors on cell surfaces, activating the JAK-STAT signaling pathway, which enhances the expression of antiviral proteins and increases the immune response against the virus.\n\n**2. Indications:**\n   - It is primarily used for the treatment of chronic hepatitis C virus (HCV"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Q6s636IDExNjayBWGeiGtITO", "custom_id": "208_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8757b4f1bc65be051e8d54bbd0d00657", "body": {"id": "chatcmpl-9St5xEi4CI6uQMoJmrPQ9vBDWK2cD", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a medication used primarily for the treatment of hepatitis C and, in some cases, for melanoma and other medical conditions. It is a pegylated form of interferon alfa-2b, which means it has a polyethylene glycol (PEG) molecule attached to it. This modification increases the half-life of the drug in the bloodstream, allowing for less frequent dosing compared to unmodified interferon.\n\nHere are several key points you should know about Peginterferon alfa-2b:\n\n1. **Mechanism of Action**: Peginterferon alfa-2b works by mimicking the body\u2019s natural interferons, which are proteins that play a role in the immune response. It helps the body fight viral infections by boosting the immune system and interfering with viral replication within host cells.\n\n2. **Indications**:\n   - **Hepatitis C**: It is typically used in combination with other antiv"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_gMbtWR62yNg20pYySAC2dWxs", "custom_id": "209_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "78dad7da3da1df3f0e56f1cbd23ab11a", "body": {"id": "chatcmpl-9St5xRUTXirB4nF4k6QAgZ9xlLpkq", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin (PLD), often sold under the brand name Doxil in the United States and Caelyx in Europe, is a formulation of the chemotherapy drug doxorubicin. It is specifically designed to increase drug delivery to the tumor site while reducing the systemic exposure to doxorubicin, thus minimizing some of the toxic side effects associated with traditional forms of this chemotherapeutic agent. Here are several key aspects of pegylated liposomal doxorubicin that you, as a physician, might find important:\n\n### Mechanism of Action\n- **Doxorubicin** is an anthracycline antibiotic that works by intercalating DNA, disrupting topoisomerase-II-mediated DNA repair, and generating free radicals, which collectively lead to apoptosis and cell death.\n- The **liposomal formulation** encapsulates doxorycin in a pegylated liposome, which alters its pharmacokinetics, prolonging circulation time in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xmtPrKjyCZH9VfAZD3cCwfr3", "custom_id": "210_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce356b4c7c957000b93865aec5a807fd", "body": {"id": "chatcmpl-9St5x1QguhEFk1FasuLunmrLhhJQH", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab, marketed under the brand name Keytruda, is an immune checkpoint inhibitor that is extensively used in the treatment of various types of cancer. It is a monoclonal antibody that specifically targets the programmed cell death protein 1 (PD-1) receptor on T cells. By inhibiting PD-1, pembrolizumab boosts the immune system\u2019s ability to detect and destroy cancer cells. Here are several key aspects of pembrolizumab that you, as a physician, should be aware of:\n\n### 1. **Indications**\nPembrolizumab is approved for the treatment of multiple types of cancer, including but not limited to:\n- Melanoma\n- Non-small cell lung cancer (NSCLC)\n- Small cell lung cancer (SCLC)\n- Head and neck squamous cell carcinoma (HNSCC)\n- Classical Hodgkin lymphoma\n- Urothelial carcinoma\n- Microsatellite instability-high"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_diyjHoq9AGF7UfMktCGVI7W1", "custom_id": "211_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e7282e2259b79acee13003ec6da02da", "body": {"id": "chatcmpl-9St5x2rYqpYiQ3o4u1fyOtvJtjwKn", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed is a chemotherapy drug used primarily to treat malignant pleural mesothelioma and non-small cell lung cancer. Here\u2019s a summary of key information about pemetrexed that might be useful for you as a physician:\n\n### 1. **Mechanism of Action**\n   Pemetrexed is classified as an antifolat\u0435. It works by inhibiting multiple folate-dependent enzymes, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This inhibition leads to disruption of DNA and RNA synthesis and subsequent cell death, particularly in rapidly dividing cells.\n\n### 2. **Indications**\n   - **Malignant Pleural Mesothelioma:** Pemetrexed is used in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma.\n   - **Non-Small Cell Lung Cancer (NSCLC):** It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x5yBXoFSvxxV4WdVgUCb812D", "custom_id": "212_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2eaa5c6b5219f98278c6f0e276100a10", "body": {"id": "chatcmpl-9St5xuL8Y2WZSLsrcqHpI9DZPrP6X", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin, also known by its brand name Nipent, is an anticancer medication primarily used in the treatment of hairy cell leukemia. It is classified as a purine analog, which interferes with DNA synthesis and thus has cytotoxic effects particularly on lymphocytes. Here are some key points that you, as a physician, should be aware of regarding Pentostatin:\n\n1. **Indications**: Pentostatin is most commonly used for the treatment of hairy cell leukemia. It may also be considered for other conditions as part of clinical trials or off-label use.\n\n2. **Mechanism of Action**: Pentostatin is a potent inhibitor of adenosine deaminase, an enzyme that is crucial in purine metabolism. The inhibition leads to the accumulation of deoxyadenosine, which can cause DNA synthesis inhibition and apoptosis in lymphoid cells.\n\n3. **Administration**: It is typically administered intravenously. The dosing regimen can vary depending on the specific condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tj9c8ODFyB3T6f6hTZMT1gKV", "custom_id": "213_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de3fa6c8f3e84c53a7bb509c7022ca38", "body": {"id": "chatcmpl-9St5xtRT1SsgmPfVGqGAs1YlAEwSC", "object": "chat.completion", "created": 1716671997, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Here are several key points you should know about pertuzumab as a physician:\n\n### Mechanism of Action\nPertuzumab targets the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some breast cancer cells. It binds to the dimerization domain (Subdomain II) of the HER2 protein and prevents receptor dimerization with other HER family members (HER1, HER3, and HER4). This action inhibits downstream signaling pathways that lead to cell growth and proliferation. Pertuzumab\u2019s mechanism of action is complementary to that of trastuzumab, another HER2-targeted therapy, which binds to a different domain (Subdomain IV) of the HER2 receptor.\n\n### Indications\nPertuzumab is approved for use in combination with trastuzumab and doc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8gmDUQp7JVuCounf0qRGgMin", "custom_id": "214_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3ca172df46a343b79d6efbad4c4a88b2", "body": {"id": "chatcmpl-9St5yCwrqA6AlTS7oxtktvpCCsCDW", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin (also known as THP-adriamycin) is a chemotherapy medication that is a derivative of doxorubicin. It is used primarily in the treatment of various cancers, including breast cancer, bladder cancer, and lymphomas. Here are some key points about pirarubicin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Pirarubicin acts similarly to other anthracyclines. It intercalates into DNA, interfering with the synthesis of DNA and RNA by inhibiting the activity of topoisomerase II. This action causes DNA damage and apoptosis in dividing cells.\n\n2. **Usage**:\n   - It is often used in the treatment of breast cancer, bladder cancer, lymphomas, and other solid tumors.\n   - It may be administered alone or in combination with other anticancer agents.\n\n3. **Pharmacokinetics**:\n   - Like other anthracyclines,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DhgXVbsLwP1IeuqfSmhXuo81", "custom_id": "215_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f4c3d9e5f74c97ecfa8b19a356cafd0", "body": {"id": "chatcmpl-9St5y5y9sEJMKjBUZ3e2eyyRb6Lbi", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a substance used as an antineoplastic (anticancer) agent. It is structurally related to anthracyclines, a class of chemotherapy drugs used to treat various cancers, but pixantrone has been designed to reduce the cardiotoxicity often associated with this class. Here are some key points about pixantrone that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pixantrone is a DNA-intercalating agent that also inhibits topoisomerase II, an enzyme important for DNA replication and repair. This dual action contributes to its cytotoxic effects against cancer cells.\n\n2. **Indications**: Pixantrone is primarily approved for the treatment of non-Hodgkin lymphoma (NHL). Its use is often considered in patients who have failed other treatments or when other treatments are not suitable.\n\n3. **Drug Administration**: It is typically administered intravenously. The dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qomcGtpzKgNXIkcQVPXkpU5V", "custom_id": "216_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d7dd762ca84d8dd684faaf87d0760cf", "body": {"id": "chatcmpl-9St5yDBzRjb1CoLkfV0KPbDa4DT6E", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin (also known as mithramycin) is a cytotoxic antibiotic that has been used primarily for its antineoplastic properties. Here are key points that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Plicamycin binds to DNA and inhibits RNA synthesis, which can lead to inhibition of protein synthesis. Its binding is preferential for G-C rich regions of the DNA, which can affect the transcription of various growth-related genes.\n\n2. **Clinical Uses**: Historically, plicamycin has been used in the treatment of testicular cancer, Paget's disease of bone, and hypercalcemia of malignancy. However, due to its toxicity and the development of more effective agents, its use has become less common.\n\n3. **Administration**: Plicamycin is administered intravenously. The dosage and treatment schedule can vary depending on the condition being treated and the overall health of the patient.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vanKXGyIFZ6oDlYgFwz2S7Jm", "custom_id": "217_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f306434830350b1aa8684f103958e8b", "body": {"id": "chatcmpl-9St5yJNuuvpNOE2TvQ6pOFkNtZgVG", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is an immunomodulatory drug that belongs to the same class as thalidomide and lenalidomide. It is primarily used in the treatment of multiple myeloma, particularly in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Here are some key aspects you should know about pomalidomide:\n\n### Mechanism of Action\nPomalidomide primarily exerts its effects by modulating the immune system and inhibiting angiogenesis (formation of new blood vessels), which are critical processes in the progression of multiple myeloma. It has been shown to:\n\n- Inhibit the proliferation of hematopoietic tumor cells\n- Enhance T cell- and natural killer (NK) cell-mediated immunity\n- Inhibit production of pro-inflammatory cytokines such as TNF-alpha and IL-6"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5AzojRVFyca8eoKisUGI9R1E", "custom_id": "218_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "51cf1f38814cb42f24b96b3e446be47b", "body": {"id": "chatcmpl-9St5y49s706B5J6BlylurVlrqgOre", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinib is a prescription medication used primarily in the treatment of certain types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that are resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n\n### Key Points about Ponatinib:\n\n1. **Mechanism of Action**:\n   - Ponatinib is a multi-targeted tyrosine kinase inhibitor. It works by inhibiting the activity of BCR-ABL tyrosine kinase, an abnormal protein that signals cancer cells to multiply. Ponatinib is particularly effective because it also inhibits the T315I mutation in the BCR-ABL gene, which is resistant to other available tyrosine kinase inhibitors.\n\n2. **Indications**:\n   - Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_KNwFJ2rolH5Z5eozkMhEaEKt", "custom_id": "219_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ff2c7b4432f097374d12c5f71348061", "body": {"id": "chatcmpl-9St5yeuEbmCrJlyqwh8hKjUA2L5q0", "object": "chat.completion", "created": 1716671998, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralatrexate, marketed under the brand name Folotyn, is a chemotherapeutic agent primarily used in the treatment of peripheral T-cell lymphoma (PTCL). Here are several key aspects you should be aware of when considering pralatrexate for treatment:\n\n### Mechanism of Action\nPralatrexate is a folate analogue metabolic inhibitor, specifically an antifolate. It inhibits dihydrofolate reductase, which leads to the inhibition of thymidylate synthase and other enzymes involved in the synthesis of DNA, RNA, and proteins. This inhibition leads to the induction of apoptosis in rapidly dividing cells.\n\n### Indications\n- **Primary Indication**: Pralatrexate is approved by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rates observed in clinical trials.\n\n### Dosage and Administration\n- Pralatrexate is administered via"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qS7KUrxma8kQHLopNYyGTXeb", "custom_id": "220_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73edf5aeeb7f549dc1655b22f3ea17f8", "body": {"id": "chatcmpl-9St5zzDt2InFVV9OQSWCjBVOpcpc2", "object": "chat.completion", "created": 1716671999, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a medication primarily used to manage elevated cholesterol levels and prevent cardiovascular disease. Here are some key points about Pravastatin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pravastatin belongs to the class of drugs known as statins. It works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This action helps reduce the levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood while modestly increasing high-density lipoprotein (HDL) cholesterol.\n\n2. **Indications**:\n   - Primary hypercholesterolemia (Fredrickson Type IIa)\n   - Mixed dyslipidemia (Fredrickson Type IIb)\n   - Hypertriglyceridemia\n   - Primary prevention of coronary events in individuals without clinical evidence of coronary heart disease but with multiple risk factors\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XBTAqpfHKYfeKWT0IG1HioTo", "custom_id": "221_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2be760447b0aa0544a88a8c7d00123cc", "body": {"id": "chatcmpl-9St5zxAoIeAD6Kz1MVCR0fuioMyKA", "object": "chat.completion", "created": 1716671999, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisolone is a corticosteroid medication used to suppress the immune system and decrease inflammation. It is commonly prescribed for a variety of conditions, including asthma, allergies, arthritis, and autoimmune diseases. Here are some key points about prednisolone that you, as a physician, should be aware of:\n\n### Mechanism of Action\nPrednisolone works by mimicking the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. It inhibits the immune response and reduces inflammation by:\n- Decreasing the migration of leukocytes and fibroblasts\n- Reducing the production of inflammatory mediators such as prostaglandins and leukotrienes\n- Suppressing the release of inflammatory cytokines\n\n### Indications\nPrednisolone is used in the treatment of:\n- Autoimmune diseases (e.g., lupus, inflammatory bowel disease)\n- Respiratory diseases (e.g., asthma, COPD)\n- Allergic reactions\n- Derm"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bmoMCobJCXv3upexKcfLQFhP", "custom_id": "222_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f28963d17a60209e8ac373c130595e56", "body": {"id": "chatcmpl-9St5zU2IZDw5ivYoT9BayuPrAQD3b", "object": "chat.completion", "created": 1716671999, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisone is a glucocorticoid medication commonly used to suppress the immune system and decrease inflammation. It is a synthetic corticosteroid similar to cortisol, a hormone that humans naturally produce in the adrenal glands. Here are some key points about Prednisone that you, as a physician, should consider:\n\n### Indications\nPrednisone is used to treat a variety of conditions, including:\n- Autoimmune diseases (e.g., lupus, autoimmune hemolytic anemia)\n- Inflammatory conditions (e.g., rheumatoid arthritis, Crohn\u2019s disease)\n- Allergic reactions\n- Asthma and COPD exacerbations\n- Some types of cancer\n- Prevention of organ transplant rejection\n\n### Mechanism of Action\nPrednisone is a prodrug that is converted by the liver into prednisolone, which is the active drug. It acts primarily by reducing inflammation and modulating the immune response. Its effects are mediated through the glucocorticoid receptor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0y9ynZ2ITk3R5wm2iTAgps24", "custom_id": "223_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a17617626d272c74a652907be1af01a", "body": {"id": "chatcmpl-9St5zTQ57SEdNMKf8iPZgVMLwjj9d", "object": "chat.completion", "created": 1716671999, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is a chemotherapy drug used primarily for treating Hodgkin's lymphoma and certain brain cancers. It belongs to the class of drugs known as alkylating agents, which work by interfering with DNA replication in cancer cells, ultimately leading to cell death. Here are key aspects you should be aware of when prescribing or managing treatment involving Procarbazine:\n\n### Mechanism of Action\n- **Alkylating agent:** Procarbazine forms highly reactive methyldiazonium ions, which methylate DNA bases, leading to DNA damage and apoptosis of cancer cells.\n\n### Indications\n- **Primary:** Most commonly used as part of combination chemotherapy regimens for Hodgkin's lymphoma (such as MOPP, which includes Mechlorethamine, Vincristine, Prednisone, and Procarbazine).\n- **Other cancers:** It is also used for certain brain tumors and other lymphomas.\n\n### Dosage and Administration\n- **Oral administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dJECczpI9bbsFKVBg4dn0mej", "custom_id": "224_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cf5b8b2f386e3d407456f7b836a07bb3", "body": {"id": "chatcmpl-9St5zBvaBSwztxZDcDnBnRYK6ZMnq", "object": "chat.completion", "created": 1716671999, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinine is a medication derived from the bark of the cinchona tree and has historically been used primarily to treat malaria. Here are key points you should be aware of as a physician:\n\n1. **Indications:**\n   - **Malaria:** Quinine is most commonly used for the treatment of malaria. It is particularly effective against Plasmodium falciparum, which is resistant to chloroquine.\n   - **Leg cramps:** Although not FDA-approved for this indication, quinine has been used to treat nocturnal leg cramps. However, due to safety concerns, this off-label use is generally discouraged.\n\n2. **Mechanism of Action:**\n   - Quinine acts primarily as a blood schizonticide, meaning it kills the erythrocytic stage of Plasmodium parasites. It interferes with the parasite's ability to digest and utilize hemoglobin by accumulating in the acidic vacuoles of the parasite.\n\n3. **Administration:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JweTxDNtV4biATYPnmdoxsrL", "custom_id": "225_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "15450b2768970f0b10dcb32ba305b824", "body": {"id": "chatcmpl-9St60InZyFYg9ra02XyqDCCuUgtGR", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib is a targeted therapy drug primarily used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about quizartinib:\n\n1. **Mechanism of Action**: Quizartinib is a tyrosine kinase inhibitor that selectively inhibits the class III receptor tyrosine kinases, including FLT3 (FMS-like tyrosine kinase 3). FLT3 is commonly mutated in AML, and these mutations are associated with a poor prognosis. By inhibiting FLT3, quizartinib can block the signaling pathways that promote the survival and proliferation of leukemic cells.\n\n2. **Indications**: Quizartinib is used for the treatment of adult patients with relapsed or refractory AML who are FLT3-ITD positive. FLT3-ITD (internal tandem duplication) is a type of mutation that can be detected by molecular testing.\n\n3. **Efficacy**: Clinical trials have shown that quizartinib can lead"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_2EPFDRUFzOCiZ4vEp9evGYzH", "custom_id": "226_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e4cc23025a51343540092ea475c58e48", "body": {"id": "chatcmpl-9St60ozxztjUUUDsQlypu0fber6Im", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinib (also known as IY5511 or Supect) is a tyrosine kinase inhibitor specifically designed to target BCR-ABL, a fusion protein that is expressed in most cases of chronic myeloid leukemia (CML). Its mechanism of action is similar to other tyrosine kinase inhibitors like imatinib, but it was developed to offer an alternative for patients who may not respond well to other treatments or who have developed resistance.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - Radotinib is primarily indicated for the treatment of chronic phase (CP) chronic myeloid leukemia patients who are resistant or intolerant to prior treatment including imatinib.\n\n2. **Mechanism of Action**:\n   - Radotinib inhibits the activity of the BCR-ABL tyrosine kinase, which is a constitutively active oncogenic protein resulting from the Philadelphia chromosome translocation. By inhibiting this kinase, rad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VIbjf1C5V0dAt3qcMlTKdz7b", "custom_id": "227_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a232870e0e27eceb8be3e26607a3a445", "body": {"id": "chatcmpl-9St60GkonV6SUXFfQaTjUXEx4OiNg", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed is a chemotherapy medication primarily used in the treatment of colorectal cancer. Here are key points you should know about the drug:\n\n1. **Mechanism of Action**: Raltitrexed belongs to the class of antifolate drugs, which inhibit the enzyme thymidylate synthase (TS). This inhibition leads to a reduction in the synthesis of thymidine, which is a nucleotide required for DNA replication and repair. Consequently, the drug impedes the growth of cancer cells.\n\n2. **Indications**: It is specifically indicated for the treatment of advanced colorectal cancer, particularly in patients who are not considered candidates for fluoropyrimidine-based therapy.\n\n3. **Administration**: Raltitrexed is administered intravenously. The dosage and regimen may vary based on factors like the patient's condition, body surface area, and overall health. Typically, it is given once every three weeks.\n\n4. **Side Effects**: Common side effects include"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1M65R1xNb1LQOWBmd8QlxLj1", "custom_id": "228_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f30c58dac8e5823a1973762fd5b8f23e", "body": {"id": "chatcmpl-9St60H9KIRpMtyOr82Yb5lQdCNsTl", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab (brand name Cyramza) is a monoclonal antibody used primarily as an antiangiogenic agent in cancer treatment. Here are key points you should know about ramucirumab as a physician:\n\n1. **Mechanism of Action**:\n   Ramucirumab works by inhibiting vascular endothelial growth factor receptor 2 (VEGFR2), which is a key receptor in the VEGF pathway that promotes the growth of new blood vessels (angiogenesis). By blocking this receptor, ramucirumab helps to inhibit the blood supply to tumors, which can limit their growth and spread.\n\n2. **Indications**:\n   - **Gastric cancer and gastro-esophageal junction adenocarcinoma**: It is approved for use in patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel.\n   - **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UkoDQMXKgyKWV6jFHudawrY9", "custom_id": "229_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "103e469ee787b13ab9083c293b47c25a", "body": {"id": "chatcmpl-9St60z4gGR3idtTPghQRe9GPQjeZr", "object": "chat.completion", "created": 1716672000, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine (also known by its chemical name, ranimustine, and under the trade name Cymerin) is a nitrosourea compound used in chemotherapy. It is primarily used in the treatment of various cancers, including brain tumors and malignant lymphoma. Here are some key aspects you should be aware of:\n\n1. **Mechanism of Action**: Ranimustine works by interfering with DNA replication and RNA transcription, primarily through alkylation and cross-linking of DNA strands. This disrupts the growth of cancer cells and leads to cell death.\n\n2. **Indications**: It is often used in the treatment of brain tumors, both primary and metastatic, as well as non-Hodgkin's lymphoma. Its use might be specific to certain protocols or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Ranimustine is typically administered intravenously. Dosage and administration schedules can vary depending on the type and stage of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fSCZVukYz3mshD2LfEUCFAYG", "custom_id": "230_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "34394d89bca03f66c351132bb3a088ad", "body": {"id": "chatcmpl-9St61lT9iEdKfyt4PPbOfJmwp7xJj", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib (brand name Stivarga) is a medication used primarily in the treatment of certain types of cancers. Here are some important aspects of Regorafenib that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - **Colorectal cancer**: Regorafenib is approved for the treatment of patients with metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.\n   - **Gastrointestinal stromal tumors (GIST)**: It is indicated for the treatment of patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate.\n   - **Hepatocellular carcinoma (HCC)**: Reg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VDTgmHrg6ztPpStpfHlFyyI1", "custom_id": "231_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d4c1059c4d15e5eeae98958cc74a0f4", "body": {"id": "chatcmpl-9St61Kc2kx2jd5W74jdGM3RX9WeuZ", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib, sold under the brand name Kisqali among others, is an oral medication used in oncology, particularly for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Here are some key points about Ribociclib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, Ribociclib helps to stop the proliferation of cancer cells.\n\n2. **Indications**: It is typically used in combination with an aromatase inhibitor (first-line treatment) or with fulvestrant in women who have received prior hormonal therapy. In premenopausal women, it is used together with a luteinizing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0JmMKK5UaQ6xbkm8zpEd7keb", "custom_id": "232_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5fe256e8fe0c9f1f9af6c3f5196f5f88", "body": {"id": "chatcmpl-9St61o3b7lv6yYdopknvvkGokQEaD", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab is a monoclonal antibody used to treat various types of blood cancers and autoimmune diseases. Here are key points about rituximab that are relevant for a physician:\n\n### Mechanism of Action\nRituximab specifically targets the CD20 antigen found on the surface of B lymphocytes. By binding to CD20, rituximab induces B-cell depletion through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and inducing apoptosis directly.\n\n### Indications\n- **Oncology**: Rituximab is approved for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and, in combination with chemotherapy, for certain types of these diseases.\n- **Autoimmune Diseases**: It is also used in rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9cjb4TGB3HKt27m09RqO6BH8", "custom_id": "233_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66c68f1de5d37a35d839c60f5e1a4ea9", "body": {"id": "chatcmpl-9St61QB9MpVvzKpodl9YmhjjKzFJl", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication used mainly for treating certain cancers and autoimmune diseases. The combination includes rituximab, a monoclonal antibody that targets the CD20 antigen on B lymphocytes, and hyaluronidase, an enzyme that increases tissue permeability and allows deeper penetration of rituximab into the tissue.\n\n### Indications:\nThis combination is specifically approved for use in:\n- **Follicular Lymphoma (FL)**: as a single agent for relapsed or refractory, follicular lymphoma, or in combination with chemotherapy for previously untreated follicular lymphoma.\n- **Diffuse Large B-Cell Lymphoma (DLBCL)**: in combination with chemotherapy for previously untreated or relapsed/refractory DLBCL.\n- **Chronic Lymphocytic Leukemia (CLL)**: in combination with chemotherapy.\n- **Granulomatosis with Polyangiitis (G"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LNA3iDJo8Xa92cOtyEQbwtQh", "custom_id": "234_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a4a5b32a4bf6ad198c2b79618ec89c3", "body": {"id": "chatcmpl-9St61hyTQLYMlS4Ci73x3MfaWBAKg", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin, also sold under the brand name Istodax, is a chemotherapy medication primarily used in the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Here are several key aspects you should be aware of regarding Romidepsin:\n\n1. **Mechanism of Action**: Romidepsin is a histone deacetylase (HDAC) inhibitor. It works by blocking the action of histone deacetylase enzymes, which leads to an increase in acetylation of histone proteins, thereby affecting gene expression. This action results in the induction of cell cycle arrest and apoptosis of cancer cells.\n\n2. **Indications**:\n   - **Cutaneous T-cell lymphoma (CTCL)**: Romidepsin is approved for the treatment of CTCL in patients who have received at least one prior systemic therapy.\n   - **Peripheral T-cell lymphoma (PTCL)**: It is also approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aB0vETo8SpggHoDN9Y8D35Am", "custom_id": "235_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2fac80912bdfaa90c0a5f5bc1ac7738b", "body": {"id": "chatcmpl-9St617sGXCV0GUUoBAWjZMo7Oz9sw", "object": "chat.completion", "created": 1716672001, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b is a medication primarily used to treat polycythemia vera, a type of blood cancer characterized by the overproduction of red blood cells. It is a long-acting, pegylated interferon, which means it has been chemically modified to act longer in the body compared to unmodified interferon. Here are some key aspects you should know about Ropeginterferon alfa-2b:\n\n1. **Mechanism of Action**: Ropeginterferon alfa-2b works by mimicking the effects of endogenous interferons, which are proteins that regulate the immune response. It exerts anti-proliferative and immunomodulatory effects, helping to control the overproduction of blood cells.\n\n2. **Indications**: The primary indication for Ropeginterferon alfa-2b is the treatment of adults with polycythemia vera without symptomatic splenomegaly. It offers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_odzdwjgtJVkalDK7ukl9hP7A", "custom_id": "236_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b76a5e0c54c3e519363ed0676842c2f0", "body": {"id": "chatcmpl-9St62CT9LzVk2VdFa0LJ6Tugs1XPW", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rucaparib is an important medication in the oncology field, specifically used as a treatment option for certain types of cancers. Here\u2019s a summary of key information about rucaparib that you, as a physician, might find useful:\n\n### 1. **Mechanism of Action**\nRucaparib is a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes play a role in DNA repair, and inhibitors like rucaparib work by interfering with the DNA repair pathways. This is particularly effective in cancer cells that have BRCA1 or BRCA2 mutations, as these cells rely more heavily on PARP for DNA repair due to their compromised homologous recombination repair mechanisms.\n\n### 2. **Indications**\n- **Ovarian Cancer:** Rucaparib is approved for the treatment of advanced ovarian cancer. Specifically, it is indicated for the treatment of adult patients with deleterious BRCA mutation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gmhcwEUPQclu9kSgmeO1vlNe", "custom_id": "237_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0bc7457041ddca69f23c0931b0bf5252", "body": {"id": "chatcmpl-9St62yR9NGcrkERsilcnvJa9EHVv0", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication primarily used in the treatment of certain hematological disorders. As a physician, here are several key points you should be aware of regarding ruxolitinib:\n\n1. **Mechanism of Action**: Ruxolitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2. These kinases are involved in the signaling pathway of various cytokines and growth factors that are important for hematopoiesis and immune function. By inhibiting these pathways, ruxolitinib modulates the overactive signaling that can lead to pathological conditions.\n\n2. **Indications**:\n   - **Myelofibrosis**: Ruxolitinib is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_towKHTr3mnmFd5uF1aQIzahX", "custom_id": "238_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7fe8009ebdfdc6911b12b02e077bfa8f", "body": {"id": "chatcmpl-9St63C8lsyLSE9bXLsdpBGggFe1BT", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sacituzumab govitecan, also known by its brand name Trodelvy, is an antibody-drug conjugate (ADC) used in oncology, particularly for the treatment of certain types of cancer. Here are some key points that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Sacituzumab govitecan combines a monoclonal antibody (sacituzumab) that targets the TROP-2 antigen, a protein commonly overexpressed in many epithelial cancers, with a potent chemotherapy drug (govitecan), a topoisomerase I inhibitor. The antibody part of the drug specifically binds to TROP-2 on cancer cells, delivering the chemotherapy directly to the tumor, thereby minimizing exposure to healthy cells.\n\n2. **Indications**:\n   - It is approved by the FDA for the treatment of triple-negative breast cancer (TNBC) in patients who have received at least two prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kYqUZe2bqBZ2xY3xBPbNdZPv", "custom_id": "239_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe950285e2a1ea182694ef2bdb7b38c0", "body": {"id": "chatcmpl-9St62dSNKD1ib22IHUuI5wzwDLohq", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim, sold under the brand name Leukine among others, is a medication that is primarily used to promote bone marrow recovery after bone marrow transplantation, during chemotherapy, or following a stem cell transplant. It is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and function of white blood cells, particularly neutrophils and macrophages. Here are some key points you should know about Sargramostim:\n\n1. **Indications**: Sargramostim is approved for use to:\n   - Hasten neutrophil recovery and reduce the incidence of infections in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.\n   - Mobilize hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.\n   - Increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_sFvznXdSe4orhIu3E6nWngBa", "custom_id": "240_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bcbc5eab16aff5e473117c83b7cef510", "body": {"id": "chatcmpl-9St62Jx2GnyqqrxZTHNJ4xK2W1n0D", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexor (brand name Xpovio) is a medication used in the treatment of multiple myeloma and certain types of lymphoma. It is considered a selective inhibitor of nuclear export (SINE) because it specifically inhibitates the nuclear export protein Exportin 1 (XPO1). Here are some key points about Selinexor that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Selinexor works by blocking XPO1, a protein involved in exporting tumor suppressor proteins from the nucleus of the cell. By inhibiting XPO1, Selinexor leads to the accumulation of these tumor suppressor proteins in the nucleus, which can help in reactivating their cancer-suppressing functions and inducing apoptosis (cell death) in cancer cells.\n\n2. **Indications**:\n   - **Multiple Myeloma**: Approved by the FDA for use in combination with dexamethasone for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_La4J436EfMNHdeiPPe0IEE6y", "custom_id": "241_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd807fca7cb9264a3ba3d02bffdc22f1", "body": {"id": "chatcmpl-9St62MbFulspdBKxO43X3dYGRaUYL", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selumetinib is a medication used in the treatment of certain types of cancer. It is a kinase inhibitor, specifically an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1 and MEK2). MEK1 and MEK2 are part of the RAS/RAF/MEK/ERK signaling pathway, which is often activated in cancers due to mutations in RAS or RAF genes. By inhibiting MEK1 and MEK2, selumetinib helps to stop or slow the growth of cancer cells.\n\nHere are some key points you should know about selumetinib:\n\n1. **Approved Indications**: Selumetinib is approved by the FDA for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. This condition causes tumors to grow along"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_da63tbzYXSm1mNV69fC5JfHG", "custom_id": "242_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "578cbeaacc0f55e3361557fa4328dbf7", "body": {"id": "chatcmpl-9St620xDtyqiMc280pfW5ZB539evm", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known by its chemical name, methyl-CCNU or under the brand name Me-CCNU, is a chemotherapeutic agent belonging to the class of nitrosoureas. It is primarily used in the treatment of various cancers, including brain tumors, Hodgkin's disease, and gastrointestinal cancers. Here are some important aspects you should know about Semustine:\n\n1. **Mechanism of Action**: Semustine works by alkylating the DNA and RNA of cancer cells, which interferes with their ability to replicate and ultimately leads to cell death. This alkylating action is not phase-specific in the cell cycle, meaning it can destroy cells at different stages of division.\n\n2. **Administration**: Semustine is typically administered orally.\n\n3. **Metabolism**: Like other nitrosoureas, semustine is highly lipophilic, allowing it to cross the blood-brain barrier, which is beneficial in treating brain tumors. It is metabolized"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yVG5Kv8R4RPeWdLlsQgww29E", "custom_id": "243_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7253cf637cf85ebd0e864c4e3c416588", "body": {"id": "chatcmpl-9St62I5XwxskuE5lidRvm4sMnEKmd", "object": "chat.completion", "created": 1716672002, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T (brand name Provenge) is a therapeutic vaccine used for the treatment of advanced prostate cancer. It is specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. Here are some key points you should be aware of regarding Sipuleucel-T:\n\n1. **Mechanism of Action**: Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers. It involves collecting a patient's own peripheral blood mononuclear cells (PBMCs), including antigen-presenting cells (APCs), which are then exposed to a fusion protein (PA2024) composed of PAP linked to granulocyte-macrophage colony-stimulating factor (GM-CSF). The activated cells are then reinfused into the patient to elicit an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mndIp3qHnK8jAyvtURIDjnlO", "custom_id": "244_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b79432f158c736daa42bbe3db10f65ae", "body": {"id": "chatcmpl-9St63e8VV1WAlqWXT6tdWrvusNw7F", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib, also known by its brand name Odomzo, is a medication used in the treatment of locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in cases where surgery or radiation therapy are not options. It is particularly relevant for patients with locally advanced or metastatic BCC.\n\nHere are some key points about Sonidegib:\n\n1. **Mechanism of Action**: Sonidegib is an inhibitor of the Hedgehog signaling pathway, which is active in most basal cell carcinomas. It specifically inhibits Smoothened, a protein involved in the Hedgehog pathway.\n\n2. **Administration**: Sonidegib is administered orally.\n\n3. **Dosage**: The typical dosage is 200 mg taken once daily, but this can vary based on the patient's condition and response to the drug.\n\n4. **Efficacy**: Clinical trials have demonstrated that Sonidegib can significantly reduce tumor size in a considerable"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_SJcHsFCuDZduay28fuKNOuU3", "custom_id": "245_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43381d319bcd742dcf300162ed60b921", "body": {"id": "chatcmpl-9St63G4wdsKouzG6fWI17uGSm8xng", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib (marketed as Nexavar) is a kinase inhibitor used in the treatment of certain types of cancers. Here's an overview of key aspects you should be aware of as a physician prescribing this medication:\n\n### Mechanism of Action\nSorafenib works primarily as a multi-kinase inhibitor, targeting several intracellular (CRAF, BRAF, and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC). This action helps inhibit tumor cell proliferation and angiogenesis.\n\n### Indications\n- **Renal Cell Carcinoma (RCC)**: Approved for the treatment of advanced renal cell carcinoma.\n- **Hepatocellular Carcinoma (HCC)**: Approved for the treatment of unresectable hepatocellular carcinoma.\n- **Thyroid Carcinoma**: Approved for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iod"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_gQL3oDdEYwrUz5MgMKIxkcSM", "custom_id": "246_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5094936937c539f5e2eedfdf49f9992c", "body": {"id": "chatcmpl-9St63DCnjZmS6GpJXeGoJRxPgR54M", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also spelled streptozotocin) is a chemotherapeutic agent and is classified as an alkylating agent. It is used primarily to treat pancreatic islet cell tumors. Here are some key points you should know about streptozocin, especially considering its use, mechanism, and side effects:\n\n### Usage\n1. **Indications:**\n   - Primarily used for the treatment of metastatic islet cell carcinoma of the pancreas.\n   - It may also be used to treat other types of neuroendocrine tumors.\n\n2. **Administration:**\n   - Streptozocin is administered intravenously. The dosing regimen can vary depending on whether it is given alone or in combination with other chemotherapeutic agents.\n\n### Mechanism of Action\n- Streptozocin is a nitrosourea compound that causes alkylation of DNA, which leads to DNA strand breaks and apoptosis of tumor cells. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WfEdVxMirRBhtI2cW14NYtQZ", "custom_id": "247_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "17a9d739b45f4b33c3484e9ea211ad4c", "body": {"id": "chatcmpl-9St63bj5yTdQlmzshZiWbEvKEMaGL", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib, marketed under the brand name Sutent among others, is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of certain types of cancers. Here are the key points you should know about sunitinib as a physician:\n\n1. **Indications**: Sunitinib is primarily used for the treatment of:\n   - Advanced renal cell carcinoma (RCC)\n   - Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib therapy\n   - Pancreatic neuroendocrine tumors (PNETs) that are unresectable, locally advanced or metastatic\n\n2. **Mechanism of Action**: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), plate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AvWRpmOC5T0yrusyjinJOi4U", "custom_id": "248_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc6f0e20ce078a9b0d92bf84c5af6fb0", "body": {"id": "chatcmpl-9St63Leo3QI7WZWVuowoU1sw1bbOw", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp (brand name Elzonris) is a targeted therapy used primarily for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive form of blood cancer. Here are some important aspects you should know about Tagraxofusp:\n\n1. **Mechanism of Action**:\n   Tagraxofusp is a fusion protein consisting of interleukin-3 (IL-3) linked to a truncated diphtheria toxin. It works by targeting and binding to the IL-3 receptor (CD123), which is overexpressed on the surface of BPDCN cells and some other hematologic malignancies. After binding to CD123 on the cell surface, the toxin portion of the drug is internalized, where it inhibits protein synthesis and induces apoptosis in the malignant cells.\n\n2. **Indications**:\n   As of the latest updates, Tagraxofusp is approved by the U.S. Food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MdudNuPEQbFGLIFfPeDWf6X6", "custom_id": "249_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1d65adac578e4fe87964a6e2494d7976", "body": {"id": "chatcmpl-9St63NztIKg8HfoZRIpJeaSoTGByN", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib is a medication primarily used in oncology, particularly for treating certain types of breast cancers. Here are some key points you should know about talazoparib:\n\n1. **Mechanism of Action**:\n   - Talazoparib works as a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes are involved in normal DNA repair. Talazoparib inhibits these enzymes, which leads to an accumulation of DNA damage in cancer cells, ultimately causing their death. This is particularly effective in cells that are already compromised in their ability to repair DNA due to mutations in genes such as BRCA1 and BRCA2.\n\n2. **Indications**:\n   - As of my last update, talazoparib is approved by the FDA for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mS5K32gGClF7TcIHY92QaDUP", "custom_id": "250_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aeba46480f28d87db74e4f41de5666ba", "body": {"id": "chatcmpl-9St63AiZn4oQod0ZDE7gzi7D9gVAb", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec, commonly referred to as T-VEC, is a genetically modified oncolytic viral therapy used for the treatment of certain types of melanoma. Here are essential aspects you should know about T-VEC:\n\n### 1. Mechanism of Action\nT-VEC is derived from the herpes simplex virus type 1 (HSV-1). It has been genetically engineered to selectively replicate within tumors and to produce the immune-stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). This results in direct lysis (destruction) of tumors as well as stimulation of a systemic immune response against cancer cells.\n\n### 2. Indications\nT-VEC is approved by the FDA for the treatment of melanoma lesions in the skin and lymph nodes that cannot be completely surgically removed, in patients with recurrent disease after initial surgery. It is typically used for treating unresectable stage IIIB to IVM1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zhfMBT2hWPpT9Zre6pCkgSer", "custom_id": "251_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "679566c516f2710c96f196b52d0cee16", "body": {"id": "chatcmpl-9St63acYZ3YFLsXnj655UMh9gnW3s", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene, also known by its chemical name Am80, is a synthetic retinoid that has been studied and used primarily in the treatment of acute promyelocytic leukemia (APL). It is structurally similar to retinoic acid but has been modified to potentially reduce common side effects associated with other retinoids. Here are some key points about Tamibarotene that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tamibarotene works by binding to retinoic acid receptors (RARs), particularly RAR\u03b1 and RAR\u03b2. This binding alters gene expression and induces the differentiation and apoptosis of leukemic cells. This mechanism is similar to that of all-trans retinoic acid (ATRA), but Tamibarotene is designed to be more potent and less toxic.\n\n2. **Indications**: Tamibarotene is primarily used for the treatment of acute promyeloc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_itCehI25iiVI1IAdfg67rGW1", "custom_id": "252_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cb7b0c28071d752a6a3d557fe92c8f0f", "body": {"id": "chatcmpl-9St63QKfM5F15EN39yHCkIzuwEThl", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a medication that is primarily used in the treatment and prevention of breast cancer. Here are some key points about Tamoxifen that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tamoxifen is a selective estrogen receptor modulator (SERM). It works by binding to estrogen receptors on breast cells, thereby blocking estrogen from binding to these receptors. This action inhibits the growth of breast cancer cells that require estrogen to grow.\n\n2. **Indications**:\n   - **Breast Cancer Treatment**: Tamoxifen is used for the treatment of hormone receptor-positive breast cancer in both premenopausal and postmenopausal women and men.\n   - **Breast Cancer Prevention**: It is also prescribed for women at high risk of developing breast cancer and for the prevention of contralateral (opposite side) breast cancer.\n\n3. **Dosage Forms**: It is commonly administered as an oral tablet.\n\n4. **Adverse"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nJ1x9VKhUIwq8xLBkHbdkZoh", "custom_id": "253_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b4b6851b9d3a02e239349ef137031d55", "body": {"id": "chatcmpl-9St64ZDXr2Rh2UhZR7kEADLiXHe9z", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur/gimeracil/oteracil, also known under the trade name Teysuno or S-1, is a combination chemotherapy drug used primarily in the treatment of gastric cancer, including gastroesophageal junction cancer. It is also investigated for use in other types of cancers such as colorectal and pancreatic cancers. This medication is a combination of three pharmacological agents which each play a role in its anti-cancer effects:\n\n1. **Tegafur**: This is a prodrug of 5-fluorouracil (5-FU), which itself is a widely used chemotherapeutic agent. Tegafur is converted into 5-FU in the body. 5-FU is a thymidylate synthase inhibitor that works by inhibiting DNA synthesis, thus preventing cancer cell growth.\n\n2. **Gimeracil (also known as 5-chloro-2,4-dihydroxypyridine or CD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eaGRRBOI6lIoF7ZTkr5DLcVh", "custom_id": "254_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "544754c2d26c035a38fa138ba4848d23", "body": {"id": "chatcmpl-9St63HpRg6mMmGqnlmekIaOvop0U9", "object": "chat.completion", "created": 1716672003, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil is a combination chemotherapy drug used primarily in the treatment of various cancers, including colorectal cancer, gastric cancer, and breast cancer. The combination is typically known under the brand name UFT or as tegafur-uracil. Here are some important aspects to consider:\n\n1. **Mechanism of Action**:\n   - **Tegafur**: This is a prodrug of 5-fluorouracil (5-FU), which gets converted into 5-FU in the body. 5-FU is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in DNA synthesis and function, which is particularly effective against rapidly dividing cancer cells.\n   - **Uracil**: This is a naturally occurring nucleoside, which is added to the formulation to increase the therapeutic efficacy of tegafur. Uracil competitively inhibits the degradation of 5-FU by di"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wfYEyVKkeM7dfIkrbfRS00OP", "custom_id": "255_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "18e0626a3688782acb1a9a85b585d675", "body": {"id": "chatcmpl-9St64rLEOEJpaVQiHqy8aWHMw9yKG", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is an oral chemotherapy drug used primarily to treat certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here\u2019s an overview of key information that you, as a physician, should know about temozolomide:\n\n### Mechanism of Action\nTemozolomide is an alkylating agent that works by adding an alkyl group to DNA, which damages the DNA and triggers cell death. It is particularly effective against rapidly dividing cells, such as cancer cells. Temozolomide is a prodrug that is converted at physiological pH to the active compound, MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide).\n\n### Indications\n- **Primary treatment** for newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.\n- **Refractory anaplastic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vaBWkcL3r2rgKcPO06TBoqSp", "custom_id": "256_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "141cf8cb9c6906336f1df86e0d63ac49", "body": {"id": "chatcmpl-9St64osOVPmRNrYXnnQU1c4odj0El", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temsirolimus is an intravenous drug primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It is a specific inhibitor of the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell growth, proliferation, and angiogenesis. By inhibiting mTOR, temsirolimus interferes with the translation and synthesis of proteins that regulate the cell cycle, thus inhibiting tumor growth.\n\nHere are some key points about temsirolimus that you, as a physician, might find important:\n\n### Mechanism of Action\n- Temsirolimus is a derivative of sirolimus (rapamycin) and works by binding to the intracellular protein FKBP-12. The resulting drug-protein complex inhibits the mTOR complex 1 (mTORC1), leading to a reduction in protein synthesis and cell proliferation.\n\n### Indications\n- The primary indication for temsirolimus is the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9nOar5qsmVG9tcktk99QtBm4", "custom_id": "257_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b7e713b4028d1ff6482cadf2405a4ccb", "body": {"id": "chatcmpl-9St64LEBYp4GcuzXq3Q6yjNX1zPKm", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teniposide is a chemotherapeutic agent primarily used in the treatment of cancer. It is classified as a topoisomerase II inhibitor, which interferes with the action of topoisomerase enzymes involved in the DNA replication of cancer cells. This action disrupts the replication process, leading to cell death, particularly in rapidly dividing cells such as those found in tumors.\n\n**Key aspects of Teniposide (VM-26) include:**\n\n1. **Indications:**\n   - Teniposide is most commonly used in the treatment of childhood acute lymphoblastic leukemia (ALL), Hodgkin's and non-Hodgkin's lymphoma, and certain types of lung cancers. It may also be used in other cancers as part of a combination chemotherapy regimen.\n\n2. **Mechanism of Action:**\n   - Teniposide works by causing DNA damage through inhibition of the topoisomerase II enzyme. This prevents DNA replication and transcription, leading to cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z8Q97QbpufEFvS94ElXzvSGF", "custom_id": "258_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2407eafd9c6c32d5fe78ffc57dc5d453", "body": {"id": "chatcmpl-9St64vI3V9zFCG8BAaF2vKa5tocnU", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a drug that has a complex history and carries significant implications for medical practice. Here are key points that you, as a physician, should be aware of:\n\n1. **Historical Context**: Initially marketed in the 1950s as a sedative and anti-nausea medication to combat morning sickness in pregnant women, thalidomide was found to cause severe birth defects, primarily phocomelia, in newborns. This led to its withdrawal from the market in the early 1960s. The tragedy surrounding thalidomide led to stricter drug regulations and monitoring in many countries.\n\n2. **Mechanism of Action**: Thalidomide is an immunomodulatory drug. It acts by inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and modulating other cytokine action. It also affects immune cell function and the expression of adhesion molecules, which can alter immune cell behavior.\n\n3. **Current Uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QVRNDTVBr3yKVxTMj82ZOdpD", "custom_id": "259_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba54ac89eae572c122e961e4851aa897", "body": {"id": "chatcmpl-9St649fNa93AeeqIfuJhk78kbT1A0", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine (6-TG), is an antimetabolite chemotherapy agent, used primarily in the treatment of acute myeloid leukemia (AML). It is also used in the management of chronic myeloid leukemia (CML) and other hematological malignancies. Here are some key points about thioguanine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Thioguanine is a purine analog. It gets incorporated into DNA and RNA in the form of fraudulent nucleotides, disrupting these critical cellular processes. The drug is metabolically activated by the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which converts it into thioguanine nucleotides (TGNs). These nucleotides then cause cell death primarily by being incorporated into DNA during the synthesis phase.\n\n2. **Indications**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_7lCVq5AipwoDuqs4u6EvLWHs", "custom_id": "260_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fa5cc5276fcfc19ba22ba5a49e8ad027", "body": {"id": "chatcmpl-9St64eHss18DNRDsHqijZWAdwgUS9", "object": "chat.completion", "created": 1716672004, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thiotepa (thiophosphamide or TSPA) is a chemotherapy agent used primarily in the treatment of various cancers, including breast cancer, ovarian cancer, bladder cancer, and certain types of lymphoma. It is also used as a conditioning agent before bone marrow transplantation. Here are key points about Thiotepa that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Thiotepa is an alkylating agent. It works by crosslinking DNA and RNA strands, thereby inhibiting the replication of cancer cells. This results in cell cycle arrest and apoptosis.\n\n2. **Indications**:\n   - Treatment of adenocarcinoma of the breast or ovary.\n   - Treatment of superficial papillary carcinoma of the urinary bladder.\n   - Use as a conditioning treatment before hematopoietic stem cell transplantation (HSCT).\n   - It may be used off-label for other types of cancer or conditions as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OcytgulGYhlY3oM8y9nPZubI", "custom_id": "261_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4b6ab1ea8a579e445baa34ff9a2ea69a", "body": {"id": "chatcmpl-9St653LUd25HMn8czY1fz7WryEZ7Q", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel, marketed under the brand name Kymriah, is a type of therapy known as CAR T-cell therapy (chimeric antigen receptor T-cell therapy). It represents a significant advance in personalized cancer treatment, specifically designed for certain types of blood cancers. Here are key points you should know about tisagenlecleucel:\n\n1. **Indications**:\n   - **B-cell Acute Lymphoblastic Leukemia (ALL)**: Tisagenlecleucel is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.\n   - **Diffuse Large B-Cell Lymphoma (DLBCL)**: It is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL, high-grade B-cell lymphoma, and DLBCL arising"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YwXC8Z1A0yPaHEPtZdG7PfDP", "custom_id": "262_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41c9a3ff61a16b5743259fb3aa5e83ac", "body": {"id": "chatcmpl-9St65cDAxUoLs1Eu7rVF83xYirfsK", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is a medication used primarily in the treatment of advanced renal cell carcinoma (RCC), which is a type of kidney cancer. Here are key points about tivozanib that you, as a physician, should know:\n\n1. **Mechanism of Action**: Tivozanib is a potent, selective, and long-acting vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. It primarily inhibits VEGFR-1, -2, and -3, which are involved in angiogenesis (the formation of new blood vessels), a process that is crucial for tumor growth and metastasis.\n\n2. **Indications**: It is approved for the treatment of advanced renal cell carcinoma after other treatments have failed. Its use can be specific to certain lines of therapy or specific patient populations depending on the regulatory guidelines in your country.\n\n3. **Administration**: Tivozanib is administered orally, and it's important to follow the dosing guidelines"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uh1azWFYohQ9jcMEnV2V3z9q", "custom_id": "263_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ba07ac5d611e574cfaa07d7a3ab376e", "body": {"id": "chatcmpl-9St65FP7HWo1eQ6YS0EUZ7Is5nK8O", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Topotecan is an anticancer medication used primarily in the treatment of certain types of cancers. Here are some key points you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   - Topotecan is a topoisomerase I inhibitor. It works by causing DNA damage which inhibits the replication of cancer cells and leads to cell death.\n\n2. **Indications**:\n   - It is commonly used for the treatment of ovarian cancer, small cell lung cancer, and certain types of cervical cancer.\n   - It can be used as a first-line treatment or in cases where other treatments have failed.\n\n3. **Administration**:\n   - Topotecan is available in both intravenous and oral formulations. The route of administration depends on the specific treatment regimen and the patient's condition.\n\n4. **Dosage**:\n   - Dosage varies depending on the type of cancer, the stage of the disease, the patient's body surface area,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HNCrlJdQRTMenPwqGowiWWJf", "custom_id": "264_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5dcd581bbe3b1467523ab882bcbfd4de", "body": {"id": "chatcmpl-9St65d30DktwiJoZbsg3sn5FYk2zU", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene is a selective estrogen receptor modulator (SERM) that is primarily used to treat metastatic breast cancer in postmenopausal women. It is chemically similar to tamoxifen, another SERM. Here are several key points you, as a physician, might consider about toremifene:\n\n1. **Mechanism of Action**: Toremifene works by binding to estrogen receptors, thereby inhibiting the effects of estrogen on breast tissue. This action blocks the growth of estrogen-dependent breast cancer cells.\n\n2. **Indications**: It is approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or unknown tumors. It may also be considered in other hormone-sensitive cancers based on clinical judgment.\n\n3. **Dosage and Administration**: The typical dosage of toremifene is 60 mg orally, once daily. It can be taken with or without food.\n\n4. **Side Effects**: Common side effects include hot flashes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Sh9TqzqfBfcU4VXmJhhxYBI8", "custom_id": "265_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "144314fdf6e105bcc4253baef126eac7", "body": {"id": "chatcmpl-9St65d9Ct6QJ9oLLUr37pny64kLzP", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 (Bexxar) was a radioimmunotherapy regimen used in the treatment of non-Hodgkin's lymphoma, specifically targeting the CD20 antigen on B-cells. This regimen combined the monoclonal antibody tositumomab with the radioisotope iodine-131, enabling targeted radiation therapy to the cancerous cells.\n\nHere are key aspects physicians should know:\n\n1. **Mechanism of Action**: Tositumomab, the monoclonal antibody component, binds to the CD20 antigen on normal and malignant B-cells. After binding, the radioactive iodine-131 delivers beta and gamma radiation directly to the B-cell, inducing cellular damage and apoptosis, primarily through DNA damage.\n\n2. **Indications**: It was primarily indicated for the treatment of CD20 positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with rit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pw4VOJg0BdjeZGejLp1w7I9n", "custom_id": "266_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "19d44024eb1d3dfa54e0b4d621c4671e", "body": {"id": "chatcmpl-9St655KVoXAjbcyEr7bqCdgNAGOia", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin, also known by its brand name Yondelis, is a chemotherapy medication used primarily to treat certain types of cancer, including advanced soft tissue sarcoma and relapsed ovarian cancer. Here are some key points about Trabectedin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   - Trabectedin binds to the minor groove of DNA, bending it toward the major groove. This binding affects various transcription factors, DNA binding proteins, and DNA repair pathways, ultimately causing cell cycle arrest and apoptosis in cancer cells.\n\n2. **Indications**:\n   - **Soft Tissue Sarcoma**: Trabectedin is approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy including an anthracycline.\n   - **Ovarian Cancer**: It is also approved for the treatment of relapsed ovarian cancer in patients who have received prior platinum-based chemotherapy.\n\n3. **Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_mCoIhq6hnlkjIuXMLnP0grbn", "custom_id": "267_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7d8915865fd495eda2b9a982d71a03b", "body": {"id": "chatcmpl-9St65EWKxOnoAr4ytXPQ2OQ2x3R8g", "object": "chat.completion", "created": 1716672005, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trametinib is a medication used in the treatment of cancer, specifically indicated for use in patients with melanoma, non-small cell lung cancer (NSCLC), and other types of tumors that exhibit BRAF V600E or V600K mutations. Here are some key points you should be aware of when considering trametinib as a treatment option:\n\n1. **Mechanism of Action**: Trametinib is a mitogen-activated protein kinase (MEK) inhibitor. MEK is part of the MAPK/ERK pathway, which is involved in cellular proliferation. By inhibiting MEK, trametinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**:\n   - It is approved for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\n   - It is also used in combination with dabraf"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_z3vByGoEeR9bQRVtPXPU7liI", "custom_id": "268_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e20b2d701029042a50a745fbcac4567", "body": {"id": "chatcmpl-9St66yFeoDIthBwdGdSAmsyNb2dUW", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tranexamic acid (TXA) is a medication that is commonly used to treat or prevent excessive blood loss from major trauma, surgery, and in various medical conditions including menstrual bleeding and hereditary angioedema. Here are some key points about tranexamic acid that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tranexamic acid is an antifibrinolytic agent. It works by inhibiting plasminogen activation and plasmin activity, thereby preventing the degradation of fibrin and helping to stabilize clots.\n\n2. **Indications**:\n   - **Heavy Menstrual Bleeding**: It is often prescribed to reduce menstrual blood loss in women with menorrhagia.\n   - **Surgical Blood Loss**: Used to reduce bleeding during and after surgery, including in cardiac surgery, orthopedic surgery, and dental extractions in patients with hemophilia.\n   - **Trauma**: Effective in reducing mortality"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BiJM2ff6qRf612BQdvFl0jLH", "custom_id": "269_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4403c98622f1e50784b6a17ea03da056", "body": {"id": "chatcmpl-9St66mbzWhj2F8fEhsXOMWTaLf28B", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab is a monoclonal antibody that is specifically designed to target and block the function of HER2 (human epidermal growth factor receptor 2), a protein that can promote the growth of cancer cells. In some cancers, particularly certain types of breast cancer, HER2 is overexpressed, and trastuzumab can be an effective treatment option. Here are some key points about trastuzumab:\n\n1. **Indications**: Trastuzumab is primarily used for the treatment of HER2-positive breast cancer. It is also approved for the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The drug can be used in several settings within breast cancer management, including adjuvant treatment, neoadjuvant treatment, and for metastatic disease.\n\n2. **Mechanism of Action**: Trastuzumab binds to the HER2 receptor on the surface of the cancer cells, inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SHSBXpaZs9HOWe2W5a9OC5Ji", "custom_id": "270_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bac8b30cca368f0911ee110f3c7a9cad", "body": {"id": "chatcmpl-9St66EPmiZqxPrNV0uliR4rKhKRnp", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is an investigational monoclonal antibody designed to bind to and inhibit the activity of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which is a protein receptor that downregulates the immune system. CTLA-4 is a negative regulator of T-cell activity, and by blocking its action, tremelimumab aims to enhance the body's immune response against cancer cells.\n\nHere are key points you should know about tremelimumab:\n\n1. **Mechanism of Action**: Tremelimumab works by blocking CTLA-4, a checkpoint inhibitor that normally helps keep immune responses in check. By inhibiting CTLA-4, tremelimumab may enhance the immune system's ability to fight cancer.\n\n2. **Clinical Trials and Indications**: Tremelimumab has been investigated in various clinical trials, primarily focusing on its use in treating different types of cancer, including melanoma, mesothelioma, and lung"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1tJWcGgttfLv0nKHAmR2LsfP", "custom_id": "271_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0c68a42fa4088085e9042e728fb26566", "body": {"id": "chatcmpl-9St66RnL7bGmBECPtlaKUWvQDkuPZ", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a medication primarily used in the treatment of ovarian cancer and as a conditioning treatment before stem cell transplantation. Here\u2019s a detailed overview of its key aspects:\n\n### Mechanism of Action\nTreosulfan is an alkylating agent. It acts by cross-linking DNA strands, thereby inhibiting DNA synthesis and function, which leads to cell death. Its mechanism makes it effective in targeting rapidly dividing cancer cells.\n\n### Indications\n1. **Ovarian Cancer:** Treosulfan is used in the treatment of advanced ovarian cancer, often in combination with other chemotherapy agents.\n2. **Conditioning Regimen:** Treosulfan is used as part of the conditioning regimen in hematopoietic stem cell transplantation (HSCT), particularly for patients who are considered to be at a high risk from conventional conditioning regimens due to age or existing comorbidities.\n\n### Administration\nTreosulfan is administered intravenously. The dosage and treatment regimen depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FbZlSq2QASHYxoONGXQKksrS", "custom_id": "272_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8db4d3a28e802c4240286a0805fa7584", "body": {"id": "chatcmpl-9St66fQOHKYtpVY2ryq1tsYiPeY9A", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil is a combination medication used primarily in the treatment of metastatic colorectal cancer and certain types of gastric or gastroesophageal junction adenocarcinoma. It is marketed under the brand name Lonsurf. Here are the key aspects you should be aware of:\n\n1. **Indications**:\n   - **Colorectal Cancer**: Trifluridine/tipiracil is indicated for the treatment of adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.\n   - **Gastric Cancer**: It is also indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6MLx3xODsDsdLv90LoHOt6dj", "custom_id": "273_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0c9080c4159a728e963a2ff3aeb28b03", "body": {"id": "chatcmpl-9St66zVbYpOrgambrXezko5pNOTPZ", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), primarily used in the management of hormone-responsive cancers such as prostate cancer, and in assisted reproduction and the treatment of estrogen-dependent conditions like endometriosis and uterine fibroids. Here are key points about Triptorelin that you, as a physician, should be aware of:\n\n### Mechanism of Action\n- Triptorelin works by initially stimulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary gland. This initial surge can lead to a transient increase in the levels of the sex hormones (testosterone and estrogen).\n- With continuous administration, Triptorelin desensitizes the GnRH receptors in the pituitary gland, leading to a significant reduction in LH and FSH levels, and consequently, a decrease in sex hormone levels (chemical castration).\n\n### Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_hsZ4LPV9rGdgY1Qu4P7KxNHf", "custom_id": "274_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b06a7b1769c9640c005337ffafc1aec0", "body": {"id": "chatcmpl-9St66kIuvENevAxprTtxrrPYaju3k", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate (also known as valproic acid, sodium valproate, or divalproex sodium) is a medication primarily used to treat epilepsy and bipolar disorder, and to prevent migraine headaches. It's important to understand both the benefits and potential risks associated with its use.\n\n### Indications\n1. **Epilepsy:** Valproate is effective for the treatment of various seizure disorders, including generalized seizures (such as absence, myoclonic, tonic-clonic) and partial seizures.\n2. **Bipolar Disorder:** It can be used for the management of manic episodes associated with bipolar disorder and as a mood stabilizer.\n3. **Migraine Prophylaxis:** Valproate is used to prevent migraine headaches but is not effective for the acute treatment of migraines.\n\n### Mechanism of Action\nValproate works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain. GABA is a neurotrans"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8Q96A9d1Sa5VcVkHiKVey7sb", "custom_id": "275_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "18de0c3e0dd8bd35449efeebd00f8350", "body": {"id": "chatcmpl-9St66A6Vm0io0WmQKNmnDjcTGX7JO", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin is a chemotherapy drug primarily used in the treatment of bladder cancer, particularly for Bacillus Calmette-Gu\u00e9rin (BCG)-resistant carcinoma in situ (CIS) of the bladder when immediate cystectomy would be associated with unacceptable morbidity or mortality. Here are some key points about valrubicin that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Valrubicin is an anthracycline, which works by intercalating DNA and inhibiting the enzyme topoisomerase II, leading to breaks in DNA strands and ultimately cell death. It is not cell cycle-specific.\n\n2. **Administration**: Valrubicin is administered intravesically, which means it is directly instilled into the bladder through a catheter. This local administration helps to minimize systemic toxicity.\n\n3. **Dosage and Treatment Regimen**: The recommended dose of valrubicin is 800 mg, administered once a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_lLBxYURePE7u66w1HPeLLs1B", "custom_id": "276_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bdc804d7ccfbd21a9dea2de048afb96e", "body": {"id": "chatcmpl-9St66ETJL002qRUlb89pZxEfRP6O2", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer, most notably medullary thyroid cancer. Here are some key points you should know about vandetanib:\n\n1. **Mechanism of Action**: Vandetanib inhibits several tyrosine kinases, including RET, VEGFR, and EGFR. These are involved in pathways that regulate tumor growth, angiogenesis, and cancer cell proliferation.\n\n2. **Indications**: Vandetanib is approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease. The effectiveness of vandetanib in the treatment of these cancers is based on an improvement in progression-free survival.\n\n3. **Dosage and Administration**: The typical dose of vandetanib is 300 mg taken orally once daily, with or without food. Dose adjustments may be necessary based on patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mQiyg2PCIsC3F5uQt4kHnDey", "custom_id": "277_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "461db6b4fa86b48d04dd8d0b2af20255", "body": {"id": "chatcmpl-9St66J3mN1e427umSBqSL2zf9vNcb", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib (brand name Zelboraf) is a medication used in the treatment of late-stage melanoma, the most dangerous type of skin cancer. Here are some key points about vemurafenib that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Vemurafenib is a BRAF inhibitor. It specifically targets and inhibits the BRAF V600E mutation. This mutation leads to the growth and proliferation of cancer cells. By inhibiting this specific mutation, vemurafenib can help in controlling the growth of malignant cells.\n\n2. **Indications**: It is approved for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. It is essential to confirm the presence of BRAF V600E mutation in patients through FDA-approved tests before initiating treatment.\n\n3. **Administration**: Vemurafenib is administered orally. The typical dosage is 960 mg twice daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nkakwk8Egs47z7s4Ajz8oCCU", "custom_id": "278_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "44763534ef2bc8416d3cc664763577b8", "body": {"id": "chatcmpl-9St66sQzYFR8c65oLV5iD8RKbvRMu", "object": "chat.completion", "created": 1716672006, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is an important drug used primarily in the treatment of certain types of blood cancers. Here are key points that you, as a physician, should know about Venetoclax:\n\n1. **Mechanism of Action**:\n   Venetoclax is a selective inhibitor of the B-cell lymphoma-2 (BCL-2) protein. By inhibiting BCL-2, venetoclax promotes apoptosis (programmed cell death) in cancer cells. BCL-2 is an anti-apoptotic protein that is overexpressed in many cancer types and is associated with resistance to chemotherapy.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Venetoclax is approved for use in patients with CLL, including those with 17p deletion, who have received at least one prior therapy. It is also used in combination with obinutuzumab for untreated CLL in adults.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SVAqbFz3FNwVh9OzEcjA9H9c", "custom_id": "279_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "857c3b1f326d525d1b3836865e805f0c", "body": {"id": "chatcmpl-9St67iNVRJ0ShePCpQZLAH0qVIOOq", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication used primarily to treat various types of cancer. As a physician, here are key points you should know about vinblastine:\n\n1. **Mechanism of Action**: Vinblastine belongs to the class of vinca alkaloids. It works by inhibiting mitosis through disruption of microtubule assembly. This leads to cell cycle arrest at the metaphase stage, ultimately resulting in apoptosis (cell death) of cancer cells.\n\n2. **Indications**: It is commonly used in the treatment of Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and some forms of sarcoma. It may also be used in other cancers as part of combination therapy.\n\n3. **Administration**: Vinblastine is administered intravenously. Proper IV administration is crucial as extravasation can cause severe tissue damage and necrosis. \n\n4. **Dosage**: The dosage of vinblastine can vary based on the type of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JZreRGwWJ60rHJMaZNRzEkaW", "custom_id": "280_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e97bfc234f7602b0d08c688814dddaa", "body": {"id": "chatcmpl-9St67HckdXWvjijrnaDYR4jvsanfT", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is an important chemotherapeutic agent commonly used in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors. Here are some key points about Vincristine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Vincristine is a vinca alkaloid that works by inhibiting microtubule formation in the mitotic spindle, thus arresting cell division at the metaphase stage. This action primarily affects rapidly dividing cells, which makes it effective against certain types of cancer.\n\n2. **Indications**: Vincristine is used in the treatment of acute lymphoblastic leukemia (ALL), Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas, rhabdomyosarcoma, neuroblastoma, Wilms' tumor, and some other malignancies. It is often given as part of combination chemotherapy regimens.\n\n3. **Administration**: Vincristine is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_T9fHyXLyheSUMz8qLMNUf6TO", "custom_id": "281_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "31aa47c3c9f453f360383e2b5fc0b000", "body": {"id": "chatcmpl-9St67tpsyM7ZaQeRafmq0ufPZnXJt", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal (brand name Marqibo) is a formulation of the chemotherapy drug vincristine, encapsulated within liposomes. This encapsulation is designed to prolong the circulation time of the drug and enhance its delivery to tumor sites while minimizing toxicity to healthy tissues. Here are some key points about Vincristine liposomal:\n\n1. **Indications**: Vincristine liposomal is approved for the treatment of certain types of cancer, including acute lymphoblastic leukemia (ALL) in patients who have relapsed or are refractory to previous treatments. It might be used in other contexts based on clinical judgment or in clinical trials.\n\n2. **Mechanism of Action**: Like traditional vincristine, vincristine liposomal works by inhibiting microtubule formation in mitotic spindles, which effectively blocks the ability of cells to divide. However, due to its liposomal delivery system, it may have a different pharmacokinetic profile, potentially leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PqaLR94oEaiKcDOCYOvXdvM6", "custom_id": "282_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9218c8b0266241e668e04a702e462150", "body": {"id": "chatcmpl-9St67nY3Cop3sIuMNce2lyBPgkgiq", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is a vinca alkaloid used in chemotherapy. It is derived from the periwinkle plant, similar to other drugs in this class like vincristine and vinblastine. Here are some key aspects you should be aware of regarding Vindesine:\n\n1. **Mechanism of Action**: Vindesine acts by inhibiting microtubule dynamics, which is essential for mitotic and interphase cellular functions. It binds to tubulin and prevents its polymerization, leading to the disruption of the mitotic spindle formation, thereby causing cell cycle arrest at the metaphase.\n\n2. **Indications**: Vindesine is primarily used in the treatment of various cancers, including acute lymphocytic leukemia (ALL), non-small cell lung cancer (NSCLC), and Hodgkin's and non-Hodgkin's lymphomas. It can be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Vindesine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KuJWaioYk2dXOBWUToYrkY7b", "custom_id": "283_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a664c1588d814f3b92730c06f7c742dd", "body": {"id": "chatcmpl-9St67VAg5cOwN7kgqnbM3ZA0WDnhi", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a synthetic vinca alkaloid and an antimitotic agent that is used in the treatment of cancer. It works by interfering with the normal function of microtubules during cell division. Here are some key points you should know about vinflunine:\n\n1. **Indications**: Vinflunine is primarily used for the treatment of advanced transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. It may also be explored in other off-label uses based on clinical judgment.\n\n2. **Mechanism of Action**: Vinflunine inhibits tubulin dynamics, which results in the inhibition of mitotic spindle formation, inducing cell cycle arrest at the G2/M phase and subsequent cell death.\n\n3. **Administration**: Vinflunine is administered intravenously. The dosage and schedule depend on the patient's body surface area, general condition, and specific clinical scenario.\n\n4. **Dosing Adjustments**: It's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1WASgvw6t7fet6MXSPtbTFIi", "custom_id": "284_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b2b9168beab36f6134c3cbb1d7762e9", "body": {"id": "chatcmpl-9St679VVZyv2QaS3T7hzYVvmGQBzI", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine (Navelbine) is a chemotherapy drug that is used primarily in the treatment of various cancers, including non-small cell lung cancer and breast cancer. It belongs to a class of chemotherapy agents known as vinca alkaloids, which are derived from the periwinkle plant (Catharanthus roseus). Here are some key points about Vinorelbine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nVinorelbine works by interfering with the microtubule structures within the cell. Specifically, it inhibits tubulin polymerization, which is essential for microtubule formation and function. This disruption leads to the inhibition of mitosis in the metaphase, causing cell death.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Vinorelbine is used as a first-line treatment in the management of advanced NSCLC, often in combination with other chemotherapy agents.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vWIpAtcQFnZ1jNvZdYcERMbn", "custom_id": "285_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ada7ff0b695605c66c9c6eb3cbc6f1b0", "body": {"id": "chatcmpl-9St67wa94ZHy65GU4IquWi0MltOjc", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib is an oral medication used primarily for the treatment of advanced basal cell carcinoma (BCC), particularly in cases where the cancer is inoperable or has metastasized. Here are some key points that you, as a physician, should know about Vismodegib:\n\n1. **Mechanism of Action**:\n   - Vismodegib works by inhibiting the Hedgehog signaling pathway, which is active in most basal cell carcinomas. It specifically targets the protein Smoothened (SMO), thereby inhibiting the growth and survival of cancer cells.\n\n2. **Indications**:\n   - Vismodegib is approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and radiation therapy.\n\n3. **Administration**:\n   - It is administered orally, typically at a dose of 150 mg once daily, with or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NEbxI2ygXkDPeEt2aGNX4rqa", "custom_id": "286_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "877114812e974b7b9d7bcce36661145d", "body": {"id": "chatcmpl-9St671I4DmUjisYTs6vtfWphMDTlg", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its brand name Zolinza, is a medication used in the treatment of cancer, specifically for cutaneous T-cell lymphoma (CTCL) when the disease persists, worsens, or returns after trying other treatments. Here are key aspects of Vorinostat you should be aware of as a physician:\n\n### Mechanism of Action\nVorinostat belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. It works by interfering with the function of histone deacetylases, which are enzymes involved in the remodeling of chromatin and the regulation of gene expression. By inhibiting these enzymes, Vorinostat increases the acetylation of histone proteins, leading to relaxed chromatin structure and, consequently, enhanced transcription of genes that suppress proliferation and induce cell cycle arrest and apoptosis of cancer cells.\n\n### Indications\n- **Primary Indication**: Treatment of cutaneous manifestations in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aqHyuHhRhNOeLbUfIjfIVtcp", "custom_id": "287_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ddc70b1c61fc1bd1c21c4aff0fba6c0", "body": {"id": "chatcmpl-9St67CNU96Zwj7MipC4lsBqCj4Uvv", "object": "chat.completion", "created": 1716672007, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zidovudine, also known by its brand name Retrovir and commonly abbreviated as AZT, is an antiretroviral medication used primarily in the treatment and prevention of human immunodeficiency virus (HIV) infection. Here are several key points about Zidovudine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Zidovudine belongs to the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). It works by inhibiting the activity of reverse transcriptase, an enzyme crucial for the replication of HIV. Zidovudine is incorporated into the viral DNA chain during replication, leading to premature chain termination and thus inhibiting the virus from multiplying.\n\n2. **Indications**:\n   - Treatment of HIV infection in combination with other antiretroviral agents.\n   - Prevention of maternal-fetal HIV transmission.\n   - It may also be used in post"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dQqK2c6JMgyktND3PIvX1oua", "custom_id": "288_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0de84e6eafbdbdf132d7338a9ed54e52", "body": {"id": "chatcmpl-9St688riqhJPCcRCaX9GgEvhA5Nqc", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, marketed under the brand name Zaltrap, is a biopharmaceutical agent used primarily in the treatment of metastatic colorectal cancer, especially in cases where the disease has progressed following an oxaliplatin-containing regimen. Here are some key points about ziv-aflibercept that you, as a physician, may find useful:\n\n### Mechanism of Action\nZiv-aflibercept is a recombinant fusion protein that acts as a soluble receptor that binds to vascular endothelial growth factor (VEGF) ligands, VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding these ligands, ziv-aflibercept inhibits their interaction with their respective receptors on the surface of endothelial cells, thus inhibiting the downstream signaling pathways that promote angiogenesis (formation of new blood vessels). This inhibition of angiogenesis is critical in preventing the growth and metastasis of tumors.\n\n### Indic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OWP31xXtwO8D6QyoHJI83ojs", "custom_id": "289_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f10428eaacbd0a61da1c935b01fb31f", "body": {"id": "chatcmpl-9St68yDOEyQ4W4xbpNGT9k2Aj7sny", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib is a targeted therapy drug used primarily for the treatment of non-small cell lung cancer (NSCLC). It is a small molecule kinase inhibitor that specifically targets MET, a tyrosine kinase receptor involved in the growth and spread of cancer cells. Here are some key points about Capmatinib that you, as a physician, might find useful:\n\n1. **Indications**: Capmatinib is approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test. This mutation is relatively rare but can be a significant driver of cancer progression in those affected.\n\n2. **Mechanism of Action**: Capmatinib inhibits the MET tyrosine kinase receptor, which may be overexpressed or mutated in some types of cancers, including NSCLC. By inhibiting this pathway, capmatinib can prevent the growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Jls0eLOYcADjz5gRpkMpz1t6", "custom_id": "290_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "577b801e7b0c5920f52229d5c9e43996", "body": {"id": "chatcmpl-9St68pd7oIZd6vxlVYZM77ndYN9vB", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (brand name: Padcev) is an antibody-drug conjugate (ADC) used primarily in the treatment of urothelial cancer. Here are some key points about Enfortumab vedotin that you, as a physician, might find important:\n\n1. **Indications**: Enfortumab vedotin is approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.\n\n2. **Mechanism of Action**: This drug works by combining an anti-Nectin-4 monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE). Nectin-4 is a protein that is highly expressed in urothelial cancers. The antibody component of enfortumab vedotin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VhqPkTEYoZablxyoMSTeGcyx", "custom_id": "291_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1d800c03083f85167ef711095713b8f9", "body": {"id": "chatcmpl-9St68y5122Fn83CLth6phefPsfKMd", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan (also known by its brand name Enhertu) is a targeted therapy drug used primarily for the treatment of certain types of breast cancer and other HER2-expressing cancers. Here are some important aspects of Trastuzumab deruxtecan that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) consisting of three components: a HER2-targeted antibody (trastuzumab), a stable linker, and a cytotoxic topoisomerase I inhibitor (deruxtecan). The trastuzumab component binds to the HER2 receptor on cancer cells, allowing the conjugate to be internalized into the cell where the cytotoxic agent (deruxtecan) is released, leading to cell death.\n\n2. **Indications**: As of the latest updates, Trastuz"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xieRHmhugEhzY8eUQ2uTaYsj", "custom_id": "292_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0f7600109032e232da251129cf531289", "body": {"id": "chatcmpl-9St68enkt6Z5evQ8NZ5ClwlD10RBk", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a medication primarily used in the management of advanced prostate cancer. Here are some key points you should know about Abarelix:\n\n1. **Mechanism of Action**: Abarelix is a gonadotropin-releasing hormone (GnRH) antagonist. It works by directly blocking the GnRH receptors in the pituitary gland, leading to a rapid decrease in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces testosterone levels. This decrease in testosterone is crucial in managing prostate cancer, as testosterone can promote the growth of prostate cancer cells.\n\n2. **Clinical Use**: It is used primarily in patients with advanced prostate cancer to help reduce the symptoms and progression of the disease. Unlike some other hormone therapies, Abarelix does not cause an initial surge in testosterone levels, which can be beneficial in avoiding a clinical flare in symptoms.\n\n3. **Administration**: Abarelix is administered as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_1yXssscTtJPv1uvIP2JGxM5t", "custom_id": "293_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0a81bf7756d31876a498239cab95711f", "body": {"id": "chatcmpl-9St68SFvF5kVHb28V5IyAIvNITcBh", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin, also known by its trade name Blenrep, is a drug used in the treatment of multiple myeloma, particularly in patients who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Here are several key points about belantamab mafodotin:\n\n1. **Mechanism of Action**: Belantamab mafodotin is a first-in-class antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA), a protein commonly expressed on the surface of myeloma cells. The drug consists of a monoclonal antibody linked to a cytotoxic agent, mafodotin, which is a microtubule inhibitor. Upon binding to BCMA on myeloma cells, the ADC is internalized, and the cytotoxic agent is released, inducing cell death.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_74kitHPFhZpdxstPUWeMSVGv", "custom_id": "294_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b007211c1890838f663653c0c7bf0042", "body": {"id": "chatcmpl-9St68fHitT7a9z1MBYoAi1SNk6aLQ", "object": "chat.completion", "created": 1716672008, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is a medication used primarily for the treatment of HER2-positive breast cancer. Here are several key points about tucatinib that you, as a physician, might find important:\n\n1. **Mechanism of Action**: Tucatinib is a tyrosine kinase inhibitor that specifically targets the HER2/neu receptor. HER2 is a growth factor receptor that is overexpressed in some types of breast cancer. By inhibiting this receptor, tucatinib helps to block the downstream signaling pathways that promote tumor growth and survival.\n\n2. **Indications**: Tucatinib is approved for use in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients who have received at least one prior anti-HER2-based regimen in the metastatic setting.\n\n3. **Clinical Efficacy**: The approval of tucatinib was based on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_PAqIujygxaXFMHAtBQA8N4ZK", "custom_id": "295_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7783416dce1a07eed3ef985826cca0bb", "body": {"id": "chatcmpl-9St69Z7pJ1y7C4Z3qb7GdigkmD3sP", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab and hyaluronidase-fihj (brand name: Darzalex Faspro) is a combination medication used in the treatment of multiple myeloma. Daratumumab is a monoclonal antibody that targets CD38, a surface protein highly expressed on myeloma cells, and promotes their destruction. Hyaluronidase is an enzyme that increases tissue permeability, facilitating the deeper and faster dispersion and absorption of daratumumab when administered subcutaneously.\n\nHere are some key points you should know about Daratumumab and hyaluronidase:\n\n1. **Indications**: This combination is approved for the treatment of adult patients with multiple myeloma, both in newly diagnosed patients (depending on the specific regimen and patient characteristics) and in those who have received previous therapies.\n\n2. **Administration**: One of the benefits of Daratumumab and hyaluronidase is its subcutaneous route of administration, which is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aIp6CJlGcynxcF3fgHTLlZH5", "custom_id": "296_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24b8ec0bc258d5548b1f4349d07bc455", "body": {"id": "chatcmpl-9St69siTA8L1YCd3HlkLzUwvKZXrQ", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin, also known as 9-cis-retinoic acid, is a medication primarily used to treat chronic hand eczema that has not responded well to other treatments such as topical steroids. It is also used for other dermatological conditions and is a systemic retinoid, related to vitamin A.\n\nHere are key points about alitretinoin that you, as a physician, might find useful:\n\n1. **Indications**: Alitretinoin is approved for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. Its use can also be explored in cases of other severe eczema types where standard treatments have failed.\n\n2. **Mechanism of Action**: Alitretinoin works by binding to both retinoic acid receptors (RAR) and retinoid X receptors (RXR). This binding activity modulates gene expression, which in turn reduces inflammation and normalizes skin growth.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aJHqyRIVToNcyOkSGvKRZ5aq", "custom_id": "297_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd7f947962e900cfe40f28b3ba491e55", "body": {"id": "chatcmpl-9St69uCbts86bcas5b72tbwWQZ3s3", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, also known by its brand name Tecartus, is a form of CAR T-cell therapy approved by the FDA for certain types of cancers. Specifically, it is designed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about brexucabtagene autoleucel:\n\n1. **Mechanism of Action**: Brexucabtagene autoleucel involves reprogramming the patient\u2019s T-cells to include a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of some B-cells. This reprogramming helps the T-cells recognize and kill cancer cells that express CD19.\n\n2. **Manufacturing and Administration**: The process of creating brexucabtagene aut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qGfliuiUxHQRIEgDQoL9H95q", "custom_id": "298_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "637c3a9139ddc91ce55fc267d207ea10", "body": {"id": "chatcmpl-9St69KRIrS6w5CWBSDHc3BKr7zxW0", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alpelisab (brand name Piqray), is a medication primarily used in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. It is specifically used in combination with fulvestrant for postmenopausal women, and men, who have progressed following endocrine therapy. Here are key points you should know about alpelisib:\n\n1. **Mechanism of Action**: Alpelisib is a kinase inhibitor that specifically targets PI3K\u03b1, a subunit of the phosphoinositide 3-kinase (PI3K) enzyme, which is involved in tumor growth and survival. Mutations in the PIK3CA gene lead to activation of PI3K\u03b1 and are found in various cancers, including breast cancer.\n\n2. **Indications**: It is approved for use in patients with advanced or metastatic breast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VucTrbQ0r4FC3vT9dzno7jFO", "custom_id": "299_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "35669fdd99210c9eac63f2fd711e7e62", "body": {"id": "chatcmpl-9St69KFpOgJzQqdLSRBGdtKpSLWzB", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide (also known by its developmental code names AS1413 or NSC 308847) is a synthetic compound that functions primarily as a DNA intercalator and topoisomerase II inhibitor, which has been investigated for its potential use in chemotherapy.\n\n### Mechanism of Action:\nAmonafide works by intercalating into DNA, which disrupts the DNA's double helix structure. This interference inhibits the function of topoisomerase II, an enzyme crucial for DNA replication and cell division. By doing so, it prevents cancer cells from multiplying, leading to cell death.\n\n### Clinical Development:\nAmonafide has been studied in a variety of cancers including breast cancer, ovarian cancer, and particularly in acute myeloid leukemia (AML). Despite showing promise in early trials, it has faced challenges in clinical development, including issues with toxicity and efficacy that have so far prevented its approval by major regulatory bodies like the U.S. Food and Drug Administration (FDA).\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xP3qaqRNMnnL5vTThlWvD4TZ", "custom_id": "300_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "492f1df5c9e8c5dc35ba88945312a241", "body": {"id": "chatcmpl-9St6AOcq5dmrmZ7ms8FfAE2Z8AXey", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin is an antibiotic that belongs to the penicillin class of antibiotics, widely used to treat a variety of bacterial infections. Here are several key points about Amoxicillin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nAmoxicillin works by inhibiting the synthesis of bacterial cell walls. It binds to penicillin-binding proteins within the bacterial cell wall, leading to the disruption of cell wall synthesis, causing bacterial lysis and death.\n\n### Spectrum of Activity\n- **Gram-positive bacteria:** Effective against many gram-positive bacteria such as Streptococcus spp., Enterococcus spp., and some Staphylococcus spp.\n- **Gram-negative bacteria:** Treats infections caused by gram-negative bacteria such as Escherichia coli, Haemophilus influenzae, and Helicobacter pylori.\n- It is also effective against certain anaerobic organisms.\n\n### Indications\nAmoxicillin is used to treat various infections"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BRL3cLB1VNwU05N1bdHvQ714", "custom_id": "301_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a90a250803ce566f72b47c09b63c4dad", "body": {"id": "chatcmpl-9St69CIW2WTZdcP1UREhzIQqBDWBt", "object": "chat.completion", "created": 1716672009, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aumolertinib, also known by its developmental code AZD-9291 or marketed as Tagrisso, is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically designed for cancers that have a mutation in the epidermal growth factor receptor (EGFR) gene.\n\n**Key Points for Physicians:**\n\n1. **Indications**:\n   - Aumolertinib is approved for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.\n   - It is also used as a first-line treatment for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.\n\n2. **Mechanism of Action**:\n   - Aumolertinib is a third-generation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rEwYJdp5LKKtgfq5rvxiYXUq", "custom_id": "302_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a6e97fa596d5962b9162003d5174eb90", "body": {"id": "chatcmpl-9St6AjpCsItdYibS5RPQJZufVwFh4", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy approved for the treatment of certain types of cancer. Here are key points you should know about this medication:\n\n1. **Mechanism of Action**: Pemigatinib is a kinase inhibitor that specifically targets and inhibits the activity of fibroblast growth factor receptors (FGFR) 1, 2, and 3. These receptors are involved in important processes such as cell growth and division, and their dysregulation has been implicated in the development of various cancers.\n\n2. **Indications**: It is primarily approved by the FDA for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Research is ongoing to explore its efficacy and safety in other FGFR-related cancers.\n\n3. **Administration**: Pemigatinib is administered orally.\n\n4. **Dosage**: The typical starting dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3jMBZNE0RZhsCbELGT3YHv3m", "custom_id": "303_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0091bd5cb73cd6d10237ef232479fc46", "body": {"id": "chatcmpl-9St6ADhLGZTT0d5kyezQBMDrPl7ST", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib, marketed under the brand name Qinlock, is a kinase inhibitor used primarily in the treatment of gastrointestinal stromal tumors (GISTs). It was approved by the FDA in May 2020 for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib.\n\nHere are key points you should know about Ripretinib:\n\n1. **Mechanism of Action**: Ripretinib is a broad-spectrum kinase inhibitor that targets KIT and PDGFRA mutant kinases, which are commonly mutated in GISTs. Importantly, it inhibits both primary and secondary mutations that confer resistance to other treatments.\n\n2. **Indications**: Ripretinib is indicated for the treatment of adult patients with advanced GIST who have previously received treatment with other targeted therapies such as imatinib, sunitinib, and regorafenib.\n\n3. **Administration**: Ripret"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IGF0HSwsmseotvRozYMHZ0Ms", "custom_id": "304_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fcf21ae5664584be74efa7d8bb0591ee", "body": {"id": "chatcmpl-9St6ATnNDlqpoou8W08scQ2O1GjDj", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib, marketed under the brand name Retevmo, is a medication used in the treatment of certain types of thyroid and lung cancers. It is specifically designed for cancers that have alterations (mutations or fusions) in the RET (rearranged during transfection) gene. Here are several key points you should know about selpercatinib:\n\n1. **Indications**:\n   - **RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)**: Selpercatinib is indicated for adult patients with metastatic RET fusion-positive NSCLC.\n   - **RET-Mutant Medullary Thyroid Cancer (MTC)**: It is used for treating adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy.\n   - **RET Fusion-Positive Thyroid Cancer**: Selpercatinib is also indicated for adult and pediatric patients 12 years of age"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WzKDrKAv9qpWfc6iyJAUgfZv", "custom_id": "305_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "607d31f8bdc9531fa864cb0d31bfdc28", "body": {"id": "chatcmpl-9St6AF4sfmBzdVe0ipAhr5hjbHvI5", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination therapy used primarily in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic stem cell disorders characterized by dysplasia and ineffective hematopoiesis. This combination can also be used for treating chronic myelomonocytic leukemia (CMML). Here are some key points about each component and their combination:\n\n### Decitabine\n1. **Mechanism of Action**: Decitabine is a cytidine analog that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This can reactivate silenced genes that suppress tumors, promoting cellular differentiation and apoptosis in malignant cells.\n2. **Indications**: It\u2019s primarily used for treating MDS and CMML. Decitabine can be used alone or in combination with other treatments.\n3. **Administration**: Traditionally administered intravenously.\n\n### Ced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dTjp3vx9CUpKAFCSXLPBki19", "custom_id": "306_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "553c97edf3d0d747bb9c9674edd180cc", "body": {"id": "chatcmpl-9St6AMEAgCLci4AMeb5lIGgSgMSrq", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat gastrointestinal disorders such as diarrhea, nausea, heartburn, and indigestion. Here are several key points that you, as a physician, should know about bismuth subsalicylate:\n\n1. **Mechanism of Action**:\n   - Bismuth subsalicylate has antacid and antimicrobial properties. It works by coating the lining of the gastrointestinal tract and protecting it from stomach acid. It also has an antimicrobial effect against bacteria like Escherichia coli and Helicobacter pylori.\n   - The salicylate component may help reduce inflammation and inhibit the synthesis of prostaglandins, which are involved in the pain and irritation processes.\n\n2. **Indications**:\n   - It is primarily indicated for the relief of symptoms associated with gastrointestinal disturbances such as diarrhea, upset stomach, heartburn, nausea, and indigestion.\n   - It is also used in the management and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RGNE1WzpKqou1gTybG6C3pFi", "custom_id": "307_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "79be5fb039a35b5efd37d51d924417bc", "body": {"id": "chatcmpl-9St6AuX7776wBWbKxx1sMmPOlisdZ", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camrelizumab is a monoclonal antibody used in the treatment of various types of cancer. It is an immune checkpoint inhibitor that specifically targets the programmed cell death-1 (PD-1) receptor on the surface of T cells. By inhibiting this pathway, camrelizumab enhances the body's immune response against cancer cells.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Camrelizumab binds to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2 ligands. This prevents the receptor from transmitting inhibitory signals to T cells, thereby enhancing the immune system's ability to attack cancer cells.\n\n2. **Indications**:\n   - It is primarily used for the treatment of Hodgkin's lymphoma and various solid tumors, including hepatocellular carcinoma and non-small cell lung cancer. The specific indications can vary based on the regulatory approvals in different countries, so it's important to check local"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LOKEe6rdKknYqO1SAj0UFN4D", "custom_id": "308_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f51b642582a7b2283be67a77c11a2f09", "body": {"id": "chatcmpl-9St6AjQke6ylkvNrmrMyPLzEBJZ7j", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Relugolix is a medication that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is used in the treatment of various conditions related to hormone-sensitive tissues and glands. Here are some key points about Relugolix that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Relugolix works by competitively binding to GnRH receptors in the pituitary gland. This binding inhibits the release of gonadotropins (luteinizing hormone and follicle-stimulating hormone), which in turn decreases the production of sex hormones such as testosterone and estrogen.\n\n2. **Indications**:\n   - **Prostate Cancer**: Relugolix is approved for use in the treatment of advanced prostate cancer. It is used to achieve and maintain castrate levels of testosterone, which is beneficial in managing prostate cancer progression.\n   - **Uterine Fibroids and Endometriosis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3igd0e1waWwMu6lmQzkGVmbm", "custom_id": "309_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b69ce3c887479b91de6ab28f00f430ef", "body": {"id": "chatcmpl-9St6ApVhh3fudgdlMOSgO7mrxD6ls", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant (also known by its developmental code name RAD1901) is a selective estrogen receptor degrader (SERD) that is being investigated for its potential use in the treatment of estrogen receptor-positive (ER+) breast cancer. As a physician, here are some key points you should be aware of regarding elacestrant:\n\n1. **Mechanism of Action**: Elacestrant functions by binding to the estrogen receptor and promoting its degradation. This leads to a decrease in the ER protein levels in the tumor cells, which can reduce the growth of ER-positive cancer cells that rely on estrogen signals for growth and survival.\n\n2. **Clinical Trials**: Elacestrant has been studied in various phases of clinical trials. The EMERALD Phase 3 clinical trial, for instance, evaluated the efficacy and safety of elacestrant compared to standard endocrine therapies (such as fulvestrant or an aromatase inhibitor) in patients with ER-positive, HER2-negative advanced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cNAbQG9vrQbCb2BxndODed6B", "custom_id": "310_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a771154ab107dbee17d5a6945897178", "body": {"id": "chatcmpl-9St6ADtjjbzHHkCXoocydc7R62fFo", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is a chemotherapy medication primarily used for the treatment of cancer and certain infections. Here are key points that you, as a physician, should know about trimetrexate:\n\n1. **Mechanism of Action**:\n   - Trimetrexate is a dihydrofolate reductase inhibitor. By inhibiting this enzyme, trimetrexate interferes with the synthesis of DNA, RNA, and proteins, which are crucial for cell replication and survival. This makes it effective in targeting rapidly dividing cells, such as cancer cells and some bacteria.\n\n2. **Indications**:\n   - **Cancer Treatment**: Trimetrexate can be used in the treatment of certain types of cancers, often in combination with other chemotherapeutic agents.\n   - **Pneumocystis Pneumonia (PCP)**: It is particularly noted for its use in the treatment of PCP in patients with AIDS when conventional treatment (e.g., trimethop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_egiLhjc2bzeJaxepx1d4Zt4l", "custom_id": "311_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a3f594b6cf617c15f1e90915948be1c", "body": {"id": "chatcmpl-9St6AJ9Au0ysrCjG5mmVaprurx96Y", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is a targeted therapy used in the treatment of cancer, specifically for the management of non-small cell lung cancer (NSCLC). Here are some key points about tepotinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tepotinib is a tyrosine kinase inhibitor that selectively inhibits the c-Met receptor tyrosine kinase. Abnormal activation of the c-Met pathway can lead to cell proliferation, motility, and survival, and is implicated in the pathogenesis of several cancers, including NSCLC.\n\n2. **Indications**: It is specifically approved for patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This mutation leads to oncogenic activation of the MET protein, and tepotinib targets this aberrant signaling pathway.\n\n3. **Efficacy**: Clinical trials, such as the VISION study, have demonstrated that tepotinib is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pdF6aYgpHYkDVWCZj61OGeQi", "custom_id": "312_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b7c51a625ad27a6b3e7f2357f2067ec", "body": {"id": "chatcmpl-9St6AU5yDwyChWIX2RbfVO5MMmPA4", "object": "chat.completion", "created": 1716672010, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib (also known by its developmental code TAS-120) is an orally bioavailable, irreversible inhibitor of the fibroblast growth factor receptor (FGFR) family, which includes FGFR1, FGFR2, FGFR3, and FGFR4. It is specifically designed to target and bind covalently to the ATP-binding pocket of FGFR, leading to the inhibition of FGFR signaling. This can result in the blockade of FGFR-mediated signal transduction pathways, which may inhibit tumor cell proliferation and induce cell death in FGFR-overexpressing cells.\n\nAs of my last update, futibatinib has been under investigation for its potential use in treating various types of cancers, particularly those characterized by aberrations in the FGFR pathways such as cholangiocarcinoma, urothelial cancer, breast cancer, and potentially others. Aberrations might include mutations, amplifications, or fusions involving FGFR genes.\n\nHere are some clinical and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W7KkUZKlyeIC08IZY9wRsjbM", "custom_id": "313_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f3efd4f78cb18ee4989f1c4aa89c808b", "body": {"id": "chatcmpl-9St6BpjKwDHRzg9favS37r4yozckW", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, also known as Optune, is a medical device used in the treatment of glioblastoma (GBM), a type of brain cancer. It is particularly used in adult patients with newly diagnosed glioblastoma as an adjunctive treatment to the standard regimen of surgery, chemotherapy (temozolomide), and radiation therapy, and in recurrent glioblastoma as a monotherapy after surgical and radiation options have been exhausted.\n\nHere are key points you should know about the NovoTTF-100A system:\n\n1. **Mechanism of Action**: Optune uses Tumor Treating Fields (TTFields), which are low-intensity, alternating electric fields delivered at specific frequencies. These fields disrupt cell division, specifically targeting rapidly dividing tumor cells, thereby inhibiting tumor growth and causing cancer cell death.\n\n2. **Usage**: The device involves placing adhesive patches (transducer arrays) on the scalp that deliver the electric fields directly to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T5VorT7Ajz3WKw201uL8ty0M", "custom_id": "314_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "08ef17a66e9dfdc53772c645c9975e0b", "body": {"id": "chatcmpl-9St6Bo4JIoDJHhepCCBHgDGS8yDNV", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel, also known as liso-cel and sold under the brand name Breyanzi, is a CAR T-cell therapy used in the treatment of certain types of B-cell lymphomas. This therapy is specifically indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, among others.\n\n### Key Aspects of Lisocabtagene Maraleucel\n\n**1. Mechanism of Action:**\n   - Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy. It involves modifying the patient's T cells to include a CAR that targets CD19, a protein expressed on the surface of B-cell lymphocytes. This modification allows the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JZRaCCAZlM4sWAafuk9aFgF1", "custom_id": "315_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3c612fe00d313d3fc3e87924c98b66e2", "body": {"id": "chatcmpl-9St6Brq3XLz8KBgPE11ZZvgQofCCz", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel, often abbreviated as ide-cel and marketed under the name Abecma, is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is used for the treatment of multiple myeloma in patients who have received at least four prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This treatment falls under the umbrella of CAR T-cell therapies, which involve modifying a patient's T-cells to include a chimeric antigen receptor (CAR) that targets cancer cells for destruction.\n\nHere are some important aspects to consider about Idecabtagene vicleucel:\n\n1. **Indication and Usage**:\n   - It is specifically indicated for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.\n\n2. **Mechanism of Action**:\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lFoza2q2gpbdpAxAP2HJUjzd", "custom_id": "316_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89c91e5a9288472b0b9d67c208ec58e2", "body": {"id": "chatcmpl-9St6BgbfoaXiqBrIkEQVc168PcUhn", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib, marketed under the brand name Ayvakit, is a medication used primarily for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) that harbor a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It is also approved for use in advanced systemic mastocytosis, including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.\n\nHere are some key points about Avapritinib:\n\n1. **Mechanism of Action**: Avapritinib is a kinase inhibitor that specifically targets KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutations, which are commonly involved in the pathogenesis of GIST and systemic mastocytosis. It works by inhibiting the kinase activity, thereby blocking the proliferation and survival signals within the cancer cells.\n\n2. **Efficacy**: Clinical trials have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cefp7xmMxk41RyIQY3HZPFRA", "custom_id": "317_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9284b61c579048871b2283b0bc69a014", "body": {"id": "chatcmpl-9St6Bhk0a7Gk2v9zogjGNxOndYzuY", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib, marketed under the brand name Turalio, is a medication used primarily for the treatment of tenosynovial giant cell tumor (TGCT), a rare, non-malignant tumor that affects the synovium, bursae, and tendon sheaths. Here are key points about pexidartinib that you, as a physician, should be aware of:\n\n1. **Indications**: Pexidartinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.\n\n2. **Mechanism of Action**: Pexidartinib is a tyrosine kinase inhibitor that inhibits colony stimulating factor 1 receptor (CSF1R), which is a driver of TGCT. It also inhibits KIT and FLT3-ITD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8IvZTmhtgGYvzomgUYQQqsi3", "custom_id": "318_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f96e07d701ef59414ce9b5b0b5479f60", "body": {"id": "chatcmpl-9St6B84WsXRj6bvxyGWNoshfBzFSt", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib, marketed under the brand name Gavreto, is a targeted therapy used in oncology, particularly for the treatment of certain types of cancers driven by specific genetic alterations. Here are some key aspects of pralsetinib that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Pralsetinib is a tyrosine kinase inhibitor that specifically targets rearranged during transfection (RET) proto-oncogene. RET gene fusions and mutations are important drivers in various cancers, including non-small cell lung cancer (NSCLC) and thyroid cancer. By inhibiting RET signaling, pralsetinib can block tumor cell growth and survival.\n\n2. **Indications**:\n   - *Non-Small Cell Lung Cancer (NSCLC)*: Pralsetinib is approved for the treatment of adult patients with metastatic RET fusion-positive NSCLC.\n   - *Thyroid"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G505dT3btxrfHH54GQCaZBCt", "custom_id": "319_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f9cc25e087b7af7e667d0ba311d81caf", "body": {"id": "chatcmpl-9St6B38MHRByJWTkAKhfHsbA6aE5O", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin is a medication used in oncology, primarily for the treatment of certain types of cancer. Here are some key points that you, as a physician, should be aware of regarding Lurbinectedin:\n\n1. **Mechanism of Action**: Lurbinectedin works by binding to the minor groove of DNA, disrupting the function of oncogenic transcription factors and DNA repair machinery, which leads to inhibition of tumor growth. It acts somewhat similarly to trabectedin, another anticancer agent.\n\n2. **Indications**: As of my last update, Lurbinectedin has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy. This approval was based on the results of a clinical trial demonstrating its efficacy in this specific patient population.\n\n3. **Administration**: Lurbinectedin is administered via intravenous infusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NbjXQtIGORoB9sMVl38xl99Z", "custom_id": "320_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "965f098fe538776909a5bc9e8eb6be76", "body": {"id": "chatcmpl-9St6B50ZOMsTymWpdAK7mDifrsGoE", "object": "chat.completion", "created": 1716672011, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antibiotic and antiprotozoal medication that is commonly used to treat a variety of infections, including those caused by bacteria and protozoa. Here are some key points that you, as a physician, should know about metronidazole:\n\n1. **Mechanism of Action**: Metronidazole is effective by entering the microbial cells and interacting with their DNA. It causes loss of helical DNA structure and strand breakage, leading to inhibition of nucleic acid synthesis and bacterial cell death.\n\n2. **Spectrum of Activity**: It is particularly effective against anaerobic bacteria and protozoa. This includes organisms such as Bacteroides, Clostridium, Giardia lamblia, and Trichomonas vaginalis.\n\n3. **Indications**:\n   - **Anaerobic bacterial infections**: Such as intra-abdominal infections, skin infections, gynecologic infections, and others.\n   - **Protozoal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PrlsJPGkMZpQgqjpJkUF3Lic", "custom_id": "321_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74e7648bf1cbc8b61701cb08630dcbfc", "body": {"id": "chatcmpl-9St6CskxhbzUIrLZjN1ekypjJrVUS", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab, marketed under the brand name Danyelza, is a monoclonal antibody used in the treatment of certain types of cancer, specifically high-risk neuroblastoma in the bone or bone marrow that has not fully responded to initial treatment, or has relapsed or refractory after treatment. Here are key aspects you should know about Naxitamab:\n\n1. **Mechanism of Action**: Naxitamab targets the GD2 antigen, which is highly expressed on neuroblastoma cells. By binding to this antigen, Naxitamab helps direct the immune system to destroy the cancer cells.\n\n2. **Indications**:\n   - Naxitamab is approved for use in pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.\n   - It is typically used when other therapeutic options have failed, or the disease has progressed despite them.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qvCF1cTSVJiNzascKXwbTPxn", "custom_id": "322_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c5e49611170e7a7a804690e6b76f4f6a", "body": {"id": "chatcmpl-9St6CtTYc3s7DL6qavrRmjukYiJLs", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of tetracycline, an antibiotic used to treat a variety of bacterial infections. Here are key aspects to consider:\n\n1. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria, thus preventing bacterial growth. It binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.\n\n2. **Spectrum of Activity**: Tetracycline is a broad-spectrum antibiotic effective against a wide range of gram-positive and gram-negative bacteria. It is also effective against atypical organisms such as Chlamydia, Mycoplasma, and Rickettsia.\n\n3. **Indications**:\n   - **Respiratory infections** caused by susceptible strains of bacteria.\n   - **Skin infections**, including acne, which is often treated with lower doses over a longer period.\n   - **Urinary tract"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Na8K3w1JL6mdk0TJtc69tNNU", "custom_id": "323_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd96a77dcf6fa1bf47b774c72bc58eee", "body": {"id": "chatcmpl-9St6Cq5rgATrUPyA5kqvHrB5diY9d", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, commonly known as bismuth subcitrate, is a medication used primarily to treat and prevent gastrointestinal disorders. Here are important aspects you should be familiar with:\n\n### 1. **Indications**\n   - **Peptic Ulcer Disease**: It is used for the treatment of active peptic ulcer disease and for maintenance therapy after a peptic ulcer has healed.\n   - **Helicobacter pylori Eradication**: Often used in combination with antibiotics and a proton pump inhibitor as part of a quadruple therapy regimen for the eradication of Helicobacter pylori, which is implicated in the pathogenesis of gastric ulcers and some types of gastric cancer.\n\n### 2. **Mechanism of Action**\n   - The exact mechanism is not completely understood, but it is believed to work by:\n     - Coating ulcers and erosions, creating a protective layer against stomach acid and pepsin.\n     - Poss"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z7n3bxaeeOklTVWGMoLAhAqA", "custom_id": "324_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f33fac86222c05a7444e16f7612c3a5f", "body": {"id": "chatcmpl-9St6Czdo3orBgMj332lkqMXGOyjCT", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan (brand name: Welireg) is a medication approved by the U.S. Food and Drug Administration (FDA) in August 2021. It is primarily indicated for the treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. Here are some key points about Belzutifan that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Belzutifan is a hypoxia-inducible factor (HIF)-2\u03b1 inhibitor. By inhibiting HIF-2\u03b1, belzutifan reduces the expression of HIF target genes involved in processes like cell proliferation and angiogenesis, which are critical for cancer growth and survival.\n\n2. **Efficacy**: Clinical trials have demonstrated that belzut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_noz0oHK71TUfSp7JMIfRntqr", "custom_id": "325_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bbb5d498ff563b118182d507ade0e163", "body": {"id": "chatcmpl-9St6C27dZlFKHmpiOmhNaik94PTmn", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab is a bispecific antibody used in cancer treatment, specifically targeting the epidermal growth factor receptor (EGFR) and MET receptor tyrosine kinases. This dual targeting is designed to help in the treatment of cancers that exhibit alterations in these pathways. Here are some key aspects you should know about amivantamab:\n\n1. **Mechanism of Action**: Amivantamab functions by simultaneously binding to EGFR and MET receptors on the surface of cancer cells. This dual binding inhibits downstream signaling pathways that promote cancer cell growth and survival.\n\n2. **Indications**: As of the latest updates, amivantamab has been approved by the FDA for the treatment of adult patients with non-small cell lung cancer (NSCLC) that exhibits specific genetic mutations and has progressed after prior treatment. Specifically, it is indicated for NSCLC with EGFR exon 20 insertion mutations.\n\n3. **Administration**: Amivantamab is administered via intravenous infusion."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rgrto1jAH46QaJyV197mksUm", "custom_id": "326_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d086361136ccee5ef6261dcf8ac82e20", "body": {"id": "chatcmpl-9St6C2gmSDkiE3BwySvOlNqH1wsZa", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, available in both injectable and oral forms, is a chemotherapy medication primarily used to treat myelodysplastic syndromes (MDS) and some types of leukemia. As a physician, here are some key points you should know about the oral formulation of azacitidine:\n\n1. **Indications**: Oral azacitidine (Onureg\u00ae) is approved for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. This is a newer indication and utilizes azacitidine as a maintenance therapy.\n\n2. **Mechanism of Action**: Azacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA, which may result in the inhibition of protein synthesis and consequent cell death in abnormal hematopoietic cells in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6OaHkMHJRsOmLmJcWca6wcOf", "custom_id": "327_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "766409501147c165f5cf05fec5cda781", "body": {"id": "chatcmpl-9St6CXlwkQKI0ECSnnw8LdSyyJ6OM", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colchicine is a medication that has been used for many years to treat and prevent gout attacks. It is also used to treat familial Mediterranean fever (FMF), a rare genetic disorder. Here are several key points about colchicine that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Colchicine works by reducing inflammation through the inhibition of microtubule polymerization, which affects the function of neutrophils. This action helps to reduce the inflammation and pain associated with acute gout flares.\n\n2. **Indications**:\n   - **Gout**: Colchicine is effective for the prophylaxis and treatment of acute gout flares.\n   - **Familial Mediterranean Fever (FMF)**: It is used for the treatment of FMF, helping to prevent attacks of abdominal pain, chest pain, or joint pain.\n   - It is sometimes used off-label for other conditions involving inflammation and pain, such as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qOWvtVCSOevo5bREAx4kW0me", "custom_id": "328_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7690c68e280af61772b71c26d7337422", "body": {"id": "chatcmpl-9St6CpyKOdmbeFE4kDfKVlQYGAP6w", "object": "chat.completion", "created": 1716672012, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used in the treatment of certain types of cancer. It is specifically designed to target the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking PD-1 interactions, dostarlimab helps to restore the body's immune response against cancer cells.\n\nHere are several key points about dostarlimab that you, as a physician, might find important:\n\n1. **Indications**: Dostarlimab is approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Additionally, it has shown promising results in other dMMR cancers.\n\n2. **Mechanism of Action**: As a PD-1 blocking antibody, dostarlimab binds to the PD-1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wkIFhrkaG7VCpai4KR6dLI9H", "custom_id": "329_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "306b4a92a66a3809aed3d497a3645e8b", "body": {"id": "chatcmpl-9St6D1kB2Ru0aQ5IeiiTcynPkdTfs", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Serplulimab is an anti-PD-1 monoclonal antibody developed for cancer immunotherapy. PD-1 (Programmed Death-1) is a checkpoint protein on T cells, which, when activated, dampens the immune response. By inhibiting PD-1, serplulimab is designed to enhance the body's immune response against cancer cells.\n\nSerplulimab has been primarily studied in clinical trials for its efficacy and safety in treating various types of cancer, including non-small cell lung cancer (NSCLC) and possibly other solid tumors. The drug works similarly to other PD-1 inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo), which are more widely known and used.\n\nWhen considering serplulimab for your patients, it's important to review the most current clinical trial data and any regulatory approvals to understand its indications, effectiveness, side effects, and how"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_O2uynK7uDXmRxq8mG6uxJwer", "custom_id": "330_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "406407fd903cfef4522da9a52ed6d2ee", "body": {"id": "chatcmpl-9St6DnOVYmXhlddCW7TexmoK2pShf", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Sugemalimab is an investigational monoclonal antibody designed for cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking this pathway, Sugemalimab helps to restore the body's immune response against cancer cells.\n\n### Key Points for Physicians:\n1. **Mechanism of Action**:\n   - Sugemalimab acts as an immune checkpoint inhibitor, specifically targeting the PD-1 pathway. It binds to PD-1 receptors on T-cells and prevents their interaction with PD-L1 and PD-L2 on tumor cells, enhancing the immune system\u2019s response against the tumor.\n\n2. **Clinical Trials**:\n   - Sugemalimab has been evaluated in several clinical trials for its efficacy and safety in various types of cancer, including non-small cell lung cancer (NSCLC) and possibly other malignancies. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QXdmXBNXaTfBPEen4ggVU4kC", "custom_id": "331_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ebce40a4bd8def870d34d1de0e70daf5", "body": {"id": "chatcmpl-9St6DIUqK9AjOgmmxWRxXS59GTvGP", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus, also known as rapamycin, is a macrolide compound used primarily for its immunosuppressive properties, particularly in preventing organ transplant rejection. It is also used in a drug-coated stent to prevent restenosis in coronary arteries following balloon angioplasty. The protein-bound form of sirolimus, while not as commonly discussed as the free compound, involves sirolimus being bound to protein carriers, potentially altering its pharmacokinetics and pharmacodynamics.\n\nAs of the last update, there isn't a specific \"sirolimus protein-bound particles\" formulation approved for clinical use unlike, for example, albumin-bound paclitaxel (nab-paclitaxel). However, the concept of binding drugs to proteins (like albumin) is employed to improve the solubility, distribution, and half-life of drugs, which can allow for better targeting of tissues or reduced toxicity.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_M8mFntfyRlFYio7LzpTu2fEV", "custom_id": "332_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a3eaa13d254e8d035c80f4ad8b96453", "body": {"id": "chatcmpl-9St6DPjhrTiymbCyyvesdRJ3QVAJ4", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication primarily used for the treatment of human sleeping sickness (African trypanosomiasis) caused by the parasite Trypanosoma brucei, and for the treatment of onchocerciasis, or river blindness, caused by the nematode Onchocerca volvulus. Here are several key points about Suramin that you, as a physician, may find useful:\n\n1. **Mechanism of Action**:\n   - Suramin works by inhibiting enzymes that are essential for the energy metabolism of the parasites, thus leading to their death. It inhibits the activities of enzymes such as dihydrofolate reductase, DNA topoisomerases, and RNA polymerases in the parasites.\n\n2. **Usage and Administration**:\n   - For African trypanosomiasis, Suramin is used in the treatment of the early stage of the disease, particularly Trypanosoma brucei rhodesiense. It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ygrErCuhzaVmDlfdLrPpDEy5", "custom_id": "333_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "796c969246652a8695e6c5764c82bd54", "body": {"id": "chatcmpl-9St6DZCZJQo2NKPrhDeal0Ac1kW7k", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adagrasib (also known by its development code MRTX849) is a novel medication that targets cancer cells with specific genetic mutations. As of my last update, here are some key points that a physician should be aware of regarding Adagrasib:\n\n1. **Mechanism of Action**: Adagrasib is a small molecule that acts as a covalent inhibitor of KRAS G12C. The KRAS G12C mutation is present in a subset of non-small cell lung cancers (NSCLC) and other solid tumors. This drug binds irreversibly to the mutated protein, preventing it from signaling and thereby inhibiting tumor cell growth.\n\n2. **Indications**: Adagrasib is primarily investigated for use in patients with NSCLC who have the KRAS G12C mutation. Research is ongoing to determine its efficacy and safety in other cancers with the same mutation, such as colorectal cancer and pancreatic cancer.\n\n3. **Clinical Trials**: Ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ncMnxbQkMdpmF0qzmaHEr7Bq", "custom_id": "334_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb7ce6e7a1a283b44c4d22045d336a66", "body": {"id": "chatcmpl-9St6DfbVSUqvSaYVakAQJry0ABwEI", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp-tebn (brand name Kimmtrak) is a novel therapeutic option specifically designed for the treatment of uveal melanoma, a rare and aggressive form of melanoma that occurs in the eye. As of my last update, it is particularly significant as it represents the first therapy approved for metastatic uveal melanoma, indicating a major advancement in treatment for this condition.\n\n### Key Points about Tebentafusp:\n\n1. **Mechanism of Action**:\n   - Tebentafusp is a bispecific protein composed of a T-cell receptor (TCR) fused to an anti-CD3 immune-effector function. It specifically targets the gp100 peptide presented by HLA-A*02:01 on melanoma cells. The mechanism is designed to redirect T-cells to kill gp100-expressing cells, thus selectively targeting melanoma cells harboring this antigen.\n\n2. **Indications**:\n   - It is approved for the treatment of H"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bhXMwKLEYPDeISx6zgzQ5yKH", "custom_id": "335_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "be3bb01d3910f637e42383eccf466ac7", "body": {"id": "chatcmpl-9St6DqNYMIKIy8uxHpodNZRHe0IED", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a medication approved for the treatment of certain types of myelofibrosis (MF), a form of chronic leukemia that affects the bone marrow. It was approved by the U.S. Food and Drug Administration (FDA) in August 2019 for adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n### Key Points about Fedratinib:\n\n1. **Mechanism of Action**:\n   - Fedratinib is a kinase inhibitor that primarily targets Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). JAK2 is a key component in the signaling pathways that regulate blood cell production and inflammation. By inhibiting JAK2, fedratinib can help manage the overproduction of blood cells and reduce spleen size, a common symptom in myelofib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_aELjrmJ8KC92Ez1J40s03lTP", "custom_id": "336_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8dbaee70242d0c1137d010e75ee6cbe6", "body": {"id": "chatcmpl-9St6DPw47ZqUPbLJgB9xslCDPGomZ", "object": "chat.completion", "created": 1716672013, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab and hyaluronidase is a combination of drugs used in the treatment of certain types of breast cancer and gastric cancer. Here are some key points you, as a physician, should know:\n\n1. **Indications**: Trastuzumab and hyaluronidase is indicated for the treatment of HER2-positive breast cancer, which can be either early-stage or metastatic. It is also used in the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n2. **Mechanism of Action**: Trastuzumab is a monoclonal antibody that targets the HER2 receptor, a protein overexpressed in some types of breast and gastric cancers. By binding to the HER2 protein, trastuzumab inhibits the proliferation of cells that overexpress the receptor. Hyaluronidase is an enzyme that increases tissue permeability, facilitating the dispersion and absorption of trastuzumab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aLONvXLKGCbwqaxzujWAg3Tr", "custom_id": "337_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8446ff774caa06d937bcbde817b30f1c", "body": {"id": "chatcmpl-9St6E1nTYXF6H62RQgyJggDhh0HFw", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib is a medication used in the treatment of certain types of blood cancers, primarily B-cell malignancies. Here are key points that every physician should consider when dealing with zanubrutinib:\n\n1. **Mechanism of Action**: Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking BTK, which is a key molecule in the B-cell receptor signaling complex. This inhibition impairs B-cell development and function, which is crucial in the pathogenesis of various B-cell malignancies.\n\n2. **Indications**: As of the last update, zanubrutinib is approved for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is also used in the treatment of Waldenstr\u00f6m's macroglobulinemia and marginal zone lymphoma under certain conditions.\n\n3. **Efficacy**: Clinical trials have shown"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QOyVnqoozYcOcDwT4ofIkWQA", "custom_id": "338_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc87caf0663620aaf3c62c82f8445c11", "body": {"id": "chatcmpl-9St6EC3ViV5uKWrodVT2R10UsImTu", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furmonertinib (also known by its development code AST2818) is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Here are some key points that you, as a physician, might need to know about Furmonertinib:\n\n1. **Mechanism of Action**: Furmonertinib specifically targets and inhibits the activity of EGFR mutations, including T790M, a resistance mutation commonly seen in patients who have developed resistance to first- and second-generation EGFR inhibitors. By blocking EGFR signaling, the drug can inhibit the growth and survival of cancer cells.\n\n2. **Indications**: Currently, Furmonertinib is primarily indicated for the treatment of patients with non-small cell lung cancer who have specific EGFR mutations and may have developed resistance to earlier generations of EGFR inhibitors. Always"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ai3qdXkqgY0ZI4RkdzW3LJgG", "custom_id": "339_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "54005dd0b4cc6a6428adbdc816daf9ea", "body": {"id": "chatcmpl-9St6EQir4h4zUxCwZ3bmimWTMjhTr", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel, often abbreviated as cilta-cel, is a chimeric antigen receptor (CAR) T-cell therapy that has been developed for the treatment of certain types of multiple myeloma, a cancer of plasma cells. This therapy represents a significant advancement in the treatment of relapsed or refractory multiple myeloma. Here are some key points that you, as a physician, might find important:\n\n1. **Mechanism of Action**: Ciltacabtagene autoleucel is a CAR T-cell therapy that involves reprogramming the patient's T cells to include a new chimeric antigen receptor that targets B-cell maturation antigen (BCMA), a protein commonly expressed on the surface of myeloma cells. This allows the modified T cells to recognize and kill BCMA-expressing cells.\n\n2. **Indications**: As of the latest updates, cilta-cel is specifically approved for the treatment of adult patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_C3Y8RVrzYP8rYfWgk1dsV8XU", "custom_id": "340_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "51816dabfbe809f9be25413342643832", "body": {"id": "chatcmpl-9St6EGdLRcRRRixetcJFTuVJmL602", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a targeted therapy used in the treatment of chronic myeloid leukemia (CML), particularly for adult patients. It was approved by the U.S. Food and Drug Administration (FDA) in October 2021. Here are some important aspects of asciminib that you should be aware of as a physician:\n\n1. **Mechanism of Action:**\n   Asciminib is a first-in-class treatment that works differently from other tyrosine kinase inhibitors (TKIs) used for CML. It specifically targets the ABL myristoyl pocket (STAMP: Specific Targeting of ABL Myristoyl Pocket) of the BCR-ABL1 protein, which is a novel mechanism. This allosteric inhibition helps in overcoming resistance to other TKIs and can be effective in patients who have developed resistance to or are intolerant of other CML therapies.\n\n2. **Indications:**\n   - Asciminib is approved for use in adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9RS6hEMkO2dS5nXZD9SiN6ZM", "custom_id": "341_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec862663102b78dbe7a932e826fd4abd", "body": {"id": "chatcmpl-9St6EcM2r2A8nKOcs1HTBSjwUWkjP", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine (brand name Zynlonta) is an antibody-drug conjugate (ADC) specifically designed for the treatment of certain types of B-cell lymphomas. This drug represents a targeted therapy that combines a monoclonal antibody\u2014which binds to a specific target on cancer cells\u2014with a cytotoxic agent, allowing direct delivery of the anticancer drug to the tumor cells while sparing normal cells. Here are some important aspects to consider:\n\n### Mechanism of Action\nLoncastuximab tesirine targets the CD19 antigen, which is widely expressed across B-cell hematologic malignancies. The monoclonal antibody component of loncastuximab tesirine binds to CD19-expressing cells. Upon binding, the conjugate is internalized, and the cytotoxic agent (SG3199, a pyrrolobenzodiazepine dimer toxin) is released inside the cell. The toxin then binds to the minor groove of DNA,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XoXOhRguLa0BvIX6fJ2VhYmQ", "custom_id": "342_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f6bfbf24513e390c6c1c00ac31f39ab9", "body": {"id": "chatcmpl-9St6Ec8kgBhctjrS37nxA4pkHxupL", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat, marketed under the brand name Tazverik, is a medication used in the treatment of certain types of cancer. It is particularly indicated for:\n\n1. **Epithelioid Sarcoma**: Tazemetostat is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This approval by the U.S. Food and Drug Administration (FDA) was granted under the Accelerated Approval based on overall response rate and duration of response, with continued approval contingent upon verification in confirmatory trials.\n\n2. **Follicular Lymphoma**: It is also approved for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies. Additionally, it is approved for the treatment of adult patients with relapsed or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SNM0PfSC2v0U1WqOVWxnDEI8", "custom_id": "343_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f15b3a14e3f9d10acdfe9a5911f701c5", "body": {"id": "chatcmpl-9St6EmnThAvJqn5PmfOWr0AQUBXmy", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s essential to be informed about the latest advancements in cancer immunotherapy, including drugs like nivolumab and relatlimab. Here\u2019s a detailed overview of these medications:\n\n### Nivolumab\n**Brand Name:** Opdivo\n**Drug Class:** PD-1 (Programmed Death-1) inhibitor\n\n**Mechanism of Action:**  \nNivolumab is a monoclonal antibody that inhibits the PD-1 receptor on T cells. By blocking this receptor, nivolumab prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often overexpressed in cancer cells. This inhibition releases the PD-1 mediated immune response suppression, thereby enhancing the body\u2019s immune response against cancer cells.\n\n**Indications:**\nNivolumab is approved for various types of cancers, including but not limited to:\n- Metastatic melanoma\n- Non-small cell lung cancer (NS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kCXIPKU0QyQeeevGSh5wo9IE", "custom_id": "344_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e46e3fcd109ae012600d7eef2997cb6c", "body": {"id": "chatcmpl-9St6Eb972e1Pvx4fjNUqMwzE1TPYS", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Interferon alfa-2c is not a standard or widely recognized form of interferon used in clinical practice. You might be referring to Interferon alfa-2b or Interferon alfa-2a, both of which are well-established in medical use. Here\u2019s a brief overview of these two for clarity:\n\n1. **Interferon alfa-2a**: This is a recombinant type of interferon used primarily for the treatment of various forms of cancer, including hairy cell leukemia, chronic myeloid leukemia, and AIDS-related Kaposi's sarcoma. It is also used in some viral infections like chronic hepatitis C and hepatitis B.\n\n2. **Interferon alfa-2b**: Similarly, this interferon is used for the treatment of hairy cell leukemia, malignant melanoma, follicular lymphoma, and also in viral infections such as hepatitis B and C. It can be administered alone or in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_d8i8n11slcUkOh5s4QLaqNSJ", "custom_id": "345_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1c5c6c15811b209c3429855c84bf0127", "body": {"id": "chatcmpl-9St6Ey8CnoRWPkUcIXnvXzvUqEIet", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1, also known as Wellferon, is a type of interferon used in the treatment of various diseases, primarily those of viral and oncological nature. Interferons are proteins that are part of the immune response and have antiviral, antiproliferative, and immunomodulatory effects. Here are some key points you should be aware of:\n\n1. **Clinical Uses**: Interferon alfa-n1 has been used in the treatment of chronic hepatitis B and C, certain types of cancer such as hairy cell leukemia, and melanoma. It might also be used for other conditions as indicated by clinical guidelines.\n\n2. **Mechanism of Action**: Interferon alfa-n1 works by binding to specific receptors on the cell surface, which activates intracellular signal pathways that induce the expression of certain genes that inhibit viral replication, modulate the immune response, and inhibit cell proliferation.\n\n3. **Administration**: It is typically administered through intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fspYAjjPkIWZuCEFmQo5LK3E", "custom_id": "346_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43fca52493cdfad36e80eee6e27f64a8", "body": {"id": "chatcmpl-9St6EtUuY6LrRnQ8Pdk7FvQn4R7SR", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is an innovative monoclonal antibody designed for the treatment of certain types of cancer, specifically those expressing the HER2 protein. It is particularly utilized in cases where other treatments have not been effective. Here are key points about margetuximab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Margetuximab is a monoclonal antibody that targets the HER2/neu receptor, a protein overexpressed in some forms of cancer, including breast cancer. It is engineered to have an increased ability to recruit immune cells compared to trastuzumab, another HER2-targeting antibody, potentially improving its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).\n\n2. **Indications**: As of the last update, margetuximab is approved by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for the treatment of adult patients with metastatic HER"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_xsYL3DGVpVRj5D6GR5ChMZSS", "custom_id": "347_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c276257bda63946859ef767bbd96f2a", "body": {"id": "chatcmpl-9St6EUUc6PBB0HCwonteGJzPtgy5X", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib (brand name Lumakras) is an important medication that physicians, especially oncologists, should be familiar with. Here are key points about Sotorasib:\n\n1. **Mechanism of Action**: Sotorasib is a small molecule inhibitor of the KRAS G12C mutation. This mutation is present in a subset of cancers and has historically been considered \"undruggable.\" Sotorasib specifically and irreversibly binds to the mutated cysteine residue in KRAS G12C, preventing downstream signaling and thereby inhibiting cancer cell growth.\n\n2. **Indications**: As of my last update, Sotorasib has been approved by the FDA for the treatment of adults with non-small cell lung cancer (NSCLC) who have the KRAS G12C mutation and have received at least one prior systemic therapy. Research is ongoing to evaluate its effectiveness in other cancers with the KRAS G12C mutation.\n\n3. **Effic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_L0h3i9Z5EvcOTa7Vu75ULRwb", "custom_id": "348_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "420c94a5b3e9cfa75a8af25d76803dec", "body": {"id": "chatcmpl-9St6EW3Rhm2CmE4AtUdWGAifJg5DH", "object": "chat.completion", "created": 1716672014, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib, also known by its brand name Ukoniq, is a medication used in the treatment of certain types of cancer, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is important for physicians to be familiar with the following aspects of umbralisib:\n\n1. **Mechanism of Action**: Umbralisib is a dual inhibitor of PI3K-delta and CK1-epsilon. The PI3K-delta inhibition is thought to reduce the proliferation of malignant B-cells, while CK1-epsilon inhibition may help in controlling the tumor microenvironment.\n\n2. **Indications**:\n   - **Marginal Zone Lymphoma (MZL)**: Umbralisib is indicated for the treatment of adult patients with MZL who have received at least one prior anti-CD20-based regimen.\n   - **Follicular Lymphoma (FL)**: It is also approved for adult patients with FL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OwrJrv7X1zRx7V85oc0Nynzb", "custom_id": "349_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24cd3cdbb4dacf61f48ee2a8cbbe69f2", "body": {"id": "chatcmpl-9St6FaEMnBBP1rtn1KG0DG0BNKnXB", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sintilimab is an immune checkpoint inhibitor used in oncology for the treatment of various cancers. It is a type of monoclonal antibody that specifically targets and binds to the programmed cell death protein 1 (PD-1) receptor on the surface of T cells. By blocking this interaction, sintilimab helps in enhancing the body\u2019s immune response against cancer cells.\n\nHere are some key points you should know about Sintilimab:\n\n1. **Mechanism of Action**: Sintilimab inhibits the PD-1 immune checkpoint pathway, which is a mechanism that tumors use to evade the immune system. By blocking PD-1 interactions, it can promote an immune-mediated attack on cancer cells.\n\n2. **Indications**: Sintilimab is used for treating several types of cancers. It has been approved in China for conditions such as classical Hodgkin lymphoma and non-small cell lung cancer. The specific indications and approval status may vary by country,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_07p7lgZIArYQQqc4qN9gCp1W", "custom_id": "350_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aab697bb03c9c015ae58b3a930087587", "body": {"id": "chatcmpl-9St6FKdERvbAtHtNmedQZZ5U8RnTD", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirtobrutinib (also known by its developmental code LOXO-305) is a novel, highly selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). It is designed to bind to both the active and inactive conformations of BTK, which may help in overcoming resistance due to mutations in the BTK binding site that can develop with covalent BTK inhibitors. This drug represents a new option in the treatment of B-cell malignancies, particularly for patients who have developed resistance to or are intolerant of other BTK inhibitors.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Pirtobrutinib inhibits BTK by binding reversibly, which differs from other BTK inhibitors that bind covalently. This reversible mechanism allows it to remain effective against BTK with the C481 mutation, a common resistance mechanism in patients treated with irreversible BTK inhibitors.\n\n2."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cYQzCWg5exGMYSnUZ2hq6Yid", "custom_id": "351_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5dc6f79925e2f5f11ca46f849a4f8dae", "body": {"id": "chatcmpl-9St6FNC6IDC6p8cRiD93jqVYEUNRm", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimab is an immune checkpoint inhibitor specifically targeting the programmed cell death protein 1 (PD-1) receptor. It is a type of monoclonal antibody used in cancer immunotherapy. Here are some key points you should know about Toripalimab:\n\n1. **Mechanism of Action**: Toripalimab works by blocking the PD-1 receptor, a protein on T cells that normally helps keep these cells from attacking other cells in the body, including cancer cells. By inhibiting PD-1, Toripalimab boosts the immune response against cancer cells.\n\n2. **Indications**: As of my last update, Toripalimab has been investigated for use in various types of cancers, including melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, among others. The specific approvals and indications can vary by country, so it\u2019s important to check the local regulatory status.\n\n3. **Clinical Trials and Effic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_yRHTOMjWHVufPsKOgYcqaRdZ", "custom_id": "352_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e3be4debd52bdba5cb4139c10e71980c", "body": {"id": "chatcmpl-9St6FWq9pAdaqVpgpzJW93lt0J3xu", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab is a bispecific antibody that targets both BCMA (B-cell maturation antigen) and CD3, which are expressed on the surface of B cells and T cells, respectively. This drug is particularly relevant in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells.\n\nHere are several key points about teclistamab:\n\n1. **Mechanism of Action**: Teclistamab functions by bringing T cells in close proximity to myeloma cells by simultaneously binding to BCMA on the myeloma cells and CD3 on the T cells. This interaction promotes T-cell activation and the targeted killing of BCMA-expressing myeloma cells.\n\n2. **Clinical Trials and Efficacy**: Teclistamab has been studied in clinical trials, including the pivotal Phase 1/2 study (MajesTEC-1), which evaluated its safety and efficacy. Results from these studies have shown promising response rates in patients with relapsed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_IOw5tsW4Htg2ilZ5ddx55X8s", "custom_id": "353_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "056c258779ade17f5831d75e1acfd1a2", "body": {"id": "chatcmpl-9St6Ffz56YyKkfeECodZT8dwAl9Jo", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib (previously known as TAK-788) is an oral tyrosine kinase inhibitor specifically designed to target EGFR (epidermal growth factor receptor) Exon 20 insertion mutations. These mutations are a type of genetic alteration found in non-small cell lung cancer (NSCLC) and are associated with resistance to other EGFR-targeted therapies. Here are some key points about mobocertinib:\n\n1. **Approval**: Mobocertinib was approved by the U.S. Food and Drug Administration (FDA) in September 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR Exon 20 insertion mutations, as detected by an FDA-approved test, who have received previous cancer treatments.\n\n2. **Mechanism of Action**: Mobocertinib selectively inhibits cancer cells with EGFR Exon 20 insertion mutations. By targeting these specific mutations, mobocertinib can interfere with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vxVz804Xi1jhyiBewy95N0BX", "custom_id": "354_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "914bc173dbfe4680cdc292454c22ff79", "body": {"id": "chatcmpl-9St6FzFNqLBt1Z1aeDybOBevI8NSY", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin (brand name Tivdak) is a novel antibody-drug conjugate (ADC) used in oncology, specifically approved for the treatment of adult patients with recurrent or metastatic cervical cancer. Here are some key points about Tisotumab vedotin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Tisotumab vedotin is composed of a human antibody (tisotumab) linked to a cytotoxic agent (vedotin, a microtubule-disrupting agent monomethyl auristatin E [MMAE]). Tisotumab targets tissue factor, which is expressed on the surface of many cancer cells and is involved in tumor growth, angiogenesis, and metastasis. Once bound to tissue factor on the cancer cells, the ADC is internalized, and the cytotoxic agent is released inside the cancer cells to induce cell death.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CpVj7iMqrIwzGLpLgGts0xRB", "custom_id": "355_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "811f518c3adff2b8a5772eb0f6d993cd", "body": {"id": "chatcmpl-9St6FGqi94dZKGgZkKIPqzmWrwpQw", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide LAR (long-acting release) is a synthetic peptide analog of somatostatin, a naturally occurring inhibitory hormone which suppresses the secretion of several other hormones, such as growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Lanreotide, specifically, is used primarily in the management of acromegaly and in the treatment of symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).\n\n### Key Points for Physicians about Lanreotide LAR:\n\n1. **Indications**:\n   - **Acromegaly**: For the treatment of patients who have had an inadequate response to surgery and/or radiotherapy, or for whom these therapies are not appropriate. The goal is to reduce GH and IGF-1 levels.\n   - **Neuroendocrine Tumors**: Effective in controlling symptoms of carcinoid syndrome and for the treatment of Grade 1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BOTq8NT6ghQnhPxX9nOIOd0r", "custom_id": "356_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60dd109ea4dce8be5e996689c52ba4dc", "body": {"id": "chatcmpl-9St6FkzoJQgsOJ5tz5aZvuMeLZkvK", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, Pimitespib (also known by its development code TAS-116) is a selective small molecule inhibitor of heat shock protein 90 (HSP90), which is a molecular chaperone involved in the proper folding and functioning of various proteins, including many oncogenes and growth receptors. By inhibiting HSP90, Pimitespib disrupts these processes, potentially leading to the degradation of oncogenic proteins and inhibition of tumor growth.\n\nHere are some key points you might consider:\n\n1. **Mechanism of Action**: Pimitespib works by binding to the ATP-binding pocket of HSP90, thereby inhibiting its activity. This inhibition can lead to the degradation of client proteins that are crucial for tumor cell growth and survival.\n\n2. **Clinical Applications**: While still under investigation, Pimitespib has been primarily studied in the context of cancer treatment. It has been evaluated in clinical trials for various cancers, including gastrointestinal st"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3ZbHYAsdtb1ugcOIbUv3niAv", "custom_id": "357_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6ff6749e28278c90f615fca3516f1698", "body": {"id": "chatcmpl-9St6FqkLc2N6t4X6mH1qwgW29Bvqo", "object": "chat.completion", "created": 1716672015, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapy medication used primarily in the treatment of certain cancers, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. It is a compound that combines the properties of two other drugs: prednisolone, a corticosteroid, and chlorambucil, an alkylating agent. Here is some key information that you, as a physician, might find useful:\n\n### Mechanism of Action\nPrednimustine works by leveraging the anti-inflammatory and immunosuppressive effects of prednisolone along with the DNA-damaging ability of chlorambucil. This dual action helps in reducing the proliferation of malignant lymphocytes.\n\n### Indications\n- **Primary Use:** Treatment of chronic lymphocytic leukemia and non-Hodgkin\u2019s lymphoma.\n- It may also be considered in other lymphoid tissue cancers depending on the case and in combination with other therapies.\n\n### Dosage and Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Fv4dRXeafCJGO9P6H631y4Ot", "custom_id": "358_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "789706aa7e4d2c2143d61b07ecb8ac22", "body": {"id": "chatcmpl-9St6Ghixiq6134iNaggaYMQfM2KRX", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is a drug primarily used in the treatment of myeloproliferative disorders, particularly polycythemia vera and essential thrombocythemia. It is also used to manage myelofibrosis. Here are some important points to consider about pipobroman:\n\n1. **Mechanism of Action**: Pipobroman is an alkylating agent, though its exact mechanism of action in treating myeloproliferative disorders is not completely understood. It is thought to work by interfering with DNA replication, which reduces the proliferation of rapidly dividing hematopoietic cells.\n\n2. **Indications**: As mentioned, it is commonly used for polycythemia vera and essential thrombocythemia. It may be considered when other treatments are contraindicated or have failed.\n\n3. **Administration**: Pipobroman is administered orally. The dosage and treatment regimen depend on the condition being treated and the patient's response to therapy.\n\n4. **Side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KRbqePgbpLnL7tqTnyeTO8DH", "custom_id": "359_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "796bbf1d84d8ba95416a6e2cc625aa37", "body": {"id": "chatcmpl-9St6GMyzfKm8faUhg0lXENP3GoFwD", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin is a targeted anticancer medication used primarily for the treatment of certain types of non-Hodgkin lymphoma. Here are several key points about the drug that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Polatuzumab vedotin is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody linked to a cytotoxic agent, monomethyl auristatin E (MMAE). The antibody specifically binds to CD79b, a protein expressed on the surface of B cells. Upon binding, the conjugate is internalized and the cytotoxic agent is released inside the cell, leading to cell death.\n\n2. **Indications**: It is approved by the FDA for use in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T4rB2jQQiAE60Hn3xooAl4KG", "custom_id": "360_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec803841f78c46d720ec633afd0fd23f", "body": {"id": "chatcmpl-9St6GPNNgZIFIr4pY08egnhazDoeE", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine, also known as IMGN853, is an antibody-drug conjugate (ADC) that targets cancer cells by combining a monoclonal antibody specific for folate receptor alpha (FR\u03b1) with a cytotoxic compound (maytansinoid DM4). The drug is specifically designed to target and kill cancer cells that overexpress the folate receptor alpha, a condition often found in various types of cancer, including ovarian cancer.\n\nHere are some key points about Mirvetuximab soravtansine:\n\n1. **Mechanism of Action**: Mirvetuximab soravtansine consists of three parts: an anti-folate receptor alpha monoclonal antibody, a linker, and the cytotoxic agent DM4. The antibody binds to FR\u03b1-expressing cancer cells, and upon internalization, the linker is cleaved, releasing DM4 inside the cancer cells. DM4 inhibits tubulin polymerization, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uPtdZUtngAL6cek7uiAgWj7v", "custom_id": "361_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "51a62ccbaef84bfd6bc0e99d7f549668", "body": {"id": "chatcmpl-9St6GVAW9gZF7AZSdIl4yRrDicIBu", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab (brand name Lunsumio) is a bispecific antibody approved for the treatment of certain types of B-cell lymphomas. As a physician, here are key aspects you should know about this medication:\n\n1. **Mechanism of Action**:\n   Mosunetuzumab is designed to target both CD20 on B cells and CD3 on T cells. It brings these two cell types into close proximity, which enhances the immune response against malignant B cells. This mechanism is particularly innovative as it can engage and activate T cells to attack B cells, which is useful in treating diseases characterized by abnormal B cells like non-Hodgkin lymphoma.\n\n2. **Indications**:\n   In the United States, mosunetuzumab has been approved by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication may vary internationally, so it's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TGxxr0dL8QooNqnroe9c2czI", "custom_id": "362_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a35f4b116b83ccbf55c745f89e308e4", "body": {"id": "chatcmpl-9St6HPXyG0bqoc1t18Q34Lpts0Xul", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec, also known by the brand name Adstiladrin, is a gene therapy used for the treatment of certain types of bladder cancer. It was approved by the FDA in December 2022 for the treatment of adults with high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Here are some key points you should know about this treatment:\n\n1. **Mechanism of Action**: Nadofaragene firadenovec is an adenovirus vector-based gene therapy. It delivers a copy of the interferon alfa-2b gene directly into the bladder cells via intravesical administration. Once the gene is inside the cells, it is expressed and produces interferon alfa-2b, a protein known for its anti-tumor effects, including immune response modulation and inhibition of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3gXQLdNPjh6E9xXvJ5bzeyu6", "custom_id": "363_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9011d5a542d4ea77396d7ad4a868d938", "body": {"id": "chatcmpl-9St6GSkuCr2keD5gmmUmxKyAD3rFR", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Olutasidenib (brand name Rezlidhia) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) with a specific genetic mutation. Here are some key points you should know:\n\n1. **Indication and Usage**: Olutasidenib is specifically indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-1 (IDH1) mutation. The presence of IDH1 mutation should be confirmed using an FDA-approved test before starting treatment.\n\n2. **Mechanism of Action**: Olutasidenib is an IDH1 inhibitor. Mutations in IDH1 lead to abnormal accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which contributes to the pathogenesis of AML by blocking normal hematopoietic differentiation."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lo5j6L97zYDNGmMPrmWYF8d2", "custom_id": "364_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae0c34f48da5c874dfedd3b108d309aa", "body": {"id": "chatcmpl-9St6Gzm9gPkfuudQDkY3wEXyCai2b", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is an oral tyrosine kinase inhibitor that targets both HER1 (EGFR) and HER2 receptors. It is primarily used in the treatment of HER2-positive breast cancer. Here are some key points you should know about Pyrotinib:\n\n1. **Mechanism of Action**:\n   - Pyrotinib works by inhibiting the intracellular tyrosine kinase domains of the HER2 and EGFR (HER1) receptors. This inhibition blocks the phosphorylation and activation of downstream signaling pathways, which are involved in the proliferation and survival of tumor cells.\n\n2. **Indications**:\n   - Pyrotinib is mainly used for the treatment of HER2-positive breast cancer. It is often indicated for patients who have received prior treatments, including trastuzumab and chemotherapy.\n\n3. **Administration**:\n   - Pyrotinib is administered orally, which can be more convenient for patients compared to intravenous administration of other HER2-target"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TFe1htRwNuPqf1F7sUNLZ4Ql", "custom_id": "365_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a27e535ef70d1ab8f79358eb21285b3b", "body": {"id": "chatcmpl-9St6GcLeHXPHWdOgOFcjw0Ddjg9od", "object": "chat.completion", "created": 1716672016, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH), used primarily in the treatment of hormone-responsive cancers such as prostate cancer, in fertility treatments, and in endometriosis management. Here are some key points about Buserelin that you as a physician might find useful:\n\n### Mechanism of Action\nBuserelin works by initially increasing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a temporary surge in testosterone (in men) and estrogen (in women). With continuous administration, Buserelin desensitizes the GnRH receptors in the pituitary gland, leading to a decrease in LH and FSH secretion, subsequently reducing the levels of sex hormones.\n\n### Indications\n1. **Prostate Cancer**: Buserelin is used in the management of advanced prostate cancer. It helps in reducing the levels of testosterone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_4xgfvh9nR5NnujvJARQUHcad", "custom_id": "366_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bf8f9fbaa4661446e26ea2dd0ff7d033", "body": {"id": "chatcmpl-9St6HBP7sFRP27djYRHrT3FNPgrsw", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel (also known by its investigational name LN-145) is an advanced cell therapy product being developed by Iovance Biotherapeutics. It is primarily designed for the treatment of patients with metastatic melanoma, but it is also being investigated for use in other types of cancers such as cervical cancer. \n\n**Mechanism of Action:**\nLifileucel utilizes the tumor-infiltrating lymphocyte (TIL) technology. In this therapy, TILs are isolated from a patient's tumor tissue. These lymphocytes are naturally occurring immune cells that have infiltrated the tumor and are believed to be involved in combating the cancer. The isolated TILs are then expanded ex vivo (outside the body) to large numbers and subsequently infused back into the patient. Prior to reinfusion, the patient undergoes a lymphodepletion regimen, typically involving chemotherapy, to improve the effectiveness of the TILs.\n\n**Treatment Process:**\n1. **Tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_fxB733WwvNlDVaeoyAvyvq7j", "custom_id": "367_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46b4e38299939d1d3525a379beea8439", "body": {"id": "chatcmpl-9St6HVgPCBPntB6wjI0aePoga2UkG", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel, often referred to as tab-cel\u00ae, is an investigational off-the-shelf, allogeneic T-cell immunotherapy. It is designed for the treatment of diseases associated with the expression of Epstein-Barr virus (EBV) antigens. This includes conditions such as EBV-positive post-transplant lymphoproliferative disease (PTLD), particularly in patients who have received an organ transplant or a stem cell transplant and have not responded to standard therapies, such as rituximab or chemotherapy.\n\nHere are some key points about Tabelecleucel that you might find useful as a physician:\n\n1. **Mechanism of Action**: Tabelecleucel is composed of T-cells derived from the blood of healthy donors with prior immunity to EBV. These T-cells are selected and expanded to target and eliminate cells displaying EBV antigens, thus helping to manage or treat EBV-associated disorders.\n\n2. **Clinical Trials**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AOjYUdwtNtX17Q7dmWcVk8ir", "custom_id": "368_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "520991378009d3af9c9dea00fa7386a1", "body": {"id": "chatcmpl-9St6HiLQo99AvW7ifeNloPCLcktB1", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (abemaciclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points that physicians should be aware of:\n\n1. **Indications**: Verzenio is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients with disease progression following endocrine therapy.\n\n2. **Mechanism of Action**: Verzenio is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by selectively inhibiting CDK4 and CDK6, which are involved in the proliferation of cancer cells. By inhibiting these kinases, Verzenio can help to prevent the progression of the cell cycle from G1 to S phase, thus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MBDBHG3dMoIJgk5AeL2AMg5t", "custom_id": "369_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b092d3417c4cffd527c5d4542d6a155d", "body": {"id": "chatcmpl-9St6I77P38ftDtva9IB7kHhEtuoaT", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no widely recognized medical or pharmaceutical reference to \"Abatitor\" as a drug, medical condition, or medical technology. It is possible that the term could be a misspelling, a non-English term, a brand name not widely known, or a new development not yet widely recognized in the medical community.\n\nIf you could provide more context or details about where you encountered the term, I might be able to assist you better. Alternatively, you might want to consult the latest medical literature or a pharmaceutical database for more accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 115, "total_tokens": 156}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8yJiyCpGu7ZFzps7nCx3vl7j", "custom_id": "370_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52b285db808a155cd930a9ebb799bc43", "body": {"id": "chatcmpl-9St6HB2wGHZWLzIDcy1co3dNiFMVO", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a medication used in the treatment of certain hematological cancers, specifically adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Calquence is a Bruton\u2019s tyrosine kinase (BTK) inhibitor. It works by blocking BTK, which is a key molecule in the signaling pathway of B-cell development and function. Inhibiting BTK leads to the death of malignant B cells that overpopulate in these types of cancers.\n\n2. **Indications**:\n   - **Mantle Cell Lymphoma (MCL)**: Approved for the treatment of MCL in patients who have received at least one prior therapy.\n   - **Chronic Lymphocytic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_ATCabQOqKemIzJoDTVcLEY2y", "custom_id": "371_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9aa2d6342303c0e5294d817cd75a3884", "body": {"id": "chatcmpl-9St6HYJ5v0qCGGTVIZKfnElpf4SZ0", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacinomycin A, also known as Aclarubicin, is an anthracycline antibiotic that is used as a chemotherapeutic agent. It is structurally similar to other anthracyclines such as doxorubicin and daunorubicin. Here are some key points that you, as a physician, should know about Aclacin:\n\n1. **Mechanism of Action**: Aclacinomycin A acts primarily through intercalating DNA, which disrupts the replication and transcription processes. It also inhibits the enzyme topoisomerase II, leading to cytotoxicity and cell death. Its mechanism also involves the generation of free radicals that damage cellular components.\n\n2. **Indications**: Aclacin is used in the treatment of various types of cancer, including acute myeloid leukemia (AML), and has been used in treating other cancers like lymphomas and breast cancer. It is often used when other treatments have failed or when patients cannot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3asJx4S6n8ykapeJmIPbS1F4", "custom_id": "372_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e6ef29e9a50d1981ea1f456d278867fc", "body": {"id": "chatcmpl-9St6HLI4QN5trSHuMB4HICX08o5yL", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kadcyla (ado-trastuzumab emtansine) is a targeted therapy used in the treatment of HER2-positive breast cancer. It's important for physicians to be familiar with several key aspects of this medication, including its mechanism of action, indications, administration, side effects, and monitoring requirements. Here\u2019s a detailed overview:\n\n### Mechanism of Action\nKadcyla is a conjugate of the monoclonal antibody trastuzumab and the cytotoxic agent DM1 (derivative of maytansine). Trastuzumab binds to the HER2 receptor, a protein overexpressed on the surface of some cancer cells. After binding, the complex is internalized and the DM1 component is released, which inhibits microtubule assembly in the cell, leading to cell death.\n\n### Indications\nKadcyla is approved for use in patients with HER2-positive breast cancer:\n- As a single agent for the treatment of patients who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_J3SUzwlhhhFLnOis2Q4V0zXy", "custom_id": "373_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "37c98839036fcd4855f2c01cb05f0e74", "body": {"id": "chatcmpl-9St6HsRxGr1VX8FmJcjbTSPtbw9r4", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Afanix\" does not appear to be a recognized medication or treatment in standard medical resources. It\u2019s possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet well-documented in the mainstream medical databases.\n\nIf you meant a different medication, or if this is a new or experimental treatment, I recommend checking the latest medical literature, clinical trial registries, or pharmaceutical databases for the most current information. Additionally, consulting with pharmacists or other medical professionals might provide more insights.\n\nIf you have more context or a different spelling of the drug, I can help look up more specific information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 136, "total_tokens": 177}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_3EFROrkGfFst3qazLZ0tnx8T", "custom_id": "374_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "231b69a5768861c9c96ddd613bad362f", "body": {"id": "chatcmpl-9St6HPRApKK91btrBdYnBRo6iOsoF", "object": "chat.completion", "created": 1716672017, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Macrolin\" is not recognized as a standard medication or substance commonly used in medical practice, at least under this specific name. It's possible that \"Macrolin\" could be a brand name, a less common name for a drug, or a misspelling of a drug name. It's also possible that it could be a new drug that has been developed after my last update.\n\nIf \"Macrolin\" is meant to be a specific medication, it's important to verify the correct name and usage. Here are some steps you can take:\n\n1. **Verify the Name**: Double-check the spelling and see if it might be a brand name or a name used in specific regions or countries.\n\n2. **Drug Databases**: Use reliable pharmaceutical databases or resources such as the FDA website, the European Medicines Agency, or drug reference books like the British National Formulary (BNF) or the Merck Manuals.\n\n3. **Consult Pharmacists"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UovXgfPZzZjb5I16iIL9M5OG", "custom_id": "375_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e91b756d9063aea3294bcecfa884f59", "body": {"id": "chatcmpl-9St6IjyFfaYY4H5ACVZcMp9TOcyTt", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alecensa (alectinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC), specifically for cancers that are anaplastic lymphoma kinase (ALK)-positive. Here are some key points about Alecensa that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Alecensa is an ALK inhibitor. It works by targeting and inhibiting the activity of the ALK protein, which can be abnormally active in some types of cancer cells due to genetic mutations. By inhibiting this protein, Alecensa can help in controlling the growth of cancer cells.\n\n2. **Indications**: It is primarily indicated for the treatment of ALK-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n3. **Efficacy**: Clinical trials have shown that Alecensa is effective in shrinking tumors in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FikBKnNoPCmD2LwNePPIsOAu", "custom_id": "376_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4b44a5364e09914a9d8ce269a5e1ae9b", "body": {"id": "chatcmpl-9St6I0cWkzdn2dzqyzSNRwqZofwEq", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Campath (alemtuzumab) is a medication used primarily in the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). As a physician, here are several important aspects you should know about Campath:\n\n1. **Mechanism of Action**: Alemtuzumab is a monoclonal antibody that targets the CD52 antigen present on the surface of mature lymphocytes and other cells of the immune system. This binding leads to the lysis and depletion of B and T lymphocytes, which are believed to be involved in the pathogenesis of CLL and MS.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is approved for the treatment of B-cell CLL, particularly in patients who have been treated with alkylating agents and have failed fludarabine therapy.\n   - **Multiple Sclerosis (MS)**: Alemtuzumab is used in the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_57DjB5B0X5YHNYlLzg41luar", "custom_id": "377_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cfcc27e2787f4b7c01f249b12e6ef656", "body": {"id": "chatcmpl-9St6IpKr0WLyXOQYUcf0Wlm6cC7pD", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is primarily used in the management of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by a translocation involving the retinoic acid receptor alpha (RAR\u03b1) gene. Here are some essential points about ATRA that you, as a physician, should know:\n\n1. **Mechanism of Action**: ATRA works by binding to the altered retinoic acid receptor in APL cells, causing differentiation and maturation of these cells into normal functioning leukocytes. This differentiation helps in the control of leukemic proliferation.\n\n2. **Indications**: The primary indication for ATRA is in the treatment of acute promyelocytic leukemia. It is often used in combination with chemotherapy and has significantly improved prognosis in APL patients, turning what was once a highly fatal disease into a highly treatable one.\n\n3. **Administration and Dosage**: A"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SpiVwiInbAouxl3gLFPSbC8Q", "custom_id": "378_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a0deef10118253c0cc406e1e8f446ac", "body": {"id": "chatcmpl-9St6IbDyHNwLR9wrQizGcsBtFnLho", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen, also known by its generic name altretamine, is a chemotherapy medication used primarily to treat ovarian cancer, particularly in cases where other treatments have failed. Here are several key aspects that physicians should be aware of when considering or administering Hexalen:\n\n1. **Indications**: Hexalen is most commonly used in the treatment of persistent or recurrent ovarian cancer. It is often considered after other chemotherapy options have not been successful.\n\n2. **Mechanism of Action**: The exact mechanism by which altretamine exerts its antineoplastic effects is not fully understood. It is believed to function as an alkylating agent, causing damage to DNA in cancer cells, which inhibits their ability to proliferate.\n\n3. **Administration**: Altretamine is taken orally, and the dosage may vary depending on factors like the patient's size, the severity of the condition, and previous treatment responses. It is important to follow specific dosing protocols to maximize efficacy and minimize side effects.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kyGfXzx5jSM6QHj3C405Urjk", "custom_id": "379_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62bb14d434ac37c8ffb793706a242b54", "body": {"id": "chatcmpl-9St6IBAXfsmyNuksrXL0b5RQca1mu", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aminoblastin\" is not recognized as a standard or common medication or supplement in medical or pharmaceutical references. It's possible that it could be a brand name, a non-standard supplement, or a product not widely recognized in the medical community. It's also important to consider that names of drugs can vary by country and some might be known only in specific regions or under different regulatory statuses.\n\nIf \"Ainoblastin\" is a specific product you're encountering in your practice, I would recommend checking the following sources for more accurate and detailed information:\n\n1. **Local Drug and Pharmaceutical References:** Check national or regional pharmaceutical reference books or databases that are updated with locally available drugs.\n\n2. **Contact the Manufacturer:** If this product is made by a specific company, reaching out directly to them for detailed product information could be beneficial.\n\n3. **FDA or Equivalent Regulatory Body:** If you are practicing in the United States, the Food and Drug Administration (FDA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ptgd5drqElePBR2M57WyrVmF", "custom_id": "380_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "189568819cfdd056000bfd0ee959f135", "body": {"id": "chatcmpl-9St6InFBl82t12WdxcFY4PW9ymCut", "object": "chat.completion", "created": 1716672018, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calsed is a brand name for the drug tamsulosin, which is primarily used to treat symptoms of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. Here are some key points about tamsulosin that you should know as a physician:\n\n1. **Mechanism of Action**: Tamsulosin is an alpha-1 receptor antagonist. It works by selectively blocking alpha-1 adrenergic receptors in the prostate, bladder neck, and urethra, which helps to relax the smooth muscles in these areas and improve urine flow.\n\n2. **Indications**: It is typically prescribed to relieve symptoms of BPH such as difficulty in starting the flow of urine, weak stream, and the need to urinate frequently or urgently.\n\n3. **Dosage and Administration**: Tamsulosin is usually administered orally, often as a capsule. The common starting dose is 0.4 mg once daily, about 30 minutes after the same meal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fIgxj4vfHG5MFMNANeQ0dCmt", "custom_id": "381_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8db7670f1e9e2c0655504e2db880dcc8", "body": {"id": "chatcmpl-9St6JDPl3SqDLU8FDqblEMmXxk23Z", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Amekrin\" does not correspond to any widely recognized medication or treatment in standard medical references. It's possible that \"Amekrin\" might be a new drug, a drug available in specific regions, a brand name, or possibly a misspelling.\n\nIf \"Amekrin\" is a medication you've encountered through patients, pharmacies, or other sources, I would recommend checking the following:\n\n1. **Verify the Spelling**: Ensure that the name is spelled correctly. Sometimes similar drug names can lead to confusion.\n\n2. **Consult Up-to-Date Resources**: Use the most current pharmaceutical references, such as the Physicians' Desk Reference (PDR), or online databases like Drugs.com, Medscape, or the FDA's website for the most reliable and updated information.\n\n3. **Contact Pharmaceutical Representatives**: If this is a new drug on the market, representatives from the manufacturing company can provide detailed information about the drug, including its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_cntVasIsb0VWxGwhzWox1wZY", "custom_id": "382_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d6c78f814e9ee918b021db18315fb375", "body": {"id": "chatcmpl-9St6J9CR3QQhNHKznPcjUpDoLvyhZ", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altraz is a medication commonly known by its generic name, anastrozole. It belongs to a class of drugs known as aromatase inhibitors, which are typically used in the treatment of breast cancer. Here are some key points you should know about Altraz (anastrozole):\n\n1. **Indications**: Anastrozole is primarily used for the treatment of breast cancer in postmenopausal women. It is particularly effective for estrogen receptor-positive breast cancer. Anastrozole works by lowering estrogen levels in the body, which can slow or stop the growth of some breast cancers that need estrogen to grow.\n\n2. **Mechanism of Action**: Anastrozole inhibits the enzyme aromatase, which is involved in estrogen synthesis. By inhibiting this enzyme, anastrozole effectively reduces the production of estrogen in the body. This is particularly important in postmenopausal women, where most of the estrogen is produced by the conversion of androg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jgOIHQ29UESwQrx3McgcWJ2D", "custom_id": "383_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a35f1e35d1485820e2271f714cbcac2", "body": {"id": "chatcmpl-9St6JWw36AtB0WcmKnGogqmquOkij", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (apalutamide) is a medication used primarily in the treatment of prostate cancer. Here are some key points about the drug that you, as a physician, might find useful:\n\n1. **Indications**: Erleada is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is used in patients who are at high risk of developing metastatic disease.\n\n2. **Mechanism of Action**: Apalutamide is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its action, which prevents the androgen receptor signaling that prostate cancer cells require for growth.\n\n3. **Dosage and Administration**: The typical dosage of Erleada is 240 mg (four 60 mg tablets), taken orally once daily, with or without food. It is important to continue treatment until disease progression or unacceptable toxicity.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gfhte1lfhLrIV6fut7sTct2K", "custom_id": "384_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "614b2d9050c6ff0ad8e369696c177157", "body": {"id": "chatcmpl-9St6J9JEUby63pEOxYzXvjNKipDjT", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Aitan\" is not recognized as a common medical term, medication, or condition. It could be a misspelling, a brand name not widely recognized, or possibly a specific term used within a certain context or region.\n\nIf you meant \"Ativan\" (which is a brand name for lorazepam), it is a benzodiazepine used primarily for the treatment of anxiety disorders. It can also be used as a sedative before surgery or to treat seizure disorders and insomnia. \n\nIf \"Aitan\" refers to something else or if you have a specific context in which this term is used, please provide more details so I can assist you more accurately."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 150, "total_tokens": 190}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i8u7BoOQnl8KHSRgvkA40s4P", "custom_id": "385_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f3fb3ae256ec6671d5d6c7fe76229074", "body": {"id": "chatcmpl-9St6JO6BEnH1gdV2Yw5on1EGszwUc", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenol, also known as arsenic trioxide, is a medication used primarily in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia. It is very effective, particularly in patients with APL characterized by the t(15;17) translocation and the PML-RARA gene.\n\nHere are some key points about Arsenol that you as a physician might find important:\n\n1. **Mechanism of Action**:\n   - Arsenic trioxide induces apoptosis and partial differentiation of leukemic cells. It is believed to cause the degradation of the oncogenic fusion protein PML-RARA, which is crucial in the pathogenesis of APL.\n\n2. **Usage**:\n   - It is used primarily for the treatment of APL, especially in patients who have relapsed after retinoid and anthracycline chemotherapy, or in those who cannot tolerate these treatments.\n   - It can be used as a part of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_RCLZWovXmoYlm2JSoIXyVIZW", "custom_id": "386_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a4d119ae97022985b80e6b82de6a417b", "body": {"id": "chatcmpl-9St6JFdyQT2rn4A8JQc50SigMdahu", "object": "chat.completion", "created": 1716672019, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is a medication primarily used in the treatment of acute lymphoblastic leukemia (ALL). It is an enzyme that helps to deplete the amino acid asparagine, which leukemia cells, unlike normal cells, cannot synthesize on their own. Here are key points you should know about asparaginase:\n\n1. **Mechanism of Action:**\n   - Asparaginase hydrolyzes asparagine into aspartic acid and ammonia. This deprives the leukemia cells of the asparagine they require for protein synthesis and survival, leading to cell death.\n\n2. **Indications:**\n   - It is mainly used in the treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric patients. It is often a part of a multi-drug chemotherapy regimen.\n\n3. **Forms and Administration:**\n   - Asparaginase is available in several forms, including *Escherichia coli*-derived and Erwinia ch"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jEfX9iczUIWbmdERRmnv4Xp5", "custom_id": "387_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66fb14008025820b277a80f430ab597c", "body": {"id": "chatcmpl-9St6KrsT1ff9lO8YIshuw1nSmMlye", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase, also known as Erwinia L-asparaginase, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). It plays a critical role, especially in patients who have developed hypersensitivity to E. coli-derived asparaginase, another common enzyme used in ALL treatment. Here are some key points about Erwinase that you should be aware of:\n\n1. **Mechanism of Action**: Erwinase works by breaking down asparagine, an amino acid that is essential for the growth of leukemia cells but not required by normal cells. Cancer cells, lacking the ability to synthesize asparagine due to a deficiency in asparagine synthetase, rely on the circulating asparagine. By depleting asparagine, Erwinase starves the leukemia cells of a necessary nutrient, leading to cell death.\n\n2. **Indications**: It is specifically used for patients who are hypersensitive to asparagin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VMC9RvKgy472vIBEKsuOpca2", "custom_id": "388_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9fd7ce9cb4229d2f41e9948eaffd892b", "body": {"id": "chatcmpl-9St6KPzgY8UQyQ7aWUS2EbfPJr083", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is a monoclonal antibody used in cancer immunotherapy. It is specifically designed to bind to the protein PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells. PD-L1 normally acts as a \"brake\" to prevent the immune system from attacking cells indiscriminately. By blocking PD-L1, Tecentriq helps to release this brake, allowing the immune system to attack cancer cells more effectively.\n\nHere are some key points to consider when discussing Tecentriq with patients or colleagues:\n\n1. **Indications:**\n   - **Non-small cell lung cancer (NSCLC):** Tecentriq is approved for use in patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P37UEtiLc3MrEL2mj0LcX79i", "custom_id": "389_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9c6bbdd1f2c1e94a4897fed6537b7b06", "body": {"id": "chatcmpl-9St6KV5U9tBEOjnoTwdyUTl2mPRRe", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio, with the generic name avelumab, is a monoclonal antibody used primarily in the treatment of certain cancers. It works as a PD-L1 blocking antibody, part of a class of drugs known as immune checkpoint inhibitors that are designed to help the immune system recognize and attack cancer cells. Here are several key points about Bavencio that you, as a physician, might find useful:\n\n1. **Indications**: Bavencio is approved for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. It is also indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.\n\n2. **Mechanism of Action**: Bavencio binds to the programmed death lig"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_74l7vNK7S6m1L951lwrjxrCj", "custom_id": "390_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f8267a549369f567f4cc98bf5b5ce28f", "body": {"id": "chatcmpl-9St6KTSAL8ErjNom9bDs7hzSHYOp6", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a form of treatment classified under CAR T-cell therapies, specifically approved for use in certain types of non-Hodgkin lymphoma. Here are several key aspects you should be aware of:\n\n### 1. **Indications**\nYescarta is approved for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma, including:\n- Diffuse large B-cell lymphoma (DLBCL)\n- Primary mediastinal large B-cell lymphoma (PMBCL)\n- High grade B-cell lymphoma\n- DLBCL arising from follicular lymphoma\n\nIt is intended for use after two or more lines of systemic therapy have failed.\n\n### 2. **Mechanism of Action**\nYescarta is a chimeric antigen receptor (CAR) T-cell therapy. It involves modifying the patient's own T cells to include a CAR that targets the CD19 antigen,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PblMrnHZbrh2MTGJROowr2pk", "custom_id": "391_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "411182fda6d89a54b93023ede8a2ece5", "body": {"id": "chatcmpl-9St6K6fVOAjbVJNluPpJ6ufnJV4R7", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or medical condition known as \"Axishil.\" It's possible that there might be a typo or a misunderstanding regarding the name. Could you please double-check the information or provide additional context? If it's a new drug or a term from recent research, I would recommend consulting the latest medical literature or a trusted medical database like PubMed, or contacting pharmaceutical companies for the most current information. If you have other questions or need information on a different topic, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 105, "total_tokens": 146}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wqeQwziTI1dgWtqOpCcZEiCh", "custom_id": "392_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7800264d62573c95566dd0807dfb871", "body": {"id": "chatcmpl-9St6KL8TTi8TvTX1HvzNtxlqLZqq3", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, also known by its brand name Vidaza, is a chemotherapy drug primarily used in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic disorders characterized by ineffective production of blood cells. Azacitidine can help manage the symptoms of MDS and may also be used in the treatment of acute myeloid leukemia (AML) under certain circumstances.\n\nHere are some key points about azacitidine that you, as a physician, might find useful:\n\n### Mechanism of Action\nAzacitidine is a nucleoside metabolic inhibitor that incorporates into DNA and RNA. It works primarily by causing hypomethylation of DNA as well as direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The hypomethylation may restore normal function to genes that are critical for the differentiation and proliferation of hematopoietic cells.\n\n### Indications\n- **Myelodys"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ig9pa2FJVYWGSGOaN7F2pvAI", "custom_id": "393_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5a714b051c275452ad53445969f3dfa2", "body": {"id": "chatcmpl-9St6KKawVHW0Fili48dgpMVxda3R4", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "TheraCys is a brand of Bacillus Calmette-Gu\u00e9rin (BCG) vaccine that is primarily used in the treatment of bladder cancer, specifically for non-muscle invasive bladder cancer as an intravesical therapy. Here are several key points you should know about TheraCys:\n\n1. **Indications**: TheraCys is indicated for the intravesical treatment of carcinoma in situ (CIS) of the bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection. It is not used for vaccination against tuberculosis in the U.S.\n\n2. **Mechanism of Action**: TheraCys works by stimulating the immune system to attack bladder cancer cells. The exact mechanism is not fully understood, but it is believed that the instillation of BCG into the bladder leads to a local immune response that may target and destroy tumor cells.\n\n3. **Administration**: Thera"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x1PqozLfNx2j2E7vUwIHBTWE", "custom_id": "394_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cd093fd6fbdc2144805067860cd6a7c6", "body": {"id": "chatcmpl-9St6KJMso6WJ7S4LhuQWDtTG4vWx0", "object": "chat.completion", "created": 1716672020, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tarvacin does not appear to be a recognized medication or treatment in widespread clinical use. It's possible that it could be a drug under investigation, a lesser-known treatment, or perhaps even a brand name not commonly used. It's also possible there might be a spelling error or a different commonly used name for the drug.\n\nIf Tarvacin is related to a specific area of research or a new drug under development, it would be best to consult the latest clinical trials, pharmaceutical updates, or drug databases. Additionally, information could be sought from resources like PubMed or directly from pharmaceutical company disclosures for the most current data.\n\nIf you meant a different drug or have a specific context or disease in mind where Tarvacin is being mentioned, please provide more details so I can assist you more accurately!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 165, "total_tokens": 206}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Jk3Zx9ZpeAjKRrnfTa8n0Hbm", "custom_id": "395_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a0e6b4141ca5bedfd032ebbca92b246a", "body": {"id": "chatcmpl-9St6LVQYlQ2QPuntsKdHREnqz94Dy", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (belinostat) is a medication used in the treatment of cancer, specifically indicated for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. Here are some key points you should know about Beleodaq:\n\n1. **Mechanism of Action**: Beleodaq is a histone deacetylase (HDAC) inhibitor. It works by interfering with the function of histone deacetylases, which are enzymes that help control gene expression by modifying proteins called histones. This action can lead to the activation of cell death pathways in cancer cells.\n\n2. **Indication and Usage**: Beleodaq is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. This is a group of rare and aggressive non-Hodgkin lymphomas that arise from T-cells.\n\n3. **Administration**: Beleodaq is administered intravenously. The typical regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oFQLqCNgu2iYFnJMHVhkmFzI", "custom_id": "396_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98a652e970533e6e20dc3d23996fc443", "body": {"id": "chatcmpl-9St6LUJgqrDxnqTVV5LDaYXt00EHL", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no specific medical or pharmaceutical reference to \"Camptobell\" in standard resources or literature. It's possible that the term might be misspelled, a brand name not widely recognized, or a new development not yet widely documented. If it relates to a drug, condition, or medical concept, I recommend double-checking the spelling or providing more context. If it's a new drug or treatment, consulting the latest medical journals, official pharmaceutical releases, or drug regulatory websites might provide the necessary information. If you have more details or a different query, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 124, "total_tokens": 166}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_4wUFeEtfRqby4rhWwuL45bdH", "custom_id": "397_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "76f1e6aa81f2f4a055854ee39093d4a7", "body": {"id": "chatcmpl-9St6LVMuGEB1UlwNPOpcf74at9Sgm", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo (bendamustine hydrochloride) is a chemotherapeutic agent used primarily in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. It is a nitrogen mustard derivative that acts as an alkylating agent, causing cross-linking of DNA strands and subsequent cell death, particularly in rapidly dividing cells.\n\nHere are some key points you should know about Belrapzo:\n\n1. **Indications**: As mentioned, it is approved for use in patients with CLL and NHL. The specific indications and treatment regimens might vary, so it's important to refer to the most recent clinical guidelines or product monograph.\n\n2. **Administration**: Belrapzo is administered intravenously. The dosage and the schedule depend on the specific condition being treated, patient body surface"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z8Pk4pPwj2LHWsA5a72B4BXb", "custom_id": "398_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29cfa87da61c8d59ea06e44acede4b59", "body": {"id": "chatcmpl-9St6LRudK6hTcmiXmnl3JSS8JiqH5", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan, known in the U.S. as bevacizumab and marketed as Avastin, is a monoclonal antibody drug used primarily in the treatment of various cancers. It functions by inhibiting vascular endothelial growth factor A (VEGF-A), a chemical signal that stimulates angiogenesis, the growth of new blood vessels. By blocking this pathway, Altuzan helps to starve tumors of the necessary nutrients and oxygen supplied by blood vessels, thereby inhibiting their growth.\n\nHere are key points to consider when prescribing or discussing Altuzan:\n\n1. **Indications**: Bevacizumab is approved for use in the treatment of several types of cancer, including colorectal, lung, glioblastoma, kidney, and ovarian cancers. It is usually used in combination with other chemotherapy regimens.\n\n2. **Administration**: Altuzan is administered intravenously. The dosage and schedule depend on the type of cancer, the treatment regimen, and the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_abRc6gYC9cJcPbRJTe85CjXF", "custom_id": "399_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c37053122c3849f724fdcf4975168771", "body": {"id": "chatcmpl-9St6LI3yDWBeY0O5W4KTlSgiU0Cs4", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't any information available on a medication or substance called \"Bexgratin.\" It's possible that the name might be misspelled, or it could be a brand name that is not widely recognized or newly introduced. If you could provide more details or clarify, I can help look up relevant information. Alternatively, checking the most recent medical literature or a pharmaceutical database might provide the correct information. If you're referring to a specific drug for treatment or research purposes, verifying the spelling or checking for alternative names could also be helpful."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 114, "total_tokens": 156}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yKwokIfCjaLnxs0KFBjtsUhR", "custom_id": "400_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d8bd5910ae4a83791a18fcfd233dcbd", "body": {"id": "chatcmpl-9St6LE5SSqWw6lCfIXqc5ieYsuB1n", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide is a medication whose active ingredient is bicalutamide. It belongs to a class of drugs known as non-steroidal antiandrogens. Here are some key points about Calutide that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Bicalutamide acts primarily by binding to the androgen receptor and inhibiting its interaction with androgens (e.g., testosterone, dihydrotestosterone). This helps to block the growth of androgen-dependent prostate cancer cells.\n\n2. **Indications**: It is primarily used in the treatment of prostate cancer. Calutide is generally used in combination with a luteinizing hormone-releasing hormone (LHRH) analog (e.g., leuprolide or goserelin) in the treatment of advanced prostate cancer.\n\n3. **Dosage and Administration**: The typical dosage is 50 mg once daily in combination with an LHRH analog. Dosage may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2SxcpUKgJ8eyYZbbVw7iYHRD", "custom_id": "401_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "076274f7d5020195f04d319abb837683", "body": {"id": "chatcmpl-9St6LVjpKDE4Ok1KFkkFoSiDCd9SB", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication used in the treatment of cancer, specifically for patients with melanoma that has a certain type of abnormal \u201cBRAF\u201d gene, and whose cancer has metastasized (spread to other parts of the body) or cannot be removed by surgery. Mektovi is used in combination with another medication called encorafenib (Braftovi). Here are some important aspects you should know about Mektovi:\n\n1. **Mechanism of Action**: Mektovi is a kinase inhibitor that works by targeting and inhibiting MEK1 and MEK2, enzymes involved in the MAPK/ERK pathway, which helps regulate cell division and survival. Inhibition of MEK prevents the growth of cancer cells that have BRAF mutations.\n\n2. **Indications**: It is specifically indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tkzp2vxy3OBVc3WV5dMj1e8e", "custom_id": "402_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d043ed10e05bb6f982d0a29a60457c3d", "body": {"id": "chatcmpl-9St6LsdZMJEL0xdny38hBv5v2k8Kh", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenoxane, also known as bleomycin, is an antineoplastic (anti-cancer) medication used primarily in the treatment of various types of cancer, including Hodgkin\u2019s lymphoma, non-Hodgkin\u2019s lymphoma, testicular cancer, and certain types of cervical and ovarian cancer. Here are some important aspects of Blenoxane that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Bleomycin acts by binding to DNA, leading to DNA strand breaks and ultimately inhibiting DNA synthesis. Its cytotoxic effects are primarily due to the generation of free radicals and oxidative damage.\n\n2. **Administration**: Bleomycin can be administered intravenously, intramuscularly, or subcutaneously. It is also used in intrapleural administration for the management of malignant pleural effusions.\n\n3. **Dosage**: The dosage of bleomycin can vary based on the type of cancer, the stage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XH0eqEJ8Oh3qZIt30SjsHpbc", "custom_id": "403_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c211300676a37b0bcfd30a7fa6d1f9f6", "body": {"id": "chatcmpl-9St6L9rFXkkpL5zhQooInUbrbHco0", "object": "chat.completion", "created": 1716672021, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of certain types of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Blincyto:\n\n1. **Indications**:\n   - **B-cell precursor ALL**: Blincyto is approved for the treatment of B-cell precursor acute lymphoblastic leukemia that is refractory or in relapse.\n   - **MRD-positive ALL**: It is also indicated for the treatment of adults and children with B-cell precursor ALL who are in remission but still have minimal residual disease (MRD) of at least 0.1%.\n\n2. **Mechanism of Action**:\n   - Blincyto is a bispecific T-cell engager (BiTE) antibody construct. It binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. This dual"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fRNPRPAjtnbFy6XxAmdex9mw", "custom_id": "404_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3cbe7fd08de9b33162fcfa27db8b2435", "body": {"id": "chatcmpl-9St6MOGiTkrXNuYY1v0Vh9QDrZRR3", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last training data, there was no specific pharmaceutical or medical product named \"Biocure\" that is universally recognized or commonly referenced in medical literature. However, the name \"Biocure\" might be used as a brand name or a specific formulation by a company for a range of products, possibly including supplements, medical devices, or medications. Here\u2019s how you can approach this:\n\n1. **Verify the Product**: Check the exact nature of the product named \"Biocure.\" Determine whether it is a drug, a supplement, or another type of medical product.\n\n2. **Active Ingredients**: Look into the active ingredients of the product. This will help you understand its potential uses, mechanism of action, and the scientific evidence supporting its efficacy and safety.\n\n3. **Clinical Evidence**: Search for clinical trial data or studies published in reputable medical journals that evaluate the efficacy and safety of the product.\n\n4. **Regulatory Status**: Check with regulatory bodies like the FDA (U.S."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Hxx27CDVjMPBtgrtWSnJQzLx", "custom_id": "405_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3650ce663c20bc00a8534966eac6438c", "body": {"id": "chatcmpl-9St6MAB70x0qYYCq90VskefBWAC7e", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosulif (bosutinib) is a prescription medication used for the treatment of certain types of chronic myelogenous leukemia (CML). Here are some key points you should know about Bosulif:\n\n1. **Indications**: Bosulif is approved by the FDA for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant to or intolerant to prior therapy.\n\n2. **Mechanism of Action**: Bosutinib is a tyrosine kinase inhibitor (TKI). It specifically targets the Bcr-Abl kinase, which is produced by the Philadelphia chromosome abnormality in CML cells. Bosutinib inhibits this kinase, which is essential for the proliferation and survival of leukemic cells.\n\n3. **Dosage and Administration**: Bosutinib is typically administered orally. The dose may vary based on the phase of CML being treated, previous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ofxoPaDTpy0j3tpNGN7Ig1h5", "custom_id": "406_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de05a368ba07233677bce7eedb862cd9", "body": {"id": "chatcmpl-9St6MlUFton1WRLC03Z4GbL1yQUVD", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (brentuximab vedotin) is a targeted therapy used primarily to treat certain types of lymphoma. It is particularly effective for Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Here are some important aspects of Adcetris that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Adcetris is an antibody-drug conjugate that combines an anti-CD30 monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE). The antibody component binds to CD30, a protein expressed on the surface of some lymphoma cells, and delivers the cytotoxic agent directly to these cells, minimizing effects on normal cells.\n\n2. **Indications**:\n   - **Hodgkin lymphoma (HL)**: Adcetris is approved for the treatment of adult patients with classical HL at high risk of relapse or progression"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rksfHPiOwUB5bH8pLwUIWkh0", "custom_id": "407_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "429baa2fb2b84329658f626f0e7a6bd1", "body": {"id": "chatcmpl-9St6MZTIVZ4NS6himOOCCsqk2g186", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig, known generically as brigatinib, is a medication approved for the treatment of non-small cell lung cancer (NSCLC) specifically in patients who have anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC. Here are some key points you should know about Alunbrig:\n\n1. **Indications**: Alunbrig is indicated for patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. It is often used in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Brigatinib is a tyrosine kinase inhibitor that targets ALK, which is a key driver in some cancers, including NSCLC. By inhibiting ALK, brigatinib can block the proliferation and survival of cancer cells.\n\n3. **Administration**: Alunbrig is administered orally. The initial dosing often starts at a lower"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GbDPQkI2U6CTGsfijBGTZ2M8", "custom_id": "408_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce525b95d687baa5abe215f423dfd820", "body": {"id": "chatcmpl-9St6MevpMmbxZL56SEbFD5nE7J7Ku", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex (busulfan) is a chemotherapy medication used primarily as a conditioning agent before hematopoietic progenitor cell transplantation, commonly known as bone marrow transplantation. It is used to treat patients with chronic myelogenous leukemia (CML) and other hematological disorders. Understanding its pharmacology, dosing strategies, potential side effects, and monitoring requirements is essential for its effective and safe use.\n\n### Pharmacology\nBusulfan belongs to the class of alkylating agents, which work by cross-linking DNA, thus preventing cell division and leading to cell death. It is highly effective in suppressing bone marrow activity, which is why it is used before bone marrow transplants to eliminate diseased or cancerous marrow cells.\n\n### Formulations and Administration\nBusilvex is available in both intravenous (IV) formulations and oral formulations, although the IV form is commonly used in the pre-transplant setting to ensure controlled dosing and patient compliance. The dosing regimen can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Pap53txvghaKMkPaueoD2Nmq", "custom_id": "409_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "138f8d2342cb49b9c535256c42a8e401", "body": {"id": "chatcmpl-9St6MeQ6nmCeCerd03iM1FUuN0E9g", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a medication specifically named \"Cabapan\" recognized in standard medical references. It's possible that there might be a typo or a brand name that is not widely recognized or used in different regions. To provide accurate and helpful information, it would be useful to confirm the correct name of the medication. If you meant a different drug or if \"Cabapan\" is a new or less common medication, please provide more details or check the latest medical resources for updates. Always ensure to use reliable and updated medical databases or resources when looking up medication information. If you have more specific details or another query, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 132, "total_tokens": 172}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QvTOwRA8yrHjQ8PFvUTeRYdN", "custom_id": "410_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43af4da8178702c0f3b0d2844fe5b818", "body": {"id": "chatcmpl-9St6MtZzk5Ee2TOba3CCa1o3kKXwg", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx, known generically as cabozantinib, is a medication primarily used in the treatment of certain types of cancer. It is particularly indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) that has been previously treated with sorafenib, and previously treated radioactive iodine-refractory differentiated thyroid cancer. Here are some key points you should know about Cabometyx:\n\n1. **Mechanism of Action**: Cabozantinib is a tyrosine kinase inhibitor (TKI). It works by inhibiting multiple tyrosine kinases, including MET, VEGFRs, and AXL, which are involved in both normal cellular functions and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.\n\n2. **Dosage and Administration**: The dosage of Cabometyx may vary based on the specific condition being treated, the presence of certain side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_SUWq6vCLhOsTMwuPugqNtxIJ", "custom_id": "411_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9d06bcfa46428c8a56f2a6962233133", "body": {"id": "chatcmpl-9St6MVEiopiH47bIXRS8UACojm5vF", "object": "chat.completion", "created": 1716672022, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be informed about Asparlas (calaspargase pegol-mknl) as it is a key medication used in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points about Asparlas:\n\n1. **Indication and Usage**: Asparlas is approved by the FDA for use in pediatric and young adult patients aged 1 month to 21 years who have acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). It is typically used as a component of a multi-agent chemotherapeutic regimen.\n\n2. **Mechanism of Action**: Asparlas is a pegylated form of L-asparaginase, an enzyme that depletes the amino acid asparagine. Tumor cells, particularly those in ALL, require asparagine for protein synthesis and survival. By depleting asparagine, Asparlas starves the leukemia cells and inhibits their ability to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pH5cSGpLcP7zgtrXWaLDswso", "custom_id": "412_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "286554c94103f11d7cf0246a737bb009", "body": {"id": "chatcmpl-9St6N35R1fvu3eh9o0ZzwtEBUlqdB", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be some confusion or a typo in your question, as \"Cabita\" does not appear to be a recognized medication, treatment, or medical term. It is possible that you meant to inquire about a different drug or medical concept. If you could provide more specific information or clarify the name, I would be more than happy to help you with accurate and relevant information. Additionally, if \"Cabita\" refers to something specific to a certain region, additional context might be necessary to provide a proper response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 104, "total_tokens": 144}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_6jwL9oXXXxwTwmzUjMLFfH1T", "custom_id": "413_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d0c5c61ad78485ead81e27a2afb9f15a", "body": {"id": "chatcmpl-9St6NeAJRRLvDMbWIzXvrl9ERC0bh", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, \"Biocarb\" is not a commonly recognized drug or supplement name in standard medical references, which might suggest it is either a non-standard, brand, or informal name for a product. However, \"Biocarb\" could hypothetically refer to a medicinal product containing activated charcoal, which is often used to manage acute poisonings or overdoses. It acts by absorbing toxins in the gastrointestinal tract, thus preventing their absorption into the body.\n\nIf \"Biocarb\" refers to a product containing activated charcoal, here are some key points you might consider:\n\n1. **Indications**: Activated charcoal is used to treat poisoning or overdose from a range of drugs and chemicals that are adsorbed by charcoal. It is most effective when administered within an hour of ingestion.\n\n2. **Dosage and Administration**: The dosage can vary depending on the substance ingested and the age or weight of the patient. It is typically administered orally or through a nasogastric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jVVGbmk7BzbqXx9W5NK5gAu9", "custom_id": "414_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6ab17f31b007bd97aa74d9fa76714cbe", "body": {"id": "chatcmpl-9St6NO9VZ6mt76I3Tc26sqIV3cgdF", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilnat is not a widely recognized name in the pharmaceutical field, and there may be some confusion or a possible misspelling. It's important to ensure the correct drug name is being referred to, as accurate information is crucial in medical practice.\n\nHowever, if you meant \"Carfilzomib,\" which is sold under the brand name Kyprolis, here is an overview:\n\nCarfilzomib is a proteasome inhibitor used in the treatment of multiple myeloma. It works by inhibiting the proteasome, which is responsible for degrading unwanted proteins within cells. By inhibiting this process, carfilzomib causes an accumulation of proteins within the cells, leading to cell death, particularly in rapidly dividing cells like cancer cells.\n\n### Key Points about Carfilzomib:\n1. **Indications**: It is approved for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YKNX8W7g9zTb76eVlFSeXfxV", "custom_id": "415_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cded7853fb391e0ede3fe608b08db953", "body": {"id": "chatcmpl-9St6NNmCm5YazWET2gc9CJIrhxnmy", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Becenun (generic name: carmustine) is an anticancer medication used mainly in the treatment of various types of brain tumors, Hodgkin\u2019s lymphoma, multiple myeloma, and non-Hodgynecancer lymphoma. It belongs to a class of drugs known as alkylating agents, which work by binding to DNA and RNA, thus interfering with the growth and reproduction of cancer cells.\n\nHere are some key points you should know about carmustine:\n\n1. **Indications**: Carmustine is used for treating different types of brain tumors including gliomas, glioblastoma multiforme, medulloblastoma, astrocytoma, and ependymoma. It is also used for treating Hodgkin\u2019s disease and non-Hodgkin's lymphomas, multiple myeloma, and as a conditioning regimen prior to bone marrow transplantation.\n\n2. **Administration**: Carmustine can be administered intravenously or as an implant ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kvm1V03HpdQu93Cau0RNzPSo", "custom_id": "416_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dbef1ce9430e611a8e582ebd46d4b9ac", "body": {"id": "chatcmpl-9St6Nyt3QjHsG0c7DNR0bzePDiqwO", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Biodel Inc. was a biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's approach primarily aimed to improve the management of blood glucose levels in diabetic patients. One of their significant efforts was to develop rapid-acting insulin formulations that could begin to work faster than existing products, potentially improving postprandial glucose control.\n\nHowever, it is important to note that the status, products, and focus of the company may have changed since the last update. Therefore, if you are looking for the most current information about Biodel and its products, I would recommend checking the latest updates from reliable medical and financial resources or directly visiting the company's website. Additionally, it's crucial to review clinical trial results and FDA approvals to understand the efficacy and safety profile of any new or existing treatments developed by the company."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 176, "total_tokens": 216}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LfmrLTyyjSWLuyWXxW8T7Zzc", "custom_id": "417_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b5436f2bf1036b828482c30d7819429c", "body": {"id": "chatcmpl-9St6NnprPqs4H4DiYdRrnMFCQ3Z9j", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Recentin is not a widely recognized drug under that specific name in major pharmacological references, so it's important to verify the name and the context in which you heard it. The name might be a brand name or an alternative name not commonly used. If you mean \"Cediranib,\" which is known by the brand name Recentin in some contexts, it is a medication used in the treatment of cancer.\n\nCediranidb is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. It is primarily researched and used for treating various cancers, including metastatic renal cell carcinoma, and has been evaluated in clinical trials for glioblastoma and other types of cancer. It works by inhibiting angiogenesis (the growth of new blood vessels), which is a critical mechanism in the growth and metastasis of cancers.\n\nAs a physician, here are a few key points you might consider about Cediranib (Recentin):\n\n1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4KHGXqmLtpoyWdLLcyZlxMf6", "custom_id": "418_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ee3b5bf11fc789f508660048e584d4a", "body": {"id": "chatcmpl-9St6NTiewl6IQ2vycqiHyNeGUjOdz", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Libtayo (cemiplimab) is a prescription medication used to treat certain types of cancer. It is classified as an immune checkpoint inhibitor, specifically targeting the PD-1 (programmed death receptor-1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1, Libtayo can enhance the body's immune response against cancer cells.\n\nHere are several important aspects about Libtayothat you should be aware of as a physician:\n\n1. **Indications**: As of my last update, Libtayo is approved for use in patients with advanced forms of cutaneous squamous cell carcinoma (CSCC) that are not curable through surgery or radiation, metastatic basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or in patients who are intolerant to these therapies, and non-small cell lung cancer (NSCLC) with certain characteristics.\n\n2. **Mechanism of Action**: Libtayo is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ID34ADNSG85gPCnMXVsZvyRS", "custom_id": "419_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a9ea5550c2c99ebc19e1c3df6a7bfc3", "body": {"id": "chatcmpl-9St6NXPUIjZ97K2tb8Dxp2Wnpl96k", "object": "chat.completion", "created": 1716672023, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo in your query, as \"Lucicer\" does not correspond to any known medical term or product. If you meant to refer to a specific drug, condition, or medical concept, could you please clarify or correct the term? If you are referring to something else, such as a cultural, historical, or non-medical term, please provide more context so I can assist you appropriately."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 84, "total_tokens": 124}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CIIsg8t6iPZ8DsQ9w5WvIY1p", "custom_id": "420_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a5b33b2188a7a60c002c93c70f9c907a", "body": {"id": "chatcmpl-9St6OigokyPEXnaYZVsga7IFEwvko", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab, marketed under the brand name Erbitux among others, is a chimeric monoclonal antibody used to treat certain types of cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and proliferation of cancer cells. Here are some key points about cetuximab that you should know as a physician:\n\n1. **Indications**: Cetuximab is primarily used for the treatment of head and neck cancer and colorectal cancer. In head and neck cancer, it is used for squamous cell carcinoma, typically in combination with radiation therapy or other chemotherapeutic agents. In colorectal cancer, it is used in cases where the cancer is metastatic and expresses EGFR, and does not have mutations in the KRAS gene that render EGFR inhibitors ineffective.\n\n2. **Mechanism of Action**: Cetuximab binds to the extracellular domain of the EGFR, preventing the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_f93orO63yGCyvcvZlKYgvozr", "custom_id": "421_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "940320f3e11a837351f2456f7f8b1f49", "body": {"id": "chatcmpl-9St6O0lwBRBrVBQ5M4fCiOHd3t0Iy", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a medication specifically named \"Epidaza\" widely recognized in standard pharmaceutical references. It's possible that there might be a typo or a brand name that is less commonly known or used in a specific region or country.\n\nIf you meant \"Vidaza\" (azacitidine), this is a medication used mainly for the treatment of myelodysplastic syndrome (MDS), a group of disorders caused by poorly formed or dysfunctional blood cells. It is also used in the treatment of acute myeloid leukemia (AML). Azacitidine is a nucleoside metabolic inhibitor that works by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The hypomethylation may restore normal function to genes that are critical for the differentiation and proliferation of bone marrow cells.\n\nIf \"Epidaza\" is a new drug or a drug used in specific regions, I recommend checking the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xmGNWo7Sc5a2o3J8vALiYQP8", "custom_id": "422_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "168a8d79f6c1a01827ae588f96d24fe0", "body": {"id": "chatcmpl-9St6O99TnEC3lHT0BKWn7AF20u6GQ", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is a chemotherapy drug used primarily to treat various types of cancer, including Hodgkin\u2019s lymphoma, non-Hodgkin\u2019s lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulinemia. It belongs to a class of drugs known as alkylating agents, which work by binding to DNA and preventing the cancer cells from dividing and growing.\n\nHere are some key points you should know about chlorambucil:\n\n1. **Indications**: As mentioned, chlorambucil is primarily used for treating certain blood cancers. It may be used alone or in combination with other therapies.\n\n2. **Mechanism of Action**: Chlorambucil acts by causing cross-linking of DNA, leading to the interruption of DNA replication and ultimately cell death. This is effective in rapidly dividing cells, particularly malignant cells.\n\n3. **Administration**: Chlorambucil is typically administered orally in the form of tablets. The dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_halYWOATwqUTCkUI4NhR0ADr", "custom_id": "423_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73bd509aab802e7529fc3d41ca06df8a", "body": {"id": "chatcmpl-9St6OBURXnKCtI0q1LBpxJcHhnNsZ", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiplatin is a brand name for cisplatin, which is a chemotherapy medication used to treat various types of cancers. Here are some key points you should know about cisplatin (Abiplatin):\n\n### Mechanism of Action\nCisplatin works by interfering with the DNA replication process in cancer cells. It forms cross-links within and between DNA strands, which prevents the cancer cells from dividing and thus induces cell death.\n\n### Indications\nCisplatin is used to treat a variety of cancers including:\n- Testicular cancer\n- Ovarian cancer\n- Bladder cancer\n- Cervical cancer\n- Lung cancer, particularly small cell lung cancer\n- Head and neck cancers\n\n### Administration\nCisplatin is typically administered intravenously. The dosage and frequency depend on the type of cancer being treated, the stage of the cancer, the patient's weight and renal function, and other health considerations.\n\n### Side Effects\nCisplatin has several"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_A3tuGPGeHWngmJFoqckxDtw8", "custom_id": "424_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "44955df42945a8290dc3e6ab8aa9d08f", "body": {"id": "chatcmpl-9St6Oh2MVIPKUyziohQoVuIFyPS16", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin is the trade name for cladribine, a chemotherapy medication used primarily to treat hairy cell leukemia and other cancers. It is also used for treating multiple sclerosis in some cases. Here are some important aspects you should know about Leustatin:\n\n1. **Mechanism of Action**: Cladribine works by interfering with the DNA synthesis in cells, leading to cell death. It is especially effective against cells that are rapidly dividing, such as cancer cells. Cladribine is cytotoxic to both dividing and non-dividing lymphocytes, making it effective in conditions with lymphocyte involvement.\n\n2. **Indications**: The primary indication for Leustatin is the treatment of hairy cell leukemia. It may also be used off-label for other leukemias and lymphomas, and in treating multiple sclerosis (MS), particularly for reducing neurological disability and/or the frequency of clinical relapses.\n\n3. **Administration**: Cladribine can be administered intravenously or subcutaneously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h90W2BHGszwOfXTmV9oCqnm1", "custom_id": "425_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd2651ecd2678bf745d761123eb36cf7", "body": {"id": "chatcmpl-9St6OnH9QzUWrvGYYnm69oDVbunrf", "object": "chat.completion", "created": 1716672024, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biaxin, known generically as clarithromycin, is an antibiotic that belongs to a class of medications known as macrolides. It is commonly used to treat various bacterial infections including respiratory tract infections, skin infections, and Helicobacter pylori infections, which are associated with stomach ulcers. Here are some important aspects about Biaxin that you, as a physician, might find useful:\n\n### Mechanism of Action\nClarithromycin works by inhibiting protein synthesis in bacteria, thereby stopping bacterial growth. It binds to the 50S ribosomal subunit, blocking the transpeptidation or translocation reactions, leading to bacterial cell death.\n\n### Indications\n- **Respiratory infections** such as bronchitis, pneumonia, and sinusitis caused by susceptible strains of bacteria.\n- **Skin and soft tissue infections** caused by Staphylococcus aureus, or Streptococcus pyogenes.\n- **Helicobacter"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_npQTXmQk0KZJto6nUXCjEGH6", "custom_id": "426_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a3467998a70fc0083944bf58fa4929f", "body": {"id": "chatcmpl-9St6PnkitZ4SpwXcNRPjkW6HHB2BP", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clolar (clofarabine) is a chemotherapy medication primarily used in the treatment of certain pediatric cancers. It was specifically designed to treat pediatric patients with acute lymphoblastic leukemia (ALL) who have not responded to or have relapsed after receiving at least two prior regimens of therapy. Here are some key points you should know about Clolar:\n\n1. **Indications and Use**: Clolar is approved by the FDA for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens. Its efficacy in older patients or in other types of leukemia is not well-established.\n\n2. **Mechanism of Action**: Clofarabine is a nucleoside analog. It integrates into DNA and RNA, which disrupts the processes necessary for DNA replication and repair, and RNA transcription. This leads to apoptosis (cell death) in cancer cells.\n\n3. **Administration**: Clolar is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LTprYhxhJZQkCe8ivLeZIUE6", "custom_id": "427_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de1d43cca7eb4470df9e8a80a40fa288", "body": {"id": "chatcmpl-9St6PSk9iPC2TFAC6sAhz6FydkpNo", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (cobimetinib) is a medication used in the treatment of cancer, specifically for melanoma that cannot be removed by surgery or is metastatic. It is a kinase inhibitor that works by interfering with specific enzymes, known as kinases, which are necessary for the growth of cancer cells.\n\nHere are some key points about Cotellic:\n\n1. **Indications**: Cotellic is approved for use in combination with vemurafenib, another medication, for the treatment of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. It is important to confirm the presence of BRAF V600E or V600K mutation in patients before starting treatment.\n\n2. **Mechanism of Action**: Cobimetinib specifically inhibits MEK1 and MEK2, which are part of the MAPK pathway. This pathway is often activated in cells with a BRAF mutation. By inhibiting MEK, cobimet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3P60VTNC4NUUovn0yRADR27R", "custom_id": "428_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5aa5c90e93bb7a41f0b08b507aba58f3", "body": {"id": "chatcmpl-9St6PeTpL466NJdqJe2En06uSPamK", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aliqopa (copanlisib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points to consider when prescribing or discussing Aliqopa with your patients:\n\n1. **Indications**: Aliqopa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The approval is under the FDA\u2019s accelerated approval program based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\n\n2. **Mechanism of Action**: Aliqopa is a kinase inhibitor that primarily targets phosphoinositide 3-kinase (PI3K) with high selectivity for the PI3K-p110\u03b1 and PI3K-p110\u03b4 isoforms found in tumor cells. By inhibiting these pathways, Aliqopa can induce apoptosis and inhibit proliferation in cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ov33xOcMVTHq8gPTjX42EpmS", "custom_id": "429_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7660426619c0707af1b4f40964855c80", "body": {"id": "chatcmpl-9St6P1IoZhy1znJ69qedkRep40dQf", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizalk is the brand name for crizotinib, which is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points that you, as a physician, should be aware of regarding Crizalk:\n\n1. **Mechanism of Action**: Crizalk (crizotinib) is an oral small-molecule inhibitor of the anaplastic lymphoma kinase (ALK) enzyme. ALK gene rearrangements can lead to the expression of oncogenic ALK fusion proteins. By inhibiting ALK, crizotinib can block signaling in a number of pathways thought to be critical for the growth and survival of tumor cells.\n\n2. **Indications**: Crizotinib is specifically indicated for the treatment of patients with locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test. This selectivity is crucial because only patients with ALK-positive NSCL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yp1kmJ05RBWYVHU3ktIY4C7p", "custom_id": "430_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "96574bf1395a3bcda5b643214c76a623", "body": {"id": "chatcmpl-9St6PkZ1s9jk2nIY1TCMGEstkvuhS", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no widely recognized medication or compound specifically called \"Alkyloxan\" in standard medical databases or resources such as the World Health Organization, U.S. Food and Drug Administration, or European Medicines Agency.\n\nIt's possible that the name might be a misspelling, a non-standard name, or a brand name not widely recognized. It could also be a newly developed drug or compound that has come into use or discussion after my last update.\n\nIf you meant a different drug, or if you have more specific details or a slightly different spelling, I could try to provide more accurate information. Otherwise, I recommend consulting the latest medical literature or a pharmaceutical database for the most up-to-date and detailed information. Additionally, discussing with pharmacological experts or checking with regulatory bodies may also provide the needed information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 173, "total_tokens": 215}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_MElwneSr8rJv69TUusti16rK", "custom_id": "431_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ca76510dbae56732259e7e029927db6", "body": {"id": "chatcmpl-9St6P2sNlRyjwkaMMjbD4NhsNxaLa", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to be well-informed about any medication you prescribe, including Androcur, which is the trade name for cyproterone acetate. Here\u2019s some key information about Androcur:\n\n### Pharmacology\n- **Active Ingredient**: Cyproterone acetate\n- **Classification**: It is classified as an antiandrogen and progestin. It has both antiandrogenic and progestogenic properties.\n- **Mechanism of Action**: Cyproterone acts by blocking the action of androgens (male hormones) at the androgen receptor and also reduces androgen production. This dual action makes it effective in conditions where androgen suppression is desirable.\n\n### Indications\n- **Hypersexuality and Sexual Deviation in Men**: It has been used to reduce sexual drive in cases of severe hypersexuality and sexual deviations.\n- **Prostate Cancer**: It can be used to treat metastatic prostate cancer.\n- **Androgen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hITTetuDefqz1xkwfKx9npGZ", "custom_id": "432_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7cc570bd3f985825f402c978a8fbc770", "body": {"id": "chatcmpl-9St6PfJudah4qH2LBsqIT5RKUDgnt", "object": "chat.completion", "created": 1716672025, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Alcysten\" does not appear to be a recognized drug or medication in standard pharmaceutical or medical resources. It's possible that the name might be misspelled, or it could be a brand name or a product not widely recognized or available. If you could provide more details or clarify the name, I would be better able to assist you.\n\nIf you are referring to a specific treatment or supplement that is new or not widely known, I recommend checking the most current medical literature, drug databases, or contacting pharmaceutical manufacturers for the most accurate and up-to-date information. Always ensure that any medication or treatment used is approved by relevant authorities like the FDA or equivalent in your country and is appropriate for your patients' specific medical conditions."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 158, "total_tokens": 200}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bdGCSyqXqOGZXGnabcUmDarS", "custom_id": "433_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0f42ad679aeb1875c840632b1ac77d17", "body": {"id": "chatcmpl-9St6QYTY8xSBkofTNWYuUX7pvb19L", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos (liposomal daunorubicin and cytarabine), also known by its generic name CPX-351, is a chemotherapy medication used primarily in the treatment of certain types of acute myeloid leukemia (AML). It is specifically indicated for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Here are some key aspects you should know about Vyxeos:\n\n1. **Mechanism of Action**:\n   Vyxeos combines two chemotherapeutic agents, daunorubicin and cytarabine, in a fixed molar ratio within liposomal nanoparticles. This unique formulation is designed to deliver these drugs directly to leukemic cells while limiting their release in the bloodstream, potentially reducing systemic toxicity and improving anti-leukemic activity.\n\n2. **Administration**:\n   Vyxeos is administered intravenously. The dosage and schedule may depend on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Sf0YePnghE2VvABzU514kEUp", "custom_id": "434_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5da1d7a7251943fffa9a3a8330053e30", "body": {"id": "chatcmpl-9St6QSQkrYycV3ZbkSV5MDZDixLPS", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Rafinlar\" does not appear to be a recognized medication or substance. It's possible that there might be a typo or confusion with the name. However, if you are referring to \"Dabrafenib\" which is marketed under the brand name Tafinlar, it is a medication used in the treatment of certain types of cancer.\n\nHere\u2019s an overview of Tafinlar (Dabrafenib):\n\n### 1. **Indications**\n   - Tafinlar is primarily used for the treatment of melanoma that cannot be removed by surgery or that has metastasized, particularly in cases where the cancer cells exhibit a mutation in the BRAF gene (BRAF V600E mutation).\n   - It is also indicated for use in combination with another medication, trametinib, for the treatment of non-small cell lung cancer (NSCLC) with the same BRAF V600E mutation and for certain"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_5GUN6qvPYcpM5nAaq3RFTyuE", "custom_id": "435_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d60c9b67fdf455ad731c568fce41314", "body": {"id": "chatcmpl-9St6QkNHxIZyCeHi1RaKlwZZvhOpa", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Bazipar\" doesn't correspond to any widely recognized medication or treatment in standard medical resources or databases. It's possible that it might be a new development, a lesser-known drug, a brand name not used globally, or potentially a misspelling.\n\nTo ensure you receive accurate and reliable information, you might want to check the following:\n\n1. **Verify the Spelling**: Double-check the spelling or consider alternative spellings that might correspond to a known drug or treatment.\n   \n2. **Consult Up-to-date Resources**: Access the latest medical databases, journals, or pharmaceutical registries that might have information on new or emerging treatments.\n\n3. **Contact a Pharmacy**: Pharmacists often have updated information on new drugs, including trade names and their medical uses.\n\n4. **Industry Updates**: If Bazipar is a brand-new drug on the market, information might be found through pharmaceutical industry news or updates from drug approval agencies like the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_erIKtYgcMX4eHu9a68CpMROK", "custom_id": "436_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a75655bfa00cf339755a8075cb978bd", "body": {"id": "chatcmpl-9St6QwzyyBLrqnQ5vJZuBqsMY1Y0I", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vizimpro (dacomitinib) is a kinase inhibitor specifically designed for the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some important points you should know about Vizimpro:\n\n1. **Indication**: Vizimpro is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Vizimpro is an oral tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It irreversibly binds to and inhibits EGFR, including the mutations involved in NSCLC. This inhibition blocks signal transduction pathways implicated in the proliferation and survival of cancer cells.\n\n3. **Administration**: Vizimpro is administered orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WON0IB5aka36IbB7fVxGr4qv", "custom_id": "437_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "39a3919d5e699c5bb8b8069b1b1995cf", "body": {"id": "chatcmpl-9St6QMUi9LzDKZaBRBkPZKQyVFQCI", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen, known generically as dactinomycin, is a chemotherapy medication used in the treatment of various types of cancer. Here\u2019s a comprehensive overview that could be useful for a physician:\n\n### Mechanism of Action\nDactinomycin binds to DNA and inhibits RNA synthesis, which disrupts the growth of cancer cells. It intercalates between guanine-cytosine base pairs, preventing the normal function of RNA polymerase and thus blocking RNA synthesis.\n\n### Indications\nCosmegen is approved for use in the treatment of:\n- Wilms\u2019 tumor\n- Rhabdomyosarcoma\n- Ewing's sarcoma\n- Metastatic non-seminomatous testicular cancer\n- Certain cases of trophoblastic neoplasms\n\nIt may also be used in the treatment of other cancers as part of research protocols or off-label use.\n\n### Dosage and Administration\nThe dosage of Cosmegen depends on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XjH68CXUcGlr8KArnvJZY8lk", "custom_id": "438_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8d472aece8e2b48244dd9cdfd73d803e", "body": {"id": "chatcmpl-9St6Q4K4FS7x0IZxZEZk5Ywrvba1i", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol, often marketed under the brand name Danatrol (among others), is a medication with multiple indications. As a physician, here are some key points you should know about Danazol:\n\n1. **Mechanism of Action**: Danazol is a synthetic steroid that works primarily by inhibiting the production of gonadotropins (FSH and LH), which reduces estrogen and progesterone levels. It also has direct effects on the endometrium (uterine lining) and immune modulation properties.\n\n2. **Indications**: Danazol is primarily used in the treatment of endometriosis and fibrocystic breast disease. It is also used for hereditary angioedema to decrease the frequency of attacks.\n\n3. **Dosage and Administration**: The dosage of Danazol varies depending on the indication, severity of symptoms, and patient response. It is typically administered orally. For endometriosis, common dosages range from 200 to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BiK9zcqFtsZCeTOTUcRIwxnP", "custom_id": "439_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "23f12cdbeee6ff4789d33bd6c2f39153", "body": {"id": "chatcmpl-9St6Q35SEDbZWy9qe2PIk7S6A0cpP", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex (daratumumab) is an important medication for physicians to be familiar with, especially if you are involved in the treatment of multiple myeloma. Here are some key points about Darzalex:\n\n1. **Indication and Mechanism of Action**:\n   - Darzalex is an FDA-approved monoclonal antibody used primarily to treat multiple myeloma. \n   - It targets CD38, a surface protein that is highly expressed on multiple myeloma cells. By binding to CD38, daratumumab triggers immune-mediated killing of these cells.\n\n2. **Administration**:\n   - Darzalex is administered via intravenous infusion. The dosing regimen can vary based on the combination therapy and the stage of treatment. Initial doses typically require longer infusion times, which can be shortened in subsequent sessions if well-tolerated by the patient.\n\n3. **Combination Therapy**:\n   - Darzalex is often used in combination with other medications such as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cDfjOjFeDTpi3Sqmigfnz50D", "custom_id": "440_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36c01fb5cf9801dba7d2340bc7f57420", "body": {"id": "chatcmpl-9St6QIAXfr7IJn25SlC8x8Tc9RvD3", "object": "chat.completion", "created": 1716672026, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is a medication used in the treatment of prostate cancer. It was approved by the FDA in 2019 and is specifically indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). Here are some key points that you, as a physician, might find useful about Nubeqa:\n\n1. **Mechanism of Action**: Darolutamide is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting the receptor's interaction with androgens (male hormones). This prevents the androgens from promoting prostate cancer cell growth.\n\n2. **Clinical Efficacy**: In clinical trials, darolutamide has shown to significantly improve metastasis-free survival compared to placebo in men with nmCRPC. It helps in delaying the spread of prostate cancer and the progression of the disease.\n\n3. **Dosage and Administration**: Nubeqa is typically administered as an oral tablet. The recommended dosage is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_N5eKfgad6kisHMJXx1qpRUys", "custom_id": "441_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0677ff3a53395c9b913ad2e1378fccb1", "body": {"id": "chatcmpl-9St6R1dTSjFCIgVXdb2u6C0pFnwHn", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel (dasatinib) is a medication used primarily in the treatment of certain types of leukemia. Here are key points you should be aware of as a physician:\n\n1. **Indications**: Sprycel is approved for the treatment of adults with chronic myeloid leukemia (CML) in chronic, accelerated, or myeloid or lymphoid blast phase and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior therapy. It is also used in pediatric patients with Ph+ CML in chronic phase.\n\n2. **Mechanism of Action**: Sprycel is a tyrosine kinase inhibitor. It specifically inhibits multiple tyrosine kinases including BCR-ABL (the fusion protein responsible for CML), SRC family kinases, c-KIT, EPHA2, and PDGFR\u03b2. This inhibition interferes with cell communication and growth, leading to the death of malignant cells.\n\n3. **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_8Ji56t44euvdQNprl6rqCvEs", "custom_id": "442_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "508850c911260b4907669446ef948400", "body": {"id": "chatcmpl-9St6RZAIJPxY7DCuwuzm2EDW6iXio", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidine (also known by its generic name, daunorubicin) is a chemotherapy medication used primarily to treat certain types of leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). It is classified as an anthracycline antibiotic and works by interfering with the growth of cancer cells, which are eventually destroyed.\n\nHere are key points you should know about Cerubidin:\n\n### Mechanism of Action\nDaunorubicin works by intercalating into DNA and inhibiting the enzyme topoisomerase II, leading to breaks in DNA strands and ultimately preventing cancer cells from growing and dividing.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**\n- **Acute Lymphocytic Leukemia (ALL)**\n- It may also be used in other types of leukemia as part of a combination chemotherapy regimen.\n\n### Administration\n- Cerubidin is administered intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jVSUCsCbwkhTyDgSk2kzkG2D", "custom_id": "443_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c559d8a5c12cdcc4378bacc203cb295c", "body": {"id": "chatcmpl-9St6R4m5PzrGlNvKcYj7umwm2eLK6", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome is the liposomal formulation of the chemotherapy drug daunorubicin, which is used primarily in the treatment of cancer. The encapsulation of daunorubicin in liposomes allows for enhanced delivery of the drug to tumor cells and can help in reducing toxicity to other tissues. Here are some key aspects about DaunoXome that you, as a physician, might find useful:\n\n1. **Indications**: DaunoXome is specifically indicated for the treatment of HIV-associated Kaposi's sarcoma. It is used when the disease is advanced or has not responded to prior therapy.\n\n2. **Mechanism of Action**: Daunorubicin, the active component, intercalates into DNA and interferes with the enzyme topoisomerase II, which is crucial for DNA replication and transcription. This results in the inhibition of DNA synthesis and function, leading to cell death. The liposomal formulation allows for a longer circulation time in the bloodstream and prefer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pP7VdOQJ97oT5uAVIjPfPzor", "custom_id": "444_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52d72836522e0690880e668721145070", "body": {"id": "chatcmpl-9St6RjH2rk3rljn242lKmvJPsCtZc", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen (decitabine) is a medication used primarily in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic disorders characterized by dysfunctional blood cell production and maturation. It is an injectable nucleoside analog that functions as a hypomethylating agent.\n\n**Key Information about Dacogen:**\n\n1. **Mechanism of Action**:\n   - Decitabine is incorporated into DNA where it inhibits DNA methyltransferase, an enzyme responsible for adding methyl groups to DNA. This action leads to hypomethylation of DNA which can reactivate genes that are typically silenced in cancer cells, including tumor suppressor genes, leading to cellular differentiation and apoptosis in malignant cells.\n\n2. **Indications**:\n   - Dacogen is approved for the treatment of patients with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary MDS of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_IAbvyya6BhiU2MbIrk8SF7nl", "custom_id": "445_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "83e22457c8d1dba50b194bbcec3fb6dd", "body": {"id": "chatcmpl-9St6RQRSonmmkRzFGYUfBWEL3rLdo", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon (degarelix) is a medication used primarily in the treatment of advanced prostate cancer. As a physician, here are several key aspects you should know about Firmagon:\n\n1. **Mechanism of Action**:\n   - Firmagon is a gonadotropin-releasing hormone (GnRH) antagonist. It works by rapidly reducing the levels of testosterone by blocking the GnRH receptors in the pituitary gland, which inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a decrease in testosterone production by the testicles.\n\n2. **Indications**:\n   - Firmagon is approved for the treatment of advanced prostate cancer. It is particularly useful in cases where immediate reduction of testosterone levels is necessary.\n\n3. **Administration**:\n   - Firmagon is administered as a subcutaneous injection in the abdominal area. The initial dose is typically a 240 mg injection, followed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UysJUZmUf8YHAhEtYKQkiYOF", "custom_id": "446_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90d13d27ef0c7bdb99159232a22420fb", "body": {"id": "chatcmpl-9St6RfvEE8EvwLQevFeSTrvgh60Kr", "object": "chat.completion", "created": 1716672027, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have detailed knowledge about any medication you might prescribe, including Ontak (denileukin diftitox). Here\u2019s a comprehensive overview:\n\n### What is Ontak?\nOntak (denileukin diftitox) is a targeted therapy used primarily in the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL). It is a fusion protein that combines portions of the diphtheria toxin with interleukin-2 (IL-2). The drug binds to the IL-2 receptor, which is overexpressed on the surface of some T-cells, including those affected by CTCL. After binding, the toxin portion of the molecule is internalized, leading to cell death.\n\n### Mechanism of Action\nOntak targets cells that express the IL-2 receptor. After binding to this receptor, the diphtheria toxin portion of the fusion protein enters the cell and inhibits protein synthesis, leading to apoptosis (cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vMgIQKA9fuBW3zhMqrlZGi0c", "custom_id": "447_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5cdfd06ba3d8a89eaeb8b622369aed11", "body": {"id": "chatcmpl-9St6SnBYbCOIZAYlbiiZdC8yDmErI", "object": "chat.completion", "created": 1716672028, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prolia (denosumab) is a medication commonly prescribed for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well as in some cases of cancer-related bone loss. Here are key points you should know about Prolia as a physician:\n\n1. **Mechanism of Action**:\n   - Prolia is a monoclonal antibody that targets and inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a protein that is essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, Prolia decreases bone resorption and turnover.\n\n2. **Indications**:\n   - **Osteoporosis**: Prolia is approved for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, including those who have had a previous fracture, are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6WbrMRK9yUZec4inlsbw6TXV", "custom_id": "448_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3084b40b85ad2a392c0ab34db06e455f", "body": {"id": "chatcmpl-9St6SAlfYBvN0ERMgipDVgepQZsns", "object": "chat.completion", "created": 1716672028, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aacidexam\" does not appear to be a recognized medication or substance commonly known in medical databases or literature. It's possible there may be a spelling error or it might be a brand name or a substance not widely recognized. If you meant \"Dexamethasone,\" which sounds somewhat similar, I can provide information on that.\n\nDexamethasone is a type of corticosteroid medication used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis. It is also used in the treatment of certain types of cancer.\n\nHere are a few key points about dexamethasone:\n1. **Mechanism of Action**: Dexamethasone works by decreasing inflammation and reducing the activity of the immune system.\n2. **Forms and Dosage**: It can be given orally, as an intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T91ZswJ9NzvFmaIVQfXckxel", "custom_id": "449_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba12d6371addab6323c10197e3b26f6d", "body": {"id": "chatcmpl-9St6SCDXPMY6j5kLMa12761c21amQ", "object": "chat.completion", "created": 1716672028, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane (dexrazoxane) is a medication primarily used to protect the heart from the potential toxic effects of certain chemotherapy drugs, particularly anthracyclines like doxorubicin. Here are some key points you should know about Cardioxane:\n\n1. **Mechanism of Action**: Dexrazoxane is a cytoprotective agent. It is believed to work by chelating iron, thus preventing the formation of iron-mediated free radicals that are thought to contribute to anthracycline-induced cardiotoxicity. Additionally, it may also protect cardiac cells by inhibiting topoisomerase II\u03b2, a mechanism distinct from its iron-chelating properties.\n\n2. **Indications**: Dexrazoxane is indicated for:\n   - Reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m\u00b2 and will continue to receive do"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_ZsmVQqDHiwXJwDOzUuMumTk9", "custom_id": "450_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8336a6afe4f5676be979b69e4dfbc975", "body": {"id": "chatcmpl-9St6SHobZpCG0Q6NKIV391nrpGDmS", "object": "chat.completion", "created": 1716672028, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a medication or product specifically known as \"Desplex\" recognized in standard medical resources or databases. It's possible that the name could be a typo, a brand name not widely recognized, or a newly released product. To provide accurate information, I would recommend verifying the spelling or providing more context. Additionally, consulting the most current medical databases or pharmaceutical resources might offer more insights. If you have any other questions or need information on a different topic, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 103, "total_tokens": 143}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i6vivSt1920ZCGAbVrckNrcT", "custom_id": "451_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24bd32c82d24c133090904f7ff68c43a", "body": {"id": "chatcmpl-9St6SHLxA2UMbnlhHu5oxqtfYKmnb", "object": "chat.completion", "created": 1716672028, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is a targeted immunotherapy used primarily for the treatment of pediatric patients with high-risk neuroblastoma, a type of cancer that most commonly affects children and originates from neuroblasts in the sympathetic nervous system. Here are key points you should be aware of about Unituxin:\n\n1. **Indication and Usage**:\n   - Unituxin is approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin in pediatric patients who have high-risk neuroblastoma and have achieved at least a partial response to prior first-line multi-agent, multimodality therapy.\n\n2. **Mechanism of Action**:\n   - Dinutuximab is a monoclonal antibody that binds to the GD2 antigen, which is highly expressed on the surface of neuroblastoma cells and other types of cancer cells. The binding of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_C0HOOb4AbqntPqS9nZEaCjtR", "custom_id": "452_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e6dfda735bb0728cc53e33c64b5ce00d", "body": {"id": "chatcmpl-9St6U82cdQ3afLVYV5uqws9WtvzRr", "object": "chat.completion", "created": 1716672030, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or substance known as \"Asodocel\" recognized in standard medical resources or databases. It's possible that the name could be misspelled, or it may be a brand name not widely recognized, or even a new drug not yet documented in widely available medical literature.\n\nIf you meant a different medication or if \"Asodocel\" is a new drug that has come into use after my last update, I would recommend checking the most current medical databases, drug formularies, or contacting a pharmaceutical company for the most accurate and up-to-date information. Additionally, consulting reliable sources like the FDA or EMA websites might provide insights into new drug approvals or clinical trials if \"Asodocel\" is indeed a new development in the medical field."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 162, "total_tokens": 204}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_S8McpX6UYhlnavwfwPSzIS4x", "custom_id": "453_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aefe411724addbecdcf309132c6091e3", "body": {"id": "chatcmpl-9St6TH8aw0fWOlprJ0zKPPuEshTYR", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox (chemical name: 3,4-dihydroxybenzohydroxamic acid) is a synthetic chemical compound that has been primarily studied for its potential use in treating cancer. It is part of the ribonucleotide reductase inhibitor class of drugs. Ribonucleotide reductase is an enzyme that is crucial for DNA synthesis and repair, and inhibiting this enzyme can prevent the growth and proliferation of cancer cells.\n\n### Key Points for Physicians:\n1. **Mechanism of Action**: Didox acts by inhibiting ribonucleotide reductase, which leads to a reduction in deoxyribonucleotide triphosphates (dNTPs) and thereby limits DNA synthesis and repair in rapidly dividing cells.\n\n2. **Research and Trials**:\n   - Didox has been studied in various preclinical trials and some early-phase clinical trials for its effectiveness and safety in treating cancers, including leukemia and solid tumors.\n   - It's important to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ToDYx6wYHVE83dtrLdelxxFq", "custom_id": "454_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7c7e2977041f1cc4520c355a80303fc1", "body": {"id": "chatcmpl-9St6TiU9JRU89vHsde5Yvl9yQSYxB", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriablastina is a brand name for the drug doxorubicin, which is a chemotherapy medication used primarily to treat various types of cancer, including breast cancer, bladder cancer, lymphoma, and leukemia, among others. Doxorubicin belongs to a class of chemotherapeutic agents known as anthracyclines, which work by intercalating DNA, interfering with the enzyme topoisomerase II, and generating free radicals, all of which contribute to inhibiting the growth of cancer cells.\n\n### Key Points for Physicians:\n1. **Mechanism of Action**:\n   - Doxorubicin acts by inserting itself between DNA base pairs, preventing the replication of DNA and thus inhibiting protein synthesis. It also inhibits topoisomerase II, an enzyme crucial for DNA replication.\n\n2. **Indications**:\n   - Commonly used for solid tumors and hematological malignancies. Specific indications may vary based on the formulation and regulatory approvals in different regions.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9SjQnP8oSGaDKpC4JV9R3sRC", "custom_id": "455_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8480c1383c0fa114df99239ccc206440", "body": {"id": "chatcmpl-9St6TIpJIVYmnhhrjORUMaVYSMusW", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imfinzi (durvalumab) is a medication used in the treatment of certain types of cancer. It is a type of immunotherapy that works by targeting the PD-L1 pathway, a mechanism that tumors use to evade the immune system. Here are some key points you should know about Imfinzi:\n\n1. **Mechanism of Action**: Imfinzi is a programmed death-ligand 1 (PD-L1) blocking antibody. By binding to PD-L1, Imfinzi helps to reactivate the immune system to detect and attack cancer cells.\n\n2. **Indications**:\n   - **Non-Small Cell Lung Cancer (NSCLC)**: Imfinzi is approved for the treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 on \u22651% of tumor cells and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JqOoKeXG4E5SZAcOweK62t3s", "custom_id": "456_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b9693df35f1e51467db614411547693", "body": {"id": "chatcmpl-9St6TREHRbT3RVlk7rBtofQTX1hLU", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avodart, known generically as dutasteride, is a medication primarily used to treat symptoms of benign prostatic hyperplasia (BPH), or enlarged prostate, in men. Here are some key points you should know:\n\n1. **Mechanism of Action**: Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to prostate growth. It does so by inhibiting both Type 1 and Type 2 forms of the enzyme 5-alpha reductase. This reduction in DHT helps decrease the size of the prostate and alleviate symptoms.\n\n2. **Indications**: The primary indication for Avodart is the treatment of BPH. It may also be prescribed off-label for male pattern hair loss.\n\n3. **Dosage and Administration**: The typical dosage is 0.5 mg taken orally once a day, with or without food. It\u2019s important to note that response to therapy can be gradual, and it may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yxIhgpLci6Xg1EChIiNqCAUV", "custom_id": "457_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f53506fde81613b67d6a693591af60f2", "body": {"id": "chatcmpl-9St6TVikn6kPaTIcATsEnHEXYPAOr", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of blood cancers. Here are some key points you should know about Copiktra:\n\n1. **Indications**: Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), after at least two prior therapies. It is also approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.\n\n2. **Mechanism of Action**: Copiktra is a dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. These enzymes are part of the PI3K signaling pathway, which plays a critical role in the proliferation and survival of malignant B-cells. By inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HqNALy1EYHivrPOUXJzqMhRQ", "custom_id": "458_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd0dfee9a7a851feb5d2681422c2cbf7", "body": {"id": "chatcmpl-9St6ToAKfxloPWuhbeKuOSKbB3NKB", "object": "chat.completion", "created": 1716672029, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "A Panorex, also known as a panoramic radiograph, is a type of dental X-ray that captures a single, flat image of the entire mouth. This includes the teeth, upper and lower jaws, surrounding structures, and tissues. It is a valuable diagnostic tool in dentistry with several applications in other medical fields as well. Here are key points that a physician should know about Panorex:\n\n1. **Comprehensive Overview**: Unlike traditional intraoral X-rays that focus on individual teeth, a Panorex provides a panoramic view of the entire dental arch and related structures. This can be crucial for comprehensive assessment in various scenarios.\n\n2. **Uses**:\n   - **Dental Evaluation**: It is used to plan treatments for dentures, braces, extractions, and implants.\n   - **Pathological Conditions**: Helps in diagnosing cysts, jaw tumors, bone irregularities, and impacted teeth, including the assessment of the wisdom teeth.\n   - **Jaw Joint Analysis**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_idnZnjyv7chhsrN3lI58tUd1", "custom_id": "459_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "630d93f42c7acd96006c72a53718e72c", "body": {"id": "chatcmpl-9St6UURJ67Y5ddvg8KayIriNRk8kK", "object": "chat.completion", "created": 1716672030, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a prescription medication used in the treatment of multiple myeloma, a type of cancer that arises from plasma cells in the bone marrow. Here are several key points about Empliciti that are important for a physician to know:\n\n1. **Mechanism of Action**: Empliciti is a monoclonal antibody that specifically targets the SLAMF7 protein, expressed on the surface of myeloma cells and natural killer cells. It works by directly activating natural killer cells and by targeting myeloma cells for destruction by the immune system.\n\n2. **Indications**: Empliciti is approved by the FDA for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one to three prior therapies. It is also approved in combination with pomalidomide and dexamethasone for the treatment of patients who have received at least two prior therapies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_g3UXpVkeoU5fS1awUhHI5WmS", "custom_id": "460_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d64310ac5bfb932eb08d46e97cdb0394", "body": {"id": "chatcmpl-9St6U6eRBbEfaC8jxmlV85gsdE2if", "object": "chat.completion", "created": 1716672030, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idhifa (enasidenib) is a prescription medication used to treat adults with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. It is specifically indicated for patients with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. Here are some key points about Idhifa that are important for a physician to know:\n\n1. **Mechanism of Action**: Idhifa is an inhibitor of the IDH2 enzyme. In AML patients with an IDH2 mutation, the enzyme produces an oncometabolite called 2-hydroxyglutarate (2-HG) that contributes to the growth and survival of cancer cells. By inhibiting IDH2, Idhifa reduces levels of 2-HG, thereby exerting an anti-leukemic effect.\n\n2. **Efficacy**: Clinical trials have demonstrated that Idhifa can induce complete rem"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uhif9CpeTqEb5jOxU7u9hdm1", "custom_id": "461_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "34c04ae30f468bc1992df80466c5d2a4", "body": {"id": "chatcmpl-9St6Vz3uzg17Qjo5LUkFld4aH2Xe5", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi, which is the brand name for encorafenib, is a medication used in oncology, specifically for treating certain types of cancer. Here are key points you should know about Braftovi:\n\n1. **Indications**: Braftovi is primarily used for the treatment of melanoma that has a specific mutation in the BRAF gene (BRAF V600E or V600K mutation). It is often used in combination with another medication, binimetinib (Mektovi), as this combination has been shown to be effective in treating this subset of melanoma patients.\n\n2. **Mechanism of Action**: Braftovi is a BRAF inhibitor. It works by selectively targeting and inhibiting the activity of mutated forms of the BRAF protein, which can play a significant role in the growth and development of melanoma. By inhibiting this protein, Braftovi helps to stop or slow the growth of the cancer cells.\n\n3. **Administration**: B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QkMAomy8TYvlNleSFU3V4QUt", "custom_id": "462_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de3ea958109ae49a73359ee7ed1435e4", "body": {"id": "chatcmpl-9St6V8s3Gc8kc0yAeHZvjdJaXrvPW", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rozlytrek (entrectinib) is a prescription medication used for the treatment of certain types of cancer. It is important for physicians to understand its indications, mechanism of action, dosage, and potential side effects. Here are some key points:\n\n### Indications\nRozlytrek is approved for:\n1. **Adults and pediatric patients 12 years of age and older with solid tumors** that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.\n2. **Adults with metastatic non-small cell lung cancer (NSCLC)** whose tumors are ROS1-positive.\n\n### Mechanism of Action\nRozlytrek is a kinase inhibitor. It works by targeting and inhibiting the kinase activities of NTRK1/2/3 (ne"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qAcCBGTjXHljFKZ1qa1jXLk3", "custom_id": "463_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4926844d1391ffc3de906592be04113", "body": {"id": "chatcmpl-9St6VRX2Bnq67XvspSJCXQ0CIfDH3", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azel is likely a shorthand or a brand name for a medication, and it's important to clarify which drug is being referred to. However, based on common abbreviations and brand names in medicine, \"Azel\" might refer to \"azelastine,\" which is an antihistamine used primarily for the treatment of allergic rhinitis and other allergic symptoms.\n\n### Azelastine Overview\n\n**1. Mechanism of Action:**\n   - Azelastine is a second-generation antihistamine that works by blocking histamine H1 receptors, thereby reducing the effects of histamine in the body. This leads to a decrease in allergy symptoms such as sneezing, itching, and runny nose.\n\n**2. Indications:**\n   - It is commonly used to treat symptoms of allergic rhinitis (both seasonal and perennial).\n   - It can also be used for the treatment of symptoms associated with other allergic conditions.\n\n**3. Forms and Administration:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lVDXKCIIcZBLW6JwZSg9JhuJ", "custom_id": "464_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ce95924846c0ab1f4749b668db8e96f", "body": {"id": "chatcmpl-9St6VO0wpJlCV0CoiUyz3KM3LWutj", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no drug called \"Alrubicin\" recognized in standard medical or pharmaceutical references. It's possible that there might be a typo or a misunderstanding regarding the drug's name. If you are referring to a specific medication, it could be beneficial to check the spelling or provide additional context. Alternatively, if you're referring to a drug similar in name such as \"Doxorubicin,\" which is a well-known chemotherapy agent used primarily for treating various types of cancer, I can provide information on that. Please confirm the exact name or provide additional details so I can assist you more accurately."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 126, "total_tokens": 168}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_onaR12GQcuzTolDVHvmZE60w", "custom_id": "465_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c168d3109beb976e85fed764f3381c20", "body": {"id": "chatcmpl-9St6VyHtrCnP67pv2537JcFWPGvKF", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has a type of susceptible fibroblast growth factor receptor (FGFR) genetic alteration, specifically FGFR2 or FGFR3 alterations, and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\nHere are some key points about Balversa:\n\n1. **Mechanism of Action**: Balversa is a kinase inhibitor that specifically binds to and inhibits the activity of FGFR1, FGFR2, FGFR3, and FGFR4. The inhibition of FGFR signaling has shown to decrease the proliferation and increase the apoptosis (programmed cell death) of cells in FGFR-driven tumor cell lines.\n\n2. **Gen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FLyizVBCLppAWyyZ7X8rKWhd", "custom_id": "466_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71e59821b07476edb8aaacf6afeece36", "body": {"id": "chatcmpl-9St6Ver3Wxi7EaSD9Ldl2EVxheU9h", "object": "chat.completion", "created": 1716672031, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't any information available about a medication or substance called \"Brutravon.\" It's possible that the name might be misspelled, misheard, or it could be a brand name not widely recognized or new to the market.\n\nIf you're dealing with a specific medication or substance, I recommend checking the most up-to-date medical resources or databases like the FDA's website, the European Medicines Agency, or other relevant professional medical databases. Additionally, consulting pharmacological references such as the Merck Manual, or using drug information services like UpToDate, Lexicomp, or Micromedex could provide accurate information.\n\nIf you provide more context or a different spelling, I could attempt to help you find more accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 154, "total_tokens": 196}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZzIIKjJhrlS3HGhjVc2kCcZC", "custom_id": "467_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98e5585ee07f9cf41d0ff85ed0ae0c78", "body": {"id": "chatcmpl-9St6W2503slumSnyTDTvYBcqpLuy1", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug erlotinib, which is used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points you, as a physician, should know about Erlocip:\n\n1. **Mechanism of Action**:\n   - Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It works by inhibiting the intracellular phosphorylation of tyrosine kinase associated with the EGFR, which can be overexpressed or mutated in certain types of cancers. This inhibition blocks the downstream signaling pathways that lead to cancer cell proliferation and survival.\n\n2. **Indications**:\n   - **Non-small cell lung cancer (NSCLC)**: Erlotinib is used primarily for the treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. It is particularly effective in patients whose tumors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6Ywps2ka28zKV3LhyYFzbcIS", "custom_id": "468_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2066a612fc4cd6515a0bbae9a4c060ad", "body": {"id": "chatcmpl-9St6W7pbccfAkKppfEEKHJPAxoSY9", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt, also known by its generic name estramustine, is a chemotherapy drug used primarily to treat prostate cancer, particularly in cases where the cancer has metastasized or is not responsive to other treatments. Here are some key points you should know about Emcyt:\n\n1. **Mechanism of Action**: Estramustine is a unique compound that combines the alkylating agent mechlorethamine with the hormone estradiol. It works by interfering with microtubule function, which is crucial for cell division, and by delivering the alkylating agent to cancer cells, leading to cell death. The estrogen component is thought to help target the drug to hormone-responsive tissues, such as prostate cancer cells.\n\n2. **Indications**: Emcyt is specifically indicated for the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. It is often used when the cancer does not respond to standard hormone therapy.\n\n3. **Administration**: Emcy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wjts7u1yGCzsiIoifTcHHOTE", "custom_id": "469_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f81efde220325c621633cc56c30ae1b0", "body": {"id": "chatcmpl-9St6WMEYLNllHk2KUYQKwHKI8Do1e", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question. \"Aside\" typically refers to a remark or passage by a character in a play that is intended to be heard by the audience but unheard by the other characters in the play. It does not relate directly to medical practice or pharmaceuticals.\n\nIf you intended to inquire about a specific medical condition, treatment, or drug that you mistakenly referred to as \"Aside,\" could you please clarify or provide the correct term? I'm here to help with accurate medical information once I have the right context or details."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 112, "total_tokens": 151}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jKXMnFZLq6LT82oj6gdRjnOi", "custom_id": "470_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd079717317f78f5d11e19d1057ae8ba", "body": {"id": "chatcmpl-9St6WG0Jwf2s9o20lcdeeOqjfEEbR", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last training data in January 2021, \"Advacan\" does not appear to be a recognized medication or substance in standard medical resources or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a very new development that was not included in my training data. \n\nIf \"Advacan\" is a drug or treatment you've heard about, it could be beneficial to check the most current drug databases, consult pharmaceutical industry updates, or inquire directly with pharmaceutical companies for the most accurate and up-to-date information. Additionally, verifying the spelling or looking for alternative names might help locate the correct information.\n\nIf you provide more context or details, I may be able to assist you better."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 151, "total_tokens": 192}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DRgOsYsVPUw7JKaiJvV0pflO", "custom_id": "471_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "caa5b770444eb4448d9469808ef0e8c3", "body": {"id": "chatcmpl-9St6WowR8fW3x181EyouTIrgUADNZ", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to know that \"Aromadex\" may be a misspelling or confusion with either \"Arimidex\" or aromatase inhibitors in general. Arimidex is a brand name for the drug anastrozole, which is commonly used in the treatment of breast cancer.\n\n**Anastrozole (Arimidex)** is a non-steroidal aromatase inhibitor and works by lowering estrogen hormone levels to help shrink tumors and slow their growth. Here are some key points about anastrozole:\n\n1. **Indications**: Anastrozole is primarily used in the treatment of hormone receptor-positive early breast cancer in postmenopausal women. It is also used for advanced or metastatic breast cancer in postmenopausal women and may be used as a first-line treatment or following tamoxifen therapy.\n\n2. **Mechanism of Action**: Anastrozole inhibits the enzyme aromatase, which is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bqeVql6sSTovwJq9zwEhMHsU", "custom_id": "472_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c0fb31de9c86b6eba45846fb979c481b", "body": {"id": "chatcmpl-9St6Wso6I3ahXGn5r34oRmPwLDAum", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "FUDR is the brand name for the drug floxuridine, which is primarily used in the treatment of cancer. Here are key points you should know about FUDR:\n\n1. **Mechanism of Action**: Floxuridine works as an antimetabolite, interfering with cells' ability to make DNA and RNA. By substituting its metabolites into the DNA during the S phase of the cell cycle, it inhibits thymidylate synthase and DNA synthesis, which leads to cell death. This makes it particularly effective against rapidly dividing cancer cells.\n\n2. **Indications**: Floxuridine is specifically approved for the treatment of metastatic colorectal cancer. It is often used in a regional chemotherapy approach, where it is administered directly into the liver artery because the liver is a common site for metastases from colorectal cancers.\n\n3. **Administration**: It is typically given via an intra-arterial route to maximize its concentration at the site of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kaHFkyu61tEfsr6nEPV8Zih5", "custom_id": "473_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9dee3802b87c84cedda401ae7be65900", "body": {"id": "chatcmpl-9St6Wrys8tEvaGvatga55zh46RdKw", "object": "chat.completion", "created": 1716672032, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beneflur is not a widely recognized medication or substance in standard medical practice, as of the last update in my training data. It's possible that it could be a new drug, a drug used in a specific region outside of mainstream awareness, or it might be known by a different name.\n\nIf Beneflur is a medication you've encountered in a specific context (such as a research trial, in a particular country, or in specialized medical literature), I would recommend consulting the most current and reliable medical databases like PubMed, or drug information databases like the FDA or EMA for the most accurate and up-to-date information. Additionally, checking with pharmacological resources or directly with pharmaceutical manufacturers could provide accurate details.\n\nIf it's a brand name or has alternative spellings, verifying the correct name and details would be essential. If you need information on a similar-sounding drug or a drug with a possibly related name, please provide more details, and I will do my best to assist you."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 198, "total_tokens": 239}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZxW4i4TvyizMxHrzsLG585dj", "custom_id": "474_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "07046c4d08ecf44a1dd3b5a11fa626c9", "body": {"id": "chatcmpl-9St6XKYQvWVhAn67ztXaAZfqW4WQi", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Accusite is a drug delivery system used primarily for the localized treatment of certain types of cancers, such as basal cell carcinoma on the skin. It is not a drug itself but a method to deliver the medication directly to the tumor site. The Accusite system typically involves a formulation that contains the active drug fluorouracil, which is a chemotherapeutic agent used to inhibit rapidly dividing cancer cells.\n\nKey points for physicians regarding Accusite include:\n\n1. **Mechanism of Action**: Accusite utilizes a gel formulation containing fluorouracil, which is applied directly to the cancerous area. Fluorouracil is a pyrimidine analog that works by interfering with DNA synthesis, thereby preventing the cancer cells from growing and multiplying.\n\n2. **Indications**: It is mainly indicated for the topical treatment of basal cell carcinoma. It's important to assess the type and stage of skin cancer to determine if Accusite is an appropriate treatment choice.\n\n3. **Application"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_PNaTZFAaaAlCaMHEb3VopWKs", "custom_id": "475_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f4c41b4ce02119cac569c41c9ebabca9", "body": {"id": "chatcmpl-9St6XBwrzJua60tatAUAPWrsPVNy1", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin, also known by its generic name fluoxymesterone, is an anabolic androgenic steroid (AAS). It is primarily used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast cancers in women. It is known for its potent androgenic effects and minimal anabolic effects.\n\nHere are some key aspects of Halotestin that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - **Male Hypogonadism**: For replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone.\n   - **Delayed Puberty**: Occasionally used to treat males with delayed puberty.\n   - **Breast Cancer**: Used palliatively to treat androgen-responsive recurrent mammary cancer in postmenopausal women.\n\n2. **Mechanism of Action**:\n   - Halotestin acts by binding to androgen receptors, leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MbVtj19Vf8VlyZGJgsW1PzDi", "custom_id": "476_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30a82e0586e35f4f3e529b419fe39793", "body": {"id": "chatcmpl-9St6X6o5PtN61rWuIjXKyOEsJsPWO", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid (flutamide) is a non-steroidal antiandrogen primarily used to treat prostate cancer. It works by inhibiting the action of androgens (male hormones) at the androgen receptor, which helps to slow the growth of prostate cancer cells that depend on androgens to grow.\n\nHere are some key points about Cytomid that you, as a physician, might find useful:\n\n1. **Indications**: Flutamide is commonly used in the management of advanced prostate cancer, often in combination with a gonadotropin-releasing hormone (GnRH) agonist or surgical castration to achieve maximal androgen blockade.\n\n2. **Mechanism of Action**: Flutamide acts as a competitive inhibitor of androgens by binding to the androgen receptors in the target tissues such as the prostate gland, preventing the stimulation of these receptors by endogenous androgens.\n\n3. **Dosage and Administration**: The typical dosage of flut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FPlOjrLL02QJstnIXPlblhqV", "custom_id": "477_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32f3865c0120cc9101837016dc4da6c3", "body": {"id": "chatcmpl-9St6X2EBgfvYmM87iw23iyGJxrgof", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or product known as \"Antrex\" commonly recognized in medical literature or among standard pharmaceuticals. It's possible that there might be a typo or a misunderstanding regarding the name of the medication you're inquiring about.\n\nHowever, if you're referring to a specific drug, it would be helpful to verify the spelling or provide additional context such as its intended use or any active ingredients if you have them. This will help me give you more accurate and relevant information.\n\nIf \"Antrex\" is a brand name or a drug marketed in a specific region outside of the major pharmaceutical markets, it could also be less widely recognized under this name. Sometimes drugs are marketed under different names in different countries.\n\nIf you provide more details, I'd be glad to help further!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 164, "total_tokens": 204}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aE3hTyA3eg5vcvKXuilhPhom", "custom_id": "478_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e35d00e89331c044380d128b7cbb1ea4", "body": {"id": "chatcmpl-9St6XEmAjtBtGGYzwGbUSsA3V6Bqu", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lentaron, known generically as formestane, is a type II steroidal aromatase inhibitor used primarily in the treatment of estrogen receptor-positive breast cancer in post-menopausal women. Aromatase inhibitors work by inhibiting the enzyme aromatase, which is responsible for converting androgens (like testosterone) into estrogens. By decreasing estrogen production, these drugs can help reduce the growth of estrogen-dependent breast cancer cells.\n\nFormestane was one of the first aromatase inhibitors developed but is less commonly used today, having been largely replaced by newer aromatase inhibitors such as anastrozole, letrozole, and exemestane, which are more effective and have better safety profiles.\n\nHere are a few key points about formestane (Lentaron):\n\n1. **Administration**: Initially, formestane was available for oral administration, but its bioavailability was poor. It has been more commonly administered intramuscularly.\n\n2. **Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Xh3OBbmPGXBUJwslcOyFturd", "custom_id": "479_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee66b22cc235ba6869640c07316d5d0a", "body": {"id": "chatcmpl-9St6X3i04QGmTL0zKWJKJ2itvoFTa", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine (also known as forodesine) is a purine nucleoside phosphorylase (PNP) inhibitor. It's primarily researched and developed for the treatment of hematological malignancies, particularly T-cell malignancies. Here are some important aspects of Fodosine that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Fodosine inhibits the enzyme purine nucleoside phosphorylase, which is crucial in the purine salvage pathway. This inhibition leads to an increase in deoxyguanosine triphosphate levels, which in turn causes apoptosis, particularly in T-lymphocytes. This selective cytotoxicity makes it a potential treatment for diseases characterized by overactive or malignant T-cells.\n\n2. **Clinical Trials and Usage**: Fodosine has been evaluated in several clinical trials, particularly for T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL)."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EQJS8e2n99NJwc1VkZdmyUl1", "custom_id": "480_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9c579a76e42aad8747ed5bc172287ec0", "body": {"id": "chatcmpl-9St6XgUViSE5bfowVbomFAmFSp9T7", "object": "chat.completion", "created": 1716672033, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Tavalisse (fostamatinib) is a medication used primarily for the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to a previous treatment. Here are some important points you should know about Tavalisse:\n\n1. **Mechanism of Action**: Tavalisse is a spleen tyrosine kinase (SYK) inhibitor. By inhibiting SYK, it helps to reduce the destruction of platelets in the spleen and improve platelet counts.\n\n2. **Indications**: It is specifically indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have failed to respond to other treatments, such as corticosteroids, immunoglobulins, or splenectomy.\n\n3. **Administration**: Tavalisse is administered orally. The initial recommended dosage is typically 100 mg twice daily, which can be adjusted based on platelet counts"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K4REmnJEfgqjtRYFEmhO27bv", "custom_id": "481_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d94b55117aa3afb055a740612ff7df5b", "body": {"id": "chatcmpl-9St6YzSAX0BuYQDfHbgo6kFC9AAIt", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Muphoran (also known by its generic name, fotemustine) is an anticancer chemotherapy drug classified as an alkylating agent. It is primarily used in the treatment of malignant melanoma, particularly when the disease has metastasized to the brain. It may also be used to treat other types of cancer, such as metastatic colorectal cancer, under certain circumstances.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Fotemustine works by forming cross-links in DNA, which inhibits DNA replication and transcription. This leads to cell cycle arrest and eventual cell death. Its structure allows better penetration across the blood-brain barrier compared to other nitrosoureas.\n\n2. **Indications**:\n   - Primary indication is for metastatic malignant melanoma, especially with brain metastases.\n   - It may also be used experimentally or off-label for other cancers with high CNS involvement.\n\n3. **Administration**:\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_oSqOuBwlvRNMHsJkJPedElGg", "custom_id": "482_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99e9d0d2350df416b9f9129ba27738a3", "body": {"id": "chatcmpl-9St6Yb3RPbETfrB726kebxiixmRPj", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faslodex (fulvestrant) is a medication used in the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women. Here are key points about its usage, mechanism, and safety profile:\n\n1. **Indications**:\n   - Faslodex is primarily used for treating HR-positive, HER2-negative advanced or metastatic breast cancer. It is often prescribed to women who have experienced disease progression following endocrine therapy.\n   - It can be used alone or in combination with other treatments, such as palbociclib, a CDK4/6 inhibitor, depending on the patient\u2019s previous treatments and the specifics of their disease.\n\n2. **Mechanism of Action**:\n   - Faslodex is a selective estrogen receptor degrader (SERD). It binds to the estrogen receptor with a higher affinity than tamoxifen, another anti-estrogen therapy, and it does not have any known estrogen agonist effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3kQ7iLPhO3rMdnRZehgFICKr", "custom_id": "483_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c0fafd0e34095b4b3157f44441d0ade", "body": {"id": "chatcmpl-9St6YZWQDs4yK3BV1nZY5p188FPSF", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medication or medical term \"Cangib\" recognized in standard medical resources or drug databases. It's possible that there might be a typo or a misunderstanding regarding the name. It could also be a brand name or a drug available in a specific region or country that isn't widely recognized internationally.\n\nIf you are referring to a new or less common drug, or if \"Cangib\" is a new term related to a specific medical condition or treatment, I recommend consulting the most current medical literature or a pharmaceutical database for the most accurate and up-to-date information. Additionally, checking with a pharmaceutical representative or a specialized medical professional in the field related to the term might provide more clarity."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 146, "total_tokens": 187}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Yw0A6qiahD4f9gIyNIMJx48b", "custom_id": "484_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "37746286de57ff12f877d539f25cfa1a", "body": {"id": "chatcmpl-9St6YlZbtDibBlUwHN8PwBHyvYjO4", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine, sold under the brand name Gemzar among others, is a chemotherapy medication used to treat several types of cancer. These include breast cancer, ovarian cancer, pancreatic cancer, lung cancer, and bladder cancer. It is given by injection into a vein.\n\n### Key Points for Physicians:\n\n#### Mechanism of Action:\nGemcitabine is a nucleoside analog, specifically a deoxycytidine analog, which becomes incorporated into DNA during the S phase of the cell cycle, leading to inhibition of DNA synthesis and eventually cell death.\n\n#### Indications:\n- **Pancreatic Cancer:** For the treatment of adenocarcinoma of the pancreas as first-line treatment in combination with other chemotherapeutic agents.\n- **Breast Cancer:** For use in metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.\n- **Non-small Cell Lung Cancer (NSCLC"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RADrCsgyJUuiBL7iWWra9vbi", "custom_id": "485_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "13321ba02fe908b43148331288ce7216", "body": {"id": "chatcmpl-9St6Yi3FC0KN0Ojdfhof0Di81O0Y7", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (gemtuzumab ozogamicin) is a targeted therapy used in the treatment of acute myeloid leukemia (AML). It is important for physicians to be aware of the following key points about Mylotarg:\n\n1. **Indications**: Mylotarg is approved for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older. It is also indicated for the treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.\n\n2. **Mechanism of Action**: Mylotarg is a conjugate of a monoclonal antibody targeting the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and normal hematopoietic cells. The antibody is linked to calicheamicin, a cytotoxic agent. When Mylotarg binds to CD33 on the surface of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wKJDfRiTAg1QS7LROob1Pf7B", "custom_id": "486_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "96b4673d47e3acd89959aca925bd2cab", "body": {"id": "chatcmpl-9St6YHXlcMk8xfbrmi2ki54xM3A3j", "object": "chat.completion", "created": 1716672034, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata, known generically as gilteritinib, is a medication used in the treatment of acute myeloid leukemia (AML). Here are several key points about Xospata that you as a physician might find important:\n\n1. **Indications**: Xospata is specifically approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Gilteritininb is a tyrosine kinase inhibitor that targets FLT3 (FMS-like tyrosine kinase 3). FLT3 mutations are one of the most common genetic abnormalities in AML. Gilteritinib inhibits both the internal tandem duplication (ITD) and the tyrosine kinase domain (TKD) mutations of FLT3, which can promote the proliferation of abnormal hematopoietic cells in AML.\n\n3. **Administration**: Xospata is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dVveWgpwwjMbQL8L5usAgc7p", "custom_id": "487_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7814e284c3a309162d820b51bc9aa3e3", "body": {"id": "chatcmpl-9St6ZhtW8IKAXtiBS6KFtGJpFhVaP", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Daurismo (glasdegib)** is a medication approved for use in the treatment of certain types of acute myeloid leukemia (AML). Here are the key points you should know about Daurismo as a physician:\n\n1. **Indication and Use**:\n   - Daurismo is approved for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients aged 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. It is used in combination with low-dose cytarabine (LDAC).\n\n2. **Mechanism of Action**:\n   - Glasdegib works as a hedgehog pathway inhibitor. It binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction. This inhibition can help to halt the proliferation of cancer cells and might induce apoptosis.\n\n3. **Dosage and Administration**:\n   - The typical dose of Daurismo"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YwLvWkvJ5xuO5nzuZp7EvouN", "custom_id": "488_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2eacfadb21132815d953efbcc7096ef8", "body": {"id": "chatcmpl-9St6ZXT6UNqgaYnQqopEdwKDXGeFJ", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a misunderstanding or typo in your question, as \"Novgos\" does not appear to be a recognized term in medical literature or practice. Could you please provide more details or clarify what you are referring to? If it's a specific drug, condition, or technology, I'd be happy to help with the correct information!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 70, "total_tokens": 110}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gYZwrsMhYBhv4BL9l8fVlxIq", "custom_id": "489_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99c65b4af8c0aa79614be767c23e5dd1", "body": {"id": "chatcmpl-9St6ZwQIxkGjlUospZi5Ac4FERLNt", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin LA (histrelin acetate) is an implant that contains a gonadotropin-releasing hormone (GnRH) agonist. It is primarily used in the treatment of central precocious puberty (CPP), which is the early onset of puberty. Here are some key points you should know about Supprelin LA:\n\n1. **Indications**: Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP), which is defined as puberty that occurs before age 8 in girls and before age 9 in boys.\n\n2. **Mechanism of Action**: Supprelin LA works by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a transient increase in gonadal steroid levels. With continuous administration, it desensitizes the pituitary gland, which leads to decreased LH and FSH levels, ultimately"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Q6p1nbr7nuo0l25ciuLX7idp", "custom_id": "490_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5c28be6235b5802b4093bd56397c1346", "body": {"id": "chatcmpl-9St6ZTJJI28VKC5gTw5zDDcxdfXMo", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Cortef (hydrocortisone)** is a synthetic glucocorticoid, similar to the naturally occurring steroid hormone cortisol produced by the adrenal glands. It is used in the treatment of a variety of conditions where glucocorticoid supplementation is required. Here are some key aspects you should know about Cortef:\n\n### Indications\nCortef is used to treat conditions such as:\n- **Adrenal insufficiency:** This includes Addison's disease and congenital adrenal hyperplasia.\n- **Inflammatory conditions:** Such as arthritis, lupus, psoriasis, ulcerative colitis, allergic reactions, and others.\n- **Immune suppression:** It can be used to prevent the body from rejecting transplanted organs.\n- **Other conditions:** Such as asthma or certain types of cancer.\n\n### Mechanism of Action\nHydrocortisone mimics the action of natural cortisol, which exerts anti-inflammatory and immunosuppressive effects. It affects nearly every"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_o1qUdM2xxvgrwpnfBbQUISHz", "custom_id": "491_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e766e4e956145482d639127d0de950ed", "body": {"id": "chatcmpl-9St6ZLa1sbAsiHbgS96XtNj9fuQnn", "object": "chat.completion", "created": 1716672035, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no recognized medication or substance called \"Biosupressin\" in standard medical references or drug databases. It's possible that the name could be a brand name, a non-standard term, or incorrectly spelled. If you provide more specific details or a different spelling, I might be able to offer more accurate information.\n\nIf you're dealing with an unfamiliar medication or substance, I recommend checking the following:\n\n1. **Consult Official Medical and Pharmaceutical Resources:** Use resources like the FDA database, the European Medicines Agency (EMA), or the World Health Organization (WHO) for the most reliable and up-to-date information.\n\n2. **Ask Colleagues or Pharmacists:** They might have encountered the substance under a different name or in a different context.\n\n3. **Check for Alternative Spellings or Names:** Sometimes substances are known by different names in different regions or under different brands.\n\nIf you clarify or provide more context, I might be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_RBwYkAu7Kss4IkYTNwgRJqTG", "custom_id": "492_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ce45918df7d97f70dbd182aaf04bf8f", "body": {"id": "chatcmpl-9St6aW2A8sZIcOP6xk1hzPkAXyxOM", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radioimmunotherapy medication used primarily in the treatment of non-Hodgkin lymphoma. Here are key aspects you should know about Zevalin:\n\n1. **Mechanism of Action**: Zevalin is a monoclonal antibody that targets the CD20 antigen on the surface of normal and malignant B cells. The medication is conjugated with the radioisotope yttrium-90 or indium-111, allowing targeted radiation delivery to B cells, including cancerous B cells. This can lead to the destruction of both the targeted cells and nearby lymphoma cells through crossfire radiation.\n\n2. **Indications**: Zevalin is approved for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). It is also used for patients with previously untreated follicular NHL who achieve a partial or complete response to first"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_3YMouHLsEbbJRIEwjnL0fH78", "custom_id": "493_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5fa5421ea516547f03851c5b6ebb1158", "body": {"id": "chatcmpl-9St6atG4QsK9mSDTuEU7wDJZNFUq2", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica among others, is a medication used to treat several forms of cancer, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstr\u00f6m's macroglobulinemia. It is also effective for marginal zone lymphoma and chronic graft versus host disease after other treatments have failed. Here are some key points a physician should know about ibrutinib:\n\n1. **Mechanism of Action**: Ibrutinib is a small molecule drug that inhibits the enzyme Bruton's tyrosine kinase (BTK). BTK is a crucial component in the B-cell receptor signaling complex, which plays a significant role in the survival, proliferation, and migration of B lymphocytes. By inhibiting BTK, ibrutinib impedes the growth and proliferation of malignant B cells.\n\n2. **Administration**: Ibrutinib is administered orally, typically once daily. The dosage may vary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LiG0Q3sHGuaa2Fs5piqumLBL", "custom_id": "494_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "57059be955fd848ebb7f976130bac378", "body": {"id": "chatcmpl-9St6avPz7kYgupDPs8Uh626y0jm4n", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Conmana is the trade name for icotinib, an oral tyrosine kinase inhibitor specifically targeting the epidermal growth factor receptor (EGFR), which is a type of protein that often has mutations in various forms of cancer. It is primarily used to treat non-small cell lung cancer (NSCLC).\n\nHere are several important aspects of Conmana (icotinib) that you should be aware of as a physician:\n\n1. **Indications**: Icotinib is approved for use in patients with advanced (or metastatic) non-small cell lung cancer who have specific EGFR mutations. Its effectiveness is particularly noted in patients who have either never smoked or are former light smokers and those who have adenocarcinoma histology.\n\n2. **Mechanism of Action**: Icotinib inhibits the tyrosine kinase activity of the EGFR, leading to the blockade of downstream signaling pathways which are involved in cancer cell proliferation and survival.\n\n3. **Effic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Y7L80EDjRpoMqiRQB1GR3gQu", "custom_id": "495_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9b0cf4bcb3b40e198a9b98b71458922b", "body": {"id": "chatcmpl-9St6aFrOfXe7bBuw6gyrU4lrdB7LB", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, which is the brand name for the drug idarubicin, is an anthracycline antibiotic used primarily as a chemotherapy agent. It is commonly used in the treatment of various types of cancer, including acute myeloid leukemia (AML) and other hematologic cancers. Here are key points you should know about Idamycin:\n\n1. **Mechanism of Action**: Idarubicin works by intercalating DNA strands and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This leads to the disruption of DNA function and cell death, particularly in rapidly dividing cells such as cancer cells.\n\n2. **Indications**: Idamycin is primarily used for the treatment of acute myeloid leukemia (AML), both in newly diagnosed patients and in those who have relapsed. It may be used alone or in combination with other chemotherapy agents.\n\n3. **Administration**: Idarubicin is typically administered intravenously. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_elZ0Fykrk8PpDM4q98NQ95Yb", "custom_id": "496_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2749877e1a23eb4bc13065c96758b7a5", "body": {"id": "chatcmpl-9St6aqdkZRREkTUPqhIzV6ogAE5NT", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zydelig (idelalisib) is a medication used in the treatment of certain hematologic cancers. It is specifically approved for use in patients with chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (NHL), and small lymphocytic lymphoma (SLL), particularly in cases where the disease is relapsed or refractory. Here are some key points you should know about Zydelig:\n\n1. **Mechanism of Action**: Zydelig is a selective inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that is overexpressed in many B-cell malignancies and plays a significant role in the proliferation, survival, and differentiation of these cells.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is approved for the treatment of patients who have received at least one prior therapy.\n   - **F"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_A6An6iGLduBvJj1mJNEjqeGL", "custom_id": "497_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1d990af13a072b12f6f0c3674f4751df", "body": {"id": "chatcmpl-9St6afhjjRinBaSa3gndEqn7eQCUw", "object": "chat.completion", "created": 1716672036, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or substance specifically known as \"Alquimid\" recognized in standard medical references or commonly accepted pharmacological resources. It's possible that the name might be a brand name, a drug available in specific markets, or a new or experimental medication not yet widely recognized.\n\nHere are a few steps you can take to obtain reliable information:\n\n1. **Verify the Name**: Double-check the spelling or see if there are any alternative spellings or names for the substance.\n\n2. **Drug Databases**: Consult comprehensive pharmaceutical databases or resources like the U.S. National Library of Medicine, FDA database, or WHO's drug information resources.\n\n3. **Professional Networks**: Ask colleagues or professionals in pharmacology or related fields if they have any knowledge of the drug.\n\n4. **Contact a Pharmacist**: Pharmacists can be a helpful resource for information on medications, including lesser-known or new drugs.\n\nIf you're dealing with a medication intended for patient care, it's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ssbygBYHVDAFJSCWJiGCO1I1", "custom_id": "498_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "28e81f45a4aa4538abf8a48a0d40d92e", "body": {"id": "chatcmpl-9St6bkUB5lmqcnTCo9uqV6DDQGVO6", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a widely recognized medication or treatment specifically named \"Enliven\" in the medical community. It\u2019s possible you might be referring to a product, treatment, or concept under a different name or one that is not extensively known or used in mainstream medicine.\n\nIf \"Enlizen\" is what you meant, it is important to note that this is a brand name for the drug Lefamulin, used to treat bacterial infections. Lefamulin is a pleuromutilin antibiotic that works by inhibiting protein synthesis in bacteria, thereby stopping their growth. It's primarily used for treating community-acquired bacterial pneumonia (CABP).\n\nIf \"Enliven\" refers to something else, such as a specific program, therapy, or a product not related to pharmaceuticals, it would be helpful to have more context or details to provide accurate information. Additionally, if this is a new or emerging treatment or product, staying updated through reliable medical and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Gos1KIAUWPfMcotvg07z55KX", "custom_id": "499_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29b324ae1eb5f0aba7671308e83bd1df", "body": {"id": "chatcmpl-9St6bZJ4IsxS5Mx49v05gN5gnZxa3", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiquint (brand name Truseltiq) is a medication indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fusion or other rearrangement of a gene called FGFR2 (fibroblast growth factor receptor 2). This medication is significant because cholangiocarcinoma is a rare and aggressive form of cancer, and patients who have this specific genetic alteration may benefit from targeted therapy.\n\n### Key Points about Truseltiq:\n\n1. **Mechanism of Action**: Truseltiq inhibits the activity of FGFR2, a tyrosine kinase that, when altered, can promote cancer cell growth and survival. By inhibiting this pathway, Truseltiq can help to slow down the progression of the cancer.\n\n2. **Approval and Indications**:\n   - Truseltiq was granted accelerated approval based on overall response rate and duration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SR2J8hhqnIMjOhaxId9u8aQw", "custom_id": "500_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "20d1ca7d52b662582357a9d724251bcd", "body": {"id": "chatcmpl-9St6bQU5lbp5Obyuqz2lnKyEPhEGM", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (inotuzumab ozogamicin) is a targeted therapy used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Besponsa:\n\n1. **Mechanism of Action**: Besponsa is an antibody-drug conjugate composed of a monoclonal antibody targeting CD22 (a protein found on the surface of B cells) linked to a cytotoxic agent, calicheamicin. Once bound to CD22, Besponsa is internalized, and the cytotoxic agent is released inside the cell, causing DNA damage and cell death.\n\n2. **Indications**: Besponsa is approved for the treatment of adult patients with relapsed or refractory B-cell precursor ALL. It\u2019s particularly used in patients who have failed previous treatments.\n\n3. **Administration**: Besponsa is administered via intravenous infusion. The dosing schedule typically involves a cycle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5EraHiUTv8ijTTEBxuE8LIP7", "custom_id": "501_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99907a041257a1e9e7c7053bf114b45f", "body": {"id": "chatcmpl-9St6bffV6Gssl2kjU4v8hINQ3rZGg", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a recognized medication or treatment known as \"Laroferon\" in common medical databases or sources. It's possible that the name might be misspelled, or it could be a brand name not widely recognized, or possibly a new or experimental treatment.\n\nIf you meant \"Interferon,\" which sounds somewhat similar, Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. They are used in the treatment of a range of conditions, including certain types of cancers and viral infections. The most common forms used in treatment are Interferon-alpha, Interferon-beta, and Interferon-gamma.\n\nInterferon therapy can have significant side effects and requires careful patient selection and monitoring. Common side effects include flu-like symptoms, fatigue, and mood changes, while more severe risks can include neutropenia, neurotoxicity, and autoimmune disorders.\n\nIf you are inquiring about a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_2MBF3GJ7Z8oCtjov3DYkQnNG", "custom_id": "502_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ed22541602ef37aa50ad9e094ccba8dc", "body": {"id": "chatcmpl-9St6brE0JvWsmjhHe2HTVxxt9LL9V", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Advaferon\" is not recognized as a standard medication or treatment in the medical community. It's possible that it could be a new drug, a brand name not widely recognized, or perhaps even a misspelling.\n\nIf Advaferon is indeed a new or emerging treatment, it\u2019s essential to consult up-to-date medical resources or pharmaceutical databases that can provide reliable information. Additionally, information about newly approved drugs or treatments can often be found on websites such as those belonging to the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).\n\nFor accurate and reliable information, consider these steps:\n\n1. **Check Medical Databases**: Utilize databases like PubMed, UpToDate, or specific pharmaceutical registries.\n2. **Consult Regulatory Agencies**: Check for any approvals or ongoing clinical trials by visiting websites of the FDA, EMA, or other relevant health authorities.\n3. **Professional Networks**: Engage with colleagues or specialists"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vDmMR4i2f1siKf0mFQympQEI", "custom_id": "503_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "916ac2542c3f1b7d81532bd6358be643", "body": {"id": "chatcmpl-9St6bXKhtUqWCsLvkdsyzcf7jDW6T", "object": "chat.completion", "created": 1716672037, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (Interferon gamma-1b) is a medication used primarily to reduce the frequency and severity of serious infections associated with chronic granulomatous disease (CGD), a rare genetic disorder that affects the immune system. It is also indicated for the treatment of severe, malignant osteopetrosis.\n\n**Key points about Actimmune include:**\n\n1. **Mechanism of Action**: Actimmune is a synthetic version of interferon gamma, a naturally occurring protein that modulates the activity of the immune system. It enhances the function of phagocytes (a type of white blood cell) which are crucial for fighting infections.\n\n2. **Administration**: The drug is administered through subcutaneous injection, typically three times per week. Proper training on injection technique is essential for patients or caregivers.\n\n3. **Dosage**: Dosage may vary based on the patient\u2019s weight and medical condition. Regular monitoring and dose adjustments may be necessary based on patient response and side effects.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rOlRsI46EUZdI83WhAr6qlsl", "custom_id": "504_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a41c4de3fab86fd7d5586336a137c7e4", "body": {"id": "chatcmpl-9St6corMrEIGY2XJqsuav65GwqTRt", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (ipilimumab) is a monoclonal antibody used in the treatment of certain cancers, primarily melanoma. Here are some important aspects to consider when using Yervoy in clinical practice:\n\n1. **Mechanism of Action**:\n   Yervoy targets CTLA-4, a molecule on T cells that plays a critical role in regulating natural immune responses. By inhibiting CTLA-4, Yervoy enhances the immune system's response against cancer cells.\n\n2. **Indications**:\n   - As of my last update, Yervoy is primarily approved for the treatment of metastatic melanoma and as adjuvant therapy for melanoma patients with a high risk of recurrence following surgery.\n   - It is also used in combination with other therapies for certain types of renal cell carcinoma, colorectal cancer, and non-small cell lung cancer, among others.\n\n3. **Administration**:\n   Yervoy is administered intravenously. The dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ofcfRSBjzwBX9HAcnepDtIMY", "custom_id": "505_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e19a4fcc6a99fc6a0dc351f922e0627", "body": {"id": "chatcmpl-9St6c6GNJJHoLBGk0CBKsCTD0Sjxs", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axinotecan is likely a misspelling or miscommunication. You might be referring to \"Irinotecan,\" an anticancer medication used primarily in the treatment of colorectal cancer. It is important for physicians to have a good understanding of this drug, including its mechanism of action, usage, side effects, and monitoring requirements. Here are some key points:\n\n1. **Mechanism of Action**: Irinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, which is necessary for DNA replication. By inhibiting this enzyme, irinotecan prevents DNA from uncoiling and replicating, leading to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**: Irinotecan is primarily used for the treatment of metastatic colorectal cancer. It is often used in combination with other drugs such as fluorouracil and leucovorin in various chemotherapy regimens. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_L12o81BB6sHhUYf8Iw0beaI2", "custom_id": "506_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "58977414941704f61a623d0faf3dfae9", "body": {"id": "chatcmpl-9St6ccZ0eKca34IVaEmtEVtavtJdv", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onivyde, known generically as irinotecan liposome injection, is a chemotherapeutic agent used in the treatment of cancer. It is specifically approved for use in patients with metastatic adenocarcinoma of the pancreas who have previously been treated with gemcitabine-based chemotherapy. Here are some key points about Onivyde that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Onivyde is a liposomal formulation of irinotecan. The encapsulation in liposomes allows for a prolonged circulation time and increased tumor accumulation. Once inside the tumor cells, irinotecan is converted into its active metabolite, SN-38, which inhibits topoisomerase I, an essential enzyme in DNA replication, leading to DNA damage and cell death.\n\n2. **Approved Indications**:\n   - It is approved by the FDA for use in combination with fluorouracil (5-FU)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_pwRGIgw70qKZP5enYkRXOHI1", "custom_id": "507_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59fc47769eecfbd6cddb6d48895c83da", "body": {"id": "chatcmpl-9St6cAj1KIFUNMFoBaCtncPwJUlkO", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa, also known by its generic name isatuximab, is a monoclonal antibody used primarily for the treatment of multiple myeloma, a type of cancer that forms in plasma cells. It was approved by the U.S. Food and Drug Administration (FDA) in March 2020. Here are some key points that a physician should know about Sarclisa:\n\n1. **Indications**: Sarclisa is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. It is also approved in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.\n\n2. **Mechanism of Action**: Isatuximab is a monoclonal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lWedebzkQ292z5t0aTaDA8qU", "custom_id": "508_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "224867165bf47ddf8c94254c6982da73", "body": {"id": "chatcmpl-9St6cr1PvzUAzZuF9WM3tnQDoPtlf", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Absorica (isotretinoin) is a form of vitamin A used to treat severe nodular acne that has not responded to other treatments, including antibiotics. Here are some key points you should know about Absorica as a physician:\n\n1. **Indications**: Absorica is specifically approved for the treatment of severe recalcitrant nodular acne. It is typically used when other acne treatments have failed to produce results.\n\n2. **Mechanism of Action**: Absorica works by decreasing sebaceous gland activity, reducing sebum production, and inhibiting sebaceous gland size. It also has anti-inflammatory properties.\n\n3. **Administration**: Absorica should be taken as directed by the prescription, usually twice daily with meals to enhance absorption. It is available in capsule form.\n\n4. **Absorption**: Unlike other forms of isotretinoin, Absorica can be taken with or without food. Food increases the absorption of isotretinoin,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x5Jf53o6TW35LNqol6hp7EXG", "custom_id": "509_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "818c0cc6ad6f502025e33c68373f9f6b", "body": {"id": "chatcmpl-9St6cwNm6lCLVJAsoyfotgkY2wAZD", "object": "chat.completion", "created": 1716672038, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tibsovo (generic name: ivosidenib) is a prescription medication used to treat certain types of cancer. It is specifically indicated for the treatment of adult patients with:\n\n1. **Acute Myeloid Leukemia (AML)**: Tibsovo is used for treating AML that is relapsed or refractory (resistant to treatment) in patients who have an isocitrate dehydrogenase-1 (IDH1) mutation. The presence of this mutation should be confirmed by an FDA-approved test before starting treatment with Tibsovo.\n\n2. **Cholangiocarcinoma**: It is also approved for the treatment of bile duct cancer in adults with an IDH1 mutation that has spread or cannot be removed by surgery.\n\n### Mechanism of Action:\nIvosidenib works by inhibiting the enzyme IDH1, which in mutated forms contributes to cancer cell growth and survival. By inhibiting this enzyme, Tibsovo can help to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9UoeJaoxgI0BRTPaxzBBFVDd", "custom_id": "510_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b2f0c136a5fe2b1c51cea9b25510dfe4", "body": {"id": "chatcmpl-9St6doPFXnPtgKwbz9b3xw0rpM5uT", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (ixabepilone) is a chemotherapy drug used in the treatment of certain types of breast cancer. Here are key points that physicians should consider when dealing with Ixempra:\n\n1. **Indications**: Ixempra is primarily indicated for the treatment of metastatic or locally advanced breast cancer. It is used in patients who have previously undergone treatment with an anthracycline and a taxane, either in the adjuvant or metastatic setting, and have developed resistance or relapsed.\n\n2. **Mechanism of Action**: Ixempra works by binding to tubulin, a protein that is a key component of the microtubule structure within the cell. By stabilizing microtubules and preventing their disassembly, Ixempra disrupts mitotic spindle formation, thereby inhibiting cell division and leading to cell death.\n\n3. **Administration**: Ixempra is administered via intravenous infusion. It is important to follow"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Gv6G3Pb9jMQPe9trMy9TKGqq", "custom_id": "511_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9feca5dc81942a7e3847fc67448afcc6", "body": {"id": "chatcmpl-9St6dhbSVRROmHSJWpROWJcDE9wWm", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Ninlaro (ixazomib), especially if you are involved in the treatment of multiple myeloma. Here are some key points about Ninlaro:\n\n1. **Indications and Usage:**\n   Ninlaro is approved by the FDA for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. This combination has been shown to be effective in improving progression-free survival in this patient population.\n\n2. **Mechanism of Action:**\n   Ixazomib is a proteasome inhibitor. It works by binding to and inhibiting the 20S proteasome, a protein complex involved in the degradation of ubiquitinated proteins. This inhibition disrupts various cellular processes, leading to cell cycle arrest and apoptosis of cancer cells.\n\n3. **Administration:**\n   Ninlaro is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6sZBZtI7HffFglsNRIOEcAis", "custom_id": "512_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c65761340cb3f534ea0506b1e4eb62ca", "body": {"id": "chatcmpl-9St6dsx6WXxieh1pajG4cuP2Sjcrj", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizoral is the brand name for the antifungal medication ketoconazole. It is used primarily to treat fungal infections that can affect different parts of the body including the scalp, skin, nails, and the mucous membranes. Ketoconazole belongs to the class of drugs known as azole antifungals and works by stopping the growth of the fungus.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - **Topical Formulations**: Used for conditions like seborrheic dermatitis, dandruff, and tinea (pityriasis) versicolor.\n   - **Oral Formulations**: Used to treat systemic fungal infections such as candidiasis, cryptococcosis, and more. However, due to potential hepatotoxicity and better alternatives, its use is now more limited and specific.\n\n2. **Mechanism of Action**:\n   - Ketoconazole inhibits the synthesis of ergosterol, a key component of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eskmrTssUR7nnnn7oQ9C4Wpa", "custom_id": "513_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "97e70bfba29671047cc70cca9c640cdb", "body": {"id": "chatcmpl-9St6de9FBvcMXZtnqGhg8Yot5jYFP", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Ipstyl\" is not a widely recognized pharmaceutical or medical term as of my last knowledge update in January 2023. It is possible that \"Ipstyl\" could be a brand name, a new drug, or a misspelling of an existing drug that has been introduced after my last update.\n\nIf \"Ipstyl\" refers to a specific medication or treatment that you need information on, I recommend checking the most current medical databases, pharmaceutical registries, or contacting a pharmaceutical company directly. Reliable sources such as the FDA (U.S. Food and Drug Administration) website, the European Medicines Agency (EMA), or similar regulatory bodies in other countries can also provide up-to-date and accurate information.\n\nIf you meant something else or need information on a similar-sounding drug, please provide more details or check for any spelling variations, and I'd be happy to assist further!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 176, "total_tokens": 216}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4qHzummF65vNSAGSRZhXqPaq", "custom_id": "514_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b34d75c07f05067e1c1ae6c8eb1b3fd6", "body": {"id": "chatcmpl-9St6dFaHkpeIHBunKAZ8KobekPGMM", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prevacid is the brand name for lansoprazole, a proton pump inhibitor (PPI) that is commonly used to treat conditions involving excess stomach acid, such as gastroesophageal reflux disease (GERD), stomach ulcers, and Zollinger-Ellison syndrome. Here are key points a physician should know about Prevacid:\n\n### Mechanism of Action\nPrevacid works by inhibiting the proton pump in the gastric parietal cell, thereby reducing gastric acid secretion. This action is dose-dependent and leads to an effective and sustained decrease in stomach acid production.\n\n### Indications\n- **Gastroesophageal Reflux Disease (GERD):** For the treatment of symptomatic GERD and for the healing of erosive esophagitis.\n- **Ulcers:** Treatment of duodenal ulcers and management of NSAID-associated gastric ulcers.\n- **Zollinger-Ellison Syndrome:** Management of this condition which involves excessive acid production.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LMHGKKxoMjH5zfZjXtdL1OSi", "custom_id": "515_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0877e52f0a362b5cdcf05f3054086cc2", "body": {"id": "chatcmpl-9St6dhLInZRfJFVo4ks8x6IBrzhW4", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a misunderstanding or a typo in your query about \"Abnib.\" Currently, there is no widely recognized medical or pharmaceutical term or product known as \"Abnib.\" It's possible that the term might be misspelled or might refer to something very specific or new that is not yet widely known in the medical community.\n\nIf you could provide more context or details, I would be better able to assist you. If \"Abnib\" refers to a drug, a condition, or a concept, additional information would be helpful. Alternatively, if you are referring to an acronym or a term from a specific medical field or region, clarifying that could lead to a more accurate and helpful response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 145, "total_tokens": 186}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SSY43qsa5KdN85SrH6SCDR5t", "custom_id": "516_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8636e80d621c295e4a3f5f25544552a3", "body": {"id": "chatcmpl-9St6dZeCsc2aa4vczyoaiAY67wGtX", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vitrakvi (larotrectinib) is a medication used in the treatment of cancer. It is specifically designed to target and inhibit certain proteins (TRK fusion proteins) that drive the growth of cancer cells in various types of solid tumors. Here are key points that you, as a physician, should know about Vitrakvi:\n\n### 1. **Mechanism of Action**\n   - Vitrakvi is a selective inhibitor of the tropomyosin receptor kinase (TRK) family of enzymes, which can become abnormally activated in many types of cancers due to genetic alterations known as TRK fusions. By inhibiting these enzymes, Vitrakvi can block the proliferation of cancer cells.\n\n### 2. **Indications**\n   - Vitrakvi is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. These"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0JGjhec16crugRzwMvAtSgxZ", "custom_id": "517_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22b515594f85f2e77d6c80280034133c", "body": {"id": "chatcmpl-9St6dZt0rHBBfkVup27QFkegD0fkf", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no recognized medication or substance called \"Adlinod\" in standard medical or pharmacological references. It's possible that the name could be a misspelling, a new drug not yet widely recognized, or a substance that is known under a different name.\n\nIf you are looking for information on a specific drug or treatment, I recommend checking reliable medical sources or databases like the FDA website, WHO publications, or reputable medical journals. Alternatively, if you provide more context or a correct spelling, I might be able to offer more detailed information. Always make sure to use the most current and credible sources in your medical practice."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 136, "total_tokens": 177}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_KYUvQlbvPLru6BdiXYO7Za2U", "custom_id": "518_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d705d848adf29cb571cc1cf05ae4342", "body": {"id": "chatcmpl-9St6dQPFQEklG3kXGxN9XKDQACrAT", "object": "chat.completion", "created": 1716672039, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for lenograstim, a granulocyte colony-stimulating factor (G-CSF) that is used primarily to stimulate the production of neutrophils, a type of white blood cell important for fighting infection. It is a recombinant form of human G-CSF and is produced using biotechnology. Here are some key points about Granocyte that might be useful for you as a physician:\n\n### Indications\nGranocyte is commonly prescribed for:\n- **Neutropenia and febrile neutropenia prevention**, particularly in patients undergoing cytotoxic chemotherapy.\n- **Mobilization of peripheral blood progenitor cells** (PBPCs) in both autologous and allogeneic settings, often in conjunction with chemotherapy and/or other mobilizing agents.\n- **Severe chronic neutropenia** (SCN), including congenital, cyclic, or idiopathic neutropenia.\n\n### Mechanism of Action\nLenograstim ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Zxl5VFMUoyZ9Gt70VrLSw27U", "custom_id": "519_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef075ff8ec72a8dcc2d94ba316cf97cf", "body": {"id": "chatcmpl-9St6ekspmdkvMIZNOVaPRvAlBSK2S", "object": "chat.completion", "created": 1716672040, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisplyx, known generically as lenvatinib, is a medication used primarily in the treatment of certain types of thyroid cancer and in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) after one prior anti-angiogenic therapy. Here are some key points you should know about Kisplyx:\n\n1. **Mechanism of Action**: Lenvatinib is a receptor tyrosine kinase inhibitor. It primarily inhibits the activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3. Additionally, lenvatinib also inhibits other kinases involved in pathogenic angiogenesis, tumor growth, and cancer progression, such as FGFR, PDGFR, and KIT.\n\n2. **Indications**:\n   - As a single agent, it is used for the treatment of progressive, locally advanced, or metastatic, differentiated thyroid carcinoma (DTC)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9Xs9nvy0lNL0YQCF9j9O8I2K", "custom_id": "520_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60837a7953dc1d9fe8d33b92a6507ea5", "body": {"id": "chatcmpl-9St6eRKZtud92KtsZxVBN3tOf7M3R", "object": "chat.completion", "created": 1716672040, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, whose generic name is letrozole, is an oral medication used primarily in the treatment of breast cancer. It falls under the class of drugs known as aromatase inhibitors, which work by decreasing the amount of estrogen produced by the body. This reduction in estrogen is particularly beneficial in treating hormone receptor-positive breast cancer. Here are some key points you should know about Femara:\n\n1. **Indications**: Femara is primarily used for the treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also used in:\n   - Extended adjuvant treatment of early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy.\n   - First-line treatment of hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.\n   - Treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.\n\n2. **Mechanism of Action**: Letrozole inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rfM37gSGaaviRzXeO2kjqVkO", "custom_id": "521_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8950c27b54783976a9912df8d1d8e367", "body": {"id": "chatcmpl-9St6eViVFu6cAm5cqMyX3N9yBvsgw", "object": "chat.completion", "created": 1716672040, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in September 2021, Camcevi (leuprolide mesylate) is a medication used in adult patients for the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) receptor agonist, which works by suppressing the production of testosterone, a hormone that can promote the growth of prostate cancer cells.\n\nHere are some key points you should know about Camcevi:\n\n1. **Administration**: Camcevi is administered as a subcutaneous injection. It is available in a formulation that allows for dosing every six months, which can be convenient for patients and may improve adherence compared to formulations requiring more frequent administration.\n\n2. **Mechanism of Action**: Camcevi acts by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in testosterone levels (known as \"testosterone flare\"). Subsequently, it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pDIXIJSa8RwkUN2iogfRTTOC", "custom_id": "522_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c917562cb610893034827f0a0c644add", "body": {"id": "chatcmpl-9St6fQA9Ce7WD5vVZHiFOp80zpcla", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ergamisol, also known by its generic name levamisole, is a medication that was originally used as an anthelmintic to treat worm infestations in humans and animals. However, its use in humans has been largely discontinued in many countries due to its side effects, though it is still used in veterinary medicine.\n\nFor physicians, it is important to know that levamisole has been found as an adulterant in illicit drugs, particularly cocaine. The presence of levamisole in cocaine can have significant clinical implications, including the following:\n\n1. **Agranulocytosis**: This is a serious and potentially fatal condition where there is a marked decrease in the number of granulocytes, a type of white blood cell. Patients may present with sudden onset of fever, sore throat, and infections.\n\n2. **Vasculitis**: Levamisole-contaminated cocaine has been associated with a form of vasculitis that can cause skin nec"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nc2D0gfifONjHaLHyyAmIBOL", "custom_id": "523_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "81867f3f94d3ab045cf7bacfe15b2afe", "body": {"id": "chatcmpl-9St6eGPvLO4IbGQH4OMe7G2kpxl9w", "object": "chat.completion", "created": 1716672040, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fusilev (levoleucovorin) is used primarily to diminish the toxic effects of methotrexate in cancer therapies. It is the pharmacologically active isomer of leucovorin (folinic acid), and it is used in situations where rapid neutralization of methotrexate is necessary, such as in cases of high-dose methotrexate therapy. Here are several key points about Fusilev that you, as a physician, might find essential:\n\n1. **Indications**:\n   - To reduce the harmful effects of methotrexate when used in high doses during cancer therapies.\n   - As a component in the palliative treatment of patients with advanced metastatic colorectal cancer, usually in combination with fluorouracil.\n\n2. **Pharmacology**:\n   - Levoleucovorin is the active enantiomer of racemic d,l-leucovorin, meaning it may require a lower dose to achieve"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kEmnfnADp0SJu7Z5iWnvMcqK", "custom_id": "524_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47217b179b77221116d466afad962f3f", "body": {"id": "chatcmpl-9St6ejQroeqjk2UfoxPnh4YZPXgX0", "object": "chat.completion", "created": 1716672040, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu, known generically as lomustine, is a type of chemotherapy drug used mainly in the treatment of various types of cancer, including brain tumors, Hodgkin's disease, and other malignancies. It belongs to the class of drugs known as alkylating agents, which work by damaging the DNA of cancer cells, thereby inhibiting their growth and multiplication.\n\nHere are some key points you should know about CeeNu:\n\n1. **Indications**: Lomustine is primarily used for treating brain tumors, both primary and metastatic, in adults and children. It is also indicated for Hodgkin's lymphoma, and sometimes used in cases of melanoma and lung cancer.\n\n2. **Administration**: Lomustine is taken orally in capsule form. The dosage and treatment schedule can vary based on the type, size, and location of the cancer, as well as the patient\u2019s overall health and response to therapy.\n\n3. **Mechanism of Action**: As"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sHabkVhJL8nq1DyoZz9tP02g", "custom_id": "525_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "75c76f9ceb231aac720ff8433eca0427", "body": {"id": "chatcmpl-9St6frsz3Q51039z8h3P6NzxRYOQD", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (lorlatinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. Here are key points that physicians should be aware of regarding Lorbrena:\n\n1. **Indication and Usage**:\n   - Lorbrena is specifically indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC who have progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.\n\n2. **Mechanism of Action**:\n   - Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI). It is designed to inhibit the activity of the ALK protein, which can drive the growth of tumors in some cancers. Lorlatinib has the ability to penetrate the blood-brain barrier, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_A6cWHOnapdH6HalTEpL5eTaR", "custom_id": "526_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "04db6c16d66d96baa68d4a4920b3480f", "body": {"id": "chatcmpl-9St6fHCENcGrc517mdayLBzODZaY3", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera (lutetium Lu 177 dotatate) is a targeted radiolabeled medication used in the treatment of certain types of neuroendocrine tumors (NETs). Specifically, it is indicated for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in patients who require systemic therapy.\n\nHere are some key points about Lutathera:\n\n1. **Mechanism of Action**: Lutathera works by binding to somatostatin receptors (primarily subtype 2) on tumor cells, which are commonly present on neuroendocrine tumors. After binding, the radiolabeled lutetium Lu 177 delivers beta radiation directly to the tumor and surrounding tissue, helping to reduce tumor size and potentially control symptoms.\n\n2. **Administration**: Lutathera is administered as an intravenous infusion. The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5HIa5jRc4KuuwfPNGtijfjcF", "custom_id": "527_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a99699b1293e0457c44e43cf9e5c795a", "body": {"id": "chatcmpl-9St6fgxAhXoVUbBwtcOPEENAg6weA", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (generic name: tafasitamab) is a monoclonal antibody used in the treatment of certain types of cancer. Specifically, it targets the CD19 antigen on B cells, making it relevant for the treatment of B-cell malignancies. Here are some key points you should know about Minjuvi:\n\n1. **Indications**: As of my last update, Minjuvi is approved for use in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).\n\n2. **Mechanism of Action**: Minjuvi binds to the CD19 antigen on the surface of pre-B and mature B lymphocytes and on many B-cell tumors. After binding, it induces immune effector functions that lead to the death of B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r39nVQ6SCMVWx7nXzRlfwdRW", "custom_id": "528_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d5ae42f68dc4d225fd03e948ec565262", "body": {"id": "chatcmpl-9St6fbSGrJ2HJVGpjbmLG9NRY7liY", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ledaga (chlormethine gel) is a medication used for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare type of non-Hodgkin lymphoma that primarily affects the skin. Here are some key points about Ledaga that you, as a physician, might find useful:\n\n1. **Active Ingredient**: Ledaga contains chlormethine, also known as mechlorethamine, which is a nitrogen mustard alkylating agent. It works by binding to DNA in cells, which interferes with their growth and replication, thereby reducing the proliferation of malignant cells.\n\n2. **Indications**: It is approved for the topical treatment of MF-CTCL in adult patients. This condition is characterized by the presence of malignant T-cells in the skin, leading to itchy rashes, plaques, and tumors.\n\n3. **Application**: Ledaga gel is applied once daily to the affected"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_ELtJoliNlFjp6apuT4ZTnrv4", "custom_id": "529_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02d308812669c159107bc7b097c6c772", "body": {"id": "chatcmpl-9St6fQbpzYZqT7a8lAOeqQ210a0Wy", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera (medroxyprogesterone acetate) is an injectable contraceptive used to prevent pregnancy. It is a form of long-acting reversible contraception that is both effective and convenient for many users. Here are several key points you should know about Depo-Provera:\n\n1. **Mechanism of Action**: Depo-Provera works primarily by preventing ovulation. It also thickens cervical mucus to prevent sperm from reaching the egg and alters the uterine lining to prevent implantation should fertilization occur.\n\n2. **Dosage and Administration**: The standard dose is 150 mg of medroxyprogesterone acetate administered intramuscularly every 12 weeks. Consistency in timing is crucial for maintaining its effectiveness. There is also a subcutaneous formulation available.\n\n3. **Effectiveness**: Depo-Provera is highly effective with a failure rate of less than 1% per year when used correctly and consistently. Its effectiveness can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wdtCgJYW8xJ71GGKyjnTavrm", "custom_id": "530_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bef6b9fb863866f63611b1c42efa5b9a", "body": {"id": "chatcmpl-9St6fimfOdJoNXSZ92Ax9FLViQyYc", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Maygace is a brand name for the drug megestrol acetate, which is a synthetic derivative of the hormone progesterone. It is commonly used for its appetite-stimulating and weight gain effects in patients experiencing anorexia, cachexia, or significant weight loss associated with cancer or AIDS. Here are some important aspects to consider when prescribing or managing treatment with Maygace:\n\n1. **Indications**:\n   - Primarily used to treat anorexia, cachexia, or unexplained, significant weight loss in patients with AIDS and cancer.\n   - It is also used in the treatment of breast cancer and endometrial cancer.\n\n2. **Mechanism of Action**:\n   - Megestrol acetate works as a progestational agent. It exerts its effects by directly stimulating the appetite center in the brain leading to an increase in appetite and caloric intake, potentially causing weight gain.\n   - It also has antigonadotropic effects ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gNu5Jt81CuDSnwfK4BzkmuVC", "custom_id": "531_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "54256d17e631445704aa7f063ac41215", "body": {"id": "chatcmpl-9St6fq5ud1YOIsnMIu2FaOtQugCMe", "object": "chat.completion", "created": 1716672041, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, the brand name for melphalan, is a chemotherapy drug used primarily to treat multiple myeloma, ovarian cancer, and amyloidosis. It belongs to a class of drugs known as alkylating agents, which work by binding to DNA and preventing the cancer cells from multiplying, leading to cell death. Here are key points you should know about Alkeran:\n\n1. **Indications**: Alkeran is mainly used for the palliative treatment of multiple myeloma and for the treatment of ovarian cancer. It is also used in conditioning regimens for hematopoietic progenitor cell transplantation.\n\n2. **Administration**: Melphalan is available in both oral and intravenous formulations. The route of administration depends on the specific condition being treated and the overall treatment plan.\n\n3. **Dosage**: The dosage varies based on the indication, patient\u2019s body surface area, and whether it is being used alone or in combination with other drugs. Dosage adjustments may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3xsI2KzmQOA5N5sRBHbsHSFT", "custom_id": "532_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62c0eefdcbe260f91a0abc361538fd63", "body": {"id": "chatcmpl-9St6gcS3O6aXoofPri4J2BaTX37aT", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol, also known by its generic name mercaptopurine or 6-MP, is a chemotherapy drug used primarily to treat leukemia, particularly acute lymphoblastic leukemia (ALL). It is also sometimes used for treating other types of cancer and autoimmune diseases. Here are some key points you should know about Purinethol:\n\n1. **Mechanism of Action**: Mercaptopurine is a purine analog. It interferes with nucleotide synthesis and metabolism, which leads to the inhibition of DNA, RNA, and protein synthesis. This makes it effective in targeting rapidly dividing cells, such as cancerous cells.\n\n2. **Indications**: While primarily used for ALL, it's also used in the management of chronic myeloid leukemia (CML) and certain non-malignant conditions, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.\n\n3. **Administration**: Mercaptopurine is administered orally. The dosage and length"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zZ5Ge84SuMce3hjMY700r7pN", "custom_id": "533_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6de4da4685c15131c7510251fee683e9", "body": {"id": "chatcmpl-9St6g035a1PZ43YJr7oo91SyepuE1", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there may be some confusion or a typo in your query. There's no widely recognized medical substance or term known as \"Anti Uron.\" It's possible that there might have been a misunderstanding or misspelling. Could you be referring to something else, such as a specific drug, treatment, or medical condition? Providing more context or clarification would help me give you the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 82, "total_tokens": 123}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_S9kkh0mkrL6nKUGUi330wKNH", "custom_id": "534_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "69ab3ea093d4d5362c2c3fdf881a91f6", "body": {"id": "chatcmpl-9St6gXGtMKq8uTiGhal5xvyVNtufZ", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication used primarily to treat certain types of cancer, such as breast cancer, lung cancer, leukemia, and lymphoma, as well as some non-malignant conditions including rheumatoid arthritis and psoriasis. Methotrexate belongs to a class of drugs known as antimetabolites and works by inhibiting the metabolism of folic acid, which is necessary for the cell to synthesize DNA, RNA, and proteins.\n\nHere are several key points about methotrexate that you, as a physician, should be aware of:\n\n1. **Indications**: Besides its use in oncology, methotrexate is effective in the treatment of autoimmune diseases due to its immunosuppressive effects. It is often prescribed for rheumatoid arthritis when other treatments have failed, and it can be used in cases of severe psoriasis.\n\n2. **Mechanism of Action**: Methotrexate competitively inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9l1F2S7RuzTj1KphE1NvkeH5", "custom_id": "535_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "372b8129a8ee28e5f184ae69ec0f38f6", "body": {"id": "chatcmpl-9St6gg7AgeRUtgxbWLjqVj5l9pBOJ", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ammoidin, also known as xanthotoxin, is a compound that belongs to a group of natural products known as furocoumarins. It is found in several plants, particularly in the Apiaceae family, like celery, parsley, and parsnips, and in the Rutaceae family, such as citrus fruits. Ammoidin has been used in medicine, primarily in the treatment of skin disorders.\n\nHere are some key points for physicians regarding Ammoidin:\n\n1. **Medical Uses**: Ammoidin is primarily used in the treatment of psoriasis and vitiligo. It is used in PUVA (psoralen and ultraviolet A) therapy where the compound is administered either topically or orally before exposure to ultraviolet A (UVA) light. This combination treatment helps to increase skin sensitivity to UVA light, thereby promoting repigmentation in vitiligo and reducing hyperproliferation of skin cells in psoriasis.\n\n2. **Mech"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FkrwOQbLFfGKEAjyHn9piuBl", "custom_id": "536_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb265cbdad995a7c7ef7c7ad40d8826a", "body": {"id": "chatcmpl-9St6glzSvxhnhjs0bcKKScjTwrEEy", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adlone is a brand name that might be used for medications in different regions, often containing different active ingredients depending on the country. Therefore, it's crucial to verify the exact medication and formulation you are referring to. In some cases, Adlone could be a reference to a corticosteroid medication, possibly methylprednisolone or a similar corticosteroid. Corticosteroids are used to reduce inflammation and suppress the immune system in a variety of conditions.\n\nIf Adlone in your context refers to a corticosteroid such as methylprednisolone, here are some key points you should be aware of:\n\n### Indications\nCorticosteroids like methylprednisolone are prescribed for a wide range of conditions, including:\n- Autoimmune diseases (e.g., lupus, rheumatoid arthritis)\n- Inflammatory conditions (e.g., asthma, COPD)\n- Allergic reactions\n- Acute and chronic dermatological diseases\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Li1SOHPAmgmPjimSDJgTzUOv", "custom_id": "537_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d8819cdd3507efd842e5b2e9507606bf", "body": {"id": "chatcmpl-9St6g6wM2MlczHOxNgv4MxtAcqo41", "object": "chat.completion", "created": 1716672042, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is a prescription medication used for the treatment of certain types of blood cancers. Here are key points you should know about Rydapt:\n\n1. **Indications**: Rydapt is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. It is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt is also indicated for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.\n\n2. **Mechanism of Action**: Rydapt is a kinase inhibitor. It works by inhibiting multiple receptor tyrosine kinases, including FLT3, which can be abnormally activated in AML patients. Inhibition of these kinases leads to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TUVLkQ1tdqlLGfGq53gTdQW6", "custom_id": "538_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c3fe608aab16ae8b709d27cc5e485ada", "body": {"id": "chatcmpl-9St6hkPOB8XPgMRWVZCH4BeKtIiia", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a medication or supplement specifically known as \"Lyomit\" recognized in standard medical references. It's possible that \"Lyomit\" could be a new drug, a less common or international drug name, or it might be misspelled.\n\nIf you meant something else or have additional details like its active ingredients or its intended use, I could try to provide more relevant information. Otherwise, I recommend checking the most recent medical literature or drug databases. Additionally, contacting pharmaceutical information services or using resources like the FDA or EMA websites might be helpful for up-to-date and accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 124, "total_tokens": 164}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_U260UmIjWWpMYXdbITd4RUIY", "custom_id": "539_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d4aa5283eaac2ddcb29afd0b7c60a026", "body": {"id": "chatcmpl-9St6hrcSTp2Z0GpgfRHo7XnD43DP1", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (mitotane) is a medication primarily used in the treatment of adrenocortical carcinoma, a rare cancer of the adrenal glands. It also has applications in managing the symptoms of Cushing's syndrome when surgery is not an option. Here are some key points you should know about Lysodren:\n\n1. **Mechanism of Action**: Mitotane works by selectively targeting and destroying cells in the adrenal cortex, which decreases the production of adrenal hormones, especially cortisol.\n\n2. **Indications**:\n   - Primary treatment for symptomatic or metastatic adrenocortical carcinoma.\n   - Used off-label for controlling hypercortisolism in Cushing's syndrome when surgery cannot be performed.\n\n3. **Administration**: Lysodren is administered orally. The dosage needs to be carefully adjusted based on therapeutic response and side effects. Treatment typically starts with a lower dose, gradually increasing to achieve optimal therapeutic levels.\n\n4. **Monitoring**: Regular monitoring"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fhZcbYriY7N5hsIQ0zTLlKMT", "custom_id": "540_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36695a5dea1e51647082981d434506d9", "body": {"id": "chatcmpl-9St6h2gwD863MZ3jQLW3wQXzyav8e", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nitrol is commonly referred to in clinical practice as nitroglycerin or glyceryl trinitrate, which is a vasodilating agent used primarily in the management of angina pectoris, heart failure, and myocardial infarction. Here are some key points about nitroglycerin that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Nitroglycerin works by relaxing smooth muscle via dose-dependent dilation of arterial and venous beds to reduce both preload and afterload. At lower doses, it primarily affects the veins, while at higher doses, it also dilates arteries.\n\n2. **Indications**:\n   - **Angina Pectoris**: It is used for the prevention and treatment of chest pain caused by angina. Nitroglycerin alleviates the pain by decreasing myocardial oxygen demand and increasing oxygen supply.\n   - **Acute Coronary Syndrome**: It is used in the management of acute coronary syndrome"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_kMuB8LMgrifbbfA5rf7127aO", "custom_id": "541_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "14c959ee25becb10019c5a17b83f6047", "body": {"id": "chatcmpl-9St6hCeaLdBWAxIqBIC3fqizioLlu", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody used in the treatment of certain types of cutaneous T-cell lymphoma (CTCL), specifically for patients who have received at least one prior systemic therapy. It targets CC chemokine receptor 4 (CCR4), a protein expressed on the surface of some cancer cells, which is involved in tumor cell proliferation and survival.\n\nHere are some key points physicians should consider when using Poteligeo:\n\n1. **Indications and Usage**: Poteligeo is approved by the FDA for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS), which are subtypes of CTCL. These are typically diagnosed in later stages of the disease.\n\n2. **Mechanism of Action**: Mogamulizumab binds to CCR4, a receptor found on some T-cells. By binding to this receptor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_o0f1KrLoSB0U1Qef7s1b5sY0", "custom_id": "542_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ed0016c5878ebaf8b99e0d83076e51f", "body": {"id": "chatcmpl-9St6hr15BrlXOd4eLRKUReOrRLzY8", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a medication used in the treatment of certain types of cancer, specifically hairy cell leukemia (HCL). Here are some key points about Lumoxiti that you, as a physician, should be aware of:\n\n1. **Indication**: Lumoxiti is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.\n\n2. **Mechanism of Action**: Lumoxiti is a CD22-directed cytotoxin. It is a recombinant immunotoxin that combines a portion of an antibody specific for the CD22 antigen on B cells with a toxin derived from Pseudomonas exotoxin A. The drug binds to CD22-expressing cells, is internalized, and then"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UolJIyXKKTBR8Uuk7gAmexEe", "custom_id": "543_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4363221789df2e0a7a8b783dfd55d250", "body": {"id": "chatcmpl-9St6hTyVPsY9wpVMo0FxC50n9bclQ", "object": "chat.completion", "created": 1716672043, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine (nadroparin calcium) is a type of anticoagulant medication that belongs to the class of drugs known as low molecular weight heparins (LMWHs). It is used to prevent and treat thromboembolic disorders, which are conditions that result from the formation of blood clots in the blood vessels. Here are some key points you should know about Fraxiparine:\n\n1. **Indications**:\n   - Prevention of venous thromboembolism (VTE) in patients undergoing surgery, especially those at high risk such as orthopedic or general surgery patients.\n   - Treatment of deep vein thrombosis (DVT) with or without pulmonary embolism.\n   - Prevention of clotting in extracorporeal circulation during hemodialysis.\n\n2. **Mechanism of Action**:\n   - Fraxiparine works by enhancing the inhibition of Factor Xa and Factor IIa through its action on antithrombin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5nbJcK3XGuXLad3w7PEjlYTx", "custom_id": "544_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dba70cae63585e867f1440ab968e0f16", "body": {"id": "chatcmpl-9St6iLsWTK57N5AKitn1bvvnWl2RU", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a monoclonal antibody used in the treatment of cancer, specifically for metastatic squamous non-small cell lung cancer (NSCLC). It targets the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells which helps them grow and divide. By targeting EGFR, necitumumab can inhibit the growth of cancer cells.\n\nHere are some key points you should be aware of as a physician:\n\n1. **Indication**: Portrazza is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer. It is not indicated for treatment of patients with non-squamous NSCLC.\n\n2. **Mechanism of Action**: Necitumumab is an EGFR antagonist which binds to the EGFR receptor and blocks the binding of the receptor\u2019s natural ligands (e.g"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_xeiFpRQu32OBVTZ4UkWdu7KA", "custom_id": "545_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d5fb42ebb26586caddae2ee44644fd5b", "body": {"id": "chatcmpl-9St6i4ArRgK6app33zTwQGkbzuds7", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no drug or medical term specifically known as \"Aqupla\" recognized in standard medical resources or databases. It's possible that the name might be misspelled, a brand name not widely recognized, or a new development that has not been extensively documented yet.\n\nIf \"Aqupla\" is a medication or medical term you've encountered in a specific context, such as a new research trial, a regional treatment, or a brand name in a particular country, it would be helpful to have more details or the correct spelling. This would enable me to provide more accurate and useful information.\n\nIf you're looking for information on a specific treatment or medication related to water-related ailments or something that sounds like \"Aqupla,\" please provide more context or details. Alternatively, checking the most current and reputable medical databases, consulting with pharmacy resources, or reaching out to colleagues might yield better results."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 182, "total_tokens": 222}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_6HxaKtOxRbpEGNg13hxzxa0G", "custom_id": "546_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98e5b2a3e1ef638e91cbeca791d214a4", "body": {"id": "chatcmpl-9St6iXA51b8jwu7dcoeRPWNlOCvVl", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon (nelarabine) is a chemotherapy medication used for the treatment of certain types of leukemia and lymphoma, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) when these diseases have not responded to or have relapsed after at least two chemotherapy regimens.\n\nHere are some key points you should know about Arranon:\n\n1. **Mechanism of Action**: Nelarabine is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), which is converted into its active form, ara-GTP, within the body. Ara-GTP accumulates preferentially in T-cells and disrupts DNA synthesis and function, leading to cell death.\n\n2. **Indications**: Arranon is approved for use in patients who have not responded to or have relapsed after treatment with at least two prior chemotherapy regimens. Its use is specific to T-cell acute"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_XPHYactE3ijUH5ikJrfsNlEv", "custom_id": "547_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4b3f5ee52d64d753d098030dae1bd234", "body": {"id": "chatcmpl-9St6iGz8wpmgPm4WFRReteR78vRZE", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (chemical name: neratinib) is a medication used in the treatment of breast cancer. It is specifically approved for the extended adjuvant treatment of HER2-positive early-stage breast cancer in adult patients who have previously been treated with trastuzumab-based therapy. Here are some key points you should know about Nerlynx:\n\n1. **Mechanism of Action**: Neratinib is a tyrosine kinase inhibitor that irreversibly binds to and inhibits the HER2 receptor kinase and other kinases in the ErbB family. This inhibition blocks signal transduction pathways, which may result in the reduction of tumor growth.\n\n2. **Indications**: As of the last update, Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. It is also approved for use in combination with capecit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZMTZzvzNUwCtsiXaW7KzmZ5Q", "custom_id": "548_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef69ec665770dc258f7f56e23242cb2a", "body": {"id": "chatcmpl-9St6iYr7oN1mT3uYyAN4uyknAXB4i", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna (nilotinib) is an oral medication used primarily for the treatment of chronic myeloid leukemia (CML). Here are some key points you should be aware of as a physician:\n\n1. **Indications**: Tasigna is approved for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive CML (Ph+ CML) in adult patients who are resistant or intolerant to prior therapy, including imatinib. It is also approved for pediatric patients with newly diagnosed Ph+ CML in chronic phase or with Ph+ CML in chronic phase who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n\n2. **Mechanism of Action**: Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor. It specifically targets the BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome abnormality in CML cells. By inhibiting this enzyme, nilotinib helps to stop the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DvX3HpsVumTlefieqCQpfu4J", "custom_id": "549_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bc4409fa565fbcfcff77b32ca96dde79", "body": {"id": "chatcmpl-9St6izKA1DuTaEDFocauRV8X21D8Y", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron, also known by its generic name nilutamide, is a medication primarily used in the treatment of prostate cancer. It belongs to a class of drugs known as nonsteroidal antiandrogens. Here are some key points that you, as a physician, should know about Anandron:\n\n1. **Mechanism of Action**: Nilutamide works by blocking the action of androgens (male hormones), such as testosterone, by binding to androgen receptors in the prostate cells. This helps slow the growth of androgen-dependent prostate cancer cells.\n\n2. **Indications**: It is typically used in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2) to suppress the flare phenomena that often accompanies the use of gonadotropin-releasing hormone (GnRH) agonists.\n\n3. **Administration**: Nilutamide is administered orally. The dosage and duration of treatment depend on the specifics of the patient's health status and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FNcfMO2y0xKNNDudpHElVaOH", "custom_id": "550_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "060373c67274b9a31f5421c8c6dd3695", "body": {"id": "chatcmpl-9St6iNAbvsQgfCKlDsaVv70ltmFlX", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a medication or treatment specifically known as \"Nidran\" in widely recognized medical databases or sources. It is possible that the name could be a brand name, a non-English term, or possibly a misspelling.\n\nIf you are referring to a specific drug, treatment, or concept, it might be helpful to check the spelling or provide additional context. If it's a new or emerging treatment or medication, it could also be beneficial to look into the latest medical journals or clinical trial registries for the most current information.\n\nIf you provide more details, I could try to offer more specific information or guidance!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 132, "total_tokens": 173}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_kMIOdsZDWhMl39oOOt9dTuhm", "custom_id": "551_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "03d2ae76417d4193f3ecc99a59534a48", "body": {"id": "chatcmpl-9St6i91rYFS71UHQdrVQseBFVIKir", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv, known generically as nintedanib, is a medication primarily used in the management of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. It is also approved for use in treating some types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Cyendiv:\n\n1. **Mechanism of Action**: Nintedanib is a tyrosine kinase inhibitor that targets multiple pathways involved in the proliferation, migration, and transformation of fibroblasts, which are central to the pathogenesis of pulmonary fibrosis. Specifically, it inhibitates platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR).\n\n2. **Indications**:\n   - **Idiopathic Pulmonary Fibrosis (IPF)**: It is approved for the treatment of IPF and is designed to slow the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HZWlmKyvYSNyoE1abgnBjFbz", "custom_id": "552_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c7eaeaf44bd6b50119b579e3f33bd925", "body": {"id": "chatcmpl-9St6iBgP7n2nSGsoZtaxdXzvuvBQ4", "object": "chat.completion", "created": 1716672044, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no widely recognized medication or substance called \"Niranib\" in standard medical databases or pharmaceutical references. It's possible that the name could be a misspelling, a new drug not yet widely documented, or perhaps a drug known more commonly under a different name.\n\nIf you're dealing with a specific medication that might be a novel treatment or under a different international branding, I recommend checking the latest medical literature or pharmaceutical databases. Alternatively, consulting with pharmacists or other drug information services could provide up-to-date insights.\n\nIf you provide more context or details about the drug, such as its intended use or any additional name details, I might be able to offer more specific information or guidance."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 150, "total_tokens": 191}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hVhUuq9ysBFCRXmzAO4DWqP5", "custom_id": "553_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b15876a043954963cef6e71e23248946", "body": {"id": "chatcmpl-9St6jbpspYuvdFEmAaC6JdWp61k8j", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is a medication used in the treatment of various types of cancer. It belongs to a class of drugs known as PD-1 (Programmed Death-1) inhibitors, which are a type of immunotherapy. Opdivo works by blocking the PD-1 pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1, Opdivo helps the immune system to better recognize and attack cancer cells.\n\n### Key Points for Physicians:\n\n#### Indications:\nOpdivo is approved for use in several types of cancers, including but not limited to:\n- Melanoma (advanced or metastatic)\n- Non-small cell lung cancer (NSCLC)\n- Renal cell carcinoma (advanced)\n- Hodgkin lymphoma (after failure of other treatments)\n- Head and neck squamous cell carcinoma\n- Urothelial carcinoma\n- Colorectal cancer (MSI-H or dMMR metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_6inlQJnEJO4eNLPJt6l0Wq9C", "custom_id": "554_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43dd7d447f682413c741092e81afad67", "body": {"id": "chatcmpl-9St6jzjZort3wCVy2QcjOGJLrQp2y", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Myocet is a liposome-encapsulated formulation of doxorubicin, a type of chemotherapy drug used to treat various cancers, including breast cancer. Here are some key points you should know about Myocet:\n\n1. **Mechanism of Action**: Like conventional doxorubicin, Myocet interferes with the growth of cancer cells by intercalating DNA and inhibiting topoisomerase II, which are crucial for DNA replication and transcription. The liposomal encapsulation is designed to enhance the delivery of doxorobicin to the tumor cells while reducing the exposure of normal tissues, potentially decreasing some of the toxic effects associated with non-encapsulated doxorubicin.\n\n2. **Indications**: Myocet is primarily indicated for use in combination with other chemotherapeutic agents for the treatment of metastatic breast cancer. The specifics of its use and combination therapies may vary based on local guidelines and the specific characteristics of the patient's cancer.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7lsPa6OoMNHj7rGaXpmV3p26", "custom_id": "555_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a15dfaf9b744fc5487a44932f245828b", "body": {"id": "chatcmpl-9St6jihamvKNmWZc4R8bPKkxyszHV", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilevar, known chemically as norethandrolone, is an anabolic steroid that was developed in the 1950s. It is one of the first anabolic steroids to be used clinically. Despite its historical significance in medicine, it is important to note that its use today is very limited and it is largely considered obsolete in most therapeutic practices.\n\n### Key Points for Physicians:\n\n1. **Medical Uses**: Historically, Nilevar was used to treat various conditions such as chronic wasting diseases, severe burn injuries, and certain types of anemia. It was intended to promote muscle growth, appetite, and red blood cell production.\n\n2. **Mechanism of Action**: As an anabolic steroid, Nilevar promotes protein synthesis and muscle growth. It also has androgenic effects, contributing to the development and maintenance of male characteristics.\n\n3. **Side Effects**: Anabolic steroids like Nilevar can cause a range of side effects. These can include liver toxicity, changes in cholesterol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_nbyCNwrSnJcYq22uVieX6waX", "custom_id": "556_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "15a5f3282128f04cf8e90f82d2d9f006", "body": {"id": "chatcmpl-9St6jsr3Z7AmDf0hxclAwPpQpDtMv", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva (obinutuzumab) is a monoclonal antibody used in the treatment of certain types of blood cancers. Here are key points that physicians should be aware of regarding this medication:\n\n1. **Indications**: Gazyva is approved for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) patients who have relapsed after, or are refractory to, a rituximab-containing regimen.\n\n2. **Mechanism of Action**: Obinutuzumab is a type II anti-CD20 monoclonal antibody. It binds to the CD20 antigen on B-cells, leading to cell death. It differs from rituximab (a type I anti-CD20 antibody) in its ability to induce direct cell death and stronger antibody-dependent cellular cytotoxicity.\n\n3. **Administration**: Gazyva is administered as an intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_babqzFhXgJeChgHY59TWd2m4", "custom_id": "557_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "467aa63ed5929ae5c44067f16b419e78", "body": {"id": "chatcmpl-9St6jNwB41lAxOyvlydOsPI0STUU7", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina, known generically as octreotide, is a synthetic analog of somatostatin, a naturally occurring inhibitory hormone which suppresses the secretion of several other hormones, such as growth hormone, insulin, and glucagon. Octreotide acts similarly to somatostatin, but with a longer duration of action.\n\nHere are some key points about octreotide (Longastatina) that you might find useful as a physician:\n\n1. **Indications**: Octreotide is primarily used in the treatment of acromegaly, where it helps to reduce the levels of growth hormone and IGF-1 (insulin-like growth factor 1). It is also used for the management of symptoms associated with neuroendocrine tumors, including carcinoid syndrome and vasoactive intestinal peptide secreting adenomas (VIPomas).\n\n2. **Other Uses**: It can help in controlling symptoms such as flushing and diarrhea associated with these tumors, and it may also be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qTDJSpulJSofxFABZvN3nmu8", "custom_id": "558_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f270fd2275ee17a439903ba17e334685", "body": {"id": "chatcmpl-9St6j3GvbQeW8if4rY6i9jRj5WikG", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR (long-acting release) is a brand name for a medication whose active ingredient is octreotide acetate. Octreotide is a synthetic octapeptide derivative of somatostatin, a natural hormone that inhibits the secretion of several other hormones, such as growth hormone, insulin, and glucagon.\n\n### Indications\nLongastatina LAR is primarily used for the treatment of:\n- **Acromegaly**: It is effective in reducing the levels of growth hormone and insulin-like growth factor 1 (IGF-1).\n- **Neuroendocrine tumors**: Particularly those originating from the gastrointestinal tract and pancreas. It helps in controlling symptoms caused by hormone-secreting tumors such as carcinoid syndrome and vasoactive intestinal peptide secreting adenomas (VIPomas).\n- **Severe diarrhea and flushing episodes associated with metastatic carcinoid tumors**: Octreotide helps to control these symptoms by inhibiting the release of serotonin and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iF5tOB0BlYYrhmFGJjpjuRG4", "custom_id": "559_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0a6673c4f99f14db4787f178be7a79ea", "body": {"id": "chatcmpl-9St6jVCWv5b2tKa8alN30JVplnbKZ", "object": "chat.completion", "created": 1716672045, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arzerra (ofatumumab) is a medication that is used primarily in the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Ofatumumab is a monoclonal antibody that specifically targets a molecule called CD20 found on the surface of B cells (a type of lymphocyte involved in CLL). By binding to CD20, Arzerra helps the immune system attack the cancer cells, leading to their destruction.\n\nHere are some key points you should know about Arzerra:\n\n1. **Indications**: Arzerra is approved for the treatment of CLL. Its use may vary between first-line therapy and therapy for relapsed or refractory CLL, depending on the patient's previous treatments and overall health status.\n\n2. **Administration**: Arzerra is administered via intravenous infusion. The dosing schedule can vary depending on the treatment line and combination therapies."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_daTdg0dfIN5DziKlHqh98Sna", "custom_id": "560_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "27e3feffffb02529b767e97393fe893a", "body": {"id": "chatcmpl-9St6kW2tdSJQourk8xROg6iqRWrWc", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza (olaparib) is a medication used in the treatment of certain types of cancers, primarily in ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It belongs to a class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors. Here are several key points about Lynparza that physicians should be aware of:\n\n1. **Mechanism of Action**: Lynparza works by inhibiting the PARP enzyme, which plays a role in repairing damaged DNA in cells. By inhibiting PARP, olaparib causes DNA damage to accumulate in cancer cells, ultimately leading to cell death. This is particularly effective in cancers where DNA repair pathways (such as those involving BRCA1 or BRCA2 proteins) are already compromised.\n\n2. **Indications**: Lynparza is approved for:\n   - The treatment of advanced ovarian cancer in patients who have a deleterious or suspected deleterious BRCA mutation and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vL4djxJmWZoWhXBRgcSvGKuT", "custom_id": "561_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd38f358ffe1c1da28397fe4f2b14391", "body": {"id": "chatcmpl-9St6kiyvVMyGSfthgaGTKEnoRMSg4", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a monoclonal antibody that targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), which is involved in the growth and development of cells, including cancer cells. Here are the key points you should know about Lartruvo:\n\n1. **Indications**: Initially, Lartruvo was granted accelerated approval by the FDA in 2016 for use in combination with doxorubicin for the treatment of adults with soft tissue sarcoma (STS) who could not be cured with radiation or surgery and who had a type of STS for which an anthracycline was an appropriate treatment. However, it's important to note that in April 2019, the FDA advised that Lartruvo should not be started in new patients outside of ongoing clinical trials. This recommendation came after a phase III study (ANNOUNCE trial) failed to confirm the clinical benefit of Lartruvo in combination with doxorubicin.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_itf0IndSIN8rWrX02XRFZ8QU", "custom_id": "562_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "927ae65258e82e5a6d5cd4631ca4a009", "body": {"id": "chatcmpl-9St6k3opSZJkR4WRBFRGX0q4Gf2kY", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Omapro\" is not a recognized or commonly known medication in the pharmaceutical industry. It's possible you may have misspelled the name or are referring to a medication that is not widely known or available under that name, especially if it's a brand name specific to certain regions or under development.\n\nIf you're referring to a specific treatment or drug, could you please provide more details or verify the spelling? This will help me provide the most accurate and relevant information. If you are looking for information on a medication used in a specific treatment or for a particular condition, I can help with that too if you provide more context or details."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 135, "total_tokens": 176}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1lNalLMHHAFa5fvmNSL3gtL0", "custom_id": "563_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89845f56173ac5d7984d652bffc2a6f9", "body": {"id": "chatcmpl-9St6kqZa9sKOGBdKvJwJVlHy1rK66", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prilosec, the brand name for omeprazole, is a medication commonly used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. It belongs to a class of drugs known as proton pump inhibitors (PPIs), which work by reducing the amount of acid produced by the stomach. Here are some key points about Prilosec that you, as a physician, might find useful:\n\n1. **Indications:**\n   - **GERD**: Prilosec is used to treat symptoms of gastroesophageal reflux disease, which includes heartburn and other symptoms caused by the backflow of stomach acid into the esophagus.\n   - **Peptic Ulcer Disease**: It is used to promote healing of erosive esophagitis (damage to the esophagus from stomach acid) and to treat ulcers of the stomach and intestines.\n   - **Zollinger-E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_CNABRdTdX67WybOmYDnODby1", "custom_id": "564_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b59954169466f72ab7866497b409daff", "body": {"id": "chatcmpl-9St6kH3xZrb7JwcuzPhikIv0vL5Ev", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib, marketed under the name Tagrisso, is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC). It is particularly effective for patients whose cancer cells have specific mutations in the epidermal growth factor receptor (EGFR) gene. Here are some key points about osimertinib that you, as a physician, might find useful:\n\n1. **Indications**: Osimertinib is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. It is also used as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.\n\n2. **Mechanism of Action**: Osimertinib is a third-generation, irreversible EGFR tyrosine kinase inhibitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_i109eFE1gwl5SdsR3TVMA2la", "custom_id": "565_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ae44e45b862fb78ef5f52143ff42dc8", "body": {"id": "chatcmpl-9St6kKlElU40yj4Js6bcbvm75Oczs", "object": "chat.completion", "created": 1716672046, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Coxatin is not a recognized medication in standard medical databases such as the U.S. National Library of Medicine or WHO's list of essential medicines. It's possible that it could be a new drug, a drug under development, or it might be known by a different name in different regions.\n\nIf Coxatin refers to a specific medication you've encountered in your practice or studies, please check for the most current and detailed information from reliable medical resources or pharmaceutical databases. Additionally, consulting peer-reviewed journals, attending medical conferences, or discussing with pharmacological experts could provide updated insights. Always ensure that your information sources are up-to-date and scientifically validated."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 139, "total_tokens": 179}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_Eu9ANlJ24usXYd0khwyHi03K", "custom_id": "566_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f17cf6a8669ce409efd847c59dbf89c6", "body": {"id": "chatcmpl-9St6lcMKUnt3OncJYNYfIqHjqrPNb", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane (paclitaxel protein-bound particles) is a chemotherapeutic agent used in the treatment of various cancers, including breast cancer, non-small cell lung cancer, and pancreatic cancer. It is a nanoparticle formulation of the taxane class drug paclitaxel, which is bound to albumin, a naturally occurring protein. This formulation allows for a solvent-free suspension, which can reduce some of the solvent-related side effects associated with conventional paclitaxel.\n\nHere are some key points about Abraxane:\n\n1. **Indications:**\n   - **Metastatic Breast Cancer:** Abraxane is approved for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.\n   - **Non-Small Cell Lung Cancer (NSCLC):** It is approved as a first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WXFwEYbZeJhsclRYyNy9kLGc", "custom_id": "567_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f41981a24ed0850db56cdb20f6d5868e", "body": {"id": "chatcmpl-9St6lfNXwZ2MwEdoDvKwS9PN948Pb", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitaxel is not a widely recognized drug under the name provided. It's possible that there might be a typo or confusion with a similar-sounding medication. One well-known medication that sounds similar is \"paclitaxel,\" which is commonly used in the treatment of various types of cancer.\n\nPaclitaxel is a chemotherapeutic agent used primarily in the treatment of breast cancer, ovarian cancer, lung cancer, and Kaposi's sarcoma. It works by inhibiting cell division, thereby blocking the growth and spread of cancer cells. Paclitaxel is in a class of drugs known as taxanes, which stabilize microtubules and consequently inhibit the process of cell division.\n\nKey points a physician should know about paclitaxel include:\n\n1. **Indications**: Paclitaxel is approved for the treatment of ovarian cancer, breast cancer, lung cancer, and Kaposi's sarcoma among other cancers. It is often used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_iz3OOmya205DTzEupS8HwKtB", "custom_id": "568_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cea1677a6ba1ec9663c8bea028b0a091", "body": {"id": "chatcmpl-9St6lOf1eJJvwcXMYhtqqrEhMvJsJ", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medical or pharmaceutical reference to \"Vonjo\" that is commonly recognized. It's possible that \"Vonjo\" could be a term from a non-English language, a brand name, a cultural reference, or something specific to a particular field or region that isn't widely documented in global medical literature.\n\nIf \"Vonjo\" refers to a drug, treatment, or medical condition not commonly known in the wider medical community, or if it's a new term or innovation, I would recommend consulting the latest medical literature, clinical trial registries, or drug approval agencies for the most current information. Alternatively, if \"Vonjo\" is a term used in a specific cultural or traditional medicine context, seeking information from sources or literature specific to that cultural or medicinal practice might be helpful.\n\nIf you provide more context or details, I might be able to offer more specific guidance or direct you to relevant resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 194, "total_tokens": 234}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NFVi7tqdXhXStYi3DghzfEeX", "custom_id": "569_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5229fcafff8529433400d03d97904795", "body": {"id": "chatcmpl-9St6luoWr9uDi4Ah9SxQStUNAZiRv", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrance (palbociclib) is a medication commonly used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here are some key points you should know about Ibrance:\n\n1. **Mechanism of Action**: Ibrance is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases are responsible for regulating the cell cycle. By inhibiting these kinases, Ibrance prevents the progression from G1 to S phase of the cell cycle, thus potentially inhibiting the growth of cancer cells.\n\n2. **Indications**: Ibrance is typically indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0XNmRCEdmHbODVrYbkEt6qOg", "custom_id": "570_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47408a05b967b388c2aca9b09629bfbf", "body": {"id": "chatcmpl-9St6lDWAFjqjfhSFphzq15pwaccI8", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vectibix (panitumumab) is a medication used in the treatment of metastatic colorectal cancer. It is a type of targeted therapy known as a monoclonal antibody, specifically designed to target the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. Here are key points that physicians should consider when prescribing or managing treatment with Vectibix:\n\n1. **Indications**: Vectibix is approved for the treatment of metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. It is specifically indicated for patients with tumors that express EGFR and are RAS wild-type (i.e., no mutations in exon 2, 3, or 4 of the KRAS or NRAS genes).\n\n2. **Mechanism of Action**: Panitumumab binds specifically to the epidermal growth factor receptor (EG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cwtylcxB42pbKcWjy82pgs2j", "custom_id": "571_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "394cc3ae28711dd71c27155949d35c83", "body": {"id": "chatcmpl-9St6lKLmuaxLSy1Ms7amiEnnROe1q", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faridak (panobinostat) is an oral medication used primarily for the treatment of multiple myeloma, a type of cancer that originates in plasma cells, which are a type of white blood cell responsible for producing antibodies. The drug is considered a histone deacetylase (HDAC) inhibitor.\n\n### Key Points for Physicians:\n1. **Indication**:\n   - Panobinostat is approved for use in combination with bortezomib and dexamethasone in patients with multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\n\n2. **Mechanism of Action**:\n   - As an HDAC inhibitor, panobinostat works by interfering with the function of histone deacetylases, which are enzymes involved in the removal of acetyl groups from the lysine residues on histone proteins. This action leads to an open chromatin structure and affects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QzP5P0uz4cXBFrWOPoFltEWu", "custom_id": "572_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32966387ae31d1abf2793956ebb253c1", "body": {"id": "chatcmpl-9St6lbSm4k5QFM3vhhSYbfJhCQtd9", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there appears to be no recognized medication or substance named \"Pazopater.\" It's possible that the name might be misspelled or it could be a brand name not widely recognized or new to the market. \n\nIf you are referring to a specific drug, could you please check the spelling or provide more context? Alternatively, if this is related to a particular treatment or medical condition, providing those details might help in identifying the correct information. If \"Pazopater\" is a new or less common medication, consulting the latest medical literature or a drug database might be helpful. Also, discussing with colleagues or pharmacists might provide insights into new or unfamiliar treatments."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 145, "total_tokens": 186}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_f6fQqYwZGaoMLgCPhc1g9aC2", "custom_id": "573_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c19f035bbc404b89a182d3bc9e334278", "body": {"id": "chatcmpl-9St6lV206cFYEn0nUCcyh1Lz4x1lg", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a medication commonly used in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that primarily affects the white blood cells. Here are several important aspects of Oncaspar that you, as a physician, should be familiar with:\n\n### 1. Mechanism of Action\nOncaspar is a modified version of the enzyme L-asparaginase, which is linked to polyethylene glycol (PEG) to increase its half-life in the body. The enzyme works by depleting the amino acid asparagine, which is essential for the growth and survival of leukemia cells. Normal cells can synthesize asparagine, but leukemia cells cannot, making them particularly vulnerable to asparagine depletion.\n\n### 2. Indications\nOncaspar is approved for use in patients with acute lymphoblastic leukemia as part of a multi-agent chemotherapeutic regimen. It is typically used in patients who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3GNMQ4oWRh2BQPPR2j2RvOHp", "custom_id": "574_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b2a712c1745807eee37c89b08549276", "body": {"id": "chatcmpl-9St6lAT2cNfpvhqeKIQWqUPRGHG9L", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegasys (peginterferon alfa-2a) is a medication used in the treatment of chronic hepatitis B and C infections. It is a form of long-acting interferon, which is a protein that modulates the immune response. Here are several key points about Pegasys that you, as a physician, might find useful:\n\n1. **Indications**:\n   - **Chronic Hepatitis C**: Pegasys is approved for the treatment of adults with chronic hepatitis C who have compensated liver disease and are not previously treated or have failed previous interferon therapy.\n   - **Chronic Hepatitis B**: It is also used for the treatment of HBeAg positive and negative chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated ALT and histologically proven liver inflammation and/or fibrosis.\n\n2. **Mechanism of Action**:\n   - Pegasys works by binding to the human type I interferon receptor,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_ptqTkjgQJtUEYvx0Sncv1573", "custom_id": "575_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3bd6805ae9f7c3a761f15358baec21ad", "body": {"id": "chatcmpl-9St6lG2pemHcl1J3x9FS0xcGe6WXi", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron (peginterferon alfa-2b) is a pegylated form of interferon alfa-2b, a protein that modifies the body's immune response and has antiviral activity. It is primarily used for the treatment of chronic hepatitis C, a viral infection that affects the liver. The pegylation process extends the half-life of the drug in the bloodstream, allowing for less frequent dosing compared to non-pegylated interferon.\n\nHere are some key points you should know about PEG-Intron:\n\n1. **Indications**: PEG-Intron is approved for the treatment of chronic hepatitis C in patients with compensated liver disease, and in some regions, it may be used in combination with other antiviral medications such as ribavirin or direct-acting antiviral agents.\n\n2. **Mechanism of Action**: PEG-Intron works by binding to the interferon receptor on cell surfaces, triggering a cascade of immune responses that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_sqoL4QLzm699wAv34peFR2wD", "custom_id": "576_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b4243e74f68ccece34a4f55ed4141ed1", "body": {"id": "chatcmpl-9St6lTJK0Bsh5ezFKMhL6zuKtRNTz", "object": "chat.completion", "created": 1716672047, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx, also known as Doxil in the United States, is a formulation of doxorubicin encapsulated in liposomes. This drug is primarily used in the treatment of various cancers, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. The liposomal encapsulation is designed to increase the efficacy of the drug while reducing some of the systemic toxic effects associated with conventional doxorubicin.\n\nHere are some key points about Caelyx:\n\n1. **Mechanism of Action**: Caelyx works by intercalating DNA, which disrupts the replication of cancer cells and induces apoptosis. The liposomal delivery system allows for a more targeted delivery to tumor cells, potentially reducing damage to healthy cells.\n\n2. **Indications**:\n   - **Ovarian Cancer**: It is used in the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.\n   - **AIDS-related Kaposi"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oc98HrtfpVZrYW0um4Qhufiu", "custom_id": "577_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "647045cd1b00b4e1e59976ff9971253a", "body": {"id": "chatcmpl-9St6mixoqBJ5VHFZB2UEj1wRatChY", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda (pembrolizumab) is an important medication in the field of oncology, used primarily for treating various types of cancer. Here are the key aspects you should know about Keytruda:\n\n1. **Mechanism of Action**: Keytruda is a monoclonal antibody that targets and blocks the programmed cell death 1 (PD-1) receptor, a protein on T cells that normally helps keep these cells from attacking other cells in the body. By blocking PD-1, Keytruda boosts the immune response against cancer cells.\n\n2. **Indications**: Keytruda has been approved by the FDA for the treatment of multiple types of cancers including melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T0rXGCpOt8Wm9ZtQyUZ6jgp2", "custom_id": "578_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e7b05c7ef63f975ef0c5f0124b6d4410", "body": {"id": "chatcmpl-9St6miwvZq5FfD3lnNQox0lpG4ZI9", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta (pemetrexed) is a chemotherapy drug used primarily in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Here are several key points about Alimta that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - Alimta is approved for the treatment of patients with malignant pleural mesothelioma (MPM) in combination with cisplatin, for those who are not candidates for curative surgery.\n   - It is also indicated for the initial treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with cisplatin.\n   - Additionally, it can be used as a maintenance treatment for locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n   - It is also indicated as a single agent for the treatment of patients with recurrent, metastatic non-squ"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Q8Ik6fN6gmDBxPb73YinzFPw", "custom_id": "579_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "612c573222ddbe1c71a9c9923132cb24", "body": {"id": "chatcmpl-9St6mI6WD0kcEBXJ2nzrtMuUcb31C", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Nipent** (pentostatin) is a chemotherapeutic agent used primarily in the treatment of hairy cell leukemia. Here are some key points that you, as a physician, might find important:\n\n### 1. **Mechanism of Action**\n   - Pentostatin is a purine analog and a potent inhibitor of adenosine deaminase (ADA), an enzyme that is particularly active in the pathways of DNA synthesis and repair. By inhibiting ADA, pentostatin induces apoptosis of lymphocytes, which is particularly effective in treating hairy cell leukemia.\n\n### 2. **Indications**\n   - The primary indication for pentostatin is for the treatment of hairy cell leukemia. It might be used in other conditions as part of investigational or off-label use, but such decisions should be based on thorough clinical judgment and literature review.\n\n### 3. **Administration**\n   - Pentostatin is administered intravenously. It is crucial to ensure proper dosing intervals"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ao9QXhAOXSzxuGNsRLog1ZbV", "custom_id": "580_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a8ed7525c153bcc8a010310ad903156", "body": {"id": "chatcmpl-9St6mIpggXWXXihlClY8MEOukwF5Z", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Omnitarg, also known as pertuzumab, is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Pertuzumab targets the HER2 receptor, a protein that can promote the growth of cancer cells. In particular, pertuzumab binds to a different epitope or part of the HER2 protein than trastuzumab (another HER2-targeting drug), and by doing so, it prevents the pairing (dimerization) of HER2 with other HER receptors, which is necessary for signaling that leads to tumor growth.\n\n### Key Points for Physicians:\n1. **Indications**:\n   - Pertuzumab is approved for use in combination with trastuzumab and chemotherapy for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.\n   - It is also used in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dRZCbXdYlcXJQodpmlEsJAq7", "custom_id": "581_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e62db0dd3c6072b1cab1773765a06538", "body": {"id": "chatcmpl-9St6mAR27kLLOBakbvldFHHAmSgOg", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Pinorubicin does not appear to be a recognized or commonly used medication in the medical community. It's possible that there might be a typographical error or confusion with another drug. Perhaps you were inquiring about a different medication, such as Doxorubicin or Daunorubicin, which are well-known anthracycline antibiotics used in cancer treatment.\n\nDoxorubicin and Daunorubicin are used to treat various types of cancer, including leukemia, lymphomas, and breast cancer, among others. They work by intercalating DNA strands, inhibiting the enzyme topoisomerase II, and creating oxygen-free radicals that damage cellular components.\n\nIf Pinorubicin was the drug in question and it is a new or less common medication, I would recommend checking the latest medical literature or pharmaceutical databases for the most accurate and up-to-date information. Always ensure to use reliable sources and consult pharmacological references or databases for information on new"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_0mFFb0xi2TJnicCr56hQvKwW", "custom_id": "582_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73847505fb39f7ee11342cdfea7bcb42", "body": {"id": "chatcmpl-9St6mMYKriQskO2QbEu5dAIbY0S4j", "object": "chat.completion", "created": 1716672048, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a cancer medication used primarily in the treatment of non-Hodgkin lymphoma. Here are some key points you should be aware of as a physician:\n\n1. **Indications**: Pixuvri is approved for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin Lymphoma (NHL). This indication is generally considered after other therapies have failed or have not been tolerated.\n\n2. **Mechanism of Action**: Pixantrone is a cytotoxic aza-anthracenedione that is structurally related to anthracyclines but designed to reduce the potential for causing cardiotoxicity. Pixantrone forms stable DNA adducts and exhibits its antineoplastic effects by interfering with DNA synthesis and repair.\n\n3. **Administration**: Pixuvri is administered intravenously. The dosing regimen typically involves administration on days 1, 8, and 15 of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_2NaetPoPMTuK5k2dkRiq5VFQ", "custom_id": "583_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2e62d65e08685944b57b51f0025e965", "body": {"id": "chatcmpl-9St6n43RJWai1EhpjdrO4VtTcSarv", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin, also known as plicamycin, is a chemotherapy drug that was historically used to treat testicular cancer and certain types of sarcomas. It is also known for its use in managing hypercalcemia (high calcium levels in the blood), especially when associated with cancer. However, its use has declined due to the development of newer agents with better efficacy and safety profiles.\n\nHere are some key aspects you should be aware of regarding Mithracin:\n\n1. **Mechanism of Action**: Mithracin acts by binding to DNA, thereby inhibiting RNA synthesis. This action can inhibit the growth of cancer cells.\n\n2. **Indications**: Historically, Mithracin was used in the treatment of testicular tumors, and it was sometimes used off-label for treating hypercalcemia of malignancy.\n\n3. **Administration**: Mithracin is administered intravenously. The dosage and treatment schedule can vary depending on the specific conditions being treated and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ju3QmJ4Cvg3XGNLt4sgqB76q", "custom_id": "584_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e42dcd8df9c9ca491a3919b48935331", "body": {"id": "chatcmpl-9St6nsApTBlOh01KFOvEsnPAbLJI7", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, Actimid, also known as pomalidomide, is a derivative of thalidomide and belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs). Pomalidomide is primarily used in the treatment of multiple myeloma, particularly in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\nHere are key points you should know about pomalidomide:\n\n1. **Mechanism of Action**: Pomalidomide works by modulating the immune system and also affects the microenvironment of tumor cells. It has multiple mechanisms of action, including anti-inflammatory effects, immunomodulatory effects, and direct antitumor effects.\n\n2. **Indications**: The primary indication for pomalidomide is for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dDJYYQ2s39curoh3eAOBPsBR", "custom_id": "585_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "86abe406aa95349f905e5fe18d71ef74", "body": {"id": "chatcmpl-9St6nAkSzldPKLOJwDLMFRYFehEGd", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a prescription medication used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some important aspects to consider about this medication:\n\n### Mechanism of Action\nIclusig is a tyrosine kinase inhibitor (TKI) that specifically targets BCR-ABL, an abnormal tyrosine kinase that promotes cancer cell proliferation in CML and Ph+ ALL. Unlike other TKIs, ponatinib is effective against a range of BCR-ABL mutations, including the T315I mutation, which is particularly resistant to other available TKIs.\n\n### Indications\nIclusig is approved for the treatment of:\n- Adult patients with chronic phase, accelerated phase, or blast phase CML or Ph+ ALL for whom no other TKI therapy is indicated.\n- Patients with T315I-positive CML (any phase) or T315I-positive Ph+"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7ybcwKY6BKkSugcpenXXSjzm", "custom_id": "586_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "818ebd981821075ee267fadce2fffd89", "body": {"id": "chatcmpl-9St6nWEffQJX0wfHdhDs2r1OJCw61", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn (pralatrexate) is a chemotherapeutic agent primarily used for the treatment of peripheral T-cell lymphoma (PTCL). Here are some key points about Folotyn that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Folotyn is a dihydrofolate reductase inhibitor. It works by inhibiting the formation of DNA and RNA, which is necessary for the growth and reproduction of cancer cells. Pralatrexate has a higher affinity for the enzyme compared to other similar agents, which may contribute to its effectiveness in T-cell lymphoma.\n\n2. **Indications**: Folotyn is specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a rare type of non-Hodgkin lymphoma that affects T-cells, and treatment options are relatively limited.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LO9fjd5egFRPXpfj3o0HEeh9", "custom_id": "587_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb0fd5506777c230a46bfb335c245faf", "body": {"id": "chatcmpl-9St6nhrG003TnDezrHKR1f8wznspS", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, whose generic name is pravastatin, is a member of the drug class known as statins or HMG-CoA reductase inhibitors. It is used primarily to lower cholesterol and triglycerides in the blood. Here are key points you should know about Pravachol:\n\n### Mechanism of Action\nPravachol works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. By inhibiting this enzyme, pravastatin effectively reduces the production of low-density lipoprotein (LDL) cholesterol (often referred to as \"bad\" cholesterol) and triglycerides, while modestly increasing levels of high-density lipoprotein (HDL) cholesterol (\"good\" cholesterol).\n\n### Indications\n- **Hyperlipidemia**: Treatment of adults and children (aged 8 years and older) with high cholesterol and triglyceride levels.\n- **Primary Prevention"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lBMwkVcA4R2fRhm8V6gvPaiZ", "custom_id": "588_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d13dcd866bc968b0933fae0ea442b5f6", "body": {"id": "chatcmpl-9St6niHhpQ9BegNn1Wljr6C9IemWX", "object": "chat.completion", "created": 1716672049, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a detailed understanding of medications you prescribe, including Adnisolone. However, it seems there might be a typo in the name you provided. If you are referring to **Prednisolone**, here is relevant information:\n\n**Prednisolone** is a synthetic adrenal corticosteroid used for its anti-inflammatory and immunosuppressive properties. Here are key points to consider:\n\n### Pharmacology:\n- **Mechanism of Action**: Prednisolone mimics the effects of cortisol, a natural steroid produced by the adrenal glands. It works by decreasing inflammation and modifying the body\u2019s immune response.\n- **Bioavailability**: Prednisolone has high bioavailability when taken orally.\n\n### Indications:\nPrednisolone is used in the treatment of various conditions, including:\n- Autoimmune diseases (e.g., lupus, rheumatoid arthritis)\n- Allergic reactions\n- Asthma and other respiratory disorders\n- Certain types"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CWd62VFP9dVFR0FLGCdHtVoa", "custom_id": "589_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e092282753c513867008ea4e9f3035b9", "body": {"id": "chatcmpl-9St6o47F1sLJlsgG0o5SFVkVXdoWC", "object": "chat.completion", "created": 1716672050, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in your question, as \"Artinizona\" doesn't appear to be a recognized medical term, pharmaceutical, or condition. It's possible you meant something else. If you can provide more specific information or clarify the term, I would be more than happy to help you with relevant information. If you are referring to something specific to Arizona, such as a health condition prevalent in the area or a medical facility, please let me know so I can assist you appropriately."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 103, "total_tokens": 144}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3cCA26AjaG2ALMMK0fGKneVR", "custom_id": "590_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60bdba345c5cc7c9e1559d154f171ab0", "body": {"id": "chatcmpl-9St6o0ECdjkxfJ1zOnjxOH01zqhe2", "object": "chat.completion", "created": 1716672050, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Indicarb is not a widely recognized medication or substance in standard medical resources or pharmacological databases. It's possible that the name \"Indicarb\" could be a brand name, a misspelling, or a non-standard term for a drug or treatment, possibly specific to certain regions or within a particular field of medicine.\n\nIf you are seeking information on a medication or treatment for a patient, it is crucial to verify the correct name and usage. Here are a few steps you can take:\n\n1. **Check the Spelling**: Verify the spelling of the medication with the source of your information to ensure it's correct.\n\n2. **Consult Reliable Sources**: Use trusted pharmacological databases, medical textbooks, or official drug information services to find accurate and up-to-date information.\n\n3. **Ask Colleagues or Specialists**: If the medication is not found in standard sources, consulting with pharmacy colleagues or specialists in the relevant field of medicine might provide insights.\n\n4. **Contact the Manufacturer**: If"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MWj33ldBRxKd0L5bEWwskTx2", "custom_id": "591_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5cf53997ebbc8d680bf20af6d74a7a41", "body": {"id": "chatcmpl-9St6ocQLzJJL2p5ySxZQewUErTBYR", "object": "chat.completion", "created": 1716672050, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin is the brand name for quinine sulfate, which is primarily used to treat malaria. Here are several important aspects you should know about Qualaquin as a physician:\n\n1. **Indications**: Qualaquin is approved for the treatment of uncomplicated Plasmodium falciparum malaria. It is often used when the organism is susceptible to quinine or when the clinical situation precludes the use of other antimalarials.\n\n2. **Mechanism of Action**: Quinine acts primarily as a blood schizonticide, interfering with the parasite's ability to metabolize and utilize erythrocyte hemoglobin. It\u2019s thought to inhibit the hemozoin biocrystallization, thus facilitating an aggregation of cytotoxic heme. This action kills the parasite in the blood.\n\n3. **Dosage and Administration**: The typical adult dosage for the treatment of malaria is 648 mg every 8 hours for 7 days. Treatment should be adjusted based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EJG1IGFUftlA5DVvgCLooYBg", "custom_id": "592_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "84e3827ec91bd6acb2007d3a208cc6c6", "body": {"id": "chatcmpl-9St6oMbf1nva0T5lQc6WV3wewl4cD", "object": "chat.completion", "created": 1716672050, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Vanflyta (quizartinib) is a medication specifically indicated for the treatment of certain types of acute myeloid leukemia (AML). It is particularly used in cases where the AML is FLT3-ITD positive, which is a genetic mutation that can influence the aggressiveness of the leukemia.\n\nHere are some key points you should know about Vanflyta (quizartinib):\n\n1. **Mechanism of Action**: Quizartinib is a tyrosine kinase inhibitor that specifically targets the FLT3 gene mutation. FLT3 mutations are one of the most common genetic abnormalities in AML and are associated with a particularly poor prognosis. By inhibiting this pathway, quizartinib can help to reduce the proliferation of leukemic cells.\n\n2. **Indications**: It is crucial to confirm the presence of the FLT3-ITD mutation in AML patients before initiating treatment with Vanflyta, as it is specifically targeted to this mutation.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Gj78FPNmA1nthYVrn19uH7iH", "custom_id": "593_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "38fbe914968171d1a9ae6e102dd43731", "body": {"id": "chatcmpl-9St6ooXlrsnvNslsU3M5DfbSMQXEY", "object": "chat.completion", "created": 1716672050, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supect (ceftaroline fosamil) is an antibiotic used for treating bacterial infections. It belongs to the class of cephalosporin antibiotics and is effective against a broad range of gram-positive and some gram-negative bacteria. Here are some key points you should know about Supect:\n\n1. **Spectrum of Activity**: Supect is particularly effective against Methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae. It also covers other common gram-positive pathogens and some gram-negative organisms, but it is not effective against Pseudomonas aeruginosa.\n\n2. **Indications**: Supect is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).\n\n3. **Administration**: It is administered intravenously, typically over a 1-hour infusion. The dosage and duration of therapy depend on the type and severity of the infection.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FLdbK5QT2tNdNK4tAEbzREJ5", "custom_id": "594_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b389a6a08f3335dc7c4a5d7e57461088", "body": {"id": "chatcmpl-9St6pHXlJb8RRgHCCYf8VH1nJRn2S", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex, known generically as raltitrexed, is a chemotherapy drug used primarily in the treatment of colorectal cancer. Here are some key points a physician should know about Tomudex:\n\n1. **Mechanism of Action**: Raltitrexed is a thymidylate synthase inhibitor. It works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis. By blocking this enzyme, the drug prevents the synthesis of thymidine monophosphate (dTMP), a nucleotide essential for DNA replication and repair, leading to cell death in rapidly dividing cells.\n\n2. **Indications**: Tomudex is primarily indicated for the treatment of advanced colorectal cancer, particularly in patients who are not candidates for or have not responded to fluorouracil-based chemotherapy.\n\n3. **Administration**: Raltitrexed is administered intravenously. The dosage and frequency of administration can vary depending on factors such as the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_clgAAyBxc5IQs4XFBO8fFLBS", "custom_id": "595_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e91c3a6f8d8e025681e342862f6e2e53", "body": {"id": "chatcmpl-9St6pfsFfFrNqjK1O9GD8V5ICEhSJ", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyramza (ramucirumab) is a monoclonal antibody used as a targeted therapy for certain types of cancer. It works by inhibiting angiogenesis, the process by which new blood vessels form, thereby reducing blood supply to tumors and limiting their growth. Here are some key points you should be aware of when considering Cyramza for treatment:\n\n1. **Indications**: Cyramza is approved for use in various cancers, including:\n   - Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with chemotherapy.\n   - Metastatic non-small cell lung cancer (NSCLC), in combination with chemotherapy.\n   - Metastatic colorectal cancer, used in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy after disease progression on a prior therapy.\n   - Hepatocellular carcinoma who have an alpha-fetoprotein (AFP)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tWQXtQRKFTOOnhPG8PVwB0L3", "custom_id": "596_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "616a665ae9d89ae54f0a134d21e14558", "body": {"id": "chatcmpl-9St6pol7vkEWj74uW7COllXpE5ljx", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cymer, an ASML company, is known for its expertise in developing and manufacturing deep ultraviolet (DUV) light sources used in photolithography\u2014a critical technology for semiconductor manufacturing. As a physician, the relevance of Cymer's technology to your field may not be direct, unless you are involved in research or applications that intersect with technology and healthcare, such as the development of medical devices or diagnostics equipment that utilize semiconductor technology.\n\nFor physicians involved in medical research or those interested in the technological advancements in healthcare equipment, understanding the role of companies like Cymer can be valuable. Their technology enables the production of increasingly smaller and more powerful microchips, which can be crucial for the development of advanced medical devices, including wearable health monitors, diagnostic imaging equipment, and other medical electronic devices.\n\nMoreover, the precision and efficiency in manufacturing enabled by photolithography technology can lead to more compact, efficient, and affordable electronics, potentially making medical devices more accessible and effective in clinical settings.\n\nIn summary, while"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_B1ovDtav9HzR0LaYhQlqA8C5", "custom_id": "597_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ca9d7e51c5f12d5cda7015a0046fa11", "body": {"id": "chatcmpl-9St6pTv5uKvQS9NEbTNM4S5O8bJti", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Nublexa (known internationally as Stivarga) is a medication primarily used in the treatment of certain types of cancers. Its active ingredient is regorafenib, which is a multi-kinase inhibitor. Here are some key points you should know about Nublexa:\n\n### Indications\nNublexa is approved for use in:\n1. **Colorectal Cancer**: It is indicated for patients with metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.\n2. **Gastrointestinal Stromal Tumors (GIST)**: For the treatment of patients with locally advanced, unresectable or metastatic GIST who have previously been treated with imatinib mesylate and sunitinib malate.\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0BiiFVyP5hYelcEuWUs4TM5B", "custom_id": "598_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b362ec9c4b7bf11243365f410e303cfa", "body": {"id": "chatcmpl-9St6pHka6KaiUl4yMsI0cW1UZHQcv", "object": "chat.completion", "created": 1716672051, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (generic name: ribociclib) is a medication used in the treatment of certain types of breast cancer. Here are key points that you, as a physician, might need to know:\n\n1. **Indications**: Kisqali is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients who have received prior endocrine therapy.\n\n2. **Mechanism of Action**: Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, ribociclib helps to stop the cell cycle progression, thereby inhibiting the growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hS03hS90FyrkDoVscbkqdiE9", "custom_id": "599_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71004c75af0ecb9abfca16a05f4dfd15", "body": {"id": "chatcmpl-9St6qwWXYkUAwl46tTfNN223eB1FH", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Ikgdar\" does not refer to any known medication, medical terminology, or treatment recognized in the medical community. It is possible that there might be a spelling error or a misunderstanding regarding the term. If you can provide more context or details, I would be happy to help you find the correct information or assist you with a related query."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 80, "total_tokens": 121}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gIT3SeBOB7IMRI8ZKzMfyxZO", "custom_id": "600_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2bf22e60c7b8e6059e4e46b7790d90f8", "body": {"id": "chatcmpl-9St6qheV4l3ZTVUxFdcJcEUz53ziE", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela (rituximab and hyaluronidase human) is a combination medication used in the treatment of certain types of cancer and other conditions. It combines rituximab, a monoclonal antibody that targets the CD20 antigen on B cells, with hyaluronidase, an enzyme that increases tissue permeability and facilitates the dispersion and absorption of rituximab. Here are some key points you should know about Rituxan Hycela:\n\n1. **Indications**: Rituxan Hycela is approved for use in adults to treat:\n   - Non-Hodgkin's lymphoma (NHL), both previously untreated and relapsed or refractory, follicular lymphoma, and diffuse large B-cell lymphoma, as part of a combination regimen.\n   - Chronic lymphocytic leukemia (CLL) in combination with chemotherapy.\n\n2. **Administration**: Unlike rituximab which is typically given by intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FhakoQrboVjJGfQQAHFlrudi", "custom_id": "601_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0bfc4168c5ff6cee370aecfe6efbca30", "body": {"id": "chatcmpl-9St6q0MBLDqrC98zIB9etopvpO6EM", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Istodax** (romidepsin) is a prescription medication used in oncology, particularly for the treatment of certain types of cancer. Here are some key points you should know about Istodax:\n\n1. **Indications**: Istodax is approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. It is also approved for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.\n\n2. **Mechanism of Action**: Romidepsin is a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC, romidepsin alters the expression of genes, leading to growth arrest and apoptosis of cancer cells. This mechanism is thought to be crucial for its effectiveness in treating hematologic cancers.\n\n3. **Administration**: Istodax is administered intravenously. The dosing schedule typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nAzJOwqfsUGARrS10zfKUBTm", "custom_id": "602_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a90561997bb7d7b186adce01ed2ede4", "body": {"id": "chatcmpl-9St6qlwlolfUWhGVO30RB0sWLAYun", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besremi (ropeginterferon alfa-2b-njft) is a medication approved by the FDA for use in treating polycythemia vera, a type of blood disorder characterized by the excessive production of red blood cells. This condition can lead to thickening of the blood and an increased risk of blood clots. Besremi is particularly indicated for the treatment of adults with polycythemia vera who do not require phlebotomy, a procedure to remove some of the blood from the body to reduce red blood cell volume.\n\nHere are some key points about Besremi:\n\n1. **Mechanism of Action**: Ropeginterferon alfa-2b-njft is a long-acting, mono-pegylated form of interferon. It works by modulating the immune system and reducing the proliferation of blood cells.\n\n2. **Administration**: Besremi is administered via subcutaneous injection. The dosing regimen typically starts with bi"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JBvu5eAn2NW6hR0r1B6LoXlH", "custom_id": "603_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1b5d793b944a94e3ff9967cc4b822a67", "body": {"id": "chatcmpl-9St6q1Vw6BUiGgn4VdROiZRpWTpCg", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rubraca (rucaparib) is a medication approved for the treatment of certain types of cancer, specifically ovarian cancer and prostate cancer. It belongs to a class of drugs known as PARP inhibitors. PARP (poly ADP-ribose polymerase) inhibitors work by interfering with the DNA repair mechanisms in cancer cells, which leads to the death of these cells. Here are key points that physicians should consider when prescribing or managing patients on Rubraca:\n\n### Indications\n1. **Ovarian Cancer**: Rubraca is approved for the treatment of adult patients with ovarian cancer who have previously been treated with two or more chemotherapies and whose tumors are BRCA mutation (germline and/or somatic)-positive as determined by an FDA-approved test.\n2. **Prostate Cancer**: It is also approved for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jOROimqYjg5kuKNHOo3an5VT", "custom_id": "604_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1659921ed56b58d88f7162221789996c", "body": {"id": "chatcmpl-9St6qcCCzT3T3ayyshFcMaUsMHs2y", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitinib) is a medication used in the treatment of certain types of bone marrow disorders, specifically myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). Here are some important aspects you should know about Jakafi:\n\n1. **Mechanism of Action**:\n   Jakafi is a Janus kinase (JAK) inhibitor. It works by inhibiting the Janus kinase (JAK) 1 and 2 enzymes, which play a role in the signaling pathways that affect blood and immune cell production. By blocking these pathways, Jakafi helps to regulate the overactive signaling that contributes to the symptoms and complications of these diseases.\n\n2. **Indications**:\n   - **Myelofibrosis**: Jakafi is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VcD9Ty4967A6MEZNgijVlhub", "custom_id": "605_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "587bb28a127e9388b068aa93b1ea8a72", "body": {"id": "chatcmpl-9St6qwtMyyV05Zeqbld2sYmOJUV2U", "object": "chat.completion", "created": 1716672052, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate (ADC) approved by the FDA for the treatment of certain types of cancer. It specifically targets the Trop-2 receptor, which is expressed in many epithelial cancers, including triple-negative breast cancer (TNBC) and urothelial carcinoma.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - **Triple-Negative Breast Cancer (TNBC)**: Trodelvy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.\n   - **Urothelial Carcinoma**: It is also approved for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n2. **Mechanism of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cRtdMSPukqVBhnsbIABecijD", "custom_id": "606_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6bd7e5d695b4057a3482eddfabb980d6", "body": {"id": "chatcmpl-9St6roEWsA3mmZwF5CzxOpHqBwa2S", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leukine (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used primarily to promote the recovery of bone marrow and enhance white blood cell production, particularly in settings such as post-chemotherapy recovery, bone marrow transplantation, and in some cases, to improve outcomes in patients with fungal infections. Here are some key points you, as a physician, should know about Leukine:\n\n1. **Indications:**\n   - **Bone Marrow Transplantation:** Leukine is used to hasten myeloid recovery in patients undergoing autologous or allogeneic bone marrow transplantation.\n   - **Neutropenia:** It is indicated for the treatment of neutropenia following chemotherapy, helping to reduce the risk of infection due to neutropenia.\n   - **Acute Radiation Syndrome:** Leukine can be used to increase survival in patients acutely exposed to myel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zIg8FG5mYUppaVx5vucxAjRv", "custom_id": "607_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7b044b47961d4fed5f67f112719ae4d8", "body": {"id": "chatcmpl-9St6rVx4KcjgnCsA5RQ1xaKRFoEGg", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Nexpovio (selinexor) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Here are some key points about Nexpovio that you, as a physician, should know:\n\n1. **Mechanism of Action**:\n   Nexpovio works by inhibiting a protein called exportin 1 (XPO1). XPO1 is involved in nuclear export, the process by which proteins and RNA molecules are transported out of the nucleus of a cell. By inhibiting XPO1, Nexpovio can lead to the accumulation of tumor suppressor proteins in the nucleus, which can induce apoptosis (cell death) in cancer cells.\n\n2. **Approved Indications**:\n   - **Multiple Myeloma**: Nexpovio has been approved for use in combination with dexamethasone for the treatment of adult patients with relapsed or refr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gAEsWhBHPor9xx3R5WpdsVNl", "custom_id": "608_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a038f2f7df6a112f53d0fafbb45fc98", "body": {"id": "chatcmpl-9St6rw7KysDukqMZG3Nxzxaaj3XOq", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication approved by the FDA for specific medical use. Here are the key points you, as a physician, should be aware of:\n\n1. **Indication**: Koselugo is indicated for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. It\u2019s important to confirm the diagnosis of NF1 according to the criteria set forth by the National Institutes of Health (NIH).\n\n2. **Mechanism of Action**: Selumetinib is a kinase inhibitor that works by selectively inhibiting the activity of mitogen-activated protein kinases 1 and 2 (MEK1/2). Inhibition of MEK1/2 leads to a decrease in the activity of the extracellular signal-regulated kinase (ERK) pathway, which is often overactive in cells of patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_otm5W7fS3qDY4Ubc5giIotdT", "custom_id": "609_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1b14ea19d655b5cb0a33e8a1004207c4", "body": {"id": "chatcmpl-9St6rCRhf5Gh0rQ353gLjPW8T1yDL", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Semustina\" does not appear to be a recognized drug name in major medical databases, including those maintained by the FDA or the World Health Organization. It is possible that the name could be a misspelling, a drug under development that is not yet well known, or perhaps a non-standard or brand name not widely recognized.\n\nIf you meant a different medication or if there has been a development more recent than my last update, I recommend consulting the latest professional medical resources or databases like PubMed, FDA, or similar authoritative sources. If you are looking for information on a specific aspect of a drug (e.g., indications, pharmacology, side effects), these databases would also be the best source for accurate and reliable information. If you provide more context or details, I can try to assist further."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 172, "total_tokens": 213}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wEhadxXrJwvImUj6JPouo0eb", "custom_id": "610_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bf5fa2f550415e33eba2833e03a0ec5c", "body": {"id": "chatcmpl-9St6rpgQCYuZfYMj6F5bFBX9e5j2w", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is a cellular immunotherapy for treating prostate cancer, specifically indicated for asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. Here are some essential aspects you should know about Provenge:\n\n1. **Mechanism of Action**: Provenge is designed to stimulate the patient's immune system to target and attack prostate cancer cells. It is personalized and made from the patient\u2019s own immune cells, which are collected and then exposed to a protein that is part of the prostate cancer cells, combined with an immune-stimulating agent. The treated cells are then reinfused into the patient to help the immune system attack cancer cells.\n\n2. **Administration**: The treatment involves a series of three infusions, typically given about two weeks apart. Each infusion requires the patient\u2019s immune cells to be collected and sent to a processing center where they are activated and then returned to the clinic for infusion.\n\n3. **E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_35CPuftkTyoilqlf9jAAFYNB", "custom_id": "611_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "18f5557de3f8a80fedd203652d365a0b", "body": {"id": "chatcmpl-9St6rRI7FPUdMx1gFIoBc7BjrVHFs", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be informed about the pharmacological aspects, therapeutic indications, potential side effects, and administration guidelines of Odomzo (sonidegib), especially if you are treating patients with advanced skin cancers. Here\u2019s a detailed overview:\n\n### 1. Mechanism of Action\nOdomzo, whose active ingredient is sonidegib, is an inhibitor of the Hedgehog signaling pathway. It selectively binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog pathway activation. This inhibition can stop the proliferation of cancer cells and reduce tumor burden, particularly in cancers where this pathway is pathologically activated.\n\n### 2. Indications\nOdomzo is approved by the FDA for the treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. It provides a therapeutic option for a condition that might otherwise require more"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_myVxmA4aaxPrHDqfC1cxQn63", "custom_id": "612_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7176a562955761f118a189193f39fccd", "body": {"id": "chatcmpl-9St6rrEB0NzFAldHek71IhTNjKOFJ", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar, known generically as sorafenib, is a medication used primarily in the treatment of certain types of cancers. Here are some key points you should know about Nexavar as a physician:\n\n1. **Indications**: Nexavar is approved for the treatment of advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinoma (HCC), and differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.\n\n2. **Mechanism of Action**: Sorafenib is a tyrosine kinase inhibitor. It works by blocking multiple enzymes in the tyrosine kinase pathways, including those involved in the serine/threonine kinases pathway (RAF kinase) and the receptor tyrosine kinases pathway (VEGFR and PDGFR). This inhibition impedes tumor cell proliferation and angiogenesis.\n\n3. **Administration**: Nexavar is administered orally, and the dosage typically recommended is 400 mg twice daily without regard to meals."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_2u9uneG4U6t9IvH7Ze5S4ZqU", "custom_id": "613_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0327c2c474067a848032394b4d4b827f", "body": {"id": "chatcmpl-9St6r5vws8HWAb9Y8uwobPKUJikiH", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanosar, known generically as streptozocin, is a chemotherapy medication used primarily to treat pancreatic cancer, particularly islet cell carcinoma or pancreatic neuroendocrine tumors. Here are key points you should know about Zanosar:\n\n### Mechanism of Action\nStreptozocin is part of the nitrosourea class of chemotherapy drugs. It works by being selectively taken up by pancreatic beta cells through the glucose transporter GLUT2. Once inside the cell, it causes alkylation of DNA, which leads to DNA damage and ultimately cell death. It also fragments DNA by a non-alkylation mechanism which contributes to its cytotoxic effects.\n\n### Indications\n- Primarily used for the treatment of metastatic islet cell carcinoma of the pancreas.\n- It may also be used for other types of pancreatic neuroendocrine tumors.\n\n### Administration\n- Zanosar is administered intravenously. \n- Dosing regimen can vary based on the protocol and the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_re1jgCAp6QDTMb2QuJSYqgDj", "custom_id": "614_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e3f813ce17e71cce34bf7db95f15777", "body": {"id": "chatcmpl-9St6rlVwqdFuVF5CwewQ9zgcB41b6", "object": "chat.completion", "created": 1716672053, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Kitent\" does not correspond to any known medication, medical condition, or medical technology that I can identify. It's possible that there was a mistake in spelling or terminology. Could you please provide more details or clarify what you are referring to? If you mean something specific related to medicine, such as a drug, a treatment modality, or a medical concept, please provide the correct term or additional context so I can assist you effectively."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 103, "total_tokens": 143}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X4QU7OOV9G4yKmnNJaVVr5ZR", "custom_id": "615_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a5fdfde80f834493919d4de50b14ee54", "body": {"id": "chatcmpl-9St6sUjfrAu7KBLMagr7dDgaUtjcq", "object": "chat.completion", "created": 1716672054, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (tagraxofusp-erzs) is an important drug for physicians to be familiar with, especially those involved in the treatment of certain types of cancer. Here\u2019s a concise overview of the key aspects of Elzonris:\n\n1. **Indication**: Elzonris is approved by the U.S. Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years and older. BPDCN is a rare and aggressive form of blood cancer.\n\n2. **Mechanism of Action**: Elzonris is a targeted therapy that consists of a recombinant fusion protein. It combines interleukin-3 (IL-3) with a truncated diphtheria toxin. The drug binds to the IL-3 receptor (CD123) which is overexpressed on BPDCN cells and other myeloid malignancies, and delivers the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ffZ6i2lJXVszx7KuPE60BuzM", "custom_id": "616_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5f53c8086f69cd0ebb4eadc9baeeed6", "body": {"id": "chatcmpl-9St6ssVvSlPRGDkduOhOfKXzb3anW", "object": "chat.completion", "created": 1716672054, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (talazoparib) is a medication used in oncology, specifically approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. This approval is generally for patients who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, unless they have HER2-negative metastatic cancer and have not received prior chemotherapy.\n\nHere are some key points about Talzenna that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Talazoparib works as a PARP inhibitor. PARP (poly ADP-ribose polymerase) enzymes are involved in normal DNA repair. Talazoparib exerts its antitumor effect by inhibiting PARP enzyme activity, which leads to an accumulation of DNA damage and ultimately cell death, particularly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SZHcNOt1Vwpr4Nf4jnuErksH", "custom_id": "617_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b0d39cdba871f8c34ccb48bffa4d31e", "body": {"id": "chatcmpl-9St6sJEwkX90J50QrYz9HGn2IHvgL", "object": "chat.completion", "created": 1716672054, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic (talimogene laherparepvec), commonly known as T-VEC, is an oncolytic virus therapy used for the treatment of melanoma lesions in the skin and lymph nodes that cannot be surgically removed. It was approved by the FDA in October 2015. Here are some key points about Imlygic that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Imlygic is a genetically modified herpes simplex virus type 1. It is engineered to selectively replicate within tumors and produce the immune-stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). It causes lysis of tumors, destroying the cancer cells, and subsequently induces a systemic immune response against cancer.\n\n2. **Indications**:\n   It is specifically indicated for the treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZPzSNKLJ1kd9FaJDdZ0a8zKo", "custom_id": "618_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f74cb7e176ce372bc569362585d397b", "body": {"id": "chatcmpl-9St6sVbEwt9rmmKMIzJKSwK4RplRN", "object": "chat.completion", "created": 1716672054, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your question, as \"Amnoid\" does not correspond to any known medication, medical condition, or terminology typically used in healthcare. Could you please provide more details or clarify what you are referring to? If you are asking about a specific drug, treatment, or medical concept, providing the correct name or additional context will help me give you the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 85, "total_tokens": 126}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B0ExhYmjeXbNL8SBulqsjZMh", "custom_id": "619_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "00fa864088f09a67211bb7ffa9a3c5a0", "body": {"id": "chatcmpl-9St6s7F4mAb62RmrG6ildjkp5zVSk", "object": "chat.completion", "created": 1716672054, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Istubal\" might be a typographical error or a less common name for a medication. One possible correct name could be \"Isturisa,\" which is the brand name for osilodrostat, a medication used in the treatment of Cushing\u2019s disease. If you meant Isturisa, or osilodrostat, here are some key points:\n\n1. **Indication**: Isturisa is approved for the treatment of adults with Cushing\u2019s disease for whom pituitary surgery is not an option or has not been curative.\n\n2. **Mechanism of Action**: Osilodrostat works by inhibiting the enzyme 11-beta-hydroxylase, which is involved in cortisol synthesis. By inhibiting this enzyme, osilodrostat reduces the production of cortisol in the adrenal glands.\n\n3. **Dosage and Administration**: The starting dose is typically 2 mg taken orally twice daily, which may be titrated based on the patient\u2019s"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fSf4Qr1voQkYQx0VmqaYSA83", "custom_id": "620_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f9a3314c12f22d9fa025064752444f96", "body": {"id": "chatcmpl-9St6thyb3TxaeGoLaBZGlZjCQu0GG", "object": "chat.completion", "created": 1716672055, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno, known also by its generic name tegafur/gimeracil/oteracil, is a medication used in the treatment of gastric cancer, specifically for advanced gastric cancer in patients for whom additional chemotherapy is required after failure of initial treatment. Here are some key points you should know about Teysuno:\n\n1. **Composition and Mechanism of Action**: Teysuno is a combination oral chemotherapy medication that contains three active substances: tegafur, gimeracil, and oteracil. Tegafur is a prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase, leading to a decrease in DNA synthesis. Gimeracil inhibits dihydropyrimidine dehydrogenase, which degrades 5-FU, thereby increasing the effectiveness and duration of action of tegafur. Oteracil primarily acts in the gastrointestinal tract to reduce the activation of teg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hxC9nRfLYsYQD68GU3v4t9Al", "custom_id": "621_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "575f2351370ea17f0c701f992900e162", "body": {"id": "chatcmpl-9St6tdu3aI78SyAfsR6ZChJ6svobQ", "object": "chat.completion", "created": 1716672055, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known as Tegafur, is a chemotherapeutic agent primarily used in the treatment of various cancers. It is a prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine analog, which means that it is converted into the active drug 5-FU in the body. Here are some important aspects that physicians should know about Ftorafur:\n\n1. **Mechanism of Action**: Tegafur is metabolized into 5-FU in the liver. 5-FU then inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This results in the disruption of DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**: It is commonly used for the treatment of various solid tumors such as gastric cancer, breast cancer, colorectal cancer, and pancreatic cancer. It may be used alone or in combination with other"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KtZF5YgXF3gzgQONUZ6j8Qpl", "custom_id": "622_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "524691c3875e3956c0907000b4979260", "body": {"id": "chatcmpl-9St6tbinC7RRlvisxFIMsYURBG5Oz", "object": "chat.completion", "created": 1716672055, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem is a brand name for the medication temozolomide, which is primarily used for treating certain types of brain cancers. Temozolomide is an alkylating agent that works by interfering with the development of cancer cells, ultimately leading to cell death. Here are some key points about Gliotem that you, as a physician, might find important:\n\n1. **Indications**: Gliotem is mainly indicated for the treatment of:\n   - Newly diagnosed glioblastoma multiforme in conjunction with radiotherapy and then as maintenance treatment.\n   - Refractory anaplastic astrocytoma, i.e., cases where the disease has progressed after standard therapy.\n\n2. **Mechanism of Action**: Temozolomide acts by methylating DNA, which damages the DNA and triggers the death of tumor cells. It specifically modifies the DNA at the O^6 and N^7 positions of guanine.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Kr51FP9mkoiqPR5sJMUYeMqy", "custom_id": "623_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9af1c27200aba30ec7bb82a40fc2767f", "body": {"id": "chatcmpl-9St6tGqV3kQWriYeTYHiDzmYxqu2Z", "object": "chat.completion", "created": 1716672055, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Torisel (temsirolimus) is an important drug used primarily in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. Here are several key points that a physician should know about Torisel:\n\n1. **Mechanism of Action**: Torisel is an inhibitor of mammalian target of rapamycin (mTOR), a serine/threonine kinase. By inhibiting mTOR, Torisel interferes with the synthesis of proteins that control cell division and growth, thereby inhibiting tumor cell proliferation and inducing apoptosis (programmed cell death) in cancer cells.\n\n2. **Indications**: The primary indication for Torisel is the treatment of advanced renal cell carcinoma. It might be used as a first-line treatment or in patients who have failed previous therapy depending on the specific clinical scenario.\n\n3. **Administration**: Torisel is administered intravenously. The dosage and schedule can vary, typically once a week, but it's important to follow specific guidelines for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CAaJMH1oAEQ6TdzUt6lhk6ki", "custom_id": "624_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8f4a6664e7d60443708a7c83e61655ce", "body": {"id": "chatcmpl-9St6tgyFQNVU0nbq1W3hpdCRWRh0s", "object": "chat.completion", "created": 1716672055, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vumon (teniposide) is a chemotherapeutic agent used primarily in the treatment of cancer. Here are some key points you should know:\n\n1. **Mechanism of Action**: Teniposide is a type II topoisomerase inhibitor. It works by causing DNA damage which inhibits the replication of cancer cells and leads to cell death.\n\n2. **Indications**: Vumon is commonly used to treat certain types of leukemia, such as acute lymphoblastic leukemia (ALL), particularly in pediatric patients. It may be used in combination with other chemotherapy agents.\n\n3. **Administration**: Teniposide is administered intravenously. Proper administration technique is crucial to avoid extravasation, which can cause serious local tissue damage.\n\n4. **Dosage**: The dosage of teniposide can vary based on factors such as the patient's age, body surface area, type of cancer, the specific protocol being used, and the patient's response and tolerance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NrFh93mw92gDriSEy8HQdQqH", "custom_id": "625_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7c0bb4cc9a79251e6ec2590a40490bbe", "body": {"id": "chatcmpl-9St6zZ5bt0JLPLaJj9UZylo9DJYeT", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan, known internationally primarily as thalidomide, was a medication marketed in the late 1950s and early 1960s in several countries under various brand names. It was initially introduced as a sedative or hypnotic, and later extensively used as a treatment for morning sickness in pregnant women.\n\n### Key Points for Physicians:\n\n1. **Historical Context**: Contergan's release led to one of the most notorious drug-related medical disasters in history. Its use by pregnant women resulted in widespread birth defects in their children, primarily phocomelia, a malformation or absence of limbs. This led to its withdrawal from the market in the early 1960s and brought significant changes in drug regulations and control measures worldwide.\n\n2. **Mechanism of Action**: Thalidomide acts by modulating the immune system and has anti-inflammatory properties. Its exact mechanism is complex and involves the inhibition of angiogenesis (formation of new blood vessels), modulation of immune cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_spLMWmylLHPTTQ8OrimHq6Zv", "custom_id": "626_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d47f34b0256579cf7e2909dbae6f06d0", "body": {"id": "chatcmpl-9St6uqLMPYJLAzkQtV366DM212VUx", "object": "chat.completion", "created": 1716672056, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanvis, known generically as thioguanine, is a medication used primarily in the treatment of acute myeloid leukemia (AML). It is one of the drugs in the class of medications called antimetabolites, which work by interfering with DNA production, thus stopping the growth and proliferation of cancer cells.\n\nHere are some key points about thioguanine that you, as a physician, should be aware of:\n\n### Mechanism of Action\nThioguanine is incorporated into DNA and RNA, leading to cellular damage and apoptosis, particularly in rapidly dividing cells like cancer cells. It is a purine analog and competes with guanine, impairing DNA and RNA synthesis.\n\n### Indications\n- Primarily used for treating acute myeloid leukemia (AML).\n- May also be used for other conditions as determined by a physician, including chronic myeloid leukemia (CML) and non-Hodgkin's lymphoma.\n\n### Dosage and Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_O5pgnY1GkAovALWa6B0sPwy8", "custom_id": "627_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8749680b29f13b1e0e136e6d3a44da21", "body": {"id": "chatcmpl-9St6uXiFDms5m1jMtmGqi84X0Zdbg", "object": "chat.completion", "created": 1716672056, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina (thiotepa) is a chemotherapy drug used primarily in the treatment of cancers, including breast cancer, ovarian cancer, bladder cancer, and certain types of lymphomas. It is also used in preparative regimens for hematopoietic stem cell transplantation (HSCT). Here are some key aspects that you, as a physician, might need to know about Tepadina:\n\n1. **Mechanism of Action**:\n   - Thiotepa is an alkylating agent that causes cross-linking of DNA and RNA, and protein synthesis inhibition, which leads to apoptosis of rapidly dividing cells.\n\n2. **Indications**:\n   - As mentioned, Tepadina is used to treat various cancers and as part of conditioning regimens before bone marrow or stem cell transplants.\n\n3. **Administration**:\n   - Thiotepa can be administered intravenously, intracavitary, or intravesically, depending on the type and location of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zYqNxCP42wD89X5TqhuHHjOu", "custom_id": "628_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "609fc09e00c1e1f4df6f5dfe72db8fae", "body": {"id": "chatcmpl-9St6uRPHb0tk29xgGM3L3M8w287Me", "object": "chat.completion", "created": 1716672056, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kymriah (tisagenlecleucel) is a type of cancer immunotherapy known as CAR T-cell therapy, approved by the FDA for specific cancer treatments. Here are key points you should be aware of as a physician:\n\n1. **Indications**: Kymriah is indicated for the treatment of patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. It is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**: Kymriah is a CAR T-cell therapy, which involves genetically modifying a patient's T-cells to include a chimeric antigen receptor (CAR) that targets CD19, a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7a9PrcldNvk7iov1mrJy3dpW", "custom_id": "629_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b108795989d06c5ca2276f3a245014e2", "body": {"id": "chatcmpl-9St6uLRzkxP9PKUUq8CEE0c3BFWeG", "object": "chat.completion", "created": 1716672056, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotivda (tivozanib) is an oral medication used in the treatment of advanced renal cell carcinoma (RCC), which is the most common type of kidney cancer. It is specifically indicated for adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies. Here are some key points about Fotivda:\n\n1. **Mechanism of Action**: Tivozanib is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. These receptors are implicated in the pathway that leads to the growth and proliferation of tumors, as well as the formation of new blood vessels (angiogenesis) that tumors need to grow.\n\n2. **Efficacy**: Clinical trials have demonstrated that tivozanib can effectively reduce tumor burden and delay disease progression. It is important to review specific study outcomes for detailed efficacy data.\n\n3. **Dosage**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FNIZnm5NY2z2t4AyllgGvgCu", "custom_id": "630_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b14b21ee10691bd337cf4a32af2d6dac", "body": {"id": "chatcmpl-9St6vWulmphlqYuLAuqG3zDDSbzQr", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Evotopin\" is not recognized as a standard medication or treatment in medical literature. It's possible that it could be a brand name, a new development, or a non-conventional treatment not widely recognized or studied within mainstream medicine.\n\nIf Evotopin relates to a specific treatment or drug, it's essential to verify its uses, efficacy, approval status, and safety profile through reliable medical sources such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), or other relevant health authorities. Checking recent medical journals, clinical trials, or pharmaceutical registries can also provide valid information.\n\nFor any medication or treatment:\n\n1. **Indications**: Understand what the medication is used for, including any specific conditions it treats.\n2. **Mechanism of Action**: Know how the medication works at a molecular or systemic level.\n3. **Dosage and Administration**: Familiarize yourself with how the medication should be administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_2KZqTzURiDaOCvIFPgMFBHSA", "custom_id": "631_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6f3cc044e31ed976fee7d1ba8338a530", "body": {"id": "chatcmpl-9St6vMcGWgEZqUiL6zd8BoofcZ4gW", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acapodene, also known as toremifene citrate, is a medication primarily used in the management of metastatic breast cancer. It acts as a selective estrogen receptor modulator (SERM), similar to tamoxifen, and is used particularly for postmenopausal women with estrogen receptor positive breast cancer. Here are some key points about Acapodene that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Toremifene binds to estrogen receptors and exhibits both estrogenic and antiestrogenic effects depending on the tissue type. In breast tissue, it generally acts as an estrogen antagonist, thereby inhibiting the proliferative action of estrogen on breast cancer cells.\n\n2. **Indications**: The primary indication for Acapodene is the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors. It may also be considered in certain cases for the prevention of breast cancer in high-risk"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_16LLwkWWwZLvNsck6AxHmBuc", "custom_id": "632_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c1ba8a6a2f7159b4e09dda02f9c86955", "body": {"id": "chatcmpl-9St6vUPQrf7pGbjd05sbIOMBnDR3U", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar (tositumomab and iodine I 131 tositumomab) is a radioimmunotherapy medication that was used for the treatment of certain types of non-Hodgkin lymphoma (NHL). It combines a monoclonal antibody (tositumomab), which targets the CD20 antigen on the surface of normal and malignant B-cells, with a radioactive isotope (iodine I 131), providing targeted radiation therapy designed to destroy the lymphoma cells.\n\nHere are some key points about Bexxar:\n\n1. **Indications**: Bexxar was specifically indicated for the treatment of patients with CD20-positive, follicular, non-Hodgkin's lymphoma, including patients who had relapsed following chemotherapy and those who were refractory to rituximab.\n\n2. **Mechanism of Action**: The mechanism involved binding of the tositumomab component to the CD20 antigen on B-c"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wsgMFHTOP89NIUdNiHzMoRwt", "custom_id": "633_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48d6a7b224240058fe5e9653e97bafce", "body": {"id": "chatcmpl-9St6v58AUu2m7zsTd0bzDabAxrCR6", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis (trabectedin) is a chemotherapy medication used primarily for the treatment of certain types of cancer, including advanced soft tissue sarcoma and, in some regions, for ovarian cancer. Here are several key points that a physician should be aware of when considering or administering Yondelis:\n\n1. **Indications**:\n   - **Soft Tissue Sarcoma**: Yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen.\n   - **Ovarian Cancer**: In some regions, such as Europe, Yondelis is approved for the treatment of recurrent ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).\n\n2. **Mechanism of Action**:\n   - Trabectedin binds to the minor groove of DNA, bending it toward the major groove and causing DNA damage that can disrupt"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FowZYXUCXtyS4v8GysT7OGkY", "custom_id": "634_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a2d4de1d8619323763a2f26c3c4fdc7d", "body": {"id": "chatcmpl-9St6vvIgJuylWJsdOY8tfuHqPcudh", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist (trametinib) is a medication used in the treatment of certain types of cancer. Here are key points you should know about Mekinist:\n\n1. **Indications**: Mekinist is approved for the treatment of metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. It is used either alone or in combination with dabrafenib, another anticancer drug. Additionally, it is used in the treatment of non-small cell lung cancer (NSCLC) with the same BRAF mutations and in some cases of anaplastic thyroid cancer (ATC) in combination therapy.\n\n2. **Mechanism of Action**: Trametinib is a mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor. It works by interfering with the MEK1 and MEK2 enzymes in the MAPK signaling"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZZ5QXV3ex9HbtF8GwLz2gTmT", "custom_id": "635_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3ddefc089c15be74bcbbe0a8d7484d15", "body": {"id": "chatcmpl-9St6v91iJLxmJ2rX8vRyU4dsypnSw", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no widely recognized medication or substance known as \"Amixam.\" It's possible that the name might be misspelled or could be a brand name not commonly known or newly introduced. If you are referring to a specific medication, could you please provide more details or check the spelling? This will help in providing accurate and relevant information. If you're looking for information on a common medication, I can certainly help with that if you provide the correct name."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 99, "total_tokens": 140}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vBqcEG3tbE4ocXDwfEGxbk6h", "custom_id": "636_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "533d114787cf84a22cafa280ffffc7b7", "body": {"id": "chatcmpl-9St6vkNEV0kCFzBfBPFusPpt4NsBy", "object": "chat.completion", "created": 1716672057, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in September 2021, Biceltis is a brand name for the drug trastuzumab, which is a monoclonal antibody used primarily for the treatment of HER2-positive breast cancer. It functions by targeting the HER2 receptor, a protein that can promote the growth of cancer cells. In some cases, trastuzumab is also used to treat stomach cancer.\n\nHere are several key points you should know about Biceltis (trastuzumab):\n\n1. **Indications**: Biceltis is indicated for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer. It is often used in combination with other chemotherapy agents.\n\n2. **Mechanism of Action**: Trastuzumab binds selectively to the HER2/neu receptor, leading to antibody-dependent cellular cytotoxicity which contributes to the destruction of cancer cells that overexpress the HER2 protein.\n\n3. **Administration**: It is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qGwkrwclz1cGctCO7rLdw1Oa", "custom_id": "637_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f3625e233f1fc088164dbe581656c2dd", "body": {"id": "chatcmpl-9St6wRnaozDoJ8BsnmvKaxm1dxRqO", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Imjudo (tremelimumab) is a monoclonal antibody used in the treatment of various types of cancer. It specifically targets the protein cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is involved in the regulation of the immune system. By inhibiting CTLA-4, Imjudo acts as an immune checkpoint inhibitor, enhancing the body's immune response against cancer cells.\n\nHere are some key points you, as a physician, might consider regarding the use of Imjudo:\n\n1. **Indications and Usage**: Imjudo, often in combination with other medications such as durvalumab, is used for the treatment of specific types of cancers, including but not limited to unresectable hepatocellular carcinoma (HCC). The specific indications can vary, so it is important to refer to the latest clinical guidelines and regulatory approvals.\n\n2. **Mechanism of Action**: Imjudo binds"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Pf68Xndpfjy5rMpfKrRnR9L8", "custom_id": "638_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90313f1808d3bffb635ffaed39be64c6", "body": {"id": "chatcmpl-9St6wUJ8dqln1hIDZSzrcgfvol1eG", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, the term \"Ovastat\" does not correspond to any widely recognized medication or medical terminology. It's possible that it could be a brand name, a term used in a specific region, or perhaps a misspelling. \n\nIf \"Ovastat\" is meant to refer to a specific drug or treatment, it would be essential to have the correct spelling or additional context to provide accurate information. It could also be a brand name not available or known in every country, which sometimes happens with medications.\n\nIf you're referring to a medication or treatment related to ovulation or reproductive health (as the prefix \"Ova-\" suggests), I could provide information on commonly known treatments in that field if that would be helpful. Otherwise, I recommend consulting a pharmaceutical database or contacting a pharmacy for the most accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 172, "total_tokens": 214}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sby9tMRzZoLzItamJ6RIHhlB", "custom_id": "639_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "53610d52eb97287ca7ff0e7260447774", "body": {"id": "chatcmpl-9St6wsWBewz9vufgZF9YDPbJF7SW9", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine and tipiracil) is a combination oral medication used primarily in the treatment of certain types of colorectal cancer and gastric cancer. It has been approved for use in patients who have previously been treated with chemotherapy and other therapies without success. Here are key points you should know about Lonsurf:\n\n1. **Indications:**\n   - Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.\n   - It is also indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, a taxane or irinotecan, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xba9xB5crEL7TaHokfBnGlDY", "custom_id": "640_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0bf6f25cd2ec5764e2e40c1c30e3a574", "body": {"id": "chatcmpl-9St6wJKKC4D7aETLFRVnfOQ7Xepzg", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl (triptorelin) is a gonadotropin-releasing hormone (GnRH) agonist used primarily in the management of hormone-responsive cancers such as prostate cancer, and in assisted reproduction and the treatment of estrogen-dependent conditions like endometriosis and uterine fibroids. It works by initially increasing, then subsequently decreasing, the levels of gonadotropins (luteinizing hormone and follicle-stimulating hormone) released from the pituitary gland. This leads to a decrease in testosterone levels in men and estrogen levels in women.\n\nHere are some key points you should know about Decapeptyl:\n\n1. **Indications and Usage**:\n   - **Prostate Cancer**: It is used for the treatment of advanced prostate cancer.\n   - **Endometriosis and Uterine Fibroids**: It helps manage symptoms by reducing estrogen production.\n   - **Precocious Puberty**: It can be used to treat children"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zOZS5KrwaS92UHlBL21SPv9i", "custom_id": "641_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "105f3f6473745590fc4bc205c17e7fac", "body": {"id": "chatcmpl-9St6wVIcusEGNF0nUaMbHKc7BLl5T", "object": "chat.completion", "created": 1716672058, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depacon (valproate sodium) is an injectable form of the medication valproic acid, primarily used in the treatment of epilepsy, bipolar disorder, and to prevent migraine headaches. It is a part of the anticonvulsant and mood stabilizer class of medications. Here are several key points you should know about Depacon:\n\n1. **Indications**: Depacon is approved for use in the treatment of seizure disorders, the prevention of migraine headaches, and for the treatment of manic episodes associated with bipolar disorder.\n\n2. **Mechanism of Action**: The exact mechanism of action is not fully understood, but it is believed to work by increasing the amounts of certain chemicals in the brain that help reduce or prevent seizures and stabilize mood.\n\n3. **Administration**: Depacon is administered intravenously, which is useful for patients who require rapid control of symptoms or cannot take oral forms of valproic acid.\n\n4. **Dosage**: The dosage of Depacon must be carefully"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cJ2jn9enPBqmkNBt2auJOjwE", "custom_id": "642_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d558d1fa7e1f5af1268721e1ce939a1", "body": {"id": "chatcmpl-9St6xuuh4ypqWUgGCArAtrcTSL2G8", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is a chemotherapy drug used in the treatment of bladder cancer, specifically for intravesical therapy. Here are some key points you should know about Valstar:\n\n1. **Indication**: Valstar is primarily indicated for the treatment of Bacillus Calmette-Guerin (BCG)-resistant carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.\n\n2. **Mechanism of Action**: Valrubicin is an anthracycline antibiotic that works by interfering with the growth of cancer cells, which are eventually destroyed. It is administered directly into the bladder, which allows for high local drug concentrations with reduced systemic toxicity.\n\n3. **Administration**: Valstar is administered intravesically, which involves instillation directly into the bladder through a catheter. Typically, the treatment regimen consists of 800 mg valrubicin in 75 mL of solution once a week"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4cq8kPTsxnH7yIt1ZmAbYXy3", "custom_id": "643_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e1c311b015b8dae91fb595b226a75b2c", "body": {"id": "chatcmpl-9St6xbHWJtFa6hfL5EBcreiZbnbax", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease. Here are several key points you should know about Caprelsa:\n\n1. **Mechanism of Action**: Caprelsa is a tyrosine kinase inhibitor that targets multiple pathways, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET-tyrosine kinase. By inhibiting these receptors, Caprelsa can interfere with tumor growth and angiogenesis.\n\n2. **Indications**: As mentioned, it is primarily used for the treatment of advanced medullary thyroid cancer. It is important to confirm the diagnosis and consider the severity of the disease before initiating treatment.\n\n3. **Dosage and Administration**: The typical starting dose of Caprelsa is 300 mg taken orally once daily. The tablet should be taken whole"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VUUex1TEyvJ9OYM1Zh6SavLw", "custom_id": "644_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "60aebae7242100e19d8d0c1d8badb255", "body": {"id": "chatcmpl-9St6xlRAXYAbkrCTpj48C8qgNQFTr", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf (vemurafenib) is a medication used in the treatment of certain types of cancer, primarily late-stage melanoma that possesses a specific genetic mutation in the BRAF gene (BRAF V600E). This mutation leads to enhanced growth and proliferation of cancer cells. Vemurafenib is a type of kinase inhibitor that specifically targets and inhibits mutated forms of the BRAF protein.\n\nHere are some key points about Zelboraf that are important for a physician to know:\n\n1. **Indications:**\n   - Zelboraf is approved for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation. It is essential to confirm the presence of BRAF V600E mutation in patient tumor samples before initiating treatment.\n\n2. **Mechanism of Action:**\n   - Vemurafenib works by selectively inhibiting the activity of the BRAF V600E kinase, which helps to slow down"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_SOmFlv5MQ5iddMulZcvdAapb", "custom_id": "645_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "88d9dd95ea4faf460b35282bfd749c9d", "body": {"id": "chatcmpl-9St6xy4rBoi9HkL6x2fzFXZWyY1wd", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a targeted therapy used in the treatment of certain types of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Here are several key aspects of Venclexta that you, as a physician, should be aware of:\n\n### 1. Mechanism of Action\nVenclexta is a BCL-2 inhibitor. BCL-2 is a protein that helps cancer cells survive. By inhibiting BCL-2, venetoclax helps to induce apoptosis (programmed cell death) in cancer cells.\n\n### 2. Indications\nVenclexta is FDA-approved for:\n- Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).\n- It is also approved in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Iw2XulhteM5CxyMaxjIr3mHa", "custom_id": "646_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36323ceb47432b5c407a35d1856194c0", "body": {"id": "chatcmpl-9St6xHp90bBWdObTYgUDFpoSf9z6D", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is not a commonly recognized medication or substance in standard medical practice, as of the last update in my training data. It is possible that it could be a trade name, a substance used in specific regions, or a newly developed drug that has not been widely documented yet.\n\nIf Alkaban-AQ refers to a specific medication or treatment, you should consult reliable sources such as drug databases, pharmacology texts, or regulatory agencies such as the FDA or EMA for the most accurate and up-to-date information. These sources can provide you with details on the drug's indications, mechanism of action, side effects, contraindications, pharmacokinetics, and dosing information.\n\nAdditionally, it\u2019s a good practice to check for any clinical trials or research studies related to Alkaban-AQ to understand its efficacy and safety profile.\n\nIf you are unable to find information in the usual databases, you might consider consulting with colleagues or reaching out to pharmaceutical companies or academic institutions that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8TAeKZlFyvc2NnQLPxqlvgV1", "custom_id": "647_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "83a7300b7194d6f44022047bb1ad18b2", "body": {"id": "chatcmpl-9St6xbN83o2odEtzbjHVXeIYRGfuS", "object": "chat.completion", "created": 1716672059, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Alcrist\" does not appear to be a recognized medication or substance in standard medical references. It's possible that there might be a typo or an alternative name or spelling for the substance you are inquiring about. To provide accurate information, I would recommend verifying the spelling or providing additional context. If \"Alcrist\" is a brand name, it might be known by a different generic name or it might be a newer or less common drug.\n\nIf you have more details or a different spelling, feel free to provide them, and I can offer more specific information. Alternatively, consulting reliable pharmacological databases or resources might help clarify what \"Alcrist\" refers to."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 142, "total_tokens": 183}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Ak3UwXvPOdcPruo4lnjhxChN", "custom_id": "648_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e470fd0bb99253db34eaf21c7ce26956", "body": {"id": "chatcmpl-9St6yIupkVIeyveDzo05SkmimUfBa", "object": "chat.completion", "created": 1716672060, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is a liposomal formulation of the conventional vincristine sulfate, a vinca alkaloid. It is encapsulated in a sphingomyelin/cholesterol liposome, which is designed to provide prolonged circulation time in the bloodstream compared to standard vincristine. This allows for increased drug accumulation at the site of the tumor.\n\nHere are several key points about Marqibo that you, as a physician, might find relevant:\n\n1. **Indications**: Marqibo is approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) who have relapsed two or more times or whose disease has progressed following two or more regimens of anti-leukemia therapy. \n\n2. **Mechanism of Action**: Like traditional vincristine, Marqibo interferes with the formation of microtubules. It binds to tubulin, inhibiting the assembly of microt"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_83mF8DJPTockMXnqlHF7CNCH", "custom_id": "649_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "26abaa0c8b721a77881cea3469507238", "body": {"id": "chatcmpl-9St6y1IMJgf8aONyU9SrDU58sx6hs", "object": "chat.completion", "created": 1716672060, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2021, \"Eldesine\" does not appear to be a recognized medication or substance in standard medical references. It's possible that the name might be misspelled or it could be a brand name not widely recognized, or possibly a new drug that was not included in my last training data.\n\nIf \"Eldesine\" is a new or less common medication, I recommend checking the most current medical literature or drug databases for information. You could also consult pharmaceutical reference resources like the Physicians' Desk Reference (PDR), Micromedex, or the official product website for accurate and up-to-date information.\n\nIf it's a term related to a specific field of medicine or a new treatment, attending professional medical conferences, reading recent journal articles, or networking with colleagues might also provide more insights.\n\nPlease ensure the spelling is correct, or provide additional context so I can assist you better. If you have any other questions or need further assistance with a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YzZ7pwlajC05qlfIwrRAzVql", "custom_id": "650_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3906dbbe2bce78b5f483b4d4dcf2e630", "body": {"id": "chatcmpl-9St6yiANYtzQidadVPcX8l46VYKdq", "object": "chat.completion", "created": 1716672060, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor is a brand name for vinflunine, which is a chemotherapy medication primarily used in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen. Vinflunine is a microtubule inhibitor; it works by inhibiting tubulin dynamics, which disrupts mitotic spindle formation, ultimately leading to cell death.\n\nHere are some key points you should consider when using or prescribing Javlor (vinflunine):\n\n### Mechanism of Action\n- Javlor inhibits the polymerization of tubulin, disrupting the assembly of microtubules. This action prevents the formation of the mitotic spindle necessary for cell division, resulting in cell cycle arrest and apoptosis.\n\n### Indications\n- Javlor is primarily used for the treatment of advanced carcinoma of the urothelial tract after failure of prior chemotherapy, particularly a platinum-containing regimen.\n\n### Dosage and Administration\n- Vinflun"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kEVRm52eyChjsQmgkgzB7Sge", "custom_id": "651_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "825906396ba62ee644942b9c1e44a195", "body": {"id": "chatcmpl-9St6y6r9VQXXR32BZ7DE2zFZvNet4", "object": "chat.completion", "created": 1716672060, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no pharmaceutical or medical substance specifically known as \"Binorel.\" It's possible that the name might be a misspelling, a new drug not widely documented yet, or a non-standard term for a drug. If you're dealing with a substance, medication, or treatment that you're unfamiliar with, I recommend checking reliable medical databases, consulting pharmacology resources, or contacting a pharmaceutical specialist. Additionally, verifying the spelling or obtaining more context about the drug's use could be helpful. If you have any more details or another name, I can assist you better!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 121, "total_tokens": 162}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wNvU0GKxC2YIEg0S7QfDzCRZ", "custom_id": "652_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab0504d3b2dad4b21df4b20eebc8d590", "body": {"id": "chatcmpl-9St6y1afv0gohKy3nQxSylXPo7CFN", "object": "chat.completion", "created": 1716672060, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is a medication used primarily in the treatment of advanced basal cell carcinoma (BCC), a type of skin cancer. Here are some key points you should know about Erivedig as a physician:\n\n1. **Mechanism of Action**: Erivedge is a hedgehog pathway inhibitor. It directly targets and inhibits the Smoothened (SMO) receptor, which is a component of the hedgehog signaling pathway. This pathway is active in most basal cell cancers, and its inhibition can suppress the growth of these cancer cells.\n\n2. **Indications**: It is approved for use in adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation.\n\n3. **Administration**: Erivedge is taken orally, usually as a once-daily capsule. The dosage and duration of treatment may depend on the patient\u2019s response and tolerance to the medication.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TOVVrGgcK3zOj0nKbFA3ezTP", "custom_id": "653_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "94f062f23fa161306951db79d0a0564c", "body": {"id": "chatcmpl-9St6zuoidlEpTUB2O3RXyU6r2urTU", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza (vorinostat) is a medication used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. As a physician, here are key points you should know about Zolinza:\n\n1. **Mechanism of Action**: Vorinostat belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. It works by causing the accumulation of acetylated histones and other proteins, leading to cell cycle arrest and/or apoptosis of some cancer cells.\n\n2. **Indications**: Zolinza is approved for the treatment of cutaneous manifestations in patients with CTCL. It is used in cases where the disease is refractory to other forms of treatment.\n\n3. **Administration**: Zolinza is administered orally. The typical dose is 400 mg once daily with food.\n\n4. **Side Effects**: Common side effects include"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Tz3mn1TBZWrxmR17MzUTU56d", "custom_id": "654_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9b8177d672b96dbc7ce25e184686b6e", "body": {"id": "chatcmpl-9St6zM849jQwUAbMz5WXxI19RKWlV", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aztec refers to the EMR (Electronic Medical Record) software developed by Prognocis, which is designed to assist healthcare providers in managing patient records and other practice management tasks electronically. As a physician, here are some key features and considerations about Aztec EMR that you should be aware of:\n\n1. **User Interface**: Aztec EMR is known for its user-friendly interface, which is designed to be intuitive for clinicians and staff. Familiarity with the layout and functionality can reduce the time spent on documentation.\n\n2. **Integration**: It supports integration with other healthcare systems and software, ensuring that patient data flows seamlessly between different service providers. This can include labs, imaging centers, pharmacies, and other healthcare facilities.\n\n3. **Customization**: Aztec EMR can be customized to fit the specific needs of your practice. This includes custom forms, templates, and workflows which can improve efficiency and adapt to your particular specialty or preferences.\n\n4. **Security**: As with any EM"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Pnk85jAB3JQTvfDYKEXJaX0x", "custom_id": "655_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9938307e249cbae340239dbb39717999", "body": {"id": "chatcmpl-9St6zAVBKJqalqKUIprP1Hf5MdlOV", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap (aflibercept) is a medication used in the treatment of various forms of cancer, most notably metastatic colorectal cancer. It is a type of anti-angiogenic agent, which works by inhibiting the blood supply to tumors. Here are some key points you should know about Zaltrap:\n\n1. **Mechanism of Action**: Zaltrap is a recombinant fusion protein that acts as a Vascular Endothelial Growth Factor (VEGF) inhibitor. It binds to VEGF receptors and prevents the VEGF proteins from stimulating the growth of new blood vessels that tumors need to grow and metastasize.\n\n2. **Indications**: Zaltrap is approved for use in combination with a FOLFIRI regimen (irinotecan, fluorouracil, and leucovorin) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_FyllJK3FZtx82IqhlHiEllCj", "custom_id": "656_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c1034434f672e8dc8322a0495a662c17", "body": {"id": "chatcmpl-9St6zrR6GUEMlGzIVF4LPUpxNOFkF", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that is metastatic and has specific mutations. These mutations are in the MET gene, specifically MET exon 14 skipping alterations. Here are some key points about Tabrecta:\n\n1. **Mechanism of Action**: Tabrecta is a kinase inhibitor that specifically targets the MET proto-oncogene. By inhibiting the MET kinase, Tabrecta can block MET-mediated signaling pathways involved in the growth and proliferation of cancer cells.\n\n2. **Indications**: It is specifically indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This makes molecular testing for MET exon 14 mutations crucial before initiating treatment with Tabrecta.\n\n3. **Administration**: Tabrecta is an oral medication, making it convenient for outpatient treatment. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Bnv1CdN4meHLnTb0BntHFiuC", "custom_id": "657_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "441fbb61f4b1d04d4c9ed3a8435cd31c", "body": {"id": "chatcmpl-9St6ziHHFTvVizHi39MNznAmaq9ov", "object": "chat.completion", "created": 1716672061, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (enfortumab vedotin-ejfv) is a medication used in the treatment of cancer, specifically for adult patients with locally advanced or metastatic urothelial cancer (bladder cancer and other types of cancer of the urinary tract) who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.\n\nHere are key facts and considerations about Padcev that you should be aware of:\n\n1. **Mechanism of Action**: Padcev is an antibody-drug conjugate (ADC) that includes an anti-Nectin-4 monoclonal antibody linked to a microtubule-disrupting agent, MMAE (monomethyl auristatin E). The drug binds to Nectin-4, a protein expressed on the surface of various tumor cells, and is internalized and released within the cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0vLGYRiTeZdOpOIqstTp1L1h", "custom_id": "658_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "080804f700e8285421385d5083f73d79", "body": {"id": "chatcmpl-9St707r4VLgLh6sHCC5phnswObnW1", "object": "chat.completion", "created": 1716672062, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enhertu (chemical name: trastuzumab deruxtecan) is a targeted therapy medication used primarily in the treatment of certain types of breast cancer and other HER2-expressing cancers. It was developed through a collaboration between Daiichi Sankyo and AstraZeneca. Here are some key points about Enhertu:\n\n1. **Mechanism of Action**: Enhertu is an antibody-drug conjugate (ADC) that combines three components: a HER2-targeting antibody similar to trastuzumab, a cleavable linker, and a cytotoxic topoisomerase I inhibitor payload. The drug binds to HER2-expressing cells, is internalized, and releases the cytotoxic agent into the cancer cells, leading to cell death.\n\n2. **Indications**:\n   - **HER2-Positive Breast Cancer**: Enhertu is approved for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G4P0GBI3Zw8nLsWtK7mjqHEV", "custom_id": "659_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5d9fd4e71a5296d0d1facefe39986b3", "body": {"id": "chatcmpl-9St70iKBNh0DXXarUlpq2g3zvvxlM", "object": "chat.completion", "created": 1716672062, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis (abarelix) is a medication used primarily in the treatment of advanced symptomatic prostate cancer in men who cannot undergo or do not respond to other hormone therapies. Here are several key points about Plenaxis that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Plenaxis is a gonadotropin-releasing hormone (GnRH) antagonist. It works by immediately blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn reduces the production of testosterone by the testes. Lower levels of testosterone can slow or stop the growth of prostate cancer cells.\n\n2. **Usage and Indications**: Plenaxis is indicated for the treatment of men with advanced prostate cancer who have symptomatic disease and for whom other hormone therapies are contraindicated or not tolerated. It is particularly useful in patients needing rapid reduction"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sueCell0VDjcaf8jlblcykxQ", "custom_id": "660_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c24aa3d1f55915451d16ec3b7ddb0304", "body": {"id": "chatcmpl-9St75HRgNsozVLnZU6t0R9G6FZ1AX", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC) specifically approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. It was granted approval on August 5, 2020. Here are key aspects of Blenrep that you, as a physician, should be aware of:\n\n1. **Indication**: Blenrep is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n2. **Mechanism of Action**: The drug consists of a monoclonal antibody targeting BCMA (B-cell maturation antigen), a protein expressed on the surface of myeloma cells. It is conjugated to a cytotoxic agent, mafodotin, which is released"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gZQjxtB70Sa0bZtzCKO5vVw0", "custom_id": "661_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30c769325c94db8258e0b138a523857d", "body": {"id": "chatcmpl-9St704TMscu31KvtunNkXxAEvLhlD", "object": "chat.completion", "created": 1716672062, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tukysa (chemical name: tucatinib) is an oral tyrosine kinase inhibitor specifically targeting HER2 (human epidermal growth factor receptor 2). It is used in the treatment of certain types of breast cancer and potentially other tumors that overexpress HER2. Here are some key aspects of Tukysa that you, as a physician, should be aware of:\n\n1. **Indications and Usage**:\n   - Tukysa is approved by the FDA in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n2. **Mechanism of Action**:\n   - Tucatinib selectively inhibits the kinase activity of HER2, thereby inhibiting the downstream signaling pathways that promote cell growth and survival"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RugZIKuppZyZIaC9YSeIYQdO", "custom_id": "662_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f0a59f6618a6c260af8440b4f6b9a64e", "body": {"id": "chatcmpl-9St71893Yxlynlt7iKliEg4umHgTr", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro\u2122 (daratumumab and hyaluronidase-fihj) is a subcutaneous formulation of daratumumab, an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Daratumumab was originally approved as an intravenous (IV) formulation, but Darzalex Faspro provides a subcutaneous route of administration that can be more convenient and often better tolerated by patients. Here are some key points about Darzalex Faspro:\n\n1. **Indications**: Darzalex Faspro is approved for use in adults with multiple myeloma in various settings, including as a monotherapy or in combination with other agents such as bortezomib, melphalan, and prednisone or with lenalidomide and dexamethasone, depending on the patient's prior treatment history and disease status.\n\n2. **Mechanism of Action**: Daratum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_raqkVM0WjAgo6Rsjf9bnvL6b", "custom_id": "663_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4aeea16b9b072555368a2a7ccb94148f", "body": {"id": "chatcmpl-9St715LR1po7r89Dl6suLKqxWoU36", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin (alitretinoin) is a medication used in dermatology, specifically for the treatment of skin lesions in patients with Kaposi's sarcoma. Kaposi's sarcoma is a type of cancer that can cause patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, or in other organs. Here are some key points you should know about Panretin:\n\n1. **Mechanism of Action**: Alitretinoin, the active ingredient in Panretin, is a retinoid, which is a synthetic derivative of vitamin A. It works by binding to retinoid receptors, which influences cell differentiation and proliferation. This action can help reduce the proliferation of abnormal cells associated with Kaposi's sarcoma.\n\n2. **Formulation**: Panretin is available as a gel for topical application. The concentration of alitretinoin in the gel is 0.1%.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_ewZMvPtnwPbGlS73jdmUNsqB", "custom_id": "664_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1725dd750e472cefbdc835b737e18287", "body": {"id": "chatcmpl-9St71GGi4Q2G9RbfnXdPzd0GDw8sF", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is a CAR T-cell therapy approved by the FDA to treat certain types of cancers. Here are some key points that you, as a physician, might find useful:\n\n1. **Indications**: Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). It is also approved for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n\n2. **Mechanism of Action**: Tecartus utilizes genetically modified autologous T cells to express a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of B-cell lymphocytes and leukemia cells. This modification allows the T cells to recognize and kill CD19-expressing cells.\n\n3. **Administration**: Before administering Tecartus, patients typically undergo a lymphodepleting chemotherapy regimen. The CAR T"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_59HTIoiLyZkslPlKCP8DfXvf", "custom_id": "665_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4db293d8f507c9340da9e342d28c3fea", "body": {"id": "chatcmpl-9St71OtVhTny0KKrsyQ1NADJE7nPJ", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray, also known by its generic name alpelisib, is a medication used primarily in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Here are some key points you should know about Piqray:\n\n1. **Indications and Usage**: Piqray is approved by the U.S. Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.\n\n2. **Mechanism of Action**: Alpelisib specifically targets and inhibits the alpha isoform of the phosphoinositide 3-kinase (PI3K) enzyme,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7ziwAwSu6zC0Wa3VuSDCAqfP", "custom_id": "666_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "772d05c3763620de42af7d60a70dbadd", "body": {"id": "chatcmpl-9St71bxcuRyq0vWUwDvakwhkQkuWN", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinamed is a brand name primarily associated with the drug darunavir, an antiretroviral medication used to treat and prevent HIV/AIDS. It is often used in combination with other medications. Here are some key points you should know about darunavir (Quinamed):\n\n1. **Mechanism of Action**: Darunavir is a protease inhibitor. It works by inhibiting the action of protease, an enzyme HIV virus needs to replicate and produce new virions.\n\n2. **Usage**: It is used in combination with ritonavir or cobicistat, both of which boost its effect by slowing the breakdown of darunavir, thereby increasing its levels in the blood. This combination is used as part of antiretroviral therapy (ART).\n\n3. **Administration**: Darunavir is administered orally and is available in the form of tablets and a suspension.\n\n4. **Dosage**: The dosage of darunavir"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_j5ZsSDxtZ1a4Yy70GqCX0XCe", "custom_id": "667_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9bda08b1eebf8fdb9044b50d6951497", "body": {"id": "chatcmpl-9St71OrOCWsCbm4zy9IkQbDzgY1Qh", "object": "chat.completion", "created": 1716672063, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin, commonly referred to as \"Amoxi,\" is a widely used antibiotic that belongs to the penicillin class of antibiotics. It is used to treat a variety of bacterial infections. Here are some key points you, as a physician, should be aware of:\n\n1. **Spectrum of Activity**: Amoxicillin is effective against a broad range of gram-positive and gram-negative bacteria. It is commonly prescribed for infections such as otitis media, sinusitis, respiratory infections, urinary tract infections, skin infections, and certain types of gastroenteritis.\n\n2. **Mechanism of Action**: Amoxicillin works by inhibiting the synthesis of bacterial cell walls. It binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, leading to the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.\n\n3. **Administration**: Amoxicillin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GsRbom89UnuVx6Joy73l45Tf", "custom_id": "668_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a2d3191c5a68909ab265d0cb30fe21b", "body": {"id": "chatcmpl-9St72ae367JoV4O5rfKJ981EORqNA", "object": "chat.completion", "created": 1716672064, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Amelie\" (also known as \"Le Fabuleux Destin d'Am\u00e9lie Poulain\") is not a medical term or a condition; it is a popular French romantic comedy film released in 2001, directed by Jean-Pierre Jeunet. The movie centers on Am\u00e9lie Poulain, a young woman who decides to change the lives of those around her for the better while grappling with her own isolation.\n\nIf your question pertains to a medical condition or topic related to the name \"Amelie,\" please provide more specific information so I can offer a more accurate and helpful response. If you are asking about psychological or social themes depicted in the film that could be relevant to your practice, such as isolation or altruism, I can provide insights into how these themes might relate to patient care or mental health."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 172, "total_tokens": 213}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x3KjpNhp33OlOaiAqmSiDw9s", "custom_id": "669_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7b815fe8d922a9d9eb86b3ac3f9cdc1", "body": {"id": "chatcmpl-9St72bnX4Qdqq5k2OZiwrjHncmvUl", "object": "chat.completion", "created": 1716672064, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemazyre (pemigatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for specific types of cancer. Here are some key points about Pemazyre that you, as a physician, might find useful:\n\n1. **Indication and Usage:**\n   Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This represents a critical option for a particularly challenging cancer type, where few other treatments may be effective.\n\n2. **Mechanism of Action:**\n   Pemazyre is a kinase inhibitor that specifically targets FGFR1, FGFR2, and FGFR3 genetic alterations. These alterations can promote tumor cell growth and survival. By inhibiting these receptors,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SI9hPG4P8g59m9CCTkBgJ2KE", "custom_id": "670_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "757a2016e19a819a344b00efb9b1311f", "body": {"id": "chatcmpl-9St72A8jQHvMp9h5SRLDWRa7QmLrO", "object": "chat.completion", "created": 1716672064, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (generic name: ripretinib) is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Here are key points that you, as a physician, should know about Qinlock:\n\n1. **Indications and Usage**: Qinlock is specifically indicated for the treatment of fourth-line GIST. It is used in patients who have progressed on or are intolerant to prior treatments that typically include imatinib, sunitinib, and regorafenib.\n\n2. **Mechanism of Action**: Ripretinib acts as a switch-control kinase inhibitor that targets a broad spectrum of mutations in KIT and PDGFRA. It works by inhibiting the kinase activity, which helps in controlling tumor growth and potentially leading to tumor shrinkage.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Epnahwho86qsNqbgk0B3gDDe", "custom_id": "671_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b937facc90229aedb44e0d36188f97c", "body": {"id": "chatcmpl-9St72KhlwnGKPFseuSKY4km0YLu49", "object": "chat.completion", "created": 1716672064, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a targeted therapy approved for the treatment of specific types of cancer with alterations in the RET (REarranged during Transfection) gene. Here are some key points you should know about Retevmo:\n\n1. **Indications:**\n   - Retevmo is specifically indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\n   - It is also indicated for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - Additionally, it is used for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n2. **Mechanism of Action:**\n   - Selpercatinib is a kinase inhibitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_2W5PBWlCoaSfoNJ0O3ulXHZO", "custom_id": "672_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f7e319be9d067571363b1d82fa56f823", "body": {"id": "chatcmpl-9St73FUjwCathYspCxlfQDE0ZDrJb", "object": "chat.completion", "created": 1716672065, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi is a prescription medication used to treat certain types of myelodysplastic syndromes (MDS), specifically those classified as intermediate-1, intermediate-2, and high-risk MDS. It is also indicated for chronic myelomonocytic leukemia (CMML). Inqovi combines two chemotherapeutic agents, decitabine and cedazuridine, in a single oral tablet.\n\n### Key Information for Physicians:\n\n1. **Indications**: Inqovi is approved for the treatment of adult patients with intermediate-1, intermediate-2, or high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML). It is suitable for patients who have previously been treated with other therapies.\n\n2. **Mechanism of Action**: \n   - **Decitabine** is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_azRmgUHYd3xrlGJ5mjuoB3iH", "custom_id": "673_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7b89958cc1b78f25561cbb0f2ccfda3b", "body": {"id": "chatcmpl-9St73VhNDLBjRmLXTY9DgncQ9g9eG", "object": "chat.completion", "created": 1716672065, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pepto-Bismol is an over-the-counter medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as nausea, heartburn, indigestion, upset stomach, and diarrhea. Here are several key points that you, as a physician, might find useful:\n\n1. **Active Ingredient**: The active ingredient in Pepto-Bismol is bismuth subsalicylate. Bismuth subsalicylate has antacid properties that help reduce stomach acid irritation and also acts as an antimicrobial against certain bacteria and viruses.\n\n2. **Mechanism of Action**: Bismuth subsalicylate works by coating the stomach lining and protecting it from stomach acid. It also has a mild antibacterial effect and can bind to toxins produced by bacteria like Escherichia coli, which can cause diarrhea.\n\n3. **Indications**:\n   - Diarrhea\n   - Heartburn\n   - Nausea\n   - Indigestion\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Toxtr7AOxv2siMKaaNrarqDk", "custom_id": "674_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7a3baa41990daf3c7b41aa63d978409", "body": {"id": "chatcmpl-9St73alW0i0uxvVIcPKJIE2IX4tAd", "object": "chat.completion", "created": 1716672065, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't specific information available about \"AiRuiKa\" in the context of medical or pharmaceutical developments. It\u2019s possible that the term could be a brand name, a specific medical device, drug, or a concept that hasn\u2019t been widely recognized or documented in accessible medical literature. \n\nTo provide accurate advice or insights, I would need more detailed information about the context in which \"AiRuiKa\" is used. If it relates to a new drug, device, or medical technology, I recommend checking the latest medical literature, clinical trial registries, or pharmaceutical product databases. Additionally, attending relevant medical conferences, consulting with peers, or reaching out to the manufacturer (if it's a product) could be beneficial.\n\nIf you have more specifics or another name that it might be known by, I can offer more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 173, "total_tokens": 215}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LILTAUQrB7MLPUumlBCMRgxV", "custom_id": "675_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9791ac19ec63845e39727ec2575a3344", "body": {"id": "chatcmpl-9St73HZeZrIuJN46fsQj8bu0GjADp", "object": "chat.completion", "created": 1716672065, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is an oral medication used primarily in the treatment of advanced prostate cancer. It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists. Orgovyx works by inhibiting the production of certain hormones from the pituitary gland, which in turn reduces the production of testosterone, a hormone that can promote the growth of prostate cancer cells.\n\nHere are some key points you should know about Orgovyx:\n\n1. **Indications**: Orgovyx is approved for the treatment of adult patients with advanced prostate cancer.\n\n2. **Mechanism of Action**: As a GnRH receptor antagonist, Orgovyx directly binds to GnRH receptors in the pituitary gland, leading to a rapid reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and consequently, testosterone levels.\n\n3. **Dosage and Administration**: The treatment starts with a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_16dgh03Rk7rUXN26C0xcZi05", "custom_id": "676_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eb75c0f60773e16041674200c0df584a", "body": {"id": "chatcmpl-9St73RP1Z7gEZuq2GbwCkkJlxQ2zc", "object": "chat.completion", "created": 1716672065, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Orserdu (elacestrant) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. Here is a detailed overview that might be relevant to you as a physician:\n\n### 1. **Indications**\nOrserdu is specifically approved for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1 mutations, which are detectable by an FDA-approved test, and who have received one or two prior lines of endocrine therapy.\n\n### 2. **Mechanism of Action**\nOrserdu is an oral selective estrogen receptor degrader (SERD). It works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting the receptor's activity. This action helps to block the growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DWdhX7I3xiep2M837PFuQrxq", "custom_id": "677_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eac46c9ca71d86aa01ce22ed5c2a287d", "body": {"id": "chatcmpl-9St74uFQQWl2RiEbjP07JOtgyG0ZJ", "object": "chat.completion", "created": 1716672066, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin (trimetrexate glucuronate) is a drug that was used as an antimicrobial agent targeting severe or life-threatening infections caused by Pneumocystis carinii pneumonia (PCP) in patients with HIV/AIDS when conventional therapy was ineffective or not tolerated. It was also investigated for its use in treating certain types of cancer due to its properties as a dihydrofolate reductase inhibitor.\n\nHere are key points you should know about Neutrexin:\n\n1. **Mechanism of Action**: Trimetrexate is a lipophilic antifolate that inhibits dihydrofolate reductase, which is essential for DNA synthesis in cells. This inhibition leads to the prevention of the production of tetrahydrofolate, necessary for synthesizing purines and thymidylate, thereby inhibiting cell growth.\n\n2. **Indications**: Neutrexin was primarily used for treating Pneumocystis carin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_EGNSgTsUJJYIqKrIbL4jLIw5", "custom_id": "678_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e42e13c05bdf1b0ff96b07204160c2b", "body": {"id": "chatcmpl-9St74nPAwfrqRy2NIikjcxhHesOXF", "object": "chat.completion", "created": 1716672066, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepmetko (tepotinib) is a medication approved by the FDA for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have mesenchymal-epithelial transition (MET) exon 14 skipping alterations. This approval is based on the efficacy demonstrated in clinical trials, specifically targeting tumors with this specific genetic alteration.\n\nHere are several key points that physicians should consider when prescribing Tepmetko:\n\n1. **Indication**: Tepmetko is indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This mutation can be detected by an FDA-approved test, which is essential for identifying eligible patients.\n\n2. **Mechanism of Action**: Tepotinib acts as a MET inhibitor. The MET gene encodes for a receptor tyrosine kinase that, when mutated, can promote tumor growth and metastasis. By inhibiting this pathway, tepotinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mLH3gI5rOr3ex85xSHLZBvsM", "custom_id": "679_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "945f019a8c6a22b1cd2b75b2edafa22a", "body": {"id": "chatcmpl-9St74CNvI3cn92yotzJ0p6Uy2DkIJ", "object": "chat.completion", "created": 1716672066, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Lytgobi, with the generic name futibatinib, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Specifically, it has been approved for the treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer) that harbors a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.\n\nHere are some key points about Lytgobi:\n\n1. **Mechanism of Action**: Futibatinib is a kinase inhibitor that specifically targets FGFR1-4, which can be abnormally activated in various cancers due to mutations, fusions, or other genetic alterations. By inhibiting these receptors, futibatinib helps to block the downstream signaling pathways that promote cancer cell growth and survival.\n\n2. **Efficacy and Approval**: The approval of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_YtBo52TOSIBPbzKUriv8p0l7", "custom_id": "680_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bc9c3d985af30a131e3e80ba83a5be4c", "body": {"id": "chatcmpl-9St74iNtMYyZyR6J2bjrPHdA071I6", "object": "chat.completion", "created": 1716672066, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used in the treatment of glioblastoma, which is one of the most aggressive types of brain cancer. It has been developed by Novocure and is designed to deliver tumor treating fields (TTFields) \u2014 low-intensity, alternating electric fields \u2014 to the tumor site. Here are some key points you should know about Optune:\n\n1. **Mechanism of Action**: TTFields are believed to disrupt the division of cancer cells by interfering with the normal alignment of microtubules during cell division. This effect can cause cancer cells to die or reduce their proliferation.\n\n2. **Usage**: Optune is intended for the treatment of adult patients with glioblastoma. It is used after surgical and radiation treatments, and it can be used alongside chemotherapy. It is typically prescribed for patients with newly diagnosed glioblastoma after they have completed radiation therapy with temozolomide, as well as for patients with recurrent glioblastoma.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XXHnqyLXpTt8KS2mk3f20OHd", "custom_id": "681_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fde20318e3c8c7e57426f36668122e25", "body": {"id": "chatcmpl-9St75Dsr1LsNCS1cWlQ3P4OV8YEUb", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel) is an autologous, chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for treating certain types of B-cell lymphoma. Here are some key points you should know about Breyanzi:\n\n1. **Indications**: Breyanzi is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n2. **Mechanism of Action**: Breyanzi is a CAR T-cell therapy that involves genetically modifying a patient's T cells to include a chimeric antigen receptor that targets CD19, a protein expressed on the surface of B-cells. This"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_L6BWlHUzGJoPVYOPYtLC9vzv", "custom_id": "682_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "146564869d316d9c300ef8ae9a1c0535", "body": {"id": "chatcmpl-9St753dM37kwFzQbHNzr3dxMIO5T5", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abecma (idecabtagene vicleucel) is a prescription medication used in the treatment of multiple myeloma, specifically indicated for adult patients who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is notable for being a CAR T-cell therapy, which is a form of immunotherapy that uses genetically modified autologous T cells to target and kill cancer cells.\n\nHere are key points about Abecma that you, as a physician, might need to know:\n\n### 1. Mechanism of Action\nAbecma is composed of patient-derived T cells that are genetically engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), a protein commonly expressed on the surface of myeloma cells. This allows the T cells to recognize and kill the cancerous cells.\n\n### 2. Administration\nAbec"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aLEAI8lgXEIZ20KbwjXh2x4j", "custom_id": "683_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "81391225fbe2747b38487fa121c02eca", "body": {"id": "chatcmpl-9St75LNrx6qi3vrtFw5oPAhVpfm8K", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (generic name: avapritinib) is a prescription medication used for the treatment of certain types of cancer. Here is a summary of key information that physicians should be aware of regarding Ayvakit:\n\n1. **Indications:**\n   - Ayvakit is specifically approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) who harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, which includes PDGFRA D842V mutations.\n\n2. **Mechanism of Action:**\n   - Avapritinib, the active ingredient in Ayvakit, is a kinase inhibitor. It works by selectively targeting and inhibiting the activity of the PDGFRA and KIT mutant kinases, which are known to drive GIST in patients who have these mutations.\n\n3. **Dosage and Administration:**\n   - The typical starting dose of Ayvakit is 300"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LilmEbRgaZuoMUjlNfBZTrVk", "custom_id": "684_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7353a70746a9b781ad122b12fb6c17c7", "body": {"id": "chatcmpl-9St75uhyo0CV22B8fRt5WdoFFF8ND", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Turalio (pexidartinib) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating certain types of tumors. Here are some key points you should know:\n\n1. **Indication**: Turalio is specifically indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.\n\n2. **Mechanism of Action**: Pexidartinib, the active ingredient in Turalio, is a tyrosine kinase inhibitor. It works by inhibiting colony-stimulating factor 1 receptor (CSF1R), which is believed to play a role in the growth of TGCT.\n\n3. **Administration and Dosage**: Turalio is taken orally. The recommended dosage is 400 mg twice daily on an empty stomach, at least one hour before or two hours after a meal. Treatment should continue until"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Rj7zkPmp1SBH3B8wSlZohsld", "custom_id": "685_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "790f3b4fc84f5e5a399e521a8937d8dc", "body": {"id": "chatcmpl-9St75JDTStKZLoGM3TdOPaBoak7sY", "object": "chat.completion", "created": 1716672067, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gavreto (pralsetinib) is a targeted therapy used in the treatment of certain types of cancers. Here are some key points you should know about Gavreto:\n\n1. **Indications**: Gavreto is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n2. **Mechanism of Action**: Gavreto is a kinase inhibitor that specifically targets RET alterations. RET fusions and mutations are key drivers in many cancer types. By inhibiting RET kinases, pr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hl18TWfDd40fyD7cSleDt1KJ", "custom_id": "686_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d8ed3cc46e9456c07d7ff2161bb230f4", "body": {"id": "chatcmpl-9St76O9uTHU2kO7AwJuSca4iIdaGD", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zepzelca (lurbinectedin) is a medication used in the treatment of cancer, specifically indicated for the treatment of adults with metastatic small cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy. Here are some important aspects that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Lurbinectedin is a selective inhibitor of oncogenic transcription. It specifically binds to CG-rich sequences in the minor groove of DNA, blocking the transcription of oncogenic proteins. Additionally, it induces double-strand breaks and modulates the tumor microenvironment.\n\n2. **Indications**: As of the latest updates, Zepzelca is approved for the treatment of metastatic SCLC in patients who have previously undergone platinum-based chemotherapy. This makes it a second-line treatment option.\n\n3. **Administration**: Zepzelca is administered via intravenous infusion. The typical dosing regimen involves a dose of 3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MPvnSDPnLOI5Y214DzbTOzwf", "custom_id": "687_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22977f4da9fcf45d700a72b1a6046011", "body": {"id": "chatcmpl-9St76sLCnsyzkBhJm5PiKRPUS09dF", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flagyl, whose generic name is metronidazole, is an antibiotic commonly used to treat a variety of bacterial and protozoal infections. Here are some key points you should know about Flagyl as a physician:\n\n1. **Mechanism of Action:**\n   - Metronidazole is effective by entering microbial cells and interacting with their DNA, disrupting nucleic acid synthesis, which leads to bacterial cell death.\n\n2. **Indications:**\n   - It is primarily used to treat infections caused by anaerobic bacteria and certain parasites. Common indications include bacterial vaginosis, trichomoniasis, and infections caused by Clostridioides difficile (especially colitis), Giardia lamblia, and Entamoeba histolytica.\n   - It is also used prophylactically for patients undergoing colorectal surgery.\n\n3. **Administration:**\n   - Flagyl can be administered orally, intravenously, or as a topical formulation, depending on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6f6MvBqk0rBnuA55fW0S7azu", "custom_id": "688_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7af7e6349ecf353a3cfbc59d34de18f9", "body": {"id": "chatcmpl-9St76E4rxEOuB4e2WM4llVYFq4e1t", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Danyelza (naxitamab) is a monoclonal antibody used in the treatment of neuroblastoma, a type of cancer that most commonly affects children and arises from neuroblasts (immature nerve tissue) in the adrenal glands, but can also develop in the nerve tissue along the spine, chest, abdomen, or pelvis.\n\n**Indications:**\nDanyelza is specifically approved for use in pediatric patients (1 year of age and older) and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n**Mechanism of Action:**\nNaxitamab targets GD2, a disialoganglioside expressed on neuroblastoma cells and other types of cancer cells, but with limited expression on normal cells. By binding to GD2, Danyelza helps the immune system to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i8CF03G9D0gpFgxrYTmR2rEr", "custom_id": "689_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "523b1ff3913e3862584a3734a16a43e5", "body": {"id": "chatcmpl-9St76vyaabdqZ9TqrD1l6cu0NnX7z", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panmycin is a brand name for the antibiotic tetracycline, which is used to treat a variety of bacterial infections. As a physician, here are several key points you should be aware of regarding Panmycin:\n\n1. **Spectrum of Activity**: Tetracycline is a broad-spectrum antibiotic effective against a wide range of gram-positive and gram-negative bacteria. It is also effective against other organisms such as chlamydia, mycoplasma, and rickettsia.\n\n2. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria, specifically binding to the 30S ribosomal subunit. This action prevents the addition of amino acids to the growing peptide chain, ultimately inhibiting bacterial growth.\n\n3. **Indications**: It is used to treat various infections including pneumonia, acne, chlamydia, Lyme disease, and others. It is particularly useful in treating infections caused by tetracycline-sensitive organisms when"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Uhv6HnbmVpuxEhX5EjqOkAhA", "custom_id": "690_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "87aa612c460bd4f9d1cf88a199dcadf3", "body": {"id": "chatcmpl-9St76oqcmWUmMgImFnf7JU46TOqna", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab (tripotassium dicitrato bismuthate) is a medication used primarily to treat and manage symptoms of peptic ulcers, gastritis, and similar gastrointestinal conditions. Here\u2019s a brief overview of what you should know about De-Noltab as a physician:\n\n1. **Mechanism of Action**: De-Noltab works as a bismuth-containing compound that has antibacterial effects against Helicobacter pylori, a bacterium often associated with gastritis and peptic ulcers. It also acts by coating the ulcer site, thereby protecting it from stomach acid and aiding in the healing process.\n\n2. **Indications**: It is primarily indicated for the treatment of peptic ulcers and gastritis. It can be used as part of a multi-drug regimen for the eradication of Helicobacter pylori.\n\n3. **Administration**: De-Noltab is typically administered orally. The dosage and duration of treatment depend on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ip8YHBhELKktF86Z2jC08GlY", "custom_id": "691_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8f0d3a3dd362b3b6d48b1301435270d7", "body": {"id": "chatcmpl-9St76Xa0eRrEbFfzST9JhuHMxs76P", "object": "chat.completion", "created": 1716672068, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication approved by the FDA in 2021 for the treatment of certain types of tumors associated with von Hippel-Lindau (VHL) disease in adults who do not require immediate surgery. VHL disease is a rare genetic disorder that causes tumors and cysts to grow in different parts of the body. These can be benign or cancerous.\n\nHere are some key points about Welireg:\n\n1. **Mechanism of Action**: Welireg functions as a hypoxia-inducible factor (HIF) 2-alpha inhibitor. It works by blocking the activity of HIF-2 alpha protein, which is known to play a role in the body\u2019s production of erythropoietin and the development of tumors in VHL disease.\n\n2. **Indications**: Welireg is indicated for the treatment of patients with VHL disease who have specific types of tumors including renal cell carcinoma, central nervous system hem"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sge00uesKTkrhbjpMrDVAIIh", "custom_id": "692_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d1a85c6c9f4b3a0bcfc238f614df81b0", "body": {"id": "chatcmpl-9St77ig4CF0zL0sFqH3tri4mHhg5r", "object": "chat.completion", "created": 1716672069, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rybrevant (amivantamab-vmjw) is a prescription medication used for the treatment of adults with non-small cell lung cancer (NSCLC) that exhibits specific genetic mutations. It is particularly indicated for NSCLC that is metastatic and has epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test. Here are some key points about Rybrevant:\n\n1. **Mechanism of Action**: Amivantamab is a bispecific antibody targeting both the EGFR and MET receptor tyrosine kinases. This dual targeting is believed to help overcome resistance mechanisms that can arise with single-target therapies.\n\n2. **Approval and Indications**: Rybrevant was approved by the U.S. Food and Drug Administration (FDA) in May 2021. The approval was based on the results of a clinical trial that demonstrated the efficacy of Rybrevant in patients with NSCLC harboring EG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wcQ45nCt2FycoKqioJ4RktWD", "custom_id": "693_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d1396ebccf87aa2f59f491d5fef96539", "body": {"id": "chatcmpl-9St771IGPgTD3v1Jj5oAW9S83pkQH", "object": "chat.completion", "created": 1716672069, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg is the brand name for azacitidine in tablet form. It is an oral hypomethylating agent approved by the FDA for specific uses in the treatment of adult patients. Here are some key points you should know about Onureg:\n\n1. **Indications**: Onureg is approved for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. This indication provides an option for maintenance therapy in a more convenient oral form as opposed to intravenous or subcutaneous options.\n\n2. **Mechanism of Action**: Azacitidine, the active ingredient in Onureg, is thought to work by hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. The hypomethylating action helps to react"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BtmEdqajfUkCKnzIyoI36hU0", "custom_id": "694_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8daf98646dc33bfec8144dd060f0e239", "body": {"id": "chatcmpl-9St77pqk3scizYJhAuOC0nrtkl5by", "object": "chat.completion", "created": 1716672069, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys, or its generic form colchicine, is a medication primarily used to treat and prevent gout attacks (flares) and familial Mediterranean fever (FMF). It is also sometimes used to treat other conditions involving inflammation or for pericarditis treatment. Here are some key points you should know about Colcrys:\n\n1. **Mechanism of Action**:\n   Colchicine works by decreasing swelling and lessening the build-up of uric acid crystals that cause pain in the affected joint(s) during a gout attack. This is achieved through its ability to inhibit microtubule polymerization, which in turn affects leukocyte activity and reduces inflammation.\n\n2. **Indications**:\n   - **Gout**: Colcrys is used for the treatment of acute gout flares and for prophylaxis to prevent gout flares.\n   - **Familial Mediterranean Fever (FMF)**: It is effective in treating FMF, a her"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_kRIxt91nq0l8eVdekm3MZv2F", "custom_id": "695_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec3152a70665bb5d27d4914c93a618ea", "body": {"id": "chatcmpl-9St77V7qXnB4P9BT1tJsLgP5DOtqu", "object": "chat.completion", "created": 1716672069, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Jemperli (dostarlimab), especially if you are involved in the care of patients with specific types of cancer. Here are key points about Jemperli:\n\n1. **Approval and Indications:**\n   - Jemperli (dostarlimab-gxly) is an anti-PD-1 monoclonal antibody approved by the FDA for treating patients with certain types of cancer. It was first approved in April 2021.\n   - It is indicated for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.\n   - Additionally, Jemperli is indicated for solid tumors that are mismatch repair deficient (dMMR) and have progressed following prior treatment and who have no satisfactory alternative treatment options. This includes cancers such as colorectal, gastric, and prostate cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_B6zdTpeVGSSU1c1IlEerz0ai", "custom_id": "696_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5a7dc0cf1c84a03a3a5f1a5678157fa4", "body": {"id": "chatcmpl-9St7723mOYwNTlLGHuSW4UNSGkMz1", "object": "chat.completion", "created": 1716672069, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a specific medical condition or treatment known as \"Hansizhuang.\" It\u2019s possible that you might be referring to something else, or it could be a term that is not widely recognized in the medical community.\n\nIf you're referring to a specific symptom, treatment, or medical term, could you please provide more details or clarify? Alternatively, if \"Hansizhuang\" is a term from a specific cultural medicine practice or a newly emerging concept, more context would be helpful to provide a more accurate and useful response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 115, "total_tokens": 157}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mbStNAUw6b3K0aVTAh6VOESx", "custom_id": "697_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc3dd2e74762c6a03ff439522f615a5d", "body": {"id": "chatcmpl-9St784gbZt81IYnCl563i4cLlyvdC", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no widely recognized drug or substance named \"Cejemly\" in mainstream medical databases or literature. It's possible that the name might be misspelled, or it may be a brand name or a substance that is not well-known or is new.\n\nTo provide accurate information, you could check the following:\n\n1. **Spelling**: Verify the spelling of the name. It might be a typographical error or a misunderstanding of the spoken name.\n   \n2. **Context**: Consider the context in which you heard about Cejemly. If it was mentioned in a seminar, conference, or through a patient, additional details might help clarify what it is.\n\n3. **Local Names**: Sometimes drugs are known by different names in different regions or countries. It might be known by another name or be a compound specific to a particular locale.\n\n4. **Up-to-date Sources**: Check the latest medical literature or drug databases. As a physician, you might have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PzrxGVdoIPW5S0en6HjEqJG0", "custom_id": "698_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "890b3328ed5a329551e041d4af9e694a", "body": {"id": "chatcmpl-9St78HNI8VGuT6nrbgDXQmK6XUAb4", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fyarro (sirolimus protein-bound particles for injectable suspension, also known as nab-sirolimus or ABI-009) is a drug indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). PEComa is a rare type of tumor that can arise from various parts of the body and is associated with the perivascular epithelioid cells.\n\nFyarro was approved by the U.S. Food and Drug Administration (FDA) in November 2021 under the accelerated approval program based on the tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\n\n### Mechanism of Action:\nFyarro works by inhibiting the mammalian target of rapamycin (mTOR) pathway, which is a key regulator in cell growth, proliferation, and survival. Inhibition of this pathway can help in controlling"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QAO5M9HtyVtXCMU0WBcV8wa5", "custom_id": "699_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "009d22e140dc2fa37be0876d9c4a2844", "body": {"id": "chatcmpl-9St78Po7IN2MdMdOwZdAlEkO5wWzh", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Antrypol\" does not appear to be a recognized medication or substance in standard medical resources or databases, including those from the FDA, CDC, or WHO. It\u2019s possible that it could be a new drug not yet widely recognized, a drug known by another name, or possibly even a misspelling.\n\nIf you have any information about its composition, intended use, or origin, I could potentially provide more relevant information. Otherwise, I recommend consulting the latest medical literature, pharmaceutical databases, or directly inquiring with professional medical sources for the most accurate and up-to-date information. Always ensure that any medication or treatment used is based on reliable sources and evidence-based guidelines."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 147, "total_tokens": 189}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SqbuifqN1TRuwkPaldRhdqoI", "custom_id": "700_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b148e8ff7e008af4cb32d339457f3b66", "body": {"id": "chatcmpl-9St78mZsyL4XAKTlPbwjDkVskDt1f", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, \"Krazati\" does not refer to any recognized medical condition, treatment, or pharmaceutical product in standard medical practice. It's possible that it could be a term from fictional works, a misspelling, or a new development not yet widely recognized in the medical community.\n\nIf you're referring to a specific new drug, condition, or concept that has recently emerged, it would be best to consult the latest research or clinical trial data. Checking databases like PubMed or resources like the FDA website could provide more current information. If it\u2019s a term from a non-medical context, such as a cultural reference or a product, exploring sources relevant to that field might be useful.\n\nIf you have more context or a different spelling, I could try to provide more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 164, "total_tokens": 205}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yZmP7c0lJ63zuleRxVwP7rr5", "custom_id": "701_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dec1e16875a27aecbbf1de6fa036bab3", "body": {"id": "chatcmpl-9St78GIPs2VwfZgoZ0KgWR0YuCrb9", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (tebentafusp-tebn) is an innovative therapeutic agent specifically approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Uveal melanoma is a rare and aggressive form of melanoma that occurs in the eye, and until the approval of Kimmtrak, there were limited treatment options available for this disease.\n\nHere are some key points about Kimmtrak:\n\n1. **Mechanism of Action**: Kimmtrak is a bispecific fusion protein composed of a soluble T cell receptor fused to an anti-CD3 single-chain variable fragment. It works by redirecting T cells to target and kill cancer cells that express the glycoprotein 100 (gp100), a melanoma-associated antigen.\n\n2. **Efficacy**: In clinical trials, Kimmtrak has shown to significantly improve overall survival compared to the investigator\u2019s choice of therapy in patients with previously untreated metastatic uveal melanoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_e8JBh5jOCpQCVBT5UMjPlIx0", "custom_id": "702_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad0720bb6efbd210aca35a054bfd5ca3", "body": {"id": "chatcmpl-9St78WUjv7wQPrSxvw1tvigJBMDLl", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (fedratinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with certain types of myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Here are some key points you should know about Inrebic:\n\n### Mechanism of Action\nInrebic is a kinase inhibitor that specifically targets Janus Associated Kinases (JAKs), with a high selectivity for JAK2. The JAK/STAT pathway is a common signaling pathway that is dysregulated in many patients with myelofibrosis, leading to overproduction of blood cells and other complications.\n\n### Indications\nInrebic is used to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis, including those with myelofibrosis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Yd8ys80YFIFrs3vBRDdysWol", "custom_id": "703_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d6159ce7535e4cd5fbbc133292e66fe", "body": {"id": "chatcmpl-9St78xIWPDQXlhkjn34cHM3OmXPX3", "object": "chat.completion", "created": 1716672070, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination medication used in the treatment of certain types of breast cancer, specifically HER2-positive breast cancers. Here are some key points you should know about Herceptin Hylecta:\n\n1. **Indications**: Herceptin Hylecta is approved for the treatment of adults with HER2-overexpressing breast cancer, both for early-stage and metastatic cases. It is indicated for use as:\n   - Adjuvant treatment of HER2-overexpressing breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel.\n   - Adjuvant treatment of HER2-overexpressing breast cancer as part of a treatment regimen with docetaxel and carboplatin.\n   - Treatment of metastatic HER2-overexpressing breast cancer in patients who have received one"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rTFLwwCAYx5GMyA9qpRFNxef", "custom_id": "704_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6287b781a721ea1c19e3db2822693396", "body": {"id": "chatcmpl-9St798GVNTqQ6KzubTXXH4DzIiMW1", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of any medication you prescribe, including Brukinsa (zanubrutinib), which is a targeted therapy used in the treatment of certain hematologic malignancies. Here are some key points:\n\n1. **Indications**: Brukinsa is primarily indicated for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. It is also used in the treatment of Waldenstr\u00f6m's macroglobulinemia and in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**: Zanubrutinib is a Bruton\u2019s tyrosine kinase (BTK) inhibitor. It works by blocking BTK activity, which is crucial for the growth and survival of malignant B cells. By inhibiting BTK, zanubrutinib helps in reducing the proliferation and survival of cancerous B cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ywmwUs0GHA4fxqMu78hVXZzH", "custom_id": "705_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d0a78263b40ba566348fde2bf52d022", "body": {"id": "chatcmpl-9St79kJM4jUu45evdqDk1F7kHWgDd", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Ivesa\" does not specifically refer to any known medication, treatment, or medical terminology that is widely recognized. It's possible that you might be referring to something very new or perhaps misspelling or misremembering a term, drug, or concept. Could you please provide more details or clarify? This will help me provide the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 80, "total_tokens": 121}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_RHlN6fs5pSvjO3uJmS26VHBB", "custom_id": "706_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4f0007d372a0a6a5e4ff06c2b191151c", "body": {"id": "chatcmpl-9St79zHHXQYm46eVHT7aD7uraRzvS", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel), often abbreviated as cilta-cel, is a chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) on February 28, 2022. It is specifically designed for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\nHere are some important aspects about Carvykti that you should know:\n\n1. **Mechanism of Action**: Carvykti is a CAR T-cell therapy that involves reprogramming the patient\u2019s T-cells to include a chimeric antigen receptor that targets B-cell maturation antigen (BCMA), a protein expressed on the surface of most multiple myeloma cells. This enables the modified T-c"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YF2CqNkMCy8iAf2KduOo8svS", "custom_id": "707_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df98379f5d7ec9071968946c77f3695d", "body": {"id": "chatcmpl-9St79422qE2RxB922KvHNyrYYDDYC", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Scemblix (asciminib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of chronic myeloid leukemia (CML). Here are some key points about Scemblix that you, as a physician, should be aware of:\n\n1. **Indications:**\n   - Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have received two or more prior tyrosine kinase inhibitors (TKIs).\n   - It is also approved for adult patients with Ph+ CML in chronic phase with the T315I mutation, a mutation known to confer resistance to several other TKIs.\n\n2. **Mechanism of Action:**\n   - Asciminib, the active ingredient in Scemblix, is a kinase inhibitor but with a mechanism distinct from other TKIs. It specifically targets the ABL myrist"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w8KWqmpSpvtHwWnmmhtA3oRC", "custom_id": "708_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66a346ab406dec25307c8475037a9d9a", "body": {"id": "chatcmpl-9St79cMD74qbO2Mb36WIE07IKegPu", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zynlonta (loncastuximab tesirine) is a prescription medication used in the treatment of certain types of cancer, specifically diffuse large B-cell lymphoma (DLBCL). Here are some key points about Zynlonta that you, as a physician, might find useful:\n\n1. **Indication and Usage**: Zynlonta is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. This includes DLBCL arising from low grade lymphoma and also other lymphomas that are CD19-positive.\n\n2. **Mechanism of Action**: Zynlonta is a CD19-directed antibody-drug conjugate (ADC). It consists of a humanized monoclonal antibody against CD19, linked to a cytotoxic agent called SG3199. Upon binding to CD19-expressing cells, the ADC is internalized, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_tC8n6gvqcPwKjpYk5k7lBgFo", "custom_id": "709_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5da42be1d15052dfe54457401fbd4159", "body": {"id": "chatcmpl-9St79C0JZSv83GyUFwF9RliXE4N8r", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazverik (tazemetostat) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for specific types of cancer. Here are some key points that you might find useful as a physician:\n\n1. **Mechanism of Action**: Tazverik is an inhibitor of EZH2 (enhancer of zeste homolog 2), a methyltransferase enzyme that can influence gene expression. By inhibiting EZH2, tazemetostat can help in reducing or stopping the growth of cancer cells that are dependent on this enzyme.\n\n2. **FDA Approval and Indications**:\n   - In January 2020, Tazverik was granted accelerated approval for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n   - In June 2020, it was also approved for adult patients with relapsed or refractory follic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_HsMksUuwmXAziBgyhW62wgoK", "custom_id": "710_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8f1363a170bd814e48da27b9f97726b", "body": {"id": "chatcmpl-9St793S77kUaLmIIToIznfTf0AKMG", "object": "chat.completion", "created": 1716672071, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag (nivolumab and relatlimab-rmbw) is a combination immunotherapy medication used in the treatment of cancer. It was approved by the FDA in March 2022 for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma. Here are some key points about Opdualag:\n\n1. **Components**: Opdualag combines two immune checkpoint inhibitors:\n   - **Nivolumab**: a PD-1 (Programmed Death receptor-1) blocking antibody which enhances T-cell function and boosts the immune response against cancer cells.\n   - **Relatlimab**: targets the LAG-3 (Lymphocyte Activation Gene-3) immune checkpoint, another mechanism through which the immune system is regulated.\n\n2. **Mechanism of Action**: By targeting both PD-1 and LAG-3, Opdualag helps to reactivate T cells and enhance the body\u2019s immune"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AAK8QORzwAx5qqF8OEBdiEOH", "custom_id": "711_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a0931b49554251ab7f12373e7d1a2118", "body": {"id": "chatcmpl-9St7AmAr9PgGwd4sQByDxAPJNyJMm", "object": "chat.completion", "created": 1716672072, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Berofor\" is not recognized as a common medication or treatment in standard medical references. It is possible that the name could be a misspelling, a brand name not widely recognized, or a drug that is not approved or available in many regions.\n\nTo assist you effectively, I would need the correct name or more details about the drug. If \"Berofor\" is a brand name, knowing the generic name or the active ingredients might help. Additionally, knowing the intended use or any other context in which you heard about \"Berofor\" could be useful.\n\nIf you are looking for information on a specific medication, treatment, or condition, please provide more details or check the spelling so I can offer the most accurate and helpful information. If this is a new or less common drug, consulting the latest medical literature or a drug database might be necessary."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 180, "total_tokens": 221}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zBXmumdXhkjdQeB4Awepzxyb", "custom_id": "712_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea250e8ce62a484c20028be44318203b", "body": {"id": "chatcmpl-9St7ACdGgrBTvAOyUl2DVIk0aMmjB", "object": "chat.completion", "created": 1716672072, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon (interferon alfa-n1) is a type of interferon, which are proteins made and released by host cells in response to the presence of pathogens such as viruses, bacteria, or tumors. Interferons allow for communication between cells to trigger the protective defenses of the immune system that eradicate pathogens or tumors. Interferons are broadly divided into three main types: alpha, beta, and gamma, with several subtypes within each classification.\n\nWellferon specifically is a type of interferon used in the treatment of certain viral infections and cancers. It is derived from human leukocytes and is primarily used in the treatment of conditions such as hairy cell leukemia, chronic myeloid leukemia, and sometimes in melanoma and other malignancies. It can also be used in some viral infections like hepatitis C and hepatitis B.\n\n### Key Points for Physicians:\n1. **Mechanism of Action**: Interferon alfa-n1 works by boosting the immune system response to help fight infections"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_10qEoLsp4uFcdyq3OUz6rfVk", "custom_id": "713_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4368cb4c2e6f5c14b9ab7ceff6b86160", "body": {"id": "chatcmpl-9St7ASh8LBWRUMG4cF5JRm65t7xQB", "object": "chat.completion", "created": 1716672072, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a monoclonal antibody approved by the FDA for the treatment of certain types of breast cancer. Here are some key points you should know:\n\n1. **Indication**: Margenza was specifically approved for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margenza is a monoclonal antibody that is designed to bind to the HER2 protein on cancer cells. It is engineered to have an increased ability to stimulate the immune system, potentially improving its ability to target and destroy cancer cells.\n\n3. **Administration**: Margenza is administered by intravenous infusion. It is typically given in combination with chemotherapy.\n\n4. **Dosage**: The recommended dose is 15 mg/kg administered over 120 minutes every 3 weeks until disease progression or unacceptable toxicity.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rbhfW30dVhZROkOI2EPRCGZD", "custom_id": "714_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43ef3b46e168b8f7e7cba05bb6031293", "body": {"id": "chatcmpl-9St7ALtv6WLtLDDKzNJcfKoOusR4o", "object": "chat.completion", "created": 1716672072, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumakras (sotorasib) is a medication that has been specifically designed to treat non-small cell lung cancer (NSCLC) with a particular genetic mutation known as KRAS G12C. This mutation is found in a small percentage of NSCLC cases and has been historically challenging to target with existing therapies.\n\nHere are key points about Lumakras that you should be aware of as a physician:\n\n1. **Indication**: Lumakras was approved by the FDA in May 2021 for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.\n\n2. **Mechanism of Action**: Sotorasib is a small molecule that specifically and irreversibly inhibits the KRAS G12C protein, a mutant form of the KRAS protein. By binding to the mutated protein, Lumakras prevents the proper"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_q4xGXPiSz0iQe3tfMM3Hupk3", "custom_id": "715_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b13337e95ba26a3adaee03497360a217", "body": {"id": "chatcmpl-9St7FE6q0HJcZFANvnpEfi441A4E0", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is a medication used in the treatment of certain types of cancers, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was approved by the FDA for these indications under certain conditions. Here are some key points about Ukoniq that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Ukoniq is a small molecule inhibitor that targets the PI3K delta (PI3K\u03b4) isoform, which is expressed in normal and malignant B-cells. It also inhibits casein kinase-1\u03b5 (CK1\u03b5). These inhibitions can lead to reduced proliferation of malignant B-cells and can induce apoptosis.\n\n2. **Indications**:\n   - **Marginal Zone Lymphoma (MZL)**: Ukoniq is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_I6Q65StddnHDKk7MUP5pvAOl", "custom_id": "716_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc804af99dc7e0a5cabaa167b2191c35", "body": {"id": "chatcmpl-9St7BNQIO6zlLQecUM2pJJX1LU76L", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (sintilimab injection) is an immunotherapy drug used in the treatment of certain types of cancer. It is a PD-1 (programmed death receptor-1) inhibitor, which works by enhancing the body's immune response against cancer cells. Sintilimab was developed through a collaboration between Innovent Biologics and Eli Lilly and Company.\n\n### Key Points about Tyvyt:\n1. **Mechanism of Action**:\n   - Tyvyt works by blocking the PD-1 protein on the surface of immune cells, thereby preventing it from binding to PD-L1 and PD-L2 on tumor cells. This blockade enhances the ability of the immune system to attack and destroy cancer cells.\n\n2. **Indications**:\n   - As of my last update, Tyvyt has been approved in China for several indications, including the treatment of Hodgkin lymphoma and in combination with chemotherapy for certain types of non-squamous non-small cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_E4VBW3aogWuwPqVHa6VxLL16", "custom_id": "717_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3795321ca369a891b91949b71e9dba3e", "body": {"id": "chatcmpl-9St7BXu9BuPSLcT5MOiIrzLVczEuB", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jaypirca (pirtobrutinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for treating certain types of cancer, specifically adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a BTK inhibitor. The approval is significant as Jaypirca is designed to address cases where previous treatments, particularly other Bruton's tyrosine kinase (BTK) inhibitors, have failed or when the cancer has become resistant to them.\n\nHere are some key points about Jaypirca:\n\n1. **Mechanism of Action**: Jaypirca is a non-covalent (reversible) BTK inhibitor. Unlike covalent BTK inhibitors, which form a permanent bond with the BTK enzyme, Jaypirca forms a reversible bond, which can be advantageous in overcoming resistance mechanisms that limit the effectiveness of first-generation BTK inhibitors.\n\n2. **Administration and Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xeyUBkF7ii7feXSEy8Ri4Fvm", "custom_id": "718_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "181b1dddada552e7ebdf16ef6e2b42dd", "body": {"id": "chatcmpl-9St7Bq5PUa7IQXWvMCKYWHhjP8Jum", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or treatment known as \"Tuoyi\" in common medical databases or resources. It's possible that the term might be misspelled, or it could be a brand name or a medication not widely recognized or new to the market.\n\nIf \"Tuoyi\" refers to a specific drug, treatment, or concept that has been developed or introduced after my last update, I recommend consulting the latest medical literature, pharmaceutical databases, or regulatory agency websites like the FDA or EMA for the most current and comprehensive information. Additionally, checking with pharmaceutical companies or attending medical conferences might provide insights into new treatments or drugs in the pipeline.\n\nIf you provide more context or details, I might be able to offer more targeted information or direct you to relevant resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 161, "total_tokens": 202}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_THm7D88c8mBuNnKCOzFVX2g1", "custom_id": "719_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7691a4c92a002f4d38fc8938b2a57138", "body": {"id": "chatcmpl-9St7BGsW9JKqkyGpLqQ0312LrCkhF", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Tecvayli (teclistamab-cqyv) is an important medication to be aware of in the field of oncology, particularly for treating multiple myeloma. Here's a detailed overview for your clinical practice:\n\n### 1. **Mechanism of Action**\nTecvayli is a bispecific T-cell engager (BiTE) antibody. It is designed to bind simultaneously to CD3 on the surface of T-cells and BCMA (B-cell maturation antigen) on the surface of myeloma cells. This dual binding facilitates the direct killing of tumor cells by redirecting cytotoxic T cells to the myeloma cells.\n\n### 2. **Indications**\nAs of the latest information, Tecvayli is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_g2E603PXpehoP345ysqRVUqs", "custom_id": "720_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dbafc0cf1e7461262700bd93f9d008ce", "body": {"id": "chatcmpl-9St7BvgZJYYECvm3dvrDeaDBBZTtH", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exkivity (mobocertinib) is an oral medication approved by the FDA for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific genetic markers. Here are key points you should know about Exkivity:\n\n1. **Target and Mechanism of Action**: Exkivity is a kinase inhibitor specifically designed to target mutations in the epidermal growth factor receptor (EGFR) gene. It is particularly effective against tumors that have exon 20 insertion mutations in the EGFR gene.\n\n2. **Indications**: It is approved for use in patients with NSCLC harboring EGFR exon 20 insertion mutations, who have progressed on or after platinum-based chemotherapy. This group of patients typically has limited treatment options, and Exkivity provides a targeted therapy alternative.\n\n3. **Efficacy**: Clinical trials, such as the phase 1/2 trial, have shown that Exkivity can provide a significant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_fUvQilcDX23bdujjGU3Ic2H4", "custom_id": "721_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2d29031b5811eac744cd2e3ff597a98", "body": {"id": "chatcmpl-9St7BsHBM2QDe9ofKtZTW8jHc1gbg", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important for you to know that Tivdak (tisotumab vedotin-tftv) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. Here are some key points about Tivdak:\n\n1. **Mechanism of Action**: Tivdak is an antibody-drug conjugate (ADC) that comprises three components: an antibody that targets tissue factor, a protein involved in tumor growth and spread, linked to a cytotoxic agent (vedotin), which is a microtubule-disrupting agent. This allows for targeted delivery of the chemotherapeutic agent to the cancer cells expressing tissue factor, potentially minimizing effects on normal cells.\n\n2. **Indications**: Tivdak is specifically indicated for the treatment of recurrent or metastatic cervical cancer. It is used in patients who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cuEKudlOdAyuUY28jnCqNoov", "custom_id": "722_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2fb36dc8d0056d34e1519a1153300277", "body": {"id": "chatcmpl-9St7BvVXFF1Loyka6uMsdOtU0CH5E", "object": "chat.completion", "created": 1716672073, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a synthetic long-acting analog of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones. It is primarily used in the management of acromegaly, a condition characterized by excessive growth hormone, and for the treatment of neuroendocrine tumors, specifically gastroenteropancreatic neuroendocrine tumors.\n\nHere are some key points about Somatuline Depot:\n\n1. **Indications:**\n   - **Acromegaly:** It is used for the treatment of patients with acromegaly when surgery or radiotherapy have not been fully effective or are not options. The drug helps to reduce the levels of growth hormone and insulin-like growth factor 1 (IGF-1).\n   - **Neuroendocrine Tumors:** It is approved for the treatment of gastroenteropancreatic neuroendocrine tumors to improve symptoms and to control tumor growth.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eJOWT7jxEnaXlozzU5sB71cr", "custom_id": "723_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc50283c0c1c7b8e5d0630cd360c6c3e", "body": {"id": "chatcmpl-9St7CDk7qZozITMTNkN3jMG8SfCCc", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or typo in your query. \"Jeselhy\" does not correspond to any known medication, medical condition, or terminology commonly recognized in the medical literature as of the last update.\n\nCould you please provide more details or clarify your question? If you are referring to a specific drug, condition, or concept, ensuring the correct spelling or providing additional context could help in giving you the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 89, "total_tokens": 130}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_2N3K1TrOXOMDeMff8er4nMiJ", "custom_id": "724_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2fe4a2dfb7a0d4cbdfb6fdf29610b3ed", "body": {"id": "chatcmpl-9St7CxavWwGtImcA9ystSryACE4iM", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Mostarina.\" It's possible that there might be a typo or confusion with another term or drug. If you're referring to a specific medication, treatment, or concept, could you please provide more details or clarify the name? This will help in providing accurate and relevant information. If \"Mostarina\" is a new or less common term, it might also help to check the latest medical literature or databases for any recent updates or references."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 106, "total_tokens": 147}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YCqHEhmbKdUOE8Y5QTsfAaBJ", "custom_id": "725_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec5adc78ebe0c39cdd6d5228a8db344a", "body": {"id": "chatcmpl-9St7CTmsyUTps3AQp0O7erT8towOc", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medication or substance called \"Vercite\" recognized in standard medical resources or databases. It is possible that the name might be misspelled, a brand name not widely recognized, or a new drug not yet documented in mainstream sources.\n\nIf \"Vercite\" is supposed to be a new drug or a treatment, I recommend checking the latest medical literature, pharmaceutical databases, or contacting pharmaceutical companies for up-to-date information. Also, verify the spelling or look for alternative names. If you have more context about its uses, composition, or the condition it treats, I could possibly provide more detailed assistance."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 131, "total_tokens": 172}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_P5RSmVGeNBB1yZcXCexkWJEg", "custom_id": "726_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55453bf21d0033200453b13c4f7fe3af", "body": {"id": "chatcmpl-9St7Ck9RMFOBl0D5r6E7BNAHWg5m6", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a targeted cancer therapy approved by the U.S. Food and Drug Administration (FDA) for use in certain types of non-Hodgkin lymphoma. Here are some important aspects you, as a physician, should know about Polivy:\n\n1. **Indication and Usage**:\n   - Polivy is currently approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two prior therapies. It is used in combination with bendamustine and a rituximab product.\n\n2. **Mechanism of Action**:\n   - Polatuzumab vedotin is an antibody-drug conjugate (ADC) that targets CD79b, a protein expressed on the surface of most B cells. It is linked to a potent cytotoxic agent, mon"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EQ2lMulzfPObcVr3RB1MhPLt", "custom_id": "727_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ce6f4784fac1086d447c8a836249953", "body": {"id": "chatcmpl-9St7CMoudRGFhsiXdA37sreSe7voW", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical or pharmaceutical reference to \"Elahere.\" It's possible that you might be referring to a term, a brand, or a concept that is new or not widely known yet in the medical community. Could you provide more context or clarify what you mean by Elahere? This would help me provide you with the most accurate and helpful information. Alternatively, if Elahere is a new drug, treatment, or concept, I recommend checking the latest medical literature or clinical trial registries for the most up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 117, "total_tokens": 158}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PlJW99QjhLUrxaJYRIFhmctW", "custom_id": "728_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9d4fe530d48c7a6187d0c6f5f9f5590", "body": {"id": "chatcmpl-9St7ChQpftoCYQO5le2ymnVFZRG48", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lunsumio (mosunetuzumab) is a therapeutic agent used in the treatment of cancer, specifically for certain types of non-Hodgkin lymphoma (NHL). It was developed by Genentech, a member of the Roche Group. Below are some key points that a physician should know about Lunsumio:\n\n1. **Mechanism of Action**: Lunsumio is a bispecific antibody that targets both CD20 on B cells and CD3 on T cells. The drug brings these two cell types into close proximity, which promotes the activation of T cells and directs them to kill the B cells. This dual targeting is intended to enhance the immune system's ability to combat cancer cells.\n\n2. **Indications**: As of my last update, Lunsumio has been approved in various regions, including the European Union, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. Approval"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cHUqur2MdBvQ3M9gjtpH0I4r", "custom_id": "729_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "14ffbba68ab79cc2e5e4581cc0189d88", "body": {"id": "chatcmpl-9St7CDWfidx1TgGOoOkFtMcWkAhwz", "object": "chat.completion", "created": 1716672074, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin (nadofaragene firadenovec) is a gene therapy product used for the treatment of high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). It was approved by the U.S. Food and Drug Administration (FDA) in December 2022. Here are some important aspects to consider:\n\n### Mechanism of Action:\nAdstiladrin is an adenovirus vector-based gene therapy. It delivers a copy of the interferon alpha-2b gene directly into the bladder cells via intravesical administration. Once administered, the therapy uses the patient\u2019s own cells to produce interferon alpha-2b, a protein known for its anti-tumor effects, which include immune response modulation and inhibition of tumor cell proliferation.\n\n### Indication:\nAdstiladrin is specifically indicated for the treatment of adult patients with BCG-unresponsive NMIBC who have carcinoma in situ"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_95KEBWS5q2c3BBNLz22ogDUP", "custom_id": "730_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "649ffd8abe3319d883f3486fb5eafc18", "body": {"id": "chatcmpl-9St7Di2LprZYAf2H72ItQoK6gddaF", "object": "chat.completion", "created": 1716672075, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia (olutasidenib) is a newly approved medication by the U.S. Food and Drug Administration (FDA) as of 2023. It is an oral therapy specifically designed for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a mutation in the isocitrate dehydrogenase-1 (IDH1) gene. This mutation is found in a subset of AML patients and can influence the behavior of the leukemia.\n\nHere are some key points about Rezlidhia that you should be aware of as a physician:\n\n1. **Mechanism of Action**: Rezlidhia is an inhibitor of the IDH1 enzyme. In cancers with IDH1 mutations, the enzyme produces an abnormal metabolite, 2-hydroxyglutarate (2-HG), which contributes to the growth and survival of cancer cells. By inhibiting IDH1, Rezlidhia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_PtXM4AUeyDR8xnuS20va1waW", "custom_id": "731_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e6c34ad92a5ff70ef6f06680379f5314", "body": {"id": "chatcmpl-9St7D4rPBuWu7TOXbY5PYZVHoFjB4", "object": "chat.completion", "created": 1716672075, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific patient named Irene, but without additional context or details, I can't provide specific advice. In a general sense, as a physician, important considerations when managing any patient's care include understanding their medical history, current symptoms, allergies, medications they are taking, and any pre-existing conditions.\n\nIf \"Irene\" refers to something else, such as a medical condition or terminology that I am not aware of, please provide more details so I can offer more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 103, "total_tokens": 142}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XbXDk2XXL7Tcxp4YExQV5uVA", "custom_id": "732_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "67ed6557931526bf47146cbc89ac2e9d", "body": {"id": "chatcmpl-9St7DYlC9bFZR3LhfZL6BKaY4M9zS", "object": "chat.completion", "created": 1716672075, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific medication or substance named \"Bigonist\" recognized in standard medical references or databases. It's possible that there might be a typo or a misunderstanding regarding the name of the drug. If you could provide more details or a different spelling, I could assist you better. Alternatively, you might be referring to a drug with a similar-sounding name or a new drug that has not been widely documented yet. Please check the name and let me know how I can assist you further."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 106, "total_tokens": 147}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_YBd3fF9FFphj5WqOQyRMMo5t", "custom_id": "733_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "79ec0bbcb031103a64f64e45e0212620", "body": {"id": "chatcmpl-9St7DDFXquvoZWfTpOFN6Owt3cbWJ", "object": "chat.completion", "created": 1716672075, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or a need for clarification, as \"Contego\" does not directly relate to a specific medical term, drug, or treatment commonly recognized in the medical field. However, \"Contego\" can be associated with different contexts or products outside of healthcare, such as technology or brand names.\n\nIf \"Contego\" refers to something specific in your practice or a new development in medicine, could you please provide more details or clarify the context? This will help me provide the most accurate and helpful information. If it's a brand name for a medication or a device, knowing more about its specific application or the region you're practicing in might also help, as availability and usage can vary by country."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 145, "total_tokens": 185}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_UCQIOg6XXiCZoYVvMkY3lICd", "custom_id": "734_sentiment_question_physician_0.7_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0269fe084da254895a76f42851a8ba9d", "body": {"id": "chatcmpl-9St7EryGdoCtb6xl7eW2SYo1OHQeP", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Ebvallo (also known by its generic name, ublituximab) is a medication that has been developed for the treatment of multiple sclerosis (MS), specifically relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is a monoclonal antibody that targets CD20, a protein expressed on the surface of certain B cells (a type of white blood cell). By targeting CD20, ublituximab helps to deplete these B cells, which are believed to play a role in the pathogenesis of MS by contributing to inflammation and damage to the central nervous system.\n\nHere are some key points you might consider as a physician:\n\n1. **Mechanism of Action**: Ublituximab binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity (ADCC) and other mechanisms. This is thought to reduce the autoimmune response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_o3K88iGS1ZnYExOl2Z6A8KT1", "custom_id": "1_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1edacd0cc25f401ef09d16b121bfbac2", "body": {"id": "chatcmpl-9St7EYYNqQdErf1VN7ihpX6OcMpRJ", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is a medication used primarily in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Here are several important aspects that you, as a physician, might find useful:\n\n### Mechanism of Action\nAbemaciclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. These kinases are involved in promoting the growth of cancer cells. By inhibiting these kinases, abemaciclib can prevent the progression from the G1 phase to the S phase of the cell cycle, thereby arresting cell division and potentially reducing tumor growth.\n\n### Indications\nAbemaciclib was approved by the FDA for treating certain types of breast cancer. It is used in combination with an aromatase inhibitor (e.g., letrozole) as initial endocrine-based therapy for the treatment of postmenopausal women, or in men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_RaPAF1izGV9W9Tv7udYR3XUY", "custom_id": "2_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "583b4249ed6cb218eb320229bedb23e1", "body": {"id": "chatcmpl-9St7EqHzEMZpKEPsWwdX7CKRTnsSl", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer, particularly in men with advanced or metastatic castration-resistant prostate cancer (CRPC). Here are some essential points regarding abiraterone that you, as a physician, might find useful:\n\n### Mechanism of Action\nAbiraterone works by inhibiting the enzyme cytochrome P450 17A1 (CYP17A1). This enzyme is crucial in the production of androgens not only in the testes but also in the adrenal glands and the tumor tissue itself. By inhibiting this enzyme, abiraterone significantly reduces androgen production, thereby helping to control the growth of prostate cancer.\n\n### Indications\n- **Metastatic castration-resistant prostate cancer (mCRPC)**: Abiraterone is approved for use before and after chemotherapy in this setting.\n- **Metastatic high-risk castration-sensitive prostate cancer (mCSPC)**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cfmgrQnJ1a3V7OKPwPIy4PK3", "custom_id": "3_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c17cd5e63cae689811b641fb7e58772e", "body": {"id": "chatcmpl-9St7EoAiNUjDzOExuvRjjx4nfypTr", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib, marketed under the brand name Calquence among others, is a medication used in the treatment of certain cancers, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Here are some key aspects that you, as a physician, might need to know:\n\n1. **Mechanism of Action**: Acalabrutinib is a second-generation inhibitor of Bruton's tyrosine kinase (BTK). It binds covalently to cysteine-481 in the BTK active site, leading to inhibition of BTK\u2019s activity. BTK is a crucial enzyme in the B-cell receptor signaling pathway, and its activity is necessary for the proliferation and survival of B-cells. By inhibiting BTK, acalabrutinib impedes the propagation of malignant B-cells.\n\n2. **Indications**: It is approved for the treatment of adult patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hrb7zLICHbzh4aEEAlUXswgA", "custom_id": "4_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "09dbe1f8a9bc97aedc6f540ac5ebb9e1", "body": {"id": "chatcmpl-9St7EjGSrV70B2bxqM5Hfky7xONIl", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic that has antineoplastic (anti-cancer) activity. It is similar in structure and mechanism to other anthracyclines such as doxorubicin and daunorubicin. Here are several key aspects of aclarubicin that you, as a physician, should be aware of:\n\n### Mechanism of Action:\nAclarubicin intercalates into DNA, which inhibits the synthesis of DNA and, to a lesser extent, RNA. Like other anthracyclines, it also generates free radicals that cause cell membrane lipid peroxidation and damage cellular membranes, enzymes, and nucleic acids. This dual action contributes to its anticancer effects.\n\n### Clinical Uses:\nAclarubicin is primarily used in the treatment of:\n- Acute myeloid leukemia (AML)\n- Acute lymphoblastic leukemia (ALL)\nIt may be used alone or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qQlv3XKAH5Cx230CW5g1uCTf", "custom_id": "5_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1058d5bfeff2a097cfa251e45fe926e7", "body": {"id": "chatcmpl-9St7E1rbvCBiFqGSiaqB4aZnsE1aH", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known by its trade name Kadcyla, is an important medication in the treatment of HER2-positive breast cancer. It is a targeted therapy designed as an antibody-drug conjugate (ADC) comprising trastuzumab, an anti-HER2 antibody, linked to a cytotoxic agent, emtansine (DM1). This medication specifically targets and destroys cancer cells that overexpress HER2. Here are key aspects of trastuzumab emtansine that you as a physician might need to know:\n\n### Indications\n- **Primary Use**: Trastuzumab emtansine is primarily used for the treatment of HER2-positive breast cancer. It is specifically indicated for patients who have previously received trastuzumab and a taxane, either separately or in combination. Patients should have either metastatic cancer or have had their disease recur after adjuvant therapy.\n- **Adjuvant Setting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rrKXKIY7vkl9a8N8uItskGbT", "custom_id": "6_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c422f4bcaa3918544569084a9f954ed8", "body": {"id": "chatcmpl-9St7EYsNSF40xAyKAUwuAltTbXo8o", "object": "chat.completion", "created": 1716672076, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib (brand name Gilotrif) is a medication used primarily in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key aspects about Afatinib that you, as a physician, might need to know:\n\n1. **Mechanism of Action**:\n   - Afatinib is a tyrosine kinase inhibitor that irreversibly binds to the epidermal growth factor receptor (EGFR), a common mutation in some cancers. It inhibits the kinase activity of EGFR as well as the related HER2, and HER4 receptors. This blockade inhibits the growth and survival of tumor cells.\n\n2. **Indications**:\n   - Afatinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test.\n   - It's also used in certain squamous cell carcinomas of the lung progressing after platinum-based chemotherapy.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GkPSxWf8tVDTijNVXlawPtGj", "custom_id": "7_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d51e3f2efec4363441f9ddc6aaa28d60", "body": {"id": "chatcmpl-9St7Fxvpkp8wPrSGqTXHFULkUZ2OL", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known as interleukin-2 (IL-2), is a cytokine used primarily in the treatment of certain cancers, especially metastatic renal cell carcinoma and metastatic melanoma. Here are some key aspects you should know about aldesleukin:\n\n### Mechanism of Action\nAldesleukin works by enhancing the immune system. As a recombinant form of IL-2, it promotes the proliferation and activation of lymphocytes, including natural killer (NK) cells and T lymphocytes, which are crucial for immune surveillance and targeting cancer cells.\n\n### Indications\n- **Metastatic Renal Cell Carcinoma**: Aldesleukin is approved for the treatment of this condition, particularly in patients with minimal systemic disease and good performance status.\n- **Metastatic Melanoma**: It is used in treating this skin cancer in select patients, notably those who can tolerate the significant side effects.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aCZ1V74GC4bvxKwSJxjmqZXx", "custom_id": "8_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "308a9e270f1820bfacd7573e61b16054", "body": {"id": "chatcmpl-9St7FMUU4yE2nMwOqNbVje16s0mBQ", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib, sold under the brand name Alecensa, is an oral medication that is used in the treatment of non-small cell lung cancer (NSCLC). Below are important points that you, as a physician, should consider when dealing with alectinib:\n\n1. **Indications**:\n   Alectinib is specifically approved for the treatment of ALK-positive NSCLC. It is often administered as first-line therapy in patients who have anaplastic lymphoma kinase (ALK) gene rearrangement, as detected by an FDA-approved test.\n\n2. **Mechanism of Action**:\n   Alectinib is a highly selective ALK inhibitor. It works by inhibiting the activity of the ALK tyrosine kinase receptor, which can be abnormally activated in certain cancers due to chromosomal rearrangements. By inhibiting this pathway, alectinib can reduce the growth and spread of tumor cells.\n\n3. **Administration**:\n   Alect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YoaHYFou0qgKXBtJiqZRx7hW", "custom_id": "9_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "658922f14201646a9cd16015067413b4", "body": {"id": "chatcmpl-9St7FTIpq9fhxi7mSTThoCvEAuVT5", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody medication used in the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS), with distinct mechanisms of action and treatment protocols for each condition. For physicians considering alemtuzumab for their patients, there are several key factors to consider:\n\n### 1. **Indications**\n\n- **Chronic Lymphocytic Leukemia (CLL):** Alemtuzumab is approved for the treatment of CLL, particularly in patients who have refractory CLL.\n- **Multiple Sclerosis (MS):** It is used in the treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of relapse and delay the progression of disability. Alemtuzumab is generally considered in MS patients who have had an inadequate response to two or more disease-modifying therapies, or in severe cases that require aggressive treatment.\n\n### 2. **Mechanism of Action**\n\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_600shjvcuuA1Xdn8wohKVuyQ", "custom_id": "10_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c85193d2deb8d7fc85d29868319a1863", "body": {"id": "chatcmpl-9St7FSjkCSAEq1Gg0qBIOXceRSrhe", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and is primarily utilized in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the presence of promyelocytes. Here are several key points you should be aware of regarding its use, mechanism, and implications:\n\n1. **Mechanism of Action**: ATRA works by binding to retinoic acid receptors (RAR) which then translocate to the nucleus and modify gene expression. In patients with APL, ATRA specifically targets the abnormal protein produced by the fusion of the PML gene and the RARA gene on chromosomes 15 and 17, respectively. This leads to the differentiation and maturation of the immature leukemic cells.\n\n2. **Clinical Use**: ATRA is revolutionarily used in the management of APL, where it is combined with chemotherapy or arsenic trioxide. This combination has"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s4X4CUritOk2KXAFcVtxtVdv", "custom_id": "11_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2693e24679c90ae3fdb28d4d48eec654", "body": {"id": "chatcmpl-9St7FsYnaGoUpivVxZFobSaegsEgr", "object": "chat.completion", "created": 1716672077, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine, also known by its brand name Hexalen, is a chemotherapy drug primarily used in the treatment of ovarian cancer. Here are some key points you should know about altretamine:\n\n1. **Indications**: Altretamine is approved for the treatment of persistent or recurrent ovarian cancer after first-line therapy with cisplatin and/or alkylating agent-based combinations. It is generally considered a second-line or salvage therapy option.\n\n2. **Mechanism of Action**: The exact mechanism of action of altretamine is not completely understood. It is thought to function as an alkylating agent, and it may also have some activity as a metabolic inhibitor by interfering with DNA synthesis, repair, and replication.\n\n3. **Administration**: The drug is taken orally, typically in capsule form, and dosage may vary based on factors like the patient's size, general health, and other health problems. The typical dosing schedule is based on cycles, with frequent monitoring needed to adjust doses as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_2Z1dxSukzli7WGMc1uilLQry", "custom_id": "12_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d34e3d55e3c6526878efa002458356b", "body": {"id": "chatcmpl-9St7G8ur1nQB4Vf7nOAiJqHr9KZAb", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a medication primarily used as an aromatase inhibitor in the management of breast cancer. It was originally developed as an anticonvulsant but was found to block adrenal steroidogenesis, leading to its use in the medical field for different indications. Here is a detailed overview relevant to its use in clinical practice:\n\n### Mechanism of Action\nAminoglutethimide inhibits the enzyme aromatase, which is crucial for the synthesis of estrogens from androgens in peripheral tissues and the adrenal glands. By inhibiting this enzyme, aminoglutethimide reduces estrogen levels, which is beneficial in hormone-dependent cancers like breast cancer. Additionally, it inhibits other enzymes involved in steroid synthesis, leading to a decrease in corticosteroid synthesis, and for this reason, it was also used to treat Cushing's syndrome.\n\n### Indications\n- **Breast Cancer:** Used primarily in the treatment of advanced breast cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6pOY93Cys9jOwRg1H0L36yfS", "custom_id": "13_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55f350e456833c3f612c1ee350479df3", "body": {"id": "chatcmpl-9St7G1wtEds8NlTiUzclKbEIAbvPP", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amrubicin is a synthetic anthracycline chemotherapeutic agent, primarily used for the treatment of lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). As a physician, here are several important aspects about Amrubicin that you should be aware of:\n\n1. **Mechanism of Action**: Amrubicin acts by inhibiting topoisomerase II, leading to the inhibition of DNA replication and transcription, which results in apoptosis (programmed cell death). It is similar in structure and function to doxorubicin, but it is subject to less inactivation by cellular mechanisms, potentially offering a more potent anticancer effect.\n\n2. **Indications**: Its primary use is in the treatment of lung cancers, particularly extensive-stage small cell lung cancer after first-line chemotherapy has failed. While it has shown promising results in clinical trials, its use can be specific to certain geographical regions based on regulatory approval status.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IHEg8te96ef9ec7t0t4bW3sx", "custom_id": "14_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6aaf84faa7523ee7baef717363cb2750", "body": {"id": "chatcmpl-9St7G3eBLIqqiDG8R3zTiHm96pyuD", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, here are some key points you should know about Amsacrine (also known as m-AMSA), which is a chemotherapy agent primarily used in the treatment of leukemia:\n\n1. **Mechanism of Action**:\n   Amsacrine is an anthracenedione antineoplastic agent. It works by intercalating into DNA, inhibiting topoisomerase II, and producing DNA strand breaks. This action disrupts DNA synthesis and cell replication, leading predominantly to cytotoxicity in rapidly dividing cells.\n\n2. **Indications**:\n   Amsacrine is primarily used in the treatment of acute leukemias. Its usage might be more specific to certain types like acute myeloid leukemia (AML) and some cases of acute lymphoblastic leukemia (ALL). It is often used when other treatments have failed or in relapsed cases.\n\n3. **Administration**:\n   It is typically administered intravenously, often as part of combination chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_c6sfCX0sdGgU0i0O8NQVLrtJ", "custom_id": "15_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dbf853fb03d061079ed20eef55520450", "body": {"id": "chatcmpl-9St7Gls4MYMHLosGCS8nSC3m2H2Pd", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole, sold under the brand name Arimidex among others, is a medication used primarily to treat breast cancer in postmenopausal women. It's particularly effective for hormone receptor-positive types of breast cancer. Here\u2019s a detailed overview of the key aspects you, as a physician, should consider:\n\n### Mechanism of Action\nAnastrozole is a nonsteroidal aromatase inhibitor. It works by blocking aromatase enzyme, which is involved in the synthesis of estrogen in the body. By inhibiting estrogen production, anastrozole helps reduce the growth of estrogen-sensitive breast cancer cells.\n\n### Indications\n- **Primary treatment of hormone receptor-positive early breast cancer** in postmenopausal women.\n- **Adjuvant treatment of early breast cancer** in postmenopausal women following initial therapy (e.g., surgery, chemotherapy, radiation).\n- **Treatment of advanced breast cancer** in postmenopausal women, including those whose disease has progressed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dSPACcjiEQmIOCx69W8OqRCM", "custom_id": "16_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9cfa76ecd962bd2a82c2f90546237e3a", "body": {"id": "chatcmpl-9St7GTejYgTd89iknhz3PO7xksYz6", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apalutamide is a medication used in the treatment of prostate cancer. Here are several key points that are important for a physician to know:\n\n1. **Indications**: Apalutamide is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). This medication acts by helping to delay the spread of prostate cancer that is still growing despite hormone therapy.\n\n2. **Mechanism of Action**: Apalutamide is a nonsteroidal antiandrogen (NSAA); it works by inhibiting the action of androgens (male hormones), such as testosterone, on the androgen receptor (AR). This inhibition interferes with the androgen receptor signaling pathway which is crucial for the growth and survival of prostate cancer cells.\n\n3. **Administration**: It is typically administered orally with a recommended dose of 240 mg daily, taken as four 60 mg tablets once a day"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Vxq64EBWGWmwstCTajNyc1t7", "custom_id": "17_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3935620dd9febb841437cb5433bba305", "body": {"id": "chatcmpl-9St7GjnMv0RHtzv4MIxjjcNix0qzd", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib, also known as Apatinib mesylate, is a small molecule tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2). VEGFR-2 is a key mediator of angiogenesis, which plays a critical role in the growth and metastasis of cancers by enabling the formation of new blood vessels to supply nutrients to tumors.\n\nHere are several key aspects of Apatinib that you, as a physician, should be aware of:\n\n### 1. **Mechanism of Action**\n   Apatinib binds to and inhibits VEGFR-2 tyrosine kinase, which blocks the pathway for angiogenesis in tumors thereby inhibiting tumor growth.\n\n### 2. **Clinical Uses**\n   Apatinib has been primarily used for the treatment of advanced gastric cancer or gastro-esophageal junction cancer in patients who have failed at least two prior lines of chemotherapy."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hNRb9RJlodZjDDwgoTv79ZLJ", "custom_id": "18_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8d205fb6f8b3ba9552a9eb4c7404ac8b", "body": {"id": "chatcmpl-9St7GofrJ0nbAaLec75VR2xp9o7i2", "object": "chat.completion", "created": 1716672078, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenic trioxide is an antineoplastic agent widely used in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by its association with the translocation t(15;17) that involves the retinoic acid receptor alpha (RAR\u03b1) gene. Here\u2019s an overview with important aspects regarding its use, mechanism, and safety profile:\n\n### Indications\n- **Primary:** Used primarily for the treatment of acute promyelocytic leukemia (APL), especially in patients who have relapsed or who are refractory to initial treatment.\n- **Research-Based:** Being investigated in the treatment of other malignancies and medical conditions but is predominantly accepted for APL.\n\n### Mechanisms of Action\nArsenic trioxide works primarily through inducing partial differentiation, apoptosis, and inhibition of angiogenesis in leukemic cells:\n- **Promotion of apoptosis:** Arsenic trioxide causes degradation of the PML-RAR\u03b1 fusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qF2NwK7O1AcIAgdJmR8Ub03l", "custom_id": "19_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c0130f58aab49f6c44ddbc12b7a84107", "body": {"id": "chatcmpl-9St7Hcn6hNqeskGnAMMYOkwNKVNvI", "object": "chat.completion", "created": 1716672079, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are key points that you, as a physician, should know about asparaginase:\n\n### Mechanism of Action:\nAsparaginase works by hydrolyzing asparagine into aspartic acid and ammonia, thereby depleting asparagine. Many leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase and are thus dependent on circulating asparagine. By depleting serum and extracellular asparagine, asparaginase starves the leukemic cells of the nutrients necessary for their survival and proliferation.\n\n### Types of Asparaginase:\n1. **E. coli-derived asparaginase (L-asparaginase)**\n2. **Erwinia chrysanthemi-derived asparaginase**: Used primarily in patients who develop hypers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Hl9H5IJKjWPUtj4tcXTr2u2G", "custom_id": "20_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a311b26e20faf7565df1ad3f2692b6f", "body": {"id": "chatcmpl-9St7HyYR21IcLAYVIkQipk7sPenS6", "object": "chat.completion", "created": 1716672079, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi (Erwinaze) is an important drug used in the treatment of acute lymphoblastic leukemia (ALL), primarily in patients who have developed hypersensitivity to E. coli-derived asparaginase. Here are several key points that you, as a physician, should be aware of regarding this medication:\n\n1. **Mechanism of Action**: Asparaginase Erwinia chrysanthemi works by depleting the amino acid asparagine. Leukemia cells, particularly those in ALL, are unable to synthesize asparagine due to lack of asparagine synthetase and are thus dependent on circulating sources. Depletion of asparagine results in inhibition of protein synthesis and subsequent cell death in these malignant cells.\n\n2. **Indications**: This drug is indicated for patients with ALL who have developed hypersensitivity to E. coli-derived asparaginase products (such as pegaspargase"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7cgkZY8ICCkP5CbjtklrRVGR", "custom_id": "21_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8bc5e702c3ddbf4c3e35a5efbbb3dd04", "body": {"id": "chatcmpl-9St7InYMq98qRkSC0L1cfyKGKXrEz", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab (marketed under the name Tecentriq) is an immune checkpoint inhibitor specifically targeting the PD-L1 protein. It falls into the category of cancer immunotherapy. Here are some key points that physicians should be aware of regarding the use of atezolizumab:\n\n1. **Mechanism of Action**: Atezolizumab works by inhibiting the interaction between PD-L1 and its receptors, PD-1 and B7.1. This blockade enhances the ability of the immune system to detect and destroy cancer cells. Atezolizumab is unique in targeting PD-L1 instead of PD-1, potentially allowing normal immune-regulatory processes in other parts of the immune system that rely on PD-1 signaling independent of PD-L1.\n\n2. **Indications**:\n   - **Non-Small Cell Lung Cancer (NSCLC)**: Atezolizumab is approved for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gXbah1Jn1AaWFLKBFZdJzjV8", "custom_id": "22_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e293e07f7a584377cb3f8f6ac9771a94", "body": {"id": "chatcmpl-9St7IrWtKdhXDYnlFbSDOFrScqSBt", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab is an immunotherapy drug used primarily in the treatment of certain types of cancer. Here are several key points you should know about avelumab:\n\n1. **Mechanism of Action**: Avelumab is a monoclonal antibody that targets the PD-L1 (programmed death-ligand 1) protein found on the surface of many cancer cells. By blocking PD-L1, avelumab helps to remove the 'invisibility cloak' that cancer cells use to avoid being attacked by the immune system. Essentially, it helps reactivate the patient's immune response against cancer cells.\n\n2. **Indications**:\n   - **Metastatic Merkel cell carcinoma (MCC)**: Avelumab is approved for the treatment of adults and pediatric patients 12 years and older with metastatic MCC, a rare and aggressive skin cancer.\n   - **Urothelial Carcinoma**: It is indicated for patients with locally advanced or metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wiQRVC50csj7PwDCi04LdmM2", "custom_id": "23_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "efa6153d7cefd4c8337f97f1e4b9ef7b", "body": {"id": "chatcmpl-9St7ImyW3UFlhfQlMopPaFEye82Us", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel, also known by its brand name Yescarta, is a form of chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for specific types of non-Hodgkin lymphoma (NHL). This therapy is used primarily for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\nHere are some key aspects of axicabtagene ciloleucel that physicians should be aware of:\n\n### Mechanism of Action\nAxicabtagene ciloleucel is a genetically modified autologous T-cell immunotherapy. T-cells are extracted from the patient, genetically engineered to express a CAR that targets CD19, a protein"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_xGppCKks0XNr5C8x49dVjTZ8", "custom_id": "24_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1cf6f6d6c01d58aac3329c1a25e612b7", "body": {"id": "chatcmpl-9St7IUtRNUs8EcEtc9XuvfaXkRcgO", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axitinib is a small molecule tyrosine kinase inhibitor used primarily in the treatment of advanced renal cell carcinoma (RCC), particularly after failure of one prior systemic therapy. Here are some key points about axitinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Axitinib works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). These receptors play a crucial role in the angiogenesis process, which is essential for tumor growth and metastasis. By inhibiting these receptors, axitinib helps to reduce angiogenesis and thus tumor growth.\n\n2. **Indications**:\n   - **Renal Cell Carcinoma (RCC)**: Axitinib is primarily used for the treatment of advanced RCC after the failure of the first-line treatment. It may also be used in cases where no suitable first-line treatment options"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2ZqpiLPvok3QKT4xsUeuyqQw", "custom_id": "25_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5129636ea27b4eb7f954a96e2ca2e803", "body": {"id": "chatcmpl-9St7IwfzamHwO0OzyJTQjlSQna5n6", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, also known by the brand name Vidaza, is a chemotherapy drug used primarily in the treatment of myelodysplastic syndromes (MDS), which are a group of hematologic conditions characterized by ineffective production of blood cells. It has also shown efficacy in treating acute myeloid leukemia (AML) under certain conditions. Here are the key aspects you should know:\n\n### Mechanism of Action\nAzacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA. It works primarily through its incorporation into RNA, disrupting ribosomal function, and to a lesser extent by being incorporated into DNA. As a DNA methyltransferase inhibitor, it reduces DNA methylation, which can reactivate silenced genes that suppress tumor growth or control cell proliferation.\n\n### Indications\nAzacitidine is FDA approved for:\n- Treatment of patients with the following subtypes of Myelodysplastic Syndromes (MDS):\n  - Refr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VMWcZo4UotzeNs5aPlTKPVj7", "custom_id": "26_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "87b78810d16b9eb3bee7c821cf6203cd", "body": {"id": "chatcmpl-9St7IkE5xzpbVY4eoCNn1Lf2xNupY", "object": "chat.completion", "created": 1716672080, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is primarily known for its use in preventing tuberculosis (TB). Here are key aspects regarding BCG that you, as a physician, should be aware of:\n\n1. **Development and Composition**:\n   - BCG is a vaccine made from a strain of Mycobacterium bovis that is attenuated, meaning it has reduced virulence. It was first developed by Albert Calmette and Camille Gu\u00e9rin in the early 20th century.\n\n2. **Efficacy and Use**:\n   - The vaccine is most effective in preventing severe forms of TB in children, such as TB meningitis and miliary disease.\n   - Its effectiveness in adults, particularly against pulmonary TB, is more variable, ranging from 0% to 80%.\n   - BCG is administered as a single intradermal injection, usually shortly after birth in countries with a high prevalence of TB.\n\n3. **Indic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_17S8ryydHnShRSRwRc9HhFAF", "custom_id": "27_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f243fc5e8d93a37da9f4e575bf89ba99", "body": {"id": "chatcmpl-9St7JjAVQhpT7I9IW6pPeC16K2W2t", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is an investigational monoclonal antibody that has been studied for its potential use in treating various diseases, including cancer and viral infections. It has a unique mechanism of targeting phosphatidylserine (PS), a lipid that is normally located on the inner leaflet of the plasma membrane but becomes exposed on the outer leaflet in certain pathologic cells, including tumor cells and cells infected with viruses.\n\n### Key Points about Bavituximab:\n\n1. **Mechanism of Action**:\n   - Bavituximab binds to phosphatidylserine (PS) on the cells that have externalized this molecule. PS exposure on the cell surface typically signals immune cells to avoid attacking the cell, as PS presentation is often a marker of cell apoptosis and part of natural tissue turnover. By binding to PS, bavituximab may help mark these cells for destruction by the immune system.\n\n2. **Clinical Applications**:\n   - **Cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_FmM7yf3rgXizhFoPdpqWsvC8", "custom_id": "28_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd6e30557504afc88bdb66017ab5b676", "body": {"id": "chatcmpl-9St7Jv8FYZTKtI3Zlm3DehxH0vhxP", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat is a chemotherapy medication used primarily in the treatment of various cancers, particularly peripheral T-cell lymphoma (PTCL). It is classified as a histone deacetylase (HDAC) inhibitor. Here are some essential aspects of belinostat that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Belinostat works by inhibiting the activity of histone deacetylase enzymes. This inhibition leads to an increase in the acetylation of histone proteins, resulting in altered gene expression. The effect of increased acetylation can include the activation of pathways that lead to cell cycle arrest, apoptosis, and inhibition of angiogenesis in cancer cells.\n\n2. **Indications**: Belinostat is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Research is ongoing to explore its efficacy and safety"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8eaeo6qIMHxIxoq3diSZLeyj", "custom_id": "29_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e80f1af8973199568c3968a18accaab4", "body": {"id": "chatcmpl-9St7J93omOgXToMz1KfK8qxLtZMV7", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan (CKD-602) is a camptothecin derivative and a topoisomerase I inhibitor used primarily in chemotherapy. It functions by interfering with the ability of topoisomerase I to ligate DNA strands, leading to DNA damage and the inhibition of replication and transcription. This induces cell death, particularly in rapidly dividing cancer cells.\n\nBelotecan has shown effectiveness in treating various types of cancers, including ovarian cancer, small cell lung cancer, and other solid tumors. Its mechanism and efficacy are similar to other topoisomerase inhibitors like topotecan and irinotecan, but it may differ in its specificity, pharmacokinetics, and side effect profile.\n\n**Key Points for Physicians:**\n1. **Indications:** Understand the specific indications for Belotecan in your country, as these can vary. It has been primarily studied in cancers like small cell lung cancer and ovarian cancer.\n\n2. **Dosage and Administration:** Dosage may depend on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_fqiZxYk8gK9CYKajZLxBfqqb", "custom_id": "30_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7865fee3faace7830cc87ed0ccc6469", "body": {"id": "chatcmpl-9St7J3qOL33LFVjORjD8IZJ3o2OW0", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy medication used predominantly in the treatment of certain types of hematologic cancers, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It has also shown efficacy against multiple myeloma in some instances. Here are several key aspects of Bendamustine that you, as a physician, might need to be aware of:\n\n### Mechanism of Action\nBendamustine is a bifunctional mechlorethamine derivative, which means it carries both alkylating and antimetabolite properties. The alkylating action causes cross-linking of DNA strands and induces breaks in single strands, thereby inhibiting DNA replication and transcription. Its antimetabolite action interferes with the synthesis of purine nucleotides, which are necessary for DNA replication.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: It's approved for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yHYkPy1IuqTzq0ADFkyUxGiz", "custom_id": "31_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "263cffa44f779a904dfce81944280b2d", "body": {"id": "chatcmpl-9St7Jnof0wWALmKbRoVNjjxHagoTm", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizinumab is a type of medication known as a monoclonal antibody, and it functions by targeting and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. Here are some important aspects to consider when dealing with Bevacizumab in a clinical setting:\n\n1. **Indications**: Bevacizumab is primarily used in the treatment of various types of cancers, including colorectal cancer, non-small cell lung cancer, glioblastoma, and renal cell carcinoma. It is also used in the treatment of age-related macular degeneration under the brand name Avastin, although this is an off-label use.\n\n2. **Mechanism of Action**: Bevacizumab inhibits the angiogenesis process, which is critical for tumor growth and metastasis. By blocking VEGF, bevacizumab deprives tumors of the necessary blood supply needed for growth.\n\n3. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Aybfa0VGQuVNi45sa9Egceei", "custom_id": "32_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5bd2c08267c4a4c00f7e7e12f0db4b81", "body": {"id": "chatcmpl-9St7JmF9ca9fkFnGqhIepQL8PywVz", "object": "chat.completion", "created": 1716672081, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is a medication primarily used for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Here are several key points about bexarotene that are essential for a physician to know:\n\n1. **Mechanism of Action:**\n   Bexarotene is a synthetic retinoid that selectively activates retinoid X receptors (RXRs). It modulates the expression of genes involved in cell proliferation, differentiation, and apoptosis. This mechanism plays a key role in its therapeutic effects in cutaneous T-cell lymphomas.\n\n2. **Indications:**\n   - The primary indication is the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who have not responded adequately to other therapies.\n   - Bexarotene has also been studied for potential use in other conditions, but its use in these areas should be based on clinical trials and approved indications.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7AL7Wa4nEuCeZExkElfd6yPU", "custom_id": "33_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "14559e98f05934a5fa89ecd49c6c14ba", "body": {"id": "chatcmpl-9St7KxEWuIhO5Cx4GZ3i0uDrg15Wa", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a medication used primarily in the treatment of prostate cancer. It belongs to a class of drugs known as nonsteroidal antiandrogens. Here are some important aspects about bicalutamide that you may find useful as a physician:\n\n### Mechanism of Action\nBicalutamide works by blocking the action of androgens (male hormones), such as testosterone, by binding to androgen receptors in prostate cancer cells. This prevents the stimulation of cancer cell growth by androgens, thereby slowing down the progression of the disease.\n\n### Indications\nBicalutamide is primarily used for the treatment of prostate cancer. It is often given in combination with a luteinizing hormone-releasing hormone (LHRH) analog or surgical castration to treat advanced prostate cancer. It may also be used in the management of locally advanced non-metastatic prostate cancer where there is a significant risk of disease progression.\n\n### Dosage and Administration\nBicalut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iP0inPghN5Rs7r8cSkmLBdra", "custom_id": "34_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d4474cfc996c874d907de5013368d859", "body": {"id": "chatcmpl-9St7KPDVEUthLcugdJEIuAsjRomD3", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Binimetinib is a medication used in the treatment of cancer, specifically indicated for the treatment of certain types of melanoma. Here are some essential points about Binimetinib that you, as a physician, might find useful:\n\n### Mechanism of Action\nBinimetinib is classified as a MEK inhibitor. It specifically inhibits MEK1 and MEK2, which are part of the MAPK (mitogen-activated protein kinase) pathway. This pathway is often upregulated in various cancers, including melanoma with BRAF mutations. By inhibiting MEK, binimetinib disrupts the signaling pathway that promotes cell growth and division, thereby exerting its anti-tumor effects.\n\n### Indications\n- **Melanoma**: Binimetinib is approved for treating unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with another medication named encorafenib (a BRAF inhibitor).\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_YkidPE1un9OyLbesCVwWXoSO", "custom_id": "35_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a490350c1e401dd002f6d4eafcddd2a", "body": {"id": "chatcmpl-9St7KHnuJMuWwgtRwMkUzX4Hl01ZX", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antibiotic that possesses antineoplastic (anticancer) properties, and it is commonly used in the treatment of various types of cancer. Here are some of the key aspects you should know about Bleomycin as a physician:\n\n1. **Mechanism of Action**:\n   Bleomycin works primarily by binding to DNA, leading to strand breakage and inhibition of DNA synthesis, which induces cell death in replicating cells. It is cell-cycle phase-specific, primarily affecting cells in the G2 and M phases.\n\n2. **Indications**:\n   It is used in the treatment of several malignancies, including Hodgkin\u2019s lymphoma, non-Hodgkin's lymphoma, testicular cancer, and some types of ovarian and cervical cancer. Bleomycin is also used for the treatment of malignant pleural effusions and in the management of several non-malignant conditions, such as verrucae, and plantar warts.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iM9aK9lmKUAB6HVCwEKDF1Kq", "custom_id": "36_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ea50ccfe14eade62afb5e2029e11b2c", "body": {"id": "chatcmpl-9St7KwaTjzHorxL1imy20i8h1kDTI", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab, marketed under the brand name Blincyto, is a bispecific CD3 x CD19 monoclonal antibody used for the treatment of certain types of cancer, specifically acute lymphoblastic leukemia (ALL). Here are some key points you should know about Blinatumomab:\n\n1. **Mechanism of Action**:\n   Blinatumomab operates by connecting CD3-positive T-cells to CD19-positive B-cells, leading to the activation and proliferation of endogenous T-cells and subsequent lysis of the B-cells. This T-cell engagement is crucial for its anti-leukemic activity.\n\n2. **Indications**:\n   It is approved for the treatment of Philadelphia chromosome-negative relapsed or refractorily B-cell precursor acute lymphoblastic leukemia (ALL). Additionally, it is indicated for B-cell precursor ALL that is Philadelphia chromosome-positive and refractory or in remission with minimal residual disease (MRD) of at least "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ccKBx8gwOrb6gAwZ8H2nksfA", "custom_id": "37_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fba15659bff0b8a58786613f6207ae35", "body": {"id": "chatcmpl-9St7KABiAlc2fVYXca2eLzoraHx3K", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib (brand name Velcade) is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Here are some key aspects of bortezomib that you, as a physician, should know:\n\n1. **Mechanism of Action:** Bortezomib works by reversibly inhibiting the 26S proteasome, a complex that degrades ubiquitinated proteins. The inhibition of proteasomal activity disrupts various cellular processes, including the regulation of cell cycle, apoptosis, and gene expression, which can lead to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications:**\n   - **Multiple Myeloma:** Bortezomib is used for the treatment of multiple myeloma patients. It is used for newly diagnosed patients as well as for those who have relapsed or refractory multiple myeloma.\n   - **Mantle Cell Lymphoma:** It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_67JOiznsJjIsM2Qna707QUtq", "custom_id": "38_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99d269c239ce3174ca666ddd90ed4770", "body": {"id": "chatcmpl-9St7KFPEE1bdmNzubIXybz3W98CYE", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib is a tyrosine kinase inhibitor (TKI) primarily used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know as a physician:\n\n1. **Indications and Usage:**\n   - Bosutinib is approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive CML with resistance or intolerance to prior therapy.\n   - It is often used when patients cannot tolerate other TKIs such as imatinib, dasatinib, or nilotinib, or when these drugs are ineffective.\n\n2. **Mechanism of Action:**\n   - Bosutinib specifically inhibits the Bcr-Abl tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome that is present in CML. Inhibition of Bcr-Abl kinase leads to a decrease in proliferation and an increase in apoptosis (cell death) of leukemic cells.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dAKunvB2kiYUZsRiOVFH383D", "custom_id": "39_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89f5c18344476e72e8c7649bb90772fe", "body": {"id": "chatcmpl-9St7KJ2GAtlmkppmakAo526Mqvfc9", "object": "chat.completion", "created": 1716672082, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brentuximab vedotin, sold under the brand name Adcetris, is a targeted anticancer therapy used primarily to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). It's part of a class of drugs known as antibody-drug conjugates (ADCs), which combine an antibody that targets cancer cells with a cytotoxic drug intended to kill those cells. Here are some important aspects you might need to consider while using Brentuximab vedotin in clinical practice:\n\n### Mechanism of Action\nBrentuximab vedotin consists of an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent, monomethyl auristatin E (MMAE). The drug binds to CD30, a cell surface antigen expressed on Reed-Sternberg cells (typical in Hodgkin lymphoma) and other lymphoma cells, then gets internalized. The linker"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tl0FZ75VMKijbx0jZhjF32Nu", "custom_id": "40_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e94117a52251bbb0ad0c15958a8e5865", "body": {"id": "chatcmpl-9St7LlUS6BmDEbJm5H6hG058ETyVY", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is an important medication in the treatment of certain types of cancer. Here are the main points you should know about this drug:\n\n1. **Indications**: Brigatinib is primarily used to treat non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive (ALK+). It is often prescribed for patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor.\n\n2. **Mechanism of Action**: Brigatinib is a tyrosine kinase inhibitor that targets the ALK fusion gene seen in some cases of non-small cell lung cancer. By inhibiting ALK, brigatinib can help to block the growth and spread of cancer cells.\n\n3. **Administration**: Brigatinib is administered orally, typically once per day.\n\n4. **Dosage**: Treatment generally starts with a dosage of 90 mg once daily for the first week, which may be increased to 180 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ABYOFeUElILQOZfjaoAmSOJR", "custom_id": "41_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9faf7acc01b2e2cc23141f72a2aa2a75", "body": {"id": "chatcmpl-9St7LnScGMsfeK4uUmfMiRsr8seYf", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is a chemotherapy medication used primarily to treat certain types of cancers, including chronic myelogenous leukemia (CML). Here are some important points that you, as a physician, should know about busulfan:\n\n1. **Mechanism of Action**:\n   Busulfan works by cross-linking DNA, which ultimately leads to inhibition of DNA replication and RNA transcription. This action causes cell cycle arrest and apoptosis, particularly targeting rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Primarily used for treating chronic myelogenous leukemia (CML).\n   - Also used as part of the conditioning regimen before bone marrow transplantation or hematopoietic stem cell transplantation, effectively helping to wipe out the existing bone marrow cells to prepare for new marrow or stem cells.\n\n3. **Administration**:\n   Busulfan can be administered orally or intravenously. The route of administration depends on the specific treatment protocol and patient needs.\n\n4. **Dosage**:\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yVdUFT6xJ885MzMvS8JCqfJp", "custom_id": "42_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ff5c68026adc1443907c2160f637644", "body": {"id": "chatcmpl-9St7LJ4OknhSGSGQsecsU3SriKKgL", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapy drug used primarily in the treatment of prostate cancer. Here are some key aspects you should be aware of as a physician:\n\n1. **Indications**: Cabazitaxel is approved for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. It is typically reserved for patients who have progressed despite other therapies.\n\n2. **Mechanism of Action**: Cabazitaxel is a taxane drug; it works by inhibiting cell division by binding to tubulin, which in turn inhibits the disassembly of microtubules, thus disrupting the mitotic and interphase cellular functions.\n\n3. **Administration**: Cabazitaxel is administered intravenously. It is usually given every 3 weeks, and the dosage may depend on the patient's body surface area, overall health, blood counts, and response to treatment.\n\n4. **Side Effects**: Common side effects include neut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_77L6XygwqztTfuJhMH8qq5vE", "custom_id": "43_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73be38f51701c75bd57f04af8f966c97", "body": {"id": "chatcmpl-9St7Lb9LrLWkEUNmm0dnl2QIpg5EZ", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is a tyrosine kinase inhibitor (TKI) with anti-neoplastic activity. It is used to treat various types of cancer, including medullary thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). Here are key points that you, as a physician, might need to know about Cabozantinib:\n\n1. **Mechanism of Action**: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, angiogenesis, and metastatic progression of cancer. Notably, it targets MET, VEGFR1, VEGFR2, VEGFR3, RET, ROS1, TYRO3, AXL, KIT, FLT3, and TIE-2.\n\n2. **Indications**:\n   - **Medullary Thyroid Cancer (MTC)**: It's approved for the treatment of progressive, metastatic M"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XFBJFOcg50uC1mMdtdZP9Low", "custom_id": "44_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8541f75086b1d9103952e8e6c5c3d50c", "body": {"id": "chatcmpl-9St7L4Pyg044vsWdgfpjMMcn66ywC", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol, also known as calaspargase pegol-mknl, is a modified form of the enzyme L-asparaginase. It is utilized in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that affects the blood and bone marrow. This medication plays a role in chemotherapy by hydrolyzing the amino acid L-asparagine, which is essential for the proliferation of leukemic cells. By depleting L-asparagine, calaspargase pegol disrupts the growth and survival of these malignant cells.\n\n**Key Points for Physicians:**\n\n1. **Indications**: Calaspargase pegol is approved for use in pediatric and young adult patients aged up to 21 years with newly diagnosed ALL or lymphoblastic lymphoma. \n\n2. **Dosing and Administration**: It is typically given intravenously and the dosing is usually based on the patient\u2019s body surface area. The dosing schedule may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vecxAP204h5jW61ySJcLHznY", "custom_id": "45_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1106df1b6270e3b602f6257bc13fe32b", "body": {"id": "chatcmpl-9St7L7hRolny5ziFI7xCPantSHV2B", "object": "chat.completion", "created": 1716672083, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapeutic agent that is commonly used to treat several types of cancers, including breast, colorectal, and gastric cancers. It is a prodrug of 5-fluorouracil (5-FU), which means that it is converted into its active form in the body, allowing for easier administration and potentially better patient compliance compared to intravenous chemotherapy.\n\n### Pharmacology and Mechanism of Action\nCapecitabine is converted enzymatically in the liver to 5'-deoxy-5-fluorocytidine (5'-DFCR) and then to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase. The active drug, 5-fluorouracil, is then produced by thymidine phosphorylase in the tumor tissue, ensuring that higher concentrations of the active drug are delivered directly to the tumor site. 5-FU itself"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IDsY0ATeiu7fp1hEbSGkem7N", "custom_id": "46_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb70fba22950d8cfdb3f40269e833637", "body": {"id": "chatcmpl-9St7M2zLi1soTb6f9ezDnvInPjqQI", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used primarily to treat various forms of cancer, including ovarian, lung, head and neck, endometrial, esophageal, bladder, breast, and cervical cancers, among others. It is a platinum-based drug and functions as an alkylating agent. Here\u2019s a brief overview of what you should know about carboplatin:\n\n### Mechanism of Action\nCarboplatin works by interfering with the DNA replication process in cancer cells. It forms cross-links within and between DNA strands, which prevents the cancer cells from dividing and leads to cell death.\n\n### Administration\nCarboplatin is typically administered intravenously. The dosage and schedule depend on various factors, including the type of cancer, the patient's size, overall health, kidney function, and whether carboplatin is being given in combination with other chemotherapy agents.\n\n### Dosage Calculation\nCarboplatin dosing can be calculated based on the area under the curve (AUC)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qe3r1ikWErhlTZw4c8XCjZPE", "custom_id": "47_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5bcf4cf5f7f35f961e908fe621a719f1", "body": {"id": "chatcmpl-9St7MZlyGsjLD3w3VsbUP2YSsdjjo", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is an antineoplastic agent primarily used in the treatment of multiple myeloma. As a physician, here are some important aspects you should know about Carfilzomib:\n\n1. **Mechanism of Action**: Carfilzomib is a proteasome inhibitor. It works by selectively and irreversibly inhibiting the chymotrypsin-like activity of the 20S proteasome, an enzyme complex involved in the degradation of ubiquitinated proteins. By inhibiting proteasomal activity, carfilzomib disrupts various cellular processes, including the regulation of cell cycle, cell growth and survival, leading to apoptosis (cell death) in cancer cells.\n\n2. **Indications**: Carfilzomib is approved for the treatment of multiple myeloma. It is used in patients who have received at least one prior therapy. It can be administered as a monotherapy or in combination with other drugs like dexameth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HuWhMPLB32yyHbdHTrK2SDUa", "custom_id": "48_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "731e60e0fa9a809ed5debd4e7f7b93ee", "body": {"id": "chatcmpl-9St7MA2YzfF8n2nLoEUOgeoGXUiPe", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine is a chemotherapy medication used primarily to treat various types of brain tumors, including gliomas, glioblastoma multiforme, medulloblastoma, astrocytoma, and ependymoma. It is also used to treat multiple myeloma and lymphomas. Here are key points that a physician should know about Carmustine:\n\n1. **Mechanism of Action**: Carmustine is a nitrosourea compound. It acts as an alkylating agent, cross-linking DNA and RNA, which inhibits DNA synthesis and RNA transcription. Due to its lipophilic nature, it can cross the blood-brain barrier, making it particularly effective in treating brain tumors.\n\n2. **Administration**: Carmustine can be administered intravenously or implanted intracranially as a wafer (Gliadel wafer). The intracranial route is used for localized therapy in patients with brain tumors.\n\n3. **Dosage**: Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TuZgdNxcXLuing3wkMe9dh0i", "custom_id": "49_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "69fed1e6b25d9db9818498c85888919f", "body": {"id": "chatcmpl-9St7MeYgVyKeTqCrLoF5Qg8tPhlWW", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafers, with the trade name Gliadel\u00ae, are an implantable treatment option for certain types of brain tumors. These wafers are impregnated with the chemotherapy agent carmustine (BCNU) and are placed in the surgical cavity after tumor removal. Here are key points that physicians, particularly neurosurgentists and oncologists, should know about Carmustine wafers (polifeprosan 20):\n\n1. **Indications**:\n   - Newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation.\n   - Recurrent glioblastoma multiforme as an adjunct to surgery.\n\n2. **Mechanism of Action**:\n   - Carmustine wafers are biodegradable and release the alkylating agent carmustine directly into the brain tissue, targeting residual tumor cells at the surgical margin. This local delivery allows for high local concentrations of the drug while minimizing systemic exposure and associated toxicities"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9Jw2yp3C97v50Whp0QgXchzL", "custom_id": "50_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a755f614162dc544b543c04954a0f5c8", "body": {"id": "chatcmpl-9St7ME582XsqnBiWYCeTdzpOVo3Fl", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), which are key regulators of angiogenesis (blood vessel growth). This antiangiogenic effect can inhibit tumor growth, which primarily relies on the development of new blood vessels for nutrient and oxygen delivery. Cediranib has been studied for use in various types of cancers including ovarian, kidney, and certain types of lung cancers. Here are the important points physicians should be aware of when considering or using cediranib in treatment:\n\n### Mechanism of Action\nCediranib inhibits the tyrosine kinase activity associated with VEGFR-1, VEGFR-2, and VEGFR-3. By inhibiting these receptors, cediranib reduces angiogenesis, thereby potentially reducing tumor growth and spread.\n\n### Indications\n- **Ovarian Cancer**: Cediranib has shown promise in the treatment of recurrent or metastatic ovarian cancer,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XDE5JsJ70TbW1NTj18KcIw3T", "custom_id": "51_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b47dd7df121af7cdc3ee30cba23cc08c", "body": {"id": "chatcmpl-9St7MabBrx6JZnMALIkwHV1H5dSUP", "object": "chat.completion", "created": 1716672084, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab, also known by the brand name Libtayo, is a monoclonal antibody that has been approved for the treatment of various types of cancer, including metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) that has progressed following prior therapy and is not suitable for curative surgery or radiation. Recently, it has also been approved for the treatment of advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression and no EGFR, ALK, or ROS1 aberrations.\n\nHere are some essential aspects of cemiplimab you should be aware of:\n\n1. **Mechanism of Action**: Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody. By inhibiting PD-1, cemiplimab enhances the body's immune response against cancer cells. PD-1 is a protein that inhibits T-cell activation, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7AyLRZ0EPGuqFgljLVoXHMmq", "custom_id": "52_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "107e050b2d575d6887794a4e107aade2", "body": {"id": "chatcmpl-9St7NMJ9Cn3S9hF18JBD9czYC1xt3", "object": "chat.completion", "created": 1716672085, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib, also known by its brand name Zykadia, is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC). It is specifically indicated for patients whose tumors are anaplastic lymphoma kinase (ALK)-positive. Here are several key points about ceritinib that might be of interest to you as a physician:\n\n1. **Mechanism of Action**: Ceritinib is an ALK inhibitor. ALK is a gene that can mutate and fuse with other genes, leading to malignant transformations. Ceritinib works by targeting and inhibiting the activity of the ALK protein, which can help in slowing down or stopping the growth of cancer cells.\n\n2. **Indications**:\n   - Ceritinib is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive.\n   - It is often used in patients who have developed resistance to or are intolerant of cr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tEWj6nF3ljNVndbgsuN8Xzfz", "custom_id": "53_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4487df624bff3f38bcd69f742a1e1125", "body": {"id": "chatcmpl-9St7NMCvta20FbXcOJfFUQpPe6Ode", "object": "chat.completion", "created": 1716672085, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab (Erbitux) is a widely used monoclonal antibody in cancer treatment, particularly for head and neck cancers as well as colorectal cancer. Here are several important aspects of cetuximab that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor. It binds to the extracellular domain of the EGFR, preventing the binding of its natural ligands. This inhibition blocks the phosphorylation and activation of receptor-associated kinases, resulting in the inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production.\n\n2. **Indications**:\n   - **Colorectal Cancer**: Cetuximab is approved for use in patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer as determined by FDA-approved tests. It is used as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eUA8onYlenzOCXeLpp4hfwQj", "custom_id": "54_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cfd0b57dc4cab01fb9852fc8d22979f7", "body": {"id": "chatcmpl-9St7OuF3ymnlR81rTxzvdoewHf4FG", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide, also known as CS055 or HBI-8000, is a selective histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancers. It has shown efficacy particularly in lymphoma. Here are the key points you should be aware of:\n\n1. **Mechanism of Action**: Chidamide selectively inhibits HDACs, including HDAC1, 2, 3, and 10. Inhibition of HDAC leads to an increase in acetylation levels of histone proteins, thereby affecting gene expression. This alteration can induce cell cycle arrest, differentiation, and apoptosis in cancer cells, and modulation of the immune response.\n\n2. **Indications**: It is primarily approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research is ongoing for its efficacy and safety in other malignancies, like breast cancer and other hematological malignancies.\n\n3. **Administration**: Ch"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PUikRLQcCgv8UIa5isSuOyZS", "custom_id": "55_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d2e6663fde9e9b717b6fe466022ab92f", "body": {"id": "chatcmpl-9St7O3SFWcHamJLcWlKXvSNNxathr", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambuco is primarily used as an antineoplastic (anticancer) agent, particularly effective against chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It belongs to the class of alkylating agents, which act by binding to DNA and preventing the cancer cells from multiplying effectively. Here are several key aspects you should consider when using or prescribing Chlorambucil:\n\n1. **Indications**: \n   - Primary treatment for chronic lymphocytic leukemia (CLL).\n   - Used in some cases of non-Hodgkin's lymphoma and Hodgkin's lymphoma, and other cancers like Waldenstrom's macroglobulinemia.\n\n2. **Mechanism of Action**: \n   - Chlorambucil is an alkylating agent that interferes with DNA replication and RNA transcription, ultimately leading to cell death. It forms covalent bonds with DNA, causing cross-links and mispair"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AGF8ohVNCVBLtIZaKUx0BY2x", "custom_id": "56_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9c4c505dd8b247f4e6d6aad763ad467", "body": {"id": "chatcmpl-9St7OjpevGBDeEO76kDAwVSfIM9ux", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including testicular, ovarian, cervical, bladder, lung, and stomach cancers among others. It is often used in combination with other medications to enhance treatment efficacy. Here\u2019s what you should know about Cisplatin:\n\n**Mechanism of Action:**\nCisplatin works primarily by cross-linking with the purine bases on the DNA, interfering with DNA repair mechanisms, causing DNA damage, and triggering apoptosis in cancer cells.\n\n**Administration:**\nCisplatin is administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient\u2019s size, and their overall health, among other factors. It\u2019s often given in cycles, with rest periods in between to allow the body to recover.\n\n**Side Effects:**\nCisplatin has a notable profile of side effects, some of which can be severe:\n- **Nephrotoxicity:** Kidney"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ed57vDtmCUzTUW1dqvjcWMe2", "custom_id": "57_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a8c0791f9fe280fa134781b46ae1cf75", "body": {"id": "chatcmpl-9St7OlwrUVwqhjVVkyC8krbzotrTA", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine is a medication primarily used in the treatment of hairy cell leukemia and other hematological disorders. Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   - Cladribine is a purine nucleoside analog that interferes with DNA synthesis and repair, leading to cell death. It is selectively toxic to lymphocytes and monocytes which are particularly sensitive to its effects.\n\n2. **Indications**:\n   - It is primarily used for treating hairy cell leukemia. It may also be used in other conditions such as multiple sclerosis (as the formulation Mavenclad) to reduce relapses.\n   - Other less common indications might include certain lymphomas and leukemias where standard treatments have not been effective.\n\n3. **Administration**:\n   - Cladribine can be administered either intravenously or subcutaneously depending on the condition being treated. For multiple sclerosis, it is administered orally.\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WvrjqmyVW0yxk28PWpJXtjUd", "custom_id": "58_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b19cbe8e0b2e68b9b4bbc20d4535ed2", "body": {"id": "chatcmpl-9St7O9EV3Sfg7l0X87YgZpoZdMkCZ", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clarithromycin is a macrolide antibiotic used to treat various bacterial infections including pneumonia, bronchitis, and infections of the ears, skin, and throat. It is also used in combination with other medications to eliminate H. pylori, a bacterium that causes ulcers. Here are key points you should know about clarithromycin:\n\n### Mechanism of Action:\nClarithromycin works by stopping the growth of bacteria. It does this by interfering with the protein synthesis in bacteria, specifically by binding to the 50S subunit of the bacterial ribosome.\n\n### Indications:\n- Respiratory tract infections (e.g., pneumonia, bronchitis)\n- Skin and soft tissue infections\n- Otitis media\n- Helicobacter pylori eradication (in combination with other drugs)\n- Pharyngitis/tonsillitis\n\n### Pharmacokinetics:\n- Clarithromycin is well absorbed from the gastrointestinal tract.\n- It has a relatively long"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_GgqdpqQi04mMMWvWmBkO2vkq", "custom_id": "59_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "14c0eb237d18dd612287df23dd26386f", "body": {"id": "chatcmpl-9St7O76NOiEhbIS7TB1cDDjFC4IEI", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). It's a purine nucleoside analog that interferes with DNA replication and repair, leading to cell death. Here are some key points to know about clofarabine:\n\n### Indications\n- **Primary:** It's approved by the FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who have not responded to at least two prior regimens.\n- **Secondary Uses:** It is also investigated for use in other hematologic cancers such as acute myeloid leukemia (AML), and in various combination therapies.\n\n### Mechanism of Action\nClofarabine incorporates into DNA and RNA, leading to an inhibition of both DNA replication and RNA transcription. This occurs because clofarabine inhibits ribonucleotide reductase and DNA polymerase, essential enzymes for DNA synthesis.\n\n### Administration\n- **Route"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FgUxpd8vPBex2UvsNXGlwkt3", "custom_id": "60_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0c58e478cc8546d66c159654b9e97cbb", "body": {"id": "chatcmpl-9St7OkzpIKWxF5uHvyrABBwUt9WLn", "object": "chat.completion", "created": 1716672086, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib, marketed under the brand name Cotellic, is a medication used in oncology primarily for its role in treating certain types of melanoma. Here are key aspects you should know about cobimetinib as a physician:\n\n1. **Mechanism of Action**:\n   Cobimetinib is a small molecule inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK) 1 and MEK 2. MEK proteins are part of the RAS/RAF/MEK/ERK pathway, which regulates cell division and survival. By inhibiting MEK, cobimetinib helps to stop or slow the growth of cancer cells.\n\n2. **Indications**:\n   It is most commonly indicated for the treatment of metastatic melanoma with a BRAF V600 mutation, specifically in combination with vemurafenib (a BRAF inhibitor). This combination has been shown to improve survival rates compared"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fZDWn2LaIAEWid9jdFpiZujh", "custom_id": "61_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d01439ee248b3dd945c3c109e0e33c63", "body": {"id": "chatcmpl-9St7PsOPdoJlgS3FTJeKlofHZVVd8", "object": "chat.completion", "created": 1716672087, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib is a kinase inhibitor used primarily in the treatment of certain types of cancers. Here are key aspects to consider when administering or recommending Copanlisib to patients:\n\n1. **Indication and Usage**: Copanlisib is approved for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. As of the last update, this is its main approved use, but ongoing trials may expand its indications.\n\n2. **Mechanism of Action**: Copanlisib inhibits several isoforms of phosphoinositide 3-kinase (PI3K), particularly PI3K-\u03b1 and PI3K-\u03b4, which are often involved in the signaling pathways that promote cell growth, proliferation and survival in cancer cells. By inhibiting these pathways, Copanlisib can induce apoptosis and reduce proliferation of malignant cells.\n\n3. **Administration**: Copanlisib is administered intravenously. It is typically given on a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NYLASNLhFsFvef0A6iSaes8L", "custom_id": "62_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2573f7d06215f7be72760c9e8b65a97f", "body": {"id": "chatcmpl-9St7PvPThO2MALOTqOPOHTXzNjacs", "object": "chat.completion", "created": 1716672087, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib is a targeted anticancer medication commonly used to treat certain types of non-small cell lung cancer (NSCLC) that are positive for anaplastic lymphoma kinase (ALK) rearrangements or ROS1 gene. It is classified as a tyrosine kinase inhibitor, specifically inhibiting the activity of ALK and ROS1, and can also affect MET proto-oncogenes. Here are some key points that you, as a physician, should know about crizotinib:\n\n### Mechanism of Action:\n- **ALK Inhibition**: Crizotinib specifically targets and inhibits the kinase activity of the ALK protein, which can drive the growth of tumours when genetically altered. ALK alterations are typically found through genetic testing of tumor samples.\n- **ROS1 Inhibition**: Similarly, it inhibits ROS1 kinase activity, benefiting patients with ROS1-positive tumors.\n  \n### Indications:\n- **NSCLC**: Primarily indicated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_skv6pDl2GYpLJT9JMQJNW4lF", "custom_id": "63_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3c497a89c33d27071c783715ff467b52", "body": {"id": "chatcmpl-9St7PGEYHJrsSsyVSQEWQkOplIRQP", "object": "chat.completion", "created": 1716672087, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is a commonly used antineoplastic medication that belongs to the class of alkylating agents. It has potent immunosuppressive properties and is used for treating various types of cancer and certain immune-mediated disorders. Here are key points you should know about cycloosphamide as a physician:\n\n1. **Mechanism of Action**:\n   Cyclophosphamide is a prodrug that requires hepatic metabolism to form its active metabolites, phosphoramide mustard and acrolein. These metabolites covalently bind to DNA, leading to cross-linking and DNA strand breakage, which inhibit DNA replication and transcription, ultimately causing cell death.\n\n2. **Indications**:\n   - **Oncological uses**: Cyclophosphamide is used in the treatment of various cancers, including lymphomas, leukemia, multiple myeloma, and solid tumors such as breast and ovarian cancer.\n   - **Autoimmune disorders**: It is used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YAiCfYq6MV6nIQRva2hNpGda", "custom_id": "64_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e371b5c16b2db075609908cb5f51e86", "body": {"id": "chatcmpl-9St7PIpgoEDXWHMtkbwnJLhnXHm4t", "object": "chat.completion", "created": 1716672087, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a thorough understanding of Cyproterone acetate (CPA) because it has specific uses and implications for patient care. Here are key points to consider:\n\n### 1. Mechanism of Action\n- **Antiandrogenic Properties:** Cyproterone acetate is a potent antiandrogen. It works primarily by blocking androgen receptors and, to a lesser extent, by suppressing gonadotropin release and decreasing testosterone levels.\n- **Progestogenic Activity:** CPA also has progestogenic properties, which contributes to its effectiveness in certain conditions like hyperandrogenism.\n\n### 2. Indications\n- **Androgen-dependent Conditions:** CPA is used in the treatment of severe acne, androgenetic alopecia, and hirsutism in women. It is also used in the management of hypersexuality and paraphilias in men.\n- **Prostate Cancer:** It is used in the management of advanced prostate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_G8NwNiri8HCBemtE5xqz34Xa", "custom_id": "65_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ba8c9cfbb6f5f7ad7a308d08ef08994", "body": {"id": "chatcmpl-9St7PuXrl17woVrkIYh7WtedxmegK", "object": "chat.completion", "created": 1716672087, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as cytosine arabinoside (Ara-C), is a chemotherapy medication used primarily to treat certain types of leukemia including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML). It is also used in the treatment of lymphomas and meningitis due to leukemia. Here are some important aspects about cytarabine that physicians should know:\n\n### Mechanism of Action\nCytarabine works as an antimetabolite by inhibiting DNA synthesis. It is a cytosine analogue that gets incorporated into DNA during the S-phase of the cell cycle, leading to DNA chain termination and eventually cell death.\n\n### Administration\nCytarabine can be administered via intravenous (IV), subcutaneous, or intrathecal routes. The mode of administration depends on the type and severity of the disease.\n\n### Dosage \nThe dosage and schedule of cytarab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_24anBeTKD78AOkdlKn0e8wwD", "custom_id": "66_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5e50861bf6e0f5b597138ef92568536", "body": {"id": "chatcmpl-9St7QZk83LcNM60TRFIKKYm9CezMd", "object": "chat.completion", "created": 1716672088, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine and daunorubicin liposomal (also known under the brand name Vyxeos) is a chemotherapy treatment used in certain types of leukemia. It is specifically indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Here\u2019s what you, as a physician, should know about this treatment:\n\n### Mechanism of Action\nVyxeos is a liposomal formulation that encapsulates cytarabine and daunorubicin in a fixed molar ratio of 5:1. This allows for enhanced delivery and uptake by leukemic cells while minimizing toxic effects to non-target cells. The two drugs act synergistically:\n- **Cytarabine**: A pyrimidine nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase and by incorporation into DNA, ultimately resulting in cell death.\n- **Daun"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 51, "completion_tokens": 200, "total_tokens": 251}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_H0cHSr0nf8PHwaHfLKqdTXNA", "custom_id": "67_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d416a1ff76062f51f1d530cde2051ad", "body": {"id": "chatcmpl-9St7QB5pgZDf1Lt5xlPIF1eUjCMI1", "object": "chat.completion", "created": 1716672088, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a prescription medication used mainly to treat certain types of skin cancer (melanoma) that cannot be treated with surgery or have metastasized, and it is specifically used for cancers that have a mutation in the BRAF V600E gene. Here are the key points you should be aware of about this medication:\n\n1. **Mechanism of Action**: Dabrafineb is classified as a BRAF inhibitor. It works by selectively targeting and inhibiting the activity of the BRAF V600E kinase, which is a mutated form of a protein that can promote cancer cell growth. By inhibiting this protein, dabrafenib can help in slowing down or stopping the growth of the cancer cells.\n\n2. **Usage**: It is imperative to confirm the presence of the BRAF V600E mutation by an FDA-approved test prior to starting treatment. Dabrafenib is often used in combination with another medication, trametinib, a MEK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Bacn8NYj6G1rjmqnY4Ez56Ri", "custom_id": "68_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d6aeaf728f2f213cdf0e9f127a1023f1", "body": {"id": "chatcmpl-9St7QU6clf1ryk3Tq7CBSWoq7sG54", "object": "chat.completion", "created": 1716672088, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine, a chemotherapeutic agent, is used primarily in the treatment of various cancers, including malignant melanoma, Hodgkin lymphoma, and sarcomas. Here are several key aspects of dacarbazine that you, as a physician, might find important to know:\n\n**1. Mechanism of Action:**\n   Dacarbazine works as an alkylating agent, although it is structurally similar to purine analogs. It requires metabolic activation in the liver where it is converted into its active form, MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide). The active compound acts by methylating guanine bases in DNA, which leads to DNA strand breaks and eventually, cell death.\n\n**2. Administration:**\n   Dacarb #azine is administered intravenously. It is important to handle it with care due to its cytotoxic nature, and it should be prepared under a biological safety cabinet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E7nZPQLywm2bkww0luKrTFPz", "custom_id": "69_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1ec7bea79b9d337a5d09009526096ba7", "body": {"id": "chatcmpl-9St7QPYAvwoKZN1CPQwtbI9tgDFCd", "object": "chat.completion", "created": 1716672088, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacomitininib is an oral, highly selective, second-generation tyrosine kinase inhibitor (TKI) used primarily for the treatment of non-small cell lung cancer (NSCLC). As a physician, here are key points you should know about Dacomitinib:\n\n1. **Indications**: Dacomitinib is approved for the first-line treatment of patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. These mutations should be confirmed by an FDA-approved test prior to initiating treatment.\n\n2. **Mechanism of Action**: Dacomitinib works by irreversibly inhibiting the activity of the EGFR family (EGFR/HER1, HER2, and HER4) of tyrosine kinases. It is effective in blocking the signaling pathways that promote cell division and proliferation which are often activated in types of cancers.\n\n3. **Administration and Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OjXLw4F2Q8j7pxfcmtvHP91a", "custom_id": "70_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4577e9624e6bd2228b34aa168efdfab1", "body": {"id": "chatcmpl-9St7RnnOYAaQ20t3Cjt301aMzBDZJ", "object": "chat.completion", "created": 1716672089, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapy medication used mainly in the treatment of a variety of cancers. It is known for its role in treating Wilms\u2019 tumor, rhabdomyosarcoma, Ewing\u2019s sarcoma, and trophoblastic neoplasms among other types. Here are some important aspects about dactinomycin that you as a physician might need to be aware of:\n\n### Mechanism of Action\nDactinomycin intercalates into DNA strands and inhibits RNA polymerase, which prevents RNA synthesis. This action is particularly detrimental to rapidly dividing cells, such as cancerous cells, making it effective as a chemotherapy agent.\n\n### Indications\n- **Wilms\u2019 tumor**\n- **Rhabdomyosarcoma**\n- **Ewing's sarcoma**\n- **Trophoblastic neoplasms**: Choriocarcinoma and other gestational trophob"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6JfdTYEDPolYxZTzcymLqNuX", "custom_id": "71_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d9a881c06fc3f4a3d74add073480637", "body": {"id": "chatcmpl-9St7R2KEAC4lDdn6DB4YDQ6Ew6J6f", "object": "chat.completion", "created": 1716672089, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid with both androgenic and anabolic properties, used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Here are key points you should know about Danazol:\n\n1. **Mechanism of Action**: Danazol acts by inhibiting the pituitary output of gonadotropins, leading to a decrease in ovarian production of estrogen and progesterone. This suppression of the hypothalamic-pituitary-ovarian axis can help reduce symptoms of diseases such as endometriosis, where estrogen-dependent processes are implicated.\n\n2. **Indications**:\n   - **Endometriosis**: Used to relieve pain and reduce lesions.\n   - **Fibrocystic Breast Disease**: Helps to reduce nodularity, pain, and tenderness.\n   - **Hereditary Angioedema**: Prevents attacks of swelling in affected individuals.\n   - Occasionally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_36yTwDjFvzvtFjKUNmtmw7Tc", "custom_id": "72_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eac43a047b00ba18a20960514a9d4e90", "body": {"id": "chatcmpl-9St7RIwYWfcbuZsvc97FdRiVbUS4t", "object": "chat.completion", "created": 1716672089, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab is an important medication in the treatment of multiple myeloma, which is a type of cancer that originates in the bone marrow's plasma cells. Here are some key aspects you should know about daratumumab:\n\n### Mechanism of Action\nDaratumumab is a human monoclonal antibody that targets and binds to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. By binding to CD38, daratumumab triggers immune-mediated killing mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.\n\n### Indications\nDaratumumab is primarily used for the treatment of multiple myeloma. Its use is recommended for patients who have received at least one prior therapy. It may be used alone or in combination with other agents such as lenalidomide, dexamethasone, bortezomib (Velcade), and others depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AHMCgLJxbvzn2dbaFU8dQMuP", "custom_id": "73_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae076fe9377653d1949d64076be954c7", "body": {"id": "chatcmpl-9St7St4Jj3K4JrQ8masXGYQiFXFgK", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a comprehensive understanding of darolutamide, especially if you treat patients with prostate cancer. Here's an overview of the key aspects of darolutamide you should be aware of:\n\n### 1. **Mechanism of Action**\n   Darolutamide is a non-steroidal antiandrogen (NSAA) that works by inhibiting the action of androgens by binding to the androgen receptor (AR) and preventing its activation. Notably, darolutamide has a high binding affinity for the androgen receptor and is also known to inhibit the receptor function by preventing its translocation into the cell nucleus.\n\n### 2. **Indications**\n   Darolutamide is approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). It is typically used in patients who are at high risk of developing metastatic disease.\n\n### 3. **Dosage and Administration**\n   The typical dosage of darolut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QThR6d1Za4yDotDrsAeB0xlx", "custom_id": "74_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48e4aa03066857162d85b9503db3be80", "body": {"id": "chatcmpl-9St7S3sWzYdRSLJKdj5VW424CyJbd", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dasatinib, sold under the brand name Sprycel, is a medication used to treat certain types of cancer, including chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). Here\u2019s a detailed overview of what you should know about dasatinib:\n\n### Mechanism of Action\nDasatinib is a tyrosine kinase inhibitor (TKI). It works by inhibiting a range of protein tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, and EPHA2. This inhibition helps block the proliferation and spread of cancer cells associated with these enzymes.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Dasatinib is approved for use in adults and children with chronic, accelerated, or myeloid or lymphoid blast phase CML that is resistant to or intolerant of prior therapy including imatinib.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_MFaQraq179bWSkZhaeQA7QD1", "custom_id": "75_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0b96665c6a8b624e2f02cc26b81781c9", "body": {"id": "chatcmpl-9St7SnNxCHQtiZ2GxmSn44HbT0WZ0", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is a chemotherapy medication primarily used to treat certain types of leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Here are several key aspects of Daunorubicin that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   Daunorubicin is an anthracycline antibiotic that works by intercalating DNA, thereby disrupting DNA replication and RNA transcription. Its antitumor activity is also attributed to its ability to generate free radicals which cause cell damage.\n\n2. **Indications**:\n   - Primarily used for the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).\n   - It may be used in combination with other cytotoxic agents depending on the specific treatment protocol.\n\n3. **Administration**:\n   Daunorobicin is administered intravenously. Dosage must be carefully calculated based on the patient\u2019s"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jsT5z6UEt3rfloJquu2F6EHc", "custom_id": "76_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9f68b348518de66de9de61b72be957b", "body": {"id": "chatcmpl-9St7S3bxHkzekKjt0bYQbURUHXTaT", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a formulation of the chemotherapy drug daunorubicin that is encapsulated in liposomes. This encapsulation technique can modify the distribution of the drug, potentially enhancing efficacy and reducing some toxicities compared to non-liposomal formulations. As a physician, here are key things you should know about Daunorubicin liposomal:\n\n1. **Indications**: Daunorubicin liposomal is primarily used in the treatment of specific types of cancer. It is indicated for the treatment of HIV-associated Kaposi's sarcoma and may be used in certain cases of acute lymphoblastic leukemia and acute myeloid leukemia. The liposomal formulation targets the drug to the tumor more specifically, potentially increasing the drug concentration at the site of the tumor while minimizing exposure to the rest of the body.\n\n2. **Mechanism of Action**: Like traditional daunorubicin, the liposomal version intercalates into DNA, disrupting the double hel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BwgGisFWulueZBjuGI0uiBau", "custom_id": "77_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e08b5fae33a9c9caa7d3ed65f31f890", "body": {"id": "chatcmpl-9St7SLMKgrz24s4iRrQlRd1n2M77q", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine, also known by its brand name Dacogen, is a chemotherapy medication used primarily in the treatment of myelodysplastic syndromes (MDS), a group of hematopoietic disorders characterized by ineffective blood cell production. Here are some crucial aspects of Decitabine that you, as a physician, should be familiar with:\n\n### Mechanism of Action\nDecitabine is a nucleoside analog of cytidine that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This action can reactivate silenced genes that are important for cell cycle regulation, differentiation, and apoptosis.\n\n### Indications\n- Primarily used for the treatment of myelodysplastic syndromes (MDS), particularly in patients who are not candidates for stem cell transplant.\n- It has also been studied and used off-label for treatment of acute myeloid leukemia (AML).\n\n### Dosage and Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RgzNVYCBYy5ctuNOWFtrCXur", "custom_id": "78_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3918f5c5ee4bf790cba6b7de8dcd0436", "body": {"id": "chatcmpl-9St7SohWLnPxYCjyI1i2w2wLQp0Vl", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) antagonists. It is primarily used in the management of advanced prostate cancer. Here are some key points you should know about Degarelix:\n\n1. **Mechanism of Action**: Degarelix works by binding to the GnRH receptors in the pituitary gland, which blocks the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a rapid reduction in the levels of the testosterone hormone, which is essential for the growth of most prostate cancers.\n\n2. **Indications**: It is specifically indicated for the treatment of advanced prostate cancer. By lowering testosterone levels, Degarelix helps to control the growth of the cancer.\n\n3. **Administration**: Degarelix is administered as a subcutaneous injection in the abdomen. The initial dose is usually a higher loading dose, followed by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nQLvJPB6KN9xTZILnIbUGfTP", "custom_id": "79_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a22cd344de38929df51ad4b70bfd20a", "body": {"id": "chatcmpl-9St7SEd9eAPgSktYSShWwhg5KBjbT", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denileukin diftitox is a targeted therapy used primarily for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL). It is a fusion protein that combines interleukin-2 (IL-2) with diphtheria toxin. Here are some key points you should know about denileukin diftitox:\n\n1. **Mechanism of Action**: Denileukin diftitox targets cells that express the IL-2 receptor. Upon binding to these cells, the diphtheria toxin component of the molecule enters the cells and inhibits protein synthesis, leading to cell death. This action is particularly effective against lymphoma cells that often express high levels of IL-2 receptors.\n\n2. **Indications**: It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL in patients who have not responded to or have recurred after other treatment options. Its use might be considered for other off-label indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sbIM9PWo1rjLNsoboNSTSFRd", "custom_id": "80_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0abec50251283cddbfa4959d47da2991", "body": {"id": "chatcmpl-9St7SETl5xm7q3UfqZc5nADvxPKK3", "object": "chat.completion", "created": 1716672090, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is an important drug used primarily in the management of conditions that affect bone density and strength. Here are several key aspects you, as a physician, should be aware of regarding its use, mechanism, indications, and safety profile:\n\n### Mechanism of Action\nDenosumab is a monoclonal antibody that targets and inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). RANKL is a crucial molecule involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, denosumab decreases bone resorption and increases bone mass and strength in various bone-affecting conditions.\n\n### Indications\n1. **Osteoporosis:** Denosumab is approved for the treatment of osteoporosis in postmenopausal women at high risk of fractures, and in men with osteoporosis.\n2. **Bone Loss in Cancer Patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ss5dnc8XmnuZ7Jt150BV8kdc", "custom_id": "81_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7210c7622d9df3fd83c9791c724a2758", "body": {"id": "chatcmpl-9St7T8BArmd8NFXNz0QtztpzVSEGs", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. Here are some key points you should know:\n\n1. **Mechanism of Action**:\n   - Dexamethasone works by decreasing inflammation through the suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It also suppresses normal immune response through various mechanisms, including the reduction of cytokine production and inhibition of T-cell activation.\n\n2. **Indications**:\n   - Dexamethasone is used in a variety of conditions where inflammation is a component of the disease process, including autoimmune disorders, severe allergic reactions, asthma, chronic obstructive pulmonary disease (COPD), brain edema, certain types of arthritis, and various skin conditions.\n   - It is also used in the treatment of croup in children, management of certain types of shock, and prevention of nausea and vomiting associated with chemotherapy.\n   - During the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FelK7xPWfzePHeEo5INwZmlc", "custom_id": "82_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "72afc9377128744c2428cae3341db7c3", "body": {"id": "chatcmpl-9St7TCitsPiCuUcsXALeXof7WxOsT", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a cytoprotective agent used primarily to reduce the cardiotoxicity associated with certain cancer chemotherapies. Here are several critical aspects you, as a physician, might need to know:\n\n### 1. **Indications**\n   - **Cardioprotection**: Dexrazoxane is approved to prevent cardiotoxicity in patients who are receiving doxorubicin or other related anthracycline chemotherapies. It is particularly used when the cumulative dose of doxorubicin exceeds a certain threshold (typically 300 mg/m\u00b2).\n   - **Extravasation**: It is also used to treat extravasation injuries caused by anthracyclines, helping to mitigate tissue damage if these drugs leak out of a vein into surrounding tissue.\n\n### 2. **Mechanism of Action**\n   Dexrazoxane acts by chelating iron, thereby reducing the formation of free radicals and preventing the iron-mediated conversion of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9UhQewRYE1ZOy9eEocvD9Dwn", "custom_id": "83_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "921e1e28f9b783cf89419779cd1e3fef", "body": {"id": "chatcmpl-9St7TZXNxizPlxIeQ82uguq8zRM8f", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic estrogen that was first synthesized in 1938 and was widely prescribed until the early 1970s. It was primarily used to prevent pregnancy complications, such as miscarriages and premature deliveries. However, its use was discontinued after studies linked it to a series of serious health effects in both the women who were prescribed DES and their offspring.\n\nHere are several key points you, as a physician, should know about DES:\n\n1. **Health Risks in Mothers**: Women who took DES have been shown to have an increased risk of developing breast cancer and are at a risk for potential complications in the reproductive system, such as an increased risk of ectopic pregnancies and infertility.\n\n2. **Health Risks in DES Daughters**: Female offspring of women who took DES, referred to as DES daughters, are at an increased risk of clear cell adenocarcinoma (CCA) of the vagina and cervix, although this is relatively rare. They"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mxmDEw7XjCFwpzuaXLUh4qAU", "custom_id": "84_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b54265665f06944937cc19945929b2a8", "body": {"id": "chatcmpl-9St7Tna7ChM5rpWIMXdxLcuhzopjU", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a targeted immunotherapy used primarily for the treatment of neuroblastoma, a type of cancer that most commonly affects children and is derived from neuroblasts located in the adrenal glands and nerve tissue. Here are key points that physicians should consider when dealing with dinutuximab:\n\n### 1. Mechanism of Action\nDinutuximab is a chimeric monoclonal antibody that binds to the GD2 glycolipid, which is highly expressed on neuroblastoma cells (and also on some other types of cancer cells). By binding to GD2, dinutuximab activates both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms, leading to the destruction of neuroblastoma cells.\n\n### 2. Indications\nDinutuximab is approved for the treatment of pediatric patients with high-risk neuroblastoma. It is typically used:\n- In combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OQLw5uoDsPhzMFe322EvdVjO", "custom_id": "85_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa7f3cec0e04f8d3f27bae7f46afbc1c", "body": {"id": "chatcmpl-9St7TQPkaqx2rPExkS6fIrn6UsQQv", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is an important chemotherapeutic agent used primarily in the treatment of various cancers. As a physician, here are some key aspects you should know about Docetaxel:\n\n1. **Mechanism of Action**:\n   - Docetaxel is a taxane, a class of drugs that stabilize microtubules and prevent their depolymerization, thereby inhibiting cell division. This mechanism is crucial in stopping cancer cells from proliferating.\n\n2. **Indications**:\n   - It is commonly used in the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancers. It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**:\n   - Docetaxel is administered intravenously. The dosage and schedule depend on the type of cancer, the patient\u2019s body surface area, and the specific treatment protocol.\n\n4. **Side Effects**:\n   - Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_w2WXNizaP4GeZsnrsf396FqC", "custom_id": "86_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b983b8bb4df81288948d1f5011185fc", "body": {"id": "chatcmpl-9St7TzEAQKjgZRTNlq5MmO9evYDdo", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine, also known as 5'-deoxy-5-fluorouridine (5'-DFUR), is a chemotherapeutic agent used primarily in the treatment of cancers. It is a fluoropyrimidine derivative and acts mainly as an antimetabolite. Here are several important points about doxifuridine that you, as a physician, might find useful:\n\n### Mechanism of Action\nDoxifluridine is a prodrug of 5-fluorouracil (5-FU), which is converted into 5-FU in the body. The active form, 5-FU, is metabolized to nucleotide analogs that can be incorporated into RNA and DNA. This results in the inhibition of thymidylate synthase, leading to a disruption of DNA synthesis, and thus, cell death occurs primarily in actively dividing cells, which is characteristic of cancer cells.\n\n### Indications\nDoxifl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6tejBY97RvbZtQ1Icu63ODVN", "custom_id": "87_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9137fd746b00ceb92a7766f6d453162a", "body": {"id": "chatcmpl-9St7TAVYWqrwlV4THrog2Y8gpWAAh", "object": "chat.completion", "created": 1716672091, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is an anthracycline antibiotic that is widely used as a chemotherapeutic agent for treating various types of cancer. Here are some key points you should know about doxorubicin:\n\n### Mechanism of Action\nDoxorubicin works primarily by intercalating DNA, disrupting the replication of DNA molecules, and inhibiting the enzyme topoisomerase II. This leads to breaks in DNA strands and ultimately induces cell death in rapidly dividing cancer cells.\n\n### Indications\nDoxorubicin is used in the treatment of a wide range of cancers, including:\n- Breast cancer\n- Bladder cancer\n- Ovarian cancer\n- Thyroid cancer\n- Stomach cancer\n- Lung cancer\n- Lymphomas\n- Leukemias\n- Soft tissue sarcomas\n- Others\n\n### Administration\nDoxorubicin is typically administered via intravenous infusion. The dosage and schedule depend on the type of cancer being"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_n0zmUf6f2ZSuGdxRAI3LPkXF", "custom_id": "88_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b6ee784c1709b15d8e46e7a9c13c4ac1", "body": {"id": "chatcmpl-9St7UwL3dOSqyQavvp8edcDQoYuTT", "object": "chat.completion", "created": 1716672092, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab (Imfinzi) is a monoclonal antibody used in cancer immunotherapy. It is specifically designed to inhibit the programmed cell death-ligand 1 (PD-L1). By blocking PD-L1, durvalumab prevents it from binding to PD-1 and B7.1 (CD80), both of which are found on T-cells. This action helps to boost the immune response against cancer cells by enhancing the ability of the immune system to detect and attack cancer cells.\n\nHere are some key points about Durvalumab:\n\n1. **Indications:**\n   - Durvalumab is approved for the treatment of certain types of urothelial carcinoma (bladder cancer) and non-small cell lung cancer (NSCLC).\n   - It is specifically approved for locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_IDpYQI7SCGNOVbPX1WVhGOEt", "custom_id": "89_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f68a84c53fadff84ed3059d09530a6c9", "body": {"id": "chatcmpl-9St7UvH0uowGM9BsOe5IDZ7tiMpWy", "object": "chat.completion", "created": 1716672092, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication primarily used in the treatment of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland. Here are several important aspects you should know about dutasteride as a physician:\n\n1. **Mechanism of Action**:\n   Dutasteride is a 5-alpha-reductase inhibitor. It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to prostate growth. Reducing DHT levels leads to a decrease in prostate size, alleviating symptoms associated with BPH such as difficulty in urinating.\n\n2. **Indications**:\n   - Primarily used for the management of BPH.\n   - It helps to improve urinary flow and may also reduce the need for prostate surgery in the future.\n\n3. **Contraindications**:\n   - Dutasteride is contraindicated in patients with a known hypersensitivity to dutasteride or other 5-alpha"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UKEiMSegdn7A02FwxsxYeriy", "custom_id": "90_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99030b5457e2c7d16fa9fe774cfd04b8", "body": {"id": "chatcmpl-9St7UF059bftKFyUQZ43UGLpbwTjf", "object": "chat.completion", "created": 1716672092, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisip is a small molecule kinase inhibitor used in the treatment of certain hematologic cancers. It specifically targets phosphoinositide 3-kinase (PI3K) delta and gamma, which are often involved in the signaling pathways that promote cancer cell growth, particularly in hematologic malignancies. Here are some critical aspects about duvelisib that you, as a physician, might need to consider:\n\n1. **Indications**: Duvelisib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior therapies. Additionally, it is approved for use in patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.\n\n2. **Mechanism of Action**: Duvelisib inhibits the activity of PI3K-delta and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Xpv2pWRGPdFOJwaP2d35Allo", "custom_id": "91_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a0a468989259f89b8f2c64dd305b862", "body": {"id": "chatcmpl-9St7Uy6ZIGGsXFqwYSNJpoVGyWYMQ", "object": "chat.completion", "created": 1716672092, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab (also known as Panorex) is a monoclonal antibody that was developed for the treatment of cancer, specifically targeting colorectal cancer. It targets the Ep-CAM (epithelial cell adhesion molecule), which is an antigen overexpressed in many human adenocarcinomas, including those of the colon, rectum, and breast.\n\n### Historical Context and Clinical Use:\n\nEdrecolomab was used in clinical settings to treat patients with colorectal cancer. In the 1990s and early 2000s, there were several clinical trials assessing its efficacy. One of the pivotal Phase III trials aimed to evaluate whether edrecolomab could improve survival rates when added to standard chemotherapy in patients with stage III colon cancer. However, the results did not demonstrate a significant improvement in patient outcomes, such as overall survival or disease-free survival compared to control groups receiving chemotherapy alone.\n\nDue to its insufficient effectiveness demonstrated in clinical trials, edrecol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ta5XDoIst8yg9KN7jMnh8abt", "custom_id": "92_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4d765a6623843479eab7991e2e1d1cb9", "body": {"id": "chatcmpl-9St7VUH7PDEQQEtmHnsoTOaSzxaQ5", "object": "chat.completion", "created": 1716672093, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab (brand name: Empliciti) is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. Here are the key aspects you should know about Elotuzumab:\n\n1. **Mechanism of Action:**\n   Elotuzumab specifically targets the SLAMF7 protein (Signaling Lymphocytic Activation Molecule Family member 7), which is highly expressed on myeloma cells and natural killer (NK) cells. By binding to SLAMF7 on myeloma cells, it directly activates the body's immune response to target and kill the malignant cells. Additionally, it indirectly activates NK cells to enhance their cytotoxic effect.\n\n2. **Indications:**\n   It is approved for use in combination with other medications, such as lenalidomide and dexamethasone, or with bortezomib and dexamethasone,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FLqhPyfct5BsxOkuI0M3OFov", "custom_id": "93_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "180b5c0357ae9cb21e87ec58bbc2ed29", "body": {"id": "chatcmpl-9St7VdGUUHnx3Qj5knGMLMF31lvVG", "object": "chat.completion", "created": 1716672093, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib (brand name Idhifa) is an important medication for physicians to understand, especially those involved in treating hematologic cancers. Here are some of the key aspects:\n\n1. **Indication**: Enasidenib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. This mutation can be identified through molecular genetic testing, which is crucial for the appropriate selection of patients for enasidenib therapy.\n\n2. **Mechanism of Action**: Enasidenib is an inhibitor of the IDH2 enzyme. In some cancers, IDH2 mutations lead to abnormal production of an oncometabolite called 2-hydroxyglutarate (2-HG), which can contribute to the formation and proliferation of cancer cells."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EhLE1uRuy8kS9c3Fcn0ypRWV", "custom_id": "94_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "96e890df4771a4064840e8b633ea7e88", "body": {"id": "chatcmpl-9St7VQmYzHPWGQjzO9Ba02PvwcJmG", "object": "chat.completion", "created": 1716672093, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Encorafenib, sold under the brand name Braftovi, is a medication used mainly for the treatment of certain types of cancer. Here are some key points you, as a physician, should know about Encorafenib:\n\n1. **Indications**: Encorafenib is approved for use in treating metastatic melanoma with a BRAF V600E mutation. It is also used for the treatment of metastatic colorectal cancer with a BRAF V600E mutation, in combination with cetuximab, after previous therapies have failed.\n\n2. **Mechanism of Action**: Encorafenib is a kinase inhibitor that specifically targets the BRAF kinase, which is a part of the RAS/RAF/MEK/ERK signaling pathway. This pathway regulates cell growth and survival. Encorafenib binds to the ATP-binding site of BRAF kinase with high affinity, particularly inhibiting the BRAF V600E mutation variant, and thus, interrupts the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZDxkWrv4UJLQTFjsUvlNWRHw", "custom_id": "95_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30a04df3e0aaccf962529f3bb89c7d11", "body": {"id": "chatcmpl-9St7VYgCYe1sY5uN87BLh3PIGQTqU", "object": "chat.completion", "created": 1716672093, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib is a targeted therapy drug used in the treatment of cancer. It is particularly useful for treating cancers that have specific genetic mutations. Here are the key points you, as a physician, should know about entrectinib:\n\n1. **Mechanism of Action**: Entrectinib is a selective tyrosine kinase inhibitor. It targets and inhibits the tropomyosin receptor kinases (TRK) A, B, and C, which are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. It also inhibits ROS1 and ALK, which are other receptor tyrosine kinases involved in the growth of certain cancer cells.\n\n2. **Indications**: Entrectinib is approved by the FDA and other regulatory agencies for the treatment of adult and pediatric patients (12 years of age and older) who have solid tumors that exhibit NTRK gene fusions, which are neurotrophic ty"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fXCpB2aNbAO3M05z8Jcy5cBR", "custom_id": "96_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "634cdc6dbf714a54dd7c5ef04a21142c", "body": {"id": "chatcmpl-9St7VKIepvu4UQ0qKKQiHYPuKFO2k", "object": "chat.completion", "created": 1716672093, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is a medication primarily used in the treatment of prostate cancer. Here\u2019s an overview that may assist you as a physician:\n\n### Mechanism of Action:\nEnzalutamide is an androgen receptor inhibitor that works by blocking the action of androgens (such as testosterone), which can promote the growth of prostate cancer cells. It has a higher affinity for the androgen receptor than earlier agents and inhibits androgen receptor signaling in three key ways:\n1. It prevents androgens from binding to the androgen receptor.\n2. It inhibits the androgen receptor from entering the nucleus of the cell.\n3. It impedes the binding of androgen receptors to DNA.\n\n### Indications:\nEnzalutamide is approved for use in several settings in prostate cancer treatment:\n- Non-metastatic and metastatic castration-resistant prostate cancer.\n- Metastatic castration-sensitive prostate cancer.\n\n### Dosage and Administration:\nThe standard dosage of en"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pH8puI2iGpoi5Sne4oMJKkFg", "custom_id": "97_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b7fda527e15839f128617fd9baac435a", "body": {"id": "chatcmpl-9St7WQly3XqJOhLm2URgDDa4bkAMD", "object": "chat.completion", "created": 1716672094, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin is an anthracycline antibiotic widely used in chemotherapy. As a physician, here are key aspects of epirubicin you should be familiar with:\n\n1. **Mechanism of Action**:\n   Epirubicin works primarily by intercalating DNA strands. It interferes with the enzyme topoisomerase II, preventing the repair of DNA damage and leading to cell death. This action is particularly effective in rapidly dividing cells, such as cancer cells.\n\n2. **Indications**:\n   Epirubicin is commonly used to treat various cancers including breast cancer, ovarian cancer, gastric cancer, soft tissue sarcomas, and others. It may be used alone or in combination with other chemotherapeutic agents.\n\n3. **Administration**:\n   Epirubicin is typically administered intravenously. The dosage and schedule depend on the type of cancer, the patient's body surface area, general health, and the specific regimen being used.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_78bfmZG3Ohm0WGXFZoMfRHU2", "custom_id": "98_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3614ded7df8214626c588e49361e0fbe", "body": {"id": "chatcmpl-9St7WelCxuPUDzYbBORpwIBJZ2P1D", "object": "chat.completion", "created": 1716672094, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib (brand name Balversa) is a medication primarily used in the treatment of cancer, specifically for urothelial carcinoma. Here are key points about Erdafitinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Erdafitinib is a kinase inhibitor that specifically targets and inhibits fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, FGFR3, and FGFR4. The inhibition of these receptors prevents the activation of the downstream signaling pathways that lead to cell growth and proliferation of cancer cells.\n\n2. **Indications**:\n   As of the latest updates, Erdafitinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations, and that has progressed during or following platinum-containing chemotherapy, including within"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tWlErA3tSPafXMbwhSoreY3D", "custom_id": "99_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "80e10fa9f8c3a433d1d243025d1f3dd0", "body": {"id": "chatcmpl-9St7WnmPg1kIZaF6eGfArmJSA4Kwp", "object": "chat.completion", "created": 1716672094, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin mesylate, marketed under the brand name Halaven, is a chemotherapy drug used in the treatment of cancer, specifically indicated for treating patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens, including an anthracycline and a taxane. It is also indicated for the treatment of liposarcoma in patients who have received prior chemotherapy that contained an anthracycline.\n\nHere are some key points about Eribulin:\n\n1. **Mechanism of Action**: Eribulin is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. It works by inhibiting the growth phase of the microtubule dynamics which causes irreversible mitotic blockade and subsequent apoptosis (programmed cell death).\n\n2. **Pharmacokinetics**: Eribulin is intravenously administered. It has a high volume of distribution, indicating extensive tissue penetration. The metabolism is hepatic,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_eDPV8YHtw3qdCzCYNGmgn80i", "custom_id": "100_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de2b63adf0238c5829efa300a58a4411", "body": {"id": "chatcmpl-9St7WfJ5FX2w04eCESILDdntHbNnh", "object": "chat.completion", "created": 1716672094, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is classified as a tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR) signaling pathways, which are involved in the proliferation and survival of cancer cells. Here are some key aspects you should know about erlotinib:\n\n### 1. **Indications**\n   - **Non-small Cell Lung Cancer (NSCLC)**: Erlotinib is approved for the treatment of patients with locally advanced or metastatic NSCLC who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.\n   - **Pancreatic Cancer**: It is used in combination with gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### 2. **Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NjxWXPYIy1sjJyq7VfSkqimD", "custom_id": "101_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1173c2c5989ce3e2c332bd7f13df60b5", "body": {"id": "chatcmpl-9St7WKBkBadvVnrfEzvtt3q5w6Hi1", "object": "chat.completion", "created": 1716672094, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Estramustine is a chemotherapy drug that is typically used in the treatment of prostate cancer. It is unique as it combines the properties of an estrogen and a nitrosourea derivative, thus having dual mechanisms of action: hormonal therapy and chemotherapy.\n\nHere\u2019s a summary of important points about estramustine:\n\n1. **Mechanism of Action**: Estramustine is a prodrug. After administration, it is metabolized into an active compound that binds to microtubule-associated proteins. This disrupts microtubule function, which is crucial for cell division, thereby exerting its cytotoxic effects primarily during the M-phase of the cell cycle. Furthermore, its estrogen component can bind to estrogen receptors, potentially reducing levels of circulating testosterone through feedback inhibition, thus exerting an additional antitumor effect on prostate cancer cells.\n\n2. **Indications**: It is primarily used for the treatment of metastatic or progressive prostate cancer, particularly in patients who have not responded to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_blYP1B8ISFmXN9HgV5XLG3Jd", "custom_id": "102_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e54248fa4313cc031744b3bc3e9dbd32", "body": {"id": "chatcmpl-9St7X3cbnV1wRTahsB8bfNSzqtOby", "object": "chat.completion", "created": 1716672095, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is a chemotherapy medication used primarily in the treatment of certain types of cancer. It belongs to a class of drugs known as topoisomerase inhibitors. Its efficacy stems from its ability to interfere with the DNA of cancer cells, preventing them from dividing and proliferating.\n\nHere are key points you should know about Etoposide:\n\n### Indications\nEtoposide is commonly used for the treatment of:\n- Small cell lung cancer\n- Testicular cancer\n- Lymphomas\n- Acute myeloid leukemia\n- Ewing sarcoma\n- Glioblastoma\n- Ovarian cancer\n- Gastric cancer (less common)\n\n### Mechanism of Action\nEtoposide works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By forming a complex with topoisomerase II and DNA, Etoposide causes breaks in the DNA strands, ultimately leading to cell death"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pJG8BSEY43Tok5yddlsKqrnd", "custom_id": "103_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c640513df6b8be8cacd37c8495b21902", "body": {"id": "chatcmpl-9St7XLAQHK1zjOWsOVkaiJpbKnxA1", "object": "chat.completion", "created": 1716672095, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is a medication used in various clinical settings, primarily for its immunosuppressive and antiproliferative properties. Here\u2019s a concise overview of its crucial aspects:\n\n### Mechanism of Action\nEverolimus is a derivative of sirolimus (rapamycin) and works similarly by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase. This inhibition reduces the activity of effector T cells and B cells by reducing their responsiveness to interleukin-2 (IL-2), ultimately suppressing both cellular and humoral immunity.\n\n### Indications\nEverolimus has several FDA-approved uses:\n1. **Prevention of Organ Rejection**: Used in adult patients to prevent organ rejection in kidney and liver transplant recipients. It is typically used in conjunction with other immunosuppressants like ciclosporin and corticosteroids.\n2. **Oncology**:\n   - **Advanced Hormone Receptor-positive, HER"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_IDdfPIk1joFD0y784D1UPiB3", "custom_id": "104_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bbc3ffd4858f534475d5dcf75b2307f2", "body": {"id": "chatcmpl-9St7Xx877cy724rcHF2cKxk7ZxN1F", "object": "chat.completion", "created": 1716672095, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane is a medication primarily used in the treatment of breast cancer. Here are several key points you should be aware of as a physician:\n\n### Mechanism of Action\nExemestane is classified as an aromatase inhibitor. It works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By decreasing estrogen levels, exemestane helps to slow the growth of hormone-sensitive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: Exemestane is typically prescribed for postmenopausal women with estrogen receptor-positive breast cancer. It is often used as adjuvant therapy following the completion of tamoxifen treatment and can also be used in the treatment of advanced breast cancer.\n\n### Dosage and Administration\n- **Standard Dosage**: The common dosage of exemestane is 25mg taken orally once daily after a meal.\n- **Duration of Treatment**: Treatment duration can vary based on the clinical scenario, ranging from a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_avjqO2wIc2iDhLlJt1HtzKiE", "custom_id": "105_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "741e9fa90a4bd478df6d0b89e31526b6", "body": {"id": "chatcmpl-9St7YGUdX7wlFGTC2Hdc9imq3oXSO", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine, also known as FUDR, is an antimetabolite chemotherapy medication primarily used to treat cancer. It is similar in structure and function to fluorouracil (5-FU), but it is more commonly administered directly into the arteries supplying the tumor, especially in cases of liver metastasis from colorectal cancer. Here are several important aspects of Floxuridine that you, as a physician, should be aware of:\n\n1. **Indications**: Floxuridine is most often used in the treatment of liver metastases of colorectal cancer. It may be used alone or in combination with other therapies.\n\n2. **Mechanism of Action**: Floxuridine is metabolized into fluorouracil in the body. It inhibits thymidylate synthase, leading to a decrease in DNA synthesis and function. This is particularly effective in rapidly dividing cells, such as cancer cells.\n\n3. **Administration**: Unlike fluorouracil,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QeMxZw1BOdGdeTqCk7VIvtFn", "custom_id": "106_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9e509a195248668ccfb898114801b0eb", "body": {"id": "chatcmpl-9St7djpYDnCp7FBs4LNDQ5uhA8H4H", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fludarabine is a chemotherapy drug commonly used in the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and some types of non-Hodgkin's lymphoma. Here are some key points about fludarabine:\n\n### Mechanism of Action\nFludarabine is a nucleoside analog of adenine. It interferes with DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase, which leads to cell death. It is especially effective in rapidly proliferating cells, such as cancer cells.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL):** It is most commonly used in the treatment of CLL, especially in patients who are younger and have not responded to initial treatments.\n- **Non-Hodgkin's Lymphoma:** It is also used to treat low-grade non-Hodgkin\u2019s lymphoma.\n\n### Administration\nFludarab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qNgz441TcBiD4Li3727jSnxT", "custom_id": "107_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b228f0fe892b04752bf9548a7e80e336", "body": {"id": "chatcmpl-9St7YdKMf5wJlScoebxtHWSiy3g9F", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil (5-FU) is a chemotherapy medication used to treat various types of cancer, including cancers of the colon, esophageal, stomach, pancreatic, breast, and skin (particularly basal cell carcinoma and actinic keratosis). It is a type of antimetabolite medication that works by interfering with DNA and RNA synthesis, which effectively stops the growth and proliferation of cancer cells. Here are some key points you should know about Fluorouracil:\n\n### Mechanism of Action\nFluorouracil inhibits the enzyme thymidylate synthase, which is involved in the synthesis of the pyrimidine thymidine, an essential building block of DNA. The lack of thymidine can inhibit cell division and lead to cell death.\n\n### Administration\nFluorouracil can be administered in several ways, depending on the type of cancer and the treatment regimen:\n- Intravenous (IV) infusion is the most common route"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1dRd4yp7eKD9W3ClzQYcCrCM", "custom_id": "108_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "766927e75aea198b8b4fe694b09b61d5", "body": {"id": "chatcmpl-9St7Y5AWIpchJ4Qrx4ZWLcumcoHFz", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone, sold under brand names such as Halotestin and Ultandren, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. It is taken by mouth. Here are the key points you should know about Fluoxymesterone:\n\n**1. Mechanism of Action:**\n   Fluoxymesterone works by binding to and activating the androgen receptor (AR). Similar to other AAS, it has both anabolic and androgenic effects. It promotes the growth of muscle mass and strength, and can stimulate the production of red blood cells by enhancing erythropoietin release.\n\n**2. Clinical Uses:**\n   - **Hypogonadism:** Treating men with low or absent testosterone due to primary hypogonadism or hypogonadotropic hypogonadism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jZUo86aSMJGAl20FXeGdPcAX", "custom_id": "109_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b33d2fe65206c8bfdf9cf70da72b0a44", "body": {"id": "chatcmpl-9St7YX75lTIj0CEfKJFn9QOvADdIt", "object": "chat.completion", "created": 1716672096, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a medication primarily used in the treatment of prostate cancer. It works as a nonsteroidal antiandrogen by blocking the action of male hormones (androgens), which can inhibit the growth and spread of prostate cancer cells. Here are key points about Flutamide that you should know:\n\n**1. Mechanism of Action:**\n   - Flutamide acts as a competitive antagonist at the androgen receptor, preventing androgens like testosterone and dihydrotestosterone (DHT) from binding to their receptor in target tissues. This decreases the influence of androgens, which can slow or stop the growth of androgen-dependent cancer cells, particularly in prostate cancer.\n\n**2. Indications:**\n   - Primarily prescribed for the treatment of stage B2-C and D2 metastatic prostate carcinoma. \n   - It is often used as part of combination therapy with a gonadotropin-releasing hormone (GnRH) agonist or after surgical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Job6TvKfFBU8VK4XBzThQ3iI", "custom_id": "110_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f52aacd9de89a692818ebb895736d4c1", "body": {"id": "chatcmpl-9St7ZfUcuEKo6020NCSwQjXV2rRhx", "object": "chat.completion", "created": 1716672097, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a form of folate (vitamin B9) used as a medication. It is important in the synthesis of DNA and RNA and is used in various clinical contexts, primarily to decrease the toxic effects of certain drugs that reduce folate levels. Here are some key points about foliniconic acid:\n\n### Uses\n1. **Chemotherapy Adjuvant**: Folinic acid is often used in combination with fluorouracil, a chemotherapeutic agent, to enhance its effects and reduce its toxicity. It is used in the treatment of colon cancer, rectal cancer, and other types of cancer.\n2. **Antidote for Methotrexate Toxicity**: Folinic acid is used to diminish the toxic effects of high-dose methotrexate therapy in osteosarcoma. It can help prevent methotrexate-induced damage by providing a source of folate that is not affected by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_quJiLVtHbSKAbJBVjb3T7k32", "custom_id": "111_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "64bda0b4bd71c5fab1c31cf227dc7074", "body": {"id": "chatcmpl-9St7ZOsqzGjOihnQkoT1dfS4mhzUm", "object": "chat.completion", "created": 1716672097, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane (chemical name: 4-hydroxyandrostenedione) is an aromatase inhibitor used primarily in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about formestane:\n\n1. **Mechanism of Action**: Formestane suppresses estrogen production by inhibiting the enzyme aromatase, which is responsible for converting androgens (produced in the adrenal glands) into estrogens. This inhibition reduces the estrogen levels in the body, which can help to slow the growth of estrogen-dependent breast cancer cells.\n\n2. **Usage**: Formestane was the first selective aromatase inhibitor used for the treatment of breast cancer. It is administered through intramuscular injections, which is different from many other aromatase inhibitors that are administered orally.\n\n3. **Indications**: It is primarily used for the treatment of estrogen-receptor positive breast cancer in postmenopausal women. Especially"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YqmSbLEObBOyvZuGS7s084bt", "custom_id": "112_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "58e88a93a015b597661e983169058d65", "body": {"id": "chatcmpl-9St7ZXAV861nQyGfhmVfQYaAYGZ3R", "object": "chat.completion", "created": 1716672097, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine is an investigational drug that acts as a purine nucleoside phosphorylase (PNP) inhibitor. It is primarily studied for its potential use in the treatment of hematological malignancies, particularly T-cell lymphomas. The drug works by inhibiting the enzyme PNP, which is critical in the purine salvage pathway. This inhibition leads to an accumulation of deoxyguanosine triphosphate, which is toxic to lymphocytes, particularly the malignant ones.\n\n**Clinical Development and Therapeutic Use:**\n- Forodesine has been under research in clinical trials for conditions such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL). \n- Its oral and intravenous formulations have been explored in different studies.\n\n**Mechanism of Action:**\n- Forodesine\u2019s mechanism involves the selective buildup of deoxyguanosine triphosphate in lymphocytes, leading to apoptosis predominantly in these cells due to their"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eHkMXOcFsqJVw5Wc6hSKxgSR", "custom_id": "113_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "10a42a311a19f26aea03ce36553ad2ab", "body": {"id": "chatcmpl-9St7ZTDrdxSXriid70FxhPbyDKXWG", "object": "chat.completion", "created": 1716672097, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is a small molecule oral spleen tyrosine kinase (Syk) inhibitor that is used in the management of immune thrombocytopenia (ITP). Here are some critical points about fostamatinib that you, as a physician, should be aware of:\n\n1. **Indication and Usage**:\n   - Fostamatinib is approved by the FDA for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. ITP is an autoimmune disorder where the immune system attacks and destroys platelets, leading to easy or excessive bruising and bleeding.\n\n2. **Mechanism of Action**:\n   - Fostamatinib works by inhibiting spleen tyrosine kinase (Syk), which is a key enzyme in the signaling pathways of several types of immune cells, including B cells and macrophages. By inhibiting Syk, fostam"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fopLvEk9Vo88UXT4VLQdEVHi", "custom_id": "114_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4923fedf1b005db8b44c26488f2215da", "body": {"id": "chatcmpl-9St7Zk5EHccTPTpbxR7tDedVUG6td", "object": "chat.completion", "created": 1716672097, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is a nitrosourea-type alkylating agent used primarily for the treatment of malignant melanoma, including metastases to the brain, and other tumors like non-Hodgkin's lymphoma. It acts by cross-linking DNA and RNA, thereby inhibiting the synthesis of nucleic acids and proteins essential for cell survival. Here are some important aspects you should be aware of when dealing with Fotemustine:\n\n1. **Mechanism of Action**: Fotemustine causes alkylation of DNA and RNA, leading to inhibition of DNA synthesis, disruption of cellular function, and eventually causing cell death. It specifically targets the O6 position of guanine.\n\n2. **Indications**: Fotemustine is primarily used in the treatment of metastatic malignant melanoma, especially when the disease has progressed after other treatments. It is also used in certain cases of glioma and other cancers like metastatic colorectal cancer.\n\n3. **Administration**: Fot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OqxsKSzHmYParPmEj7GvvtH0", "custom_id": "115_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74e855b2d107f2cac1f41aa92cd269c1", "body": {"id": "chatcmpl-9St7bhVch7NbgntOtLfYJOZCzBKTY", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestripant, sold under the brand name Faslodex among others, is used as a hormone therapy for postmenopausal women with certain types of hormone receptor-positive, metastatic breast cancer. Here are some key aspects to consider:\n\n**1. Mechanism of Action:**\n   Fulvestrant is a selective estrogen receptor degrader (SERD). It works by binding to estrogen receptors on breast cancer cells, thereby blocking the effect of estrogen. Unlike other anti-estrogens, it also accelerates the degradation of estrogen receptors.\n\n**2. Indications:**\n   - Fulvestrant is primarily used for treating hormone receptor-positive metastatic breast cancer in postmenopausal women.\n   - It may also be prescribed for hormone receptor-positive advanced breast cancer in premenopausal women in combination with ovarian suppression.\n   - In certain cases, it is used in combination with other drugs, such as palbociclib, to treat specific types of breast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TicSj5comdoIik5csWUviutz", "custom_id": "116_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b0c7bc99af5d08200c6c98fba61d4683", "body": {"id": "chatcmpl-9St7ahNG4WVM0Tk809FL3vUF7F1bF", "object": "chat.completion", "created": 1716672098, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is an antineoplastic medication primarily used in the treatment of non-small cell lung cancer (NSCLC). Here are key facts and considerations for physicians regarding Gefitinib:\n\n### Mechanism of Action\nGefitinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds to the adenosine triphosphate (ATP)-binding site of the enzyme, which leads to inhibition of the intracellular phosphorylation of EGFR, thereby blocking the signal transduction pathways implicated in the proliferation and survival of cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Gefitinib is specifically indicated for the first-line treatment of patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations as detected by an FDA-approved test.\n\n### Pharmacokinetics\n- **Absorption:** Gefitinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gKEn4ivCLM3OaAbt8boKMO4L", "custom_id": "117_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d986feb6c42b2633a41bb63f2c705d1", "body": {"id": "chatcmpl-9St7a9GRxCyQuwDzuEZ56UpFI4QYu", "object": "chat.completion", "created": 1716672098, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine is a chemotherapy drug used mainly in the treatment of various types of cancer, including pancreatic cancer, breast cancer, ovarian cancer, and non-small cell lung cancer. Here are some important aspects that you, as a physician, should know about gemcitabine:\n\n### Mechanism of Action\nGemcitabine is a nucleoside analog of deoxycytidine. It gets incorporated into DNA during the S phase of the cell cycle, leading to inhibition of DNA synthesis and subsequently inducing cell death. It also inhibits ribonucleotide reductase, which is responsible for making deoxynucleotides necessary for DNA synthesis.\n\n### Indications\n1. **Pancreatic Cancer:** Gemcitabine is used as a first-line treatment for locally advanced or metastatic pancreatic cancer and can be used in adjuvant settings.\n2. **Non-Small Cell Lung Cancer (NSCLC):** Used as first-line treatment in locally advanced or metast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tVNMPCBpw2rHDDYkPWZeq7dS", "custom_id": "118_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ca488c7c54b4517af600a3714f50af1", "body": {"id": "chatcmpl-9St7aQFctEwGSFnrm5JAywAvg6lO0", "object": "chat.completion", "created": 1716672098, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is an important drug in the treatment of certain types of cancer. Here are key points to consider as a physician:\n\n1. **Indication**: Gemtuzumab ozogamicin is approved for the treatment of acute myeloid leukemia (AML). It is specifically indicated for newly diagnosed CD33-positive AML in adults and for relapsed or refractory CD33-positive AML in adult and pediatric patients aged 2 years and older. The expression of the CD33 antigen on leukemia cells is essential for the indication of this drug.\n\n2. **Mechanism of Action**: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeted against the CD33 antigen, linked to a cytotoxic agent, calicheamicin. Upon binding to CD33-expressing cells, the conjugate is internalized and the cytotoxin is released inside the cell, leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_nQwMoMq3Ot2gwpCsjwNc7oRa", "custom_id": "119_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "190fde5640b657309df5ddbcfec101e2", "body": {"id": "chatcmpl-9St7aRZcjvhDJjpNUgY1DHRcTDa8A", "object": "chat.completion", "created": 1716672098, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib, marketed under the brand name Xospata, is an oral medication used primarily for the treatment of acute myeloid leukemia (AML). Here are some key points you, as a physician, should be aware of when considering or prescribing gilteritinib:\n\n1. **Indications**: Gilteritinib is approved for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation as detected by an FDA-approved test. The FLT3 (FMS-like tyrosine kinase 3) gene mutations are one of the most common genetic abnormalities in AML.\n\n2. **Mechanism of Action**: Gilteritinimib is a tyrosine kinase inhibitor that targets the FLT3 mutations. It can inhibit the FLT3 internal tandem duplication (ITD) mutations, as well as the tyrosine kinase domain (TKD) mutations. This inhibition leads to decreased viability of malignant cells.\n\n3. **Dosage and Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VhuMjjvOFJsU9sp9diqpUC9a", "custom_id": "120_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d826741156e4a2ecd84ec42a3542883", "body": {"id": "chatcmpl-9St7bmTCQXxq50774A7aYZCv1n95v", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Glasdegib (marketed under the name Daurismo) is a medication used in oncology, specifically for the treatment of acute myeloid leukemia (AML). Here are some essential aspects of Glasdegib that you, as a physician, should be aware of:\n\n1. **Indication**: Glasdegib is approved for use in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are 75 years of age or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n2. **Mechanism of Action**: Glasdegib works as a hedgehog pathway inhibitor. It binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction. This inhibition can help stop the growth of cancer cells.\n\n3. **Dosage and Administration**: The typical dose of Glasdegib when used in combination with low-dose cytarab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JOFmspXkYDdOoGPkzd9Y0mnI", "custom_id": "121_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22f5c639ef2515222cb8a04e51091e42", "body": {"id": "chatcmpl-9St7bsKTmbpNfvWRWeenZ72XLG2pU", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Goserelin is a type of medication known as a gonadotropin-releasing hormone (GnRH) agonist, which is used primarily in the management of hormone-sensitive cancers of the breast and prostate, as well as in conditions like endometriosis and uterine fibroids. Here are several key points you should be aware of regarding the prescribing and use of Goserelin:\n\n1. **Mechanism of Action**:\n   Goserelin works by initially increasing and then subsequently decreasing the secretion of gonadotropins (LH and FSH) from the pituitary gland, leading to a decrease in testosterone and estrogen production. This effect, often referred to as \"chemical castration\" in the context of prostate cancer, helps to inhibit the growth of hormone-sensitive cancer cells.\n\n2. **Indications**:\n   - **Prostate cancer**: Particularly for advanced prostate cancer as part of palliative care or in combination with other treatments.\n   - **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jGEz7Pbwr9Iw1QITOcOf23Wz", "custom_id": "122_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae84ffb269ad1d94007ec822f439fad0", "body": {"id": "chatcmpl-9St7bqzxCe6mKR8Cun7KFDHVRtPuK", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Histrelin is a medication used in the treatment of hormone-responsive cancers such as prostate cancer in men and to manage central precocious puberty (CPP) in children. It is a synthetic analogue of gonadotropin-releasing hormone (GnRH) and functions as a GnRH agonist. Here\u2019s a concise overview that covers its mechanism, uses, administration, and potential side effects:\n\n**Mechanism of Action:**\nHistrelin works by initially stimulating the release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, with prolonged administration, histrelin desensitizes the pituitary gland, leading to a significant reduction in LH and FSH secretion, which ultimately decreases testosterone levels in men and estrogen levels in women.\n\n**Indications:**\n1. **Prostate Cancer:** Histrelin is used in the management of advanced prostate cancer."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3HDSRNUjCGaz663VEGIx4gSr", "custom_id": "123_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ed745e78989cf805210e4a59593dca66", "body": {"id": "chatcmpl-9St7bS2liUakaF0DtufzU4HgBm15S", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydrocortisone is a corticosteroid medication used in a wide range of conditions for its anti-inflammatory and immunosuppressive effects. Here are some key points you should know about hydrocortisone:\n\n**1. Mechanism of Action:** Hydrocortisone works by mimicking the actions of steroids normally produced by the adrenal glands. It inhibits inflammatory responses in the body, including the activity of various cells and chemicals involved in inflammation.\n\n**2. Indications:** Hydrocortisone is used to treat numerous conditions, including:\n   - Adrenal insufficiency (e.g., Addison\u2019s disease)\n   - Inflammatory conditions (such as arthritis, lupus, and skin conditions like eczema and psoriasis)\n   - Allergic reactions\n   - Asthma and other respiratory conditions\n   - Certain types of cancer (as part of chemotherapy regimens)\n\n**3. Forms and Administration:** Hydrocortisone is available in several"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7kAnPnIjsEPT9rHzTIVgEdmU", "custom_id": "124_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "970f1f564768e03bcfb50300d834ed8b", "body": {"id": "chatcmpl-9St7ba4aBLGj6BZ08IEBD5ziuXE0V", "object": "chat.completion", "created": 1716672099, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxyurea is a medication commonly used in the treatment of several chronic conditions, particularly in hematology and oncology. Here is an overview of important aspects to consider when prescribing hydroxyurea:\n\n### 1. **Indications**\n- **Sickle Cell Disease**: Hydroxyurea is used to reduce the frequency of painful crises and to decrease the need for blood transfusions. It increases the production of fetal hemoglobin (HbF), which can decrease the sickling of red blood cells.\n- **Chronic Myeloid Leukemia (CML)**: It is used in the management of CML, especially when newer tyrosine kinase inhibitors are not suitable.\n- **Polycythemia Vera**: Hydroxyurea is employed to reduce the hematocrit and control the high white blood cell and platelet count.\n- **Essential Thrombocythemia**: It is used to lower excessive platelet counts and reduce the risk of throm"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_r2U2jfKOWeJ5Kivq5ySbOmaj", "custom_id": "125_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a6dc068ed17f6ff32f96d7b8286179f6", "body": {"id": "chatcmpl-9St7cPyemPCjigeR9StVbgC3Pzgzj", "object": "chat.completion", "created": 1716672100, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan, marketed under the name Zevalin, is a radioimmunotherapy medication predominantly used for the treatment of non-Hodgkin's lymphoma (NHL). It specifically targets the CD20 antigen, a protein expressed on the surface of B-cells, making it applicable for treating B-cell NHL. Here are several key aspects that you, as a physician, should be aware of:\n\n### Mechanism of Action\nIbritumomab tiuxetan is a conjugate of the monoclonal antibody ibritumomab and the radioactive isotope yttrium-90 (90Y). The antibody portion targets the CD20 protein on B-cells, and once bound, the radioisotope delivers beta radiation directly to the target cells and their nearby vicinity, causing cell death.\n\n### Indications\n- **Primary Indication:** It is approved for the treatment of patients with relapsed or refractory, low-grade or follic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_MgtF1bkhGyIuoIu93vux7Z3q", "custom_id": "126_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c168861941e72ae5ea2952c0d4ee5043", "body": {"id": "chatcmpl-9St7cZK7Vcs4ysxb64mg3FYNnVCVY", "object": "chat.completion", "created": 1716672100, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a medication that plays a critical role in the treatment of various types of B-cell malignancies. As a physician, here are key points you should be familiar with:\n\n### 1. **Mechanism of Action**\n   Ibrutinib is a small molecule drug that inhibits Bruton's tyrosine kinase (BTK). BTK is an essential component in the B-cell receptor signaling pathway, which is critical for the survival and proliferation of B cells. By inhibiting BTK, ibrutinib impedes the survival of malignant B cells that rely on this pathway.\n\n### 2. **Indications**\n   Ibrutinib is approved for use in:\n   - Chronic lymphocytic leukemia (CLL)\n   - Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy\n   - Waldenstr\u00f6m's macroglobulinemia\n   - Marginal zone lymphoma ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_A1qgTXtZZQM9klw27r9we0qg", "custom_id": "127_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9bdddd193d2935ad76b8aa8343c0ec93", "body": {"id": "chatcmpl-9St7c4r4Q15I3mdou9nsWjAp08NBJ", "object": "chat.completion", "created": 1716672100, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is primarily used in the treatment of non-small cell lung cancer (NSCLC). Below are some key points you should be aware of regarding its use, mechanism, and pharmacology:\n\n1. **Indication and Usage**:\n   - Icotinib is specifically designed for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). It is particularly effective in patients who have specific mutations in the EGFR gene, such as exon 19 deletions or exon 21 (L858R) substitution mutations.\n\n2. **Mechanism of Action**:\n   - Icotinib works by selectively inhibiting the tyrosine kinase activity of the EGFR. The EGFR is a transmembrane glycoprotein that, when activated, initiates a signal transduction cascade that promotes cellular proliferation and survival. Mutations in the EGFR gene can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_QQbON5g2GOGqMTh3ABobB5DS", "custom_id": "128_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7807d4a8152e310c2c5ada32335f7f64", "body": {"id": "chatcmpl-9St7cnAGAGyjN8hylffhnw6IdidRT", "object": "chat.completion", "created": 1716672100, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an anthracycline antineoplastic agent, commonly used in the treatment of various cancers, notably acute myeloid leukemia (AML) and other hematological malignancies. Here are several important aspects that you, as a physician, should know about idarubicin:\n\n1. **Mechanism of Action**:\n   Idarubicin acts primarily by intercalating DNA strands. It inhibits the enzyme topoisomerase II, which leads to breaks in DNA strands and ultimately inhibits DNA replication and RNA synthesis. Its action mechanism also generates free radicals, which cause additional damage to cellular components.\n\n2. **Indications**:\n   Idarubicin is approved for the treatment of acute myeloid leukemia, both as a single agent and in combination with other chemotherapeutic agents. It can also be used in other leukemias and lymphomas as part of clinical trials or in specific circumstances.\n\n3. **Administration**:\n   Idar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ROWzXSmDnN8ynoLdGzvtalvz", "custom_id": "129_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cb108b638a3241e147ed03743287e79a", "body": {"id": "chatcmpl-9St7dmrza6WHztV7JaHThPv8t0iCP", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib, marketed under the brand name Zydelig, is a medication used primarily in the treatment of certain hematological cancers, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma. This drug is particularly indicated for patients who have received at least one prior therapy. Here are several key aspects of idelalisib that you, as a physician, might find important:\n\n1. **Mechanism of Action:**\n   Idelalisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that is overexpressed in B-cell malignancies and plays a significant role in the viability and proliferation of B-cells. By inhibiting PI3K delta, idelalisib induces apoptosis and inhibits proliferation of malignant B-cells.\n\n2. **Indications:**\n   - **Chronic Lymphocytic Leuk"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_xqjhAuvsOZnrB46JMMwmh1LA", "custom_id": "130_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32ad91c06114ce19c70a59108c975bec", "body": {"id": "chatcmpl-9St7d2cau6OyCYuZ8fcHFL7PlxoIn", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ifosfamide is a chemotherapeutic agent used primarily for treating various types of cancer. Here are several key points you should know about ifosfamide:\n\n1. **Mechanism of Action**:\n   - Ifosfamide is an alkylating agent that interferes with the growth of cancer cells by cross-linking DNA strands and inhibiting DNA replication, which ultimately leads to cell death.\n\n2. **Indications**:\n   - It is primarily used to treat testicular cancer, as well as sarcomas (including soft tissue sarcoma). Ifosfamide may also be used in the treatment of lymphomas, lung cancer, ovarian cancer, and breast cancer, often in combination with other chemotherapy agents.\n\n3. **Administration**:\n   - Ifosfamide is administered intravenously. It is typically given in a hospital setting due to its potent nature and the need for close monitoring of side effects.\n\n4. **Dosage**:\n   - The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5Gk8fZmQbwMzO8Wxuz2jFFXE", "custom_id": "131_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b86848f177ebf38612074e7a2bb04e1f", "body": {"id": "chatcmpl-9St7dR6DhFb3AYjZtxUz48r8iVOW5", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a detailed understanding of imatinib, especially since it's a critical medication used primarily in the treatment of certain cancers. Here is a concise overview:\n\n**1. Mechanism of Action:**\n   Imatinib is a tyrosine kinase inhibitor that specifically targets BCR-ABL tyrosine kinase, the abnormal protein produced by the Philadelphia chromosome that is characteristic of chronic myeloid leukemia (CML). It also inhibates other tyrosine kinases including PDGFR (platelet-derived growth factor receptor) and c-kit, which play roles in other forms of cancers.\n\n**2. Indications:**\n   - Primary treatment for chronic myeloid leukemia (CML).\n   - Gastrointestinal stromal tumors (GIST) that are CD117 (c-KIT) positive.\n   - Other approved indications include certain types of myelodysplastic/myeloproliferative diseases, hypereosin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ufwS0rIB40w6I499f9i2aSfZ", "custom_id": "132_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4e6eb76828ffd7a31193a2ae5e10a1df", "body": {"id": "chatcmpl-9St7dBBijQ79asvrdIukszAKTwvFh", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib is an oral medication that functions as a tyrosine kinase inhibitor specifically targeting the fibroblast growth factor receptor (FGFR) family of receptors. Here is an overview of some key aspects about Infigratinib:\n\n1. **Indication**: Infigratinib is approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements. It is important to confirm the presence of FGFR2 fusion or rearrangement with an FDA-approved test prior to initiating treatment.\n\n2. **Mechanism of Action**: Infigratinib selectively inhibits the tyrosine kinase activity of FGFR1, FGFR2, and FGFR3, which may result in the inhibition of FGFR-mediated signal transduction pathways. Thereby, it could impede the proliferation and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4hgFeaDDvC1bKRcg6OpSpGLQ", "custom_id": "133_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8416ec8bb42cac185cc7628e9d37dc16", "body": {"id": "chatcmpl-9St7dzGIBLXmoTOjkif9Gzr5CXJhL", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is a monoclonal antibody-drug conjugate used primarily in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is an important treatment option that combines targeted therapy with a cytotoxic agent to specifically attack cancer cells. Here are key points you should know about Inotuzumab ozogamicin:\n\n1. **Mechanism of Action**: Inotuzumab ozogamicin consists of a monoclonal antibody targeting CD22, a marker expressed almost universally on B-cell ALL cells, linked to the cytotoxic agent calicheamicin. Upon binding to CD22, the conjugate is internalized and the linker is cleaved, releasing calicheamicin which induces double-strand DNA breaks and subsequently cell death.\n\n2. **Indications**: It is approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_evC1iGgoSoKCO0hwQTjfO03R", "custom_id": "134_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "37204ae49f1438e1826db1e4be771790", "body": {"id": "chatcmpl-9St7dDA2dUDtIsfSAYZnCGablvK5X", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a recombinant version of interferon alpha, a protein naturally produced by the body in response to viral infections and other pathogens. It is used primarily in the treatment of viral hepatitis (hepatitis B and C) and certain types of cancer, including hairy cell leukemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, and malignant melanoma. Here are several key points you should know about Interferon alfa-2a:\n\n1. **Mechanism of Action**: \n   - Interferon alfa-2a has antiviral, antiproliferative, and immunomodulatory effects. It works by binding to specific cell surface receptors, activating intracellular antiviral activities, and influencing the expression of numerous genes, including those regulating apoptosis and cell proliferation.\n\n2. **Indications**:\n   - Chronic hepatitis B and C: Helps decrease the amount of virus in the liver, reduce liver"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_C6M9fBXSmXbfe7YRVhK208nM", "custom_id": "135_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4522745a0ae32b4b52a8aeb9f1d5cdd6", "body": {"id": "chatcmpl-9St7deGNl4dBK9FAlHUwJcBEyWXsb", "object": "chat.completion", "created": 1716672101, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of medication known as an interferon, which is a group of natural proteins produced by the cells of the immune system in response to challenges such as viruses, bacteria, parasites, and cancer cells. It is used in the treatment of various diseases due to its antiviral, antiproliferative, and immune-modulating effects. Here are some key points about Interferon alfa-2b that you, as a physician, may find useful:\n\n### Indications\nInterferon alfa-2b is approved for the treatment of a range of conditions including:\n- Chronic hepatitis B and C\n- Malignant melanoma\n- Follicular lymphoma\n- Kaposi's sarcoma associated with AIDS\n- Genital warts\n- Some leukemias and renal cell carcinoma\n\n### Mechanism of Action\nInterferon alfa-2b works by:\n- **Antiviral activity:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iyfkfGAufcvD8DcqdOuuGNcC", "custom_id": "136_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66fb591681611b67b94ff3de01b2b812", "body": {"id": "chatcmpl-9St7eaEAw6f6DmSwSA5zlvXD5BFFe", "object": "chat.completion", "created": 1716672102, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b (also known by its brand name Actimmune) is a synthetic version of a naturally occurring protein in the body, important for modulating the immune response. It is used primarily for its immunomodulatory and antiviral effects. Here are key points that you, as a physician, should consider:\n\n### Indications:\n1. **Chronic Granulomatous Disease (CGD):** Interferon gamma-1b is approved for reducing the frequency and severity of infections associated with this rare genetic disorder, which affects the functioning of neutrophils, a type of white blood cell important in fighting infections.\n2. **Severe Malignant Osteopetrosis (SMO):** It is also indicated for delaying time to disease progression in patients with severe malignant osteopetrosis, a genetic disorder that affects bone resorption and formation.\n\n### Mechanism of Action:\nInterferon gamma-1b works by enhancing the activity of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_uHgBSqcWa0GFC8HPhUa3n2YA", "custom_id": "137_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7510739fcee2d5b97a434d3f8f5a8f87", "body": {"id": "chatcmpl-9St7ekePXrF69ZH7CdW5oQ1UjHa6v", "object": "chat.completion", "created": 1716672102, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab, marketed under the brand name Yervoy, is a monoclonal antibody used in the treatment of melanoma and other cancers. Here are key points about Ipilimumab that you, as a physician, should be familiar with:\n\n1. **Mechanism of Action**: Ipilimumab is a CTLA-4 inhibitor. CTLA-4 is a molecule found on T-cells that acts as an immune checkpoint, downregulating immune responses. By blocking CTLA-4, Ipilimumab enhances the body's immune response against cancer cells.\n\n2. **Indications**:\n   - It is primarily indicated for the treatment of metastatic melanoma.\n   - It is also approved for use in patients with intermediate or poor-risk, previously untreated advanced renal cell carcinoma in combination with nivolumab.\n   - Treatment of adult and pediatric patients (12 years and older) with microsatellite instability-high (MSI-H) or mismatch repair deficient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_toVAcQvXkAwgQo8gJBhX8B7C", "custom_id": "138_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e36b44c4fa5e7145d07f510e2783630", "body": {"id": "chatcmpl-9St7eNZ0DeWtXxieEE6WFIXhhrjPK", "object": "chat.completion", "created": 1716672102, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapy medication used primarily to treat cancers of the colon and rectum, particularly in cases where the cancer has metastasized. It is often used in combination with other chemotherapy agents. Here are some key points about irinotecan that you, as a physician, might find important:\n\n1. **Mechanism of Action**:\n   Irinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that relieves torsional strain in DNA by inducing reversible single-strand breaks. This inhibition leads to DNA damage and cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Metastatic colorectal cancer, commonly used as second-line therapy.\n   - It may be used in other cancers as part of clinical trials or in specific circumstances, such as certain gastric cancers, lung cancers, and gliomas.\n\n3. **Administration**:\n   - Ir"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_k4BiUjbVOxGiar8O0SAdzZi0", "custom_id": "139_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2623c18d434a3c45f83e6fdbfb34c743", "body": {"id": "chatcmpl-9St7fv5w8aLqpSSeakLnXUoeG4ZXv", "object": "chat.completion", "created": 1716672103, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome injection is a form of chemotherapy used primarily in the treatment of pancreatic cancer. Specifically, it's approved for use in patients with metastatic pancreatic adenocarcinoma following the failure of gemcitabine-based therapy. Here's a summary of key points:\n\n### Brand Name\n- **Onivyde**\n\n### Mechanism of Action\n- Irinotecan liposome is a topoisomerase inhibitor. It works by interfering with the replication of DNA, thereby slowing or stopping the growth of cancer cells. The liposomal formulation allows for a longer circulation time in the bloodstream, potentially increasing tumor exposure to the drug and reducing systemic toxicity.\n\n### Dosage and Administration\n- **Onivyde** is administered intravenously. It\u2019s often given as part of a regimen that includes fluorouracil and leucovorin.\n- Dosage adjustments may be necessary based on patient tolerance and the occurrence of adverse effects.\n\n### Side Effects\nCommon side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1vhywyrFNCW4HLJT3ki0ZKpZ", "custom_id": "140_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d61a5bd60ec2ed4e10f67896ac031265", "body": {"id": "chatcmpl-9St7fkt6lpv5aODvO8pV9fy0q9y1k", "object": "chat.completion", "created": 1716672103, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab (brand name Sarclisa) is a monoclonal antibody used in the treatment of multiple myeloma. Here are key points you should know about this medication:\n\n1. **Mechanism of Action**: Isatuximab targets a specific epitope on the CD38 molecule, which is highly expressed on multiple myeloma cells. By binding to CD38, isatuximab induces antitumor activity through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptotic induction without cross-linking. Additionally, it has immunomodulatory effects.\n\n2. **Indications**: As of the knowledge cutoff in 2023, isatuximab is approved for use in:\n   - Adult patients with relapsed or refractory multiple myeloma, in combination with pomalidomide and dexamethasone (for patients who have received at least two prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_g9ZvCks3tbBvLHMAsLh3K8se", "custom_id": "141_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "35812ed4e5bbcbe4285e30436fa0e7d2", "body": {"id": "chatcmpl-9St7f0Kg023YlMHc8mzQPmpk956mR", "object": "chat.completion", "created": 1716672103, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isotretinoin, commonly known under the brand name Accutane among others, is a potent medication primarily used for the treatment of severe acne, particularly cystic acne that has not responded adequately to other treatments. Below are some important aspects a physician should be aware of when considering isotretinoin therapy:\n\n### Indications\n- **Severe recalcitrant nodular acne**: The primary indication for isotretinoin is severe nodular acne that is resistant to conventional treatments including antibiotics.\n- **Other uses**: It may also be used for treating less severe acne that is persistent or has caused significant scarring.\n\n### Mechanism of Action\nIsotretinoin works by:\n- Reducing the size and secretion of the sebaceous glands.\n- Inhibiting sebaceous gland function.\n- Normalizing skin cell shedding to prevent buildup in the follicles.\n- Anti-inflammatory properties on the skin.\n\n### Administration\n- **Oral**: Isotretinoin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jBjVPe8mKhcFr1xuK7jdTOl8", "custom_id": "142_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e5ff62ac36208765ce9c4a3df8b579c", "body": {"id": "chatcmpl-9St7fEH0qoE5hROU32WxqIfEuml9o", "object": "chat.completion", "created": 1716672103, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib (marketed under the brand name Tibsovo) is an oral medication used primarily in the treatment of certain types of cancer. It is a small molecule inhibitor that targets isocitrate dehydrogenase 1 (IDH1), an enzyme that is mutated in several forms of cancer, including acute myeloid leukemia (AML) and cholangiocarcinoma. By inhibiting this mutated enzyme, ivosidenib can help to block the abnormal cell growth associated with these mutations.\n\n### Indications\n1. **Acute Myeloid Leukemia (AML)**: Ivosidenib is approved for the treatment of adult patients with relapsed or refractory AML with an IDH1 mutation, as detected by an FDA-approved test.\n2. **Cholangiocarcinoma**: It is also approved for the treatment of adults with previously treated locally advanced or metastatic cholangiocarcinoma that have an IDH1 mutation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_vw4diyt6nVcC8cOqEzaK5cT4", "custom_id": "143_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "874109bb0113096bdd51da21e6a296f3", "body": {"id": "chatcmpl-9St7fLMj9wezjjRPB9ZT8HlGZNpSJ", "object": "chat.completion", "created": 1716672103, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixabepilone is a chemotherapy drug used primarily in the treatment of some types of breast cancer. Here are key points that you, as a physician, might need to know:\n\n1. **Mechanism of Action:** Ixabepilone is a microtubule inhibitor, belonging to the class of drugs called epothilones. It works by stabilizing microtubules and thereby inhibiting their depolymerization, leading to cell cycle arrest and apoptosis (cell death) in cancer cells.\n\n2. **Indications:** It is primarily used for the treatment of metastatic or locally advanced breast cancer. Specifically, it has been indicated for use in patients who are resistant to anthracyclines, taxanes, and capecitabine.\n\n3. **Dosage and Administration:** Ixabepilone is administered intravenously. The dosage and treatment schedules may vary based on the patient\u2019s condition, body surface area, and other chemotherapy agents being used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K6L4nlgK55XboXTnwrWJ1ntH", "custom_id": "144_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7dcffea6169a323504c550a2eaf65bc", "body": {"id": "chatcmpl-9St7gNivqiAOm8DEngcKKjUtVmySB", "object": "chat.completion", "created": 1716672104, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib is an oral proteasome inhibitor used primarily in the treatment of multiple myeloma. It is marketed under the brand name Ninlaro. Here are some key points you might find useful as a physician:\n\n1. **Mechanism of Action:**\n   Ixazomib works by inhibiting the 20S proteasome, which is a protein complex that degrades ubiquitinated proteins. Inhibition of proteasomes results in an accumulation of proteins within cells, leading to cell cycle arrest and apoptosis, particularly in cancer cells that have a high rate of protein turnover.\n\n2. **Indications:**\n   - Ixazomib is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy.\n   - It offers the convenience of oral administration, which can be preferable for patients compared to intravenous options.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Q1NXNs0P9jFN2MoqhkmMEt2g", "custom_id": "145_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4e096ac3b5211ce62a59880a29739a82", "body": {"id": "chatcmpl-9St7gg3gc5rc780S3axtu1KHVb93t", "object": "chat.completion", "created": 1716672104, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketoconazole is an antifungal medication used primarily to treat fungal infections, although it has additional clinical uses due to its mechanism of action. Here are several key points about Ketoconazole that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Ketoconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. It interferes with the fungal CYP450 enzymes, which are critical for the conversion of lanosterol to ergosterol.\n\n2. **Spectrum of Activity**: It is effective against a broad range of fungi including dermatophytes and yeasts such as Candida spp. and Malassezia spp. However, its effectiveness can vary depending on the species and the site of infection.\n\n3. **Formulations and Administration**:\n   - **Topical**: Used for conditions like athlete's foot, ringworm, jock itch, and dandruff/seborrheic dermatitis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9bwMTdaWg5aA6C4gSRn8aUnX", "custom_id": "146_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "50d3056a2e68d753f01bdfcebe743a19", "body": {"id": "chatcmpl-9St7gElfSApU5TNiYSMNOiYn0eOwO", "object": "chat.completion", "created": 1716672104, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide is a synthetic analog of somatostatin, a peptide that naturally inhibits the release of several hormones, such as growth hormone (GH), insulin, and glucagon. Lanreotide has similar pharmacologic effects and is primarily used in the management of hormone-related disorders. Here are the key aspects of Lanreotide that you, as a physician, should be aware of:\n\n### Indications\n1. **Acromegaly**: Lanreotide is used for the treatment of patients with acromegaly when surgery or radiotherapy have not been fully successful, or when surgery is not an option. It helps to control excess growth hormone production.\n2. **Neuroendocrine Tumors**: It is indicated for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to inhibit tumor growth and control symptoms related to hormone secretion.\n3. **Carcinoid Syndrome**: Lanreotide can help manage symptoms of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ba87je6o8wFg8omwj8ObK4ED", "custom_id": "147_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8fb2c82507bca3dc48f1170e0ff2868c", "body": {"id": "chatcmpl-9St7gc3wz2JDHXQMUIQjZtPmYoNWj", "object": "chat.completion", "created": 1716672104, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lansoprazole is a proton pump inhibitor (PPI) used primarily to manage gastroesophageal reflux disease (GERD), peptic ulcer disease, and conditions associated with excessive stomach acid production such as Zollinger-Ellison syndrome. Here are key points you should be aware of when considering lansoprazole for treatment:\n\n### Mechanism of Action\nLansoprazole works by inhibiting the H+/K+ ATPase enzyme system (the proton pump) in the gastric parietal cell of the stomach, which reduces the production of gastric acid.\n\n### Indications\n- **Gastroesophageal Reflux Disease (GERD)**: Treatment and maintenance of healing of erosive esophagitis.\n- **Peptic Ulcer Disease**: Used in combination with antibiotics for the eradication of Helicobacter pylori, which, if untreated, can lead to ulcers or gastric cancer.\n- **Zollinger-Ellison Syndrome**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_RUS7wvsShqEn1M1FmNjwFgwY", "custom_id": "148_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d5d1328a4bb295027988b465996d165", "body": {"id": "chatcmpl-9St7hkCjxgrX6xeM3AaTWsjiaisaJ", "object": "chat.completion", "created": 1716672105, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatinib is an oral medication used primarily for the treatment of advanced or metastatic breast cancer, particularly in patients whose tumors overexpress the HER2/neu receptor (human epidermal growth factor receptor 2). Here are several key points about Lapatinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Lapatinib is a tyrosine kinase inhibitor that targets both HER2/neu and epidermal growth factor receptor (EGFR) pathways. By inhibiting these receptors, Lapatinib helps to block the proliferation of cancer cells and can lead to tumor cell death.\n\n2. **Indications**: This drug is typically used in patients with breast cancers that are HER2-positive, often in combination with other chemotherapeutic agents like capecitabine or letrozole. It may be considered after other treatments such as trastuzumab (another HER2-targeted therapy) have been tried without success.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Z7KYQQnpmJ8iymLuKFZwof1X", "custom_id": "149_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f1d303e7c496b543b922b80f8b7ad48d", "body": {"id": "chatcmpl-9St7hzKOwL75mV3iUrPGSjYLUKbIN", "object": "chat.completion", "created": 1716672105, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib, sold under the brand name Vitrakvi, is a medication used in the treatment of cancer, specifically for cancers that have a specific genetic feature known as a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation. This treatment is an example of targeted therapy, which aims to attack specific cancer cells based on their genetic characteristics without affecting normal cells.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:  \n   Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) family, which includes TRKA, TRKB, and TRKC. These kinases are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. Larotrectinib binds to these kinases in their kinase domain and inhibits their activity, which can inhibit the growth of cancer cells.\n\n2. **Indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_leYgthUbeqb6z8aWniZa3kHL", "custom_id": "150_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d76856b3a590f1e20a0244a8dc878ee7", "body": {"id": "chatcmpl-9St7hpukFCe99cIFhCzt1cdOB6CkU", "object": "chat.completion", "created": 1716672105, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide is a medication used primarily in the treatment of certain hematological disorders, including multiple myeloma and myelodysplastic syndromes. Here are some key points you should know about lenalidomide:\n\n1. **Mechanism of Action**: Lenalidomide is an immunomodulatory drug (IMiD) that possesses anti-inflammatory, antiangiogenic, and antineoplastic properties. It modulates the immune system and affects various cytokines and growth factors. It also has direct cytotoxic effects on cancer cells and impacts the tumor microenvironment.\n\n2. **Indications**:\n   - **Multiple Myeloma**: Lenalidomide is approved for the treatment of multiple myeloma, particularly in combination with dexamethasone or as maintenance therapy after stem cell transplantation.\n   - **Myelodysplastic Syndromes (MDS)**: It is specifically used for MDS characterized by deletion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BC1QCRpOMyfeBg52GAICIgAF", "custom_id": "151_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1a5793a4f00e23edc3766bf0ba150bc3", "body": {"id": "chatcmpl-9St7hkmkocloPnED2o0twOy0LbZHu", "object": "chat.completion", "created": 1716672105, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim is a granulocyte colony-stimulating factor (G-CSF) that is used to stimulate the production of white blood cells (neutrophils). It is a recombinant form of human G-CSF and is primarily used to reduce the incidence and duration of neutropenia in patients undergoing myelosuppressive chemotherapy or bone marrow transplantation, and to mobilize hematopoietic stem cells for harvest in peripheral blood.\n\nHere are some key points regarding lenograstim:\n\n1. **Indications**: Lenograstim is generally indicated for the prevention and treatment of neutropenia in cancer patients receiving myelosuppressive chemotherapy and in those undergoing bone marrow transplantation. It is also used to increase neutrophil counts in patients with congenital, cyclic, or idiopathic neutropenia.\n\n2. **Mechanism of Action**: Lenograstim works by binding to specific G-CSF receptors on the surface of hematopoietic stem cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cQcrTYLBP85oVKE1paD9HrrC", "custom_id": "152_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9621d6caac15e1089c01ee66a2edbca7", "body": {"id": "chatcmpl-9St7hGI0zxK0ZWA6F7xRAAHQ8jii1", "object": "chat.completion", "created": 1716672105, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib (marketed under the brand name Lenvima, among others) is a medication used in the treatment of certain kinds of cancer. It is particularly effective as a treatment for differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Here are some key points to consider regarding its use, mechanism of action, side effects, and prescribing information:\n\n### Mechanism of Action\nLenvatinib is a tyrosine kinase inhibitor (TKI) that primarily works by blocking the activities of several receptor tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth growth factor receptor alpha (PDGFR\u03b1), RET, and KIT signaling networks. By inhibiting these pathways, lenvatinib helps in reducing angiogenesis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GPMrPU2tO6K3IErhZvceAvkJ", "custom_id": "153_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "28d86176a6ef9ad7f5b167c6e534c919", "body": {"id": "chatcmpl-9St7iNzxii4gsFwXinQ1Oxae6OoSu", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole, commonly known by the brand name Femara, is a non-steroidal aromatase inhibitor used primarily to treat hormone receptor-positive breast cancer in postmenopausal women. Here is a summary of key information that you, as a physician, might find helpful regarding Letrozole:\n\n### Mechanism of Action:\nLetrozole inhibits the enzyme aromatase, which is responsible for converting androgens into estrogens. By lowering estrogen levels, letrozole can help reduce the growth of hormone receptor-positive breast cancer cells.\n\n### Indications:\n- **Adjuvant treatment:** prescribed for the adjuvant (additional) treatment of postmenopausal women with hormone receptor-positive early breast cancer.\n- **Extended adjuvant treatment:** it may also be indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy.\n- **Advanced breast cancer:** used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eACR2UlWz4QjnV0ROQGuiS2S", "custom_id": "154_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb3ca60d8e654f8cbb4d8581eb82034b", "body": {"id": "chatcmpl-9St7irdh9hTBkwqmOw80IpEFc39Vb", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide, also known as leuprorelin, is a medication used in the treatment of hormone-responsive cancers such as prostate cancer and in conditions like endometriosis, uterine fibroids, and early puberty (central precocious puberty). It is a type of gonadotropin-releasing hormone (GnRH) agonist, which acts by reducing the amount of sex hormones (testosterone and estrogen) the body makes.\n\nHere are some key points you should know about leuprolide:\n\n### Indications\n1. **Prostate cancer**: Used mainly in the management of advanced prostate cancer. It helps to reduce the production of testosterone, which can slow the growth of cancer cells.\n2. **Breast cancer**: Sometimes used in premenopausal women for hormone-sensitive tumors.\n3. **Endometriosis and fibroids**: Helps in reducing the size of endometrial and fibroid tissue by decreasing estrogen levels.\n4. **Central prec"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_UJXfh4yzJ32u8SA2zbZkrhwO", "custom_id": "155_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a9fbe0900c297fe69671611471923d2e", "body": {"id": "chatcmpl-9St7i5BDxsQLy9GB60jaDEpUD1qfp", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is a medication primarily used as an immunomodulatory agent and an anthelmintic (anti-worm agent). Here are some key aspects you should know about Levamisole:\n\n1. **Anthelmintic Use**: Historically, levamisole was used extensively to treat parasitic worm infections in humans; however, due to its side effects, its use in humans has largely been discontinued in many countries. It remains commonly used in veterinary medicine to treat worm infections in animals.\n\n2. **Immunomodulatory Properties**: Levamisole has been shown to enhance immune response, which makes it useful in treating conditions like rheumatoid arthritis, nephrotic syndrome, and as an adjuvant therapy in colorectal cancer. It stimulates various components of the immune system including macrophages and T cells, enhancing their ability to attack cancer cells.\n\n3. **Use in Cancer Treatment**: In the treatment of colon cancer, levamisole"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pFQYdmcCeMx5v4RklnwZkUHp", "custom_id": "156_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "21938d216b4d102962b07982224e10a8", "body": {"id": "chatcmpl-9St7itz6xNGqXKDQRPYyBsikzkT7W", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin, also known as leucovorin calcium, is a chemically reduced derivative of folic acid that is used to diminish the toxic and anti-tumor effects of folic acid antagonists, such as methotrexate. It is also used in combination with fluorouracil to enhance its antitumor activity. Here are some key points about Levoleucovorin for a physician:\n\n1. **Indications**:\n   - **Rescue** after high-dose methotrexate therapy in osteosarcoma.\n   - **Enhancing Antitumor activity** of 5-fluorouracil in the treatment of colorectal cancer.\n   - **Treatment of toxic effects** of inadvertent overdosage of folic acid antagonists or impaired methotrexate elimination.\n\n2. **Mechanism of Action**:\n   - Levoleucovorin is a racemic mixture where the active (6"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BV6N8DAuwAEAD3PDcyByaaEy", "custom_id": "157_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3234c27a83412de988c2d015af63f43d", "body": {"id": "chatcmpl-9St7i4i8gtEF2zldH4JOnd4gSZtsy", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine, also known by its brand name CeeNU among others, is a chemotherapy medication used to treat various types of cancer, including brain tumors, Hodgkin\u2019s lymphoma, melanoma, and lung cancer. Here are some important aspects:\n\n1. **Mechanism of Action**: Lomustine belongs to a class of drugs known as nitrosoureas. It works as an alkylating agent, which means it inhibits cancer cell growth by cross-linking the DNA and RNA, making it impossible for the cancer cells to grow and divide.\n\n2. **Administration**: Lomustine is typically administered orally in the form of capsules. The dosing regimen often involves a single dose taken every 6 weeks, as lomustine is usually given in cycles depending on the patient's response and blood counts.\n\n3. **Side Effects**: Lomustine can lead to various side effects, some of which can be severe. Common side effects include nausea, vomiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TuqPqYyQrMPUg8g1WzV9hoQl", "custom_id": "158_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46de3a919ff1ab256cd3c12d58ba53b9", "body": {"id": "chatcmpl-9St7i67ENsW2HTlmWJgYXjM7wyXs1", "object": "chat.completion", "created": 1716672106, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib, also known by its brand name Lorbrena, is a third-generation anaplastic lymphoma kinase (ALK) inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are several key aspects of lorlatinib that you, as a physician, should be aware of:\n\n1. **Indications**: Lorlatin\u200bib is approved for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.\n\n2. **Mechanism of Action**: Lorlatinib works by inhibiting the activity of ALK tyrosine kinase, which is a driver of tumor growth in some cancers. It is active against most known resistance mutations of ALK and can cross the blood-brain barrier, which is particularly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1BvMRuqEnKez7hJxOt0bFn3j", "custom_id": "159_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa95334c9d6a30e940a8c18507954a4a", "body": {"id": "chatcmpl-9St7jrt96rCQUVhE2ay50asdrOLJu", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate, marketed under the brand name Lutathera, is a targeted radiotherapeutic agent used in the treatment of certain types of neuroendocrine tumors (NETs), specifically those that are somatostatin receptor-positive. As a physician, here are some important aspects to consider regarding its usage, mechanism, and safety profile:\n\n### Indication\nLutetium Lu 177 dotatate is approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. It is typically used in patients with progressive, well-differentiated, metastatic tumors.\n\n### Mechanism of Action\nLutetium Lu 177 dotatate works as a radiolabeled somatostatin analog. The somatostatin analog portion targets and binds to somatostatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AVetJCGjWg1xVbf8vgPRYZY6", "custom_id": "160_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f3307bc4aaf35bb63c185419003128c8", "body": {"id": "chatcmpl-9St7jP2z7OR1TT7PeekTfFchIwyVu", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab is a monoclonal antibody designed for the treatment of certain types of cancers, such as B-cell lymphomas. Here are some key points about tafasitamab that you, as a physician, may find relevant:\n\n1. **Mechanism of Action**: Tafasitamab is a CD19-directed cytolytic antibody. CD19 is a protein expressed on the surface of B-cells, a type of lymphocyte involved in the normal immune response. By targeting CD19, tafasitamab promotes direct cytotoxic effects and induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against cancerous B-cells.\n\n2. **Indications**: As of my last update, tafasitamab (under the brand name Monjuvi, in combination with lenalidomide) is approved by the U.S. Food and Drug Administration (FDA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vpILRaSGNQP7eTyN49HRuL3d", "custom_id": "161_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3da91f2da10d4cbfc55ceafadb4dee58", "body": {"id": "chatcmpl-9St7jGn07MwjbtbAOhlfu4Ip1mMNx", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard, is a chemotherapy agent primarily used in the treatment of cancer. It belongs to the class of alkylating agents, which work by binding to DNA and preventing the cancer cells from growing and dividing. Here are some key points about mechlorethamine you should be aware of as a physician:\n\n1. **Indications:**\n   - Mechlorethamine is most commonly used in the treatment of Hodgkin lymphoma as a component of the MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy regimen.\n   - It is also used in treating other types of non-Hodgkin lymphomas and mycosis fungoides (a type of cutaneous T-cell lymphoma).\n\n2. **Mechanism of Action:**\n   - As an alkylating agent, mechlorethamine forms cross-links in DNA, which can result in cell death. It inter"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_pb8rFmfpRsPh82e7MVpydu6a", "custom_id": "162_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5f1e2b8553eb98a2b404eac7f6884fc9", "body": {"id": "chatcmpl-9St7jj2geosz8tFq9QvGryvFmenxM", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone acetate (MPA) is a synthetic derivative of the naturally occurring female progestin, progesterone. It is used in various formulations and for multiple clinical purposes. Here is an overview of what you, as a physician, might need to know about medroxyprogesterone:\n\n### Uses\n1. **Contraception**: It is used both as an injectable contraceptive (Depo-Provera, typically given every 3 months) and in combination with an estrogen in oral contraceptives.\n2. **Menstrual Disorders**: It can be prescribed for managing amenorrhea or irregular menstrual cycles.\n3. **Endometrial Hyperplasia**: Used in the treatment and prevention of endometrial hyperplasia, particularly in women receiving estrogen replacement therapy.\n4. **Hormone Replacement Therapy (HRT)**: Given together with estrogen as part of HRT, it helps to prevent the estrogen's thickening effect on the ut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MAJyzCERg52tMrfoUBAOl942", "custom_id": "163_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2178e5bc59a479cf737725a4f1e95840", "body": {"id": "chatcmpl-9St7jfYw3Oq6gq0osl4F01ZLnYG4A", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol acetate is a synthetic derivative of the naturally occurring steroid hormone, progesterone. It is primarily used as an appetite stimulant and to treat weight loss and anorexia in patients with AIDS and cancer. Additionally, megestrol is used in the treatment of advanced breast cancer and endometrial cancer. Here are several key points you should be aware of when considering megestrol in clinical practice:\n\n1. **Indications**:\n   - To improve appetite and cause weight gain in cancer and AIDS patients experiencing anorexia or cachexia.\n   - Treatment of advanced breast and endometrial cancers.\n\n2. **Mechanism of Action**: \n   - Megestrol acts as a progestational agent (similar to progesterone), which can directly stimulate the appetite center in the brain leading to increased feelings of hunger and food intake.\n   - It may also exert anti-estrogen effects by decreasing the circulating levels of estrogen through its action on the pituit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_agZz1QkyocKFENmhNjGNnE1Q", "custom_id": "164_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "03d581752c6533c662471b0bd7a4f695", "body": {"id": "chatcmpl-9St7jGOxzxkTOSQoqhp09K1VtvStF", "object": "chat.completion", "created": 1716672107, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is a chemotherapy drug used primarily for treating multiple myeloma and ovarian cancer, among other malignant diseases. It belongs to the nitrogen mustard class of alkylating agents and is available under various brand names, including Alkeran. Here are several important aspects about Melphalan you should be aware of as a physician:\n\n### Mechanism of Action\nMelphalan works by cross-linking guanine bases in double-stranded DNA, leading to breaks in DNA strands which inhibits DNA replication and transcription. This results in cell cycle arrest and ultimately apoptosis (cell death).\n\n### Indications\n- **Multiple Myeloma:** It is often used as part of conditioning regimens before stem cell transplant and for palliative treatment in non-transplant cases.\n- **Ovarian Cancer:** Used in the treatment of epithelial ovarian cancer.\n- **Other Cancers:** It can also be used off-label for other types of cancer such as breast cancer and sarcomas.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SUwA1bbS2ws3Vw1LXKMkvKC3", "custom_id": "165_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62b6face9ce4c5306ceca42afb41fb66", "body": {"id": "chatcmpl-9St7kKM3LDOM8td00FVJwip3mMNjC", "object": "chat.completion", "created": 1716672108, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, also known by its brand name Purinethol among others, is an important medication used primarily in the treatment of cancer and autoimmune diseases. It is a chemotherapy drug that belongs to a class of medications known as purine analogs, which are used to inhibit DNA synthesis and thereby reduce the proliferation of rapidly dividing cells. Here are some key aspects to consider when treating patients with Mercaptopurine:\n\n1. **Indications**: Mercaptopurine is commonly used in the treatment of acute lymphoblastic leukemia (ALL) and is also used in certain autoimmune conditions such as Crohn's disease and ulcerative colitis, especially when patients have not responded to other treatments.\n\n2. **Mechanism of Action**: Mercaptopurine interferes with the metabolism and synthesis of nucleic acids, crucial for the replication of cells, thus it inhibits the growth of cells, particularly those which divide rapidly, such as leukemic cells.\n\n3. **Administration**: It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lrPDF9aalo9YfHEYUOupTQMG", "custom_id": "166_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e4f8e546e8973ac7186f0a5caeacf807", "body": {"id": "chatcmpl-9St7krMDC8leZU9QisG0l8gAu2jur", "object": "chat.completion", "created": 1716672108, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to understand several aspects of Mesna (sodium 2-mercaptoethanesulfonate) due to its specific use and mechanism in clinical settings. Here\u2019s a detailed overview:\n\n### 1. Purpose and Mechanism:\nMesna is primarily used as a chemoprotective agent in oncology. It is employed to prevent hemorrhagic cystitis caused by the administration of cyclophosphamide or ifosfamide, two cytotoxic chemotherapy drugs known for their bladder-toxic side effects. Mesna works by binding to acrolein, a metabolite of these drugs that is harmful to the bladder epithelium. This binding helps to neutralize toxic effects, thereby preventing damage to the bladder lining.\n\n### 2. Administration:\nMesna can be administered orally or intravenously. The route of administration often depends on the chemotherapy regimen. In cases involving high doses of cyclophosphamide or ifosfamide, Mesna"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2Q15XZjxRihS2wnM0p59mTjd", "custom_id": "167_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb4e34a7b7de96ce4f91298a269b41ca", "body": {"id": "chatcmpl-9St7kcN0MtDhVYNSRZU25crUQx4zM", "object": "chat.completion", "created": 1716672108, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s crucial to have a comprehensive understanding of methotrexate due to its wide application in both oncologic and rheumatologic conditions. Here\u2019s an overview of the key points:\n\n### 1. Mechanism of Action\n- **Antimetabolite:** Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase (DHFR), which is critical in the DNA synthesis pathway. By limiting the production of tetrahydrofolate, methotrexatee effectively reduces the synthesis of purine nucleotides and thymidylate, leading to the inhibition of DNA synthesis, repair, and cellular replication.\n\n### 2. Clinical Uses\n- **Oncology:** Used to treat various types of cancers such as acute lymphoblastic leukemia, breast cancer, and non-Hodgkin\u2019s lymphoma.\n- **Rheumatology:** Commonly prescribed for rheumatoid arthritis, psoriatic arthritis, and severe"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1g0DIfXl9Onjwkn0BX5qms1M", "custom_id": "168_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c0e6eb2318f7c9991b6611729bd0cec5", "body": {"id": "chatcmpl-9St7loEOADMYuaDoEOmcDTvG3p0qk", "object": "chat.completion", "created": 1716672109, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen (also known as 8-methoxypsoralen, 8-MOP) is a medication used in conjunction with UVA radiation therapy (PUVA therapy) for the treatment of severe psoriasis, eczema, vitiligo, and some types of cutaneous T-cell lymphoma, including mycosis fungoides.\n\nHere are the key points a physician should know about Methoxsalen:\n\n### Pharmacodynamics:\n- Methoxsalen is a photoactive substance that is part of the psoralen group. It acts by intercalating into DNA and, upon exposure to UVA light, forms cross-links between adjacent pyrimidine bases. This cross-linking inhibits DNA synthesis and cellular replication, particularly in rapidly dividing cells.\n\n### Administration:\n- Methoxsalen is available in oral and topical formulations. The oral form should be taken with food or milk to enhance absorption.\n- The timing of UVA exposure after administration is crucial:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5C3LoTamRNc7ssAgrnOLU9xR", "custom_id": "169_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f305550d7d34d598d302186d3278101c", "body": {"id": "chatcmpl-9St7lcHGsteXrtmK591WkstYx56rW", "object": "chat.completion", "created": 1716672109, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a corticosteroid medication used to suppress the immune system and reduce inflammation. It is similar to a natural hormone produced by the adrenal glands and has numerous applications in the management of various inflammatory and autoimmune conditions. Here are some key points about methylpredniplesolone that you, as a physician, might find relevant:\n\n### Therapeutic Uses\n- **Allergic Reactions:** Severe allergic reactions, including anaphylaxis.\n- **Dermatological Diseases:** Such as pemphigus and severe psoriasis.\n- **Gastrointestinal Diseases:** Including Crohn\u2019s disease and ulcerative colitis.\n- **Endocrine Disorders:** Management of adrenocortical insufficiency.\n- **Hematologic Disorders:** Used in conditions like thrombocytopenic purpura.\n- **Neurological Disorders:** Management of acute exacerbations of multiple sclerosis.\n- **Respiratory Diseases:** Helpful in managing severe asthma and COP"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BrTH477aUBKJ5STcNLqyDSk5", "custom_id": "170_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3de202a3db8aaec37d2d4e4ea7e3d001", "body": {"id": "chatcmpl-9St7lcmfwUzmqWuGbDtueGnQWhjWs", "object": "chat.completion", "created": 1716672109, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is a kinase inhibitor used primarily in the treatment of certain types of blood cancers. Here are important aspects that you, as a physician, should be aware of regarding midostaurin:\n\n1. **Indications**:\n   - **Acute Myeloid Leukemia (AML)**: Midostaurin is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test. It is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.\n   - **Systemic Mastocytosis**: Midostaurin is also used for treating adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.\n\n2. **Mechanism of Action**:\n   - Midostaurin inhibits multiple receptor tyrosine kinases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_kHvRuw0sJmraeJkuPuflRJVk", "custom_id": "171_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3dec69cc2a71d898364ac6c50a11bfbd", "body": {"id": "chatcmpl-9St7myksUEf167sb1vjZw0upWJsAO", "object": "chat.completion", "created": 1716672110, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin C is an antineoplastic antibiotic derived from Streptomyces caespitosus. It has potent cytotoxic activity often used in cancer treatment. Here are key points that you, as a physician, should be aware of regarding Mitomycin:\n\n### Mechanism of Action\n- **DNA Cross-linking**: Mitomycin acts primarily by cross-linking DNA, which inhibits DNA synthesis and function. It generates reactive oxygen species and causes single-strand and double-strand DNA breaks, which ultimately lead to apoptosis of cancer cells.\n\n### Indications\n- **Cancers**: Primarily used in the treatment of gastric and pancreatic cancer. It\u2019s also used in the management of non-small cell lung cancer, breast cancer, and as a part of adjuvant therapy in bladder cancer.\n- **Ophthalmic Use**: Mitomycin C has applications in ophthalmology as well, such as in trabeculectomy for glaucoma to prevent scarring"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IpbPcLdQWEslw71x2ix2rwj2", "custom_id": "172_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "87e7edb76fb5b3954c9b00199d8ef334", "body": {"id": "chatcmpl-9St7mIcoyJLPWQpPuVaVbKrZA4rBn", "object": "chat.completion", "created": 1716672110, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane is a medication predominantly used in the treatment of adrenocortical carcinoma, a rare type of cancer that affects the adrenal glands. Since you are a physician, here are essential aspects of Mitotane you should be familiar with:\n\n1. **Mechanism of Action**: Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. It has cytotoxic activity against adrenocortical cells, leading to adrenal atrophy and reduced hormone production.\n\n2. **Indications**:\n   - **Primary Use**: Treatment of inoperable adrenocortical carcinoma.\n   - It may also be used off-label to help control hypercortisolism in Cushing\u2019s Syndrome when surgery is not feasible.\n\n3. **Administration Guidelines**:\n   - Mitotane is taken orally and can be taken with or without food; however, taking it with food may help increase its absorption and reduce gastrointestinal side effects.\n   - The dosing is highly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_iUo75NIG5INfa8gEoNM8JIPE", "custom_id": "173_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee0cf7d574367b40b32631946f1fff24", "body": {"id": "chatcmpl-9St7mM6xlToLamIHUIi6nEu7ekBMQ", "object": "chat.completion", "created": 1716672110, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is a type 2 topoisomerase inhibitor used as a chemotherapy medication to treat certain types of cancers, including acute myeloid leukemia, non-Hodgkin's lymphoma, and prostate cancer. It can also be used in treating multiple sclerosis, specifically secondary-progressive and progressive-relapsing forms. Here are some key points you should consider when dealing with Mitoxantrone:\n\n### Pharmacology\n- **Mechanism of Action:** Mitoxantrone disrupts DNA replication and repair by intercalating into DNA and inhibiting topoisomease II enzyme activity. This leads to DNA strand breaks, inhibition of RNA and protein synthesis, and ultimately induces apoptosis in rapidly proliferating cells.\n\n### Indications\n- **Cancer:** Used in the treatment of certain leukemias, lymphomas, and metastatic hormone-refractory prostate cancer.\n- **Multiple Sclerosis:** Approved for reducing neurologic disability and/or the frequency of clinical rel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iZPWWkDuCREe05MpPFU2J3wn", "custom_id": "174_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5bbfe841488730d7c3c840c926d4fe3a", "body": {"id": "chatcmpl-9St7m40QAZ1d6W3IOx7dNBhGk4Ss4", "object": "chat.completion", "created": 1716672110, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumaphas been used primarily to treat certain types of blood cancers. Here are several key points about mogamulizumab:\n\n1. **Indications:**\n    Mogamulizumab, marketed under the brand name Poteligeo, is approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS), which are types of cutaneous T-cell lymphomas (CTCL).\n\n2. **Mechanism of Action:**\n    Mogamulizumab is a humanized monoclonal antibody that targets CC chemokine receptor 4 (CCR4). CCR4 is frequently overexpressed on the surface of tumor cells in certain hematologic malignancies and solid tumors. By binding to CCR4, mogamulizumab mediates antibody-dependent cellular cytotoxicity (ADCC), helping to eliminate malignant cells.\n\n3. **Administration:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LnWxGqFZDQLMQn6vQK8VONt7", "custom_id": "175_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a10ea0bfb0543846bcdf7e1d7be58a10", "body": {"id": "chatcmpl-9St7nFGYDNloDPuW81y85L9XKWcVI", "object": "chat.completion", "created": 1716672111, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox-tdfk, sold under the brand name Lumoxiti, is an innovative medication used primarily for the treatment of certain types of cancer. Specifically, it is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with hairy cell leukemia (HCL) who have already received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Here are key points you should know about this medication:\n\n### Mechanism of Action\nMoxetumomab pasudotox is a recombinant immunotoxin that consists of a monoclonal antibody targeting CD22 (a protein commonly expressed on the surface of B cells and overexpressed in HCL cells) linked to a fragment of pseudomonas exotoxin (PE38). This drug binds to the CD22 antigen on B cells, is internalized, and the toxin portion inhibits protein synthesis, leading to apoptotic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_y0wJ3JSs63ydS3ZIiF6ZcXEU", "custom_id": "176_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a309cf234ff5719180aaab54830e2837", "body": {"id": "chatcmpl-9St7nVRC4UoTYjw69ZP4ovVBA0EfB", "object": "chat.completion", "created": 1716672111, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) used primarily for the prevention and treatment of thromboembolic disorders. As a physician, here are some important aspects you should know about Nadroparin:\n\n1. **Mechanism of Action**: Nadroparin works by inhibiting Factor Xa and Factor IIa with a higher ratio of anti-Factor Xa to anti-Factor IIa activity, typical of low molecular weight heparins. This action reduces the ability of blood to clot.\n\n2. **Indications**: It is commonly used for the prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic or general surgery. It's also used in the treatment of DVT with or without pulmonary embolism, and in the prevention of clotting during hemodialysis.\n\n3. **Administration**: Nadroparin is administered subcutaneously. The dose depends on the patient's body weight, the condition being treated, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PehqGi0Sv82sfsI8u1dP49Dw", "custom_id": "177_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df2029279b7f5f44e72e3c985a04532f", "body": {"id": "chatcmpl-9St7nHvYNIVY1hU430Bvlcd8tzjEK", "object": "chat.completion", "created": 1716672111, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab (trade name Portrazza) is a recombinant human IgG1 monoclonal antibody used as a cancer treatment. It specifically targets the epidermal growth factor receptor (EGFR), a receptor found on the surface of many tumor cells as well as normal cells. Here are some key points you should be aware of:\n\n1. **Indications:**\n   Necitumumab is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.\n\n2. **Mechanism of Action:**\n   The drug binds to the extracellular domain of the EGFR, blocking the binding of the natural ligands (EGF and TGF-alpha). This inhibition prevents the activation of the receptor and downstream signaling pathways that are involved in the proliferation and survival of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_LezBsP9P4L1YSqBRi88lzpM8", "custom_id": "178_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "285950b80f089048cb2524fe22c223b2", "body": {"id": "chatcmpl-9St7nqTRnyVtGJ8tk2qAtG50X0p8i", "object": "chat.completion", "created": 1716672111, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is a chemotherapy medication used primarily in cancer treatment. As a platinum-based anticancer drug, it is chemically similar to cisplatin but was designed to reduce some of the nephrotoxicity and gastrointestinal toxicity associated with cisplatin. Nedaplatin is widely used in the treatment of various cancers, including ovarian, bladder, esophageal, lung, and head and neck cancers. Here are several important aspects to consider:\n\n1. **Mechanism of Action**:\n   Nedaplatin works by causing cross-links in DNA, preventing DNA replication and transcription, which leads to cell death. Its action is similar to other platinum compounds through the formation of platinum-DNA adducts.\n\n2. **Usage**:\n   Depending on the specific type of cancer, nedaplatin can be used alone or in combination with other anticancer agents. It's important to consult specific treatment guidelines or clinical trials for optimal combinations and dosing regimens.\n\n3. **Administration**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WZkBwzEW8843ppmbOO9oYOk6", "custom_id": "179_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "809a99abd0691e33c6cb415df846f6f3", "body": {"id": "chatcmpl-9St7nnFwTciXbOnQo3QgdhZnJ7equ", "object": "chat.completion", "created": 1716672111, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nelarabine is a chemotherapeutic agent used mainly in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are key points about nelarabine that you as a physician might need to know:\n\n1. **Mechanism of Action**:\n   Nelarabine is a prodrug of ara-G (9-beta-D-arabinofuranosylguanine), which is a nucleoside analog. Once nelarabine is administered, it gets converted into ara-G through demethylation, and subsequently to ara-GTP. Ara-GTP accumulates inside leukemic cells and inhibits DNA synthesis, thereby leading to cell death.\n\n2. **Indications**:\n   Nelarabine is approved for use in patients who have not responded to or have relapsed after receiving standard chemotherapy treatments for T-ALL and T-LBL. Its efficacy in B-cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qu8jgzEnQkMq8cX6TM03ZyQG", "custom_id": "180_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd340398cbdf4ea39625923679b13de9", "body": {"id": "chatcmpl-9St7oI8gKEoWZsbZeueiK4yphqZb0", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib (brand name Nerlynx) is an oral tyrosine kinase inhibitor that is primarily used in the treatment of breast cancer. Here are some important aspects about neratinib that you, as a physician, might need to know:\n\n1. **Indications**: Neratinib is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. It is also used for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.\n\n2. **Mechanism of Action**: Neratinib works by irreversibly binding to HER1, HER2, and HER4, which leads to inhibition of the kinase activity of these receptors. The inhibition of these receptors prevents downstream signaling pathways that promote cell growth and survival, particularly in HER2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wEctVk9VzREfJDceyWViRmuW", "custom_id": "181_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "431d2e729e5eb6c1113f47ead42e18fc", "body": {"id": "chatcmpl-9St7oqzyuzegmtukN2Pxw7GxEj0F2", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilotinib is an oral medication used primarily for the treatment of a type of blood cancer known as chronic myeloid leukemia (CML). Here are several important aspects about Nilotinib that you, as a physician, should be aware of:\n\n### 1. **Mechanism of Action**\nNilotinib works by inhibiting the Bcr-Abl tyrosine kinase, an abnormal protein produced by the Philadelphia chromosome that is found in most cases of CML. This inhibition prevents the proliferation and survival of leukemia cells.\n\n### 2. **Indications**\nNilotinib is approved for the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase. It is also indicated for patients who are resistant to or have intolerance of prior therapy including imatinib.\n\n### 3. **Administration and Dosage**\n- **Dosage:** It is typically taken at 300 mg twice daily for newly diagnosed patients and may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wdqy8cz7DpjyznnAuRvvoMxj", "custom_id": "182_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ec5fc79e763e3bc1ce74ae9828ac556", "body": {"id": "chatcmpl-9St7oi9MFqJi0VIbku6kIURaSEtlT", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen primarily used in the treatment of prostate cancer. Here are some key points you should know about nilutamide:\n\n1. **Mechanism of Action**: Nilutamide works by blocking androgen receptors and inhibiting testosterone and dihydrotestosterone from promoting the growth of prostate cancer cells. This helps in controlling the progression of the disease.\n\n2. **Usage**: It is specifically used in combination with surgical or medical castration for the treatment of metastatic prostate cancer. This is to block the effects of the adrenal androgens that remain after castration.\n\n3. **Dosage and Administration**: The dose and treatment schedule can vary, but typically, it involves an initial loading dose followed by a maintenance dose. It is important to adhere strictly to the prescribed regimen to optimize the therapeutic effects and minimize side effects.\n\n4. **Side Effects**: Common side effects include hot flashes, alcohol intolerance (resulting in facial flushing, nausea, and malaise"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FYPTxTPxUF6kGlUYR3ChnA98", "custom_id": "183_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e27675cd307e1f4379cfabd79e78076", "body": {"id": "chatcmpl-9St7oAj4GqR4cGJKaq60QubsrgEm2", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine (also known by its abbreviation ACNU) is a nitrosourea compound used primarily as a chemotherapeutic agent. It is often used in the treatment of various types of cancer, including brain tumors, malignant melanoma, and Hodgkin's lymphoma, among others. Here\u2019s an overview of key points regarding nimustine that could be useful for a physician:\n\n1. **Mechanism of Action**:\n   - Nimustine is an alkylating agent. It works by cross-linking DNA and RNA, thereby inhibiting DNA synthesis. This disrupts the cancer cells' ability to reproduce and repair, ultimately leading to cell death.\n\n2. **Pharmacokinetics**:\n   - After administration, nimustine is known to cross the blood-brain barrier, which makes it particularly useful in treating brain tumors. It undergoes hepatic metabolism and has a relatively short plasma half-life.\n\n3. **Administration**:\n   - Nimustine is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_XGzPEg1niBYheGUFuSH0fK8N", "custom_id": "184_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c42181867aa0f101ef58ac30d9c94070", "body": {"id": "chatcmpl-9St7o2hbXv775PPS0jiggJcbKbmXb", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib, marketed under the brand name Ofev among others, is a medication widely used in the management of idiopathic pulmonary fibrosis (IPF) and other lung diseases characterized by fibrosis. It has also been approved for the treatment of certain types of non-small cell lung cancer (NSCLC) and some chronic fibrosing interstitial lung diseases with a progressive phenotype. Here are several key points about Nintedanib that you may find useful as a physician:\n\n**1. Mechanism of Action:**\nNintedanib is an intracellular inhibitor that targets multiple tyrosine kinases, including those involved in the vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, and platelet-derived growth factor (PDGF) receptors. These pathways are implicated in the pathological processes of fibrosis, including proliferation and migration of fibroblasts and angiogenesis.\n\n**2. Indications:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_doGtUg9fkwmx8jD9TJu9o58L", "custom_id": "185_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bf651e14bdcf6287cdf48eb8998476d5", "body": {"id": "chatcmpl-9St7oZTeTg3z0y9fEYT2TWxrFAwNC", "object": "chat.completion", "created": 1716672112, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib is an oral anticancer medication used primarily in the treatment of ovarian, fallopian tube, or primary peritoneal cancer. Here are the key points you should know as a physician:\n\n1. **Mechanism of Action**: Niraparib is a PARP (poly (ADP-ribose) polymerase) inhibitor. PARP enzymes play a crucial role in the repair of single-stranded DNA breaks. By inhibiting PARP, niraparib causes DNA damage to accumulate, which ultimately leads to cancer cell death. This is particularly effective in cells that are already compromised in their ability to repair DNA due to defects in BRCA1 or BRCA2.\n\n2. **Indications**: It is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Additionally, it has received approval for the treatment of advanced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XWvivUcXR2OPfDlJogoVBq5J", "custom_id": "186_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1997132a46f0edfda9eead2a2604b600", "body": {"id": "chatcmpl-9St7pz4vyLhtaRbgKwk9DPt0OUjAN", "object": "chat.completion", "created": 1716672113, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab (marketed under the brand name Opdivo) is a medication used primarily in oncology, acting as an immune checkpoint inhibitor. It is a monoclonal antibody that specifically targets and blocks the programmed cell death-1 (PD-1) receptor, found on T cells. Here's what you, as a physician, should know about Nivolumab:\n\n### Mechanism of Action:\nNivolumab works by inhibiting the PD-1 receptor, a protein on the surface of T cells, which is normally involved in decreasing the immune system\u2019s response. By blocking PD-1, Nivolumab prevents the cancer cells from using the PD-1 pathway to suppress the immune response, thereby allowing the immune system to recognize and attack cancer cells.\n\n### Indications:\nNivolumab has been approved for use in several types of cancer, including but not limited to:\n- Metastatic melanoma\n- Non-small cell lung cancer (NSCL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_osCPR8lsZhexTMhr1n5wOmWX", "custom_id": "187_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62368abc3b8b19765285664374368bef", "body": {"id": "chatcmpl-9St7pxSrwVx7z1ajd95b9U7a7Vdvp", "object": "chat.completion", "created": 1716672113, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Non-pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin that is encapsulated within liposomes. This formulation alters the distribution of the drug in the body, which can reduce some of the toxicity typically seen with conventional doxorubicin while preserving its anti-cancer efficacy. Here are key points you should know about non-pegylated liposomal doxorubicin:\n\n**1. Mechanism of Action:**\n   - Similar to traditional doxorubicin, non-pegylated liposomal doxorycin works by intercalating DNA strands which inhibits the replication of DNA and promotes apoptosis in rapidly multiplying cancer cells.\n\n**2. Pharmacokinetics:**\n   - Encapsulation in liposomes changes the pharmacokinetics of doxorubicin. The liposomal shell helps in prolonging the circulation time of the drug and allows for a more targeted delivery to tumor cells by exploiting the enhanced permeability and retention (EPR) effect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_d3UiPGU3DaGBoBoUpZSEtGRg", "custom_id": "188_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d2874faa76e6e3c1d48b7efecf9c990e", "body": {"id": "chatcmpl-9St7qT0h90vZpk5dB1Hs4Iur1QndD", "object": "chat.completion", "created": 1716672114, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone, known by its trade name Nilevar, is an anabolic steroid developed in the 1950s. It is a synthetic derivative of testosterone and was used primarily for its tissue-building properties. Here are some important points you should know about Norethandrolone:\n\n1. **Medical Uses**: Historically, norethandrolone was used to treat various medical conditions such as chronic debilitating diseases, severe burns, cancer-associated cachexia, and specific types of anemia. It was also used to promote muscle mass and tissue growth in patients who were underdeveloped or had malnutrition.\n\n2. **Mechanism of Action**: As an anabolic steroid, norethandrolone helps increase the production of protein within cells, particularly in skeletal muscles. It also aids in the retention of nitrogen, which enhances the growth of muscle tissue and may improve the production of erythropoietin in the kidneys, thereby increasing hemoglobin and red blood"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JXO9DbztQlsNYh6WmPti3VwQ", "custom_id": "189_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a6abd2af907f998bec541c9cda4bb84a", "body": {"id": "chatcmpl-9St7qaMOLvTjBKkfBYq8zEe2g3Vx3", "object": "chat.completion", "created": 1716672114, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Obinutuzumab is a monoclonal antibody used primarily in the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is marketed under the brand name Gazyva. As a physician, here are some key points you should be aware of when considering or administering obinutuzumab:\n\n1. **Mechanism of Action**: Obinutuzumab is a type II anti-CD20 monoclonal antibody. It binds specifically to the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding, it induces apoptosis and mediates B-cell lysis through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: It is approved for use in combination with chlorambucil for patients with previously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_iwM2WlOmVgrc9GsfA9iohNTf", "custom_id": "190_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a4fa54420dacca1cd27cfed252cb83a8", "body": {"id": "chatcmpl-9St7qyE2CWrfukJyvir7meb7PMsER", "object": "chat.completion", "created": 1716672114, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic octapeptide analog of somatostatin, a naturally occurring inhibitory hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with somatostatin receptors. Octreotide's primary actions mimic those of natural somatostatin, though it has a longer duration of action.\n\nHere are key points about octreotide that you, as a physician, might find important:\n\n### Mechanism of Action:\n- Octreotide inhibits the secretion of a variety of hormones, including growth hormone (GH), thyroid-stimulating hormone (TSH), and certain gastrointestinal hormones such as gastrin, serotonin, insulin, glucagon, and secretin. It achieves this by binding to somatostatin receptors (primarily sst2 and sst5 subtypes), leading to reduced hormone release.\n\n### Indications:\n- **Acromegaly:** It is effective in reducing GH and IGF-1 levels in patients with ac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_NRRvrUx9v9hQhVDILtDPoQHD", "custom_id": "191_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad3aad9fe79d489cfdb12a4c3c83bf75", "body": {"id": "chatcmpl-9St7qHniwZ3652z4UaB3HdBnpld7g", "object": "chat.completion", "created": 1716672114, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide long-acting release (LAR) is a pharmaceutically extended-release formulation of octreotide, which is a synthetic octapeptide analog of somatostatin. It has a broad range of applications in medicine, particularly due to its inhibitory effects on certain hormones and secretion processes. Here are key aspects you should be aware of regarding Octreotide LAR:\n\n### Indications\n1. **Acromegaly** - Octreotide LAR is primarily used for long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy or for whom these therapies are not suitable. It helps to reduce growth hormone (GH) and IGF-1 levels.\n2. **Neuroendocrine Tumors** - It is effective for the management of symptoms associated with functional gastroenteropancreatic neuroendocrine tumors, like carcinoid tumors, to control diarrhea and flushing episodes.\n3. **Vasoactive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_q6t53zUMhFFW1JnqZNjTh90o", "custom_id": "192_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0814411845fdc1ce9dbcb803da23236e", "body": {"id": "chatcmpl-9St7r0WXGcoIzTvrSZEEHxDEijR8o", "object": "chat.completion", "created": 1716672115, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a monoclonal antibody used primarily for its immunomodulatory effects in the treatment of diseases like chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). Below are some of the key points you should know about ofatumumab, including its mechanisms, uses, administration, and safety profile:\n\n### Mechanism of Action\n- Ofatumumab targets CD20, a surface antigen found on pre-B and mature B lymphocytes. By binding to CD20, ofatumumab induces B-cell lysis through mechanisms including complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n- Its mechanism is similar to other CD20-targeting antibodies like rituximab, but it binds to a different epitope on the CD20 molecule, which may influence its activity and patient response.\n\n### Indications\n#### 1. **Chronic Lymphocytic Leukemia (CLL)**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PtGpfh5b6ttTSn3GLowGhjZ1", "custom_id": "193_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca320ce83d1a63caec7b460dbfcce64a", "body": {"id": "chatcmpl-9St7rbPsc9OBklgf8tmJGAJfx1uhO", "object": "chat.completion", "created": 1716672115, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib (brand name Lynparza) is a targeted therapy medication used primarily in oncology, specifically for the treatment of certain types of cancers associated with defective DNA repair mechanisms due to mutations in the BRCA1 and BRCA2 genes. Here are important aspects of Olaparib that you, as a physician, might need to know:\n\n1. **Mechanism of Action**:\n   Olaparib belongs to a class of drugs known as PARP inhibitors. PARP (poly ADP-ribose polymerase) is an enzyme that helps repair DNA damage in cells. By inhibiting PARP, Olaparib causes DNA damage to accumulate in cancer cells, ultimately leading to cell death, particularly in cells that are already compromised genetically by BRCA mutations.\n\n2. **Indications**:\n   - **Ovarian Cancer**: It is approved for the treatment of advanced ovarian cancer in patients who have received previous chemotherapy and have BRCA mutations (either ger"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_p92bL84Jp41Y3AaUhX5EO4IP", "custom_id": "194_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "044f3294b9ad100eaa34702bd42dfbd5", "body": {"id": "chatcmpl-9St7r6YYrNhCQkvYSn0N0jTZPxJJ3", "object": "chat.completion", "created": 1716672115, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the latest available information, olaratumab is a monoclonal antibody that was designed to target the platelet-derived growtha ctornor (PDGFR-\u03b1), with the intention of disrupting tumor growth and angiogenesis in cancer.\n\nHere are some key points about olaratumab for a medical physician:\n\n1. **Indications**: Olaratumab was initially approved by the FDA in 2016 for use in combination with doxorubicin for the treatment of certain patients with soft tissue sarcoma (STS) who could not be cured with radiotherapy or surgery and who had not received prior chemotherapy for metastatic disease. However, later large-scale clinical trials (specifically, the ANNOUNCE trial) failed to show a clinical benefit. As a result, the drug was withdrawn from the market, and the FDA officially removed its approval in 2020.\n\n2. **Mechanism of Action**: Olaratumab binds to PDGFR-\u03b1 and inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2Tf0lHhh1rhKThWFWRRlStC8", "custom_id": "195_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3896978ac2151a91dc04978d9b8a5470", "body": {"id": "chatcmpl-9St7rjrqqxy6PIVBJrB4PyLvZbe2a", "object": "chat.completion", "created": 1716672115, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, marketed under the name Synribo, is a medication used in the treatment of chronic myeloid leukemia (CML). Here are some key points you need to know about omacetaxine as a physician:\n\n1. **Mechanism of Action**: Omacetaxine works by a dual mechanism of action. Primarily, it acts as a protein translation inhibitor by binding to the A-site cleft of the ribosome, thus inhibiting the initial elongation step of protein synthesis. This action is different from tyrosine kinase inhibitors (TKIs) which target the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome abnormality in CML.\n\n2. **Indications**: Omacetaxine is approved for the treatment of adult patients with chronic or accelerated phase CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors. This makes it a valuable option for patients who do not respond"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xlLZJMkoEW6wy9Ka6cxWIlBL", "custom_id": "196_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dfe6818d24f8640767ca40a6413464aa", "body": {"id": "chatcmpl-9St7sSy75pomQLjn78OMVvofdO1wX", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omeprazole is a widely used medication, primarily prescribed to treat gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions involving excessive stomach acid production. As a physician, here are some key points you should know about omeprazole:\n\n### 1. **Mechanism of Action**\n   Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) in the gastric parietal cells. This action significantly reduces the production of stomach acid.\n\n### 2. **Indications**\n   - **Gastroesophageal Reflux Disease (GERD)**: For the treatment of symptomatic GERD and for long-term management of healed esophagitis to prevent relapse.\n   - **Peptic Ulcer Disease (PUD)**: Used for the treatment of gastric and duoden"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GIxJwIwkNySHvK9whNMONSJD", "custom_id": "197_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9c8d30500507c066ea2b220e8aa2aa2e", "body": {"id": "chatcmpl-9St7su1xNJ4sIZxGTuAbnNkecqfR1", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib (brand name Tagrisuo) is a medication used in the management of specific types of non-small cell lung cancer (NSCLC). Here are some key points about Osimertinib that you, as a physician, may find helpful:\n\n1. **Mechanism of Action**: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It selectively inhibits both EGFR tyrosine kinase activity and the T790M mutation, which is a common mutation in EGFR that can cause resistance to other EGFR inhibitors.\n\n2. **Indications**:\n   - **First-line treatment** for patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\n   - For the treatment of patients with NSCLC who have progressed on or after EGFR TKI therapy and have the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BlqSCTkBWeIPSpJaWuRAZtWj", "custom_id": "198_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1dc04ea096948c1f7a514e4ceffbb0a1", "body": {"id": "chatcmpl-9St7s2hgXfAzOEoNYXhROmEQS1xhg", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. Here are some key points every physician should know about Oxaliplatin:\n\n### Mechanism of Action\nOxaliplatin works by forming platinum-DNA adducts in cancer cells which inhibit DNA synthesis and transcription, leading to cell death. Unlike other platinum compounds, oxaliplatin exhibits activity partly through the formation of inter- and intra-strand DNA crosslinks.\n\n### Indications\n- **Colorectal Cancer:** Oxaliplatin is most commonly used as part of the FOLFOX regimen (combined with fluorouracil and leucovorin) for the treatment of advanced colorectal cancer. It is used in both adjuvant therapy for patients with stage III colon cancer and for the treatment of metastatic colorectal cancer.\n- It may also be used in other chemotherapeutic combinations and for other cancers based on clinical trials and off-label"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PXdQ73XDmSvW1LXS6naik4Cj", "custom_id": "199_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52812e94084d693ec3d28048fcff2125", "body": {"id": "chatcmpl-9St7sU5WfLfIlrp78zdynqFgiRR2e", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel nanoparticle albumin-bound, known commercially as Abraxane, is a novel formulation of the chemotherapy drug paclitaxel that is bound to albumin, a human protein. This formulation was developed to improve the solubility of paclitaxel and enable its delivery without the solvents used in traditional formulations, which are often responsible for causing significant side effects such as hypersensitivity reactions.\n\nHere are some key points you should know about Paclitaxel nanoparticle albumin-bound:\n\n### Mechanism of Action\nLike traditional paclitaxel, the albumin-bound version works by stabilizing microtubules and preventing them from depolymerizing, which inhibits cell division and promotes apoptosis. The binding to albumin allows for a more favorable distribution of the drug into the tumor through enhanced permeability and retention effect.\n\n### Indications\nPaclitaxel nanoparticle albumin-bound is approved by the FDA for:\n- Met"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9WFNL9u7xh3mKKgDLMOoVByH", "custom_id": "200_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46a56ed9d3308a92b83d496996049184", "body": {"id": "chatcmpl-9St7sFXMMonqG8PCs472CRDhBQls4", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is a chemotherapy medication commonly used in the treatment of various cancers. It operates as a mitotic inhibitor, disrupting the normal process of cell division. Here are several key aspects of Paclitaxel that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   - Paclitaxel promotes microtubule assembly from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stabilization results in the inhibition of mitosis in cells, leading to cell death.\n\n2. **Indications**:\n   - Paclitaxel is principally used for the treatment of ovarian cancer, breast cancer, lung cancer, and Kaposi\u2019s sarcoma. It may also be used for other types of cancers as part of research protocols or in special circumstances.\n\n3. **Administration**:\n   - It is typically administered intravenously, and the dosage depends on the type of cancer,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_u8VkpvuyEvfqsDn65PkxKRhs", "custom_id": "201_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c0ccc03aed41effec016804933886c82", "body": {"id": "chatcmpl-9St7t77is9qibmQwcoex41a0qBwm4", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is a medication of interest in the field of oncology, specifically for the treatment of certain hematologic disorders. Here are some key points about Pacritinib that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pacritinib is an oral kinase inhibitor with activity against Janus-associated kinases (JAK) JAK2 and FLT3. Inhibition of these kinases interrupts signaling pathways that are crucial for the growth and development of certain types of cancer cells, particularly those involved in myelofibrosis.\n\n2. **Indications**: Pacritinib is primarily investigated for the treatment of myelofibrosis, a chronic disorder characterized by the scarring of bone marrow which disrupts the body's ability to produce blood cells. It may be particularly beneficial in patients with thrombocytopenia (low platelet levels) associated with myelofibrosis.\n\n3. **Efficacy and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_E33aCDNQ68wydUOzgOuhxKZA", "custom_id": "202_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee59fea616a95bc1e54b81e41dc09ef4", "body": {"id": "chatcmpl-9St7soNnKD1XvpicqgEPjXZVqEAb4", "object": "chat.completion", "created": 1716672116, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib is a medication used primarily in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is an oral drug that functions as a specific inhibitor of cyclin-dependent kinases (CDK) 4 and 6, which are enzymes involved in the proliferation of cancer cells. Here are some key points about Palbociclib that you, as a physician, might find relevant:\n\n1. **Indications**: Palbociclib is approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women or men with HR+/HER2- advanced or metastatic breast cancer. It is also approved for use with fulvestrant in patients with HR+/HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy.\n\n2. **Mechanism of Action**: By inhibiting CDK4 and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QCJau8KjjpxMXcxHbdDc8oZ4", "custom_id": "203_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52132e19336404c714ad7056c3674605", "body": {"id": "chatcmpl-9St7tmfZzt832OlVzc1TXpgVdU4jK", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab (brand name Vectibix) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points that you, as a physician, should know about Panitumumab:\n\n1. **Mechanism of Action**: Panitumumab targets and binds to the epidermal growth factor receptor (EGFR) on the surface of cancer cells. EGFR is involved in the growth and spread of cancer cells. By binding to this receptor, Panitumumab blocks the pathways that promote tumor growth.\n\n2. **Indications**: It is approved for use in patients with metastatic colorectal cancer whose tumors express EGFR and do not have mutations in the KRAS gene (KRAS wild-type). It is important to test for KRAS mutations as Panitumumab is ineffective in KRAS-mutated tumors.\n\n3. **Administration**: Panitumumab is administered as an intravenous infusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tyDgja0L9WS7AU4Q16ndmbjd", "custom_id": "204_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "abfac3347acb36fb7f2efac8ba1e9bf9", "body": {"id": "chatcmpl-9St7tPsnNNsv7PO4qE54X2d7JCJry", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat (brand name Farydak) is a prescription medication used primarily in the treatment of multiple myeloma. As a physician, here are some key aspects you should know about this drug:\n\n1. **Mechanism of Action**: Panobinostat is classified as a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC, panobinostat interferes with the function of histone deacetylases, which play an integral role in the regulation of gene expression by modifying the acetylation status of histones and other cellular proteins. This action can induce cell cycle arrest, apoptosis, and inhibit tumor growth and proliferation.\n\n2. **Indications**: Panobinostat is approved for use in combination with bortezomib (a proteasome inhibitor) and dexamethasone in patients with multiple myeloma who have received at least two prior regimens including bortezomib and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aTFJZUwTtBwRSYqV8fA8SJWN", "custom_id": "205_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "46398c73b00f15b2d3617a7f41e7ef49", "body": {"id": "chatcmpl-9St7tSVJm3Vr6liJWuGgeeTrlyRNl", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib is a medication used primarily in the treatment of kidney cancer (renal cell carcinoma) and soft tissue sarcoma. It is a tyrosine kinase inhibitor that interferes with the growth of cancer cells and slows their spread in the body.\n\nHere are key points about Pazopanib that you, as a physician, should consider:\n\n1. **Indications**:\n   - Pazopanib is approved for the treatment of advanced renal cell carcinoma (RCC).\n   - It is also approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.\n\n2. **Mechanism of Action**:\n   - Pazopanib inhibits multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-\u03b1 and \u03b2, and c-Kit. These are involved in both tumor growth and angiogenesis.\n\n3. **Administration**:\n   - Pazop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_otGlVS7UhGr6y6KCyknNg2Li", "custom_id": "206_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f442e5953b784e769fd6d44517628860", "body": {"id": "chatcmpl-9St7tmrRjwTY0rHLCY417oJ6hi4Wp", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase, also known by the trade name Oncaspar, is a chemotherapeutic agent primarily used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients. Here are some critical aspects you should consider as a physician:\n\n### Mechanism of Action\nPegaspargase is a modified version of L-asparaginase, an enzyme that catalyzes the hydrolysis of the amino acid asparagine into aspartic acid and ammonia. Cancer cells, particularly those in patients with ALL, are unable to synthesize asparagine due to a lack of asparagine synthetase and thus depend on external sources of the amino acid. Depletion of asparagine, which results from pegaspargase treatment, inhibits protein synthesis and leads to apoptosis of leukemic cells.\n\n### Differences from L-asparaginase\nPegaspargase has a polyethylene glycol (PEG) molecule added, which increases its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w0QkJsjeSwR1jWNMR2omOZoW", "custom_id": "207_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4cd1219a0ebdbfbf3172698002a289e7", "body": {"id": "chatcmpl-9St7tSf6gGw3vPQy1EkQAbs1caEIF", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2a is a medication used primarily for the treatment of chronic hepatitis C infections and, in some cases, chronic hepatitis B infections. It is a form of interferon, a protein that is naturally produced by the body in response to viral infections, modified to have a polyethylene glycol (PEG) molecule attached. This pegylation process extends its half-life, allowing for less frequent dosing compared to unmodified interferon.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - **Chronic Hepatitis C:** Often used in combination with other antiviral agents, such as ribavirin and direct-acting antivirals (DAAs), depending on the genotype of the virus and patient factors.\n   - **Chronic Hepatitis B:** Less commonly used for this indication, and generally in select cases where nucleotide/nucleoside analogues are not suitable.\n\n2. **Mechanism of Action:**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GzTfEqBBrcC9R6CSxFj4vvtX", "custom_id": "208_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f507b8ea0281fdc57a699957fc4bdcb5", "body": {"id": "chatcmpl-9St7tNxSPW0XulecrQWjfrY0Zv9MZ", "object": "chat.completion", "created": 1716672117, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a pegylated interferon used to treat several medical conditions, primarily chronic hepatitis B and C infections. The medication is a form of long-acting interferon, which is a protein that modulates the immune response. By attaching a polyethylene glycol (PEG) molecule to interferon alfa-2b, its half-life is extended, allowing for less frequent dosing compared to its non-pegylated counterpart. Here are several key aspects about Peginterferon alfa-2b that you, as a physician, might find important:\n\n### Indications\n- **Chronic Hepatitis B**: It is used in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B who have compensated liver disease and evidence of viral replication, persistently elevated ALT and AST levels, and histologically active disease.\n- **Chronic Hepatitis C**: Generally used in combination with other antiviral drugs (such as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dUAQcaUnhodwgCPcMPqHAnhC", "custom_id": "209_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "080ce44cebcfce7ceaf462364788ad58", "body": {"id": "chatcmpl-9St7utUL6z9Eon55lW5BgrwZhKhxL", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin, which is encapsulated within liposomes that have been modified with polyethylene glycol (PEG), enhancing the drug\u2019s pharmacokinetic profile and therapeutic efficacy while reducing some of the common toxic effects associated with conventional doxorubicin. Here are several key aspects you should know about pegylated liposomal doxorubicin as a physician:\n\n1. **Mechanism of Action:**\n   Pegylated liposomal doxorubicin works similarly to conventional doxorobicin. It intercalates DNA strands and inhibits topoisomerase II, which interrupts DNA replication and ultimately leads to cell death. The liposomal encapsulation helps to prolong the circulation time and alters the distribution of the drug, thereby enhancing tumor targeting via the enhanced permeability and retention (EPR) effect.\n\n2. **Indications:**\n   This drug is primarily used in the treatment of various cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9fwA2sTdaLmpouOqDRWpaLnq", "custom_id": "210_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5d407af774fbfb9caa535c519f83846", "body": {"id": "chatcmpl-9St7u9lokIc5AsEtKJm9m5eFjgilH", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab (marketed under the brand name Keytruda) is an important drug in the treatment of various cancers, acting as an immune checkpoint inhibitor. It specifically targets the programmed cell death protein 1 (PD-1) receptor, a mechanism that tumors use to shield themselves from the immune system. By inhibiting PD-1, pembrolizumab helps reactivate the immune system to recognize and destroy cancer cells.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   Pembrolizumab has been approved for use in several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers, gastric cancer, cervical cancer, hepatocellular carcinoma, and more. The indications continue to expand as more research supports its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oBatNwU0NnSHr5pnBsTR6dMC", "custom_id": "211_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "99fc89fcb932533917c4e6e315cb73de", "body": {"id": "chatcmpl-9St7uWom2ANSKgbywcqKRNlQGQJeJ", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed (brand name Alimta) is a chemotherapeutic agent primarily used for the treatment of pleural mesothelioma and non-small cell lung cancer. As a physician, here are key points you should be aware of regarding pemetrexed:\n\n### Mechanism of Action\nPemetrexed is an antifolate which inhibits several enzymes that are involved in purine and pyrimidine synthesis, namely thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). This inhibition leads to a reduction in DNA, RNA, and protein synthesis, which predominantly affects rapidly dividing cells.\n\n### Indications\n- **Malignant Pleural Mesothelioma:** Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ryh14IgE9kUFaX4MDR6dvcOJ", "custom_id": "212_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7d84a526a474da6d55a977f8da5a934", "body": {"id": "chatcmpl-9St7u2UxqxvZxl2fnC8y3kESCPewV", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin is a chemotherapy medication primarily used to treat hairy cell leukemia. As a physician, here are several key points you should be aware of:\n\n1. **Mechanism of Action:**\n   - Pentostatin (also known by its brand name Nipent) is an inhibitor of adenosine deaminase, an enzyme that is particularly active in cells of the lymphoid system. By inhibiting this enzyme, pentostatin causes an accumulation of deoxyadenosine triphosphate (dATP), which in turn leads to a faulty DNA synthesis and apoptosis (cell death) in lymphocytes.\n\n2. **Indications:**\n   - The primary indication for pentostatin is the treatment of hairy cell leukemia. It may also be used off-label for other conditions as deemed appropriate based on the physician's discretion and the patient's need.\n\n3. **Administration:**\n   - Pentostatin is administered intravenously. Proper administration and dosing schedules are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_a4bOyCxVRHbXTaVI0me2Iavo", "custom_id": "213_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c7cdd08a26d993a8817fdf25c6be0c31", "body": {"id": "chatcmpl-9St7uhLidlXZYs0k1nSy824d4NhZI", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pertuzumab is a monoclonal antibody that targets the HER2 receptor, a protein overexpressed in some types of breast cancer. Pertuzumab binds to the dimerization domain (Subdomain II) of HER2, inhibiting the pairing (dimerization) of HER2 with other HER receptors (HER1, HER3, and HER4). This action blocks signaling pathways which are involved in cell growth and survival. Pertuzumab's mechanism is complementary to trastuzumab, another HER2-targeted therapy, which binds to a different domain (Subdomain IV) of the HER2 receptor.\n\n**Clinical Uses:**\n1. **Breast Cancer:** Pertuzumab is primarily used for the treatment of HER2-positive metastatic breast cancer. It is often administered in combination with trastuzumab and docetaxel for patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Pertuzum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XtQcER3LajpewfISImRdS6Wz", "custom_id": "214_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36eaa425332bef79a59910a1645b1de9", "body": {"id": "chatcmpl-9St7uwMBCfs7mZzc7qP3eKjslYLXR", "object": "chat.completion", "created": 1716672118, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin (also known as Theprubicin) is an anthracycline antibiotic closely related to doxorubicin and is used as a chemotherapeutic agent. It is primarily used in the treatment of various cancers, including breast cancer, bladder cancer, and lymphomas.\n\n### Mechanism of Action\nPirarubicin acts primarily by intercalating into DNA, thus disrupting the replication of DNA and inhibiting transcription. It also generates free radicals that cause damage to cellular components, including DNA. Its action is cell-cycle nonspecific.\n\n### Indications\nPirarubicin is used to treat various types of cancer, notably:\n- Breast cancer\n- Bladder cancer (often used in intravesical therapy to treat superficial bladder tumors)\n- Lymphoma\n- Some types of leukemia\n\n### Pharmacokinetics\n- **Absorption and Distribution**: After intravenous administration, pirarubicin exhibits widespread distribution throughout the body.\n- **Metabol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5LwPkMIPDy5bFkBO1P4w2Zss", "custom_id": "215_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "06121460b923516546f88722b6f79c64", "body": {"id": "chatcmpl-9St7vCDMYIhLUIu3Xug4LRkkdczEU", "object": "chat.completion", "created": 1716672119, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a chemotherapy medication used primarily in the treatment of non-Hodgkin lymphoma. It is a structurally novel aza-anthracenedione that is related to anthracyclines but has been designed to reduce cardiotoxicity and improve efficacy. Here are some key points that you, as a physician, might find useful about pixantrone:\n\n1. **Mechanism of Action**: Pixantrone is a cytotoxic agent that intercalates into DNA and inhibits topoisomerase II, leading to errors in DNA repair and replication, and ultimately causing cell death. Its structure helps limit the formation of reactive oxygen species, hence potentially reducing cardiotoxicity compared to traditional anthracyclines.\n\n2. **Indications**: Pixantrone is approved for the treatment of non-Hodgkin lymphoma, specifically in patients who have failed multiple previous therapies. Its approval and usage might vary by regulatory agency and geography, so it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ol9DsAJC4NFwGfVtJhJKZhJl", "custom_id": "216_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dfd59cb0d0df546ba044b6ef485196b6", "body": {"id": "chatcmpl-9St7vvYDCyoHE6oQ9WEay6Jo9SZLN", "object": "chat.completion", "created": 1716672119, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin, also known as mithramycin, is a chemotherapeutic antibiotic originally derived from the bacterium *Streptomyces plicatus*. It primarily works by binding to DNA and inhibiting RNA synthesis, which interferes with the growth of cancer cells. Plicamycin has been used primarily in the treatment of testicular cancer, Paget's disease of bone, and certain types of hypercalcemia, particularly those associated with cancer.\n\nHere are several key points about plicamycin that are important for physicians:\n\n1. **Mechanism of Action**: Plicamycin binds to GC-rich regions of DNA, preventing RNA polymerase from initiating transcription effectively. This inhibits RNA synthesis which, in turn, can reduce protein synthesis and impede cancer cell growth.\n\n2. **Indications**: It has been used to treat various conditions including:\n   - Testicular cancer\n   - Hypercalcemia of malignancy, where it can help reduce serum calcium"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nnu7MmEFVrkq43sxHcJbun9T", "custom_id": "217_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab225c4b1a4f94cc7c8c51a1e66a904f", "body": {"id": "chatcmpl-9St7v1ny4Fjl8JJyj4uB04ZYgcIBd", "object": "chat.completion", "created": 1716672119, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is a medication primarily used for the treatment of multiple myeloma, a type of cancer that arises from plasma cells. As a physician, you should be aware of several key aspects of pomalidomide:\n\n1. **Mechanism of Action**: Pomalidomide is an immunomodulatory drug (IMiD) that shares structural and functional similarities with thalidomide and lenalidomide. It works by modulating the immune system, promoting anti-inflammatory and anti-proliferative effects. Pomalidomide also inhibits angiogenesis (formation of new blood vessels), which is critical for tumor growth. Additionally, it modulates various cytokines and enhances T cell and natural killer (NK) cell-mediated immunity.\n\n2. **Indications**: Pomalidomide is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_owlKM6oteLxIlvj4IOqx49yy", "custom_id": "218_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "63310c86d2f4fc431dbf09d63cb0ba47", "body": {"id": "chatcmpl-9St7vfYhp0MvGzQBhxqvV2RGWZ8RN", "object": "chat.completion", "created": 1716672119, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinb, marketed under the brand name Iclusig, is an oral medication primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that are resistant or intolerant to prior tyrosine kinase inhibitor therapy. Here are some important aspects that a physician should be aware of when considering ponatinib in a treatment regimen:\n\n### Mechanism of Action\nPonatinib is a tyrosine kinase inhibitor (TKI) that targets BCR-ABL, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL. It is known for its activity against a broad spectrum of BCR-ABL mutations, including the T315I mutation, which is particularly resistant to other available TKIs.\n\n### Indications\nPonatinib is approved for the treatment of:\n- Adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c3f0bbC0MP4sZbdxfAYblDJh", "custom_id": "219_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e696e1fcee722f9fd40d47e80e9848a8", "body": {"id": "chatcmpl-9St7vcGGTFUrHtXacqvUkuH5TNwev", "object": "chat.completion", "created": 1716672119, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralatrexate (brand name Folotyn) is a chemotherapeutic agent primarily used in the treatment of peripheral T-cell lymphoma (PTCL), a type of non-Hodgkin lymphoma. Here are several key points you should be aware of when considering or administering pralatrexate:\n\n1. **Mechanism of Action**:\n   Pralatrexate is a folate analogue metabolic inhibitor. It competitively inhibits dihydrofolate reductase, which is crucial for thymidylate synthesis. Its structure allows for a higher affinity for the reduced folate carrier-1, enhancing its cellular uptake and retention. Pralatrexate interferes with DNA synthesis, thereby inhibiting tumor growth.\n\n2. **Indications**:\n   It is approved by the FDA specifically for the treatment of relapsed or refractory peripheral T-cell lymphoma. Research may be ongoing for other indications, so it's useful to stay updated on new developments"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5XAktbupcnkI3Ee6ufmmQM26", "custom_id": "220_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6363efb01b9e488d87d69a8b0b993e56", "body": {"id": "chatcmpl-9St7whBKr2Oam0mBkYD50ufRyBUCK", "object": "chat.completion", "created": 1716672120, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a member of the drug class known as statins, which are used primarily to lower cholesterol levels and reduce the risk of cardiovascular disease. Here are several key points about pravastatin that you should be aware of as a physician:\n\n1. **Mechanism of Action**: Pravastatin works by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that plays a central role in the production of cholesterol in the liver.\n\n2. **Indications**:\n   - Hypercholesterolemia (high levels of cholesterol in the blood)\n   - Mixed dyslipidemia\n   - Primary prevention of cardiovascular disease: to reduce the risk of myocardial infarction, stroke, and the need for revascularization procedures in patients at risk.\n   - Secondary prevention of cardiovascular events in patients with clinically evident coronary heart disease.\n\n3. **Dosage and Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_e2xE5MF27G0VIUE29o1GZWQC", "custom_id": "221_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a7ee0c8899276669d2098bcfc5fcf92", "body": {"id": "chatcmpl-9St7wEyZ8ofCfXbdnhku0TflqzqDA", "object": "chat.completion", "created": 1716672120, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisolone is a corticosteroid medication that is commonly used in the treatment of various inflammatory and autoimmune conditions. Here are some key points you, as a physician, should know about Prednisolone:\n\n### Pharmacology\n- **Mechanism of Action:** Prednisolone mimics the effects of cortisol, a steroid hormone naturally produced by the adrenal glands. It works by reducing inflammation and modifying the body's immune response. It exerts these effects by inhibiting the accumulation of inflammatory cells, release of inflammatory mediators, and edema during inflammation.\n\n### Indications\nPrednisolone is indicated for a wide range of conditions, including:\n- Autoimmune disorders (e.g., lupus, autoimmune hepatitis)\n- Inflammatory conditions (e.g., asthma, rheumatoid arthritis)\n- Allergies and hypersensitivity reactions\n- Adrenal insufficiency\n- Certain hematological disorders\n- Some types of cancer as part of treatment regimen\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_g1gnUsVV3SlRyJAsYGNgHuSN", "custom_id": "222_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e97f553eec35a5cc3f2ce1bf5b768fd9", "body": {"id": "chatcmpl-9St7whS355L0StWZepzUnz9j5K9U6", "object": "chat.completion", "created": 1716672120, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have comprehensive knowledge of medications like Prednisone, especially considering its wide range of uses and potential side effects. Here's a detailed outline to guide you:\n\n### Overview\nPrednisone is a synthetic glucocorticoid used primarily for its anti-inflammatory and immunosuppressive properties. It is a prodrug that is converted in the liver to prednisolone, which is the active drug.\n\n### Indications\nPrednisone is prescribed for various conditions, including, but not limited to:\n- Autoimmune diseases (e.g., lupus, rheumatoid arthritis)\n- Inflammatory conditions (e.g., asthma, COPD, inflammatory bowel disease)\n- Allergic reactions\n- Prevention of organ rejection in transplant patients\n- Certain types of cancer (as part of chemotherapy)\n\n### Mechanism of Action\nPrednisone mimics the action of cortisol, a naturally-occurring steroid hormone produced by the adrenal glands. It acts primarily by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_WsyMF2FfF5z2rWkq4BfcdHsi", "custom_id": "223_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8a9109729316253f5a257ceea8574032", "body": {"id": "chatcmpl-9St7x27SAPvoBCepv3GLXs7zdkyih", "object": "chat.completion", "created": 1716672121, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is an antineoplastic chemotherapeutic agent used primarily to treat Hodgkin's disease (Hodgkin's lymphoma). It is often administered as part of combination chemotherapy regimens, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone).\n\nHere are some key points you should know about procarbazine as a physician:\n\n1. **Mechanism of Action**:\n   - Procarbazine is believed to work by inhibiting DNA, RNA, and protein synthesis, mainly through its metabolites which have alkylating activity. It's not completely understood, but it is hypothesized to act as a methylating agent.\n\n2. **Indications**:\n   - Its primary indication is for the treatment of Hodgkin's lymphoma. It may also be used in certain brain cancers and other types of non-Hodgkin's lymphomas, often depending on the treatment protocol.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z8XZqYQ6t4NGVpAE7cVLgKxn", "custom_id": "224_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d71c534f50e99389c3016ccfabffda1", "body": {"id": "chatcmpl-9St7x9Hp1YkJS0Q5d1GUwCr64H7aV", "object": "chat.completion", "created": 1716672121, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinine is an alkaloid derived from the bark of the cinchona tree, which is native to South America. Historically, it has been used primarily for its ability to treat malaria, thanks to its antimalarial properties. Here are several key aspects of quinine that you, as a physician, might find important:\n\n1. **Indications:**\n   - **Malaria:** Quinine is effective against Plasmodium falciparum, particularly in areas where resistance to chloroquine is an issue. It's often used in combination with other antimalarials like doxycycline or clindamycin.\n   - **Leg cramps (off-label use):** Despite its historical use for nocturnal leg cramps, this is not recommended due to potential adverse effects and limited evidence of benefit.\n\n2. **Mechanism of Action:**\n   - Quinine acts primarily by interfering with the hemozoin formation, a crucial process in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_39DWVqFNRsQ5LsJgoAv0KPPo", "custom_id": "225_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "10811cc0d748d0ffead64006b7fb9d58", "body": {"id": "chatcmpl-9St7x2Peq9FkoTZg95tpJwhmWwNVU", "object": "chat.completion", "created": 1716672121, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib is a tyrosine kinase inhibitor specifically designed to target FLT3 (Fms-like tyrosine kinase 3), a receptor tyrosine kinase that is a clinically significant molecular target in acute myeloid leukemia (AML). The FLT3 gene is one of the most frequently mutated genes in AML, and these mutations are associated with a poor prognosis in AML patients.\n\n### Key Points about Quizartinib:\n1. **Mechanism of Action**:\n   - Quizartinib selectively inhibits the FLT3 kinase, which can be constitutively active due to internal tandem duplication (ITD) mutations or other types of mutations in the FLT3 gene. By inhibiting FLT3, quizartinib disrupts several pathways that drive the growth and survival of leukemic cells.\n\n2. **Clinical Use**:\n   - Quizartinib is primarily explored in the treatment of acute myeloid leukemia, especially in patients who have FLT3-ITD mutations. FLT3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IHLWAyodpgIenHpKrJY2hqYU", "custom_id": "226_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "26a0e37527615f794060f484bfc5fdb2", "body": {"id": "chatcmpl-9St7yKXRNIvxafsQucAX8lwAEeC0Q", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinab is an oral tyrosine kinase inhibitor specifically designed to target the BCR-ABL1 protein and is used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Radotinib inhibits the tyrosone kinase activity of BCR-ABL1, the abnormal protein that drives the growth of CML cells. It also inhibits other kinases such as SRC family kinases, which may contribute to its therapeutic effects.\n\n2. **Indications**: It is primarily used for the treatment of CML, especially in patients who have developed resistance to other first-line treatments such as imatinib, dasatinib, or nilotinib. It may be particularly effective in patients with specific mutations in the ABL kinase domain that confer resistance to these other drugs.\n\n3. **Dosage and Administration**: The dosage of radotinib needs to be carefully"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6gPH42whPQNg4jcr0hNLwvJC", "custom_id": "227_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "643a4ab499d213211d41e1eb4908fb90", "body": {"id": "chatcmpl-9St7yshYslRqlQq3IwdlhOmcTGVua", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed, marketed under the brand name Tomudex, is a chemotherapy drug specifically designed as an antimetabolite, which works by inhibiting thymidylate synthase\u2014an enzyme necessary for DNA replication. Here are some specific aspects you should be aware of as a physician:\n\n### Mechanism of Action\n- **Enzyme Inhibition:** Raltitrexed inhibits thymidylate synthase, leading to a depletion of thymidine monophosphate (dTMP), which is crucial for DNA synthesis. This inhibition ultimately results in DNA damage and apoptosis in cancer cells.\n\n### Indications\n- **Colorectal Cancer:** It is primarily used in the treatment of advanced colorectal cancer. The effectiveness of raltitrexed varies, and it is often considered in cases where patients may not tolerate other forms of chemotherapy.\n\n### Administration\n- **Route:** It is typically administered intravenously.\n- **Dosage Regimen:** Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aHq37RTqXFtGpRAjCpAR3lKr", "custom_id": "228_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65d3e121d440c130ad9f6ef5cf398790", "body": {"id": "chatcmpl-9St7yQYj6bnuvvfDmMZBj5WzjURZq", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab (brand name Cyramza) is a targeted anticancer medication used in the treatment of specific types of cancer. Here is a concise overview that can be particularly useful for physicians:\n\n1. **Mechanism of Action**:\n   Ramucirumab is a monoclonal antibody that specifically binds to the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2, ramucirumab inhibits the interaction of VEGFR2 with its ligands (VEGF-A, VEGF-C, and VEGF-D). This blockage inhibits angiogenesis (the formation of new blood vessels), which is necessary for the growth of tumors.\n\n2. **Indications**:\n   Ramucirumab has been approved for use in the treatment of various cancers, often in combination with other chemotherapeutic agents. Its indications include:\n   - Metastatic gastric cancer or gastro-esophageal junction"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_52FtQEuyr3Y9K3xlaRnEFuiP", "custom_id": "229_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "25fc38da5e8bc5c3e59f8586c5a127f4", "body": {"id": "chatcmpl-9St7yfRZnZ7Ccc1XZrH9S5m6NjMVA", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine (also known by its trade name Cymerin) is a chemotherapeutic agent used primarily in the treatment of certain types of cancers such as malignant lymphomas and brain tumors. Here are some important aspects that a physician should consider when dealing with Ranimustine:\n\n1. **Mechanism of Action**: Ranimustine belongs to the nitrosourea class of chemotherapy drugs. It acts by alkylating DNA and RNA, which disrupts the growth of cancer cells by causing cross-linking of DNA strands, abnormal base pairing, or strand breaks, ultimately leading to cell death.\n\n2. **Indications**: Ranimustine is mainly used in the treatment of cerebral tumors, malignant lymphomas, and leukemias. In particular, it has been found to be effective in treating patients with recurrent or refractory diseases.\n\n3. **Administration**: Ranimustine is typically administered intravenously. Dosing schedules can vary depending on the type of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ICXXgbgySWLyjneAD0WpCmDG", "custom_id": "230_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32a37868432c8b7dde4aa292d205c5e4", "body": {"id": "chatcmpl-9St7yr3gTzk3g0Neh8BzAMOAQj09U", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib, marketed under the brand name Stivarga among others, is an oral multi-kinase inhibitor that you as a physician might prescribe for the treatment of certain types of cancers. Here's a concise overview of several important aspects of regorafenib:\n\n### Indications\nRegorafenib is approved for use in:\n1. **Colorectal Cancer**: For the treatment of patients with metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.\n2. **Gastrointestinal Stromal Tumors (GIST)**: For the treatment of patients with locally advanced, unresectable or metastatic GIST who have previously been treated with imatinib mesylate and sunitinib malate.\n3. **Hepatocellular Carcin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1lsqFMl3oGMd0OBO0wlROzfv", "custom_id": "231_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2b390997a8615d44d6255287f45498f8", "body": {"id": "chatcmpl-9St7yQNT4AkQGgpstDHp0EuxHluyh", "object": "chat.completion", "created": 1716672122, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib, sold under the brand name Kisqali, is a targeted therapy used in the treatment of certain types of breast cancer. Here are key points you should be aware of as a physician prescribing Ribociclib:\n\n### 1. **Indications**\n   - Ribociclib is primarily used for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor (e.g., letrozole) as initial endocrine-based therapy in postmenopausal women, or in premenopausal women in combination with a luteinizing hormone-releasing hormone (LHRH) agonist. \n   - It can also be used in combination with fulvestrant in women who have previously received hormonal therapy.\n\n### 2. **Mechanism of Action**\n   - Ribociclib is a selective inhibitor of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_y6zZKyIuRQ50NIhekVWtRKMv", "custom_id": "232_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ecde07201fc278eab602a711fd34025f", "body": {"id": "chatcmpl-9St7zg2urA4zPARp3uH40B75stOK0", "object": "chat.completion", "created": 1716672123, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab (brand name Rituxan, among others) is a monoclonal antibody used to treat various autoimmune diseases and cancers. Its primary mechanism is targeting the CD20 protein found on the surface of B cells, leading to their destruction. Here are some critical points you should know about rituximab:\n\n### Indications\nRituximab is indicated in the treatment of:\n- **Non-Hodgkin's lymphoma**: Both as a single agent and in combination with other chemotherapy regimens.\n- **Chronic lymphocytic leukemia** (CLL) in combination with chemotherapy.\n- **Rheumatoid arthritis** (RA): In patients who have had an inadequate response to one or more TNF inhibitor therapies.\n- **Granulomatosis with polyangiitis** and **microscopic polyangiitis**.\n- **Pemphigus vulgaris**.\n\n### Mechanism of Action\nRituximab binds specifically to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E7Zmy5bg6FFrT2iUUaz47gRv", "custom_id": "233_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f1339d5530a5d9ea1b6cd343d02af24b", "body": {"id": "chatcmpl-9St7zgpz7XHpg1eL48R1TlCkNm3IY", "object": "chat.completion", "created": 1716672123, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication used mainly in oncology to treat certain types of cancer, such as follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. It combines rituximab, a monoclonal antibody that targets the CD20 antigen on B lymphocytes, with hyaluronidase, an enzyme that helps increase the dispersion and absorption of administered drugs.\n\nHere are some important points you should know about this combination:\n\n1. **Mechanism of Action**:\n   - **Rituximab**: Works by selectively depleting CD20-positive B cells. It binds to the CD20 antigen on B cells and mediates B-cell lysis, potentially through mechanisms involving complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis.\n   - **Hyaluronidase**: Increases tissue permeability by temporarily degrading hyaluronan, a glycosaminog"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ihEUMyLFmZoD5LzjnwQGakrw", "custom_id": "234_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5b0d3048fcf0a5ad2690945aae22b8e7", "body": {"id": "chatcmpl-9St7zlUuhgCpSsj9nu6VvnKLHuGsj", "object": "chat.completion", "created": 1716672123, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin, also known by its brand name Istodax, is a medication used in cancer treatment, specifically indicated for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. It is classified as a histone deacetylase (HDAC) inhibitor.\n\n### Mechanism of Action:\nRomidepsin works by inhibiting the activity of histone deacetylase (HDAC). This inhibition leads to an increase in the acetylation of histone proteins, resulting in alterations in gene expression. These changes can induce cell cycle arrest, apoptosis (programmed cell death), and inhibition of angiogenesis in cancer cells, thereby exerting its antitumor effects.\n\n### Indications:\n1. **Cutaneous T-cell Lymphoma (CTCL)**: Romidepsin is approved for the treatment of CTCL in patients who have received at least one"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lrMGRHOQUSa0KvPwjOQcO99w", "custom_id": "235_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef91bd57c78bc8d103fc92d71b734a99", "body": {"id": "chatcmpl-9St7z8XvI9xokRShKXhTNQH3m2nFO", "object": "chat.completion", "created": 1716672123, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b, also known as Besremi, is a pegylated interferon used in the treatment of certain medical conditions, most notably polycythemia vera, a type of blood cancer characterized by the excessive production of red blood cells. Here are several important aspects you, as a physician, should know about Ropeginterferon alfa-2b:\n\n1. **Indications**: Ropeginterferon alfa-2b is approved for use in adults with polycythemia vera without symptomatic splenomegaly. It's designed for patients who need therapy for their condition, and can be used regardless of their previous treatment history.\n\n2. **Mechanism of Action**: As a pegylated form of interferon alpha-2b, it works by mimicking the body\u2019s immune response. The pegylation process, which involves attaching polyethylene glycol to the interferon molecule, prolongs the duration of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TtialhZN14rzZ15HpoRh4Jul", "custom_id": "236_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3ede46ed0f36eba9be4125f0175b7f26", "body": {"id": "chatcmpl-9St80KzrLhNDrnWa8puYYEfceicGe", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rucaparib is a medication primarily used in the treatment of certain types of ovarian cancer, including fallopian tube cancer or primary peritoneal cancer. It belongs to a class of drugs known as PARP (poly ADP ribose polymerase) inhibitors. These drugs work by blocking the PARP enzymes, which play a role in DNA repair. When PARP enzymes are inhibited, cancer cells that have defective DNA repair mechanisms (common in cancers with BRCA mutations) are unable to repair themselves, leading to cell death.\n\n### Key Aspects of Rucaparib Include:\n\n#### Indications:\n- **Maintenance treatment** of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n- **Treatment** of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7U8Lr3Wym1G60XcovfKitvJV", "custom_id": "237_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "53acfec6299438dc0de5980dd824cb5b", "body": {"id": "chatcmpl-9St800spBe025n1wyrQHnq5NxpIo0", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication used primarily in the treatment of certain blood disorders, including myelofibrosis and polycythemia vera, which are types of myeloproliferative neoplasms. It is also prescribed for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in some cases. Here are the key points you should know about ruxolitinib:\n\n1. **Mechanism of Action**: Ruxolitinib is a Janus kinase (JAK) inhibitor that inhibits the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, which is involved in the regulation of blood and immune cell production. By inhibiting this pathway, ruxolitinib can reduce inflammation and modify the immune response.\n\n2. **Indications**:\n   - **Myelofibrosis**: It can be used for the treatment of intermediate or high-risk myelof"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_t0T8PyVWCw5R7ygXSkBLnkOz", "custom_id": "238_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d91803c8bdcb3a88f93ce00a7f655ea", "body": {"id": "chatcmpl-9St80tYpJrbb62cTC25901o6qQbD6", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sacituzumab govitecan, marketed under the brand name Trodelvy, is a novel antibody-drug conjugate (ADC) used in oncology. It's specifically directed against Trop-2, a cell-surface glycoprotein expressed in a variety of epithelial cancers, including breast cancer, urothelial cancer, and potentially others. Here are the key aspects you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   Sacituzumab govitecan combines a monoclonal antibody (directed against Trop-2) with a cytotoxic drug, SN-38. SN-38 is the active metabolite of irinotecan, an inhibitor of topoisomerase I. The antibody component of sacituzumab govitecan binds to Trop-2 on tumor cells, facilitating the delivery of SN-38 directly to the cancer cells, which helps minimize systemic exposure and reduce side effects.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xk2eD3d60u5BJiTYQf3AvU4P", "custom_id": "239_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2050176323918bc2c63b37316e7c31e9", "body": {"id": "chatcmpl-9St80gHtuk0EOi4X871XIxIyv8K6y", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), is a medication primarily used to accelerate bone marrow recovery after bone marrow transplantation, during chemotherapy, or after induction chemotherapy in older adults with acute myelogenous leukemia. It is also used in the treatment of neutropenia and is effective in enhancing the function of existing white blood cells, thereby reducing the risk of infection.\n\nHere are key points you should know about Sargramostim as a physician:\n\n### 1. Mechanism of Action\nSargramostim acts by stimulating the differentiation, proliferation, and activation of hematopoietic cells, which include neutrophils, monocytes/macrophages, and eosinophils. It binds to the GM-CSF receptor, which induces downstream signaling that leads to these effects.\n\n### 2. Indications\n- **Bone marrow recovery**: It is used to promote marrow recovery after autolog"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_alKLoXkdVNMXOF2yrRi5NmZ2", "custom_id": "240_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bca4c67f3c4ad9d077d8f22913c60389", "body": {"id": "chatcmpl-9St80FiS5ePSM1wCeumxcM7YL0JyF", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexort, marketed under the brand name Xpovio, is a medication primarily used in the treatment of multiple myeloma and certain types of lymphoma. It is a selective inhibitor of nuclear export (SINE) that selectively blocks the nuclear export protein exportin 1 (XPO1). Here are some key points about Selinexor that might be useful for a physician:\n\n### Mechanism of Action\nSelinexor works by inhibiting the nuclear export protein XPO1. This inhibition leads to the accumulation of tumor suppressor proteins and growth regulatory proteins within the nucleus, enhancing their anti-cancer activity by promoting the death of cancer cells and reducing their proliferation.\n\n### Indications\n- **Multiple Myeloma**: Selinexor is approved by the FDA for the treatment of relapsed or refractory multiple myeloma, typically in combination with dexamethasone or other agents like bortezomib, especially after patients have received other"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mhJV09DIh7Xlu5GBmRQzpJ2b", "custom_id": "241_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55c62497120845f9d032c70ae2acb80f", "body": {"id": "chatcmpl-9St80LsDDzbkyjrbiqmacF7Z1Ybir", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selumetinib is a medication primarily used in the treatment of certain cancers. It is a MEK inhibitor that works by targeting the mitogen-activated protein kinase (MAPK) pathway, which is a signaling pathway that plays a significant role in the regulation of cell growth and survival. MEK is a part of this pathway, and by inhibiting MEK, selumetinib aims to prevent the growth of cancer cells.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Selumetinib is approved for use in patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. These are typically non-cancerous tumors that develop in the nerves and can cause significant discomfort or complications.\n   - Research and clinical trials are ongoing for its effectiveness in other types of cancers.\n\n2. **Mechanism of Action:**\n   - As a MEK inhibitor,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ekarAvKLTgmCeKvY6Gq39ux4", "custom_id": "242_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f4748738908017ef31200c1666f59e7", "body": {"id": "chatcmpl-9St80AI9jQO7ro7ZzIE0AcyA3gNPX", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known by its chemical name methyl-CCNU or under the brand name Me-CCNU, is a type of chemotherapy drug known as a nitrosourea. Nitrosoureas are alkylating agents that are used in the treatment of cancer. They work by cross-linking DNA and RNA, thereby disrupting the growth of cancer cells. Semustine can be used to treat various types of cancers, although its use may vary by country and is subject to specific clinical guidelines and regulations.\n\nHere are some key points you should know about Semustine:\n\n1. **Mechanism of Action**: Semustine forms alkyl groups that bind with DNA, causing breaks in the DNA strands and consequently, apoptosis or cell death. This disrupts the cellular replication of cancer cells.\n\n2. **Indications**: Historically, Semustine has been used to treat various cancers including brain tumors, Hodgkin\u2019s disease, and gastrointestinal malignancies. However, its use has"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_cvCeaT2h6YclZkNsSIqRF3Ff", "custom_id": "243_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f10d06a66672aa45f8f39781cf4d4c5", "body": {"id": "chatcmpl-9St80TVSjquSUJWfvHb6Pu7TvZXm9", "object": "chat.completion", "created": 1716672124, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T (brand name: Provenge) is a therapeutic vaccine used in the treatment of prostate cancer. It is specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant (hormone-refractory) prostate cancer. Here are some key aspects you should know about Sipuleucel-T:\n\n1. **Mechanism of Action**:\n   Sipuleucel-T is an autologous cellular immunotherapy. It works by stimulating the patient\u2019s immune system to target and attack prostate cancer cells. The treatment involves collecting a patient's own immune cells (specifically, peripheral blood mononuclear cells including antigen-presenting cells) through a process called leukapheresis. These cells are then exposed to a protein that is a fusion of prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancer cells, and granulocyte-macrophage colony-stimulating factor (GM-CSF). The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bbDsqkJXyU8llq6G2YXfBlv0", "custom_id": "244_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a30bd9da62927203b7bc96464613194", "body": {"id": "chatcmpl-9St81jIhAXdDSHyOnTvIrV9piErdr", "object": "chat.completion", "created": 1716672125, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib, also known by the brand name Odomzo, is a medication used in the treatment of locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in cases where surgery or radiation is not appropriate. It was approved by the FDA in July 2015. Here are some key aspects of Sonidegib you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   Sonidegib is an inhibitor of the Hedgehog pathway, which is active in basal cell cancers. It specifically targets and inhibits Smoothened, a protein that is a key component in the Hedgehog signaling pathway. This inhibition can stop or reduce the growth of cancer cells.\n\n2. **Indications**:\n   It is indicated for the treatment of adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dzd6tIbI616ID98Q8A46WRLN", "custom_id": "245_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "07ce38c543540274fbf7979438befe57", "body": {"id": "chatcmpl-9St81zgUNVLeVholUF6YOxu280SjY", "object": "chat.completion", "created": 1716672125, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib, marketed under the brand name Nexavar, is a tyrosine kinase inhibitor with broad antitumor activity that is used primarily to treat advanced renal cell carcinoma, unresectable hepatocellular carcinoma (HCC), and radioactive iodine-resistant thyroid carcinoma. Here are key points you should know when considering Sorafenib for treatment:\n\n### Mechanism of Action\n1. **Tyrosine Kinase Inhibition**: Sorafenib inhibits multiple intracellular (CRAF, BRAF, and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-2, VEGFR-3, and PDGFR-\u03b2). These kinases are involved in both tumor cell proliferation and tumor angiogenesis.\n2. **Anti-Angiogenic and Antiproliferative**: By inhibiting these targets, sorafenib blocks tumor cell proliferation and angiogenesis, disrupting the growth of the tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YW0CRlDbzoT2jJqOSpCK0hY6", "custom_id": "246_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f18e061fdee774a8c8fca8f61a37068c", "body": {"id": "chatcmpl-9St81HXVnBkpMZSiZmdiTSAGoTzho", "object": "chat.completion", "created": 1716672125, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also known as streptozotocin or Zanosar) is a chemotherapeutic agent used primarily to treat pancreatic cancer, specifically metastatic islet cell carcinoma or pancreatic neuroendocrine tumors. It has unique properties and considerations that you, as a physician, should be aware of when prescribing or discussing this treatment option with patients.\n\n### Mechanism of Action\nStreptozocin is a naturally occurring nitrosourea alkylating agent derived from Streptomyces achromogenes. It is both cytotoxic and diabetogenic. Its mechanism involves:\n- Alkylating DNA, which leads to DNA strand breaks and apoptosis of the tumor cells.\n- Selectivity for pancreatic beta cells, due to its glucose-like structure which allows preferential uptake via the glucose transport protein GLUT2.\n\n### Indications\n- Mainly indicated for the treatment of metastatic islet cell carcinoma of the pancreas.\n- It can be used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IqZpA2jH6xFvshlPBdVwAWHw", "custom_id": "247_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1d2837763dcbd3abbd91d9c75c960fc3", "body": {"id": "chatcmpl-9St81oaegar2VqXQfViY8wPIU6IQc", "object": "chat.completion", "created": 1716672125, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib, marketed under the brand name Sutent among others, is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was originally approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Since its approval, it has also been used in other indications, depending on the regulatory status in different countries.\n\nHere are some key aspects of Sunitinib that you as a physician might find important:\n\n### Mechanism of Action\nSunitinib inhibits multiple receptor tyrosine kinases (RTKs). These include platelet-derived growth factor receptors (PDGFR\u03b1 and PDGFR\u03b2), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), FLT3, RET, and colony-stimulating factor 1 receptor (CSF"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_rNDMv9c7bsTphG5NMDE1w49a", "custom_id": "248_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb8abb6249e4590a8222479b4bb0d388", "body": {"id": "chatcmpl-9St81SMzk2unwgCFfB7mIBV4mX7r5", "object": "chat.completion", "created": 1716672125, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp, also known by its brand name Elzonris, is a targeted therapy drug used primarily for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic cancer. Here are some critical aspects of Tagraxofusp you should be aware of:\n\n1. **Mechanism of Action**: Tagraxofusp is a fusion protein that consists of interleukin-3 (IL-3) linked to a truncated diphtheria toxin. The IL-3 component targets the CD123 (interleukin-3 receptor alpha chain), which is overexpressed on the surface of certain cells, including BPDCN cells. Upon binding to CD123+ cells, the toxin component of Tagraxofusp is internalized, leading to the inhibition of protein synthesis and subsequent cell death.\n\n2. **Indications**: Tagraxofusp is approved by the U.S. Food and Drug Administration ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GS9iup08qowfVRDfh9mxiAhQ", "custom_id": "249_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "10b8a078b2396af5bb5efde0b1cb254f", "body": {"id": "chatcmpl-9St82TcP9LsCQRskhKn65LasEw2IX", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib (marketed under the brand name Talzenna) is an orally administered medication used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about Talazoparib:\n\n1. **Mechanism of Action**: Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. It works by inhibiting the enzyme PARP, which is involved in DNA repair. By inhibiting PARP, talazoparib causes DNA damage to accumulate in cancer cells, leading to their death. This is particularly effective in cells that are already compromised in their ability to repair DNA, such as those with BRCA mutations.\n\n2. **Indications**: Talazoparib is approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients must be selected"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_PR24n9oxEEMHbrQixmeQgnYH", "custom_id": "250_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "63a42c73c1976ffc87ff773f4e1d8169", "body": {"id": "chatcmpl-9St82tew71I40lfBo4bckhCviAJZf", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec, commonly abbreviated as T-VEC and sold under the brand name Imlygic, is an oncolytic virus therapy used to treat melanoma lesions that cannot be surgically removed. It was the first oncolytic virus therapy approved by the U.S. Food and Drug Administration (FDA) in October 2015. Here are several key points about Talimogene laherparepvec that might be useful for a physician:\n\n1. **Mechanism of Action**: Talimogene laherparepvec is a genetically modified herpes simplex virus type 1. It is engineered to selectively replicate within tumor cells and produce granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune system stimulant. The virus causes lysis of tumor cells, releasing tumor-derived antigens, which along with GM-CSF, may promote an antitumor immune response.\n\n2. **Indications**: This treatment is specifically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_uCtPMMqaBn2KqBklowcORwjX", "custom_id": "251_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "929eeb64824258b443bbb38b3f9d8401", "body": {"id": "chatcmpl-9St82VYCd46tA4eJZ9dhhTD5AA05r", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene, also known by its chemical name Am80, is a synthetic retinoid that is structurally related to vitamin A. It has been primarily used in the treatment of acute promyelocytic leukemia (APL), particularly in cases that are resistant to all-trans retinoic acid (ATRA), which is the standard treatment. Here are some key points you should know about Tamibarotene:\n\n1. **Mechanism of Action**: Tamibarotene functions as a retinoic acid receptor (RAR) \u03b1/\u03b2 agonist. It binds selectively to these receptors, which leads to the modulation of gene expression that promotes cell differentiation and inhibits proliferation.\n\n2. **Clinical Use**:\n   - Primarily used in Japan for the treatment of APL, particularly in patients who are either resistant or relapsed after treatment with ATRA.\n   - Tamibarotene is believed to be more potent and less toxic compared to ATRA because"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GEvPoboyJjJNMGr4EuoTFCLb", "custom_id": "252_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "03af72db3bbe1fc562cd0dfa1d59cc98", "body": {"id": "chatcmpl-9St823gMpnLe4iQSa3j0brG54BCwj", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a medication that is primarily used in the treatment and prevention of breast cancer. It is classified as a selective estrogen receptor modulator (SERM) and works by binding to estrogen receptors, which can inhibit the growth of breast cancer cells that rely on estrogen for growth and survival. Here are some key points you, as a physician, should know about Tamoxifen:\n\n1. **Indications**:\n   - **Breast Cancer Treatment**: Tamoxifen is used to treat some types of breast cancer in men and women.\n   - **Breast Cancer Prevention**: It is also used to reduce the chances of breast cancer in high-risk patients.\n\n2. **Mechanism of Action**: \n   - Tamoxifen binds to estrogen receptors on breast cancer cells, preventing estrogen from binding to these receptors. This action blocks the growth-promoting effect of estrogen on the cancer cells.\n\n3. **Administration and Dosage**:\n   - Tamoxifen is typically administered orally. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ICQlGXt4t19YmOEl1G20oehE", "custom_id": "253_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c70dd9a01bf9beebc5f0d1f1108ed6b1", "body": {"id": "chatcmpl-9St82pzYRUM4VeaTuWsVE6UvWUD5u", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur/gimeracil/oteracil, often referred to by the trade name Teysuno or S-1, is an orally administered chemotherapy medication primarily used in the treatment of gastric cancer, including gastroesophageal junction cancer. It combines three different compounds which synergistically work to inhibit cancer cell growth:\n\n1. **Tegafur**: This is a prodrug of 5-fluorouracil (5-FU), which itself is a widely used chemotherapeutic agent. In the body, tegafur is converted into 5-FU, which is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in DNA synthesis and function, which is particularly effective in rapidly dividing cells like cancer cells.\n\n2. **Gimeracil (also known as 5-chloro-2,4-dihydroxypyridine or CDHP)**: This agent inhibits dihydropyrim"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 50, "completion_tokens": 200, "total_tokens": 250}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X3mNVoXZ2SkZA6D3CrdGug24", "custom_id": "254_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1c654fcdbd7244ae40901c8ea4176db2", "body": {"id": "chatcmpl-9St82Ob6GeFj2PvgSs9AI8uhPjRxA", "object": "chat.completion", "created": 1716672126, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil is a combination chemotherapy agent frequently utilized in the treatment of various cancers, particularly colorectal cancer. Here are several key points you should be aware of:\n\n1. **Combination and Mechanism**: Tegafur is a prodrug of 5-fluorouracil (5-FU), which means it is converted into 5-FU in the body. 5-FU itself is a pyrimidine analog that functions primarily as a thymidylate synthase inhibitor, disrupting DNA synthesis and thus has cytotoxic effects on rapidly dividing cancer cells. Uracil is included in the combination to increase the concentration of 5-FU in tumors. It competitively inhibits the enzyme dihydropyrimidine dehydrogenase that degrades 5-FU, thereby increasing the bioavailability of 5-FU.\n\n2. **Clinical Uses**: This combination is mainly used for gastrointestinal cancers, including colorectal cancer, gastric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9jSQx0WO2qwbR3nROd1EgFvl", "custom_id": "255_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd3f0a04b6bc575e879b70f970dbf967", "body": {"id": "chatcmpl-9St83AOZfBAagMvtMZX8jkRnNyWfZ", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is an oral chemotherapy drug primarily used for treating certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here are some key points that you as a physician might need to know about Temozolomide:\n\n1. **Mechanism of Action**: Temozolomide is an alkylating agent that works by methylating guanine bases in DNA, which leads to DNA damage and triggers apoptosis in tumor cells. Its activity is largely dependent on the cell cycle phase, specifically targeting rapidly dividing cells.\n\n2. **Indications**: It is approved for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment, and for refractory anaplastic astrocytoma (i.e., patients who have relapsed or progressed after standard therapy).\n\n3. **Administration**: Temozolomide is available in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HOILou8LqRGwRevjbbZxhmyS", "custom_id": "256_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e91c1be7e3f7bfef38b9e22e8f11d130", "body": {"id": "chatcmpl-9St83SP7uPHHbAK4VvcSv6vZitAFt", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temsirolimus is an mTOR (mammalian target of rapamycin) inhibitor used primarily in the treatment of advanced renal cell carcinoma (RCC). It inhibits the mTOR kinase, a key protein in a cellular pathway that promotes cell growth and proliferation. By targeting and inhibiting mTOR, temsirolimus interferes with the synthesis of proteins that control the cell cycle, resulting in the inhibition of tumor growth.\n\nHere are some key points about temsirolimus that you might consider as a physician:\n\n### Indications\n- **Primary Indication**: Advanced renal cell carcinoma.\n- **Potential Uses**: It is also being researched for its effectiveness in treating other types of cancers (like mantle cell lymphoma, endometrial cancer, etc.), but these uses are less established.\n\n### Mechanism of Action\n- Temsirolimus specifically inhibits the mTOR (mechanistic target of rapamycin) kinase, which is a part of the PI3K"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_83nQ2gCBZDD8dPFOWU6ryPtW", "custom_id": "257_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "19f09540a776b4f77fd5d61be39d1158", "body": {"id": "chatcmpl-9St83eUOY4WQdepJhoebrReWyhR6j", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several key aspects of teniposide you should be aware of when considering its use in treatment:\n\n1. **Mechanism of Action**: Teniposide is a chemotherapeutic agent classified as a topoisomerase II inhibitor. It works by causing DNA damage primarily through inducing DNA strand breaks, interfering with the function of the enzyme topoisomerase II, which is essential for DNA replication and cell division. This action disrupts the cell cycle and leads to cell death, particularly in rapidly dividing cells.\n\n2. **Indications**: Teniposide is primarily used for the treatment of childhood acute lymphoblastic leukemia (ALL), often in combination with other chemotherapy agents. It may also be used for other types of cancer as part of research or in specific clinical scenarios.\n\n3. **Administration**: It is usually administered intravenously. The dosing and schedule depend on the protocol being used, the type of cancer, the patient's age, body"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ETxO1JRw4FiZPG3eDkCbauxC", "custom_id": "258_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b71d9058947503f4e0b018bb34a36773", "body": {"id": "chatcmpl-9St83G90dBjj5wxhplEo2yLbDLD9w", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a medication with a complex history, initially synthesized in the 1950s and marketed as a sedative or hypnotic, antiemetic, and to treat anxiety, insomnia, and morning sickness. However, it became infamous due to its teratogenic effects, leading to serious birth defects when taken by pregnant women. It was subsequently banned from the marketplace in the early 1960s after these effects became apparent. Here are key points you should know about thalidomide:\n\n1. **Current Indications**: Despite its history, thalidomide is still used today under strict regulations. It is effective in treating multiple myeloma, erythema nodosum leprosum (ENL), and certain conditions like complications of HIV, Crohn\u2019s disease, and other cancers and inflammatory conditions off-label.\n\n2. **Mechanism of Action**: Thalidomide acts as an immunomodulatory agent. It inhibits the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z6obSFwykXgoaX2TGsqx6CBH", "custom_id": "259_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "951417e2c0ba797e2c38b5e21bac468d", "body": {"id": "chatcmpl-9St83hvqQgxFChuIfT7r3SuHvyrmj", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine (6-TG), is a purine analog and antimetabolite drug that is primarily used in the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and in some cases of non-Hodgkin\u2019s lymphoma. Here are several key points you should be aware of regarding Thioguanine:\n\n1. **Mechanism of Action**: Thioguanine incorporates into DNA and RNA once it is metabolized, which interferes with their synthesis and function. It competes with guanine and ultimately inhibits DNA and RNA synthesis, which is critical for cell division and growth. This causes cell cycle arrest and apoptosis of rapidly dividing cells, especially malignant cells.\n\n2. **Administration and Dosage**: Thioguanine is typically administered orally. The dosage and treatment regimen depend on the specific condition being treated, patient\u2019s age"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_7WGSUZ0i982efOVx2RNsqNqw", "custom_id": "260_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b1407a270daa3c15ec855a77c97fead9", "body": {"id": "chatcmpl-9St83jKxQPnrpn41tQeLbzJYpF6kW", "object": "chat.completion", "created": 1716672127, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thiotepa (thiophosphamide or TSPA) is a chemotherapy drug primarily used to treat various types of cancer, including breast cancer, ovarian cancer, bladder cancer, and certain types of lymphoma. It belongs to the class of alkylating agents that work by binding to DNA, leading to cross-linking of DNA strands and ultimately disrupting DNA replication, which inhibits cancer cell growth. Here are several important aspects of Thiotepa that you should be aware of as a physician:\n\n1. **Indications and Use**: Thiotepa is used to treat a variety of cancers. It is also employed in reduced-intensity conditioning regimens for hematopoietic stem cell transplantation. In addition to intravenous administration, Thiotepa can be administered intracavitary or intravesically for certain types of cancers, specifically for superficial bladder cancer.\n\n2. **Mechanism of Action**: As an alkylating agent, Thiotepa causes cross-links"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ziJAgoOpdU5xVIO4UsSoGwVm", "custom_id": "261_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "704690c1438663e17f3cea358512a890", "body": {"id": "chatcmpl-9St85PcBImLSDvs4RZYLYVJNJ1Q4v", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel, marketed under the name Kymriah, is a form of therapy known as CAR T-cell therapy, approved for use in certain types of cancer. Here are the key aspects you should know:\n\n1. **Indications**: Tisagenlecleucel is approved for use in:\n   - Pediatric and young adult patients up to age 25 with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.\n   - Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**: Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy. It involves genetically modifying the patient\u2019s own T cells to include a CAR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SzDdqcdo6E2UqIckDfNA7gjt", "custom_id": "262_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "987e0a9bb6abba9ca9906d9f39969108", "body": {"id": "chatcmpl-9St84gfkGbzQMRrQyoZZFwVdyv3Zs", "object": "chat.completion", "created": 1716672128, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is an oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. Here's a concise overview of key information based on what was known up to my last update in 2023:\n\n### Mechanism of Action\n\nTivozanib works principally by inhibiting all three VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3). These receptors are involved in the signaling pathways that lead to angiogenesis (the formation of blood vessels), which is crucial for tumor growth and metastasis. By inhibiting these receptors, tivozanib reduces the blood supply to tumors, which can limit their growth and potentially reduce their size.\n\n### Indications\n\nTivozanid's indications can vary by country, but it is primarily used for the treatment of advanced renal cell carcinoma (RCC). It may also be considered for other types of tumors in clinical trials or under different"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_L5kQg8pjhMTfpVvNxETays6R", "custom_id": "263_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c9ae22adba2aa814f3f2d562f0946861", "body": {"id": "chatcmpl-9St84nXD8FCKqTaSDV0iz8vU786F5", "object": "chat.completion", "created": 1716672128, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-versed with various medications, including topotecan. Here are key points about topotecan that might be relevant in clinical practice:\n\n### 1. Mechanism of Action\nTopotecan is a topoisomerase I inhibitor. It works by inhibiting the ability of topoisomerase I to religate single-strand breaks in DNA that it has made. This causes DNA damage and apoptosis, primarily affecting rapidly dividing cells, which is why it is effective as a chemotherapeutic agent.\n\n### 2. Indications\nTopotecan is approved for the treatment of:\n- Small cell lung cancer (SCLC) for patients who have relapsed or are refractory after first-line therapy.\n- Metastatic ovarian cancer in patients who have failed initial or subsequent chemotherapy.\n- It's also used as part of combination therapy or alone for various other cancers under specific conditions or in clinical trials.\n\n### 3. Pharmacokin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FmjtcU10PdSwZ2LXHADTXYW5", "custom_id": "264_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a85c9bc4e2d8741f6a098ac593367934", "body": {"id": "chatcmpl-9St84nWEp5ZMi9zoeCCsVux0wUfLZ", "object": "chat.completion", "created": 1716672128, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene (brand name Fareston) is a medication that belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). It is primarily used for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors. Here's an overview that might be useful for your practice:\n\n### Mechanism of Action\nToremifene works by binding to estrogen receptors and blocking the effects of estrogen on tumors. This action is similar to that of tamoxifen, another SERM. By competing with estrogen for binding sites on cancer cells, toremifene can inhibit the growth of tumors that require estrogen to grow.\n\n### Indications\n- **Primary use**: Treatment of metastatic breast cancer in postmenopausal women.\n- It may also be investigated for other uses, such as prevention of prostate cancer or treatment of other types of cancers, although these uses are less common and not always approved.\n\n### Pharmacokinetics\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JyfWAQmAq8eu90tEa05pVqwh", "custom_id": "265_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc83f33b28588a1184ec17cde7c03b55", "body": {"id": "chatcmpl-9St84CrNe1te6zgl1KwuKuLeJTfgD", "object": "chat.completion", "created": 1716672128, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 Tositumomab (commonly known as Bexxar) used to be treatments involving radioimmunotherapy primarily for non-Hodgkin's lymphoma (NHL). This combination used a monoclonal antibody (tositumomab) linked to a radioactive iodine isotope (Iodine-131). The approach was designed to deliver targeted radiation to the malignant lymphocytes, minimizing exposure to healthy tissues.\n\nHere are several key aspects that were important for physicians:\n\n1. **Mechanism of Action**: Tositumomab is a murine monoclonal antibody targeting the CD20 antigen on B-cells. I-131 emits both beta and gamma radiation, effectively destroying targeted B-cells when attached to the tositumomab antibody.\n\n2. **Indications**: This treatment was specifically indicated for patients with CD20-positive, follicular, non-Hodgkin's lymphoma, with and without"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GqwNdSGCEIpwzhHIL3nABViq", "custom_id": "266_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1eb8d8751283a05967d55ee5ef21a93f", "body": {"id": "chatcmpl-9St84alteicyOMEf7q5CyrXKh7Bpo", "object": "chat.completion", "created": 1716672128, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin, also known by its brand name Yondelis, is a chemotherapy drug primarily used in the treatment of certain types of cancer, including advanced soft tissue sarcoma and relapsed ovarian cancer. It originated from a compound isolated from the sea squirt Ecteinascidia turbinata. Here are some key points about Trabectedin that you, as a physician, should be aware of:\n\n### Mechanism of Action\nTrabectedin binds to the minor groove of DNA, interfering with cell division and DNA repair mechanisms, which leads to cancer cell death. It is thought to have a specific impact on the transcriptional process, particularly affecting cancer cells more than normal cells.\n\n### Indications\n1. **Soft Tissue Sarcoma (STS)**: Trabectedin is approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy including an anthracycline.\n2. **Ovarian Cancer**: It is also approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_DtWh6nNGpi9PsVKUgg6I0lQa", "custom_id": "267_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "91bc0aede0bf0e29ec8aff2dfbd5bcdb", "body": {"id": "chatcmpl-9St85qlWYhhhQJEy0VKceaaptxVgo", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trametinib (also known by its brand name Mekinist) is a medication used predominantly in the treatment of cancer. It is classified as a MEK inhibitor, which specifically inhibitates MEK1 and MEK2. Here's a comprehensive overview that might be useful for your practice:\n\n### Indications\nTrametinib is primarily used for the treatment of specific types of cancers, including:\n- **Metastatic melanoma** with BRAF V600E or V600K mutations, as detected by an FDA-approved test.\n- In combination with dabrafenib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) exhibiting BRAF V600E mutation.\n- Trametinib, in combination with dabrafenib, is also used for treating patients with locally advanced or metastatic anaplastic thyroid cancer with a BRAF V600E mutation.\n\n### Mechanism of Action\nTrametinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SLXS6xvj33iWwDH1GA82JuAR", "custom_id": "268_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4b17d55bbf84288b3339645045d9b048", "body": {"id": "chatcmpl-9St85gLJpV8GWFj1DDBlmwgw8K94t", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tranexamic acid is an important medication that physicians should be familiar with due to its various applications, primarily in managing bleeding. Here are some key points you should know about Tranexamic acid:\n\n1. **Mechanism of Action**:\n   Tranexamic acid is an antifibrinolytic agent. It works by binding to plasminogen and preventing its interaction with fibrin, thus inhibiting the fibrinolysis process. This action helps in reducing bleeding.\n\n2. **Indications**:\n   - **Menorrhagia**: It is effective in reducing menstrual blood loss.\n   - **Surgical bleeding**: Used in surgeries to reduce blood loss, including cardiac surgery, orthopedic surgery, and dental extractions, especially in patients with hemophilia.\n   - **Trauma**: It is used in the management of trauma patients at risk of significant hemorrhage.\n   - **Hereditary angioedema**: Though not a primary treatment, it can be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bYKIqaC2NYXqhZRPyN2HbwyK", "custom_id": "269_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f46dc7c2dd7d57c6dca19faa3ae662b6", "body": {"id": "chatcmpl-9St85WhF02e7yd0nIB8IVPjhBKG5y", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab (sold under the brand name Herceptin among others) is a monoclonal antibody that is commonly used in the treatment of HER2-positive breast cancer. Understanding the following key aspects is essential for a physician prescribing or managing patients on Trastuzumab:\n\n1. **Mechanism of Action**: Trastuzumab specifically binds to the HER2/neu receptor, a protein overexpressed in 15-30% of early-stage breast cancers. By binding to the HER2 protein, Trastuzumab inhibits the proliferation of cells that overexpress this receptor. \n\n2. **Indications**:\n   - **Breast Cancer**: Used primarily for HER2-positive breast cancer. It is effective in both early-stage and metastatic scenarios. It can be used as a single agent or in combination with other chemotherapeutic agents.\n   - **Gastric Cancer**: Also approved for the treatment of HER2-positive metastatic gastric or gastro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_85y2pKZVbexnxpHD2BOda0D9", "custom_id": "270_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f531b6b42c0b354a04c6fca30914ade5", "body": {"id": "chatcmpl-9St85EHQolwqwAHWNowlHTIHMgqBH", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is an investigational monoclonal antibody targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a receptor on T cells that, when activated, downregulates the immune response. By inhibiting CTLA-4, tremelimumab acts as an immune checkpoint inhibitor, enhancing the body's immune response against cancer cells.\n\nHere are several key aspects that physicians should consider about Tremelimumab:\n\n1. **Mechanism of Action**: Tremelimumab works by binding to CTLA-4, blocking its interaction with its ligands (CD80/CD86). This blockade prevents the inhibitory signals typically sent by CTLA-4 from being transmitted, which potentially increases the activity of the immune system against cancer cells.\n\n2. **Clinical Trials and Efficacy**: Tremelimumab has been studied in various clinical trials involving patients with different types of cancer, including melanoma, mesothelioma, and non-small"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LoCBOx7pMHxNFMIZbQT7wDgX", "custom_id": "271_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4fb5b5d0cd2ec92488489fe6182db02b", "body": {"id": "chatcmpl-9St85zM0397kOAtcRGQYzojKWt9HQ", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a medication primarily used as a chemotherapeutic agent and in conditioning regimens for hematopoietic stem cell transplantation (HSCT). Here are the key points you should know about Treosulfan:\n\n1. **Mechanism of Action**:\n   Treosulfan is a prodrug that, upon activation, gets converted to alkylating agents, predominantly diepoxybutane. It causes cross-linking of DNA, leading to cell cycle arrest and apoptosis in cancer cells. The mechanism is similar to other alkylating agents like cyclophosphamide, but its specific characteristics and metabolites may offer some advantages in terms of toxicity profiles and efficacy.\n\n2. **Indications**:\n   Treosulfan is primarily used for:\n   - Ovarian cancer treatment, both as a first-line therapy and in recurrent cases.\n   - As part of conditioning regimens prior to hematopoietic stem cell transplantation, particularly beneficial in elderly patients or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YRoawcLXfa03UF0E5ZeguY4W", "custom_id": "272_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "40bf01462d5cd5f1c9221758e0aabe9b", "body": {"id": "chatcmpl-9St8575yLPE4qdzUlrlajjn80U5re", "object": "chat.completion", "created": 1716672129, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil, marketed under the brand name Lonsurf, is a combination medication used for the treatment of certain types of cancer. Here are some key points about it:\n\n1. **Indications**: Trifluridine and tipiracil is approved for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Additionally, it is also approved for the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, taxane, and possibly HER2/neu-targeted therapy in HER2/neu positive tumors.\n\n2. **Mechanism of Action**: Triflur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_m1y5MGnPJvzNaLI3WcJInwiU", "custom_id": "273_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2c5b3a42e194a35f0886b3dda086e9ef", "body": {"id": "chatcmpl-9St86CfGwkd9KYPX7iqIW4RMn6zo4", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-responsive cancers such as prostate cancer, and for conditions like endometriosis and uterine fibroids. Here are several key points that you, as a physician, should be aware of regarding Triptorelin:\n\n1. **Mechanism of Action**: Triptorelin acts by initially stimulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, which leads to an increase in testosterone (in males) and estrogen (in females). With sustained administration, Triptorelin desensitizes the pituitary gland, leading to a decrease in FSH and LH levels, ultimately reducing the levels of sex hormones.\n\n2. **Indications**:\n   - **Prostate Cancer**: It is used for the treatment of advanced prostate cancer by reducing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DRybqeODlgtmrGGAFj1nuW20", "custom_id": "274_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6d86da293cbf52b251cba882a20a7e04", "body": {"id": "chatcmpl-9St86OsHwNuqUw94xzSbGxouDqB4R", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate (valproic acid or sodium valproate, and also known as divalproex sodium when combined with sodium valproate) is a medication primarily used to treat epilepsy and bipolar disorder, and to prevent migraine headaches. It is essential for physicians to be aware of several important aspects of valproate, including its mechanisms of action, uses, side effects, and special considerations:\n\n### Mechanism of Action\nValproate acts as an anticonvulsant and mood stabilizer. It is believed to work by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain, a neurotransmitter that helps to calm nerve activity. Additionally, it modulates sodium and calcium channels, which contributes to its anticonvulsant properties.\n\n### Indications\n1. **Epilepsy**: Valproate is effective for the treatment of various seizure types, including absence seizures, tonic-clonic seizures, myoclonic seizures, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7sDZ2SW1quF6PLen3Jcm2rKH", "custom_id": "275_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3af882d60c78fe2450c06203314eeb98", "body": {"id": "chatcmpl-9St86EYSu3jY3hYumgofnvwAVb1BN", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin (brand name Valstar) is a chemotherapy medication primarily used in the treatment of Bacillus Calmette-Guerin (BCG) resistant carcinoma in situ (CIS) of the urinary bladder. Here are some key points you should know about Valrubicin:\n\n1. **Indication and Usage**: Valrubicin is approved for intravesical therapy in patients with BCG-resistant CIS of the urinary bladder who are not candidates for immediate cystectomy. It is vital for treating patients who either cannot undergo surgery or choose not to as an immediate treatment option.\n\n2. **Mechanism of Action**: Valrubicin is an anthracycline antibiotic that has antitumor activity. It interferes with the growth of cancer cells, which are eventually destroyed by the body. It is administered directly into the bladder through a catheter, minimizing systemic exposure and side effects.\n\n3. **Administration**: It is administered intravesically, which involves instillation directly into"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MM3bpSE4XfaGJLyZ6jBr7eYE", "custom_id": "276_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d2787b6bc84e5176774be3e3c0f6581", "body": {"id": "chatcmpl-9St86uiQIx2Uu0VikU8WuxRiYn7FE", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a targeted therapy medication used primarily in the treatment of medullary thyroid cancer (MTC). Here are some crucial points about Vandetanib that can assist you in clinical settings:\n\n1. **Indications**: Vandetanib is approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. The effectiveness of vandetanib in this setting is based on an improvement in progression-free survival. Final survival data is not yet conclusive.\n\n2. **Mechanism of Action**: Vandetanib is a tyrosine kinase inhibitor. It inhibits multiple targets including VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), and RET (rearranged during transfection) tyrosine kinases. These pathways can contribute to tumorigenesis in medullary thyroid cancer, angiogenesis, and tumor growth.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_is6vLMpkJy8dWxE8LQAvCrUd", "custom_id": "277_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62978973a0ed99fd730fbdbf91f138b3", "body": {"id": "chatcmpl-9St86dZgytGv2rdeNDG8S2IrsN75w", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib (brand name Zelboraf) is a medication used primarily in the treatment of late-stage melanoma, the most serious type of skin cancer, which exhibits a specific genetic mutation known as BRAF V600E. Here are some key aspects you should be aware of:\n\n### Mechanism of Action\nVemurafenib is a BRAF inhibitor. It specifically inhibits the BRAF protein with the V600E mutation but not wild-type BRAF. This mutation leads to abnormal stimulation of the downstream MEK-ERK signaling pathway, promoting cell growth. By inhibiting this mutant BRAF protein, vemurafenib helps to stop or slow the growth of the cancer cells.\n\n### Indications\n- **Melanoma:** Vemurafenib is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. It is not effective in patients whose melanoma lacks this mutation.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cwvQNJWDp3o2ZEd25MHFf3Dj", "custom_id": "278_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "def8bd1625fb2f757f319e95a60b01ef", "body": {"id": "chatcmpl-9St86TScZbdw0GVMcPDCqTcklSW6B", "object": "chat.completion", "created": 1716672130, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is a targeted therapy used primarily in the treatment of chronic lymphocytic leukemia (CLL) and some other hematological malignancies. As a physician, here are some key points you should know about venetoclax:\n\n### Mechanism of Action\nVenetoclax is a selective inhibitor of the B-cell lymphoma 2 (BCL-2) protein. By inhibiting BCL-2, venetoclax promotes apoptosis (cell death) in cancer cells that overexpress this protein. BCL-2 is an anti-apoptotic protein and is found to be overexpressed in many types of cancers, particularly in CLL.\n\n### Indications\n1. **Chronic Lymphocytic Leukemia (CLL) with 17p deletion**: It is indicated for the treatment of CLL in patients who have a chromosomal abnormality called 17p deletion and have received at least one prior therapy.\n2. **CLL without "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bzvmXgseC0nVFOuyy7iKKL3d", "custom_id": "279_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "076cb5cab8ffb5ca4ac6fa7f9d0fa7b8", "body": {"id": "chatcmpl-9St87U57rEiWOfAJ0ER93KA9MUFiK", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication used in the treatment of various cancers. As a physician, here are some key points you should know about vinblastine:\n\n1. **Mechanism of Action**: Vinblastine belongs to the class of vinca alkaloids. It works by inhibiting microtubule formation, which is essential for cell division. This disruption leads to cell cycle arrest at the metaphase, ultimately inhibiting mitosis.\n\n2. **Indications**: Vinblastine is primarily used for the treatment of Hodgkin's lymphoma, non-Hodgkin's lymphomas, testicular cancer, and other types of cancer such as breast cancer and bladder cancer.\n\n3. **Administration**: Vinblastine is administered intravenously. Proper administration technique is crucial to prevent extravasation, which can cause severe local tissue damage.\n\n4. **Dosage**: The dosage of vinblastine varies based on the type of cancer, the patient\u2019s body surface area, overall health"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zQqyYY5ez45qQ6wmask9Ufrw", "custom_id": "280_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e3e153008b9bc4ba66ccad11979e951", "body": {"id": "chatcmpl-9St8755UhgNSTYrq7OG72wFkC5svt", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is a chemotherapy drug widely used in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors such as breast and lung cancers. It belongs to a class of drugs known as vinca alkaloids, which are derived from the periwinkle plant (Catharanthus roseus). Here are some key points you should know about Vincristine:\n\n1. **Mechanism of Action:**\n   Vincristine works by binding to tubulin, a protein that is a structural component of microtubules necessary for cell division. By binding to tubulin, vincristine inhibits the assembly of microtubules, thereby blocking the ability of cells to form the spindle apparatus necessary for mitosis. This leads to cell cycle arrest at the metaphase, ultimately resulting in cell death.\n\n2. **Indications:**\n   Vincristino is used in the treatment of:\n   - Acute lymphocytic leukemia (ALL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JNI8fP1yS27jv1wGnyahuand", "custom_id": "281_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4699300b5ac7d1ccb2bc6c0ebb120894", "body": {"id": "chatcmpl-9St87XM8A3BV3yg47eXx2hVSW5BHG", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal is a form of the standard vincristine drug, which has been encapsulated within liposomes. This formulation method is typically employed to improve the drug's delivery and to decrease certain side effects. Here\u2019s what you should know about Vincristine liposomal:\n\n### Mechanism of Action\nJust like traditional vincristine, vincristine liposomal inhibits microtubule formation in the mitotic spindle, which results in the disruption of the mitotic process and cell cycle arrest at the metaphase. This mechanism is crucial for its efficacy in treating cancer by preventing cancer cells from successfully reproducing.\n\n### Indications\nVincristine liposomal is primarily used in the treatment of acute lymphoblastic leukemia (ALL). It is important to verify if there are new or additional indications by checking the latest clinical guidelines or official drug label information.\n\n### Pharmacokinetics\nThe liposomal delivery system modifies the distribution and half-life of vincristine in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KwiZfSEUuphCE3TjBYX2stqR", "custom_id": "282_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41d4f906a195430d434f8a10c1efb91b", "body": {"id": "chatcmpl-9St87GL7mmyMPD08z6B94sPkiggbL", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is a chemotherapeutic agent belonging to the vinca alkaloid family, similar to vincristine and vinblastine. It is primarily used in the treatment of various cancers, including acute lymphocytic leukemia, lung cancer, and melanoma. Here are some crucial aspects you should know about vindesine as a physician:\n\n**Mechanism of Action:**\nVindesine works by inhibiting microtubule formation in the mitotic spindle, which leads to cell cycle arrest at the metaphase. This disruption in mitosis eventually causes apoptosis or programmed cell death in cancer cells.\n\n**Indications:**\nVindesine is mainly used in chemotherapy protocols for certain types of cancers, including:\n- Acute lymphocytic leukemia (ALL)\n- Non-small cell lung cancer (NSCLC)\n- Breast cancer\n- Malignant melanoma\n\n**Administration:**\nVindesine is administered intravenously. Dosage and administration schedules may vary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_s1oQNyNT7M3OIAmm4t6gzbzW", "custom_id": "283_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8447285ed35ab53e930da6fb867c9c06", "body": {"id": "chatcmpl-9St871UV1IL1LXMZEYdzLHKL1wkE4", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a semi-synthetic vinca alkaloid that is derived from vinblastine, a microtubule inhibitor used primarily for the treatment of cancer. As a physician, here are key points you should know about vinflunine:\n\n1. **Indications**: Vinflunine is approved in some regions, such as the European Union, for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen. Its use can vary by country based on local approval status.\n\n2. **Mechanism of Action**: Vinflunine inhibits microtubule dynamics, which results in the inhibition of mitotic and interphase cellular functions. It disrupts microtubule assembly and leads to cell cycle arrest and apoptosis. Its anti-tumor activity is also attributed to anti-angiogenic effects.\n\n3. **Administration**: The drug is administered intravenously, and dosing typically depends on factors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oZ2PEDRK8b8S0KjbdjMKxwR3", "custom_id": "284_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "39056ef0a8f14022ef9c266a2e33c734", "body": {"id": "chatcmpl-9St87BPoYlBhhkWi6rfcz2lb8BKMY", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine (also known by its brand name Navelbine) is a chemotherapy medication used primarily in the treatment of various cancers, including non-small cell lung cancer and breast cancer. It is a member of the vinca alkaloid class of anticancer agents, derived from the periwinkle plant. Here\u2019s an overview of key information you should know about Vinorelbine:\n\n### Mechanism of Action\nVinorelbine works by interfering with the microtubule structures within the cell. It inhibits mitosis (cell division) by binding to tubulin and preventing the polymerization of the microtubules, leading to cell death.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Often used as a single agent or in combination with cisplatin or other anticancer agents.\n- **Advanced Breast Cancer:** Used in metastatic settings, either as monotherapy or in combination with other chemotherapeutic drugs.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zNjK5HcgcIdukpFoNQoGcLUe", "custom_id": "285_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5c7db2f71c64ac1d078790a3eb4899d4", "body": {"id": "chatcmpl-9St874vMQ9RsiYpV8wTgKz0SdkKNZ", "object": "chat.completion", "created": 1716672131, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib (trade name Erivedge) is an oral medication used primarily for the treatment of advanced basal cell carcinoma (BCC). Here are several important aspects about Vismodegib that you, as a physician, may find useful:\n\n1. **Mechanism of Action**: Vismodegib acts as an inhibitor of the Hedgehog signaling pathway, which is crucial in the development and homeostasis of tissues and organs. This pathway is aberrantly activated in most basal cell carcinomas. Vismodegib specifically targets and inhibits a protein called Smoothened (SMO), a component of the Hedgehog pathway.\n\n2. **Indications**:\n   - It is approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery, or who are not candidates for surgery or radiation.\n   - It is also being studied for other types of cancers where the Hedgehog pathway is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_Rz6ZN6fsZCwg1NbrLGokCwiz", "custom_id": "286_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "054d847e0a8984c32d1cfd05ddc992b4", "body": {"id": "chatcmpl-9St880Dam8q51sZwYt6DzWB6cSzeR", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its brand name Zolinza, is a histone deacetylase (HDAC) inhibitor used in the treatment of cancer. Here are some key points you should know about vorinostat:\n\n1. **Mechanism of Action**: Vorinostat works by inhibiting the activity of histone deacetylase enzymes. This inhibition leads to an increase in the acetylation of histone proteins, thereby altering the expression of genes that control cell survival, proliferation, and differentiation. This can induce cancer cell apoptosis (programmed cell death), differentiation, and/or senescence.\n\n2. **Indications**: Vorinostat is approved by the FDA for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. Research is ongoing for its potential use in other types of cancers.\n\n3. **Administration**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pt3PgiFy4JRNz2RLYtgAe3bP", "custom_id": "287_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0d708f6472eaebb85ec09200e0895fcb", "body": {"id": "chatcmpl-9St88rSOy4qPLfKpFVgIau5iHQyce", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zidovudine (AZT) is an antiretroviral medication that is primarily used to treat HIV/AIDS. As a physician, there are several important aspects you should be aware of regarding the use, mechanism, side effects, and considerations of zidovudine:\n\n### 1. Mechanism of Action\nZidovudine belongs to the class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). It works by inhibiting the activity of reverse transcriptase, an enzyme crucial for the replication of HIV. By doing so, zidovudine interferes with the viral replication cycle and helps decrease the viral load in the body.\n\n### 2. Indications\n- **HIV treatment:** Zidovudine is used in combination with other antiretroviral medications to treat HIV-1 infection.\n- **Prevention of mother-to-child transmission:** It can be used to prevent vertical transmission of HIV from an infected"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2bdC9kQPPFs7FQAPip5ynGmj", "custom_id": "288_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1e54c396d28853824311afe1c1d4e39d", "body": {"id": "chatcmpl-9St88nC5pWaYErVw3j0E0rybgELpY", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, marketed under brand names such as Zaltrap, is a biologic medication that functions as a vascular endothelial growth factor (VEGF) inhibitor. It\u2019s engineered through the fusion of the Fc portion of human IgG1 to the extracellular domains of VEGF receptors 1 and 2, which acts to bind VEGF and prevent it from attaching to its receptors on the surface of endothelial cells. This inhibits the growth of blood vessels that supply tumors with oxygen and nutrients, thereby halting tumor growth.\n\n### Key Points for Physicians:\n\n**1. Indications:**\n   - Ziv-aflibercept is primarily approved for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.\n\n**2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_JSYH3MTyTlMigbzR836m6MXk", "custom_id": "289_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5077036f3778839a12ca59e456fe1829", "body": {"id": "chatcmpl-9St88SAmqfwLGu3ebOZcGQi4JtNIz", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib is a targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are key points that you, as a physician, might find important:\n\n1. **Mechanism of Action**:\n   Capmatinib is a small molecule inhibitor of the c-Met receptor tyrosine kinase. The c-Met receptor can be oncogenic when mutated or overexpressed, and is known to be involved in cancer cell growth, invasion, and angiogenesis.\n\n2. **Indications**:\n   As of my last update, Capmatinib is specifically approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. It's important that this mutation is confirmed through genomic testing prior to starting treatment.\n\n3. **Administration**:\n   Capmatinib is administered orally, which can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qyQFOkYDUqX9EaqfDF8Vg8eY", "custom_id": "290_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d7ee9b310efd773ede23d907541d8cf6", "body": {"id": "chatcmpl-9St88KPhuJRNLkL4XuoACmlZaWbuf", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (brand name Padcev) is a medication used in oncology, specifically for the treatment of urothelial carcinoma. Here are the key points you should know about Enfortumab vedotin:\n\n1. **Indication and Usage**: Enfortumab vedotin is approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy. In December 2021, it was also approved for patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.\n\n2. **Mechanism of Action**: Enfortumab vedotin is an antibody-drug conjugate (ADC). The antibody component targets Nectin-4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FncXnRw0FAQ2oXRwOGZsXPiQ", "custom_id": "291_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98771341fbc9c83777dd537ec330cf5b", "body": {"id": "chatcmpl-9St88oEsk763izggxzza6ky9iKKzj", "object": "chat.completion", "created": 1716672132, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan, also known as fam-trastuzumab deruxtecan-nxki, is an antibody-drug conjugate (ADC) indicated for the treatment of patients with certain types of breast cancer and other HER2-expressing cancers. Here are some important aspects of Trastuzumab deruxtecan that you, as a physician, should know:\n\n1. **Mechanism of Action**: Trastuzum_decoruxtecan consists of three main components: a HER2-targeting antibody (trastuzumab), a cleavable linker, and a cytotoxic agent (deruxtecan, a topoisomerase I inhibitor). The antibody specifically binds to the HER2 receptor on cancer cells, leading to internalization of the ADC and release of the cytotoxic agent within the cancer cell, causing cell death.\n\n2. **Indications**: As of the latest updates:\n   - It has been approved by regulatory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tqi0lwd3PbU7xKvlTxMp5m01", "custom_id": "292_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c89ec136828f85db541dba2c3d6966a6", "body": {"id": "chatcmpl-9St894qZhQTxKdA0G60izpPcWaAJ2", "object": "chat.completion", "created": 1716672133, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a medication used primarily in the management of advanced prostate cancer. As a physician, here are key aspects you should know about Abarelix:\n\n1. **Mechanism of Action**: Abarelix works as a gonadotropin-releasing hormone (GnRH) antagonist. It directly blocks the GnRH receptors in the pituitary gland, leading to a rapid reduction in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn leads to decreased testosterone production by the testes.\n\n2. **Indications**: The primary use of Abarelix is for the treatment of hormone-responsive advanced prostate cancer. It is particularly used to manage cases where immediate androgen deprivation is needed.\n\n3. **Administration**: Abarelix is administered via intramuscular injection. The dosing regimen typically starts with a higher dose followed by regular monthly injections.\n\n4. **Side Effects**: Common side effects include hot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TjfTCmcE7m3ViwOYXWb4QcbI", "custom_id": "293_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3ebed49887dbffe811b6e0cc89f3f811", "body": {"id": "chatcmpl-9St89QvjtpXTcSyCa6Reh0VcUEy1Y", "object": "chat.completion", "created": 1716672133, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin, also known by its brand name Blenrep, is an antibody-drug conjugate (ADC) approved for the treatment of certain types of multiple myeloma. It consists of a monoclonal antibody targeting B-cell maturation antigen (BCMA), a protein commonly expressed on the surface of myeloma cells, linked to a cytotoxic agent, mafodotin, which is a microtubule inhibitor. Here are key points you should know about Belantamab mafodotin:\n\n1. **Indication**: Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n2. **Mechanism of Action**: As an ADC, the drug specifically binds to BCMA on my"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_08NxSNpqsNjbHu6nv0DbDlil", "custom_id": "294_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "68eb04237e90a0f677df4cd38ae93469", "body": {"id": "chatcmpl-9St89q6KHM2qInfL1YqiGdGyqyPgp", "object": "chat.completion", "created": 1716672133, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is a medication used primarily in oncology, specifically for the treatment of breast cancer. Here are some key points about tucatinib that you should know as a physician:\n\n1. **Indication and Use**:\n   - Tucatinib is approved for the treatment of HER2-positive breast cancer. It is specifically indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases.\n   - Tucatinib is used in combination with trastuzumab and capecitabine for patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n2. **Mechanism of Action**:\n   - Tucatinib is a tyrosine kinase inhibitor (TKI) that specifically inhibits the kinase activity of HER2 (human epidermal growth factor receptor 2), which is overexpressed in certain types of breast cancer. By inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_P4XMaEeCY1hciVvT2UTuZY8e", "custom_id": "295_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e29261f594db108345b3bc889042f6a", "body": {"id": "chatcmpl-9St89wf0WcxxPrarJSyRWI2WLsqAO", "object": "chat.completion", "created": 1716672133, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of any medication you administer, including daratumumab and hyaluronidase-fihj, which is a combination used under the brand name Darzalex Faspro. Here are key aspects to consider:\n\n1. **Indication and Usage:**\n   - Daratumumab and hyaluronidase-fihj is approved for use in treating patients with multiple myeloma. Specifically, it may be prescribed both for newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and for patients who have previously received treatment.\n\n2. **Mechanism of Action:**\n   - **Daratumumab** is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to CD38, daratumumab induces cell death through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cyt"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0tIuu763hpGfrnLDd8H7SmQE", "custom_id": "296_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1f0e40fc356fb993c099c9bda690b8d7", "body": {"id": "chatcmpl-9St89tQoiYHLCLO83Z5zwu3KQyJyT", "object": "chat.completion", "created": 1716672133, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin, also known as 9-cis-retinoic acid, is an oral retinoid medication primarily used to treat chronic hand eczema (CHE) that is unresponsive to topical corticosteroids. It is known for its ability to modulate gene expression by binding to both retinoid X receptors (RXRs) and retinoic acid receptors (RARs), influencing cell differentiation and proliferation.\n\nHere are key points about alitretinoin that you, as a physician, might find useful:\n\n**1. Indications:**\n   - Primarily prescribed for severe chronic hand eczema not adequately responsive to potent topical steroids.\n   - May also be explored for use in other conditions such as severe forms of other skin diseases, but these uses are less commonly documented.\n\n**2. Mechanism of Action:**\n   - Alitretinoin binds to both RXR and RAR nuclear receptors, which leads to modulation of gene expression."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aQ41xuNLYwjB6kQDuULOxbBU", "custom_id": "297_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "adcf70467799ea8d91cb9bad7da5da0e", "body": {"id": "chatcmpl-9St8ATWsc7VcOCYVDuwAOhb673TGn", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, also known by its brand name Tecartus\u2122, is an autologous, anti-CD19 transduced CD3-positive cell, chimeric antigen receptor (CAR) T-cell therapy. It's primarily approved for the treatment of certain types of hematologic malignancies, including relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL) in adult patients.\n\nHere are some key points that you, as a physician, should know about brexucabtagene autoleucel:\n\n1. **Mechanism of Action**: The therapy involves modifying the patient's own T cells to include a chimeric antigen receptor (CAR) that specifically targets CD19, a protein expressed on the surface of some B cells. This modification allows the T cells to recognize and kill CD19-expressing cancer cells.\n\n2. **Indications**:\n   - **Mant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_R9MBVIc1UzLJWNtipN7axD1H", "custom_id": "298_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "34ba5c8044b237ad98df1315bc10333e", "body": {"id": "chatcmpl-9St8AIneXLqlxTZb4UrCcVSKvJRKK", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alpelisib is an orally administered medication that is used primarily to treat certain types of breast cancer. Here are the key points you should consider as a physician:\n\n1. **Indication**: Alpelisib, sold under the brand name Piqray, is approved by the FDA to be used in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. The presence of a PIK3CA mutation needs to be confirmed by an FDA-approved test before starting treatment.\n\n2. **Mechanism of Action**: Alpelisib specifically inhibits the PI3K (phosphoinositide 3-kinase) alpha isoform. PI3K is a part of the PI3K/AKT/mTOR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MT4db3H94KRI56rYZSFPXQGC", "custom_id": "299_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0b89a877c41585e384fa4283257a8c1", "body": {"id": "chatcmpl-9St8AbOoGODu4A5CymyGj9BDQXCYa", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide (also known as benzantrazole or amonafide malate) is a chemotherapeutic agent classified as a DNA intercalator and topoisomerase II inhibitor. Initially researched for its potential in treating various types of cancer, amonafide functions primarily by interfering with DNA replication and transcription, leading to apoptosis or programmed cell death in cancer cells.\n\nHere are a few key points a physician should know about Amonafide:\n\n1. **Mechanism of Action**: Amonafide intercalates into DNA and inhibits topoisomerase II, an enzyme crucial for DNA replication and transcription. This disruption leads to the inhibition of tumor cell growth and induction of apoptosis.\n\n2. **Clinical Trials and Usage**: Amonafide has been evaluated in clinical trials for its effectiveness in treating various cancers, including breast cancer, leukemia, and solid tumors. However, it is not widely used today, largely due to its side effect profile and the availability of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2pvl392XGK982t3SNn43CQtx", "custom_id": "300_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "efecf1cb1620632a6b43726e4254549d", "body": {"id": "chatcmpl-9St8ALyTZZ1U8V2WDjg28mOpbzZuX", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin is a commonly used antibiotic that falls under the category of penicillin-like antibiotics. It is used to treat a wide range of bacterial infections, including pneumonia, bronchitis, and infections of the ear, nose, throat, skin, and urinary tract. Here are some key points you, as a physician, should know about amoxicillin:\n\n### 1. **Mechanism of Action**\n   Amoxicillin works by inhibiting the synthesis of bacterial cell walls, ultimately leading to cell lysis and death. It achieves this by binding to penicillin-binding proteins located inside the bacterial cell wall.\n\n### 2. **Spectrum of Activity**\n   Amoxicillin is effective against a wide range of Gram-positive and some Gram-negative bacteria. This includes pathogens like Streptococcus spp., Enterococcus spp., and Escherichia coli. However, it is not effective against methicillin-resistant Staphylococcus aureus (MRSA) or P"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ZbZSHkKIe4OquvsOaAx2BA3C", "custom_id": "301_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e1d68b9a8aae4d6d8e1a1bc812319fe7", "body": {"id": "chatcmpl-9St8Aj1d7Ed0CtEqFqtwNA4pYgkg5", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Aumolertinib (also known by its research code AST2818) is a third-generation oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It has been designed to target both EGFR mutations and the T790M resistance mutation, which can emerge after treatment with first- and second-generation EGFR inhibitors. Here are some key aspects you should be aware of:\n\n1. **Mechanism of Action:** Aumolertinib selectively inhibits both EGFR sensitizing mutations and the T790M resistance mutation. By doing this, it helps in managing non-small cell lung cancer (NSCLC) in patients who have developed resistance to earlier generation EGFR TKIs due to the T790M mutation.\n\n2. **Efficacy and Usage:** It is mainly used for the treatment of NSCLC, particularly in patients who have specific EGFR mutations and have developed resistance to other treatments. Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zfLR0L4j2Zoap541jm9VEjDd", "custom_id": "302_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6f65b5ebe88f7ce37333250d482e6cab", "body": {"id": "chatcmpl-9St8AK1OBTbnoVZcA3XDpVMyC0Lr5", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy medication primarily used for the treatment of certain types of cancer. Here are some key points you should know about pemiginatib as a physician:\n\n1. **Indications**: Pemigatinib is approved by the FDA for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This condition is a type of bile duct cancer that is rare and aggressive.\n\n2. **Mechanism of Action**: Pemigatinib is a kinase inhibitor, specifically targeting the fibroblast growth factor receptors (FGFR) family. FGFRs play an essential role in cell growth and survival. By inhibiting these receptors, pemigatinib can block the growth of cancer cells that have mutations or alterations in these receptors.\n\n3. **Administration**: P"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G1TDZQGAfZ1rhUQuf6RggOvo", "custom_id": "303_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6b6733053c40c311320b5a0c820c10ea", "body": {"id": "chatcmpl-9St8ATd8UZ6hHfCBFOdcGXhauJo3F", "object": "chat.completion", "created": 1716672134, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib, approved by the FDA in May 2020, is an oral kinase inhibitor predominantly used for the treatment of gastrointestinal stromal tumors (GIST). Here are some key points about Ripretinib that you, as a physician, should be aware of:\n\n1. **Indications**: Ripretinib is indicated for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib. It may also be used in other contexts based on emerging research and off-label uses.\n\n2. **Mechanism of Action**: Ripretinib acts by inhibiting a spectrum of kinases, including KIT and PDGFRA mutant kinases, which are commonly mutated in GIST. It inhibits both the primary activation of these kinases and their mutated forms across a broad spectrum of mutations.\n\n3. **Dosage and Administration**: Typically, Ripretinib is administered orally at a dose of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_Y4UPLXwoZLqL2nJyuCPwE0gJ", "custom_id": "304_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9e9ee1b6ca650f9b23afc724f426c7fe", "body": {"id": "chatcmpl-9St8BYHJHQP8Rj6QGPfvsEwAiDA2L", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib (brand name Retevmo) is a medication approved for the treatment of certain types of cancer, particularly those driven by rearranged during transfection (RET) alterations. Here are some key aspects that you, as a physician, should know about selpercatinib:\n\n1. **Indications**: Selpercatinib is indicated for the treatment of:\n   - Advanced RET fusion-positive non-small cell lung cancer (NSCLC).\n   - Advanced or metastatic RET-mutant medullary thyroid cancer (MTC).\n   - Advanced RET fusion-positive thyroid cancer.\n   The approval of selpercatinib for these indications is particularly important given the difficulty in effectively treating cancers with RET alterations using traditional chemotherapy.\n\n2. **Mechanism of Action**: Selpercatinib is a selective RET kinase inhibitor. It specifically targets and inhibits the activity of the RET protein, which can drive tumor growth when altered or overactive.\n\n3. **E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sz9Ng88hKlGGubOCDiAV1ueD", "custom_id": "305_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c08a87e7883b2a47b5be5d438bad1cb6", "body": {"id": "chatcmpl-9St8Bgsnodh7ImSodmyda5svkt6yW", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination medication that physicians should be aware of, especially those dealing with hematologic conditions. Here's an overview to assist in understanding how this combination works and its clinical applications:\n\n### Mechanism of Action:\n- **Decitabine**: Decitabine is a nucleoside metabolic inhibitor that specifically inhibits DNA methyltransferase, an enzyme responsible for methylating DNA. This demethylation can reactivate silenced genes that suppress tumors, essential in treating cancer. Decitabine is incorporated into DNA and results in hypomethylation which can inhibit the growth of cancer cells.\n- **Cedazuridine**: Cedazuridine is a cytidine deaminase inhibitor. By inhibiting this enzyme, cedazuridine helps to increase the bioavailability of decitabine when administered orally by reducing its degradation in the gastrointestinal tract and liver.\n\n### Indications:\n- **Brand Name (example: In"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MYAkbnH2z3bD4WBtj8u6J0d6", "custom_id": "306_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3178df61103c737a969ec732db193988", "body": {"id": "chatcmpl-9St8BOvs18uNalZFopJ4BTsUtVv2F", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as nausea, heartburn, indigestion, upset stomach, and diarrhea. Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**: Bismuth subsalicylate has antacid and mild antibacterial properties. It acts by coating the lining of the gastrointestinal tract and protecting it against stomach acid and bacterial toxins. Additionally, it has antisecretory properties, reducing fluid secretions in the intestines, and anti-inflammatory effects due to the salicylate component.\n\n2. **Indications**: It is mainly used for the relief of symptoms related to:\n   - Diarrhea (including traveler's diarrhea)\n   - Gastroenteritis\n   - Nausea and upset stomach\n   - Heartburn\n   \n3. **Dosage and Administration**: Adult dosages commonly involve 524 mg tablets or liquid equivalent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Wl2F5YaBjOQXtP9Ff8GzaULt", "custom_id": "307_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d29b4fd214b8e94368bd33e52958f3a9", "body": {"id": "chatcmpl-9St8BOVNpda8eN5jKw2Q0Vds652W7", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Camrelizumab is an anti-PD-1 monoclonal antibody used in the treatment of various types of cancer. It works by inhibiting the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking PD-1 interactions, camrelizumab enhances the body's immune response against cancer cells.\n\nHere are a few key points about camrelizumab that might be useful for a physician:\n\n1. **Indications and Approval:**\n   Camrelizumab has been approved in China for several indications, including Hodgkin's lymphoma, hepatocellular carcinoma, and non-small cell lung cancer. Its usage may vary based on regional regulatory approvals, so it's important to check local guidelines.\n\n2. **Mechanism of Action:**\n   As an anti-PD-1 antibody, camrelizumab binds to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KIDRGr3Xsyg56Wm8DsxhoTgd", "custom_id": "308_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "233796074df1e92875edd3386eb470e3", "body": {"id": "chatcmpl-9St8B4RB5AuUtjzebL6IIxNvdaw63", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Relugolix is an oral medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the production of certain hormones from the pituitary gland, thus reducing the levels of sex hormones \u2014 testosterone in men and estrogen and progesterone in women. Here are some key points you might consider as a physician:\n\n1. **Indications:**\n   - **In Men:** Relugolix is used for the treatment of advanced prostate cancer. It is utilized to achieve androgen deprivation therapy (ADT).\n   - **In Women:** Relugolix is used in combination therapy with estradiol and norethindrone acetate for the management of moderate to severe symptoms of uterine fibroids in premenopausal women. Additionally, it is used for the management of moderate to severe endometriosis pain.\n\n2. **Mechanism of Action:**\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hJ6xopB5OY2w5ZjSBLMZYOEG", "custom_id": "309_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b29c0e4f0306d8ee37ebf879b9b2bd5", "body": {"id": "chatcmpl-9St8BSeeboZhfIvS9vvkwzM21PduY", "object": "chat.completion", "created": 1716672135, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant is a novel oral selective estrogen receptor degrader (SERD) that is being investigated for its potential use in the treatment of estrogen receptor-positive (ER+) breast cancer. Here are several key points that physicians should know about Elacestrant:\n\n1. **Mechanism of Action**: Elacestrant functions by binding to the estrogen receptor and promoting its degradation. This leads to decreased ER signaling, which can inhibit the growth of estrogen receptor-positive breast cancer cells. Unlike selective estrogen receptor modulators (SERMs) and aromatase inhibitors, SERDs like Elacestrant can degrade the estrogen receptor, providing a potentially more complete inhibition of ER signaling.\n\n2. **Clinical Trials**: Elacestrant has been evaluated in clinical trials, including the pivotal Phase 3 trial known as EMERALD. The EMERALD trial focused on patients with ER+, HER2- advanced or metastatic breast cancer who had disease progression on or after prior endocrine therapy, including"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_G09cLIM1I1cwDgPxpLHrjdwe", "custom_id": "310_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1936646a39b309aba8d3e120e0cace84", "body": {"id": "chatcmpl-9St8CifG7jmljLS7jhK0OLjzbrkNL", "object": "chat.completion", "created": 1716672136, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is a chemotherapeutic agent that falls under the category of dihydrofolate reductase inhibitors. It is similar in action to methotrexate but is often used for different indications due to its unique properties and pharmacokinetics. Here are key points you should know about trimetrexate:\n\n1. **Mechanism of Action**:\n   - Trimetrexate works by inhibiting dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, which is essential for DNA synthesis and cell replication. By inhibiting DHFR, trimetrexate results in the depletion of tetrahydrofolate, leading to inhibition of nucleic acid synthesis and ultimately cell death in rapidly dividing cells.\n\n2. **Clinical Uses**:\n   - Trimetrexate has been primarily used in the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in patients with AIDS when conventional treatment (e.g"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dJLUhwm6cvXcFZiQGMrzm0Vg", "custom_id": "311_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6151b152b06589e65166d0f816e66e1c", "body": {"id": "chatcmpl-9St8C1kAFQ81y54RL5J0F9QBlIE0d", "object": "chat.completion", "created": 1716672136, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is a targeted therapy drug used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are key aspects you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   Tepotinib is a selective small-molecule inhibitor of the c-Met receptor tyrosine kinase. It specifically targets MET exon 14 skipping mutations. The c-Met protein is normally involved in cellular processes, such as growth, survival, and angiogenesis. Abnormal MET activation (as seen with mutations or amplifications) can lead to uncontrolled tumor growth and resistance to other treatments.\n\n2. **Indications**:\n   Tepotinib is specifically indicated for the treatment of adults with metastatic NSCLC harboring MET exon 14 skipping alterations. This is typically verified through FDA-approved tests for the detection of MET exon 14 alterations.\n\n3. **Efficacy**:\n   Clinical trials have demonstrated effectiveness of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ulOtyA2lM6Guy9lsOPVfeTW0", "custom_id": "312_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dfc85427ee15a7f871562591f3539942", "body": {"id": "chatcmpl-9St8Cv72OJKRlfPcRGM6tREg7mYJ5", "object": "chat.completion", "created": 1716672136, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib (Taiho Oncology), also known by its developmental code TAS-120, is a small molecule inhibitor specifically designed to target the fibroblast growth factor receptor (FGFR) family, which is involved in various physiological processes including cell proliferation, differentiation, and angiogenesis. Here\u2019s what is relevant for a physician:\n\n1. **Mechanism of Action**: Futibatinib is an irreversible inhibitor of FGFR 1, 2, 3, and 4. Its irreversible binding provides a sustained inhibitory effect on FGFR kinase activity, which can be crucial in treating cancers where FGFR alterations contribute to tumor growth and survival.\n\n2. **Indications**: By 2023, research mainly focuses on the use of futibatinib in cancers with FGFR genetic alterations. The most significant progress has been made in treating biliary tract cancers (cholangiocarcinoma) with FGFR2 fusions or other rearrangements. Its utility"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_suDnY8uHxK3nfqcIVbNR78sZ", "custom_id": "313_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6347643f551d0e62e192b6592c98be03", "body": {"id": "chatcmpl-9St8C8tnDXpLP8FhGVd6JxG9vBULD", "object": "chat.completion", "created": 1716672136, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, commercially known as Optune, is a medical device used for the treatment of glioblastoma multiforme (GBM), which is the most common and aggressive form of primary brain tumor in adults. Here are some key points a physician should know about this treatment:\n\n1. **Mechanism of Action**: Optune uses Tumor Treating Fields (TTF), which are low-intensity, alternating electric fields delivered at specific frequencies to disrupt cell division. This interference affects cells that are rapidly dividing, like cancer cells, more than normal non-dividing cells.\n\n2. **Indications**:\n   - **Newly Diagnosed GBM**: In conjunction with temozolomide, after maximal resection and completion of radiation therapy.\n   - **Recurrent GBM**: As a monotherapy after surgical and radiation options have been exhausted.\n\n3. **Usage**: The device involves the application of transducer arrays to the scalp,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_T7oCFnrGvclg6OMYIzkpvMOo", "custom_id": "314_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "17ab19aaa6a9524b1ec0a4830467542a", "body": {"id": "chatcmpl-9St8CoHOKkAErpDcpt4HkeKeThAp0", "object": "chat.completion", "created": 1716672136, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel, also known as liso-cel and marketed under the brand name Breyanzi, is an autologous, anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy. It is used for the treatment of certain types of B-cell lymphomas. This therapy involves modifying the patient\u2019s own T cells to include a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of B-cells. This modification enables the T cells to recognize and kill CD19-expressing cells.\n\n### Indications\nLisocabtagene maraleucel is approved by the U.S. Food and Drug Administration (FDA) for the treatment of:\n- Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h101RkY7fyRMyNNc28gS87Qw", "custom_id": "315_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "08e0dd1e721d3bbdf5a7e004875f1911", "body": {"id": "chatcmpl-9St8DaHb5YrnedSwjNrJ7ojjIensD", "object": "chat.completion", "created": 1716672137, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel (brand name Abecma) is a novel cancer immunotherapy approved by the U.S. Food and Drug Administration (FDA) for certain adult patients with relapsed or refractory multiple myeloma. Here are key aspects you should be aware of as a physician:\n\n1. **Type of Therapy**: Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. It involves the patient's own T cells being reprogrammed to include a CAR that targets BCMA, a protein commonly expressed on the surface of myeloma cells.\n\n2. **Indication**: It is approved for the treatment of adult patients with multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This therapy is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_H3Sx0ob9MYrJHJvyYWEKhOZ6", "custom_id": "316_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "efe53fc66056dccd65daeb07f180363e", "body": {"id": "chatcmpl-9St8Doh7A64Tn4POyaSANK7s3kI88", "object": "chat.completion", "created": 1716672137, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib is a medication primarily used for the treatment of specific types of cancer. It is a kinase inhibitor that specifically targets the KIT and PDGFRA mutant kinases. Here are some key points you, as a physician, should know about Avapritinib:\n\n1. **Indications**:\n   - Avapritinib is approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) that harbor a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, which are resistant to other treatments.\n   - It may also be used in research settings or clinical trials for other conditions related to abnormal kinase activity.\n\n2. **Mechanism of Action**:\n   - Avapritinib acts as a tyrosine kinase inhibitor, selectively targeting the mutant forms of PDGFRA and KIT kinases. By inhibiting these kinases, it prevents the downstream signaling pathways that lead"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nZ2grIZki1SWlvxbVvaJm6ey", "custom_id": "317_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3be9054ccebc24fd78a2d29a6af05bf9", "body": {"id": "chatcmpl-9St8DaAqySklCa0YRYXts9JJnsWqG", "object": "chat.completion", "created": 1716672137, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib, marketed under the trade name Turalio, is a medication primarily used in the treatment of tenosynovial giant cell tumor (TGCT), a rare disorder characterized by the non-cancerous growth of the joint synovium. In August 2019, the U.S. Food and Drug Administration (FDA) approved pexidartinib for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not responsive to surgical intervention. Here are some key points you should know:\n\n**1. Mechanism of Action:**\n   - Pexidartinib is a tyrosine kinase inhibitor (TKI) that inhibits the colony stimulating factor 1 receptor (CSF1R), a key driver in the proliferation of TGCT. It also inhibits KIT and FLT3-ITD.\n\n**2. Indication:**\n   - It is approved specifically for the treatment of adults with symptomatic TG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xT5eN4wVpzlYcVtrRAkVbjvW", "custom_id": "318_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9e22ffd69aedf7783612c5fc2fe50bbb", "body": {"id": "chatcmpl-9St8DhBsj6zVTgcL0DFxIhkIZmqd9", "object": "chat.completion", "created": 1716672137, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib, sold under the brand name Gavreto, is a targeted therapy drug used primarily for the treatment of certain types of cancers. It is a tyrosine kinase inhibitor specifically designed to target RET (rearranged during transfection) proto-oncogene alterations. RET mutations or fusions can drive the development of various cancers, including non-small cell lung cancer (NSCLC), thyroid cancer, and other tumor types.\n\n### Key Points for Physicians:\n\n#### 1. **Indications:**\n   - **NSCLC**: Pralsetinib is approved for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.\n   - **Thyoid Cancer**: It is also approved for adult and pediatric patients (12 years of age and older) with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Eglc9pscAH7UGF9VeqMR7coO", "custom_id": "319_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8119ad4675bc729a158a365c83dfa930", "body": {"id": "chatcmpl-9St8D5LYG6b236UcwggLIHPquAnei", "object": "chat.completion", "created": 1716672137, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin is a medication used in the treatment of certain types of cancer, particularly small cell lung cancer (SCLC). Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**: Lurbinectedin is a selective inhibitor of oncogenic transcription. It specifically binds to CG-rich sequences in the minor groove of DNA, blocking the transcription of oncogenes and other genes involved in the cell cycle. Additionally, it induces double-strand breaks and apoptosis in cancer cells.\n\n2. **Indications**: As of the last update, Lurbinectedin is approved by the FDA under accelerated approval for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy. This approval is based on overall response rate and duration of response, but continued approval may be contingent upon verification and description of clinical benefits in confirmatory trials.\n\n3. **Administration**: Lur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Zx1OEGpR1a0Rgly9kUav67O6", "custom_id": "320_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24fa9703dccf1cfa6b0064dd6fa6778d", "body": {"id": "chatcmpl-9St8EklCIZMRkejqJNw0vXGOQ2TEJ", "object": "chat.completion", "created": 1716672138, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antibiotic that is commonly used to treat a variety of bacterial and protozoal infections. Here are some key points that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Metronidazole works by entering bacterial and protozoal cells and interacting with their DNA, causing breaks and loss of helical structure, which inhibits nucleic acid synthesis and results in bacterial cell death.\n\n2. **Indications**: It is primarily indicated for treating anaerobic bacterial infections, which are common in the gut and pelvic region. It is also used for:\n   - Bacterial vaginosis\n   - Trichomoniasis\n   - Giardiasis\n   - Amoebiasis\n   - Certain infections caused by anaerobic pathogens like Bacteroides, Fusobacterium, Clostridium, Peptostreptococcus, and Prevotella species.\n   - Helicob"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_A35azaUE4knJQnYOWm6lZyfX", "custom_id": "321_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2544da4e880a70b7d5f9b608b391f939", "body": {"id": "chatcmpl-9St8EgKnBXUOjkJGd5G97HpcTTJZZ", "object": "chat.completion", "created": 1716672138, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab is a monoclonal antibody used in the medical field, particularly for treating cancer. Here are the key points you should know about naxitamab:\n\n1. **Indication**: Naxitamab is FDA-approved for the treatment of high-risk neuroblastoma and other GD2-positive cancers. Neuroblastoma is a type of cancer that most often occurs in young children and affects the nerve tissue of the adrenal glands, neck, chest, or spinal cord.\n\n2. **Mechanism of Action**: Naxitamab targets the GD2 ganglioside, which is highly expressed on neuroblastoma cells (and cells of other types of cancer), but has limited expression on normal cells. By binding to GD2, naxitamab can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity, leading to the destruction of cancer cells.\n\n3. **Administration**: Naxitamab is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nIbU0NZJez5FRAfafO6j0hY7", "custom_id": "322_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cde5466ba486241bbce224211e4b5783", "body": {"id": "chatcmpl-9St8ECLBNXM3zjihh4rvAUC0sAm5D", "object": "chat.completion", "created": 1716672138, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tetracycline is an antibiotic that belongs to a class of medications known as tetracyclines. It works by inhibiting protein synthesis, thereby stopping the growth and multiplication of bacteria. Here are some key points you should know about tetracycline if you are a physician:\n\n1. **Spectrum of Activity**: Tetracycline is effective against a broad range of gram-positive and gram-negative bacteria. It is commonly used to treat infections such as acne, chlamydia, Lyme disease, cholera, urinary tract infections, and respiratory infections.\n\n2. **Mechanism of Action**: Tetracycline binds to the 30S subunit of the bacterial ribosome, which prevents the addition of amino acids to the growing peptide chain. This inhibits protein synthesis and ultimately halts bacterial growth.\n\n3. **Resistance**: The use of tetracycline has led to the development of resistance among some bacterial strains. Mechanisms of resistance include decreased permeability to the drug"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3U38pBLerXOXCP9L07hQ4QA9", "custom_id": "323_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "002115b1290141dd5065d43306620cf9", "body": {"id": "chatcmpl-9St8EHqhSnJ1C7g4iVxzrmlhhXxED", "object": "chat.completion", "created": 1716672138, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, also known as bismuth subcitrate, is a compound used in medical treatment, most commonly for gastrointestinal disorders. Here are some key details you should know about it as a physician:\n\n### 1. **Brand Names and Formulation**\n   - It is marketed under various brand names such as De-Nol among others.\n   - Available primarily in tablet form.\n\n### 2. **Therapeutic Uses**\n   - **Peptic Ulcer Disease:** It is used for the treatment of peptic ulcers due to its antimicrobial effects against Helicobacter pylori, a common cause of gastritis and ulcers.\n   - **Gastrointestinal Protection:** It may also be used to protect the lining of the stomach and intestine, and to treat dyspexia (indigestion).\n\n### 3. **Mechanism of Action**\n   - The exact mechanism of action is not fully understood, but it is believed to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cOYI7it2N6VSy7yBfsJgFoqm", "custom_id": "324_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9a8e65fe604cd61ac892c04d257c0eb", "body": {"id": "chatcmpl-9St8EwwWMdTcNRTtFUKTpPX5DtUEv", "object": "chat.completion", "created": 1716672138, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan (brand name Welireg) is a medication approved by the U.S. Food and Drug Administration (FDA) for certain types of cancer. Here are some key points you should know about belzutifan:\n\n1. **Indications**: As of the latest update, belzutifan is used to treat adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. \n\n2. **Mechanism of Action**: Belzutifan works by inhibiting hypoxia-inducible factor 2 alpha (HIF-2\u03b1), which is a transcription factor involved in the body's response to low oxygen levels. In certain cancers, such as those associated with VHL disease, HIF-2\u03b1 is overactive, promoting tumor growth and vascularization. By blocking HIF-2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sTnmfmMKks0LuQpei4yxpFqU", "custom_id": "325_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad2037195f986c2ffab1661ed64714ad", "body": {"id": "chatcmpl-9St8FlVmS5Pn5TJGMJ7oV6f24QXTr", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab, marketed under the brand name Rybrevant, is a bispecific antibody used for the treatment of adult patients with non-small cell lung cancer (NSCLC) with specific genetic alterations. Here are several key aspects you should know:\n\n1. **Mechanism of Action**: Amivantamab is designed to target both the epidermal growth factor receptor (EGFR) and the MET proto-oncogene. It binds to these two receptors, thereby inhibiting their signaling pathways which play a critical role in tumor growth and proliferation.\n\n2. **Indications**: As of my last update, amivantamab is approved for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. These mutations are known to be resistant to standard EGFR tyrosine kinase inhibitor therapies.\n\n3. **Administration**: Amivantamab is administered via intravenous infusion. The dosing schedule typically starts with a loading dose,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7DyyWW7RYXcu4H4UZl3x3Bxc", "custom_id": "326_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd2e808109b37c62fa49f62ce24ee10e", "body": {"id": "chatcmpl-9St8FaFpykSGsUnbmB4Vm9KGKFPsf", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, commonly known by the brand name Onureg, is an oral formulation of the drug commonly used for the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). Here are some key points you, as a physician, should know about oral azacitidine:\n\n1. **Indications**:\n   - Oral azacitidine (Onureg) is approved by the FDA for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.\n   \n2. **Mechanism of Action**:\n   - Azacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA, which results in the inhibition of DNA methylation and cytotoxicity. The demethylation leads"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LANM50MFQnFTNEzZVFPVwXiQ", "custom_id": "327_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "841435a1b2dc3db0083fa13087627ea9", "body": {"id": "chatcmpl-9St8F94q5BSi4wmrLb7KaJsuQIElT", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colchicine is an anti-inflammatory medication primarily used to treat and prevent gout attacks. It also has applications in managing familial Mediterranean fever, pericarditis, and other inflammatory conditions. Here are some key points you should know about using colchicine:\n\n### Mechanism of Action\nColchicine works by reducing inflammation through several mechanisms, mainly by inhibiting tubulin polymerization in microtubes, which decreases neutrophil motility and activity, reducing the inflammatory response.\n\n### Indications\n- **Gout:** Used to prevent and treat gout flares. It is particularly effective when started early in the course of an attack.\n- **Familial Mediterranean Fever (FMF):** Used for prophylaxis in patients with FMF to decrease the frequency and severity of attacks.\n- **Pericollection:** May be used as a treatment for acute and recurrent pericarditis.\n\n### Dosage and Administration\n- **Gout Prophylaxis:** typically "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_m6HD2JeztSTRBKk0DkTIlT2v", "custom_id": "328_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b53a06f193a768ca1a8c8d5bcfd4355a", "body": {"id": "chatcmpl-9St8Fsz9JB6Jl1yOMawNQAFhgsv6d", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab, sold under the brand name Jemperli, is a medication used in oncology particularly for treating certain types of cancer. It is a programmed cell death protein 1 (PD-1) blocking antibody, a type of immunotherapy that works by blocking the PD-1 pathway, which is an immune checkpoint. This blockade enhances the body\u2019s immune responses against cancer cells.\n\nHere are some key points regarding Dostarlimab:\n\n1. **Indications**: As of the latest updates, Dostarlimab is approved for use in patients with recurrent or advanced endometrial cancer that has progressed on or after treatment with a platinum-containing regimen. This use is generally considered for cases characterized by mismatch repair deficiency (dMMR), which are likely to respond better to immunotherapy. \n\n2. **Mechanism of Action**: Dostarlimab inhibits the PD-1 receptor, a negative regulator of the immune function on the surface of T cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jLMtnN7cxVn7f6I4KiuRXEFb", "custom_id": "329_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b1421e189266b20ddee11fb17dde17cc", "body": {"id": "chatcmpl-9St8F3qEvpgPhpyLjKyeOrW5mi6El", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Serplulimab is an investigational PD-1 inhibitor monoclonal antibody being developed for the treatment of various cancers. It works by targeting the PD-1 (programmed cell death protein 1) pathway, which is a mechanism that tumors use to evade the immune system. By inhibiting PD-1 interactions, serplulimab can potentially enhance the body\u2019s immune response against cancer cells.\n\nAs of the last update, serplulimab has been involved in clinical trials for multiple types of cancer, including extensive-stage small-cell lung cancer (ES-SCLC). For instance, it has shown promising results in phase III trials, which could potentially lead to its approval and use in clinical settings pending further validation and regulatory review.\n\nAs a physician, it\u2019s important to stay updated on the outcomes of these trials and the regulatory status of serplulimab to understand its efficacy, safety profile, and approved indications if it becomes available for clinical use. Also, consider how"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_62M2fPG2NAG5yqTVi9vr2gpT", "custom_id": "330_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "47e8929f70170e90fb5abb2361c7a096", "body": {"id": "chatcmpl-9St8FxY9OwWzB8gh15gy6Wc70ESqN", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sugemalimab is an anti-PD-L1 monoclonal antibody designed for use in cancer immunotherapy. Sugemalimab, developed by CStone Pharmaceuticals, is part of a class of immune checkpoint inhibitors that function by targeting the programmed death-ligand 1 (PD-L1). By inhibiting PD-L1, sugemalimab enhances the body's immune response against cancer cells.\n\nHere are some key points you should know about Sugemalimab:\n\n1. **Mechanism of Action:**\n   Sugemalimab works by binding to PD-L1 expressed on the surface of tumor cells and some immune cells. This prevents PD-L1 from interacting with its receptor, PD-1, which is found on the surface of T-cells. This interaction normally suppresses T-cell activation and allows cancer cells to evade the immune response. By blocking this interaction, sugemalimab helps to reactivate the immune system against the tumor.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JkLKY3NayglhkHKSSC5zfExc", "custom_id": "331_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3851a1c1bb5e0dcc377553dea33b12f4", "body": {"id": "chatcmpl-9St8FsIXhXcp3w8MZg2Pusenq96AP", "object": "chat.completion", "created": 1716672139, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus protein-bound particles, available under the brand name Afinitor, are used mainly in the treatment of certain types of cancers and advanced kidney diseases. Sirolimus, the active component, is a macrolide compound that works primarily as an immunosuppressant and antiproliferative agent. Here are some key points you should know:\n\n1. **Mechanism of Action**: Sirolimus acts by inhibiting the mammalian target of rapamycin (mTOR) pathway, which plays a central role in cellular growth, proliferation, and survival. By inhibiting this pathway, sirolimus can halt the growth of cancer cells and reduce the immune response.\n\n2. **Indications**: The medication is approved for various conditions, including renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, and certain pancreatic neuroendocrine tumors. It is also used in transplant medicine to prevent organ rejection, particularly in kidney transplants"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hnPc7RsZdoPc7MF8pf5dDSQo", "custom_id": "332_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad77b900624abc872c36ee745384638a", "body": {"id": "chatcmpl-9St8GSGGR05EiKSh7HyxDFtnxEBOE", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication with several historical and contemporary uses, primarily known for its role in treating African trypanosomiasis, also known as sleeping sickness, caused by parasites transmitted by tsetse flies. Here are key points you should know about Suramin:\n\n1. **Mechanism of Action**: Suramin works by inhibiting enzymes that are essential for the parasites' energy metabolism, leading to their death. Its mechanism involves inhibiting enzymes and processes that facilitate the growth and reproduction of the parasites.\n\n2. **Indications**:\n   - **Primary**: Treatment of human African trypanosomiasis caused by *Trypanosoma brucei rhodesiense*. It is less commonly used for *Trypanosoma brucei gambiense* as there are other preferred treatments.\n   - **Secondary Uses**: Suramin has been used experimentally in the treatment of other diseases, including some viral infections and certain cancers, although these uses are not well established"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FbZCJGmDIU5d9SoOocjXiH5S", "custom_id": "333_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c44ea92fcb14a3c3dd0a5616936565a5", "body": {"id": "chatcmpl-9St8GRDzCLNEBjndNucpLH4JJApI5", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, adagrasib is a medication primarily used in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) where patients have previously received systemic therapy. Here are key points you should know about adagrasib:\n\n### Mechanism of Action\nAdagrasib specifically targets and inhibits the KRAS G12C mutation. This mutation is a common aberration found in various cancers, including NSCLC, and contributes to cancer cell growth and survival. By selectively inhibiting KRAS G12C, adagrasib is designed to interfere with tumor growth.\n\n### Indications\nAs of my last update, adagrasib has been granted accelerated approval by the FDA for patients with KRAS G12C-mutated NSCLC who have previously received at least one systemic therapy. This approval is based on the response rate and duration of response observed in clinical trials, though continued"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5lDjKhuUjOcTa3OLDKhIElI8", "custom_id": "334_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c1b74ec2138c65d0f1cb1ab97939bb5", "body": {"id": "chatcmpl-9St8GTf5OHHy1dELB6TrFNPGtrSpD", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp-tebn (brand name: Kimmtrak) is a novel therapeutic agent specifically designed for the treatment of uveal melanoma, a rare and aggressive form of melanoma that occurs in the eye. It is noteworthy for being the first T-cell receptor (TCR) therapeutic to receive regulatory approval. Here are some key points about Tebentafusp that you, as a physician, may find useful:\n\n1. **Mechanism of Action**:\n   - Tebentafusp is a bispecific protein composed of a soluble TCR fused to an anti-CD3 immune-effector function. It uniquely binds to the gp100 peptide presented by HLA-A*02:01 on melanoma cells, while the other end binds CD3 on T-cells. This interaction directs the T-cells to target and kill the melanoma cells.\n\n2. **Indication**:\n   - As of its approval, Tebentafusp is indicated for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_xfPe188Q3SvYBFhXdNYZkkxm", "custom_id": "335_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ef9f8482f84cd4b530bb737d976c848", "body": {"id": "chatcmpl-9St8GDPmv2c1cKGMxSLRnyLOwsxsR", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a kinase inhibitor specifically designed for the treatment of certain types of myeloproliferative disorders. It is primarily used in the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n\nHere are several important aspects to consider regarding fedratinib:\n\n**1. Mechanism of Action:**\n   Fedratinib inhibits Janus kinase 2 (JAK2), a kinase involved in signaling pathways that regulate blood cell production. This inhibition can reduce the abnormal production of blood cells associated with myelofibrosis.\n\n**2. Approval Status:**\n   Fedratinib was approved by the U.S. Food and Drug Administration (FDA)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3JZevrSSXX135ClUHDqKgDdr", "custom_id": "336_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f40022315ccb3a67ca18eecd6b56d880", "body": {"id": "chatcmpl-9St8Gds8bZVoPntNoqDrSN6dDSokR", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab and hyaluronidase-oysk is a combination medication used in oncology, specifically in the treatment of certain types of breast cancer. Here\u2019s a detailed outline of what you need to know about this medication:\n\n### 1. **Indications**\n   - **Breast Cancer:** Trastuzumab and hyaluronidase is approved for the treatment of HER2-overexpressing breast cancer. It is used in several contexts including as part of a treatment regimen for early breast cancer, metastatic breast cancer, and in some cases, after surgery to treat any remaining cancer cells and reduce the risk of recurrence.\n   - **Gastric Cancer:** It can also be used in the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n### 2. **Mechanism of Action**\n   - Trastuzumab is a monoclonal antibody that specifically binds to the HER2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SYiVk2SnqeKD1TpkVrMXGZu5", "custom_id": "337_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d2aff72461adc82e4f01efa29c284568", "body": {"id": "chatcmpl-9St8GhQwFvs7A9xWirmMZPMBoOwTL", "object": "chat.completion", "created": 1716672140, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib, marketed under the name Brukinsa, is a medication used in the treatment of certain types of blood cancers. Here are some key points you should know about zanubrutinib:\n\n1. **Mechanism of Action**: Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It specifically blocks the activity of BTK, a key molecule in the B cell receptor signaling complex, which plays a critical role in the B-cell development. By inhibiting BTK, zanubrutinib can help reduce the proliferation and survival of B cells, which are malignant in some forms of cancer.\n\n2. **Approved Indications**: It is mainly approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The indications can vary by regulatory agency, and ongoing studies could expand its use to other B-cell malignancies.\n\n3. **Effic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_6jIpmMMVDU8UFWOTDSEIAvzo", "custom_id": "338_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3852344f9ce8ea3300a6bae5c168006", "body": {"id": "chatcmpl-9St8HyoX7IZA71cZjdahcABCwj0jK", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furmonertinib (also known as AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for the treatment of non-small cell lung cancer (NSCLC). Here are some key points about Furmonertinib that are relevant for physicians:\n\n1. **Target and Mechanism of Action**:\n   - Furmonertinib specifically targets the EGFR mutations that are common in NSCLC. It is designed to inhibit both the activation of wild-type EGFR and the mutated forms of the EGFR gene, including those resistant to first- and second-generation EGFR TKIs (such as T790M mutations).\n\n2. **Indications**:\n   - It is primarily used for treating patients with NSCLC who have specific EGFR mutations. Because its effectiveness is dependent on the presence of these mutations, testing for EGFR gene mutations is essential before starting treatment.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_PtGLFKf7xM0QvbdVGLnj0U5g", "custom_id": "339_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "761bc2b243824a3905485b5320e027e3", "body": {"id": "chatcmpl-9St8HTtaTt2ZHJQJ4RpMtFJ9RvwWj", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel, commonly known as cilta-cel, is a chimeric antigen receptor (CAR) T-cell therapy. Approved by the FDA in February 2023, it is marketed under the name Carvykti. This therapy has been specifically developed for the treatment of multiple myeloma, and it is indicated for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.\n\nHere are several key points about ciltacabtagene autoleucel that you, as a physician, might find important:\n\n1. **Mechanism of Action**: Cilta-cel is a CAR T-cell therapy designed to target and eliminate cells expressing B-cell maturation antigen (BCMA), which is prevalently expressed on the surface of multiple myeloma cells. The therapy involves extracting T-cells from the patient, genetically modifying them to express the CAR that targets BCMA, and then infusing these"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_gXcz4XFW5HMipkVZcrFmy46w", "custom_id": "340_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ea05a20d2dfdafc2a5202ed2711d948", "body": {"id": "chatcmpl-9St8HjPUXKQFcCagJ3vMYaEaJqNXj", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a newer medication used to treat chronic myeloid leukemia (CML). Here are some important points you, as a physician, should be aware of regarding asciminib:\n\n### 1. **Mechanism of Action**\n   Asciminib works by a unique mechanism compared to other tyrosine kinase inhibitors (TKIs) commonly used in CML treatment. It is known as a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. This drug specifically binds to the myristoyl site of the ABL kinase of the BCR-ABL oncoprotein, inhibiting its activity, which is a novel mechanism distinct from other TKIs that typically target the ATP-binding site.\n\n### 2. **Indications**\n   As of the last update, Asciminib is approved for the treatment of adult patients with Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP) who have received at least two prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_d3fhS4soNu86bugV2VPfGzRZ", "custom_id": "341_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8e5e3ac253a841954ba72fa9f2501ac", "body": {"id": "chatcmpl-9St8Hd8ocCJLIVMgmOS9o8Y38mKWN", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine (brand name Zynlonta) is an antibody-drug conjugate (ADC) used for the treatment of certain types of B-cell lymphomas. Here are several important aspects about Loncastuzimab tesirine that you, as a physician, should be aware of:\n\n1. **Indications**: Loncastuximab tesirine is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and also high-grade B-cell lymphoma.\n\n2. **Mechanism of Action**: Loncastuximab tesirine consists of a monoclonal antibody (loncastuximab) that targets CD19, a protein typically expressed on the surface of B-cells. This antibody is linked to a cytotoxic agent (tesirine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4aVbjf3djFzTza6vcwS7eVjN", "custom_id": "342_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c982cdcb85322892573809abbbb99b87", "body": {"id": "chatcmpl-9St8He89Jz8JcDtaZhAD7rGwFJAin", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat is an oral, small molecule inhibitor of the EZH2 (enhancer of zeste homolog 2) enzyme, which plays a role in gene repression through the regulation of histone methylation. It is significant particularly in the context of certain cancers where EZH2 is known to be dysregulated.\n\nHere are some key points that you, as a physician, might need to know about Tazemetostat:\n\n1. **FDA Approval and Indications:**\n   - Tazemetostat received FDA approval in June 2020 under the brand name Tazverik. It is approved for the treatment of:\n     - Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n     - Adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vDWVdncMZAJhPSHXlhfykg7M", "custom_id": "343_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8b654b45f02b3d9d90c36a4d84dec6ed", "body": {"id": "chatcmpl-9St8HLS34PMfqQHXIOV39Dw7gvyZW", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab and relatlimab are immunotherapeutic agents used in the treatment of various cancers. Understanding the mechanisms, indications, side effects, and administration protocols of these agents is crucial for their effective use in clinical practice.\n\n### Nivolumab\n\n**Mechanism of Action:**\nNivolumab is a programmed death receptor-1 (PD-1) blocking antibody. It works by inhibiting the PD-1 receptor on T cells, which normally functions as an immune checkpoint, preventing the immune system from attacking the body's own cells, including cancer cells. By blocking this receptor, nivolumab enhances the body\u2019s immune response against cancer cells.\n\n**Indications:**\nNivolumab is approved for the treatment of several types of cancers, including:\n- Metastatic melanoma\n- Non-small cell lung cancer (NSCLC)\n- Renal cell carcinoma (RCC)\n- Hodgkin lymphoma\n- Head and neck cancer\n- Uro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_isviJvSWjrthqaxT78HUebQC", "custom_id": "344_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "20290a301bfcb052768b50a40bd15693", "body": {"id": "chatcmpl-9St8Hv3koPPa7XNygkyokP8f9ktyl", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Interferon alfa-2c is not a commonly referenced drug in clinical medicine. It is possible you are inquiring about Interferon alfa-2a or Interferon alfa-2b, both of which are more prevalent sorts of interferon used in clinical settings. Here is a brief overview of these related medications:\n\n1. **Interferon Alfa-2a and Interferon Alfa-2b**: These are types of interferons, which are proteins naturally produced by the body in response to viral infections. They are synthesized and used therapeutically to treat various medical conditions, including certain types of cancers and viral infections. The primary mechanism of action involves enhancing the immune response against the pathogenic cells.\n\n2. **Medical Uses**: \n   - *Chronic Hepatitis B and C*: They are used to treat hepatitis B and C by helping to reduce viral levels and improve liver histology.\n   - *Cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Y1i81bAhWyWRKyJWvTVs7qc9", "custom_id": "345_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "858df63be4295a073cc68f510ae1e026", "body": {"id": "chatcmpl-9St8HOSjqHBGoZQEVi1eawqHggusJ", "object": "chat.completion", "created": 1716672141, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1, a type of interferon alpha, is a recombinant therapeutic agent used primarily to treat various forms of cancer and viral infections. Interferons are proteins produced by the body as part of the immune response. They are also made synthetically for use in medical treatments. Here are some key points you should consider as a physician when it comes to interferon alfa-n1:\n\n### Mechanism of Action\n- **Antiviral Activity:** Interferon alfa-n1 exhibits its effects by binding to specific receptors on cell surfaces, leading to the activation of intracellular signaling pathways that inhibit viral replication.\n- **Antiproliferative Effects:** It also has effects on cell growth and differentiation, which are useful in oncological applications. It can inhibit the proliferation of malignant cells and promote immune surveillance.\n- **Immunomodulation:** Interferon alfa-n1 enhances the immune response, including increasing the activity of natural killer cells and macro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mIotwyTAf00vpVXvaquIA8Mj", "custom_id": "346_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ec1b791dc86eaef47dc1b74a3e675929", "body": {"id": "chatcmpl-9St8ItQgCQNrxWfJeRfCOPkMocGqo", "object": "chat.completion", "created": 1716672142, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is a novel anti-HER2 antibody used in the treatment of certain types of cancer, specifically those expressing the HER2 protein. Approved by the FDA in December 2020, margetuximab is marketed under the brand name Margenza. It is primarily used for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. \n\nHere are some key aspects of margetuximab you should be aware of:\n\n### Mechanism of Action\nMargetuximab is a monoclonal antibody that targets the HER2/neu receptor, a protein overexpressed in some cancer cells which promotes their growth. Margetuximab has been engineered with an altered Fc region, which enhances its ability to recruit immune effector cells and increases antibody-dependent cellular cytotoxicity compared to unmodified antibodies like trastuzum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fnpMroXkuokNjffVTUlSg4PM", "custom_id": "347_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7db945819e1a18a3016b2daf64c650ad", "body": {"id": "chatcmpl-9St8IRkfaGR8EXTbmQgjno8WeJnAv", "object": "chat.completion", "created": 1716672142, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib (brand name Lumakras) is an important medication to be aware of, particularly in the field of oncology. Here\u2019s a concise overview that covers its essential aspects:\n\n1. **Mechanism of Action**: Sotorasib is a small molecule inhibitor specifically targeting the KRAS G12C mutation. The KRAS G12C mutation is a specific genetic alteration where a cysteine substitutes glycine at the 12th position of the KRAS protein, promoting oncogenic activity. By selectively and irreversibly binding to this mutated form of KRAS, sotorasib blocks its signaling and downstream oncogenic activity, which can lead to tumor growth inhibition.\n\n2. **Indications**: As of the latest updates, sotorasib has been approved by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLSC), as determined by an FDA-approved test,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GNg3HILj5RJ3S0Cn3sd0fpp4", "custom_id": "348_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24c7770a37df076f27a09dcf5eae7fa1", "body": {"id": "chatcmpl-9St8I4LFomNp15F9h0bMiPSnqFowC", "object": "chat.completion", "created": 1716672142, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib (brand name Ukoniq), developed by TG Therapeutics, is a medication designed for the treatment of certain types of cancers, specifically in the realm of hematological malignancies. As a dual inhibitor of PI3K-delta and casein kinase-1 epsilon, umbralisib has a novel mechanism of action that targets signaling pathways critical for the survival and proliferation of cancer cells.\n\n### Key Information for Physicians:\n\n1. **Indications:**\n   Umbralisib was approved by the FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, and for relapsed or refractory follicular lymphoma (FL) in patients who have undergone at least three prior lines of systemic therapy.\n\n2. **Mechanism of Action:**\n   Umbralisib inhibits phosphoinositide 3-kinase delta (PI3K-\u03b4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JVpluLOLgo2XYxQzvhjMvU6g", "custom_id": "349_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eefd7ad270f08ab8ec94e26e3c25a758", "body": {"id": "chatcmpl-9St8IUgFUx7IpTLztGDhB6OqvOB0b", "object": "chat.completion", "created": 1716672142, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sintilimab is an immunotherapy drug used primarily for treating certain types of cancer. It belongs to a class of drugs known as PD-1 (programmed death-1) inhibitors. PD-1 is a checkpoint protein on immune cells that, when activated, helps keep the body's immune responses under control. By inhibiting PD-1, sintilimab helps to boost the immune system\u2019s ability to fight cancer cells.\n\nHere are some key points about sintilimab:\n\n1. **Indications**: Sintilimab is approved in some regions for the treatment of various conditions, such as non-small cell lung cancer (NSCLC) and Hodgkin\u2019s lymphoma. The specific indications can vary by country, so it's important to check local regulatory approvals.\n\n2. **Mechanism of Action**: Sintilimab binds to the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, which are expressed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KlknmHvR87aqQpoOWTVZZOBv", "custom_id": "350_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2fd03d8299572288a72a62171d6ed809", "body": {"id": "chatcmpl-9St8IvceYr8vLcTDrz25CnJsw5IzW", "object": "chat.completion", "created": 1716672142, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, pirtobrutinib (also known by its development code LOXO-305) is a novel, highly selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). BTK inhibitors are critical in the treatment of various B-cell malignancies, as BTK plays a key role in B-cell receptor signaling, which is important for the proliferation, survival, and migration of B-cells.\n\n### Key Aspects of Pirtobrutinib:\n\n1. **Mechanism of Action**:\n   Pirtobrutinib binds reversibly to the BTK enzyme. This distinguishes it from other BTK inhibitors (like ibrutinib, acalabrutinib, and zanubrutinib), which bind irreversibly. The reversible binding potentially leads to a different adverse effect profile and may overcome resistance developed against irreversible BTK inhibitors.\n\n2. **Indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dbRqptiX0ZTYNuModAOathHa", "custom_id": "351_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "67a4ad5338312c74e03f122d9742c50a", "body": {"id": "chatcmpl-9St8J1nLtRW8BvFIp7Ol5wVQL7pRA", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimap is an anti-PD-1 monoclonal antibody used in cancer immunotherapy. It is designed to block the activity of PD-1, a protein on T cells that helps keep the body's immune responses in check. By inhibiting PD-1, Toripalimab helps to enhance the body's immune response against cancer cells.\n\nHere are some key points you should be aware of:\n\n1. **Mechanism of Action**: Toripalimab targets and binds to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and PD-L2 on cancer cells. This blockade can potentially restore the anti-tumor activity of the immune system.\n\n2. **Indications**: The specific indications for Toripalimab can vary by regulatory environment. It has been investigated in multiple types of cancers including melanoma, nasopharyngeal carcinoma, and non-small cell lung cancer among others. You should refer to the local guidelines and approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_q7AXQQCFmdTYS4SlcuiqMUBw", "custom_id": "352_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65389646d8567c2955cd447a8e15d6f3", "body": {"id": "chatcmpl-9St8J3LPcs44LfsS6m2tkqWdCDr1q", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab (brand name Tecvayli) is a bispecific antibody used in the treatment of multiple myeloma. This therapeutic agent, specifically designed to target both BCMA (B-cell maturation antigen) and CD3, plays a pivotal role in directing T-cells to eliminate BCMA-expressing myeloma cells.\n\n### Key Information for Physicians:\n\n1. **Mechanism of Action**:\n   - Teclistamab is a bispecific T-cell engager (BiTE) that binds to CD3 on T-cells and BCMA on myeloma cells. This interaction brings the T-cells into close proximity with the myeloma cells, leading to T-cell activation and subsequent killing of the cancerous cells.\n\n2. **Indications**:\n   - It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapy lines including a proteasome inhibitor, an immunom"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WNV5Q6rz4iCZPsMtxOnau8VU", "custom_id": "353_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f79fcb52e2c14c9492a8d46e96f28fa7", "body": {"id": "chatcmpl-9St8JZN6lJCtNEQtER2ViiqcZVWf9", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib (sold under the brand name Exkivity) is a medication used to treat non-small cell lung cancer (NSCLC) that has a specific mutation called the epidermal growth factor receptor (EGFR) Exon 20 insertion mutation. It belongs to the class of drugs known as tyrosine kinase inhibitors (TKIs). Here are some key points you should know about mobocertinib:\n\n1. **Indication**: Mobocertinib is specifically approved for adult patients with locally advanced or metastatic NSCLC harboring EGFR Exon 20 insertion mutations, as detected by an FDA-approved test, and who have progressed on or after platinum-based chemotherapy. This provides a targeted therapy option for patients with this type of genetic mutation, which is less common and historically harder to treat than other EGFR mutations.\n\n2. **Mechanism of Action**: Mobocertinib targets and inhibits EGFR tyrosine kinase, which includes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_sDhMqhZPwTXgmjL8BAvqdpHL", "custom_id": "354_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f169c599492f3ae3d9e4f80d28af128c", "body": {"id": "chatcmpl-9St8Jsr96nc8Bl2ikD7gY4FhPmTXK", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin (brand name Tivdak) is an antibody-drug conjugate (ADC) that can be used for the treatment of certain types of cancer. It was approved by the U.S. Food and Drug Administration (FDA) in September 2021. Here are key points about Tisotumab vedotin that you as a physician may need to know:\n\n1. **Indication**: Tisotumab vedotin is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.\n\n2. **Mechanism of Action**: Tisotumab vedotin consists of a human monoclonal antibody (tisotumab) that targets tissue factor, a protein frequently expressed on many solid tumors and associated with tumor growth, angiogenesis, and metastasis. The antibody is conjugated to a cytotoxic agent (monomethyl auristatin E or MMAE), which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Fx1NvmOynLjkU5eUhXLSLJhb", "custom_id": "355_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "54f253a57c98882dca0102b7373dfbd8", "body": {"id": "chatcmpl-9St8JQJY2YCzFHNv3vjg3xOrIlQkN", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide LAR (long-acting release) is a synthetic analog of somatostatin, a hormone that inhibits the release of several other hormones. It is commonly marketed under the brand name Somatuline Depot. Here are the key aspects you should be aware of when considering this medication for your patients:\n\n### Indications\nLanreotide LAR is primarily used for:\n1. **Treatment of neuroendocrine tumors (NETs)** - particularly those from the gastrointestinal tract and the pancreas that are unresectable, locally advanced, or metastatic.\n2. **Acromegaly** - for patients who have had an inadequate response to surgery and/or radiotherapy, or when surgery is not an option. Lanreotide helps to reduce the levels of growth hormone and insulin-like growth factor-1 (IGF-1).\n3. **Symptomatic control of carcinoid syndrome** - it helps in reducing the frequency of diarrhea and flushing episodes.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0hiXKjqVFYlCVPQrmrLkc2zm", "custom_id": "356_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "89db737ac25b4a5ba582c9830b8029c1", "body": {"id": "chatcmpl-9St8JfdUzCufOey40DsVgpYWpOWhp", "object": "chat.completion", "created": 1716672143, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in September 2021, Pimitespib, also known by its code name TAS-116, is a selective inhibitor of heat shock protein 90 (HSP90), a protein that plays a crucial role in the folding, stability, and function of many client proteins, many of which are involved in oncogenic signaling pathways. The inhibition of HSP90 can disrupt these pathways, leading to the degradation of client proteins and subsequent tumor growth inhibition and apoptosis (programmed cell death).\n\n### Therapeutic Use:\nPimitespib is primarily being investigated for its potential in the treatment of various cancers. The inhibition of HSP90 is thought to be a promising strategy in oncology due to its ability to affect multiple pathways involved in tumor growth, angiogenesis, and metastasis.\n\n### Clinical Trials:\nPimitespib has been involved in clinical trials assessing its efficacy and safety in the treatment of various malignancies. It is important to review current and up-to-date resources"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9Z7fEhdkqHROFCwuCpMiJXsT", "custom_id": "357_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e26201b8901b50452fd7ec79f1312bdc", "body": {"id": "chatcmpl-9St8KS5VY6AtsxYZEQGDvg7O57nyf", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapy medication historically used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma. It is a compound that combines the alkylating agent chlorambucil with the corticosteroid prednisolone. This combination is designed to leverage the anti-inflammatory and immunosuppressive effects of prednisolone with the DNA-alkylating mechanism of chlorambucil.\n\n### Pharmacology:\n- **Mechanism of action**: Prednimustine acts through the chlorambucil component, which alkylates DNA, leading to disruption of DNA replication and transcription, inducing cell death. The prednisolone component helps in reducing inflammation and modifies the immune response.\n- **Metabolism**: It is metabolized in the liver, and its bioavailability and metabolic pathways can be influenced by liver function.\n\n### Clinical Use:\n- **Indications**: Mainly used in the treatment of lymphoid malignancies like chronic lymph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CtTsdpbz7zO7er7atJtKvWhd", "custom_id": "358_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bfc36aab25e6fffb4ff5f822aeed013b", "body": {"id": "chatcmpl-9St8KJUF9lc7lF5p213yGNBJsEiE1", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is a chemotherapeutic agent that you might encounter in the treatment of certain hematological disorders. It is primarily used for the management of polycythemia vera and has been used in essential thrombocythemia as well. Here are some important points about pipobroman:\n\n1. **Mechanism of Action**: Pipobroman is an alkylating agent. It works by binding to DNA, interfering with its replication and thus inhibiting the proliferation of rapidly dividing cells, particularly malignant cells.\n\n2. **Indications**: Its main use is in the treatment of polycythemia vera, a myeloproliferative disorder characterized by the overproduction of red blood cells. It may also be used in essential thrombocythemia and rarely in other conditions as deemed appropriate based on clinical judgment.\n\n3. **Administration**: Pipobroman is administered orally, which can be more convenient for patients compared to therapies requiring hospital visits for administration.\n\n4. **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z42ws9SAJXHQrHbgro5GaZ8a", "custom_id": "359_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "31583fbe11925942a01e4a3b44018f46", "body": {"id": "chatcmpl-9St8KY4sLUjSkdQAU34M4UOGHQMR1", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate (ADC) used for the treatment of certain types of non-Hodgkin lymphoma. Here are some key points you should be aware of:\n\n1. **Indication**: Polatuzumab vedotin is specifically approved for the treatment of diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, in patients who have relapsed or are refractory after at least two prior therapies. It is not indicated for the treatment of patients who are candidates for hematopoietic stem cell transplant.\n\n2. **Mechanism of Action**: The drug consists of a monoclonal antibody (Anti-CD79b) linked to a cytotoxic agent, monomethyl auristatin E (MMAE). The antibody component binds to CD79b, a protein expressed on the surface of most B-cells, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4VUEOeDjN8QoSgPAkNQKM44h", "custom_id": "360_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d435e912eea093cbd4af0c5625b042c3", "body": {"id": "chatcmpl-9St8KolsWtYxcglB10eTc9X3trw7G", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine, also known as IMGN853, is an antibody-drug conjugate (ADC) specifically designed for the treatment of cancers expressing the folate receptor alpha (FR\u03b1), which is frequently overexpressed in several types of epithelial cancers, including ovarian cancer. Here are some key points you should know about this drug:\n\n1. **Mechanism of Action**: Mirvetuximab soravtansine comprises a monoclonal antibody that targets FR\u03b1 linked to a cytotoxic drug. The antibody binds to FR\u03b1-expressing cancer cells, and the complex is internalized, releasing the cytotoxic payload directly into the cancer cell. This process aims to increase the antitumor efficacy while minimizing the impact on normal cells.\n\n2. **Indications**: It is primarily investigated for its use in ovarian cancer, especially in patients with platinum-resistant ovarian cancer who demonstrate high FR\u03b1 expression. The efficacy and safety of this targeted therapy could"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K8cWiDFJYQ4cwpd3cboWq7cX", "custom_id": "361_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "77de48613560ce8cd12c5585d0fc4300", "body": {"id": "chatcmpl-9St8KX53pEAvQdwI77jgD87xoIp3B", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab is an investigational bispecific antibody designed for the treatment of certain types of B-cell non-Hodgkin\u2019s lymphoma (NHL), among other B-cell malignancies. Below are key aspects you should be aware of regarding mosunetuzumab:\n\n1. **Mechanism of Action**:\n   Mosunetuzumab is a bispecific T-cell engaging antibody designed to target CD20 on B cells and CD3 on T cells. By binding to these two different targets, mosunetuzumab brings the T cells into close proximity to the malignant B cells, promoting T-cell activation and subsequent killing of the B-cell.\n\n2. **Clinical Trials**:\n   As of the knowledge cutoff in 2023, mosunetuzumab has been tested in a variety of clinical settings, primarily focused on relapsed or refractory non-Hodgkin's lymphoma. Clinical outcomes have shown promise in response rates, prompting further investigation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cTW245IW1krXB9nbAxijFfzH", "custom_id": "362_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24741b994cf680eb31826cae2216a1a1", "body": {"id": "chatcmpl-9St8KVcJFB1AxkTmieCtoUo2Ivm81", "object": "chat.completion", "created": 1716672144, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec (Adstiladrin) is a novel gene therapy approved by the U.S. Food and Drug Administration (FDA) in December 2022 for use in adults with high-risk Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This therapy represents a significant advancement in the treatment of this difficult-to-manage form of bladder cancer.\n\nHere are key aspects you should know about Nadofaragene firadenovec:\n\n1. **Mechanism of Action**: Nadofaragene firadenovec works by delivering a recombinant adenovirus vector containing the human interferon alpha-2b gene directly into the bladder via intravesical administration. Once inside the bladder cells, the gene is expressed and produces interferon alpha-2b, a protein that promotes anti-tumor immune responses and inhibits tumor growth.\n\n2. **Administration**: The treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vG1jCHpH3ZUQxsT1McEqhxED", "custom_id": "363_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6974758925deb17a4d6bd5b8276b0942", "body": {"id": "chatcmpl-9St8Ljg3Vh4ghvU6O82kVk5zO1M0t", "object": "chat.completion", "created": 1716672145, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olutasidenib (brand name Rezlidhia) is an oral medication approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. It is specifically indicated for patients who have previously been treated with other therapies. As of my last update, here are some important points to consider:\n\n1. **Mechanism of Action**: Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. In AML, mutations in the IDH1 gene lead to an abnormal enzyme that produces the oncometabolite 2-hydroxyglutarate (2-HG), which contributes to the growth and survival of cancer cells. By inhibiting the mutant IDH1 enzyme, olutasidenib reduces levels of 2-HG, thereby helping to inhibit the growth of cancer cells.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_27lmJkS0g6JzixPYJYHZXT91", "custom_id": "364_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a8d6d21c084b51ec8a752af2e295ff01", "body": {"id": "chatcmpl-9St8LSYXxCk6OMy5X1Q4mKPQNblDj", "object": "chat.completion", "created": 1716672145, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is a tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2), a protein that can be overexpressed in certain types of breast cancer. As a physician, here are several key points about Pyrotinib that may be relevant to your practice:\n\n1. **Indications**: Pyrotinib is primarily used in the treatment of HER2-positive breast cancer. It has shown efficacy in patients who have received prior treatment with other HER2-targeted therapies such as trastuzumab and pertuzumab.\n\n2. **Mechanism of Action**: Pyrotinib inhibits the intracellular tyrosine kinase domains of the HER2 receptor, leading to blockade of downstream signaling pathways that promote tumor cell growth and survival.\n\n3. **Clinical Usage and Efficacy**:\n   - Pyrotinib has been tested in clinical trials mostly in combination with other chemotherapy agents. For instance, in a Phase III trial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_evDdovFaEexFeHgJIJ1r5P1r", "custom_id": "365_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8850d26468ac5839f0e7c1dbff20e79", "body": {"id": "chatcmpl-9St8Mj0zQ9eSfbjwP8unirkONe7IZ", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a synthetic form of a naturally occurring hormone known as gonadotropin-releasing hormone (GnRH). It is primarily used in the management of hormone-responsive cancers such as prostate cancer, and in assisted reproduction and the treatment of endometriosis. Here are some critical points about Buserelin that you, as a physician, might find useful:\n\n### 1. Mechanism of Action\n- **Buserelin** works by initially increasing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which results in a temporary increase in the levels of sex hormones (estrogen and testosterone).\n- Following the initial surge, continuous administration of Buserelin leads to downregulation of GnRH receptors in the pituitary gland which ultimately decreases LH and FSH levels, leading to a significant reduction in sex hormone production (castration levels of testosterone in men).\n\n### 2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aVZY8BvMhXokr1GPWdVB1g4X", "custom_id": "366_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd3d27fe312ce4a5130577635a5b8983", "body": {"id": "chatcmpl-9St8Mg75ylW0HQ9QMx9QvCrQzuGNH", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel (also known by its developmental code name LN-144) is a cell-based gene therapy developed for the treatment of certain types of cancer, particularly metastatic melanoma. Lifileucel is a form of adoptive cell therapy, specifically, tumor-infiltrating lymphocyte (TIL) therapy. Here are some key aspects you should know:\n\n1. **Mechanism**: TIL therapy involves extracting tumor-infiltrating lymphocytes from a patient\u2019s tumor tissue. These lymphocytes are then expanded and activated ex vivo before being infused back into the patient. The theory behind TIL therapy is that these lymphocytes, being naturally present in the tumor, have recognized the tumor cells as abnormal. By expanding them outside the body, their numbers increase significantly, and their tumor-fighting properties are enhanced.\n\n2. **Treatment Process**: The process involves the removal of a piece of the patient\u2019s tumor to harvest the TILs. Once harvested, the TILs are expanded"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PKL6aD1Chezfz2SxvArLT32w", "custom_id": "367_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "640768a7f5eacb3d9cabdab9cb17707e", "body": {"id": "chatcmpl-9St8MocvXSWBI7kaNBxSNPAVGzkdz", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel, commonly referred to as tab-cel\u00ae, is an investigational, off-the-shelf allogeneic T-cell immunotherapy. It targets cancers that express the Epstein-Barr virus (EBV) antigens. These cancers can include conditions like post-transplant lymphoproliferative disorder (PTLD), especially in patients who are immunocompromised and have received an organ or stem cell transplant.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Tabelecleucel is composed of EBV-specific cytotoxic T-lymphocytes derived from the blood of healthy donors who are seropositive for EBV. These T cells are then matched to patients based on HLA (human leukocyte antigen) compatibility.\n   - The therapy targets cells expressing latent membrane proteins (LMP1 and LMP2) of EBV, making it potentially effective against EBV-positive malignancies.\n\n2. **Indic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dceyO3IV67jT9s3OmyxnS00V", "custom_id": "368_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9d1adbdd71e717c2401109c0109bfe4c", "body": {"id": "chatcmpl-9St8MbvMOvmVtdosG9KbGwVf3Oy4y", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (abemaciclib) is a medication used in the treatment of certain types of breast cancer. Here are the key points you, as a physician, should know about Verzenoid:\n\n1. **Indications**: Verzenio is approved by the FDA for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or with fulvestrant in patients who have received prior endocrine therapy. In pre-, peri-, or postmenopausal women, the endocrine therapy should be combined with a gonadotropin-releasing hormone agonist.\n\n2. **Mechanism of Action**: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. It specifically inhibits CDK4 and CDK6. These kin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VqxY76BYLxKkpbio4eMoMRkT", "custom_id": "369_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "909d82e9e3fd274993182e2c1b3f585d", "body": {"id": "chatcmpl-9St8MycJtFNhd9VvTC5IToFSQMpSp", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no widely recognized medical or pharmaceutical reference to \"Abatitor\" in the context of health care, medicine, or pharmaceuticals. It's possible that the term might be a misspelling, a non-standard term, or a brand name not registered or recognized internationally. It could also be a new term or product that has not yet become widely recognized or documented in medical literature.\n\nIf \"Abatitor\" refers to a specific drug, treatment, or concept in a particular region or within a specific medical community, I would recommend consulting the most recent and reliable medical literature, databases like PubMed, or regulatory bodies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) for the most accurate and up-to-date information.\n\nIf you provide more specific information or context, I could try to assist you further!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 178, "total_tokens": 219}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yufZ9KtmQ0jyNUr9SzXpFf7Y", "custom_id": "370_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da6cad3302d0a14913b2d774e12aa986", "body": {"id": "chatcmpl-9St8MXN2vSpRk3UDXldj7GF5ZjUx4", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a medication used in the treatment of certain types of blood cancers, specifically adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Here are some key points that you, as a physician, might need to know:\n\n1. **Mechanism of Action**:\n   - Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. It works by blocking BTK, a key molecule in the signaling pathway of B-cell development and function, which plays an important role in the proliferation and survival of malignant B cells.\n\n2. **Indications**:\n   - FDA approved for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.\n   - Also approved for the treatment of adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yfebTySh9cDfJujZ3KnCKoMp", "custom_id": "371_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b81ee66d37d3e70ec6e36662ac76cc30", "body": {"id": "chatcmpl-9St8MglaRsDraNUGXMqvuupSEv6KM", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacin (also known as Aclarubicin or Aclacinomycin) is an anthracycline antibiotic that functions as an antineoplastic agent. It is similar in structure and function to other anthracyclines like doxorubicin and daunorubicin. Here is an overview of key points regarding its usage, mechanism, and clinical considerations:\n\n**1. Mechanism of Action:**\n   - Aclacin inhibits the synthesis of DNA by intercalating between base pairs of the DNA strands, thereby preventing the replication of rapidly growing cancer cells. Additionally, it interferes with RNA synthesis and can generate cytotoxic free radicals, contributing to its anticancer effects.\n\n**2. Uses:**\n   - Aclacin is used primarily in the treatment of leukemia, including acute myeloid leukemia (AML) and other types of malignancies. Its use may vary based on geographic region and specific treatment protocols.\n\n**3. Administration:**\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xvLYmrWhE9dTlVErhdcEhiHq", "custom_id": "372_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "98beb4780a289f23d041d22ab5c9a6a9", "body": {"id": "chatcmpl-9St8M2MllxGzWIhR2KADhuyUfwMTi", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kadcyla (ado-trastuzumab emtansine) is a targeted therapy drug used primarily to treat HER2-positive breast cancer. It is a combination of trastuzumperzumab, a monoclonal antibody that targets the HER2 receptor, and DM1 (emtansine), a chemotherapy agent. Here are some key aspects that you, as a physician, should be aware of when considering or managing treatment with Kadcyla:\n\n1. **Indications**:\n   - Kadcyla is approved for use in patients with HER2-positive, metastatic breast cancer who have previously received trastuzumab and a taxane, either separately or in combination. Patients should have already been treated for their metastatic cancer or have had their disease recur during or within six months of completing adjuvant therapy.\n   - It is also approved as adjuvant treatment for people with HER2-positive early breast cancer who have residual invasive disease after neoad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7inmEZtrQEYenOaNLPLQcZZj", "custom_id": "373_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6a9abf2f0ab99d66a97c61331f8d5fe2", "body": {"id": "chatcmpl-9St8MEjdp5rCy5Li0nti0fIU3Su6d", "object": "chat.completion", "created": 1716672146, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Afanix is not a recognized medication or substance in standard medical resources such as the databases from the FDA, EMA, or other typical pharmaceutical and medical references. It's possible that the name \"Afanix\" could be a misspelling, a non-commercial name, or a brand name not widely recognized or new to the market.\n\nIf \"Afanix\" is supposed to be a drug or treatment in use or under consideration in your practice, here are a few steps you could take:\n\n1. **Verify the Spelling**: Double-check the spelling with the source of your inquiry to ensure it\u2019s correct.\n\n2. **Research**: Use reliable medical databases like PubMed, clinical trial registries, or FDA and EMA databases to find information.\n\n3. **Contact a Pharmacist**: Pharmacists can be a great resource for information on new or obscure medications.\n\n4. **Industry Resources**: Look through pharmaceutical industry publications or websites which might have information on new"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aJhiYugkmtSPesA1Ppls0Nd6", "custom_id": "374_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "621fee2d47631e01d2895271cb70eabf", "body": {"id": "chatcmpl-9St8NkAvzJSNwieZ2bEfGAjAXNqZH", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, \"Macrolin\" does not appear to correspond to any commonly recognized medication or substance in pharmaceutical contexts based on the data I have. It's possible that \"Macrolin\" might be a brand name, a name used in specific regions, or possibly a misspelling of a medication.\n\nIf \"Macrolin\" is supposed to be a specific drug or treatment, I'd recommend double-checking the spelling or any other details you might have. If it is a brand name or a drug not widely recognized or new on the market, consulting the most recent drug databases, pharmaceutical references, or drug regulatory authority websites might provide accurate and relevant information. Also, reaching out to colleagues or other healthcare professionals could be helpful.\n\nFor accurate prescribing and patient care information, always refer to the most current and reliable medical resources or direct communication with pharmaceutical companies or drug regulatory authorities."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 185, "total_tokens": 226}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7H7dvjkhbIPIDAMgSziFR1CG", "custom_id": "375_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "029567f70b6dd1a9cb71f3a201139835", "body": {"id": "chatcmpl-9St8NkF0h2PBKLBkALqssmljZgEQQ", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alecensa (alectinib) is an oral medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you might consider:\n\n1. **Indication**: Alecensa is specifically indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. It is generally used in patients who have previously been treated with crizotinib, another ALK inhibitor, but may also be used as a first-line treatment.\n\n2. **Mechanism of Action**: Alectinib is an inhibitor of the anaplastic lymphoma kinase (ALK) protein. By inhibiting ALK, alectinib can interfere with the growth and development of cancer cells.\n\n3. **Efficacy**: Clinical trials have shown alectinib to be effective in controlling disease progression in ALK-positive NSCLC. The response rates are high, and it has shown efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nk8jaikPPPMTFoxT6vyaflJ4", "custom_id": "376_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "822cdfb510d3232c082e2db2cd056189", "body": {"id": "chatcmpl-9St8NSLScYG3ZAYM3GaPfBelvyDdA", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Campath (alemtuzumab) is a medication that is primarily used in the treatment of certain medical conditions, including chronic lymphocytic leukemia (CLL) and relapsing-remitting multiple sclerosis (RRMS). Here is an overview of key points to consider when using Campath in clinical settings:\n\n### Mechanism of Action\nAlemtuzumab, the active component in Campath, is a monoclonal antibody that targets the CD52 antigen, a protein found on the surface of mature lymphocytes, but not on hematopoietic stem cells. Its binding leads to the depletion of circulating T and B lymphocytes through antibody-dependent cellular cytotoxicity and complement-mediated lysis.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL):** Campath was originally approved for the treatment of CLL, especially for fludarabine-refractory CLL.\n- **Multiple Sclerosis (MS):** More recently, ale"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JyDAlFD8sSLOTivQeCU6lsVQ", "custom_id": "377_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36f958de8d4efabd130773293e986483", "body": {"id": "chatcmpl-9St8NekM7qRf3QkrKCLTwuEYBTkzh", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a pharmaceutical drug primarily used to treat acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the presence of the t(15;17) translocation. Here are some critical points you should know about using ATRA in a clinical setting:\n\n### Mechanism of Action:\nATRA works by binding to the retinoic acid receptor (RAR) on promyelocytes, leading to changes in gene expression that promote the differentiation and maturation of these cells into normal white blood cells. This differentiation helps in resolving the promyelocytic blasts characteristic of APL.\n\n### Indications:\n- **Primary Indication**: ATRA is primarily indicated for the induction of remission in patients with acute promyelocytic leukemia (APL).\n- It may also have roles in dermatology, such as for the treatment of acne, though formulations and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9yghdrn3VOruyf4y2lJbdrvy", "custom_id": "378_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d8e13f6bd59931616093eba8f393aa2e", "body": {"id": "chatcmpl-9St8ND0qo4DsHdFAY0CKwW37cuQyD", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen, also known by its generic name altretamine, is a cancer medication primarily used to treat ovarian cancer, particularly in patients who have relapsed after initial therapy. Here's a concise summary of the essential aspects you need to know as a physician:\n\n### Mechanism of Action\nAltretamine is a cytotoxic agent believed to function as an alkylating agent, although its exact mechanism of action remains not fully understood. It is thought to damage DNA in cancer cells, leading to cell death.\n\n### Indications\n- **Primary Use:** Effective in the treatment of persistent or recurrent ovarian cancer, especially in patients who have failed initial treatment with cisplatin or similar chemotherapy drugs.\n- It may also have off-label uses in other cancers based on clinical discretion.\n\n### Dosage and Administration\n- Altretamine is administered orally.\n- The typical dosage is 260 mg/m\u00b2 per day given in divided doses, often taken with meals and at bedtime to minimize nausea.\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CFJhbkKihUcD6YPbNlTa96ak", "custom_id": "379_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5247342f41863915191229d82e021bf6", "body": {"id": "chatcmpl-9St8N1SLKPmlbzUUEmSi4sNE2NbYL", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Aminoblawtin\" does not appear to correspond to a known drug or compound in mainstream medical or pharmaceutical references. It's possible that the name might be misspelled, a brand name not widely recognized, or a name used in specific regions or under specific circumstances that aren't widely documented.\n\nIf the intent is to inquire about a specific medication or therapy for treatment purposes, it would be best to verify the correct name or active ingredient of the drug. Additionally, you might want to consult more direct and current resources or databases dedicated to healthcare professionals, such as the Physician's Desk Reference (PDR), pharmacological databases, or even contacting the manufacturer directly if it's a commercial product.\n\nPlease ensure you have the correct spelling or any additional context regarding the drug's applications, as this might help in providing more accurate and specific information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 43, "completion_tokens": 175, "total_tokens": 218}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_59eueYPRfUkec1BQ9WDTmIxi", "custom_id": "380_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9f0a80378d16e2482c11761977a542c3", "body": {"id": "chatcmpl-9St8NhgDYSL1mlSmTvv16INu1vbya", "object": "chat.completion", "created": 1716672147, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calsed is a brand name for Tamsulosin hydrochloride, a medication commonly used to treat symptoms of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland that can cause problems with urination. Here are several key points you should know about Tamsulosin (Calsed):\n\n1. **Mechanism of Action**: Tamsulosin is a selective alpha-1A adrenergic receptor antagonist. By selectively blocking these receptors, which are primarily located in the prostate, bladder neck and urethra, Tamsulosin helps to relax the muscles in these areas, facilitating easier urination.\n\n2. **Indications**: It is primarily prescribed to alleviate the symptoms of BPH such as frequent urination, difficulty in starting urination, and the need to urinate during the middle of the night. It is not used to reduce the size of the prostate but rather to relieve symptoms.\n\n3. **Dosage and Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ScmiyHkm5TGIjTtoOPNtxG47", "custom_id": "381_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3187aedee399a7235a6460a0dadaab2e", "body": {"id": "chatcmpl-9St8OHll7JsqX2AICDkCvDWVQB9ZO", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amekrin (tegoprubart), developed by Astellas Pharma, is an innovative oncology medication aimed at addressing advanced biliary tract cancer. It acts as a WEE1 inhibitor, targeting a specific protein in cancerous cells that allows them to repair their DNA and continue dividing. By obstructing this repair process, Amekrin aims to limit cancer cells' proliferation, essentially enhancing the effectiveness of other treatments like chemotherapy.\n\nFor a physician, here are several key aspects to consider:\n\n1. **Indications**: Amekrin is designed for use in patients with advanced biliary tract cancer. It is especially for those who have progressed after receiving first-line chemotherapy treatments.\n\n2. **Mechanism of Action**: As a WEE1 inhibitor, Amekrin works by inhibiting the WEE1 protein, which is crucial for the DNA damage response in cells. The inhibition leads to increased DNA damage during DNA synthesis, causing cell death, especially in cancer cells that are rapidly dividing.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tQgqUGmOolz3ed82fD55k3Gw", "custom_id": "382_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65066fd465c0897517054a0994d0f95a", "body": {"id": "chatcmpl-9St8OavC2dXRQg2M6QNkE4t8XJpsc", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altraz is a medication whose active ingredient is anastrozole. It is commonly used in the treatment of breast cancer, specifically hormone receptor-positive breast cancer in postmenopausal women. Anastrozole belongs to a class of drugs known as aromatase inhibitors. Aromatase inhibitors work by reducing the production of estrogen in the body, which can help reduce the growth of hormone receptor-positive types of breast cancer.\n\n### Key Points for Physicians to Consider:\n\n1. **Indications**: Altrash is primarily indicated for the adjuvant treatment of hormonally-receptor positive early breast cancer in postmenopausal women. It might also be used for advanced or metastatic breast cancer in similar populations.\n\n2. **Mechanism of Action**: Anastrozole inhibits the enzyme aromatase, which is involved in estrogen synthesis. For postmenopausal women, estrogen is mainly produced by conversion of androgens into estrogens through this enzyme. An"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_G9oPeBC6wLkwXWG4sJJZlk6X", "custom_id": "383_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "292a4a1b4d8eb3d66973688895a2e87b", "body": {"id": "chatcmpl-9St8OxkJc3t8mdFT1nt75TR1qKwMw", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (apalutamide) is a medication used primarily for the treatment of prostate cancer. Here are some key points you should know as a physician:\n\n1. **Indications and Usage**: Erleada is approved by the FDA for the treatment of non-metastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (CSPC). It is designed to be used in men who have cancer that continues to grow despite treatment that lowers testosterone levels.\n\n2. **Mechanism of Action**: Apalutamide, the active ingredient in Erleada, is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its activation and subsequent translocation into the cell nucleus. By blocking the action of androgens (such as testosterone), it can help inhibit the growth of prostate cancer cells.\n\n3. **Administration**: Erleada is administered orally, and the recommended dosage is typically 240 mg ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7ZXhkFaAynCv9KIM39I3qh2t", "custom_id": "384_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df37bd20d49b2dd81e9cde64458e9da8", "body": {"id": "chatcmpl-9St8Oa0fs3oOum1ZbCoXS5IiAqqDq", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems you might be referring to something specific with the term \"Aitan,\" but it's not clear from your question what exactly that refers to. \"Aitan\" could be a typo, a name of a drug, a condition, or something else in a different context. Could you please clarify or provide more details so I can offer the most accurate and helpful information?"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 75, "total_tokens": 115}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_b263q7NEwc6KHB2o4mrGQxco", "custom_id": "385_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a27bc906f72db3e47b88d777bcafe4ee", "body": {"id": "chatcmpl-9St8OfwwbNWAyhzzzRycYTQl8DYPg", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no standard medication or substance named \"Arsenol\" commonly recognized in medical practice. It's important to verify the name and spelling of the substance you're inquiring about. If it's a specific drug, chemical, or a new or less common treatment, I could provide you more accurate information if you could provide additional details or context.\n\nHowever, it is possible that you might be referring to something that is known under a different name or a new drug that has recently come into use after my last update. \n\nAdditionally, if \"Arsenol\" is a typo or mistaken name for \"arsenic,\" which is a known toxic chemical element, used in various contexts from industry to medicine, proper context and spelling would be key. In the context of medicine, arsenic has been used in cancer treatment and in traditional medicines, but its use is highly controlled due to its toxicity.\n\nAlways consult up-to-date, professional sources or databases for the latest information on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lCGEZPZziJJYSjskZaLljy2t", "custom_id": "386_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6754d9991d0ff5dab385a1744b3cbf35", "body": {"id": "chatcmpl-9St8OEfy6EyFLUSkeorMqI0MFoiUL", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about the medications you use to treat your patients, such as Asparaginase, which is a crucial drug in the treatment of acute lymphoblastic leukemia (ALL) and some other malignancies. Here are the key aspects to consider:\n\n### 1. **Mechanism of Action:**\n   - Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia, effectively reducing blood levels of asparagine. Certain malignant cells, like those in ALL, are unable to synthesize asparagine due to lack of asparagine synthetase and are dependent on the circulating asparagine. Deprivation of asparagine leads to inhibition of protein synthesis and subsequent cell death in these asparagine-dependent leukemia cells.\n\n### 2. **Indications:**\n   - Primarily used in the treatment of acute lymphoblastic leukemia (ALL).\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Dg9fZQ8Pj96STqZtbDS5g0q5", "custom_id": "387_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d57ba47b65528b57771efa95b0c9b579", "body": {"id": "chatcmpl-9St8OyQOxclsU12wQqgLVo19Eefm2", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase, also known as Erwinaze, is the brand name for the drug asparaginase Erwinia chrysanthemi. It is a chemotherapy drug used primarily in the treatment of acute lymphoblastic leukemia (ALL) when other forms of treatment, particularly L-asparaginase derived from Escherichia coli, are not tolerated due to hypersensitivity or other contraindications. Here are key points that a physician should know about Erwinase:\n\n1. **Mechanism of Action**: Erwinase works by converting asparagine, an amino acid that is essential for the growth of leukemic cells, into aspartic acid and ammonia. This deprives the leukemic cells of the asparagine they need to survive and proliferate.\n\n2. **Indications**: It is specifically used in patients with ALL who have developed hypersensitivity to E. coli-derived asparaginase or have experienced pancreatitis as a complication of such treatments"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_b1Z8C7u7fizZkyGQvrsAtAyl", "custom_id": "388_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "83e4fe57576d7b440fa68f8c5c44fea3", "body": {"id": "chatcmpl-9St8OxE6shIH4vDuZwOpLVaImG7Lw", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is an immune checkpoint inhibitor that belongs to a class of drugs known as monoclonal antibodies. It specifically targets and blocks the programmed death-ligand 1 (PD-L1) protein, which can be expressed on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1, Tecentriq enhances the body's immune response against cancer cells.\n\nHere are some key points you should know about Tecentriq as a physician:\n\n1. **Indications**: Tecentriq is approved for use in various types of cancers including, but not limited to, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), certain types of urothelial carcinoma, and in combination with other drugs for specific types of breast cancer and hepatocellular carcinoma. Its indications may vary by country and new approvals may have been added, so it's important to check the latest guidelines"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2IX0b5g74pJedZnRmHkNovnl", "custom_id": "389_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48a646110cd96015deb1d5228ba23bea", "body": {"id": "chatcmpl-9St8OZZhpO4yActj4fFoKtfy1cVm1", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio (avelumab) is a monoclonal antibody used as a medication in cancer immunotherapy. Here are some key points about Bavencio that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Bavencio is a human immunoglobulin G1 (IgG1) lambda monoclonal antibody that binds to PD-L1 (programmed death ligand 1). PD-L1 is expressed on tumor cells and tumor-infiltrating immune cells and functions by interacting with PD-1 and B7.1, both of which are found on the surface of T cells. By binding to PD-L1, Bavencio blocks its interactions with PD-1 and B7.1 receptors, reducing PD-1 mediated T-cell suppression. This action can potentially enhance the body's immune response against cancer cells.\n\n2. **Indications**:\n   - **Metastatic Merkel cell carcinoma (MCC)**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XxLT5s7mXcy1SCf2G5jTSbPq", "custom_id": "390_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "66fa9d9b114c1c99f2abdcd87afbae3b", "body": {"id": "chatcmpl-9St8OkSRq96zRiT1wYEFINMbwA2Lc", "object": "chat.completion", "created": 1716672148, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a type of cancer treatment known as a chimeric antigen receptor (CAR) T-cell therapy. It is specifically designed for adult patients with certain types of large B-cell lymphoma who have not responded to or have relapsed after at least two other kinds of treatment. Yescarta is one of the first CAR T-cell therapies to be approved by the U.S. Food and Drug Administration (FDA), marking a significant advance in immunotherapy for aggressive non-Hodgkin lymphoma.\n\nHere are some key aspects of Yescarta that you, as a physician, might need to know:\n\n### Indications\nYescarta is approved for the treatment of adult patients with:\n- Relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UOx9fkPYEfzAtxh8HfnRjs5W", "custom_id": "391_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "28b9db1beec8c237acbba0048183c5ca", "body": {"id": "chatcmpl-9St8PTzfh04NE2bn1ACF0uHAPD6YE", "object": "chat.completion", "created": 1716672149, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no recognized medication or medical term called \"Axishil.\" It is possible that the name might be misspelled, refer to a lesser-known or new drug, or it could be a brand name not widely recognized. It's important to ensure the correct spelling or to have more context to provide accurate information. If you can provide more details or clarify, I would be better able to assist you. Otherwise, I recommend consulting a current pharmaceutical database or a drug information resource for the most accurate and up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 112, "total_tokens": 153}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ud8grFVxcSwvo2gl8qAcg4xD", "custom_id": "392_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a37bcefb5941cbc26ed6775f2c206636", "body": {"id": "chatcmpl-9St8PIM7fW5D9I56fwzmdYNgxLiVa", "object": "chat.completion", "created": 1716672149, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, sold under the brand name Vidaza, is a chemotherapy medication used primarily to treat myelodysplastic syndromes (MDS) and some forms of acute myeloid leukemia (AML). Here are some important aspects of azacitidine that you, as a physician, might need to know:\n\n### 1. **Mechanism of Action**\nAzacitidine is a nucleoside metabolic inhibitor that incorporates into RNA and DNA. It works primarily by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The hypomethylation may restore normal function to genes that are critical for cell differentiation and proliferation.\n\n### 2. **Indications**\n- **Myelodysplastic Syndromes (MDS):** Azacitidine is indicated for the treatment of various subtypes of MDS, which include certain types of refractory anemia.\n- **Acute"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZoXm943GsNgzX4Qx2EI5nFkJ", "custom_id": "393_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0828e30bd0a62388a7bb73712cb2ed64", "body": {"id": "chatcmpl-9St8PtJzJbcK6O5eat9ojrLos6hnS", "object": "chat.completion", "created": 1716672149, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "TheraCys is a preparation of Bacillus Calmette-Gu\u00e9rin (BCG), which is a live attenuated strain of Mycobacterium bovis. It is primarily used as a bladder cancer treatment, particularly for non-muscle invasive bladder cancer (NMIBC). Here are some essential aspects of TheraCys that you, as a physician, should be aware of:\n\n### 1. Indications\nTheraCys is indicated for the intravesical treatment of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of recurrence following transurethral resection in patients with NMIBC (Ta and/or T1 tumors).\n\n### 2. Mechanism of Action\nThe exact mechanism of action is not fully understood. However, it is believed that instillation of TheraCys leads to an immune response that is both local and systemic. Activated immune cells, including macrophages and cytotoxic T cells,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_08UIcrPkPJHYN4dzvtiU4hmd", "custom_id": "394_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "65571860949e94ac67b522240ff6afad", "body": {"id": "chatcmpl-9St8PcoDbKk0I7KDK4IPTjjDspyV3", "object": "chat.completion", "created": 1716672149, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there's no drug named \"Tarvacin\" officially recognized in standard medical or pharmaceutical references. It is crucial to verify the name or look for any possible updates about this drug. If Tarvacin is a novel or experimental medication, it would be necessary to consult the latest clinical research, potential case studies, or drug approval databases such as those from the FDA or EMA.\n\nFor any experimental drug, you should look into:\n1. **Clinical Trial Data**: Determine the phase of clinical trials it is in, its safety profile, reported efficacy, and any side effects noted during trials.\n2. **Indications and Usage**: Understand the conditions the drug is indicated for and any therapeutic benefits it offers.\n3. **Mechanism of Action**: Knowing how the drug works can help in determining potential interactions with other medications and predicting side effects.\n4. **Dosage and Administration**: Guidelines for how the drug should be administered, dosage ranges, and adjustments needed for specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Js27WnGe3tf4bG5EOh0aim75", "custom_id": "395_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "015bedb26828fce2cf296b29ac612093", "body": {"id": "chatcmpl-9St8PXVfuvaLWRg5JnR5LsJvbbMoy", "object": "chat.completion", "created": 1716672149, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (belinostat) is a medication used in the treatment of cancer, specifically for peripheral T-cell lymphoma (PTCL). It falls under the class of drugs known as histone deacetylase inhibitors. Here are some key points that you, as a physician, might find useful:\n\n1. **Indications**: Beleodaq is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. This approval is based on overall response rates in clinical trials, and the drug was granted accelerated approval by the FDA.\n\n2. **Mechanism of Action**: Belinostat works by inhibiting the enzyme histone deacetylase. This action leads to an increase in acetylation of histone proteins, resulting in alterations in gene expression that induce cell cycle arrest and apoptosis of cancer cells.\n\n3. **Administration**: Beleodaq is administered intravenously. The typical dosage involves a cycle of administration over 5 consecutive days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MjqZBBAYTfwIrFv3VKJhiH5j", "custom_id": "396_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f133a910238351e10679650e981c56b9", "body": {"id": "chatcmpl-9St8QxJZ2RybVWmzLiog2l0fO40sw", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't any widely recognized medical or pharmaceutical reference to \"Camptobell.\" It's possible you might be referring to a specific drug, condition, or term that has a similar spelling or pronunciation. Could you please provide more details or clarify? If it's a new or less common term, I'd recommend consulting the latest medical literature or databases for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 82, "total_tokens": 124}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BWatSwQUdnqJ0hvDkks0D10j", "custom_id": "397_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4b9308851a5fb845c1c678451ed0b18", "body": {"id": "chatcmpl-9St8QtAmOIwmpikCzNrPR4q07m931", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo (bendamustine hydrochloride) is a chemotherapy drug that is typically used in the treatment of certain types of blood cancers. It is most commonly used to treat chronic lymphocyclic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma that has progressed during or after treatment with other chemotherapy agents.\n\n### Key Points for Physicians:\n\n**1. Mechanism of Action:**\n   - Belrapzo works primarily as an alkylating agent, causing cross-linking of DNA, which disrupts DNA synthesis and function leading to cell death. It also has properties of a purine analog, leading to mispairing of the DNA strands.\n\n**2. Indications:**\n   - **Chronic Lymphocytic Leukemia (CLL):** For the treatment of patients with CLL. Efficacy relative to first-line therapies other than chlorambucil has not been established.\n   - **Non-Hodgkin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_l7ZCH8rW6peQ3VtAxLt1DfOS", "custom_id": "398_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3c0445b7c514efcf9859b6364e4f4477", "body": {"id": "chatcmpl-9St8QxSauRDVidyA3CoCYM8GKe0WO", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan, known in the U.S. as Bevacizumab and marketed under the brand name Avastin, is an antivascular endothelial growth factor (anti-VEGF) monoclonal antibody. It\u2019s primarily used in the treatment of various cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, ovarian, cervical, and renal cancers among others.\n\nHere are some key points physicians should consider regarding Altuzan:\n\n1. **Mechanism of Action**: Bevacizumab works by binding to the vascular endothelial growth factor (VEGF), which is a substance that stimulates the formation of new blood vessels (angiogenesis). By inhibiting VEGF, Bevacizumab prevents the growth of new blood vessels that feed tumors, thereby inhibiting tumor growth.\n\n2. **Indications**: Be aware of the specific indications approved for Altuzan in your region as these can vary. For example, it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_STCpcPyvpxGbk6ZyQi8YtFqv", "custom_id": "399_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "177f9f6667bd1c577821236c82102581", "body": {"id": "chatcmpl-9St8QtVXmBpElKSjBiL6bIh1lhsQe", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a recognized medication or substance named \"Bexgratin.\" It's possible that the name might be misspelled, misheard, or it could be a brand name that's less well-known or new on the market. To provide accurate and relevant information, please check the spelling or provide more context. If you're looking for information on a specific medication, treatment, or condition, please provide any additional details you might have, and I'd be glad to help with the information that's available."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 109, "total_tokens": 151}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Sco92TznJdtW69VqoTvolz51", "custom_id": "400_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7c689e3fbbec52f72e2e8fe409e0b246", "body": {"id": "chatcmpl-9St8Qz8Vk81XMXlO9l7HBjxC4L7Ad", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide, known generically as bicalutamide, is a medication that is commonly used in the treatment of prostate cancer. It belongs to a class of drugs known as non-steroidal antiandrogens. Here are some key points about Calutide that you, as a physician, might find useful:\n\n1. **Mechanism of Action:**\n   Calutide works by blocking the action of androgens (male hormones), such as testosterone, by binding to androgen receptors. This inhibits the growth of androgen-dependent prostate cancer cells.\n\n2. **Indications:**\n   Calutide is primarily used for the treatment of prostate cancer. It is often prescribed in combination with a gonadotropin-releasing hormone (GnRH) agonist or before radiation therapy to reduce the risk of disease progression.\n\n3. **Dosage and Administration:**\n   The typical dose of Calutide is 50 mg taken orally once daily. The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_J08zXa15CJwhG1NnwlYBghwt", "custom_id": "401_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9bf39d23b483b5665e1a714d96fb2822", "body": {"id": "chatcmpl-9St8QLqDl9loDO2c8Twna1F7DaY7k", "object": "chat.completion", "created": 1716672150, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication used in the treatment of cancer. It is specifically approved for use in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Below are some important aspects to consider when prescribing Mektivi:\n\n1. **Mechanism of Action**: Mektovi is a kinase inhibitor that works by targeting and inhibiting MEK1 and MEK2. These enzymes are part of the MAPK/ERK pathway, which is involved in the regulation of cell division and survival. By inhibiting MEK, Mektovi helps to stop or slow the growth of cancer cells.\n\n2. **Efficacy**: Clinical trials have shown that the combination of Mektovi with encorafenib can provide significant improvements in survival and delayed disease progression compared to other treatments for BRAF-mutant melanoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZcPeIZybB2V1SJNvWIpOQ3uj", "custom_id": "402_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7ec3b10160fe98c6c264c04dfc7d4da8", "body": {"id": "chatcmpl-9St8Rr8umhvKQXBYTGq2Sav36THiR", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Blenoxane,\" which is the brand name for bleomycin, is a medication used primarily in the treatment of several types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and certain types of ovarian cancer. It may also be used to treat squamous cell carcinomas. Here are some key points about Blenoxane that you might find useful as a physician:\n\n### Mechanism of Action\nBleomycin acts by inducing DNA strand breaks, primarily through the formation of free radicals and iron-mediated oxidative damage, leading to cell cycle arrest and apoptosis in cancer cells.\n\n### Indications\n- **Hodgkin\u2019s lymphoma**\n- **Non-Hodgkin\u2019s lymphoma**\n- **Testicular cancer**\n- **Squamous cell carcinomas of the head, neck, skin, and cervix**\n- **Malignant pleural effusion** (as part of palliative care)\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_dwK8OS0g6etzB5vNGx7Tkkn1", "custom_id": "403_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2e1d31d5f6005ab4828fb19b13231987", "body": {"id": "chatcmpl-9St8R1qjcMypWMPBjtpHVaA4Qx36G", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager used in the treatment of certain types of leukemia. Here are key points you should be aware of:\n\n1. **Indications**: Blincyto is approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. It is also used in patients who are Philadelphia chromosome-negative and have minimal residual disease (MRD) greater than 0.1%.\n\n2. **Mechanism of Action**: Blincyto works by linking CD19, which is widely expressed across B-cell lineages, including leukemia cells, to CD3, which is present on T cells. This connection activates the T cells to exert cytotoxic activity on the targeted B cells.\n\n3. **Administration**: It is administered through continuous intravenous infusion over 28 days, usually followed by a 14-day treatment-free interval. This 6"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1h7LbyqNLqHqSL281wMM1O6x", "custom_id": "404_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b5b9078e2a8a927f2f29b54bd8ac7934", "body": {"id": "chatcmpl-9St8RphPDMDi2IwptcDkxYDYcIlUZ", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a specific medication or product named \"Biocure\" that is widely recognized or documented in standard medical or pharmaceutical references. The name \"Biocure\" could potentially be a brand name, a company name, or a term used in marketing various health-related products or services, but it does not refer to a specific, commonly known medical treatment or drug.\n\nIf \"Biocure\" refers to a new or emerging product, therapy, or company in the medical field, here are a few general steps you might consider as a physician:\n\n1. **Research**: Check medical databases, journals, and the FDA or equivalent regulatory body's information to find any data, clinical trial information, approvals, or notices regarding \"Biocuture.\" Websites like PubMed or the official FDA site can be beneficial.\n\n2. **Company Information**: If \"Biocure\" is a company, visit the company's official website to learn about their products, research focus, and any"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_thNE7NS9HS4CCTWjc6LqxGgy", "custom_id": "405_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f57fc1fd0eff327abf41f9c017fd3d0", "body": {"id": "chatcmpl-9St8RF8Q8pifeiKGPRPDELYdaQ6Ib", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosulipf (bosutinib) is a tyrosine kinase inhibitor (TKI) marketed by Pfizer, which is most commonly used in the treatment of chronic myelogenous leukemia (CML). Here are some key points you should know about Bosulif:\n\n1. **Indications:**\n   - Bosulif is approved for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.\n\n2. **Mechanism of Action:**\n   - Bosutinib works by inhibiting the Bcr-Abl tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome that plays a role in CML. Bosulif specifically targets this enzyme and other Src-family kinases, disrupting their signaling pathways, which can reduce or prevent the proliferation of cancerous cells.\n\n3. **Administration:**\n   - Bosulipf is administered orally. It's important for patients to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_I7VoTjJBt9SMGXF5iLb44ufY", "custom_id": "406_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "52dccde820c823718ab33a711c5d274b", "body": {"id": "chatcmpl-9St8RcFnjhJwWMqjLfq1mDELOsX19", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (brentuximab vedotin) is a targeted therapy used primarily for the treatment of certain types of lymphoma. It combines an anti-CD30 antibody with a drug that interferes with cell division. Here are key points every physician should consider regarding Adcetris:\n\n### 1. Indications\nAdcetris is approved for use in:\n- **Hodgkin lymphoma** (HL) after failure of other treatments or in cases where the use of autologous hematopoietic stem cell transplantation (HSCT) or at least two prior multi-agent chemotherapy regimens have failed.\n- HL at high risk of relapse or progression as post-autologous HSCT consolidation.\n- **Systemic anaplastic large cell lymphoma (sALCL)**, for patients who have not responded to other treatments.\n\n### 2. Mechanism of Action\nAdcetris is a conjugate of an anti-CD30"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cTUTODQ49iX257IVMOCCDKGq", "custom_id": "407_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea0f6b6385883221063377d9e4d15859", "body": {"id": "chatcmpl-9St8RHk8l2F9bLGBwsFCLRBqFNBUi", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig (brigatinib) is an oral medication used in the treatment of non-small cell lung cancer (NSCLC), specifically for patients whose cancer is anaplastic lymphoma kinase-positive (ALK+) as determined by an FDA-approved test. Here are key points you should know about Alunbrig:\n\n1. **Indication and Usage**:\n   Alunbrig is approved by the FDA for the treatment of ALK-positive metastatic NSCLC in patients who have progressed on or are intolerant to crizotinib, which is another ALK inhibitor. In more recent updates, it has also been approved as a first-line treatment option for ALK+ NSCLC.\n\n2. **Mechanism of Action**:\n   Brigatinib is a kinase inhibitor that targets ALK phosphorylation and ALK-mediated signaling pathways. By doing so, it inhibits proliferation and induces apoptosis (cell death) in tumor cells relying on ALK signaling for growth and survival.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CTod4P26fZxRmSSgnY59qsqx", "custom_id": "408_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f0a06d43df9c9afc059b8a21164bcdd9", "body": {"id": "chatcmpl-9St8RG659na5o0bfnlt3clI4R6uRt", "object": "chat.completion", "created": 1716672151, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex (busulfan) is an alkylating agent used primarily in the preparative regimen prior to hematopoietic progenitor cell transplantation (often referred to as bone marrow transplantation). Here are some key points you, as a physician, should be aware of when considering or using Busilvex:\n\n### Indications\n- **Busilvex is often used in combination** with other chemotherapeutic agents or conditioning regimens in the treatment of patients undergoing hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) and other hematological disorders.\n\n### Mechanism of Action\n- Busulfan works by alkylating DNA, which cross-links DNA at the 1,6 positions of guanine, leading to DNA strand breaks and apoptosis of cells. This makes it effective in eradicating diseased cells in preparation for transplantation.\n\n### Administration\n- **Formulation**: Busilvex is available as an intravenous formulation.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PKnlzpuWVWbz0pi39VyMuvyW", "custom_id": "409_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2bf2dfce5b0af0a9d4839d4c545919a1", "body": {"id": "chatcmpl-9St8S9nk4NxHkywo1cuW5fJ6WR6Ib", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last training cut-off in September 2021, there isn't a drug specifically named \"Cabapan\" widely recognized in standard pharmacological resources or in clinical practice. It is possible that you might be referring to a drug under a different name or a newly developed medication that was not included in my last update.\n\nIn case you're dealing with a new or less common medication, or if the spelling might be incorrect, here are a few general steps you could take:\n\n1. **Verify the Name**: Double-check the spelling of the medication. Sometimes, drug names can be easily misspelled or confused with others.\n   \n2. **Consult Updated Resources**: Look up the medication in the most recent and reliable medical databases such as the FDA's drug information database, WHO's medicine database, or newer editions of pharmacology textbooks. Websites like Medscape or UpToDate can also be helpful for the latest information.\n\n3. **Contact a Pharmacy**: Pharmacists are often up-to-date with new"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IBxHRbInQ35LfWOhsQsyyqth", "custom_id": "410_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29a01e0693998758c00654bcb2c26c22", "body": {"id": "chatcmpl-9St8SVIWygcYNvY5oT7XaiaMHoje6", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx, which contains the active ingredient cabozantinib, is a medication used in the treatment of certain types of cancer. Cabozantinib is a tyrosine kinase inhibitor that targets various receptors, including VEGFR, MET, and AXL, which are involved in the pathogenesis of cancer, including angiogenesis, tumor growth, and metastatic progression.\n\nHere are some key points about Cabometyx that you, as a physician, might find useful:\n\n1. **Indications**: \n   - **Renal cell carcinoma (RCC)**: Cabometyx is approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.\n   - **Hepatocellular carcinoma (HCC)**: It is also approved for patients with previously treated advanced hepatocellular carcinoma.\n   - **Thyroid cancer**: Additionally, it can be used for the treatment of patients with progressive, metastatic med"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_COuIIsyI0iiNZ1mix09YQMs3", "custom_id": "411_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "61c060674f23d6115fdeb630b6d31543", "body": {"id": "chatcmpl-9St8SWsb4S7YlNBFUa5LhgX46JvYb", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparlas, known generically as calaspargase pegol-mknl, is a modified form of L-asparaginase, an enzyme used in the treatment of acute lymphoblastic leukemia (ALL). It is specifically designed to have an extended circulating half-life compared to native L-asparaginase forms. Here are some of the key points you, as a physician, should know about Asparlas:\n\n1. **Indication**: Asparlas is approved for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years. It is intended as a component of a multi-agent chemotherapeutic regimen.\n\n2. **Mechanism of Action**: Asparlas works by depleting the amino acid asparagine, which leukemic cells cannot synthesize sufficiently. Normal cells, however, can make enough asparagine on their own. By degrading asparagine, Asparlas starves the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kSrxgeCaWN4kDOl0FGmPWjJ6", "custom_id": "412_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "75231a04c2b50379063a37233ea35134", "body": {"id": "chatcmpl-9St8S20GcP1nUswQ0yMl7dfatSwL1", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in my training data, there is no widely recognized medication or treatment known as \"Cabita.\" It's possible you may have misspelled the name or it might be a brand name or a drug not commonly recognized under this name. To provide accurate information, could you please verify the spelling or provide additional context? If it's a new drug or a less commonly known substance, checking the latest medical literature or a drug database might also be helpful."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 95, "total_tokens": 135}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BDMfTO3ad9a8Zck8YRv1SLBD", "custom_id": "413_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "45a83abe139f83d244b6798d9ca67f08", "body": {"id": "chatcmpl-9St8S5kShZjv92IjyRusic38eEvj9", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to understand both the clinical usage and pharmacological aspects of any medication or substance involved in patient care. \"Biocarb\" can refer to different products, depending mostly on the context or region. For instance, it could be shorthand for a bicarbonate or refer to products designed as carbon absorbing agents, which are typically used as dietary supplements or for treating hyperacidity.\n\nHere\u2019s a generalized breakdown that might help:\n\n### If referring to Bicarbonate (e.g., Sodium Bicarbonate):\n1. **Use Cases:**\n   - Sodium bicarbonate is primarily used to treat and manage conditions related to acidosis, such as those occurring in severe renal diseases or cardiac arrest where rapid correction of blood pH is crucial.\n   - It's also used for relieving heartburn or acid indigestion by neutralizing stomach acid.\n\n2. **Mechanism of Action:**\n   - Sodium bicarbonate reacts with stomach acid (hydrochloric acid) to produce sodium"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DOZ9yM3GFmMbpgKUueZh7vHv", "custom_id": "414_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "973b1ecf4c143f49cb2dc13aec6ca1bb", "body": {"id": "chatcmpl-9St8SDszEFVEknbk5R62ZQWJ2AaX7", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilnat is likely a reference to carfilzomib, a proteasome inhibitor used in the treatment of multiple myeloma. Although I couldn't find specific references to \"Carfilnat,\" pharmaceutical names can differ by region or be under different brand or generic names, so it's important to verify the exact drug and its approved uses based on your region.\n\nCarfilzomib (brand name Kyprolis) works by inhibiting the proteasome, which is an enzyme complex that degrades ubiquitinated proteins. Inhibition of the proteasome interferes with the regulated degradation and turnover of proteins, which is particularly effective against rapidly dividing cells like cancer cells.\n\n**Here are some key points about carfilzomib (Kyprolis) that are relevant for a physician:**\n\n1. **Indications:**\n   - Carfilzomib is approved for the treatment of patients with multiple myeloma who have received one or more previous therapies."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TaQCRwQ04cSd3z38TXFRFvpG", "custom_id": "415_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a412a082f1cbe04509a3ebe839836375", "body": {"id": "chatcmpl-9St8S6PLxyNLc7pbFuohBgPgfxh0J", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Becenun (carmustine)** is a chemotherapy drug used primarily for treating various types of cancers, including multiple myeloma, brain tumors, Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. It is classified as an alkylating agent, which works by cross-linking DNA and RNA strands, inhibiting cancer cell growth and replication. Here are some key points about Becenun:\n\n### Mechanism of Action:\n- Carmustine causes alkylation of DNA and RNA which leads to the disruption of DNA replication and RNA transcription. This damage triggers cell cycle arrest and ultimately leads to apoptosis (cell death).\n\n### Indications:\n- **Primary and metastatic brain tumors:** including glioma, glioblastoma multiforme, medulloblastoma, astrocytoma.\n- **Multiple myeloma:** particularly when used in combination with other chemotherapeutic agents.\n- **Hodgkin\u2019s disease and non-Hodgkin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sW87Dvs6XuDreZotMWcu4qTf", "custom_id": "416_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d0ec05f139eeb3308ff7212c9de6512", "body": {"id": "chatcmpl-9St8Sr0Otd0K90ZTKpvX7u8Nx3SAQ", "object": "chat.completion", "created": 1716672152, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, information about Biodel is not immediately clear based on your question alone. This lack of clarity could be attributed to the presence of multiple entities or topics that might relate to the term \"Biodel\". For example, there could be a product, company, or medical term with that name. To assist you more accurately, could you please provide more specific information or clarify the context in which you are inquiring about Biodel? If it's a drug, a new technology, or a company, any additional details would be helpful for providing the relevant information to you as a physician."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 125, "total_tokens": 165}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_M1Yg4tbckYhGNM5SmxSDsPrA", "custom_id": "417_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5748108dedaaedf2f04c44d5f210ec80", "body": {"id": "chatcmpl-9St8TbMdkyH3I6TC9ZcYqIgGOsDiB", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Recentin is not a commonly recognized name for a medication in major pharmacological databases, and as such, might be known under a different name, or it may be a new or less common drug. However, you may be referring to \"Cetuximab,\" which is marketed under the brand name Erbitux in many countries. Sometimes commercial names for drugs can differ by region or over time, and this can lead to confusion without up-to-date drug reference resources.\n\nCetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used primarily in the treatment of metastatic colorectal cancer and head and neck cancers. It is a chimeric (mouse/human) monoclonal antibody that inhibits the EGFR. EGFR is a key component in cellular growth signaling pathways, and its expression is often upregulated in certain types of cancer cells.\n\n### Key Points about Cetuximab:\n1. **Indications**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_u1QiaGVNzdK6DxY3MfjIDgpl", "custom_id": "418_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d71f1263a9c754be9003241db419ffa9", "body": {"id": "chatcmpl-9St8T7JqSjQykjAk6elShGX1P82hM", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Libtayo\" (cemiplimab) is a medication used in the treatment of certain types of cancers, particularly cutaneous squamous cell carcinoma (CSCC) that is metastatic or locally advanced and cannot be cured by surgery or radiation. Additionally, it has been approved for use in basal cell carcinoma (BCC) that has progressed following treatment with a hedgehog pathway inhibitor or for which these treatments are not suitable. Moreover, it has applications in non-small cell lung cancer (NSCLC).\n\nHere are some important aspects of Libtayo you might need to know as a physician:\n\n1. **Mechanism of Action**: Libtayo is a fully human monoclonal antibody that belongs to a class of cancer therapies known as immune checkpoint inhibitors. Specifically, it targets the immune checkpoint receptor PD-1 (programmed death receptor-1), thereby enhancing the body\u2019s immune response against cancer cells.\n\n2. **Administration**: Libtayo is administered via intravenous infusion typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_c4pxVhxEQWEKvFyiTeVZHNAt", "custom_id": "419_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ef3178c95267176d95e3ad72b13bfe7e", "body": {"id": "chatcmpl-9St8TjjSSBMDEv3XOflLYkIGrJG86", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo in your question. You mentioned \"Lucicer,\" which doesn't correspond to any known medical term, medication, or treatment. If you meant to refer to a specific drug, disease, or medical concept, could you please provide the correct term or more context? I'm here to help with accurate and relevant medical information once the correct topic is identified."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 77, "total_tokens": 117}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wYirpkpq53ar1ZNE9B31rnRx", "custom_id": "420_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb5e1a1b97892e06676f9daa80e9077e", "body": {"id": "chatcmpl-9St8TPczfm5ndbnxSV8cYOrewLU1h", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab, marketed as Erbitux among others, is a chimeric (mouse/human) monoclonal antibody used in cancer therapy. It specifically targets the epidermal growth factor receptor (EGFR), which is a common element involved in the signaling pathways that lead to cell growth and survival. Here are several key points about cetuximab that you, as a physician, might find important:\n\n1. **Indications**:  \n   Cetuximab is primarily used for the treatment of metastatic colorectal cancer and head and neck cancers. In metastatic colorectal cancer, it is used in patients whose tumors express EGFR and who have not responded to chemotherapy. In head and neck cancer, it can be used both in combination with radiation therapy for locally advanced tumors and as a part of first-line treatment in combination with chemotherapy.\n\n2. **Mechanism of Action**:  \n   Cetuximab works by binding to the extracellular domain of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_0UWmm0cIF9CeG5hYOvt3986z", "custom_id": "421_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "094ccd1e7538ef41621cebc874bff3ee", "body": {"id": "chatcmpl-9St8TBk419VIX63xfUlimJ0Vpdoxi", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no widely recognized medication specifically called \"Epidaza\" in standard pharmaceutical databases. It's possible that the name might be misspelled, could be a brand name not available in all regions, or a newer medication that has not yet been widely documented or approved.\n\nTo provide you with accurate information, I\u2019d recommend confirming the name or the spelling of the drug. If it is a specific brand name or a new drug, checking recent medical literature, pharmaceutical regulatory updates, or directly consulting detailed pharmaceutical resources might be useful. Alternatively, if you provide additional context or details, like the intended use or active ingredients, I might be able to offer more specific information.\n\nFor any medication, it's important to understand its mechanism of action, indications, contraindications, side effects, and any special considerations like interactions with other drugs. Always rely on updated and credible sources or databases for the most accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 196, "total_tokens": 236}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_gdO5DA86n6eTYERgnbP48eS3", "custom_id": "422_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "48323dbc4797f946da10deb39de730bd", "body": {"id": "chatcmpl-9St8TyJ3zjkCsAeiy2RQiLFqGdkDH", "object": "chat.completion", "created": 1716672153, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil, often referred to by its brand name Leukeran, is a chemotherapy drug used primarily to treat certain kinds of cancer, including chronic lymphocytic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It belongs to a class of medications known as alkylating agents, which work by interfering with the DNA replication process in cancer cells, thereby slowing or stopping their growth.\n\n### Important Information for Physicians\n\n1. **Indications**: Chlorambucil is used primarily for:\n   - Chronic lymphocytic leukemia (CLL)\n   - Hodgkin\u2019s lymphoma\n   - Non-Hodgkin's lymphoma\n   - Waldenstr\u00f6m macroglobulinemia\n   - Certain other hematological disorders\n\n2. **Mechanism of Action**: As an alkylating agent, chlorambucil causes cross-linking of DNA strands, ultimately leading to cell death. This makes it effective in treating prolifer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_i1frPb0OlsuS3U52vO5B7pPV", "custom_id": "423_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2870cd599db7adadf61442538117d8cc", "body": {"id": "chatcmpl-9St8UFVgSyNbG2y06spuqZnsFJJqL", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiplatin is a platinum-based chemotherapy drug, generically known as cisplatin. It is widely used in the treatment of various types of cancers, including testicular, ovarian, cervical, bladder, lung, and stomach cancers. As a physician, here are some key points you should know about cisplatin:\n\n### Mechanism of Action:\nCisplatin works primarily by causing DNA damage. It forms platinum-DNA adducts which interfere with DNA replication and transcription, leading to cell death. This makes it effective against rapidly dividing cancer cells.\n\n### Administration:\n- Cisplatin is typically administered intravenously. \n- The dosage and schedule depend on various factors including the type of cancer, the stage of the disease, the patient\u2019s kidney function, and overall health.\n\n### Side Effects:\nCisplatin is known for its significant side effects, which can sometimes limit its use. Key side effects include:\n- **Nephrotoxicity**: Kidney damage is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8pICqKvT4F4R2zDwZeORjir0", "custom_id": "424_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9165ec49166316ac1decd1f11f62ccd4", "body": {"id": "chatcmpl-9St8U8UKhxMVOHpt56R7JodeynVqJ", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin, known generically as cladribine, is a medication primarily used in the treatment of hairy cell leukemia and other hematologic malignancies such as chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma.\n\nHere are key points you should know about Leustatin:\n\n1. **Mechanism of Action**: Cladribine is a purine nucleoside analog that interferes with the synthesis and repair of DNA. This action is particularly effective in targeting lymphocytes and lymphocyte precursors, which makes cladribine useful in the treatment of diseases involving these cells.\n\n2. **Administration**: Leustatin can be administered intravenously or subcutaneously, depending on the condition being treated and other patient-specific factors. The dosage and schedule of administration depend on the type of disease, level of disease activity, patient size, and overall patient health.\n\n3. **Indications**: The primary indication of Leustatin is for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_LHUe0jnHouIUn9jcuU9ylM4v", "custom_id": "425_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "64d6e227740e7d7842a797a99fe32b8d", "body": {"id": "chatcmpl-9St8UKDVkde6CvoE1fefeeD7Qqza2", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biaxin, known generically as clarithromycin, is an antibiotic belonging to the macrolide class. It is commonly used to treat various bacterial infections including respiratory tract infections, skin infections, and Helicobacter pylori infection, which is associated with stomach ulcers. Here are some key points you should know about Biaxin as a physician:\n\n1. **Mechanism of Action**: Clarithromycin works by inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, leading to a bacteriostatic effect which can be bactericidal at higher concentrations.\n\n2. **Spectrum of Activity**: It has a broad spectrum of activity which includes many gram-positive and gram-negative bacteria, and is also effective against atypical pathogens like Mycoplasma, Chlamydia, and Legionella.\n\n3. **Indications**:\n   - Treatment of upper and lower respiratory tract infections such as bronchitis, sinusitis, and community"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_Fw1N8F0g6kgT3LgrsnA6G5ll", "custom_id": "426_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb03ec1d2bfcdb1028564bf178fb9d9d", "body": {"id": "chatcmpl-9St8ULLRi1KNQxOGvKqGA7svinOYt", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clolar, with the generic name clofarabine, is a chemotherapeutic agent classified as a nucleoside metabolic inhibitor used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are key aspects you should know about Clolar:\n\n1. **Indications**:\n   Clolar is approved for pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens. Its efficacy in previously untreated patients or other leukemias has not been established.\n\n2. **Mechanism of Action**:\n   Clofarabine inhibits DNA synthesis by reducing the ability of enzymes involved in DNA replication and repair. It incorporates into DNA chains and leads to chain termination, thereby halting cell division and causing cell death in rapidly dividing cancer cells.\n\n3. **Administration**:\n   Clolar is administered intravenously. The dosing regimen typically involves daily infusions for five consecutive days, repeated every"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RhhBHnhqCzxGlpYStOVOVfD1", "custom_id": "427_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "62ce5129bdc181b7c1a9e139443a25ae", "body": {"id": "chatcmpl-9St8Uii1Mb4WIGBE83jeucpNdCc78", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (cobimetinib) is a medication used in the treatment of cancer, specifically for its use in combination with another drug called vemurafenib (Zelboraf) to treat advanced melanoma that cannot be treated with surgery or that has spread to other parts of the body. This combination is usually prescribed for melanoma with a specific type of abnormal BRAF gene, as vemurafenib targets the BRAF V600 mutation.\n\nHere are key points about Cotellic:\n\n1. **Mechanism of Action**: Cobimetinib is a MEK inhibitor that works by interfering with the MEK proteins, which are part of a larger signaling pathway (the MAPK/ERK pathway) involved with cell division and survival. By inhibiting MEK, cobimetinib can help slow down or stop the growth of cancer cells.\n\n2. **Indications**: As mentioned, Cotellic is approved for use in combination with vemurafenib in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dCw8apsvuyTNvaO2yhYruUQ4", "custom_id": "428_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9c61c807b6d3594439072764b2a70463", "body": {"id": "chatcmpl-9St8UiFuKYEum8iENHEDtPJ9ptzu2", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Aliqopa** (copanlisib) is a medication used in the treatment of certain types of cancer, particularly follicular lymphoma. Here are some key points you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Aliqopa is a kinase inhibitor, specifically targeting the phosphatidylinositol-3-kinase (PI3K) pathway, which is known to play a significant role in the growth and survival of tumor cells. Copanlisib predominantly inhibits the PI3K-alpha and PI3K-delta isoforms expressed in malignant cells.\n\n2. **Indications**: Aliqopa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The approval was based on overall response rate and duration of response in clinical trials, but improvements in patient-reported outcomes or survival data were not yet established"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KNVHj7fFLLwPEAYUCpqDR3LZ", "custom_id": "429_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32cd85cd0fa4c9902b80620d976c3925", "body": {"id": "chatcmpl-9St8Uswiaof594psIPIMY13ErKSff", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizalk is the brand name for the drug crizotinib, which is primarily used in the treatment of non-small cell lung cancer (NSCLC). Crizotinib is a small molecule tyrosine kinase inhibitor that targets ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1), both of which can be involved in the growth of cancer cells.\n\nHere are some key points about Crizalk (crizotinib) that you might find useful:\n\n1. **Indications:**\n   - Crizalk is indicated for the treatment of patients with non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.\n   - It is also used for treating NSCLC patients whose tumors are ROS1-positive.\n\n2. **Mechanism of Action:**\n   - Crizotinib inhibits the enzyme activity of ALK and ROS1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_RQmUAQ3tJCe1Cn6snuhm2zqE", "custom_id": "430_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e35825c352d6fb6cdecb89e3951b23f5", "body": {"id": "chatcmpl-9St8UfXnjvxbV649sOFGRYlqoYBcg", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Alkyloxan\" does not correspond to a recognized drug or chemical compound in standard medical or pharmaceutical references. It's possible that the name might be misspelled or it could be a brand name not widely recognized, or even a substance not commonly used in clinical settings.\n\nIf you meant to inquire about a different substance or if \"Alkyloxan\" is a new or less common drug, I would recommend consulting the most current medical literature or drug databases. Additionally, confirming the correct spelling or obtaining more specific information about its applications, mechanisms of action, side effects, and clinical guidelines from reliable sources or directly from the manufacturer can be valuable. For any medication, it's essential to understand its interactions, contraindications, and the proper context of use, especially in a clinical setting. Please let me know if there's another way I can assist you!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 181, "total_tokens": 223}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_5TMnzpC0A2p6zvIk6L3SPgLz", "custom_id": "431_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "604c71dbb8fc923479f1d8416bf8dca3", "body": {"id": "chatcmpl-9St8UyEUCxMVbBv1rYiGKQY8jHtq1", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Androcur, whose generic name is cyproterone acetate, is a medication primarily used in the management of sexual aggression in men with hypersexuality and/or sexual deviation. It is also employed in the treatment of androgen-dependent conditions like acne, hirsutism, and in transgender hormone therapy as part of masculinizing suppression. Here are several key points you should know about Androcur:\n\n1. **Mechanism of Action**: Cyproterone acetate acts as a potent progestogen with anti-androgenic properties. It works by blocking androgen receptors and inhibiting the release of gonadotropins (LH and FSH), which in turn decreases testosterone levels.\n\n2. **Indications**:\n   - Treatment of severe sexual deviance in men.\n   - Androgenic conditions such as severe acne, androgenic alopecia, and hirsutism in females.\n   - Part of hormone therapy in transgender individuals.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_w5CDqt0wvmzlpZcFi1tSjeRi", "custom_id": "432_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2757f2ecde8734fd4c6dbf7922525c0b", "body": {"id": "chatcmpl-9St8UQUJ1t0NL4olmeU1C8Q5X4KYj", "object": "chat.completion", "created": 1716672154, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Alcysten\" does not appear to be a recognized medication or substance in standard medical literature, including pharmacological databases or clinical guidelines. It's possible you might have the name misspelled or it might be a brand name that's not widely known. Alternatively, it could be a new or experimental treatment.\n\nTo provide accurate advice or information:\n\n1. **Double-check the spelling**: Ensure that the spelling is correct and that it is not a misspelled version of a known pharmaceutical or substance.\n\n2. **Confirm the context**: If this came from a patient, colleague, or medical record, verify the source and context in which the term was used.\n\n3. **Search for alternative names**: Sometimes drugs are known by different names in different countries, or a brand name might be less well-known than its generic counterpart.\n\n4. **Consult reliable sources**: Use trusted medical databases like PubMed, FDA, or WHO websites to find information about unfamiliar medications or substances"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z9slPZgkWGsxsIbBdcg495Nc", "custom_id": "433_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "452780143f3fab15d2fb8db9432702d3", "body": {"id": "chatcmpl-9St8VEwDxmRasbOEMY8gOqk27dJCA", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos is a chemotherapy medication used to treat certain types of acute myeloid leukemia (AML). It is specifically indicated for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Here are several important aspects of Vyxeos that you should be aware of as a physician:\n\n1. **Active Ingredients and Formulation**: Vyxeos is a liposomal combination of two chemotherapeutic agents, cytarabine and daunorubicin, encapsulated in a fixed molar ratio of 5:1. The liposomal formulation helps in delivering a synergistic ratio to the targeted leukemic cells and may aid in reducing systemic toxicity.\n\n2. **Mechanism of Action**: Both drugs in Vyxeos interfere with DNA replication and repair, leading to cell death. Cytarabine is a nucleoside metabolic inhibitor, and daunorubicin is an anth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9MbezuvFE0nzSK52Af8MloCM", "custom_id": "434_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8145cf288e4ff1fb85a10d24699348c", "body": {"id": "chatcmpl-9St8VeapjaUlCJxsxn09e9KM8shyo", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no medication specifically named \"Rafinlar\" recognized in standard pharmaceutical references. It's possible there may be a misspelling or confusion with a similarly named medication. \n\nHowever, if you're referring to \"Dabrafenib,\" which is marketed under the brand name Tafinlar, here\u2019s what you should know:\n\n**Overview**:  \nDabrafenib is a kinase inhibitor used in the treatment of certain types of cancers, most notably melanoma that is metastatic or unresectable and tests positive for BRAF V600E mutation. It is also indicated for use in combination with trametinib (another kinase inhibitor) for treating patients with non-small cell lung cancer (NSCLC) harboring the same mutation.\n\n**Mechanism of Action**:  \nDabrafenib selectively inhibits the activity of the BRAF V600E kinase, which is a mutated form that can cause excessive signaling in the MAPK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0bmncwyRziqPbHTox7mN0Wqj", "custom_id": "435_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4db73025ed2e5fb0dce0d32016a8073", "body": {"id": "chatcmpl-9St8VmrbAkDGx2rRag0KC1acGfg7y", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no widely recognized medication or substance known as \"Bazipar\" in the pharmaceutical industry or medical field. It is important to cross-check the name for any spelling errors or to consider that it might be a new or experimental drug that has come into use after my last update. Alternatively, it could be a drug known by a different name or a brand name that is less commonly recognized.\n\nTo obtain accurate and safe information, I recommend consulting the most recent and reliable medical databases, such as PubMed, or drug reference resources like the Physicians' Desk Reference (PDR) or Medscape. Additionally, contacting pharmaceutical manufacturers directly or checking with regulatory agencies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) could provide up-to-date data about new or uncommon medications."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 175, "total_tokens": 216}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Us5ru4ya50f0XoNanS5IR5hN", "custom_id": "436_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0fb02ae02c99eadfa7403d9d1c70a13", "body": {"id": "chatcmpl-9St8VBvlDpvbzbQrcYmnXkRhrxIk7", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Vizimpro (dacomitinib) is an oral medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Vizimpro:\n\n1. **Indications:**\n   Vizimpro is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.\n\n2. **Mechanism of Action:**\n   Vizimpro is a tyrosine kinase inhibitor (TKI). It specifically inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and development of cancer cells. By inhibiting EGFR, Vizimpro can help in controlling tumor growth.\n\n3. **Administration:**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DZrYLRnKRzehG8nYZplrp30d", "custom_id": "437_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab935d6244ee42c3c08da6b5f573ed8e", "body": {"id": "chatcmpl-9St8VCFVBNJtblxpkpeO5ghsbrDi2", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen, known generically as dactinomycin, is a chemotherapy drug used in the treatment of various types of cancer, including Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, testicular cancer, and certain types of ovarian cancer, among others. It functions as an anticancer antibiotic by intercalating DNA and inhibiting RNA synthesis, which ultimately disrupts the growth and replication of cancer cells. Here are some important considerations about Cosmegen:\n\n### Mechanism of Action\nDactinomycin binds to DNA and intercalates between guanine-cytosine base pairs, inhibiting RNA polymerase and other essential enzymes involved in RNA synthesis. This action prevents the transcription of DNA into mRNA, thereby stopping protein synthesis and cell proliferation.\n\n### Indications\nCosmegen is approved for:\n- Wilms\u2019 tumor\n- Childhood rhabdomyosarcoma\n- Ewing\u2019s sarcoma\n- Metast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_shijyysTG3KqPnuwyfNrxMJF", "custom_id": "438_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ba190859ccc00b123be0722166b28e67", "body": {"id": "chatcmpl-9St8Vw2eRe0Ejcuq7gNbFIGC7qlwu", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danatrol, also known as danazol, is a medication with several important uses and considerations that you as a physician might need to be aware of. Below are some key points regarding danazol:\n\n1. **Indications**: Danazol is primarily used for the treatment of endometriosis and fibrocystic breast disease. It can also be used in men and women for the management of hereditary angioedema.\n\n2. **Mechanism of Action**: Danazol is a synthetic steroid that works by inhibiting pituitary output of gonadotropins, which decreases ovarian production of estrogen and progesterone. In hereditary angioedema, danazol helps increase the levels of C1 inhibitor and C4 protein in the blood, thus reducing the frequency and severity of attacks.\n\n3. **Dosage and Administration**: The dosage of danazol varies based on the condition being treated, severity of symptoms, and the patient\u2019s response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WQEGTR9MhyrcIS1GbHSFC8hA", "custom_id": "439_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30a1ed5e605eeed1199f095dddb190ec", "body": {"id": "chatcmpl-9St8Wjo7XlQfUGPrYcNrsgVnJrWe3", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Darzalex (daratumumab)** is a monoclonal antibody that targets the CD38 protein, which is widely expressed on the surface of multiple myeloma cells as well as other cells of the immune system. Daratumumab is used primarily for the treatment of multiple myeloma. Here are key points about Darzalex that you as a physician might find useful:\n\n### 1. Mechanism of Action:\nDaratumumab works by binding to CD38 on the surface of multiple myeloma cells. This binding induces direct apoptosis and triggers immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).\n\n### 2. Indications:\nDarzalex is approved for use in patients with multiple myeloma. Its use varies based on the line of therapy:\n- **Monotherapy** for heavily pretreated patients: Those who have received at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_58V5q17RzHMksvKrGsDn4Wi3", "custom_id": "440_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3cf5a22eec45481488423ee98fbd57e8", "body": {"id": "chatcmpl-9St8VvMbEkYC4JHa7hLuGYfR8WFYV", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is a medication approved for the treatment of prostate cancer. Here are some key points you should know about Nubequence:\n\n1. **Indications:** Nubeqa is indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). This is a stage of cancer where the disease does not respond to traditional hormonal therapy but has not yet spread to other parts of the body.\n\n2. **Mechanism of Action:** Nubeqa is an androgen receptor inhibitor. It works by binding to the androgen receptor in prostate cancer cells, which inhibits the receptor's interaction with hormones that promote tumor growth. This helps slow down the growth and spread of prostate cancer cells.\n\n3. **Dosage and Administration:** The typical dosage of Nubeqa is 600 mg, taken orally twice daily with food. The tablets should be swallowed whole and not chewed, divided, or crushed.\n\n4. **Efficacy:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QL9FR6gD86sq327ClVxisXq0", "custom_id": "441_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c1f0a809673ac6fd2f87b78f6a1041d1", "body": {"id": "chatcmpl-9St8V4Kg6I6un0izmRgby4EZmlX30", "object": "chat.completion", "created": 1716672155, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel (dasatinib) is a targeted therapy drug used primarily in the treatment of certain types of leukemia. Here's an overview of key information you should be familiar with as a physician:\n\n### General Information\n**Chemical Name:** Dasatinib\n**Brand Name:** Sprycel\n**Drug Class:** Tyrosine kinase inhibitor\n\n### Indications\nSprycel is approved for use in:\n- Chronic myeloid leukemia (CML) in the chronic phase, accelerated phase, or blast crisis. It is used in adults and children who have been newly diagnosed or who have resistance or intolerance to prior therapy, including imatinib.\n- Acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-positive (Ph+). It can be used in both adults and children who are resistant or intolerant to prior therapy.\n\n### Mechanism of Action\nDasatinib works by inhibiting a range of tyrosine kinases, including BCR-ABL,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TTCGS3zfbJdvopsLe2AutMLG", "custom_id": "442_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bede1d41c21a22942d38238c88cf8d8c", "body": {"id": "chatcmpl-9St8W5PXcftaYIEcz2Cvnie4Wluuq", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidine (daunorubicin) is a type of chemotherapy medication used primarily in the treatment of certain types of leukemia, including acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). It belongs to the anthracycline class of chemotherapy drugs and works by interfering with the growth and proliferation of cancer cells.\n\n### Key Points to Consider as a Physician:\n\n#### Mechanism of Action:\n- Daunorubicin acts by intercalating DNA strands, thereby inhibiting the replication of DNA and RNA synthesis. It also generates free radicals, which can cause damage to cellular components including the DNA.\n\n#### Indications:\n- **Primary:** Treatment of acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).\n- **Other Uses:** May be used in other types of leukemias and cancers as part of a combination chemotherapy regimen.\n\n#### Dosing:\n- The dosing of Cerubidine can vary widely depending on the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_mXauXZTMSRemaCjVMBlE7Bgf", "custom_id": "443_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a18c713fe5cfd7a09accd0608a843b4b", "body": {"id": "chatcmpl-9St8WxgDGQdV81gReLrmOdnjC83S5", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome is a liposomal formulation of the chemotherapeutic agent daunorubicin. It is specifically designed for targeted delivery to tumor cells, which can potentially reduce the systemic toxicity associated with traditional formulations of daunorubicin. Here are the key aspects you should be aware of:\n\n1. **Indications**: DaunoXome is primarily used for the treatment of HIV-associated Kaposi's sarcoma. It is indicated for patients with advanced disease or those intolerant to standard treatments.\n\n2. **Mechanism of Action**: DaunoXome works by intercalating DNA, which inhibitates the replication of DNA and the transcription of RNA. The liposomal encapsulation of daunorubicin helps in delivering the drug directly to tumor cells and prolongs its circulation time in the bloodstream.\n\n3. **Dosage and Administration**: The typical dose and schedule may vary depending on the patient\u2019s condition and other factors, such as body size and overall health. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oPd3YO8xAgav5QxkwmUbyniE", "custom_id": "444_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "437765174d3aff95d82ae31814cf57b0", "body": {"id": "chatcmpl-9St8WkBOhOzCHtbbKazPyNloqZ7Ay", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen (decitabine) is a medication used primarily in the treatment of myelodysplastic syndromes (MDS), which are a group of hematopoietic disorders characterized by dysplasia and ineffective hematopoiesis. It is also used in the management of acute myeloid leukemia (AML), particularly in older patients who are not candidates for standard induction chemotherapy.\n\nHere are some key points you should know about Dacogen:\n\n1. **Mechanism of Action**: Decitabine is a nucleoside metabolic inhibitor that incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA. This action can reactivate gene expression and alter cell differentiation and proliferation.\n\n2. **Indications**:\n   - Treatment of patients with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Tg7HU4ZSh5552fwk6ZlxladJ", "custom_id": "445_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6e1dc18eaa8800e657940fe782f64a3e", "body": {"id": "chatcmpl-9St8WHUJ4IB7YU5Ft6uP4A3HktvKw", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon (degarelix) is a medication primarily used in the management of advanced prostate cancer. As a physician, there are several key points you should be aware of when considering or prescribing Firmagon:\n\n1. **Mechanism of Action:**\n   Firmagon is a gonadotropin-releasing hormone (GnRH) antagonist. It works by immediately reducing the production of testosterone by binding to the GnRH receptors in the pituitary gland, which inhibits the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a rapid decrease in testosterone levels, which is crucial in the management of hormone-sensitive prostate cancer.\n\n2. **Indications:**\n   Firmagon is specifically indicated for the treatment of patients with advanced prostate cancer. It is often utilized when quick testosterone suppression is desired or necessary.\n\n3. **Administration:**\n   Firmagon is administered as a subcutaneous injection in the abdominal region"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oXpuOdy3U4zrIGtUWHv52zUH", "custom_id": "446_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c2900b6aee083321fd53c8a3ff66cb51", "body": {"id": "chatcmpl-9St8WcMIxIrFNN21FPI39Jo0EJM10", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ontak (denileukin diftitox) is a targeted therapy used in the treatment of certain types of cancers, specifically for persistent or recurrent cutaneous T-cell lymphoma (CTCL). The therapeutic substance consists of interleukin-2 (IL-2) linked to fragments of diphtheria toxin. Here is some fundamental information about Ontak:\n\n### Mechanism of Action:\nOntak targets cells that express the IL-2 receptor. The fusion protein binds to the receptor on the cancer cell, and the diphtheria toxin component enters the cell. It then inhibits protein synthesis by ADP-ribosylating elongation factor 2, which causes cell death.\n\n### Indications:\nOntak is primarily indicated for the treatment of patients with persistent or recurrent CTCL. The patients suited for this therapy typically express the CD25 component of the IL-2 receptor, which the drug targets.\n\n### Administration:\nOntak is given as an intravenous infusion."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dd2faYCs23n816cFZmGw49PD", "custom_id": "447_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "da0008154ca45b6f1e004213ebeb049e", "body": {"id": "chatcmpl-9St8WRuoMJDq5ANXmbq2i7JW79vXT", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician prescribing Prolia (denosumab), it's important to understand both its mechanism of action, indications, and safety profile. Here is an overview:\n\n**1. Mechanism of Action:**\nProlia is a human monoclonal antibody that targets and binds to RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). By binding to RANKL, denosumab inhibits the formation, function, and survival of osteoclasts, which decreases bone resorption and increases bone mass and strength in cortical and trabecular bone.\n\n**2. Indications:**\nProlia is indicated for:\n   - Treatment of postmenopausal women with osteoporosis at high risk for fracture.\n   - Increase of bone mass in men with osteoporosis at high risk for fracture.\n   - Treatment of bone loss in patients undergoing hormone ablation therapy for prostate or breast cancer at significant risk for fractures.\n   - Treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_mZKI2XyIVuzgBqump21yIT2v", "custom_id": "448_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0f43e9e619f27ae76b12d5f55fec7ee5", "body": {"id": "chatcmpl-9St8WzkrPNlqgWBmHsxZQRMIiJGpf", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Aacidexam doesn't appear to be a recognized medication or substance under that name in standard medical resources. It's possible there may be a typo or misunderstanding regarding the name. If you meant \"Dexamethasone,\" which phonetically is somewhat similar, that is a well-known corticosteroid used in a wide variety of conditions for its anti-inflammatory and immunosuppressant effects.\n\nIf \"Aacidexam\" is a brand name, a formulation specific to a region, or a new product on the market after my last update, it would be wise to consult the latest drug databases, pharmacological resources, or pharmaceutical product information for accurate and detailed information.\n\nFor guidance specific to known medications, more accurate naming or details would be required. If you have other specifics or a different medication in mind, please provide that to help give you the most accurate and useful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 183, "total_tokens": 224}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dyCKA0KyXpn186pfiN4qCQ04", "custom_id": "449_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d53aade4d228a752ef6eb12c9e3fab1c", "body": {"id": "chatcmpl-9St8WgALzm5T4ReVLCxBx4SBvgUvg", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane, known generically as dexrazoxane, is primarily used to protect against cardiotoxicity in patients undergoing chemotherapy with anthracyclines, particularly doxorubicin. It acts as a chelating agent to help reduce the formation of free radicals and reactive oxygen species that are known to damage cardiac cells during anthracycline treatment.\n\nHere are some key points a physician should know about Cardioxane:\n\n### Indications\n- **Cardioprotection**: Cardioxane is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in patients with advanced or metastatic cancer.\n- **Extravasation**: It is also used to treat accidental extravasation of anthracyclines.\n\n### Mechanism of Action\nDexrazoxane is a cyclic derivative of EDTA and functions by chelating iron, thus inhibiting the formation of iron-mediated free radicals that can cause damage to the DNA and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_66BEkJJFWHKDuYgWPOur532C", "custom_id": "450_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c89f89f9f461311c0f3fda5dd49e28a2", "body": {"id": "chatcmpl-9St8WrKpJEdzusSJpiWDoJAJ7Guli", "object": "chat.completion", "created": 1716672156, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a widely recognized medication or substance known as \"Desplex\" in standard medical databases or sources. It's possible that the name might be a brand name, a new drug, a misspelling, or a drug available in specific regions outside mainstream pharmaceutical markets.\n\nIf you're referring to a specific medication that might be known under a different name, or if it's a new drug or a compound I am not updated about, it would be helpful to have more context or details such as its chemical composition, its intended uses, or any other names it might be known by. Always make sure to consult current, reliable medical sources or pharmaceutical databases for the most accurate and updated information. Also, consider contacting pharmaceutical companies directly or checking with regulatory agencies for the most up-to-date and relevant information regarding new or unfamiliar drugs."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 172, "total_tokens": 212}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Oth6kSV7mHbhM8ebaJEsbxbU", "custom_id": "451_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9af4baad2b8fa84d4376f186ace7f7d5", "body": {"id": "chatcmpl-9St8XX30FHWLwBMMfkGb4ivn8R09x", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is an immunotherapy drug used primarily in the treatment of neuroblastoma, a type of cancer that most commonly affects children. Here are key points a physician should know about Unituxin:\n\n### 1. **Indication**\nUnituxin is approved for the treatment of pediatric patients with high-risk neuroblastoma. It is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin after these patients have received induction chemotherapy and autologous stem cell transplantation (ASCT).\n\n### 2. **Mechanism of Action**\nUnituxin is a chimeric monoclonal antibody that specifically binds to the GD2 antigen located on neuroblastoma cells. It works by mediating antibody-dependent cell-mediated cytotoxicity (ADCC), helping the immune system to destroy cancer cells.\n\n### 3. **Administration**\nUnit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EGXxQtEoiEwBHs39UnBFwjdF", "custom_id": "452_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "45305b15ec4cf9179268cdccee80d3a3", "body": {"id": "chatcmpl-9St8X7rHAaY45uONBrR12fXqeXkez", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Asodocel\" does not match any known medications commonly recognized in the healthcare industry, including any FDA-approved drugs. It's possible there may be new developments or specific context (such as a regional brand name, experimental medication, or a recent market entry) that I am not updated with or that \"Asodocel\" might be a misspelling or incorrect transcription.\n\nTo ensure accuracy and safety in your practice:\n\n1. Verify the spelling or nature of \"Asodocel\" if it was communicated verbally or through unclear handwriting.\n2. Consult the most current and trusted medical databases or resources.\n3. Contact a pharmacist or refer to official pharmacological sources for the most up-to-date information.\n\nIf you provide more specific information or context, I can assist better or guide you to the appropriate resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 170, "total_tokens": 212}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AFvzhy7zhH7Fqlqp1qB7UuHN", "custom_id": "453_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e33c4b60c86c44dd63761250fe69635c", "body": {"id": "chatcmpl-9St8Xav2xQRcIqRsHkNTwkKeafwoc", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox (chemical name: 3,4-dihydroxybenzohydroxamic acid) is a synthetic chemical compound that has been studied for its potential therapeutic effects, particularly as an anti-cancer and anti-inflammatory agent. It is not a commonly used medication in clinical practice, but here are some key points that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Didox acts primarily as a ribonucleotide reductase inhibitor. Ribonucleotide reductase is an essential enzyme for DNA synthesis, and by inhibiting this enzyme, Didox can disrupt the proliferation of rapidly dividing cells, such as cancer cells.\n\n2. **Research and Trials**: Most of the studies involving Didox have been preclinical, meaning they have been conducted in vitro (in the lab) or in vivo in animal models. It has shown some promise in these settings, particularly against certain types of cancer cells, including leukemia and breast cancer cells.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_J3yVA0ieUj4jV9mn9mbFcA82", "custom_id": "454_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a8d2a8351ffa77815550853c0ec7c9c8", "body": {"id": "chatcmpl-9St8XNi5n5hy3dDouaklzQEkGfzGD", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriamycin, also known by its generic name doxorubicin, is often marketed as Adriablastina in various parts of the world. This drug is a chemotherapy medication used primarily to treat a variety of cancers, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. Here are some key points that you, as a physician, should be aware of regarding Adriamycin:\n\n1. **Mechanism of Action**: Adriamycin works by intercalating DNA, disrupting the DNA repair mechanism, and inhibiting the progression of the enzyme topoisomerase II, which is critical for DNA replication. These effects lead to the inhibition of cancer cell growth and eventual cell death.\n\n2. **Administration**: The drug is typically administered intravenously, and the dosage and schedule depend on the type of cancer being treated, the patient's body size, and their overall health condition.\n\n3. **Side Effects**: Common side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1R6ub0RyFTOvcjFeyD8PoytP", "custom_id": "455_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "542a9192ad9e7735d2b7318d6e21494e", "body": {"id": "chatcmpl-9St8XVoriJkCXHKJDonEG4YuBc7mQ", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Imfinzz\"i (durvalumab) is a medication used in the treatment of certain types of cancer. It is a type of immunotherapy that works by blocking the interaction between PD-L1, a protein expressed on tumor cells and immune cells, and PD-1 receptors on T cells. This blockage helps the immune system in detecting and attacking cancer cells. Here are some important aspects you should know about Imfinzi:\n\n1. **Indications**: Imfinzi is approved for use in several types of cancers, including:\n   - Locally advanced or metastatic urothelial carcinoma (bladder cancer) that cannot be removed surgically or has spread to other parts of the body.\n   - Stage III non-small cell lung cancer (NSCLC) after tumor reduction with chemotherapy and radiation, where the cancer has not progressed.\n   - Extensive-stage small cell lung cancer (SCLC) in combination with etoposide and either carboplatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LmPOQpC35J4x7Nd89XKctb5B", "custom_id": "456_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c490a2e4e576909f0cb452df59349a2d", "body": {"id": "chatcmpl-9St8XpmiBiYLx4cUXImANyBxIwJWD", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avodart, which contains the active ingredient dutasteride, is a medication primarily used to treat symptoms of benign prostatic hyperplasia (BHP), or enlarged prostate, in men. Here are some key points you should be aware of regarding Avodart:\n\n### Mechanism of Action\n- **Dutasteride**, the active component of Avodart, is a 5-alpha-reductase inhibitor. It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT). DHT plays a major role in the development and enlargement of the prostate gland. By lowering DHT levels, Avodart can help reduce prostate size and relieve associated symptoms.\n\n### Indications\n- **Benign Prostatic Hyperplasia (BPH):** Avodart is used to treat symptomatic BPH in men with an enlarged prostate. It helps improve urinary flow and may also reduce the need for prostate surgery later on.\n\n### Dosage and Administration\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rz3StzBLWCIINJBHKshPCaar", "custom_id": "457_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3dce9126d8c67a116e661021a3ea7906", "body": {"id": "chatcmpl-9St8XvR0hTnAHKpVgZfoixKaLg0Y6", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication approved by the FDA for the treatment of certain hematologic cancers. Here are some key points you should know about Copiktra:\n\n1. **Indications**: Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or follicular lymphoma (FL) after at least two prior systemic therapies.\n\n2. **Mechanism of Action**: Duvelisib, the active ingredient in Copiktra, is a phosphoinositide 3-kinase (PI3K) inhibitor, specifically targeting the delta and gamma isoforms of PI3K. By inhibiting these isoforms, duvelisib disrupts signaling pathways that are critical for the proliferation and survival of malignant B-cells and also affects the tumor microenvironment.\n\n3. **Administration**: Copiktra is administered orally, which can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JmKB4gbRoY7ZVoaUGraO9jjE", "custom_id": "458_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "470177f920f71e2477ded5a77f203926", "body": {"id": "chatcmpl-9St8Xl87FgEfC3yWKkWEnpBPTcEeE", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "A Panorex, also known as a panoramic radiograph or panoramic X-ray, is a type of imaging technology used extensively in dental medicine. It provides a comprehensive view of the entire dental arch \u2013 capturing the teeth, upper and lower jaws, temporomandibular joints (TMJ), sinuses, and other structures in a single, flat representation. Here are some key points you, as a physician, might need to know about Panorex:\n\n1. **Overview and Usage**:\n   - A Panorex image helps in visualizing the bone structure and the position of all the teeth, including any that have not yet erupted (like wisdom teeth).\n   - It is essential for assessing the progression of dental and jaw development, diagnosing diseases, evaluating trauma, planning orthodontic treatments, and preparing for dental implants.\n\n2. **Technological Aspects**:\n   - The X-ray generator and detector rotate around the patient's head, capturing data without physical discomfort generally associated with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IrVJsx4tDhDeB6lXdAU5Ybml", "custom_id": "459_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a287d0fae09079cb8a461b8043ede1a", "body": {"id": "chatcmpl-9St8XyqM1OqGn1TyHD0lAyjrVYPP1", "object": "chat.completion", "created": 1716672157, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that forms in plasma cells. It was approved by the U.S. Food and Drug Administration (FDA) for use in specific types of treatment regimens for patients with multiple myeloma. Here are some key points you might need to know:\n\n1. **Indications and Use**: Empliciti is indicated for the treatment of multiple myeloma in adult patients who have received one to three prior therapies. It is typically used in combination with other medications, such as lenalidomide and dexamethasone, or with bortezomib and dexamethasone.\n\n2. **Mechanism of Action**: Empliciti specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) on myeloma cells. It works by directly activating the body\u2019s natural killer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vtZeCgVtFLnXc6NTYvkFR6C5", "custom_id": "460_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bd2f559dbfbb64e16688585ad93a5253", "body": {"id": "chatcmpl-9St8YrZiAec5KW3j8mzMJE4iNOyRb", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Idhifa (enasidenib)** is a medication approved for the treatment of certain types of acute myeloid leukemia (AML). Here are the key points a physician should know about Idhifa:\n\n1. **Indication:**\n   Idhifa is specifically indicated for the treatment of adult patients with relapsed or refractory AML who have an isocitrate dehydrogenase-2 (IDH2) mutation. The presence of IDH2 mutations should be confirmed through an FDA-approved test before starting treatment with Idhifa.\n\n2. **Mechanism of Action:**\n   Enasidenib, the active compound in Idhifa, is an inhibitor of the IDH2 enzyme. Mutations in IDH2 lead to abnormal accumulation of 2-hydroxyglutarate (2-HG), which contributes to the oncogenesis of AML. By inhibiting IDH2, enasidenib decreases 2-HG levels and induces cellular"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eeAidlrZhHautuixs9kk4bSc", "custom_id": "461_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f5d2a2adbdb3e30238331d06155e8d7", "body": {"id": "chatcmpl-9St8YLhiyRq1CWxa7yfhqnNEuEYHF", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi\u00ae (encorafenib) is a medication used in the treatment of cancer, specifically for patients with BRAF V600E-mutated melanoma, which is a type of skin cancer, and metastatic colorectal cancer with the same mutation. Here are some important aspects you should know about Braftovi:\n\n### Mechanism of Action\nBraftovi is a BRAF inhibitor. BRAF is a protein kinase involved in the mitogen-activated protein kinase (MAPK)/ERK signaling pathway, which helps control cell growth. Mutations in the BRAF gene, like V600E, can lead to uncontrolled tumor growth. Encorafenib targets and inhibits the activity of mutated BRAF proteins, thereby helping to stop or slow the growth of cancer cells.\n\n### Indications\n- **Melanoma**: Braftovi, in combination with binimetinib (a MEK inhibitor), is indicated for the treatment of patients with unresectable"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0tk1efwClRRp1A8t2P9kmTGv", "custom_id": "462_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "26ede63c9cc639db87015a98fad21ba6", "body": {"id": "chatcmpl-9St8Ya6D3QDbbzyFx3r4mpRcJ7M4Y", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rozlytrek (entrectinib) is a targeted therapy approved for the treatment of specific types of cancer with certain genetic features. Here are key points you should be aware of:\n\n1. **Indications**:\n   - **NTRK Fusion-Positive Solid Tumors**: Rozlytrek is approved for adult and pediatric patients (12 years of age and older) with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have no satisfactory alternative treatments or whose cancer has progressed following treatment. These tumors should be identified using an FDA-approved test.\n   - **ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)**: It is also approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.\n\n2. **Mechanism of Action**:\n   - Rozlytrek is a kinase inhibitor. It works by blocking the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_KnUkELOmd9znwgkDb9sr1pXn", "custom_id": "463_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f28ff98c37e84702490ff94b24d5b6c", "body": {"id": "chatcmpl-9St8Y5AvSGI4cn0Z5PONsJIT3A1E4", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azelastine (often marketed under the brand name Astelin among others) is a medication primarily used as a nasal spray for the treatment of allergic rhinitis. It is a second-generation antihistamine and works by blocking histamine H1-receptors, which helps reduce the symptoms of allergies.\n\nHere are some key points about Azelastine that a physician might consider:\n\n1. **Indications**: Azelastine is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and children six years of age and older. It can also be used for perennial allergic rhinititis in adults and children 12 years of age and older.\n\n2. **Mechanism of Action**: As an antihistamine, Azelastine works by inhibiting the histamine response that causes allergy symptoms like sneezing, itching, and runny nose.\n\n3. **Dosage and Administration**: The typical dosage is one or two sprays per nostril"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jbJvZaFVlZfgNshqsd8BWdxh", "custom_id": "464_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d074e99bb106fb3a60327984354ad019", "body": {"id": "chatcmpl-9St8Y2PkRJN9B74fOo5MmVSqIqzzh", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no medication or substance specifically known as \"Alrubicin\" recognized in standard pharmacological sources or in the medical field. It's possible that there may be a typo or a misunderstanding with the name of the drug. However, there are drugs with similar sounding names such as \"Doxorubicin\", which is a chemotherapy medication used in cancer treatment.\n\nDoxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, which is crucial for DNA replication. It is used in the treatment of a variety of cancers, including breast cancer, leukemia, and lymphomas.\n\nIf \"Alrubicin\" was supposed to refer to a specific new drug or a drug under research that isn't widely recognized yet, it would be best to look for the most recent and credible medical literature or clinical trial registries for the most accurate and up-to-date information.\n\nIf there is anything more specific or another"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OPgtaMmcf56slbaEaDR0lxhf", "custom_id": "465_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b05fd2a0b3ef14e98fcf801b6fdc6471", "body": {"id": "chatcmpl-9St8ZHtq6bxt3uaD5MUmGNYFxdp1w", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is a prescription medication developed by Janssen Pharmaceuticals, specifically for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) that has susceptible fibroblast growth factor receptor (FGFR) genetic alterations and who have progressed during or following at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant treatment.\n\nHere are the key points about Balversa:\n\n1. **Mechanism of Action**: Balversa is a kinase inhibitor, specifically targeting the fibroblast growth factor receptors FGFR1, FGFR2, FGFR3, and FGFR4. These receptors are involved in tumorigenic processes such as proliferation and survival when altered genetically.\n\n2. **Approval and Indications**: In 2019, the US Food and Drug Administration (FDA) approved Balversa under the accelerated approval program based on the response rate and duration of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ph6AKWBNMroLKw5ZNesM2tcY", "custom_id": "466_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "baf787ea69aa3ab93eee3a61355f0c99", "body": {"id": "chatcmpl-9St8YWCOZaRDmhKrUGQqPICVbCKsM", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in early 2023, there's no widely recognized medication or substance known as \"Brutravon\" in medical or pharmacological resources. It\u2019s possible that there might be a typo or a different brand name or chemical name that you are referring to. If you could provide more context or a description, I could help identify the correct substance or provide relevant information about it.\n\nIf \"Brutravon\" is a newly developed drug or a substance under trial that has come up after my last update, I recommend consulting current medical literature such as recent publications, clinical trial registries, pharmaceutical databases, or directly contacting pharmaceutical companies involved.\n\nAlways make sure to use reliable and up-to-date sources to get the most accurate and relevant information for your medical practice."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 157, "total_tokens": 199}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_N98X6UmhteQBntHXo0ac9eZp", "custom_id": "467_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9fa41c017c860d78380f888a8b3c3754", "body": {"id": "chatcmpl-9St8YzcQmQ9rQ5ApVNCy2Bxgs2A09", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug Erlotinib, which is used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is categorized as an epidermal growth factor receptor (EGFR) inhibitor.\n\nHere are some key points to consider:\n\n### Mechanism of Action\nErlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and development of cancer cells. By inhibiting this receptor, Erlotinib helps to stop the proliferation of cancer cells and can lead to their death.\n\n### Indications\n- **Non-small Cell Lung Cancer (NSCLC):** Erlotinib is used for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. It is particularly effective in patients who have tumors that express the mutations in the EGFR gene.\n- **Pancreatic Cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_82D1rUOycvF5FcypDYaYBR60", "custom_id": "468_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "56527f4ae136bb6da413d7e6b373993a", "body": {"id": "chatcmpl-9St8YXxblt8V9p6ggaf8xsSoxMJsE", "object": "chat.completion", "created": 1716672158, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt (estradiol mustine) is a medication used in the treatment of prostate cancer. It belongs to a group of drugs known as estrogen derivatives. Here are some key points you, as a physician, should know about Emcyt:\n\n1. **Mechanism of Action**: Emcyt works by inhibiting the production of testosterone, a hormone that can promote the growth of prostate cancer cells. By reducing testosterone levels, this drug can help to slow the growth of the cancer.\n\n2. **Indications**: It is primarily used for the palliative treatment of patients with metastatic and/or progressive prostate cancer.\n\n3. **Administration**: Emcyt is administered orally in capsule form.\n\n4. **Dosage**: The specific dosage and schedule may vary based on the patient's condition and response to the treatment, but a typical starting dose might be around 140 mg/m\u00b2/day, given in divided doses. Always refer to the most current guidelines or product insert for detailed prescribing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SIf039Vsjl3LhITcRq4zxpI3", "custom_id": "469_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a5bacef9995a9e455518337fbf41f2c", "body": {"id": "chatcmpl-9St8Z014RBPjDlRbYin8qvb4KpTdy", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a misunderstanding or a typo in your question. \"Aside\" generally means something mentioned as an additional point or reference. If you are asking about a specific medical topic, drug, treatment, or concept, could you please clarify or provide more specific details? This way, I can offer more targeted and useful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 67, "total_tokens": 106}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_WLZLDtrHV3qdBE5rUl0ujg9V", "custom_id": "470_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ff1ae46642d5efee4e0c25f7983f8e9", "body": {"id": "chatcmpl-9St8ZIGIjC6ncQMC4ngk0XLJ0ukrZ", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, \"Advacan\" does not appear to be a recognized medication or substance commonly known in the medical community, including within pharmaceuticals or clinical treatment protocols. It's possible that there might be a spelling error or it might be a brand name not widely recognized or new on the market.\n\nIf \"Advacan\" is a drug you've encountered in a specific context, such as a new drug on the market, experimental treatment, or a product available in a specific region, I would recommend consulting the latest pharmaceutical literature, product information sheets, or drug databases for the most accurate and updated information. Ensure also to check regulatory bodies like the FDA, EMA, or other relevant organizations depending on your location for any approved indications, usage guidelines, and safety information.\n\nIf you have more details or a different spelling, I can help look up more precise information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 177, "total_tokens": 218}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hKHJEvEyLzcw4IiyhCWLkEjv", "custom_id": "471_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8dfd3a338831f665ee9c0680bc401335", "body": {"id": "chatcmpl-9St8ZmPcHwpUMgvBUAuKPqP5zAgYR", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in January 2021, \"Aromadex\" does not appear to be a widely recognized medical drug under that specific name in standard pharmaceutical references or among common clinical resources. It\u2019s possible that the name \"Aromadex\" could be a brand name, a name used in a specific region, or even possibly a misspelling or misunderstanding of a similar-sounding drug.\n\nIf you meant \"Arimidex,\" which is a brand name for the drug anastrozole, it is an important medication primarily used in the treatment of breast cancer. Here is a brief overview of anastrozole:\n\n### Anastrozole (Arimidex)\n- **Classification:** Anastrozole belongs to a class of medications known as aromatase inhibitors. Aromatase inhibitors work by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens. Lowering estrogen levels is a critical aspect of treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yqMKU4Wev3Nzo3zTDH0x60PH", "custom_id": "472_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e3cb8beafe429e5583070190f5f1ed0", "body": {"id": "chatcmpl-9St8ZzNx1WhlQAKCpNucCuot4aR4k", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "FUDR is the abbreviation for floxuridine, a chemotherapy medication primarily used for the treatment of gastrointestinal cancers, particularly colorectal cancer. Here are some key aspects about floxuridine (FUDR) that you as a physician might find important:\n\n1. **Mechanism of Action**: Floxuridine works as an antimetabolite by interfering with the synthesis of nucleic acids in cancer cells. It is a fluorinated pyrimidine analogue, similar to 5-fluorouracil (5-FU), but it is administered differently and has distinct pharmacokinetic properties. \n\n2. **Indications**: FUDR is often used in the treatment of metastatic colorectal cancer, particularly in the setting of hepatic metastases. It is commonly administered intra-arterially (directly into the artery feeding the tumor) to maximize the drug concentration at the tumor site and minimize systemic toxicity.\n\n3. **Administration**: As mentioned, floxur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9YLj8hHOjoGrkRxfXMqPxwzp", "custom_id": "473_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ca046fba141b0a239913c8c6552abc94", "body": {"id": "chatcmpl-9St8ZZcwjXtzPORucdr4hLVzLVL6r", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beneflur is not a well-known medication or substance in widely accepted medical references or databases. It\u2019s possible that there might be a spelling error or it is a brand name not widely recognized or used under another name. To provide accurate information, I would need the correct name or more details about the drug. If it is a new or less common medication, the best approach would be to consult the most current drug information databases, pharmaceutical literature, or regulatory agency resources for the most accurate and up-to- date information. This would include details on its indications, dosage, potential side effects, interactions, pharmacology, and guidelines for use. Always ensure to stay updated with reputable medical and pharmaceutical resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 140, "total_tokens": 181}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_faa6Ti6x88EcQfcvqnsTEpUd", "custom_id": "474_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee8e287bc4fc5446625620726ca79152", "body": {"id": "chatcmpl-9St8ZkC8nH8hS6DSECCDwQvWtUyYy", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Accusite is a drug delivery system that was used in the context of chemotherapy, particularly for the treatment of diseases such as cancer. Specifically, it was designed for intraperitoneal administration to deliver high concentrations of drugs directly to the peritoneal cavity, where many gastrointestinal cancers and ovarian cancers metastasize. The primary goal of this system was to maximize the exposure of the tumor to the drug while minimizing systemic exposure and thus reducing side effects.\n\nHowever, as of the last available data, Accusite is not a commonly referenced system in contemporary medical texts or recent clinical guidelines relating to cancer treatment. It's important to confirm the current status and relevance of this treatment modality through up-to-date resources or clinical trials registries if it's being considered for use.\n\nFor physicians considering or encountering treatments involving any specialized or less common drug delivery systems like Accusite, it is critical to:\n\n1. **Review Current Literature and Guidelines:** Ensure that any treatment plan involving such technologies is supported by the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LvXFrKynfnPCs2QfWN90Yycc", "custom_id": "475_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "331081fa3fe01bb1ea6e278e986f2c64", "body": {"id": "chatcmpl-9St8ZLXLjLigazt4jB86wLnvlR246", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin, known generically as fluoxymesterone, is a potent synthetic androgen, chemically derived from testosterone. It is primarily used in the treatment of low testosterone levels in males and, in certain cases, breast cancer in women. It is known for its high androgenic properties and minimal anabolic effects. Here are several key points that you, as a physician, should consider when dealing or prescribing Halotestin:\n\n### Indications\n1. **Hypogonadism in Males**: Halotestin is prescribed to supplement testosterone in conditions where natural testosterone levels are abnormally low.\n2. **Breast Cancer**: It has been used in women to treat certain forms of advanced breast cancer, although this is less common with the availability of newer treatments.\n3. **Delayed Puberty in Boys**: Occasionally, it\u2019s used to stimulate puberty in carefully selected males with clearly delayed puberty.\n\n### Mechanism of Action\nHalotestin binds"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Weba9Q7K85HS78bVVkBHbBFn", "custom_id": "476_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "683cc84512e68b91f303f0a0131e1e21", "body": {"id": "chatcmpl-9St8ZbBbmwGROJxukj4g66Kq5OE79", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid, known generically as Flutamide, is a medication used primarily in the management of prostate cancer. It falls under the category of nonsteroidal antiandrogens. Here are some key points that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Flutamide acts as a competitive antagonist at androgen receptors, thereby inhibiting the action of androgens (such as testosterone). This inhibition is crucial in the treatment of prostate cancer, where androgen hormones can stimulate the growth of cancer cells.\n\n2. **Indications**:\n   - It is primarily indicated for the treatment of advanced prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) agonist or surgical castration.\n   - It may also be used off-label for other conditions influenced by androgens, such as polycystic ovary syndrome (PCOS), hirsutism, and androgenic alopecia,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yTgwGgFnAHXYD8KUTIsFVAmU", "custom_id": "477_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "85366f925017a46e57be8a9ddd7de66c", "body": {"id": "chatcmpl-9St8ZEaDmf9CANbyOB01TU4nSm6Ta", "object": "chat.completion", "created": 1716672159, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Antrex\" isn't a recognized or commonly known medication in standard pharmaceutical or medical resources. It's possible that there might be a typo or a mix-up in the name. Alternatively, it could be a brand name that is not widely recognized or a new drug not yet broadly documented. \n\nIf \"Antrex\" refers to a specific medicine, supplement, or treatment, it could be beneficial to verify the spelling or to get additional context such as its ingredients or the conditions it's intended to treat. Another possibility is that it might be a drug known by a different name in different regions or under different brand names.\n\nWhen encountering unfamiliar drug names, checking with reliable pharmacological resources or databases, such,bool as the FDA database (for U.S.-approved medications), or consulting with a pharmacist can provide accurate information.\n\nIf you have more specifics or can provide additional details, I'm here to help look into that."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 189, "total_tokens": 229}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YXuMhOX2U9LLdCXLQ0QLdBcz", "custom_id": "478_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f549647eafa7fcc0310d3faaeea428bd", "body": {"id": "chatcmpl-9St8aePkhnDZkmfeEvs300e1TBI8H", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lentaron, known generically as formestane, is a type II irreversible steroidal aromatase inhibitor. It works by inhibiting the aromatase enzyme that is responsible for converting androgens to estrogens, thereby lowering the level of estrogen in the body. This mechanism of action is particularly useful in the treatment of estrogen receptor-positive breast cancer in postmenopausal women.\n\nHere are a few key points to consider:\n\n1. **Indications:**\n   - Lentaron is primarily used for treating estrogen receptor-positive breast cancer in postmenopausal women, especially for those who have progressed following anti-estrogen therapy.\n\n2. **Mechanism of Action:**\n   - Formestane suppresses estrogen production by binding to and irreversibly inhibiting the aromatase enzyme, which is crucial for the biosynthesis of estrogens from androgens. \n\n3. **Administration:**\n   - Formestane was originally available as an injectable formulation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SN84hNjynR9uURFJQw6NbiIe", "custom_id": "479_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "edf5d0130e1249c9312ff54f5b1eb729", "body": {"id": "chatcmpl-9St8aaXfhUUQPigrnnKsmq5MGUMAE", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine\u2122 is an investigational drug which falls under the category of nucleoside analogs, specifically targeting purine biosynthesis. Its active component, forodesine hydrochloride, has been studied primarily for its potential use in treating hematological malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL).\n\n**Mechanism of Action**:\nForodesine hydrochloride acts as a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP). By inhibiting this enzyme, the drug leads to an accumulation of deoxyguanosine triphosphate (dGTP), which in turn induces apoptosis, particularly in T-cells where the enzyme is highly active. This targeted action makes forodesine particularly useful in conditions with overactive T-cell mediation.\n\n**Clinical Trials and Efficacy**:\nAs of the latest updates, forodesine has undergone Phase I"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_moxOm9zTc9EQpsEpLcW4V3if", "custom_id": "480_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "169b9397287e25e100e27ab3a6897131", "body": {"id": "chatcmpl-9St8aFWIM5Dza2bGDiX1bYiiXw9VN", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tavalisse (fostamatinib) is a medication approved for the treatment of chronic immune thrombocytopenia (ITP) when other treatments have not been sufficient. Immune thrombocytopenia is a disorder in which the immune system attacks and destroys platelets, which are necessary for normal blood clotting.\n\nHere are several important aspects about Tavalisse that you should know as a physician:\n\n1. **Mechanism of Action**: \n   Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor. It works by blocking the SYK enzyme, which is part of the signaling pathway that leads to the destruction and phagocytosis of platelets in patients with ITP.\n\n2. **Indications**:\n   It is indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.\n\n3. **Administration**:\n   Taval"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_ymdX7JJA82wnZ6PaK63D1RR0", "custom_id": "481_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e2bfb2e646ef367ad483c22c89770f23", "body": {"id": "chatcmpl-9St8aMOHN53NeECcifELHFUvbDrfY", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Muphoran (fotemustine) is a type of chemotherapy drug classified as a nitrosourea alkylating agent. It is primarily used in the treatment of metastatic melanoma, especially when the cancer has spread to the brain. Fotemustine has also been investigated for use in other types of cancers such as gliomas, non-small cell lung cancer, and other malignancies.\n\n### Mechanism of Action:\nFotemustine causes cross-links in DNA that prevent cell replication and lead to cell death. Due to its lipophilicity, it has a good ability to cross the blood-brain barrier, making it a viable option for treating brain metastases from malignant melanoma.\n\n### Indications:\n- Primary treatment for metastatic malignant melanoma\n- Treatment for other cancers as part of clinical trials or based on the oncologist's discretion\n\n### Administration:\nMuphoran is administered intravenously. Treatment generally includes an induction phase followed by a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PeJbE1hJBOSYPbLeApG23spw", "custom_id": "482_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3ce387a759304311f0e81e32f11dfb8", "body": {"id": "chatcmpl-9St8aGvHArtWiQz6nDVAD7jG4n1Ql", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Faslodex (fulvestrant)** is a medication used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. As a physician, here are key points you should know about Faslodex:\n\n1. **Mechanism of Action**:\n   - Faslodex is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors on breast cancer cells, causing receptor degradation and thus blocking the estrogen signaling that the cancer cells require for growth.\n\n2. **Indications**:\n   - It is approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women. \n   - It is often used in patients who have progressed on or after adjuvant antiestrogen therapy or previous endocrine therapy.\n\n3. **Administration**:\n   - Faslodex is administered via intramus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_2vPF9R9G07PK9XADv8TdiKxI", "custom_id": "483_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d09b097c03f97d1109a7dabca5545e6c", "body": {"id": "chatcmpl-9St8aNoXc2wS56p0P6rG8CKm42RfR", "object": "chat.completion", "created": 1716672160, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a drug or medical treatment known specifically as \"Cangib.\" It's possible that the name might be a typo, a new development not included in my last update, or a term specific to a particular region or dialect that isn't widely recognized in mainstream medical literature.\n\nIf \"Cangib\" refers to a medication, treatment, or concept introduced after my last update, I recommend consulting the most current medical databases, pharmaceutical records, or drug administration updates. Reliable sources like PubMed, clinical trial repositories, or the official websites of regulatory agencies like the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) could also be useful. Additionally, checking pharmaceutical company releases or attending medical conferences might provide up-to-date information.\n\nIf this name pertains to a specific condition, theory, or notion in medicine outside the pharmaceutical context, turning to recent medical journals or contacting a specialist in the relevant field could provide clarity.\n\nCould you"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OuYladO1UJbbNVUuI70SjMJX", "custom_id": "484_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0b52b6084351425290c4d41a47f4b560", "body": {"id": "chatcmpl-9St8bMxpwsRECGpwGPqqN3AEDa61I", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine, sold under the brand name Gemzar among others, is a chemotherapy medication used to treat a variety of cancers. It is commonly used for the treatment of pancreatic cancer, breast cancer, ovarian cancer, and non-small cell lung cancer. Here are some key points you, as a physician, should consider:\n\n### Pharmacodynamics\nGemcitabine is a nucleoside analog that interferes with DNA synthesis. It is metabolized intracellularly into two active nucleotide analogs, dFdCDP and dFdCTP. These metabolites cause the reduction in DNA synthesis (dFdCTP) and inhibition of ribonucleotide reductase (dFdCDP).\n\n### Mode of Administration\nGemcitabine is administered via intravenous infusion. The dosage and schedule depend on the type of cancer being treated, the patient's body surface area, general health, concurrent treatments, and response to therapy.\n\n### Dosage\n- **Pancreatic Cancer:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lHOMaQtdaV1w9Q3kqWU4ZTJU", "custom_id": "485_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "698456dd37adc331340e4db5892c92a7", "body": {"id": "chatcmpl-9St8bV3c7qEt1GRFUggC8jpFB5dXg", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (gemtuzumab ozogamicin) is a targeted therapy used in the treatment of acute myeloid leukemia (AML), particularly in certain patient subgroups. Here are some key points that might be useful for your clinical practice:\n\n1. **Mechanism of Action**:\n   Mylotarg is an antibody-drug conjugate (ADC). The antibody part binds to a protein called CD33, which is expressed on the surface of myeloid cells, including leukemic cells in AML. The drug that is conjugated to the antibody, a cytotoxic agent called calicheamicin, is then internalized into the cell where it induces DNA damage, leading to cell death.\n\n2. **Indications**:\n   - Mylotarg is approved by the FDA for the treatment of newly diagnosed CD33-positive AML in adult and pediatric patients 1 month and older.\n   - It is also used for the treatment of relapsed or refractory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_tstCAKUCfa9IPfLceF1gZJwU", "custom_id": "486_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f1254fe122d62e753b2e7c2cb6585e68", "body": {"id": "chatcmpl-9St8bfMWxeeuNhntA7JNRKyhMofBv", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata, also known by its generic name gilteritinib, is a medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are key points that physicians should be aware of:\n\n1. **Indication**:\n   - Xospota is approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.\n\n2. **Mechanism of Action**:\n   - Gilteritinib is a kinase inhibitor. It works by inhibiting the receptor tyrosine kinases FLT3 (FMS-like tyrosine kinase 3) and AXL, which are involved in the proliferation and survival of leukemic cells in AML. Inhibition of these kinases leads to the death of leukemic cells.\n\n3. **Dosage and Administration**:\n   - The typical dose is 120 mg taken orally once daily with water, with or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CdCa3TS2yMLHN6IeFJFTcwGZ", "custom_id": "487_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "01fa1de83780a618f4e0ea0d6d7d7208", "body": {"id": "chatcmpl-9St8bzhaxrxGcEVZ0Qd4KQdduB41m", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daurismo (glasdegib) is a medication approved by the FDA for the treatment of certain types of acute myeloid leukemia (AML). Here are several key points about Daurismo that you, as a physician, should know:\n\n1. **Indications**: Daurismo is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. It is used in combination with low-dose cytarabine (LDAC).\n\n2. **Mechanism of Action**: Glasdegib works as a hedgehog pathway inhibitor. It inhibits Smoothened, a protein that regulates the hedgehog pathway, which plays a significant role in stem cell and basal cell carcinoma pathways. In AML, blocking this pathway can inhibit the growth of cancer cells.\n\n3. **Dosage and Administration**: Daurismo is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SbMGdP7vJd0jTOPvZKHzUsaN", "custom_id": "488_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "29ac95f08fe4c72e83f83eb96537f8aa", "body": {"id": "chatcmpl-9St8bkfgHig61tBRQWYJJGRMLCi2c", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in September 2023, \"Novgos\" does not appear to refer to any known medication, medical terminology, or concept commonly recognized within the healthcare industry. It's possible that there may be a typographical error or a misunderstanding regarding the term. If you're referring to a specific drug, condition, or medical tool, please provide additional information or clarify so I can assist you accurately. Alternatively, if \"Novgos\" is a new or less common subject in medicine after September 2023, I recommend consulting the latest clinical resources or databases like PubMed, UpToDate, or official medical organization websites for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 131, "total_tokens": 171}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VjlhZBQh8rqT06INbK0EGaQR", "custom_id": "489_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "13ebe0e4215a6e1271d942d6876a9489", "body": {"id": "chatcmpl-9St8bOx4PA2dFVLZU06AWWF6xMGFH", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin LA (histrelin acetate) is an implant that is used primarily in the treatment of central precocious puberty (CPP), a condition where children show early onset puberty significantly earlier than usual. As a physician, here are key points you should know about Supprelin LA:\n\n1. **Indication**: Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP), which is characterized by the development of secondary sexual characteristics before the age of 8 in girls and 9 in boys.\n\n2. **Mechanism of Action**: Supprelin LA is a gonadotropin-releasing hormone (GnRH) agonist. It works by initially stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). However, with continued use, it desensitizes the pituitary gland leading to a decrease in FSH and LH levels, ultimately reducing the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AT33A3GPSeVVcAMGTiDBTtrF", "custom_id": "490_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b88ee3a9d5ae084c72c06abe77b108bc", "body": {"id": "chatcmpl-9St8bDaJ0IgoUQGBbX1c1zqWNKKdu", "object": "chat.completion", "created": 1716672161, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cortef, known generically as hydrocortisone, is a glucocorticoid medication commonly used to treat a variety of conditions involving inflammation and autoimmune responses. Here are some key aspects about Cortef that you, as a physician, might find useful:\n\n### 1. Indications\nCortef is used to treat several conditions including, but not limited to:\n- Adrenal insufficiency (e.g., Addison's disease)\n- Inflammatory disorders (such as rheumatoid arthritis)\n- Allergic reactions\n- Asthma\n- Certain types of colitis\n- Some skin conditions\n\n### 2. Mechanism of Action\nHydrocortisone mimics the actions of cortisol, a naturally occurring hormone produced by the adrenal glands. It works by reducing inflammation, suppressing the immune response, and altering the body\u2019s response to stress.\n\n### 3. Dosage and Administration\nThe dosage of Cortef can vary widely depending on the condition being treated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_YbkCONo04oPHxmmR2p5mShjP", "custom_id": "491_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9942d79e4912ce57498764b42b96c374", "body": {"id": "chatcmpl-9St8cJF5hWqdjJyyLI4d1zsR1J5fM", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medication or substance called \"Biosupressin\" in standard medical or pharmaceutical references. It\u2019s possible that the name could be a brand name, a non-standard treatment, or incorrectly spelled. It's important to double-check the spelling or provide more context regarding the medication or its intended use. If it involves a new or experimental treatment, consulting the latest research or clinical trial databases may provide you with up-to-date information. Also, consider checking authoritative sources like the FDA or EMA websites, or drug information databases for the most accurate and reliable information. If you have questions about a specific treatment or medication, engaging with pharmaceutical representatives or consulting with colleagues might also provide insights."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 145, "total_tokens": 187}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_1uNLu3AKVcGrDOha2zDKrgnz", "custom_id": "492_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c8676064fa1d4fe6a217da992c27dcb", "body": {"id": "chatcmpl-9St8c9AOv0hfHFr7iwUjoJLK4U7Iq", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radiolabeled monoclonal antibody used primarily in the treatment of non-Hodgkin lymphoma (NHL). Here are some important aspects about Zevalin that you, as a physician, might need to know:\n\n### Mechanism of Action\nZevalin is a conjugate of the monoclonal antibody ibritumomab and the radioisotope yttrium-90 (90Y) or indium-111 (111In) for imaging. Ibritumomab targets the CD20 antigen on the surface of normal and malignant B-cells, and after binding, the radioisotope delivers beta radiation directly to the target cells, which helps in destroying them.\n\n### Indications\nZevalin is approved for the treatment of:\n- Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.\n- Previously untreated folliculer NHL in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1OgTyDJNHEQnodT3lcOoQxUQ", "custom_id": "493_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "201f5718566831c756ad83e31d12d6a2", "body": {"id": "chatcmpl-9St8cgvUt8ZaGrwNZ8CwDG4q0voW8", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a medication used in the treatment of certain types of cancer, primarily B-cell malignancies. Here are some key points that you, as a physician, should be aware of regarding ibrutinib:\n\n1. **Mechanism of Action**: Ibrutinib is a potent inhibitor of Bruton\u2019s tyrosine kinase (BTK), which is a crucial enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, ibrutinib blocks the proliferation and survival of B cells, which are critical in many B-cell malignancies.\n\n2. **Indications**: Ibrutinib is approved for the treatment of several conditions, including:\n   - Chronic lymphocytic leukemia (CLL)\n   - Small lymphocytic lymphoma (SLL)\n   - Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy\n   - Waldenstr\u00f6m\u2019s macroglobulinemia\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pzHn8cPrRgk517kzEUui9Y4L", "custom_id": "494_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f10d734272ed5a6eddfe417f142b29e4", "body": {"id": "chatcmpl-9St8cFQVZDe0USPxeZcR6sB3ei0pN", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Conmana is the brand name for icotinib, which is an oral tyrosine kinase inhibitor specifically targeting the epidermal growth factor receptor (EGFR). It has been mainly used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients who have specific mutations in the EGFR gene that are known to be responsive to EGFR tyrosine kinase inhibitors.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Conmana (icotinib) is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with EGFR mutations. These mutations lead to the activation of molecular pathways that promote tumor growth and survival.\n  \n2. **Mechanism of Action:**\n   - Icotinib works by inhibiting the tyrosine kinase activity associated with the EGFR. EGFR is often overexpressed or mutated in certain types of cancers, including NSCLC. By inhibiting this"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_IilZK9CaxCyCDJWMOQyvvisr", "custom_id": "495_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "246aa177d2a0c77d780bf1e9791cca34", "body": {"id": "chatcmpl-9St8cN6T7B8aVcLQ32ft22FPV2AaC", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, which contains the active ingredient idarubicin, is a type of chemotherapy drug used primarily in the treatment of acute myeloid leukemia (AML). It is an anthracycline antibiotic that works by interfering with the growth and reproduction of cancer cells.\n\nHere are some key points you should know about Idamycin:\n\n1. **Mechanism of Action**: Idarubicin acts primarily by intercalating with DNA, disrupting the enzyme topoisomerase II, which leads to breaks in DNA strands and ultimately inhibits DNA synthesis and function.\n\n2. **Indications**: Idamycin is most commonly used to treat acute myeloid leukemia, but it can also be used for other types of leukemia as part of a combination chemotherapy regimen.\n\n3. **Administration**: Idarubicin is typically administered intravenously. The dosage and schedule depend on various factors including the patient's size, type of cancer, staging of the cancer, and overall health.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_1LShr3JVdvWmaqVBxJAeO1Fn", "custom_id": "496_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fd9336c601b0835b43a454eeb55eb5b3", "body": {"id": "chatcmpl-9St8cEqxzalMW8YGjMg0yY4Xj4Z7W", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zydelig (idelalisib) is a medication indicated for the treatment of certain chronic lymphocytic leukemias (CLL) and indolent non-Hodgkin lymphomas. Here are some key points a physician should know about Zydelig:\n\n1. **Mechanism of Action**:\n   Zydelig is a selective inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that is overexpressed in many B-cell malignancies and plays a significant role in the survival, proliferation, and homing of these cancer cells.\n\n2. **Indications**:\n   - **CLL**: It is approved for use in patients who have received at least one prior therapy, in combination with rituximab. It can offer an alternative for patients for whom chemoimmunotherapy is considered inappropriate.\n   - **Follicular Lymphoma (FL)**: Indicated for patients who have received at least"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZEAUJYrIiuVUtedgBmBr9sxO", "custom_id": "497_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "94e95b4718a941be9c04b6e5f1e6d775", "body": {"id": "chatcmpl-9St8czFoELkTDTLrrhNrXVHLMKOWa", "object": "chat.completion", "created": 1716672162, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no recognized medication or substance named \"Alquimid\" in mainstream medical literature or databases. It is possible that the name could be a misspelling, a brand name not widely recognized, or a substance not approved or recognized by medical authorities.\n\nIf \"Alquimid\" is related to a specific treatment or chemical, I would recommend verifying the correct spelling or consulting comprehensive pharmaceutical databases, or discussing with colleagues in pharmacology or the relevant medical specialty. Always refer to reliable and authoritative sources for medical information to ensure safety and efficacy in treatment."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 116, "total_tokens": 157}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BRsQMDfZSuNUc1D1uaycHOdo", "custom_id": "498_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8fdf8d8f9060bc68b3da44fc70f564b7", "body": {"id": "chatcmpl-9St8drTShVLZVR5BY7s8dHEBLdSb0", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in January 2023, there is no specific drug named \"Enliven\" widely recognized in the medical community. However, it\u2019s possible that \"Enliven\" could be a brand name for a drug or a product newly released on the market, or it might be a brand name used in a specific country or region. It's also feasible that \"Enlizen\" could be a typo or a mispronunciation of another drug.\n\nIf you mean \"Enliven\" in a different context or if there has been recent development, I would need more specific information to provide a meaningful response. It would be best to consult the latest databases, drug formularies, or pharmaceutical information sources such as the FDA or EMA websites for the most current and accurate information regarding any medical product or drug. If it is a proprietary product or a device, checking manufacturer information might also be useful.\n\nFor accurate and safe medical practice, always ensure you have the most current"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_F2wcNP3DQK1rKtYdxQNfPtNy", "custom_id": "499_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3f4b60f74d3077aecbeb77b6262dac86", "body": {"id": "chatcmpl-9St8dpy8HtooG0VJJqF1iq9Vgoq48", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiq (infigratinib) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This approval, granted in May 2021, is specifically for patients who have progressed on or after at least one prior line of systemic therapy.\n\n### Key Points for Physicians:\n\n1. **Mechanism of Action**:\n   - Truseltiq is a kinase inhibitor that primarily targets FGFR2 genetic alterations. FGFR2 fusions or rearrangements lead to abnormal signaling pathways that can promote cancer cell growth and survival. By inhibiting these receptors, Truseltiq can interfere with tumor growth and proliferation.\n\n2. **Indications**:\n   - It is vital to confirm the presence"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x0A94ZjWTXKoUZxpR9GUeWWs", "custom_id": "500_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9a3f65394ed55c820a76601e2729af50", "body": {"id": "chatcmpl-9St8dpW77vEBwJRaK5r5VBjxkPn42", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (inotuzumab ozogamicin) is a monoclonal antibody drug conjugate used primarily in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The active component of Besponsa, inotuzumab, is a monoclonal antibody that targets CD22, a marker expressed on the surface of B-cells. This antibody is linked to ozogamicin, a cytotoxic agent.\n\nHere are some important points you should consider as a physician when dealing with Besponsa:\n\n1. **Indications and Use:**\n   Besponsa is approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n\n2. **Mechanism of Action:**\n   Inotuzumab ozogamicin binds to CD22 on B cells, followed by internalization of the drug-antibody complex. The ozogamicin then releases its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_fDqrR7ur6xYT9gqJb73O9HrI", "custom_id": "501_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "01c0dcf4a245b5d1f2ea8209ae690547", "body": {"id": "chatcmpl-9St8dDvqhhpcBXZaN0Jg990LyBtVo", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a well-known drug by the name \"Laroferon.\" It's possible that the name could be misspelled, a less common or newly introduced medication, or not widely recognized under this name in most pharmacological or medical references. To provide accurate and relevant information, I would recommend double-checking the spelling or providing additional context. If \"Laroferon\" refers to a specific drug that is used in certain regions or under experimental conditions, more specific details would help in giving a precise explanation. \n\nIf you are inquiring about an interferon-based medication (as the name might suggest, loosely hinting at \"interferon\"), these are typically used to treat various conditions including viral infections and certain types of cancer. Interferon drugs work by boosting the immune system's ability to fight diseases. If this is not the medication you're referring to, please provide more information, and I'll do my best to assist you."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 198, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sx1PXwWg4jaT6wSlnWIXtRFV", "custom_id": "502_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9dd995c6886072a19c232e29fa3883df", "body": {"id": "chatcmpl-9St8dOQWvEe7I488tmRhVNyBreldr", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Advaferon\" is not recognized as a specific medication or treatment in standard medical databases or resources. It\u2019s possible that it could be a brand name, a less common drug, or possibly a misspelling or miscommunication of the drug name.\n\nHowever, if you are referring to a medication for treating conditions like anemia or related to interferon therapy (given the similarity in naming), I would recommend double-checking the correct spelling or name of the medication. Once you have the correct information, you can look up details in trusted medical databases like the FDA database, PubMed, or drug information resources such as Lexicomp or UpToDate.\n\nIf you provide more specific details or context, I'd be more than happy to help you find accurate and relevant information. Always ensure to consult the latest clinical guidelines or pharmaceutical references for the most current and comprehensive drug information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 181, "total_tokens": 223}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_q9VPdhYoXwlPwZQieAeUfLVZ", "custom_id": "503_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d02284de262e94d79e9ed9193e10f6e2", "body": {"id": "chatcmpl-9St8dgDcg8AYvWoMUWNKQLcz0c9Km", "object": "chat.completion", "created": 1716672163, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (generic name: interferon gamma-1b) is a medication used primarily to treat chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. It is a synthetic version of a substance naturally produced by the body's immune system.\n\n### Key Points for Physicians:\n1. **Indications:**\n   - **Chronic Granulomatous Disease (CGD):** Actimmune is indicated to reduce the frequency and severity of serious infections associated with CGD.\n   - **Severe Malignant Osteopetrosis:** It is indicated for delaying the time to disease progression in patients.\n\n2. **Mechanism of Action:**\n   - Actimmune enhances the function of the immune system by promoting the activity of phagocytes and macrophages, which are essential in fighting infections and disease processes in CGD and osteopetrosis.\n\n3. **Administration:**\n   - Actimmune is administered via subcutaneous injection. Proper"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NV18sI9Htmw753Dv3VzqNFsx", "custom_id": "504_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7269de4dc1d805f9e43d74e232f6017d", "body": {"id": "chatcmpl-9St8eleLlD9ZIIOsY2rnHmXLyySj3", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (ipilimumab) is a monoclonal antibody used in cancer treatment, specifically for managing melanoma. As a physician, here are some key aspects you should consider:\n\n1. **Mechanism of Action**: Yervoy targets CTLA-4, a protein receptor that downregulates the immune system. By inhibiting CTLA-4, Yervoy enhances the immune system's response against melanoma cells.\n\n2. **Indications**:\n   - It is primarily used for the treatment of melanoma that has spread (metastatic) or cannot be removed by surgery (unresectable).\n   - It's also approved for adjuvant treatment of melanoma with the involvement of lymph nodes or metastatic disease after complete surgical resection.\n   - Yervoy has been studied in combination with other immunotherapy agents like nivolumab for advanced melanoma, showing improved response rates compared to Yervoy alone.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cyUh4ywTaYQUVyBn1GAT7yUo", "custom_id": "505_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ab6dfe9973dda2c5dffcbcdd3350bdfc", "body": {"id": "chatcmpl-9St8e91CCJygN3WME7UkNQLwpLbJk", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axinotecan (commonly misspelled as \"Axinotecan\") might be a typo or confusion with Irinotecan, which is a chemotherapeutic agent used in the treatment of cancer. Irinotecan is indeed a significant drug to understand in the context of cancer treatment. Below I've provided key information about Irinotecan:\n\n### Generic Name\nIrinotecan\n\n### Mechanism of Action\nIrinotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that facilitates the unwinding of DNA for replication. By inhibiting this enzyme, Irinotecan prevents DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\nIrinotecan is primarily used for:\n- Metastatic colorectal cancer, either as a first-line treatment when combined with other agents (like 5-fluorouracil and le"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pEll6H6qifsPxI4RiI69qwTG", "custom_id": "506_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7fdf3da764731d527bb644b253ce6c3a", "body": {"id": "chatcmpl-9St8eT9Za6L6o2cuzCTACgkjHjnsa", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have detailed knowledge about Onivyde (irinotecan liposome injection), particularly if you are involved in the treatment of pancreatic cancer or other relevant conditions. Here are the key points to know:\n\n### 1. **Indication and Usage**\n   - Onivyde is approved for use in combination with fluorouracil (5-FU) and leucovorin for treating patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It\u2019s vital to confirm that this treatment is appropriate based on the specific patient's stage and history of cancer treatment.\n\n### 2. **Mechanism of Action**\n   - Onivyde is a liposomal formulation of irinotecan, which allows for a prolonged circulation time and an increased delivery of the drug to the tumor site. Irinotecan itself is a prodrug that is converted into its active metabolite, SN-38"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_o5gpJwxdH4o7dDjn2qI4EKVO", "custom_id": "507_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2ec72e436863da524e993d55bfd9b6d6", "body": {"id": "chatcmpl-9St8e7Tlp2aFYNUTSjJSXEut6UihY", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa, known generically as isatuximab, is a monoclonal antibody medication primarily used for the treatment of multiple myeloma. As a physician treating patients in this domain, here are some key aspects of Sarclisa you should be aware of:\n\n1. **Indication and Usage**: Sarclisa is approved for use in combination with other drugs for the treatment of multiple myeloma. Specifically, it is indicated for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. The typical regimes involve combinations with drugs like pomalidomide and dexamethasone, or carfilzomib and dexamethasone.\n\n2. **Mechanism of Action**: Isatuximab works by targeting the CD38 molecule on the surface of myeloma cells. CD38 is highly expressed on myeloma cells, and isatuximab binds to it, leading to multiple"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yAKnzeXuvhSVloMnReI4c9JB", "custom_id": "508_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0369f30ec17eb1d3700639d46beddc72", "body": {"id": "chatcmpl-9St8ew5AcBZbDhyDY6SjHtq3gNI1S", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician considering the prescription of Absorica (isotretinoin), here are some key points to keep in mind:\n\n1. **Indications**: Absorica is a form of isotretinoin, primarily indicated for the treatment of severe recalcitrant nodular acne that has not responded to other treatments, such as antibiotics.\n\n2. **Mechanism of Action**: Isotretinoin works by reducing the amount of oil released by oil glands in your skin, helping your skin renew itself more quickly.\n\n3. **Formulation**: Absorica is known for its enhanced bioavailability when compared with traditional isotretinoin products. Absorica does not require administration with a high-fat meal to enhance absorption, unlike traditional isotretinoin, which could improve compliance.\n\n4. **Dosage and Administration**: Dosage must be carefully considered based on the patient's weight and severity of the acne. It's usually administered twice daily, and the course typically lasts"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sYPRF5frWSt23apwTF8gK2Lp", "custom_id": "509_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a31a9c886e5a5ea61be7f1853f1fba9", "body": {"id": "chatcmpl-9St8e3t16CIbWf7a9I6Z3x2rwCD65", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tibsovo (generic name: ivosidenib) is an oral medication used in the treatment of certain types of cancer. It was approved by the U.S. Food and Drug Administration (FDA) for specific cancer indications. Here\u2019s what you need to know about Tibsova as a physician:\n\n1. **Indications**: Tibsovo is approved for the treatment of:\n   - Adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the isocitrate dehydrogenase-1 (IDH1) gene. It's approved for use in patients with this mutation as detected by an FDA-approved test.\n   - Patients with newly diagnosed AML who are \u226575 years old or who have comorbidities that preclude the use of intensive induction chemotherapy, again specifically for those with an IDH1 mutation.\n\n2. **Mechanism of Action**: Tibsovo works by inhibiting the enzyme ID"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_k46RktVn4oGiRfdpCWZizOmS", "custom_id": "510_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ee9287d99228db3bb421d14be9bdb7a3", "body": {"id": "chatcmpl-9St8ehCWexwJMPoOhCG3ztQ56qBAM", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (ixabepilone) is an antineoplastic agent, specifically a microtubule inhibitor, used primarily in the treatment of cancer. Here are some key points that you, as a physician, should know about Ixempra:\n\n### Mechanism of Action\nIxempra is a semi-synthetic analog of epothilone B, which works by stabilizing microtubules and thereby inhibiting their depolymerization. This mechanism disrupts microtubule dynamics, which is crucial for mitotic and interphase cellular functions, leading to apoptosis of cancer cells.\n\n### Indications\nIxempra is approved by the FDA for the treatment of:\n- **Metastatic or locally advanced breast cancer**: It is used in patients who have previously received an anthracycline and a taxane in either the adjuvant or metastatic setting, and patients whose cancer has progressed on an anthracycline, a taxane,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rh4Y6ACqlX4yM1BY1LG3c9kG", "custom_id": "511_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "59540d172697145c8ec4a80080031f1c", "body": {"id": "chatcmpl-9St8eUXeQVsgwUJQQMzXyxBDEZXbK", "object": "chat.completion", "created": 1716672164, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ninlaro (ixazomib) is an oral medication used primarily for treating multiple myeloma, a type of blood cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2015. Here are some key points about Ninlaro that you, as a physician, might find important:\n\n1. **Mechanism of Action**:\n   Ninlaro is a proteasome inhibitor. It works by blocking the activity of proteasomes, which are enzyme complexes that break down proteins in cells. This blockade leads to an accumulation of excess proteins within cells, particularly cancer cells, which in turn induces cell death. This mechanism is somewhat similar to bortezomib, another proteasome inhibitor.\n\n2. **Indications**:\n   Ninlaro is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E3lSTdWJgQdayTvyXqes9rMO", "custom_id": "512_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3d75c4e37b41adbdcd2e680635cd3372", "body": {"id": "chatcmpl-9St8fNeiWY5yCuNi9AGim8jbjzdHd", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizorable (ketoconazole) is an antifungal medication used primarily to treat fungal infections. Here are some key points for physicians regarding Nizoral:\n\n1. **Uses**: Nizoral is effective against a wide range of fungal infections, typically those caused by Candida and dermatophytes. It is used to treat infections such as athlete's foot, ringworm, jock itch, yeast infections, and certain kinds of dandruff. Additionally, it can be used for systemic fungal infections, although other antifungal agents are now more commonly preferred due to Nizoral's safety profile.\n\n2. **Formulations**: Ketoconazole is available as a tablet, cream, and shampoo. The topical form is used for skin, scalp, and mucous membrane infections, while the oral form is typically reserved for more severe, systemic infections due to the risk of serious side effects.\n\n3. **Mechanism of Action**: Ketoconazole works by inhibiting the synthesis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_cj5b7Ja3qERt5R4j5Qu9nEcJ", "custom_id": "513_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "992292f8feaf6c87e63c09db78ae1ca7", "body": {"id": "chatcmpl-9St8fNWvAkddhJh4GZQkLsFiSdWno", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipstyl is a brand name for the drug lanreotide, which is a synthetic analogue of somatostatin, a peptide that inhibits the release of several other hormones. Lanreotide is primarily used in the management of acromegaly, a condition characterized by excessive growth of the body due to overproduction of growth hormone, usually caused by a pituitary adenoma. It is also used for the treatment of symptoms associated with neuroendocrine tumors, particularly those arising from the gastrointestinal tract and the pancreas.\n\nIpstyl works by mimicking the action of natural somatostatin, thus inhibiting the secretion of growth hormone and other related hormones. This helps to control the symptoms and biochemical markers associated with hormone-secreting tumors or conditions like acromegaly.\n\n### Key Points for Physicians:\n1. **Indications**:\n   - Treatment of patients with acromegaly when surgery or radiotherapy have not been fully successful or are not options.\n   - Management"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wF5NqYuLPwfoAB5rq4eDdGXk", "custom_id": "514_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ede482847a9ff40c9986b3a2cbbe53ad", "body": {"id": "chatcmpl-9St8fQy1BMRkFZVub9MDwqMfjwFfy", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prevacid (lansoprazole) is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach. Here are key points that physicians should be aware of when considering Prevacid for patients:\n\n1. **Indications**:\n   - Gastroesophageal reflux disease (GERD)\n   - Erosive esophagitis (EE)\n   - Zollinger-Ellison syndrome\n   - Healing and maintenance of duodenal ulcers\n   - Treatment and maintenance of healing of erosive esophagitis\n   - Part of triple therapy for Helicobacter pylori eradication\n\n2. **Mechanism of Action**:\n   Lansoprazole inhibits the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell, thereby blocking the final step of acid production and reducing gastric acidity.\n\n3. **Dosage and Administration**:\n   - Dosage varies depending on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TDZaHDpWE6It5QAYgk7fKZid", "custom_id": "515_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "27f239c216317527a8b5ba536415f6f4", "body": {"id": "chatcmpl-9St8f0CAAlUz4S1OawGhDZQ5c52vy", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be some confusion or a typo in your query. \"Abnib\" does not correspond to any known medical term, drug, or condition. It's possible that the word was mistyped or misunderstood. Could you please clarify or provide additional details about what you are referring to? If you are asking about a specific medication, condition, or medical concept, I'd be happy to help with the correct information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 86, "total_tokens": 127}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_F55zcHEodyfda60qFRBi4ZhA", "custom_id": "516_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b4a0d11eb3aba4b1d7414434457b69c8", "body": {"id": "chatcmpl-9St8fxVPG7887KgZGRnOEuyzJ5Apu", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vitrakvi (larotrectinib) is a medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is specifically designed to target and inhibit tropomyosin receptor kinases (TRKs), which are implicated in the growth of certain types of cancer cells. Here are some key points that may be useful for you as a physician:\n\n1. **Indication and Use**: Vitrakvi is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. These fusions are rare but can occur in various types of cancer, including lung, thyroid, melanoma, gastrointestinal, and soft tissue cancers among others. Importantly, the tumors should be metastatic or where surgical resection is likely to result in severe morbidity, and there should be no satisfactory alternative treatments or the cancers must have progressed following treatment.\n\n2."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_8h8gmnPU7F1aQiO35aifDMAA", "custom_id": "517_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41a733ad76c56964056eebac42715cfe", "body": {"id": "chatcmpl-9St8fRUC2Dv9Q1QfUhzHPsd4V4l3d", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no recognized medication or medical term \"Adlinod.\" It's possible that there might be a typo or a misunderstanding of the term. It's essential to ensure the correct spelling or obtain additional context. Could you please provide more information or check the spelling? This will allow me to assist you accurately, especially if you're looking for information on a specific medication, treatment, or medical condition. Alternatively, if this is a new or less commonly known drug, consulting current medical literature or a pharmaceutical database might be helpful."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 111, "total_tokens": 152}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ULXiE1u93m6jg8LD4pyoEy91", "custom_id": "518_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8d8f30abee11028607b70dde9e244562", "body": {"id": "chatcmpl-9St8fCM9LPYxsNE3DK9X8rhDDxo4H", "object": "chat.completion", "created": 1716672165, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for the drug known generically as lenograstim, which is a recombinant form of human granulocyte colony-stimulating factor (G-CSF). It is commonly used to stimulate the production of neutrophils, a type of white blood cell, in the bone marrow. Here are some key points you, as a physician, should be aware of when considering the use of Granocyte:\n\n1. **Indications**:\n   - **Neutropenia**: Granocyte is primarily indicated for the reduction in the duration of neutropenia and the occurrence of febrile neutropenia in patients undergoing cytotoxic chemotherapy (especially for malignant diseases) or bone marrow transplantation.\n   - **Mobilization of Peripheral Blood Progenitor Cells (PBPCs)**: It is also used to mobilize PBPCs for collection and subsequent transplantation.\n\n2. **Mechanism of Action**:\n   - Lenograstim works by binding to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qpKWqa8dhICjq4U994yKdOzD", "custom_id": "519_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eb699f14a1252641c57e46f460617d0a", "body": {"id": "chatcmpl-9St8gTUH2flVWAjIOivpZw3wyVtew", "object": "chat.completion", "created": 1716672166, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last training data, Kisplyx (lenvatinib) is an oral medication approved for the treatment of certain types of cancer. Here are some key points about Kisplyx that you, as a physician, might find useful:\n\n1. **Indications**:\n   - Kisplyx is primarily used for the treatment of advanced renal cell carcinoma (RCC).\n   - It is also approved in some regions for use in combination with everolimus for the treatment of patients with advanced RCC following one prior anti-angiogenic therapy.\n   - Additionally, in some jurisdictions, it might be indicted for use in hepatocellular carcinoma (HCC) after the failure of sorafenib treatment.\n\n2. **Mechanism of Action**:\n   - Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor. It primarily targets vascular endothelial growth factor (VEGF) receptors, which play a key role in angiogenesis (the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_7Y21Phr3xEwvvWfasjSIvwJM", "custom_id": "520_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "57fae3301dd128c72c5d346369f13a72", "body": {"id": "chatcmpl-9St8gHFIddgL7f7eyjw5xkIIfv1rJ", "object": "chat.completion", "created": 1716672166, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, which is the brand name for letrozole, is an oral medication primarily used as a treatment for hormone receptor-positive breast cancer in postmenopausal women. Here are some key points about Femara that you, as a physician, might find essential:\n\n1. **Mechanism of Action**: Letrozole is a non-steroidal aromatase inhibitor. It works by inhibiting the aromatase enzyme, which is involved in estrogen production. Since many breast cancers require estrogen to grow, lowering estrogen levels in the body can help inhibit the growth of hormone receptor-positive breast cancers.\n\n2. **Indications**:\n   - **Adjuvant Treatment**: Femara is FDA-approved for the adjuvant (post-surgery) treatment of hormone receptor-positive early breast cancer in postmenopausal women.\n   - **Extended Adjuvant Treatment**: It is also approved for extended adjuvant treatment of early breast cancer in postmenopausal women who have received"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_oiwkQvDF5Au8U4GqYOiiqk3O", "custom_id": "521_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "730e990b132f1a3715f0439563946bcc", "body": {"id": "chatcmpl-9St8gOUS1zJLHlhguCIZ0Wo63eHPe", "object": "chat.completion", "created": 1716672166, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camcevi (leuprolide mesylate) is a medication used in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) antagonist that works by reducing the amount of testosterone produced by the testicles, which helps slow the growth of prostate cancer cells. Here are key points you should know about Camcevi:\n\n1. **Indications**: Camcevi is indicated for the treatment of advanced prostate cancer. It is used to manage symptoms and slow the progression of the disease.\n\n2. **Administration**: Camcevi is administered as a subcutaneous injection. It is available in a formulation that is typically given once every 6 months, which can be convenient for patients in terms of adherence and clinic visits.\n\n3. **Mechanism of Action**: The active ingredient, leuprolide mesylate, is a synthetic analogue of GnRH. It initially increases the levels of luteinizing hormone (LH"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_AJVDCDf6SycAexILdC4CZiDh", "custom_id": "522_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fc0d46d7748f41895d7281f2f2b62806", "body": {"id": "chatcmpl-9St8gtooS3Kf5LaSBFkN2Ji5khG8n", "object": "chat.completion", "created": 1716672166, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Ergamisol,\" chemically known as levamisole, is a medication originally used as an anthelmintic to treat worm infestations in both humans and animals. However, its use in humans has significantly declined due to the safer alternatives now available and its serious side effects.\n\n### Key Points for Physicians:\n\n1. **Indications:**\n   - Historically, Ergamisol was used to treat worm infections like nematode infestations.\n   - It has been investigated and used as an immune modulator, particularly in the treatment of colon cancer. However, its usage in this context is less common today.\n\n2. **Mechanism of Action:**\n   - Levamisole enhances immune response, possibly through influencing various immune cells and stimulating certain cytokine release.\n   - It interferes with the energy metabolism of worms, leading to their paralysis and death.\n\n3. **Adverse Effects:**\n   - **Hematological:** The most concerning adverse effect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9FVbd8fqQEkPiIWECSyBi6Ga", "custom_id": "523_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3fcc835b1dad7c54145e3ba892bf5dd2", "body": {"id": "chatcmpl-9St8hVIH70mZlrUGbCzvTZO6pEZOK", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician considering Fusilev (levoleucovorin) for your patients, here are some important points to note:\n\n1. **Indications and Usage**:\n   - **Fusilev** is primarily used to reduce the toxic effects of methotrexate in cancer therapies. It is also indicated for use in the treatment of metastatic colorectal cancer in combination with fluorouracil.\n   - It is often administered after high-dose methotrexate therapy in osteosarcoma. The levoleucovorin helps to rapidly lower the levels of methotrexate, reducing its toxicity, particularly in renal impairment scenarios.\n\n2. **Mechanism of Action**:\n   - **Fusilev**, the levorotatory isomer of racemic leucovorin, acts as a folinic acid derivative. It provides reduced folates necessary for nucleic acid synthesis, effectively bypassing the inhibition of dihydrofolate reduct"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wyHbV6HvuO9aXV80M1LB4SvR", "custom_id": "524_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8021212d50c86d39ac3a415ccb06fec1", "body": {"id": "chatcmpl-9St8hqUdrn1yWrlQCWE7Pup3j75Ph", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu, which is the brand name for lomustine, is an oral chemotherapy medication primarily used in the treatment of various types of cancer, including brain tumors, Hodgkin\u2019s lymphoma, and other malignancies. It belongs to a class of drugs known as alkylating agents, specifically the nitrosoureas, which work by damaging DNA in cancer cells, thereby inhibiting their growth and reproduction.\n\nHere are some important points about CeeNu (lomustine) that you, as a physician, should know:\n\n1. **Indications**: Lomustine is often used for the treatment of brain tumors and Hodgkin\u2019s lymphoma, but it can also be prescribed for other cancers as part of a chemotherapy regimen.\n\n2. **Administration**: Lomustine is taken orally, typically in capsule form. Unlike many other chemotherapy drugs, it is usually given in cycles that could range from every six weeks to several weeks apart, depending on the specific regimen and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_Igxg0lh7wjhNmkCwB8bdrMDB", "custom_id": "525_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8ae4aa9aa4f05cdb83bd221043392529", "body": {"id": "chatcmpl-9St8h5daeTABrGfY3pBciXSRFk0o1", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (lorlatinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points that a physician should know about Lorbrena:\n\n1. **Indication and Usage**:\n   - Lorbrena is specifically indicated for patients with NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.\n   - It is often used in patients who have progressed on or are intolerant to crizotinib and other ALK inhibitors.\n\n2. **Mechanism of Action**:\n   - Lorbrena is a third-generation ALK tyrosine kinase inhibitor (TKI). It works by inhibiting the kinase activity of ALK, which is a genetic driver of some types of NSCLC.\n   - It is designed to inhibit the most common ALK mutations that lead to drug resistance and it has the ability to penetrate the blood-brain barrier, which can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_1FYvuCGLuLk1jwxVFNWTCWX0", "custom_id": "526_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f725cf5c5b5e7cd8f16aacca460a5c78", "body": {"id": "chatcmpl-9St8hwHNctksDRj45E1nQqEdzxQLb", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera (lutetium Lu 177 dotatate) is a radiopharmaceutical used in targeted therapy for treating certain types of neuroendocrine tumors (NETs). Specifically, it is indicated for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. It was approved by the U.S. Food and Drug Administration (FDA) in 2018. Here are some key points to consider:\n\n### Mechanism of Action\nLutathera works by targeting the somatostatin receptors that are overexpressed on the surface of certain NET cells. It is a radiolabeled somatostatin analog, where the lutetium-177 isotope is linked to the peptide through the chelator DOTA. The drug binds to the somatostatin receptors and, upon internalization, delivers targeted"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_3QuapqlHpvwQPPUZiHtuD2wl", "custom_id": "527_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b8a2222a6aa5e2cf0734031c467aeb57", "body": {"id": "chatcmpl-9St8h84RAoE2p41BKHGDdVRMyLiB0", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (generic name: tafasitamab) is a monoclonal antibody used in the treatment of certain types of cancer. It targets CD19, a protein that is expressed on the surface of B cells, making it useful in the treatment of B-cell malignancies. Tafasitamab is specifically approved for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant.\n\n**Key Points about Minjuvi (Tafasitamab) for Clinical Practice:**\n\n1. **Indication and Usage**:\n   - Minjuvi, combined with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are ineligible for autologous stem cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TZKRmQMVX4ECln2RRqE3peo8", "custom_id": "528_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "43ac836e94bcfb047a95c5a8ce1c02e7", "body": {"id": "chatcmpl-9St8hkCfsRWwN3UBCjxFYK6GMs6OZ", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ledaga (chlormethine gel) is used for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare type of non-Hodgkin\u2019s lymphoma that primarily affects the skin. Ledaga is the brand name for the formulation of chlormethine, also known as mechlorethamine, in a gel form, which is designed for direct application to the skin.\n\nHere are several key points about Ledaga:\n\n1. **Indication**: Ledaga is indicated for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in adult patients who have received prior skin-directed therapy.\n\n2. **Mechanism of Action**: Chlormethine, the active ingredient in Ledaga, is a nitrogen mustard-based alkylating agent. It works by cross-linking DNA strands and causing cytotoxicity, primarily in rapidly dividing cells, which is believed to help in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_6oYgmPuEwZGazpP80LE6Pyl7", "custom_id": "529_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "91064edd3cbb1682fa90b8d1aef97d66", "body": {"id": "chatcmpl-9St8hOVvWBd8sQ4EGL8fwmEiHTthw", "object": "chat.completion", "created": 1716672167, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera (medroxyprogesterone acetate) is a contraceptive injection that contains the hormone progestin. It is widely used for its efficacy and convenience as a birth control method. Here are some key points that physicians should be aware of when considering Depo-Provera for their patients:\n\n**1. Mechanism of Action:**\n   - Depo-Provera works primarily by preventing ovulation. It thickens the cervical mucus to prevent sperm from reaching an egg and alters the uterine lining to prevent implantation should fertilization occur.\n\n**2. Efficacy:**\n   - It is a highly effective method of birth control when used correctly. The failure rate is approximately 0.3% in the first year of typical use, similar to that of intrauterine devices and implants.\n\n**3. Dosage and Administration:**\n   - Depo-Provera is administered as an intramuscular injection of 150 mg every 3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_INvVNrZy8iW61ff961I7sPgc", "custom_id": "530_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3dc61c240b380e4d1b441094525a469f", "body": {"id": "chatcmpl-9St8iny5OPGnn7RzUGGon6voLZVGG", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Maygace (megestrol acetate) is commonly used in the medical field for its appetite-stimulating and weight gain promoting properties, particularly in patients suffering from cancer or AIDS-related cachexia (wasting syndrome). Here are some key points you should know about Maygace:\n\n1. **Indications**: Maygace is primarily indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). It is also used off-label for its appetite-stimulating effects in non-AIDS patients with cancer.\n\n2. **Mechanism of Action**: Megestrol acetate, the active ingredient in Maygace, is a synthetic progestational agent. While the exact mechanism by which it stimulates appetite isn't fully understood, it's thought to involve modifications in hormone levels, particularly those affecting appetite (like glucocorticoids) and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_m6tUqBVKGNwRZlsgmPs3Tvn9", "custom_id": "531_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "45365a09e27230751f7ad039847b944d", "body": {"id": "chatcmpl-9St8iEIHGYosViOPWAmzIiGmrFxzK", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, which is the trade name for melphalan, is an alkylating agent used primarily in the treatment of multiple myeloma and ovarian cancer. It is also employed in palliative treatment of other malignancies. Here are key points that you, as a physician, should consider when prescribing or managing care involving Alkeran:\n\n### 1. **Indications**\n   - **Multiple Myeloma:** Often used as part of induction therapy, sometimes in combination with prednisone.\n   - **Ovarian Cancer:** Used to treat epithelial ovarian cancer.\n   - **Other Uses:** Can be used for conditioning treatment before bone marrow transplant and in palliative care for other malignancies.\n\n### 2. **Mechanism of Action**\n   - Melphalan causes cross-linking of DNA strands, ultimately leading to cell death. It is cell cycle non-specific.\n\n### 3. **Administration**\n   - Available in both oral and intravenous formulations.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_iuSp4ZktjMV6ctOsFA5TKIXG", "custom_id": "532_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74a3ac1baa1761b43369e3856533974d", "body": {"id": "chatcmpl-9St8iYud83FxdVM6H2lvMtkmV7I2y", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol is the brand name for mercaptopurine, a medication that falls into the category of antimetabolites used primarily in the treatment of cancer, specifically as a chemotherapeutic agent. Here are some key points that physicians should be aware of regarding Purinethol (mercaptopurine):\n\n1. **Indications:**\n   - Primarily used to treat acute lymphoblastic leukemia (ALL).\n   - It may also be used in the management of chronic myeloid leukemia (CML) and some autoimmune diseases, such as inflammatory bowel disease, under certain circumstances.\n\n2. **Mechanism of Action:**\n   - Mercaptopurine interferes with nucleotide synthesis and metabolism, leading to the inhibition of DNA, RNA, and protein synthesis. This effect is particularly harmful to rapidly multiplying cells, such as cancer cells.\n   - It is a purine analogue that gets incorporated into DNA and RNA, causing cell cycle arrest and apoptosis.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RvTXYByogYAVP9OmDRYGnRiB", "custom_id": "533_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "be2b42a48b2439add530a750b0874592", "body": {"id": "chatcmpl-9St8iKp0R8rWBzerwqHsk45EQcsuq", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn\u2019t any recognized medication or substance known as \"Anti Uron\". It\u2019s possible that you may have encountered a typo, a colloquial, or brand name that is not widely recognized. To provide you with accurate information, I would need the correct name or a clearer context regarding the substance or medication.\n\nIf you are referring to something specific within a medical or biochemical context, please provide more details. It\u2019s always good to refer to reputable medical sources or databases for the most accurate and up-to-date information. If this is a new or experimental treatment, consulting clinical trial registries or the latest medical literature might also be beneficial."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 134, "total_tokens": 175}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qic6imKcxIxf4eqGpfMtSBtr", "custom_id": "534_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "be0dcebac7fae439ace737087934251f", "body": {"id": "chatcmpl-9St8iPmPOV8Z0hoDOWXBGfxxC5Mgi", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication commonly used in the management of certain types of cancers and autoimmune diseases. Here\u2019s a detailed overview of the essential aspects to consider:\n\n### Indications\nMethotrexate is utilized in the treatment of:\n- Various types of cancer such as leukemia, breast cancer, and lung cancer\n- Rheumatoid arthritis\n- Severe psoriasis\n- Certain other autoimmune diseases\n\n### Mechanism of Action\nMethotrexate works by inhibiting the enzyme dihydrofolate reductase, which is crucial for DNA synthesis. By blocking this enzyme, methotrexate interferes with the growth of rapidly dividing cells, which is a characteristic of both cancerous cells and certain immune cells causing autoimmune damage.\n\n### Dosage and Administration\n- **Cancer:** Dosage varies extensively based on the type of cancer, the specific protocol used, and the patient\u2019s overall health and body surface area.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_z5h5D4d8cgURjgSAYkE2ketf", "custom_id": "535_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5202161a96e5c4a2409ccde0650aa5a", "body": {"id": "chatcmpl-9St8i10nnP6DRNKENviiASKsJ7SH5", "object": "chat.completion", "created": 1716672168, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ammoidin, also known as methoxsalen or xanthotoxin, is a medication primarily used in the treatment of psoriasis, eczema, vitiligo, and some types of cutaneous lymphoma. It belongs to a group of drugs known as psoralens, which are photosensitizing agents used in combination with UVA light therapy, a treatment process known as PUVA (psoralen and ultraviolet A).\n\nHere are key points you should be aware of:\n\n### Pharmacodynamics\n- **Mechanism of Action:** Ammoidin intercalates with DNA and, upon exposure to UVA radiation, forms monoadducts and cross-links in DNA, inhibiting DNA synthesis and cell division. This action reduces the pathological over-proliferation of skin cells, which is a characteristic feature in conditions like psoriasis.\n\n### Indications\n- **Primary Uses:** Effective in the treatment of psoriasis, vitiligo, and certain types of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lXxGHRFJrV1gHQmxQvekDpjK", "custom_id": "536_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "842fe057e517d97280a589e0da556fd2", "body": {"id": "chatcmpl-9St8j3DN3VUie3MsgnLh0BYFW1ip8", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adlone is often a trade name for formulations containing a glucocorticoid, typically used for its anti-inflammatory and immunosuppressive properties. The most common active ingredient in medications with similar names (like Adlone, Medrol, or similar sounding names) is usually a corticosteroid such as methylprednisolone.\n\n**Uses**: Methylprednisolone and similar corticosteroids are used to treat a variety of conditions including but not limited to allergies, asthma, autoimmune diseases, and as part of treatment regimens in certain cancers.\n\n**Mechanism of Action**: Corticosteroids like methylprednisolone work by mimicking the effects of hormones produced by the adrenal glands. They inhibit the immune system by preventing the release of substances in the body that cause inflammation.\n\n**Dosage and Administration**: The dosing of methylprednisolone can vary widely depending on the condition being treated, the severity of the condition, the formulation of the drug ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NYiovA3b6JPWofn6uCWRQz2c", "custom_id": "537_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ddbc8bb871be4d7518d18bf2dd7cee1", "body": {"id": "chatcmpl-9St8jd8NNnZTUccXnoCYpLYyr5LrT", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is an oral medication used for the treatment of certain types of blood cancers. It is specifically approved for:\n\n1. **Acute Myeloid Leukemia (AML)**: Rydapt is used for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test. It is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.\n\n2. **Systemic Mastocytosis**: Rydapt is also used to treat adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia.\n\n### Mechanism of Action\nRydapt is a kinase inhibitor. It works by inhibiting multiple receptor tyrosine kinases, including FLT3, which is involved in the proliferation and survival of malignant cells in AML"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FOrAVUbw6VRl0i43xAt70xUN", "custom_id": "538_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f89e5ed1a898aee612e882a19aab18b1", "body": {"id": "chatcmpl-9St8jVMRVEqbkhNasEFJSG6SnBDHl", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a medication or treatment recognized under the name \"Lyomit\" in standard medical resources or databases. It's possible that the name could be a brand name, a name used in a specific country, or potentially a misspelling. It could also be a new product or drug that has been introduced after my last update.\n\nIf \"Lyomit\" refers to a medication or supplement, it would be essential to verify this name and gather appropriate information such as its active ingredients, intended use, effectiveness, side effects, interactions with other medications, and any regulatory approvals.\n\nIf you need reliable information about a specific medication, consulting databases such as those provided by the FDA, CDC, or WHO, or accessing professional medical resources like PubMed or Medscape, would be beneficial. Additionally, discussing with colleagues or consulting pharmaceutical manufacturers directly could provide further insights.\n\nAlways ensure that any clinical decisions are based on credible and updated medical resources to provide safe and effective care to patients. If"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bWH4kzkUs1dqymLn00UrPss2", "custom_id": "539_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "372d677a73cf8d8914b34cdbbb279c0a", "body": {"id": "chatcmpl-9St8jhnwC4NpfvaJ7y5lRd2XJ0P68", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (mitotane) is a medication used primarily for the treatment of inoperable adrenal cortical carcinoma, a type of cancer that affects the adrenal glands. Here are several key aspects you, as a physician, should know about Lysodren:\n\n1. **Mechanism of Action**:\n   - Lysodren works by being selectively cytotoxic to the cells of the adrenal cortex. It alters the metabolism of steroids in the adrenal cortex, which leads to atrophy and functional impairment, and induces necrosis of the adrenal cells.\n\n2. **Indications**:\n   - Primarily used to treat unresectable, metastatic, or recurrent adrenal cortical carcinoma.\n   - It is also occasionally used off-label to manage Cushing's syndrome due to its ability to decrease cortisol production.\n\n3. **Dosage and Administration**:\n   - Treatment typically begins with a dose-escalation schedule, starting with a smaller dose and gradually increasing to minimize adverse effects. D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mGHcE4bfPscDzhKoMfwuzLGH", "custom_id": "540_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24028896da6a15bbe9e9a48872726867", "body": {"id": "chatcmpl-9St8jQbVkpHt2fnRCjjjAfjyKQKki", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nitrol is commonly used as a brand name for nitroglycerin products, which are part of a class of medications called nitrates. Nitroglycerin is primarily used to prevent and treat angina pectoris (chest pain) caused by heart disease. Here are some key points about nitroglycerin:\n\n1. **Mechanism of Action**: Nitroglycerin works by relaxing and widening blood vessels, which allows more blood to flow to the heart while reducing its workload. It can also dilate veins, which decreases venous return and preload, ultimately reducing cardiac output, which can be beneficial in patients with ischemic symptoms.\n\n2. **Forms and Administration**: Nitroglycerin is available in various forms, including sublingual tablets, sprays, transdermal patches, and ointments. The choice of form depends on the rapidity and duration of effect required. Sublingual tablets or spray are used for rapid onset in acute angina, whereas patches and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_X0liBUl3NcneKA5Lt9oOzmcf", "custom_id": "541_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e86b0b156053067044b9351a9d0baa2", "body": {"id": "chatcmpl-9St8jb6wwhX4hQEsDLpkJlhHXgPM6", "object": "chat.completion", "created": 1716672169, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody used for the treatment of certain types of lymphoma. Here are several important aspects that physicians should be aware of:\n\n1. **Indications:**\n   - Poteligeo is approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) after at least one prior systemic therapy. These are the two most common subtypes of cutaneous T-cell lymphoma (CTCL).\n\n2. **Mechanism of Action:**\n   - Mogamulizumab is a humanized monoclonal antibody that targets CC chemokine receptor 4 (CCR4), which is frequently expressed on the surface of T cells in CTCL. By binding to CCR4, mogamulizumab can induce antibody-dependent cellular cytotoxicity (ADCC) against the tumor cells.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_LFD8KCWjNYqXEMsFW8GCGEum", "custom_id": "542_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de4315b1d9c501ae8bad0836296876cd", "body": {"id": "chatcmpl-9St8kzi1ykBU2OGMSLkSd23yeMPxK", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. It is specifically indicated for adult patients with hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Here are some key points about Lumoxiti that you should be aware of as a physician:\n\n### 1. Mechanism of Action:\nLumoxiti is a CD22-directed cytotoxin and is classified as an antibody-drug conjugate (ADC). It specifically targets the CD22 antigen on B cells, and once bound, the conjugate internalizes and releases moxetumomab pasudotox, a toxin which inhibits protein synthesis, leading to apoptotic cell death specifically in the target cells.\n\n### 2. Dosage and Administration:\nLumoxiti is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_GYb4T5IZiDC8LyPHD0DVWkOa", "custom_id": "543_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f08dcb8c8000e6c4f29036e5d794db94", "body": {"id": "chatcmpl-9St8kRQkRXLDN4N5HwJsVWLYZmE17", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine (nadroparin calcium) is a type of anticoagulant that belongs to the low molecular weight heparin (LMWH) class. It is primarily used to prevent and treat thromboembolic disorders. Here are some key points you should know about Fraxiparine:\n\n1. **Indications:** Fraxiparine is indicated for the prophylaxis and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in the prophylaxis of clotting in the extracorporeal circulation during hemodialysis and for the prevention of clot formation in high-risk surgical patients.\n\n2. **Mechanism of Action:** Like other LMWHs, Fraxiparine works by enhancing the inhibitory effect of antithrombin III on factor Xa and factor IIa (thrombin). This leads to a decrease in the ability"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mK0hFxdxGyMOWmvgHFf2vwAW", "custom_id": "544_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3e67c1280f62a07266bc16bd051bb2b8", "body": {"id": "chatcmpl-9St8kIKd4IATGSFwN116XdhwQlFdl", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a medication used in the treatment of cancer, specifically for advanced squamous non-small cell lung cancer (NSCLC). Here are some key points a physician should know about Portrazza:\n\n1. **Indications**: Portrazza is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous NSCLC. It is not indicated for treatment of non-squamous NSCLC.\n\n2. **Mechanism of Action**: Necitumumab is a recombinant human IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). By binding to EGFR, necitumumab inhibits downstream signaling which is involved in cancer cell proliferation, migration, and angiogenesis.\n\n3. **Dosing and Administration**: The typical dose of Portrazza is 800 mg administered as an intravenous infusion over"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_D7j6YSWrCH6IO82Uu4x5INMn", "custom_id": "545_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02023357c7a5d2de2311cfdd69ebd618", "body": {"id": "chatcmpl-9St8k09EhuY4N55kggUrff5AIFaWU", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there does not appear to be a recognized medication or substance called \"Aqupla\" in standard medical resources or databases. It's possible there might be a typo or a regional brand name not widely recognized. To assist you better, could you please provide more context or check the spelling? If it\u2019s a new drug, further details about its usage, pharmacology, and approvals would be helpful."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 84, "total_tokens": 124}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_XLHxtL4D59gTNNtcLkIco9e8", "custom_id": "546_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3add41c0e558b426afe9344f944372a", "body": {"id": "chatcmpl-9St8k1gweyIp7IBCBZIJv05LczWU3", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon (nelarabine) is a chemotherapy medication used to treat certain types of leukemia and lymphoma. Specifically, it is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that are refractory to or have relapsed after other treatments. Here are some key points you should know about Arranon:\n\n1. **Mechanism of Action**: Nelarabine, the active ingredient in Arranon, is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), which is a nucleoside analog. It gets converted into its active metabolite ara-GTP, which is then incorporated into DNA during the S-phase of the cell cycle, leading to DNA synthesis inhibition and cell death.\n\n2. **Administration**: Arranon is administered intravenously. The dosing regimen might vary based on factors like patient age, overall health,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_V2ItaHpQnf6ZpzfxHJ1jCTe8", "custom_id": "547_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f9531739f6cf0673b915d334920b17d4", "body": {"id": "chatcmpl-9St8kwEHbO5z7an6oPMyFQFY2LwaQ", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (neratinib) is a medication used primarily in the treatment of breast cancer. Here are several key points you should know about Nerlynx as a physician:\n\n1. **Mechanism of Action**:\n   Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. This action is important for the treatment of cancers that overexpress the HER2 protein.\n\n2. **Indications**:\n   - As of the last update, Nerlynx is approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.\n   - It is also used for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sjzRd1erazGah8ZdUhW5SrV2", "custom_id": "548_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "077211ee4844ac2c8be60d2b128d2bf8", "body": {"id": "chatcmpl-9St8ksXTDsbbjKhMAft6CHoNyiAcW", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna, with the generic name nilotinib, is an oral medication used primarily to treat chronic myeloid leukemia (CML). As a physician, here are several key points you should be aware of regarding Tasigna:\n\n### 1. **Mechanism of Action**\n   Tasigna is a second-generation tyrosine kinase inhibitor (TKI) specifically designed to inhibit the BCR-ABL tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome in CML cells. By inhibiting this enzyme, Tasigna helps to reduce the proliferation of cancer cells.\n\n### 2. **Indications**\n   - **Chronic Phase and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)**: Tasigna is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, as well as patients in chronic or accelerated phase who are resistant to or intolerant to prior therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K5bHL0v338UN3pFP80bubFwt", "custom_id": "549_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5ed3bfdcef8d0fcd5a2c8e38c0dd09c0", "body": {"id": "chatcmpl-9St8kARP7cONjl0vJElzuR0E7vyB5", "object": "chat.completion", "created": 1716672170, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron, known generically as nilutamide, is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Anandryon:\n\n1. **Mechanism of Action**: Nilutamide acts by binding to androgen receptors and thereby inhibits the action of androgens (male hormones), such as testosterone. This inhibition prevents androgen from activating its receptor, which is crucial for the growth and proliferation of prostate cancer cells.\n\n2. **Indications**: It is specifically used for the treatment of prostate cancer, normally in combination with surgical castration. Nilutamide is used in the setting of metastatic prostate cancer, particularly in combination with other forms of hormone therapy that reduce testosterone levels.\n\n3. **Administration and Dosage**: Nilutond is typically given orally, and the dosage may vary based on the specifics of the treatment regimen and the patient\u2019s condition. The typical starting dose when used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_qfYQihKins6HQZb2bVZwcHTK", "custom_id": "550_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "55c98e2f03960f86856e70cdd5acf7c4", "body": {"id": "chatcmpl-9St8lECb7xi65hr1UTEl7LIIilS1a", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in January 2023, \"Nidran\" does not reference any commonly known pharmaceutical or medical term used widely within the healthcare field. It is possible that \"Nidran\" could be a brand name, a term from a non-English language, or possibly a niche or new product that has not become broadly recognized in the medical community.\n\nIf you're referring to a specific medication, treatment, or concept named \"Nidran,\" I would recommend checking the most current medical or pharmaceutical reference sources or databases. Additionally, consulting with pharmacological resources or reaching out to colleagues in pharmacy might provide more up-to-date information. It is crucial to use reliable sources and confirm the information when dealing with unfamiliar medical terminology or products to ensure safe and effective patient care."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 159, "total_tokens": 200}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8EpvS07wBL7EmQWCJuM457Ll", "custom_id": "551_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3909d14751a9c2ff3f9bd200352a9319", "body": {"id": "chatcmpl-9St8lMIBDAK6VKiPuAbcNIN8Ndajh", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv, known generically as nintedanib, is a medication used in the management of certain lung conditions. Here is an overview that could be helpful for you as a physician:\n\n### 1. General Information\n- **Brand Name**: Cyendiv\n- **Generic Name**: Nintedanib\n- **Drug Class**: Tyrosine kinase inhibitor (TKI)\n\n### 2. Indications\nCyendiv is used for:\n- **Idiopathic Pulmonary Fibrosis (IPF)**: It's approved for the treatment of idiopathic pulmonary fibrosis, which is a chronic and ultimately fatal disease characterized by a progressive decline in lung function.\n- **Chronic Fibrosing Interstitial Lung Diseases (ILDs)**: Cyendiv is also indicated for other ILDs with a progressive phenotype.\n- **Scleroderma-associated ILD**: It helps slow the rate of decline in pulmonary function in patients with this condition.\n\n### "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_zyGSLlMgdyLEl3vZdcH95WZ3", "custom_id": "552_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "171a6ebb6a69ba85c08087f5b1ab9c9e", "body": {"id": "chatcmpl-9St8lRSlwRx228fqYe17esGPNbOuM", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in September 2021, \"Niranib\" is not recognized as a standard medication or compound in medical or pharmaceutical references. It's possible that the name might be misspelled or it could be a brand name that is not widely recognized. It\u2019s also possible that it's a new drug introduced after 2021, for which I wouldn\u2019t have information.\n\nIf you meant \"Neratinib\" (Nerlynx), here\u2019s a brief overview:\n\n**Neratinib** is an oral tyrosine kinase inhibitor that specifically targets HER2 (human epidermal growth factor receptor 2) and is used for the treatment of breast cancer. It\u2019s particularly indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.\n\n### Key Points about Neratinib:\n\n- **Mechanism of Action:** Neratinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_K3nirzg7z6a56srVkjAtyZ7h", "custom_id": "553_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6af3eb448009a209dd46af9599218f3d", "body": {"id": "chatcmpl-9St8lthQ3OHpntDms9JzHFDDHGhAu", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is a medication used in the treatment of various types of cancer. It is a type of immunotherapy drug, specifically classified as a programmed death-1 (PD-1) inhibitor. PD-1 is a protein on T cells, which are a type of immune cell, that helps keep the body's immune responses in check. Opdivo works by blocking PD-1, thereby enhancing the body\u2019s immune response against cancer cells.\n\n### Key Information for Physicians:\n\n**Indications**:\nOpdivo is approved for use in several types of cancer, including but not limited to:\n- Melanoma\n- Non-small cell lung cancer (NSCLC)\n- Kidney (renal cell carcinoma)\n- Head and neck cancer\n- Hodgkin lymphoma\n- Urothelial carcinoma\n- Colorectal cancer (specifically with MSI-H or dMMR biomarkers)\n\nIt can be used as a single agent or in combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tW07Bjz0xW3eUp7nYB4pyFxa", "custom_id": "554_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8a3b20c882a19a91100348c76757d244", "body": {"id": "chatcmpl-9St8llXkY3SH2hXntNtm7zyy8Njeq", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Myocet (non-pegylated liposomal doxorubicin) is a formulation of the chemotherapy drug doxorubicin, which is encased in liposomes. These liposomes are designed to allow for a more targeted delivery of the drug to tumor cells, potentially reducing some of the systemic side effects associated with conventional doxorubicin, while maintaining its anticancer efficacy. Here are key points you should be aware of as a physician:\n\n### 1. Indication\nMyocet is primarily used in the treatment of metastatic breast cancer. It can be used alone or in combination with other agents, such as cyclophosphamide.\n\n### 2. Mechanism of Action\nDoxorubicin works by intercalating DNA, disrupting the enzyme topoisomerase II, which controls the unwinding of DNA, necessary for replication. This causes the DNA to break, thus preventing cancer cells from growing and multiplying.\n\n### 3. Advantages over Conventional"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_YSdMBOFgPd8U1X6uQWWEu2R7", "custom_id": "555_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "218245ccc1becc451fcf32c7e83244bd", "body": {"id": "chatcmpl-9St8lndnTFVX1xuDzi4bmdBnxZnzQ", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilevar (chemical name: norethandrolone) is an anabolic steroid developed in the 1950s. It is one of the first anabolic steroids synthesized and has been used for various medical and non-medical purposes. Here are some important aspects a physician should consider regarding Nilevar:\n\n**1. Medical Uses:**\nNilevar was initially used to treat various medical conditions such as chronic wasting diseases, severe burns, and to promote weight gain and muscle growth in debilitated patients. It was also used to treat certain types of anemia and some breast cancer types due to its anabolic properties.\n\n**2. Mechanism of Action:**\nNorethandrolone, like other anabolic steroids, works by mimicking the effects of naturally occurring testosterone, which promotes protein synthesis and muscle growth. It also has some androgenic effects, which can contribute to both therapeutic and side effects.\n\n**3. Side Effects:**\nThe use of Nilevar,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OnDWXn36vrdRw8mjzl5YKMEk", "custom_id": "556_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "423415a1865df03573612b48aa58296d", "body": {"id": "chatcmpl-9St8luTFkN4xMKL8gCSzHlYySVcca", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva (obinutuzumab) is a therapeutic monoclonal antibody used primarily in the treatment of certain types of blood cancers. Here are several key points about Gazyva you should be aware of as a physician:\n\n1. **Indications**:\n   - Gazyva is approved for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for patients with previously untreated or relapsed/refractory follicular lymphoma (FL).\n   - In CLL, its use is based on studies demonstrating effectiveness in combination with chlorambucil compared to treatment with chlorambucil alone.\n   - In follicular lymphoma, it can be used in combination with bendamustine following treatments that include a rituximab-containing regimen, or as initial therapy with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission.\n\n2. **Mechanism of Action**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Ie4l6FwCuXPQxzw6z97N0JLP", "custom_id": "557_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c4706206a1a9ced40da7ce16ed07f0c", "body": {"id": "chatcmpl-9St8lzarx3CCBeXUUPIL3NOD5a5U2", "object": "chat.completion", "created": 1716672171, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina is the trade name for a formulation of the drug octreotide, which is used primarily in the management of acromegaly and symptoms caused by certain types of tumors such as neuroendocrine tumors, including carcinoid syndrome and vasoactive intestinal peptide secreting adenomas (VIPomas).\n\nOctreotide is a synthetic analog of somatostatin, a natural inhibitory hormone that suppresses the secretion of several other hormones, including growth hormone, insulin, and various gastrointestinal hormones such as gastrin, cholecystokinin, and secretin. Its effects are similar but have a longer duration than natural somatostatin.\n\n**Here are key points about octreotide (Longastatina) in clinical use:**\n\n1. **Indications:**\n   - **Acromegaly:** Used for reducing excessive growth hormone levels.\n   - **Carcinoid Tumors:** Helps manage flushing and diarrhea associated with carcinoid syndrome.\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_5jyGiKYJc9KrWTdqPWHbRNTe", "custom_id": "558_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "44ffe699704aa010c0c7503e42afab16", "body": {"id": "chatcmpl-9St8mEMdeagxqUFTWnX09ja9RL9SO", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR (long-acting release), known generically as Octreotide, is a synthetic version of a naturally occurring hormone called somatostatin. It is primarily used for the treatment of acromegaly, a condition caused by excessive production of growth hormone, and the symptoms of certain types of tumors such as carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas).\n\n### Key Aspects of Longastatina LAR:\n\n1. **Indications:**\n   - **Acromegaly:** It helps to reduce the levels of growth hormone and IGF-1 (insulin-like growth factor 1).\n   - **Neuroendocrine Tumors:** Reduces symptoms such as flushing and diarrhea in carcinoid syndrome, and controls the symptoms of VIPomas.\n   - It is also used in the management of other conditions as per clinical judgment, including certain pituitary tumors (TSH-secreting), and in the prevention of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ltw17MK45GGHncMT2fZPpkKY", "custom_id": "559_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e9d3d98d181a7377147022cdf94ca05", "body": {"id": "chatcmpl-9St8miYtAcOYvhhlq83I5JwjqmGVc", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Arzerra (ofatumumab)** is a monoclonal antibody therapy used primarily in the treatment of chronic lymphocytic leukemia (CLL). Here are key aspects you should know about Arzerra:\n\n### 1. **Mechanism of Action**\n   - Ofatumumab targets the CD20 antigen expressed on B cells. It binds to the small and large extracellular loops of the CD20 molecule, leading to immune-mediated B cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n### 2. **Indications**\n   - Arzerra is approved for the treatment of CLL. It has been used in patients who are refractory to fludarabine and alemtuzumab. It may also be used in other specific contexts depending on the regulatory approvals in your country, such as in combination with other chemotherapeutic agents.\n\n### 3. **Dosage and Administration**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wprbZiQ3D6aexX5suDLGdIKB", "custom_id": "560_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "afefecf409e426a434843960c38333c0", "body": {"id": "chatcmpl-9St8mjHSbO5tHXosupRuR6CwZ5mtj", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza (olaparib) is an important medication used primarily in oncology, specifically for treating certain types of cancers that have specific genetic profiles. Here are some key points you should know about Lynparza as a physician:\n\n1. **Mechanism of Action**: Lynparza is a PARP (poly ADP-ribose polymerase) inhibitor. It works by interfering with the PARP enzymes that help repair DNA damage in cells. By inhibiting these enzymes, Lynparza causes DNA damage to accumulate in cancer cells, eventually leading to cell death. This is particularly effective in cells that are already compromised in their ability to repair DNA due to mutations in the BRCA1 or BRCA2 genes.\n\n2. **Indications**: Lynparza is approved for use in several specific cancer types, including:\n   - Advanced ovarian cancer in patients with defective BRCA genes (germline or somatic) who have been treated with three or more prior lines of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_davM9i5wCNhqFpmYprDJgYtA", "custom_id": "561_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d439f9a4aef93e2f6bbadef4c7e178f9", "body": {"id": "chatcmpl-9St8mtuVCY06vQhBmDDKUobmzjCIg", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a monoclonal antibody that was initially used in the treatment of soft tissue sarcoma. It targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), which is involved in tumor growth and proliferation.\n\nLartruvo received accelerated approval from the FDA in 2016 for use in combination with doxorubicin for the treatment of adults with certain types of soft tissue sarcoma (STS) who could not be cured with radiation or surgery and who had a type of STS for which an anthracycline was an appropriate treatment. This decision was based on early clinical trial data that suggested Lartruvo, in combination with doxorubicin, could improve overall survival compared to doxorubicin alone.\n\nHowever, subsequent studies did not confirm the clinical benefit of Lartruvo. A phase III clinical trial (ANNOUNCE) did not meet its primary endpoints of overall survival in the full population or in the leiomyos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_MPeozbP6TvtiEOxhbO1V0HUb", "custom_id": "562_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb47dc91b5c79ed548e73f0877d887f5", "body": {"id": "chatcmpl-9St8mRLfixxGJzBJyRaQmNgpwm7PZ", "object": "chat.completion", "created": 1716672172, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Omapro\" does not specifically refer to a known medication in widely used pharmaceutical references. However, it's possible that the name could be a brand name, a new drug, or it might be misspelled or misheard. Often, drug names can vary by region or due to trademark issues.\n\nIf you meant \"Omacor,\" this is an established medication known primarily for its active ingredient, omega-3-acid ethyl esters, which are used to treat high triglyceride levels and to help prevent cardiovascular problems. If \"Omapro\" is indeed a specific drug you're inquiring about, it could be under development, newly released, or perhaps not extensively recognized.\n\nFor accurate and current information, it's recommended to consult the latest medical resources or drug databases, check with a pharmacy, or contact the pharmaceutical manufacturer directly. If you have the generic name or can describe the intended use or chemical composition of \"Omapro,\" I"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_aTXyDkz8ETAWFG6TmgNhQd0G", "custom_id": "563_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae4fbd7c12a98550bda1552d4b2222f0", "body": {"id": "chatcmpl-9St8n189tLDFS5I9fEEBcgFlJCJUF", "object": "chat.completion", "created": 1716672173, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Prilosec (omeprazole), a commonly prescribed medication for various gastrointestinal conditions. Here are crucial aspects to keep in mind:\n\n1. **Mechanism of Action**: Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by inhibiting the hydrogen-potassium ATPase pump in the gastric parietal cells, reducing the production of stomach acid.\n\n2. **Indications**:\n   - **Gastroesophageal Reflux Disease (GERD)**: Omeprazole is used to treat symptoms of GERD, a condition in which stomach acid flows back into the esophagus, causing heartburn and potential injury to the mucosa.\n   - **Peptic Ulcers**: It is used for the treatment of peptic ulcers including those associated with Helicobacter pylori infection, requiring combination therapy with antibiotics.\n   - **Zoll"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xhtGZ19Rj7LKMQXi598fdcFX", "custom_id": "564_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "58b278ce3a89904f7911553bdd3d65ca", "body": {"id": "chatcmpl-9St8npAE0bRF5qwvOZxUtjAHeCxeK", "object": "chat.completion", "created": 1716672173, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib, sold under the brand name Tagrisso, is a medication used in the treatment of non-small-cell lung carcinoma (NSCLC). It is specifically designed for cases where the cancer cells exhibit certain mutations in the epidermal growth factor receptor (EGFR) gene.\n\nHere are some key points about osimertinib that you, as a physician, might find helpful:\n\n1. **Indications**: Osimertinib is approved for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It is also used in the first-line treatment of patients with metastatic NSCLC whose tumors have exon 19 deletions or exon 21 L858R mutations.\n\n2. **Mechanism of Action**: Osimertinib is a third-generation irreversible EGFR tyrosine kinase inhibitor that selectively inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XWhtxDXGNru9GBWjI2te9fd1", "custom_id": "565_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2dfcc57085f76ad368e6425c42641e69", "body": {"id": "chatcmpl-9St8n1MciR0Ysj95UN4WMqugl4Gqt", "object": "chat.completion", "created": 1716672173, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't a specific drug named \"Coxatin\" widely recognized in standard medical references. It is possible that the name could be a brand name, a new drug not yet widely documented, or it could be a misspelling of a drug with a similar name. \n\nIf you suspect it is a new or less common medication, I recommend checking the latest medical databases, pharmaceutical registers, or directly consulting information from drug manufacturers. Additionally, it might be beneficial to verify the spelling with your source or consult a pharmacist for clarification.\n\nFor accurate and safe medical practice, always ensure you have the correct information about any medication, including its uses, dosage, interactions, side effects, and contraindications. If you find the correct name or more details about the drug, feel free to ask for more specific information!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 170, "total_tokens": 210}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_t7HkMcs2nRiArvbFUy4MBrjL", "custom_id": "566_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dd58b42cdd20a603523d4b00c73978f0", "body": {"id": "chatcmpl-9St8nei0PZJb7pt49fjau4lGPvMVk", "object": "chat.completion", "created": 1716672173, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane (nanoparticle albumin-bound paclitaxel) is a chemotherapy drug used primarily in the treatment of certain types of cancers, including breast cancer, non-small cell lung cancer, and pancreatic cancer. It is a formulation of the antimitotic medication paclitaxel, which was originally derived from the Pacific yew tree. Abraxane functions by inhibiting cell division, which is particularly effective against rapidly dividing cancer cells.\n\n### Key Information:\n\n1. **Indications**:\n   - **Breast Cancer**: Abraxane is approved for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.\n   - **Non-Small Cell Lung Cancer (NSCLC)**: It is also approved as first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin.\n   - **Pancreatic Cancer**: For the treatment of metastatic aden"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8f2QAuFhuMTJczQBC6SM8mgk", "custom_id": "567_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bed8524210ce0d4d2ebd978f4cea6c45", "body": {"id": "chatcmpl-9St8oePhOPaPQXNyRGFcp6su8WiqC", "object": "chat.completion", "created": 1716672174, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a widely recognized medication specifically known as \"Abitaxel\" in standard pharmaceutical contexts or among commonly referenced healthcare databases. It is possible that there might be a typographical error or a new drug that has not yet gained widespread recognition. However, you might be referring to **\"Abiraterone\"** or **\"Paclitaxel\"** which are well-known medications in medical practice.\n\n1. **Abiraterone**: This medication is used primarily to treat prostate cancer. It is often prescribed in combination with prednisone for men with advanced prostate cancer that has spread to other parts of the body. Abiraterone works by reducing androgen production in the body, which prostate cancer cells typically use to grow and multiply.\n\n2. **Paclitaxel**: A chemotherapy drug commonly used in the treatment of various forms of cancer including ovarian, breast, lung, pancreatic, and other cancers. It works by inhibiting the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_mZKti0pDDG6bZexqIM2mZEwk", "custom_id": "568_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0b19f06f6c9bca08cca148f517f526f1", "body": {"id": "chatcmpl-9St8olDcr0DxrFNiOvhazW0zcccyV", "object": "chat.completion", "created": 1716672174, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, 'Vonjo' is not widely recognized as a common term or name related to specific medical conditions, treatments, or medications in mainstream medical practice. It\u2019s possible that 'Vonjo' may refer to a term from a different field, a brand name, a product, or something specific to a particular region or culture that is not globally recognized or established within the medical community.\n\nIf 'Vonjo' relates to a new drug, treatment, or concept that has emerged recently, it would be best to consult the latest medical literature, drug databases, or professional medical resources for the most current information. Additionally, attending medical conferences, participating in professional forums, or discussing with colleagues might provide more insights into new or lesser-known medical topics.\n\nIf you provide more specific information or context regarding 'Vonjo', I could attempt to offer a more detailed and relevant explanation or clarification."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 187, "total_tokens": 227}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_QeucGeUiSdVfHHDb26XZ3wBk", "custom_id": "569_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d13d8800319007d9665a033adf617e7d", "body": {"id": "chatcmpl-9St8oE6SIWuDdXPzpzeoKWnZFzh6V", "object": "chat.completion", "created": 1716672174, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician prescribing Ibrance (palbociclib), it\u2019s important to be aware of its indications, mechanism of action, side effects, and necessary monitoring. Here\u2019s a detailed overview:\n\n### Indications\nIbrance is primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often used in combination with an aromatase inhibitor (e.g., letrozole) or with fulvestrant in patients who have progressed following endocrine therapy.\n\n### Mechanism of Action\nIbrance is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in promoting the cell cycle transition from G1 to S phase. By inhibiting these kinases, Ibrance causes a reduction in cellular proliferation and an increase in cancer cell apoptosis.\n\n### Dosage and Administration\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vWRCJKXpzaf38jyZK7za2yci", "custom_id": "570_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f0d88c062892da1d0233c56034e98da1", "body": {"id": "chatcmpl-9St8oWy4r4UqHyaexbySoOnnKAk06", "object": "chat.completion", "created": 1716672174, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vectibix (panitumumab) is a targeted therapy used in the treatment of metastatic colorectal cancer, specifically for patients with wild-type RAS (KRAS and NRAS) tumors, as it has not shown effectiveness in RAS-mutated cases. Here are some key points that you, as a physician, should know about Vectibix:\n\n### Mechanism of Action\nVectibix is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR). EGFR is a protein found on the surface of some cancer cells which, when activated, promotes cell growth and division. By binding to EGFR, Vectibix inhibits the pathways involved in cell proliferation and survival, thereby slowing tumor growth.\n\n### Indications\n- Vectibix is approved for the treatment of metastatic colorectal cancer in patients whose tumors are wild-type for RAS genes (both KRAS and NRAS). This is critical as the presence"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pUGmKl66Ljwk8ylTpDivyTVw", "custom_id": "571_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d31d56a5131c0fd9cef5c43e60315a27", "body": {"id": "chatcmpl-9St8pOkBW08GCSbJme97pxgJJnL24", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faridak, known chemically as panobinostat, is an oral medication primarily used in the treatment of multiple myeloma, a type of cancer that forms in a type of white blood cell called a plasma cell. Plasmacytes help you fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells.\n\n### Key Points about Panobinostat (Faridak):\n\n1. **Mechanism of Action**:\n   Panobinostat is a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC, panobinostat increases the acetylation of histone proteins, leading to a more open chromatin structure and affecting gene expression. This can result in growth inhibition and death of cancer cells.\n\n2. **Indications**:\n   Panobinostat is approved for use in combination with bortezomib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_EvTEwx0SRvRz7rtDRpjz0lVt", "custom_id": "572_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "30cf05ac1319abf306d8ed29408bad78", "body": {"id": "chatcmpl-9St8pczHEE8bQtdPp5czNJIYOjacu", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Pazopanib (marketed as Votrient) is an oral medication used primarily for the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. Here are several key points you should know about this medication:\n\n1. **Mechanism of Action**:\n   Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI). It works by inhibiting multiple receptor tyrosine kinases that are involved in the pathogenesis of cancer, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-\u03b1 and PDGFR-\u03b2), and c-Kit.\n\n2. **Indications**:\n   - It is FDA-approved for the treatment of advanced renal cell carcinoma (RCC).\n   - It is also approved for the treatment of advanced soft tissue sar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_RUbg4GqoHYlFZyC3Rbov88TF", "custom_id": "573_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a161a97862edd648a475acf1241d13e4", "body": {"id": "chatcmpl-9St8puydR2YtnHzmelCzmXeHazfoA", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a pharmaceutical medication used primarily in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that affects the white blood cells. Here are essential aspects you should be aware of about Oncaspar:\n\n1. **Mechanism of Action**: Oncaspar is a modified enzyme that works by depleting the amino acid asparagine. Some leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase, making them dependent on an external supply of asparagine. Pegaspargase breaks down asparagine, depriving cancer cells of the ability to grow and survive.\n\n2. **Formulation**: Oncaspar is a pegylated form of L-asparaginase. Pegylation helps to increase the half-life of the medication, allowing for less frequent dosing compared to non-pegylated forms.\n\n3. **Indications**: It is used as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nyM7JWRgGbVUXoAEWqv4K6wv", "custom_id": "574_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0b42efc93ea6b2845b57df517fbb194", "body": {"id": "chatcmpl-9St8puaJZEVY97x0jlXGBjCN9daJ1", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegasys (peginterferon alfa-2a) is a medication used primarily for the treatment of chronic hepatitis B and C infections. It belongs to a class of drugs known as pegylated interferons, which are synthetic versions of a substance naturally produced by the body in response to viral infections. Here are some important aspects about Pegasys that you, as a physician, might need to consider when managing patients:\n\n1. **Indications**:\n   - **Hepatitis C**: Pegasys is indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not received previous interferon therapy. It's often used in combination with other antiviral drugs.\n   - **Hepatitis B**: It is also used for the treatment of adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B who have compensated liver disease and evidence of viral replication, persistently elevated ALT and histologically active disease.\n\n2. **Mech"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_SLOyeW4GhJwGcWPQlPWNhYGj", "custom_id": "575_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a7ca01d295dc03666fd25816b8fd4eaa", "body": {"id": "chatcmpl-9St8pxS5Th2ecOrgskLF3yZHxpLpO", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron (peginterferon alfa-2b) is a medication used primarily in the treatment of hepatitis C. It belongs to a class of drugs known as interferons, which help the body's immune system fight viral infections. PEG-Intron is a pegylated form of interferon, which means it has been chemically modified to allow the drug to stay in the body longer, thereby extending its activity.\n\nHere are some key points about PEG-Intron that are important for a physician to consider:\n\n### Mechanism of Action\n- **Antiviral Effects:** PEG-Intron works by enhancing the immune response against the hepatitis C virus. It stimulates the production of interferon-stimulated genes which exert antiviral effects.\n- **Immunomodulatory Effects:** It also modifies the immune response, which can help in reducing inflammation and fibrosis in the liver.\n\n### Indications\n- **Chronic Hepatitis C:** PEG-Intron is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pme5eOwrQhxQkJ1soham8yeq", "custom_id": "576_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4209925a592a50e32f3f7a9d89626a3", "body": {"id": "chatcmpl-9St8pA4dPYOLfNfr7d6S9Q8xMRZim", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx, also known as liposomal doxorubicin or doxorubicin hydrochloride liposome, is a formulation of the chemotherapy drug doxorubicin that is encapsulated within liposomes. These liposomes are tiny vesicles made from the same material as cell membranes, which encapsulate the drug, helping to prolong its circulation time in the bloodstream and reduce toxicity. Here are some key aspects you should know about Caelyx:\n\n### Indications\nCaelyx is commonly used in the treatment of various cancers, including:\n- Ovarian cancer\n- Kaposi\u2019s sarcoma in patients with AIDS\n- Multiple myeloma\n- Breast cancer\n\nIt is particularly used in patients where standard anthracycline-based therapy is unsuitable due to cardiac issues or other health concerns, as the liposomal formulation reduces cardiac toxicity.\n\n### Mechanism of Action\nCaelyx works similarly to conventional doxorubicin by intercalating DNA strands, which inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NzktfPjYdvvrWCuYjvbFXaYP", "custom_id": "577_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "07b761bb5925a4c25c741d5156d24559", "body": {"id": "chatcmpl-9St8pOJQpQ8Zy7hEBE6EcfQ8Ewwv7", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda (pembrolizumab) is an important drug in the field of oncology, particularly for its use in immunotherapy. It is a monoclonal antibody designed to block the programmed cell death-1 (PD-1) receptor, a protein on T cells that generally helps keep these cells from attacking other cells in the body, including cancer cells. By inhibiting PD-1, Keytruda helps the immune system to recognize and attack cancer cells.\n\nHere are important aspects to consider about Keytruda:\n\n### Indications:\nKeytruda has been approved by the U.S. Food and Drug Administration (FDA) for treating various types of cancer, including:\n- Melanoma\n- Non-small cell lung cancer (NSCLC)\n- Small cell lung cancer (SCLC)\n- Head and neck squamous cell carcinoma (HNSCC)\n- Classical Hodgkin lymphoma\n- Urothelial carcinoma\n- Colorectal cancer\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8FI9AAQQZWU2zNyeew76AoSF", "custom_id": "578_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8604380629e2694eed128a9cb2852b23", "body": {"id": "chatcmpl-9St8pgv1wiGqCv6XVrUYwiaM5x3Az", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta (pemetrexed) is a chemotherapy drug used primarily in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. As a physician, here are several important aspects you should be aware of regarding Alimta:\n\n1. **Mechanism of Action**: Alimta is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It specifically inhibits several enzymes, including thymidylate synthase, which is critical in DNA synthesis and repair.\n\n2. **Indications**:\n   - **Non-Small Cell Lung Cancer (NSCLC)**: Alimta is approved for the treatment of patients with locally advanced or metastatic non-squamous NSCLC:\n       - As first-line treatment in combination with cisplatin.\n       - As maintenance treatment when disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n       - As a single agent for second-line treatment after prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_b1pwDWiGYL61q35YReBxXbJC", "custom_id": "579_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "de38fac119c11b705ace7bebe91d12d0", "body": {"id": "chatcmpl-9St8pQ9qZFqrbnYCYsOay6xCj0TJ1", "object": "chat.completion", "created": 1716672175, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nipent (pentostatin) is a chemotherapeutic agent used primarily for the treatment of hairy cell leukemia. It inhibits the enzyme adenosine deaminase, which is essential in the proliferation of lymphocytes, particularly those involved in hairy cell leukemia.\n\n**Key Points for Physicians:**\n\n1. **Indications:**\n   - Primarily used for hairy cell leukemia.\n   - May be used in certain clinical trials for other conditions.\n\n2. **Mechanism of Action:**\n   - Nipent is an inhibitor of adenosine deaminase, leading to accumulation of deoxyadenosine and deoxyATP. This accumulation causes cell apoptosis, particularly in lymphocytes.\n\n3. **Administration:**\n   - Administered intravenously.\n   - Dosage must often be adjusted based on renal function and patient tolerance.\n\n4. **Monitoring:**\n   - Regular monitoring of complete blood counts (CBC) with differential, kidney function, and liver enzymes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_A65Q5jeWNSrN2VZP9vV2jWP6", "custom_id": "580_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "63c789f9e3c9e41a5c5b71fca5c6a7a4", "body": {"id": "chatcmpl-9St8qTaIiOLxGJ3cfRPHOYZUBcGHl", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omnitarg, also known by its generic name pertuzumab, is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. Pertuzumab targets the HER2 receptor, a protein overexpressed in some types of breast cancer, which promotes the growth of cancer cells. By binding to the HER2 receptor, pertuzumab inhibits the receptor's ability to receive growth signals, thereby slowing or stopping the growth of the tumor.\n\nHere are some key points about pertuzumab that you, as a physician, might find useful:\n\n1. **Mechanism of Action**: Pertuzumab uniquely binds to the dimerization domain (extracellular domain II) of the HER2 receptor, preventing it from pairing with other HER family receptors (HER1, HER3, HER4). This inhibition of dimerization is crucial because these pairings are necessary for signal transduction that promotes tumor growth.\n\n2. **Clinical Use**: Pertuz"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_cNFYnzfdD9MNnze8lZzU85Z5", "custom_id": "581_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1c5d3a48c3d6911f7d17a8f0b7d8e4ec", "body": {"id": "chatcmpl-9St8q4RdQl2JL8j2r3QcKlljMRP2E", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pinorubicine is not a well-known drug under this specific name, and it appears you might be referring to a different drug or possibly misspelled the name. If you are inquiring about a chemotherapy agent, you might mean \"Doxorubicin\" or another drug within the anthracycline class, widely used in cancer treatment.\n\nDoxorubicin is used in the treatment of various types of cancers including breast cancer, leukemia, and lymphoma. It works by intercalating DNA, disrupting topoisomerase-II-mediated DNA repair, and generating free radicals that damage cellular components.\n\nAs a physician, here are key points regarding Doxorubicin:\n\n1. **Mechanism of Action**: Doxorubicin works by intercalating into DNA and disrupting the DNA repair enzyme topoisomerase II, which causes breaks in DNA strands that inhibit replication and transcription, leading to cell death.\n\n2. **Uses**: It is commonly used to treat a variety of cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SOsbb0IMXCwIr6CxjXqAcGqZ", "custom_id": "582_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ae31f301831432c2440dca1a166a1bf1", "body": {"id": "chatcmpl-9St8qxubwuGbZ3z8u0qfMYw2nr1ws", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a cancer medication used to treat non-Hodgkin lymphoma. Here\u2019s a brief overview that might be useful for your practice:\n\n### Mechanism of Action\nPixuvri is a cytotoxic aza-anthracenedione that acts as a topoisomerase II inhibitor. Unlike anthracyclines, which are structurally related, pixantrone forms stable DNA adducts and induces non-targeted DNA damage. Its structure leads to a reduction in the generation of oxygen free radicals, thereby causing less cardiac toxicity compared to traditional anthracyclines.\n\n### Indications\nPixuvri is specifically approved for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is used particularly in scenarios where there are limited treatment options and the disease is progressing.\n\n### Administration\nPixuvri is administered intravenously, usually in a hospital or clinical setting under the supervision"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ktsEHwwseq9tiKQ3fsWWFvQJ", "custom_id": "583_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a17aeca67070e39da941bd905840b9db", "body": {"id": "chatcmpl-9St8qajNYKcJTFEPxzZb367ZMucxW", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin, also known as plicamycin, is a chemotherapy drug previously used in the treatment of certain types of cancers, including testicular cancer and some forms of bone cancer. It is derived from the bacterium *Streptomyces plicatus*. Here are some important aspects that a physician should consider:\n\n1. **Mechanism of Action**: Mithracin functions by binding to DNA and inhibiting RNA synthesis, which in turn disrupts protein synthesis. This action prevents the proliferation of cancer cells.\n\n2. **Indications**: Historically, Mithracin was used to treat testicular tumors and to manage hypercalcemia and hypercalciuria in patients with various types of tumors. It is important to note that usage of Mithracin in clinical settings is now rare, largely because of its toxicity and the availability of newer, less harmful therapies.\n\n3. **Administration**: If used, Mithracin is typically administered intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oUEhHUREhXmCuGeLiD7XaIjV", "custom_id": "584_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "852dc73c120876e4cb91fb24f10efc4b", "body": {"id": "chatcmpl-9St8qWOMbeLlNdVFUkPEprSMLXOBk", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Actimid, also known under the generic name pomalidomide, is a derivative of thalidomide and belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs). It primarily works by affecting the immune system and modifying the body's immune response to help slow down the growth and development of certain cells, particularly in cancerous conditions.\n\nHere are several key aspects that you, as a physician, might need to know about pomalidomide (Actimid):\n\n1. **Indications**: Pomalidomide is most commonly used for the treatment of multiple myeloma. It is usually prescribed for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\n2. **Mechanism of Action**: Pomalidomide\u2019s mechanism includes immunomodulatory and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QVQYY3wuQ31f5h1YHyJjzwlO", "custom_id": "585_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "73740e285a500f421cdb14d9bf710bfb", "body": {"id": "chatcmpl-9St8qLyRjKRtjVkqIFh598HGiMRDO", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a prescription medication designed for the treatment of certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), which are specific types of blood cancers. Here are some cornerstone aspects of Iclusig that you, as a physician, might need to consider:\n\n1. **Indications**: Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase, or blast phase CML, or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is appropriate. This includes patients with T315I-positive CML and T315I-positive Ph+ ALL.\n\n2. **Mechanism of Action**: Ponatinib is a TKI that specifically targets BCR-ABL, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL cells. Importantly, it is able to inhibit the activity of the T315I mutation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_J0Ovz6BI0GeqRLfJvY9LYrZU", "custom_id": "586_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02e2c9e6f57c582094ec516753b6d9cc", "body": {"id": "chatcmpl-9St8qaGDcTdQnaTmT2A7DQM9U2BuV", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn (pralatrexate) is a prescription medication used for the treatment of certain types of cancer. Below are some key points to consider:\n\n1. **Indication**: Folotyn is primarily indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is typically used for patients who have failed on previous therapies.\n\n2. **Mechanism of Action**: Pralatrexate is a folate analog metabolic inhibitor. It selectively enters cells via the reduced folate carrier and folate receptors. Once inside the cell, pralatrexate is efficiently polyglutamylated, which leads to its retention in cells and increased antifolate activity. It inhibits dihydrofolate reductase (DHFR), hence inhibiting thymidylate synthase and other enzymes involved in the folate pathway, leading to inhibition of DNA and RNA synthesis and cell death.\n\n3. **Administration**: Folot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HDEdglDXiel7EeDVlcTC8lRZ", "custom_id": "587_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "02ba1f123ca4333a4e2fbf77c5900dad", "body": {"id": "chatcmpl-9St8qdUlEGZtam73cOekm4a07667R", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, the brand name for pravastatin, is a lipid-lowering medication that belongs to a group known as statins. It's commonly prescribed to help lower cholesterol and prevent cardiovascular disease. Here are key aspects you should be aware of when prescribing Pravachol:\n\n### 1. Indications\nPravachol is primarily used to:\n- Lower LDL cholesterol and triglycerides\n- Raise HDL cholesterol\n- Reduce the risk of heart attacks, strokes, and angioplasty in patients with cardiovascular disease\n- Prevent cardiovascular disease in high-risk patients\n\n### 2. Mechanism of Action\nPravachol works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This inhibition leads to a decrease in the internal production of cholesterol, thus lowering the levels of cholesterol in the blood.\n\n### 3. Dosage and Administration\n- The dosage of Pravachol can vary depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_vTEw4gq5t9Oo8wnypSpAlc6E", "custom_id": "588_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "213d61a6e460e5ea4a57c07ad051a80c", "body": {"id": "chatcmpl-9St8qs71PsYdzoEMZRXiF7MsYq77a", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisolone is a corticosteroid drug used to treat a variety of conditions that involve inflammation in the body. It mimics the effects of hormones produced naturally in the adrenal glands. Here are the key points you, as a physician, might consider about prednisolone:\n\n1. **Uses**: Prednisolone is commonly prescribed for conditions such as asthma, chronic obstructive pulmonary disease (COPD), lupus, rheumatoid arthritis, allergies, inflammatory bowel diseases (IBD) like Crohn\u2019s disease and ulcerative colitis, and autoimmune disorders. It is also used in the management of multiple sclerosis exacerbations and as part of cancer therapy.\n\n2. **Mechanism of Action**: Prednisolone works by reducing inflammation and modifying the body's immune response. It inhibits the migration of leukocytes and fibroblasts, stabilizes lysosomal membranes, and suppresses the immune system by reducing the activity and volume of the lymphatic system.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sbec3u8wUSO91Qwt7QwYQeDF", "custom_id": "589_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "71a1f145ce3a94dcdd7fc3c8fba7392f", "body": {"id": "chatcmpl-9St8q0YkY8Nv3wraWlZ69GlVzXmhr", "object": "chat.completion", "created": 1716672176, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Artinizona\" does not appear to refer to any recognized medical term, condition, medication, or treatment currently known in the medical community as of the last update. It's possible that there might be a typo or misunderstanding in the name. If you can provide additional context or clarify what \"Artinizona\" refers to, I would be better able to assist you. Alternatively, if \"Artinizona\" is a concept, product, or term from outside the standard medical scope or emerging from recent developments, I recommend checking the latest medical literature or databases for any updates or references."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 118, "total_tokens": 159}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XVt8SXWS2vCNvT7N57N4B2V7", "custom_id": "590_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "26c63f97201899bfd7f3a92cda3d4ba5", "body": {"id": "chatcmpl-9St8rQAG1UuMIEvG4SXk34jmzgv4W", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it would be important to understand various aspects of Indicarb if you plan to use it in your practice. Indicarb seems to refer to a specific formulation of a medication or compound used in healthcare. However, the term \"Indicarb\" itself isn't widely recognized in standard pharmaceutical references. There can be cases where brand names or specific formulations might not be widely known or may be specific to certain regions or countries.\n\nIt's essential to verify the following details to ensure safe and effective use:\n\n1. **Active Ingredients**: Knowing the active ingredients of Indicarb is crucial. This will help you understand its mechanisms of action, therapeutic effects, and potential interactions with other medications.\n\n2. **Indications**: Understand what medical conditions Indicarb is approved to treat. This will guide appropriate prescribing and ensure it is used within its therapeutic indications.\n\n3. **Dosage and Administration**: Familiarize yourself with the recommended dosages, routes of administration, and any specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VaWZ2kARwSOwzJdpuqaxQ1yQ", "custom_id": "591_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eeafc1c622a11e63bef73ced411205d1", "body": {"id": "chatcmpl-9St8rGW8MPijEz1yfkzusQKYKt17q", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin, primarily composed of quinine sulfate, is a medication predominantly used for the treatment of uncomplicated Plasmodium falciparum malaria. Here are several key points that you, as a physician, should be aware of when considering or using Qualaquin:\n\n1. **Indications**: Qualaquin is approved for the treatment of uncomplicated malaria caused by Plasmodium falciparum. It is typically used when the strain is known to be sensitive to quinine or when the causative strain of malaria is unknown.\n\n2. **Mechanism of Action**: Quinine acts primarily as a blood schizonticide, interrupting the asexual intracellular development of the malaria parasite within erythrocytes. It alters the parasite's ability to metabolize and utilize hemoglobin.\n\n3. **Dosage and Administration**: The typical dosage for adults is 648 mg every 8 hours for 7 days. It\u2019s essential to administer the medication with food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_WczK0qHIK9MrsyoGk87ux6Sd", "custom_id": "592_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8a8aa8e336f2c050169d05c098f4c999", "body": {"id": "chatcmpl-9St8rusCvgsnPWCMBD2vTQUzxcCFF", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vanflyta (quizartinib) is a prescription medication used in the treatment of certain types of acute myeloid leukemia (AML), specifically those with a FLT3-ITD (FMS-like tyrosine kinase 3 - internal tandem duplication) mutation, a common type of genetic alteration seen in AML patients. It functions primarily as a FLT3 inhibitor.\n\nHere are key points physicians should consider regarding Vanflyta:\n\n1. **Indication**: Vanflyta is specifically approved for use in patients with relapsed or refractory AML with a FLT3-ITD mutation. It's important to confirm the FLT3-ITD mutation status in patients through molecular diagnostic testing before initiating treatment.\n\n2. **Mechanism of Action**: Quizartinib, the active ingredient in Vanflyta, works by inhibiting the signaling and proliferation of leukemia cells driven by the FLT3 mutations. FLT3 is a receptor tyrosine kinase that, when mutated, plays a significant role in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_bfP05ZShi1OqrfxKwO1EbhCQ", "custom_id": "593_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6478e5f1e7366fe9f4cc5fdfda8bec54", "body": {"id": "chatcmpl-9St8ra9ntM4IyJg8R1MjQuh2C3ECO", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or treatment specifically known as \"Supect\". It's possible the name could be a misspelling, a new drug not listed in my latest database, or a drug that is used in a specific non-English speaking country and therefore not widely recognized internationally under that name.\n\nIf you meant a drug with a similar sounding name or something else, please provide more details or check the spelling so I can offer the most accurate and relevant information. Additionally, always consulting up-to-date medical databases or drug information resources directly can provide the most reliable and current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 121, "total_tokens": 161}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_x1ADRKGnYKyVRU299m4HAvfD", "custom_id": "594_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "144f06af931a968f07bd3ca76fda98c6", "body": {"id": "chatcmpl-9St8rPMzxu14dAIAYvFRUPJ1y9RHA", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex, known generically as raltitrexed, is a chemotherapy medication used in the treatment of cancer. It falls under the category of antifolates, which are folate analog metabolic inhibitors. The drug is primarily used to manage colorectal cancer, although it may also have uses in other types of cancers based on clinical determinations.\n\n### Mechanism of Action:\nRaltitrexed inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. By inhibiting this enzyme, raltitrexed results in the depletion of thymidine monophosphate (dTMP), leading to a disruption in DNA replication and repair.\n\n### Indications:\n- **Primary**: It's mainly used for the treatment of advanced colorectal cancer, particularly in patients who are not considered suitable for fluorouracil-based treatment.\n- **Secondary**: May be considered in other settings based on professional judgment and potential clinical trials.\n\n### Administration:\nTomudex is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hvwz4Zog4nNR4a3z07Y9EZ88", "custom_id": "595_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4f4ecc1aeef9cd290f075915d8bfd9f8", "body": {"id": "chatcmpl-9St8rhSMbreJCCGZD1YnmqEdqaYAJ", "object": "chat.completion", "created": 1716672177, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyramza (ramucirumab) is a medication used in the treatment of certain types of cancer. It is a monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2), which plays a key role in angiogenesis (the formation of new blood vessels). By inhibiting VEGFR2, Cyramza helps to block the blood supply that tumors need to grow and spread.\n\n### Indications\nCyramza is approved by the FDA for use in the treatment of several types of cancers, including:\n- Advanced gastric cancer or gastroesophageal junction adenocarcinoma, as a single agent or in combination with chemotherapy.\n- Non-small cell lung cancer (NSCLC) in combination with docetaxel, after other chemotherapy has failed.\n- Colorectal cancer, in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan), following progression on a prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_dWNyoP0aFeEoCDN0U1QSIUlH", "custom_id": "596_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2a603bcea0970a8655b8b966664d82fc", "body": {"id": "chatcmpl-9St8slYFZSAaR7lkHaWq8OOXScsZ8", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there's no specific medical information available related to \"Cymer,\" especially if it hasn't been clearly defined in a medical context. It is essential to clarify what Cymer refers to. However, Cymer is known as a company, specifically associated with photolithography equipment used for the manufacturing of semiconductors.\n\nIf Cymer is related to something specific in medicine or a term or topic you're referring to, could you please provide more details or clarify? This will help me give you more accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 111, "total_tokens": 151}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_KZP8bNJIjk5OLTe9nj7dFNoh", "custom_id": "597_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "41001e93e550f4c72d91c416db052071", "body": {"id": "chatcmpl-9St8sOw19HlvgYPkmwiW51gDXpOv0", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nublexa (known as Stivarga in the United States and some other markets) is a brand name for the drug regorafenib, which is an oral multi-kinase inhibitor. It has been approved for the treatment of various types of cancer, including metastatic colorectal cancer, gastrointestinal stromal tumors (GIST) that have become resistant to other treatments, and hepatocellular carcinoma. Here are several key points you should know about regorafenix:\n\n1. **Mechanism of Action**:\n   Regorafenib works by inhibiting multiple protein kinases involved in the regulation of tumor angiogenesis, oncogenesis, metastasis, and tumor immunity. By blocking these pathways, it can hinder tumor growth and spread.\n\n2. **Indications**:\n   - **Colorectal Cancer**: Regorafenib is used for the treatment of patients with metastatic colorectal cancer who have previously been treated with fluoropyrimidine-, oxaliplatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ve9UUSUwe3FZHjSLMbKYLoNh", "custom_id": "598_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bbb5a8e2e0dff57198e3eec382a46dec", "body": {"id": "chatcmpl-9St8sbPUyuzKyocrwlXuzEIkjb4Nz", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (generic name: ribociclib) is a targeted therapy used in the treatment of certain types of breast cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which block the activity of cyclin-dependent kinase 4 and 6, enzymes involved in promoting the growth of cancer cells. Here's a brief overview of what you might need to know about Kisqali as a physician:\n\n### Indications\nKisqali is FDA-approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. It is used:\n1. As initial endocrine-based therapy, in combination with an aromatase inhibitor (such as letrozole) in postmenopausal women, or\n2. In combination with fulvestrant for women who are hormone receptor-positive and human epidermal growth factor receptor 2-negative and have received prior end"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_3jQ19QfqE7ArofnOMFOlgyvQ", "custom_id": "599_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0e02c153c51cbd0971f3e3d5c03cc19e", "body": {"id": "chatcmpl-9St8sTxAhn2uHfBlNsPPtM6zFrlFq", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last training data in January 2023, there is no information or medical context related to \"Ikgdar.\" It may be a typo, misspelling, or an unfamiliar term not widely recognized in the medical literature or practice. If you can provide more context or clarify the term, I'll do my best to assist you! Alternatively, if \"Ikgdar\" pertains to a specific condition, medication, or medical technology introduced after January 2023, I would recommend consulting up-to-date medical resources or databases for the most accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 114, "total_tokens": 155}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jutiZMqKZ1UZx30Lfw7rkRWl", "custom_id": "600_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ad0f2c1e769a693374a7dccb2312f0a3", "body": {"id": "chatcmpl-9St8sdDl1i4ZA9uENj1RtTnDzAdlQ", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela\u2122 (rituximab/hyaluronidase human) is a medication that combines rituximab and hyaluronidase for subcutaneous injection. It's used in treating certain types of cancer, including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Here are some key aspects you should be aware of as a physician:\n\n### 1. **Mechanism of Action:**\n   - **Rituximab** is a monoclonal antibody that targets the CD20 antigen on B lymphocytes and mediates B-cell lysis.\n   - **Hyaluronidase** is an enzyme that increases tissue permeability, facilitating the dispersion and absorption of rituximab when administered subcutaneously.\n\n### 2. **Indications:**\n   - **Follicular Lymphoma:** For the treatment of patients who are relapsed or refractory, as a single"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4m5e8Jm1MsqrZ6YQ7M4xMQlb", "custom_id": "601_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "eefe0f00537f7c81fc1a2261f4e0f63c", "body": {"id": "chatcmpl-9St8siJSutbFwggMQniDHdXAeQ7aG", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istodax (romidepsin) is a prescription medication used in the field of oncology, specifically for the treatment of certain types of cancer. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. The medication works by interfering with the function of histone deacetylases, which play a role in regulating gene expression. By inhibiting these enzymes, Istodax can induce cell cycle arrest and apoptosis (programmed cell death) in cancer cells.\n\n### Key points about Istodax:\n\n1. **Indications**:\n   - Istodax is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.\n   - It is also approved for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.\n\n2. **Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_ywtvvdsdIoFomcBLmWN5Yvh4", "custom_id": "602_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "36a9a8f3d6e3d49abecb462d5eb4cb1d", "body": {"id": "chatcmpl-9St8sDXswBVIYTQ5bjYFfNH8yaYM4", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Besremi (ropeginterferon alfa-2b-njft) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with polycythemia vera, a type of blood disorder in which the bone marrow makes too many red blood cells. This can lead to thickening of the blood and an increased risk of blood clots, which can cause serious health problems including heart attack or stroke.\n\n**Key Points About Besremi:**\n\n1. **Mechanism of Action**:\n   - Besremi is an interferon, specifically a pegylated form of interferon alpha-2b. Interferons are proteins that are part of the immune response and have antiviral, antiproliferative, and immune-modulating effects. Ropeginterferon alfa-2b-njft works by influencing the bone marrow to slow down the production of blood cells.\n\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Kd7cFcJqGkLbWzMLFjIFfhW0", "custom_id": "603_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3048459cfbcda5fe4ae16ed9ab81eaea", "body": {"id": "chatcmpl-9St8sqbj81Mwo7EyliWRGEcxoVSVd", "object": "chat.completion", "created": 1716672178, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Rubraca (rucaparib) is a medication approved for the treatment of certain types of cancers, primarily ovarian cancer. It falls under the category of PARP (poly ADP-ribose polymerase) inhibitors, which are a group of drugs that target specific enzymes in cancer cells, thus helping to prevent the repair of damaged DNA in these cells, leading to their death.\n\n### Indications\nRubraca is approved for the following indications:\n1. **Treatment of advanced ovarian cancer** in patients who have been treated with two or more chemotherapies and whose tumors have a deleterious BRCA mutation (germline and/or somatic) as identified by an FDA-approved test.\n2. **Maintenance treatment of ovarian cancer** in patients who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA mutation status.\n3. **Treatment of BRCA-mutated metastatic castration-resistant prostate cancer** (m"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9oByHyIHhnR63VkI4mRK8h1W", "custom_id": "604_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7b09f22a5d51e24704f35fd217824280", "body": {"id": "chatcmpl-9St8teSkQmNWIT09jnK11kdNaiLbY", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitininib) is a medication that has been approved by the U.S. Food and Drug Administration (FDA) to treat specific conditions related to bone marrow disorders. It is particularly used in the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Here are several key points that physicians should know when considering Jakafi for their patients:\n\n1. **Indications**:\n   - **Myelofibrosis**: Jakafi is used for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n   - **Polycythemia Vera**: It is used in patients who have an inadequate response to or are intolerant of hydroxyurea.\n   - **Graft-Versus-Host Disease**: It is approved for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pZQoPOcudDxhMLAlXzpx33Gr", "custom_id": "605_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5df0b0a67e0f189477486bacde163d5", "body": {"id": "chatcmpl-9St8tiepblSULRFz52EoqeNetXwoC", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) approved by the FDA for certain cancer treatments. Here are some essential aspects you should know about Trodelvy:\n\n1. **Indications**: Trodelvy is primarily approved for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Additionally, it has been approved for use in adult patients with locally advanced or metastatic urothelial cancer (bladder cancer) who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n2. **Mechanism of Action**: Trodelvy is composed of a monoclonal antibody that targets the Trop-2 antigen, a protein frequently overexpressed in several types of epithelial cancers. The antibody is linked to SN-38, the active metabolite"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_75ZSoytFGLGfg10s3RuGpaSk", "custom_id": "606_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa29d1429fa681b4ac544409a679af94", "body": {"id": "chatcmpl-9St8tOctkd71uZ8i9f8ScCmxdAGXc", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leukine (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used to enhance white blood cell counts. It is primarily used to speed up neutrophil recovery and reduce the incidence of infection in patients who have undergone bone marrow transplantation, are receiving myelosuppressive anti-cancer drugs, or are recovering from myelosuppressive therapies.\n\nHere are key points you should be aware of when considering or administering Leukine:\n\n1. **Indications**: \n   - To shorten neutrophil recovery time and reduce the incidence of sepsis following autologous or allogeneic bone marrow transplantation.\n   - To accelerate myeloid recovery in patients undergoing autologous bone marrow transplantation.\n   - To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).\n   - To increase neut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_HiZKV7A0403CgBMR5xe0aVep", "custom_id": "607_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "74fa8a6d66771f15e4043f9aafc40dca", "body": {"id": "chatcmpl-9St8ttLXQcL8KJnFa94Jxc8xUG4O8", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be informed about several important aspects of the drug Nexpovio (selinexor). This drug has both oncological and pharmaceutical relevance as it has been approved for specific cancer treatments. Here are the key points to consider:\n\n1. **Mechanism of Action**: Selinexor (Nexpovio) works primarily as a selective inhibitor of nuclear export. It specifically targets and inhibits the nuclear export protein XPO1 (exportin 1). This inhibition leads to the accumulation of tumor suppressor proteins in the nucleus and enhances their ability to combat cancer cells, thereby inducing apoptosis (cell death) in malignant cells.\n\n2. **Indications**: Nexpovio has been approved by the FDA for use in certain types of cancers. For instance, it is approved for the treatment of:\n   - Relapsed or refractory multiple myeloma (RRMM), in combination with dexamethasone.\n   - Relapsed or refractory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ZZfRecU9Bgg1Fn7vayGNDZVW", "custom_id": "608_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "90120cd976d05c6aed9f47f544ccf7da", "body": {"id": "chatcmpl-9St8tnK6XzZYInseepxoTdc0jVSYU", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication approved for use in treating specific types of cancers by targeting certain cellular signaling pathways. Here are key points you should consider:\n\n1. **Indication and Usage**: Koselugo is indicated for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. This is a rare genetic disorder that causes tumors to grow along nerves.\n\n2. **Mechanism of Action**: Koselugo is an inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1 and MEK2). MEK proteins are part of a key signaling pathway that regulates cell division and differentiation, which can be hyperactive in several types of cancer.\n\n3. **Dosage and Administration**: The dosage is usually based on body surface area and may vary depending on the specific needs of the patient. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kFanjxiwUD5rghO0ZZnwNdxg", "custom_id": "609_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "802f317acfd0de14dbd35f5bee7d5a8c", "body": {"id": "chatcmpl-9St8tJgBUt55cw56OwksjWDE0FmgK", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, there is no registered medication or substance named \"Semustina\" in standard pharmaceutical references or regulatory databases. It is possible that the name \"Semustina\" could be a typographical error, a non-standard or local name for a drug, or an emerging treatment not yet widely recognized or approved.\n\nIf you are referring to a medication intended for use in your practice, it is critical to verify the correct name and obtain reliable information about its uses, pharmacology, dosagen, interactions, side effects, and regulatory status. Sources such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or your local drug regulatory body can be valuable for this purpose.\n\nIf you meant to refer to another medication with a similar name or need information on a specific drug class or treatment, please provide more details so I can assist you accurately. Alternatively, verifying the drug name and details through your workplace's pharmaceutical database or consulting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IaXKZA4Cgm2aoOcajrGscA5r", "custom_id": "610_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "dc5150b1a947e7e215e795506d9ee333", "body": {"id": "chatcmpl-9St8t7wlHeaNaNfauIaoxGluzwZ7y", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is a cellular immunotherapy for advanced prostate cancer that uses the body's own immune system to fight the disease. Here are crucial points about Provenge that you, as a physician, should know:\n\n1. **Indication**: Provenge is approved by the FDA for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.\n\n2. **Mechanism of Action**: Provenge is designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers. To prepare Provenge, a patient's own peripheral blood mononuclear cells (PBMCs), including antigen-presenting cells (APCs), are collected and exposed to a recombinant protein that combines PAP with an immune-stimulatory factor. The activated cells are then reinfused into the patient to potentially initiate an immune response against the cancer cells.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NOfQTkCCvxD6SlSaeZuYNz62", "custom_id": "611_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af74868b111702547c227d982979019f", "body": {"id": "chatcmpl-9St8teJnzYGMyJ0dr1pDKevIqP1ya", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Odomzo (sonidegib) is a medication used in the treatment of basal cell carcinoma (BCC), a type of skin cancer. It is particularly prescribed for adult patients with locally advanced basal cell carcinoma that has recurred after surgery or radiation therapy, or for those who are not candidates for surgery or radiation therapy. Here are key points about Odomzo that you as a physician might need to know:\n\n### Mechanism of Action\nOdomzo is an inhibitor of the hedgehog signaling pathway, which is active in most basal cell carcinomas. Specifically, it targets and inhibits Smoothened, a component of this pathway. By inhibiting Smoothened, Odomzo can suppress the proliferation of cancer cells in BCC.\n\n### Administration\n- **Dosage Form**: It is available as oral capsules.\n- **Strength**: Commonly prescribed at 200 mg taken once daily.\n- **Administration Advice**: Odomzo should be taken on an empty stomach at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Cpt9z0XAL9sR917BgGczYZNd", "custom_id": "612_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7c1c024dcb61b66d120643b31b21ff26", "body": {"id": "chatcmpl-9St8tVIQ5awpWEzbxI0tVoJCPJ5Mz", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar, also known by its generic name sorafenib, is a medication primarily used in the treatment of certain types of cancers. Here are key points about the drug that you, as a physician, might find useful:\n\n1. **Indications**: Nexavar is approved for the treatment of advanced renal cell carcinoma (kidney cancer), unresectable hepatocellular carcinoma (liver cancer), and differentiated thyroid carcinoma when radioactive iodine therapy has been ineffective.\n\n2. **Mechanism of Action**: Sorafenib is a tyrosine kinase inhibitor. It works by blocking the action of certain proteins and kinases that are involved in the signaling pathways that regulate cell division and growth in cancer cells. By blocking these pathways, sorafenib helps slow the growth and spread of cancer cells.\n\n3. **Dosage and Administration**: The typical dosage of Nexavar is 400 mg taken orally twice daily, without food (at least 1 hour before or 2 hours after eating)."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_9D7OahUY49RFBl2OAiTfBCQx", "custom_id": "613_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a2900cca545829a5725062bcda7d624d", "body": {"id": "chatcmpl-9St8tSQ1Y26QlVGrpcqEbNOmB9yXz", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanosar, known generically as streptozocin, is a chemotherapy medication used primarily to treat pancreatic cancer, specifically islet cell carcinoma (a type of neuroendocrine tumor). Here are some key points that physicians should consider when prescribing or managing treatment with Zanosar:\n\n### Mechanism of Action\n- Streptozocin is an alkylating agent that causes damage by transferring alkyl groups to DNA and RNA. Its chemical structure allows it to be preferentially taken up by pancreatic beta cells, which may explain its activity against islet cell tumors.\n\n### Indications\n- **Primary Use**: Treatment of metastatic islet cell carcinoma of the pancreon.\n- It may also be tried in other types of pancreatic cancer but with less efficacy compared to its use in islet cell tumors.\n\n### Administration\n- Zanosar is administered via intravenous infusion. It is important to handle it with care due to its cytotoxic nature.\n\n### Dosage\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_dG05nkSfSaNiOAQB9hjv5X5D", "custom_id": "614_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e82231ee21b4e32099a1cc20366f0282", "body": {"id": "chatcmpl-9St8tCr2bWRsg55h7PWb1dGqJWgRW", "object": "chat.completion", "created": 1716672179, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a typo or misunderstanding in your query about \"Kitent.\" Currently, there is no widely recognized medical or pharmaceutical term \"Kitent.\" It's possible that you might be referring to a different term, drug, or medical concept. Could you please provide more specific details or clarify what you are referring to? If you're looking for information on a particular medication, treatment, or medical condition, I'd be happy to help with the correct information!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 94, "total_tokens": 134}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BQ7nbXaH5RXmAF390movF2xa", "custom_id": "615_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ce778d2ee6ed632d121afaabdcc47798", "body": {"id": "chatcmpl-9St8uTjHZ4edjQqei5G3LbADjuLbN", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (tagraxofusp-erzs) is a targeted therapy specifically indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years of age and older. It was first approved by the U.S. Food and Drug Administration (FDA) in December 2018. As a physician, here are several important aspects of Elzonris that you should be aware of:\n\n1. **Mechanism of Action**: Elzonris is a fusion protein consisting of interleukin-3 (IL-3) linked to a truncated diphtheria toxin. It works by binding to the IL-3 receptor (CD123) which is overexpressed on BPDCN cells, and subsequently delivering the cytotoxic diphtheria toxin directly into the cells, leading to cell death.\n\n2. **Indications**: It is specifically approved for the treatment of BPDCN, a rare and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_JY9VuTFYQ0xofMhHRm8Lr477", "custom_id": "616_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8859bc757498a2ee9dd11840b5baaacb", "body": {"id": "chatcmpl-9St8uLMhYp9FplAHJFBYK9ckTZxdq", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (talazoparib) is a medication used predominantly in oncology, specifically for the treatment of certain types of breast cancers. Below are some key aspects you should know about Talzenna:\n\n1. **Indication**: Talzenna is approved by the FDA for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. This approval is particularly relevant for patients who have been identified as BRCA mutation carriers through an FDA-approved genetic test.\n\n2. **Mechanism of Action**: Talazoparib belongs to a class of drugs known as PARP inhibitors. PARP (poly ADP ribose polymerase) enzymes are involved in normal cellular homeostasis, including DNA repair. Talazoparib works by inhibiting PARP enzymes, which leads to DNA damage in cancer cells, particularly affecting those with existing deficiencies in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Lo0IJjxtaSw6euTFqmGAMN4H", "custom_id": "617_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b39efeca8012556ec58034f8833c88b5", "body": {"id": "chatcmpl-9St8uz2bFe5QzZQwawwPvSwc1gHoX", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic, also known by its generic name talimogene laherparepvec, is a biologically based therapy used in the treatment of melanoma lesions in the skin and lymph nodes. It is noteworthy for being the first oncolytic virus therapy to be approved by the U.S. Food and Drug Administration (FDA), with its approval coming in October 2015. Here are some key points that you, as a physician, should know about Imlygic:\n\n### Mechanism of Action\nImlygic is derived from the herpes simplex virus type 1 (HSV-1). It has been genetically modified to replicate within tumors and produce the immune-stimulating protein granulocyte-macrophage colony-stimulating factor (GM-CSF). Imlygic causes lysis (destruction) of cancer cells, which subsequently releases tumor-derived antigens and potentially triggers a systemic antitumor immune response.\n\n### Indications\nImlygic is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_BdlsJUwzn6DsbrLch9oHtmyR", "custom_id": "618_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9ced9c6f4711c6b7a441b47b66c7d6af", "body": {"id": "chatcmpl-9St8uIwax9isi8exlRSKnmnl66fXy", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there was a misunderstanding or typo in your query regarding \"Amnoid.\" There isn\u2019t any widely recognized medical or pharmacological reference to \"Amnoid\" in the context of medicine or healthcare. It\u2019s possible that you meant \"amniotic,\" relating to amniotic fluid or membranes, which are very relevant in pregnancy and childbirth, or perhaps another term or drug. If you could provide more context or clarify the term, I'd be glad to offer more specific and accurate information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 101, "total_tokens": 142}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_OfSjEo1Y6JPN4hRV2xbGYJRX", "custom_id": "619_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "09124974fdf7b6b24c1dfa4a5c038b73", "body": {"id": "chatcmpl-9St8ubY60OaA8ADnexIq9H9H0A6X0", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Istubal\" is not a recognized or standard medication name. It\u2019s possible that there might be a typo or miscommunication regarding the name of the drug. It's important to verify the correct name and details of the medication.\n\nIf you meant **\"Isturisa\"** (osilodrostat), it is a medication approved for the treatment of adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative. Isturisa works by inhibiting the enzyme 11-beta-hydroxylase, which is involved in cortisol synthesis. As excessive cortisol production is a hallmark of Cushing's disease, reducing cortisol synthesis can help manage the condition.\n\nKey points about Isturisa (osilodrostat) include:\n\n1. **Indications:** Isturisa is primarily used for the treatment of Cushing\u2019s disease in adults for whom pituitary surgery is not an option or insufficient.\n\n2. **Mechanism of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_prbB68kIxRkfzwgGdPShDT01", "custom_id": "620_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f3e16b6f7513e763e467479fbaa50b6b", "body": {"id": "chatcmpl-9St8uutVzLtMUFH2NhflNnXj8OGQW", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno, known generically as tegafur, gimeracil, and oteracil, is an oral anticancer medication used in combination therapy for advanced gastric cancer. It's designed as a combination drug to enhance efficacy while minimizing toxic effects. Here's what you should know:\n\n**1. Mechanism of Action:**\n   - Teysuno contains a cytotoxic component, tegafur, which is a prodrug of 5-fluorouracil (5-FU). Tegafur is metabolically converted into 5-FU in the body.\n   - Gimeracil inhibits the degradation of 5-FU, thereby increasing its effectiveness and prolonging its plasma life.\n   - Oteracil primarily works at the gastrointestinal level to inhibit the phosphorylation of 5-FU, decreasing the gastrointestinal toxicity associated with 5-FU.\n\n**2. Indications:**\n   - Teysuno is primarily indicated for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ueNTQAKwkFqzFGhlHuMhtTtD", "custom_id": "621_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "00221c39a04bdd97984e1ca87add3bd7", "body": {"id": "chatcmpl-9St8u6Dd8BiXN0P8z0WwMp8VzsFQD", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known as Tegafur, is an antineoplastic chemotherapy drug, primarily used to treat various types of cancers. It is a prodrug of fluorouracil (5-FU), which means that it is metabolized in the body to become active. Here are some key points about Ftorafur that might be helpful for your practice:\n\n1. **Mechanism of Action**:\n    - Ftorafur is converted in the body to fluorouracil (5-FU). The active metabolite, 5-FU, inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This results in the disruption of DNA synthesis and function, particularly affecting rapidly dividing cells, such as cancer cells.\n\n2. **Indications**:\n    - It is commonly used in the treatment of various cancers including colorectal cancer, stomach cancer, breast cancer, and pancreatic cancer. Its use may vary based on the formulation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_QihFkY2FY9h5ooe6iTK8lEfe", "custom_id": "622_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "22131ec3c915948bb9873394d6ae765f", "body": {"id": "chatcmpl-9St8uIomrseqrCrJpcJM7yIl6G2Pe", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem is a brand name for temozolomide, which is an oral chemotherapy drug used primarily to treat certain brain cancers, including glioblastoma multiforme and anaplastic astrocytoma. Here\u2019s a summary of the key information about Gliotem that you, as a physician, might find useful:\n\n### Mechanism of Action\nTemozolomide, the active ingredient in Gliotem, is an alkylating agent. It works by methylating DNA, which damages the DNA and triggers the death of tumor cells. Its effect is particularly significant on the O6 and N7 positions of guanine.\n\n### Indications\n- **Glioblastoma Multiforme:** Used for the treatment of newly diagnosed glioblastoma multiforme. Typically used concomitantly with radiotherapy and then as maintenance therapy.\n- **Anaplastic Astrocytoma:** Indicated for treatment when the disease shows recurrence"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_8hAAGi5LH6o11e7tX0GtygKg", "custom_id": "623_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e5a1b43a78e86be35e10bf466a396435", "body": {"id": "chatcmpl-9St8uPIaIPB1RAhqLqK173h9Elkjy", "object": "chat.completion", "created": 1716672180, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Torisel (temsirolimus) is an anticancer medication primarily used for the treatment of advanced renal cell carcinoma (kidney cancer). Here\u2019s what you need to know about Torisel to better serve your patients:\n\n### Mechanism of Action\nTorisel is an inhibitor of the mammalian target of rapamycin (mTOR), a serine-threonine kinase. By inhibiting mTOR, it interferes with the synthesis of proteins that regulate cell division and growth, leading to cell cycle arrest and reduced tumor blood supply, ultimately inhibiting cancer cell proliferation.\n\n### Indications\nPrimarily indicated for the treatment of advanced renal cell carcinoma. Research may extend its use to other types of cancers as ongoing clinical trials suggest, but it is important to stick to the current guidelines and approved indications.\n\n### Administration\n- **Route:** Torisel is administered intravenously.\n- **Pre-treatment:** Patients often receive an antihistamine about 30 minutes before infusion to reduce the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VMYkBl4Gk0nMUUFpftWd0kv2", "custom_id": "624_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6aae7f0c46542af47e3fb4b320d35d73", "body": {"id": "chatcmpl-9St8vIi1VlJ7zBZstwFn6XSv4UhxN", "object": "chat.completion", "created": 1716672181, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vumon (teniposide) is a chemotherapeutic agent used primarily in the treatment of cancer. Here are some key points you should know about Vumok:\n\n1. **Mechanism of Action**: Vumon is a topoisomerase II inhibitor. It works by causing DNA damage in cancer cells, which ultimately leads to cell death. The drug interferes with the normal breakage-reunion reaction of DNA strand transfer catalyzed by topoisomerase II, an essential enzymatic process in DNA replication.\n\n2. **Indications**: Vumon is commonly used in the treatment of certain types of cancers, particularly in pediatric patients. It is most notably used in treating acute lymphoblastic leukemia (ALL). It may also be used in other malignancies as part of combination chemotherapy.\n\n3. **Administration**: Teniposide is administered intravenously. Proper administration techniques are crucial to avoid extravasation, which can cause severe local tissue damage.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4mKi9ueEHWtxASulSl3Q4nXa", "custom_id": "625_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4ec4a2bc9883e6943334d1c5c5950fc2", "body": {"id": "chatcmpl-9St8vdyIut2bSBYa6PcMz7g5mF9jR", "object": "chat.completion", "created": 1716672181, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan is the trade name of a drug containing thalidomide that was developed by the German pharmaceutical company Chemie Gr\u00fcnenthal. It was marketed in the late 1950s and early 1960s as a sedative or hypnotic, and also promoted for use to alleviate morning sickness in pregnant women. However, it became infamous for causing severe birth defects when it was discovered that thalidomide crossed the placenta and led to malformations in fetuses.\n\nKey points that physicians should know about Contergan (thalidomide) include:\n\n1. **Teratogenic Effects**: Thalidomide is highly teratogenic, meaning it has the potential to cause developmental abnormalities in a fetus. Pregnant women should never use thalidomide, as exposure during pregnancy can lead to serious congenital disabilities, commonly affecting the limbs, but also ears, eyes, face, and many other parts of the body.\n\n2. **Reg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_f7frlJJOwAdvHmFePJSS98DC", "custom_id": "626_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4aaf5c4e6671686d2240364321b91385", "body": {"id": "chatcmpl-9St8volkqKC9bQ2XkfmihOgigZVkZ", "object": "chat.completion", "created": 1716672181, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanvis is a brand name for the drug tioguanine, also known as thioguanine. It belongs to a class of medications known as purine analogs, which are used in the treatment of certain types of cancer. Here are some key points you should know about Lanvis (tioguanine):\n\n1. **Indications**: Lanvis is primarily used in the treatment of acute myeloid leukemia (AML). It can be used in other conditions as per clinical judgment, but its main indication is AML.\n\n2. **Mechanism of Action**: Tioguanine works by incorporating into DNA and RNA of the cancer cells, which inhibits their synthesis and function. This disrupts the growth and survival of these cells.\n\n3. **Administration**: It is usually administered orally.\n\n4. **Dosage**: Dosage must be carefully adjusted according to the patient's clinical condition, response to therapy, and hematologic profile. Regular monitoring of blood counts is crucial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_iCR1wzIL59frjYSXukI6mjZW", "custom_id": "627_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb9ad05a6c304e59acf8709c5cb7cdd0", "body": {"id": "chatcmpl-9St8v2gDg579Tc0Y3sAh5R1pdOEQ8", "object": "chat.completion", "created": 1716672181, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina, known by its generic name thiotepa, is a medication that belongs to the class of alkylating agents used primarily in the treatment of cancer. Here\u2019s a detailed overview to assist you in clinical practice:\n\n### Therapeutic Indications\nThiotepa is used for the treatment of various cancers, including:\n- Breast cancer\n- Ovarian cancer\n- Bladder cancer\n- Lymphomas\n- Intracavitary effusions due to diffuse or localized neoplastic diseases\n\nIt is also used as a conditioning agent before hematopoietic stem cell transplantation (HSCT).\n\n### Mechanism of Action\nThiotepa acts as an alkylating agent, meaning it interferes with the replication of DNA and RNA by causing cross-linking of DNA strands, abnormal base pairing, or by breaking DNA strands entirely. This disruption leads to cell death, particularly affecting rapidly dividing cells, such as cancer cells.\n\n### Dosage and Administration\nThe"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bzctVBopxmkX8DB26wk9rYdN", "custom_id": "628_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af021396ccd143d3dd3a4d0c9e54c0f7", "body": {"id": "chatcmpl-9St8v5Fm6eSWs5iTxzhEB0RIJG1nL", "object": "chat.completion", "created": 1716672181, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Kymriah\" (tisagenlecleucel) is a type of therapy known as CAR T-cell therapy, which has been a significant advancement in treating certain types of cancer. Approved by the FDA, Kymriah is designed to treat patients with specific types of blood cancers. Here are key points that you, as a physician, might need to know:\n\n1. **Indications**:\n   - **B-cell Acute Lymphoblastic Leukemia (ALL)**: Kymriah is approved for the treatment of patients up to 25 years old with B-cell precursor ALL that is refractory or in second or later relapse.\n   - **Diffuse Large B-cell Lymphoma (DLBCL)**: For adults with relapsed or refractory DLBCL after two or more lines of systemic therapy. This includes DLBCL arising from follicular lymphoma (i.e., transformation) but excludes primary central nervous system lymphoma.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_7dwAt6YNE8g3w2i7D9RfCD7l", "custom_id": "629_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "78c2d8c25bb9e9985f21f7bfc18e0692", "body": {"id": "chatcmpl-9St8w9lh74ouh5jyZasdNxGoTJlMf", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Fotivda** (tivozanib) is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of various cancers, most notably renal cell carcinoma (RCC). Here are some key points that you, as a physician, might find useful:\n\n### 1. **Indications**\n- **Fotivda** was approved by the FDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies.\n\n### 2. **Mechanism of Action**\n- Fotivda works by inhibiting the activities of VEGFR-1, VEGFR-2, and VEGFR-3. These receptors are involved in the regulation of angiogenesis (formation of new blood vessels) which is crucial for tumor growth and metastasis. By inhibiting these receptors, Fotivda reduces the blood supply"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lawV3K2MsN3Dg7ZxwDwtDGUe", "custom_id": "630_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5e6e8f544e07103f2b9b063bea6dd59f", "body": {"id": "chatcmpl-9St8wy1ayK6dCfvhfSbzgpx7Horql", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a recognized medication or supplement named \"Evotopin\" in standard medical or pharmacological resources. It\u2019s possible that the name could be a brand name, a name used in specific regions, a newly developed drug, or perhaps a misspelling.\n\nIf you are referring to a specific treatment or product, it would be helpful to have more accurate or additional information. However, here are a few general steps you can take to find reliable information about a medication:\n\n1. **Verify the Name**: Double-check the spelling and see if there are any alternative spellings, or if it might be known by another name.\n\n2. **Databases and Resources**: Use trusted medical databases like PubMed, MedlinePlus (U.S. National Library of Medicine), or the FDA's drug database to find information. These resources can provide details about drug efficacy, usage, approval status, side effects, and ongoing clinical trials.\n\n3. **Consult Pharmacists**: They"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_FWis0ihg7e9kSdRO33M1jyl5", "custom_id": "631_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1cf99e576b8590b48c26c2a9b072af3b", "body": {"id": "chatcmpl-9St8waG8QnAQXrn5KKsRupHFc5MGR", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acapodene, known by its generic name toremifene, is a nonsteroidal antiestrogen medication. It is primarily used to treat advanced breast cancer in postmenopausal women. Toremifene works by binding to estrogen receptors, thereby blocking the effects of estrogen on breast tissue, which can reduce the growth of certain types of breast tumors that require estrogen to grow.\n\nIn addition to its use in breast cancer, toremifene has been associated with potential applications in other conditions. Some studies have explored its use in preventing prostate cancer in men with high-grade prostatic intraepithelial neoplasia (PIN), though it is not yet widely adopted for this indication.\n\nHere are several key points about toremifene that you might find relevant as a physician:\n\n1. **Indications:** Toremifene is primarily prescribed for the management of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors.\n\n2. **Mech"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_qvf0O1nhwUN8YIFuqSoEmmwM", "custom_id": "632_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b5ce7cfac2ce67c0b07fcfa64c75aba6", "body": {"id": "chatcmpl-9St8wSmEF0jRbJ2vNnPa9uQDlAQhV", "object": "chat.completion", "created": 1716672182, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar (tositumomab and iodine I 131 tositumomab) is a radioimmunotherapy agent that was used for the treatment of certain types of non-Hodgkin's lymphoma (NHL). It combined a monoclonal antibody targeting the CD20 antigen on B cells with a radioactive iodine component, Iodine-131, which delivers radiation directly to the targeted cells, theoretically minimizing damage to normal tissues.\n\n**Key Points for Physicians:**\n\n1. **Mechanism of Action:**\n   - Bexxar was designed to target the CD20 antigen present on the surface of B lymphocytes and most B-cell neoplasms. The monoclonal antibody component (tositumomab) binds to the CD20 positive cells, and the attached radioactive Iodine-131 delivers cytotoxic radiation to the B-cell, causing cell death.\n\n2. **Indication:**\n   - Bexxar was used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_sH5fVCgwevfFnsGW265YvwF1", "custom_id": "633_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "26d0b72bdcfba9fc0e699564c0341cad", "body": {"id": "chatcmpl-9St8xs5SaWYKnm8MD66xsc8nEkmzj", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis (trabectedin) is a chemotherapy drug used primarily to treat certain types of cancer, including soft tissue sarcomas and ovarian cancer. Here are key points you should know about Yondelis:\n\n1. **Mechanism of Action**:\n   - Trabectedin binds to the minor groove of DNA and bends it toward the major groove, causing disruptions in the cell cycle, ultimately leading to cell death. It interferes with various transcription factors, DNA binding proteins, and DNA repair pathways.\n\n2. **Indications**:\n   - **Soft Tissue Sarcoma**: Yondelis is approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received an anthracycline-based chemotherapy.\n   - **Ovarian Cancer**: It is also approved for the treatment of patients with recurrent epithelial ovarian cancer, specifically in those whose disease has progressed after platinum-based chemotherapy.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lsTU9uWxofUPPfBnw8T4E8En", "custom_id": "634_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7164406871042b128678458a8c4b5afa", "body": {"id": "chatcmpl-9St8x2OnEk7ijJvfg7RRtcSFPSUVT", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist (trametinib) is a medication primarily used in the treatment of certain types of melanoma (skin cancer) that cannot be removed by surgery or has metastasized, and it is often utilized in combination with another drug called dabrafenib. Mekinist is also used for treating some patients with non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer that exhibits specific types of abnormal \"BRAF\" genes.\n\nHere are key points about Mekinist:\n\n1. **Mechanism of Action**: Mekinist belongs to a class of drugs known as MEK inhibitors. MEK (mitogen-activated protein kinase) is part of a signaling pathway that includes BRAF and plays an important role in the growth and survival of cancer cells. By inhibiting MEK, Mekinist helps to stop or slow the growth of cancer cells.\n\n2. **Usage**: It is important to confirm the presence of a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_XyJq9fOkEqvmGj0dnLbrVyjK", "custom_id": "635_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "cc52340482bb73dc956154c1049e8b43", "body": {"id": "chatcmpl-9St8xWyt2WF8EKwjvR32tnpogwQrE", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update, Amixam does not correspond to any recognized medication or treatment in standard medical resources. It is possible that \"Amixam\" could be a misspelling or a non-standard name for a drug or medical concept. If you can provide more context or clarify, I would be more equipped to provide relevant information. Alternatively, it could also be helpful to check the spelling or source where you encountered this term to obtain accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 95, "total_tokens": 136}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_osQOC8CJuDce8bOCII7ilgk0", "custom_id": "636_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "91ceff09804605de759fe558f161e6b0", "body": {"id": "chatcmpl-9St8x2HtFf4cK4phT9puXlrKTtiWW", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biceltis, with the active ingredient trastuzumab, is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer. Herceptin is a well-known brand of trastuzumab. Biceltis works by targeting the HER2 receptor, a protein that can promote the growth of cancer cells in a subset of breast cancer patients.\n\n### Key Points for Physicians:\n\n1. **Indications**:\n   - **Breast Cancer**: Given primarily to patients with HER2-positive breast cancer, Biceltis is used for both early-stage and metastatic cases. It can be administered as a monotherapy or in combination with other chemotherapeutic agents.\n   - **Gastric Cancer**: It is also indicated for use in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, typically in combination with chemotherapy.\n\n2. **Mechanism of Action**:\n   - Biceltis binds to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_0C0fvBlb9unSCk1pXy7KqmVA", "custom_id": "637_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9c87604c0a5e408da682b548414a36d2", "body": {"id": "chatcmpl-9St8xdehjHwGx5742cStJnE19kuCU", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imjudo (tremelimumab) is an immunotherapy drug used in the treatment of certain cancers. It is designed as a monoclonal antibody that targets the protein CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a molecule on T-cells that plays a crucial role in regulating the immune system. By blocking CTLA-4, tremelimumab enhances the immune response against cancer cells.\n\n**Key Points as of my last update:**\n\n1. **Approval and Indications:**\n   Imjumo, in combination with other approved drugs such as durvalumab (Imfinzi), has been FDA approved for specific indications, including for the treatment of certain types of liver cancer, like hepatocellular carcinoma (HCC). Always check the latest guidelines as indications for use can expand or change over time.\n\n2. **Mechanism of Action:**\n   By inhibiting CTLA-4, Imjudo effectively amplifies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NWz8Vi3LJfFi6iHRCeT8zMwf", "custom_id": "638_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "ea59c006b6e60ab6566c207142a13a6a", "body": {"id": "chatcmpl-9St8xw62kkM5wtlqOpPrbF99oGtof", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in my training data, \"Ovastat\" is not a widely recognized medication or supplement. It's possible that it could be a brand name, a product available only in specific regions, or a newer or less common drug not extensively documented in mainstream medical literature.\n\nIf you're referring to a specific product by the name Ovastat, it would be important to consult the following sources for the most accurate and relevant information:\n\n1. **Manufacturer's Information**: Look for any official product information provided by the manufacturer, which should include indications, dosage, mechanism of action, contraindications, and side effects.\n\n2. **Regulatory Agencies**: Check with health regulatory agencies such as the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) for any approved uses, safety data, and clinical trial results.\n\n3. **Pharmacological Databases**: Online databases like Drugs.com, MedlinePlus, or the World Health"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_AxlnKlsm1Rvoq1lsdOQXe6g3", "custom_id": "639_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7e7d06ea82dda00e4f330604dbcec180", "body": {"id": "chatcmpl-9St8xbBVypwcq09E3SZoHm48Lczui", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine and tipiracil) is a combination medication used in the treatment of certain types of cancers, primarily metastatic colorectal cancer and gastric cancer, including gastroesophageal junction adenocarciNoMA after previous chemotherapy treatments have failed. Here are some relevant aspects of Lonsurf that physicians should be aware of:\n\n**1. Mechanism of Action:**\n   - **Trifluridine** is a thymidine-based nucleoside analog, which gets incorporated into DNA and inhibits tumor growth by causing DNA dysfunction.\n   - **Tipiracil** is a thymidine phosphorylase inhibitor which increases the bioavailability of trifluridine by inhibiting its degradation.\n\n**2. Indications:**\n   - Lonsurf is approved for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_IMoSNiYJmk1tDC7EufbVxZS3", "custom_id": "640_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f094c0b0802b237b848aa1eb416d0292", "body": {"id": "chatcmpl-9St8xHv6gC118P4af6QU34YtOY8LD", "object": "chat.completion", "created": 1716672183, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl (triptorelin) is a synthetic analogue of gonadotropin-releasing hormone (GnRH) used in various medical contexts. Here's a summary of its key aspects, indications, administration, and considerations:\n\n### Mechanism of Action\nDecapeptyl acts by initially stimulating the release of pituitary gonadotropins, which in turn increases the levels of sex hormones (testosterone and estrogen). However, with continuous administration, Decapeptyl causes downregulation of the GnRH receptors in the pituitary gland, leading to a significant reduction in the secretion of gonadotropins and consequently a decrease in sex hormone levels to castrate or near-castrate levels.\n\n### Indications\nDecapeptyl is used in the treatment of several hormone-responsive conditions, which include:\n- **Prostate Cancer:** It is used mainly in the management of advanced prostate cancer by reducing testosterone levels, which is essential for most prostate cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WvuQnBQhdbscr1PEBT8uVrNl", "custom_id": "641_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "af42bb2fc99c11d90ca199b6af15caca", "body": {"id": "chatcmpl-9St8yseX1RT8XEUNapx176JlWl2A9", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depacon (valproate sodium) is a medication commonly used for treating various conditions such as seizure disorders, bipolar disorder, and for the prevention of migraine headaches. It is the sodium salt form of valproic acid, which works primarily by increasing the availability of gamma-aminobutyric acid (GABA) in the brain, a neurotransmitter that helps to calm nerve activity.\n\nHere are several key points that physicians should consider when prescribing Depacon:\n\n1. **Indications:**\n   - **Seizures:** Effective for the treatment of various types of seizure disorders.\n   - **Bipolar Disorder:** Used to treat manic episodes associated with bipolar disorder.\n   - **Migraine Prevention:** Can be used prophylactically to reduce the frequency of migraine headaches.\n\n2. **Administration:**\n   - Depacon is available in an intravenous form. The dosing varies based on age, weight, and specific condition being treated. Monitoring plasma levels can help in adjusting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PX1K19ecB2OMMk5fsl6Ze6p1", "custom_id": "642_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7df754686c11d2d5661bff3dffb083c1", "body": {"id": "chatcmpl-9St8ybP17LGDBXEADz8V7uIIQNyB5", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is a chemotherapy drug used primarily in the treatment of Bacillus Calmette-Gu\u00e9rin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here are some key points about Valstar that you, as a physician, might need to know:\n\n1. **Mechanism of Action:** Valrubicin is an anthracycline antibiotic that interferes with the growth of cancer cells by inducing DNA strand breaks and inhibiting DNA synthesis which ultimately leads to cell death.\n\n2. **Indications:**\n    - Valstar is specifically approved for intravesical therapy in bladder cancer patients who are not considered immediate candidates for surgical bladder removal (cystectomy).\n    - It is most often used when other treatments, particularly BCG therapy, have failed.\n\n3. **Administration:**\n    - Valstar is administered directly into the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Y2sXkKAEvxw0AB18ky5BwgMK", "custom_id": "643_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4c24312b8a58004ebaa84f3a2487e8fe", "body": {"id": "chatcmpl-9St8y0yJwcSAiNvTLfqvWtdRn2wvv", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication primarily used in the management of certain types of thyroid cancer. Here\u2019s an overview of the critical aspects you need to know about Caprelsa:\n\n**1. Indications:** Caprelsa is approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Its use is generally considered when the disease is not amenable to surgery and the benefits outweigh the risks associated with treatment.\n\n**2. Mechanism of Action:** Vandetanib is a tyrosine kinase inhibitor. It targets the RET (rearranged during transfection) proto-oncogene and vascular endothelial growth factor receptor (VEGFR), among other kinases. By inhibiting these pathways, vandetanib can interfere with tumor growth and angiogenesis (formation of new blood vessels that feed tumors).\n\n**3. Dosage and Administration:** Vandetanib is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HZGyoXcK8pdFDFDaX40AFnU9", "custom_id": "644_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c6bfbf7859a4be0816de8ba26813ed7e", "body": {"id": "chatcmpl-9St8yQ9nw0WteYHkBExwcAyEfQE46", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf (vemurafenib) is a medication used primarily in the treatment of late-stage melanoma that harbors a specific mutation in the BRAF gene (BRAF V600E). The drug belongs to a class known as BRAF inhibitors, which function by specifically targeting and inhibiting mutated forms of the BRAF protein, thus slowing the growth of the cancer.\n\n### Key Information for Physicians:\n1. **Indications:**\n   - Zelboraf is approved for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. \n   - It is essential to confirm the presence of BRAF V600E mutation in tumor specimens via an FDA-approved test before starting treatment with Zelboraf.\n\n2. **Mechanism of Action:**\n   - Vemurafenib selectively binds to and inhibits the activity of BRAF V600E kinase, which leads to a decrease in the proliferative signaling pathway downstream"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_C4OkyRn5xeFwsmNP1yTFbNMZ", "custom_id": "645_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "652a45be4460507af1a83fc4ed7d238c", "body": {"id": "chatcmpl-9St8yOnC6gru5h5bonZjk1koyieSr", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a targeted therapy used in the treatment of certain types of chronic leukemias and lymphomas. Here are key aspects that you, as a physician, should be aware of:\n\n1. **Indications and Usage**:\n   - **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)**: Venclexta is approved for the treatment of adult patients with CLL or SLL, either alone or in combination with other drugs such as rituximab.\n   - **Acute Myeloid Leukemia (AML)**: It is also approved for use in adults with AML who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n2. **Mechanism of Action**:\n   - Venclexta is a BCL-2 inhibitor. BCL-2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_eJ6IHEM4qirY6yNpcqov6Fw7", "custom_id": "646_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e12a62893924516116c7ee7e36dda613", "body": {"id": "chatcmpl-9St8yHVpBsHQVAzqHXcEl96RrIjSY", "object": "chat.completion", "created": 1716672184, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is not a commonly recognized medication under the mentioned name. It is possible that the name could be misspelled or it might be a brand name that is not widely known. To provide accurate information, it would be helpful to have the correct name or additional details about the medication such as its generic name, its intended use, or its active ingredients.\n\nIf Alkaban-AQ is a medication you encounter in a patient\u2019s medication list, it is important to verify its purpose, dosage, mechanism of action, and potential side effects. Always refer to trustworthy sources such as official drug compendiums, recent clinical guidelines, or pharmaceutical databases to ensure safe and effective patient care.\n\nIf you have other specific questions or need information on a different medication, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 43, "completion_tokens": 160, "total_tokens": 203}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_qIXKOWuCbeUlxSXSHYCx0RQb", "custom_id": "647_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a572cfd9b1c581ae3f47010a287ca43", "body": {"id": "chatcmpl-9St8zz1jpL8Fp90fWPCkh10314wla", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Alcrist\" is not recognized as a common medication or treatment within standard medical resources. It's possible that the name might be misspelled, a brand name not widely recognized, or a new drug still under development or limited to specific regions.\n\nIf \"Alcrist\" is indeed a medication or treatment you've encountered in your practice, it could be beneficial to check up-to-date medical references or databases. You might also consider consulting pharmacological resources or contacting pharmaceutical companies directly for the most accurate and current information.\n\nIf you provide more context or details about \"Alcrist,\" I could attempt to offer more specific guidance or look up similar-sounding drugs that might be relevant."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 144, "total_tokens": 185}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jIf5ALeI5QEcpmH2i6VQDQRU", "custom_id": "648_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d3ef371a7ae00e9d2d7d26342e35ddf0", "body": {"id": "chatcmpl-9St8zodx22Fc99ffp7cr9oiwCjtt2", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is an anticancer medication used in the treatment of certain types of cancer, primarily focusing on Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). As a physician, here are some key aspects of Marqibo that you should be aware of:\n\n1. **Indication and Usage**: Marqibo is specifically indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This form of vincristine is encapsulated in liposomes, which are designed to allow a longer circulation time and altered distribution of vincristine in the body.\n\n2. **Mechanism of Action**: Marqibo\u2019s active ingredient, vincristine sulfate, is a vinca alkaloid that works by disrupting microtubule formation in the mitotic spindle, thus inhibiting mitosis and inducing apoptosis in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_xaZN2OUJ5h8VraNR1Dk3kMG1", "custom_id": "649_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4f695dd30300c777befe74be36a9fb4d", "body": {"id": "chatcmpl-9St8zJQVGanUxAiBTJIEvaluGQir5", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no drug known as \"Eldesine\" recognized in standard medical databases or pharmacopeia. It's possible there could be a spelling error or a brand name that is not widely recognized. If you meant a different medication, or if the drug is new and information has not yet fully circulated, please provide more details or check the most recent and reliable medical resources. Alternatively, you can tell me the intended use or known components of the medication, and I might be able to provide more relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 109, "total_tokens": 150}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_v9p4Mv7alcOn5eWxCk1PvGyY", "custom_id": "650_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1fe05c48315eeeb715b85a5761315a10", "body": {"id": "chatcmpl-9St8zUrdkUjnJt9a70Dis67SF9GyM", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor, known generically as vinflunine, is a chemotherapy medication used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen. Here are some important aspects to consider:\n\n1. **Mechanism of Action:**\n   Vinflunine is a microtubule inhibitor vinca alkaloid. It works by inhibiting the polymerization of microtubules, which disrupts the formation of the mitotic spindle, leading to cell cycle arrest at the G2/M phase, and eventual cell death.\n\n2. **Indications:**\n   - It is mainly indicated for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after the failure of a prior platinum-containing regimen.\n   - It may also be explored for other off-label uses based on clinical judgment and emerging research.\n\n3. **Administration:**\n   Vinflunine is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_22waSRd13kRSmi79PBhXQ9fZ", "custom_id": "651_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe64d230d93e17511f39b6be81b8212f", "body": {"id": "chatcmpl-9St8zgFfv49cJvUmQagxlLnH8AzLO", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Binorel\" does not appear to be a recognized medication or treatment in standard medical resources or databases. It's possible that the name could be a misspelling, a non-standard or brand name not widely recognized, or a product not approved or recognized by mainstream medical bodies.\n\nIf you heard about Binorel from a patient or a non-medical source, it would be prudent to:\n\n1. Verify the spelling and exact nature of the product.\n2. Check reliable medical and pharmacological databases or sources.\n3. Understand whether it's a drug, supplement, or another kind of treatment.\n4. Investigate whether any clinical trials or research papers exist concerning its safety, efficacy, and intended use.\n\nSince I don't have information on Binorel, I recommend consulting a trusted drug database, contacting a pharmaceutical expert, or accessing medical literature for the most accurate and reliable information. Additionally, if this product pertains to a specific field or specialty, consulting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_lB4pgr2T28AhtxjDLpvznmHZ", "custom_id": "652_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5ca2cfa9fad3078e261dc9066b2ae7ec", "body": {"id": "chatcmpl-9St8zcupRj9Q470nJahqqf657QxUE", "object": "chat.completion", "created": 1716672185, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is a medication used for the treatment of advanced basal cell carcinoma (BCC), a type of skin cancer. Here are key points that physicians should be aware of regarding Erivedge:\n\n1. **Indications**: Erivedge is approved for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and not candidates for radiation.\n\n2. **Mechanism of Action**: Erivedge works by inhibiting the Hedgehog signaling pathway, which is active in most basal cell carcinomas. By inhibiting this pathway, vismodegib can help to block the growth and spread of cancer cells.\n\n3. **Administration**: Vismodegib is taken orally, with a recommended dose of 150 mg once daily. The medication can be taken with or without food.\n\n4. **Side Effects**: Common side effects of Erivedge include"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_wVuLkhkgpDtMIiC9IAsPIZCc", "custom_id": "653_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df5eb87d130c9aeb62af4090656099bf", "body": {"id": "chatcmpl-9St90PB5PTq87AnKL1k6BOmy4WUPu", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza (vorinostat) is a medication used in the treatment of cancer, specifically indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received previous systemic therapy. Here are some key points about Zolinza that you, as a physician, might find useful:\n\n1. **Mechanism of Action**:\n   Zolinza is a histone deacetylase (HDAC) inhibitor. It works by inhibiting the enzyme activity of HDAC, leading to an accumulation of acetylated histones and other proteins. This alteration in protein acetylation can lead to changes in gene expression, cell cycle arrest, and apoptosis (programmed cell death) in malignant cells.\n\n2. **Indications**:\n   It is approved by the FDA for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent, or recurrent disease on or following two systemic therapies.\n\n3. **Administration**:\n   Zolin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_4iuoAcneyo5yekgtoNZjJMbh", "custom_id": "654_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bf2050565b807289c42e38f6b2de5436", "body": {"id": "chatcmpl-9St90p3xmzCEOOITbuJqFWK7tFBFA", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Aztec\" could refer to either the ancient civilization or to a software product used in medical laboratories.\n\n1. **Aztec Civilization**: If you are interested in the historical aspect, the Aztec civilization was a Mesoamerican culture that flourished in central Mexico in the post-classic period from 1300 to 1521. While knowing about the Aztecs might not directly impact modern clinical practices, understanding the health practices and conditions of ancient civilizations can provide insights into the history of medicine, epidemiology, and the evolution of diseases and treatments. The Aztecs had advanced understanding for their time of herbal medicine, surgeries, and the spiritual aspects of healing.\n\n2. **Aztec (Software)**: If you are referring to a software or product named \"Aztec\" in the context of laboratory or medical use, this could relate to specific equipment or systems used for data management, analysis, or diagnostics in medical laboratories. It is important to familiarize yourself with the specific functionalities,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_yTu9Fyql68ZvEosopkqzDovm", "custom_id": "655_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e9206f2ac74fbf4640e2abcdeae3084d", "body": {"id": "chatcmpl-9St90nDPO3U5xqK16e181AHE3FenE", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap (aflibercept) is a biologic medication used as an anti-angiogenic agent in the treatment of certain types of cancer. Here are the key aspects you should be aware of:\n\n1. **Indications**: Zaltrap is primarily used in combination with FOLFIRI (irinotecan, fluorouracil, and leucovorin) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.\n\n2. **Mechanism of Action**: Aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), inhibiting their binding to VEGF receptors on the surface of endothelial cells. This inhibits angiogenesis (the formation of new blood vessels), which is essential for tumor growth.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DQoGPSe57r1c2haS9lz5Vo1H", "custom_id": "656_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c8e4ea89aa45340664cff46943697bd1", "body": {"id": "chatcmpl-9St90cLnVFz8US3QUkmWnPXvGqjBE", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a medication used for the treatment of non-small cell lung cancer (NSCLC), specifically for tumors that have a mutation leading to MET exon 14 skipping. Here are key points you should know as a physician:\n\n1. **Indication:**\n   Tabrecta is specifically indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test.\n\n2. **Mechanism of Action:**\n   Capmatinib is a MET inhibitor. The MET gene encodes for a tyrosine kinase receptor involved in the signaling pathways regulating cell growth, proliferation, and survival. Mutations leading to MET exon 14 skipping result in enhanced MET signaling and are associated with cancer growth and proliferation. Capmatinib inhibits this signaling pathway, leading to reduced tumor growth and cell death.\n\n3. **Administration:**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_NLHa3OH5hmITmNhFDz0FkNf9", "custom_id": "657_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f6d32dff026f2f5baab2982e789220ab", "body": {"id": "chatcmpl-9St90UbTex5PSaoaju9l6CVhF9ell", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (enfortumab vedotin-ejfv) is a prescription medication used in the treatment of adult patients with certain types of urothelial cancer (cancer of the bladder and related urinary tract). It is particularly indicated for patients who have previously received treatment with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy, and whose cancer has progressed during or following such treatments.\n\nHere are key points you should know about Padcev:\n\n1. **Mechanism of Action**:\n   - Enfortumab vedotin is an antibody-drug conjugate (ADC). The antibody component targets Nectin-4, a protein found on the surface of many urothelial cancer cells. After binding to Nectin-4, the drug is internalized and releases a cytotoxic agent (MMAE) that disrupts the microtubule network within the cancer cells, leading to cell death.\n\n2. **Approval and Usage**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_CamGiOTo2Dr5fYe8HeQj58mZ", "custom_id": "658_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2622aad2c1153356c1d2df975afb20d2", "body": {"id": "chatcmpl-9St90GBAO2ASsjy2Rw8WPKD78IQmQ", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have detailed knowledge about any medication you might prescribe, including Enhertu (generic name: fam-trastuzumab deruxtecan-nxki). Here are key points to consider:\n\n1. **Indications**: Enhertu is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. It is also approved for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.\n\n2. **Mechanism of Action**: Enhertu is an antibody-drug conjugate consisting of a HER2-targeted monoclonal antibody linked to a cytotoxic topoisomerase I inhibitor (a derivative of exatecan). The drug binds to HER2-expressing cells, allowing the delivery of the cytotoxic agent directly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zkiWpDWTQdT421INUIi35NOz", "custom_id": "659_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "11c572135b6a3dc6404c52b20e9fceb1", "body": {"id": "chatcmpl-9St90sAOe3VU3TzDFeySeXJlI4rPP", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis (abarelix) is a drug that was used for the treatment of hormone-responsive cancers of the prostate in men. It acts as a gonadotropin-releasing hormone antagonist (GnRH antagonist), effectively reducing the production of testosterone, which is often needed for the growth of prostate cancer cells. Here are some key aspects you may need to know:\n\n1. **Mechanism of Action**: Plenaxis works by directly blocking the GnRH receptors in the pituitary gland, which leads to reduced secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, and subsequently, a decrease in testosterone levels.\n\n2. **Indications**: It was primarily indicated for the treatment of advanced symptomatic prostate cancer in patients who refused or were not candidates for other hormonal treatment options like luteinizing hormone-releasing hormone (LHRH) agonists, which could also cause a temporary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_jNlJDIo6pNCyxshpRGJEYuTv", "custom_id": "660_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "f5f2879b4221da690012c5393bd95bc6", "body": {"id": "chatcmpl-9St90VJnDrviXGLghZUnF4np7KdkB", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin-blmf) is a medication used in the treatment of multiple myeloma, particularly approved for adult patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Here are some important aspects you should know about Blenrep:\n\n### Mechanism of Action\nBlenrep is an antibody-drug conjugate comprised of a humanized anti-BCMA (B-cell maturation antigen) monoclonal antibody linked to a cytotoxic agent, auristatin F via a non-cleavable linker. The BCMA is primarily expressed on the surface of mature B lymphocytes and is involved in the growth, survival, and differentiation of plasma cells. By targeting BCMA, Blenrep induces apoptosis of BCMA-expressing cells.\n\n### Indications\n- Blenrep is indicated for the treatment of relapsed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rprPwFincpSIcrwFaIuJ67o4", "custom_id": "661_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fdc7cb18bdbc216e30988940fd7671c0", "body": {"id": "chatcmpl-9St90zgsohORHXGfzDx0uWbGN3R9f", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tukysa (chemical name: tucatinib) is a medication approved by the FDA commonly used in the treatment of HER2-positive breast cancer. Here are some essential aspects you should be familiar with as a physician:\n\n### Mechanism of Action\nTukysa is a tyrosine kinase inhibitor that selectively inhibits HER2 (human epidermal growth factor receptor 2). HER2 is an enzyme that can promote the growth of cancer cells. By inhibiting this receptor, Tukysa helps to stop the proliferation of cancer cells that overexpress HER2.\n\n### Indications\nTukysa is approved for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases. It is used in combination with trastuzumab and capecitabine for patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n### Efficacy\nClinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nfPafdDZb8YWgbREpOklzFLD", "custom_id": "662_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d42ca2ecda9c0210fb7d1edb21d1a303", "body": {"id": "chatcmpl-9St90lwPd6lqlz3TD3eZjIEUkFfuQ", "object": "chat.completion", "created": 1716672186, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro (generic name: daratumumab and hyaluronidase-fihj) is a formulation used for the treatment of multiple myeloma. Designed for subcutaneous injection, it combines daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an enzyme that helps increase the dispersion and absorption of injected drugs. Here are some important aspects about Darzalex Faspro you should know:\n\n### Indications\nDarzalex Faspro is indicated for the treatment of adult patients with multiple myeloma, both as a monotherapy and in combination with other therapies such as lenalidomide, bortezomib, and dexamethasone. The specific indications vary based on the line of therapy and other factors related to the patient's treatment history and disease stage.\n\n### Mechanism of Action\nDaratumumab binds to CD38, which is expressed on the surface of multiple"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VoMSuf64FPvGOl4zZ627DbSI", "custom_id": "663_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0ea02dc9b775c46313155f2090c6b0dd", "body": {"id": "chatcmpl-9St91HV6NOeL7jDKjbu2WNZeWzbDv", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin, also known by its generic name alitretinoin, is a topical medication used specifically for treating skin lesions in patients with Kaposi's sarcoma, a type of cancer that often affects individuals with AIDS. It is a retinoid, which means it is a derivative of vitamin A and works by slowing or stopping the growth of certain cells. Here are some key points that physicians should consider when prescribing Panretin:\n\n1. **Indications and Usage**: Panretin gel is approved for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. It is not intended for systemic treatment of Kaposi's sarcoma or for use on other types of cancers.\n\n2. **Mechanism of Action**: Like other retinoids, alitretinoin modulates the expression of genes involved in cell differentiation and proliferation. It has been shown to induce cell death in Kaposi's sarcoma cells in vitro.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CBLAHP65tb93BBzi81VIpjBf", "custom_id": "664_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8101c7e2490a12db5ae35759316cf0ec", "body": {"id": "chatcmpl-9St91yZd2EjN0qidfIR9BCxmP3eYT", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is a type of CAR T-cell therapy that has been developed for the treatment of certain types of cancer. Specifically, it is approved by the FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children aged 2 years and older. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Tecartus utilizes genetically modified autologous T-cells that are engineered to express a chimeric antigen receptor (CAR) that targets CD19, a protein expressed on the surface of B-cell lymphocytes. This allows the T-cells to specifically recognize and eliminate CD19-expressing cells.\n\n2. **Manufacturing and Administration**: The process involves collecting the patient's own T-cells, genetically modifying them"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_kIw1UKmWLC4E61Xb6Ft1ikOi", "custom_id": "665_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6b6cbf26341692ad8b474a0757d3ad04", "body": {"id": "chatcmpl-9St91LkI78veFR5ovVRQ3WN91PGQS", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray (alpelisib) is a medication approved by the U.S. Food and Drug Administration (FDA) for use in certain patients with breast cancer. Here are some key points you should know about Piqray as a physician:\n\n1. **Indication:** Piqray is indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant after the disease has progressed following an endocrine-based regimen.\n\n2. **Mechanism of Action:** Piqray is an inhibitor of phosphatidylinositol-3-kinase (PI3K), specifically the PI3K\u03b1 isoform, which is a part of the PI3K/AKT/mTOR pathway, an intracellular signaling pathway important in the regulation of cell cycle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Vg55xTovjKhSyrToa3UfnPAL", "custom_id": "666_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9383df1093e30c436dc152013d35e835", "body": {"id": "chatcmpl-9St91ZkGcec01QkZqdssbiZeFAGri", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinamed is not a widely recognized medication name in standard pharmaceutical databases, so there might be some ambiguity or confusion about the specific drug you are referring to. It\u2019s possible that Quinamed could be a trade or brand name for a medication used in specific countries or regions, or it could be a misspelling or variation of another drug name.\n\nIf you suspect it might be a variation or a specific brand name of a more commonly known medication, I could help provide information based on a more known or similar sounding name. For example, if you are asking about a quinoline medication used for malaria, it could relate to quinine. Please provide more context or check the spelling so I can give you the most accurate and helpful information.\n\nFor information about any medication, including those less commonly known, it's important to consult drug-specific resources or databases such lottery MedlinePlus, the FDA database, or a local pharmaceutical registry that your national health system provides. This can provide details on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_bpbPxGk0XVcCK8EEEx7baqd2", "custom_id": "667_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8e5fab5bafb0a28537bba10d705daaa2", "body": {"id": "chatcmpl-9St91TEinZOdOeJfbIrYsOZL2oWMY", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin, commonly referred to as Amoxi, is a widely used antibiotic that falls under the penicillin class of medications. It's essential for treating various bacterial infections, including pneumonia, bronchitis, infections of the ear, nose, throat, urinary tract, and skin. Here\u2019s a summary of key points you should consider when prescribing Amoxi:\n\n**1. Mechanism of Action:**\nAmoxicillin works by inhibiting the synthesis of bacterial cell walls, ultimately leading to bacterial cell death. It is a bactericidal antibiotic effective against a broad spectrum of gram-positive and some gram-negative bacteria.\n\n**2. Indications:**\nAmoxicillin is indicated for the treatment of various bacterial infections, including but not limited to:\n   - Otitis media (middle ear infections)\n   - Sinusitis\n   - Respiratory tract infections\n   - Urinary tract infections (UTIs)\n   - Skin and soft tissue infections\n   - Helicob"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Z8LS0r7VaoNMF91YED6BooMY", "custom_id": "668_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5bffa22505a78841f40e06075873437b", "body": {"id": "chatcmpl-9St91DHlYIVciNSfszPnnNhiE7ExH", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "To provide accurate information, it's important to clarify whether you are referring to a medical condition or another topic related to the name \"Amelie.\" If you're asking about a medical condition related to the name, I would need more specific details as there is no widely recognized medical condition named \"Amelie.\"\n\nHowever, if \"Amelie\" refers to something else, such as the film \"Am\u00e9lie\" from 2001, or a different context entirely, please provide additional details so that the information can be tailored accurately to your needs."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 112, "total_tokens": 153}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wSv7vTFwAFrA0PPxeiQ1Xl29", "custom_id": "669_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "80b13f14018a1ee4a52045bf3dc591fe", "body": {"id": "chatcmpl-9St91rZ3nRbid67cSFek4z16g2DlD", "object": "chat.completion", "created": 1716672187, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Pemazyre** (pemigatinib) is a targeted therapeutic agent used in oncology, specifically approved for the treatment of certain types of cancers. Here are key points you should be aware of:\n\n### 1. **Indications**\nPemazyre is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) characterized by a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. It is important to confirm FGFR2 fusion or rearrangement via an FDA-approved test before initiating treatment.\n\n### 2. **Mechanism of Action**\nPemazyre is a kinase inhibitor that specifically targets FGFR1, FGFR2, and FGFR3 gene abnormalities. By inhibiting these fibroblast growth factor receptors, Pemagytre can hinder the tumor cells'"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_3VZGBTUrHz4N1hxEZIZ870A5", "custom_id": "670_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a4e135023bb49ca055e73017af588e25", "body": {"id": "chatcmpl-9St92u1ytVmXjiPFl7JzChW4GmHRT", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (generic name: ripretinib) is a kinase inhibitor specifically designed for the treatment of advanced gastrointestinal stromal tumors (GISTs). It was approved by the U.S. Food and Drug Administration (FDA) in May 2020. Here are some important aspects of Qinlock that you as a physician might need to know:\n\n1. **Indications**: Qinlock is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. \n\n2. **Mechanism of Action**: Ripretinib works as a kinase inhibitor by targeting a range of kinases including KIT and PDGFRA (platelet-derived growth factor receptor alpha). These kinases often have mutations that can contribute to the growth and spread of cancer cells. Ripretinib is designed to inhibit both the wild-type and mutant forms of these kinases.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_4U3VTxUG8AQNA97jzhFO2fym", "custom_id": "671_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b782bad63f55543fff19d7ea17206944", "body": {"id": "chatcmpl-9St92GH1B1im4PmaudR0SX9Vg8rNX", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a medication approved by the FDA for the treatment of specific types of thyroid cancer and non-small cell lung cancer (NSCLC) that have specific genetic mutations involving the RET (rearranged during transfection) proto-oncogene. Here are some key aspects that you, as a physician, might need to know about Retevmo:\n\n1. **Indications**:\n   - **RET Fusion-Positive Non-Small Cell Lung Cancer**: Retevmo is indicated for the treatment of adults with metastatic RET fusion-positive NSCLC.\n   - **RET-Mutant Medullary Thyroid Cancer (MTC)**: It is approved for adult and pediatric patients 12 years of age and older with advanced or metastatic MTC who require systemic therapy and who have a RET mutation.\n   - **RET Fusion-Positive Thyroid Cancer**: Retevmo is indicated for adult and pediatric patients 12 years of age and older"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fYnN0tXjYEKa3j59RLTA1Wp0", "custom_id": "672_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a070b55a2ad45df87dc2fdf1c2c6b362", "body": {"id": "chatcmpl-9St92FgygshEHLvSXiVCIIzZUhTR3", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi (decitabine and cedazuridine) is a prescription medication approved for the treatment of adult patients diagnosed with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.\n\nHere are some important aspects of Inqovi that you, as a physician, should consider:\n\n1. **Mechanism of Action**: Inqovi combines two active components: decitabine, a hypomethylating agent, and cedazuridine, a cytidine deaminase inhibitor. Decitabine is incorporated into DNA and inhibits DNA methyltransferase, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_fiPuTh5wsHRsgmuvf88PbEQj", "custom_id": "673_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d524143f3ff02374c02197f785154932", "body": {"id": "chatcmpl-9St92nJNVUH3yjKgOpkB5RMW4wgTm", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pepto-Bismol (bismuth subsalicylate) is an over-the-counter medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as nausea, heartburn, indigestion, upset stomach, and diarrhea. Here are its key aspects you should be aware of as a physician:\n\n### Mechanism of Action\n1. **Antimicrobial Effects:** It inhibits the growth of bacteria like H. pylori and can also bind bacterial toxins.\n2. **Anti-Inflammatory Properties:** It reduces inflammation by inhibiting prostaglandin synthesis.\n3. **Antacid Effects:** It has mild antacid properties to neutralize stomach acid.\n4. **Binding Action:** It can coat the mucosa, providing a protective layer which can be soothing for irritation and erosion in the gastrointestinal tract.\n\n### Indications\n- Nausea\n- Heartburn\n- Indigestion\n- Upset stomach\n- Diarrhea\n- It can be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_09w9oqFWpj8LX2gS5TxLJAg4", "custom_id": "674_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "641ba7befb383a36c8e15a181472269f", "body": {"id": "chatcmpl-9St925mSDjGNBIRZ3Ywb0TytqwIRQ", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in January 2023, AiRuiKa doesn't specifically refer to anything well-known or recognized in the medical, technology, or pharmaceutical sectors. It's possible that it might be a term specific to a local context, a new development, or a misspelling. If AiRuxxxxx has relevance in a specific field or region, I would recommend checking the latest professional databases, publications, or news sources in your field for the most accurate and updated information. If you can provide more context or details, I might be able to help you better."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 118, "total_tokens": 160}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_nOb0Eqb4iE2Ims0IA7X3iilM", "custom_id": "675_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "806dbb9c6c55939f30c8b1b70a4c10c3", "body": {"id": "chatcmpl-9St92EnRT3lt6VXpaaN0QbzhSF5nM", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is an oral medication approved for the treatment of advanced prostate cancer. Here are key points that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Orgovyx is a gonadotropin-releasing hormone (GnRH) receptor antagonist. By blocking the GnRH receptors in the pituitary gland, it decreases the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a reduction in testosterone levels in men. This reduction in testosterone is crucial in managing hormone-sensitive prostate cancer.\n\n2. **Indications**: Orgovyx is specifically indicated for the treatment of adults with advanced prostate cancer. It is a part of a group of hormone therapies aiming to reduce the levels of hormones that can promote cancer growth.\n\n3. **Dosage and Administration**: The typical starting dose is a loading dose of 360 mg taken orally on the first day"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_EbpVG71Iigv6X3tz0GQv5K9U", "custom_id": "676_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "922192c99722e0fd439b0af3cc7d229e", "body": {"id": "chatcmpl-9St92vwh6QdIObY9JLUhZld64C7x0", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orserdu (elacestrant) is an oral medication approved for the treatment of certain types of breast cancer. It specifically targets estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women and adult men. This medication functions as an estrogen receptor degrader (ERD).\n\nKey points for physicians to consider about Orserdu include:\n\n1. **Indications**: Orserdu is indicated for patients who have previously been treated with endocrine therapy and have either progressed during or after the treatment. It's crucial to confirm the ER-positive, HER2-negative status of the tumor through laboratory testing before initiation.\n\n2. **Mechanism of Action**: Orserpast acts by binding to the estrogen receptor, leading to the degradation of the receptor itself, thereby reducing the effect of estrogen on cancer cells which reduces tumor growth and potentially causes tumor shrinkage.\n\n3. **Efficacy**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FUrMQsHwLZcXoXCeAcagNOT2", "custom_id": "677_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d07f5b3d75ad34a03f69c26d90ec8ca7", "body": {"id": "chatcmpl-9St92gyoR2HUZFmaNrkhpTZWcaNEz", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin, known generically as trimetrexate, is a chemotherapy agent and dihydrofolate reductase inhibitor, which was once used primarily for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in patients with AIDS when conventional therapy was inappropriate. Trimetrexate works by inhibiting the enzyme involved in the synthesis of tetrahydrofolate, which is necessary for DNA synthesis, repair, and cellular replication.\n\nHere are some key points you should be aware of:\n\n1. **Indications**: Historically, Neutrexin was typically administered in combination with leucovorin (folinic acid) to mitigate bone marrow suppression, a common side effect of trimetrexate, since trimetrexate is a potent inhibitor of human dihydrofolate reductase as well.\n\n2. **Administration**: Trimetrexate was administered intravenously, and dosing was dependent on the specific indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_E5jSg6xMJ7e8pwZpBqLLbuyu", "custom_id": "678_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "494fdf3cc9bdcbeed2d675fca82c972a", "body": {"id": "chatcmpl-9St92mFSONej0kc4N1cbRnRh2E0iO", "object": "chat.completion", "created": 1716672188, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepmetko (tepotinib) is a medication that has been approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Here are some key aspects you should be aware of:\n\n### 1. Mechanism of Action\nTepmetko is a tyrosine kinase inhibitor that specifically targets the MET gene. It inhibitates the hepatocyte growth factor receptor (HGFR), which can be oncogenic when mutated or overexpressed.\n\n### 2. Indications\nTepmetko is specifically approved for use in patients with metastatic NSCLC who have MET exon 14 skipping alterations. These alterations lead to enhanced MET signaling and tumor growth, and they are identifiable through molecular testing.\n\n### 3. Administration \nIt is administered orally, which can often be more convenient for patients compared to intravenous options.\n\n### 4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_VZXwTOhbstuYAXfrR3BiNTN1", "custom_id": "679_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d9926ac8c35b69bd6347c87d695501a0", "body": {"id": "chatcmpl-9St935WHcIdgW2pwgysS1V7KYIr8Q", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in 2023, \"Lytgobi\" is a trade name for the drug pafolacianine, which is used for medical purposes. Pafolacianine is a fluorescent imaging agent approved by the U.S. Food and Drug Administration (FDA) in November 2021. It is designed to assist surgeons in identifying ovarian cancer lesions during surgery.\n\n**Brand Name:** Lytgobi\n**Generic Name:** Pafolacianine\n**Usage:** It is indicated for adult patients with ovarian cancer to help surgeons identify cancerous lesions during surgery. The agent is administered intravenously and used in conjunction with a near-infrared fluorescence imaging system approved by the FDA.\n\n**Mechanism of Action:** Pafolacianine is a fluorescent dye linked to a folate analog. The folate analog allows the dye to bind to folate receptors, which are often overexpressed in ovarian cancer cells. When illuminated with specific wavelengths of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PytZfIs23DYFCHaFoTiQfKhn", "custom_id": "680_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a75fe0edd7efab6b781c1d345951741d", "body": {"id": "chatcmpl-9St93kYNAKTmRdOGPkMPmiAYl8ip0", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used in the treatment of glioblastoma, one of the most aggressive and common types of primary brain tumors. Important points to consider when discussing or considering the use of Optune include:\n\n1. **Mechanism of Action**: Optune uses Tumor Treating Fields (TTF), which are low-intensity alternating electric fields delivered at specific frequencies to disrupt cell division, specifically targeting the mitotic spindle formation. This interference reduces tumor growth and can cause cancer cell death.\n\n2. **Usage**: Optune is indicated for the treatment of adult patients with newly diagnosed glioblastoma (GBM) as an adjunctive therapy following maximal debulking surgery, and chemoradiation therapy. It is also indicated for the treatment of recurrent GBM as a monotherapy after surgical and radiation options have been exhausted.\n\n3. **Application and Adherence**: Optune involves the continuous application of four transducer arrays placed on the shaved scalp. The device is portable and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_CFmScQXnv9Fgs8dGAM1IALNI", "custom_id": "681_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3a9ad4d744264e29e9ac32681a739422", "body": {"id": "chatcmpl-9St93aPAXnPWHB5c3mrxAICqHkY6u", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel, also known as liso-cel) is an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It was approved by the U.S. Food and Drug Administration (FDA) for certain types of lymphoma. Here is an essential summary of what you, as a physician, should know about Breyanzi:\n\n1. **Indications**: Breyanzi is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n2. **Mechanism of Action**: Breyanzi consists of T cells that are genetically modified to include a chimeric antigen receptor (CAR) that targets CD19, a protein"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Nf4Yut9neSbsCEYymaPkcf7V", "custom_id": "682_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a3c0ba86757ba012c218f32ef5ce91b4", "body": {"id": "chatcmpl-9St939E48w9jlz8A1F8VoTwpRd2Fb", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abecma (idecabtagene vicleucel), abbreviated as ide-cel, is a type of therapy known as a chimeric antigen receptor (CAR) T-cell therapy. It is specifically designed for the treatment of adult patients with relapsed or refractory multiple myeloma. This follows after patients have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n**Key Points about Abecma:**\n\n1. **Mechanism of Action**: Abecma involves reprogramming the patient's own T-cells to include a new gene that codes for a protein directing the T-cells to target and kill myeloma cells. The protein allows T-cells to bind to a specific protein on the myeloma cells, known as B-cell maturation antigen (BCMA), which plays a role in the proliferation of malignant myeloma cells.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_UxFwI4ZtQP6F6n1F6TxbaoNy", "custom_id": "683_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6481194c8f8c0fb545d7df52e7c96fed", "body": {"id": "chatcmpl-9St93CwW9GaijSrMRjwFjF4B4RtTq", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (generic name: avapritinib) is a prescription medication used in the treatment of certain types of cancers. It is particularly indicated for adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who have a specific mutation in the PDGFRA gene (exon 18 mutation, including PDGFRA D842V mutations). Here are some key points you should know about Ayvakit:\n\n1. **Mechanism of Action**: Avapritinib is a kinase inhibitor that specifically targets the KIT and PDGFRA mutant kinases. It is highly selective for these mutations, particularly the PDGFRA exon 18 mutations, which are associated with a subset of GISTs.\n\n2. **Indications**: Its primary indication is for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, which includes the most common D842V mutation. It's important to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_wMnuuVX08d7iukduHyoRxGuv", "custom_id": "684_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "2d586a213de9ee65b70d49f90d1d8022", "body": {"id": "chatcmpl-9St93Yql5EVDwCoQlLdFSYtAbYGmb", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Turalio (pexidartinib) is a medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. TGCT, also known as pigmented villonodular synovitis (PVNS), is a rare, typically non-malignant tumor that affects the joints and can lead to significant joint damage and discomfort.\n\nHere are several key points about Turalio:\n\n1. **Mechanism of Action**: Turalio is a kinase inhibitor that works by inhibiting CSF1R (colony stimulating factor-1 receptor) and other kinases, which are believed to play roles in the proliferation of malignant cells in certain cancers and in the development of TGCT.\n\n2. **Use and Indication**: It is approved for the treatment of adult patients with symptomatic TGCT"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_HwK2K6ue8FWb61VT0z3oUQKP", "custom_id": "685_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fe07deaa9b4de6bfe67c7fe80c60ecff", "body": {"id": "chatcmpl-9St93RFWujtS3E2yKUEDVxWSly0Rf", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, Gavreto (pralsetinib) is a targeted therapy used in oncology, specifically in the treatment of certain types of cancer marked by specific genetic alterations. Here\u2019s a concise summary of what you should know about Gavreto:\n\n1. **Indications:**\n   - **Non-small cell lung cancer (NSCLC):** Gavreto is approved for the treatment of adult patients with metastatic NSCLC associated with RET (rearranged during transfection) gene fusions, a subgroup of NSCLC. This approval is irrespective of the line of therapy.\n   - **Thyroid cancer:**\n     - It is also approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n     - Patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_pNm73nsSa8LPGlbva7qsAvrT", "custom_id": "686_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b8384cf74bbef430074ebb20c7e705f1", "body": {"id": "chatcmpl-9St93vk0ZXsqH6qSno9vrEaTAUBfI", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician considering Zepzelca (lurbinectedin) for treatment, here are key points you should be aware of:\n\n**1. Indications and Usage:**\nZepzelca is approved by the FDA for the treatment of adults with metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy. This indication is particularly relevant given the aggressive nature of SCLC and the limited options available after first-line therapy.\n\n**2. Mechanism of Action:**\nLurbinectedin works by inhibiting transcription and inducing DNA double-strand breaks, ultimately leading to apoptosis (cell death) in cancer cells. This mechanism is somewhat unique compared to traditional chemotherapy agents.\n\n**3. Efficacy:**\nThe approval of Zepzelca was based primarily on the results from a phase II clinical trial that showed promising response rates in patients with relapsed SCLC. It is important to review the latest clinical data and real-world"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_ILx58IVY6Ch9eEecasvT40Dw", "custom_id": "687_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "747468f9607f3cde4bb5f50ff85068a2", "body": {"id": "chatcmpl-9St93F4JJK8XtEhm5OcdddrBGVKTM", "object": "chat.completion", "created": 1716672189, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flagyl, whose generic name is metronidazole, is an antibiotic and antiprotozoal medication commonly used to treat various infections, including those caused by bacteria and certain parasites. Here are some key points that you, as a physician, should be aware of regarding Flagyl:\n\n### Indications\n1. **Anaerobic Bacterial Infections**: Effective against infections caused by anaerobic bacteria, including intra-abdominal infections, skin infections, gynecologic infections, and others.\n2. **Protozoal Infections**: Used to treat protozoal infections such as giardiasis, trichomoniasis, and amebiasis.\n3. **Pseudomembranous Colitis**: Used to treat pseudomembranous colitis caused by Clostridium difficile, although vancomycin or fidaxomicin are now more commonly recommended.\n4. **Other Uses**: It can be used in a combination regimen for the treatment of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_FoLNfdDHF5CV05iYbSfRg0pS", "custom_id": "688_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b3a62fe4dcf6cb6e891a8dc41bc64a4c", "body": {"id": "chatcmpl-9St948wHemuKKJ30QyDbLjXnLWHV8", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danyelza (naxitamab-gqgk) is a targeted cancer therapy approved by the U.S. Food and Drug Administration (FDA) for use in certain pediatric and adult patients. Here are some critical aspects of Danyelza that you, as a physician, might need to know:\n\n1. **Indication**: Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n2. **Mechanism of Action**: Danyelza is a monoclonal antibody that specifically binds to the glycolipid GD2, which is expressed on neuroblastoma cells and other types of cancer cells, but with limited expression on normal cells."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PryDSSYXqabbwrBxUrshMYkF", "custom_id": "689_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b478af5d4e55fd7a545107e73e34ea4a", "body": {"id": "chatcmpl-9St94GvfU36bVZmQY5H4uBX8nJKjv", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panmycin is a brand name for tetracycline, which is an antibiotic used to treat a variety of bacterial infections. As a physician, here are some key points you should know about Panmycin (tetracycline):\n\n1. **Spectrum of Activity**: Tetracycline is a broad-spectrum antibiotic effective against a wide range of Gram-positive and Gram-negative bacteria. It is commonly used to treat respiratory infections, skin infections, urinary tract infections, and is effective against Chlamydia, Mycoplasma, and some protozoa.\n\n2. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria, thereby preventing the growth of bacteria. It binds to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site, which inhibits the addition of amino acids to the growing peptide chain.\n\n3. **Administration**: Panmycin can be taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_QUw4SydA7W41Cczg8g7qgoYl", "custom_id": "690_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c19d2d9ff4683a641fdbb8f275528f4d", "body": {"id": "chatcmpl-9St942XqrYeV1ztRa38cvnyplXsEQ", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab (tripotassium dicitrato bismuthate) is a medication used primarily for the treatment of peptic ulcers and to manage associated symptoms. Here\u2019s some key information that you, as a physician, might find helpful:\n\n### Mechanism of Action\nDe-Noltab works primarily through its active ingredient, bismuth. Bismuth has several actions:\n- **Antibacterial Effects:** It can inhibit the growth of Helicobacter pylori, bacteria strongly associated with the development of gastric and duodenal ulcers.\n- **Protective Barrier Formation:** Bismuth forms a protective coating over the ulcer site, shielding it from stomach acid and allowing it to heal.\n\n### Indications\nPrimarily used for:\n- **Peptic Ulcer Disease (PUD):** Effective in both treatment and prevention of relapse in peptic ulcer disease.\n- **Dyspepsia:** Sometimes used to alleviate symptoms of indigestion that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_BIz5XoXy6MV15zFa0rFxshZ3", "custom_id": "691_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c4eac432f69dc663a0e462260418ff4b", "body": {"id": "chatcmpl-9St94doloiCaRu3V1RV4dVSf5dMyw", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of tumors associated with von Hippel-Lindau (VHL) disease. VHL disease is a hereditary condition that causes tumors and cysts to grow in multiple organs.\n\nKey points about Welireg include:\n\n1. **Indications**: Welireg is specifically indicated for adult patients with VHL disease who require therapy for certain types of tumors that are not in need of immediate surgery. These tumors include renal cell carcinoma (with no requirement for systematic therapy), central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors.\n\n2. **Mechanism of Action**: Welireg works as a hypoxia-inducible factor (HIF) inhibitor. It specifically inhibits HIF-2\u03b1, which is a transcription factor that plays a critical role in cellular responses to oxygen deficiency. By blocking H"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_hl0wASWY0B2dyLmtqLjpvzKJ", "custom_id": "692_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "535ee8f62337d6b498296b1adc7b13eb", "body": {"id": "chatcmpl-9St94hl03lENlJm9doZ6ei00IZ9at", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rybrevant (amivantamab-vmjw) is a monoclonal antibody used for the treatment of adults with non-small cell lung cancer (NSCLC) with specific genetic alterations. Here are some important details to consider:\n\n1. **Indications**: Rybrevant was approved by the FDA for the treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, who have progressed on or after platinum-based chemotherapy. This treatment fills a significant need as cancers with EGFR exon 20 insertion mutations often have limited treatment options and poor prognosis.\n\n2. **Mechanism of Action**: Rybrevant is a bispecific antibody that targets both EGFR and MET receptor tyrosine kinases. By binding to these receptors, Rybrevant blocks the growth signals in cancer cells, thereby inhibiting tumor growth.\n\n3. **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_2TmJHCwVuKv1WWW53EzYWJTo", "custom_id": "693_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1face22e282a546b310af117a61b050c", "body": {"id": "chatcmpl-9St94yiABbc2HYVVyj80q173hAxz3", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg is the brand name for azacitidine in tablet form, an oral hypomethylating agent. It was approved by the FDA for certain uses, including the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy.\n\nHere are several key aspects to consider when treating patients with Onureg:\n\n1. **Indications**: Onureg is indicated specifically for patients with AML who are in remission but cannot undergo further intensive curative therapy, such as a stem cell transplant. This treatment helps in maintaining remission and potentially prolonging survival.\n\n2. **Dosage and Administration**: The typical starting dose of Onureg is 300 mg taken orally once daily with food on Days 1 to 14 of each 28-day cycle. It\u2019s important to instruct"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yzvlS05offKy6jydAmdrNh4Z", "custom_id": "694_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "618382d6d0cec26fa006f7a3233fad40", "body": {"id": "chatcmpl-9St94jc07ShB98B0SFROua4THGkhH", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys, a brand name for the medication colchicine, is primarily used to prevent and treat gout attacks and familial Mediterranean fever (FMF). Here are several important clinical aspects that physicians should be aware of when prescribing Colcrys:\n\n**Mechanism of Action:**\nColchicine works by reducing inflammation through the inhibition of microtubule formation, which subsequently interferes with neutrophil motility and activity, reducing the inflammatory response to deposited urate crystals in joint tissues.\n\n**Indications:**\n1. **Gout Prophylaxis and Treatment:** Colcrys is used to prevent gout flares and to treat acute gouty arthritis.\n2. **Familial Mediterranean Fever (FMF):** It is prescribed to treat and prevent FMF, which is an inherited inflammatory disorder.\n\n**Dosage and Administration:**\n- For acute gout flares, the usual dosage is 1.2 mg at the first sign of the flare followed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hgpxPP92bGJcS5BBWQB1osYv", "custom_id": "695_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e90e21f6ad6b6945eb618d8f0bc8c4ee", "body": {"id": "chatcmpl-9St94GC09KPy1U8pc2j4YtvfgUh5E", "object": "chat.completion", "created": 1716672190, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jemperli (dostarlimab) is a medication that plays an important role in the treatment of certain types of cancer. It is a programmed death receptor-1 (PD-1)\u2013blocking antibody, used primarily to treat endometrial cancer and other solid tumors with specific genetic characteristics. Here are key aspects you should know about Jemperli:\n\n1. **Indications:**\n   - Jemperli is approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen.\n   - It is also indicated for patients with dMMR recurrent or advanced solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options.\n\n2. **Mechanism of Action:**\n   - Dostarlimab works by blocking the PD-1 receptor, a protein found on T cells which, when activated, inhibits T-cell activation and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_4Kx8Qwk1YPinUNCbNXpNZkmF", "custom_id": "696_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5134b62c1a9c99cece69e418352afdfd", "body": {"id": "chatcmpl-9St951EHIPXAbw0IxjZrw0rrVfWJb", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Hansizhuang\" does not appear to be a medical term or condition recognized in widely-known medical literature or contexts. It's possible that it could be a term from a specific dialect, a rare or lesser-known condition not widely documented, or potentially a misspelling or incorrect transcription of another term.\n\nIf you could provide more context or details about where you encountered this term or in what specific aspect you are interested, I might be able to help more accurately or guide you to relevant information. Alternatively, checking with professional peers, reviewing medical literature databases, or consulting sources from the specific regional or cultural context where the term was used might shed light on what \"Hansizhuang\" refers to."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 142, "total_tokens": 184}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Geyk00AoNfZCSWUqghunjOek", "custom_id": "697_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "9871c9cb0b9ce0ae6687d451ae05323a", "body": {"id": "chatcmpl-9St95wkzOdyOsTgYwT20ORHgw76Qn", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or substance called \"Cejemly\" in mainstream medical practice. It is possible that the name might be misspelled, a brand name not widely recognized, or a term specific to certain contexts or regions that are not covered in available medical literature up to 2023.\n\nIf \"Cejemly\" refers to a drug, device, or a treatment method used in specific medical circles or emerging therapies, I recommend consulting the latest medical databases, pharmaceutical registries, or regulatory agency resources such as the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency). These resources often provide up-to-date information on approved medications, their indications, contraindications, and any associated research. Alternatively, checking with pharmaceutical companies directly can also be helpful in obtaining the most current information.\n\nIf you could provide more context or details, such as the condition it's intended to treat or any additional spelling variations,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hfCBHb8V43gun1Fh7U8uxoY1", "custom_id": "698_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "c39f94093731ab273960b7f7aaf48a98", "body": {"id": "chatcmpl-9St95tjQEn46Z40rvGAQt1ZygtvQI", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Fyarro\" does not refer to any specific medical term, drug, or treatment recognized in standard practice. It's possible you might be referring to something new or not widely recognized under this name. Could it be a brand name, a term from a specific medical facility, or perhaps a misspelling? It might help to provide more context or check the spelling so I can assist you more accurately. If it's a new drug or treatment, consulting the latest medical literature or drug databases like those provided by the FDA or EMA might offer more up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 122, "total_tokens": 163}, "system_fingerprint": "fp_0737e0dfd9"}}, "error": null}
{"id": "batch_req_wNwYhtfplXttva79FtVvF0U5", "custom_id": "699_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "34a49edadd84886a7b72fafac1757f34", "body": {"id": "chatcmpl-9St95hpBz4PeTTL3EmC9ds6tQuINV", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no recognized medication or substance called \"Antrypol\" in standard medical databases or resources like the World Health Organization, the U.S. Food and Drug Administration, or the European Medicines Agency. It is possible that the name could be misspelled, it could be a brand name that is not widely recognized, or it could be a substance that is not approved or recognized by major regulatory bodies.\n\nIf you are referring to a specific medication that you believe may exist under this name, please check for the correct spelling or provide additional details. Alternatively, the substance might be known by another name or could be a novel or experimental compound. If it\u2019s critical for patient care or prescription purposes, verifying the identity and approval status of the medication is essential to ensure safety and compliance with medical standards and regulations.\n\nIf you have any specific information or context about the substance or condition it's supposed to treat, please provide more details, and I will do my best to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_scqGCqvrLgypwoejNcg388B4", "custom_id": "700_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e0238ae757bf536e711f55a19c3c4e44", "body": {"id": "chatcmpl-9St956eJ9TztnSSDVK3kZ4EdsLvex", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of now, there is no widely recognized medication or substance called \"Krazati.\" It is possible that the name might be a new or less known drug, a substance not approved or recognized by major medical authorities, or could even be a typographical error. \n\nAs a physician, when encountering unfamiliar medical terms, drugs, or treatments, it is crucial to:\n\n1. **Consult Reliable Sources:** Check trustworthy medical and pharmacological resources or databases. Websites like the FDA, CDC, WHO, or equivalent governing bodies in your country are good starting points.\n\n2. **Peer-reviewed Journals:** For the most recent studies and reviews about new drugs or treatments, using databases like PubMed can be invaluable.\n\n3. **Networking with Colleagues:** Sometimes, more seasoned colleagues or specialists might have early information about new treatments and medications through conferences, seminars, or internal communications within the medical community.\n\n4. **Pharmaceutical Advisories:** If the substance is a newly approved drug, there should be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_q54dF8VXAp4lXhAeBnZrVSiz", "custom_id": "701_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b309576c0ec2138e4e1163f5c1fb97e7", "body": {"id": "chatcmpl-9St95OROAI8JwLi1ZCTg9QaFo7D6P", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (tebentafusp-tebn) is an innovative treatment mainly used for patients with uveal melanoma, a rare type of melanoma that occurs in the eye. Here are some essential aspects about Kimmtrak that you, as a physician, should know:\n\n### 1. **Mechanism of Action**\n   Kimmtrak is a bispecific fusion protein designed to direct T-cells to fight cancer cells. One part of Kimmtrak binds specifically to gp100, a melanoma-associated antigen present on melanocytes, while the other part binds to CD3 on T-cells, facilitating the T-cell's ability to recognize and destroy the cancer cells.\n\n### 2. **Indication**\n   It is approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. This specificity for HLA-A*02:01 is critical as Kimmtrak is only effective in patients who express this particular"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_oOGYZ5rCqPx9dfunmtVIDVrA", "custom_id": "702_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "731de1c0ac272e70af230ad2d845510f", "body": {"id": "chatcmpl-9St95pTJYYNBVF8HqEnFvyZM3nS1w", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (fedratinib) is a prescription medication used to treat adults with certain types of myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Here are the key aspects you should know about Inrebic as a physician:\n\n1. **Mechanism of Action**: Fedratinib is a kinase inhibitor that primarily targets Janus Associated Kinases (JAKs) with activity against JAK2 and FLT3. Its mechanism involves inhibiting these kinases which are involved in the signaling pathways that affect the growth and development of certain blood cells.\n\n2. **Indications**: Inrebic is approved for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n3. **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_SoiHC9YnR1gacI3YTwKOQKv4", "custom_id": "703_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "45d129af7f701c95e8d3136f84be2a7c", "body": {"id": "chatcmpl-9St95YinfvvLZxFZ4lkdFaucFqAmQ", "object": "chat.completion", "created": 1716672191, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta is a prescription medication used for treating certain types of breast cancer. It combines trastuzumab, a monoclonal antibody targeting the HER2 receptor, and recombinant human hyaluronidase. Here are some key points that physicians should know:\n\n1. **Indications**: Herceptin Hylecta is specifically used for the treatment of HER2-positive breast cancer. It is indicated for:\n   - Adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel.\n   - Adjuvant treatment of HER2-overexpressing breast cancer in patients who have received prior therapy including an anthracycline and a taxane in either the adjuvant or metastatic setting.\n\n2. **Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_aQCaRpeNPOgcO72bITdTqj6j", "custom_id": "704_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7d68bb21c94cc300093f1d5cfa4346e3", "body": {"id": "chatcmpl-9St96ZpIDglTeveNK1P9SPW12r1Vs", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brukinsa (zanubrutinib) is a medication approved for the treatment of certain types of blood cancers, specifically, it is used in patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of Waldenstr\u00f6m's macroglobulinemia. Here are some key points about Brukinsa:\n\n1. **Mechanism of Action**: Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking the activity of BTK, a key protein that promotes the survival and proliferation of malignant B-cells. By inhibiting BTK, zanubrutinib can help to stop the growth of cancer cells.\n\n2. **Indications**: \n   - **Mantle Cell Lymphoma**: Indicated for the treatment of adult patients who have received at least one prior therapy.\n   - **Waldenstr\u00f6m's Macroglobulin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_yIDCT0nWI9VJ876q4VQ1Xm2E", "custom_id": "705_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a38293b739388bded56ae0c73757befb", "body": {"id": "chatcmpl-9St96kvnctzzwyAnPe6HzF1L0ukQN", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there isn't any widely recognized medical information or pharmaceutical reference concerning a medication or condition specifically named \"Ivesa\". It's possible that the name might be misspelled, abbreviated, or it could be a brand name not widely known yet.\n\nIf \"Ivesa\" refers to a specific drug, treatment, medical condition, or technology that is new or under development, I recommend consulting the latest medical literature, reputable medical websites, or pharmaceutical databases for the most current information. Additionally, you might want to check with pharmaceutical representatives or colleagues who specialize in the relevant field. If it is a new term or product in your field, staying updated through continuing medical education (CME) courses and professional conferences might also be beneficial.\n\nIf you have more context or another name associated with \"Ivesa,\" I can try to provide more targeted information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 176, "total_tokens": 217}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_h4xJJNM8lNKC7Q0isRDFJQDY", "custom_id": "706_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7a585964f2a4cc25240417a63f042595", "body": {"id": "chatcmpl-9St96NEy3d8rOWfiGBknTCdf4mxiG", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel, also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in adults. Specifically, it is indicated for patients who have already tried at least four therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and have not found successful treatment results with these therapies.\n\nHere are several key aspects about Carvykti that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**: Carvykti involves reprogramming the patient\u2019s T-cells to include a chimeric antigen receptor (CAR) that targets BCMA (B-cell maturation antigen), a protein prevalently expressed on myeloma cells. This re-engineering allows the T-cells to recognize"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_74SMLHDt1FwewBK4sW38Q1Ap", "custom_id": "707_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "b8a7d2dd1c310bd6df19883a45180159", "body": {"id": "chatcmpl-9St96ZclEfYTW8S5fMiLxOeD9aoN3", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Scemblix is the brand name for asciminib, a prescription medication approved for treating specific types of chronic myeloid leukemia (CML). Here are some crucial points to consider:\n\n### 1. **Indications**\n   Scemblix is specifically approved for the treatment of adult patients with Philadelphia chromosome-positive CML (Ph+ CML) in two scenarios:\n   - In chronic phase (CML-CP) who have received two or more prior therapies with tyrosine kinase inhibitors (TKIs).\n   - In chronic phase (CML-CP) with the T315I mutation, which is known for its resistance to several other TKIs.\n\n### 2. **Mechanism of Action**\n   Asciminib operates through a mechanism distinct from that of other TKIs. It is a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. Unlike traditional TKIs that target the ATP-binding site of BCR-ABL, Scemb"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_FGDR7dDc7wyRsKslOto2ctnQ", "custom_id": "708_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "24f2f8542edd613710f42c8a20e717fb", "body": {"id": "chatcmpl-9St96Ild3fPouVLVzDKQ3rHqFtlOj", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zynlonta (loncastuximab tesirine-lpyl) is a prescription medication used in the treatment of certain types of cancer. It is specifically indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Here are some key points about Zynlonta that you might find useful as a physician:\n\n### Mechanism of Action\nZynlonta is an antibody-drug conjugate (ADC). The drug consists of a humanized monoclonal antibody that targets CD19, a protein frequently expressed on the surface of B-cell lymphomas. The antibody is linked to a cytotoxic agent, pyrrolobenzodiazepine (PBD) dimer, which is released upon binding to the CD19-expressing cell, causing cell death.\n\n### Indications\nZynlonta is approved for the treatment of adult patients with:\n- Relapsed or refr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_eLr0yImaLjwcKyOlC9SPWSdi", "custom_id": "709_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6c2ea2a9cf9bb384c4fcb1abc4a22690", "body": {"id": "chatcmpl-9St96LckshRd2YI2r6zbFcAvUKtVB", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazverik (tazemetostat) is an oral, small molecule inhibitor of the EZH2 (enhancer of zeste homolog 2) enzyme, approved by the U.S. Food and Drug Administration (FDA) for specific oncological indications. EZH2 is a histone methyltransferase that can be dysregulated in certain cancer types, influencing tumor growth and behavior. Here are some key aspects about Tazverik for clinical use:\n\n### Indications\n1. **Epithelioid Sarcoma:**\n   - Tazverik is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This was the first FDA approval granted to Tazverik in January 2020.\n   \n2. **Follicular Lymphoma:**\n   - In June 2020, Tazverik received accelerated approval for adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_0uIuAvHVIPAOF0EQnh1bOZgT", "custom_id": "710_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7274df8a87399ae8ea0115bc376bfc18", "body": {"id": "chatcmpl-9St96ZHtcEAIjWRmryeD8o4JZr26G", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag (nivolumab and relatlimab-rmbw) is a combination immunotherapy drug used in the treatment of cancer, specifically melanoma. It combines two checkpoint inhibitors that target different pathways involved in the immune response against cancer cells. Here are some key aspects you should know:\n\n1. **Components**:\n   - **Nivolumab**: This is a PD-1 blocking antibody. It works by inhibiting the PD-1 receptor, a protein on T cells, which are a type of immune cell. Cancer cells can exploit this pathway to avoid being attacked by the immune system. By blocking PD-1, nivolumab allows the immune system to better recognize and attack cancer cells.\n   - **Relatlimab-rmbw**: This targets LAG-3, another immune checkpoint receptor that inhibits T-cell function. By blocking LAG-3, relatlimab can help to restore or enhance the activity of T cells against cancer cells.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_rhIkmaf5hAmHTcqoUCYZDHtR", "custom_id": "711_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "75d20dd684440c60b6cb81be6ce41d28", "body": {"id": "chatcmpl-9St96ZrDWrOqB1r1h9q4vSXp4tvkt", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in my training data, \"Berofor\" does not appear to be a recognized drug or treatment in standard medical sources. It's possible that the name might be misspelled, referred to by a different name, or it could be a brand new development not widely recognized yet.\n\nIf you meant a different drug or need information on a similarly named medication, please provide more details or check the spelling. It's also recommended to consult the most current medical databases or drug information resources for accurate and up-to-date information. If \"Berofor\" refers to a new or less common medication, you might also consider contacting pharmaceutical manufacturers or accessing specialized medical databases that your medical licensing provides access to."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 144, "total_tokens": 185}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_edGNDkxFGZVLQ8yDEWegWGUq", "custom_id": "712_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "aa4052564b03d527547c3070e52fe622", "body": {"id": "chatcmpl-9St96milIq9O9NTdM83YQkFkcyLom", "object": "chat.completion", "created": 1716672192, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon is a medication that was used primarily for the treatment of viral infections, specifically hepatitis B, and certain types of cancer such as hairy cell leukemia. The active substance in Wellferan is interferon gamma, which is a type of interferon used to modulate the immune system. Interferon gamma is a cytokine that plays a crucial role in innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control.\n\nHowever, as of my last update in March 2023, Wellferon is not commonly used in clinical practice anymore and might not even be commercially available. The therapeutic approaches to hepatitis B and certain cancers have evolved, with new antiviral therapies and targeted treatments providing more efficacy and fewer side effects. \n\nFor hepatitis B, treatments typically involve antiviral medications such as tenofovir and entecavir, rather than interferon-based therapies. Cancer treatments have also advanced significantly with the emergence of targeted therapy, immunotherapy, and precision medicine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_u86YeSJMhxPEazDsm3dHktNv", "custom_id": "713_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7c184cf9f95a20b04def4be3016b0162", "body": {"id": "chatcmpl-9St97hRFosHfn4utNFnMbxKf95kmd", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a monoclonal antibody designed for the treatment of certain types of cancer. Here are some key points you should know about Margenza:\n\n1. **Approval and Indications**: Margenza was approved by the U.S. Food and Drug Administration (FDA) in December 2020 for use in combination with chemotherapy. It is indicated for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margenza is a monoclonal antibody that targets the HER2 receptor, a protein expressed on the surface of some cancer cells. It is engineered to have an increased ability to recruit immune cells to kill the tumor cells by enhancing immune-mediated mechanisms, which differentiates it from other HER2-targeting agents like trastuzumab.\n\n3. **Administration**: This"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_YUHaURo6TWMmDFI6iAHHo7TE", "custom_id": "714_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "8bc993e69b25aa07975c7fd81baa5c20", "body": {"id": "chatcmpl-9St97LU4TBg5BvSJwnQVPLBL3jOv7", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumakras\u2122 (sotorasib) is a medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of adults with non-small cell lung cancer (NSCLC) that is locally advanced or metastatic and harbors specific mutations in the KRAS gene (KRAS G12C mutation). This approval, as of my last update in 2023, marks a significant advancement since it targets a mutation that was previously considered \"undruggable.\"\n\n### Key Points About Lumakras:\n1. **Indication**:\n   - Lumakras is indicated for use in patients with NSCLC who have a KRAS G12C mutation and whose disease has progressed on or after at least one prior systemic therapy. This mutation must be confirmed by an FDA-approved test before initiating treatment.\n\n2. **Mechanism of Action**:\n   - Sotorasib, the active compound in Lumakras, works by specifically targeting and inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_hl6VV3cezF9LMxPBfEzakGWL", "custom_id": "715_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d781b701eb5d6545eede04fa8a6899c1", "body": {"id": "chatcmpl-9St978ikM1PpE0xOrOGgmqdr2j0s4", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is a medication used in the treatment of certain cancers, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was initially approved by the U.S. Food and Drug Administration (FDA) in February 2021. Ukoniq is an oral small molecule inhibitor that targets both the PI3K-delta and casein kinase-1 epsilon.\n\nHere are some key points physicians should consider about Ukoniq:\n\n1. **Indications**: Ukoniq is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen, and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.\n\n2. **Mechanism of Action**: Ukoniq works by inhibiting phosphoinositide 3-kin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_W0VxnHCcJqRsnzWJuv5H9UG1", "custom_id": "716_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "bb052838e2edba6027be7a996e40f43b", "body": {"id": "chatcmpl-9St9705PHzkaPS4HluNsvKUUYvmQR", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (generic name: sintilimab) is an immunotherapy drug used primarily in the treatment of certain types of cancer. It is a type of medication known as a programmed death receptor-1 (PD-1) inhibitor. This class of drugs works by blocking the PD-1 pathway, which cancer cells often exploit to avoid being attacked by the immune system. By inhibiting PD-1 interactions, sintilimab can enhance the body\u2019s immune response against cancer cells.\n\n### Indications\nAs of the latest updates, Tyvyt is approved in several regions, including China, for indications such as:\n\n- Non-small cell lung cancer (NSCLC)\n- Hodgkin lymphoma\n- Other potential approvals for different types of cancer might be ongoing or vary by region.\n\n### Mechanism of Action\nSintilimab binds to the PD-1 receptors on T-cells, a type of white blood cell that plays a critical role in the immune response."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_dHPFzkOpbBcpC7EaXz87GF3q", "custom_id": "717_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e3c161a19889ae53b44c5c84614e2881", "body": {"id": "chatcmpl-9St97JMJL2isWfC1PGvA5Yz0JwJyX", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jaypirca (pirtobrutinib) is a medication used to treat certain types of cancer, specifically indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least one line of therapy. It was approved by the FDA in January 2023. Pirtobrutinib is classified as a Bruton\u2019s tyrosine kinase (BTK) inhibitor.\n\nHere are some key points about Jaypirca:\n\n1. **Mechanism of Action**: Pirtobrutinib inhibits the enzyme Bruton\u2019s tyrosine kinase, which plays a critical role in the growth and proliferation of B-cells. By blocking this pathway, pirtobrutinib helps in controlling the spread and progression of B-cell malignancies.\n\n2. **Indication**: It is specifically approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have tried at least one previous therapy. This specificity in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_TCYWp8UoD92I73QerXP7GqrX", "custom_id": "718_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "32cb7e82319ce2db39230b3dcac684b5", "body": {"id": "chatcmpl-9St975t4twPtr5KKajttwip4hLJ5N", "object": "chat.completion", "created": 1716672193, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Tuoyi\" does not refer to a recognizable medical term, therapy, or treatment commonly known in the healthcare sector. It's possible that \"Tuoyi\" could be a typo, a brand name, a term from a non-English language, or something new or less known in a specific medical specialization that hasn't become widely recognized yet.\n\nFor accurate and up-to-date information, particularly for anything involving medical practice, it's crucial to consult current medical literature or trusted medical databases. Additionally, discussing with colleagues or checking with pharmaceutical and medical regulatory bodies might provide more insights. If you provide more context or details, I might be able to assist you better."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 140, "total_tokens": 181}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Zimowj0dqplI4H8tulvJdfpx", "custom_id": "719_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "fb063a5f7ae960b8289b46c63e41d604", "body": {"id": "chatcmpl-9St98cWxzHf6okDEzSuWgQstGxzmV", "object": "chat.completion", "created": 1716672194, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecvayli (teclistamab-cqyv) is a medication approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli was approved by the U.S. Food and Drug Administration (FDA) in October 2022.\n\nTecvayli is a bispecific T-cell engager (BiTE) antibody. It targets both CD3 on T-cells and BCMA (B-cell maturation antigen) on myeloma cells. By binding to these two different cell types, Tecvayli promotes the engagement and activation of T-cells, leading to the killing of BCMA-expressing myeloma cells.\n\n### Key Points for Physicians:\n1. **Indications**: Tecvayli is indicated for patients with heavily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_zJlMidyaxCZeEeZSkQBQTOvO", "custom_id": "720_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "4bb3cfe278498f2c469d3505bd965913", "body": {"id": "chatcmpl-9St982TL6iYgPXA2Digocbt8w6eU6", "object": "chat.completion", "created": 1716672194, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exkivity (mobocertinib) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. This approval, which came in September 2021, addresses a specific patient group where there are limited treatment options.\n\nHere are key points you should know about Exkivity:\n\n1. **Indication and Efficacy**: Exkivity is specifically indicated for NSCLC patients who have tumors with EGFR exon 20 insertion mutations. The efficacy of mobocertinib was demonstrated in a multicenter, open-label, multi-cohort clinical trial. The major efficacy outcomes were overall response rate (ORR) and duration of response (DOR).\n\n2. **Mechanism of Action**: Mobocertinib is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_qfSLXS4SOoOMIwk4vJWqesCH", "custom_id": "721_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "6fda9b2a85c1f078f4b87b0b36eb50b3", "body": {"id": "chatcmpl-9St98wTnzHBU15NNZe5kcoBJ5V99Z", "object": "chat.completion", "created": 1716672194, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivdak (tisotumab vedotin-tftv) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or metastatic cervical cancer who have previously undergone chemotherapy. This drug was approved in September 2021.\n\n**Mechanism of Action:**  \nTivdak is an antibody-drug conjugate (ADC) that consists of a human tissue factor (TF)-specific monoclonal antibody conjugated to a microtubule-disrupting agent, monomethyl auristatin E (MMAE). The drug binds to tissue factor, which is expressed on the surface of tumor cells, and delivers the MMAE directly into the cancer cells. Upon binding, the conjugate is internalized, and MMAE is released, leading to cell cycle arrest and apoptosis.\n\n**Indications:**  \nTivdak is specifically indicated for the treatment of recurrent or metastatic cervical cancer. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_b1DdRzF2AhkdVj65SxZ9eLKK", "custom_id": "722_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "7f155981c601fd008b93444903652d69", "body": {"id": "chatcmpl-9St98DJC5xwkcncXzR73mQztif2br", "object": "chat.completion", "created": 1716672194, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a synthetic long-acting analog of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones. Here are some key points you, as a physician, might need to know about Somatuline Depot:\n\n1. **Indications**: Somatuline Depot is approved for use in the treatment of:\n   - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are unresectable, locally advanced, or metastatic.\n   - Acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom these therapies are not suitable. It helps in reducing growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels.\n   - Severe symptoms of carcinoid syndrome to reduce the frequency of short-acting somatostatin analog rescue therapy.\n\n2. **Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_tcbCl6itVkzl63rsYNlJ53MS", "custom_id": "723_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "38cb26dcf878851a007950ee1a8f7f80", "body": {"id": "chatcmpl-9St99iKZ3XAtxLM2RtT3xIxFEbDUB", "object": "chat.completion", "created": 1716672195, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no specific medical or pharmaceutical reference to something called \"Jeselhy.\" It's possible that it could be a typo, a brand name, a substance, or a product not widely recognized or new to the market.\n\nIf it's related to a specific medication, treatment, or concept that is new or less known in the medical community, you might consider checking the latest medical literature, reputable medical websites, or pharmaceutical databases. It could also be helpful to consult with pharmacists or other healthcare professionals who might have information on new or emerging treatments or products.\n\nIf you provide more context or details, I would be more than happy to try to assist you further!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 140, "total_tokens": 181}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DJlZjNGa1AyGhmW1k2EElr9N", "custom_id": "724_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "a4525921b9669c827eb74a46ab865b20", "body": {"id": "chatcmpl-9St99HhityuahXU2bfjUgySR86NTs", "object": "chat.completion", "created": 1716672195, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update in early 2023, \"Mostarina\" does not appear to refer to any known medication, treatment, or condition in the medical field. It's possible that there may have been a misunderstanding or a misspelling. If you are referring to a specific drug, treatment, or medical term, could you please provide more details or clarify? This will help in giving a precise and accurate response. If \"Mostarina\" is a new development or specific term in a particular medical specialty or region, it could be beneficial to consult the latest medical literature or a trusted medical database."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 123, "total_tokens": 164}, "system_fingerprint": "fp_53e33d3c75"}}, "error": null}
{"id": "batch_req_NFuFRqyXlpwBN7xbBP1Ob7GJ", "custom_id": "725_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "51868f40715455dfa300f44e468d1d10", "body": {"id": "chatcmpl-9St993ANxCDXKvi46D4KNQgAysMom", "object": "chat.completion", "created": 1716672195, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no medication or substance known as \"Vercite\" in mainstream medical databases or sources. It's possible that the name might be misspelled, or it could be a new or less common substance that isn't widely recognized yet. If \"Vercite\" is a brand name, experimental drug, or a substance from outside conventional pharmaceuticals (like a supplement or herbal medication), additional specifics would be needed to provide accurate information.\n\nIf you're looking for information on a drug or treatment that is possibly wrongly spelled or newly introduced, I recommend checking the latest medical literature or databases like PubMed, contacting the manufacturer directly, or consulting specialized databases that include experimental drugs and clinical trial information. If you have more details or an alternate spelling, I\u2019m here to help look up the information you need."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 167, "total_tokens": 208}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_K4vZ12XkDzM2Hg37XDTQWjnT", "custom_id": "726_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "1cff19539c0af3e3ce2d30567f987d26", "body": {"id": "chatcmpl-9St99sQ4XT2emcaREpNB2wI3eznRy", "object": "chat.completion", "created": 1716672195, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer, specifically B-cell lymphomas. Here are some essential points you should be aware of as a physician:\n\n1. **Indications**: Polivy is FDA-approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two prior therapies. It's used in combination with bendamustine and a rituximab product (a chemotherapy regimen).\n\n2. **Mechanism of Action**: Polivy specifically targets CD79b, a protein expressed on the surface of B-cells. Once bound, the antibody-drug conjugate is internalized and releases its cytotoxic payload (MMAE, a microtubule inhibitor), leading to cell cycle arrest and apoptosis of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_Llzd4p9i6tAtUaSS39PZzhOr", "custom_id": "727_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "df348fdf97c63d81dd715045b97b6d89", "body": {"id": "chatcmpl-9St99qiG8A4lZ66eN7AB2nj6oGFVc", "object": "chat.completion", "created": 1716672195, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there is no specific medical or pharmaceutical information regarding something named \"Elahere.\" It's possible that it could be a brand, product, or term not widely recognized in the medical community or it might be a typographical error. Could you please provide more context or clarify what \"Elahere\" refers to? This would help in providing a precise and helpful response. If it\u2019s a drug, a disease, or a medical condition, additional details would enable a more informed discussion."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 103, "total_tokens": 144}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_PepeeLPsdJZNtqSpCQo2GgdF", "custom_id": "728_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3966865b161d8055f9da728aa8641ab0", "body": {"id": "chatcmpl-9St9AxUGs7Aj5DLiRO3Nrfa6oDN5f", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, Lunsumio (mosunetuzumab) is a therapeutic agent used in oncology, specifically in the treatment of certain types of blood cancer. It's important for physicians to be aware of its indications, mechanism of action, potential side effects, and the necessary monitoring that accompanies its use.\n\n### 1. **Indication**\nLunsumio is approved for the treatment of relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma. Its use is generally considered after other treatments have failed or when the disease has recurred following prior therapies.\n\n### 2. **Mechanism of Action**\nMosunetuzumab is a bispecific antibody, meaning it targets two different antigens. It brings T-cells (a type of immune cell) and B-cells (cancer cells in the case of follic Akoma lymphomarticularer lymphoma) into close proximity, thereby enabling the immune system"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_WZqnsdMX2p8afvVe6JMqPEs9", "custom_id": "729_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "3b4cd143b1e1be80725e330de06fd3b6", "body": {"id": "chatcmpl-9St9AwIiUxyQNUQeQ3kk3w7Pw0MnL", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin (nadofaragene firadenovec-vncg) is an innovative treatment approved for therapeutic use in certain medical contexts, specifically in urology. It is a non-replicating adenoviral vector gene therapy used for the treatment of patients with high-risk, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) that has carcinoma in situ (CIS) with or without concomitant papillary disease. Here are some key points you should know:\n\n### Mechanism of Action:\nAdstiladrin is designed to deliver a recombinant interferon alpha-2b gene directly into the bladder using a viral vector (adenovirus). Once administered via intravesical instillation, the gene is taken up by bladder cells, which then begin producing interferon alpha-2b. Interferon alpha-2b is a protein with anti-tumor properties"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_uTF7vxbNJ3KmeSsR2R5eLGsA", "custom_id": "730_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "d35ee6ad081e4f07b057ebed0d087d33", "body": {"id": "chatcmpl-9St9AG9YHFtHp8CJHdrmHfyXpHUAQ", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia (generic name: olutasidenib) was approved by the U.S. Food and Drug Administration (FDA) for medical use in the treatment of cancer. Specifically, it is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation known as an isocitrate dehydrogenase-1 (IDH1) mutation. This approval was based on the drug's ability to inhibit the IDH1 enzyme, which is involved in the metabolic pathway that is crucial for cell growth and survival. \n\nHere are some key points a physician should know about Rezlidhia:\n\n1. **Indication**: It is used for treating adult patients with relapsed or refractory AML with a confirmed IDH1 mutation.\n\n2. **Mechanism of Action**: Rezlidhia works by inhibiting the mutant IDH1 enzyme, which in some AML patients results in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_DgWyjWSD9YlIgnnITRkMi4UX", "custom_id": "731_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "93ea025c0a3e1bed31aa7fb6ab6bed94", "body": {"id": "chatcmpl-9St9AesOYOfyuEReiZ91cImwEuplR", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you may be asking about a specific Irene in a medical or clinical context, but you didn't provide specific details about her. If you are asking about a patient named Irene, it's important to maintain confidentiality and privacy according to HIPAA guidelines in the United States, or equivalent in other countries. Please ensure you access her medical records through proper channels to understand her medical history, current conditions, and any other relevant information that would be important in her care and treatment.\n\nIf this isn't the context you meant, could you please provide more details to assist you appropriately?"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 116, "total_tokens": 155}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_3z7c2ZzfqBnPLz3rgSsAdD48", "custom_id": "732_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "0bcd7aa6a9969e28a62d20d36bbfb4ba", "body": {"id": "chatcmpl-9St9AxdYqf8Cztw2NRBYAeEIBAcyZ", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Bigonist\" does not refer to a recognized medication or medical term. It\u2019s possible that there might be a typo or misunderstanding concerning the name of the drug or concept you\u2019re asking about. However, to provide helpful guidance, I need the correct or complete information. \n\nIf you're inquiring about a specific drug or treatment, please ensure the spelling is correct, or provide additional context so I can assist you better. Alternatively, if \"Bigonist\" pertains to a new or less common drug or therapy, it might be helpful to refer to recent medical literature or a database that includes updated pharmaceutical information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 131, "total_tokens": 172}, "system_fingerprint": "fp_fe1929285d"}}, "error": null}
{"id": "batch_req_TKAGqJrqqjNM666twUPNrEqo", "custom_id": "733_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "5781b9e2b886b13a294a0b59fa14e16e", "body": {"id": "chatcmpl-9St9AU9eWR84zrOwV2J6qe3vorTG9", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of the last update, there isn't a specific medical or pharmaceutical reference to \"Contego\" that is commonly recognized in the medical community. It's possible that \"Contego\" could be a brand name, a company, or a product not directly related to the field of medicine, or it could be a fictional term.\n\nIf \"Contego\" is related to a specific medical device, medication, or technique that has emerged recently, I would recommend checking the latest medical literature, FDA releases, or clinical trial registries for accurate and updated information. Additionally, it could be helpful to consult pharmaceutical databases or professional medical organizations for further details.\n\nIf you provide more context or specify the field or usage, I could attempt to offer more targeted information or guide you to relevant resources."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 156, "total_tokens": 196}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
{"id": "batch_req_HRHJAZubxDt67ptmltp9x99S", "custom_id": "734_sentiment_question_physician_1.0_gpt-4-turbo", "response": {"status_code": 200, "request_id": "e4206de5fbe69b4405bbc3b5c73a376c", "body": {"id": "chatcmpl-9St9AL2QkMnIRGSeclDpumBcm90d8", "object": "chat.completion", "created": 1716672196, "model": "gpt-4-turbo-2024-04-09", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in January 2023, Ebvallo is a vaccine developed by Daiichi Sankyo for the purpose of protecting against the Ebola virus. Here are some key aspects a physician should be aware of regarding Ebvallo:\n\n1. **Target Virus**: Ebvallo targets the Zaire ebolavirus species, which is responsible for the majority of Ebola outbreaks, including the particularly devastating 2014-2016 West Africa epidemic.\n\n2. **Vaccine Type**: The specific technology or platform used by Ebvallo may differ from other Ebola vaccines like rVSV-ZEBOV (Ervebo), which is a vesicular stomatitis virus-based vaccine. Understanding the underlying technology of Ebvallo, such as whether it's a viral vector, mRNA, protein subunit, or inactivated virus, will be important for clinical practice, particularly in managing potential side effects or contraindications.\n\n3. **Efficacy and Effectiveness**: Information on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_f17df3916f"}}, "error": null}
